PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	MERGET, R; STOLLFUSS, J; WIEWRODT, R; FRUHAUF, H; KOCH, U; BOLMAUDORFF, U; BIENFAIT, HG; HILTL, G; SCHULTZEWERNINGHAUS, G				MERGET, R; STOLLFUSS, J; WIEWRODT, R; FRUHAUF, H; KOCH, U; BOLMAUDORFF, U; BIENFAIT, HG; HILTL, G; SCHULTZEWERNINGHAUS, G			DIAGNOSTIC-TESTS IN ENZYME ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ENZYMES; ALLERGY; ASTHMA; DIAGNOSIS; ENZYME ALLERGOSORBENT TEST; BRONCHIAL PROVOCATION TEST; SKIN TEST	BRONCHIAL PROVOCATION TEST; PAPAIN-INDUCED ASTHMA; OCCUPATIONAL ASTHMA; SKIN-TEST; IGE-ANTIBODIES; LUNG-FUNCTION; WORKERS; RAST; NITROCELLULOSE; HYPERSENSITIVITY	Background: Allergies to enzymes occur frequently in enzyme manufacturing plants. In epidemiologic studies the number of exposed subjects with symptoms is considerably higher than the number of sensitizations as assessed by skin tests or RAST It was the aim of this study to evaluate the sensitivity and specificity of skin prick tests, enzyme allergosorbent test, and immunoprint with enzymes by using the results of bronchial provocation tests as the ''gold standard. '' Methods: We performed 82 bronchial provocation tests with nine different enzymes in 42 chemical plant workers, all of whom had reported work-related symptoms. All tests with the exception of bronchial provocation tests were also performed in 10 atopic and 10 healthy control subjects. Results: Thirteen workers showed positive results to bronchial provocation tests (50% or greater fall in specific airway conductance) with an enzyme at a maximal concentration of 10 mg/ml Equivocal test results, that is, tests with a 30% or greater and less than 50% fall in specific airway conductance were seldom. Skin prick tests with nondialyzed aqueous enzyme extracts at a concentration of 10 mg/ml yielded a sensitivity of 100% and a specificity of 93%. Control subjects had no cutaneous reactions to enzymes. Discrepancies between skin tests and bronchial provocation tests occurred in 5 of 82 tests, all with a positive skin test and a negative bronchial provocation test False-positive skin tests were considered more likely in four subjects and a false-negative bronchial challenge more likely in one case. Enzyme allergosorbent test was 62% sensitive and 96% specific, and atopic control subjects showed positive results in two cases. Results of immunoprint with amylase showed one main band at pH 3.4; this band was also found in exposed subjects without further signs of sensitization, but was not found in control subjects. All but one person with positive results to bronchial provocation tests with enzymes showed bronchial hyperresponsiveness. We identified 13 subjects with bronchial hyperresponsiveness, but without occupational allergy: five of these had sensitizations to nonoccupational allergens and the remainder showed bronchial hyperresponsiveness without any detectable cause. Conclusions: Occupation-related symptoms were not indicative of occupational allergy. Bronchial provocation tests and skin prick tests with nondialyzed aqueous enzyme extracts were appropriate techniques for the diagnosis of enzyme allergy.	MINIST WOMEN LABOUR & SOCIAL WELF,WIESBADEN,GERMANY; UNIV FRANKFURT,DEPT PNEUMOL,W-6000 FRANKFURT,GERMANY	Goethe University Frankfurt	MERGET, R (corresponding author), KRANKENANSTALTEN BERGMANNSHEIL,PNEUMOL & ALLERGOL ABT,GILSINGSTR 14,D-44789 BOCHUM 1,GERMANY.							BATTEIGER B, 1982, J IMMUNOL METHODS, V55, P297, DOI 10.1016/0022-1759(82)90089-8; BAUR X, 1984, DEUT MED WOCHENSCHR, V109, P257, DOI 10.1055/s-2008-1069177; BAUR X, 1979, CLIN ALLERGY, V9, P75, DOI 10.1111/j.1365-2222.1979.tb01525.x; BAUR X, 1979, CLIN ALLERGY, V9, P451, DOI 10.1111/j.1365-2222.1979.tb02508.x; BAUR X, 1982, CLIN ALLERGY, V12, P9, DOI 10.1111/j.1365-2222.1982.tb03121.x; BAUR X, 1986, LANCET, V1, P43; BAUR X, 1988, J ALLERGY CLIN IMMUN, V81, P613; BELIN L, 1970, LANCET, V2, P1153; BELIN LGA, 1977, CLIN ALLERGY, V7, P55, DOI 10.1111/j.1365-2222.1977.tb01425.x; BERNSTEIN IL, 1972, J ALLERGY CLIN IMMUN, V49, P219; BERNSTEIN JA, 1990, J ALLERGY CLIN IMMUN, V86, P532, DOI 10.1016/S0091-6749(05)80209-X; BIRNBAUM J, 1988, REV MAL RESPIR, V5, P519; BOLMAUDORFF U, 1991, 30TH P M GERM SOC OC, P201; CARTIER A, 1984, J ALLERGY CLIN IMMUN, V73, P574, DOI 10.1016/0091-6749(84)90513-X; COLTEN HR, 1975, NEW ENGL J MED, V292, P1050, DOI 10.1056/NEJM197505152922003; DOR PJ, 1986, J ALLERGY CLIN IMMUN, V78, P877, DOI 10.1016/0091-6749(86)90234-4; FLINDT MLH, 1969, LANCET, V1, P1177; FLOOD DFS, 1985, BRIT J IND MED, V42, P43; GAILHOFER G, 1988, CLIN ALLERGY, V18, P445, DOI 10.1111/j.1365-2222.1988.tb02894.x; GALLAGHER JS, 1989, J ALLERGY CLIN IMMUN, V83, P261; GALLEGUILLOS F, 1978, CLIN ALLERGY, V8, P21, DOI 10.1111/j.1365-2222.1978.tb00443.x; GALSON S K, 1988, American Review of Respiratory Disease, V137, P485; GILSON JC, 1976, THORAX, V31, P621; GONSIOR E, 1976, ACTA ALLERGOL, V31, P283, DOI 10.1111/j.1398-9995.1976.tb01689.x; HAAS H, 1986, INT ARCH ALLER A IMM, V79, P434, DOI 10.1159/000234014; HARTMANN AL, 1983, SCHWEIZ MED WSCHR, V113, P265; KEENAN W, 1979, J ALLERGY CLIN IMMUN, V63, P150; LEARY JJ, 1983, P NATL ACAD SCI-BIOL, V80, P4045, DOI 10.1073/pnas.80.13.4045; LISS GM, 1984, J ALLERGY CLIN IMMUN, V73, P348, DOI 10.1016/0091-6749(84)90407-X; LOSADA E, 1986, J ALLERGY CLIN IMMUN, V77, P635, DOI 10.1016/0091-6749(86)90358-1; LOSADA E, 1992, J ALLERGY CLIN IMMUN, V89, P118, DOI 10.1016/S0091-6749(05)80048-X; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MITCHELL CA, 1971, AM REV RESPIR DIS, V104, P1; NEWHOUSE ML, 1970, LANCET, V1, P689; NOVEY HS, 1979, J ALLERGY CLIN IMMUN, V63, P98, DOI 10.1016/0091-6749(79)90198-2; NOVEY HS, 1980, CLIN ALLERGY, V10, P721, DOI 10.1111/j.1365-2222.1980.tb02157.x; PAUWELS R, 1978, LANCET, V1, P669; PELTRE G, 1982, IMMUNOL LETT, V5, P127, DOI 10.1016/0165-2478(82)90096-7; PEPYS J, 1969, LANCET, V1, P1181; QUANJER PH, 1983, B EUR PHYSIOPATH RES, V19, P1; REESE G, 1989, IMMUN INFEKT, V17, P165; RIGHETTI PG, 1974, J CHROMATOGR, V98, P271, DOI 10.1016/S0021-9673(00)92076-4; SARLO K, 1990, J ALLERGY CLIN IMMUN, V86, P393, DOI 10.1016/S0091-6749(05)80103-4; TARLO SM, 1978, CLIN ALLERGY, V8, P207, DOI 10.1111/j.1365-2222.1978.tb03216.x; Teculescu D B, 1985, Eur J Respir Dis, V67, P78; VANTOORENENBERGEN AW, 1991, J ALLERGY CLIN IMMUN, V87, P650, DOI 10.1016/0091-6749(91)90383-Y; WEILL H, 1971, J AMER MED ASSOC, V217, P425, DOI 10.1001/jama.217.4.425; ZETTERSTROM O, 1977, CLIN ALLERGY, V7, P355, DOI 10.1111/j.1365-2222.1977.tb01463.x; ZWEIMAN B, 1967, J ALLERGY, V39, P11, DOI 10.1016/0021-8707(67)90121-9	49	22	23	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1993	92	2					264	277		10.1016/0091-6749(93)90170-K	http://dx.doi.org/10.1016/0091-6749(93)90170-K			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LT469	8349937				2022-12-18	WOS:A1993LT46900007
J	MELTZER, EO				MELTZER, EO			INTRANASAL ANTICHOLINERGIC THERAPY OF RHINORRHEA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	CONF ON INTRANASAL ANTICHOLINERGIC TREATMENT OF NASAL DISORDERS	MAR   06, 1991	SAN FRANCISCO, CA	BOEHRINGER INGELHEIM PHARM		RHINORRHEA; ANTICHOLINERGIC AGENT; METHACHOLINE CHALLENGE	NASAL METHACHOLINE CHALLENGE; VASOMOTOR RHINITIS; IPRATROPIUM BROMIDE; EFFICACY; ATROVENT; ATROPINE; SAFETY	This article reviews the role of anticholinergic therapy for the rhinorrhea that occurs in various rhinopathies, including irritant reactions, perennial nonallergic rhinitis, viral infection rhinitis, allergic rhinitis, and temperature-induced rhinitis. The use of a topical anticholinergic medication, ipratropium bromide, and its ability to inhibit methacholine and rhinitis-induced hypersecretion is emphasized. Ipratropium bromide appears to be both safe and effective in reducing this troublesome symptom.	UNIV CALIF SAN DIEGO,ALLERGY & ASTHMA MED GRP & RES CTR,SAN DIEGO,CA 92103	University of California System; University of California San Diego								BORUM P, 1987, POSTGRAD MED J, V63, P61; Borum P, 1979, Acta Otorhinolaryngol Belg, V33, P528; BORUM P, 1983, CLIN OTOLARYNGOL, V8, P267, DOI 10.1111/j.1365-2273.1983.tb01440.x; BORUM P, 1981, AM REV RESPIR DIS, V123, P418; BORUM P, 1979, J ALLERGY CLIN IMMUN, V63, P253, DOI 10.1016/0091-6749(79)90109-X; DOLOVICH J, 1987, J ALLERGY CLIN IMMUN, V80, P274, DOI 10.1016/0091-6749(87)90031-5; DOLOVICH J, 1989, AM J RHINOL, V3, P221; GAFFEY MJ, 1987, AM REV RESPIR DIS, V135, P241; GAFFEY MJ, 1988, ANTIMICROB AGENTS CH, V32, P1644, DOI 10.1128/AAC.32.11.1644; JACKSON RT, 1981, ARCH OTOLARYNGOL, V107, P288; KAILA T, 1990, Rhinology (Utrecht), V28, P83; KIRKEGAARD J, 1987, J ALLERGY CLIN IMMUN, V79, P585, DOI 10.1016/S0091-6749(87)80153-7; KNIGHT A, 1986, ANN ALLERGY, V57, P348; KRIEGER E, 1975, POSTGRAD MED J S, V51, P103; MALMBERG H, 1983, CLIN OTOLARYNGOL, V8, P273, DOI 10.1111/j.1365-2273.1983.tb01441.x; MCLEAN JA, 1976, J ALLERGY CLIN IMMUN, V58, P563, DOI 10.1016/0091-6749(76)90202-5; MILFORD CA, 1990, J LARYNGOL OTOL, V104, P123, DOI 10.1017/S0022215100112022; MYGIND N, 1983, EUR J RESPIR DIS, V64, P167; OHI M, 1984, Rhinology (Utrecht), V22, P241; SANWIKARJA S, 1986, ANN ALLERGY, V56, P162; SJOGREN I, 1988, ACTA OTO-LARYNGOL, V106, P453, DOI 10.3109/00016488809122270; SPECTOR SL, 1975, J ALLERGY CLIN IMMUN, V56, P308, DOI 10.1016/0091-6749(75)90105-0	22	22	22	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1992	90	6	2	S			1055	1064		10.1016/0091-6749(92)90123-J	http://dx.doi.org/10.1016/0091-6749(92)90123-J			10	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KD635	1460208	Bronze			2022-12-18	WOS:A1992KD63500006
J	BIANCO, S; VAGHI, A; PIERONI, MG; ROBUSCHI, M; REFINI, RM; SESTINI, P				BIANCO, S; VAGHI, A; PIERONI, MG; ROBUSCHI, M; REFINI, RM; SESTINI, P			PROTECTIVE ACTIVITY OF INHALED NONSTEROIDAL ANTIINFLAMMATORY DRUGS ON BRONCHIAL RESPONSIVENESS TO ULTRASONICALLY NEBULIZED WATER	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						BRONCHIAL ASTHMA; BRONCHIAL HYPERREACTIVITY; LYSINE ACETYLSALICYLATE; INDOMETHACIN	AIRWAY RESPONSIVENESS; INHALATION; ASTHMA; INDOMETHACIN; INHIBITION; HISTAMINE	Relatively high doses of oral aspirin are needed to afford a significant protective effect against the bronchial obstructive reaction to ultrasonically nebulized distilled water (UNDW) in asthmatic patients. Sodium salicylate at similar doses and indomethacin at normal dose afford no protection. The present study was undertaken to assess the protective activity of these drugs taken by inhalation. Thirteen asthmatic patients performed two UNDW challenges 20 minutes and 24 hours after inhalation of 900 mg lysine acetylsalicylate (L-ASA) or placebo. The volume of UNDW causing a 20% fall in FEV1 (UNDW PD20) was calculated by linear interpolation on the dose-response curve. UNDW response after placebo was not significantly different from the preliminary test (PD20 4.3 +/- 0.7 and 4.1 +/- 04 ml, respectively, mean +/- SE), whereas after L-ASA, UNDW PD20 increased to 17 +/- 2.7 ml (p < 0.01 vs placebo) and remained significantly increased after 24 hours. In another group of 12 patients under the same experimental conditions, an equivalent dose of inhaled sodium salicylate caused no effect. Finally, in a third group of asthmatic patients pretreatment with inhaled indomethacin at two dose levels (6 patients, 25 mg; 10 patients, 50 mg) resulted in a significant dose-related protective effect. These findings indicate that inhaled indomethacin and especially L-ASA exert against UNDW-induced bronchoconstriction a potent protective effect, which appears to be mediated by inhibition of local prostaglandin synthesis in the airways. This fact could have therapeutic implications.	UNIV SIENA,INST RESP DIS,VIA TUFI 1,I-53100 SIENA,ITALY; UNIV MILAN,OSPED S RAFFAELE,INST CARDIOVASC & RESP DIS,I-20122 MILAN,ITALY; UNIV MILAN,INST RESP DIS,I-20122 MILAN,ITALY; HOSP GARBAGNATE,MILAN,ITALY	University of Siena; University of Milan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Milan			Sestini, Piersante/AAF-8570-2019	Sestini, Piersante/0000-0002-8195-0811				BIANCO S, 1983, EUR J RESPIR DIS, V64, P213; Bianco S, 1985, Prog Biochem Pharmacol, V20, P132; BIANCO S, 1977, IRCS J MED SCI, V129, P5; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; Cochran W.G, 1957, STAT METHODS, V6th ed; COCKCROFT DW, 1988, J ALLERGY CLIN IMMUN, V81, P111, DOI 10.1016/0091-6749(88)90229-1; DJUVANOVICH R, 1990, AM REV RESPIR DIS, V142, P434; FINNERTY JP, 1990, EUR RESPIR J, V3, P540; HAMBERG M, 1972, BIOCHEM BIOPH RES CO, V49, P720, DOI 10.1016/0006-291X(72)90470-6; INSEL P A, 1990, P638; JUNIPER EF, 1981, THORAX, V36, P575, DOI 10.1136/thx.36.8.575; MATTOLI S, 1987, J ALLERGY CLIN IMMUN, V79, P678, DOI 10.1016/S0091-6749(87)80165-3; NEEDS CJ, 1985, CLIN PHARMACOKINET, V10, P164, DOI 10.2165/00003088-198510020-00004; Newman SP, 1984, AEROSOLS LUNG, P197; OBRYNE PM, 1986, AM REV RESPIR DIS, V134, P69; QUANJER PH, 1983, B EUR PHYSIOPATH RES, V19, P1; ROBUSCHI M, 1989, Pulmonary Pharmacology, V1, P187, DOI 10.1016/S0952-0600(89)80016-X; ROBUSCHI M, 1988, Respiration, V54, P100; ROBUSCHI M, 1991, AM REV RESPIR DIS, V143, pA422; SWEET JM, 1990, J ALLERGY CLIN IMMUN, V85, P59, DOI 10.1016/0091-6749(90)90222-P; TOIVANEN J, 1985, THROMB RES, V37, P493, DOI 10.1016/0049-3848(85)90095-7	21	22	22	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1992	90	5					833	839		10.1016/0091-6749(92)90109-F	http://dx.doi.org/10.1016/0091-6749(92)90109-F			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JZ319	1430708				2022-12-18	WOS:A1992JZ31900015
J	KAMADA, AK; LEUNG, DYM; GLEASON, MC; HILL, MR; SZEFLER, SJ				KAMADA, AK; LEUNG, DYM; GLEASON, MC; HILL, MR; SZEFLER, SJ			HIGH-DOSE SYSTEMIC GLUCOCORTICOID THERAPY IN THE TREATMENT OF SEVERE ASTHMA - A CASE OF RESISTANCE AND PATTERNS OF RESPONSE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note									NATL JEWISH CTR IMMUNOL & RESP MED,DEPT PEDIAT,1400 JACKSON ST K-926,DENVER,CO 80206; NATL JEWISH CTR IMMUNOL & RESP MED,DEPT MED,DENVER,CO 80206; IRA J & JACQUELINE NEIMARK LAB CLIN PHARMACOL PEDIAT,DENVER,CO; UNIV COLORADO,HLTH SCI CTR,DEPT PEDIAT,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT PHARMACOL,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,SCH PHARM,DENVER,CO 80262; NATL JEWISH CTR IMMUNOL & RESP MED,DIV ALLERGY CLIN IMMUNOL,DENVER,CO 80206	National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Jewish Health					NHLBI NIH HHS [HL-36577] Funding Source: Medline; FDA HHS [FD-R-000278] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036577] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); FDA HHS; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CARMICHAEL J, 1981, BRIT MED J, V282, P1419, DOI 10.1136/bmj.282.6274.1419; ELLULMIC.R, 1974, CLIN SCI MOL MED, V47, P105, DOI 10.1042/cs0470105; FERGUSON AC, 1989, CHEST, V96, P988, DOI 10.1378/chest.96.5.988; HARRIS JB, 1987, J PEDIATR-US, V110, P627, DOI 10.1016/S0022-3476(87)80567-X; TURNERWARWICK M, 1986, ASTHMA CLIN PHARM TH, P347	5	22	23	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1992	90	4	1				685	687		10.1016/0091-6749(92)90144-Q	http://dx.doi.org/10.1016/0091-6749(92)90144-Q			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JT995	1401649				2022-12-18	WOS:A1992JT99500017
J	COHEN, AJ; LASKIN, C; TARLO, S				COHEN, AJ; LASKIN, C; TARLO, S			C1 ESTERASE INHIBITOR IN PREGNANCY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note							HEREDITARY ANGIOEDEMA; MANAGEMENT		TORONTO HOSP,TORONTO WESTERN DIV,DIV RESPIROL,CTR ASTHMA,EDITH CAVELL WING 4-008,TORONTO,ONTARIO,CANADA; TORONTO HOSP,DEPT RHEUMATOL,TORONTO,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto				Tarlo, Susan/0000-0002-4746-5310				FRANK MM, 1976, ANN INTERN MED, V84, P580, DOI 10.7326/0003-4819-84-5-580; GARRIGA MM, 1991, J ALLERGY CLIN IMMUN, V87, P821, DOI 10.1016/0091-6749(91)90128-B; HALBMAYER WM, 1991, THROMB HAEMOSTASIS, V2, P134; OGSTON D, 1981, THROMB RES, V23, P454; SIM TC, 1990, AM J MED, V88, P656, DOI 10.1016/0002-9343(90)90535-L	5	22	23	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1992	90	3	1				412	413		10.1016/S0091-6749(05)80025-9	http://dx.doi.org/10.1016/S0091-6749(05)80025-9			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JP520	1527327				2022-12-18	WOS:A1992JP52000023
J	LANZA, DC; KENNEDY, DW				LANZA, DC; KENNEDY, DW			CURRENT CONCEPTS IN THE SURGICAL-MANAGEMENT OF CHRONIC AND RECURRENT ACUTE SINUSITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	SYMP ON MECHANISMS, DIAGNOSIS, AND TREATMENT OF SINUSITIS IN CHILDREN AND ADULTS	JAN 24-25, 1992	SCOTTSDALE, AZ	ALLEN & HANBURYS		SURGERY; SINUSITIS; ENDOSCOPY; THERAPY; DIAGNOSIS	SURGERY; DIAGNOSIS; CT	It was previously believed that sinusitis lasting longer than 3 months might lead to irreversible disease. Experience with functional endoscopic sinus surgery indicates that this is rarely the case. Functional endoscopic sinus surgery describes an approach whereby target areas of obstruction are cleared of disease, which allows for ventilation of secondarily involved sinuses and return of mucociliary function. Although endoscopic sinus surgery is one of the techniques most frequently used to manage chronic sinus disease, it is not a suitable surgical approach for every otolaryngologist or all patient settings. Success with this endoscopic approach for chronic sinus disease is based primarily on rigorous perioperative medical care and postoperative surgical debridement. The greatest advancement that the nasal endoscope has brought to patient care is the ability to diagnose disease and follow objectively the effects of different treatment modalities. This advantage is recognized by allergists and used at several centers.			LANZA, DC (corresponding author), HOSP UNIV PENN,DEPT OTORHINOLARYNGOL HEAD & NECK SURG,5 SILVERSTEIN PAVIL,PHILADELPHIA,PA 19104, USA.							BENNINGER MS, 1991, OTOLARYNG HEAD NECK, V105, P641, DOI 10.1177/019459989110500502; BOLGER WE, 1991, LARYNGOSCOPE, V101, P56; CASTELLANOS J, 1989, J ALLERGY CLIN IMMUN, V83, P91, DOI 10.1016/0091-6749(89)90481-8; Hadfield E H, 1970, Ann R Coll Surg Engl, V46, P301; HILDING AC, 1944, ANN OTO RHINOL LARYN, V53, P35; KENNEDY DW, 1985, ARCH OTOLARYNGOL, V111, P576; KERN EB, 1984, J ALLERGY CLIN IMMUN, V73, P25, DOI 10.1016/0091-6749(84)90480-9; LANZA DC, 1991, ESSENTIAL OTOLARYNGO, V21, P373; NAUMANN H, 1965, 8 P INT C OT AMST, P80; SCHAEFER SD, 1989, LARYNGOSCOPE, V99, P1; STANKIEWICZ JA, 1989, LARYNGOSCOPE, V99, P686; TORJUSSEN W, 1979, CANCER, V44, P963, DOI 10.1002/1097-0142(197909)44:3<963::AID-CNCR2820440326>3.0.CO;2-H; WOLFSDORF J, 1969, PEDIATRICS, V43, P799; ZINREICH SJ, 1988, RADIOLOGY, V169, P439, DOI 10.1148/radiology.169.2.3174990	14	22	25	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1992	90	3	2	S			505	511		10.1016/0091-6749(92)90175-2	http://dx.doi.org/10.1016/0091-6749(92)90175-2			7	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JP521	1527341				2022-12-18	WOS:A1992JP52100016
J	STEWART, GA; BIRD, CH; THOMPSON, PJ				STEWART, GA; BIRD, CH; THOMPSON, PJ			DO THE GROUP-II DUST MITE ALLERGENS CORRESPOND TO LYSOZYME	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							DERMATOPHAGOIDES				STEWART, GA (corresponding author), PRINCESS MARGARET HOSP,WESTERN AUSTRALIAN RES INST CHILD HLTH,THOMAS ST,SUBIACO PERTH,WA 6008,AUSTRALIA.							CHUA KY, 1991, CLIN EXP ALLERGY, V21, P161, DOI 10.1111/j.1365-2222.1991.tb00825.x; CHUA KY, 1990, INT ARCH ALLER A IMM, V91, P118, DOI 10.1159/000235101; LIND P, 1985, J ALLERGY CLIN IMMUN, V76, P753, DOI 10.1016/0091-6749(85)90682-7; LOMBARDERO M, 1990, J IMMUNOL, V144, P1353; THOMPSON PJ, 1989, ALLERGOLOGIE, V12, P34	5	22	22	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1992	90	1					141	142		10.1016/S0091-6749(06)80029-1	http://dx.doi.org/10.1016/S0091-6749(06)80029-1			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JE255	1629505				2022-12-18	WOS:A1992JE25500023
J	GREENSTEIN, JL; MORGENSTERN, JP; LARAIA, J; COUNSELL, CM; GOODWIN, WH; LUSSIER, A; CRETICOS, PS; NORMAN, PS; GARMAN, RD				GREENSTEIN, JL; MORGENSTERN, JP; LARAIA, J; COUNSELL, CM; GOODWIN, WH; LUSSIER, A; CRETICOS, PS; NORMAN, PS; GARMAN, RD			RAGWEED IMMUNOTHERAPY DECREASES T-CELL REACTIVITY TO RECOMBINANT AMB-A-I.1	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	22	22	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1992	89	1	2				322	322						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HB760					2022-12-18	WOS:A1992HB76000660
J	SCHOU, C; FERNANDEZCALDAS, E; LOCKEY, RF; LOWENSTEIN, H				SCHOU, C; FERNANDEZCALDAS, E; LOCKEY, RF; LOWENSTEIN, H			ENVIRONMENTAL ASSAY FOR COCKROACH ALLERGENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							HOUSE DUST MITE; P-I; F-I; DERMATOPHAGOIDES; IMMUNOELECTROPHORESIS; PTERONYSSINUS; ASTHMA	A sandwich ELISA was developed to measure the concentration of cockroach allergen in the environment. The assay was based on a monospecific rabbit antibody preparation reactive with determinants shared by the important allergens, Per a I and Bla g I, from American and German cockroaches. The sensitivity was 0.2 ng Lowry protein of Per a I equivalents per milliliter, corresponding to 1 ng of Per a I equivalents per gram of dust (Per a I eq/gm). The assay did not react with noncockroach-allergen sources. Dust samples from 73 households in a cockroach-infested area were assayed. The concentration in these samples varied from below detection to 200,000 ng of Per a eq/gm of dust. Three commercial cockroach-allergen extracts all contained the allergen. The assay will be valuable for studies of the clinically relevant cockroach-allergen exposure levels and for assessment of efficacy of allergen-avoidance measures. Furthermore, the assay could be used for sanitary documentation in bakeries, restaurants, etc.	UNIV S FLORIDA, TAMPA, FL 33620 USA	State University System of Florida; University of South Florida	SCHOU, C (corresponding author), ALK RES, BOGE ALLE 10-12, DK-2970 HORSHOLM, DENMARK.							BERNTON HS, 1967, SOUTH MED J, V60, P852, DOI 10.1097/00007611-196708000-00012; CHAPMAN MD, 1987, J ALLERGY CLIN IMMUN, V80, P184, DOI 10.1016/0091-6749(87)90128-X; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KANG B, 1978, ANN ALLERGY, V41, P333; KANG B, 1976, J ALLERGY CLIN IMMUN, V58, P357, DOI 10.1016/0091-6749(76)90115-9; LIND P, 1986, ALLERGY, V41, P442, DOI 10.1111/j.1398-9995.1986.tb00325.x; LIND P, 1988, J ALLERGY CLIN IMMUN, V81, P269, DOI 10.1016/0091-6749(88)90637-9; LOMBARDERO M, 1988, J IMMUNOL METHODS, V108, P71, DOI 10.1016/0022-1759(88)90404-8; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; Mckittrick F.A., 1964, EVOLUTIONARY STUDIES; MONK BE, 1987, BRIT MED J, V294, P935, DOI 10.1136/bmj.294.6577.935; PLATTSMILLS TAE, 1989, J ALLERGY CLIN IMMUN, V83, P416, DOI 10.1016/0091-6749(89)90128-0; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P505, DOI 10.1016/0091-6749(91)90009-D; SCHOU C, 1990, J ALLERGY CLIN IMMUN, V86, P935, DOI 10.1016/S0091-6749(05)80157-5; SKJODT K, 1984, J IMMUNOL METHODS, V72, P243, DOI 10.1016/0022-1759(84)90452-6; SVENDSEN PJ, 1973, SCAND J IMMUNOL, V2, P69, DOI 10.1111/j.1365-3083.1973.tb03781.x; THOMPSON SJ, 1988, INT ARCH ALLER A IMM, V85, P312, DOI 10.1159/000234523; ZSCHUNKE E, 1978, CONTACT DERMATITIS, V4, P313, DOI 10.1111/j.1600-0536.1978.tb04579.x	19	22	22	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1991	87	4					828	834		10.1016/0091-6749(91)90129-C	http://dx.doi.org/10.1016/0091-6749(91)90129-C			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FG059	2013677				2022-12-18	WOS:A1991FG05900012
J	STRUNK, RC; MASCIA, AV; LIPKOWITZ, MA; WOLF, SI				STRUNK, RC; MASCIA, AV; LIPKOWITZ, MA; WOLF, SI			REHABILITATION OF A PATIENT WITH ASTHMA IN THE OUTPATIENT SETTING	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							EXERCISE-INDUCED ASTHMA; CHILDREN; FITNESS; PERFORMANCE; ENDURANCE; DISEASE		ST LOUIS CHILDRENS HOSP, DIV PULM MED, ST LOUIS, MO 63178 USA; GEORGE WASHINGTON UNIV, DEPT CHILD HLTH, WASHINGTON, DC USA; ST LOUIS CHILDRENS HOSP, DIV ALLERGY IMMUNOL, ST LOUIS, MO 63178 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT PEDIAT, NEW YORK, NY 10032 USA	St. Louis Children's Hospital; Washington University (WUSTL); George Washington University; St. Louis Children's Hospital; Washington University (WUSTL); Columbia University	STRUNK, RC (corresponding author), WASHINGTON UNIV, SCH MED, DEPT PEDIAT, 400 S KINGSHIGHWAY BLVD, ST LOUIS, MO 63110 USA.							ARBORELIUS M, 1984, EUR J RESPIR DIS, V65, P25; BLACKBURN H, 1988, NEW ENGL J MED, V319, P1217, DOI 10.1056/NEJM198811033191808; CLARK CJ, 1988, THORAX, V43, P745, DOI 10.1136/thx.43.10.745; CREER TL, 1971, J CHRON DIS, V24, P507, DOI 10.1016/0021-9681(71)90034-8; EDMUNDS AT, 1978, AM REV RESPIR DIS, V117, P247; FINE BT, 1953, ANN ALLERGY, V11, P275; FITCH KD, 1976, ARCH DIS CHILD, V51, P190, DOI 10.1136/adc.51.3.190; FITCH KD, 1986, ANN ALLERGY, V57, P90; FITCH KD, 1983, ASTHMATIC CHILD PLAY, P246; FREUDENBERG N, 1980, J SCHOOL HEALTH, V50, P522, DOI 10.1111/j.1746-1561.1980.tb02079.x; GRAMMER LC, 1989, J ALLERGY CLIN IMMUN, V84, P805, DOI 10.1016/0091-6749(89)90343-6; GUTSTADT LB, 1989, AM J DIS CHILD, V143, P471, DOI 10.1001/archpedi.1989.02150160101020; HOLZER FJ, 1984, AUST PAEDIATR J, V20, P297; ITKIN IH, 1966, J ALLERGY, V37, P253, DOI 10.1016/S0021-8707(96)90009-X; KENDALL M, 1983, ASTHMATIC CHILD PLAY, P372; LARSON EB, 1987, ARCH INTERN MED, V147, P353, DOI 10.1001/archinte.147.2.353; Livingstone JL, 1935, LANCET, V2, P705; LUDWICK SK, 1986, J PEDIATR-US, V109, P446, DOI 10.1016/S0022-3476(86)80115-9; MCFADDEN ER, 1986, J CLIN INVEST, V78, P18, DOI 10.1172/JCI112549; MCNICOL KN, 1973, BRIT MED J, V4, P7, DOI 10.1136/bmj.4.5883.7; MITCHELL RG, 1973, ARCH DIS CHILD, V48, P467, DOI 10.1136/adc.48.6.467; MORTON AR, 1981, PHYSICIAN SPORTSMED, V9, P51; MRAZEK DA, 1988, ALLERGY PRINCIPLES P, P1176; NICKERSON BG, 1983, PEDIATRICS, V71, P147; NORRISH M, 1977, ARCH DIS CHILD, V52, P912, DOI 10.1136/adc.52.12.912; ORENSTEIN DM, 1985, J PEDIATR-US, V106, P556, DOI 10.1016/S0022-3476(85)80071-8; OSEID S, 1978, SWIMMING MED, V4, P32; PARCEL GS, 1979, PEDIATRICS, V64, P878; PIERSON WE, 1988, NEW ENGL REG ALLERGY, V9, P209; RACKEMANN FM, 1952, NEW ENGL J MED, V246, P815, DOI 10.1056/NEJM195205222462104; RONNIMANN S, 1986, CHEST, V90, P480; SANDER N, BREATHING BUDDIES MA; SCHNALL R, 1982, AUST PAEDIATR J, V18, P23; SPARROW D, 1982, AM REV RESPIR DIS, V125, P319; STRICK L, 1969, PEDIATR CLIN N AM, V16, P31; STRUNK RC, 1989, PEDIATRICS, V84, P460; STRUNK RC, 1988, AM J DIS CHILD, V142, P940, DOI 10.1001/archpedi.1988.02150090038019; SVENONIUS E, 1983, ACTA PAEDIATR SCAND, V72, P23, DOI 10.1111/j.1651-2227.1983.tb09658.x; WOLF SI, 1988, ANN ALLERGY, V61, P357; 1980, GUIDELINES GRADED EX; 1984, PEDIATRICS, V74, P155; 1970, PEDIATRICS, V45, P150	42	22	22	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1991	87	3					601	611		10.1016/0091-6749(91)90374-W	http://dx.doi.org/10.1016/0091-6749(91)90374-W			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FB801	2005311				2022-12-18	WOS:A1991FB80100001
J	BERMAN, BA				BERMAN, BA			PERENNIAL ALLERGIC RHINITIS - CLINICAL EFFICACY OF A NEW ANTIHISTAMINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	CONF ON ADVANCEMENTS IN ANTIALLERGIC THERAPY : BEYOND CONVENTIONAL ANTIHISTAMINES	OCT 12-15, 1989	NAPLES, FL	PFIZER LAB			DOUBLE-BLIND; CETIRIZINE	Nasal itching, sneezing, and rhinorrhea are troublesome symptoms in patients with perennial allergic rhinitis. Most first-generation H-1-receptor agonists achieve a 50% reduction in these symptoms, but their benefits are frequently offset by annoying anticholinergic and sedative side effects. Cetirizine is a major metabolite of hydroxyzine that has little anticholinergic activity and causes significantly less sedation. In addition, it can be given once a day. In placebo-controlled comparisons with terfenadine, both active drugs were comprably effective and significantly better than placebo in relieving sneezing, rhinorrhea, and nasal itching. In a multicenter, double-blind comparison with placebo, both cetirizine, 10 and 20 mg given once daily, were similarly effective and superior to placebo in reducing the overall symptoms of rhinitis. In another multicenter, double-blind study, cetirizine was comparable with diphenhydramine and significantly superior to placebo in reducing total symptom severity, sneezing, rhinorrhea, and ocular itching. The safety of cetirizine was demonstrated in all studies. Cetirizine tended to be less sedating than diphenhydramine.	TUFTS UNIV,BROOKLINE,MA; ST ELIZABETH HOSP,BROOKLINE,MA	Tufts University								[Anonymous], DATA FILE; BRUTTMANN G, 1989, ACTA THERAP, V15, P99; MANSMANN HC, 1990, IN PRESS J ALLERGY C; SCHMEISSER KJ, 1989, ACTA THERAP, V15, P87; SNYDER SH, 1987, ANN ALLERGY, V59, P4	5	22	25	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1990	86	6	2	S			1004	1008		10.1016/S0091-6749(05)80244-1	http://dx.doi.org/10.1016/S0091-6749(05)80244-1			5	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ER131	1979794				2022-12-18	WOS:A1990ER13100003
J	SOTER, NA				SOTER, NA			URTICARIA - CURRENT THERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	CONF ON ADVANCEMENTS IN ANTIALLERGIC THERAPY : BEYOND CONVENTIONAL ANTIHISTAMINES	OCT 12-15, 1989	NAPLES, FL	PFIZER LAB			CHRONIC IDIOPATHIC URTICARIA; DELAYED PRESSURE URTICARIA; SOLAR URTICARIA; COLD URTICARIA; HEAT URTICARIA; COMBINED H-1; SYMPTOMATIC DERMOGRAPHISM; GASTRIC-CANCER; HUMAN-SKIN; ANTAGONISTS	Although the ideal treatment for urticaria is identification and removal of its cause, no underlying cause can be discerned in the majority of instances. The chief clinical problem is the treatment of chronic idiopathic urticaria. H-1-receptor antagonists are the major class of therapeutic agents used in the management of chronic idiopathic urticaria. The H-1 antagonists have been divided into subgroups based on their chemical structure. The second-generation H-1 antagonists now available are particularly advantageous for individuals who must remain alert while working. Terbutaline, a beta-adrenergic agonist, is of occasional benefit as an adjunct therapy in combination with an H-1 antagonist. The oral administration of disodium cromoglycate is ineffective in patients with chronic idiopathic urticaria, although a few individuals with urticaria caused by food allergy may respond to this drug. It is best to avoid repeated injections of epinephrine and the systemic administration of corticosteroids. Urticaria has a capricious course: it may respond to the administration of placebos or it may resolve spontaneously. About 50% of the patients with urticaria are free of lesions within 1 year, but 20% continue to have episodes for more than 20 years.			SOTER, NA (corresponding author), NYU MED CTR,SCH MED,DEPT DERMATOL,550 1ST AVE,NEW YORK,NY 10016, USA.			Soter, Nicholas/0000-0003-3518-3209				AVELLA J, 1978, LANCET, V1, P624; BENTLEYPHILLIPS CB, 1976, LANCET, V2, P63; BERNHARD JD, 1984, J AM ACAD DERMATOL, V10, P29, DOI 10.1016/S0190-9622(84)80037-7; BEROVA N, 1974, BRIT J DERMATOL, V90, P431; BREATHNACH SM, 1983, CLIN EXP DERMATOL, V8, P463, DOI 10.1111/j.1365-2230.1983.tb01814.x; CHAMPION RH, 1969, BRIT J DERMATOL, V81, P588, DOI 10.1111/j.1365-2133.1969.tb16041.x; COMMENS CA, 1978, BRIT J DERMATOL, V99, P675, DOI 10.1111/j.1365-2133.1978.tb07062.x; COOK J, 1983, ACTA DERM-VENEREOL, V63, P260; COUTTS A, 1982, CLIN EXP DERMATOL, V7, P529, DOI 10.1111/j.1365-2230.1982.tb02471.x; CREAN GP, 1979, LANCET, V2, P797; DAVIS KC, 1986, J ALLERGY CLIN IMMUN, V77, P566, DOI 10.1016/0091-6749(86)90346-5; DELORME P, 1969, J ALLERGY, V43, P284, DOI 10.1016/0021-8707(69)90149-X; ELDER JB, 1979, LANCET, V1, P1005, DOI 10.1016/S0140-6736(79)92757-0; GREAVES MW, 1981, BRIT MED J, V282, P2008, DOI 10.1136/bmj.282.6281.2008; GREENE SL, 1985, J AM ACAD DERMATOL, V12, P669, DOI 10.1016/S0190-9622(85)70092-8; HANNUKSELA M, 1985, ACTA DERM-VENEREOL, V65, P449; HARTO A, 1985, DERMATOLOGICA, V170, P90, DOI 10.1159/000249507; HARVEY RP, 1981, J ALLERGY CLIN IMMUN, V68, P262, DOI 10.1016/0091-6749(81)90149-4; HUSTON DP, 1986, ANN INTERN MED, V104, P507, DOI 10.7326/0003-4819-104-4-507; IRWIN RB, 1985, J ALLERGY CLIN IMMUN, V76, P35, DOI 10.1016/0091-6749(85)90801-2; JOHNSTON WE, 1982, NEW ENGL J MED, V306, P219, DOI 10.1056/NEJM198201283060406; JUHLIN L, 1969, ACTA DERM-VENEREOL, V49, P26; KAUR S, 1981, BRIT J DERMATOL, V104, P185, DOI 10.1111/j.1365-2133.1981.tb00043.x; KEAHEY TM, 1984, BRIT J DERMATOL, V110, P327, DOI 10.1111/j.1365-2133.1984.tb04639.x; KENNES B, 1977, CLIN ALLERGY, V7, P35, DOI 10.1111/j.1365-2222.1977.tb01422.x; KERDEL FA, 1983, RECENT ADV DERMATOLO, V6, P265; KRAUSE LB, 1984, BRIT J DERMATOL, V110, P73, DOI 10.1111/j.1365-2133.1984.tb07315.x; KRAUSE LB, 1985, BRIT J DERMATOL, V112, P447, DOI 10.1111/j.1365-2133.1985.tb02319.x; LEIGH IM, 1975, BRIT J DERMATOL, V92, P191, DOI 10.1111/j.1365-2133.1975.tb03057.x; MANSFIELD LE, 1983, ANN ALLERGY, V50, P264; MARTENS BPM, 1984, BRIT J DERMATOL, V111, P481; MATTHEWS CNA, 1979, BRIT J DERMATOL, V101, P57, DOI 10.1111/j.1365-2133.1979.tb15293.x; MICHELL P, 1980, DERMATOLOGICA, V160, P198, DOI 10.1159/000250495; MONROE EW, 1981, ARCH DERMATOL, V117, P404, DOI 10.1001/archderm.117.7.404; MOOREROBINSON M, 1968, BRIT J DERMATOL, V80, P794, DOI 10.1111/j.1365-2133.1968.tb11948.x; NEITTAANMAKI H, 1984, J AM ACAD DERMATOL, V11, P483, DOI 10.1016/S0190-9622(84)70196-4; NOID HE, 1974, ARCH DERMATOL, V109, P866, DOI 10.1001/archderm.109.6.866; PARRISH JA, 1982, BRIT J DERMATOL, V106, P575, DOI 10.1111/j.1365-2133.1982.tb04561.x; PHANUPHAK P, 1978, CLIN ALLERGY, V8, P429, DOI 10.1111/j.1365-2222.1978.tb01493.x; RAMSAY CA, 1977, ARCH DERMATOL, V113, P1222, DOI 10.1001/archderm.113.9.1222; RANTANEN T, 1980, ACTA DERM-VENEREOL, V60, P363; RUDZKI E, 1970, ACTA ALLERGOL, V25, P70, DOI 10.1111/j.1398-9995.1970.tb01383.x; SAIHAN EM, 1981, BRIT J DERMATOL, V104, P205; SAIHAN EM, 1983, BRIT J DERMATOL, V109, P31, DOI 10.1111/j.1365-2133.1983.tb11579.x; SCHENTAG JJ, 1979, LANCET, V1, P177, DOI 10.1016/S0140-6736(79)90578-6; SHELLEY WB, 1985, LANCET, V2, P1031; SIBBALD RG, 1981, BRIT J DERMATOL, V105, P297, DOI 10.1111/j.1365-2133.1981.tb01289.x; SIGLER RW, 1980, J ALLERGY CLIN IMMUN, V65, P309, DOI 10.1016/0091-6749(80)90161-X; SOTER NA, 1981, SPRINGER SEMIN IMMUN, V4, P73, DOI 10.1007/BF01891887; SOTER NA, 1987, DERMATOLOGY GENERAL, P1282; SPANGLER DL, 1980, ANN ALLERGY, V45, P246; SULLIVAN TJ, 1982, J ALLERGY CLIN IMMUN, V69, P260, DOI 10.1016/S0091-6749(82)80002-X; SUSSMAN GL, 1982, J ALLERGY CLIN IMMUN, V70, P337, DOI 10.1016/0091-6749(82)90022-7; THORMANN J, 1980, ALLERGY, V35, P139, DOI 10.1111/j.1398-9995.1980.tb01728.x; TING S, 1983, J ALLERGY CLIN IMMUN, V71, P546, DOI 10.1016/0091-6749(83)90435-9; TOTHKASA I, 1983, J INVEST DERMATOL, V80, P34, DOI 10.1111/1523-1747.ep12530993; VANTHIEL DH, 1979, NEW ENGL J MED, V300, P1012, DOI 10.1056/NEJM197905033001803; VAZ GA, 1978, LANCET, V1, P1066; WANDERER AA, 1971, J ALLERGY CLIN IMMUN, V48, P366, DOI 10.1016/0091-6749(71)90083-2; WANDERER AA, 1985, ARCH DERMATOL, V113, P1375; WONG E, 1987, BRIT J DERMATOL, V116, P553, DOI 10.1111/j.1365-2133.1987.tb05877.x; ZACHARIAE H, 1969, ACTA DERM-VENEREOL, V49, P49	62	22	22	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1990	86	6	2	S			1009	1014		10.1016/S0091-6749(05)80245-3	http://dx.doi.org/10.1016/S0091-6749(05)80245-3			6	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ER131	1979795	Bronze			2022-12-18	WOS:A1990ER13100004
J	SARLO, K; CLARK, ED; RYAN, CA; BERNSTEIN, DI				SARLO, K; CLARK, ED; RYAN, CA; BERNSTEIN, DI			ELISA FOR HUMAN IGE ANTIBODY TO SUBTILISIN A (ALCALASE) - CORRELATION WITH RAST AND SKIN-TEST RESULTS WITH OCCUPATIONALLY EXPOSED INDIVIDUALS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CINCINNATI,DEPT MED,DIV IMMUNOL,CINCINNATI,OH 45221	University of Cincinnati	SARLO, K (corresponding author), PROCTER & GAMBLE CO,MIAMI VALLEY LABS,POB 398707,CINCINNATI,OH 45239, USA.							BROWN WE, 1982, TOXICOL APPL PHARM, V63, P45, DOI 10.1016/0041-008X(82)90025-4; DEUSCHL H, 1977, CLIN ALLERGY, V7, P195, DOI 10.1111/j.1365-2222.1977.tb01442.x; DOR PJ, 1986, J ALLERGY CLIN IMMUN, V78, P877, DOI 10.1016/0091-6749(86)90234-4; FINNERTY JP, 1989, CLIN EXP ALLERGY, V19, P51, DOI 10.1111/j.1365-2222.1989.tb02343.x; FLINDT MLH, 1969, LANCET, V1, P1177; FLOOD DFS, 1985, BRIT J IND MED, V42, P43; GALLAGHER JS, 1989, J ALLERGY CLIN IMMUN, V83, P261; GUNTELBERG A. V., 1954, COMPT REND TRAV LAB CARLSBERG SER CHIM, V29, P36; HARTLEY BS, 1959, BIOCHIM BIOPHYS ACTA, V34, P243, DOI 10.1016/0006-3002(59)90254-9; JACOBY B, 1976, J IMMUNOL METHODS, V11, P37, DOI 10.1016/0022-1759(76)90016-8; JUNIPER CP, 1984, J SOC OCCUP MED, V34, P127; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P210, DOI 10.1016/0091-6749(73)90059-6; PEPYS J, 1985, CLIN ALLERGY, V15, P101, DOI 10.1111/j.1365-2222.1985.tb02262.x; PEPYS J, 1969, LANCET, V1, P1181; PEPYS J, 1973, Clinical Allergy, V3, P143, DOI 10.1111/j.1365-2222.1973.tb01318.x; STENIUS B, 1971, Clinical Allergy, V1, P37, DOI 10.1111/j.1365-2222.1971.tb02446.x; WEILL H, 1974, ANN NY ACAD SCI, V221, P76, DOI 10.1111/j.1749-6632.1974.tb28201.x; ZETTERSTROM O, 1977, CLIN ALLERGY, V7, P355, DOI 10.1111/j.1365-2222.1977.tb01463.x	18	22	23	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1990	86	3	1				393	399		10.1016/S0091-6749(05)80103-4	http://dx.doi.org/10.1016/S0091-6749(05)80103-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EA859	2212411				2022-12-18	WOS:A1990EA85900014
J	LAGIER, F; CARTIER, A; SOMER, J; DOLOVICH, J; MALO, JL				LAGIER, F; CARTIER, A; SOMER, J; DOLOVICH, J; MALO, JL			OCCUPATIONAL ASTHMA CAUSED BY GUAR GUM	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HOP SACRE COEUR, DEPT CHEST MED, 5400 W GOUIN, MONTREAL H4J 1C5, QUEBEC, CANADA; HOP ST MARGUERITE, DEPT CHEST DIS & ALLERGOL, MARSEILLE, FRANCE; MCMASTER UNIV, DEPT PEDIAT, HAMILTON L8S 4L8, ONTARIO, CANADA	Universite de Montreal; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; McMaster University								[Anonymous], 1987, AM REV RESPIR DIS, V136, P1285; BOHNER CB, 1940, J ALLERGY, V12, P290; BULLEN SS, 1934, J ALLERGY, V5, P484; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; DEHAUT P, 1983, THORAX, V38, P516, DOI 10.1136/thx.38.7.516; DELUCA S, 1988, EUR RESPIR J, V1, P540; FOWLER PBS, 1952, LANCET, V263, P755; GELFAND HH, 1943, J ALLERGY, V14, P203; KANERVA L, 1988, CLIN ALLERGY, V18, P245, DOI 10.1111/j.1365-2222.1988.tb02866.x; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; LACHANCE P, 1988, J ALLERGY CLIN IMMUN, V81, P385, DOI 10.1016/0091-6749(88)90906-2; MALO JL, 1983, AM REV RESPIR DIS, V128, P8, DOI 10.1164/arrd.1983.128.1.8; MOIRA CY, 1986, AM REV RESPIR DIS, V133, P686; Montgomery R., 1959, CHEM PLANT GUMS MUCI; PAULI G, 1986, CLIN RESPIR PHYSL, V2, P399; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; SPIELMAN AD, 1933, JAMA-J AM MED ASSOC, V101, P466; TARLO SM, 1978, CLIN ALLERGY, V8, P207, DOI 10.1111/j.1365-2222.1978.tb03216.x	18	22	22	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1990	85	4					785	790		10.1016/0091-6749(90)90199-E	http://dx.doi.org/10.1016/0091-6749(90)90199-E			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DA437	2324416	Bronze			2022-12-18	WOS:A1990DA43700016
J	GONG, H; TASHKIN, DP; DAUPHINEE, B; DJAHED, B; WU, TC				GONG, H; TASHKIN, DP; DAUPHINEE, B; DJAHED, B; WU, TC			EFFECTS OF ORAL CETIRIZINE, A SELECTIVE H-1 ANTAGONIST, ON ALLERGEN-INDUCED AND EXERCISE-INDUCED BRONCHOCONSTRICTION IN SUBJECTS WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											GONG, H (corresponding author), UNIV CALIF LOS ANGELES,MED CTR,DEPT MED,DIV PULM & CRIT CARE MED,LOS ANGELES,CA 90024, USA.							ANDERSON S, 1979, J ALLERGY CLIN IMMUN, V64, P612, DOI 10.1016/0091-6749(79)90024-1; ANDERSON SD, 1976, AM REV RESPIR DIS, V114, P493; BERNHEIM J, 1987, CETIRIZINE RECENT AD; Box G., 1978, STAT EXPERIMENTERS A, P245; BRIK A, 1987, J ALLERGY CLIN IMMUN, V80, P51, DOI 10.1016/S0091-6749(87)80190-2; BROIDE DH, 1988, J ALLERGY CLIN IMMUN, V81, P176, DOI 10.1016/0091-6749(88)90268-0; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CHARLESWORTH EN, 1989, J ALLERGY CLIN IMMUN, V83, P905, DOI 10.1016/0091-6749(89)90104-8; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; EGGLESTON PA, 1979, J ALLERGY CLIN IMMUN, V64, P642, DOI 10.1016/0091-6749(79)90028-9; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; FADEL R, 1987, CLIN ALLERGY, V17, P373, DOI 10.1111/j.1365-2222.1987.tb02027.x; FINNERTY JP, 1988, J ALLERGY CLIN IMMUN, V81, P240, DOI 10.1016/0091-6749(88)90524-6; FISH JE, 1981, J APPL PHYSIOL, V50, P1079, DOI 10.1152/jappl.1981.50.5.1079; GAYARD P, 1975, AM REV RESPIR DIS, V111, P433; GENGO FM, 1987, CLIN PHARMACOL THER, V42, P265, DOI 10.1038/clpt.1987.145; GHYS L, 1989, J INT MED RES, V17, P24, DOI 10.1177/030006058901700103; HOLGATE ST, 1989, J ALLERGY CLIN IMMUN, V83, P537, DOI 10.1016/0091-6749(89)90035-3; HOLTZMAN MJ, 1979, AM REV RESPIR DIS, V120, P1059; HOWARTH PH, 1985, J ALLERGY CLIN IMMUN, V75, P166, DOI 10.1016/0091-6749(85)90383-5; JUHLIN L, 1988, BRIT J DERMATOL, V119, P67, DOI 10.1111/j.1365-2133.1988.tb07103.x; KAISER H, 1987, CETIRIZINE RECENT AD; KALINER M, 1978, AM REV RESPIR DIS, V118, P1015; KEMP JP, 1987, J ALLERGY CLIN IMMUN, V79, P893, DOI 10.1016/0091-6749(87)90238-7; KONIG P, 1981, CLIN ALLERGY, V11, P597, DOI 10.1111/j.1365-2222.1981.tb02180.x; MCFADDEN ER, 1987, CHEST, V91, pS151, DOI 10.1378/chest.91.6.151S; MICHEL L, 1988, J ALLERGY CLIN IMMUN, V82, P101, DOI 10.1016/0091-6749(88)90058-9; MORRIS JF, 1971, AM REV RESPIR DIS, V103, P57; PATEL KR, 1984, BRIT MED J, V288, P1496, DOI 10.1136/bmj.288.6429.1496; PATEL KR, 1987, J ALLERGY CLIN IMMUN, V79, P355, DOI 10.1016/0091-6749(87)90155-2; PHIPPS RJ, 1985, BRONCHIAL ASTHMA MEC, P741; PLATSHON LF, 1978, J CLIN INVEST, V62, P1113, DOI 10.1172/JCI109230; RAFFERTY P, 1987, AM REV RESPIR DIS, V136, P369, DOI 10.1164/ajrccm/136.2.369; RAFFERTY P, 1987, AM REV RESPIR DIS, V135, P181; RAFFERTY P, 1988, J ALLERGY CLIN IMMUN, V82, P1113, DOI 10.1016/0091-6749(88)90151-0; SEIDEL WF, 1987, ANN ALLERGY, V59, P58; SIMONS FE, 1987, ANN ALLERGY, V59, P20; SIMONS FER, 1988, J ALLERGY CLIN IMMUN, V81, P975, DOI 10.1016/0091-6749(88)90164-9; SNYDER SH, 1987, ANN ALLERGY, V59, P4; TASHKIN DP, 1987, ANN ALLERGY, V59, P49; TOWNLEY RJ, 1987, J ALLERGY CLIN IMMUN, V80, P111, DOI 10.1016/0091-6749(87)90116-3; UNGERER RG, 1981, J ALLERGY CLIN IMMUN, V68, P471, DOI 10.1016/0091-6749(81)90201-3; WOOD SG, 1987, ANN ALLERGY, V59, P31; ZAMEL N, 1983, CHEST, V83, P35, DOI 10.1378/chest.83.1.35; 1975, POLLEN GUIDE ALLERGY; 1984, UCB PO71 INVESTIGATO	47	22	22	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1990	85	3					632	641		10.1016/0091-6749(90)90104-C	http://dx.doi.org/10.1016/0091-6749(90)90104-C			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CU668	1968919				2022-12-18	WOS:A1990CU66800015
J	NELSON, DR; COLLINS, AM; HELLMICH, RL; JONES, RT; HELM, RM; SQUILLACE, DL; YUNGINGER, JW				NELSON, DR; COLLINS, AM; HELLMICH, RL; JONES, RT; HELM, RM; SQUILLACE, DL; YUNGINGER, JW			BIOCHEMICAL AND IMMUNOCHEMICAL COMPARISON OF AFRICANIZED AND EUROPEAN HONEYBEE VENOMS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO CLIN & MAYO FDN,ALLERG DIS RES LAB,406 GUGGENHEIM BLDG,ROCHESTER,MN 55905; USDA ARS,HONEYBEE BREEDING GENET & PHYSIOL,BATON ROUGE,LA; MAYO CLIN & MAYO GRAD SCH MED,DEPT PEDIAT,ROCHESTER,MN 55901; MAYO CLIN & MAYO GRAD SCH MED,DEPT INTERNAL MED ALLERGY,ROCHESTER,MN 55901; MAYO CLIN & MAYO GRAD SCH MED,DEPT IMMUNOL,ROCHESTER,MN 55901	Mayo Clinic; United States Department of Agriculture (USDA); Mayo Clinic; Mayo Clinic; Mayo Clinic					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021398] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-21398] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adolphson C. R., 1986, MANUAL CLIN LABORATO, P652; ANDERSON MC, 1983, RAST INHIBITION PROC; [Anonymous], BIOGEOGRAPHY TAXONOM, DOI DOI 10.1007/978-3-642-72649-1; BENTON AW, 1963, SCIENCE, V142, P228, DOI 10.1126/science.142.3589.228; CAMAZINE S, 1988, AM SCI, V76, P465; COLLINS AM, 1982, SCIENCE, V218, P72, DOI 10.1126/science.218.4567.72; FRANKLIN R, 1975, J ALLERGY CLIN IMMUN, V55, P285, DOI 10.1016/0091-6749(75)90001-9; GLEICH GJ, 1980, J ALLERGY CLIN IMMUN, V65, P20, DOI 10.1016/0091-6749(80)90172-4; Kerr W.E., 1967, S AFR BEE J, V39, P3; KING TP, 1976, ARCH BIOCHEM BIOPHYS, V172, P661, DOI 10.1016/0003-9861(76)90121-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARSH DG, 1986, B WORLD HEALTH ORGAN, V64, P767; PAULL BR, 1977, J ALLERGY CLIN IMMUN, V59, P334, DOI 10.1016/0091-6749(77)90056-2; RICHMAN PG, 1988, J BIOL STAND, V16, P225, DOI 10.1016/0092-1157(88)90010-8; SCHUMACHER MJ, 1989, NATURE, V337, P413, DOI 10.1038/337413a0; TAYLOR OR, 1977, BEE WORLD, V58, P19, DOI 10.1080/0005772X.1977.11097632; VILLA JD, 1988, ANN BEE J, V128, P799; Winston, 1987, BIOL HONEYBEE	18	22	22	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1990	85	1	1				80	85		10.1016/0091-6749(90)90225-S	http://dx.doi.org/10.1016/0091-6749(90)90225-S			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CM378	2299109				2022-12-18	WOS:A1990CM37800013
J	WOOLCOCK, AJ				WOOLCOCK, AJ			USE OF CORTICOSTEROIDS IN TREATMENT OF PATIENTS WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review											WOOLCOCK, AJ (corresponding author), UNIV SYDNEY,ROYAL PRINCE ALBERT HOSP,DEPT THORAC MED,SYDNEY 2050,AUSTRALIA.							BHAGAT RG, 1985, AM REV RESPIR DIS, V131, P902; BURGE PS, 1982, CLIN ALLERGY, V12, P523, DOI 10.1111/j.1365-2222.1982.tb02551.x; CAMERON SJ, 1973, BRIT MED J, V4, P205, DOI 10.1136/bmj.4.5886.205; DAHL R, 1982, EUR J RESPIR DIS, V63, P167; EASTON JG, 1981, J ALLERGY CLIN IMMUN, V67, P388, DOI 10.1016/0091-6749(81)90084-1; FANTA CH, 1983, AM J MED, V74, P845, DOI 10.1016/0002-9343(83)91076-8; FIEL SB, 1983, AM J MED, V75, P259, DOI 10.1016/0002-9343(83)91202-0; HARTLEY JPR, 1984, THORAX, V39, P706; KRAAN J, 1985, J ALLERGY CLIN IMMUN, V76, P628, DOI 10.1016/0091-6749(85)90786-9; MATTOLI S, 1985, J ALLERGY CLIN IMMUN, V76, P214, DOI 10.1016/0091-6749(85)90704-3; RYAN G, 1985, J ALLERGY CLIN IMMUN, V75, P25, DOI 10.1016/0091-6749(85)90007-7; SOTOMAYOR H, 1984, AM REV RESPIR DIS, V130, P56; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760; 1976, BR J DIS CHEST, V70, P95; 1979, BR J DIS CHEST, V73, P121	15	22	22	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1989	84	6	1				975	978		10.1016/0091-6749(89)90397-7	http://dx.doi.org/10.1016/0091-6749(89)90397-7			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CG293	2689498				2022-12-18	WOS:A1989CG29300018
J	CASTELLANOS, J; AXELROD, D				CASTELLANOS, J; AXELROD, D			FLEXIBLE FIBEROPTIC RHINOSCOPY IN THE DIAGNOSIS OF SINUSITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MT CARMEL MERCY HOSP,DEPT MED,RHEUMATOL SECT,6071 W OUTER DR,DETROIT,MI 48235; MT CARMEL MERCY HOSP,DEPT MED,ALLERGY SECT,DETROIT,MI 48235; MT CARMEL MERCY HOSP,DEPT INTERNAL MED,DETROIT,MI 48235									EVANS FO, 1975, NEW ENGL J MED, V293, P735, DOI 10.1056/NEJM197510092931502; FORBES WSC, 1978, CLIN RADIOL, V29, P501, DOI 10.1016/S0009-9260(78)80037-3; KIM H N, 1985, Yonsei Medical Journal, V26, P59; LEVINE H, 1978, ARCH OTOLARYNGOL, V104, P585; LEW D, 1983, NEW ENGL J MED, V309, P1149, DOI 10.1056/NEJM198311103091904; ROHR A, 1983, ANN ALLERGY, V50, P380; SELNER JC, 1985, ANN ALLERGY, V54, P479; SHAPIRO GG, 1986, J ALLERGY CLIN IMMUN, V77, P59, DOI 10.1016/0091-6749(86)90324-6	8	22	23	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1989	83	1					91	94		10.1016/0091-6749(89)90481-8	http://dx.doi.org/10.1016/0091-6749(89)90481-8			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T0419	2913140				2022-12-18	WOS:A1989T041900012
J	HORNER, WE; IBANEZ, MD; LIENGSWANGWONG, V; SALVAGGIO, JE; LEHRER, SB				HORNER, WE; IBANEZ, MD; LIENGSWANGWONG, V; SALVAGGIO, JE; LEHRER, SB			CHARACTERIZATION OF ALLERGENS FROM SPORES OF THE OYSTER MUSHROOM, PLEUROTUS-OSTREATUS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									TULANE UNIV,SCH MED,DEPT MED,CLIN IMMUNOL SECT,NEW ORLEANS,LA 70112	Tulane University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007376] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020331] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07376] Funding Source: Medline; NIAID NIH HHS [AI 20331] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALEXOPOULAS CJ, 1979, INTRO MYCOLOGY, P587; BURGE HA, 1985, CLIN REV ALLERG, V3, P319, DOI 10.1007/BF02992998; BUSH RK, 1987, CLIN REV ALLERG, V5, P3; BUTCHER BT, 1987, J ALLERGY CLIN IMMUN, V80, P803, DOI 10.1016/S0091-6749(87)80269-5; DAVIS WE, 1988, J CLIN ALLERGY, V18, P261; DEMEULEMESTER C, 1987, ELECTROPHORESIS, V8, P71, DOI 10.1002/elps.1150080113; HASNAIN SM, 1985, NEW ZEAL MED J, V98, P342; HASNAIN SM, 1985, NEW ZEAL MED J, V98, P393; HERXHEIMER H, 1969, LANCET, V2, P131; IBANEZ MD, 1988, J ALLERGY CLIN IMMUN, V82, P787, DOI 10.1016/0091-6749(88)90080-2; KENDRICK B, 1985, 5TH KINGDOM, P317; KING TP, 1974, IMMUNOCHEMISTRY, V11, P83, DOI 10.1016/0019-2791(74)90321-8; LEHRER SB, 1986, J ALLERGY CLIN IMMUN, V78, P478, DOI 10.1016/0091-6749(86)90036-9; LEHRER SB, 1983, CLIN CHEST MED, V4, P23; LIENGSWANGWONG V, 1987, CLIN ALLERGY, V17, P191, DOI 10.1111/j.1365-2222.1987.tb02003.x; LOPEZ M, 1976, J ALLERGY CLIN IMMUN, V57, P480, DOI 10.1016/0091-6749(76)90064-6; PADY SM, 1967, J ALLERGY, V39, P302, DOI 10.1016/0021-8707(67)90094-9; SALVAGGIO J, 1981, J ALLERGY CLIN IMMUN, V68, P327, DOI 10.1016/0091-6749(81)90131-7; SALVAGGIO J, 1971, J ALLERGY CLIN IMMUN, V48, P82, DOI 10.1016/0091-6749(71)90090-X; SANTILLI J, 1985, ANN ALLERGY, V55, P469; TARLO SM, 1979, J ALLERGY CLIN IMMUN, V64, P43, DOI 10.1016/0091-6749(79)90082-4	21	22	22	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1988	82	6					978	986						9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	R6311	3204256				2022-12-18	WOS:A1988R631100005
J	RAFFERTY, P; HARRISON, PJ; AURICH, R; HOLGATE, ST				RAFFERTY, P; HARRISON, PJ; AURICH, R; HOLGATE, ST			THE INVIVO POTENCY AND SELECTIVITY OF AZELASTINE AS AN H-1 HISTAMINE-RECEPTOR ANTAGONIST IN HUMAN AIRWAYS AND SKIN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ADVISORY SERV LTD,LONDON,ENGLAND; DEGUSSA PHARMA GRP,FRANKFURT,FED REP GER	Evonik Industries	RAFFERTY, P (corresponding author), SOUTHAMPTON GEN HOSP,IMMUNOPHARMACOL GRP,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND.							ALBAZZAZ MK, 1987, THORAX, V42, P724; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CHAND N, 1983, J ALLERGY CLIN IMMUN, V71, P149, DOI 10.1016/0091-6749(83)90365-2; CHAND N, 1983, EUR J PHARMACOL, V96, P227, DOI 10.1016/0014-2999(83)90311-4; DAHLEN SE, 1980, NATURE, V288, P484, DOI 10.1038/288484a0; DIAMANTIS W, 1984, Federation Proceedings, V43, P614; DIAMANTIS W, 1982, PHARMACOLOGIST, V24, P200; FIELDS DAS, 1984, J ALLERGY CLIN IMMUN, V73, P400, DOI 10.1016/0091-6749(84)90415-9; FIELDS DAS, 1981, PHARMACOLOGIST, V23, P161; KATAYAMA S, 1981, ARZNEIMITTEL-FORSCH, V31-2, P1196; KEMP JP, 1987, J ALLERGY CLIN IMMUN, V79, P893, DOI 10.1016/0091-6749(87)90238-7; LAUDRON PM, 1982, MOL PHARMACOL, V21, P294; LITTLE MM, IN PRESS J ALLERGY C; NORGRADY SG, 1978, THORAX, V33, P479; OLLIER S, 1986, J ALLERGY CLIN IMMUN, V78, P358, DOI 10.1016/S0091-6749(86)80090-2; POPA VT, 1980, CHEST, V78, P442, DOI 10.1378/chest.78.3.442; POPA VT, 1977, J ALLERGY CLIN IMMUN, V59, P54, DOI 10.1016/0091-6749(77)90177-4; RAFFERTY P, 1987, AM REV RESPIR DIS, V136, P369, DOI 10.1164/ajrccm/136.2.369; RAFFERTY P, 1987, AM REV RESPIR DIS, V135, P181; SPECTOR SL, 1987, J ALLERGY CLIN IMMUN, V80, P75, DOI 10.1016/S0091-6749(87)80194-X; STORMS W, 1985, J ALLERGY CLIN IMMUN, V75, P167, DOI 10.1016/0091-6749(85)90386-0; TANIGAWA T, 1981, ARZNEIMITTEL-FORSCH, V31-2, P1212; ZECHEL HJ, 1981, ARZNEIMITTEL-FORSCH, V31-2, P1184	23	22	25	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1988	82	6					1113	1118		10.1016/0091-6749(88)90151-0	http://dx.doi.org/10.1016/0091-6749(88)90151-0			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	R6311	2904931				2022-12-18	WOS:A1988R631100022
J	SPRENGER, JD; ALTMAN, LC; ONEIL, CE; AYARS, GH; BUTCHER, BT; LEHRER, SB				SPRENGER, JD; ALTMAN, LC; ONEIL, CE; AYARS, GH; BUTCHER, BT; LEHRER, SB			PREVALENCE OF BASIDIOSPORE ALLERGY IN THE PACIFIC NORTHWEST	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WASHINGTON,DEPT MED,DIV ALLERGY & INFECT DIS,RM 13,SEATTLE,WA 98105; TULANE UNIV,MED CTR,DEPT MED,CLIN IMMUNOL SECT,NEW ORLEANS,LA 70118	University of Washington; University of Washington Seattle; Tulane University					NHLBI NIH HHS [HL 32621] Funding Source: Medline; NIAID NIH HHS [AI 20331] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R23HL032621] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020331] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BIGELOW HE, 1979, MUSHROOM POCKET FIEL; BUTCHER BT, 1987, J ALLERGY CLIN IMMUN, V80, P803, DOI 10.1016/S0091-6749(87)80269-5; CESKA M, 1972, IMMUNOCHEMISTRY, V9, P1021, DOI 10.1016/0019-2791(72)90112-7; GIANNINI EH, 1975, ANN ALLERGY, V35, P372; GILBERTSON RL, 1986, N AM POLYPORES, V1, P356; GREGORY PH, 1957, J GEN MICROBIOL, V17, P135, DOI 10.1099/00221287-17-1-135; HASNAIN SM, 1985, NEW ZEAL MED J, V98, P393; HERXHEIMER H, 1969, LANCET, V2, P131; HYDE H. A., 1960, ACTA ALLERGOL, V15, P159; KARR RM, 1981, J ALLERGY CLIN IMMUN, V67, P194, DOI 10.1016/0091-6749(81)90061-0; LEHRER SB, 1986, J ALLERGY CLIN IMMUN, V78, P478, DOI 10.1016/0091-6749(86)90036-9; LEHRER SB, 1983, CLIN CHEST MED, V4, P23; LOPEZ M, 1976, J ALLERGY CLIN IMMUN, V57, P480, DOI 10.1016/0091-6749(76)90064-6; LOPEZ M, 1987, J ALLERGY CLIN IMMUN, V79, P207; ONEIL CE, 1988, INT ARCH ALLER A IMM, V85, P161, DOI 10.1159/000234496; SALVAGGIO J, 1971, J ALLERGY CLIN IMMUN, V48, P96, DOI 10.1016/0091-6749(71)90091-1; SALVAGGIO JE, 1981, J ALLERGY CLIN IMMUN, V68, P237; SANTILLI J, 1985, ANN ALLERGY, V55, P469; WEISSMAN DN, 1987, INT ARCH ALLER A IMM, V84, P56, DOI 10.1159/000234398	19	22	23	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1988	82	6					1076	1080		10.1016/0091-6749(88)90146-7	http://dx.doi.org/10.1016/0091-6749(88)90146-7			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	R6311	3204251				2022-12-18	WOS:A1988R631100017
J	CHANAL, I; HORST, M; SEGALEN, C; DREBORG, S; MICHEL, FB; BOUSQUET, J				CHANAL, I; HORST, M; SEGALEN, C; DREBORG, S; MICHEL, FB; BOUSQUET, J			COMPARISON BETWEEN MODIFIED SKIN PRICK TEST WITH STANDARDIZED ALLERGEN EXTRACTS AND PHAZET	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CHU MONTPELLIER,MALAD RESP CLIN,AVE MAJOR FLANDRE,F-34059 MONTPELLIER,FRANCE; LABS PHARM,BOIS DARCY,FRANCE; PHARMACIA DIAGNOST AB,UPPSALA,SWEDEN	Universite de Montpellier; CHU de Montpellier; Pfizer; Pharmacia Corporation			Bousquet, Jean/O-4221-2019					ARGAWAL MK, 1982, J ALLERGY CLIN IMMUN, V70, P432; BELIN L, 1987, 4TH P INT P EHRL SEM, P145; BELIN L, 1985, ALLERGY S4, V40, P60; BOUSQUET J, 1985, J ALLERGY CLIN IMMUN, V76, P734, DOI 10.1016/0091-6749(85)90680-3; BOUSQUET J, 1985, CLIN ALLERGY, V15, P29, DOI 10.1111/j.1365-2222.1985.tb02251.x; BOUSQUET J, 1988, ALLERGY PRINCIPLES P, V1, P419; DIDIERLAURENT A, 1984, INT ARCH ALLER A IMM, V73, P27, DOI 10.1159/000233433; DREBORG S, 1987, THESIS LINKOPING; EINARSSON R, 1987, 4TH P INT P EHRL SEM, P131; FALTHMAGNUSSON K, IN PRESS ALLERGY; Galen RS, 1975, PREDICT VALUE EFFIC; HOLGERSSON M, 1985, ALLERGY S4, V40, P64; HORST M, IN PRESS CLIN ALLERG; MALLING HJ, 1985, ALLERGY, V40, P354, DOI 10.1111/j.1398-9995.1985.tb00247.x; MICHEL FB, 1986, J ALLERGY CLIN IMMUN, V77, P222; Pepys J., 1975, BR J HOSP MED, V14, P412; Pepys J, 1985, 12 INT C ALL CLIN IM; PETERSSON G, 1986, ALLERGY, V41, P398, DOI 10.1111/j.1398-9995.1986.tb00319.x; UHLIN T, 1984, ALLERGY, V39, P125, DOI 10.1111/j.1398-9995.1984.tb01944.x; VOORHORST R, 1973, ANN ALLERGY, V31, P195	20	22	22	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1988	82	5	1				878	881		10.1016/0091-6749(88)90093-0	http://dx.doi.org/10.1016/0091-6749(88)90093-0			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	R1708	3192871				2022-12-18	WOS:A1988R170800024
J	FIREMAN, P				FIREMAN, P			OTITIS-MEDIA AND NASAL DISEASE - A ROLE FOR ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV PITTSBURGH,SCH MED,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	FIREMAN, P (corresponding author), CHILDRENS HOSP PITTSBURGH,DIV ALLERGY IMMUNOL & RHEUMATOL,PITTSBURGH,PA 15213, USA.							ACKERMAN MN, 1984, J ALLERGY CLIN IMMUN, V73, P604, DOI 10.1016/0091-6749(84)90519-0; BERNSTEIN JM, 1983, AM J OTOL, V5, P66; CANTEKIN EI, 1983, NEW ENGL J MED, V308, P297, DOI 10.1056/NEJM198302103080601; DOYLE WJ, 1985, ARCH OTOLARYNGOL, V111, P502; DOYLE WJ, 1985, J ALLERGY CLIN IMMUN, V76, P551, DOI 10.1016/0091-6749(85)90774-2; DOYLE WJ, 1980, ANN OTOL RHINOL LARY, V89, P4146; FIREMAN P, 1983, J ALLERGY CLIN IMMUN, V71, P155, DOI 10.1016/0091-6749(83)90390-1; FIREMAN P, 1987, IMMUNOL ALLERGY CLIN, V7, P133; FRIEDMAN PA, 1983, J ALLERGY CLIN IMMUN, V71, P442; MIGLETS A, 1973, LARYNGOSCOPE, V83, P1355, DOI 10.1288/00005537-197309000-00001; SKONER DP, 1986, ARCH OTOLARYNGOL, V112, P840; SKONER DP, 1987, J ALLERGY CLIN IMMUN, V79, P27, DOI 10.1016/S0091-6749(87)80012-X; TEELE DW, 1980, ANN OTO RHINOL LARYN, V89, P5, DOI 10.1177/00034894800890S304; WALKER SB, 1985, J ALLERGY CLIN IMMUN, V76, P158, DOI 10.1016/0091-6749(85)90694-3; YAMASHITA T, 1980, ANN OTO RHINOL LARYN, V89, P147, DOI 10.1177/00034894800890S337	15	22	22	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1988	82	5	2	S			917	926		10.1016/0091-6749(88)90034-6	http://dx.doi.org/10.1016/0091-6749(88)90034-6			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	R2353	3057044				2022-12-18	WOS:A1988R235300005
J	SHERMAN, MS; LAZAR, EJ; EICHACKER, P				SHERMAN, MS; LAZAR, EJ; EICHACKER, P			A BRONCHODILATOR ACTION OF GLUCAGON	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MONTEFIORE MED CTR,BRONX,NY 10467	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	SHERMAN, MS (corresponding author), BRONX MUNICIPAL HOSP CTR,N CENT BRONX HOSP,ALBERT EINSTEIN COLL MED,DEPT MED,DIV PULM,BRONX,NY 10467, USA.							BOND JH, 1980, AM J PHYSIOL, V238, pG434, DOI 10.1152/ajpgi.1980.238.5.G434; el-Naggar M, 1974, Crit Care Med, V2, P82; FAIN JN, 1982, HDB EXPT PHARM, V58, P89; FARAH A, 1960, J PHARMACOL EXP THER, V129, P49; FRISHMAN W, 1979, AM HEART J, V98, P798, DOI 10.1016/0002-8703(79)90480-0; HARRIES AD, 1981, BRIT MED J, V282, P1321, DOI 10.1136/bmj.282.6272.1321-b; MADDEN JJ, 1971, AM J SURG, V122, P85, DOI 10.1016/0002-9610(71)90355-2; MUGER BL, 1972, GLUCAGON, P7; MURAD F, 1974, AM REV RESPIR DIS, V110, P111; PERSSON CGA, 1982, ARCH INT PHARMACOD T, V258, P267; RAINE JM, 1981, BRIT MED J, V282, P548, DOI 10.1136/bmj.282.6263.548; STAUB A, 1957, P SOC EXP BIOL MED, V94, P57; 1962, AM REV RESPIR DIS, V86, P762	13	22	22	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1988	81	5	1				908	911		10.1016/0091-6749(88)90949-9	http://dx.doi.org/10.1016/0091-6749(88)90949-9			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	N7036	3372910				2022-12-18	WOS:A1988N703600021
J	HELM, RM; SQUILLACE, DL; YUNGINGER, JW				HELM, RM; SQUILLACE, DL; YUNGINGER, JW			PRODUCTION OF A PROPOSED INTERNATIONAL REFERENCE-STANDARD ALTERNARIA EXTRACT .2. RESULTS OF A COLLABORATIVE TRIAL	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO CLIN & MAYO FDN,ALLERGEN RESOURCE REFERENCE LAB,ROCHESTER,MN 55905; MAYO MED SCH,DEPT IMMUNOL,ROCHESTER,MN 55901; MAYO MED SCH,DEPT PEDIAT,ROCHESTER,MN 55901; MAYO MED SCH,DEPT INTERNAL MED ALLERGY,ROCHESTER,MN 55901	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI016791, N01AI012675] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-16791, AI-12675] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON MC, 1986, RAST INHIBITION PROC; AUKRUST L, 1981, EUR ACAD ALLERGY CLI, V2, P1050; AXELSEN NH, 1983, SCAND J IMMUNOL S10, V17, P103; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; FORD A, 1985, J ALLERGY CLIN IMMUN, V75, P676, DOI 10.1016/0091-6749(85)90093-4; GJESING B, 1985, J ALLERGY CLIN IMMUN, V75, P258, DOI 10.1016/0091-6749(85)90055-7; HEINRIKSON RL, 1984, ANAL BIOCHEM, V136, P65, DOI 10.1016/0003-2697(84)90307-5; HELM RM, 1987, INT ARCH ALLER A IMM, V82, P178, DOI 10.1159/000234184; HELM RM, 1984, J ALLERGY CLIN IMMUN, V73, P790, DOI 10.1016/0091-6749(84)90449-4; HORDLE DA, 1984, J IMMUNOL METHODS, V75, P369, DOI 10.1016/0022-1759(84)90121-2; Kirkwood TBL, 1979, BIOMETRICS, V35, P908; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lowenstein H, 1978, Prog Allergy, V25, P1, DOI 10.1159/000314432; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Norman P, 1986, MANUAL CLIN LABORATO, P660; NYHOLM L, 1983, J ALLERGY CLIN IMMUN, V71, P461, DOI 10.1016/0091-6749(83)90462-1; REIMER CB, 1978, J BIOL STAND, V6, P133, DOI 10.1016/S0092-1157(78)80045-6; SPACKMAN DH, 1958, ANAL CHEM, V30, P1190, DOI 10.1021/ac60139a006; STERINGER I, 1987, INT ARCH ALLER A IMM, V84, P190, DOI 10.1159/000234422; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEINSTEIN D, 1976, ANAL BIOCH, V70, P241; Yman L, 1975, Dev Biol Stand, V29, P151; YUNGINGER JW, 1980, J ALLERGY CLIN IMMUN, V66, P138, DOI 10.1016/0091-6749(80)90061-5; 1978, WHO TECH REP SER, V626	25	22	24	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1988	81	4					651	663		10.1016/0091-6749(88)91035-4	http://dx.doi.org/10.1016/0091-6749(88)91035-4			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	N0650	3356846	Bronze			2022-12-18	WOS:A1988N065000004
J	RUHNO, J; DENBURG, J; DOLOVICH, J				RUHNO, J; DENBURG, J; DOLOVICH, J			INTRANASAL NEDOCROMIL SODIUM IN THE TREATMENT OF RAGWEED-ALLERGIC RHINITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MCMASTER UNIV, MED CTR, DEPT PEDIAT, ROOM 3V41, 1200 MAIN ST W, HAMILTON L8N 3Z5, ONTARIO, CANADA; MCMASTER UNIV, MED CTR, DEPT MED, HAMILTON L8N 3Z5, ONTARIO, CANADA	McMaster University; McMaster University								BROWN H M, 1974, Clinical Allergy, V4, P331, DOI 10.1111/j.1365-2222.1974.tb01394.x; COCKCROFT DW, 1976, CAN MED ASSOC J, V115, P523; DAHL R, 1985, 4TH P C EUR SOC PNEU, P65; FYANS PG, 1986, CLIN ALLERGY, V16, P505, DOI 10.1111/j.1365-2222.1986.tb01988.x; JUNIPER EF, 1981, CLIN ALLERGY, V11, P61, DOI 10.1111/j.1365-2222.1981.tb01567.x; MYGIND N, 1973, BRIT MED J, V4, P464, DOI 10.1136/bmj.4.5890.464; OKUDA M, 1985, ANN ALLERGY, V55, P721; ORR TSC, 1986, ASTHMA CLIN PHARM TH, P265; OTSUKA H, 1985, J ALLERGY CLIN IMMUN, V76, P695, DOI 10.1016/0091-6749(85)90673-6; ROBERTS JA, 1985, CLIN ALLERGY, V15, P377, DOI 10.1111/j.1365-2222.1985.tb03006.x; SHAW RJ, 1985, BRIT J DIS CHEST, V79, P385, DOI 10.1016/0007-0971(85)90073-7; YOUNGCHAIYUD P, 1986, CLIN ALLERGY, V16, P129, DOI 10.1111/j.1365-2222.1986.tb00756.x	12	22	22	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1988	81	3					557	563		10.1016/0091-6749(88)90196-0	http://dx.doi.org/10.1016/0091-6749(88)90196-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M6181					2022-12-18	WOS:A1988M618100012
J	PATTERSON, R				PATTERSON, R			DIAGNOSIS AND TREATMENT OF DRUG ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,CHICAGO,IL 60611	Northwestern University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 11403] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		COOMBS RRA, 1975, CLIN ASPECTS IMMUNOL; DESWARTE RD, 1985, ALLERGIC DISEASES, P505; GRAMMER LC, IN PRESS CLIN ORTHOP; GREENBERGER PA, 1985, ARCH INTERN MED, V145, P2197, DOI 10.1001/archinte.145.12.2197; GREENBERGER PA, IN PRESS PROG CARDIO; HENDRIX S, 1981, J ALLERGY CLIN IMMUN, V67, P8, DOI 10.1016/0091-6749(81)90038-5; PATTERSON R, 1983, J ALLERGY CLIN IMMUN, V71, P604, DOI 10.1016/0091-6749(83)90443-8; PATTERSON R, 1973, Journal of Immunology, V110, P1135; PATTERSON R, 1986, NEW ENGL REG ALLERGY, V7, P325; SALE SR, 1982, INT ARCH ALLER A IMM, V67, P329, DOI 10.1159/000233042; SOGN DD, 1983, J ALLERGY CLIN IMMUN, V71, P147, DOI 10.1016/0091-6749(83)90358-5; VANARSDEL PP, 1983, ALLERGY PRINCIPLES P, V2, P1389	12	22	22	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1988	81	2					380	384		10.1016/0091-6749(88)90905-0	http://dx.doi.org/10.1016/0091-6749(88)90905-0			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M0993	3276764	Bronze			2022-12-18	WOS:A1988M099300003
J	ZIMMERMAN, B; CHAMBERS, C; FORSYTH, S				ZIMMERMAN, B; CHAMBERS, C; FORSYTH, S			ALLERGY IN ASTHMA .2. THE HIGHLY ATOPIC INFANT AND CHRONIC ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HOSP SICK CHILDREN,RES CTR,DEPT PEDIAT,TORONTO M5G 1X8,ONTARIO,CANADA; UNIV TORONTO,DEPT IMMUNOL,TORONTO M5S 1A1,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	ZIMMERMAN, B (corresponding author), HOSP SICK CHILDREN,DIV ALLERGY,555 UNIV AVE,TORONTO M5G 1X8,ONTARIO,CANADA.							Coca AF, 1923, J IMMUNOL, V8, P163; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; FISER PM, 1979, J IMMUNOL, V123, P1788; FOUCARD T, 1973, ACTA PAEDIATR SCAND, V62, P633, DOI 10.1111/j.1651-2227.1973.tb17078.x; KEMP A, 1984, AUST PAEDIATR J, V20, P161; LEUNG DYM, 1986, J CLIN IMMUNOL, V6, P273, DOI 10.1007/BF00917327; LOWHAGEN O, 1985, J ALLERGY CLIN IMMUN, V75, P460, DOI 10.1016/S0091-6749(85)80018-X; MARTIN AJ, 1982, AUST PAEDIATR J, V18, P84; MCNICHOL KN, 1973, BRIT MED J, V4, P12, DOI 10.1136/bmj.4.5883.12; MCNICOL KN, 1983, BRIT MED J, V4, P7; NELSON HS, 1985, ANN ALLERGY, V551, P441; Pepys J., 1975, , Clinical aspects of immunology., P877; PHILLIPS L, 1987, J ALLERGY CLIN IMMUN, V79, P933, DOI 10.1016/0091-6749(87)90243-0; RICCI M, 1985, INT ARCH ALLER A IMM, V77, P32, DOI 10.1159/000233749; ROMAGNANI S, 1985, INT ARCH ALLER A IMM, V76, P34, DOI 10.1159/000233733; SOTOMAYOR H, 1984, AM REV RESPIR DIS, V130, P56; UMETSU DT, 1985, J EXP MED, V162, P202, DOI 10.1084/jem.162.1.202; ZEIGER RS, 1986, J ALLERGY CLIN IMMUN, V78, P224, DOI 10.1016/0091-6749(86)90016-3; ZIMMERMAN B, 1986, J ALLERGY CLIN IMMUN, V77, P70, DOI 10.1016/0091-6749(86)90326-X; ZIMMERMAN B, 1988, J ALLERGY CLIN IMMUN, V81, P63, DOI 10.1016/0091-6749(88)90221-7	20	22	22	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1988	81	1					71	77		10.1016/0091-6749(88)90222-9	http://dx.doi.org/10.1016/0091-6749(88)90222-9			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M0274	3339193				2022-12-18	WOS:A1988M027400011
J	CREER, TL				CREER, TL			SELF-MANAGEMENT IN THE TREATMENT OF CHILDHOOD ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											CREER, TL (corresponding author), OHIO UNIV,DEPT PSYCHOL,ATHENS,OH 45701, USA.							Averill B.A., 1980, CIENC BIOL COIMBRA, V5, P167; BANDURA A, 1986, SOCIAL F THOUGHT ACT; Bandura A., 1977, SOCIAL LEARNING THEO; BAUM D, 1986, J ASTHMA, V23, P49, DOI 10.3109/02770908609077475; CALIFANO JA, 1986, AM HLTH CARE REVOLUT; CREER TL, 1983, J ALLERGY CLIN IMMUN, V72, P607, DOI 10.1016/0091-6749(83)90488-8; CREER TL, IN PRESS HLTH ED Q; CREER TL, IN PRESS ADV BEHAVIO, V6; CREER TL, 1986, J RESP DIS       OCT, P27; CREER TL, 1987, CHILDHOOD ASTHMA PSY; GREENHOUSE S, 1986, NY TIMES        0824; HINDIALEXANDER MC, 1984, J ALLERGY CLIN IMMUN, V74, P505, DOI 10.1016/0091-6749(84)90386-5; Kimble GA., 1961, HILGARD MARQUIS COND; Levin L. S., 1979, SELF CARE LAY INITIA; MARION RJ, 1983, J ASTHMA, V20, P183, DOI 10.3109/02770908309114942; MISCHEL W, 1986, INTRO PERSONALITY NE; RENNE CM, 1976, J APPL BEHAV ANAL, V9, P1, DOI 10.1901/jaba.1976.9-1; SKINNER BF, 1953, SCI HUMAN BEHAVIOR; SNYDER S, IN PRESS J ASTHMA; THORESEN CE, 1983, J ALLERGY CLIN IMMUN, V72, P596, DOI 10.1016/0091-6749(83)90487-6; [No title captured], DOI DOI 10.1037/H0092976	21	22	22	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1987	80	3	2	S			500	505		10.1016/0091-6749(87)90086-8	http://dx.doi.org/10.1016/0091-6749(87)90086-8			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K1037	3624707				2022-12-18	WOS:A1987K103700033
J	STRUNK, RC				STRUNK, RC			WORKSHOP ON THE IDENTIFICATION OF THE FATALITY-PRONE PATIENT WITH ASTHMA - SUMMARY OF WORKSHOP DISCUSSION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material																			0	22	22	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1987	80	3	2	S			455	457		10.1016/0091-6749(87)90073-X	http://dx.doi.org/10.1016/0091-6749(87)90073-X			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K1037					2022-12-18	WOS:A1987K103700022
J	GRAMMER, LC; SHAUGHNESSY, MA; BERNHARD, MI; FINKLE, SM; PYLE, HR; SILVESTRI, L; PATTERSON, R				GRAMMER, LC; SHAUGHNESSY, MA; BERNHARD, MI; FINKLE, SM; PYLE, HR; SILVESTRI, L; PATTERSON, R			THE SAFETY AND ACTIVITY OF POLYMERIZED RAGWEED - A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL IN 81 PATIENTS WITH RAGWEED RHINITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									KEY PHARMACEUT INC,MIAMI,FL; NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,CHICAGO,IL 60611	Northwestern University				Grammer, Leslie/0000-0001-6860-2014	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 11403] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BACAL E, 1978, J ALLERGY CLIN IMMUN, V62, P289, DOI 10.1016/0091-6749(78)90160-4; Freeman J, 1911, LANCET, V2, P814; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P261, DOI 10.1016/0091-6749(82)90062-8; GRAMMER LC, 1985, J ALLERGY CLIN IMMUN, V76, P123, DOI 10.1016/0091-6749(85)90815-2; GRAMMER LC, 1982, J ALLERGY CLIN IMMUN, V69, P494, DOI 10.1016/0091-6749(82)90173-7; HENDRIX S, 1980, J ALLERGY CLIN IMMUN, V65, P57, DOI 10.1016/0091-6749(80)90177-3; HENDRIX SG, 1980, J ALLERGY CLIN IMMUN, V66, P486, DOI 10.1016/0091-6749(80)90010-X; LEVY DA, 1980, REGULATORY CONTROL S, P178; LICHTENSTEIN LM, 1971, ANN INTERN MED, V75, P663, DOI 10.7326/0003-4819-75-5-663; LIDD D, 1962, J ALLERGY, V33, P45, DOI 10.1016/0021-8707(62)90062-X; LOCKEY R, 1985, J ALLERGY CLIN IMMUN, V75, P166, DOI 10.1016/0091-6749(85)90381-1; NORMAN PS, 1971, IMMUNOLOGIC DISEASES, V2, P840; PARKER CW, 1980, CLIN IMMUNOLOGY, V2, P1372; PATTERSON R, 1978, J ALLERGY CLIN IMMUN, V61, P28, DOI 10.1016/0091-6749(78)90470-0; PATTERSON R, 1983, ALLERGY PRINCIPLES P, V2, P1119; ZEISS CR, 1981, J ALLERGY CLIN IMMUN, V67, P105, DOI 10.1016/0091-6749(81)90004-X; ZEISS CR, 1977, CLIN EXP IMMUNOL, V28, P250	17	22	22	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1987	80	2					177	183		10.1016/0091-6749(87)90127-8	http://dx.doi.org/10.1016/0091-6749(87)90127-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	J6575	3301986				2022-12-18	WOS:A1987J657500009
J	LITTLE, MM; CASALE, TB				LITTLE, MM; CASALE, TB			AZELASTINE INHIBITS BOTH HUMAN-LUNG AND BASOPHIL DEGRANULATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract													Casale, Thomas B/K-4334-2013	Casale, Thomas B/0000-0002-3149-7377					0	22	22	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1987	79	1					204	204						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	F8810					2022-12-18	WOS:A1987F881000342
J	WALKER, WA				WALKER, WA			ALLERGEN ABSORPTION IN THE INTESTINE - IMPLICATION FOR FOOD ALLERGY IN INFANTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MASSACHUSETTS GEN HOSP,COMBINED PROGRAM PEDIAT GASTROENTEROL & NUTR,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	WALKER, WA (corresponding author), CHILDRENS HOSP MED CTR,300 LONGWOOD AVE,BOSTON,MA 02115, USA.							ALLANSMITH M, 1968, J PEDIATR-US, V72, P276, DOI 10.1016/S0022-3476(68)80324-5; AMMANN AJ, 1966, P SOC EXP BIOL MED, V122, P1098, DOI 10.3181/00379727-122-31335; ANTONOWICZ I, 1977, GASTROENTEROLOGY, V72, P1299; BEACH RC, 1982, ARCH DIS CHILD, V57, P141, DOI 10.1136/adc.57.2.141; BLOCH KJ, 1979, GASTROENTEROLOGY, V77, P1039; BRESSON JL, 1980, GASTROENTEROLOGY, V79, P1145; BURGIO GR, 1980, PEDIATR RES, V14, P1111, DOI 10.1203/00006450-198010000-00004; CHANDRA RK, 1979, ACTA PAEDIATR SCAND, V68, P691, DOI 10.1111/j.1651-2227.1979.tb18439.x; CHANDRA RK, 1978, NUTR REV, V36, P265, DOI 10.1111/j.1753-4887.1978.tb07393.x; CHENG H, 1974, AM J ANAT, V141, P461, DOI 10.1002/aja.1001410403; CRANE CW, 1968, DIABETES, V17, P625, DOI 10.2337/diab.17.10.625; CUNNINGHAMRUNDLES C, 1979, J CLIN INVEST, V64, P272, DOI 10.1172/JCI109448; CUNNINGHAMRUNDLES C, 1978, P NATL ACAD SCI USA, V75, P3387, DOI 10.1073/pnas.75.7.3387; DEBOTH NJ, 1975, DIFFERENTIATION, V4, P175, DOI 10.1111/j.1432-0436.1975.tb01456.x; DUCKER DA, 1980, GUT, V21, P133, DOI 10.1136/gut.21.2.133; Etzler ME, 1979, CIBA F S, V70, P51; Gamo I, 1966, Acta Paediatr Jpn, V8, P1; GOLDSTEIN JL, 1979, NATURE, V279, P679, DOI 10.1038/279679a0; GRAND RJ, 1976, GASTROENTEROLOGY, V70, P790; Grulee CG, 1936, J PEDIATR-US, V9, P223, DOI 10.1016/S0022-3476(36)80058-4; HANEBERG B, 1975, CLIN EXP IMMUNOL, V22, P210; HEIRD WC, 1977, PEDIATR RES, V11, P406, DOI 10.1203/00006450-197704000-00224; IYENGAR L, 1972, ARCH DIS CHILD, V47, P411, DOI 10.1136/adc.47.253.411; JAKOBBSON I, 1978, LANCET, V1, P437; KAPLAN J, 1981, SCIENCE, V212, P14, DOI 10.1126/science.6259730; KENNY JF, 1967, PEDIATRICS, V39, P202; KRAEHENBUHL JP, 1969, J CELL BIOL, V42, P345, DOI 10.1083/jcb.42.2.345; Kraft S C, 1967, Clin Exp Immunol, V2, P321; KRAMER MS, 1981, J PEDIATR-US, V98, P546, DOI 10.1016/S0022-3476(81)80757-3; LAKE AM, 1982, J PEDIATR-US, V101, P906, DOI 10.1016/S0022-3476(82)80008-5; Lojda Z, 1974, Biomembranes, V4A, P43; LUST F, 1913, JB KINDERH, V77, P243; OGRA PL, 1979, PEDIATRICS, V64, P765; OGRA SS, 1977, J IMMUNOL, V119, P245; OWEN RL, 1977, GASTROENTEROLOGY, V72, P440; OWEN RL, 1974, GASTROENTEROLOGY, V66, P189, DOI 10.1016/s0016-5085(74)80102-2; QUARONI A, 1980, BIOCHEM J, V192, P133, DOI 10.1042/bj1920133; RASMUSSEN JE, 1978, ALLERGY PRINCIPLES P, V2, P1039; RAUL F, 1977, CELL TISSUE RES, V176, P167; ROBERTON DM, 1982, ARCH DIS CHILD, V57, P369, DOI 10.1136/adc.57.5.369; RODEWALD R, 1970, J CELL BIOL, V45, P635, DOI 10.1083/jcb.45.3.635; RODEWALD R, 1976, MATERNOFOETAL TRANSM, P137; SAARINEN UM, 1979, LANCET, V2, P163; SAARINEN UM, 1980, LANCET, V1, P166; SAFFRAN M, 1979, CAN J BIOCHEM CELL B, V57, P548, DOI 10.1139/o79-069; Schloss OM, 1916, AM J DIS CHILD, V11, P342; SELNER JC, 1968, J PEDIATR-US, V72, P685, DOI 10.1016/S0022-3476(68)80014-9; SILVERSTEIN SC, 1977, ANNU REV BIOCHEM, V46, P669, DOI 10.1146/annurev.bi.46.070177.003321; TOOFANIAN F, 1974, RES VET SCI, V16, P382, DOI 10.1016/S0034-5288(18)33739-1; UDALL JN, 1982, J PEDIATR GASTR NUTR, V1, P295, DOI 10.1097/00005176-198201030-00004; UDALL JN, 1981, PEDIATR RES, V15, P245, DOI 10.1203/00006450-198103000-00009; VUKAVIC T, 1983, J PEDIATR GASTR NUTR, V2, P248, DOI 10.1097/00005176-198302020-00006; Walker W. A., 1981, PHYSL GASTROINTESTIN, P1271; WALKER WA, 1977, NEW ENGL J MED, V297, P767, DOI 10.1056/NEJM197710062971407; WALKER WA, 1974, GASTROENTEROLOGY, V67, P531; WALKER WA, 1983, ANN ALLERGY, V51, P240; WALKER WA, 1975, GASTROENTEROLOGY, V69, P1223; WIDDOWSON EM, 1976, BIOL NEONATE, V28, P272, DOI 10.1159/000240828; ZOPPI G, 1972, PEDIATR RES, V6, P880, DOI 10.1203/00006450-197212000-00005	59	22	24	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1986	78	5	2	S			1003	1009		10.1016/0091-6749(86)90293-9	http://dx.doi.org/10.1016/0091-6749(86)90293-9			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	E9719	3537083				2022-12-18	WOS:A1986E971900014
J	MAGUIRE, JF; GEHA, RS; UMETSU, DT				MAGUIRE, JF; GEHA, RS; UMETSU, DT			MYOCARDIAL SPECIFIC CREATINE-PHOSPHOKINASE ISOENZYME ELEVATION IN CHILDREN WITH ASTHMA TREATED WITH INTRAVENOUS ISOPROTERENOL	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115	Harvard University; Harvard Medical School	MAGUIRE, JF (corresponding author), CHILDRENS HOSP MED CTR,DIV ALLERGY,300 LONGWOOD AVE,BOSTON,MA 02115, USA.				NIAID NIH HHS [K07 AI0440-01] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BIER CB, 1979, J MOL CELL CARDIOL, V11, P961; BIERMAN CW, 1980, ALLERGIC DISEASES IN, P602; BRITTON CV, 1980, CHEST, V77, P758, DOI 10.1378/chest.77.6.758; FIREMAN P, 1983, ALLERGY PRINCIPLES P, P997; GALEN RS, 1975, JAMA-J AM MED ASSOC, V232, P145, DOI 10.1001/jama.232.2.145; GUIDERI G, 1974, CARDIOVASC RES, V8, P775, DOI 10.1093/cvr/8.6.775; HERMAN JJ, 1983, CRIT CARE MED, V11, P716, DOI 10.1097/00003246-198309000-00009; KURLAND G, 1979, J ALLERGY CLIN IMMUN, V63, P407, DOI 10.1016/0091-6749(79)90214-8; LEHR D, 1981, CARDIAC TOXICOLOGY, V2, P75; LOOMIS JC, 1978, ANN M SOC AN, P199; MATSON JR, 1978, J PEDIATR-US, V92, P776, DOI 10.1016/S0022-3476(78)80150-4; NICKLAS RA, 1982, NEW ENGL J MED, V307, P557; PARRY WH, 1976, AM J DIS CHILD, V130, P39, DOI 10.1001/archpedi.1976.02120020041006; RACHELEFSKY GS, 1985, J ALLERGY CLIN IMMUN, V76, P409, DOI 10.1016/0091-6749(85)90718-3; RONA G, 1959, ARCH PATHOL, V67, P443; WEINER N, 1985, PHARMACOL BASIS THER, P160; WOOD DW, 1973, ANN ALLERGY, V31, P607; WOOD DW, 1972, J ALLERGY CLIN IMMUN, V50, P75, DOI 10.1016/0091-6749(72)90002-4; 1981, FDA DRUG B, V11, P1920	19	22	23	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1986	78	4	1				631	636		10.1016/0091-6749(86)90081-3	http://dx.doi.org/10.1016/0091-6749(86)90081-3			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	E5682	3771954				2022-12-18	WOS:A1986E568200012
J	BANKS, JR; KAGEYSOBOTKA, A; LICHTENSTEIN, LM; EGGLESTON, PA				BANKS, JR; KAGEYSOBOTKA, A; LICHTENSTEIN, LM; EGGLESTON, PA			SPONTANEOUS HISTAMINE-RELEASE AFTER EXPOSURE TO HYPEROSMOLAR SOLUTIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,BALTIMORE,MD 21218; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21218	Johns Hopkins University; Johns Hopkins University					NIAID NIH HHS [AI-07007, AI-21073, AI-07290] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021073] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASSEM ESK, 1983, BRIT J RADIOL, V56, P647, DOI 10.1259/0007-1285-56-669-647; BHAT KN, 1976, ANN ALLERGY, V37, P169; BOCK SA, 1978, J ALLERGY CLIN IMMUN, V62, P327, DOI 10.1016/0091-6749(78)90132-X; COLEMAN WP, 1964, SOUTHERN MED J, V57, P1401, DOI 10.1097/00007611-196412000-00004; CZARNY D, 1980, MED J AUSTRALIA, V2, P255, DOI 10.5694/j.1326-5377.1980.tb131845.x; EGGLESTON PA, 1984, AM REV RESPIR DIS, V130, P86; FINDLAY SR, 1981, J CLIN INVEST, V67, P1604, DOI 10.1172/JCI110195; FINDLAY SR, 1980, AM REV RESPIR DIS, V122, P53; FINDLAY SR, 1984, J ALLERGY CLIN IMMUN, V73, P578, DOI 10.1016/0091-6749(84)90514-1; FREYRIA AM, 1982, J ALLERGY CLIN IMMUN, V69, P397, DOI 10.1016/0091-6749(82)90152-X; LASIE EC, 1974, RADIOLOGY, V110, P49; LICHTENSTEIN LM, 1977, ALLERGY CLIN IMMUNOL, P109; LIEBERMAN P, 1978, J ALLERGY CLIN IMMUN, V62, P174, DOI 10.1016/0091-6749(78)90103-3; MAY CD, 1982, CLIN ALLERGY, V12, P229, DOI 10.1111/j.1365-2222.1982.tb02523.x; MAY CD, 1976, J ALLERGY CLIN IMMUN, V58, P432, DOI 10.1016/0091-6749(76)90124-X; MAY CD, 1976, J ALLERGY CLIN IMMUN, V58, P500, DOI 10.1016/0091-6749(76)90194-9; PLAUT M, 1982, ALLERGY PRINCIPLES P, P119; RICE MC, 1983, J ALLERGY CLIN IMMUN, V72, P180, DOI 10.1016/0091-6749(83)90527-4; RING J, 1978, CLIN EXP IMMUNOL, V32, P105; ROCKOFF SD, 1971, INVEST RADIOL, V6, P186; SEIDEL G, 1974, AGENTS ACTIONS, V4, P143, DOI 10.1007/BF01970254; SHEHADI WH, 1980, RADIOLOGY, V137, P299, DOI 10.1148/radiology.137.2.7433658; SIEGLE RL, 1976, INVEST RADIOL, V11, P98, DOI 10.1097/00004424-197603000-00004; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; SMITH PL, 1980, J CLIN INVEST, V66, P1072, DOI 10.1172/JCI109936; SOBOTKA AK, 1979, J IMMUNOL, V122, P511; SPAETH GL, 1967, ARCH OPHTHALMOL-CHIC, V78, P583; TUNG R, 1982, J IMMUNOL, V128, P2067; WILTEN DM, 1973, AM J ROENTGENOL RADI, V119, P832; WITTEN DM, 1973, AM J ROENTGENOL, V119, P832, DOI 10.2214/ajr.119.4.832	30	22	22	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1986	78	1	1				51	57		10.1016/0091-6749(86)90114-4	http://dx.doi.org/10.1016/0091-6749(86)90114-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	D2996	2424960				2022-12-18	WOS:A1986D299600009
J	SOGN, D				SOGN, D			MEDICATIONS AND THEIR USE IN THE TREATMENT OF ADVERSE REACTIONS TO FOODS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											SOGN, D (corresponding author), NIAID,ASTHMA ALLERGY BRANCH,5333 WESTBARD AVE,WESTWOOD BLDG,ROOM 752,BETHESDA,MD 20892, USA.							ANDERSON JA, 1984, NIH842442163169 PUBL; ANDERSON JB, 1983, P NUTR SOC, V42, P257, DOI 10.1079/PNS19830030; AZADKHAN AK, 1977, LANCET, V2, P892; BAHNA SL, 1983, ANN ALLERGY, V50, P295; BAHNA SL, 1983, ANN ALLERGY, V51, P574; Basomba A, 1977, Acta Allergol, VSuppl 13, P95; BERMAN BA, 1983, PEDIATR CLIN N AM, V30, P915; BERNSTEIN IL, 1978, ANN INTERN MED, V89, P228, DOI 10.7326/0003-4819-89-2-228; BOLIN TD, 1980, GUT, V21, P848, DOI 10.1136/gut.21.10.848; BROGDEN RN, 1974, DRUGS, V7, P164, DOI 10.2165/00003495-197407030-00002; BROSTOFF J, 1979, LANCET, V1, P1268; BUISSERET P, 1980, AM J CLIN NUTR, V33, P865, DOI 10.1093/ajcn/33.4.865; BUISSERET PD, 1978, LANCET, V1, P906; BURKS A, 1986, J ALLERGY CLIN IMMUN, V77, P184; BUSINCO L, 1983, ANN ALLERGY, V51, P47; CALDWELL JH, 1978, GASTROENTEROLOGY, V74, P825; CHURCH MK, 1978, MED ACT DRUGS TODAY, V14, P281; COLLIER HOJ, 1974, PROSTAGLANDIN SYNTHE, P121; COX J S G, 1971, British Journal of Diseases of the Chest, V65, P189, DOI 10.1016/0007-0971(71)90028-3; CUMMINGS JH, 1973, NATURE, V243, P169, DOI 10.1038/243169a0; DAHL R, 1978, CLIN ALLERGY, V8, P419, DOI 10.1111/j.1365-2222.1978.tb01491.x; DAHL R, 1978, ALLERGY, V33, P120, DOI 10.1111/j.1398-9995.1978.tb01520.x; DAHL R, 1981, ALLERGY, V36, P161, DOI 10.1111/j.1398-9995.1981.tb01831.x; DANNAEUS A, 1979, CLIN ALLERGY, V9, P263, DOI 10.1111/j.1365-2222.1979.tb01552.x; DANNAEUS A, 1977, CLIN ALLERGY, V7, P109, DOI 10.1111/j.1365-2222.1977.tb01431.x; DENMAN AM, 1979, MAST CELL ITS ROLE H, P597; ELKON KB, 1977, S AFR MED J, V52, P838; ESTEBAN MM, 1977, ACTA ALLERGOL S, V13, P102; FALTHMAGNUSSON K, 1984, CLIN ALLERGY, V14, P277, DOI 10.1111/j.1365-2222.1984.tb02207.x; FREIER S, 1977, Acta Allergologica Supplementum, V32, P109; FREIER S, 1973, LANCET, V1, P913; GERRARD JW, 1979, ANN ALLERGY, V42, P135; GRAHAM P, 1984, BRIT J DERMATOL, V110, P457, DOI 10.1111/j.1365-2133.1984.tb04661.x; HARRIES MG, 1978, CLIN ALLERGY, V8, P423, DOI 10.1111/j.1365-2222.1978.tb01492.x; KINGSLEY PJ, 1974, LANCET, V2, P1011; KOCOSHIS S, 1979, JAMA-J AM MED ASSOC, V242, P1169; LEINBACH GE, 1970, GASTROENTEROLOGY, V59, P874; LINDSKOV R, 1983, ALLERGY, V38, P161, DOI 10.1111/j.1398-9995.1983.tb01601.x; MOLKHOU P, 1981, ANN ALLERGY, V47, P173; MOSS GF, 1971, TOXICOL APPL PHARM, V20, P147, DOI 10.1016/0041-008X(71)90041-X; NEFFEN H, 1980, ALLERGOL IMMUNOPATH, V8, P97; NIZAMI RM, 1977, ANN ALLERGY, V39, P102; ORTOLANI C, 1983, ANN ALLERGY, V50, P105; PAGANELLI R, 1979, LANCET, V1, P1270; PATTERSON R, 1979, NIH79387222 PUBL; PEARCE FL, 1981, ALLERGY, V36, P279, DOI 10.1111/j.1398-9995.1981.tb01577.x; PHANUPHAK P, 1978, CLIN ALLERGY, V8, P429, DOI 10.1111/j.1365-2222.1978.tb01493.x; RATNER PH, 1984, JUN INT S PREV ALL D; RELEULMICALLEF R, 1983, THORAX, V38, P527; ROBERT A, 1976, ADV PROSTAG THROMB R, V2, P507; SALBERG DJ, 1980, JAMA-J AM MED ASSOC, V244, P546; SCUDAMORE HH, 1982, J ALLERGY CLIN IMMUN, V70, P129, DOI 10.1016/0091-6749(82)90241-X; SETTIPANE GA, 1979, JAMA-J AM MED ASSOC, V241, P811, DOI 10.1001/jama.241.8.811; SHEFFER AL, 1975, NEW ENGL J MED, V293, P1220, DOI 10.1056/NEJM197512112932402; SOOTHILL JF, 1979, MAST CELL, P825; SOTER NA, 1979, MAST CELL ITS ROLE H, P550; VAZ GA, 1978, LANCET, V1, P1066; WALDMANN TA, 1967, NEW ENGL J MED, V276, P762; WATSON JBG, 1979, ARCH DIS CHILD, V54, P77, DOI 10.1136/adc.54.1.77; ZANUSSI C, 1983, ANN ALLERGY, V51, P307	60	22	22	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1986	78	1	2	S			238	243		10.1016/0091-6749(86)90017-5	http://dx.doi.org/10.1016/0091-6749(86)90017-5			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	D2997	2873162				2022-12-18	WOS:A1986D299700017
J	CIBULAS, W; MURLAS, CG; MILLER, ML; VINEGAR, A; SCHMIDT, DJ; MCKAY, RT; BERNSTEIN, IL; BROOKS, SM				CIBULAS, W; MURLAS, CG; MILLER, ML; VINEGAR, A; SCHMIDT, DJ; MCKAY, RT; BERNSTEIN, IL; BROOKS, SM			TOLUENE DIISOCYANATE-INDUCED AIRWAY HYPERREACTIVITY AND PATHOLOGY IN THE GUINEA-PIG	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CINCINNATI,DEPT ENVIRONM HLTH,231 BETHESDA AVE,CINCINNATI,OH 45267; UNIV CINCINNATI,DEPT MED,CINCINNATI,OH 45267	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034228, K08HL001535] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-01535, HL-34228] Funding Source: Medline; NIEHS NIH HHS [ES-02847] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BROOKS SM, 1982, J ALLERGY CLIN IMMUN, V70, P56, DOI 10.1016/0091-6749(82)90202-0; BRUGSCH HG, 1963, NEW ENGL J MED, V268, P353, DOI 10.1056/NEJM196302142680705; BUTCHER BT, 1977, J ALLERGY CLIN IMMUN, V59, P223, DOI 10.1016/0091-6749(77)90153-1; BUTCHER BT, 1976, J ALLERGY CLIN IMMUN, V58, P89, DOI 10.1016/0091-6749(76)90110-X; CHEN SE, 1982, J ALLERGY CLIN IMMUN, V70, P383, DOI 10.1016/0091-6749(82)90029-X; CHESTER EH, 1979, CHEST, V75, P229, DOI 10.1378/chest.75.2_Supplement.229; CIBULAS W JR, 1984, American Review of Respiratory Disease, V129, pA159; FISH JE, 1978, J ALLERGY CLIN IMMUN, V61, P140, DOI 10.1016/0091-6749(78)90277-4; HULBERT WC, 1981, AM REV RESPIR DIS, V123, P320; HULBERT WM, 1985, AM REV RESPIR DIS, V132, P7; KAROL MH, 1983, TOXICOL APPL PHARM, V68, P229, DOI 10.1016/0041-008X(83)90007-8; KAROL MH, 1978, AM IND HYG ASSOC J, V39, P454, DOI 10.1080/0002889778507789; MAPP CE, 1985, J ALLERGY CLIN IMMUN, V75, P568, DOI 10.1016/0091-6749(85)90031-4; MILLER M, 1982, J ULTRASTRUCT RES, V779, P85; MURLAS C, 1986, J APPL PHYSL, V61, P37; MURLAS CG, 1985, AM REV RESPIR DIS, V131, P314; OBRIEN IM, 1979, CLIN ALLERGY, V9, P7, DOI 10.1111/j.1365-2222.1979.tb01517.x; PEPYS J, 1972, Clinical Allergy, V2, P225, DOI 10.1111/j.1365-2222.1972.tb01287.x; ROUM JH, 1984, J APPL PHYSIOL, V57, P1783, DOI 10.1152/jappl.1984.57.6.1783; RUBINFELD AR, 1977, AM REV RESPIR DIS, V115, P381; TSE CST, 1979, TOXICOL APPL PHARM, V51, P39, DOI 10.1016/0041-008X(79)90006-1; ZEISS CR, 1980, J ALLERGY CLIN IMMUN, V65, P346, DOI 10.1016/0091-6749(80)90211-0; 1977, MANUAL ANAL METHODS, V1	23	22	22	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1986	77	6					828	834		10.1016/0091-6749(86)90380-5	http://dx.doi.org/10.1016/0091-6749(86)90380-5			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	C8694	3011873	Bronze			2022-12-18	WOS:A1986C869400007
J	ROWE, MS; BAILEY, J; OWNBY, DR				ROWE, MS; BAILEY, J; OWNBY, DR			EVALUATION OF THE CAUSE OF NASAL AND OCULAR SYMPTOMS ASSOCIATED WITH LAWN MOWING	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HENRY FORD HOSP,DEPT PEDIAT,DETROIT,MI 48202	Henry Ford Health System; Henry Ford Hospital	ROWE, MS (corresponding author), HENRY FORD HOSP,DEPT MED,DIV ALLERGY & CLIN IMMUNOL,2799 W GRAND BLVD,DETROIT,MI 48202, USA.							AGARWAL MK, 1984, J ALLERGY CLIN IMMUN, V74, P687, DOI 10.1016/0091-6749(84)90231-8; BOOTH BH, 1980, ALLERGIC DISEASES DI, P88; EVANS R, 1981, J ALLERGY CLIN IMMUN, V68, P79, DOI 10.1016/0091-6749(81)90127-5; GUTMAN AA, 1980, ALLERGIC DISEASES DI, P135; KENDALL C, 1983, J IMMUNOL METHODS, V56, P329, DOI 10.1016/S0022-1759(83)80022-2; RAO PVS, 1983, J IMMUNOL METHODS, V57, P71, DOI 10.1016/0022-1759(83)90066-2; SOLOMON WR, 1983, ALLERGY PRINCIPLES P, P1180; SOLOMON WR, 1983, ALLERGY PRINCIPLES P, P1181	8	22	22	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1986	77	5					714	719		10.1016/0091-6749(86)90416-1	http://dx.doi.org/10.1016/0091-6749(86)90416-1			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	C3903	3700896				2022-12-18	WOS:A1986C390300014
J	BERNSTEIN, IL; BERNSTEIN, DI				BERNSTEIN, IL; BERNSTEIN, DI			EFFICACY AND SAFETY OF ASTEMIZOLE, A LONG-ACTING AND NONSEDATING H-1 ANTAGONIST FOR THE TREATMENT OF CHRONIC IDIOPATHIC URTICARIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											BERNSTEIN, IL (corresponding author), UNIV CINCINNATI,CTR MED,DEPT MED,DIV IMMUNOL,231 BETHESDA AVE,CINCINNATI,OH 45226, USA.							BATEMAN DN, 1983, EUR J CLIN PHARMACOL, V25, P547, DOI 10.1007/BF00542126; BERNSTEIN I L, 1984, Journal of Allergy and Clinical Immunology, V73, P144; HEYKANTS J, 1984, ASTEMIZOLE NEW NONSE, P25; HOWARTH PH, THORAX; KNIGHT A, 1984, ASTEMIZOLE NEW NONSE, P95; LADURON PM, 1982, MOL PHARMACOL, V21, P294; MATHEWS KP, 1983, J ALLERGY CLIN IMMUN, V72, P1, DOI 10.1016/0091-6749(83)90042-8; NICHOLSON AN, 1982, BRIT J CLIN PHARMACO, V13, P199, DOI 10.1111/j.1365-2125.1982.tb01356.x; RICHARDS DM, 1984, DRUGS, V28, P38, DOI 10.2165/00003495-198428010-00003; WILSON JD, 1982, CLIN ALLERGY, V12, P131	10	22	22	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1986	77	1	1				37	42		10.1016/0091-6749(86)90319-2	http://dx.doi.org/10.1016/0091-6749(86)90319-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AZD36	3080510	Bronze			2022-12-18	WOS:A1986AZD3600007
J	CHAN, SC; HANIFIN, JM; HOLDEN, CA; THOMPSON, WJ; HIRSHMAN, CA				CHAN, SC; HANIFIN, JM; HOLDEN, CA; THOMPSON, WJ; HIRSHMAN, CA			ELEVATED LEUKOCYTE PHOSPHODIESTERASE AS A BASIS FOR DEPRESSED CYCLIC ADENOSINE-MONOPHOSPHATE RESPONSES IN THE BASENJI GREYHOUND DOG-MODEL OF ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									OREGON HLTH SCI UNIV,DEPT ANESTHESIOL,3181 SW SAM JACKSON PARK RD,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT DERMATOL,PORTLAND,OR 97201; UNIV S ALABAMA,DEPT PHARMACOL,MOBILE,AL 36688	Oregon Health & Science University; Oregon Health & Science University; University of South Alabama					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL025831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018615, R01AI015557] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 2R01 25831] Funding Source: Medline; NIAID NIH HHS [2 RO1 AI 15557, 1 RO1 AI 18615] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALSTON WC, 1974, BRIT MED J, V1, P90, DOI 10.1136/bmj.1.5898.90; BOWLES CA, 1975, J IMMUNOL, V114, P399; BRODDE OE, 1981, LIFE SCI, V29, P2189, DOI 10.1016/0024-3205(81)90490-2; BROOKS SM, 1979, J ALLERGY CLIN IMMUN, V63, P401, DOI 10.1016/0091-6749(79)90213-6; BUTLER JM, 1983, J AM ACAD DERMATOL, V8, P33, DOI 10.1016/S0190-9622(83)70004-6; BUTLER JM, 1983, J ALLERGY CLIN IMMUN, V71, P490, DOI 10.1016/0091-6749(83)90467-0; CHAN SC, 1982, J CYCLIC NUCL PROT, V8, P211; DAVIS P B, 1981, American Review of Respiratory Disease, V123, P214; EPSTEIN PM, 1980, CANCER RES, V40, P379; GALANT SP, 1980, AM REV RESPIR DIS, V122, P231; GLANTZ BA, 1981, PRIMER BIOSTATISTICS, P63; GOLD WM, 1980, PHYSL PHARM AIRWAYS, P123; GREWE SR, 1982, J ALLERGY CLIN IMMUN, V70, P452, DOI 10.1016/0091-6749(82)90008-2; HEDMAN SE, 1982, EUR J PHARMACOL, V83, P107, DOI 10.1016/0014-2999(82)90292-8; HIRSHMAN CA, 1983, J APPL PHYSIOL, V54, P1101, DOI 10.1152/jappl.1983.54.4.1101; HIRSHMAN CA, 1981, J APPL PHYSIOL, V51, P1423, DOI 10.1152/jappl.1981.51.6.1423; HIRSHMAN CA, 1983, J APPL PHYSIOL, V54, P1108, DOI 10.1152/jappl.1983.54.4.1108; HIRSHMAN CA, 1983, PROSTAGLANDINS, V25, P481, DOI 10.1016/0090-6980(83)90020-5; HIRSHMAN CA, 1981, RESP PHYSIOL, V43, P377, DOI 10.1016/0034-5687(81)90117-1; HIRSHMAN CA, 1980, J APPL PHYSIOL, V49, P953, DOI 10.1152/jappl.1980.49.6.953; LOGSDON PJ, 1972, J ALLERGY CLIN IMMUN, V50, P45, DOI 10.1016/0091-6749(72)90078-4; MACDONALD AG, 1967, BRIT J ANAESTH, V39, P919, DOI 10.1093/bja/39.12.919; MACKLER B, 1971, INT ARCH ALLER A IMM, V41, P765, DOI 10.1159/000230567; MCNEILL RS, 1964, LANCET, V2, P1101; MEURS H, 1982, J ALLERGY CLIN IMMUN, V70, P272, DOI 10.1016/0091-6749(82)90063-X; NIAUDET P, 1976, EUR J IMMUNOL, V6, P834, DOI 10.1002/eji.1830061117; ORANGE RP, 1971, J EXP MED, V134, pS136; PARKER C W, 1973, P185; PARKER CW, 1973, J CLIN INVEST, V52, P48, DOI 10.1172/JCI107173; PETERS JE, 1982, J IMMUNOL, V129, P1245; PRATT ML, 1984, 12TH P INT C BIOCH S; RICHARDSON PS, 1969, BMJ-BRIT MED J, V3, P143, DOI 10.1136/bmj.3.5663.143; RINARD GA, 1979, P NATL ACAD SCI USA, V76, P1472, DOI 10.1073/pnas.76.3.1472; SAFKO MJ, 1981, J ALLERGY CLIN IMMUN, V68, P218, DOI 10.1016/0091-6749(81)90187-1; Salomon Y, 1979, Adv Cyclic Nucleotide Res, V10, P35; SEAMON KB, 1981, P NATL ACAD SCI-BIOL, V78, P3363, DOI 10.1073/pnas.78.6.3363; SNAPPER JR, 1978, J APPL PHYSIOL, V44, P738, DOI 10.1152/jappl.1978.44.5.738; STRADA SJ, 1984, ADV CYCLIC NUCL PROT, V16, P13; SULLIVAN TJ, 1975, J IMMUNOL, V114, P1480; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; TASHKIN DP, 1982, AM REV RESPIR DIS, V125, P185; TATTERSFIELD AE, 1973, J APPL PHYSIOL, V35, P613, DOI 10.1152/jappl.1973.35.5.613; THOMPSON WJ, 1971, BIOCHEMISTRY-US, V10, P311; THOMPSON WJ, 1976, J BIOL CHEM, V251, P4922; VONNEERGAARD K, 1927, Z KLIN MED, V105, P51; VULLIEMOZ Y, 1977, BIOCH SMOOTH MUSCLE, P293; ZAID G, 1966, NEW ENGL J MED, V275, P580, DOI 10.1056/NEJM196609152751103	47	22	23	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	2					148	158		10.1016/0091-6749(85)90693-1	http://dx.doi.org/10.1016/0091-6749(85)90693-1			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	APE88	2991358				2022-12-18	WOS:A1985APE8800005
J	KIM, HC; KESARWALA, HH; COLVIN, M; SAIDI, P				KIM, HC; KESARWALA, HH; COLVIN, M; SAIDI, P			HYPERSENSITIVITY REACTION TO A METABOLITE OF CYCLOPHOSPHAMIDE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MED & DENT NEW JERSEY,RUTGERS MED SCH,DEPT PEDIAT,NEW BRUNSWICK,NJ 08903; JOHNS HOPKINS UNIV HOSP,CTR ONCOL,PHARMACOL LAB,BALTIMORE,MD 21205	Rutgers State University New Brunswick; Rutgers State University Medical Center; Johns Hopkins University; Johns Hopkins Medicine	KIM, HC (corresponding author), UNIV MED & DENT NEW JERSEY,RUTGERS MED SCH,DEPT MED,CN-19,NEW BRUNSWICK,NJ 08903, USA.							BOOTH BH, 1972, ALLERGIC DISEASES DI, P76; COLVIN M, 1982, SEMIN ONCOL, V9, P2; CORNWELL GG, 1979, CANCER TREAT REP, V63, P399; Friedman O.M., 1979, ADV CANCER CHEMOTHER, V1, P143; GREEN GR, 1971, J ALLERGY CLIN IMMUN, V48, P331, DOI 10.1016/0091-6749(71)90079-0; HOHORST HJ, 1976, CANCER RES, V36, P2278; KRUTCHIK AN, 1978, ARCH INTERN MED, V138, P1725, DOI 10.1001/archinte.138.11.1725; LAKIN JD, 1976, J ALLERGY CLIN IMMUN, V58, P160, DOI 10.1016/0091-6749(76)90151-2; LEGHA SS, 1978, CANCER TREAT REP, V62, P180; PARKER CW, 1962, J EXP MED, V115, P821, DOI 10.1084/jem.115.4.821; ROSS WE, 1977, CANCER TREAT REP, V61, P495; SCHMIDT JD, 1979, J UROLOGY, V121, P185, DOI 10.1016/S0022-5347(17)56714-2; WEISS RB, 1981, ANN INTERN MED, V94, P66, DOI 10.7326/0003-4819-94-1-66	13	22	22	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	4					591	594		10.1016/0091-6749(85)90780-8	http://dx.doi.org/10.1016/0091-6749(85)90780-8			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ATH66	4056247	Bronze			2022-12-18	WOS:A1985ATH6600011
J	KRAY, KT; SQUIRE, EN; TIPTON, WR; SELNER, JC; ODEA, J; NELSON, HS				KRAY, KT; SQUIRE, EN; TIPTON, WR; SELNER, JC; ODEA, J; NELSON, HS			CROMOLYN SODIUM IN SEASONAL ALLERGIC CONJUNCTIVITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									FITZSIMONS ARMY MED CTR,ALLERGY & IMMUNOL SERV,AURORA,CO 80045; USA,DENVER,CO 80240; USA,PEDIAT SERV,PEDIAT SERV,FT CARSON,CO									BERNSTEIN IL, 1978, ANN INTERN MED, V89, P228, DOI 10.7326/0003-4819-89-2-228; BUCKLEY RJ, 1979, MAST CELL ITS ROLE H, P518; COLLUM LMT, 1981, IRISH MED J, V74, P14; DAWSON JP, 1979, MAST CELL ITS ROLE H, P506; EASTY D L, 1972, Clinical Allergy, V2, P99, DOI 10.1111/j.1365-2222.1972.tb01274.x; FOSTER CS, 1980, PERSPECT OPHTHALMOL, V4, P35; FOSTER CS, 1980, AM J OPHTHALMOL; HAVNEN J, 1979, ADV ALLERGOLOGY CLIN, P660; HENNAWI ME, 1980, BR J OPHTHALMOL, V64, P483; KINGSLEY PJ, 1978, ALLERGY PRINCIPLES P; LINDSAYMILLER ACM, 1979, CLIN ALLERGY, V9, P271, DOI 10.1111/j.1365-2222.1979.tb01553.x; MEISLER DM, 1982, ARCH OPHTHALMOL-CHIC, V100, P1608; MEISLER DM, 1981, AM J OPHTHALMOL, V92, P368, DOI 10.1016/0002-9394(81)90526-2; NIZAMI RM, 1977, ANN ALLERGY, V38, P42; NIZAMI RM, 1981, ANN ALLERGY, V47, P5; OGDEN EC, 1967, J ALLERGY, V40, P1, DOI 10.1016/0021-8707(67)90053-6; SIMONLICHT IF, 1983, ANN ALLERGY, V49, P220; TADA R, 1979, FOLIA OPHTHALMOL JAP, V30, P1176; 1979, PRACTITIONER, V222, P854	19	22	22	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	4					623	627		10.1016/0091-6749(85)90785-7	http://dx.doi.org/10.1016/0091-6749(85)90785-7			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ATH66	3932499				2022-12-18	WOS:A1985ATH6600016
J	NORMAN, PS				NORMAN, PS			NEWER ANTIHISTAMINIC AGENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21205	Johns Hopkins University	NORMAN, PS (corresponding author), GOOD SAMARITAN HOSP,5601 LOCH RAVEN BLVD,BALTIMORE,MD 21239, USA.							AUSTEN KF, 1963, ADV IMMUNOL, V3, P1, DOI 10.1016/S0065-2776(08)60810-X; CHAPMAN PH, 1983, BR J CLIN PHARM, V13, pP593; Douglas W. W., 1980, PHARMACOL BASIS THER, P609; LICHTENSTEIN LM, 1975, J PHARMACOL EXP THER, V192, P441; LOEW E R, 1952, BMQ, V3, P1; NACLERIO RM, 1983, EUR J RESPIR DIS, V64, P26; NETTER KJ, 1967, BIOCHEM PHARMACOL, V16, P1627, DOI 10.1016/0006-2952(67)90141-4; NICHOLSON AN, 1982, ARZNEIMITTEL-FORSCH, V32-2, P1191; NICHOLSON AN, 1982, BRIT J CLIN PHARMACO, V13, P199, DOI 10.1111/j.1365-2125.1982.tb01356.x; ROSE C, 1982, ARZNEIMITTEL-FORSCH, V32-2, P1171; SCHWARTZ JC, 1980, J NEUROCHEM, V35, P26, DOI 10.1111/j.1471-4159.1980.tb12485.x; UZAN A, 1979, J PHARM PHARMACOL, V31, P701, DOI 10.1111/j.2042-7158.1979.tb13632.x; WASSERMAN SI, 1983, J ALLERGY CLIN IMMUN, V72, P101, DOI 10.1016/0091-6749(83)90512-2	13	22	22	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	2					366	368		10.1016/0091-6749(85)90655-4	http://dx.doi.org/10.1016/0091-6749(85)90655-4			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	APE89	2862177				2022-12-18	WOS:A1985APE8900019
J	REISMAN, RE				REISMAN, RE			STINGING INSECT ALLERGY - PROGRESS AND PROBLEMS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material																		BLAAUW PJ, 1985, J ALLERGY CLIN IMMUN, V75, P556, DOI 10.1016/0091-6749(85)90029-6; BOCK SA, 1978, J ALLERGY CLIN IMMUN, V62, P327, DOI 10.1016/0091-6749(78)90132-X; HOFFMAN DR, 1985, J ALLERGY CLIN IMMUN, V75, P611, DOI 10.1016/0091-6749(85)90038-7; HOFFMAN DR, 1985, J ALLERGY CLIN IMMUN, V75, P599, DOI 10.1016/0091-6749(85)90036-3; HOFFMAN DR, 1985, J ALLERGY CLIN IMMUN, V75, P606, DOI 10.1016/0091-6749(85)90037-5; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; KING TP, 1985, J ALLERGY CLIN IMMUN, V75, P621, DOI 10.1016/0091-6749(85)90040-5; KING TP, 1978, BIOCHEMISTRY-US, V17, P5165, DOI 10.1021/bi00617a016; MAURIELLO PM, 1984, J ALLERGY CLIN IMMUN, V74, P494, DOI 10.1016/0091-6749(84)90384-1; MUELLER U, 1981, J ALLERGY CLIN IMMUN, V67, P290, DOI 10.1016/0091-6749(81)90024-5; PARKER JL, 1982, J ALLERGY CLIN IMMUN, V69, P200, DOI 10.1016/0091-6749(82)90100-2; RANDOLPH CC, 1985, J ALLERGY CLIN IMMUN, V75, P151, DOI 10.1016/0091-6749(85)90320-3; REISMAN RE, 1982, J ALLERGY CLIN IMMUN, V70, P281, DOI 10.1016/0091-6749(82)90064-1; REISMAN RE, 1984, TOXICON, V22, P148, DOI 10.1016/0041-0101(84)90148-X; REISMAN RE, 1982, J ALLERGY CLIN IMMUN, V69, P268, DOI 10.1016/S0091-6749(82)80003-1; REISMAN RE, J ALLERGY CLIN IMMUN; SCHUBERTH KC, 1983, J PEDIATR-US, V102, P361, DOI 10.1016/S0022-3476(83)80649-0; WYPYCH JI, 1979, J ALLERGY CLIN IMMUN, V63, P267, DOI 10.1016/0091-6749(79)90111-8	18	22	22	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	5					553	555		10.1016/0091-6749(85)90028-4	http://dx.doi.org/10.1016/0091-6749(85)90028-4			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AHV07	3989139				2022-12-18	WOS:A1985AHV0700002
J	TAYLOR, RJ; LONG, WF; NELSON, HS				TAYLOR, RJ; LONG, WF; NELSON, HS			THE DEVELOPMENT OF SUBSENSITIVITY TO CHLORPHENIRAMINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									FITZSIMONS ARMY MED CTR,ALLERGY IMMUNOL SERV,AURORA,CO 80045									ARNOLD SB, 1979, ANN INTERN MED, V91, P345, DOI 10.7326/0003-4819-91-3-345; BOUDOULAS H, 1977, ANN INTERN MED, V87, P433, DOI 10.7326/0003-4819-87-4-433; BOURNE HR, 1983, HARRISONS PRINCIPLES, P480; BYE CE, 1977, EUR J CLIN PHARMACOL, V12, P181, DOI 10.1007/BF00609857; COOK TJ, 1973, J ALLERGY CLIN IMMUN, V51, P71, DOI 10.1016/S0091-6749(73)80002-8; DANNENBERG TB, 1951, J ALLERGY, V22, P330, DOI 10.1016/0021-8707(51)90033-0; GLAUBIGER GA, 1977, CIRCULATION, V56, P158; GOODMAN LS, 1980, PHARMACOL BASIS THER, P622; GRAYSON LD, 1963, ANN ALLERGY, V21, P168; MITENKO PA, 1973, NEW ENGL J MED, V289, P600, DOI 10.1056/NEJM197309202891202; MONASH S, 1950, J INVEST DERMATOL, V15, P1, DOI 10.1038/jid.1950.61; NELSON HS, 1983, J ALLERGY CLIN IMMUN, V72, P371, DOI 10.1016/0091-6749(83)90502-X; PEARLMAN DS, 1976, DRUGS, V12, P258, DOI 10.2165/00003495-197612040-00002; PECK AW, 1975, EUR J CLIN PHARMACOL, V8, P455, DOI 10.1007/BF00562321; TAYLOR RJ, 1983, ANN ALLERGY, V52, P240; TIPTON WR, 1981, LUNG, V159, P199, DOI 10.1007/BF02713916; WEBER RW, 1982, J ALLERGY CLIN IMMUN, V70, P417, DOI 10.1016/0091-6749(82)90003-3; WEBER RW, 1979, J ALLERGY CLIN IMMUN, V63, P116, DOI 10.1016/0091-6749(79)90201-X	18	22	22	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	1					103	107		10.1016/0091-6749(85)90811-5	http://dx.doi.org/10.1016/0091-6749(85)90811-5			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AMV84	4008807	Bronze			2022-12-18	WOS:A1985AMV8400014
J	GIUSTINA, TA; CHAN, SC; THIEL, ML; BAKER, JW; HANIFIN, JM				GIUSTINA, TA; CHAN, SC; THIEL, ML; BAKER, JW; HANIFIN, JM			INCREASED LEUKOCYTE SENSITIVITY TO PHOSPHODIESTERASE INHIBITORS IN ATOPIC-DERMATITIS - TACHYPHYLAXIS AFTER THEOPHYLLINE THERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									OREGON HLTH SCI UNIV,DEPT DERMATOL,PORTLAND,OR 97201	Oregon Health & Science University					NIAID NIH HHS [1-RO1-AI-18615] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018615] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERGSTRAND H, 1980, EUR J RESPIR DIS, V61, P37; BUSSE WW, 1979, J INVEST DERMATOL, V73, P184, DOI 10.1111/1523-1747.ep12581674; BUSSE WW, 1981, J ALLERGY CLIN IMMUN, V67, P70, DOI 10.1016/0091-6749(81)90048-8; GREWE SR, 1982, J ALLERGY CLIN IMMUN, V70, P452, DOI 10.1016/0091-6749(82)90008-2; HANIFIN JM, 1982, J AM ACAD DERMATOL, V6, P1, DOI 10.1016/S0190-9622(82)70001-5; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; PARKER CW, 1977, J INVEST DERMATOL, V68, P302, DOI 10.1111/1523-1747.ep12494569; SAFKO MJ, 1981, J ALLERGY CLIN IMMUN, V68, P218, DOI 10.1016/0091-6749(81)90187-1; SIMS JA, 1978, J ALLERGY CLIN IMMUN, V62, P15, DOI 10.1016/0091-6749(78)90066-0; Thompson W J, 1979, Adv Cyclic Nucleotide Res, V10, P69; THOMPSON WJ, 1980, J CYCLIC NUCL PROT, V6, P25; VANDELLEN RG, 1979, MAYO CLIN PROC, V54, P733; WEINBERGER M, 1980, EUR J RESPIR DIS, V61, P120; WEISS RM, 1981, BIOCHEM PHARMACOL, V30, P2371, DOI 10.1016/0006-2952(81)90117-9; WOMBACHER H, 1982, BIOCHEM PHARMACOL, V31, P3441, DOI 10.1016/0006-2952(82)90624-4	15	22	22	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	3					252	257		10.1016/0091-6749(84)90254-9	http://dx.doi.org/10.1016/0091-6749(84)90254-9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TJ808	6088608				2022-12-18	WOS:A1984TJ80800006
J	KUEHL, FA; DEHAVEN, RN; PONG, SS				KUEHL, FA; DEHAVEN, RN; PONG, SS			LUNG-TISSUE RECEPTORS FOR SULFIDOPEPTIDE LEUKOTRIENES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											KUEHL, FA (corresponding author), MERCK INST THERAPEUT RES,DEPT BIOCHEM INFLAMMAT,POB 2000,RAHWAY,NJ 07065, USA.							BORGEAT P, 1976, J BIOL CHEM, V251, P7816; GOLDMAN DW, 1982, J IMMUNOL, V129, P1600; KOSKI G, 1982, J BIOL CHEM, V257; KRILIS S, 1983, J CLIN INVEST, V72, P1516, DOI 10.1172/JCI111109; KUEHL FA, 1972, P NATL ACAD SCI USA, V69, P480, DOI 10.1073/pnas.69.2.480; KUEHL FA, 1984, BIOCHEM PHARMACOL, V33, P1, DOI 10.1016/0006-2952(84)90362-9; LAPETINA EG, 1979, BIOCHIM BIOPHYS ACTA, V573, P394, DOI 10.1016/0005-2760(79)90072-9; LIMBIRD LE, 1983, TRENDS PHARMACOL SCI, V4, P135, DOI 10.1016/0165-6147(83)90331-0; PONG SS, 1983, P NATL ACAD SCI-BIOL, V80, P7415, DOI 10.1073/pnas.80.24.7415; PONG SS, 1983, J BIOL CHEM, V258, P9616; TATE SS, 1978, P NATL ACAD SCI USA, V75, P4806, DOI 10.1073/pnas.75.10.4806	11	22	22	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	3					378	381		10.1016/0091-6749(84)90134-9	http://dx.doi.org/10.1016/0091-6749(84)90134-9			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TQ633	6088614				2022-12-18	WOS:A1984TQ63300014
J	DESHAZO, RD; HENDRICK, DJ; DIEM, JE; NORDBERG, JA; BASER, Y; BEVIER, D; JONES, RN; BARKMAN, HW; SALVAGGIO, JE; WEILL, H				DESHAZO, RD; HENDRICK, DJ; DIEM, JE; NORDBERG, JA; BASER, Y; BEVIER, D; JONES, RN; BARKMAN, HW; SALVAGGIO, JE; WEILL, H			IMMUNOLOGICAL ABERRATIONS IN ASBESTOS CEMENT WORKERS - DISSOCIATION FROM ASBESTOSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									TULANE UNIV,SCH MED,DEPT MED,PULM DIS SECT,NEW ORLEANS,LA 70112	Tulane University	DESHAZO, RD (corresponding author), TULANE UNIV,SCH MED,DEPT MED,CLIN IMMUNOL SECT,HERBERT J HARVEY JR IMMUNOL LAB,NEW ORLEANS,LA 70112, USA.				NHLBI NIH HHS [HL-15092] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL015092] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BIGNON J, 1980, AM REV RESPIR DIS, V121, pS257; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; CAMPBELL MJ, 1980, CLIN EXP IMMUNOL, V39, P176; CHESS L, 1974, J IMMUNOL, V113, P1113; COONS AH, 1950, J EXP MED, V91, P1, DOI 10.1084/jem.91.1.1; DESHAZO RD, 1983, J ALLERGY CLIN IMMUN, V71, P418, DOI 10.1016/0091-6749(83)90072-6; DESHAZO RD, 1982, J ALLERGY CLIN IMMUN, V70, P41, DOI 10.1016/0091-6749(82)90200-7; DOLL NJ, 1980, J CLIN INVEST, V66, P457, DOI 10.1172/JCI109876; GERARD JW, 1980, ANN ALLERGY, V44, P261; GREENBERG SD, 1982, SEMIN RESPIR MED, V4, P130, DOI 10.1055/s-2007-1012477; HASLAM PL, 1978, CLIN EXP IMMUNOL, V31, P178; HAUSKONEN MS, 1978, SCAND J RESPIR DIS, V59, P326; HOLT PG, 1977, BACTERIOL REV, V41, P205, DOI 10.1128/MMBR.41.1.205-216.1977; HUNNINGHAKE GW, 1979, AM REV RESPIR DIS, V120, P49; KAGAN E, 1977, CLIN EXP IMMUNOL, V28, P261; KAGAN E, 1977, CLIN EXP IMMUNOL, V28, P268; KANG KY, 1974, NEW ENGL J MED, V291, P735; KUNG PC, 1979, SCIENCE, V206, P347, DOI 10.1126/science.314668; LANGE A, 1980, ENVIRON RES, V22, P162, DOI 10.1016/0013-9351(80)90128-0; LANGE A, 1980, ENVIRON RES, V22, P176, DOI 10.1016/0013-9351(80)90129-2; LAWRENCE C, 1980, STAIN TECHNOL, V54, P321; MASCARTLEMONE F, 1982, CLIN EXP IMMUNOL, V48, P148; MICHALSKI JP, 1977, ARTHRITIS RHEUM, V20, P851, DOI 10.1002/art.1780200315; MORIMOTO C, 1982, J IMMUNOL, V128, P1645; MORIMOTO C, 1981, J CLIN INVEST, V67, P753, DOI 10.1172/JCI110092; NETER J, 1974, APPLIED LINEAR STATI, P685; NETER J, 1974, APPLIED LINEAR STATI, P477; PISCIOTT.AV, 1967, NATURE, V215, P193, DOI 10.1038/215193a0; REINHERZ EL, 1979, P NATL ACAD SCI USA, V76, P4061, DOI 10.1073/pnas.76.8.4061; STANKUS RP, 1981, CURRENT PULMONOLOGY, P61; WAGNER MMF, 1979, CLIN EXP IMMUNOL, V38, P323; Weill H, 1973, J Occup Med, V15, P248; WEILL H, 1979, AM REV RESPIR DIS, V120, P345; WEILL H, 1975, ARCH ENVIRON HEALTH, V30, P88, DOI 10.1080/00039896.1975.10666650; WINCHESTER RJ, 1974, J CLIN INVEST, V54, P1082, DOI 10.1172/JCI107852; 1980, ILO 1980 INT CLASSIF	36	22	22	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	5					454	461		10.1016/0091-6749(83)90581-X	http://dx.doi.org/10.1016/0091-6749(83)90581-X			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RR916	6355248				2022-12-18	WOS:A1983RR91600005
J	NELSON, BL; JACOBS, RL				NELSON, BL; JACOBS, RL			RESPONSE OF THE NON-ALLERGIC RHINITIS WITH EOSINOPHILIA (NARES) SYNDROME TO 4-PERCENT CROMOLYN SODIUM NASAL SOLUTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									WILFORD HALL USAF MED CTR,ALLERGY IMMUNOL SERV,LACKLAND AFB,TX 78236	United States Department of Defense; United States Air Force								BLAIR H, 1975, Clinical Allergy, V5, P139, DOI 10.1111/j.1365-2222.1975.tb01846.x; COHAN RH, 1976, J ALLERGY CLIN IMMUN, V58, P121, DOI 10.1016/0091-6749(76)90147-0; CONNELL JT, 1979, CELLULAR MOL CLIN AS, P409; CONNELL JT, 1976, BRONCHIAL ASTHMA MEC, P481; CULLEN KJ, 1973, AUST FAM PHYSICIAN, V2, P411; JACOBS RL, 1981, J ALLERGY CLIN IMMUN, V67, P253, DOI 10.1016/0091-6749(81)90019-1; KNIGHT A, 1979, CLIN ALLERGY, V9, P159, DOI 10.1111/j.1365-2222.1979.tb01537.x; MULLARKEY MF, 1980, J ALLERGY CLIN IMMUN, V65, P122, DOI 10.1016/0091-6749(80)90196-7; SPATARO AC, 1976, BIOCHEM PHARMACOL, V25, P505, DOI 10.1016/0006-2952(76)90378-6; TAYLOR G, 1971, Clinical Allergy, V1, P189, DOI 10.1111/j.1365-2222.1971.tb03018.x; THEOHARIDES TC, 1980, SCIENCE, V207, P80, DOI 10.1126/science.6153130	11	22	23	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	70	2					125	128		10.1016/0091-6749(82)90240-8	http://dx.doi.org/10.1016/0091-6749(82)90240-8			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PB591	6808048				2022-12-18	WOS:A1982PB59100009
J	OWNBY, DR				OWNBY, DR			COMPUTERIZED MEASUREMENT OF ALLERGEN-INDUCED SKIN REACTIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note											OWNBY, DR (corresponding author), HENRY FORD HOSP,DIV ALLERGY & CLIN IMMUNOL,DETROIT,MI 48202, USA.							BAER H, 1970, J ALLERGY, V45, P347, DOI 10.1016/0021-8707(70)90043-2; FINE SR, 1980, INT ARCH ALLER A IMM, V61, P241, DOI 10.1159/000232439; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; IMBEAU SA, 1978, J ALLERGY CLIN IMMUN, V62, P193, DOI 10.1016/0091-6749(78)90207-5; NORMAN PS, 1978, J ALLERGY CLIN IMMUN, V62, P314, DOI 10.1016/0091-6749(78)90164-1; NORMAN PS, 1980, MANUAL CLIN IMMUNOLO, P789; TURKELTAUB PC, 1981, QUANTITATIVE INTRADE	7	22	23	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	69	6					536	538		10.1016/0091-6749(82)90180-4	http://dx.doi.org/10.1016/0091-6749(82)90180-4			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NT025	7076996				2022-12-18	WOS:A1982NT02500011
J	TIPTON, WR; NELSON, HS				TIPTON, WR; NELSON, HS			EXPERIENCE WITH DAILY IMMUNOTHERAPY IN 59 ADULT ALLERGIC PATIENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											TIPTON, WR (corresponding author), FITZSIMONS ARMY MED CTR,ALLERGY IMMUNOL SERV,AURORA,CO 80045, USA.							ADKINSON NF, 1981, J ALLERGY CLIN IMMUN, V67, P87, DOI 10.1016/0091-6749(81)90001-4; COLMES A, 1932, J ALLERGY, V3, P449; COLMES A, 1932, J ALLERGY, V4, P473; DANTZLER BS, 1980, ANN ALLERGY, V45, P213; Freeman J, 1930, LANCET, V1, P744; LEVIN SJ, 1936, J ALLERGY, V8, P26; LOVELESS MH, 1940, SOUTH MED J, V33, P869; MAY CD, 1972, PEDIATRICS, V49, P536; REMINGTON RD, 1970, STATISTICS APPLICATI; Sherman WB, 1941, J IMMUNOL, V40, P289; SHERMAN WILLIAM B., 1940, JOUR ALLERGY, V11, P225, DOI 10.1016/S0021-8707(40)90568-8; SOBOTKA AK, 1976, J IMMUNOL, V117, P84; SPRECACE GA, 1966, J ALLERGY, V38, P9, DOI 10.1016/0021-8707(66)90068-2; ZEISS CR, 1977, CLIN EXP IMMUNOL, V28, P250	14	22	22	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	69	2					194	199		10.1016/0091-6749(82)90099-9	http://dx.doi.org/10.1016/0091-6749(82)90099-9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NC581	7056950				2022-12-18	WOS:A1982NC58100005
J	MEYERS, DA; MARSH, DG				MEYERS, DA; MARSH, DG			REPORT ON A NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS-DISEASES SPONSORED WORKSHOP ON THE GENETICS OF TOTAL IMMUNOGLOBULIN-E LEVELS IN HUMANS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material									JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21218; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST LAB,BALTIMORE,MD 21218	Johns Hopkins University; Johns Hopkins University					NIAID NIH HHS [AI 13370] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADKINSON NF, 1976, MANUAL CLIN IMMUNOLO, P590; BARBEE RA, 1976, ANN INTERN MED, V84, P129, DOI 10.7326/0003-4819-84-2-129; BLUMENTHAL M, 1979, J ALLERGY CLIN IMMUN, V63, P169; ELSTON RC, 1971, HUM HERED, V21, P523, DOI 10.1159/000152448; ELSTON RC, 1979, AM J HUM GENET, V31, P62; FREIDHOFF LR, AM J MED GENET; GERRARD JW, 1978, AM J HUM GENET, V30, P46; GERRARD JW, 1977, ANN ALLERGY, V38, P396; HASSTEDT S, 1980, 1979 U UT DEP MED BI; MARSH DG, 1974, P NATL ACAD SCI USA, V71, P3588, DOI 10.1073/pnas.71.9.3588; MEYERS DA, UNPUBLISHED; MORTON NE, 1974, AM J HUM GENET, V26, P489; OTT J, 1979, AM J HUM GENET, V31, P161; RAO DC, 1980, AM J HUM GENET, V32, P620	14	22	22	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	67	3					167	170		10.1016/0091-6749(81)90056-7	http://dx.doi.org/10.1016/0091-6749(81)90056-7			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LG778	7462533				2022-12-18	WOS:A1981LG77800001
J	REISMAN, RE; LAZELL, M; DOERR, J				REISMAN, RE; LAZELL, M; DOERR, J			INSECT VENOM ALLERGY - A PROSPECTIVE CASE-STUDY SHOWING LACK OF CORRELATION BETWEEN IMMUNOLOGICAL REACTIVITY AND CLINICAL SENSITIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SUNY BUFFALO,DEPT MED,BUFFALO,NY 14214; BUFFALO GEN HOSP,ALLERGY RES LAB,BUFFALO,NY 14203	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Buffalo General Medical Center					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI014501] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI14501] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BENTON AW, 1963, SCIENCE, V142, P228, DOI 10.1126/science.142.3589.228; GEORGITIS J, 1981, 37TH P ANN M AM AC A; HAMILTON RG, 1979, J IMMUNOL, V122, P1173; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; LIGHT WC, 1976, CLIN ALLERGY, V6, P293, DOI 10.1111/j.1365-2222.1976.tb01909.x; PARKER JL, 1980, J ALLERGY CLIN IMMUN, V65, P198	6	22	22	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	68	5					406	408		10.1016/0091-6749(81)90140-8	http://dx.doi.org/10.1016/0091-6749(81)90140-8			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MQ454	7299004				2022-12-18	WOS:A1981MQ45400010
J	GODFREY, S				GODFREY, S			RELATIVE MERITS OF CROMOLYN SODIUM AND HIGH-DOSE THEOPHYLLINE THERAPY IN CHILDHOOD ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review											GODFREY, S (corresponding author), HEBREW UNIV JERUSALEM,HADASSAH HOSP & MED SCH,DEPT PEDIAT,JERUSALEM,ISRAEL.							ANDERSON SD, 1975, BRIT J DIS CHEST, V69, P1; BELL T, 1978, PEDIATRICS, V62, P352; BERMAN BA, 1975, PEDIATRICS, V55, P621; BERNSTEIN IL, 1972, J ALLERGY CLIN IMMUN, V50, P235, DOI 10.1016/0091-6749(72)90017-6; BIERMAN CW, 1977, PEDIATRICS, V60, P845; CHAI H, 1970, 7 P INT C ALL, V232, P385; COX J S G, 1971, British Journal of Diseases of the Chest, V65, P189, DOI 10.1016/0007-0971(71)90028-3; CURRY SH, 1975, BRIT J CLIN PHARMACO, V2, P267, DOI 10.1111/j.1365-2125.1975.tb01586.x; DAWOOD AG, 1977, CLIN ALLERGY, V7, P161, DOI 10.1111/j.1365-2222.1977.tb01437.x; EDMONDS AT, 1979, BRIT J DIS CHEST, V73, P149; EDMUNDS AT, 1978, AM REV RESPIR DIS, V117, P247; ELLIS EF, 1976, PEDIATRICS, V58, P542; GODFREY S, 1976, THORAX, V31, P137, DOI 10.1136/thx.31.2.137; GODFREY S, 1978, ALLERGY, V33, P229, DOI 10.1111/j.1398-9995.1978.tb01542.x; GODFREY S, 1975, J PEDIATR-US, V87, P465, DOI 10.1016/S0022-3476(75)80663-9; GODFREY S, 1974, BTTA REV BRIT THO TU, V4, P1; HAMBLETON G, 1977, LANCET, V1, P381; HENDELES L, 1978, AM REV RESPIR DIS, V118, P97; HILLER EJ, 1977, ARCH DIS CHILD, V52, P875, DOI 10.1136/adc.52.11.875; HILLER EJ, 1975, BRIT J DIS CHEST, V69, P103; JENNE JW, 1972, CLIN PHARMACOL THER, V13, P349; JONES RS, 1962, BRIT J DIS CHEST, V56, P78, DOI 10.1016/S0007-0971(62)80005-9; KONIG P, 1973, CLIN ALLERGY, V3, P395, DOI 10.1111/j.1365-2222.1973.tb01347.x; MCKENZIE S, 1979, J INT MED RES, V7, P22; MCKENZIE SA, 1978, ARCH DIS CHILD, V53, P167, DOI 10.1136/adc.53.2.167; MCNICOL KN, 1973, BRIT MED J, V4, P7, DOI 10.1136/bmj.4.5883.7; MITENKO PA, 1973, NEW ENGL J MED, V289, P600, DOI 10.1056/NEJM197309202891202; ORR TSC, 1975, ACTA ALLERGOL, V30, P13, DOI 10.1111/j.1398-9995.1975.tb02305.x; PEPYS J, 1968, LANCET, V2, P134; POLLOCK J, 1977, PEDIATRICS, V60, P840; SETTIPANE GA, 1979, JAMA-J AM MED ASSOC, V241, P811, DOI 10.1001/jama.241.8.811; SILVERMAN M, 1973, THORAX, V28, P574, DOI 10.1136/thx.28.5.574; SILVERMAN M, 1972, BMJ-BRIT MED J, V3, P378, DOI 10.1136/bmj.3.5823.378; SILVERMAN M, 1972, ARCH DIS CHILD, V47, P419, DOI 10.1136/adc.47.253.419; SMITH J M, 1972, Clinical Allergy, V2, P143, DOI 10.1111/j.1365-2222.1972.tb01279.x; SMITH JM, 1968, BRIT MED J, V1, P340; TREMBATH PW, 1979, J INT MED RES, V7, P4; TURNERWARWICK M, 1957, BRIT MED J, V2, P67, DOI 10.1136/bmj.2.5036.67; WEINBERG.MM, 1974, J PEDIATR-US, V84, P421; WEINBERGER M, 1978, NEW ENGL J MED, V299, P852, DOI 10.1056/NEJM197810192991603; WEINBERGER M, 1978, J PEDIATR-US, V92, P1, DOI 10.1016/S0022-3476(78)80058-4; 1972, BRIT MED J, V4, P383; 1976, BRIT MED J, V1, P361	43	22	22	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	65	2					97	104		10.1016/0091-6749(80)90192-X	http://dx.doi.org/10.1016/0091-6749(80)90192-X			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JF199	6766152				2022-12-18	WOS:A1980JF19900003
J	WATT, GD; BUI, TC; BEWTRA, AK; TOWNLEY, RG				WATT, GD; BUI, TC; BEWTRA, AK; TOWNLEY, RG			PROTECTIVE EFFECT OF LODOXAMIDE TROMETHAMINE ON ALLERGEN INHALATION CHALLENGE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CREIGHTON UNIV,SCH MED,OMAHA,NE 68178; UNIV HOSP JACKSONVILLE,DEPT PEDIAT,JACKSONVILLE,FL 32209	Creighton University; State University System of Florida; University of Florida								CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; COX JSG, 1967, NATURE, V216, P1328, DOI 10.1038/2161328a0; DUNNETT CW, 1955, J AM STAT ASSOC, V50, P1096, DOI 10.2307/2281208; JOHNSON H, 1978, INT ARCH ALLERGY APP, V56, P487; JOHNSON HG, 1978, INT ARCH ALLER A IMM, V56, P416, DOI 10.1159/000232051; KANG B, 1976, BMJ-BRIT MED J, V1, P867, DOI 10.1136/bmj.1.6014.867; KOLOTKIN BM, 1974, J ALLERGY CLIN IMMUN, V53, P288, DOI 10.1016/0091-6749(74)90108-0; RYO UY, 1976, JAMA-J AM MED ASSOC, V236, P927; TAYLOR WA, 1974, INT ARCH ALLER A IMM, V47, P175, DOI 10.1159/000231212; TOWNLEY RG, 1975, ADV ASTHMA ALLERGY, V2, P7	10	22	25	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	66	4					286	294		10.1016/0091-6749(80)90023-8	http://dx.doi.org/10.1016/0091-6749(80)90023-8			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KM254	7419830				2022-12-18	WOS:A1980KM25400005
J	WICHER, K; REISMAN, RE				WICHER, K; REISMAN, RE			ANAPHYLACTIC REACTION TO PENICILLIN (OR PENICILLIN-LIKE SUBSTANCE) IN A SOFT DRINK	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SUNY BUFFALO,DEPT MED,BUFFALO,NY 14214; SUNY BUFFALO,DEPT MICROBIOL,BUFFALO,NY 14214; BUFFALO GEN HOSP,ALLERGY RES LAB,BUFFALO,NY 14203; ERIE CTY LAB,DIV MICROBIOL & IMMUNOL,BUFFALO,NY	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Buffalo General Medical Center								REISMAN RE, 1968, J AMER MED ASSOC, V203, P986; SIEGEL B B, 1959, Bull World Health Organ, V21, P703; WELCH H, 1957, AM J PUBLIC HEALTH N, V47, P701, DOI 10.2105/AJPH.47.6.701; WICHER K, 1969, J AMER MED ASSOC, V208, P143, DOI 10.1001/jama.208.1.143	4	22	22	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	66	2					155	157		10.1016/0091-6749(80)90063-9	http://dx.doi.org/10.1016/0091-6749(80)90063-9			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KD119	6967496				2022-12-18	WOS:A1980KD11900010
J	MAY, JC; SIH, JTC; MILLER, JR; SELIGMANN, EB				MAY, JC; SIH, JTC; MILLER, JR; SELIGMANN, EB			OPTIMIZATION OF PARAMETERS IN PROTEIN NITROGEN UNIT PRECIPITATION PROCEDURE FOR ALLERGENIC EXTRACTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											MAY, JC (corresponding author), BUR BIOL,DIV CONTROL ACTIV,8800 ROCKVILLE PIKE,BETHESDA,MD 20014, USA.							BAER H, COMMUNICATION; BERRENS L, 1971, CHEM ATOPIC ALLERGEN, P203; BLAEDEL WJ, 1963, ELEMENTARY QUANTITAT, P203; Brown EA, 1943, J IMMUNOL, V47, P89; COOKE RA, 1933, J ALLERGY, V4, P87; COOKE RA, 1947, ALLERGY THEORY PRACT, P529; GLEICH GJ, 1976, MANUAL CLIN IMMUNOLO, P575; HORWITZ W, 1975, OFFICIAL METHODS ANA, P927; KABAT EA, 1961, EXPERIMENTAL IMMUNOC, P476; STULL ARTHUR, 1933, JOUR ALLERGY, V4, P455, DOI 10.1016/S0021-8707(33)90098-2; VERSIE R, 1965, ACTA ALLERGOL, V20, P15, DOI 10.1111/j.1398-9995.1965.tb03352.x	11	22	22	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	63	2					87	97		10.1016/0091-6749(79)90197-0	http://dx.doi.org/10.1016/0091-6749(79)90197-0			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GJ748	759467	Bronze			2022-12-18	WOS:A1979GJ74800005
J	GARACI, E; RONCHETTI, R; DELGOBBO, V; TRAMUTOLI, G; RINALDIGARACI, C; IMPERATO, C				GARACI, E; RONCHETTI, R; DELGOBBO, V; TRAMUTOLI, G; RINALDIGARACI, C; IMPERATO, C			DECREASED SERUM THYMIC FACTOR ACTIVITY IN ASTHMATIC-CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV ROME,INST MICROBIOL,PEDIAT CLIN 2,I-00100 ROME,ITALY; UNIV ROME,CHAIR GEN PATHOL 2,I-00100 ROME,ITALY	Sapienza University Rome; Sapienza University Rome				RINALDI, Cristina/0000-0002-7445-1854				AAS K, 1971, J ALLERGY CLIN IMMUN, V48, P143; BACH JF, 1973, IMMUNOLOGY, V25, P353; BACH JF, 1975, ANN NY ACAD SCI, V249, P186, DOI 10.1111/j.1749-6632.1975.tb29068.x; BACH JF, 1976, PROG ALLERGY, V21, P342, DOI 10.1159/000314007; BACH JF, 1972, J UROL NEPHROL, V78, P994; BACH JF, 1973, TRANSPL P, V5, P523; BACH MA, 1976, J IMMUNOL, V117, P760; BARTHOLD DR, 1974, J IMMUNOL, V112, P9; BEKKUM DW, 1975, BIOL ACTIVITY THYMIC; BLAYLOCK WK, 1976, J ALLERGY CLIN IMMUN, V57, P62, DOI 10.1016/0091-6749(76)90080-4; DEVRIES MJ, 1967, IMMUNOLOGY, V12, P179; DJACZENKO W, 1976, CLIN IMMUNOL IMMUNOP, V6, P213, DOI 10.1016/0090-1229(76)90113-6; FRICK OL, 1970, J ALLERGY, V45, P220, DOI 10.1016/0021-8707(70)90133-4; GARACI E, 1976, EXPERIENTIA, V32, P1475, DOI 10.1007/BF01937444; GLEICH GJ, 1970, J ALLERGY, V45, P108; GOTTLIEB BR, 1974, CLIN RES, V22, P159; GROVE DI, 1975, J ALLERGY CLIN IMMUN, V55, P152, DOI 10.1016/0091-6749(75)90011-1; GUPTA S, 1975, J ALLERGY CLIN IMMUN, V55, P99; Hall R, 1966, Clin Exp Immunol, V1, P285; HENDERSON LL, 1971, J ALLERGY CLIN IMMUN, V48, P361, DOI 10.1016/0091-6749(71)90082-0; KUMAR L, 1971, J ALLERGY CLIN IMMUN, V48, P305, DOI 10.1016/0091-6749(71)90032-7; LAKIN JD, UNPUBLISHED; Mancini G, 1965, Immunochemistry, V2, P235, DOI 10.1016/0019-2791(65)90004-2; MILLER JFA, 1963, WOLSTENHOLME KNIGHT, P62; MILLER JFAP, 1975, ANN NY ACAD SCI, V249, P9, DOI 10.1111/j.1749-6632.1975.tb29052.x; OKUMURA K, 1971, J IMMUNOL, V106, P1019; OKUMURA K, 1971, J IMMUNOL, V107, P6; ROWE DS, 1970, INT ARCH ALLER A IMM, V39, P1; SERAFINI U, 1965, LANCET, V2, P81; SERAFINI U, 1965, WORLD ASTHMA C EASTB, P73; TADA T, 1972, J IMMUNOL, V108, P1535; THURMAN GB, 1975, B I SIEROTER MILAN, V54, P203; WIDE L, 1967, LANCET, V2, P1105; WIDE L, 1966, BIOCHIM BIOPHYS ACTA, V130, P257, DOI 10.1016/0304-4165(66)90032-8	34	22	22	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	62	6					357	362		10.1016/0091-6749(78)90136-7	http://dx.doi.org/10.1016/0091-6749(78)90136-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GA292	309476	Bronze			2022-12-18	WOS:A1978GA29200007
J	GELLER, M; FLAHERTY, DK; DICKIE, HA; REED, CE				GELLER, M; FLAHERTY, DK; DICKIE, HA; REED, CE			LYMPHOPENIA IN ACUTE NITROFURANTOIN PLEUROPULMONARY REACTIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WISCONSIN,CTR HLTH SCI,ALLERGY IMMUNOL SECT,MADISON,WI 53706; UNIV WISCONSIN,CTR HLTH SCI,CHEST MED SECT,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison								BONE RC, 1976, AM J MED, V60, P697, DOI 10.1016/0002-9343(76)90505-2; FLAHERTY DK, 1976, AM REV RESPIR DIS, V114, P1093; GELLER DP, 1976, DISCRETE MATH, V6, P9, DOI 10.1016/0012-365X(76)90089-3; GELLER M, 1976, ANN ALLERGY, V37, P275; GOLDSTEIN R A, 1974, Medical Annals of the District of Columbia, V43, P115; HAILEY FJ, 1969, NEW ENGL J MED, V281, P1087, DOI 10.1056/NEJM196911132812002; ISRAEL HL, 1962, NEW ENGL J MED, V266, P1024, DOI 10.1056/NEJM196205172662002; LUNDGREN R, 1975, SCAND J RESPIR DIS, V56, P208; PEARSALL HR, 1974, J LAB CLIN MED, V83, P728; ROCKLIN RE, 1971, J ALLERGY CLIN IMMUN, V48, P276, DOI 10.1016/0091-6749(71)90028-5; ROSENOW EC, 1972, ANN INTERN MED, V77, P977, DOI 10.7326/0003-4819-77-6-977	11	22	22	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	59	6					445	448		10.1016/0091-6749(77)90008-2	http://dx.doi.org/10.1016/0091-6749(77)90008-2			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DJ990	864103				2022-12-18	WOS:A1977DJ99000007
J	WESTON, WL; HUMBERT, JR; AUGUST, CS; HARNETT, J; MASS, MF; DEAN, PB; HAGEN, IM				WESTON, WL; HUMBERT, JR; AUGUST, CS; HARNETT, J; MASS, MF; DEAN, PB; HAGEN, IM			HYPER-IMMUNOGLOBULIN-E SYNDROME WITH NORMAL CHEMOTAXIS INVITRO AND DEFECTIVE LEUKOTAXIS INVIVO	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV COLORADO,MED CTR,DEPT MED,DENVER,CO 80220; UNIV COLORADO,MED CTR,DEPT PEDIAT,DENVER,CO 80220; UNIV COLORADO,MED CTR,DEPT DERMATOL,DENVER,CO 80220	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver								BAISERO MH, 1973, SCHWEIZ MED WSCHR, V103, P1599; BUCKLEY RH, 1972, PEDIATRICS, V49, P59; CLARK RA, 1973, ANN INTERN MED, V78, P595; EHLENBERGER AG, 1976, J CLIN INVEST, V57, P53, DOI 10.1172/JCI108268; EIFE RF, 1974, CELL IMMUNOL, V14, P435, DOI 10.1016/0008-8749(74)90194-4; EIFE RF, 1973, CELL IMMUNOL, V9, P163, DOI 10.1016/0008-8749(73)90177-9; GLEICH GJ, 1971, J LAB CLIN MED, V77, P690; HILL HR, 1974, LANCET, V2, P617; HILL HR, 1974, LANCET, V1, P183; HILL HR, 1975, PHAGOCYTIC CELL HOST; MASS MF, 1975, J LAB CLIN MED, V86, P1040; NISHIURA M, 1974, IMMUNOLOGY, V27, P1023; SNYDERMAN R, 1968, J EXP MED, V128, P259, DOI 10.1084/jem.128.2.259; STIEHM ER, 1973, IMMUNOLOGIC DISORDER, P152; TAN JS, 1971, J LAB CLIN MED, V78, P316; VANEPPS DE, 1974, J IMMUNOL, V113, P189; Weston W L, 1975, Int J Dermatol, V14, P699, DOI 10.1111/j.1365-4362.1975.tb00086.x; WESTON WL, 1975, J IMMUNOL METHODS, V8, P213, DOI 10.1016/0022-1759(75)90114-3	18	22	22	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	59	2					115	119		10.1016/0091-6749(77)90212-3	http://dx.doi.org/10.1016/0091-6749(77)90212-3			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CV622	299862				2022-12-18	WOS:A1977CV62200004
J	CRAWFORD, LV; LIEBERMAN, P; HARFI, HA; HALE, R; NELSON, H; SELNER, J; WITTIG, H; POSTMAN, M; ZIETZ, H				CRAWFORD, LV; LIEBERMAN, P; HARFI, HA; HALE, R; NELSON, H; SELNER, J; WITTIG, H; POSTMAN, M; ZIETZ, H			DOUBLE-BLIND-STUDY OF SUBCUTANEOUS FOOD TESTING SPONSORED BY FOOD COMMITTEE OF AMERICAN ACADEMY OF ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	22	22	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	57	3					236	236						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BJ240					2022-12-18	WOS:A1976BJ24000114
J	REISMAN, RE; LIGHT, WC; WYPYCH, JI; ARBESMAN, CE				REISMAN, RE; LIGHT, WC; WYPYCH, JI; ARBESMAN, CE			IMMUNOLOGICAL STUDIES OF EFFECT OF WHOLE-BODY INSECT EXTRACTS IN TREATMENT OF STINGING INSECT ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									BUFFALO GEN HOSP,ALLERGY RES LAB,BUFFALO,NY 14203; SUNY BUFFALO,DEPT MED,BUFFALO,NY; SUNY BUFFALO,DEPT MICROBIOL,BUFFALO,NY	Buffalo General Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo								BARNARD JH, 1973, J ALLERGY CLIN IMMUN, V52, P259, DOI 10.1016/0091-6749(73)90044-4; BENTON AW, 1963, SCIENCE, V142, P228, DOI 10.1126/science.142.3589.228; BUSSE WW, 1975, JAMA-J AM MED ASSOC, V231, P1154, DOI 10.1001/jama.231.11.1154; FUJITA Y, 1975, INT ARCH ALLERGY APP, V49, P727; ILEA V, 1975, J ALLERGY CLIN IMMUN, V55, P74; Lichtenstein L. M., 1975, Hospital Practice, V10, P67; LICHTENSTEIN LM, 1974, N ENGL J MED, V290, P122; REISMAN RE, 1975, J ALLERGY CLIN IMMUN, V56, P443, DOI 10.1016/0091-6749(75)90062-7; REISMAN RE, 1975, PEDIATR CLIN N AM, V22, P185; REISMAN RE, 1975, J ALLERGY CLIN IMMUN, V55, P79; REISMAN RE, 1975, INT ARCH ALLER A IMM, V48, P721, DOI 10.1159/000231360; SCHWARTZ HJ, 1965, J AMER MED ASSOC, V194, P703, DOI 10.1001/jama.194.7.703; SHEPHERD GW, 1974, PREP BIOCHEM, V4, P71, DOI 10.1080/00327487408068187; SOBOTKA AK, 1976, J ALLERGY CLIN IMMUN, V57, P29, DOI 10.1016/0091-6749(76)90076-2; SOBOTKA AK, 1974, J ALLERGY CLIN IMMUN, V53, P170, DOI 10.1016/0091-6749(74)90005-0; TORSNEY PJ, 1973, J ALLERGY CLIN IMMUN, V52, P303, DOI 10.1016/0091-6749(73)90049-3; WIDE L, 1967, LANCET, V2, P1105	17	22	22	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	57	6					547	553		10.1016/0091-6749(76)90005-1	http://dx.doi.org/10.1016/0091-6749(76)90005-1			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BV054	932341				2022-12-18	WOS:A1976BV05400005
J	JENNE, JW; STRICKLAND, RD; CHICK, TW; WALL, FJ				JENNE, JW; STRICKLAND, RD; CHICK, TW; WALL, FJ			INDUCTION OF BETA-RECEPTOR TOLERANCE BY TERBUTALINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	22	22	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	55	2					96	97						2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	V5498					2022-12-18	WOS:A1975V549800070
J	SOLOMON, WR; BURGE, HP				SOLOMON, WR; BURGE, HP			ASPERGILLUS-FUMIGATUS LEVELS INDOORS AND OUT-OF-DOORS IN URBAN AIR	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	22	22	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	55	2					90	91						2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	V5498					2022-12-18	WOS:A1975V549800055
J	RAYNOR, GS; OGDEN, EC; HAYES, JV				RAYNOR, GS; OGDEN, EC; HAYES, JV			VARIATION IN RAGWEED POLLEN CONCENTRATION TO A HEIGHT OF 108 METERS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									BROOKHAVEN NATL LAB,UPTON,NY 11973	United States Department of Energy (DOE); Brookhaven National Laboratory								HIRST JM, 1952, ANN APPL BIOL, V39, P257, DOI 10.1111/j.1744-7348.1952.tb00904.x; OGDEN EC, 1967, J ALLERGY, V40, P1, DOI 10.1016/0021-8707(67)90053-6; OGDEN EC, 1960, J ALLERGY, V31, P307, DOI 10.1016/0021-8707(60)90067-8; OGDEN EC, 1960, 378 NEW YORK STAT MU, P104; RAYNOR GS, 1968, J ALLERGY, V41, P217, DOI 10.1016/0021-8707(68)90044-0; RAYNOR GS, 1970, BNL50224T564, P33; SINGER IA, 1953, J METEOROL, V19, P121	7	22	22	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1973	51	4					199	207		10.1016/0091-6749(73)90139-5	http://dx.doi.org/10.1016/0091-6749(73)90139-5			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P3010	4689138				2022-12-18	WOS:A1973P301000002
J	RUPP, GH; WASSERMAN, K; OGAWA, M; HEINER, DC				RUPP, GH; WASSERMAN, K; OGAWA, M; HEINER, DC			BRONCHOPULMONARY FLUIDS IN PULMONARY ALVEOLAR PROTEINOSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF, HARBOR GEN HOSP, SCH MED, DEPT PEDIAT, LOS ANGELES, CA 90024 USA; UNIV CALIF, HARBOR GEN HOSP, SCH MED, DEPT INTERN MED, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center								BAZARAL M, 1972, J ALLERGY CLIN IMMUN, V49, P189, DOI 10.1016/0091-6749(72)90113-3; BUTLER WT, 1970, J IMMUNOL, V105, P584; COLON AR, 1971, AM J DIS CHILD, V121, P481, DOI 10.1001/archpedi.1971.02100170063006; DANIGELIS JA, 1969, AM J DIS CHILD, V118, P871, DOI 10.1001/archpedi.1969.02100040873010; FALK GA, 1972, AM REV RESPIR DIS, V105, P14; FRANK ST, 1969, SOUTHERN MED J, V62, P867, DOI 10.1097/00007611-196907000-00024; GLEICH GJ, 1971, J LAB CLIN MED, V77, P690; HALL GFM, 1960, LANCET, V1, P1383; HAND W L, 1972, Clinical Research, V20, P52; HAWKINS JE, 1967, AM J CLIN PATHOL, V48, P14; HEINER DC, 1970, CLIN EXP IMMUNOL, V6, P773; HIRAMOTO RN, 1970, P SOC EXP BIOL MED, V134, P996; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KEIMOWITZ RI, 1964, J LAB CLIN MED, V63, P54; KUHN C, 1966, LAB INVEST, V15, P492; LARSON RK, 1965, ANN INTERN MED, V62, P292, DOI 10.7326/0003-4819-62-2-292; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANCINI G, 1964, PROTIDES BIOLOGICAL, P370; MCCLENAHAN JB, 1972, CLIN RES, V20, P242; OUCHTERLONY O, 1958, PROG ALLERGY, V5, P1, DOI 10.1159/000273347; RAMIREZ RJ, 1965, AM REV RESPIR DIS, V94, P244; RAMIREZR J, 1968, AM J MED, V45, P502, DOI 10.1016/0002-9343(68)90166-6; RAMIREZR J, 1963, ARCH INTERN MED, V112, P419, DOI 10.1001/archinte.1963.03860030173021; ROSEN SH, 1958, NEW ENGL J MED, V258, P1123, DOI 10.1056/NEJM195806052582301; SCHULTZE HE, 1966, MOLECULAR BIOLOGY HU, V1, P176; SEARD C, 1970, AM REV RESPIR DIS, V101, P877; STANSIFER PD, 1965, AM J CLIN PATHOL, V44, P539; SUMMERS JE, 1966, CALIF MED, V104, P428; TAXAY EP, 1960, AM J CLIN PATHOL, V34, P532; Tomasi T B Jr, 1968, Adv Immunol, V9, P1, DOI 10.1016/S0065-2776(08)60441-1; WASSERMA.K, 1968, AM J MED, V44, P611, DOI 10.1016/0002-9343(68)90062-4; WASSERMAN K, 1952, Cardiologia, V21, P296, DOI 10.1159/000165210	32	22	22	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1973	51	4					227	237		10.1016/0091-6749(73)90142-5	http://dx.doi.org/10.1016/0091-6749(73)90142-5			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P3010	4631917				2022-12-18	WOS:A1973P301000005
J	SOLINGER, A; BERNSTEI.IL; GLUECK, HI				SOLINGER, A; BERNSTEI.IL; GLUECK, HI			EFFECT OF EPINEPHRINE ON PLATELET-AGGREGATION IN NORMAL AND ATOPIC SUBJECTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CINCINNATI,MED CTR,DEPT INTERN MED,DIV HEMATOL,COAGULATION LAB,CINCINNATI,OH 45229; UNIV CINCINNATI,MED CTR,DEPT INTERN MED,DIV IMMUNOL,CINCINNATI,OH 45229	University of Cincinnati; University of Cincinnati								BOURNE HR, 1972, J IMMUNOL, V108, P695; BUCHER HW, 1969, EXPERIENTIA, V25, P280, DOI 10.1007/BF02034393; CONNELL JT, 1967, J ALLERGY, V39, P358, DOI 10.1016/0021-8707(67)90048-2; FISHEL CW, 1970, FED P, V26, P640; HASLAM RJ, 1971, BIOCHEM J, V125, P377, DOI 10.1042/bj1250377; MILLS DCB, 1967, J PHYSIOL-LONDON, V193, P443, DOI 10.1113/jphysiol.1967.sp008369; MITCHELL JR, 1964, BRIT J HAEMATOL, V10, P78, DOI 10.1111/j.1365-2141.1964.tb00681.x; OBRIEN JR, 1962, J CLIN PATHOL, V15, P452; SALZMAN EW, 1972, NEW ENGL J MED, V286, P358; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2	10	22	22	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1973	51	1					29	34						6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	O5651	4682229				2022-12-18	WOS:A1973O565100004
J	HADDAD, ZH; CAMPBELL, DH; MARSH, DG				HADDAD, ZH; CAMPBELL, DH; MARSH, DG			STUDIES ON ALLERGOIDS PREPARED FROM NATURALLY OCCURRING ALLERGENS .2 EVALUATION OF ALLERGENICITY AND ASSAY OF ANTIGENICITY OF FORMALINIZED MIXED GRASS POLLEN EXTRACTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		AUGUSTIN R, 1959, IMMUNOLOGY, V2, P230; CARTER EB, 1935, Patent No. 2019808; CONNELL JT, 1964, J ALLERGY, V35, P169, DOI 10.1016/0021-8707(64)90031-0; CONNELL JT, 1969, J ALLERGY, V43, P22, DOI 10.1016/0021-8707(69)90017-3; FUCHS AM, 1959, J ALLERGY, V30, P66, DOI 10.1016/0021-8707(59)90060-7; JOHNSON P, 1966, IMMUNOCHEMISTRY, V3, P101, DOI 10.1016/0019-2791(66)90291-6; JOHNSON P, 1965, NATURE, V206, P935, DOI 10.1038/206935b0; JOHNSON P, 1965, EUR POLYM J, V1, P63; LEVY DA, 1971, J CLIN INVEST, V50, P360, DOI 10.1172/JCI106503; LICHTENS.LM, 1968, AM J MED, V44, P514, DOI 10.1016/0002-9343(68)90052-1; LICHTENSTEIN LM, 1968, J IMMUNOL, V101, P317; LICHTENSTEIN LM, 1966, J CLIN INVEST, V45, P1126, DOI 10.1172/JCI105419; LOVELESS MH, 1957, J IMMUNOL, V79, P68; Loveless MH, 1940, J IMMUNOL, V38, P25; Mancini G, 1965, Immunochemistry, V2, P235, DOI 10.1016/0019-2791(65)90004-2; MARSH DG, 1970, IMMUNOLOGY, V18, P705; MARSH DG, 1966, INT ARCH ALLER A IMM, V29, P521, DOI 10.1159/000229739; MARSH DG, 1971, INT ARCH ALLER A IMM, V40, P680; NATERMAN HL, 1965, J ALLERGY, V36, P226, DOI 10.1016/0021-8707(65)90080-8; NATERMAN HL, 1957, J ALLERGY, V28, P76, DOI 10.1016/0021-8707(57)90072-2; NORMAN PS, 1971, J ALLERGY, V47, P273, DOI 10.1016/S0091-6749(71)80005-2; NORMAN PS, 1970, J ALLERGY, V45, P114; PRUZANSKY JJ, 1968, J AMER MED ASSOC, V203, P805, DOI 10.1001/jama.203.9.805; SADAN N, 1969, NEW ENGL J MED, V280, P623, DOI 10.1056/NEJM196903202801201; SHERMAN WILLIAM B., 1940, JOUR ALLERGY, V11, P225, DOI 10.1016/S0021-8707(40)90568-8; STARR MS, 1970, INT ARCH ALLER A IMM, V38, P514, DOI 10.1159/000230304; STULL ARTHUR, 1940, JOUR ALLERGY, V11, P439, DOI 10.1016/S0021-8707(40)90456-7; VANARSDEL P, 1961, J ALLERGY, V32, P348, DOI 10.1016/0021-8707(61)90103-4	28	22	22	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1972	49	4					197	&		10.1016/0091-6749(72)90083-8	http://dx.doi.org/10.1016/0091-6749(72)90083-8			0	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M1477	4622163				2022-12-18	WOS:A1972M147700001
J	SPIES, JR; STEVAN, MA; STEIN, WJ				SPIES, JR; STEVAN, MA; STEIN, WJ			CHEMISTRY OF ALLERGENS .21. EIGHT NEW ANTIGENS GENERATED BY SUCCESSIVE PEPSIN HYDROLYSES OF BOVINE BETA-LACTOGLOBULIN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		COULSON EJ, 1953, J ALLERGY, V24, P458, DOI 10.1016/0021-8707(53)90048-3; HANSON LA, 1959, EXPERIENTIA, V15, P377, DOI 10.1007/BF02158961; HANSON LA, 1959, EXPERIENTIA, V15, P471, DOI 10.1007/BF02158261; HARTEN MAX, 1939, JOUR ALLERGY, V10, P478; OUCHTERLONY O, 1962, PROG ALLERGY, V6, P30, DOI 10.1159/000313795; SPIES JR, 1970, J ALLERGY, V45, P208, DOI 10.1016/0021-8707(70)90132-2; SPIES JR, 1945, J ALLERGY, V16, P267, DOI 10.1016/0021-8707(45)90012-8; WALZER ABRAHAM, 1935, JOUR ALLERGY, V6, P532, DOI 10.1016/S0021-8707(35)90248-9; Walzer Matthew, 1942, JOUR ALLERGY, V13, P554, DOI 10.1016/S0021-8707(42)90068-6	9	22	22	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1972	50	2					82	&		10.1016/0091-6749(72)90003-6	http://dx.doi.org/10.1016/0091-6749(72)90003-6			0	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	N1795	4114295				2022-12-18	WOS:A1972N179500003
J	Howard, E; Lewis, G; Galle-Treger, L; Hurrell, BP; Helou, DG; Shafiei-Jahani, P; Painter, JD; Muench, GA; Soroosh, P; Akbari, O				Howard, Emily; Lewis, Gavin; Galle-Treger, Lauriane; Hurrell, Benjamin P.; Helou, Doumet Georges; Shafiei-Jahani, Pedram; Painter, Jacob D.; Muench, German Aleman; Soroosh, Pejman; Akbari, Omid			IL-10 production by ILC2s requires Blimp-1 and cMaf, modulates cellular metabolism, and ameliorates airway hyperreactivity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Lung inflammation; group 2 innate lymphoid cell; AHR; IL-10; asthma; ILC2		Background: Group 2 innate lymphoid cells (ILC2s) are the dominant innate lymphoid cell population in the lungs at steady state, and their release of type 2 cytokines is a central driver in responding eosinophil infiltration and increased airway hyperreactivity. Our laboratory has identified a unique subset of ILC2s in the lungs that actively produce IL-10 (ILC2(10)s). Objective: Our aim was to characterize the effector functions of ILC2(10)s in the development and pathology of allergic asthma. Methods: IL-4-stimulated ILC2(10)s were isolated to evaluate cytokine secretion, transcription factor signaling, metabolic dependence, and effector functions in vitro. ILC2(10)s were also adoptively transferred into Rag2(-/-) gamma c(-/-) mice, which were then challenged with IL-33 and assessed for airway hyperreactivity and lung inflammation. Results: We have determined that the transcription factors cMaf and Blimp-1 regulate IL-10 expression in ILC2(10)s. Strikingly, our results demonstrate that ILC2(10)s can utilize both autocrine and paracrine signaling to suppress proinflammatory ILC2 effector functions in vitro. Further, this subset dampens airway hyperreactivity and significantly reduces lung inflammation in vivo. Interestingly, ILC2(10)s demonstrated a metabolic dependency on the glycolytic pathway for IL-10 production, shifting from the fatty acid oxidation pathway conventionally utilized for proinflammatory effector functions. Conclusion: These findings provide an important and previously unrecognized role of ILC2(10)s in diseases associated with ILC2s such as allergic lung inflammation and asthma. They also provide new insights into the metabolism dependency of proinflammatory and anti-inflammatory ILC2 phenotypes.	[Howard, Emily; Galle-Treger, Lauriane; Hurrell, Benjamin P.; Helou, Doumet Georges; Shafiei-Jahani, Pedram; Painter, Jacob D.; Akbari, Omid] Univ Southern Calif, Keck Sch Med, Dept Mol Microbiol & Immunol, NRT 5505,1450 Biggy St, Los Angeles, CA 90033 USA; [Lewis, Gavin; Muench, German Aleman; Soroosh, Pejman] Janssen Res & Dev, San Diego, CA USA	University of Southern California	Akbari, O (corresponding author), Univ Southern Calif, Keck Sch Med, Dept Mol Microbiol & Immunol, NRT 5505,1450 Biggy St, Los Angeles, CA 90033 USA.	akbari@usc.edu	HELOU, Georges Doumet/AAJ-9458-2021	HELOU, Georges Doumet/0000-0002-5835-9214; Painter, Jacob/0000-0003-0273-8597	National Institutes of Health Public Health Service [R01 ES025786, R01 ES021801, R01 HL144790, R21 AI109059]	National Institutes of Health Public Health Service(United States Department of Health & Human ServicesUnited States Public Health ServiceNational Institutes of Health (NIH) - USA)	Supported by the National Institutes of Health Public Health Service (grants R01 ES025786, R01 ES021801, R01 HL144790, and R21 AI109059 [to O.A.]).	Aguer C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028536; Akbari O, 2008, J IMMUNOL, V180, P5448, DOI 10.4049/jimmunol.180.8.5448; Angajala A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01605; Aron JL, 2017, ALLERGY, V72, P1148, DOI 10.1111/all.13139; Bal SM, 2016, NAT IMMUNOL, V17, P636, DOI 10.1038/ni.3444; Bando JK, 2020, J EXP MED, V217, DOI 10.1084/jem.20191520; Barlow JL, 2013, J ALLERGY CLIN IMMUN, V132, P933, DOI 10.1016/j.jaci.2013.05.012; Berod L, 2014, NAT MED, V20, P1327, DOI 10.1038/nm.3704; Buck MD, 2017, CELL, V169, P570, DOI 10.1016/j.cell.2017.04.004; Cameron GJM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00826; Cao Q, 2020, KIDNEY INT, V97, P130, DOI 10.1016/j.kint.2019.07.019; Cao SJ, 2005, J IMMUNOL, V174, P3484, DOI 10.4049/jimmunol.174.6.3484; Chang YJ, 2011, NAT IMMUNOL, V12, P631, DOI 10.1038/ni.2045; Gabrysova L, 2018, NAT IMMUNOL, V19, P497, DOI 10.1038/s41590-018-0083-5; Galle-Treger L, 2020, J ALLERGY CLIN IMMUN, V145, P502, DOI 10.1016/j.jaci.2019.10.035; Galle-Treger L, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08449-x; Garg G, 2019, CELL REP, V26, P1854, DOI 10.1016/j.celrep.2019.01.070; Golebski K, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09883-7; Helou DG, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17813-1; Hurrell BP, 2019, CELL REP, V29, P4509, DOI 10.1016/j.celrep.2019.11.102; Hurrell BP, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02694; Junttila IS, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00888; Kase ET, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059972; Lewis G, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02051; Li Y, 2019, CELL MOL IMMUNOL, V16, P75, DOI 10.1038/s41423-018-0182-0; Liu M, 2018, SCAND J IMMUNOL, V88, DOI 10.1111/sji.12701; Maazi H, 2017, IMMUNOL REV, V278, P192, DOI 10.1111/imr.12554; Maazi H, 2015, ONCOTARGET, V6, P24584, DOI 10.18632/oncotarget.5245; Martins GA, 2006, NAT IMMUNOL, V7, P457, DOI 10.1038/ni1320; Michalek RD, 2011, J IMMUNOL, V186, P3299, DOI 10.4049/jimmunol.1003613; Mindt BC, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00840; Miyamoto C, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08365-0; Monticelli LA, 2015, P NATL ACAD SCI USA, V112, P10762, DOI 10.1073/pnas.1509070112; Morita H, 2019, J ALLERGY CLIN IMMUN, V143, P2190, DOI 10.1016/j.jaci.2018.12.1018; Neumann C, 2014, J EXP MED, V211, P1807, DOI 10.1084/jem.20131548; Oeser K, 2015, ALLERGY, V70, P1440, DOI 10.1111/all.12705; Oh JW, 2002, J ALLERGY CLIN IMMUN, V110, P460, DOI 10.1067/mai.2002.127512; Ohne Y, 2016, NAT IMMUNOL, V17, P646, DOI 10.1038/ni.3447; Parsa R, 2012, DIABETES, V61, P2881, DOI 10.2337/db11-1635; Rigas D, 2017, J ALLERGY CLIN IMMUN, V139, P1468, DOI 10.1016/j.jaci.2016.08.034; Seehus CR, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02023-z; Sun MM, 2019, J IMMUNOL, V202, P79, DOI 10.4049/jimmunol.1701697; Symowski C, 2019, EUR J IMMUNOL, V49, P1421, DOI 10.1002/eji.201948161; Till SJ, 2004, J ALLERGY CLIN IMMUN, V113, P1025, DOI 10.1016/j.jaci.2004.03.024; Wang YH, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01909; Wilhelm C, 2016, J EXP MED, V213, P1409, DOI 10.1084/jem.20151448; Xie Q, 2016, J BIOL CHEM, V291, P3947, DOI 10.1074/jbc.M115.705103; Xu JN, 2009, J IMMUNOL, V182, P6226, DOI 10.4049/jimmunol.0900123; Xu M, 2018, NATURE, V554, P373, DOI 10.1038/nature25500; Yang WC, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01508; Zhang KN, 2017, J IMMUNOL, V198, P1798, DOI 10.4049/jimmunol.1601421; Zhu B, 2013, J IMMUNOL, V191, P3139, DOI 10.4049/jimmunol.1300329; Zhu JF, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01571	53	21	21	4	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2021	147	4					1281	+		10.1016/j.jaci.2020.08.024	http://dx.doi.org/10.1016/j.jaci.2020.08.024		APR 2021	20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RJ1NP	32905799				2022-12-18	WOS:000637368900018
J	Vandenborght, LE; Enaud, R; Urien, C; Coron, N; Girodet, PO; Ferreira, S; Berger, P; Delhaes, L				Vandenborght, Louise-Eva; Enaud, Raphael; Urien, Charlotte; Coron, Noemie; Girodet, Pierre-Olivier; Ferreira, Stephanie; Berger, Patrick; Delhaes, Laurence			Type 2-high asthma is associated with a specific indoor mycobiome and microbiome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Indoor environment; mycobiome; microbiome; severe asthma; FENO; type 2 asthma	EXHALED NITRIC-OXIDE; FUNGAL DIVERSITY; SPUTUM SAMPLES; BACTERIAL; DUST; DNA; COMMUNITIES; BURDEN; INNATE; RISK	Background: The links between microbial environmental exposures and asthma are well documented, but no study has combined deep sequencing results from pulmonary and indoor microbiomes of patients with asthma with spirometry, clinical, and endotype parameters. Objective: The goal of this study was to investigate the links between indoor microbial exposures and pulmonary microbial communities and to document the role of microbial exposures on inflammatory and clinical outcomes of patients with severe asthma (SA). Methods: A total of 55 patients with SA from the national Cohort of Bronchial Obstruction and Asthma cohort were enrolled for analyzing their indoor microbial flora through the use of electrostatic dust collectors (EDCs). Among these patients, 22 were able to produce sputum during "stable" or pulmonary "exacerbation" periods and had complete pairs of EDC and sputum samples, both collected and analyzed. We used amplicon targeted metagenomics to compare microbial communities from EDC and sputum samples of patients according to type 2 (T2)-asthma endotypes. Results: Compared with patients with T2-low SA, patients with T2-high SA exhibited an increase in bacterial alpha-diversity and a decrease in fungal alpha-diversity of their indoor microbial florae, the latter being significantly correlated with fraction of exhaled nitric oxide levels. The beta-diversity of the EDC mycobiome clustered significantly according to T2 endotypes. Moreover, the proportion of fungal taxa in common between the sputum and EDC samples was significantly higher when patients exhibited acute exacerbation. Conclusion: These results illustrated, for the first time, a potential association between the indoor mycobiome and clinical features of patients with SA, which should renew interest in deciphering the interactions between indoor environment, fungi, and host in asthma.	[Vandenborght, Louise-Eva; Enaud, Raphael; Girodet, Pierre-Olivier; Berger, Patrick; Delhaes, Laurence] Univ Bordeaux, Ctr Rech Cardiothorac Bordeaux, U1045, CIC 1401, F-33000 Bordeaux, France; [Vandenborght, Louise-Eva; Enaud, Raphael; Girodet, Pierre-Olivier; Berger, Patrick; Delhaes, Laurence] Ctr Rech Cardiothorac Bordeaux, INSERM, U1045, CIC 1401, F-33000 Bordeaux, France; [Vandenborght, Louise-Eva; Urien, Charlotte; Ferreira, Stephanie] GenoScreen, Dept Res & Dev, Microbiota Team, Lille, France; [Enaud, Raphael; Coron, Noemie; Girodet, Pierre-Olivier; Berger, Patrick; Delhaes, Laurence] CHU Bordeaux, Lab Parasitol Mycol, Serv Explorat Fonct Resp, Serv Pharmacol,CIC 1401, F-33604 Pessac, France	UDICE-French Research Universities; Universite de Bordeaux; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; CHU Bordeaux	Vandenborght, LE (corresponding author), Ctr Rech Cardio Thorac Bordeaux, Inserm, Plateforme Technol Innovat Biomed, Hop Xavier Arnozan,U1045, Ave Haut Leveque, F-33604 Pessac, France.	laurence.delhaes@u-bordeaux.fr	Berger, Patrick/D-8779-2012	Berger, Patrick/0000-0003-4702-0343; Girodet, Pierre-Olivier/0000-0002-9298-9711; Delhaes, Laurence/0000-0001-7489-9205; Enaud, Raphael/0000-0001-9493-5218	GenoScreen society; Fondation de l'Universite de Bordeaux (Fonds FGLMR/AVAD pour les maladies chroniques); Bronch-Asp project grant	GenoScreen society; Fondation de l'Universite de Bordeaux (Fonds FGLMR/AVAD pour les maladies chroniques); Bronch-Asp project grant	This work was supported by the GenoScreen society (which provided a grant to L.-E.V.) and Fondation de l'Universite de Bordeaux (Fonds FGLMR/AVAD pour les maladies chroniques), in which L.D. was a laureate (recipient of Bronch-Asp project grant).	Adams RI, 2015, MICROBIOME, V3, DOI 10.1186/s40168-015-0108-3; Agarwal R, 2013, CLIN EXP ALLERGY, V43, P850, DOI 10.1111/cea.12141; Bartemes KR, 2018, J ALLERGY CLIN IMMUN, V142, P353, DOI 10.1016/j.jaci.2018.06.015; Bassis CM, 2015, MBIO, V6, DOI 10.1128/mBio.00037-15; Butto LF, 2017, J ALLERGY CLIN IMMUN, V139, P1092, DOI 10.1016/j.jaci.2017.02.010; Caillaud D, 2018, EUR RESPIR REV, V27, DOI 10.1183/16000617.0137-2017; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Carpagnano GE, 2016, ALLERGY ASTHMA PROC, V37, pE41, DOI 10.2500/aap.2016.37.3943; Chien JW, 2013, CLIN EXP ALLERGY, V43, P1018, DOI 10.1111/cea.12119; Chung KF, 2017, ANN AM THORAC SOC, V14, pS326, DOI 10.1513/AnnalsATS.201702-138AW; Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013; Coombs K, 2018, SCI TOTAL ENVIRON, V610, P212, DOI 10.1016/j.scitotenv.2017.07.274; de Souza RSC, 2016, SCI REP-UK, V6, DOI 10.1038/srep28774; Dannemiller KC, 2014, INDOOR AIR, V24, P236, DOI 10.1111/ina.12072; Dannemiller KC, 2016, J ALLERGY CLIN IMMUN, V138, P76, DOI 10.1016/j.jaci.2015.11.027; Denning DW, 2014, CLIN TRANSL ALLERGY, V4, DOI 10.1186/2045-7022-4-14; Dixon P, 2003, J VEG SCI, V14, P927, DOI 10.1111/j.1654-1103.2003.tb02228.x; Durack J, 2017, J ALLERGY CLIN IMMUN, V140, P63, DOI 10.1016/j.jaci.2016.08.055; Edgar RC, 2010, BIOINFORMATICS, V26, P2460, DOI 10.1093/bioinformatics/btq461; Fraczek MG, 2018, J ALLERGY CLIN IMMUN, V142, P407, DOI 10.1016/j.jaci.2017.09.039; Global Initiative for Asthma, GINA ANN REP; Hanson B, 2016, ENVIRON SCI-PROC IMP, V18, P713, DOI [10.1039/c5em00639b, 10.1039/C5EM00639B]; Hauptmann M, 2016, FEBS LETT, V590, P3721, DOI 10.1002/1873-3468.12421; Hegarty B, 2018, INDOOR AIR, V28, P548, DOI 10.1111/ina.12459; Hermon L, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00089; Huang YJ, 2015, J ALLERGY CLIN IMMUN, V136, P874, DOI 10.1016/j.jaci.2015.05.044; Kuo CHS, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.02135-2016; Li NJ, 2017, RESP MED, V131, P192, DOI 10.1016/j.rmed.2017.08.016; Li XN, 2020, J ALLERGY CLIN IMMUN, V145, P430, DOI 10.1016/j.jaci.2019.08.031; Liu CM, 2012, BMC MICROBIOL, V12, DOI 10.1186/1471-2180-12-255; Loss GJ, 2016, AM J RESP CRIT CARE, V193, P889, DOI 10.1164/rccm.201507-1493OC; Loverdos K, 2019, J CLIN MED, V8, DOI 10.3390/jcm8111967; Martinez FD, 2019, AM J RESP CRIT CARE, V199, P397, DOI 10.1164/rccm.201901-0013ED; McMurdie PJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061217; Miskoff JA, 2019, CUREUS, V11, DOI 10.7759/cureus.4864; Mutius S, 2019, ERS MONOGRAPHS, V83; Nilsson RH, 2019, NAT REV MICROBIOL, V17, P95, DOI 10.1038/s41579-018-0116-y; Norback D, 2017, SCI TOTAL ENVIRON, V577, P148, DOI [10.1016/j.scitotenv.2016.10.148, 10.1016/j.scitotenv2016.10.148]; Nordon C, 2018, RESP MED, V144, P42, DOI 10.1016/j.rmed.2018.10.002; O'Connor GT, 2018, J ALLERGY CLIN IMMUN, V141, P1468, DOI 10.1016/j.jaci.2017.06.040; Ozier A, 2011, RESP MED, V105, P989, DOI 10.1016/j.rmed.2011.01.006; Paulson JN, 2013, NAT METHODS, V10, P1200, DOI [10.1038/NMETH.2658, 10.1038/nmeth.2658]; Pretolani M, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.00019-2017; Reboux G, 2019, INDOOR AIR, V29, P5, DOI 10.1111/ina.12516; Richardson M, 2019, MED MYCOL, V57, pS145, DOI 10.1093/mmy/myy149; Richardson M, 2019, MICROBIOME, V7, DOI 10.1186/s40168-019-0695-5; Rocchi S, 2017, J MICROBIOL METH, V139, P107, DOI 10.1016/j.mimet.2017.05.014; Rufo JC, 2017, PEDIAT ALLERG IMM-UK, V28, P332, DOI 10.1111/pai.12704; Scherer E, 2014, SCI TOTAL ENVIRON, V466, P716, DOI 10.1016/j.scitotenv.2013.07.054; Segata N, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-6-r60; Shan YF, 2019, INT MICROBIOL, V22, P297, DOI 10.1007/s10123-019-00057-5; Sharma A, 2019, J ALLERGY CLIN IMMUN, V144, P1214, DOI 10.1016/j.jaci.2019.06.025; Sharma A, 2018, CURR OPIN MICROBIOL, V44, P79, DOI 10.1016/j.mib.2018.08.003; Sharpe RA, 2015, J ALLERGY CLIN IMMUN, V135, P110, DOI 10.1016/j.jaci.2014.07.002; Silkoff PE, 2016, RESP RES, V17, DOI 10.1186/s12931-016-0360-5; Soret P, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60015-4; Stein MM, 2016, NEW ENGL J MED, V375, P411, DOI 10.1056/NEJMoa1508749; Sverrild A, 2017, J ALLERGY CLIN IMMUN, V140, P407, DOI 10.1016/j.jaci.2016.10.046; Tangedal S, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0645-3; Taylor SL, 2018, J ALLERGY CLIN IMMUN, V141, P94, DOI 10.1016/j.jaci.2017.03.044; Tham R, 2019, ENVIRON RES, V178, DOI 10.1016/j.envres.2019.108675; Tong XZ, 2017, MICROBIOME, V5, DOI 10.1186/s40168-017-0346-7; van Kampen V, 2019, AM J IND MED, V62, P663, DOI 10.1002/ajim.22996; van Woerden HC, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-69; Venkataraman A, 2015, MBIO, V6, DOI 10.1128/mBio.02284-14; Wang Q, 2007, APPL ENVIRON MICROB, V73, P5261, DOI 10.1128/AEM.00062-07; Whiteson KL, 2014, AM J RESP CRIT CARE, V189, P1309, DOI 10.1164/rccm.201312-2129PP; Yashiro E, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16132335; Zhang QL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152724	69	21	21	5	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2021	147	4					1296	+		10.1016/j.jaci.2020.08.035	http://dx.doi.org/10.1016/j.jaci.2020.08.035		APR 2021	16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RJ1NP	32926879	Bronze, Green Published			2022-12-18	WOS:000637368900019
J	Xia, L; Wang, X; Liu, LJ; Fu, JR; Xiao, WF; Liang, QY; Han, X; Huang, SH; Sun, LC; Gao, YJ; Zhang, CY; Yang, L; Wang, LB; Qian, LL; Zhou, YF				Xia, Li; Wang, Xiang; Liu, Lijuan; Fu, Jinrong; Xiao, Wenfeng; Liang, Qiuyan; Han, Xiao; Huang, Saihua; Sun, Licheng; Gao, Yajing; Zhang, Caiyan; Yang, Lan; Wang, Libo; Qian, Liling; Zhou, Yufeng			lnc-BAZ2B promotes M2 macrophage activation and inflammation in children with asthma through stabilizing BAZ2B pre-mRNA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; lncRNA; macrophage activation; BAZ2B	LONG NONCODING RNAS; EPIGENETIC REGULATION; REGULATORY ELEMENTS; T-CELLS; POLARIZATION; IL-8; ACETYLATION; SUPPRESSES; MECHANISMS; EXPRESSION	Background: Dysregulation of long noncoding RNAs (lncRNAs) is associated with a variety of human diseases; however, whether they have a role in childhood asthma is unknown. Objective: We sought to determine the differential expression profiles of lncRNAs in PBMCs of children with asthma and the mechanisms underlying the effects of lncRNAs on the pathogenesis of asthma. Methods: The differential expression profiles of lncRNAs were analyzed by transcriptome microarray. The effects and mechanisms by which lncRNAs influence macrophageactivation were detected by real-time quantitative PCR, Western blot, RNase protection assay, and chromatin immunoprecipitation assay. The roles played by lncRNAs in asthma were tested in a cockroach allergen extract (CRE)-induced mouse model. Results: We identified 719 lncRNAs that were differentially expressed in PBMCs of children with asthma, 502 of which were upregulated and 217 were downregulated. An lncRNA of unknown function, lnc-BAZ2B, was dominantly expressed in monocytes and significantly upregulated in children with asthma. lnc-BAZ2B promotes M2 macrophage activation by enhancing BAZ2B expression and exacerbated lung inflammation in an M2 macrophage-associated CRE-induced asthma model. Mechanistically, lnc-BAZ2B promoted the expression of its cis target gene BAZ2B by stabilizing its pre-mRNA. BAZ2B, a reader of H3K14ac modification, enhanced the transcription of IRF4 and promoted M2 macrophage activation. lnc-BAZ2B expression was correlated with that of BAZ2B in PBMCs from children with asthma. Baz2b knockdown could alleviate asthma severity in a CRE-induced asthma model. Conclusion: lnc-BAZ2B promotes M2 macrophage activation and inflammation in children with asthma and may serve as a potential therapeutic and diagnostic target in children with asthma.	[Xia, Li; Wang, Xiang; Liu, Lijuan; Fu, Jinrong; Xiao, Wenfeng; Liang, Qiuyan; Han, Xiao; Huang, Saihua; Sun, Licheng; Gao, Yajing; Zhang, Caiyan; Yang, Lan; Zhou, Yufeng] Fudan Univ, Inst Pediat, Childrens Hosp, Shanghai, Peoples R China; [Xia, Li; Wang, Xiang; Liu, Lijuan; Fu, Jinrong; Xiao, Wenfeng; Liang, Qiuyan; Han, Xiao; Huang, Saihua; Sun, Licheng; Gao, Yajing; Zhang, Caiyan; Yang, Lan; Zhou, Yufeng] Fudan Univ, Shanghai Key Lab Med Epigenet, Int Colab Med Epigenet & Metab, Minist Sci & Technol,Inst Biomed Sci, Shanghai, Peoples R China; [Liu, Lijuan; Fu, Jinrong; Wang, Libo; Qian, Liling] Fudan Univ, Dept Resp Med, Childrens Hosp, Shanghai, Peoples R China; [Zhou, Yufeng] Fudan Univ, Natl Hlth Commiss Key Lab Neonatal Dis, Shanghai, Peoples R China	Fudan University; Fudan University; Fudan University; Fudan University	Zhou, YF (corresponding author), 399 Wanyuan Rd, Shanghai 201102, Peoples R China.; Qian, LL (corresponding author), 399 Wanyuan Rd, Shanghai 201102, Peoples R China.	llqian@126.com; yfzhou1@fudan.edu.cn		zhou, Yufeng/0000-0002-6050-4951; wang, xiang/0000-0003-0992-8553; Xiao, WenFeng/0000-0002-4369-9371	National Key RAMP;D Program of China [2016YFC1305102]; National Natural Science Foundation of China [81671561, 81974248, 81900751]; International Joint Laboratory Program of National Children's Medical Center [EK1125180109]; Program for Outstanding Medical Academic Leader [2019LJ19]; Shanghai Municipal Planning Commission of Science and Research Fund [201740065, 20174Y0079]; Shanghai Pujiang Program [16PJ1401600]; Shanghai Committee of Science and Technology [19ZR1406400, 16411950700]	National Key RAMP;D Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); International Joint Laboratory Program of National Children's Medical Center; Program for Outstanding Medical Academic Leader; Shanghai Municipal Planning Commission of Science and Research Fund; Shanghai Pujiang Program(Shanghai Pujiang Program); Shanghai Committee of Science and Technology(Shanghai Science & Technology Committee)	This work was supported by grants from the National Key R&D Program of China (grant 2016YFC1305102 [to Y.Z.]), the National Natural Science Foundation of China (grants 81671561 and 81974248 to [Y.Z.] and grant 81900751 to [H.X.]), the International Joint Laboratory Program of National Children's Medical Center (grant EK1125180109 to [Y.Z.]), the Program for Outstanding Medical Academic Leader (grant 2019LJ19 [to Y.Z.]), the Shanghai Municipal Planning Commission of Science and Research Fund (grants 201740065 [to Y.Z.] and 20174Y0079 [to H.X.]), the Shanghai Pujiang Program (16PJ1401600 [to F.J.]), and the Shanghai Committee of Science and Technology (grants 19ZR1406400 [to F.J.] and 16411950700 [to L.Q.]).	Anastasiadou E, 2018, NAT REV CANCER, V18, P5, DOI 10.1038/nrc.2017.99; [Anonymous], 2018, GLOBAL ASTHMA REPORT; Bosco MC, 2019, J ALLERGY CLIN IMMUN, V143, P1348, DOI 10.1016/j.jaci.2018.12.995; Bouhlel MA, 2007, CELL METAB, V6, P137, DOI 10.1016/j.cmet.2007.06.010; Cao J, 2019, CANCER IMMUNOL RES, V7, P292, DOI 10.1158/2326-6066.CIR-18-0145; Charrad R, 2017, LUNG, V195, P749, DOI 10.1007/s00408-017-0058-6; Chi XW, 2019, J CELL PHYSIOL, V234, P13242, DOI 10.1002/jcp.27996; Du M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02229-1; Fahy JV, 2015, NAT REV IMMUNOL, V15, P57, DOI 10.1038/nri3786; Fan MY, 2019, BIOCHEM BIOPH RES CO, V508, P749, DOI 10.1016/j.bbrc.2018.11.187; Ferguson FM, 2014, BIOCHEMISTRY-US, V53, P6706, DOI 10.1021/bi500909d; Filippakopoulos P, 2012, CELL, V149, P214, DOI 10.1016/j.cell.2012.02.013; Girodet PO, 2016, AM J RESP CELL MOL, V55, P467, DOI 10.1165/rcmb.2015-0295OC; Global Initiative for Asthma, 2018, GLOB STRAT ASTHM MAN; Gong CG, 2011, NATURE, V470, P284, DOI 10.1038/nature09701; Grob M, 2003, ALLERGY, V58, P239, DOI 10.1034/j.1398-9995.2003.00035.x; Guetg C, 2010, EMBO J, V29, P2135, DOI 10.1038/emboj.2010.17; Han X, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aax9230; Hong JG, 2018, J ASTHMA, V55, P1138, DOI 10.1080/02770903.2017.1396474; Hsieh KH, 1996, J ALLERGY CLIN IMMUN, V98, P580, DOI 10.1016/S0091-6749(96)70092-1; Hu WQ, 2012, EMBO REP, V13, P971, DOI 10.1038/embor.2012.145; Ishii M, 2009, BLOOD, V114, P3244, DOI 10.1182/blood-2009-04-217620; Ivashkiv LB, 2013, TRENDS IMMUNOL, V34, P216, DOI 10.1016/j.it.2012.11.001; Jiang XG, 2018, J ASTHMA, V55, P111, DOI 10.1080/02770903.2017.1318141; Karmodiya K, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-424; Kostrhon S, 2017, J BIOL CHEM, V292, P17643, DOI 10.1074/jbc.M117.801464; Kueh AJ, 2011, MOL CELL BIOL, V31, P845, DOI 10.1128/MCB.00159-10; Lloyd CM, 2010, NAT REV IMMUNOL, V10, P838, DOI 10.1038/nri2870; Martinez-Nunez RT, 2011, J BIOL CHEM, V286, P1786, DOI 10.1074/jbc.M110.169367; Mishima Y, 2011, BLOOD, V118, P2443, DOI 10.1182/blood-2011-01-331892; Murray PJ, 2017, ANNU REV PHYSIOL, V79, P541, DOI 10.1146/annurev-physiol-022516-034339; Poole JA, 2009, AM J PHYSIOL-LUNG C, V296, pL1085, DOI 10.1152/ajplung.90622.2008; Qiu YY, 2019, BIOMED PHARMACOTHER, V111, P386, DOI 10.1016/j.biopha.2018.12.080; Saradna A, 2018, TRANSL RES, V191, P1, DOI 10.1016/j.trsl.2017.09.002; Satoh T, 2010, NAT IMMUNOL, V11, P936, DOI 10.1038/ni.1920; Sha Li, 2015, Zhonghua Jie He He Hu Xi Za Zhi, V38, P664; Sigdel KR, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/848790; Sun LC, 2020, J ALLERGY CLIN IMMUN, V145, P402, DOI 10.1016/j.jaci.2019.10.008; The Subspecialty Group of Respiratory Diseases The Society of PediatricsChinese Medical Association Editorial Board of Chinese Journal of Pediatrics, 2016, ZHONGHUA ER KE ZA ZH, V54, P167, DOI [10.3760/cma.j.issn.0578-1310.2016.03.003, DOI 10.3760/EMA.J.ISSN.0578-1310.2016.03.003]; Tripathi V, 2010, MOL CELL, V39, P925, DOI 10.1016/j.molcel.2010.08.011; Turner M, 2014, NAT IMMUNOL, V15, P484, DOI 10.1038/ni.2887; Wang CX, 2017, MOL THER, V25, P192, DOI 10.1016/j.ymthe.2016.09.001; Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018; Wapinski O, 2011, TRENDS CELL BIOL, V21, P354, DOI 10.1016/j.tcb.2011.04.001; Wei JW, 2017, ONCOL REP, V37, P3, DOI 10.3892/or.2016.5236; Yang IV, 2012, J ALLERGY CLIN IMMUN, V130, P1243, DOI 10.1016/j.jaci.2012.07.052; Yang XS, 2014, MOL ENDOCRINOL, V28, P565, DOI 10.1210/me.2013-1293; Yoon JH, 2012, MOL CELL, V47, P648, DOI 10.1016/j.molcel.2012.06.027; Zhang Y, 2016, CELL MOL IMMUNOL, V13, P138, DOI 10.1038/cmi.2015.68; Zhou YF, 2018, J ALLERGY CLIN IMMUN, V141, P350, DOI 10.1016/j.jaci.2017.04.049	50	21	22	6	22	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2021	147	3					921	+		10.1016/j.jaci.2020.06.034	http://dx.doi.org/10.1016/j.jaci.2020.06.034		MAR 2021	21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RA9TV	32712329				2022-12-18	WOS:000631762400014
J	Francuzik, W; Rueff, F; Bauer, A; Bilo, MB; Cardona, V; Christoff, G; Dolle-Bierke, S; Ensina, L; Rivas, MF; Hawranek, T; Hourihane, JO; Jakob, T; Papadopoulos, NG; Pfohler, C; Poziomkowska-Gesicka, I; Van der Brempt, X; Hofmeier, KS; Treudler, R; Wagner, N; Wedi, B; Worm, M				Francuzik, Wojciech; Rueeff, Franziska; Bauer, Andrea; Bilo, Maria Beatrice; Cardona, Victoria; Christoff, George; Doelle-Bierke, Sabine; Ensina, Luis; Rivas, Montserrat Fernandez; Hawranek, Thomas; Hourihane, Jonathan O'b; Jakob, Thilo; Papadopoulos, Nicos G.; Pfoehler, Claudia; Poziomkowska-Gesicka, Iwona; Van der Brempt, Xavier; Hofmeier, Kathrin Scherer; Treudler, Regina; Wagner, Nicola; Wedi, Bettina; Worm, Margitta			Phenotype and risk factors of venom-induced anaphylaxis: A case-control study of the European Anaphylaxis Registry	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anaphylaxis; epinephrine (adrenaline); beta-blockers; insect venom allergy; Hymenoptera	KIT D816V MUTATION; ALLERGY; HYMENOPTERA; MASTOCYTOSIS; ACADEMY; ADULTS; BLOOD	Background: Venom-induced anaphylaxis (VIA) is a common, potentially life-threatening hypersensitivity reaction associated with (1) a specific symptom profile, 2) specific cofactors, and 3) specific management. Identifying the differences in phenotypes of anaphylaxis is crucial for future management guidelines and development of a personalized medicine approach. Objective: This study aimed to evaluate the phenotype and risk factors of VIA. Methods: Using data from the European Anaphylaxis Registry (12,874 cases), we identified 3,612 patients with VIA and analyzed their cases in comparison with sex- and age-matched anaphylaxis cases triggered by other elicitors (non-VIA cases [n = 3,605]). Results: VIA more frequently involved more than 3 organ systems and was associated with cardiovascular symptoms. The absence of skin symptoms during anaphylaxis was correlated with baseline serum tryptase level and was associated with an increased risk of a severe reaction. Intramuscular or intravenous epinephrine was administered significantly less often in VIA, in particular, in patients without a history of anaphylaxis. A baseline serum tryptase level within the upper normal range (8-11.5 ng/mL) was more frequently associated with severe anaphylaxis. Conclusion: Using a large cohort of VIA cases, we have validated that patients with intermediate baseline serum tryptase levels (8-11 ng/mL) and without skin involvement have a higher risk of severe VIA. Patients receiving beta-blockers or angiotensin-converting enzyme inhibitors had a higher risk of developing severe cardiovascular symptoms (including cardiac arrest) in VIA and non-VIA cases. Patients experiencing VIA received epinephrine less frequently than did cases with non-VIA.	[Francuzik, Wojciech; Doelle-Bierke, Sabine; Worm, Margitta] Charite Univ Med Berlin, Div Allergy & Immunol, Dept Dermatol Venerol & Allergol, Berlin, Germany; [Francuzik, Wojciech; Doelle-Bierke, Sabine; Worm, Margitta] Free Univ Berlin, Berlin, Germany; [Francuzik, Wojciech; Doelle-Bierke, Sabine; Worm, Margitta] Humboldt Univ, Berlin, Germany; [Francuzik, Wojciech; Doelle-Bierke, Sabine; Worm, Margitta] Berlin Inst Hlth, Berlin, Germany; [Rueeff, Franziska] Ludwig Maximilians Univ Munchen, Dept Dermatol & Allergy, Munich, Germany; [Bauer, Andrea] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Univ Allergy Ctr, Dresden, Germany; [Bilo, Maria Beatrice] Univ Hosp Osped Riuniti Ancona, Dept Internal Med, Allergy Unit, Ancona, Italy; [Bilo, Maria Beatrice] Polytech Univ Marche, Dept Clin & Mol Sci, Ancona, Italy; [Cardona, Victoria] Hosp Valle De Hebron, Dept Internal Med, Allergy Sect, Barcelona, Spain; [Cardona, Victoria; Rivas, Montserrat Fernandez] ARADyAL Res Network, Madrid, Spain; [Christoff, George] Med Univ Sofia, Fac Publ Hlth, Sofia, Bulgaria; [Christoff, George] Tokuda Med Ctr, Allergy Outpatient Dept, Acibadem CityClin, Sofia, Bulgaria; [Ensina, Luis] Univ Fed Sao Paulo, Dept Pediat, Div Allergy Clin Immunol & Rheumatol, Sao Paulo, SP, Brazil; [Rivas, Montserrat Fernandez] Univ Complutense, Hosp Clin San Carlos, IdISSC, Dept Allergy, Madrid, Spain; [Hawranek, Thomas] Paracelsus Med Univ, Univ Hosp Salzburg, Dept Dermatol, Salzburg, Austria; [Hourihane, Jonathan O'b] DM Univ Coll Cork, Cork, Ireland; [Hourihane, Jonathan O'b] Cork Univ Hosp, Cork, Ireland; [Jakob, Thilo] Justus Liebig Univ Giessen, Univ Med Ctr Giessen & Marburg, Dept Dermatol & Allergol, Giessen, Germany; [Jakob, Thilo] Univ Freiburg, Allergy Res Grp, Med Ctr, Freiburg, Germany; [Papadopoulos, Nicos G.] Natl & Kapodistrian Univ Athens, Allergy Dept, Pediat Clin 2, Athens, Greece; [Papadopoulos, Nicos G.] Univ Manchester, Div Infect Immun & Resp Med, Manchester, Lancs, England; [Pfoehler, Claudia] Saarland Univ, Dept Dermatol, Med Ctr, Homburg, Germany; [Poziomkowska-Gesicka, Iwona] Pomeranian Med Univ, Clin Allergol Dept, Szczecin, Poland; [Van der Brempt, Xavier] Allergy Vigilance Network, Nancy, France; [Hofmeier, Kathrin Scherer] Univ Basel, Univ Hosp Basel, Dept Dermatol, Div Allergy, Basel, Switzerland; [Treudler, Regina] Univ Hosp, Dept Dermatol Venereol & Allergol, Leipzig Interdisciplinary Allergy Ctr, Comprehens Allergy Ctr, Leipzig, Germany; [Wagner, Nicola] Friedrich Alexander Univ Erlangen Nurnberg, Univ Hosp Erlangen, Dept Dermatol, Erlangen, Germany; [Wedi, Bettina] Hannover Med Sch, Comprehens Allergy Ctr, Dept Dermatol & Allergy, Hannover, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Berlin Institute of Health; University of Munich; Technische Universitat Dresden; Carl Gustav Carus University Hospital; Marche Polytechnic University; Hospital Universitari Vall d'Hebron; Medical University Sofia; Universidade Federal de Sao Paulo (UNIFESP); Complutense University of Madrid; Hospital Clinico San Carlos; Paracelsus Private Medical University; University College Cork; Justus Liebig University Giessen; University Hospital of Giessen & Marburg; University of Freiburg; National & Kapodistrian University of Athens; University of Manchester; Universitatsklinikum des Saarlandes; Pomeranian Medical University; University of Basel; Leipzig University; University of Erlangen Nuremberg; Hannover Medical School	Worm, M (corresponding author), Klin Dermatol Venerol & Allergol, Charitepl 1, D-10117 Berlin, Germany.	margitta.worm@charite.de	Francuzik, Wojciech/H-6773-2019; Christoff, George/ABF-9789-2021; VAN DER BREMPT, Xavier/GLT-1646-2022; Wedi, Bettina/ABE-3636-2021; Cardona, Victoria/GRX-4196-2022; Poziomkowska-Gęsicka, Iwona/M-5162-2014; ENSINA, LUIS FELIPE/N-4545-2014	Francuzik, Wojciech/0000-0001-5361-9876; Wedi, Bettina/0000-0002-9868-6308; Fernandez-Rivas, Montserrat/0000-0003-1748-2328; Scherer, Kathrin/0000-0002-5235-2556; ENSINA, LUIS FELIPE/0000-0001-8652-3619; Christoff, George/0000-0003-4549-7711; Worm, Margitta/0000-0002-3449-1245; Dolle-Bierke, Sabine/0000-0002-3339-0709				Aurich S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00750; Bilo BM, 2008, CURR OPIN ALLERGY CL, V8, P330, DOI 10.1097/ACI.0b013e32830638c5; Bischof RO, 1996, J FAM PRACTICE, V43, P271; Bonadonna P, 2010, CURR OPIN ALLERGY CL, V10, P347, DOI 10.1097/ACI.0b013e32833b280c; Braganza SC, 2006, ARCH DIS CHILD, V91, P159, DOI 10.1136/adc.2004.069914; BUCKLAND ST, 1993, J APPL ECOL, V30, P478, DOI 10.2307/2404188; Fehr D, 2019, CLIN TRANSL ALLERGY, V9, DOI 10.1186/s13601-019-0292-5; Galili T, 2018, BIOINFORMATICS, V34, P1600, DOI 10.1093/bioinformatics/btx657; Gangadharan V, 2013, CARDIOVASC DIAGN THE, V3; Grabenhenrich LB, 2016, J ALLERGY CLIN IMMUN, V137, P1128, DOI 10.1016/j.jaci.2015.11.015; Ho DE, 2011, J STAT SOFTW, V42; Jara-Acevedo M, 2015, MODERN PATHOL, V28, P1138, DOI 10.1038/modpathol.2015.72; Kristensen T, 2017, ALLERGY, V72, P1737, DOI 10.1111/all.13187; LANTNER R, 1989, J ALLERGY CLIN IMMUN, V84, P900, DOI 10.1016/0091-6749(89)90387-4; Muraro A, 2017, ALLERGY, V72, P1006, DOI 10.1111/all.13132; Muraro A, 2014, ALLERGY, V69, P1026, DOI 10.1111/all.12437; Nittner-Marszalska M, 2015, POL ARCH MED WEWN, V125, P929, DOI 10.20452/pamw.3216; RCore Team, 2022, R LANG ENV STAT COMP; RING J, 1977, LANCET, V1, P466; Rueff F, 2009, J ALLERGY CLIN IMMUN, V124, P1047, DOI 10.1016/j.jaci.2009.08.027; Sampson HA, 2006, ANN EMERG MED, V47, P373, DOI 10.1016/j.annemergmed.2006.01.018; Sharma Tarun, 2016, J Family Med Prim Care, V5, P879, DOI 10.4103/2249-4863.201165; Sinkiewicz Wladyslaw, 2008, Cardiol J, V15, P220; SMITH PL, 1980, J CLIN INVEST, V66, P1072, DOI 10.1172/JCI109936; SPRADBERY JP, 1992, AUST J ZOOL, V40, P495, DOI 10.1071/ZO9920495; Stoevesandt J, 2020, ALLERGY, V75, P535, DOI 10.1111/all.13945; Stoevesandt J, 2012, J ALLERGY CLIN IMMUN, V130, P698, DOI 10.1016/j.jaci.2012.03.024; Strobl C, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-25; Sturm GJ, 2018, ALLERGY, V73, P744, DOI 10.1111/all.13262; Tham EH, 2019, ALLERGY ASTHMA IMMUN, V11, P4, DOI 10.4168/aair.2019.11.1.4; Valent P, 2019, INT ARCH ALLERGY IMM, V180, P44, DOI 10.1159/000501079; Jimenez-Rodriguez TW, 2018, J ASTHMA ALLERGY, V11, P121, DOI 10.2147/JAA.S159411; Worm M, 2018, ALLERGY, V73, P1322, DOI 10.1111/all.13380; Zanotti R, 2015, J ALLERGY CLIN IMMUN, V136, P135, DOI 10.1016/j.jaci.2014.11.035	34	21	21	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2021	147	2					653	+		10.1016/j.jaci.2020.06.008	http://dx.doi.org/10.1016/j.jaci.2020.06.008		FEB 2021	19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QF1NF	32585173	Bronze			2022-12-18	WOS:000616665800027
J	Schon, MP; Manzke, V; Erpenbeck, L				Schoen, Michael P.; Manzke, Veit; Erpenbeck, Luise			Animal models of psoriasis-highlights and drawbacks	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Psoriasis; animal model; skin inflammation; preclinical; imiquimod; adoptive transfer; transgenic; xenotransplantation; drug testing; dermatology; skin immunity; chronic inflammation; hyperproliferation; epidermis; preclinical therapeutic study		Research into the pathophysiology of psoriasis remains challenging, because this disease does not occur naturally in laboratory animals. However, specific aspects of its complex immune-pathology can be illuminated through transgenic, knockout, xenotransplantation, immunological reconstitution, drug-induced, or spontaneous mutation models in rodents. Although some of these approaches have already been pursued for more than 5 decades and even more models have been described in recent times, they have surprisingly not yet been systematically validated. As a consequence, researchers regularly examine specific aspects that only partially reflect the complex overall picture of the human disease. Nonetheless, animal models are of great utility to investigate inflammatory mediators, the communication between cells of the innate and the adaptive immune systems, the role of resident cells as well as new therapies. Of note, various manipulations in experimental animals resulted in rather similar phenotypes. These were called "psoriasiform'', "psoriasis-like'' or even "psoriasis'' usually on the basis of some similarities with the human disorder. Xenotransplantation of human skin onto immunocompromised animals can overcome this limitation only in part. In this review, we elucidate approaches for the generation of animal models of psoriasis and assess their strengths and limitations with a certain focus on more recently developed models.	[Schoen, Michael P.; Manzke, Veit; Erpenbeck, Luise] Univ Med Ctr Gottingen, Dept Dermatol Venereol & Allergol, Gottingen, Germany; [Schoen, Michael P.] Univ Med Ctr Gottingen, Lower Saxony Inst Occupat Dermatol, Gottingen, Germany	University of Gottingen; University of Gottingen	Schon, MP (corresponding author), Univ Med Ctr Gottingen, Dept Dermatol Venereol & Allergol, Gottingen, Germany.	michael.schoen@med.uni-goettingen.de						Amigo M, 2006, LIFE SCI, V79, P2395, DOI 10.1016/j.lfs.2006.08.003; Arakawa A, 2018, J INVEST DERMATOL, V138, P1338, DOI 10.1016/j.jid.2017.12.024; Arakawa A, 2015, J EXP MED, V212, P2203, DOI 10.1084/jem.20151093; Atochina O, 2006, EXP DERMATOL, V15, P461, DOI 10.1111/j.1600-0625.2006.00431.x; BAKER BS, 1992, BRIT J DERMATOL, V126, P105, DOI 10.1111/j.1365-2133.1992.tb07805.x; Baker BS, 2001, CLIN EXP IMMUNOL, V124, P516, DOI 10.1046/j.1365-2249.2001.01563.x; Baker BS, 1997, ARCH DERMATOL RES, V289, P671, DOI 10.1007/s004030050260; Benhadou F, 2018, DISEASES, V6; Billi AC, 2020, J CLIN INVEST, V130, P3151, DOI 10.1172/JCI133159; Blauvelt A, 2018, CLIN REV ALLERG IMMU, V55, P379, DOI 10.1007/s12016-018-8702-3; Blessing M, 1996, J CELL BIOL, V135, P227, DOI 10.1083/jcb.135.1.227; Blumberg H, 2007, J EXP MED, V204, P2603, DOI 10.1084/jem.20070157; Boehncke WH, 1996, NATURE, V379, P777, DOI 10.1038/379777a0; Boehncke WH, 1999, ARCH DERMATOL RES, V291, P367, DOI 10.1007/s004030050424; Boehncke WH, 2015, LANCET, V386, P983, DOI 10.1016/S0140-6736(14)61909-7; Boehncke WH, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.b5666; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; Bowcock AM, 2005, NAT REV IMMUNOL, V5, P699, DOI 10.1038/nri1689; Boyman O, 2004, J EXP MED, V199, P731, DOI 10.1084/jem.20031482; Breban M, 1996, J IMMUNOL, V156, P794; Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385; Bromley SK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058196; Brown DW, 2001, ARCH DERMATOL RES, V293, P165, DOI 10.1007/s004030100218; BROWN WR, 1988, CLIN EXP DERMATOL, V13, P74, DOI 10.1111/j.1365-2230.1988.tb00661.x; Bullard DC, 1996, P NATL ACAD SCI USA, V93, P2116, DOI 10.1073/pnas.93.5.2116; Cargill M, 2007, AM J HUM GENET, V80, P273, DOI 10.1086/511051; Carroll JM, 1997, J INVEST DERMATOL, V108, P412, DOI 10.1111/1523-1747.ep12289702; CARROLL JM, 1995, CELL, V83, P957, DOI 10.1016/0092-8674(95)90211-2; Chan JR, 2006, J EXP MED, V203, P2577, DOI 10.1084/jem.20060244; Chang HW, 2018, MICROBIOME, V6, DOI 10.1186/s40168-018-0533-1; Chiricozzi A, 2011, J INVEST DERMATOL, V131, P677, DOI 10.1038/jid.2010.340; Coda AB, 2012, GENOMICS, V100, P18, DOI 10.1016/j.ygeno.2012.05.004; Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143; Conrad C, 2007, NAT MED, V13, P836, DOI 10.1038/nm1605; Conrad C, 2018, CLIN REV ALLERG IMMU, V54, P102, DOI 10.1007/s12016-018-8668-1; Cook PW, 1997, J CLIN INVEST, V100, P2286, DOI 10.1172/JCI119766; Croxford AL, 2014, J INVEST DERMATOL, V134, P728, DOI 10.1038/jid.2013.404; DARMIENTO J, 1995, MOL CELL BIOL, V15, P5732; Detmar M, 1998, J INVEST DERMATOL, V111, P1, DOI 10.1046/j.1523-1747.1998.00262.x; Douglas T, 2015, J IMMUNOL, V195, P2365, DOI 10.4049/jimmunol.1500542; El Malki K, 2013, J INVEST DERMATOL, V133, P441, DOI 10.1038/jid.2012.318; Fallon PG, 2009, NAT GENET, V41, P602, DOI 10.1038/ng.358; Feng BJ, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000606; FLANAGAN SP, 1966, GENET RES, V8, P295, DOI 10.1017/S0016672300010168; FRAKI JE, 1982, SCIENCE, V215, P685, DOI 10.1126/science.7036342; Garzorz-Stark N, 2018, J ALLERGY CLIN IMMUN, V141, P1320, DOI 10.1016/j.jaci.2017.07.045; GATES AH, 1965, SCIENCE, V148, P1471, DOI 10.1126/science.148.3676.1471; Gijbels MJJ, 2000, EXP DERMATOL, V9, P351, DOI 10.1034/j.1600-0625.2000.009005351.x; Grine L, 2015, CYTOKINE GROWTH F R, V26, P25, DOI 10.1016/j.cytogfr.2014.10.009; GROVES RW, 1995, P NATL ACAD SCI USA, V92, P11874, DOI 10.1073/pnas.92.25.11874; Gudjonsson JE, 2007, J INVEST DERMATOL, V127, P1292, DOI 10.1038/sj.jid.5700807; Gudmundsdottir AS, 1999, CLIN EXP IMMUNOL, V117, P580; Gunderson AJ, 2013, J INVEST DERMATOL, V133, P955, DOI 10.1038/jid.2012.390; GUO LF, 1993, EMBO J, V12, P973, DOI 10.1002/j.1460-2075.1993.tb05738.x; HAMMER RE, 1990, CELL, V63, P1099, DOI 10.1016/0092-8674(90)90512-D; Harden JL, 2015, J AUTOIMMUN, V64, P66, DOI 10.1016/j.jaut.2015.07.008; Hawkes JE, 2017, J INVEST DERMATOL, V137, P546, DOI 10.1016/j.jid.2016.10.024; Herster F, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13756-4; Hida S, 2000, IMMUNITY, V13, P643, DOI 10.1016/S1074-7613(00)00064-9; Hobbs RM, 2004, J INVEST DERMATOL, V123, P503, DOI 10.1111/j.0022-202X.2004.23225.x; HOGENESCH H, 1993, AM J PATHOL, V143, P972; Hong K, 1999, J IMMUNOL, V162, P7480; Hu SCS, 2016, SCI REP-UK, V6, DOI 10.1038/srep31119; Huffmeier U, 2014, BRIT J DERMATOL, V170, P202, DOI 10.1111/bjd.12548; Igney FH, 2006, EXPERT OPIN DRUG DIS, V1, P53, DOI 10.1517/17460441.1.1.53; Ippagunta SK, 2016, P NATL ACAD SCI USA, V113, pE6162, DOI 10.1073/pnas.1606996113; JAYO MJ, 1988, VET PATHOL, V25, P282, DOI 10.1177/030098588802500406; Johnston A, 2017, J ALLERGY CLIN IMMUN, V140, P109, DOI 10.1016/j.jaci.2016.08.056; Johnston A, 2013, J IMMUNOL, V190, P2252, DOI 10.4049/jimmunol.1201505; Kabashima K, 2017, CURR OPIN IMMUNOL, V48, P99, DOI 10.1016/j.coi.2017.08.010; Keijsers RRMC, 2014, EXP DERMATOL, V23, P799, DOI 10.1111/exd.12487; Kess D, 2003, J IMMUNOL, V171, P5697, DOI 10.4049/jimmunol.171.11.5697; Korber A, 2013, J INVEST DERMATOL, V133, P2634, DOI 10.1038/jid.2013.214; KRUEGER GG, 1981, J CLIN INVEST, V68, P1548, DOI 10.1172/JCI110409; KRUEGER GG, 1975, J INVEST DERMATOL, V64, P307, DOI 10.1111/1523-1747.ep12512256; Kulig P, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13466; Kumari S, 2013, IMMUNITY, V39, P899, DOI 10.1016/j.immuni.2013.10.009; Lande R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6621; LANE PW, 1972, J HERED, V63, P135, DOI 10.1093/oxfordjournals.jhered.a108252; Lauffer F, 2020, J DTSCH DERMATOL GES, DOI 10.1111/ddg.14124; Lee E, 2004, J EXP MED, V199, P125, DOI 10.1084/jem.20030451; Leon F, 2006, J IMMUNOL, V177, P6974, DOI 10.4049/jimmunol.177.10.6974; Li AG, 2004, EMBO J, V23, P1770, DOI 10.1038/sj.emboj.7600183; Li H, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03704-z; Lin AM, 2011, J IMMUNOL, V187, P490, DOI 10.4049/jimmunol.1100123; Lindroos J, 2011, J INVEST DERMATOL, V131, P1110, DOI 10.1038/jid.2010.432; LOWE NJ, 1981, J INVEST DERMATOL, V76, P141, DOI 10.1111/1523-1747.ep12525484; Lowes MA, 2007, NATURE, V445, P866, DOI 10.1038/nature05663; Lowes MA, 2014, ANNU REV IMMUNOL, V32, P227, DOI 10.1146/annurev-immunol-032713-120225; Mabuchi T, 2013, J INVEST DERMATOL, V133, P164, DOI 10.1038/jid.2012.260; Mabuchi T, 2011, J IMMUNOL, V187, P5026, DOI 10.4049/jimmunol.1101817; Markham T, 2006, J AM ACAD DERMATOL, V54, P1003, DOI 10.1016/j.jaad.2006.01.038; Marrakchi S, 2011, NEW ENGL J MED, V365, P620, DOI 10.1056/NEJMoa1013068; Matos TR, 2017, J CLIN INVEST, V127, P4031, DOI 10.1172/JCI93396; McGeachy MJ, 2009, NAT IMMUNOL, V10, P314, DOI 10.1038/ni.1698; McKelvey Kelly, 2014, World J Biol Chem, V5, P169, DOI 10.4331/wjbc.v5.i2.169; Meier M, 2009, CURR PROBL DERMATOL, V38, P1, DOI 10.1159/000232301; Mellett M, 2018, J INVEST DERMATOL, V138, P2010, DOI 10.1016/j.jid.2018.03.1525; Michalek IM, 2017, J EUR ACAD DERMATOL, V31, P205, DOI 10.1111/jdv.13854; Mossner R, 2008, CLIN DERMATOL, V26, P486, DOI 10.1016/j.clindermatol.2007.10.030; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Murphy M, 2007, CLIN DERMATOL, V25, P524, DOI 10.1016/j.clindermatol.2007.08.005; Nestle FO, 2005, J EXP MED, V202, P135, DOI 10.1084/jem.20050500; Neubert E, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06263-5; Nickoloff BJ, 2007, CLIN DERMATOL, V25, P568, DOI 10.1016/j.clindermatol.2007.08.011; Nishimoto S, 2013, J IMMUNOL, V191, P3065, DOI 10.4049/jimmunol.1300348; Norsgaard H, 2012, BRIT J DERMATOL, V166, P649, DOI 10.1111/j.1365-2133.2011.10713.x; Onoufriadis A, 2011, AM J HUM GENET, V89, P432, DOI 10.1016/j.ajhg.2011.07.022; Pantelyushin S, 2012, J CLIN INVEST, V122, P2252, DOI 10.1172/JCI61862; Pasparakis M, 2002, NATURE, V417, P861, DOI 10.1038/nature00820; Pollock RA, 2017, J AUTOIMMUN, V78, P29, DOI 10.1016/j.jaut.2016.12.002; Potter CS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085666; Presland RB, 2000, J INVEST DERMATOL, V115, P1072, DOI 10.1046/j.1523-1747.2000.00178.x; Raychaudhuri SP, 2004, PROG BRAIN RES, V146, P433; Raychaudhuri SR, 2004, J INVEST DERMATOL, V122, P812, DOI 10.1111/j.0022-202X.2003.12602.x; Sander JD, 2014, NAT BIOTECHNOL, V32, P347, DOI 10.1038/nbt.2842; Sano S, 2005, NAT MED, V11, P43, DOI 10.1038/nm1162; Schneider MR, 2015, EXP DERMATOL, V24, P340, DOI 10.1111/exd.12664; Schon MP, 2008, EXP DERMATOL, V17, P703, DOI 10.1111/j.1600-0625.2008.00751.x; Schon MP, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01764; Schon MP, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01323; Schon MP, 2017, EXP DERMATOL, V26, P305, DOI 10.1111/exd.13067; Schon MP, 2014, EXP DERMATOL, V23, P804, DOI 10.1111/exd.12541; Schon M, 2000, J INVEST DERMATOL, V114, P976, DOI 10.1046/j.1523-1747.2000.00953.x; Schon MP, 2000, J IMMUNOL, V165, P6583, DOI 10.4049/jimmunol.165.11.6583; Schon MP, 1997, NAT MED, V3, P183, DOI 10.1038/nm0297-183; Schonthaler HB, 2013, IMMUNITY, V39, P1171, DOI 10.1016/j.immuni.2013.11.011; Schonthaler HB, 2009, P NATL ACAD SCI USA, V106, P21264, DOI 10.1073/pnas.0907550106; Senra L, 2016, J INVEST DERMATOL, V136, P1970, DOI 10.1016/j.jid.2016.06.009; Shepherd J, 2004, J INVEST DERMATOL, V122, P665, DOI 10.1111/j.0022-202X.2004.22305.x; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; Stenderup K, 2009, BRIT J DERMATOL, V160, P284, DOI 10.1111/j.1365-2133.2008.08890.x; Stratis A, 2006, J CLIN INVEST, V116, P2094, DOI 10.1172/JCI27179; Stritesky GL, 2008, J IMMUNOL, V181, P5948, DOI 10.4049/jimmunol.181.9.5948; Sumida H, 2014, J IMMUNOL, V192, P4361, DOI 10.4049/jimmunol.1302959; SUNDBERG JP, 1994, J INVEST DERMATOL, V102, P781, DOI 10.1111/1523-1747.ep12377741; SUNDBERG JP, 1990, J INVEST DERMATOL, V95, pS62, DOI 10.1111/1523-1747.ep12505816; Swindell WR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018266; Tanaka M, 2018, J IMMUNOL, V200, P71, DOI 10.4049/jimmunol.1700995; Tanigawa H, 2016, SCI REP-UK, V6, DOI 10.1038/srep34690; Tortola L, 2012, J CLIN INVEST, V122, P3965, DOI 10.1172/JCI63451; TURKSEN K, 1992, P NATL ACAD SCI USA, V89, P5068, DOI 10.1073/pnas.89.11.5068; van der Fits L, 2009, J IMMUNOL, V182, P5836, DOI 10.4049/jimmunol.0802999; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; Villanova F, 2014, J INVEST DERMATOL, V134, P984, DOI 10.1038/jid.2013.477; Voskas D, 2005, AM J PATHOL, V166, P843, DOI 10.1016/S0002-9440(10)62305-X; Walter A, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2566; Wang HL, 2008, J CLIN INVEST, V118, P2629, DOI 10.1172/JCI34916; Wang HL, 2006, J CLIN INVEST, V116, P2105, DOI 10.1172/JCI27180; Wang YM, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.89384; Ward NL, 2011, BRIT J DERMATOL, V164, P750, DOI 10.1111/j.1365-2133.2010.10129.x; Wei JCJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15830-7; Wilsmann-Theis D, 2018, J DERMATOL, V45, P850, DOI 10.1111/1346-8138.14318; Winge MCC, 2016, J CLIN INVEST, V126, P2661, DOI 10.1172/JCI85738; Wolfram JA, 2009, AM J PATHOL, V174, P1443, DOI 10.2353/ajpath.2009.080858; WroneSmith T, 1996, J CLIN INVEST, V98, P1878, DOI 10.1172/JCI118989; Xia YP, 2003, BLOOD, V102, P161, DOI 10.1182/blood-2002-12-3793; Xu M, 2018, IMMUNITY, V48, P787, DOI 10.1016/j.immuni.2018.03.019; Xue ML, 2011, J BIOL CHEM, V286, P6742, DOI 10.1074/jbc.M110.181388; Zakostelska Z, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159539; Zenz R, 2005, NATURE, V437, P369, DOI 10.1038/nature03963; Zheng Y, 1999, NAT GENET, V23, P268, DOI 10.1038/15446; Zhuang L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068827; Zibert JR, 2011, J CLIN INVEST, V121, P410, DOI 10.1172/JCI41295	164	21	21	3	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2021	147	2					439	455		10.1016/j.jaci.2020.04.034	http://dx.doi.org/10.1016/j.jaci.2020.04.034		FEB 2021	17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QF1NF	32560971	hybrid			2022-12-18	WOS:000616665800003
J	Greenhawt, M; Shaker, M; Wang, J; Oppenheimer, JJ; Sicherer, S; Keet, C; Swaggart, K; Rank, M; Portnoy, JM; Bernstein, J; Chu, DK; Dinakar, C; Golden, D; Horner, C; Lang, DM; Lang, ES; Khan, DA; Lieberman, J; Stukus, D; Wallace, D				Greenhawt, Matthew; Shaker, Marcus; Wang, Julie; Oppenheimer, John J.; Sicherer, Scott; Keet, Corinne; Swaggart, Keri; Rank, Matthew; Portnoy, Jay M.; Bernstein, Jonathan; Chu, Derek K.; Dinakar, Chitra; Golden, David; Horner, Carolyn; Lang, David M.; Lang, Eddy S.; Khan, David A.; Lieberman, Jay; Stukus, David; Wallace, Dana			Peanut allergy diagnosis: A 2020 practice parameter update, systematic review, and GRADE analysis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Peanut allergy; diagnosis; practice parameter update; systematic review; GRADE analysis; Ara h 2; peanut components; skin prick testing; serologic IgE testing; likelihood ratio; evidence to recommendation; meta-analysis; cost-effectiveness analysis	ARA H 2; ORAL FOOD CHALLENGE; COMPONENT-RESOLVED DIAGNOSTICS; SKIN PRICK; IGE CONCENTRATIONS; ADVERSE-REACTIONS; NATIONAL-HEALTH; YOUNGER SIBLINGS; NATURAL-HISTORY; TEST RESPONSES	Given the burden of disease and the consequences of a diagnosis of peanut allergy, it is important that peanut allergy be accurately diagnosed so that an appropriate treatment plan can be developed. However, a test that indicates there is peanut sensitization present (eg, a "positive"test) is not always associated with clinical reactivity. This practice parameter addresses the diagnosis of IgE-mediated peanut allergy, both in children and adults, as pertaining to 3 fundamental questions, and based on the systematic reviews and meta-analyses, makes recommendations for the clinician who is evaluating a patient for peanut allergy. These questions relate to when diagnostic tests should be completed, which diagnostic tests to utilize, and the utility (or lack thereof) of diagnostic testing to predict the severity of a future allergic reaction to peanut.	[Greenhawt, Matthew] Univ Colorado, Sch Med, Childrens Hosp Colorado, Sect Allergy & Immunol,Dept Pediat, Aurora, CO USA; [Shaker, Marcus] Dartmouth Geisel Sch Med, Dartmouth Hitchcock Med Ctr, Sect Allergy & Immunol, Lebanon, NH USA; [Wang, Julie; Sicherer, Scott] Icahn Sch Med Mt Sinai, Dept Pediat, Div Pediat Allergy & Immunol, New York, NY 10029 USA; [Wang, Julie; Sicherer, Scott] Jaffe Food Allergy Inst, New York, NY USA; [Oppenheimer, John J.] Univ Med & Dent New Jersey, Morristown, NJ USA; [Keet, Corinne] Johns Hopkins Sch Med, Dept Pediat, Div Pediat Allergy & Immunol, Baltimore, MD USA; [Golden, David] Johns Hopkins Sch Med, Dept Med, Dept Allergy Clin Immunol, Baltimore, MD USA; [Swaggart, Keri] Childrens Mercy Hosp, Lib Serv, Kansas City, MO 64108 USA; [Rank, Matthew] Mayo Clin, Div Allergy Asthma & Clin Immunol, Scottsdale, AZ USA; [Rank, Matthew] Phoenix Childrens Hosp, Div Pulmonol, Phoenix, AZ USA; [Portnoy, Jay M.] Childrens Mercy Hosp, Dept Pediat, Div Allergy Asthma & Immunol, Kansas City, MO 64108 USA; [Bernstein, Jonathan] Univ Cincinnati, Dept Internal Med, Div Immunol, Cincinnati, OH USA; [Chu, Derek K.] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Dept Med, Hamilton, ON, Canada; [Chu, Derek K.] Res Inst St Joes, Hamilton, ON, Canada; [Dinakar, Chitra] Stanford Univ, Sch Med, Dept Pediat, Div Allergy & Asthma, Palo Alto, CA 94304 USA; [Horner, Carolyn] Washington Univ, Sch Med, Div Allergy Immunol & Pulm Med, St Louis, MO USA; [Lang, David M.] Cleveland Clin, Dept Allergy & Clin Immunol, Cleveland, OH 44106 USA; [Lang, Eddy S.] Univ Calgary, Cumming Sch Med, Dept Emergency Med, Calgary, AB, Canada; [Khan, David A.] Univ Texas Southwestern Med Ctr Dallas, Dept Med, Div Allergy & Immunol, Dallas, TX 75390 USA; [Lieberman, Jay] Univ Tennessee, Dept Pediat, Div Allergy & Immunol, Memphis, TN USA; [Stukus, David] Ohio State Univ, Coll Med, Dept Pediat, Div Allergy & Immunol, Columbus, OH 43210 USA; [Wallace, Dana] Nova Southeastern Univ, Coll Allopath Med, Ft Lauderdale, FL 33314 USA	Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Dartmouth College; Icahn School of Medicine at Mount Sinai; Rutgers State University New Brunswick; Rutgers State University Medical Center; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Children's Mercy Hospital; Mayo Clinic; Mayo Clinic Phoenix; Phoenix Children's Hospital; Children's Mercy Hospital; University System of Ohio; University of Cincinnati; McMaster University; Stanford University; Washington University (WUSTL); Cleveland Clinic Foundation; University of Calgary; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Tennessee System; University of Tennessee Health Science Center; University System of Ohio; Ohio State University; Nova Southeastern University	Greenhawt, M (corresponding author), Univ Colorado, Sch Med, Childrens Hosp Colorado, Sect Allergy & Immunol,Food Challenge & Res Unit, 13123 E 16th Ave, Aurora, CO 80045 USA.	Matthew.Greenhawt@childrenscolorado.org		Chu, Derek/0000-0001-8269-4496; Bernstein, Jonathan/0000-0002-3476-1196	Aquestive; Aimmune; Merck; Allergenis; Allergy Therapeutics; Sanofi Genzyme; Genentech; GlaxoSmithKline; Aravax; Prota; Before Brands; Institute for Clinical and Economic Review; American College of Asthma, Allergy, and Immunology; DBV Technologies; Intrommune; Agency of Healthcare Research and Quality; ALK-Abello; Regeneron; TEVA; GlaxoSmithKline Adjudication/Data Safety Monitoring Board; AstraZeneca; Novartis; Sanofi; Food Allergy Research and Education Clinical Center; John Hopkins University Press; HAL Allergy Group; AAAAI; UpToDate; National Institutes of Allergy and Infectious Disease; American College of Asthma, Allergy, and Immunology (ACAAI); National Institutes of Health; Levin Family Foundation; Thermo Fisher Scientific; Kaleo; Hycor; BoehringerIngelheim; Sanofi Regeneron; Optinose; Takeda; CSL Behring; Biocryst; Pharming; Taylor and Francis; INEOS; Canadian Allergy, Asthma and Immunology Foundation (CAAIF); Canadian Society of Allergy and Clinical Immunology (CSACI); AllerGen NCE Inc. (the Allergy, Genes and Environment Network); Propeller Health; ACAAI; American Association of Allergists of Indian Origin; Sandoz; Stallergenes-Greer; Biotest Pharma; Abbott Nutrition; American Academy of Pediatrics; Mylan; Bryan	Aquestive; Aimmune; Merck(Merck & Company); Allergenis; Allergy Therapeutics; Sanofi Genzyme(Sanofi-AventisGenzyme Corporation); Genentech(Roche HoldingGenentech); GlaxoSmithKline(GlaxoSmithKline); Aravax; Prota; Before Brands; Institute for Clinical and Economic Review; American College of Asthma, Allergy, and Immunology; DBV Technologies; Intrommune; Agency of Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); ALK-Abello; Regeneron(Regeneron); TEVA(Teva Pharmaceutical Industries); GlaxoSmithKline Adjudication/Data Safety Monitoring Board; AstraZeneca(AstraZeneca); Novartis(Novartis); Sanofi; Food Allergy Research and Education Clinical Center; John Hopkins University Press; HAL Allergy Group(HAL Allergy Group); AAAAI; UpToDate; National Institutes of Allergy and Infectious Disease(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); American College of Asthma, Allergy, and Immunology (ACAAI); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Levin Family Foundation; Thermo Fisher Scientific; Kaleo; Hycor; BoehringerIngelheim(Boehringer Ingelheim); Sanofi Regeneron(Regeneron); Optinose; Takeda(Takeda Pharmaceutical Company Ltd); CSL Behring; Biocryst; Pharming; Taylor and Francis; INEOS; Canadian Allergy, Asthma and Immunology Foundation (CAAIF); Canadian Society of Allergy and Clinical Immunology (CSACI); AllerGen NCE Inc. (the Allergy, Genes and Environment Network); Propeller Health; ACAAI; American Association of Allergists of Indian Origin; Sandoz(Novartis); Stallergenes-Greer; Biotest Pharma; Abbott Nutrition(Abbott Laboratories); American Academy of Pediatrics; Mylan; Bryan	Disclosure of potential conflict of interest: The Joint Task Force on Practice Parameters (JTFPP) members' and work group members' conflict of interest disclosure forms can be found at www.allergyparameters.org.Matthew Greenhawt has received financial support from Aquestive, Aimmune, Merck, Allergenis, Allergy Therapeutics, Sanofi Genzyme, Genentech, GlaxoSmithKline, Merck, Aravax, Prota, Before Brands, the Institute for Clinical and Economic Review, American College of Asthma, Allergy, and Immunology, DBV Technologies, and Intrommune; is supported by the Agency of Healthcare Research and Quality; has served on the advisory board of International Food Protein Induced Enterocolitis Syndrome Association, the Asthma and Allergy Foundation of America, and the National Peanut Board; and is Associate Editor of the Annals of Allergy, Asthma, and Immunology. Marcus Shaker is a member of the Joint Task Force on Allergy Practice Parameters; has a family member who is chief executive officer of Altrix Medical; and serves on the Editorial Board of the Journal of Food Allergy and the Annals of Allergy, Asthma, and Immunology. Julie Wang has received financial support from ALK-Abello, Regeneron, DBV Technologies, and Aimmune; is an UpToDate author; serves on the ExecutiveCommittee of the American Academy of Pediatrics Section on Allergy and Immunology; and serves as Vice Chair of the American Academy of Allergy, Asthma, and Immunology (AAAAI) Anaphylaxis, Dermatitis, Drug Allergy Interest Section. John J. Oppenheimer has received financial support from DBV Technologies, TEVA, GlaxoSmithKline Adjudication/Data Safety Monitoring Board, AstraZeneca, Novartis, and Sanofi; and is Associate Editor of the Annals of Allergy, Asthma, and Immunology and AllergyWatch, an American Board of Internal Medicine (ABIM) Council Member, and American Board of Allergy and Immunology Liaison to the ABIM, UpToDate Reviewer, American College of Chest Physicians Cough Guideline Committee Member, and WebMD Editor. Scott Sicherer has received financial support from Food Allergy Research and Education Clinical Center, John Hopkins University Press, HAL Allergy Group, AAAAI, UpToDate, and National Institutes of Allergy and Infectious Disease; and is a Medical Advisor at International Food Protein Induced Enterocolitis Syndrome Association and member of the Executive Committee at the American Academy of Pediatrics. Corinne Keet received royalties from UpToDate; is an Associate Editor for the Journal of Allergy and Clinical Immunology; and is a Board Member for the American Board of Allergy and Immunology. Matthew Rank has received financial support from the American College of Asthma, Allergy, and Immunology (ACAAI), National Institutes of Health, and Levin Family Foundation; has served as Chair of theAAAAI Health Education Delivery and Quality (HEDQ) Interest Section; and is Research Director of the Phoenix Children's Hospital Breathmobile. Jay M. Portnoy has received financial support from Thermo Fisher Scientific, Kaleo, TEVA, Novartis, Hycor, and BoehringerIngelheim.; Jonathan Bernstein has received financial support from Sanofi Regeneron, AstraZeneca, Merck, Optinose, Takeda, CSL Behring, Biocryst, Pharming, the National Institutes of Health, Taylor and Francis, and INEOS; is Editor-in-Chief of the Journal of Asthma, INEOS medical immunosurveillance director, Vice Chair and Lectureship Chair of the AAAAI Foundation, chairman of Allergists for Israel (AFI), ACAAI Asthma Chair, Scientific Chair, and Young Investigator Award Chair; and serves on the Board of Directors and Scientific Committee of Interasma. Derek K. Chu is a CAAIF-CSACI-AllerGen Emerging Clinician-Scientist Research Fellow; and is supported by the Canadian Allergy, Asthma and Immunology Foundation (CAAIF), the Canadian Society of Allergy and Clinical Immunology (CSACI), and AllerGen NCE Inc. (the Allergy, Genes and Environment Network). Chitra Dinakar has received financial support from Propeller Health, ACAAI (stipend for Editorial Board of AllergyWatch), and the American Association of Allergists of Indian Origin; serves on the Board of Directors of the AAAAI and on the Medical Advisory Board of Food Equity Initiative; and is Assistant Editor of AllergyWatch. David Golden has received financial support from Aquestive, Sandoz, ALK-Abello, Genentech, Stallergenes-Greer, and UpToDate. Carolyn Horner has served as Committee Chair for the American Academy of Allergy, Asthma, and Asthma Diagnosis and Treatment Interest Section, Interest Section Coordinating Committee, and In-Training Exam Coordinating Committee. David M. Lang is on the Editorial Board for Allergy and Asthma Proceedings, Topic Editor for DynaMed, Associate Editor for Journal of Asthma, and Delegate to National Quality Forum representing the AAAAI. David A. Khan has received financial support from UpToDate and Aimmune; serves on the Board of Directors of the AAAAI; as ACAAI (Chair of Literature Review, as CoChair of Conjoint Board Review, and as Texas Allergy, Asthma, and Immunology Society Chair of Meetings Committee; and is Associate Editor of the Journal of Allergy and Clinical Immunology In Practice. Jay Lieberman has received financial support from the ACAAI, Aquestive, Aimmune, DBV Technologies, Biotest Pharma, and Regeneron; and is Associate Editor of the Annals of Allergy, Asthma, and Immunology, Vice Chair for the ACAAI Food Allergy Committee, and Medical Director for Food Allergy Alliance of the MidSouth. David Stukus has received financial support from Aimmune, Before Brands, Abbott Nutrition, the American Academy of Pediatrics, and ACAAI; and has served as Committee Chair for the AAAAI and ACAAI. Dana Wallace has received financial support from Mylan, Kaleo, Optinose, ALK-Abello, Bryan, and Sanofi. The rest of the authors declare that they have no relevant conflicts of interest.	Abrams EM, 2018, J ALLER CL IMM-PRACT, V6, P414, DOI 10.1016/j.jaip.2018.01.002; Abrams EM, 2017, ALLERGY ASTHMA CL IM, V13, DOI 10.1186/s13223-017-0215-8; [Anonymous], 2016, FINDING PATH SAFETY; Arbes SJ, 2005, J ALLERGY CLIN IMMUN, V116, P377, DOI 10.1016/j.jaci.2005.05.017; Asarnoj A, 2012, INT ARCH ALLERGY IMM, V159, P209, DOI 10.1159/000336027; Asarnoj A, 2012, J ALLERGY CLIN IMMUN, V130, P468, DOI 10.1016/j.jaci.2012.05.019; Ballmer-Weber BK, 2015, ALLERGY, V70, P391, DOI 10.1111/all.12574; Begin P, 2016, ALLERGY, V71, P1762, DOI 10.1111/all.12956; Beigelman A, 2012, ALLERGY ASTHMA PROC, V33, P467, DOI 10.2500/aap.2012.33.3607; Bernard H, 2003, ALLERGY, V58, P1285, DOI 10.1046/j.1398-9995.2003.00300.x; Bernstein IL, 2008, ANN ALLERG ASTHMA IM, V100, pS1, DOI 10.1016/S1081-1206(10)60305-5; Beyer K, 2015, ALLERGY, V70, P90, DOI 10.1111/all.12530; Bird JA, 2020, J ALLER CL IMM-PRACT, V8, P75, DOI 10.1016/j.jaip.2019.09.029; Brenner H, 1996, J CLIN EPIDEMIOL, V49, P1435, DOI 10.1016/S0895-4356(96)00215-6; Brown BB, 1968, DELPHI PROCESS METHO; Brozek JL, 2011, ALLERGY, V66, P588, DOI 10.1111/j.1398-9995.2010.02530.x; Brozek JL, 2009, ALLERGY, V64, P1109, DOI 10.1111/j.1398-9995.2009.02083.x; Brozek JL, 2009, ALLERGY, V64, P669, DOI 10.1111/j.1398-9995.2009.01973.x; Bunyavanich S, 2014, J ALLERGY CLIN IMMUN, V133, P1373, DOI 10.1016/j.jaci.2013.11.040; Chafen JJS, 2010, JAMA-J AM MED ASSOC, V303, P1848, DOI 10.1001/jama.2010.582; Chinthrajah RS, 2018, ANN ALLERG ASTHMA IM, V121, P69, DOI 10.1016/j.anai.2018.04.020; Comberiati P, 2016, INT J MOL CELL MED, V5, P160; DALKEY N, 1963, MANAGE SCI, V9, P458, DOI 10.1287/mnsc.9.3.458; Dang TD, 2012, J ALLERGY CLIN IMMUN, V129, P1056, DOI 10.1016/j.jaci.2012.01.056; Du Toit G, 2015, NEW ENGL J MED, V372, P803, DOI 10.1056/NEJMoa1414850; Du Toit G, 2013, J ALLERGY CLIN IMMUN, V131, P135, DOI 10.1016/j.jaci.2012.09.015; DunnGalvin A, 2011, J ALLERGY CLIN IMMUN, V127, P633, DOI 10.1016/j.jaci.2010.12.004; Dwamena Ben, 2007, MIDAS STATA MODULE M; Ebisawa M, 2015, J ALLER CL IMM-PRACT, V3, P131, DOI 10.1016/j.jaip.2014.10.014; Ebisawa M, 2012, PEDIAT ALLERG IMM-UK, V23, P573, DOI 10.1111/j.1399-3038.2012.01332.x; Eller E, 2013, ALLERGY, V68, P190, DOI 10.1111/all.12075; Fleischer DM, 2011, J PEDIATR-US, V158, P578, DOI 10.1016/j.jpeds.2010.09.027; Glaumann S, 2012, ALLERGY, V67, P242, DOI 10.1111/j.1398-9995.2011.02754.x; Grimes DA, 2005, LANCET, V365, P1500, DOI 10.1016/S0140-6736(05)66422-7; Guilloux L, 2009, INT ARCH ALLERGY IMM, V149, P91, DOI 10.1159/000189190; Gupta RS, 2018, PEDIATRICS, V142, DOI 10.1542/peds.2018-1235; Gupta RS, 2014, J ALLER CL IMM-PRACT, V2, P300, DOI 10.1016/j.jaip.2013.12.006; Gupta RS, 2011, PEDIATRICS, V128, pE9, DOI 10.1542/peds.2011-0204; Hammond C, 2018, IMMUNOL ALLERGY CLIN, V38, P153, DOI 10.1016/j.iac.2017.09.011; Johannsen H, 2011, CLIN EXP ALLERGY, V41, P994, DOI 10.1111/j.1365-2222.2011.03717.x; Keet CA, 2013, J ALLER CL IMM-PRACT, V1, P101, DOI 10.1016/j.jaip.2012.08.007; Kelso JM, 2018, J ALLER CL IMM-PRACT, V6, P362, DOI 10.1016/j.jaip.2017.08.021; Kim JF, 2018, ALLERGY, V73, P1609, DOI 10.1111/all.13399; Klemans RJB, 2015, CLIN EXP ALLERGY, V45, P1237, DOI 10.1111/cea.12558; Klemans RJB, 2015, CLIN EXP ALLERGY, V45, P720, DOI 10.1111/cea.12412; Klemans RJB, 2013, J ALLER CL IMM-PRACT, V1, P632, DOI 10.1016/j.jaip.2013.07.014; Klemans RJB, 2013, J ALLERGY CLIN IMMUN, V131, P157, DOI 10.1016/j.jaci.2012.08.010; Kukkonen AK, 2015, ALLERGY, V70, P1239, DOI 10.1111/all.12671; Leo SH, 2015, J ALLER CL IMM-PRACT, V3, P968, DOI 10.1016/j.jaip.2015.04.001; Lewis SA, 2005, CLIN EXP ALLERGY, V35, P767, DOI 10.1111/j.1365-2222.2005.02252.x; Lieberman JA, 2013, J ALLER CL IMM-PRACT, V1, P75, DOI 10.1016/j.jaip.2012.11.002; Linstone HA, 1975, DELPHI METHOD TECHNI; Liu Andrew H, 2010, J Allergy Clin Immunol, V126, P798, DOI 10.1016/j.jaci.2010.07.026; Ludman S, 2013, PEDIAT ALLERG IMM-UK, V24, P276, DOI 10.1111/pai.12059; Martinet J, 2016, INT ARCH ALLERGY IMM, V169, P216, DOI 10.1159/000446181; MAY CD, 1976, J ALLERGY CLIN IMMUN, V58, P500, DOI 10.1016/0091-6749(76)90194-9; McGowan EC, 2013, J ALLERGY CLIN IMMUN, V132, P1216, DOI 10.1016/j.jaci.2013.07.018; Moher D, 2009, BMJ-BRIT MED J, V339, DOI [10.1136/bmj.b2535, 10.1186/2046-4053-4-1, 10.1136/bmj.i4086]; Nelson Adin, 2018, MedEdPORTAL, V14, P10771, DOI 10.15766/mep_2374-8265.10771; Nicolaou N, 2011, J ALLERGY CLIN IMMUN, V127, P684, DOI 10.1016/j.jaci.2010.12.012; Nowak-Wegrzyn A, 2017, J ALLERGY CLIN IMMUN, V139, P1111, DOI 10.1016/j.jaci.2016.12.966; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, P668, DOI 10.1016/j.jaci.2011.01.039; Peeters KABM, 2007, CLIN EXP ALLERGY, V37, P108, DOI 10.1111/j.1365-2222.2006.02628.x; Perry TT, 2004, J ALLERGY CLIN IMMUN, V114, P144, DOI 10.1016/j.jaci.2004.04.009; Peters R, 2019, J ALLERGY CLIN IMMUN, V143, pAB421, DOI 10.1016/j.jaci.2018.12.946; Peters RL, 2015, J ALLERGY CLIN IMMUN, V135, P1257, DOI 10.1016/j.jaci.2015.01.002; Peters RL, 2013, J ALLERGY CLIN IMMUN, V132, P874, DOI 10.1016/j.jaci.2013.05.038; Pongracic JA, 2012, J ALLERGY CLIN IMMUN, V129, P564, DOI 10.1016/j.jaci.2011.09.024; Preece K, 2014, CLIN EXP ALLERGY, V44, P371, DOI 10.1111/cea.12258; Rajput S, 2018, J ALLERGY CLIN IMMUN, V141, P457, DOI 10.1016/j.jaci.2017.05.001; Rance F, 2002, J ALLERGY CLIN IMMUN, V109, P1027, DOI 10.1067/mai.2002.124775; */* S   5, 2010, J ALLERGY CLIN IMM S, V126, pS, DOI DOI 10.1016/J.JACI.2010.10.007; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Sampson HA, 2014, J ALLERGY CLIN IMMUN, V134, P1016, DOI 10.1016/j.jaci.2014.05.013; Sastre J, 2010, CLIN EXP ALLERGY, V40, P1442, DOI 10.1111/j.1365-2222.2010.03585.x; Schots M, 2016, DIAGNOSIS, V3, P31, DOI 10.1515/dx-2015-0032; Schunemann HJ, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l4606; Sellaturay P, 2015, ANN ALLERG ASTHMA IM, V115, P229, DOI 10.1016/j.anai.2015.07.005; Shaker MS, 2020, ANN ALLERG ASTHMA IM, V124, P526, DOI 10.1016/j.anai.2020.03.009; Shaker MS, 2019, ALLERGY, V74, P2251, DOI 10.1111/all.13846; Shea BJ, 2017, BMJ-BRIT MED J, V358, DOI 10.1136/bmj.j4008; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1322, DOI 10.1016/j.jaci.2010.03.029; Song Y, 2015, ANN ALLERG ASTHMA IM, V114, P319, DOI 10.1016/j.anai.2015.01.006; Stiefel G, BSACI GUIDELINE DIAG, V47, P719; Suratannon N, 2013, PEDIAT ALLERG IMM-UK, V24, P665, DOI 10.1111/pai.12125; Togias A, 2017, J ALLERGY CLIN IMMUN, V139, P29, DOI 10.1016/j.jaci.2016.10.010; van Erp FC, 2013, PEDIAT ALLERG IMM-UK, V24, P596, DOI 10.1111/pai.12107; Vereda A, 2011, J ALLERGY CLIN IMMUN, V127, P603, DOI 10.1016/j.jaci.2010.09.010; Wainstein BK, 2007, PEDIAT ALLERG IMM-UK, V18, P231, DOI 10.1111/j.1399-3038.2007.00517.x; Wainstein BK, 2010, PEDIAT ALLERG IMM-UK, V21, P603, DOI 10.1111/j.1399-3038.2010.01063.x; Wensing M, 2002, J ALLERGY CLIN IMMUN, V110, P915, DOI 10.1067/mai.2002.129235; Whiting PF, 2011, ANN INTERN MED, V155, P529, DOI 10.7326/0003-4819-155-8-201110180-00009	93	21	22	1	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2020	146	6					1302	1334		10.1016/j.jaci.2020.07.031	http://dx.doi.org/10.1016/j.jaci.2020.07.031			33	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PC3XH	32810515	Bronze			2022-12-18	WOS:000596937900011
J	Dribin, TE; Sampson, HA; Camargo, CA; Brousseau, DC; Spergel, JM; Neuman, MI; Shaker, M; Campbell, RL; Michelson, KA; Rudders, SA; Assa'ad, AH; Risma, KA; Castells, M; Schneider, LC; Wang, JL; Lee, J; Mistry, RD; Vyles, D; Vaughn, LM; Schumacher, DJ; Witry, JK; Viswanathan, S; Page, EM; Schnadower, D				Dribin, Timothy E.; Sampson, Hugh A.; Camargo, Carlos A., Jr.; Brousseau, David C.; Spergel, Jonathan M.; Neuman, Mark, I; Shaker, Marcus; Campbell, Ronna L.; Michelson, Kenneth A.; Rudders, Susan A.; Assa'ad, Amal H.; Risma, Kimberly A.; Castells, Mariana; Schneider, Lynda C.; Wang, Julie; Lee, Juhee; Mistry, Rakesh D.; Vyles, David; Vaughn, Lisa M.; Schumacher, Daniel J.; Witry, John K.; Viswanathan, Shiv; Page, Erica M.; Schnadower, David			Persistent, refractory, and biphasic anaphylaxis: A multidisciplinary Delphi study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anaphylaxis; biphasic anaphylaxis; biphasic nonanaphylactic reactions; Delphi; emergency department; persistent anaphylaxis; persistent nonanaphylactic reactions; refractory anaphylaxis	EMERGENCY-DEPARTMENT DIAGNOSIS; GRADING SYSTEM; ALLERGY; PREDICTORS; SEVERITY; CRITERIA; UPDATE; TIME	Background: The use of inconsistent definitions for anaphylaxis outcomes limits our understanding of the natural history and epidemiology of anaphylaxis, hindering clinical practice and research efforts. Objective: Our aim was to develop consensus definitions for clinically relevant anaphylaxis outcomes by utilizing a multidisciplinary group of clinical and research experts in anaphylaxis. Methods: Using Delphi methodology, we developed agenda topics and drafted questions to review during monthly conference calls. Through online surveys, a 19-member panel consisting of experts in allergy and/or immunology and emergency medicine rated their level of agreement with the appropriateness of statements on a scale of 1 to 9. Amedianvalue of 1.0 to 3.4 was considered inappropriate, a median value of 3.5 to 6.9 was considered uncertain, and a median value of 7.0 to 9.0 was considered appropriate. Adisagreement index was then calculated, with values less than 1.0 categorized as "consensus reached.'' If consensus was not reached after the initial survey, subsequent surveys incorporating the aggregate deidentified responses from prior surveys were sent to panelmembers. This process was repeated until consensus was reached or 4 survey rounds had been completed, after which the question was categorized as "no consensus reached.'' Results: The panel developed outcome definitions for persistent, refractory, and biphasic anaphylaxis, as well as for persistent and biphasic nonanaphylactic reactions. There was also consensus among panel members regarding the need to develop an anaphylaxis severity grading system. Conclusion: Dissemination and application of these definitions in clinical care and research will help standardize the terminology used to describe anaphylaxis outcomes and serve as the foundation for future research, including research aimed at development of an anaphylaxis severity grading system.	[Dribin, Timothy E.; Schumacher, Daniel J.; Witry, John K.; Viswanathan, Shiv; Schnadower, David] Cincinnati Childrens Hosp Med Ctr, Div Emergency Med, Cincinnati, OH 45229 USA; [Dribin, Timothy E.; Assa'ad, Amal H.; Risma, Kimberly A.; Schumacher, Daniel J.; Schnadower, David] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA; [Sampson, Hugh A.; Wang, Julie] Icahn Sch Med Mt Sinai, Div Allergy & Immunol, New York, NY 10029 USA; [Camargo, Carlos A., Jr.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02115 USA; [Brousseau, David C.; Vyles, David] Med Coll Wisconsin, Dept Pediat, Sect Pediat Emergency Med, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA; [Spergel, Jonathan M.; Lee, Juhee] Univ Penn, Childrens Hosp Philadelphia, Div Allergy & Immunol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Neuman, Mark, I; Michelson, Kenneth A.] Boston Childrens Hosp, Div Emergency Med, Boston, MA USA; [Neuman, Mark, I; Michelson, Kenneth A.; Rudders, Susan A.; Schneider, Lynda C.] Harvard Med Sch, Dept Pediat, Boston, MA 02115 USA; [Shaker, Marcus] Dartmouth Geisel Sch Med, Hanover, NH USA; [Shaker, Marcus] Dartmouth Hitchcock Med Ctr, Hanover, NH USA; [Campbell, Ronna L.] Mayo Clin, Dept Emergency Med, Rochester, MN USA; [Rudders, Susan A.; Schneider, Lynda C.] Boston Childrens Hosp, Div Immunol, Boston, MA USA; [Assa'ad, Amal H.; Risma, Kimberly A.] Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, Cincinnati, OH 45229 USA; [Castells, Mariana] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Div Allergy & Clin Immunol, Boston, MA 02115 USA; [Mistry, Rakesh D.] Childrens Hosp Colorado, Dept Pediat, Sect Emergency Med, Aurora, CO USA; [Vaughn, Lisa M.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA; [Vaughn, Lisa M.] Univ Cincinnati, Coll Med, Cincinnati, OH USA; [Page, Erica M.] Univ Cincinnati, Cincinnati, OH USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Icahn School of Medicine at Mount Sinai; Harvard University; Harvard Medical School; Massachusetts General Hospital; Medical College of Wisconsin; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Dartmouth College; Dartmouth College; Mayo Clinic; Harvard University; Boston Children's Hospital; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Children's Hospital Colorado; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Dribin, TE (corresponding author), Cincinnati Childrens Hosp, 3244 Burnet Ave, Cincinnati, OH 45229 USA.	Timothy.Dribin@cchmc.org	Mistry, Rakesh/ABI-1930-2020; Camargo, Carlos A./C-2145-2008; Schneider, Lynda C/AAY-6545-2021	Camargo, Carlos A./0000-0002-5071-7654; Schneider, Lynda C/0000-0002-5633-0178; Viswanathan, Shiv Kumar/0000-0002-3825-3121	Division of Emergency Medicine, Cincinnati Children's Hospital Medical Center	Division of Emergency Medicine, Cincinnati Children's Hospital Medical Center	Supported by the Division of Emergency Medicine, Cincinnati Children's Hospital Medical Center.	Alqurashi W, 2015, ANN ALLERG ASTHMA IM, V115, P217, DOI 10.1016/j.anai.2015.05.013; Andorf S, 2018, LANCET GASTROENTEROL, V3, P85, DOI 10.1016/S2468-1253(17)30392-8; Brauer CEL, 2016, J ALLER CL IMM-PRACT, V4, P1220, DOI 10.1016/j.jaip.2016.06.003; Brown SGA, 2004, J ALLERGY CLIN IMMUN, V114, P371, DOI 10.1016/j.jaci.2004.04.029; Burks AW, 2012, NEW ENGL J MED, V367, P233, DOI 10.1056/NEJMoa1200435; Campbell RL, 2014, ANN ALLERG ASTHMA IM, V113, P599, DOI 10.1016/j.anai.2014.10.007; Campbell RL, 2012, J ALLERGY CLIN IMMUN, V129, P748, DOI 10.1016/j.jaci.2011.09.030; Castells M, 2017, J ALLERGY CLIN IMMUN, V140, P321, DOI 10.1016/j.jaci.2017.06.012; Cox LS, 2017, J ALLER CL IMM-PRACT, V5, P58, DOI 10.1016/j.jaip.2016.11.009; Du Toit G, 2015, NEW ENGL J MED, V372, P803, DOI 10.1056/NEJMoa1414850; Fitch K, 2001, RAND UCLA APPROPRIAT; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Hopkins PM, 2019, BRIT J ANAESTH, V123, pE29, DOI 10.1016/j.bja.2019.02.029; Lee JM, 2000, PEDIATRICS, V106, P762, DOI 10.1542/peds.106.4.762; Lee S, 2017, J ALLER CL IMM-PRACT, V5, P1295, DOI 10.1016/j.jaip.2017.07.020; Lee S, 2016, CURR OPIN ALLERGY CL, V16, P346, DOI 10.1097/ACI.0000000000000279; Lee S, 2015, J ALLER CL IMM-PRACT, V3, P408, DOI 10.1016/j.jaip.2014.12.010; Maverakis E, 2017, JAMA DERMATOL, V153, P587, DOI 10.1001/jamadermatol.2017.0160; Michelson KA, 2020, J ALLER CL IMM-PRACT, V8, P767, DOI 10.1016/j.jaip.2019.07.018; MUELLER HL, 1959, NEW ENGL J MED, V261, P374, DOI 10.1056/NEJM195908202610803; Muraro A, 2018, ALLERGY, V73, P1792, DOI 10.1111/all.13408; Muraro A, 2017, ALLERGY, V72, P1006, DOI 10.1111/all.13132; Niggemann B, 2016, ALLERGY, V71, P135, DOI 10.1111/all.12765; RING J, 1977, LANCET, V1, P466; Rohacek M, 2014, ALLERGY, V69, P791, DOI 10.1111/all.12404; Sampson HA, 2003, PEDIATRICS, V111, P1601; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Sampson HA, 2012, J ALLERGY CLIN IMMUN, V130, P1260, DOI 10.1016/j.jaci.2012.10.017; Shaker MS, 2020, J ALLERGY CLIN IMMUN, V145, P1082, DOI 10.1016/j.jaci.2020.01.017; Simons FER, 2011, WORLD ALLERGY ORGAN, V4, P13, DOI 10.1097/WOX.0b013e318211496c; Turner K, 2019, INT J INSTR, V12, P1, DOI 10.29333/iji.2019.1221a; Wolf R, 2013, WORLD ALLERGY ORGAN, V6, pP134	32	21	21	1	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2020	146	5					1089	1096		10.1016/j.jaci.2020.08.015	http://dx.doi.org/10.1016/j.jaci.2020.08.015			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	OP5VH	32853640	Bronze, Green Accepted			2022-12-18	WOS:000588153700013
J	Charles-Messance, H; Mitchelson, KAJ; Castro, ED; Sheedy, FJ; Roche, HM				Charles-Messance, Hugo; Mitchelson, Kathleen A. J.; Castro, Elena De Marco; Sheedy, Frederick J.; Roche, Helen M.			Regulating metabolic inflammation by nutritional modulation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Metabolic inflammation; obesity; NAFLD; T2D; innate immunity; microbiota; trained immunity	SATURATED FATTY-ACIDS; ENDOPLASMIC-RETICULUM STRESS; BINDING CASSETTE TRANSPORTERS; FOAM CELL-FORMATION; YEAST BETA-GLUCAN; NLRP3 INFLAMMASOME; GUT MICROBIOTA; LIVER-DISEASE; MOLECULAR-MECHANISMS; INSULIN-RESISTANCE	Metabolic inflammation (metaflammation) is characteristic of obesity-related metabolic disorders, associated with increased risk of development of type 2 diabetes, nonalcoholic fatty liver disease (NAFLD), or cardiovascular disease. Metaflammation refers to a chronic, low-grade systemic inflammation as opposed to the classical transient and acute inflammatory responses of the innate immune system. Metaflammation is driven by a range of adverse dietary factors, including saturated fatty acids and some sugars, suggesting that certain dietary triggers may be particularly relevant beyond simple excessive dietary intake presenting as obesity. Importantly, obese patients with diabetes have a higher risk of infection and display gut microbiota profiles characteristic of dysfunctional immunity. Targeting metaflammation has also emerged as a strategy to attenuate metabolic disease. In this review we explore how different nutrition interventions may reconfigure disrupted metabolic inflammation in type 2 diabetes and nonalcoholic fatty liver disease by reestablishing a conventional proinflammatory program in innate immune cells and/or correcting dysbiosis to dampen systemic inflammation. We begin by reviewing concepts of metabolic inflammation relating to IL-1 beta inflammation and how it is induced by dietary and/or metabolic stressors. We then explore whether and how dietary interventions may attenuate processes pertaining to metaflammation, either directly or indirectly via the microbiome. Hence, we hope to bring new perspectives to alleviate the metaflammation typifying metabolic disease.	[Charles-Messance, Hugo; Sheedy, Frederick J.] Trinity Coll Dublin, Sch Biochem & Immunol, Macrophage Homeostasis Res Grp, Dublin, Ireland; [Charles-Messance, Hugo; Sheedy, Frederick J.] Trinity Coll Dublin, Trinity Biomed Sci Inst, Dublin, Ireland; [Mitchelson, Kathleen A. J.; Castro, Elena De Marco; Roche, Helen M.] Univ Coll Dublin, Sch Publ Hlth Physiotherapy & Sports Sci, Nutrigen Res Grp, Dublin, Ireland; [Mitchelson, Kathleen A. J.; Castro, Elena De Marco; Roche, Helen M.] Univ Coll Dublin, Conway Inst, Diabet Complicat Res Ctr, Inst Food & Hlth, Dublin, Ireland; [Roche, Helen M.] Queens Univ Belfast, Inst Global Food Secur, Belfast, Antrim, North Ireland	Trinity College Dublin; Trinity College Dublin; University College Dublin; University College Dublin; Queens University Belfast	Roche, HM (corresponding author), Univ Coll Dublin, UCD Conway Inst, Diabet Complicat Res Ctr, UCD Inst Food & Hlth, Dublin 4, Ireland.	helen.roche@ucd.ie		de Marco Castro, Elena/0000-0003-3581-2570; CHARLES-MESSANCE, Hugo/0000-0002-6627-2098; Sheedy, Frederick/0000-0003-2645-8493	Irish Research Council Postdoctoral Fellowship Programme [GOIPD/2019/807]; Irish Department of Agriculture, Food and the Marine [14/F/828]; Precision Oncology Ireland [18/SPP/3522]; Science Foundation Ireland Strategic Partnership Programme; Irish Research Council PhD Scholarship Scheme [EBPPG/2018/137]; Enterprise Ireland Innovation Partnership Programme [IP/2018/0710]; Science Foundation Ireland Frontiers Award Programme [SFI 19/FFP/6625]	Irish Research Council Postdoctoral Fellowship Programme(Irish Research Council for Science, Engineering and Technology); Irish Department of Agriculture, Food and the Marine; Precision Oncology Ireland; Science Foundation Ireland Strategic Partnership Programme(Science Foundation Ireland); Irish Research Council PhD Scholarship Scheme(Irish Research Council for Science, Engineering and Technology); Enterprise Ireland Innovation Partnership Programme; Science Foundation Ireland Frontiers Award Programme(Science Foundation Ireland)	H.C.-M. is funded by the Irish Research Council Postdoctoral Fellowship Programme (GOIPD/2019/807). K.A.J.M. is funded by the Irish Department of Agriculture, Food and the Marine (14/F/828 ImmunoMet Programme) and Precision Oncology Ireland (18/SPP/3522), which is partly funded by the Science Foundation Ireland Strategic Partnership Programme. E.D.M.C. is supported by the Irish Research Council PhD Scholarship Scheme (EBPPG/2018/137). H.M.R. is funded by the Irish Department of Agriculture, Food and the Marine (14/F/828 "ImmunoMet" Programme) and Precision Oncology Ireland (18/SPP/3522), which is part funded by the Science Foundation Ireland Strategic Partnership Programme. F.J.S. and H.M.R. are supported by the Science Foundation Ireland Frontiers Award Programme (SFI 19/FFP/6625). H.C.-M. and F.J.S. are supported by the Enterprise Ireland Innovation Partnership Programme (IP/2018/0710).	Abdelmalek MF, 2010, HEPATOLOGY, V51, P1961, DOI 10.1002/hep.23535; Abenavoli L, 2019, NUTRIENTS, V11, DOI 10.3390/nu11112690; Al-Sharea A, 2018, ATHEROSCLEROSIS, V271, P166, DOI 10.1016/j.atherosclerosis.2018.02.028; Amar J, 2011, EMBO MOL MED, V3, P559, DOI 10.1002/emmm.201100159; Arguello G, 2015, BBA-MOL BASIS DIS, V1852, P1765, DOI 10.1016/j.bbadis.2015.05.015; Arts RJW, 2016, CELL METAB, V24, P807, DOI 10.1016/j.cmet.2016.10.008; Asrih M, 2013, J ENDOCRINOL, V218, pR25, DOI 10.1530/JOE-13-0201; Bae IY, 2010, NEW BIOTECHNOL, V27, P85, DOI 10.1016/j.nbt.2009.11.003; Bashiri A, 2016, BBA-MOL CELL BIOL L, V1861, P594, DOI 10.1016/j.bbalip.2016.04.005; Bekkering S, 2018, CELL, V172, P135, DOI 10.1016/j.cell.2017.11.025; Bekkering S, 2016, ATHEROSCLEROSIS, V254, P228, DOI 10.1016/j.atherosclerosis.2016.10.019; Bekkering S, 2014, ARTERIOSCL THROM VAS, V34, P1731, DOI 10.1161/ATVBAHA.114.303887; Bieghs V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030668; Blok WL, 1997, EUR J CLIN INVEST, V27, P1003, DOI 10.1046/j.1365-2362.1997.2240775.x; Bozzetto L, 2012, DIABETES CARE, V35, P1429, DOI 10.2337/dc12-0033; Bronner DN, 2015, IMMUNITY, V43, P451, DOI 10.1016/j.immuni.2015.08.008; Broz P, 2016, NAT REV IMMUNOL, V16, P407, DOI 10.1038/nri.2016.58; Calder PC, 2002, EUR J CLIN NUTR, V56, pS14, DOI 10.1038/sj.ejcn.1601478; Calder PC, 2013, BRIT J CLIN PHARMACO, V75, P645, DOI 10.1111/j.1365-2125.2012.04374.x; Cani PD, 2009, GUT, V58, P1091, DOI 10.1136/gut.2008.165886; Cao Y, 2017, J AGR FOOD CHEM, V65, P9665, DOI 10.1021/acs.jafc.7b03782; Cao Y, 2016, MOL NUTR FOOD RES, V60, P2678, DOI 10.1002/mnfr.201600032; Chalasani N, 2018, HEPATOLOGY, V67, P328, DOI 10.1002/hep.29367; Chambers ES, 2019, GUT, V68, P1430, DOI 10.1136/gutjnl-2019-318424; Chan KL, 2015, J BIOL CHEM, V290, P16979, DOI 10.1074/jbc.M115.646992; Chang PV, 2014, P NATL ACAD SCI USA, V111, P2247, DOI 10.1073/pnas.1322269111; Chen L, 2015, INT J ENDOCRINOL, V2015, DOI 10.1155/2015/508409; Cheng SC, 2014, SCIENCE, V345, P1579, DOI 10.1126/science.1250684; Choi WJ, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-57615-5; Choudhury RP, 2016, J AM COLL CARDIOL, V68, P1769, DOI 10.1016/j.jacc.2016.07.768; Christ A, 2018, CELL, V172, P162, DOI 10.1016/j.cell.2017.12.013; Ciarlo E, 2018, J INFECT DIS, V9, P2936; Cluny NL, 2012, BRAIN BEHAV IMMUN, V26, P691, DOI 10.1016/j.bbi.2012.01.004; Cox AJ, 2015, LANCET DIABETES ENDO, V3, P207, DOI 10.1016/S2213-8587(14)70134-2; Cox LM, 2014, CELL, V158, P705, DOI 10.1016/j.cell.2014.05.052; Csak T, 2011, HEPATOLOGY, V54, P133, DOI 10.1002/hep.24341; Cullberg KB, 2014, NUTR DIABETES, V4, DOI 10.1038/nutd.2014.10; Daniali M, 2020, EXPERT REV ENDOCRINO, V15, P1, DOI 10.1080/17446651.2020.1719068; Dao MC, 2016, GUT, V65, P426, DOI 10.1136/gutjnl-2014-308778; Dasu MR, 2010, DIABETES CARE, V33, P861, DOI 10.2337/dc09-1799; Deehan EC, 2017, MICROBIOL SPECTR, V5, DOI 10.1128/microbiolspec.BAD-0019-2017; Della Corte KW, 2018, NUTRIENTS, V10, DOI 10.3390/nu10050606; den Besten G, 2013, AM J PHYSIOL-GASTR L, V305, pG900, DOI 10.1152/ajpgi.00265.2013; Depommier C, 2019, NAT MED, V25, P1096, DOI 10.1038/s41591-019-0495-2; Deveaux V, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005844; Di Caro V, 2019, SHOCK, V51, P526, DOI 10.1097/SHK.0000000000001180; Drewnowski A, 2007, EPIDEMIOL REV, V29, P160, DOI 10.1093/epirev/mxm011; Duewell P, 2010, NATURE, V464, P1357, DOI 10.1038/nature08938; El Khoury D, 2012, J NUTR METAB, V2012, DOI [10.1155/2012/703490, 10.1155/2012/851362]; El-Assaad W, 2003, ENDOCRINOLOGY, V144, P4154, DOI 10.1210/en.2003-0410; El-Remessy AB, 2006, AM J PATHOL, V168, P235, DOI 10.2353/ajpath.2006.050500; Endo H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063388; Endo M, 2006, J IMMUNOL, V176, P6245, DOI 10.4049/jimmunol.176.10.6245; Errazuriz I, 2017, J CLIN ENDOCR METAB, V102, P1765, DOI 10.1210/jc.2016-3722; Everard A, 2013, P NATL ACAD SCI USA, V110, P9066, DOI 10.1073/pnas.1219451110; Feldstein AE, 2004, HEPATOLOGY, V40, P185, DOI 10.1002/hep.20283; Finucane OM, 2015, DIABETES, V64, P2116, DOI 10.2337/db14-1098; Fisher EA, 2002, J BIOL CHEM, V277, P17377, DOI 10.1074/jbc.R100068200; FLEET JC, 1992, J NUTR, V122, P294, DOI 10.1093/jn/122.2.294; Freemerman AJ, 2014, J BIOL CHEM, V289, P7884, DOI 10.1074/jbc.M113.522037; GALEANO NF, 1994, J BIOL CHEM, V269, P511; Ganz M, 2014, WORLD J GASTROENTERO, V20, P8525, DOI 10.3748/wjg.v20.i26.8525; Grimm H, 2002, BRIT J NUTR, V87, pS59, DOI 10.1079/BJN2001457; Harada S, 2017, J PHARM PHARMACOL, V69, P698, DOI 10.1111/jphp.12705; Harris WS, 2018, PROSTAG LEUKOTR ESS, V132, P34, DOI 10.1016/j.plefa.2018.03.003; Haversen L, 2009, ATHEROSCLEROSIS, V202, P382, DOI 10.1016/j.atherosclerosis.2008.05.033; Hensen J, 2013, DIABETES METAB, V39, P524, DOI 10.1016/j.diabet.2013.07.003; Hert KA, 2014, NUTR RES, V34, P58, DOI 10.1016/j.nutres.2013.10.005; Holmes E, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004244; Hotamisligil GS, 2010, CELL, V140, P900, DOI 10.1016/j.cell.2010.02.034; Hotamisligil GS, 2017, NATURE, V542, P177, DOI 10.1038/nature21363; Huang SR, 2012, J LIPID RES, V53, P2002, DOI 10.1194/jlr.D029546; Ioannou GN, 2017, J LIPID RES, V58, P1067, DOI 10.1194/jlr.M072454; Ishisono K, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02979; Ishisono K, 2017, J NUTR BIOCHEM, V50, P38, DOI 10.1016/j.jnutbio.2017.07.016; Jadoon KA, 2016, DIABETES CARE, V39, P1777, DOI 10.2337/dc16-0650; Jager J, 2007, ENDOCRINOLOGY, V148, P241, DOI 10.1210/en.2006-0692; Jayachandran M, 2018, J NUTR BIOCHEM, V61, P101, DOI 10.1016/j.jnutbio.2018.06.010; Jialal I, 2012, DIABETES CARE, V35, P900, DOI 10.2337/dc11-2375; Jiang YG, 2012, BIOCHEM BIOPH RES CO, V425, P121, DOI 10.1016/j.bbrc.2012.07.011; Kamari Y, 2011, J HEPATOL, V55, P1086, DOI 10.1016/j.jhep.2011.01.048; Kawasaki N, 2012, SCI REP-UK, V2, DOI 10.1038/srep00799; Ke P, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155076; Kelley DS, 1998, LIPIDS, V33, P125, DOI 10.1007/s11745-998-0187-9; Kelly B, 2015, CELL RES, V25, P771, DOI 10.1038/cr.2015.68; Kendall DA, 2017, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00294; Kim Y, 2020, GUT MICROBES, V11, DOI 10.1080/19490976.2020.1730149; Kobyliak N, 2020, J DIABETES METAB DIS, V19, P289, DOI 10.1007/s40200-020-00506-3; Kobyliak N, 2018, DIABETES METAB SYND, V12, P617, DOI 10.1016/j.dsx.2018.04.015; Kobyliak N, 2016, NUTR METAB, V13, DOI 10.1186/s12986-016-0067-0; Lancaster GI, 2018, CELL METAB, V27, P1096, DOI 10.1016/j.cmet.2018.03.014; Larsen CM, 2007, NEW ENGL J MED, V356, P1517, DOI 10.1056/NEJMoa065213; Leamy AK, 2013, PROG LIPID RES, V52, P165, DOI 10.1016/j.plipres.2012.10.004; Lebeaupin C, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.248; Lebeaupin C, 2018, HEPATOLOGY, V68, P515, DOI 10.1002/hep.29847; Li LX, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-019-57068-5; Liebig M, 2019, THER ADV CHRONIC DIS, V10, DOI 10.1177/2040622319872118; Maki KC, 2015, J NUTR, V145, P159, DOI 10.3945/jn.114.195149; Makki K, 2018, CELL HOST MICROBE, V23, P705, DOI 10.1016/j.chom.2018.05.012; Mann JI, 2006, NUTR REV, V64, P422, DOI 10.1111/j.1753-4887.2006.tb00227.x; Martinez-Medina M, 2014, GUT, V63, P116, DOI 10.1136/gutjnl-2012-304119; Martinez-Micaelo N, 2016, FOOD FUNCT, V7, P3480, DOI [10.1039/C6FO00477F, 10.1039/c6fo00477f]; Martinon F, 2010, NAT IMMUNOL, V11, P411, DOI 10.1038/ni.1857; Maslowski KM, 2009, NATURE, V461, P1282, DOI 10.1038/nature08530; Mastrocola R, 2016, OXID MED CELL LONGEV, V2016, P1, DOI [10.1155/2016/3480637, DOI 10.1155/2016/3480637]; Menu P, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2011.132; Meroni M, 2019, NUTRIENTS, V11, DOI 10.3390/nu11112642; Mitroulis I, 2018, CELL, V172, P147, DOI 10.1016/j.cell.2017.11.034; Mogilenko DA, 2019, CELL, V177, P1201, DOI 10.1016/j.cell.2019.03.018; Moon JS, 2015, CELL REP, V12, P102, DOI 10.1016/j.celrep.2015.05.046; Moore KJ, 2013, NAT REV IMMUNOL, V13, P709, DOI 10.1038/nri3520; Morowitz MJ, 2017, CRIT CARE MED, V45, pE516, DOI [10.1097/ccm.0000000000002291, 10.1097/CCM.0000000000002291]; Mota M, 2016, METABOLISM, V65, P1049, DOI 10.1016/j.metabol.2016.02.014; Mridha AR, 2017, J HEPATOL, V66, P1037, DOI 10.1016/j.jhep.2017.01.022; Munoz-Planillo R, 2013, IMMUNITY, V38, P1142, DOI 10.1016/j.immuni.2013.05.016; Nakagawa H, 2014, CANCER CELL, V26, P331, DOI 10.1016/j.ccr.2014.07.001; Netea MG, 2020, NAT REV IMMUNOL, V20, P375, DOI 10.1038/s41577-020-0285-6; Nicholson JK, 2012, SCIENCE, V336, P1262, DOI 10.1126/science.1223813; Noe A, 2014, CLIN THER, V36, P1625, DOI 10.1016/j.clinthera.2014.08.004; O'Reilly M, 2016, CIRCULATION, V133, P1838, DOI 10.1161/CIRCULATIONAHA.115.020278; Ohmura H, 2002, METABOLISM, V51, P1081, DOI 10.1053/meta.2002.34695; Ouyang X, 2008, J HEPATOL, V48, P993, DOI 10.1016/j.jhep.2008.02.011; Ozcan U, 2004, SCIENCE, V306, P457, DOI 10.1126/science.1103160; Parry SA, 2020, DIABETES CARE, V43; PEKALA P, 1983, J EXP MED, V157, P1360, DOI 10.1084/jem.157.4.1360; Petersen IG, 2019, BMJ-BRIT MED J, V365, DOI 10.1136/bmj.l2157; Pilla DM, 2014, P NATL ACAD SCI USA, V111, P6046, DOI 10.1073/pnas.1321700111; Plovier H, 2017, NAT MED, V23, P107, DOI 10.1038/nm.4236; Puri P, 2007, HEPATOLOGY, V46, P1081, DOI 10.1002/hep.21763; Quintin J, 2012, CELL HOST MICROBE, V12, P223, DOI 10.1016/j.chom.2012.06.006; Rajamaki K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011765; Rajesh M, 2007, AM J PHYSIOL-HEART C, V293, pH610, DOI 10.1152/ajpheart.00236.2007; Rajesh M, 2010, J AM COLL CARDIOL, V56, P2115, DOI 10.1016/j.jacc.2010.07.033; Razani B, 2012, CELL METAB, V15, P534, DOI 10.1016/j.cmet.2012.02.011; Reynolds CM, 2012, MOL NUTR FOOD RES, V56, P1212, DOI 10.1002/mnfr.201200058; Rhoads JP, 2017, J IMMUNOL, V198, P2105, DOI 10.4049/jimmunol.1601563; Ridker PM, 2017, NEW ENGL J MED, V377, P1119, DOI 10.1056/NEJMoa1707914; Sabio G, 2008, SCIENCE, V322, P1539, DOI 10.1126/science.1160794; Salman H, 2008, BIOMED PHARMACOTHER, V62, P579, DOI 10.1016/j.biopha.2008.07.058; SALOMAA V, 1990, METABOLISM, V39, P1285, DOI 10.1016/0026-0495(90)90185-F; Savage DB, 2007, PHYSIOL REV, V87, P507, DOI 10.1152/physrev.00024.2006; Savard C, 2013, HEPATOLOGY, V57, P81, DOI 10.1002/hep.25789; Schilling JD, 2013, J BIOL CHEM, V288, P2923, DOI 10.1074/jbc.M112.419978; Schneeberger M, 2015, SCI REP-UK, V5, DOI 10.1038/srep16643; Seijkens T, 2014, FASEB J, V28, P2202, DOI 10.1096/fj.13-243105; Seimon TA, 2010, CELL METAB, V12, P467, DOI 10.1016/j.cmet.2010.09.010; Serhan CN, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a016311; Serhan CN, 2014, NATURE, V510, P92, DOI 10.1038/nature13479; Shao BZ, 2014, CNS NEUROSCI THER, V20, P1021, DOI 10.1111/cns.12349; Sharifnia T, 2015, AM J PHYSIOL-GASTR L, V309, pG270, DOI 10.1152/ajpgi.00304.2014; Sheedy FJ, 2013, NAT IMMUNOL, V14, P812, DOI 10.1038/ni.2639; Shen LL, 2017, J LIPID RES, V58, P1808, DOI 10.1194/jlr.M075879; Shen RL, 2011, J AGR FOOD CHEM, V59, P8895, DOI 10.1021/jf200678q; Shi H, 2006, J CLIN INVEST, V116, P3015, DOI 10.1172/JCI28898; Shi X, 2015, J STROKE CEREBROVASC, V24, P2455, DOI 10.1016/j.jstrokecerebrovasdis.2015.03.024; Sohrabi Y, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03155; Souza CO, 2020, BBA-MOL CELL BIOL L, V1865, DOI 10.1016/j.bbalip.2020.158776; Stanley CP, 2013, EUR J PHARMACOL, V720, P376, DOI 10.1016/j.ejphar.2013.10.002; Steinberg GR, 2019, NAT REV DRUG DISCOV, V18, P527, DOI 10.1038/s41573-019-0019-2; Suganami T, 2007, BIOCHEM BIOPH RES CO, V354, P45, DOI 10.1016/j.bbrc.2006.12.190; Sui YH, 2016, WORLD J GASTROENTERO, V22, P2533, DOI 10.3748/wjg.v22.i8.2533; Swanson KV, 2019, NAT REV IMMUNOL, V19, P477, DOI 10.1038/s41577-019-0165-0; Swirski FK, 2007, J CLIN INVEST, V117, P195, DOI 10.1172/JCI29950; Szymanski J, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071576; Tan L, 2020, FASEB J, V34, P5818, DOI 10.1096/fj.201902746R; Taskinen MR, 2011, ARTERIOSCL THROM VAS, V31, P2144, DOI 10.1161/ATVBAHA.111.224808; Thies F, 2001, LIPIDS, V36, P1183, DOI 10.1007/s11745-001-0831-4; Tierney AC, 2011, INT J OBESITY, V35, P800, DOI 10.1038/ijo.2010.209; Tso GHW, 2018, SCIENCE, V362, P589, DOI 10.1126/science.aat0537; Turnbaugh PJ, 2006, NATURE, V444, P1027, DOI 10.1038/nature05414; Vandanmagsar B, 2011, NAT MED, V17, P179, DOI 10.1038/nm.2279; Vessby B, 2001, DIABETOLOGIA, V44, P312, DOI 10.1007/s001250051620; VESSBY B, 1994, DIABETES, V43, P1353, DOI 10.2337/diabetes.43.11.1353; Wang JJ, 2015, ISME J, V9, P1, DOI 10.1038/ismej.2014.99; Wang T, 2020, EUR J NUTR, V59, P2709, DOI 10.1007/s00394-019-02117-y; Weldon SM, 2007, J NUTR BIOCHEM, V18, P250, DOI 10.1016/j.jnutbio.2006.04.003; Wen HT, 2011, NAT IMMUNOL, V12, P408, DOI 10.1038/ni.2022; Westerterp M, 2013, CIRC RES, V112, P1456, DOI 10.1161/CIRCRESAHA.113.301086; Williamson RM, 2011, DIABETES CARE, V34, P1139, DOI 10.2337/dc10-2229; Wree A, 2014, J MOL MED, V92, P1069, DOI 10.1007/s00109-014-1170-1; Xu CF, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06522-5; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; Yang G, 2016, SCI REP-UK, V6, DOI 10.1038/srep24399; Yao ST, 2014, J BIOL CHEM, V289, P4032, DOI 10.1074/jbc.M113.524512; You SP, 2013, FOOD FUNCT, V4, P1360, DOI 10.1039/c3fo60081e; Yvan-Charvet L, 2010, SCIENCE, V328, P1689, DOI 10.1126/science.1189731; Zeng X, 2020, NUTR METAB, V17, DOI 10.1186/s12986-020-0434-8; Zhang C, 2017, SCI REP, V7; Zhu ZZ, 2019, FOOD RES INT, V123, P355, DOI 10.1016/j.foodres.2019.05.003; Zou SL, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030833; Zucko J, 2020, CURR OPIN FOOD SCI, V32, P45, DOI 10.1016/j.cofs.2020.01.007	191	21	21	0	26	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2020	146	4					706	720		10.1016/j.jaci.2020.08.013	http://dx.doi.org/10.1016/j.jaci.2020.08.013			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	OH2JO	32841652	hybrid			2022-12-18	WOS:000582395800003
J	Butler, MW; O'Reilly, A; Dunican, EM; Mallon, P; Feeney, ER; Keane, MP; McCarthy, C				Butler, Marcus W.; O'Reilly, Aoife; Dunican, Eleanor M.; Mallon, Patrick; Feeney, Eoin R.; Keane, Michael P.; McCarthy, Cormac			Prevalence of comorbid asthma in COVID-19 patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							OUTBREAK		[Butler, Marcus W.; Dunican, Eleanor M.; Mallon, Patrick; Feeney, Eoin R.; Keane, Michael P.; McCarthy, Cormac] St Vincents Univ Hosp, Dublin, Ireland; [Butler, Marcus W.; O'Reilly, Aoife; Dunican, Eleanor M.; Mallon, Patrick; Feeney, Eoin R.; Keane, Michael P.; McCarthy, Cormac] Univ Coll Dublin, Sch Med, Dublin, Ireland	University College Dublin; Saint Vincent's University Hospital; University College Dublin	Butler, MW (corresponding author), St Vincents Univ Hosp, Dublin, Ireland.; Butler, MW (corresponding author), Univ Coll Dublin, Sch Med, Dublin, Ireland.	marcus.butler@ucd.ie		Mallon, Patrick/0000-0002-4337-6222; McCarthy, Cormac/0000-0003-2896-5210; Butler, Marcus/0000-0003-2026-7709; Feeney, Eoin/0000-0003-4118-4945				Centers for Disease Control and Prevention, MOST REC ASTHM STAT; Chiambaretta Navel V, 2020, J ALLERGY CLIN IMMUN, DOI 10.1016/j.jaci.2020.04.026.; Chirumbolo S, 2020, J ALLERGY CLIN IMMUN, V146, P331, DOI 10.1016/j.jaci.2020.05.011; Department of Health, HLTH IR SURV 2019; Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419; Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00597-2020; Lupia T, 2020, J GLOB ANTIMICROB RE, V21, P22, DOI 10.1016/j.jgar.2020.02.021	7	21	22	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2020	146	2					334	335		10.1016/j.jaci.2020.04.061	http://dx.doi.org/10.1016/j.jaci.2020.04.061			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MZ0TA	32553599	Green Published, Bronze			2022-12-18	WOS:000558835000022
J	Forster-Ruhrmann, U; Szczepek, AJ; Bachert, C; Olze, H				Foerster-Ruhrmann, Ulrike; Szczepek, Agnieszka J.; Bachert, Claus; Olze, Heidi			COVID-19 in a patient with severe chronic rhinosinusitis with nasal polyps during therapy with dupilumab	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									[Foerster-Ruhrmann, Ulrike; Szczepek, Agnieszka J.; Olze, Heidi] Charite Univ Med Berlin, Dept Otorhinolaryngol Head & Neck Surg, Berlin, Germany; [Foerster-Ruhrmann, Ulrike; Szczepek, Agnieszka J.; Olze, Heidi] Free Univ Berlin, Berlin, Germany; [Foerster-Ruhrmann, Ulrike; Szczepek, Agnieszka J.; Olze, Heidi] Humboldt Univ, Berlin, Germany; [Foerster-Ruhrmann, Ulrike; Szczepek, Agnieszka J.; Olze, Heidi] Berlin Inst Hlth, Berlin, Germany; [Bachert, Claus] Univ Ghent, Upper Airways Res Lab, Ghent, Belgium; [Bachert, Claus] Univ Ghent, Dept Otorhinolaryngol, Ghent, Belgium	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Berlin Institute of Health; Ghent University; Ghent University	Olze, H (corresponding author), Charite Univ Med Berlin, Dept Otorhinolaryngol Head & Neck Surg, Berlin, Germany.; Olze, H (corresponding author), Free Univ Berlin, Berlin, Germany.; Olze, H (corresponding author), Humboldt Univ, Berlin, Germany.; Olze, H (corresponding author), Berlin Inst Hlth, Berlin, Germany.	heidi.olze@charite.de	Szczepek, Agnieszka/AAK-8514-2021; Bachert, Claus/J-8825-2012; Szczepek, Agnieszka J./C-1434-2019	Szczepek, Agnieszka/0000-0002-9292-6606; Szczepek, Agnieszka J./0000-0002-9292-6606; Olze, Heidi/0000-0001-9987-6392				Achuthan A, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0332-4; Bachert C, 2019, LANCET, V394, P1638, DOI 10.1016/S0140-6736(19)31881-1; Hopkins C, 2009, CLIN OTOLARYNGOL, V34, P447, DOI 10.1111/j.1749-4486.2009.01995.x; Li CKF, 2008, J IMMUNOL, V181, P5490, DOI 10.4049/jimmunol.181.8.5490; Liu F, 2020, INT J INFECT DIS, V95, P183, DOI 10.1016/j.ijid.2020.03.013; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; Russell B, 2020, ECANCERMEDICALSCIENC, V14, P1, DOI 10.3332/ecancer.2020.1022; Wollenberg A, 2020, BRIT J DERMATOL, V182, P1120, DOI 10.1111/bjd.18434	8	21	21	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2020	146	1					218	220		10.1016/j.jaci.2020.05.005	http://dx.doi.org/10.1016/j.jaci.2020.05.005			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	OC5BB	32417136	Green Published, Bronze			2022-12-18	WOS:000579170500035
J	Damsky, W; Wang, A; Olamiju, B; Peterson, D; Galan, A; King, B				Damsky, William; Wang, Alice; Olamiju, Brianna; Peterson, Danielle; Galan, Anjela; King, Brett			Treatment of severe lichen planus with the JAK inhibitor tofacitinib	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									[Damsky, William; Wang, Alice; Olamiju, Brianna; Peterson, Danielle; Galan, Anjela; King, Brett] Yale Sch Med, Dept Dermatol, New Haven, CT 06510 USA; [Galan, Anjela] Yale Sch Med, Dept Pathol, New Haven, CT USA	Yale University; Yale University	King, B (corresponding author), Yale Sch Med, Dept Dermatol, New Haven, CT 06510 USA.	brett.king@yale.edu		Wang, Alice/0000-0003-1771-2103	Children's Hospital of Michigan; Children's Research Center of Michigan [10-CHM-0485]	Children's Hospital of Michigan; Children's Research Center of Michigan	Supported by the Children's Hospital of Michigan and the Children's Research Center of Michigan (grant 10-CHM-0485). The content is solely the responsibility of the authors and does not necessarily represent the official views of the sponsor.	Damsky W, 2017, J AM ACAD DERMATOL, V76, P736, DOI 10.1016/j.jaad.2016.12.005; Di Lernia V, 2016, MED HYPOTHESES, V92, P60, DOI 10.1016/j.mehy.2016.04.042; Escudier M, 2007, BRIT J DERMATOL, V157, P765, DOI 10.1111/j.1365-2133.2007.08106.x; Schwager Z, 2019, J AM ACAD DERMATOL, V81, P1397, DOI 10.1016/j.jaad.2019.04.027; Shao S, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aav7561; Yang CC, 2018, DERMATOL THER, V31, DOI 10.1111/dth.12656	6	21	20	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2020	145	6					1708	+		10.1016/j.jaci.2020.01.031	http://dx.doi.org/10.1016/j.jaci.2020.01.031			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LW4ZZ	32018031	Bronze			2022-12-18	WOS:000539157800032
J	Dunn, JLM; Shoda, T; Caldwell, JM; Wen, T; Aceves, SS; Collins, MH; Dellon, ES; Falk, GW; Leung, J; Martin, LJ; Menard-Katcher, P; Rudman-Spergel, AK; Spergel, JM; Wechsler, JB; Yang, GY; Furuta, GT; Rothenberg, ME				Dunn, Julia L. M.; Shoda, Tetsuo; Caldwell, Julie M.; Wen, Ting; Aceves, Seema S.; Collins, Margaret H.; Dellon, Evan S.; Falk, Gary W.; Leung, John; Martin, Lisa J.; Menard-Katcher, Paul; Rudman-Spergel, Amanda K.; Spergel, Jonathan M.; Wechsler, Joshua B.; Yang, Guang-Yu; Furuta, Glenn T.; Rothenberg, Marc E.		Consortium Eosinophilic Gastrointe	Esophageal type 2 cytokine expression heterogeneity in eosinophilic esophagitis in a multisite cohort	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; cytokine; eosinophil; fibrosis; IL-5; IL-13; inflammation; precision medicine; resolution; T(H)2 cells	GENE-EXPRESSION; DIAGNOSIS; CHILDREN; IL-13; NUMBERS	Background: There is strong evidence for a role of type 2 cytokines in the pathogenesis of eosinophilic esophagitis (EoE); however, heterogeneity in type 2 gene expression has not been examined. Objective: We examined type 2 immunity-associated gene expression in esophageal biopsy specimens, aiming to determine the degree of cytokine heterogeneity and its potential clinical significance. Methods: Patients (n = 312) were recruited from 10 sites associated with the Consortium of Eosinophilic Gastrointestinal Disease Researchers. In addition to histologic and endoscopic assessment, esophageal biopsy specimens were examined for expression of 96 genes within the EoE diagnostic panel. Results: Five subgroups of patients with active EoE were identified by unsupervised clustering based on expression of IL4, IL5, IL13, C-C motif chemokine ligand 26 (CCL26), thymic stromal lymphopoietin (TSLP), Charcot-Leyden crystal (CLC), C-C motif chemokine receptor 3 (CCR3), and CPA3. These groups differed in age (P<.02) and EoE diagnostic panel score (P < 1.08E-30) but not in eosinophil levels. The group V patients had the highest expression of IL5, TSLP, and CCL26 and genes associated with tissue remodeling, such as COL8A1, actin gamma-2 (ACTG2), and tetraspanin 12 (TSPAN12). IL5 and IL13 were highly expressed in group IV; however, groups IV and V differed in age (34 vs 14 years [P<.05]). Groups II and III, which exhibited intermediate expression of IL5 and CPA3, were differentiated by high TSLP and IL13 in group III. Conclusion: We observed heterogeneous type 2 gene expression among patients with active EoE. Type 2 gene overexpression was not directly proportional to disease features; this was especially true for tissue remodeling events. These findings highlight a clinical opportunity for leveraging molecular endotypes to implement personalized medicine in EoE.	[Dunn, Julia L. M.; Shoda, Tetsuo; Caldwell, Julie M.; Wen, Ting; Rothenberg, Marc E.] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Dept Pediat,Div Allergy & Immunol, 3333 Burnet Ave, Cincinnati, OH 45229 USA; [Aceves, Seema S.] Univ Calif San Diego, Div Allergy Immunol, San Diego, CA 92103 USA; [Aceves, Seema S.] Rady Childrens Hosp, San Diego, CA USA; [Dellon, Evan S.] Univ N Carolina, Sch Med, Ctr Esophageal Dis & Swallowing, Chapel Hill, NC 27515 USA; [Dellon, Evan S.] Univ N Carolina, Sch Med, Div Gastroenterol & Hepatol, Chapel Hill, NC 27515 USA; [Falk, Gary W.] Hosp Univ Penn, Div Gastroenterol, Philadelphia, PA 19104 USA; [Spergel, Jonathan M.] Univ Penn, Sch Med, Childrens Hosp Philadelphia, Div Allergy & Immunol, Philadelphia, PA 19104 USA; [Leung, John] Tufts Med Ctr, Div Gastroenterol, Boston, MA 02111 USA; [Martin, Lisa J.] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Human Genet, Cincinnati, OH 45229 USA; [Martin, Lisa J.] Univ Cincinnati, Coll Med, Cincinnati, OH 45229 USA; [Menard-Katcher, Paul] Univ Colorado, Div Gastroenterol & Hepatol, Anschutz Med Campus, Boulder, CO 80309 USA; [Rudman-Spergel, Amanda K.] NIAID, Allergy Asthma & Airway Biol Branch, Div Allergy Immunol & Transplantat, NIH, Rockville, MD USA; [Wechsler, Joshua B.] Lurie Childrens Hosp Chicago, Div Gastroenterol Hepatol & Nutr, Chicago, IL USA; [Yang, Guang-Yu] Northwestern Univ Feinberg, Sch Med, Dept Pathol, Chicago, IL USA; [Furuta, Glenn T.] Univ Colorado, Sch Med, Gastrointestinal Eosinophil Dis Program, Childrens Hosp Colorado,Digest Hlth Inst, Aurora, CO USA; [Collins, Margaret H.] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Dept Pediat,Div Pathol, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University of California System; University of California San Diego; Rady Childrens Hospital San Diego; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Tufts Medical Center; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Rothenberg, ME (corresponding author), Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Dept Pediat,Div Allergy & Immunol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	Rothenberg@cchmc.org	Martin, Lisa/E-2425-2016	Martin, Lisa/0000-0001-8702-9946; Shoda, Tetsuo/0000-0001-8337-5438; Dunn, Julia/0000-0002-4339-2396	CEGIR [U54 AI117804]; Rare Diseases Clinical Research Network, an initiative of the Office of Rare Diseases Research, National Center for Advancing Translational Sciences - National Institute of Allergy and Infectious Diseases; National Institute of Diabetes and Digestive and Kidney Diseases; National Center for Advancing Translational Sciences; American Partnership for Eosinophilic Disorders and the Campaign Urging Research for Eosinophilic Disease	CEGIR; Rare Diseases Clinical Research Network, an initiative of the Office of Rare Diseases Research, National Center for Advancing Translational Sciences - National Institute of Allergy and Infectious Diseases; National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); National Center for Advancing Translational Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); American Partnership for Eosinophilic Disorders and the Campaign Urging Research for Eosinophilic Disease	CEGIR (U54 AI117804) is part of the Rare Diseases Clinical Research Network, an initiative of the Office of Rare Diseases Research, National Center for Advancing Translational Sciences; it is cofunded by the National Institute of Allergy and Infectious Diseases, the National Institute of Diabetes and Digestive and Kidney Diseases, and the National Center for Advancing Translational Sciences. CEGIR is also supported by patient advocacy groups, including the American Partnership for Eosinophilic Disorders and the Campaign Urging Research for Eosinophilic Disease.	Aceves SS, 2018, J ALLERGY CLIN IMMUN, V142, P130, DOI 10.1016/j.jaci.2018.05.014; Assa'ad AH, 2011, GASTROENTEROLOGY, V141, P1593, DOI 10.1053/j.gastro.2011.07.044; Blanchard C, 2011, J ALLERGY CLIN IMMUN, V127, P208, DOI 10.1016/j.jaci.2010.10.039; Cheng Katherine, 2017, Transl Sci Rare Dis, V2, P141, DOI 10.3233/TRD-170016; Collins MH, 2017, DIS ESOPHAGUS, V30, DOI 10.1111/dote.12470; D'Mello RJ, 2016, MUCOSAL IMMUNOL, V9, P744, DOI 10.1038/mi.2015.98; Davis BP, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.86355; Dellon ES, 2018, GASTROENTEROLOGY, V155, P1022, DOI 10.1053/j.gastro.2018.07.009; Dellon ES, 2017, CLIN TRANSL GASTROEN, V8, DOI 10.1038/ctg.2017.2; Dellon ES, 2015, J GASTROINTEST LIVER, V24, P151, DOI 10.15403/jgld.2014.1121.242.bsy; Dellon ES, 2014, GASTROINTEST ENDOSC, V79, P577, DOI 10.1016/j.gie.2013.10.027; Finkelman FD, 2005, J IMMUNOL, V174, P4630, DOI 10.4049/jimmunol.174.8.4630; Fulkerson PC, 2014, J IMMUNOL, V193, P4043, DOI 10.4049/jimmunol.1400732; Geslewitz WE, 2018, CLIN EXP ALLERGY, V48, P29, DOI 10.1111/cea.13050; Gour N, 2015, CYTOKINE, V75, P68, DOI 10.1016/j.cyto.2015.05.014; Gupta SK, 2019, GASTROENTEROLOGY, V156, P838, DOI 10.1053/j.gastro.2018.10.057; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Hirano I, 2019, GASTROENTEROLOGY, V156, P592, DOI 10.1053/j.gastro.2018.10.051; Hirano I, 2013, GUT, V62, P489, DOI 10.1136/gutjnl-2011-301817; Johansson MW, 2013, CLIN EXP ALLERGY, V43, P292, DOI 10.1111/j.1365-2222.2012.04065.x; Kottyan LC, 2017, MUCOSAL IMMUNOL, V10, P580, DOI 10.1038/mi.2017.4; Kottyan LC, 2014, NAT GENET, V46, P895, DOI 10.1038/ng.3033; Lucendo AJ, 2017, UNITED EUR GASTROENT, V5, P335, DOI 10.1177/2050640616689525; Mishra A, 2008, GASTROENTEROLOGY, V134, P204, DOI 10.1053/j.gastro.2007.10.002; Otani IM, 2013, J ALLERGY CLIN IMMUN, V131, P1576, DOI 10.1016/j.jaci.2013.02.042; Perkins C, 2006, J ALLERGY CLIN IMMUN, V118, P410, DOI 10.1016/j.jaci.2006.06.004; Rochman M, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.96789; Rothenberg ME, 2015, J ALLERGY CLIN IMMUN, V135, P500, DOI 10.1016/j.jaci.2014.07.049; Rothenberg ME, 2010, NAT GENET, V42, P289, DOI 10.1038/ng.547; Schoepfer AM, 2013, GASTROENTEROLOGY, V145, P1230, DOI 10.1053/j.gastro.2013.08.015; Shoda T, 2020, J ALLERGY CLIN IMMUN, V145, P255, DOI 10.1016/j.jaci.2019.11.007; Shoda T, 2018, LANCET GASTROENTEROL, V3, P477, DOI 10.1016/S2468-1253(18)30096-7; Simon D, 2016, ALLERGY, V71, P611, DOI 10.1111/all.12846; Sleiman PMA, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6593; Spergel JM, 2012, J ALLERGY CLIN IMMUN, V129, P456, DOI 10.1016/j.jaci.2011.11.044; Straumann A, 2010, GUT, V59, P21, DOI 10.1136/gut.2009.178558; Straumann A, 2012, GASTROENTEROLOGY, V142, P1409, DOI 10.1053/j.gastro.2012.04.039; Upadhyaya B, 2011, J IMMUNOL, V187, P3111, DOI 10.4049/jimmunol.1101283; Walsh SV, 1999, AM J SURG PATHOL, V23, P390, DOI 10.1097/00000478-199904000-00003; Wambre E, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aam9171; Wechsler JB, 2018, CLIN GASTROENTEROL H, V16, P1056, DOI 10.1016/j.cgh.2017.12.019; Wen T, 2019, J CLIN INVEST, V129, P2014, DOI 10.1172/JCI125917; Wen T, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00108; Wen T, 2013, GASTROENTEROLOGY, V145, P1289, DOI 10.1053/j.gastro.2013.08.046; Wheeler JC, 2019, J ALLERGY CLIN IMMUN, V143, P2131, DOI 10.1016/j.jaci.2018.10.070; Zuo L, 2010, J IMMUNOL, V185, P660, DOI 10.4049/jimmunol.1000471	46	21	22	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2020	145	6					1629	+		10.1016/j.jaci.2020.01.051	http://dx.doi.org/10.1016/j.jaci.2020.01.051			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LW4ZZ	32197970	Bronze, Green Accepted			2022-12-18	WOS:000539157800018
J	Barnthaler, T; Theiler, A; Zabini, D; Trautmann, S; Stacher-Priehse, E; Lanz, I; Klepetko, W; Sinn, K; Flick, H; Scheidl, S; Thomas, D; Olschewski, H; Kwapiszewska, G; Schuligoi, R; Heinemann, A				Baernthaler, Thomas; Theiler, Anna; Zabini, Diana; Trautmann, Sandra; Stacher-Priehse, Elvira; Lanz, Ilse; Klepetko, Walter; Sinn, Katharina; Flick, Holger; Scheidl, Stefan; Thomas, Dominique; Olschewski, Horst; Kwapiszewska, Grazyna; Schuligoi, Rufina; Heinemann, Akos			Inhibiting eicosanoid degradation exerts antifibrotic effects in a pulmonary fibrosis mouse model and human tissue	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						PGE(2); 15-PGDH; idiopathic pulmonary fibrosis; fibrocytes	PROSTAGLANDIN E-2; LUNG INJURY; EPITHELIAL-CELLS; LIPID MEDIATORS; TGF-BETA; CYCLOOXYGENASE-2; DEHYDROGENASE; FIBROBLASTS; APOPTOSIS; INFLAMMATION	Background: Idiopathic pulmonary fibrosis (IPF) is a disease with high 5-year mortality and few therapeutic options. Prostaglandin (PG) E-2 exhibits antifibrotic properties and is reduced in bronchoalveolar lavage from patients with IPF. 15-Prostaglandin dehydrogenase (15-PGDH) is the key enzyme in PGE(2) metabolism under the control of TGF-beta and microRNA 218. Objective: We sought to investigate the expression of 15-PGDH in IPF and the therapeutic potential of a specific inhibitor of this enzyme in a mouse model and human tissue. Methods: In vitro studies, including fibrocyte differentiation, regulation of 15-PGDH, RT-PCR, and Western blot, were performed using peripheral blood from healthy donors and patients with IPF and A549 cells. Immunohistochemistry, immunofluorescence, 15-PGDH activity assays, and in situ hybridization as well as ex vivo IPF tissue culture experiments were done using healthy donor and IPF lungs. Therapeutic effects of 15-PGDH inhibition were studied in the bleomycin mouse model of pulmonary fibrosis. Results: We demonstrate that 15-PGDH shows areas of increased expression in patients with IPF. Inhibition of this enzyme increases PGE(2) levels and reduces collagen production in IPF precision cut lung slices and in the bleomycin model. Inhibitor-treated mice show amelioration of lung function, decreased alveolar epithelial cell apoptosis, and fibroblast proliferation. Pulmonary fibrocyte accumulation is also decreased by inhibitor treatment in mice, similar to PGE2 that inhibits fibrocyte differentiation from blood of healthy donors and patients with IPF. Finally, microRNA 218-5p, which is downregulated in patients with IPF, suppressed 15-PGDH expression in vivo and in vitro. Conclusions: These findings highlight the role of 15-PGDH in IPF and suggest 15-PGDH inhibition as a promising therapeutic approach.	[Baernthaler, Thomas; Theiler, Anna; Lanz, Ilse; Schuligoi, Rufina; Heinemann, Akos] Med Univ Graz, Otto Loewi Res Ctr, Div Pharmacol, Graz, Austria; [Zabini, Diana; Stacher-Priehse, Elvira; Kwapiszewska, Grazyna] Med Univ Graz, Otto Loewi Res Ctr, Div Physiol, Graz, Austria; [Zabini, Diana; Olschewski, Horst; Kwapiszewska, Grazyna] Ludwig Boltzmann Inst Lung Vasc Res, Graz, Austria; [Trautmann, Sandra; Thomas, Dominique] Goethe Univ Frankfurt, Inst Clin Pharmacol, Pharmazentrum Frankfurt ZAFES, Frankfurt, Germany; [Klepetko, Walter; Sinn, Katharina] Med Univ Vienna, Div Thorac Surg, Dept Surg, Vienna, Austria; [Flick, Holger; Scheidl, Stefan; Olschewski, Horst] Med Univ Graz, Div Pulmonol, Dept Internal Med, Graz, Austria	Medical University of Graz; Medical University of Graz; Ludwig Boltzmann Institute; Goethe University Frankfurt; Medical University of Vienna; Medical University of Graz	Heinemann, A (corresponding author), Med Univ Graz, Div Pharmacol, Otto Loewi Res Ctr Vasc Biol Immunol & Inflammat, Univ Pl 4, A-8010 Graz, Austria.	akos.heinemann@medunigraz.at		Schuligoi, Rufina/0000-0002-9338-6904; Barnthaler, Thomas/0000-0002-4988-3700	Austrian Science Fund (FWF) [P22521-B18, P26185-B19]; Jubilaumsfonds of the Austrian National Bank [14263]; LOEWE program from the state of Hesse (Translational Medicine and Pharmacology, TMP); PhD program DK-MOLIN [FWF-W1241]; Medical University of Graz; Austrian Academy of Sciences	Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); Jubilaumsfonds of the Austrian National Bank; LOEWE program from the state of Hesse (Translational Medicine and Pharmacology, TMP); PhD program DK-MOLIN; Medical University of Graz; Austrian Academy of Sciences	This research was supported by the Austrian Science Fund (FWF; grant no. P22521-B18 to A.H. and grant no. P26185-B19 to R.S.), the Jubilaumsfonds of the Austrian National Bank (grant no. 14263 to A.H.), and the LOEWE program from the state of Hesse (Translational Medicine and Pharmacology, TMP, to D.T.). T.B. was funded by the PhD program DK-MOLIN (FWF-W1241) and the Start Funding Program of the Medical University of Graz. T.B. and A.T. are recipients of a doctoral fellowship of the Austrian Academy of Sciences.	Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005; Aguilar S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008013; Ando M, 2003, AM J RESP CELL MOL, V28, P582, DOI 10.1165/rcmb.2002-0162OC; Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028; Barnthaler T, 2019, J ALLERGY CLIN IMMUN, V143, P794, DOI 10.1016/j.jaci.2018.09.030; Bannenberg G, 2010, BBA-MOL CELL BIOL L, V1801, P1260, DOI 10.1016/j.bbalip.2010.08.002; Barbas-Filho JV, 2001, J CLIN PATHOL, V54, P132, DOI 10.1136/jcp.54.2.132; Barnthaler T, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08228-y; Bauman KA, 2010, J CLIN INVEST, V120, P1950, DOI 10.1172/JCI38369; Bergmann C, 2011, EXP DERMATOL, V20, P532, DOI 10.1111/j.1600-0625.2011.01248.x; Berschneider B, 2014, INT J BIOCHEM CELL B, V53, P432, DOI 10.1016/j.biocel.2014.06.011; Bhavsar PK, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-71; Bjoraker JA, 1998, AM J RESP CRIT CARE, V157, P199, DOI 10.1164/ajrccm.157.1.9704130; BOROK Z, 1991, AM REV RESPIR DIS, V144, P1080, DOI 10.1164/ajrccm/144.5.1080; Bozyk PD, 2011, AM J RESP CELL MOL, V45, P445, DOI 10.1165/rcmb.2011-0025RT; Card JW, 2007, AM J RESP CELL MOL, V37, P300, DOI 10.1165/rcmb.2007-0057OC; Cheng J, 2016, FASEB J, V30, P160, DOI 10.1096/fj.14-268458; Clish CB, 2000, J BIOL CHEM, V275, P25372, DOI 10.1074/jbc.M002863200; Coggins KG, 2002, NAT MED, V8, P91, DOI 10.1038/nm0202-91; Cong RJ, 2017, MOL MED REP, V16, P9347, DOI 10.3892/mmr.2017.7795; Dackor RT, 2011, AM J PHYSIOL-LUNG C, V301, pL645, DOI 10.1152/ajplung.00176.2011; Epa AP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135266; Evans IC, 2016, CLIN SCI, V130, P575, DOI 10.1042/CS20150697; Failla M, 2009, AM J RESP CELL MOL, V41, P50, DOI 10.1165/rcmb.2007-0438OC; Fan Y, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0309-0; Fernandez Isis E, 2012, Proc Am Thorac Soc, V9, P111, DOI 10.1513/pats.201203-023AW; Frei RB, 2016, ALLERGY, V71, P944, DOI 10.1111/all.12858; George G, 2016, CLIN PHARMACOL THER, V99, P30, DOI 10.1002/cpt.283; Gomer RH, 2013, CURR ALLERGY ASTHM R, V13, P607, DOI 10.1007/s11882-013-0377-5; Guilherme RF, 2013, AM J RESP CELL MOL, V49, P1029, DOI 10.1165/rcmb.2012-0462OC; Heukels P, 2018, RESP RES, V19, DOI 10.1186/s12931-018-0798-8; Hodges RJ, 2004, AM J PATHOL, V165, P1663, DOI 10.1016/S0002-9440(10)63423-2; Horikiri T, 2017, RESP MED, V122, P43, DOI 10.1016/j.rmed.2016.11.017; Huang SK, 2008, CHEST, V133, P1442, DOI 10.1378/chest.08-0306; Huang SK, 2019, AM J RESP CELL MOL, V60, P499, DOI 10.1165/rcmb.2018-0392ED; Huang SK, 2010, AM J PATHOL, V177, P2245, DOI 10.2353/ajpath.2010.100446; Huang SK, 2009, FASEB J, V23, P4317, DOI 10.1096/fj.08-128801; Hubner RH, 2008, BIOTECHNIQUES, V44, P14; Huebner RH, 2008, BIOTECHNIQUES, V44, P507, DOI 10.2144/000112729; Inomata M, 2014, RESP RES, V15, DOI 10.1186/1465-9921-15-16; Ivanova V, 2013, EUR J PHARM BIOPHARM, V84, P335, DOI 10.1016/j.ejpb.2012.11.023; JARABAK J, 1979, PROSTAGLANDINS, V18, P241, DOI 10.1016/0090-6980(79)90109-6; Jenkins RG, 2017, AM J RESP CELL MOL, V56, P667, DOI 10.1165/rcmb.2017-0096ST; Jiang WJ, 2015, SCIENCE, V349, P283, DOI 10.1126/science.aaa1442; JORDANA M, 1988, AM REV RESPIR DIS, V137, P579, DOI 10.1164/ajrccm/137.3.579; King TE, 2014, NEW ENGL J MED, V370, P2083, DOI 10.1056/NEJMoa1402582; Kolodsick JE, 2003, AM J RESP CELL MOL, V29, P537, DOI 10.1165/rcmb.2002-0243OC; Lama V, 2002, AM J RESP CELL MOL, V27, P752, DOI 10.1165/rcmb.4857; Lappi-Blanco E, 2006, AM J CLIN PATHOL, V126, P717, DOI 10.1309/PFGXCLNG2N17PJX9; Liang HH, 2014, MOL THER, V22, P1122, DOI 10.1038/mt.2014.42; Lovgren AK, 2006, AM J PHYSIOL-LUNG C, V291, pL144, DOI 10.1152/ajplung.00492.2005; Luzina IG, 2018, CELL IMMUNOL, V325, P1, DOI 10.1016/j.cellimm.2018.01.002; Maher TM, 2010, AM J RESP CRIT CARE, V182, P73, DOI 10.1164/rccm.200905-0674OC; Martin C, 1996, EUR RESPIR J, V9, P2479, DOI 10.1183/09031936.96.09122479; Martins V, 2009, J IMMUNOL, V182, P5374, DOI 10.4049/jimmunol.0802259; Mikamo M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020474; MITCHELL JA, 1994, BRIT J PHARMACOL, V113, P1008, DOI 10.1111/j.1476-5381.1994.tb17093.x; Moeller A, 2008, INT J BIOCHEM CELL B, V40, P362, DOI 10.1016/j.biocel.2007.08.011; Moeller A, 2009, AM J RESP CRIT CARE, V179, P588, DOI 10.1164/rccm.200810-1534OC; Moore BB, 2005, J IMMUNOL, V174, P5644, DOI 10.4049/jimmunol.174.9.5644; Mukherjee S, 2019, AM J PHYSIOL-LUNG C, V316, pL810, DOI 10.1152/ajplung.00403.2018; NAKANO J, 1969, EUR J BIOCHEM, V11, P386, DOI 10.1111/j.1432-1033.1969.tb00784.x; Nikam VS, 2011, AM J RESP CELL MOL, V45, P692, DOI 10.1165/rcmb.2010-0240OC; Oga T, 2009, NAT MED, V15, P1426, DOI 10.1038/nm.2066; Okunishi K, 2011, J BIOL CHEM, V286, P32231, DOI 10.1074/jbc.M111.235606; Pandit KV, 2010, AM J RESP CRIT CARE, V182, P220, DOI 10.1164/rccm.200911-1698OC; Petkova DK, 2003, HISTOPATHOLOGY, V43, P381, DOI 10.1046/j.1365-2559.2003.01718.x; Pfister R, 2012, INT J CARDIOL, V155, P268, DOI 10.1016/j.ijcard.2010.10.013; Pilling Darrell, 2012, Methods Mol Biol, V904, P191, DOI 10.1007/978-1-61779-943-3_16; Rafii R, 2013, J THORAC DIS, V5, P48, DOI 10.3978/j.issn.2072-1439.2012.12.07; Raghu G, 2014, LANCET RESP MED, V2, P566, DOI 10.1016/S2213-2600(14)70101-8; Raghu G, 2011, AM J RESP CRIT CARE, V183, P788, DOI 10.1164/rccm.2009-040GL; Rayamajhi M, 2011, J VIS EXP, V51; Roach KM, 2015, J IMMUNOL, V195, P2852, DOI 10.4049/jimmunol.1500936; Rock JR, 2011, P NATL ACAD SCI USA, V108, pE1475, DOI 10.1073/pnas.1117988108; Safaeian L, 2013, RES PHARM SCI, V8, P43; Sato S, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0654-2; Schlosser K, 2018, THERANOSTICS, V8, P1213, DOI 10.7150/thno.22912; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; SEAMAN MA, 1991, PSYCHOL BULL, V110, P577, DOI 10.1037/0033-2909.110.3.577; Seifert W, 2009, EUR J HUM GENET, V17, P1570, DOI 10.1038/ejhg.2009.104; Shi ZM, 2017, ONCOGENE, V36, P2577, DOI 10.1038/onc.2016.414; Snetselaar R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189467; Sturm EM, 2008, J IMMUNOL, V181, P7273, DOI 10.4049/jimmunol.181.10.7273; Tai HH, 2002, PROSTAG OTH LIPID M, V68-9, P483, DOI 10.1016/S0090-6980(02)00050-3; Tai HH, 2007, PROSTAG OTH LIPID M, V83, P203, DOI 10.1016/j.prostaglandins.2007.01.007; Taira A, 1976, Nihon Kyobu Geka Gakkai Zasshi, V24, P1127; Ulcar R, 2004, EUR J PHARMACOL, V501, P9, DOI 10.1016/j.ejphar.2004.08.003; Vanoirbeek JAJ, 2010, AM J RESP CELL MOL, V42, P96, DOI 10.1165/rcmb.2008-0487OC; WILBORN J, 1995, J CLIN INVEST, V95, P1861, DOI 10.1172/JCI117866; Xaubet A, 2004, SARCOIDOSIS VASC DIF, V21, P35; Yan M, 2004, P NATL ACAD SCI USA, V101, P17468, DOI 10.1073/pnas.0406142101; Yoon YS, 2016, SCI REP-UK, V6, DOI 10.1038/srep20992; Zhang YY, 2015, SCIENCE, V348, DOI 10.1126/science.aaa2340	94	21	22	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2020	145	3					818	+		10.1016/j.jaci.2019.11.032	http://dx.doi.org/10.1016/j.jaci.2019.11.032			27	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KT1GD	31812575	Green Published, hybrid			2022-12-18	WOS:000518756700020
J	Korde, A; Ahangari, F; Haslip, M; Zhang, XC; Liu, Q; Cohn, L; Gomez, JL; Chupp, G; Pober, JS; Gonzalez, A; Takyar, SS				Korde, Asawari; Ahangari, Farida; Haslip, Maria; Zhang, Xuchen; Liu, Qing; Cohn, Lauren; Gomez, Jose L.; Chupp, Geoffrey; Pober, Jordan S.; Gonzalez, Anjelica; Takyar, Shervin S.			An endothelial microRNA-1-regulated network controls eosinophil trafficking in asthma and chronic rhinosinusitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eosinophil trafficking; vascular endothelium; micro-RNA; asthma; chronic rhinosinusitis; P-selectin	THYMIC STROMAL LYMPHOPOIETIN; DISCRIMINATES CLINICAL PHENOTYPES; BRONCHIAL EPITHELIAL-CELLS; CD8(+) T-CELLS; P-SELECTIN; ALLERGIC INFLAMMATION; MICRORNA EXPRESSION; MURINE MODEL; PHOSPHOINOSITIDE 3-KINASE; NONINVASIVE ANALYSIS	Background: Airway eosinophilia is a prominent feature of asthma and chronic rhinosinusitis (CRS), and the endothelium plays a key role in eosinophil trafficking. To date, microRNA-1 (miR-1) is the only microRNA known to be regulated in the lung endothelium in asthma models. Objective: We sought to determine the role of endothelial miR-1 in allergic airway inflammation. Methods: We measured microRNA and mRNA expression using quantitative RT-PCR. We used ovalbumin and house dust mite models of asthma. Endothelium-specific overexpression of miR-1 was achieved through lentiviral vector delivery or induction of a transgene. Tissue eosinophilia was quantified by using Congo red and anti-eosinophil peroxidase staining. We measured eosinophil binding with a Sykes-Moore adhesion chamber. Target recruitment to RNA-induced silencing complex was assessed by using anti-Argonaute2 RNA immunoprecipitation. Surface P-selectin levels were measured by using flow cytometry. Results: Serum miR-1 levels had inverse correlations with sputum eosinophilia, airway obstruction, and number of hospitalizations in asthmatic patients and sinonasal tissue eosinophilia in patients with CRS. IL-13 stimulation decreased miR-1 levels in human lung endothelium. Endothelium-specific overexpression of miR-1 reduced airway eosinophilia and asthma phenotypes in murine models and inhibited IL-13 induced eosinophil binding to endothelial cells. miR-1 recruited P-selectin, thymic stromal lymphopoietin, eotaxin-3, and thrombopoietin receptor to the RNA-induced silencing complex; downregulated these genes in the lung endothelium; and reduced surface P-selectin levels in IL-13 stimulated endothelial cells. In our asthma and CRS cohorts, miR-1 levels correlated inversely with its target genes. Conclusion: Endothelial miR-1 regulates eosinophil trafficking in the setting of allergic airway inflammation. miR-1 has therapeutic potential in asthmatic patients and patients with CRS.	[Korde, Asawari; Ahangari, Farida; Liu, Qing; Cohn, Lauren; Gomez, Jose L.; Chupp, Geoffrey; Takyar, Shervin S.] Yale Sch Med, Sect Pulm Crit Care & Sleep Med, New Haven, CT USA; [Zhang, Xuchen] Yale Sch Med, Dept Pathol, New Haven, CT USA; [Zhang, Xuchen; Pober, Jordan S.] Yale Sch Med, Dept Immunobiol, New Haven, CT USA; [Haslip, Maria] Yale Sch Nursing, Orange, CT USA; [Gonzalez, Anjelica] Yale Sch Engn & Appl Sci, New Haven, CT USA	Yale University; Yale University; Yale University	Takyar, SS (corresponding author), Yale Univ, Dept Internal Med, Sect Pulm Crit Care & Sleep Med, 300 Cedar St,TAC S-455B,POB 208057, New Haven, CT 06520 USA.	seyedtaghi.takyar@yale.edu	ahangari, farida/HGC-0407-2022; zhang, xu/GYE-3558-2022	Zhang, Xuchen/0000-0002-1484-4672	National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI) [R00 HL098695]; NIH/National Institute of Allergy and Infectious Diseases [R56 AI125411-01]; American Thoracic Society Foundation Recognition Award for Outstanding Established Investigators	National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIH/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); American Thoracic Society Foundation Recognition Award for Outstanding Established Investigators	This work was supported by National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI) grant R00 HL098695; NIH/National Institute of Allergy and Infectious Diseases grant R56 AI125411-01; and the American Thoracic Society Foundation Recognition Award for Outstanding Established Investigators (R to R; to S.S.T.).	Agache I, 2015, CURR ALLERGY ASTHM R, V15, DOI 10.1007/s11882-015-0529-x; Alam R, 2011, CLIN EXP ALLERGY, V41, P149, DOI 10.1111/j.1365-2222.2010.03658.x; Allakhverdi Z, 2007, J EXP MED, V204, P253, DOI 10.1084/jem.20062211; Asosingh K, 2018, J CLIN INVEST, V128, P3116, DOI 10.1172/JCI97720; Asosingh K, 2013, J IMMUNOL, V190, P3458, DOI 10.4049/jimmunol.1202095; Asosingh K, 2009, BIOCHEM SOC T, V37, P805, DOI 10.1042/BST0370805; Barnes PJ, 2011, IMMUNOL REV, V242, P31, DOI 10.1111/j.1600-065X.2011.01020.x; Barrett NA, 2009, J IMMUNOL, V182, P1119, DOI 10.4049/jimmunol.182.2.1119; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bartel S, 2017, SCI REP-UK, V7, DOI 10.1038/srep46026; Becerra-Diaz Mireya, 2017, F1000Res, V6, P1014, DOI 10.12688/f1000research.11198.1; Borchers MT, 2002, J LEUKOCYTE BIOL, V71, P1033; Broide DH, 1998, AM J RESP CELL MOL, V18, P218, DOI 10.1165/ajrcmb.18.2.2829; Broide DH, 1998, BLOOD, V91, P2847, DOI 10.1182/blood.V91.8.2847.2847_2847_2856; Butz H, 2018, ONCOTARGET, V9, P4661, DOI 10.18632/oncotarget.23163; Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Carr TF, 2018, AM J RESP CRIT CARE, V197, P22, DOI 10.1164/rccm.201611-2232PP; Carr TF, 2016, WORLD ALLERGY ORGAN, V9, DOI 10.1186/s40413-016-0112-5; Chen RF, 2010, CLIN EXP ALLERGY, V40, P1482, DOI 10.1111/j.1365-2222.2010.03592.x; Chiba Y, 2009, AM J RESP CRIT CARE, V180, P713, DOI 10.1164/rccm.200903-0325OC; Chupp GL, 2007, NEW ENGL J MED, V357, P2016, DOI 10.1056/NEJMoa073600; Corrigan CJ, 2011, P NATL ACAD SCI USA, V108, P1579, DOI 10.1073/pnas.1014241108; Cuvelier SL, 2001, J EXP MED, V194, P1699, DOI 10.1084/jem.194.12.1699; Denis CV, 2001, P NATL ACAD SCI USA, V98, P4072, DOI 10.1073/pnas.061307098; Errahali YJ, 2009, J INTERF CYTOK RES, V29, P227, DOI 10.1089/jir.2008.0051; Eubank TD, 2003, J IMMUNOL, V171, P2637, DOI 10.4049/jimmunol.171.5.2637; Fahy JV, 2015, NAT REV IMMUNOL, V15, P57, DOI 10.1038/nri3786; Feng MJ, 2012, INT IMMUNOPHARMACOL, V13, P347, DOI 10.1016/j.intimp.2012.05.001; Fulkerson PC, 2013, NAT REV DRUG DISCOV, V12, P117, DOI 10.1038/nrd3838; Gauvreau GM, 2014, NEW ENGL J MED, V370, P2102, DOI 10.1056/NEJMoa1402895; Goebeler M, 1997, IMMUNOLOGY, V91, P450, DOI 10.1046/j.1365-2567.1997.00263.x; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Haj-Salem I, 2015, ALLERGY, V70, P212, DOI 10.1111/all.12551; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; HAMILOS DL, 1995, J ALLERGY CLIN IMMUN, V96, P537, DOI 10.1016/S0091-6749(95)70298-9; Heit B, 2005, J CELL SCI, V118, P5205, DOI 10.1242/jcs.02632; Holgate ST, 2008, CLIN EXP ALLERGY, V38, P872, DOI 10.1111/j.1365-2222.2008.02971.x; Hu RX, 2014, FASEB J, V28, P2347, DOI 10.1096/fj.13-247247; Islam SA, 2012, NAT MED, V18, P705, DOI 10.1038/nm.2760; Jacobsen EA, 2017, AM J RESP CRIT CARE, V195, P1321, DOI 10.1164/rccm.201606-1129OC; Jardim MJ, 2012, AM J RESP CELL MOL, V47, P536, DOI 10.1165/rcmb.2011-0160OC; Johansson MW, 2012, AM J RESP CRIT CARE, V185, P498, DOI 10.1164/rccm.201109-1712OC; Jude JA, 2012, AM J PHYSIOL-LUNG C, V303, pL460, DOI 10.1152/ajplung.00041.2012; Kato A, 2015, ALLERGOL INT, V64, P121, DOI 10.1016/j.alit.2014.12.006; Kaushansky K, 2005, J CLIN INVEST, V115, P3339, DOI 10.1172/JCI26674; Kim CH, 2006, J ASTHMA, V43, P345, DOI 10.1080/02770900600701424; Korde A, 2017, AM J RESP CRIT CARE, V196, P1443, DOI 10.1164/rccm.201610-2157OC; Kotowicz K, 1996, INT IMMUNOL, V8, P1915, DOI 10.1093/intimm/8.12.1915; Kumar M, 2011, J ALLERGY CLIN IMMUN, V128, P1077, DOI 10.1016/j.jaci.2011.04.034; Lambrecht BN, 2015, NAT IMMUNOL, V16, P45, DOI 10.1038/ni.3049; Larbi KY, 2003, J LEUKOCYTE BIOL, V73, P65, DOI 10.1189/jlb.0302126; Larose MC, 2015, J ALLERGY CLIN IMMUN, V136, P904, DOI 10.1016/j.jaci.2015.02.039; Levanen B, 2013, J ALLERGY CLIN IMMUN, V131, P894, DOI 10.1016/j.jaci.2012.11.039; Ley K, 2007, NAT REV IMMUNOL, V7, P678, DOI 10.1038/nri2156; Lin CY, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3829; Liu F, 2012, MOL MED REP, V6, P1178, DOI 10.3892/mmr.2012.1030; Liu WM, 2008, J ALLERGY CLIN IMMUN, V121, P893, DOI 10.1016/j.jaci.2008.02.004; Lloyd CM, 2010, NAT REV IMMUNOL, V10, P838, DOI 10.1038/nri2870; Lotvall J, 2011, J ALLERGY CLIN IMMUN, V127, P355, DOI 10.1016/j.jaci.2010.11.037; Lu J, 2014, ONCOTARGET, V5, P11319, DOI 10.18632/oncotarget.2435; Lu TX, 2013, J ALLERGY CLIN IMMUN, V132, P3, DOI 10.1016/j.jaci.2013.04.039; Lu TX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059397; Lu TX, 2013, J IMMUNOL, V190, P1576, DOI 10.4049/jimmunol.1202897; Lu TX, 2009, J IMMUNOL, V182, P4994, DOI 10.4049/jimmunol.0803560; Lukacs NW, 2002, J IMMUNOL, V169, P2120, DOI 10.4049/jimmunol.169.4.2120; Luster AD, 2005, NAT IMMUNOL, V6, P1182, DOI 10.1038/ni1275; Ma ZX, 2015, INFLAMM RES, V64, P885, DOI 10.1007/s00011-015-0870-5; Maes T, 2016, J ALLERGY CLIN IMMUN, V137, P1433, DOI 10.1016/j.jaci.2016.02.018; Malmhall C, 2014, J ALLERGY CLIN IMMUN, V133, P1429, DOI 10.1016/j.jaci.2013.11.008; Mattes J, 2009, P NATL ACAD SCI USA, V106, P18704, DOI 10.1073/pnas.0905063106; McGrath KW, 2012, AM J RESP CRIT CARE, V185, P612, DOI 10.1164/rccm.201109-1640OC; Mestas J, 2004, J IMMUNOL, V172, P2731, DOI 10.4049/jimmunol.172.5.2731; Nagarkar DR, 2013, J ALLERGY CLIN IMMUN, V132, P593, DOI 10.1016/j.jaci.2013.04.005; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; Nashed BF, 2007, EUR J IMMUNOL, V37, P416, DOI 10.1002/eji.200636401; Patel KD, 1997, J IMMUNOL, V159, P4555; Pelaia G, 2012, NAT REV DRUG DISCOV, V11, P958, DOI 10.1038/nrd3792; Perry MM, 2014, AM J RESP CELL MOL, V50, P7, DOI 10.1165/rcmb.2013-0067OC; Pober JS, 2012, TRENDS IMMUNOL, V33, P49, DOI 10.1016/j.it.2011.09.006; Polikepahad Sumanth, 2010, J Biol Chem, V285, P30139, DOI 10.1074/jbc.M110.145698; Pua HH, 2016, IMMUNITY, V44, P821, DOI 10.1016/j.immuni.2016.01.003; Pua HH, 2015, CURR OPIN IMMUNOL, V36, P101, DOI 10.1016/j.coi.2015.07.006; Qin HB, 2012, INFLAMMATION, V35, P1595, DOI 10.1007/s10753-012-9474-1; Rebane A, 2015, ADV EXP MED BIOL, V888, P331, DOI 10.1007/978-3-319-22671-2_17; Rebane A, 2014, CURR ALLERGY ASTHM R, V14, DOI 10.1007/s11882-014-0424-x; Schleimer RP, 2017, ANNU REV PATHOL-MECH, V12, P331, DOI 10.1146/annurev-pathol-052016-100401; Shah SA, 2016, J INFLAMM-LOND, V13, DOI 10.1186/s12950-016-0121-8; Shinkai A, 1999, J IMMUNOL, V163, P1602; Shoda T, 2016, ALLERGOL INT, V65, P21, DOI 10.1016/j.alit.2015.08.001; Simeone-Penney MC, 2007, J IMMUNOL, V178, P6191, DOI 10.4049/jimmunol.178.10.6191; Solberg OD, 2012, AM J RESP CRIT CARE, V186, P965, DOI 10.1164/rccm.201201-0027OC; Southworth T, 2018, BIOMARK RES, V6, DOI 10.1186/s40364-018-0128-9; Stahlhut C, 2012, DEVELOPMENT, V139, P4356, DOI 10.1242/dev.083774; Steinke JW, 2016, ANN ALLERG ASTHMA IM, V117, P234, DOI 10.1016/j.anai.2016.06.006; SYMON FA, 1994, J EXP MED, V180, P371, DOI 10.1084/jem.180.1.371; Symon FA, 1996, J IMMUNOL, V157, P1711; Szczeklik A, 2003, J ALLERGY CLIN IMMUN, V111, P913, DOI 10.1067/mai.2003.1487; Takai T, 2012, ALLERGOL INT, V61, P3, DOI 10.2332/allergolint.11-RAI-0395; Takyar S, 2013, J EXP MED, V210, P1993, DOI 10.1084/jem.20121200; Teijaro JR, 2011, CELL, V146, P980, DOI 10.1016/j.cell.2011.08.015; Tibbles HE, 2002, BIOCHEM BIOPH RES CO, V292, P987, DOI 10.1006/bbrc.2002.6759; Tsitsiou E, 2012, J ALLERGY CLIN IMMUN, V129, P95, DOI 10.1016/j.jaci.2011.08.011; Ulfman LH, 2003, AM J RESP CELL MOL, V28, P512, DOI 10.1165/rcmb.4806; Vrugt B, 2000, EUR RESPIR J, V15, P1014, DOI 10.1034/j.1399-3003.2000.01507.x; Walker JA, 2012, EUR J IMMUNOL, V42, P1368, DOI 10.1002/eji.201242425; Watson B, 2014, EXPERT OPIN THER TAR, V18, P771, DOI 10.1517/14728222.2014.915314; Wenzel S, 2013, NEW ENGL J MED, V368, P2455, DOI 10.1056/NEJMoa1304048; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Wierzbicki T, 2003, J LEUKOCYTE BIOL, V74, P420, DOI 10.1189/jlb.1102571; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wilson JW, 2006, CURR OPIN ALLERGY CL, V6, P51, DOI 10.1097/01.all.0000200505.54425.47; Woltmann G, 2000, BLOOD, V95, P3146; Wu LW, 2000, J BIOL CHEM, V275, P6059, DOI 10.1074/jbc.275.9.6059; Wu XB, 2014, INT J CLIN EXP MED, V7, P1307; Wust S, 2018, CELL METAB, V27, P1026, DOI 10.1016/j.cmet.2018.02.022; Xia GH, 2015, J NANOSCI NANOTECHNO, V15, P2132, DOI 10.1166/jnn.2015.9161; Yan XT, 2016, ANN AM THORAC SOC, V13, pS104, DOI 10.1513/AnnalsATS.201510-681MG; Yan XT, 2015, AM J RESP CRIT CARE, V191, P1116, DOI 10.1164/rccm.201408-1440OC; Ying S, 2005, J IMMUNOL, V174, P8183, DOI 10.4049/jimmunol.174.12.8183; Ying S, 1997, J IMMUNOL, V158, P3539; Yoo EJ, 2017, AM J RESP CELL MOL, V56, P700, DOI 10.1165/rcmb.2016-0308TR; Zaglia T, 2017, P NATL ACAD SCI USA, V114, pE9006, DOI 10.1073/pnas.1708772114; Zhang YN, 2012, LARYNGOSCOPE, V122, P2621, DOI 10.1002/lary.23517; Zhao Y, 2005, NATURE, V436, P214, DOI 10.1038/nature03817	125	21	25	1	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2020	145	2					550	562		10.1016/j.jaci.2019.10.031	http://dx.doi.org/10.1016/j.jaci.2019.10.031			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KK6ZG	32035607	Bronze, Green Accepted			2022-12-18	WOS:000512887400018
J	Hauptman, M; Gaffin, JM; Petty, CR; Sheehan, WJ; Lai, PS; Coull, B; Gold, DR; Phipatanakul, W				Hauptman, Marissa; Gaffin, Jonathan M.; Petty, Carter R.; Sheehan, William J.; Lai, Peggy S.; Coull, Brent; Gold, Diane R.; Phipatanakul, Wanda			Proximity to major roadways and asthma symptoms in the School Inner-City Asthma Study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; school; geographic information systems; spatial analysis; traffic proximity; environmental health disparities; School Inner-City Asthma Study; environmental exposure	AIR-POLLUTION EXPOSURE; LUNG-FUNCTION; CHILDHOOD ASTHMA; ALLERGIC SENSITIZATION; DIESEL EXHAUST; CHILDREN; STRESS; ASSOCIATION; MORBIDITY; POPULATION	Background: Traffic proximity has been associated with adverse respiratory health outcomes. Less is known about the combined impact of residential and school exposures on pediatric asthma. Objective: We sought to use spatial analysis methodology to analyze residential and school proximity to major roadways and pediatric asthma morbidity. Methods: The School Inner-City Asthma Study (n = 350) recruited school-aged children with asthma. Each participant's school and home addresses were geocoded, and distances from major roadways were measured to calculate a composite measure accounting for both home and school traffic exposure. Generalized estimating equation models were clustered by subject and adjusted for age, race/ethnicity, sex, income, environmental tobacco smoke, controller medication, upper respiratory tract infections, and seasonality. Results: The majority of participants (62%) attended schools within 100 m from major roadways, and 40% also resided within 100 m of major roadways. In multivariate analyses major roadway proximity was independently associated with increased asthma symptom days. At greater than the threshold of 100 m, children had 29% less odds of a symptom day over the past 2 weeks for each 100-m increase in distance from a major roadway (odds ratio, 0.71; 95% CI, 0.58-0.87; P < .01). Children farther from a major roadway also had significantly less reported health care use (odds ratio, 0.63; 95% CI, 0.47-0.85; P <.01) and were significantly less likely to have poor asthma control (odds ratio, 0.80; 95% CI, 0.69-0.94; P <.01). There was not a meaningful association between distance to a major roadway and lung function outcomes. Conclusions: Proximity to a major roadway, a composite measure of home and school exposure but primarily driven by home exposure, was associated with greater asthma morbidity. More studies are needed to evaluate the independent effect of school distance to a roadway on asthma morbidity.	[Hauptman, Marissa] Boston Childrens Hosp, Div Gen Pediat, Boston, MA USA; [Gaffin, Jonathan M.] Boston Childrens Hosp, Div Resp Dis, Boston, MA USA; [Sheehan, William J.; Phipatanakul, Wanda] Boston Childrens Hosp, Div Allergy & Immunol, Boston, MA USA; [Hauptman, Marissa] Reg 1 New England Pediat Environm Hlth Specialty, Boston, MA USA; [Hauptman, Marissa; Gaffin, Jonathan M.; Sheehan, William J.; Lai, Peggy S.; Gold, Diane R.; Phipatanakul, Wanda] Harvard Med Sch, Boston, MA 02115 USA; [Petty, Carter R.] Boston Childrens Hosp, Inst Ctr Clin & Translat Res, Boston, MA USA; [Petty, Carter R.] Harvard Med Sch, Dept Pediat, Boston, MA 02115 USA; [Lai, Peggy S.; Coull, Brent; Gold, Diane R.] Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA; [Lai, Peggy S.] Massachusetts Gen Hosp, Div Pulm & Crit Care, Boston, MA 02114 USA; [Gold, Diane R.] Brigham & Womens Hosp, Channing Lab, Div Resp Epidemiol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital	Phipatanakul, W (corresponding author), 300 Longwood Ave,Fegan 6, Boston, MA 02116 USA.	wanda.phipatanakul@childrens.harvard.edu		Hauptman, Marissa/0000-0002-0028-8927; GAFFIN, JONATHAN/0000-0003-2213-4504	National Institutes of Health (NIH) [R01AI073964, R01AI073964-02S1, K24AI106822, U10HL098102, U01AI110397, U19AR06952, 1R01HL137192, K23AI106945, K23AI104780, K23ES023700, P01 ES009825, 1U19AR069525, P30ES000002]; United States Environmental Protection Agency (USEPA) [RD-83479801]; American College of Allergy, Asthma & Immunology Young Faculty Award; Boston Children's Hospital Division of Immunology Clinical Research Advisory Group Research Grant; Allergy and Asthma Awareness Initiative; Harvard Catalyst/Harvard Clinical and Translational Science Center (NIH) [UL1TR001102]; Harvard University; Agency for Toxic Substances and Disease Registry (ATSDR) [FAIN: U61TS000237]; USEPA [DW-75-92301301]; 2017 Academic Pediatric Association's Michael Shannon Research Award	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); United States Environmental Protection Agency (USEPA)(United States Environmental Protection Agency); American College of Allergy, Asthma & Immunology Young Faculty Award; Boston Children's Hospital Division of Immunology Clinical Research Advisory Group Research Grant; Allergy and Asthma Awareness Initiative; Harvard Catalyst/Harvard Clinical and Translational Science Center (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Harvard University; Agency for Toxic Substances and Disease Registry (ATSDR); USEPA(United States Environmental Protection Agency); 2017 Academic Pediatric Association's Michael Shannon Research Award	Supported by National Institutes of Health (NIH) grants R01AI073964 (to W.P.), R01AI073964-02S1 (to W.P.), K24AI106822 (to W.P.), U10HL098102 (to W.P.), U01AI110397 (to W.P.), U19AR06952 (to W.P.), 1R01HL137192 (to W.P.), K23AI106945 (to J.M.G.), K23AI104780 (to W.J.S.), K23ES023700 (to P.S.L.), P01 ES009825 (to D.R.G.), 1U19AR069525 (to W.P. and M.H.), and P30ES000002 (to D.R.G. and M.H.) and United States Environmental Protection Agency (USEPA) grant RD-83479801. This work was also supported in part by the American College of Allergy, Asthma & Immunology Young Faculty Award; a Boston Children's Hospital Division of Immunology Clinical Research Advisory Group Research Grant; and the Allergy and Asthma Awareness Initiative. This work was conducted with support from Harvard Catalyst/Harvard Clinical and Translational Science Center (NIH award no. UL1TR001102) and financial contributions from Harvard University and its affiliated academic healthcare centers. This work was also funded in part by cooperative agreement award number FAIN: U61TS000237 from the Agency for Toxic Substances and Disease Registry (ATSDR). The USEPA supports the Pediatric Environmental Health Specialty Units by providing partial funding to the ATSDR under Inter-Agency Agreement no. DW-75-92301301. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Harvard Catalyst, Harvard University, and its affiliated academic health care centers; the National Center for Research Resources; or the NIH. Its contents are solely the responsibility of the grantee and do not necessarily represent the official views of the ATSDR or USEPA. Furthermore, USEPA or ATSDR do not endorse the purchase of any commercial products or services mentioned in the publication. Supplies were generously donated or discounted as follows: Lincoln Diagnostics (Decatur, Ill) donated Multi-Test II devices and Greer Laboratories (Lenoir, NC) donated allergenic extracts for skin testing. Aspects of this manuscript were presented at the 2017 Pediatric Academic Societies Meeting; M.H. was awarded the 2017 Academic Pediatric Association's Michael Shannon Research Award for this work.	Alexis NE, 2014, INT IMMUNOPHARMACOL, V23, P347, DOI 10.1016/j.intimp.2014.08.009; Amr S, 2003, ANN ALLERG ASTHMA IM, V90, P34, DOI 10.1016/S1081-1206(10)63611-3; [Anonymous], 2017, ENV JUST MAPP SCREEN; Bacharier LB, 2004, AM J RESP CRIT CARE, V170, P426, DOI 10.1164/rccm.200308-1178OC; Baumann LM, 2011, J ALLERGY CLIN IMMUN, V127, P875, DOI 10.1016/j.jaci.2010.11.031; Beydon N, 2007, AM J RESP CRIT CARE, V175, P1304, DOI 10.1164/rccm.200605-642ST; Bowatte G, 2017, J ALLERGY CLIN IMMUN, V139, P122, DOI 10.1016/j.jaci.2016.05.008; Brandt EB, 2015, J ALLERGY CLIN IMMUN, V136, P295, DOI 10.1016/j.jaci.2014.11.043; Brandt SJ, 2012, EUR RESPIR J, V40, P363, DOI 10.1183/09031936.00157811; Brauer M, 2007, EUR RESPIR J, V29, P879, DOI 10.1183/09031936.00083406; Brugge D, 2007, ENVIRON HEALTH-GLOB, V6, DOI 10.1186/1476-069X-6-13; Bruzzese JM, 2009, J ALLERGY CLIN IMMUN, V124, P195, DOI 10.1016/j.jaci.2009.05.040; Busse WW, 2011, NEW ENGL J MED, V364, P1005, DOI 10.1056/NEJMoa1009705; Centers for Disease Control and Prevention (CDC), 2019, MOST REC NAT ASTHM D; Chew GL, 2005, INDOOR AIR, V15, P228, DOI 10.1111/j.1600-0668.2005.00363.x; Clougherty JE, 2007, ENVIRON HEALTH PERSP, V115, P1140, DOI 10.1289/ehp.9863; D'Amato G, 2016, ALLERGY ASTHMA IMMUN, V8, P391, DOI 10.4168/aair.2016.8.5.391; Dilley MA, 2017, PEDIAT ALLERG IMM-UK, V28, P610, DOI 10.1111/pai.12756; DUNGY CI, 1986, ANN ALLERGY, V56, P218; Eggleston PA, 1998, J ALLERGY CLIN IMMUN, V102, P563, DOI 10.1016/S0091-6749(98)70272-6; Executive Office of Transportation Massachusetts Highway Department, 2006, PROJ DEV DES GUID; Gaffin JM, 2018, J ALLERGY CLIN IMMUN, V141, P2249, DOI 10.1016/j.jaci.2017.08.028; Gauderman WJ, 2005, EPIDEMIOLOGY, V16, P737, DOI 10.1097/01.ede.0000181308.51440.75; Gruzieva O, 2014, J ALLERGY CLIN IMMUN, V133, P767, DOI 10.1016/j.jaci.2013.07.048; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; Jerrett M, 2008, ENVIRON HEALTH PERSP, V116, P1433, DOI 10.1289/ehp.10968; Kattan M, 1997, PEDIATR PULM, V24, P253, DOI 10.1002/(SICI)1099-0496(199710)24:4<253::AID-PPUL4>3.0.CO;2-L; Kim JJ, 2004, AM J RESP CRIT CARE, V170, P520, DOI 10.1164/rccm.200403-281OC; Kingsley SL, 2014, J EXPO SCI ENV EPID, V24, P253, DOI 10.1038/jes.2014.5; Kopel LS, 2017, J ALLER CL IMM-PRACT, V5, P1132, DOI 10.1016/j.jaip.2017.02.026; Lai PS, 2015, CHEST, V148, P1251, DOI 10.1378/chest.15-0098; Lee A, 2016, J ALLERGY CLIN IMMUN, V138, P740, DOI 10.1016/j.jaci.2016.01.014; Lee AG, 2017, ANN ALLERG ASTHMA IM, V119, P153, DOI 10.1016/j.anai.2017.05.025; MacIntyre EA, 2014, ENVIRON HEALTH PERSP, V122, P107, DOI 10.1289/ehp.1306755; Matsui EC, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-2589; McConnell R, 2010, ENVIRON HEALTH PERSP, V118, P1021, DOI 10.1289/ehp.0901232; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Mitchell H, 1997, PEDIATR PULM, V24, P237; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; Nardone A, 2018, CURR ALLERGY ASTHM R, V18, DOI 10.1007/s11882-018-0782-x; Office of Geographic Information (MASSGIS), 2014, MASSGIS DAT SCH PREK; Orellano P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174050; Perez L, 2012, ENVIRON HEALTH PERSP, V120, P1619, DOI 10.1289/ehp.1104785; Permaul Perdita, 2012, Pediatr Allergy Immunol, V23, P543, DOI 10.1111/j.1399-3038.2012.01327.x; Perzanowski MS, 1999, J ALLERGY CLIN IMMUN, V103, P1018, DOI 10.1016/S0091-6749(99)70173-9; Phipatanakul W, 2011, J ASTHMA, V48, P1007, DOI 10.3109/02770903.2011.624235; Rice MB, 2016, AM J RESP CRIT CARE, V193, P881, DOI 10.1164/rccm.201506-1058OC; Rice MB, 2015, PEDIATR PULM, V50, P252, DOI 10.1002/ppul.23029; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Schiavoni G, 2017, ANN ALLERG ASTHMA IM, V118, P269, DOI 10.1016/j.anai.2016.12.019; Schultz ES, 2012, AM J RESP CRIT CARE, V186, P1286, DOI 10.1164/rccm.201206-1045OC; Schultzl ES, 2016, AM J RESP CRIT CARE, V193, P171, DOI 10.1164/rccm.201505-0928OC; Sheehan WJ, 2017, JAMA PEDIATR, V171, P31, DOI 10.1001/jamapediatrics.2016.2543; Silverstein MD, 2001, J PEDIATR-US, V139, P278, DOI 10.1067/mpd.2001.115573; Steerenberg PA, 2003, INT ARCH ALLERGY IMM, V131, P127, DOI 10.1159/000070928; Strunk RC, 2006, J ALLERGY CLIN IMMUN, V118, P1040, DOI 10.1016/j.jaci.2006.07.053; Wickens K, 1997, J ALLERGY CLIN IMMUN, V99, P587, DOI 10.1016/S0091-6749(97)70017-4; Wright RJ, 2013, CURR OPIN PEDIATR, V25, P232, DOI 10.1097/MOP.0b013e32835e78cc; Wyler C, 2000, EPIDEMIOLOGY, V11, P450, DOI 10.1097/00001648-200007000-00015; Yang TC, 2010, HEALTH PLACE, V16, P803, DOI 10.1016/j.healthplace.2010.04.005; Zandbergen Paul A, 2014, Adv Med, V2014, P567049, DOI 10.1155/2014/567049; Zar HJ, 2014, PEDIATR PULM, V49, P430, DOI 10.1002/ppul.23030; Zhou Y, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-89	63	21	21	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2020	145	1					119	+		10.1016/j.jaci.2019.08.038	http://dx.doi.org/10.1016/j.jaci.2019.08.038			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KA1WZ	31557500	Green Accepted, Bronze			2022-12-18	WOS:000505590800019
J	Li, XN; Hastie, AT; Peters, MC; Hawkins, GA; Phipatanakul, W; Li, HS; Moore, WC; Busse, WW; Castro, M; Erzurum, SC; Gaston, B; Israel, E; Jarjour, NN; Levy, BD; Wenzel, SE; Meyers, DA; Fahy, JV; Bleecker, ER				Li, Xingnan; Hastie, Annette T.; Peters, Michael C.; Hawkins, Gregory A.; Phipatanakul, Wanda; Li, Huashi; Moore, Wendy C.; Busse, William W.; Castro, Mario; Erzurum, Serpil C.; Gaston, Benjamin; Israel, Elliot; Jarjour, Nizar N.; Levy, Bruce D.; Wenzel, Sally E.; Meyers, Deborah A.; Fahy, John V.; Bleecker, Eugene R.			Investigation of the relationship between IL-6 and type 2 biomarkers in patients with severe asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									[Li, Xingnan; Li, Huashi; Meyers, Deborah A.; Bleecker, Eugene R.] Univ Arizona, Dept Med, Div Genet Genom & Precis Med, Tucson, AZ 85721 USA; [Hastie, Annette T.; Moore, Wendy C.] Wake Forest Sch Med, Dept Internal Med, Winston Salem, NC 27101 USA; [Peters, Michael C.; Fahy, John V.] Univ Calif San Francisco, Dept Med, Div Pulm & Crit Care Med, San Francisco, CA 94143 USA; [Hawkins, Gregory A.] Wake Forest Sch Med, Dept Biochem, Winston Salem, NC 27101 USA; [Phipatanakul, Wanda] Boston Childrens Hosp, Boston, MA USA; [Phipatanakul, Wanda] Harvard Med Sch, Div Allergy & Immunol, Boston, MA 02115 USA; [Busse, William W.; Jarjour, Nizar N.] Univ Wisconsin, Sch Med, Dept Med, Madison, WI USA; [Castro, Mario] Washington Univ, Sch Med, Div Pulm & Crit Care Med, St Louis, MO USA; [Erzurum, Serpil C.] Rainbow Babies & Childrens Hosp, Div Pediat Pulmonol, 2101 Adelbert Rd, Cleveland, OH 44106 USA; [Gaston, Benjamin] Cleveland Med Ctr, Cleveland, OH USA; [Israel, Elliot; Levy, Bruce D.] Brigham & Womens Hosp, Div Pulm & Crit Care Med, 75 Francis St, Boston, MA 02115 USA; [Israel, Elliot; Levy, Bruce D.] Harvard Med Sch, Boston, MA 02115 USA; [Wenzel, Sally E.] Univ Pittsburgh, Dept Environm & Occupat Hlth, Pittsburgh, PA USA	University of Arizona; Wake Forest University; University of California System; University of California San Francisco; Wake Forest University; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; University of Wisconsin System; University of Wisconsin Madison; Washington University (WUSTL); Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Li, XN (corresponding author), Univ Arizona, Dept Med, Div Genet Genom & Precis Med, Tucson, AZ 85721 USA.	lixingnan1@deptofmed.arizona.edu	Peters, Michael/AAO-6544-2020	Wenzel, Sally/0000-0002-4242-0164	National Institutes of Health (NIH) [HL69116, HL69130, HL69149, HL69155, HL69167, HL69170, HL69174, HL69349, UL1RR024992, M01RR018390, M01RR07122, M01RR03186, HL087665, HL091762]; National Heart, Lung, and Blood Institute (NHLBI) [U10 HL109172, HL109168, HL109152, HL109257, HL109046, HL109250, HL109164, HL109086]	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	SARP1 and SARP2 were supported by National Institutes of Health (NIH) grants HL69116, HL69130, HL69149, HL69155, HL69167, HL69170, HL69174, HL69349, UL1RR024992, M01RR018390, M01RR07122, M01RR03186, HL087665, and HL091762. SARP3 was funded by National Heart, Lung, and Blood Institute (NHLBI) grants U10 HL109172, HL109168, HL109152, HL109257, HL109046, HL109250, HL109164, and HL109086.	Buniello A, 2019, NUCLEIC ACIDS RES, V47, pD1005, DOI 10.1093/nar/gky1120; Calabrese LH, 2014, NAT REV RHEUMATOL, V10, P720, DOI 10.1038/nrrheum.2014.127; Gevaert E, 2017, J ALLERGY CLIN IMMUN, V139, P1849, DOI 10.1016/j.jaci.2017.01.019; Hastie AT, 2010, J ALLERGY CLIN IMMUN, V125, P1028, DOI 10.1016/j.jaci.2010.02.008; Hawkins GA, 2012, J ALLERGY CLIN IMMUN, V130, P510, DOI 10.1016/j.jaci.2012.03.018; Persson EK, 2019, SCIENCE, V364, P751, DOI 10.1126/science.aaw4295; Peters MC, 2016, LANCET RESP MED, V4, P574, DOI 10.1016/S2213-2600(16)30048-0; Phipatanakul W, 2017, AM J RESP CRIT CARE, V195, P1439, DOI 10.1164/rccm.201607-1453OC; Rose-John S, 2017, NAT REV RHEUMATOL, V13, P399, DOI 10.1038/nrrheum.2017.83; Sandrini A, 2010, RESPIROLOGY, V15, P57, DOI 10.1111/j.1440-1843.2009.01616.x; White SR, 2019, J ALLERGY CLIN IMMUN, V144, P304, DOI 10.1016/j.jaci.2019.04.007; Zhang NW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114241	12	21	23	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2020	145	1					430	+		10.1016/j.jaci.2019.08.031	http://dx.doi.org/10.1016/j.jaci.2019.08.031			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KA1WZ	31513878	Bronze, Green Accepted			2022-12-18	WOS:000505590800046
J	Shoda, T; Wen, T; Caldwell, JM; Collins, MH; Besse, JA; Osswald, GA; Abonia, JP; Arva, NC; MDd, DA; Capocelli, KE; Dellon, ES; Falk, GW; Gonsalves, N; Gupta, SK; Hirano, I; Mukkada, VA; Putnam, PE; Sheridan, RM; Spergel, AKR; Spergel, JM; Wechsler, JB; Yang, GY; Aceves, SS; Furuta, GT; Rothenberg, ME				Shoda, Tetsuo; Wen, Ting; Caldwell, Julie M.; Collins, Margaret H.; Besse, John A.; Osswald, Garrett A.; Abonia, J. Pablo; Arva, Nicoleta C.; MDd, Dan Atkins; Capocelli, Kelley E.; Dellon, Evan S.; Falk, Gary W.; Gonsalves, Nirmala; Gupta, Sandeep K.; Hirano, Ikuo; Mukkada, Vincent A.; Putnam, Philip E.; Sheridan, Rachel M.; Spergel, Amanda K. Rudman; Spergel, Jonathan M.; Wechsler, Joshua B.; Yang, Guang-Yu; Aceves, Seema S.; Furuta, Glenn T.; Rothenberg, Marc E.		Consortium Eosinophilic Gastrointe	Molecular, endoscopic, histologic, and circulating biomarker-based diagnosis of eosinophilic gastritis: Multi-site study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Biomarker; diagnostic panel; eosinophil; eosinophilic gastritis; transcriptome	GASTROINTESTINAL-TRACT; GASTROENTERITIS; ESOPHAGITIS; EOTAXIN-3	Background: Eosinophilic gastritis (EG) is a clinicopathologic disorder with marked gastric eosinophilia and clinical symptoms. There is an unmet need among patients with EG for more precise diagnostic tools. Objective: We aimed to develop tissue- and blood-based diagnostic platforms for EG. Methods: Patients with EG and control subjects without EG were enrolled across 9 Consortium of Eosinophilic Gastrointestinal Disease Researchers-associated sites. An EG Diagnostic Panel (EGDP; gastric transcript subset) and EG blood biomarker panel (protein multiplex array) were analyzed. EGDP(18 )scores were derived from the expression of 18 highly dysregulated genes, and blood EG scores were derived from dysregulated cytokine/chemokine levels. Results: Gastric biopsy specimens and blood samples from 185 subjects (patients with EG, n = 74; control subjects without EG, n = 111) were analyzed. The EGDP (1) identified patients with active EG (P < .0001, area under the curve >= 0.95), (2) effectively monitored disease activity in longitudinal samples (P = .0078), (3) highly correlated in same-patient samples (antrum vs body, r = 0.85, P < .0001), and (4) inversely correlated with gastric peak eosinophil levels (r = -0.83, P < .0001), periglandular circumferential collars (r = -0.73, P < .0001), and endoscopic nodularity (r = -0.45, P < .0001). For blood-based platforms, eotaxin-3, thymus and activation-regulated chemokine, IL-5, and thymic stromal lymphopoietin levels were significantly increased. Blood EG scores (1) distinguished patients with EG from control subjects without EG (P < .0001, area under the curve >= 0.91), (2) correlated with gastric eosinophil levels (plasma: r = 0.72, P = .0002; serum: r = 0.54, P = .0015), and (3) inversely correlated with EGDP(18) scores (plasma: r = -0.64, P = .0015; serum: r = -0.46, P = .0084). Plasma eotaxin-3 levels strongly associated with gastric CCL26 expression (r = 0.81, P < .0001). Conclusion: We developed tissue- and blood-based platforms for assessment of EG and uncovered robust associations between specific gastric molecular profiles and histologic and endoscopic features, providing insight and clinical readiness tools for this emerging rare disease.	[Shoda, Tetsuo; Wen, Ting; Caldwell, Julie M.; Besse, John A.; Osswald, Garrett A.; Abonia, J. Pablo; Rothenberg, Marc E.] Univ Cincinnati, Coll Med, Div Allergy & Immunol, Cincinnati, OH USA; [Collins, Margaret H.; Sheridan, Rachel M.] Univ Cincinnati, Coll Med, Div Pathol, Cincinnati, OH USA; [Mukkada, Vincent A.; Putnam, Philip E.] Univ Cincinnati, Coll Med, Div Gastroenterol Hepatol & Nutr, Cincinnati, OH USA; [Mukkada, Vincent A.; Putnam, Philip E.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA; [Arva, Nicoleta C.] Northwestern Univ, Feinberg Sch Med, Ann & Robert H Lurie Childrens Hosp Chicago, Dept Pathol, Evanston, IL USA; [Yang, Guang-Yu] Northwestern Univ, Dept Pathol & Lab Med, Evanston, IL USA; [MDd, Dan Atkins] Childrens Hosp Colorado, Sect Pediat Allergy & Immunol, Aurora, CO USA; [Capocelli, Kelley E.] Childrens Hosp Colorado, Dept Pathol, Aurora, CO USA; [Dellon, Evan S.] Univ N Carolina, Sch Med, Div Gastroenterol & Hepatol, Chapel Hill, NC 27515 USA; [Falk, Gary W.] Univ Penn, Div Gastroenterol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Gonsalves, Nirmala; Hirano, Ikuo] Northwestern Univ, Feinberg Sch Med, Div Gastroenterol & Hepatol, Chicago, IL USA; [Gupta, Sandeep K.] Univ Illinois, Coll Med, Childrens Hosp Illinois, Div Pediat Gastroenterol Hepatol & Nutr, Peoria, IL 61656 USA; [Spergel, Amanda K. Rudman] NIAID, Allergy Asthma & Airway Biol Branch, Div Allergy Immunol & Transplantat, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Spergel, Jonathan M.] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Div Allergy & Immunol, Philadelphia, PA 19104 USA; [Wechsler, Joshua B.] Univ Calif San Diego, Ann & Robert H Lurie Childrens Hosp Chicago, Gastroenterol Hepatol & Nutr, San Diego, CA 92103 USA; [Aceves, Seema S.] Univ Calif San Diego, Div Allergy Immunol, San Diego, CA 92103 USA; [Aceves, Seema S.] Rady Childrens Hosp, San Diego, CA USA; [Furuta, Glenn T.] Childrens Hosp Colorado, Digest Hlth Inst, Sect Pediat Gastroenterol Hepatol & Nutr, Aurora, CO USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Northwestern University; Children's Hospital Colorado; Children's Hospital Colorado; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of Pennsylvania; Pennsylvania Medicine; Northwestern University; Feinberg School of Medicine; University of Illinois System; University of Illinois Peoria; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of California System; University of California San Diego; University of California System; University of California San Diego; Rady Childrens Hospital San Diego; Children's Hospital Colorado	Rothenberg, ME (corresponding author), Univ Cincinnati, Coll Med, Dept Pediat, Div Allergy & Immunol,Cincinnati Childrens Hosp, 3333 Bumet Ave,ML 7028, Cincinnati, OH 45229 USA.	rothenberg@cchmc.org		Besse, John/0000-0002-9874-5822; Shoda, Tetsuo/0000-0001-8337-5438	Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR), Rare Diseases Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR), National Center for Advancing Translational Sciences (NCATS) [U54 AI117804]; National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Center for Advancing Translational Sciences (NCATS); American Partnership for Eosinophilic Disorders (APFED); Campaign Urging Research for Eosinophilic Disease (CURED); Eosinophilic Family Coalition (EFC)	Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR), Rare Diseases Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR), National Center for Advancing Translational Sciences (NCATS); National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); National Center for Advancing Translational Sciences (NCATS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); American Partnership for Eosinophilic Disorders (APFED); Campaign Urging Research for Eosinophilic Disease (CURED); Eosinophilic Family Coalition (EFC)	This study was supported by Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR; U54 AI117804), which is part of the Rare Diseases Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR), National Center for Advancing Translational Sciences (NCATS), and is cofunded by the National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and National Center for Advancing Translational Sciences (NCATS). CEGIR is also supported by patient advocacy groups including the American Partnership for Eosinophilic Disorders (APFED), Campaign Urging Research for Eosinophilic Disease (CURED), and Eosinophilic Family Coalition (EFC).	Bedell A, 2018, DIGEST DIS SCI, V63, P1148, DOI 10.1007/s10620-018-4978-7; Blanchard C, 2006, J CLIN INVEST, V116, P536, DOI 10.1172/JCI26679; Blanchard C, 2007, J ALLERGY CLIN IMMUN, V120, P1292, DOI 10.1016/j.jaci.2007.10.024; Caldwell JM, 2014, J ALLERGY CLIN IMMUN, V134, P1114, DOI 10.1016/j.jaci.2014.07.026; Chehade M, 2006, J PEDIATR GASTR NUTR, V42, P516, DOI 10.1097/01.mpg.0000221903.61157.4e; de Chambrun GP, 2011, CLIN GASTROENTEROL H, V9, P950, DOI 10.1016/j.cgh.2011.07.017; DeBrosse CW, 2006, PEDIATR DEVEL PATHOL, V9, P210, DOI 10.2350/11-05-0130.1; Gupta SK, 2019, GASTROENTEROLOGY, V156, P838, DOI 10.1053/j.gastro.2018.10.057; Hines BT, 2018, ANN ALLERG ASTHMA IM, V121, P218, DOI 10.1016/j.anai.2018.05.005; Hirano I, 2019, GASTROENTEROLOGY, V156, P592, DOI 10.1053/j.gastro.2018.10.051; Jensen ET, 2016, J PEDIATR GASTR NUTR, V62, P36, DOI 10.1097/MPG.0000000000000865; Ko HM, 2014, AM J GASTROENTEROL, V109, P1277, DOI 10.1038/ajg.2014.166; Lwin T, 2011, MODERN PATHOL, V24, P556, DOI 10.1038/modpathol.2010.221; Matoso A, 2013, MODERN PATHOL, V26, P665, DOI 10.1038/modpathol.2013.41; Matsushita T, 2015, AM J SURG PATHOL, V39, P521, DOI 10.1097/PAS.0000000000000370; O'Shea KM, 2018, GASTROENTEROLOGY, V154, P333, DOI 10.1053/j.gastro.2017.06.065; Pesek RD, 2019, AM J GASTROENTEROL, V114, P984, DOI 10.14309/ajg.0000000000000228; Peterson KA, 2018, ALIMENT PHARM THER, V48, P219, DOI 10.1111/apt.14825; Polzer K, 2008, RHEUMATOLOGY, V47, P804, DOI 10.1093/rheumatology/ken033; Rothenberg ME, 2004, J ALLERGY CLIN IMMUN, V113, P11, DOI 10.1016/j.jaci.2003.10.047; Sato M, 2017, J ALLER CL IMM-PRACT, V5, P1639, DOI 10.1016/j.jaip.2017.03.030; Sherrill JD, 2014, GENES IMMUN, V15, P361, DOI 10.1038/gene.2014.27; Shoda T, 2018, LANCET GASTROENTEROL, V3, P477, DOI 10.1016/S2468-1253(18)30096-7; Shoda T, 2017, J ALLERGY CLIN IMMUN, V139, P2010, DOI 10.1016/j.jaci.2016.11.028; Shoda T, 2016, J ALLERGY CLIN IMMUN, V138, P299, DOI 10.1016/j.jaci.2015.11.042; Walker MM, 2018, LANCET GASTROENTEROL, V3, P271, DOI 10.1016/S2468-1253(18)30005-0; Wen T, 2013, GASTROENTEROLOGY, V145, P1289, DOI 10.1053/j.gastro.2013.08.046; Yamada T, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00074	28	21	22	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2020	145	1					255	269		10.1016/j.jaci.2019.11.007	http://dx.doi.org/10.1016/j.jaci.2019.11.007			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KA1WZ	31738990	Bronze, Green Accepted			2022-12-18	WOS:000505590800031
J	Westerhout, J; Baumert, JL; Blom, WM; Allen, KJ; Ballmer-Weber, B; Crevel, RWR; Dubois, AEJ; Fernandez-Rivas, M; Greenhawt, MJ; Hourihane, JO; Koplin, JJ; Kruizinga, AG; Le, TM; Sampson, HA; Shreffler, WG; Turner, PJ; Taylor, SL; Houben, GF; Remington, BC				Westerhout, Joost; Baumert, Joseph L.; Blom, W. Marty; Allen, Katrina J.; Ballmer-Weber, Barbara; Crevel, Rene W. R.; Dubois, Anthony E. J.; Fernandez-Rivas, Montserrat; Greenhawt, Matthew J.; Hourihane, Jonathan O'B.; Koplin, Jennifer J.; Kruizinga, Astrid G.; Thuy-My Le; Sampson, Hugh A.; Shreffler, Wayne G.; Turner, Paul J.; Taylor, Steve L.; Houben, Geert F.; Remington, Benjamin C.			Deriving individual threshold doses from clinical food challenge data for population risk assessment of food allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; food challenge; double-blind; placebo-controlled food challenge; threshold; eliciting dose; risk assessment; risk management; decision-making process; no observed adverse effect level-lowest observed adverse effect level derivation	DOUBLE-BLIND; PEANUT; CHILDREN; DIAGNOSIS; EUROPE	Background: Food allergies are a significant public health issue, the only effective management option currently available is strict avoidance of all foods containing the allergen. In view of the practical impossibility of limiting risks to zero, quantitative allergen risk assessment and management strategies are needed. Objective: We sought to develop appropriate methods for informing population-based risk assessments and risk management programs to benefit all stakeholders but particularly patients with food allergy. Methods: Individual thresholds for food allergens (maximum tolerable doses and minimum eliciting doses) can ideally be established through double-blind, placebo-controlled food challenges. If double-blind, placebo-controlled food challenge data are not available, data from widely used open food challenges using predefined objective criteria can also provide useful data regarding minimum eliciting doses. For more than 20 years, the Netherlands Organisation for Applied Scientific Research and the Food Allergy Research and Resource Program at the University of Nebraska-Lincoln have been collecting individual maximum tolerable doses and minimum eliciting doses that produce objective symptoms from published and unpublished clinical data to better refine knowledge regarding the sensitivity of the population to food allergens. Results: In this article we provide in-depth insights into the methodology applied by the Netherlands Organisation for Applied Scientific Research and Food Allergy Research and Resource Program to derive individual maximum tolerable doses and minimum eliciting doses for objective symptoms from clinical food challenge data. More than 90 examples for determining individual allergic thresholds are presented. Conclusion: With the methodology presented in this article, we aim to stimulate harmonization and transparency in quantitative food allergen risk assessment and risk management programs, encouraging their wider adoption.	[Westerhout, Joost; Blom, W. Marty; Kruizinga, Astrid G.; Houben, Geert F.; Remington, Benjamin C.] Netherlands Org Appl Sci Res TNO, Zeist, Netherlands; [Baumert, Joseph L.; Taylor, Steve L.] Univ Nebraska, Dept Food Sci & Technol, Food Allergy Res & Resource Program, Lincoln, NE 68583 USA; [Allen, Katrina J.; Koplin, Jennifer J.] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Allen, Katrina J.] Univ Melbourne, Sch Populat & Global Hlth, Melbourne, Vic, Australia; [Ballmer-Weber, Barbara] Univ Hosp, Dept Dermatol, Allergy Unit, Zurich, Switzerland; [Ballmer-Weber, Barbara] Univ Zurich, Fac Med, Zurich, Switzerland; [Ballmer-Weber, Barbara] Kantonsspital St Gallen, Clin Dermatol & Allergol, St Gallen, Switzerland; [Crevel, Rene W. R.] Rene Crevel Consulting, Bedford, England; [Dubois, Anthony E. J.] Univ Groningen, Univ Med Ctr Groningen, Dept Pediat Pulmonol & Pediat Allergy, GRIAC Res Inst, Groningen, Netherlands; [Fernandez-Rivas, Montserrat] Univ Complutense Madrid, Allergy Dept, Hosp Clin San Carlos, Madrid, Spain; [Greenhawt, Matthew J.] Univ Colorado, Sch Med, Childrens Hosp Colorado, Boulder, CO 80309 USA; [Hourihane, Jonathan O'B.] Univ Coll Cork, INFANT Ctr, Cork, Ireland; [Hourihane, Jonathan O'B.] Univ Coll Cork, Paediat & Child Hlth, Cork, Ireland; [Thuy-My Le] Univ Med Ctr Utrecht, Dept Dermatol & Allergol, Utrecht, Netherlands; [Sampson, Hugh A.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA; [Shreffler, Wayne G.] Harvard Med Sch, Food Allergy Ctr, Boston, MA 02115 USA; [Shreffler, Wayne G.] Harvard Med Sch, Ctr Immunol & Inflammatory Dis, Boston, MA 02115 USA; [Shreffler, Wayne G.] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA 02115 USA; [Turner, Paul J.] Imperial Coll London, Sect Paediat, London, England; [Turner, Paul J.] Univ Sydney, Discipline Child & Adolescent Hlth, Sydney, NSW, Australia	Netherlands Organization Applied Science Research; University of Nebraska System; University of Nebraska Lincoln; Murdoch Children's Research Institute; University of Melbourne; University of Zurich; University Zurich Hospital; University of Geneva; University of Zurich; Kantonsspital St. Gallen; University of Groningen; Complutense University of Madrid; Hospital Clinico San Carlos; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder; University College Cork; University College Cork; Utrecht University; Utrecht University Medical Center; Icahn School of Medicine at Mount Sinai; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts General Hospital; Imperial College London; University of Sydney	Blom, WM (corresponding author), Utrechtseweg 48, NL-3704 HE Zeist, Netherlands.	marty.blom@tno.nl		Koplin, Jennifer/0000-0002-7576-5142; Turner, Paul/0000-0001-9862-5161; Houben, Geert/0000-0001-7261-3912; Blom, W.M./0000-0002-6853-0900	Dutch Ministry of Economic Affairs; Food Allergy Research and Resource Program (FARRP) of the University of Nebraska; MRC [MR/K010468/1] Funding Source: UKRI	Dutch Ministry of Economic Affairs(Ministry of Economic Affairs, Netherlands); Food Allergy Research and Resource Program (FARRP) of the University of Nebraska; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This project was funded by The Dutch Ministry of Economic Affairs and the Food Allergy Research and Resource Program (FARRP) of the University of Nebraska.	Agostoni C, 2014, EFSA J, V12, DOI 10.2903/j.efsa.2014.3894; Allen KJ, 2014, J ALLERGY CLIN IMMUN, V133, P156, DOI 10.1016/j.jaci.2013.06.042; Ballmer-Weber BK, 2007, J ALLERGY CLIN IMMUN, V119, P1489, DOI 10.1016/j.jaci.2007.01.049; Blom WM, 2013, J ALLERGY CLIN IMMUN, V131, P172, DOI 10.1016/j.jaci.2012.10.034; Blumchen K, 2014, J ALLERGY CLIN IMMUN, V134, P390, DOI 10.1016/j.jaci.2014.03.035; Buchanan R, 2008, J FOOD PROTECT, V71, P1043; Cochrane SA, 2012, ALLERGY, V67, P107, DOI 10.1111/j.1398-9995.2011.02715.x; Crevel RWR, 2007, FOOD CHEM TOXICOL, V45, P691, DOI 10.1016/j.fct.2006.09.005; Dano D, 2015, FOOD CHEM TOXICOL, V83, P48, DOI 10.1016/j.fct.2015.05.011; Dubois AEJ, 2018, ALLERGY, V73, P1383, DOI 10.1111/all.13405; DunnGalvin A, 2015, ALLERGY, V70, P1039, DOI 10.1111/all.12614; Eller E, 2012, ANN ALLERG ASTHMA IM, V108, P332, DOI 10.1016/j.anai.2012.03.010; Entink RHK, 2014, FOOD CHEM TOXICOL, V70, P134, DOI 10.1016/j.fct.2014.05.001; Grabenhenrich LB, 2018, PEDIAT ALLERG IMM-UK, V29, P58, DOI 10.1111/pai.12811; Houben G, 2016, FOOD CHEM TOXICOL, V89, P8, DOI 10.1016/j.fct.2015.12.028; Hourihane JO, 2017, J ALLERGY CLIN IMMUN, V139, P1583, DOI 10.1016/j.jaci.2017.01.030; Muraro A, 2018, ALLERGY, V73, P1792, DOI 10.1111/all.13408; Niggemann B, 2007, J PEDIATR GASTR NUTR, V45, P399, DOI 10.1097/MPG.0b013e318054b0c3; Pettersson ME, 2018, ALLERGY, V73, P1532, DOI 10.1111/all.13423; Remington BC, 2013, FOOD CHEM TOXICOL, V62, P179, DOI 10.1016/j.fct.2013.08.030; Rimbaud L, 2010, RISK ANAL, V30, P7, DOI 10.1111/j.1539-6924.2009.01322.x; Sampson HA, 2012, J ALLERGY CLIN IMMUN, V130, P1260, DOI 10.1016/j.jaci.2012.10.017; Shaker M, 2018, J ALLER CL IMM-PRACT, V6, P2073, DOI 10.1016/j.jaip.2018.04.036; Sicherer SH, 2018, J ALLERGY CLIN IMMUN, V141, P41, DOI 10.1016/j.jaci.2017.11.003; Sicherer SH, 2000, J ALLERGY CLIN IMMUN, V105, P582, DOI 10.1067/mai.2000.104941; Spanjersberg MQI, 2007, FOOD CHEM TOXICOL, V45, P49, DOI 10.1016/j.fct.2006.07.018; Taylor SL, 2004, CLIN EXP ALLERGY, V34, P689, DOI 10.1111/j.1365-2222.2004.1886.x; Taylor SL, 2014, FOOD CHEM TOXICOL, V63, P9, DOI 10.1016/j.fct.2013.10.032; Taylor SL, 2010, FOOD CHEM TOXICOL, V48, P814, DOI 10.1016/j.fct.2009.12.013; Taylor SL, 2009, FOOD CHEM TOXICOL, V47, P1198, DOI 10.1016/j.fct.2009.02.011; Turner PJ, 2017, ALLERGY, V72, P9, DOI 10.1111/all.12997; Turner PJ, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d6180; van Erp FC, 2014, CLIN TRANSL ALLERGY, V4, DOI 10.1186/s13601-014-0043-6	33	21	24	1	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2019	144	5					1290	1309		10.1016/j.jaci.2019.07.046	http://dx.doi.org/10.1016/j.jaci.2019.07.046			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JK7EU	31445097	Bronze, Green Published			2022-12-18	WOS:000495004700020
J	Tabar, AI; Prieto, L; Alba, P; Nieto, A; Rodriguez, M; Torrecillas, M; Huertas, B; Gomez, E; Fernandez, FJ; Blanca, M; Rodriguez, D; Palacios, R				Isabel Tabar, Ana; Prieto, Luis; Alba, Pilar; Nieto, Antonio; Rodriguez, Mercedes; Torrecillas, Miguel; Huertas, Beatriz; Gomez, Elisa; Javier Fernandez, Francisco; Blanca, Miguel; Rodriguez, David; Palacios, Ricardo			Double-blind, randomized, placebo-controlled trial of allergen-specific immunotherapy with the major allergen Alt a 1	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergen immunotherapy; clinical trial; Alt a 1; molecular immunotherapy; rhinoconjunctivitis; efficacy; safety; fungal allergy; subcutaneous immunotherapy; purified allergen; adults; children	ALTERNARIA-ALTERNATA IMMUNOTHERAPY; CLINICAL-EFFICACY; EXPOSURE; ALT-A-1; ASTHMA; FUNGI; IGG4	Background: There have been few studies conducted on the efficacy and safety of specific immunotherapy with allergen extracts of fungi compared with other allergen extracts, and there are no data on the major allergen Alt a 1 of the fungus Alternaria alternata. Objectives: We sought to evaluate the efficacy and safety of subcutaneous immunotherapy with 2 different doses of Alt a 1 in patients with rhinoconjunctivitis caused by sensitization to A alternata. Method: We performed a multicenter, randomized, double-blind, placebo-controlled trial with Alt a 1 administered subcutaneously in patients with allergic rhinoconjunctivitis with or without controlled asthma aged 12 to 65 years. Three groups were included: the placebo group and active groups receiving 0.2 or 0.37 mu g of Alt a 1 per dose. The main end point was the combined symptom and medication score. Secondary end points were cutaneous reactivity and serum IgE and IgG(4) levels to Alt a 1. Recorded adverse reactions were graded according to World Allergy Organization criteria. Results: There were significant reductions in the combined symptom and medication score for the 0.37-mu g dose of Alt a 1 compared with placebo at 12 months of treatment. Reduced cutaneous reactivity and IgE levels, together with increased IgG(4) levels, were demonstrated for the 2 active groups versus the placebo group. A similar safety profile was found for both active groups compared with the placebo group. No serious adverse drug reactions were reported. Conclusion: Immunotherapy with Alt a 1 was efficacious and safe, reducing the symptoms and medication consumption associated with rhinoconjunctivitis after only 1 year of treatment. The clinical benefits were associated with reduced skin reactivity and specific IgE levels and increased IgG(4) levels.	[Isabel Tabar, Ana] Complejo Hosp Navarra, Pamplona, Spain; [Prieto, Luis] Hosp Univ Dr Peset, Valencia, Spain; [Alba, Pilar] Hosp Manises, Valencia, Spain; [Nieto, Antonio] Hosp Univ La Fe, Valencia, Spain; [Rodriguez, Mercedes] Hosp Univ Principe de Asturias, Madrid, Spain; [Torrecillas, Miguel] Hosp Univ Nuestra Senora del Perpetuo Socorro, Albacete, Spain; [Huertas, Beatriz] Hosp Sureste, Madrid, Spain; [Gomez, Elisa] Hosp Univ Ciudad Real, Ciudad Real, Spain; [Javier Fernandez, Francisco] Hosp Gen Univ Alicante, Alicante, Spain; [Blanca, Miguel] Hosp Reg Univ Carlos Haya, Malaga, Spain; [Rodriguez, David; Palacios, Ricardo] Diater Labs SA, Ave Gregorio Peces Barba 2, Madrid 28918, Spain	Servicio Navarro de Salud - Osasunbidea; Hospital Universitari i Politecnic La Fe; Prince of Asturias University Hospital; General University Hospital of Alicante; Hospital Carlos Haya	Rodriguez, D (corresponding author), Diater Labs SA, Ave Gregorio Peces Barba 2, Madrid 28918, Spain.	d.rodriguez@diater.com	Fernandez, Javier/B-6425-2018; Prieto, Luis Enrique/HFZ-7903-2022	Fernandez, Javier/0000-0003-1065-7199; 	Laboratorios Diater S. A., Leganes, Madrid, Spain	Laboratorios Diater S. A., Leganes, Madrid, Spain	Supported by Laboratorios Diater S. A., Leganes, Madrid, Spain.	AALBERSE RC, 1993, ALLERGY, V48, P559, DOI 10.1111/j.1398-9995.1993.tb00749.x; [Anonymous], EMEACPMPICH13595; [Anonymous], 2008, EMEACHMPEWP185042006; Arbes SJ, 2005, J ALLERGY CLIN IMMUN, V116, P377, DOI 10.1016/j.jaci.2005.05.017; Chruszcz M, 2012, J ALLERGY CLIN IMMUN, V130, P241, DOI 10.1016/j.jaci.2012.03.047; Cox L, 2010, J ALLERGY CLIN IMMUN, V125, P569, DOI 10.1016/j.jaci.2009.10.060; Denning DW, 2006, EUR RESPIR J, V27, P615, DOI 10.1183/09031936.06.00074705; EMEA (European Medincines Agency committee for medicinal products for human use), 2008, EMEACHMPBWP304831200; Esch RE, 2004, J ALLERGY CLIN IMMUN, V113, P210, DOI 10.1016/j.jaci.2003.11.024; Esch RE, 2017, ANN ALLERG ASTHMA IM, V118, P399, DOI 10.1016/j.anai.2016.05.012; Brito FF, 2012, J INVEST ALLERG CLIN, V22, P154; Gabriel MF, 2016, ENVIRON INT, V89-90, P71, DOI 10.1016/j.envint.2016.01.003; Gravesen S, 1994, MICROFUNGI; Gutierrez-Rodriguez A, 2011, MED MYCOL, V49, P892, DOI 10.3109/13693786.2011.576350; Hesselmar B, 2003, CLIN EXP ALLERGY, V33, P1681, DOI 10.1111/j.1365-2222.2003.01821.x; Hong SG, 2005, FUNGAL GENET BIOL, V42, P119, DOI 10.1016/j.fgb.2004.10.009; HORST M, 1990, J ALLERGY CLIN IMMUN, V85, P460, DOI 10.1016/0091-6749(90)90156-X; Klimek L, 2015, ALLERGO J, V24, P88, DOI 10.1007/s40629-015-0051-7; Kuna P, 2011, J ALLERGY CLIN IMMUN, V127, P502, DOI 10.1016/j.jaci.2010.11.036; Malling HJ, 2004, ALLERGY, V59, P482, DOI 10.1111/j.1398-9995.2004.00501.x; Malling HJ, 1998, ALLERGY, V53, P461; Martinez J, 2006, J INVEST ALLERG CLIN, V16, P279; Martinez-Canavate A, 2005, Allergol Immunopathol (Madr), V33, P138, DOI 10.1157/13075696; Moreno A, 2016, ALLERGY ASTHMA IMMUN, V8, P428, DOI 10.4168/aair.2016.8.5.428; National Institutes of Health, NIH PUBLICATION; Pfaar O, 2014, ALLERGO J, V23, P28, DOI 10.1007/s15007-014-0707-5; Platts-Mills TAE, 2001, INT ARCH ALLERGY IMM, V124, P126, DOI 10.1159/000053689; Prieto Luis, 2010, Allergy Asthma Clin Immunol, V6, P27, DOI 10.1186/1710-1492-6-27; Salo PM, 2005, J ALLERGY CLIN IMMUN, V116, P623, DOI 10.1016/j.jaci.2005.05.030; Schwarz A, 2016, J ALLERGY CLIN IMMUN, V138, P1426, DOI 10.1016/j.jaci.2016.01.057; Shamji MH, 2017, ALLERGY, V72, P1156, DOI 10.1111/all.13138; Shamji MH, 2011, CLIN EXP ALLERGY, V41, P1235, DOI 10.1111/j.1365-2222.2011.03804.x; Tabar AI, 2008, PEDIAT ALLERG IMM-UK, V19, P67, DOI 10.1111/j.1399-3038.2007.00589.x; Lizaso MT, 2008, PEDIAT ALLERG IMM-UK, V19, P76, DOI 10.1111/j.1399-3038.2007.00587.x; Twaroch TE, 2015, ALLERGY ASTHMA IMMUN, V7, P205, DOI 10.4168/aair.2015.7.3.205; Twaroch TE, 2012, J ALLERGY CLIN IMMUN, V129, P1148, DOI 10.1016/j.jaci.2011.10.008; Vailes L, 2001, J ALLERGY CLIN IMMUN, V107, P641, DOI 10.1067/mai.2001.114118	37	21	21	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2019	144	1					216	+		10.1016/j.jaci.2019.02.029	http://dx.doi.org/10.1016/j.jaci.2019.02.029			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IF9SM	30879998	hybrid			2022-12-18	WOS:000473432800024
J	Kasagi, Y; Dods, K; Wang, JX; Chandramouleeswaran, PM; Benitez, AJ; Gambanga, F; Kluger, J; Ashorobi, T; Gross, J; Tobias, JW; Klein-Szanto, AJ; Spergel, JM; Cianferoni, A; Falk, GW; Whelan, KA; Nakagawa, H; Muir, AB				Kasagi, Yuta; Dods, Kara; Wang, Joshua X.; Chandramouleeswaran, Prasanna M.; Benitez, Alain J.; Gambanga, Fiona; Kluger, Jonathan; Ashorobi, Tokunbo; Gross, Jonathan; Tobias, John W.; Klein-Szanto, Andres J.; Spergel, Jonathan M.; Cianferoni, Antonella; Falk, Gary W.; Whelan, Kelly A.; Nakagawa, Hiroshi; Muir, Amanda B.			Fibrostenotic eosinophilic esophagitis might reflect epithelial lysyl oxidase induction by fibroblast-derived TNF-alpha	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eosinophilic esophagitis; lysyl oxidase; TNF-alpha; TGF-beta; coculture; fibrosis	GENE-EXPRESSION; TGF-BETA; GROWTH; TGF-BETA-1; FIBROSIS; CELLS; LIVER; DISTENSIBILITY; SUPPRESSION; MECHANISM	Background: Fibrosis and stricture are major comorbidities in patients with eosinophilic esophagitis (EoE). Lysyl oxidase (LOX), a collagen cross-linking enzyme, has not been investigated in the context of EoE. Objective: We investigated regulation of epithelial LOX expression as a novel biomarker and functional effector of fibrostenotic disease conditions associated with EoE. Methods: LOX expression was analyzed by using RNA-sequencing, PCR assays, and immunostaining in patients with EoE; cytokine-stimulated esophageal 3-dimensional organoids; and fibroblast epithelial cell coculture, the latter coupled with fluorescence-activated cell sorting. Results: Gene ontology and pathway analyses linked TNF-alpha and LOX expression in patients with EoE, which was validated in independent sets of patients with fibrostenotic conditions. TNF-alpha-mediated epithelial LOX upregulation was recapitulated in 3-dimensional organoids and coculture experiments. We find that fibroblast-derived TNF-alpha stimulates epithelial LOX expression through activation of nuclear factor kappa B and TGF-beta-mediated signaling. In patients receiver operating characteristic analyses suggested that LOX upregulation indicates disease complications and fibrostenotic conditions in patients with EoE. Conclusions: There is a novel positive feedback mechanism in epithelial LOX induction through fibroblast-derived TNF-alpha secretion. Esophageal epithelial LOX might have a role in the development of fibrosis with substantial translational implications.	[Kasagi, Yuta; Dods, Kara; Wang, Joshua X.; Benitez, Alain J.; Gambanga, Fiona; Kluger, Jonathan; Ashorobi, Tokunbo; Gross, Jonathan; Muir, Amanda B.] Childrens Hosp Philadelphia, Div Pediat Gastroenterol Hepatol & Nutr, Philadelphia, PA 19104 USA; [Spergel, Jonathan M.; Cianferoni, Antonella] Childrens Hosp Philadelphia, Div Allergy & Immunol, Philadelphia, PA 19104 USA; [Chandramouleeswaran, Prasanna M.; Falk, Gary W.; Nakagawa, Hiroshi] Univ Penn, Dept Med, Div Gastroenterol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Tobias, John W.] Univ Penn, Perelman Sch Med, Penn Genom Anal Core, Philadelphia, PA 19104 USA; [Spergel, Jonathan M.; Cianferoni, Antonella; Muir, Amanda B.] Univ Penn, Perelman Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; [Chandramouleeswaran, Prasanna M.; Nakagawa, Hiroshi] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA; [Klein-Szanto, Andres J.] Fox Chase Canc Ctr, Histopathol Facil, 7701 Burholme Ave, Philadelphia, PA 19111 USA; [Klein-Szanto, Andres J.] Fox Chase Canc Ctr, Canc Biol Program, 7701 Burholme Ave, Philadelphia, PA 19111 USA; [Whelan, Kelly A.] Temple Univ, Lewis Katz Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19122 USA; [Whelan, Kelly A.] Temple Univ, Lewis Katz Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19122 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Fox Chase Cancer Center; Fox Chase Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Muir, AB (corresponding author), Univ Penn, Abramson Res Ctr, Perlman Sch Med, Div Gastroenterol, 3615 Civ Ctr Blvd 902E, Philadelphia, PA 19104 USA.	muira@email.chop.edu			National Institutes of Health (NIH) [P01CA098101, P30ES013508]; University of Pennsylvania Center of Excellence in Environmental Toxicology [R01DK114436, K01DK103953, F32CA174176, K08DK106444, F32DK100088]; iPS Core Facilities at the NIH/National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [P30-DK050306]; NASPGHAN Foundation/Takeda Pharmaceutical Products Research Innovation Award; Joint Penn-CHOP Center in Digestive, Liver and Pancreatic Medicine at the University of Pennsylvania Perelman School of Medicine - Stuart Starr Endowed Chair, Food Allergy Research and Education; Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR); CEGIR [U54 AI117804]; Rare Diseases Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR); National Center for Advancing Translational Sciences (NCATS); National Institute of Allergy and Infectious Diseases (NIAID); NIDDK; NCATS; NATIONAL CANCER INSTITUTE [P01CA098101] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR001879] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U54AI117804] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R03DK118304, K01DK103953, R01DK114436, P30DK050306, K08DK106444] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES013508] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Pennsylvania Center of Excellence in Environmental Toxicology; iPS Core Facilities at the NIH/National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NASPGHAN Foundation/Takeda Pharmaceutical Products Research Innovation Award; Joint Penn-CHOP Center in Digestive, Liver and Pancreatic Medicine at the University of Pennsylvania Perelman School of Medicine - Stuart Starr Endowed Chair, Food Allergy Research and Education; Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR); CEGIR; Rare Diseases Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR); National Center for Advancing Translational Sciences (NCATS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCATS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by the following National Institutes of Health (NIH) grants: P01CA098101 (to K.A.W., A.J.K.-S., and H.N.) and P30ES013508, University of Pennsylvania Center of Excellence in Environmental Toxicology (to H.N.); and R01DK114436 (to H.N.), K01DK103953 (to K.A.W.), F32CA174176 (to K.A.W.), K08DK106444 (to A.B.M.), and F32DK100088 (to A.B.M.), Molecular Pathology and Imaging Core, Host-Microbial Analytic and Repository Core, and Cell Culture and iPS Core Facilities at the NIH/National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) P30-DK050306 Center of Molecular Studies in Digestive and Liver Diseases. Additional support was provided by the NASPGHAN Foundation/Takeda Pharmaceutical Products Research Innovation Award (to H.N.) and the Joint Penn-CHOP Center in Digestive, Liver and Pancreatic Medicine at the University of Pennsylvania Perelman School of Medicine (to K.A.W. and H.N.). J.M.S. is funded by the Stuart Starr Endowed Chair, Food Allergy Research and Education. J.M.S. and A.B.M. are funded in part by the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR). CEGIR (U54 AI117804) is part of the Rare Diseases Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR), National Center for Advancing Translational Sciences (NCATS), and is funded through collaboration between the National Institute of Allergy and Infectious Diseases (NIAID), NIDDK, and NCATS. CEGIR is also supported by patient advocacy groups, including APFED, CURED, and EFC.	Aceves SS, 2014, DIGEST DIS, V32, P15, DOI 10.1159/000357004; Aceves SS, 2007, J ALLERGY CLIN IMMUN, V119, P206, DOI 10.1016/j.jaci.2006.10.016; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Audetat KA, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00626-16; Beppu LY, 2014, J ALLERGY CLIN IMMUN, V134, P1100, DOI 10.1016/j.jaci.2014.04.004; Bitzer M, 2000, GENE DEV, V14, P187; Blanchard C, 2006, J CLIN INVEST, V116, P536, DOI 10.1172/JCI26679; Bouhnik Y, 2018, GUT, V67, P53, DOI 10.1136/gutjnl-2016-312581; Carlson DA, 2016, NEUROGASTROENT MOTIL, V28, P1844, DOI 10.1111/nmo.12888; Chandramouleeswaran PM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150968; Cheng E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157376; Cianferoni A, 2015, EXPERT REV GASTROENT, V9, P1501, DOI 10.1586/17474124.2015.1094372; Dellon ES, 2017, NAT REV GASTRO HEPAT, V14, P479, DOI 10.1038/nrgastro.2017.56; Dellon ES, 2014, GASTROINTEST ENDOSC, V79, P577, DOI 10.1016/j.gie.2013.10.027; Denney L, 2015, IMMUNITY, V43, P945, DOI 10.1016/j.immuni.2015.10.012; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Gao AE, 2016, BIOCHEM BIOPH RES CO, V475, P70, DOI 10.1016/j.bbrc.2016.05.037; Georges PC, 2007, AM J PHYSIOL-GASTR L, V293, pG1147, DOI 10.1152/ajpgi.00032.2007; Harlow CR, 2003, ENDOCRINOLOGY, V144, P154, DOI 10.1210/en.2002-220652; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Iwasaki A, 2016, J BIOL CHEM, V291, P72, DOI 10.1074/jbc.M115.691519; Kasagi Y, 2018, CELL MOL GASTROENTER, V5, P333, DOI 10.1016/j.jcmgh.2017.12.013; Kothapalli D, 2012, CELL REP, V2, P1259, DOI 10.1016/j.celrep.2012.09.018; Kottyan LC, 2014, NAT GENET, V46, P895, DOI 10.1038/ng.3033; Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040; Lopez B, 2010, AM J PHYSIOL-HEART C, V299, pH1, DOI 10.1152/ajpheart.00335.2010; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Menard-Katcher C, 2017, AM J GASTROENTEROL, V112, P1466, DOI 10.1038/ajg.2017.131; Meng XM, 2016, NAT REV NEPHROL, V12, P325, DOI 10.1038/nrneph.2016.48; Mudge JM, 2015, MAMM GENOME, V26, P366, DOI 10.1007/s00335-015-9583-x; Muir AB, 2016, J PEDIATR GASTR NUTR, V63, P200, DOI 10.1097/MPG.0000000000001100; Muir AB, 2015, EXP CELL RES, V330, P102, DOI 10.1016/j.yexcr.2014.08.026; Muir AB, 2013, EXP CELL RES, V319, P850, DOI 10.1016/j.yexcr.2012.12.002; Mun H, 2016, ADV EXP MED BIOL, V933, P35, DOI 10.1007/978-981-10-2041-4_4; Nagarajan RP, 2000, BIOCHEM J, V348, P591, DOI 10.1042/0264-6021:3480591; Natsuizaka M, 2014, AM J CANCER RES, V4, P29; Nilsson G, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2196-2; Noti M, 2013, NAT MED, V19, P1005, DOI 10.1038/nm.3281; Ohashi S, 2010, GASTROENTEROLOGY, V139, P2113, DOI 10.1053/j.gastro.2010.08.040; Perepelyuk M, 2013, AM J PHYSIOL-GASTR L, V304, pG605, DOI 10.1152/ajpgi.00222.2012; Persad R, 2012, J PEDIATR GASTR NUTR, V55, P251, DOI 10.1097/MPG.0b013e31824b6391; Potter RM, 2017, AM J PHYSIOL-REG I, V312, pR157, DOI 10.1152/ajpregu.00439.2016; Rawson R, 2016, J ALLERGY CLIN IMMUN, V138, P791, DOI 10.1016/j.jaci.2016.02.028; Rieder F, 2014, GASTROENTEROLOGY, V146, pe1; Rieder F, 2014, GASTROENTEROLOGY, V146, P1266, DOI 10.1053/j.gastro.2014.01.051; Rieder F, 2008, J CROHNS COLITIS, V2, P279, DOI 10.1016/j.crohns.2008.05.009; Schoepfer AM, 2013, GASTROENTEROLOGY, V145, P1230, DOI 10.1053/j.gastro.2013.08.015; Sherrill JD, 2014, GENES IMMUN, V15, P361, DOI 10.1038/gene.2014.27; Singla MB, 2015, CLIN TRANSL GASTROEN, V6, DOI 10.1038/ctg.2015.62; Straumann A, 2008, J ALLERGY CLIN IMMUN, V122, P425, DOI 10.1016/j.jaci.2008.06.012; Voloshenyuk TG, 2011, CYTOKINE, V55, P90, DOI 10.1016/j.cyto.2011.03.024; Wang Y, 2017, NATURE, V4, P842; Wei MM, 2017, ONCOL LETT, V14, P7767, DOI 10.3892/ol.2017.7206; Whelan KA, 2017, ONCOGENE, V36, P4843, DOI 10.1038/onc.2017.102; Whelan KA, 2017, GUT, V66, P1197, DOI 10.1136/gutjnl-2015-310341; Wordinger Robert J, 2014, J Glaucoma, V23, pS55, DOI 10.1097/IJG.0000000000000127; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Xu ZB, 2013, ONCOL LETT, V6, P401, DOI 10.3892/ol.2013.1409; Yang Yoon Mee, 2015, Curr Pathobiol Rep, V3, P253; Zhao MT, 2017, P NATL ACAD SCI USA, V114, pE11111, DOI 10.1073/pnas.1708991114	60	21	21	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2019	144	1					171	182		10.1016/j.jaci.2018.10.067	http://dx.doi.org/10.1016/j.jaci.2018.10.067			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IF9SM	30578874	Bronze, Green Accepted			2022-12-18	WOS:000473432800020
J	Winters, A; Bahnson, HT; Ruczinski, I; Boorgula, MP; Malley, C; Keramati, AR; Chavan, S; Larson, D; Cerosaletti, K; Sayre, PH; Plaut, M; Du Toit, G; Lack, G; Barnes, KC; Nepom, GT; Mathias, RA				Winters, Alexandra; Bahnson, Henry T.; Ruczinski, Ingo; Boorgula, Meher P.; Malley, Claire; Keramati, Ali R.; Chavan, Sameer; Larson, David; Cerosaletti, Karen; Sayre, Peter H.; Plaut, Marshall; Du Toit, George; Lack, Gideon; Barnes, Kathleen C.; Nepom, Gerald T.; Mathias, Rasika A.		Immune Tolerance Network LEAP S	The MALT1 locus and peanut avoidance in the risk for peanut allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							INFANTS		[Winters, Alexandra; Malley, Claire; Keramati, Ali R.; Mathias, Rasika A.] Johns Hopkins Univ, Dept Med, Baltimore, MD 21218 USA; [Bahnson, Henry T.; Cerosaletti, Karen] Benaroya Res Inst, Seattle, WA USA; [Bahnson, Henry T.; Sayre, Peter H.; Nepom, Gerald T.] Immune Tolerance Network, San Francisco, CA USA; [Ruczinski, Ingo] Johns Hopkins Univ, Dept Biostat, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA; [Boorgula, Meher P.; Chavan, Sameer; Larson, David; Barnes, Kathleen C.] Univ Colorado, Dept Med, Anschutz, CO USA; [Sayre, Peter H.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA; [Plaut, Marshall] NIAID, Allergy Asthma & Airway Biol Branch, Div Allergy Immunol & Transplantat, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Du Toit, George; Lack, Gideon] Kings Coll London, Div Asthma Allergy & Lung Biol, Dept Pediat Allergy, London, England; [Du Toit, George; Lack, Gideon] Guys & St Thomas NHS Fdn Trust, London, England	Johns Hopkins University; Benaroya Research Institute; Immune Tolerance Network; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of California System; University of California San Francisco; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust	Mathias, RA (corresponding author), Johns Hopkins Univ, Dept Med, Baltimore, MD 21218 USA.	rmathias@jhmi.edu	Boorgula, Meher Preethi/AAC-6252-2022; Malley, Claire/ABG-1967-2021; Chavan, Sameer/AAU-2285-2021	Malley, Claire/0000-0002-2352-8479; Chavan, Sameer/0000-0002-0220-0845; Du Toit, George/0000-0002-0321-2928; Lack, Gideon/0000-0001-7350-4021	National Institute of Allergy and Infectious Diseases of the National Institutes of Health [UM1AI109565]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [UM1AI109565] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This research was performed as a project of the Immune Tolerance Network, an international clinical research consortium headquartered at the Benaroya Research Institute, and supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award no. UM1AI109565. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Asai Y, 2018, J ALLERGY CLIN IMMUN, V141, P1513, DOI 10.1016/j.jaci.2017.10.047; Asai Y, 2018, J ALLERGY CLIN IMMUN, V141, P991, DOI 10.1016/j.jaci.2017.09.015; Du Toit G, 2015, NEW ENGL J MED, V372, P803, DOI 10.1056/NEJMoa1414850; Du Toit G, 2013, J ALLERGY CLIN IMMUN, V131, P135, DOI 10.1016/j.jaci.2012.09.015; Mathias RA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12522; Meininger I, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11292; Thome M, 2004, NAT REV IMMUNOL, V4, P348, DOI 10.1038/nri1352; Togias A, 2017, ALLERGY ASTHMA CL IM, V13, DOI 10.1186/s13223-016-0175-4; Vickery BP, 2011, PEDIATR CLIN N AM, V58, P363, DOI 10.1016/j.pcl.2011.02.012	9	21	21	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2019	143	6					2326	2329		10.1016/j.jaci.2019.02.016	http://dx.doi.org/10.1016/j.jaci.2019.02.016			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IB2QG	30825465	Green Accepted, hybrid			2022-12-18	WOS:000470113200046
J	Jorgensen, SF; Holm, K; Macpherson, ME; Storm-Larsen, C; Kummen, M; Fevang, B; Aukrust, P; Hov, JR				Jorgensen, Silje Fjellgard; Holm, Kristian; Macpherson, Magnhild Eide; Storm-Larsen, Christopher; Kummen, Martin; Fevang, Borre; Aukrust, Pal; Hov, Johannes Roksund			Selective IgA deficiency in humans is associated with reduced gut microbial diversity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									[Jorgensen, Silje Fjellgard; Holm, Kristian; Macpherson, Magnhild Eide; Storm-Larsen, Christopher; Kummen, Martin; Fevang, Borre; Aukrust, Pal; Hov, Johannes Roksund] Natl Hosp Norway, Oslo Univ Hosp, Internal Med Res Inst, Div Surg Inflammatory Dis & Transplantat, Oslo, Norway; [Jorgensen, Silje Fjellgard; Macpherson, Magnhild Eide; Fevang, Borre; Aukrust, Pal] Natl Hosp Norway, Oslo Univ Hosp, Dept Rheumatol Dermatol & Infect Dis, Sect Clin Immunol & Infect Dis, Oslo, Norway; [Jorgensen, Silje Fjellgard; Holm, Kristian; Macpherson, Magnhild Eide; Storm-Larsen, Christopher; Kummen, Martin; Fevang, Borre; Aukrust, Pal; Hov, Johannes Roksund] Univ Oslo, Inst Clin Med, Oslo, Norway; [Holm, Kristian; Storm-Larsen, Christopher; Kummen, Martin; Hov, Johannes Roksund] Natl Hosp Norway, Oslo Univ Hosp, Div Surg Inflammatory Dis & Transplantat, Norwegian PSC Res Ctr, Oslo, Norway; [Hov, Johannes Roksund] Natl Hosp Norway, Oslo Univ Hosp, Sect Gastroenterol, Dept Transplantat Med, Oslo, Norway	University of Oslo; National Hospital Norway; University of Oslo; National Hospital Norway; University of Oslo; University of Oslo; National Hospital Norway; University of Oslo; National Hospital Norway	Jorgensen, SF (corresponding author), Natl Hosp Norway, Oslo Univ Hosp, Internal Med Res Inst, Div Surg Inflammatory Dis & Transplantat, Oslo, Norway.; Jorgensen, SF (corresponding author), Natl Hosp Norway, Oslo Univ Hosp, Dept Rheumatol Dermatol & Infect Dis, Sect Clin Immunol & Infect Dis, Oslo, Norway.; Jorgensen, SF (corresponding author), Univ Oslo, Inst Clin Med, Oslo, Norway.	s.f.jorgensen@medisin.uio.no	Kummen, Martin/I-6663-2019	Kummen, Martin/0000-0001-9660-6290	Research Council of Norway [240787/F20]	Research Council of Norway(Research Council of Norway)	J.R.H. is funded by the Research Council of Norway (no. 240787/F20).	Bokulich NA, 2013, NAT METHODS, V10, P57, DOI [10.1038/NMETH.2276, 10.1038/nmeth.2276]; Bushnell B, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185056; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Fadlallah J, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aan1217; Girardot C, 2016, BMC BIOINFORMATICS, V17, DOI 10.1186/s12859-016-1284-2; Jorgensen SF, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-35367-7; Jorgensen SF, 2016, MUCOSAL IMMUNOL, V9, P1455, DOI 10.1038/mi.2016.18; Jorgensen SF, 2016, AM J GASTROENTEROL, V111, P1467, DOI 10.1038/ajg.2016.329; Kaetzel CS, 2014, IMMUNOL LETT, V162, P10, DOI 10.1016/j.imlet.2014.05.008; Kato LM, 2014, IMMUNOL REV, V260, P67, DOI 10.1111/imr.12185; Kopylova E, 2012, BIOINFORMATICS, V28, P3211, DOI 10.1093/bioinformatics/bts611; Mandal Siddhartha, 2015, Microbial Ecology in Health and Disease, V26, P27663, DOI 10.3402/mehd.v26.27663; Martin M., 2011, EMBNET J, V17, P10, DOI [10.14806/ej.17.1.200, DOI 10.14806/EJ.17.1.200]; Quast C, 2013, NUCLEIC ACIDS RES, V41, pD590, DOI 10.1093/nar/gks1219; Shulzhenko N, 2018, CLIN IMMUNOL, V197, P139, DOI 10.1016/j.clim.2018.09.008; Tessler M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06665-3; Yazdani R, 2017, SCAND J IMMUNOL, V85, P3, DOI 10.1111/sji.12499	17	21	21	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2019	143	5					1969	+		10.1016/j.jaci.2019.01.019	http://dx.doi.org/10.1016/j.jaci.2019.01.019			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HW6FP	30707969	Bronze			2022-12-18	WOS:000466784600042
J	Wang, AL; Datta, S; Weiss, ST; Tantisira, KG				Wang, Alberta L.; Datta, Soma; Weiss, Scott T.; Tantisira, Kelan G.			Remission of persistent childhood asthma: Early predictors of adult outcomes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Pediatric asthma; asthma remission; prognostication	INHALED CORTICOSTEROIDS; CHILDREN; SENSITIZATION; RISK	Background: Few data exist on the predictors of asthma remission by early adulthood in North America. Objective: The predictors of adult asthma remission were determined in a multiethnic population of patients with mild-to-moderate persistent childhood asthma. Methods: Asthma remission in early adulthood was measured by using 2 definitions: a clinical and a strict definition. Both included normal lung function and the absence of symptoms, exacerbations, and medication use. The strict definition also included normal airways responsiveness. Predictors were identified from 23 baseline measures by using multivariate logistic regression. The probability of remission was modeled by using decision tree analysis. Results: In 879 subjects the mean +/- SD baseline age was 8.8 +/- 2.1 years, 59.4% were male, and 68.7% were white. By adulthood, 229 (26.0%) of 879 participants were in clinical remission, and 111 (15.0%) of 741 participants were in strict remission. The degree of FEV1/forced vital capacity (FVC) ratio impairment was the largest predictor of asthma remission. More than half of boys and two thirds of girls with baseline FEV1/FVC ratios of 90% or greater were in remission at adulthood. Decreased airways responsiveness was also a predictor for both remission definitions (clinical remission odds ratio, 1.23 [95% CI, 1.09-1.39]; strict remission odds ratio, 1.52 [95% CI, 1.26-1.84]). The combination of normal FEV1/FVC ratio, airways responsiveness, and serum eosinophil count at baseline yielded greater than 80% probability of remission by adulthood. Conclusion: A considerable minority of patients with persistent childhood asthma will have disease remission by adulthood. Clinical prognostic indicators of asthma remission, including baseline lung function, can be seen from an early age.	[Wang, Alberta L.; Datta, Soma; Weiss, Scott T.; Tantisira, Kelan G.] Harvard Med Sch, Brigham & Womens Hosp, Channing Div Network Med, Boston, MA 02115 USA; [Wang, Alberta L.] Harvard Med Sch, Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA; [Tantisira, Kelan G.] Harvard Med Sch, Brigham & Womens Hosp, Div Pulm & Crit Care Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Tantisira, KG (corresponding author), Brigham & Womens Hosp, Channing Div Network Med, 181 Longwood Ave, Boston, MA 02115 USA.	rekgt@channing.harvard.edu		Wang, Alberta/0000-0002-2151-4823	National Institutes of Health (NIH) [T32 AI007306, T32 HL007427, R01 HL127332, R01 HL129935, U01 HL65899]; Childhood Asthma Management Program (CAMP) trial and CAMP Continuation Study [NO1-HR-16044, NO1-HR-16045, NO1-HR-16046, NO1-HR-16047, NO1-HR-16048, NO1-HR-16049, NO1-HR-16050, NO1-HR-16051, NO1-HR-16052]; National Heart, Lung, and Blood Institute and General Clinical Research Center [M01RR00051, M01RR0099718-24, M01RR02719-14]; National Center for Research Resources [RR00036]; National Heart, Lung, and Blood Institute [U01HL075232, U01HL075407, U01HL075408, U01HL075409, U01HL075415, U01HL075416, U01HL075417, U01HL075419, U01HL075420]; National Center for Research Resources/NIH [UL1RR025780]; National Center for Advancing Translational Sciences/NIH [UL1TR000154]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL129935, R01HL127332] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007306] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Childhood Asthma Management Program (CAMP) trial and CAMP Continuation Study; National Heart, Lung, and Blood Institute and General Clinical Research Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)NIH National Center for Research Resources (NCRR)); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Center for Research Resources/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Center for Advancing Translational Sciences/NIH; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health (NIH) grants T32 AI007306, T32 HL007427, R01 HL127332, R01 HL129935, and U01 HL65899. The Childhood Asthma Management Program (CAMP) trial and CAMP Continuation Study were supported by contracts NO1-HR-16044, 16045, 16046, 16047, 16048, 16049, 16050, 16051, and 16052 with the National Heart, Lung, and Blood Institute and General Clinical Research Center grants M01RR00051, M01RR0099718-24, M01RR02719-14, and RR00036 from the National Center for Research Resources. The CAMP Continuation Study/Phases 2 and 3 were supported by grants U01HL075232, U01HL075407, U01HL075408, U01HL075409, U01HL075415, U01HL075416, U01HL075417, U01HL075419, and U01HL075420 from the National Heart, Lung, and Blood Institute. The National Jewish Health site was also supported in part by Colorado CTSA grant UL1RR025780 from the National Center for Research Resources/NIH and UL1TR000154 from National Center for Advancing Translational Sciences/NIH.	Andersson M, 2013, PEDIATRICS, V132, pE435, DOI 10.1542/peds.2013-0741; [Anonymous], 2017, ASTHM DIAGN MON CHRO; Bisgaard H, 2006, NEW ENGL J MED, V354, P1998, DOI 10.1056/NEJMoa054692; BLAIR H, 1977, ARCH DIS CHILD, V52, P613, DOI 10.1136/adc.52.8.613; Burgess JA, 2011, THORAX, V66, P508, DOI 10.1136/thx.2010.146845; Carpaij OA, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.01974-2016; Cherniack R, 1999, CONTROL CLIN TRIALS, V20, P91; Couriel JM, 2006, CURR PAEDIAT, V16, P413; Covar RA, 2010, J ALLERGY CLIN IMMUN, V125, P359, DOI 10.1016/j.jaci.2009.10.037; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Culver BH, 2017, AM J RESP CRIT CARE, V196, P1463, DOI 10.1164/rccm.201710-1981ST; Global Initiative for Asthma, 2018, GLOB STRAT ASTHM MAN; Grunstein MM, 2001, AM J PHYSIOL-LUNG C, V280, pL229, DOI 10.1152/ajplung.2001.280.2.L229; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; Hothorn T, 2006, J COMPUT GRAPH STAT, V15, P651, DOI 10.1198/106186006X133933; Kuhn M, 2008, J STAT SOFTW, V28, P1, DOI 10.18637/jss.v028.i05; McGeachie MJ, 2016, NEW ENGL J MED, V374, P1842, DOI 10.1056/NEJMoa1513737; Nagarajan S, 2018, ALLERGY ASTHMA PROC, V39, P281, DOI 10.2500/aap.2018.39.4147; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Panhuysen CIM, 1997, AM J RESP CRIT CARE, V155, P1267, DOI 10.1164/ajrccm.155.4.9105065; Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-77; ROORDA RJ, 1993, AM REV RESPIR DIS, V148, P1490, DOI 10.1164/ajrccm/148.6_Pt_1.1490; Rosser FJ, 2014, AM J RESP CRIT CARE, V189, P1316, DOI 10.1164/rccm.201401-0186PP; Sachs MC, 2017, J STAT SOFTW, V79, DOI 10.18637/jss.v079.c02; Sears MR, 2015, J ALLERGY CLIN IMMUN, V136, P829, DOI 10.1016/j.jaci.2015.04.048; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Stern DA, 2008, LANCET, V372, P1058, DOI 10.1016/S0140-6736(08)61447-6; Strunk RC, 2009, J PEDIATR-US, V154, P682, DOI 10.1016/j.jpeds.2008.11.036; SZEFLER S, N ENGL J MED, V343, P1054; Tai A, 2014, J ALLERGY CLIN IMMUN, V133, P1572, DOI 10.1016/j.jaci.2013.12.1033; Vonk JM, 2004, THORAX, V59, P925, DOI 10.1136/thx.2003.016246; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1	33	21	21	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2019	143	5					1752	+		10.1016/j.jaci.2018.09.038	http://dx.doi.org/10.1016/j.jaci.2018.09.038			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HW6FP	30445065	Bronze, Green Accepted			2022-12-18	WOS:000466784600011
J	Bosco, MC				Bosco, Maria Carla			Macrophage polarization: Reaching across the aisle	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Macrophages; M1-to-M2 polarization; inflammatory conditions; cystic fibrosis; asthma	PLASTICITY		[Bosco, Maria Carla] Ist Giannina Gaslini, IRCCS, Lab Biol Mol, Genoa, Italy	University of Genoa; IRCCS Istituto Giannina Gaslini	Bosco, MC (corresponding author), Ist Giannina Gaslini, Lab Biol Mol, Padiglione 2,Lgo G Gaslini 5, I-16147 Genoa, Italy.	mariacarlabosco@gaslini.org	Bosco, Maria Carla/J-7928-2016	Bosco, Maria Carla/0000-0003-1857-7193				Becker M, 2015, SCI REP-UK, V5, DOI 10.1038/srep13351; Bruscia EM, 2011, J IMMUNOL, V186, P6990, DOI 10.4049/jimmunol.1100396; Gharib SA, 2019, J ALLERGY CLIN IMMUN, V143, P1536, DOI 10.1016/j.jaci.2018.10.046; Martinez FO, 2013, BLOOD, V121, pE57, DOI 10.1182/blood-2012-06-436212; Martinez FO, 2014, F1000PRIME REP, V6, P13, DOI DOI 10.12703/P6-13; Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008; Raggi F, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01097; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Tarique AA, 2015, AM J RESP CELL MOL, V53, P676, DOI 10.1165/rcmb.2015-0012OC; Xue J, 2014, IMMUNITY, V40, P274, DOI 10.1016/j.immuni.2014.01.006	10	21	22	7	22	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2019	143	4					1348	1350		10.1016/j.jaci.2018.12.995	http://dx.doi.org/10.1016/j.jaci.2018.12.995			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HR7QE	30639344	Bronze			2022-12-18	WOS:000463348900010
J	Gignoux, CR; Torgerson, DG; Pino-Yanes, M; Uricchio, LH; Galanter, J; Roth, LA; Eng, C; Hu, DL; Nguyen, EA; Huntsman, S; Mathias, RA; Kumar, R; Rodriguez-Santana, J; Thakur, N; Oh, SS; McGarry, M; Moreno-Estrada, A; Sandoval, K; Winkler, CA; Seibold, MA; Padhukasahasram, B; Conti, DV; Farber, HJ; Avila, P; Brigino-Buenaventura, E; Lenoir, M; Meade, K; Serebrisky, D; Borrell, LN; Rodriguez-Cintron, W; Thyne, S; Joubert, BR; Romieu, I; Levin, AM; Sienra-Monge, JJ; del Rio-Navarro, BE; Gan, WN; Raby, BA; Weiss, ST; Bleecker, E; Meyers, DA; Martinez, FJ; Gauderman, WJ; Gilliland, F; London, SJ; Bustamante, CD; Nicolae, DL; Ober, C; Sen, S; Barnes, K; Williams, LK; Hernandez, RD; Burchard, EG				Gignoux, Christopher R.; Torgerson, Dara G.; Pino-Yanes, Maria; Uricchio, Lawrence H.; Galanter, Joshua; Roth, Lindsey A.; Eng, Celeste; Hu, Donglei; Nguyen, Elizabeth A.; Huntsman, Scott; Mathias, Rasika A.; Kumar, Rajesh; Rodriguez-Santana, Jose; Thakur, Neeta; Oh, Sam S.; McGarry, Meghan; Moreno-Estrada, Andres; Sandoval, Karla; Winkler, Cheryl A.; Seibold, Max A.; Padhukasahasram, Badri; Conti, David V.; Farber, Harold J.; Avila, Pedro; Brigino-Buenaventura, Emerita; Lenoir, Michael; Meade, Kelley; Serebrisky, Denise; Borrell, Luisa N.; Rodriguez-Cintron, William; Thyne, Shannon; Joubert, Bonnie R.; Romieu, Isabelle; Levin, Albert M.; Sienra-Monge, Juan-Jose; Estela del Rio-Navarro, Blanca; Gan, Weiniu; Raby, Benjamin A.; Weiss, Scott T.; Bleecker, Eugene; Meyers, Deborah A.; Martinez, Fernando J.; Gauderman, W. James; Gilliland, Frank; London, Stephanie J.; Bustamante, Carlos D.; Nicolae, Dan L.; Ober, Carole; Sen, Saunak; Barnes, Kathleen; Williams, L. Keoki; Hernandez, Ryan D.; Burchard, Esteban G.			An admixture mapping meta-analysis implicates genetic variation at 18q21 with asthma susceptibility in Latinos	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; asthma exacerbations; admixture mapping; meta-analysis; Latinos; SMAD2; gene expression; targeted sequencing; rare variation	GENOME-WIDE ASSOCIATION; AFRICAN-AMERICAN; POPULATION-STRUCTURE; GALA II; RISK; EXPRESSION; ANCESTRY; VARIANT; LOCI; INDIVIDUALS	Background: Asthma is a common but complex disease with racial/ethnic differences in prevalence, morbidity, and response to therapies. Objective: We sought to perform an analysis of genetic ancestry to identify new loci that contribute to asthma susceptibility. Methods: We leveraged the mixed ancestry of 3902 Latinos and performed an admixture mapping meta-analysis for asthma susceptibility. We replicated associations in an independent study of 3774 Latinos, performed targeted sequencing for fine mapping, and tested for disease correlations with gene expression in the whole blood of more than 500 subjects from 3 racial/ethnic groups. Results: We identified a genome-wide significant admixture mapping peak at 18q21 in Latinos (P = 6.8 x 10(-6)), where Native American ancestry was associated with increased risk of asthma (odds ratio [OR], 1.20; 95% CI, 1.07-1.34; P = .002) and European ancestry was associated with protection (OR, 0.86; 95% CI, 0.77-0.96; P = .008). Our findings were replicated in an independent childhood asthma study in Latinos (P = 5.3 3 10(-3), combined P = 2.6 3 10(-7)). Fine mapping of 18q21 in 1978 Latinos identified a significant association with multiple variants 59 of SMAD family member 2 (SMAD2) in Mexicans, whereas a single rare variant in the same window was the top association in Puerto Ricans. Low versus high SMAD2 blood expression was correlated with case status (13.4% lower expression; OR, 3.93; 95% CI, 2.12-7.28; P <.001). In addition, lower expression of SMAD2 was associated with more frequent exacerbations among Puerto Ricans with asthma. Conclusion: Ancestry at 18q21 was significantly associated with asthma in Latinos and implicated multiple ancestry-informative noncoding variants upstream of SMAD2 with asthma susceptibility. Furthermore, decreased SMAD2 expression in blood was strongly associated with increased asthma risk and increased exacerbations.	[Gignoux, Christopher R.; Hernandez, Ryan D.; Burchard, Esteban G.] Univ Calif San Francisco, Program Pharmaceut Sci & Pharmacogen, San Francisco, CA 94143 USA; [Gignoux, Christopher R.; Uricchio, Lawrence H.; Galanter, Joshua; Hernandez, Ryan D.; Burchard, Esteban G.] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA; [Torgerson, Dara G.; Pino-Yanes, Maria; Roth, Lindsey A.; Eng, Celeste; Hu, Donglei; Nguyen, Elizabeth A.; Huntsman, Scott; Thakur, Neeta; Oh, Sam S.; Thyne, Shannon; Burchard, Esteban G.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA; [McGarry, Meghan] Univ Calif San Francisco, Dept Pediat, San Francisco, CA USA; [Pino-Yanes, Maria] Inst Salud Carlos III, CIBER Enfermedades Resp, Madrid, Spain; [Mathias, Rasika A.; Barnes, Kathleen] Johns Hopkins Univ, Dept Med, Baltimore, MD USA; [Kumar, Rajesh] Ann & Robert H Lurie Childrens Hosp Chicago, Chicago, IL 60611 USA; [Avila, Pedro] Northwestern Univ, Feinberg Sch Med, Div Allergy Immunol, Chicago, IL 60611 USA; [Rodriguez-Santana, Jose] Ctr Neumol Pediat, San Juan, PR USA; [Moreno-Estrada, Andres; Sandoval, Karla; Bustamante, Carlos D.] Stanford Univ, Dept Genet, Palo Alto, CA 94304 USA; [Winkler, Cheryl A.] Frederick Natl Lab Canc Res, Mol Genet Epidemiol Sect, Frederick, MD USA; [Seibold, Max A.] Natl Jewish Hlth, Integrated Ctr Genes Environm & Hlth, Dept Pediat, Div Pulm & Crit Care Med, Denver, CO USA; [Padhukasahasram, Badri; Levin, Albert M.; Williams, L. Keoki] Henry Ford Hlth Syst, Ctr Hlth Policy & Hlth Serv Res, Detroit, MI USA; [Conti, David V.; Gauderman, W. James; Gilliland, Frank] Univ Southern Calif, Dept Preventat Med, Los Angeles, CA USA; [Meade, Kelley] Childrens Hosp & Res Ctr Oakland, Oakland, CA USA; [Farber, Harold J.] Baylor Coll Med, Dept Pediat, Sect Pulmonol, Houston, TX 77030 USA; [Farber, Harold J.] Texas Childrens Hosp, Houston, TX 77030 USA; [Brigino-Buenaventura, Emerita] Kaiser Permanente Vallejo Med Ctr, Dept Allergy & Immunol, Vallejo, CA USA; [Lenoir, Michael] Bay Area Pediat, Oakland, CA USA; [Serebrisky, Denise] Jacobi Med Ctr, Pediat Pulm Div, Bronx, NY USA; [Borrell, Luisa N.] CUNY, Dept Hlth Sci, Grad Program Publ Hlth, Lehman Coll, Bronx, NY USA; [Rodriguez-Cintron, William] Vet Caribbean Hlth Care Syst, San Juan, PR USA; [Joubert, Bonnie R.; London, Stephanie J.] NIEHS, NIH, POB 12233, Res Triangle Pk, NC 27709 USA; [Romieu, Isabelle] Int Agcy Res Canc, Nutr Epidemiol Grp, Lyon, France; [Sienra-Monge, Juan-Jose; Estela del Rio-Navarro, Blanca] Clin Hosp Infantil Mexico Federico Gomez, Dept Alergia & Inmunol, Mexico City, DF, Mexico; [Gan, Weiniu] NHLBI, Div Lung Dis, Bldg 10, Bethesda, MD 20892 USA; [Raby, Benjamin A.; Weiss, Scott T.] Harvard Med Sch, Dept Med, Boston, MA 02115 USA; [Bleecker, Eugene; Meyers, Deborah A.] Wake Forest Univ, Ctr Genom & Personalized Med, Winston Salem, NC 27109 USA; [Martinez, Fernando J.] Univ Arizona, BIO5 Inst, Tucson, AZ USA; [Nicolae, Dan L.] Univ Chicago, Div Phys Sci, Dept Stat, Chicago, IL 60637 USA; [Ober, Carole] Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA; [Sen, Saunak] Univ Tennessee, Ctr Hlth Sci, Dept Prevent Med, Memphis, TN 38163 USA; [Williams, L. Keoki] Henry Ford Hlth Syst, Dept Internal Med, Detroit, MI USA; [Gignoux, Christopher R.] Stanford Univ, Dept Genet, Stanford Ctr Computat Evolutionary & Human Genom, Stanford, CA 94305 USA; [Uricchio, Lawrence H.] Stanford Univ, Dept Biol, Stanford Ctr Computat Evolutionary & Human Genom, Stanford, CA 94305 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; CIBER - Centro de Investigacion Biomedica en Red; CIBERES; Instituto de Salud Carlos III; Johns Hopkins University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Stanford University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Jewish Health; Henry Ford Health System; Henry Ford Hospital; University of Southern California; Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland; Baylor College of Medicine; Baylor College of Medicine; Kaiser Permanente; Jacobi Medical Center; City University of New York (CUNY) System; Lehman College (CUNY); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); World Health Organization; International Agency for Research on Cancer (IARC); Hospital Infantil de Mexico Federico Gomez; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Harvard University; Harvard Medical School; Wake Forest University; University of Arizona; University of Chicago; University of Chicago; University of Tennessee System; University of Tennessee Health Science Center; Henry Ford Health System; Henry Ford Hospital; Stanford University; Stanford University	Gignoux, CR (corresponding author), Univ Colorado Denver Anschutz Med Campus, Colorado Ctr Personalized Med, Aurora, CO 80045 USA.; Gignoux, CR (corresponding author), Univ Colorado Denver Anschutz Med Campus, Colorado Ctr Personalized Med, Dept Biostat, Aurora, CO 80045 USA.	chris.gignoux@ucdenver.edu	Pino-Yanes, Maria/C-8498-2017; London, Stephanie/C-3734-2019; Raby, Benjamin/AAK-3866-2021; Moreno-Estrada, Andres/AAP-4657-2021; Moreno-Estrada, Andres/R-3950-2017; Borrell, Luisa N./G-8753-2018	Pino-Yanes, Maria/0000-0003-0332-437X; London, Stephanie/0000-0003-4911-5290; Moreno-Estrada, Andres/0000-0001-8329-8292; Moreno-Estrada, Andres/0000-0001-8329-8292; Borrell, Luisa N./0000-0002-0560-4853; Ober, Carole/0000-0003-4626-9809; Galanter, Joshua/0000-0002-2561-6384; Joubert, Bonnie/0000-0001-7952-1180; Bustamante, Carlos D./0000-0002-4187-7920; McGarry, Meghan/0000-0002-8562-7018; Nicolae, Dan/0000-0002-0918-4630; Sandoval, Karla/0000-0002-6175-2463; Kumar, Rajesh/0000-0002-1962-7108	National Institutes of Health (NIH) [AI061774, AI077439, AI079139, CA113710, DK064695, ES015794, HL078885, HL079055, HL087699, HL088133, HL104608, M01-RR00188, MD006902]; ARRA grant [RC2 HL101651]; Flight Attendant Medical Research Institute (FAMRI); UCSF; NIH [T32GM007175, T32HG000044]; RWJF Amos Medical Faculty Development Award; Sandler Foundation; American Asthma Foundation; NHLBI K23 [K23HL111636]; NCATS KL2 [KL2TR000143]; Fundacion Ramon Areces; Mary Beryl Patch Turnbull Scholar Program; MOSAIC initiative of Johns Hopkins University; National Center for Advancing Translational Sciences, NIH, through UCSF-CTSI grant [KL2TR000143]; National Cancer Institute, National Institutes of Health [HHSN26120080001E]; Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research; NATIONAL CANCER INSTITUTE [T32CA113710, ZIABC010022] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL111636, R01HL104608, R01HL118267] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [T32HG000044] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI077439] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK113003] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES049019] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007175, T32GM067547] Funding Source: NIH RePORTER; National Institute on Minority Health and Health Disparities [P60MD006902] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ARRA grant; Flight Attendant Medical Research Institute (FAMRI); UCSF; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); RWJF Amos Medical Faculty Development Award; Sandler Foundation; American Asthma Foundation; NHLBI K23(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCATS KL2; Fundacion Ramon Areces; Mary Beryl Patch Turnbull Scholar Program; MOSAIC initiative of Johns Hopkins University; National Center for Advancing Translational Sciences, NIH, through UCSF-CTSI grant; National Cancer Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))	Supported in part by the National Institutes of Health (NIH; AI061774, AI077439, AI079139, CA113710, DK064695, ES015794, HL078885, HL079055, HL087699, HL088133, HL104608, M01-RR00188, and MD006902); ARRA grant RC2 HL101651; the Flight Attendant Medical Research Institute (FAMRI); UCSF Chancellor's Research Fellowship, Dissertation Year Fellowship, and in part by NIH Training Grant T32GM007175 and T32HG000044 (to C.R.G.); an RWJF Amos Medical Faculty Development Award (to E.G.B.); the Sandler Foundation; the American Asthma Foundation (to E.G.B. and L.K.W.); and NHLBI K23 (K23HL111636) and NCATS KL2 (KL2TR000143; to J.M.G.). M.P.-Y. was funded by a Postdoctoral Fellowship from Fundacion Ramon Areces. K.B. was supported in part by the Mary Beryl Patch Turnbull Scholar Program. R.A.M. was supported in part by the MOSAIC initiative of Johns Hopkins University. This publication was supported by the National Center for Advancing Translational Sciences, NIH, through UCSF-CTSI grant no. KL2TR000143. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. This project has been funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under contract HHSN26120080001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government. This research was supported in part by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research.	[Anonymous], 2013, CATALOG PUBLISHED GE; Ardlie KG, 2015, SCIENCE, V348, P648, DOI 10.1126/science.1262110; Baran Y, 2012, BIOINFORMATICS, V28, P1359, DOI 10.1093/bioinformatics/bts144; Brisbin A, 2012, HUM BIOL, V84, P343, DOI 10.3378/027.084.0401; Bryc K, 2010, P NATL ACAD SCI USA, V107, P8954, DOI 10.1073/pnas.0914618107; Bryc K, 2010, P NATL ACAD SCI USA, V107, P786, DOI 10.1073/pnas.0909559107; Burchard EG, 2004, AM J RESP CRIT CARE, V169, P386, DOI 10.1164/rccm.200309-1293OC; Bustamante CD, 2011, NATURE, V475, P163, DOI 10.1038/475163a; Cheng CY, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000490; Choudhry S, 2006, HUM GENET, V118, P652, DOI 10.1007/s00439-005-0071-3; Choudhry S, 2008, HUM GENET, V123, P455, DOI 10.1007/s00439-008-0495-7; Cohen JC, 2006, NEW ENGL J MED, V354, P1264, DOI 10.1056/NEJMoa054013; Drake KA, 2014, J ALLERGY CLIN IMMUN, V133, P370, DOI 10.1016/j.jaci.2013.06.043; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Freedman ML, 2006, P NATL ACAD SCI USA, V103, P14068, DOI 10.1073/pnas.0605832103; Galanter JM, 2014, J ALLERGY CLIN IMMUN, V134, P295, DOI 10.1016/j.jaci.2013.08.055; Galanter JM, 2011, J ALLERGY CLIN IMMUN, V128, P37, DOI 10.1016/j.jaci.2011.03.050; Gravel S, 2011, P NATL ACAD SCI USA, V108, P11983, DOI 10.1073/pnas.1019276108; Han B, 2011, AM J HUM GENET, V88, P586, DOI 10.1016/j.ajhg.2011.04.014; Hansen G, 2000, J CLIN INVEST, V105, P61, DOI 10.1172/JCI7589; Hoffmann TJ, 2011, GENOMICS, V98, P422, DOI 10.1016/j.ygeno.2011.08.007; Hough C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042513; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Lee S, 2012, BIOSTATISTICS, V13, P762, DOI 10.1093/biostatistics/kxs014; Lee S, 2012, AM J HUM GENET, V91, P224, DOI 10.1016/j.ajhg.2012.06.007; Mobini R, 2009, BMC SYST BIOL, V3, DOI 10.1186/1752-0509-3-19; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Moreno-Estrada A, 2014, SCIENCE, V344, P1280, DOI 10.1126/science.1251688; Myers RA, 2012, J ALLERGY CLIN IMMUN, V130, P1294, DOI 10.1016/j.jaci.2012.07.054; Need AC, 2009, TRENDS GENET, V25, P489, DOI 10.1016/j.tig.2009.09.012; Nishimura KK, 2013, AM J RESP CRIT CARE, V188, P309, DOI 10.1164/rccm.201302-0264OC; Ober C, 2006, GENES IMMUN, V7, P95, DOI 10.1038/sj.gene.6364284; Palmer C, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-115; Pasaniuc B, 2009, BIOINFORMATICS, V25, pI213, DOI 10.1093/bioinformatics/btp197; Pino-Yanes M, 2015, J ALLERGY CLIN IMMUN, V135, P1502, DOI 10.1016/j.jaci.2014.10.033; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; R_Core_Team, 2012, R LANG ENV STAT COMP; R Development Core Team, 2018, R LANG ENV STAT COMP; Sagara H, 2002, J ALLERGY CLIN IMMUN, V110, P249, DOI 10.1067/mai.2002.126078; Schwartz AG, 2011, CARCINOGENESIS, V32, P312, DOI 10.1093/carcin/bgq252; SPIELMAN RS, 1993, AM J HUM GENET, V52, P506; Van der Auwera Geraldine A, 2013, Curr Protoc Bioinformatics, V43, DOI [10.1002/0471250953.bi1201s43, 10.1002/0471250953.bi1110s43]; Thakur N, 2013, AM J RESP CRIT CARE, V188, P1202, DOI 10.1164/rccm.201306-1016OC; Torgerson DG, 2012, J ALLERGY CLIN IMMUN, V130, P622, DOI 10.1016/j.jaci.2012.03.045; Torgerson DG, 2012, J ALLERGY CLIN IMMUN, V130, P76, DOI 10.1016/j.jaci.2012.02.040; Torgerson DG, 2011, NAT GENET, V43, P887, DOI 10.1038/ng.888; Willemsen G, 2008, TWIN RES HUM GENET, V11, P132, DOI 10.1375/twin.11.2.132; Wu H, 2010, J ALLERGY CLIN IMMUN, V125, P321, DOI 10.1016/j.jaci.2009.09.007	50	21	21	1	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2019	143	3					957	969		10.1016/j.jaci.2016.08.057	http://dx.doi.org/10.1016/j.jaci.2016.08.057			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HN6CQ	30201514	Green Accepted, Bronze			2022-12-18	WOS:000460272900016
J	Tirosh, I; Yamazaki, Y; Frugoni, F; Ververs, FA; Allenspach, EJ; Zhang, Y; Burns, S; Al-Herz, W; Noroski, L; Walter, JE; Gennery, AR; van der Burg, M; Notarangelo, LD; Lee, YN				Tirosh, Irit; Yamazaki, Yasuhiro; Frugoni, Francesco; Ververs, Francesca A.; Allenspach, Eric J.; Zhang, Yu; Burns, Siobhan; Al-Herz, Waleed; Noroski, Lenora; Walter, Jolan E.; Gennery, Andrew R.; van der Burg, Mirjam; Notarangelo, Luigi D.; Lee, Yu Nee			Recombination activity of human recombination-activating gene 2 (RAG2) mutations and correlation with clinical phenotype	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Recombination-activating gene 2; VDJ recombination; severe combined immunodeficiency; Omenn syndrome; autoimmunity; genotype-phenotype correlation	SEVERE COMBINED IMMUNODEFICIENCY; OMENN-SYNDROME; V(D)J RECOMBINATION; IMMUNE-DEFICIENCY; SPECTRUM; DEFECTS; DISEASE; RAG1/2	Background: Mutations in recombination-activating gene (RAG) 1 and RAG2 are associated with a broad range of clinical and immunologic phenotypes in human subjects. Objective: Using a flow cytometry-based assay, we aimed to measure the recombinase activity of naturally occurring RAG2 mutant proteins and to correlate our results with the severity of the clinical and immunologic phenotype. Methods: Abelson virus-transformed Rag2(-/-) pro-B cells engineered to contain an inverted green fluorescent protein (GFP) cassette flanked by recombination signal sequences were transduced with retroviruses encoding either wild-type or 41 naturally occurring RAG2 variants. Bicistronic vectors were used to introduce compound heterozygous RAG2 variants. The percentage of GFP-expressing cells was evaluated by using flow cytometry, and high-throughput sequencing was used to analyze rearrangements at the endogenous immunoglobulin heavy chain (Igh) locus. Results: The RAG2 variants showed a wide range of recombination activity. Mutations associated with severe combined immunodeficiency and Omenn syndrome had significantly lower activity than those detected in patients with less severe clinical presentations. Four variants (P253R, F386L, N474S, and M502V) previously thought to be pathogenic were found to have wild-type levels of activity. Use of bicistronic vectors permitted us to assess more carefully the effect of compound heterozygous mutations, with good correlation between GFP expression and the number and diversity of Igh rearrangements. Conclusions: Our data support genotype-phenotype correlation in the setting of RAG2 deficiency. The assay described can be used to define the possible disease-causing role of novel RAG2 variants and might help predict the severity of the clinical phenotype.	[Tirosh, Irit; Frugoni, Francesco; Ververs, Francesca A.] Harvard Med Sch, Boston Childrens Hosp, Div Immunol, Boston, MA USA; [Yamazaki, Yasuhiro; Zhang, Yu; Notarangelo, Luigi D.] NIAID, Lab Clin Immunol & Microbiol, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Allenspach, Eric J.] Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA; [Allenspach, Eric J.] Seattle Childrens Res Inst, Ctr Immun & Immunotherapies, Seattle, WA USA; [Burns, Siobhan] UCL, Inst Immun & Transplantat, London, England; [Burns, Siobhan] Royal Free London NHS Fdn Trust, Dept Immunol, London, England; [Al-Herz, Waleed] Kuwait Univ, Fac Med, Dept Pediat, Safat, Kuwait; [Noroski, Lenora] Texas Childrens Hosp, Baylor Coll Med, Div Allergy & Immunol, Houston, TX 77030 USA; [Walter, Jolan E.] Univ S Florida, Div Pediat Allergy Immunol, St Petersburg, FL 33701 USA; [Walter, Jolan E.] Johns Hopkins All Childrens Hosp, St Petersburg, FL USA; [Gennery, Andrew R.] Newcastle Upon Tyne Hosp, NHS Fdn Trust, Dept Pediat Immunol, Newcastle Upon Tyne, Tyne & Wear, England; [Gennery, Andrew R.] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne, Tyne & Wear, England; [van der Burg, Mirjam] Univ Med Ctr Rotterdam, Erasmus MC, Dept Immunol, Rotterdam, Netherlands; [Lee, Yu Nee] Tel Aviv Univ, Tel Hashomer Ramat Gan & Sackler Fac Med, Sheba Med Ctr,Pediat Dept A, Edmond & Lily Safra Childrens Hosp,Jeffrey Modell, Tel Aviv, Israel; [Lee, Yu Nee] Tel Aviv Univ, Tel Hashomer Ramat Gan & Sackler Fac Med, Sheba Med Ctr,Immunol Serv, Edmond & Lily Safra Childrens Hosp,Jeffrey Modell, Tel Aviv, Israel; [Tirosh, Irit] Edmond & Lily Safra Childrens Hosp, Sheba Med Ctr, Pediat Dept B, Ramat Gan, Israel	Harvard University; Boston Children's Hospital; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Washington; University of Washington Seattle; Seattle Children's Hospital; University of London; University College London; University of London; University College London; Royal Free London NHS Foundation Trust; Kuwait University; Baylor College of Medicine; State University System of Florida; University of South Florida; Johns Hopkins University; Johns Hopkins Medicine; Newcastle University - UK; Newcastle Upon Tyne Hospitals NHS Foundation Trust; Newcastle University - UK; Erasmus University Rotterdam; Erasmus MC; Chaim Sheba Medical Center; Tel Aviv University; Chaim Sheba Medical Center; Tel Aviv University; Chaim Sheba Medical Center	Notarangelo, LD (corresponding author), NIAID, Lab Clin Immunol & Microbiol, DIR, NIH,DHHS, Bldg 10 CRC,Room 5W-3940,10 Ctr Dr, Bethesda, MD 20892 USA.; Lee, YN (corresponding author), Tel Aviv Univ, Sheba Med Ctr, Inst Pediat Res, Pediat Immunol, Lab Bldg,2nd Floor,Rm 266,Emeck HaEla 1, IL-5265601 Ramat Gan, Israel.	luigi.notarangelo2@nih.gov; yuneeya4u@gmail.com		Burns, Siobhan/0000-0002-3356-9506	National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH) [2R01AI100887]; Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health; JSPS Research Fellowship for Japanese Biomedical and Behavioral Research at NIH; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001222, R01AI100887] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); JSPS Research Fellowship for Japanese Biomedical and Behavioral Research at NIH; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH; grant 2R01AI100887 to L.D.N.); the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health; and the JSPS Research Fellowship for Japanese Biomedical and Behavioral Research at NIH (to Y.Y.). The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services nor does the mention of trade names, commercial products, or organizations imply endorsement by the US Government.	Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; Alamyar Eltaf, 2012, Methods Mol Biol, V882, P569, DOI 10.1007/978-1-61779-842-9_32; Alsmadi O, 2009, BMC MED GENET, V10, DOI 10.1186/1471-2350-10-116; Asai E, 2011, CLIN IMMUNOL, V138, P172, DOI 10.1016/j.clim.2010.11.005; Chou J, 2012, J ALLERGY CLIN IMMUN, V130, P1414, DOI 10.1016/j.jaci.2012.06.012; Corneo B, 2000, J BIOL CHEM, V275, P12672, DOI 10.1074/jbc.275.17.12672; Corneo B, 2001, BLOOD, V97, P2772, DOI 10.1182/blood.V97.9.2772; Couedel C, 2010, J CLIN INVEST, V120, P1337, DOI 10.1172/JCI41305; Dalal I, 2011, CLIN IMMUNOL, V140, P284, DOI 10.1016/j.clim.2011.04.011; de Villartay JP, 2005, J CLIN INVEST, V115, P3291, DOI 10.1172/JCI25178; Dutmer CM, 2015, J CLIN IMMUNOL, V35, P754, DOI 10.1007/s10875-015-0207-8; Ehl S, 2005, J CLIN INVEST, V115, P3140, DOI 10.1172/JCI25221; Elkin SK, 2005, J BIOL CHEM, V280, P28701, DOI 10.1074/jbc.M504731200; Goda V, 2018, J ALLER CL IMM-PRACT, V6, P1769, DOI 10.1016/j.jaip.2018.01.015; Gomez CA, 2000, MOL CELL BIOL, V20, P5653, DOI 10.1128/MCB.20.15.5653-5664.2000; Heimall J, 2017, BLOOD, V130, P2718, DOI 10.1182/blood-2017-05-781849; Kircher M, 2014, NAT GENET, V46, P310, DOI 10.1038/ng.2892; Ktiouet S, 2009, J EUR ACAD DERMATOL, V23, P1449, DOI 10.1111/j.1468-3083.2009.03232.x; Kwan A, 2014, JAMA-J AM MED ASSOC, V312, P729, DOI 10.1001/jama.2014.9132; Lawless D, 2018, J ALLERGY CLIN IMMUN, V141, P2303, DOI 10.1016/j.jaci.2018.02.007; Lee YN, 2014, J ALLERGY CLIN IMMUN, V133, P1099, DOI 10.1016/j.jaci.2013.10.007; Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057; Lev A, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/261470; Meshaal S, 2015, CLIN IMMUNOL, V158, P167, DOI 10.1016/j.clim.2015.04.003; Noordzij JG, 2002, BLOOD, V100, P2145; Notarangelo LD, 2016, NAT REV IMMUNOL, V16, P234, DOI 10.1038/nri.2016.28; Poliani PL, 2009, BLOOD, V114, P105, DOI 10.1182/blood-2009-03-211029; Rechavi E, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa0072; Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30; Rigoni R, 2016, J EXP MED, V213, P355, DOI 10.1084/jem.20151116; Robins HS, 2009, BLOOD, V114, P4099, DOI 10.1182/blood-2009-04-217604; Safaeil S, 2011, IRAN J ALLERGY ASTHM, V10, P129, DOI 010.02/ijaai.129132; Schuetz C, 2008, NEW ENGL J MED, V358, P2030, DOI 10.1056/NEJMoa073966; Schwarz K, 1996, SCIENCE, V274, P97, DOI 10.1126/science.274.5284.97; Shearer WT, 2014, J ALLERGY CLIN IMMUN, V133, P1092, DOI 10.1016/j.jaci.2013.09.044; Sobacchi C, 2006, HUM MUTAT, V27, P1174, DOI 10.1002/humu.20408; Tabori U, 2004, CLIN GENET, V65, P322, DOI 10.1111/j.1399-0004.2004.00227.x; Villa A, 2002, ISRAEL MED ASSOC J, V4, P218; Villa A, 2001, BLOOD, V97, P81, DOI 10.1182/blood.V97.1.81; Walter JE, 2015, J CLIN INVEST, V125, P4135, DOI 10.1172/JCI80477; Walter JE, 2015, J ALLERGY CLIN IMMUN, V135, P272, DOI 10.1016/j.jaci.2014.07.063	41	21	21	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2019	143	2					726	735		10.1016/j.jaci.2018.04.027	http://dx.doi.org/10.1016/j.jaci.2018.04.027			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HK2DJ	29772310	Green Accepted, Bronze			2022-12-18	WOS:000457718700031
J	McGovern, AE; Short, KR; Moe, AAK; Mazzone, SB				McGovern, Alice E.; Short, Kirsty R.; Moe, Aung Aung Kywe; Mazzone, Stuart B.			Translational review: Neuroimmune mechanisms in cough and emerging therapeutic targets	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Cough hypersensitivity syndrome; sensitization; vagal; sensory; inflammation	URGE-TO-COUGH; CENTRAL SENSITIZATION; SENSORY NEURONS; NOCICEPTOR NEURONS; VIRAL-INFECTIONS; NEURAL CREST; BRAIN-STEM; RECEPTOR; PAIN; INFLAMMATION	Cough is an essential defensive behavior for maintaining airway patency and to protect the lungs from potentially harmful agents. However, inflammatory pathologies can sensitize and activate the neural pathways regulating cough, leading to excessive and nonproductive coughing that serves little protective utility. Problematic cough continues to be one of the most common reasons for seeking medical advice, yet for many patients, it can be refractory to disease-specific treatments and currently available antitussive therapies. The effect of inflammation on cough neural processing occurs not only at the level of the bronchopulmonary sensory nerve terminals but also within the nervous system at multiple peripheral and central sites. Sensory nerves also actively regulate inflammation, and it is therefore a complex interplay between the immune and nervous systems that contributes to chronic cough and the associated sensory hypersensitivities. In this review we provide a brief overview of cough neurobiology in health and disease and then explore the peripheral and central nervous system sites at which neuroimmune interactions can occur. We present advancements in the development of effective antitussive therapies and suggest novel targets for future consideration.	[McGovern, Alice E.; Moe, Aung Aung Kywe; Mazzone, Stuart B.] Univ Melbourne, Dept Anat & Neurosci, Med Bldg 181,Parkville Campus, Melbourne, Vic 3010, Australia; [Short, Kirsty R.] Univ Queensland, Sch Chem & Mol Biosci, Brisbane, Qld, Australia; [Short, Kirsty R.] Univ Queensland, Australian Infect Dis Res Ctr, Brisbane, Qld, Australia	University of Melbourne; University of Queensland; University of Queensland	Mazzone, SB (corresponding author), Univ Melbourne, Dept Anat & Neurosci, Med Bldg 181,Parkville Campus, Melbourne, Vic 3010, Australia.	stuart.mazzone@unimelb.edu.au	Moe, Aung Aung Kywe ./O-7248-2015; Moe, Aung Aung Kywe/AAX-9746-2021	Moe, Aung Aung Kywe ./0000-0002-9629-7923; Mazzone, Stuart/0000-0001-5270-1333; Short, Kirsty/0000-0003-4963-6184; McGovern, Alice/0000-0003-3906-8611	National Health and Medical Research Council of Australia [GNT1078943, GNT1121376]; Australian Research Council DECRA Fellowship [DE180100512]	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Australian Research Council DECRA Fellowship(Australian Research Council)	S.B.M. and A.E.M. are funded by the National Health and Medical Research Council of Australia (project grant GNT1078943 and Fellowship award GNT1121376). K.R.S. holds an Australian Research Council DECRA Fellowship (DE180100512).	Abdulqawi R, 2015, LANCET, V385, P1198, DOI 10.1016/S0140-6736(14)61255-1; Allette YM, 2014, BRAIN BEHAV IMMUN, V42, P169, DOI 10.1016/j.bbi.2014.06.199; Ando A, 2016, THORAX, V71, P323, DOI 10.1136/thoraxjnl-2015-207425; Ando A, 2014, NEUROSCI BIOBEHAV R, V47, P457, DOI 10.1016/j.neubiorev.2014.09.018; Audrit KJ, 2017, CELL TISSUE RES, V367, P571, DOI 10.1007/s00441-016-2559-7; Baral P, 2018, NAT MED, V24, P417, DOI 10.1038/nm.4501; Belvisi MG, 2017, AM J RESP CRIT CARE, V196, P1255, DOI 10.1164/rccm.201704-0769OC; Benfante A, 2018, LANCET RESP MED, V6, pE37, DOI 10.1016/S2213-2600(18)30190-5; Birdsong WT, 2010, NEURON, V68, P739, DOI 10.1016/j.neuron.2010.09.029; Birrell MA, 2014, J ALLERGY CLIN IMMUN, V133, P679, DOI 10.1016/j.jaci.2013.12.003; Bonvini SJ, 2016, J ALLERGY CLIN IMMUN, V138, P249, DOI 10.1016/j.jaci.2015.10.044; Borghi SM, 2018, CURR MED CHEM; Brian M.J.M., 2015, RAT NERVOUS SYSTEM, P315; Canning BJ, 2009, PULM PHARMACOL THER, V22, P75, DOI 10.1016/j.pupt.2009.01.003; Carr M J, 2001, Curr Opin Pulm Med, V7, P1, DOI 10.1097/00063198-200101000-00001; Chamberlain SAF, 2015, LUNG, V193, P401, DOI 10.1007/s00408-015-9701-2; Chang AB, 2007, EUR RESPIR J, V30, P66, DOI 10.1183/09031936.00150006; Chen CY, 2001, J ALLERGY CLIN IMMUN, V108, P557; Chounlamountry K, 2015, J NEUROCHEM, V134, P857, DOI 10.1111/jnc.13193; Chung KF, 2008, LANCET, V371, P1364, DOI 10.1016/S0140-6736(08)60595-4; Chung KF, 2014, J THORAC DIS, V6, pS699, DOI 10.3978/j.issn.2072-1439.2014.08.41; Chung KF, 2013, LANCET RESP MED, V1, P414, DOI 10.1016/S2213-2600(13)70043-2; Clarke R, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.00995-2017; Dakhama A, 2005, AM J PHYSIOL-LUNG C, V288, pL761, DOI 10.1152/ajplung.00143.2004; Davenport P. W., 2009, V187, P263, DOI 10.1007/978-3-540-79842-2_13; Deng Z, 2018, AM J RESP CRIT CARE, V198, P868, DOI 10.1164/rccm.201709-1813OC; Dicpinigaitis P, 2017, EUR RESP J, V50; Dicpinigaitis PV, 2017, PULM PHARMACOL THER, V47, P45, DOI 10.1016/j.pupt.2017.01.013; Driessen AK, 2017, PULM PHARMACOL THER, V47, P9, DOI 10.1016/j.pupt.2017.01.010; Le DD, 2016, NEUROIMMUNOMODULAT, V23, P18, DOI 10.1159/000440622; Edwards MR, 2017, J ALLERGY CLIN IMMUN, V140, P909, DOI 10.1016/j.jaci.2017.07.025; Foster SL, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01463; Ganong WF, 2000, CLIN EXP PHARMACOL P, V27, P422, DOI 10.1046/j.1440-1681.2000.03259.x; Gibson PG, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h5590; Gibson PG, 2014, CURR OPIN ALLERGY CL, V14, P55, DOI 10.1097/ACI.0000000000000027; Grabowski M, 2013, THORAX, V68, P125, DOI 10.1136/thoraxjnl-2012-201895; Hale MW, 2012, CHEM IMMUNOL ALLERGY, V98, P118, DOI 10.1159/000336505; Haque RA, 2005, CHEST, V127, P1710, DOI 10.1378/chest.127.5.1710; Hazari MS, 2007, AM J PHYSIOL-LUNG C, V292, pL992, DOI 10.1152/ajplung.00216.2006; Heck S, 2017, NEUROIMMUNOMODULAT, V24, P331, DOI 10.1159/000487140; Hilton E, 2015, RESP MED, V109, P701, DOI 10.1016/j.rmed.2015.03.011; Hunter DD, 2000, AM J RESP CRIT CARE, V161, P1985, DOI 10.1164/ajrccm.161.6.9908051; Irwin RS, 1998, CHEST, V114, p133S, DOI 10.1378/chest.114.2_Supplement.133S; Jartti T, 2017, J ALLERGY CLIN IMMUN, V140, P895, DOI 10.1016/j.jaci.2017.08.003; Ji RR, 2016, SCIENCE, V354, P572, DOI 10.1126/science.aaf8924; Ji RR, 2015, PULM PHARMACOL THER, V35, P81, DOI 10.1016/j.pupt.2015.09.001; Kawasaki Y, 2008, J NEUROSCI, V28, P5189, DOI 10.1523/JNEUROSCI.3338-07.2008; Keller JA, 2017, CHEST, V152, P833, DOI 10.1016/j.chest.2017.05.016; Kollarik M, 2018, J PHYSIOL-LONDON, V596, P1419, DOI 10.1113/JP275698; Komegae EN, 2018, BRAIN BEHAV IMMUN, V73, P441, DOI 10.1016/j.bbi.2018.06.005; Kwong K, 2008, AM J PHYSIOL-LUNG C, V295, pL858, DOI 10.1152/ajplung.90360.2008; Le DD, 2014, RESP RES, V15, DOI 10.1186/1465-9921-15-73; Lieu TM, 2012, AM J PHYSIOL-LUNG C, V302, pL941, DOI 10.1152/ajplung.00366.2011; Lim KG, 2011, ANN ALLERG ASTHMA IM, V107, P360, DOI 10.1016/j.anai.2011.07.010; Lin RL, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00411; Liu BY, 2016, P NATL ACAD SCI USA, V113, pE7572, DOI 10.1073/pnas.1606608113; Liu YR, 2009, J VIROL, V83, P6837, DOI 10.1128/JVI.00379-09; Maher SA, 2015, EUR RESPIR J, V45, P1108, DOI 10.1183/09031936.00061614; Martelli D, 2014, AUTON NEUROSCI-BASIC, V182, P65, DOI 10.1016/j.autneu.2013.12.007; Martelli D, 2014, J PHYSIOL-LONDON, V592, P1677, DOI 10.1113/jphysiol.2013.268573; Mazzone SB, 2007, AM J RESP CRIT CARE, V176, P327, DOI 10.1164/rccm.200612-1856OC; Mazzone Stuart B, 2004, Treat Respir Med, V3, P201, DOI 10.2165/00151829-200403040-00001; Mazzone SB, 2018, LANCET RESP MED, V6, P636, DOI 10.1016/S2213-2600(18)30150-4; Mazzone SB, 2016, PHYSIOL REV, V96, P975, DOI 10.1152/physrev.00039.2015; Mazzone SB, 2011, J NEUROSCI, V31, P2948, DOI 10.1523/JNEUROSCI.4597-10.2011; McGovern AE, 2014, AUTON NEUROSCI-BASIC, V182, P95, DOI 10.1016/j.autneu.2013.12.008; Morice AH, 2017, EUR RESPIR J, P50; Morice AH, 2014, EUR RESPIR J, V44, P1149, DOI 10.1183/09031936.00217813; Mutolo D, 2017, RESP PHYSIOL NEUROBI, V243, P60, DOI 10.1016/j.resp.2017.05.008; Nassenstein C, 2010, J PHYSIOL-LONDON, V588, P4769, DOI 10.1113/jphysiol.2010.195339; O'Neill J, 2013, PULM PHARMACOL THER, V26, P476, DOI 10.1016/j.pupt.2013.06.010; Park CK, 2014, NEURON, V82, P47, DOI 10.1016/j.neuron.2014.02.011; Rees CJ, 2009, ANN OTO RHINOL LARYN, V118, P247, DOI 10.1177/000348940911800402; Riteau N, 2010, AM J RESP CRIT CARE, V182, P774, DOI 10.1164/rccm.201003-0359OC; Ryan NM, 2018, EXPERT OPIN PHARMACO, V19, P687, DOI 10.1080/14656566.2018.1462795; Sekizawa SI, 2008, EUR J NEUROSCI, V28, P771, DOI 10.1111/j.1460-9568.2008.06378.x; Sekizawa S, 2011, BRIT J PHARMACOL, V163, P782, DOI 10.1111/j.1476-5381.2011.01271.x; Simonyan K, 2012, FRONT INTEGR NEUROSC, V6, DOI 10.3389/fnint.2012.00097; Skaper SD, 2017, IMMUNOLOGY, V151, P1, DOI 10.1111/imm.12717; Smith JA, 2016, THORAX, V71, pA17, DOI 10.1136/thoraxjnl-2016-209333.33; Smith J, 2017, EUR RESPIR J, V50, DOI 10.1183/1393003.congress-2017.OA2932; Smith JA, 2017, INT J CLIN PHARM TH, V55, P712, DOI 10.5414/CP202804; Spaziano G, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/980983; Stephan G, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03728-5; Sun H, 2017, PULM PHARMACOL THER, V47, P38, DOI 10.1016/j.pupt.2017.05.010; Talbot S, 2015, NEURON, V87, P341, DOI 10.1016/j.neuron.2015.06.007; Tonelli Leonardo H, 2010, Front Biosci (Schol Ed), V2, P135; Trankner D, 2014, P NATL ACAD SCI USA, V111, P11515, DOI 10.1073/pnas.1411032111; Troche MS, 2014, CHEST, V146, P1294, DOI 10.1378/chest.14-0066; Undem BJ, 2014, J ALLERGY CLIN IMMUN, V133, P1521, DOI 10.1016/j.jaci.2013.11.027; Vertigan AE, 2013, RESPIROLOGY, V18, P948, DOI 10.1111/resp.12103; Wang JY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185985; Wang QS, 2008, NEUROCHEM RES, V33, P1776, DOI 10.1007/s11064-008-9628-6; Widdicombe J, 2011, PULM PHARMACOL THER, V24, P344, DOI 10.1016/j.pupt.2010.12.010; Wilson SR, 2013, CELL, V155, P285, DOI 10.1016/j.cell.2013.08.057; Xanthos DN, 2014, NAT REV NEUROSCI, V15, P43, DOI 10.1038/nrn3617; Xu ZZ, 2015, NAT MED, V21, P1326, DOI 10.1038/nm.3978; Zaccone EJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155526; Zambreanu L, 2005, PAIN, V114, P397, DOI 10.1016/j.pain.2005.01.005; Zech A, 2016, ONCOTARGET, V7, P80288, DOI 10.18632/oncotarget.13375	100	21	25	8	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2018	142	5					1392	1402		10.1016/j.jaci.2018.09.004	http://dx.doi.org/10.1016/j.jaci.2018.09.004			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GZ5BL	30409248	Bronze			2022-12-18	WOS:000449429800002
J	Siddiqui, S; Shikotra, A; Richardson, M; Doran, E; Choy, D; Bell, A; Austin, CD; Eastham-Anderson, J; Hargadon, B; Arron, JR; Wardlaw, A; Brightling, CE; Heaney, LG; Bradding, P				Siddiqui, Salman; Shikotra, Aarti; Richardson, Matthew; Doran, Emma; Choy, David; Bell, Alex; Austin, Cary D.; Eastham-Anderson, Jeffrey; Hargadon, Beverley; Arron, Joseph R.; Wardlaw, Andrew; Brightling, Christopher E.; Heaney, Liam G.; Bradding, Peter			Airway pathological heterogeneity in asthma: Visualization of disease microclusters using topological data analysis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Severe asthma; remodeling; airway inflammation; topological data analysis; phenotyping	SMOOTH-MUSCLE; INFLAMMATION; EXPRESSION; RECEPTOR; PERSISTENCE; CANCER; SPUTUM; CELLS; SET	Background: Asthma is a complex chronic disease underpinned by pathological changes within the airway wall. How variations in structural airway pathology and cellular inflammation contribute to the expression and severity of asthma are poorly understood. Objectives: Therefore we evaluated pathological heterogeneity using topological data analysis (TDA) with the aim of visualizing disease clusters and microclusters. Methods: A discovery population of 202 adult patients (142 asthmatic patients and 60 healthy subjects) and an external replication population (59 patients with severe asthma) were evaluated. Pathology and gene expression were examined in bronchial biopsy samples. TDA was applied by using pathological variables alone to create pathology-driven visual networks. Results: In the discovery cohort TDA identified 4 groups/networks with multiple microclusters/regions of interest that were masked by group-level statistics. Specifically, TDA group 1 consisted of a high proportion of healthy subjects, with a microcluster representing a topological continuum connecting healthy subjects to patients with mild-to-moderate asthma. Three additional TDA groups with moderate-to-severe asthma (Airway Smooth Muscle(High), Reticular Basement Membrane(High), and Remodeling(Low) groups) were identified and contained numerous microclusters with varying pathological and clinical features. Mutually exclusive T(H)2 and T(H)17 tissue gene expression signatures were identified in all pathological groups. Discovery and external replication applied to the severe asthma subgroup identified only highly similar "pathological data shapes'' through analyses of persistent homology. Conclusions: We have identified and replicated novel pathological phenotypes of asthma using TDA. Our methodology is applicable to other complex chronic diseases.	[Siddiqui, Salman; Shikotra, Aarti; Richardson, Matthew; Bell, Alex; Hargadon, Beverley; Wardlaw, Andrew; Brightling, Christopher E.; Bradding, Peter] Univ Leicester, Glenfield Hosp, Inst Lung Hlth, Dept Infect Immun & Inflammat, Leicester, Leics, England; [Doran, Emma; Choy, David; Austin, Cary D.; Eastham-Anderson, Jeffrey; Arron, Joseph R.] Genentech Inc, San Francisco, CA 94080 USA; [Heaney, Liam G.] Queens Univ Belfast, Ctr Infect & Immun, Hlth Sci Bldg, Belfast, Antrim, North Ireland; [Bell, Alex] Univ Leicester, Dept Math, Leicester, Leics, England	University Hospitals of Leicester NHS Trust; University of Leicester; Glenfield Hospital; Roche Holding; Genentech; Queens University Belfast; University of Leicester	Siddiqui, S (corresponding author), Univ Hosp Leicester, Inst Lung Hlth, Resp Biomed Res Unit, Leicester LE3 9QP, Leics, England.	ss338@le.ae.uk		Siddiqui, Salman/0000-0003-3770-7870; Arron, Joseph/0000-0001-7677-9979; brightling, chris/0000-0002-9345-4903; Wardlaw, Andrew/0000-0001-6583-0791; Bradding, Peter/0000-0001-8403-0319	National Institute for Health Research (NIHR) Leicester Respiratory Biomedical Research Unit; Asthma UK [AUK-PG-2013-208]; Jules Thorne Trust Clinical Senior Lecturer Award; Genentech; GlaxoSmithKline [RES100767, RES100769]; Wellcome Trust; MRC; MRC [MR/M016579/1] Funding Source: UKRI	National Institute for Health Research (NIHR) Leicester Respiratory Biomedical Research Unit; Asthma UK; Jules Thorne Trust Clinical Senior Lecturer Award; Genentech(Roche HoldingGenentech); GlaxoSmithKline(GlaxoSmithKline); Wellcome Trust(Wellcome TrustEuropean Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by the National Institute for Health Research (NIHR) Leicester Respiratory Biomedical Research Unit and project grants (to S.S., P.B., J.R.A., and L.G.H.) from Asthma UK (AUK-PG-2013-208 [project title: Endotyping asthma for the benefit of patients]) and from the Jules Thorne Trust Clinical Senior Lecturer Award ("Systems medicine: novel mathematical approaches to personalised care in asthma patients''; to S.S.). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. Additional funding was received from Genentech (to P.B.) to support this study. Biopsy samples and additional funding from the GlaxoSmithKline-sponsored studies RES100767 (clinicaltrials.gov: NCT00331058) and RES100769 (clinicaltrials.gov: NCT00327197) were provided by GlaxoSmithKline (to A.J.W.) to support this study. In addition, biopsy samples were provided by C.E.B. to support this study from studies funded by an MRC intermediate and a Wellcome Trust senior fellowship award.	[Anonymous], 2014, LECT NOTES COMPUTER, V8592, P129; Benayoun L, 2003, AM J RESP CRIT CARE, V167, P1360, DOI 10.1164/rccm.200209-1030OC; Berair R, 2014, DRUGS, V74, P1345, DOI 10.1007/s40265-014-0250-4; Beunk L, 2013, EXPERT REV CLIN IMMU, V9, P53, DOI [10.1586/ECI.12.82, 10.1586/eci.12.82]; Boucherat O, 2013, EXP LUNG RES, V39, P207, DOI 10.3109/01902148.2013.791733; Bousquet J, 2010, J ALLERGY CLIN IMMUN, V126, P926, DOI 10.1016/j.jaci.2010.07.019; BRADDING P, 1992, J EXP MED, V176, P1381, DOI 10.1084/jem.176.5.1381; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; Bubenik P, 2015, J MACH LEARN RES, V16, P77; Burgess JK, 2016, J PATHOL, V240, P397, DOI 10.1002/path.4808; Busse WW, 2013, AM J RESP CRIT CARE, V188, P1294, DOI 10.1164/rccm.201212-2318OC; Butler CA, 2012, THORAX, V67, P392, DOI 10.1136/thoraxjnl-2011-200760; Choy DF, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab3142; Choy DF, 2011, J IMMUNOL, V186, P1861, DOI 10.4049/jimmunol.1002568; Davies DE, 1999, ALLERGY, V54, P771; Desai D, 2013, AM J RESP CRIT CARE, V188, P657, DOI 10.1164/rccm.201208-1470OC; Edelsbrunner H, 2002, DISCRETE COMPUT GEOM, V28, P511, DOI 10.1007/s00454-002-2885-2; Fasy BT, 2014, ANN STAT, V42, P2301, DOI 10.1214/14-AOS1252; Gandhi NA, 2016, NAT REV DRUG DISCOV, V15, P35, DOI 10.1038/nrd4624; Hong Y, 2007, CLIN CANCER RES, V13, P1107, DOI 10.1158/1078-0432.CCR-06-1633; Huang YJ, 2015, J ALLERGY CLIN IMMUN, V136, P874, DOI 10.1016/j.jaci.2015.05.044; Hubers AJ, 2015, BRIT J CANCER, V112, P1105, DOI 10.1038/bjc.2014.636; Jia GQ, 2012, J ALLERGY CLIN IMMUN, V130, P647, DOI 10.1016/j.jaci.2012.06.025; Kelly MM, 2012, BRIT J PHARMACOL, V165, P1737, DOI 10.1111/j.1476-5381.2011.01620.x; Knobel M, 2015, CELL TISSUE RES, V360, P583, DOI 10.1007/s00441-014-2105-4; Li L, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa9364; Lum PY, 2013, SCI REP-UK, V3, DOI 10.1038/srep01236; McGarvey LP, 2014, J ALLERGY CLIN IMMUN, V133, P704, DOI 10.1016/j.jaci.2013.09.016; MILLER PL, 1990, LAB INVEST, V63, P862; Nielson JL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9581; Notterman DA, 2001, CANCER RES, V61, P3124; Partridge Martyn R, 2006, BMC Pulm Med, V6, P13, DOI 10.1186/1471-2466-6-13; Pretolani M, 2014, AM J RESP CRIT CARE, V190, P1452, DOI 10.1164/rccm.201407-1374LE; Robinson D, 2017, CLIN EXP ALLERGY, V47, P161, DOI 10.1111/cea.12880; Shikotra A, 2012, J ALLERGY CLIN IMMUN, V129, P104, DOI 10.1016/j.jaci.2011.08.031; Siddiqui S, 2007, EUR RESPIR J, V30, P1043, DOI 10.1183/09031936.00162506; Siddiqui S, 2008, J ALLERGY CLIN IMMUN, V122, P335, DOI 10.1016/j.jaci.2008.05.020; Siddiqui S, 2007, J ALLERGY CLIN IMMUN, V120, P813, DOI 10.1016/j.jaci.2007.05.028; Sousa AR, 2017, CLIN EXP ALLERGY, V47, P890, DOI 10.1111/cea.12954; Stinson SE, 2015, J ALLERGY CLIN IMMUN, V135, P395, DOI 10.1016/j.jaci.2014.08.027; Sullivan P, 1998, EUR RESPIR J, V12, P811, DOI 10.1183/09031936.98.12040811; Wilson SJ, 2016, EUR RESPIR J, V48, P1307, DOI 10.1183/13993003.01129-2016; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Wright DB, 2013, PULM PHARMACOL THER, V26, P42, DOI 10.1016/j.pupt.2012.08.005; Zomorodian A, 2005, DISCRETE COMPUT GEOM, V33, P249, DOI 10.1007/s00454-004-1146-y	45	21	21	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2018	142	5					1457	1468		10.1016/j.jaci.2017.12.982	http://dx.doi.org/10.1016/j.jaci.2017.12.982			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GZ5BL	29550052	Bronze			2022-12-18	WOS:000449429800009
J	Hellkvist, L; Hjalmarsson, E; Georen, SK; Karlsson, A; Lundkvist, K; Winqvist, O; Westin, U; Cardell, LO				Hellkvist, Laila; Hjalmarsson, Eric; Georen, Susanna Kumlien; Karlsson, Agneta; Lundkvist, Karin; Winqvist, Ola; Westin, Ulla; Cardell, Lars Olaf			Intralymphatic immunotherapy with 2 concomitant allergens, birch and grass: A randomized, double-blind, placebo-controlled trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							INTERNATIONAL CONSENSUS; STANDARDIZATION; CARD9		[Hellkvist, Laila; Hjalmarsson, Eric; Georen, Susanna Kumlien; Karlsson, Agneta; Lundkvist, Karin; Cardell, Lars Olaf] Karolinska Inst, Dept Clin Sci Intervent & Technol, Div ENT Dis, Stockholm, Sweden; [Hellkvist, Laila; Karlsson, Agneta; Cardell, Lars Olaf] Karolinska Inst, Unit Translat Immunol, Dept Med, Stockholm, Sweden; [Winqvist, Ola] Karolinska Univ Hosp, Dept ENT Dis, Stockholm, Sweden; [Westin, Ulla] Lund Univ, Skane Univ Hosp, Dept Otorhinolaryngol Malmo, Lab Clin & Expt Allergy Res, Malmo, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Lund University; Skane University Hospital	Cardell, LO (corresponding author), Karolinska Inst, Dept Clin Sci Intervent & Technol, Div ENT Dis, Stockholm, Sweden.; Cardell, LO (corresponding author), Karolinska Inst, Unit Translat Immunol, Dept Med, Stockholm, Sweden.	lars-olaf.cardell@ki.se		Kumlien Georen, Susanna/0000-0001-7292-9255; winqvist, Ola/0000-0003-0842-4441				Cox LS, 2017, J ALLER CL IMM-PRACT, V5, P58, DOI 10.1016/j.jaip.2016.11.009; Gavino C, 2016, J ALLERGY CLIN IMMUN, V137, P1178, DOI 10.1016/j.jaci.2015.09.016; Hsu YMS, 2007, NAT IMMUNOL, V8, P198, DOI 10.1038/ni1426; Hylander T, 2013, J ALLERGY CLIN IMMUN, V131, P412, DOI 10.1016/j.jaci.2012.10.056; Jutel M, 2016, J ALLERGY CLIN IMMUN, V137, P358, DOI 10.1016/j.jaci.2015.12.1300; Jutel M, 2015, J ALLERGY CLIN IMMUN, V136, P556, DOI 10.1016/j.jaci.2015.04.047; Lionakis MS, 2011, J INNATE IMMUN, V3, P180, DOI 10.1159/000321157; Noble A, 2006, BLOOD, V107, P4475, DOI 10.1182/blood-2005-10-3994; Patterson AM, 2016, ANN ALLERG ASTHMA IM, V116, P168, DOI 10.1016/j.anai.2015.11.010; Pfaar O, 2014, ALLERGY, V69, P854, DOI 10.1111/all.12383; Senti G, 2008, P NATL ACAD SCI USA, V105, P17908, DOI 10.1073/pnas.0803725105; Witten M, 2013, J ALLERGY CLIN IMMUN, V132, P1248, DOI 10.1016/j.jaci.2013.07.033	12	21	21	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2018	142	4					1338	+		10.1016/j.jaci.2018.05.030	http://dx.doi.org/10.1016/j.jaci.2018.05.030			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GV7RG	29908212	Bronze			2022-12-18	WOS:000446327300032
J	Garcet, S; Nograles, K; da Rosa, JC; Schafer, PH; Krueger, JG				Garcet, Sandra; Nograles, Kristine; da Rosa, Joel Correa; Schafer, Peter H.; Krueger, James G.			Synergistic cytokine effects as apremilast response predictors in patients with psoriasis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							SEVERE PLAQUE PSORIASIS; PHOSPHODIESTERASE-4 INHIBITOR; PDE4 INHIBITOR; PHASE-III; EFFICACY; MODERATE; SAFETY		[Garcet, Sandra; da Rosa, Joel Correa; Krueger, James G.] Rockefeller Univ, Lab Invest Dermatol, 1230 York Ave, New York, NY 10021 USA; [Nograles, Kristine] Celgene Corp, Clin Res & Dev, Summit, NJ USA; [Schafer, Peter H.] Celgene Corp, Dept Translat Dev, Summit, NJ USA	Rockefeller University; Bristol-Myers Squibb; Celgene Corporation; Bristol-Myers Squibb; Celgene Corporation	Krueger, JG (corresponding author), Rockefeller Univ, Lab Invest Dermatol, 1230 York Ave, New York, NY 10021 USA.	James.krueger@rockefeller.edu	Da Rosa, Joel/AAU-1238-2020; Nograles, Kristine/V-3648-2019	Da Rosa, Joel/0000-0003-4221-1976; Garcet, Sandra/0000-0002-4465-8547	Celgene Corporation	Celgene Corporation(Bristol-Myers SquibbCelgene Corporation)	This study was sponsored by Celgene Corporation.	Baliwag J, 2015, CYTOKINE, V73, P342, DOI 10.1016/j.cyto.2014.12.014; Chiricozzi A, 2011, J INVEST DERMATOL, V131, P677, DOI 10.1038/jid.2010.340; Lowes MA, 2014, ANNU REV IMMUNOL, V32, P227, DOI 10.1146/annurev-immunol-032713-120225; Papp K, 2015, J AM ACAD DERMATOL, V73, P37, DOI 10.1016/j.jaad.2015.03.049; Paul C, 2015, BRIT J DERMATOL, V173, P1387, DOI 10.1111/bjd.14164; Schafer PH, 2014, CELL SIGNAL, V26, P2016, DOI 10.1016/j.cellsig.2014.05.014; Schafer PH, 2010, BRIT J PHARMACOL, V159, P842, DOI 10.1111/j.1476-5381.2009.00559.x; Schafer P, 2012, BIOCHEM PHARMACOL, V83, P1583, DOI 10.1016/j.bcp.2012.01.001; Schafer PH, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/906349	9	21	24	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2018	142	3					1010	1013		10.1016/j.jaci.2018.05.039	http://dx.doi.org/10.1016/j.jaci.2018.05.039			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GS5RJ	29936103	Bronze			2022-12-18	WOS:000443726500042
J	Altunbulakli, C; Costa, R; Lan, F; Zhang, N; Akdis, M; Bachert, C; Akdis, CA				Altunbulakli, Can; Costa, Rita; Lan, Feng; Zhang, Nan; Akdis, Mubeccel; Bachert, Claus; Akdis, Cezmi A.			Staphylococcus aureus enhances the tight junction barrier integrity in healthy nasal tissue, but not in nasal polyps	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							CHRONIC RHINOSINUSITIS; ASTHMA; PHENOTYPES; POLYMORPHISM; IMMUNOLOGY		[Altunbulakli, Can; Costa, Rita; Akdis, Mubeccel; Akdis, Cezmi A.] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Zurich, Switzerland; [Altunbulakli, Can; Akdis, Mubeccel; Akdis, Cezmi A.] Christine Kuhne Ctr Allergy Res & Educ, Davos, Switzerland; [Lan, Feng; Zhang, Nan; Bachert, Claus] Univ Ghent, Dept Otorhinolaryngol, Ghent, Belgium; [Lan, Feng] Capital Med Univ, Beijing TongRen Hosp, Dept Otolaryngol Head & Neck Surg, Beijing Inst Otolaryngol, Beijing, Peoples R China; [Bachert, Claus] Karolinska Inst, Div ENT Dis, CLINTEC, Stockholm, Sweden	Swiss Institute of Allergy & Asthma Research; University of Zurich; Ghent University; Capital Medical University; Karolinska Institutet	Akdis, CA (corresponding author), Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Zurich, Switzerland.; Akdis, CA (corresponding author), Christine Kuhne Ctr Allergy Res & Educ, Davos, Switzerland.	akdisac@siaf.uzh.ch	Akdis, Cezmi/AAV-4844-2020; Zhang, Nan/AAQ-3944-2020; Bachert, Claus/J-8825-2012; Costa, Rita/AAS-8860-2020	Akdis, Cezmi/0000-0001-8020-019X; Costa, Rita/0000-0003-0710-3611; Altunbulakli, Can/0000-0003-2264-7377	European Commission [260895]; Post-infectious immune reprogramming and its association with persistence and chronicity of respiratory allergic diseases [PreDicta]; Swiss National Science Foundation [310030_156823, 320030-140772]; Christine Kuhne-Center for Allergy Research and Education; Flemish Scientific Research Board (The Research Foundation-Flanders (FWO)) [A12/5-HB-KH3, G.0436.04, 3G.0489, G.0642.10N]; Interuniversity Attraction Poles Program Belgian State Belgian Science Policy [IAP P7/30]	European Commission(European CommissionEuropean Commission Joint Research Centre); Post-infectious immune reprogramming and its association with persistence and chronicity of respiratory allergic diseases [PreDicta]; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Christine Kuhne-Center for Allergy Research and Education; Flemish Scientific Research Board (The Research Foundation-Flanders (FWO))(FWO); Interuniversity Attraction Poles Program Belgian State Belgian Science Policy(Belgian Federal Science Policy Office)	The authors' laboratories are supported by the European Commission's Seventh Framework programme (grant agreement no. 260895; Post-infectious immune reprogramming and its association with persistence and chronicity of respiratory allergic diseases [PreDicta]); the Swiss National Science Foundation (grant nos. 310030_156823 and 320030-140772 to C.A.), Christine Kuhne-Center for Allergy Research and Education, the Flemish Scientific Research Board (The Research Foundation-Flanders (FWO); grant no. A12/5-HB-KH3, projects G.0436.04, 3G.0489, and G.0642.10N, to CB.), and by the Interuniversity Attraction Poles Program Belgian State Belgian Science Policy (grant no. IAP P7/30 to C.B.).	Akdis CA, 2013, J ALLERGY CLIN IMMUN, V131, P1479, DOI 10.1016/j.jaci.2013.02.036; Bachert C, 2015, J ALLERGY CLIN IMMUN, V136, P1431, DOI 10.1016/j.jaci.2015.10.010; Chalermwatanachai T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136068; Georas SN, 2014, J ALLERGY CLIN IMMUN, V134, P509, DOI 10.1016/j.jaci.2014.05.049; Global Initiative for Asthma, 2021, GLOB STRAT ASTHM MAN; Hirai K, 2017, CLIN EXP ALLERGY, V47, P1374, DOI 10.1111/cea.12970; Kubo T, 2015, J ALLERGY CLIN IMMUN, V136, P1413, DOI 10.1016/j.jaci.2015.05.006; Leung TF, 2006, PEDIATR PULM, V41, P649, DOI 10.1002/ppul.20428; Okano M, 2015, J ALLERGY CLIN IMMUN, V136, P343, DOI 10.1016/j.jaci.2014.10.058; Ramakrishnan VR, 2015, J ALLERGY CLIN IMMUN, V136, P334, DOI 10.1016/j.jaci.2015.02.008; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Soyka MB, 2012, J ALLERGY CLIN IMMUN, V130, P1087, DOI 10.1016/j.jaci.2012.05.052; Yu HS, 2015, J ALLERGY CLIN IMMUN, V135, P827, DOI 10.1016/j.jaci.2014.10.040	13	21	22	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2018	142	2					665	+		10.1016/j.jaci.2018.01.046	http://dx.doi.org/10.1016/j.jaci.2018.01.046			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GP2LN	29518417	Bronze			2022-12-18	WOS:000440664400032
J	Peng, H; Ning, H; Wang, QH; Lu, WB; Chang, YZ; Wang, TT; Lai, JP; Kolattukudy, PE; Hou, R; Hoft, DF; Dykewicz, MS; Liu, JG				Peng, Hui; Ning, Huan; Wang, Qinghong; Lu, Wenbao; Chang, Yingzi; Wang, Tony T.; Lai, Jinping; Kolattukudy, Pappachan E.; Hou, Rong; Hoft, Daniel F.; Dykewicz, Mark S.; Liu, Jianguo			Monocyte chemotactic protein-induced protein 1 controls allergic airway inflammation by suppressing IL-5-producing T(H)2 cells through the Notch/Gata3 pathway	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						RNA-Binding protein; MCPIP1; mRNA decay; T(H)2 cells; IL-4; IL-5; IL-13; Gata3; Notch; asthma	TRANSCRIPTION FACTOR; IMMUNE-RESPONSES; GATA3 EXPRESSION; RNA-BINDING; T-CELLS; CYTOKINE; INNATE; DIFFERENTIATION; IL-5; NOTCH	Background: Asthmatic and allergic inflammation is mediated by T(H)2 cytokines (IL-4, IL-5, and IL-13). Although we have learned much about how T(H)2 cells are differentiated, the T(H)2 checkpoint mechanisms remain elusive. Objectives: In this study we investigate how monocyte chemotactic protein-induced protein 1 (MCPIP1; encoded by the Zc3h12a gene) regulates IL-5-producing T(H)2 cell differentiation and T(H)2-mediated inflammation. Methods: The functions of Zc3h12a(-/-) CD4 T cells were evaluated by checking the expression of T(H)2 cytokines and transcription factors in vivo and in vitro. Allergic airway inflammation of Zc3h12a(-/-) mice was examined with murine asthma models. In addition, antigen-specific CD4 T cells deficient in MCPIP1 were transferred to wild-type recipient mice, challenged with ovalbumin (OVA) or house dust mite (HDM), and accessed for T(H)2 inflammation. Results: Zc3h12a(-/-) mice have spontaneous severe lung inflammation, with an increase in mainly IL-5- and IL-13-0producing but not IL-4-producing T(H)2 cells in the lung. Mechanistically, differentiation of IL-5-producing Zc3h12a(-/-) T(H)2 cells is mediated through Notch signaling and Gata3 independent of IL-4. Gata3 mRNA is stabilized in Zc3h12a(-/-) T(H)2 cells. MCPIP1 promotes Gata3 mRNA decay through the RNase domain. Furthermore, deletion of MCPIP1 in OVA-or HDM-specific T cells leads to significantly increased T(H)2-mediated airway inflammation in OVA or HDM murine models of asthma. Conclusions: Our study reveals that MCPIP1 regulates the development and function of IL-5-producing T(H)2 cells through the Notch/Gata3 pathway. MCPIP1 represents a new and promising target for the treatment of asthma and other T(H)2-mediated diseases.	[Peng, Hui; Ning, Huan; Wang, Qinghong; Lu, Wenbao; Hou, Rong; Hoft, Daniel F.; Dykewicz, Mark S.; Liu, Jianguo] St Louis Univ, Sch Med, Div Infect Dis Allergy & Immunol, Dept Internal Med, 1100 S Grand Blvd,DRC Rm 811, St Louis, MO 63104 USA; [Chang, Yingzi] St Louis Univ, Sch Med, Dept Pathol, St Louis, MO 63104 USA; [Wang, Tony T.] AT Still Univ, Dept Pharmacol, Kirksville, MO USA; [Lai, Jinping] SRI Int, Harrisonburg, VA USA; [Kolattukudy, Pappachan E.] Univ Cent Florida, Coll Med, Burnett Sch Biomed Sci, Orlando, FL 32816 USA	Saint Louis University; Saint Louis University; A.T. Still University of Health Sciences; SRI International; State University System of Florida; University of Central Florida	Liu, JG (corresponding author), St Louis Univ, Sch Med, Div Infect Dis Allergy & Immunol, Dept Internal Med, 1100 S Grand Blvd,DRC Rm 811, St Louis, MO 63104 USA.	jianguo.liu@health.slu.edu	Lai, Jinping/AAZ-6861-2021; , Hui/AAT-5093-2020; NING, HUAN/R-4786-2018	, Hui/0000-0002-2646-129X; 	National Cancer Institute of the National Institutes of Health [R01CA163808]; NATIONAL CANCER INSTITUTE [R01CA163808] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK088787] Funding Source: NIH RePORTER	National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported by the National Cancer Institute of the National Institutes of Health under award no. R01CA163808 (to J.L.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Amsen D, 2004, CELL, V117, P515, DOI 10.1016/S0092-8674(04)00451-9; Amsen D, 2007, IMMUNITY, V27, P89, DOI 10.1016/j.immuni.2007.05.021; Amsen D, 2009, CURR OPIN IMMUNOL, V21, P153, DOI 10.1016/j.coi.2009.03.010; Anderson P, 2008, NAT IMMUNOL, V9, P353, DOI 10.1038/ni1584; Barlow JL, 2012, J ALLERGY CLIN IMMUN, V129, P191, DOI 10.1016/j.jaci.2011.09.041; Bartemes KR, 2012, J IMMUNOL, V188, P1503, DOI 10.4049/jimmunol.1102832; Blonska M, 2012, J IMMUNOL, V188, P3160, DOI 10.4049/jimmunol.1102943; COFFMAN RL, 1986, J IMMUNOL, V136, P4538; Cohn L, 2004, ANNU REV IMMUNOL, V22, P789, DOI 10.1146/annurev.immunol.22.012703.104716; Fallon PG, 2006, J EXP MED, V203, P1105, DOI 10.1084/jem.20051615; Fang TC, 2007, IMMUNITY, V27, P100, DOI 10.1016/j.immuni.2007.04.018; FINKELMAN FD, 1988, J IMMUNOL, V141, P2335; Finkelman FD, 2010, J IMMUNOL, V184, P1663, DOI 10.4049/jimmunol.0902185; Fort MM, 2001, IMMUNITY, V15, P985, DOI 10.1016/S1074-7613(01)00243-6; Garg AV, 2015, IMMUNITY, V43, P475, DOI 10.1016/j.immuni.2015.07.021; He M, 2013, ARTERIOSCL THROM VAS, V33, P1384, DOI 10.1161/ATVBAHA.113.301490; Hoyler T, 2012, IMMUNITY, V37, P634, DOI 10.1016/j.immuni.2012.06.020; Huang SP, 2013, CELL SIGNAL, V25, P1228, DOI 10.1016/j.cellsig.2013.02.009; Jeltsch KM, 2014, NAT IMMUNOL, V15, P1079, DOI 10.1038/ni.3008; Kafasla P, 2014, NAT IMMUNOL, V15, P492, DOI 10.1038/ni.2884; Kang ZZ, 2012, IMMUNITY, V36, P821, DOI 10.1016/j.immuni.2012.03.021; Kubo M, 2007, IMMUNITY, V27, P3, DOI 10.1016/j.immuni.2007.07.005; Lambrecht BN, 2015, NAT IMMUNOL, V16, P45, DOI 10.1038/ni.3049; Lee HJ, 1998, J IMMUNOL, V160, P2343; Liang J, 2008, J BIOL CHEM, V283, P6337, DOI 10.1074/jbc.M707861200; Liang JA, 2010, J EXP MED, V207, P2959, DOI 10.1084/jem.20092641; Licona-Limon P, 2013, NAT IMMUNOL, V14, P536, DOI 10.1038/ni.2617; Lin RJ, 2014, J IMMUNOL, V193, P4159, DOI 10.4049/jimmunol.1400337; Lin RJ, 2013, NUCLEIC ACIDS RES, V41, P3314, DOI 10.1093/nar/gkt019; Liu SF, 2013, P NATL ACAD SCI USA, V110, P19083, DOI 10.1073/pnas.1316208110; Lloyd CM, 2010, NAT REV IMMUNOL, V10, P838, DOI 10.1038/nri2870; Maekawa Y, 2003, IMMUNITY, V19, P549, DOI 10.1016/S1074-7613(03)00270-X; Matsushita K, 2009, NATURE, V458, P1185, DOI 10.1038/nature07924; McKenzie GJ, 1998, IMMUNITY, V9, P423, DOI 10.1016/S1074-7613(00)80625-1; Miao RD, 2013, IMMUNOL CELL BIOL, V91, P368, DOI 10.1038/icb.2013.11; Mino T, 2015, CELL, V161, P1058, DOI 10.1016/j.cell.2015.04.029; Mowen KA, 2004, IMMUNOL REV, V202, P203, DOI 10.1111/j.0105-2896.2004.00209.x; Niu JX, 2013, EMBO J, V32, P3206, DOI 10.1038/emboj.2013.247; OHNISHI T, 1993, AM REV RESPIR DIS, V147, P901, DOI 10.1164/ajrccm/147.4.901; Ouyang WJ, 2000, IMMUNITY, V12, P27, DOI 10.1016/S1074-7613(00)80156-9; Paul WE, 2010, NAT REV IMMUNOL, V10, P225, DOI 10.1038/nri2735; PEARCE EJ, 1991, J EXP MED, V173, P159, DOI 10.1084/jem.173.1.159; Pot C, 2009, J IMMUNOL, V183, P797, DOI 10.4049/jimmunol.0901233; Qi YF, 2010, FEBS LETT, V584, P3065, DOI 10.1016/j.febslet.2010.05.040; Radtke F, 2013, NAT REV IMMUNOL, V13, P427, DOI 10.1038/nri3445; Salek-Ardakani S, 2003, J EXP MED, V198, P315, DOI 10.1084/jem.20021937; Seki Y, 2003, NAT MED, V9, P1047, DOI 10.1038/nm896; Simpson TR, 2010, CURR OPIN IMMUNOL, V22, P326, DOI 10.1016/j.coi.2010.01.001; Tindemans I, 2014, IMMUNITY, V41, P191, DOI 10.1016/j.immuni.2014.06.006; Tu LL, 2005, J EXP MED, V202, P1037, DOI 10.1084/jem.20050923; Tumes DJ, 2013, IMMUNITY, V39, P819, DOI 10.1016/j.immuni.2013.09.012; Uehata T, 2013, CELL, V153, P1036, DOI 10.1016/j.cell.2013.04.034; YAMAGUCHI Y, 1988, J EXP MED, V167, P43, DOI 10.1084/jem.167.1.43; Yang XO, 2009, NAT IMMUNOL, V10, P1260, DOI 10.1038/ni.1821; Yang YN, 2011, J CLIN INVEST, V121, P1373, DOI 10.1172/JCI42579; Zhang J, 1997, J IMMUNOL, V159, P5412; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8; Zhou LM, 2006, CIRC RES, V98, P1177, DOI 10.1161/01.RES.0000220106.64661.71; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909; Zhu JF, 2004, NAT IMMUNOL, V5, P1157, DOI 10.1038/ni1128; Zhu JF, 2006, P NATL ACAD SCI USA, V103, P18214, DOI 10.1073/pnas.0608981103	61	21	25	1	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2018	142	2					582	+		10.1016/j.jaci.2017.09.031	http://dx.doi.org/10.1016/j.jaci.2017.09.031			23	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GP2LN	29111212	Bronze, Green Accepted			2022-12-18	WOS:000440664400025
J	Imkamp, K; Berg, M; Vermeulen, CJ; Heijink, IH; Guryev, V; Kerstjens, HAM; Koppelman, GH; van den Berge, M; Faiz, A				Imkamp, Kai; Berg, Marijn; Vermeulen, Cornelis J.; Heijink, Irene H.; Guryev, Victor; Kerstjens, Huib A. M.; Koppelman, Gerard H.; van den Berge, Maarten; Faiz, Alen			Nasal epithelium as a proxy for bronchial epithelium for smoking-induced gene expression and expression Quantitative Trait Loci	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							GENOME-WIDE ASSOCIATION; LUNG-FUNCTION; ASTHMA; DEFICIENCY; ACTIVATION		[Imkamp, Kai; Berg, Marijn; Vermeulen, Cornelis J.; Kerstjens, Huib A. M.; Koppelman, Gerard H.; van den Berge, Maarten; Faiz, Alen] Univ Med Ctr Groningen, Dept Pulmonol, Groningen, Netherlands; [Imkamp, Kai; Berg, Marijn; Vermeulen, Cornelis J.; Heijink, Irene H.; Guryev, Victor; Kerstjens, Huib A. M.; Koppelman, Gerard H.; van den Berge, Maarten; Faiz, Alen] Univ Med Ctr Groningen, Beatrix Childrens Hosp, GRIAC, Groningen, Netherlands; [Berg, Marijn; Heijink, Irene H.; Faiz, Alen] Univ Med Ctr Groningen, Sect Med Biol, Dept Pathol & Med Biol, Groningen, Netherlands; [Guryev, Victor] Univ Med Ctr Groningen, European Res Inst Biol Ageing, Groningen, Netherlands; [Koppelman, Gerard H.] Univ Med Ctr Groningen, Beatrix Childrens Hosp, Dept Pediat Pulmonol & Pediat Allergol, Groningen, Netherlands	University of Groningen; University of Groningen; University of Groningen; University of Groningen; University of Groningen	Imkamp, K (corresponding author), Univ Med Ctr Groningen, Dept Pulmonol, Groningen, Netherlands.; Imkamp, K (corresponding author), Univ Med Ctr Groningen, Beatrix Childrens Hosp, GRIAC, Groningen, Netherlands.	k.imkamp@umcg.nl	Kerstjens, Huib/N-4754-2017; Koppelman, Gerard/AAG-9187-2020; Faiz, Alen/AAB-7132-2019	Kerstjens, Huib/0000-0001-7705-7927; Faiz, Alen/0000-0003-1740-3538; Vermeulen, Corneel/0000-0002-3280-1414; Berg, Marijn/0000-0002-9870-1571; van den Berge, Maarten/0000-0002-9336-7340; Guryev, Victor/0000-0002-5810-6022; Koppelman, Gerard/0000-0001-8567-3252	Junior Investigator Longfonds grant [4.2.16.132JO]; Stichting Astma Bestrijding grant	Junior Investigator Longfonds grant; Stichting Astma Bestrijding grant	A.F. was funded by a Junior Investigator Longfonds grant (4.2.16.132JO) and a Stichting Astma Bestrijding grant.	Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001; Bonnelykke K, 2014, NAT GENET, V46, P51, DOI 10.1038/ng.2830; Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493; Forneris F, 2010, SCIENCE, V330, P1816, DOI 10.1126/science.1195821; Fredrikson GN, 1996, J IMMUNOL, V157, P3666; Hirota T, 2011, NAT GENET, V43, P893, DOI 10.1038/ng.887; Hobbs BD, 2017, NAT GENET, V49, P426, DOI 10.1038/ng.3752; Katschke KJ, 2012, J BIOL CHEM, V287, P12886, DOI 10.1074/jbc.M112.345082; Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057; Lindorff-Larsen K, 2010, PROTEINS, V78, P1950, DOI 10.1002/prot.22711; Lo JC, 2014, CELL, V158, P41, DOI 10.1016/j.cell.2014.06.005; Noguchi E, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002170; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Poole A, 2014, J ALLERGY CLIN IMMUN, V133, P670, DOI 10.1016/j.jaci.2013.11.025; Sprong T, 2006, BLOOD, V107, P4865, DOI 10.1182/blood-2005-07-2820; Sridhar S, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-259; Torgerson DG, 2011, NAT GENET, V43, P887, DOI 10.1038/ng.888; Wain LV, 2017, NAT GENET, V49, P416, DOI 10.1038/ng.3787; Zhang XL, 2010, PHYSIOL GENOMICS, V41, P1, DOI 10.1152/physiolgenomics.00167.2009	19	21	21	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2018	142	1					314	317		10.1016/j.jaci.2018.01.047	http://dx.doi.org/10.1016/j.jaci.2018.01.047			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GM1OC	29522853	Bronze			2022-12-18	WOS:000437837500041
J	Calzetti, F; Tamassia, N; Micheletti, A; Finotti, G; Bianchetto-Aguilera, F; Cassatella, MA				Calzetti, Federica; Tamassia, Nicola; Micheletti, Alessandra; Finotti, Giulia; Bianchetto-Aguilera, Francisco; Cassatella, Marco A.			Human dendritic cell subset 4 (DC4) correlates to a subset of CD14(dim/-) CD16(++) monocytes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							ANTIBODY		[Calzetti, Federica; Tamassia, Nicola; Micheletti, Alessandra; Finotti, Giulia; Bianchetto-Aguilera, Francisco; Cassatella, Marco A.] Univ Verona, Dept Med, Sect Gen Pathol, Verona, Italy	University of Verona	Cassatella, MA (corresponding author), Univ Verona, Dept Med, Sect Gen Pathol, Verona, Italy.	marco.cassatella@univr.it	Cassatella, M A/B-8037-2013; Bianchetto Aguilera, Francisco Miguel Angel/GNW-3583-2022; Tamassia, Nicola/J-8621-2016	Cassatella, M A/0000-0001-7824-1806; Bianchetto Aguilera, Francisco Miguel Angel/0000-0003-3910-4715; Tamassia, Nicola/0000-0003-2990-3003	Associazione Italiana per la Ricerca sul Cancro Italy (AIRC) [IG-15454]; University of Verona; "Fondazione Umberto Veronesi''; "Fondazione Italiana per la Ricerca sul Cancro"	Associazione Italiana per la Ricerca sul Cancro Italy (AIRC)(Fondazione AIRC per la ricerca sul cancro); University of Verona; "Fondazione Umberto Veronesi''(Fondazione Umberto Veronesi); "Fondazione Italiana per la Ricerca sul Cancro"(Fondazione AIRC per la ricerca sul cancro)	Supported by grants from Associazione Italiana per la Ricerca sul Cancro Italy (AIRC, IG-15454) and the University of Verona (Ricerca di Base 2015; to M.A.C.). A.M. and G.F. are recipients of postdoctoral fellowships from "Fondazione Umberto Veronesi'' and "Fondazione Italiana per la Ricerca sul Cancro,'' respectively.	Bacher R, 2017, NAT METHODS, V14, P584, DOI 10.1038/nmeth.4263; Breton G, 2016, J EXP MED, V213, P2861, DOI 10.1084/jem.20161135; Haniffa M, 2015, SEMIN CELL DEV BIOL, V41, P59, DOI 10.1016/j.semcdb.2015.05.004; Lundberg K, 2014, IMMUNOLOGY, V142, P279, DOI 10.1111/imm.12252; Ober RJ, 2001, INT IMMUNOL, V13, P1551, DOI 10.1093/intimm/13.12.1551; Schakel K, 2006, IMMUNITY, V24, P767, DOI 10.1016/j.immuni.2006.03.020; Tsunoda K, 2003, J IMMUNOL, V170, P2170, DOI 10.4049/jimmunol.170.4.2170; van Leeuwen-Kerkhoff N, 2017, J LEUKOCYTE BIOL, V102, P1055, DOI 10.1189/jlb.3MA0117-037R; Vermi W, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4029; Villani AC, 2017, SCIENCE, V356, DOI 10.1126/science.aah4573; Ziegler-Heitbrock L, 2010, BLOOD, V116, pE74, DOI 10.1182/blood-2010-02-258558	11	21	21	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2018	141	6					2276	2279		10.1016/j.jaci.2017.12.988	http://dx.doi.org/10.1016/j.jaci.2017.12.988			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GI7SD	29366702	Bronze			2022-12-18	WOS:000434701600034
J	Rice, MB; Rifas-Shiman, SL; Litonjua, AA; Gillman, MW; Liebman, N; Kloog, I; Luttmann-Gibson, H; Coull, BA; Schwartz, J; Koutrakis, P; Oken, E; Mittleman, MA; Gold, DR				Rice, Mary B.; Rifas-Shiman, Sheryl L.; Litonjua, Augusto A.; Gillman, Matthew W.; Liebman, Nicole; Kloog, Itai; Luttmann-Gibson, Heike; Coull, Brent A.; Schwartz, Joel; Koutrakis, Petros; Oken, Emily; Mittleman, Murray A.; Gold, Diane R.			Lifetime air pollution exposure and asthma in a pediatric birth cohort	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							LUNG-FUNCTION DECLINE; TRAFFIC POLLUTION; CHILDHOOD; PARTICLES; WHEEZE; RISK		[Rice, Mary B.; Liebman, Nicole] Beth Israel Deaconess Med Ctr, Dept Med, Div Pulm Crit Care & Sleep Med, Boston, MA 02215 USA; [Rifas-Shiman, Sheryl L.; Oken, Emily] Harvard Med Sch, Div Chron Dis Res Lifecourse, Dept Populat Med, Boston, MA USA; [Rifas-Shiman, Sheryl L.; Oken, Emily] Harvard Pilgrim Hlth Care Inst, Boston, MA USA; [Litonjua, Augusto A.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA; [Gillman, Matthew W.] NIH, Environm Influences Child Hlth Outcomes ECHO Prog, Off Director, Bldg 10, Bethesda, MD 20892 USA; [Kloog, Itai] Ben Gurion Univ Negev, Dept Geog & Environm Dev, Beer Sheva, Israel; [Luttmann-Gibson, Heike; Coull, Brent A.; Schwartz, Joel; Koutrakis, Petros; Oken, Emily; Mittleman, Murray A.; Gold, Diane R.] Harvard TH Chan Sch Publ Hlth, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard Pilgrim Health Care; Harvard University; Brigham & Women's Hospital; National Institutes of Health (NIH) - USA; Ben Gurion University; Harvard University; Harvard T.H. Chan School of Public Health	Rice, MB (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Pulm Crit Care & Sleep Med, Boston, MA 02215 USA.	mrice1@bidmc.harvard.edu		Mittleman, Murray/0000-0001-9788-7274	US National Institutes of Health [K23ES026204, P30ES000002, P01ES009825, K24HD069408, R37HD034568, R01AI102960, UG3OD023286]; US Environmental Protection Agency (EPA) [RD-835872]; American Thoracic Society Foundation; American Lung Association; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD034568, R37HD034568, K24HD069408] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI102960] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K23ES026204, P01ES009825, P30ES000002] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [UG3OD023286] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US Environmental Protection Agency (EPA)(United States Environmental Protection Agency); American Thoracic Society Foundation; American Lung Association; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Supported by the US National Institutes of Health (K23ES026204, P30ES000002, P01ES009825, K24HD069408, R37HD034568 R01AI102960, and UG3OD023286), the US Environmental Protection Agency (EPA; RD-835872), the American Thoracic Society Foundation, and the American Lung Association. This publication's contents are solely the responsibility of the grantee and do not necessarily represent the official views of the EPA. Further, the EPA does not endorse the purchase of any commercial products or services mentioned in the publication. The views expressed in this article do not necessarily represent the views of the US Government, the Department of Health and Human Services, or the National Institutes of Health.	Brunst KJ, 2015, AM J RESP CRIT CARE, V192, P421, DOI 10.1164/rccm.201407-1314OC; Camargo CA, 2007, AM J CLIN NUTR, V85, P788, DOI 10.1093/ajcn/85.3.788; Fleisch AF, 2017, PEDIATR OBES, V12, P48, DOI 10.1111/ijpo.12106; Fleisch AF, 2015, EPIDEMIOLOGY, V26, P43, DOI 10.1097/EDE.0000000000000203; Gehring U, 2015, LANCET RESP MED, V3, P933, DOI 10.1016/S2213-2600(15)00426-9; Gryparis A, 2007, J R STAT SOC C-APPL, V56, P183, DOI 10.1111/j.1467-9876.2007.00573.x; Klein SL, 2016, NAT REV IMMUNOL, V16, P626, DOI 10.1038/nri.2016.90; Kloog I, 2014, ATMOS ENVIRON, V95, P581, DOI 10.1016/j.atmosenv.2014.07.014; Kloog I, 2014, REMOTE SENS ENVIRON, V150, P132, DOI 10.1016/j.rse.2014.04.024; Kloog I, 2011, ATMOS ENVIRON, V45, P6267, DOI 10.1016/j.atmosenv.2011.08.066; Lepeule J, 2014, AM J RESP CRIT CARE, V190, P542, DOI 10.1164/rccm.201402-0350OC; Oken E, 2015, INT J EPIDEMIOL, V44, P37, DOI 10.1093/ije/dyu008; Raherison C, 2007, RESP MED, V101, P107, DOI 10.1016/j.rmed.2006.04.010; Ranciere F, 2017, ENVIRON HEALTH PERSP, V125, P737, DOI 10.1289/EHP239; Rice MB, 2016, AM J RESP CRIT CARE, V193, P881, DOI 10.1164/rccm.201506-1058OC; Rice MB, 2015, AM J RESP CRIT CARE, V191, P656, DOI 10.1164/rccm.201410-1875OC; Rice MB, 2014, PEDIAT PULMONOL; Sbihi H, 2017, AM J RESP CRIT CARE, V195, P607, DOI 10.1164/rccm.201601-0164OC; Zhou Y, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-89; Zhu YF, 2002, J AIR WASTE MANAGE, V52, P1032, DOI 10.1080/10473289.2002.10470842	20	21	23	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2018	141	5					1932	+		10.1016/j.jaci.2017.11.062	http://dx.doi.org/10.1016/j.jaci.2017.11.062			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GF7KX	29410045	Bronze, Green Accepted			2022-12-18	WOS:000432148200050
J	Strickland, I; Sleeman, MA; Herath, A; May, RD; Bruijnzeel-Koomen, CAFM; Knol, EF; Giovannone, B; de Bruin-Weller, MS; Nierkens, S; Hijnen, DJ				Strickland, Ian; Sleeman, Matthew A.; Herath, Athula; May, Richard D.; Bruijnzeel-Koomen, Catharina A. F. M.; Knol, Edward F.; Giovannone, Barbara; de Bruin-Weller, Marjolein S.; Nierkens, Stefan; Hijnen, Dirk Jan			EASI p-EASI: Utilizing a combination of serum biomarkers offers an objective measurement tool for disease severity in atopic dermatitis patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ACTIVATION-REGULATED CHEMOKINE; T-CELLS; THYMUS; IL-22		[Bruijnzeel-Koomen, Catharina A. F. M.; Knol, Edward F.; Giovannone, Barbara; de Bruin-Weller, Marjolein S.; Hijnen, Dirk Jan] Univ Med Ctr, Dept Dermatol & Allergol, Utrecht, Netherlands; [Knol, Edward F.; Nierkens, Stefan; Hijnen, Dirk Jan] Lab Translat Immunol, Utrecht, Netherlands; [Strickland, Ian; Sleeman, Matthew A.; Herath, Athula; May, Richard D.] Medimmune Inc, Granta Pk, Cambridge, England; [Nierkens, Stefan] Univ Med Ctr Utrecht, U DAIR, Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; AstraZeneca; Medimmune; Utrecht University; Utrecht University Medical Center	Hijnen, DJ (corresponding author), Univ Med Ctr, Dept Dermatol & Allergol, Utrecht, Netherlands.; Hijnen, DJ (corresponding author), Lab Translat Immunol, Utrecht, Netherlands.	dirkjanhijnen@gmail.com	Hijnen, DirkJan/L-1387-2015; Nierkens, Stefan/AAQ-5564-2021; Drylewicz, Julia/I-4703-2019	Hijnen, DirkJan/0000-0003-3379-3425; Nierkens, Stefan/0000-0003-3406-817X; Drylewicz, Julia/0000-0002-9434-8459; Herath, Athula/0000-0002-9465-7841; Giovannone, Barbara/0000-0003-3143-1922; May, Richard/0000-0001-7825-2716; Knol, Edward/0000-0001-7368-9820	MedImmune	MedImmune(AstraZenecaMedimmune)	The study was supported in part by MedImmune.	GAULTON GN, 1994, CHEM IMMUNOL, V59, P91; Gutowska-Owsiak D, 2011, BRIT J DERMATOL, V165, P492, DOI 10.1111/j.1365-2133.2011.10400.x; Hijnen D, 2013, J INVEST DERMATOL, V133, P973, DOI 10.1038/jid.2012.456; Imai T, 1999, INT IMMUNOL, V11, P81, DOI 10.1093/intimm/11.1.81; Landheer J, 2014, J AM ACAD DERMATOL, V71, P1160, DOI 10.1016/j.jaad.2014.07.031; Nograles KE, 2009, J ALLERGY CLIN IMMUN, V123, P1244, DOI 10.1016/j.jaci.2009.03.041; Thijs JL, 2015, CLIN EXP ALLERGY, V45, P698, DOI 10.1111/cea.12486; Thijs J, 2015, CURR OPIN ALLERGY CL, V15, P453, DOI 10.1097/ACI.0000000000000198; WALKER C, 1993, CLIN EXP ALLERGY, V23, P145, DOI 10.1111/j.1365-2222.1993.tb00310.x	9	21	21	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2017	140	6					1703	+		10.1016/j.jaci.2017.06.046	http://dx.doi.org/10.1016/j.jaci.2017.06.046			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FO9KI	28823810	Bronze			2022-12-18	WOS:000417206000026
J	Jensen-Jarolim, E; Turner, MC; Karagiannis, SN				Jensen-Jarolim, Erika; Turner, Michelle C.; Karagiannis, Sophia N.			AllergoOncology: IgE- and IgG(4)-mediated immune mechanisms linking allergy with cancer and their translational implications	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Allergy; cancer; tumor; tolerance; IgE; effector cells; antibody-dependent cell-mediated cytotoxicity; AllergoOncology; clinical oncology; oncoimmunology	B-CELLS; ASSOCIATION; IGG4; TOLERANCE; DISEASE		[Jensen-Jarolim, Erika] Med Univ Vienna, Inst Pathophysiol & Allergy Res, Ctr Pathophysiol Infectiol & Immunol, Wahringer G 18-20, A-1090 Vienna, Austria; [Jensen-Jarolim, Erika] Med Univ Vienna, Univ Vet Med Vienna, Interuniv Messerli Res Inst, Vienna, Austria; [Jensen-Jarolim, Erika] Univ Vienna, Vienna, Austria; [Turner, Michelle C.] Barcelona Inst Global Hlth ISGlobal, Barcelona, Spain; [Turner, Michelle C.] UPF, Barcelona, Spain; [Turner, Michelle C.] CIBERESP, Madrid, Spain; [Turner, Michelle C.] Univ Ottawa, McLaughlin Ctr Populat Hlth Risk Assessment, Ottawa, ON, Canada; [Karagiannis, Sophia N.] Kings Coll London, St Johns Inst Dermatol, Fac Life Sci & Med, Div Genet & Mol Med, London, England; [Karagiannis, Sophia N.] Kings Coll London, Guys & St Thomas Hosp, NIHR Biomed Res Ctr, London, England; [Karagiannis, Sophia N.] Kings Coll London, Guys Hosp, London, England	Medical University of Vienna; Medical University of Vienna; University of Veterinary Medicine Vienna; University of Vienna; ISGlobal; Pompeu Fabra University; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; University of Ottawa; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Jensen-Jarolim, E (corresponding author), Med Univ Vienna, Inst Pathophysiol & Allergy Res, Ctr Pathophysiol Infectiol & Immunol, Wahringer G 18-20, A-1090 Vienna, Austria.	erika.jensen-jarolim@meduniwien.ac.at	Karagiannis, Sophia/H-1097-2011; Jensen-Jarolim, Erika/C-5120-2018; Turner, Michelle/F-7659-2017	Karagiannis, Sophia/0000-0002-4100-7810; Jensen-Jarolim, Erika/0000-0003-4019-5765; Turner, Michelle/0000-0002-6431-1997	European Academy for Allergy and Clinical Immunology, as an initiative of its AllergoOncology Task Force; Austrian Science Fund FWF [SFB F4606-B28]; National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) based at Guy's and St Thomas' NHS Foundation Trust and King's College London; Medical Research Council [MR/L023091/1]; Cancer Research UK [C30122/A11527, C30122/A15774]; Academy of Medical Sciences; Breakthrough Breast Cancer [147]; CR UK/NIHR in England/DoH for Scotland, Wales; Northern Ireland Experimental Cancer Medicine Centre [C10355/A15587]; MRC [MR/L023091/1] Funding Source: UKRI	European Academy for Allergy and Clinical Immunology, as an initiative of its AllergoOncology Task Force; Austrian Science Fund FWF(Austrian Science Fund (FWF)); National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) based at Guy's and St Thomas' NHS Foundation Trust and King's College London; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Academy of Medical Sciences(Academy of Medical Sciences (AMS)); Breakthrough Breast Cancer; CR UK/NIHR in England/DoH for Scotland, Wales; Northern Ireland Experimental Cancer Medicine Centre; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by the European Academy for Allergy and Clinical Immunology, as an initiative of its AllergoOncology Task Force. E.J.-J. was supported by the Austrian Science Fund FWF (grant SFB F4606-B28). S.N.K. was supported by the National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) based at Guy's and St Thomas' NHS Foundation Trust and King's College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. S.N.K. was also supported by the Medical Research Council (MR/L023091/1), Cancer Research UK (C30122/A11527; C30122/A15774), the Academy of Medical Sciences, Breakthrough Breast Cancer (147), and the CR UK/NIHR in England/DoH for Scotland, Wales, and Northern Ireland Experimental Cancer Medicine Centre (C10355/A15587). ISGlobal is a member of the CERCA Programme, Generalitat de Catalunya.	Amirian ES, 2016, CANCER EPIDEM BIOMAR, V25, P282, DOI 10.1158/1055-9965.EPI-15-0847; Asano J, 2015, J RHEUMATOL, V42, P2135, DOI 10.3899/jrheum.150436; Crescioli S, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-015-0580-7; Davies AM, 2015, IMMUNOL REV, V268, P139, DOI 10.1111/imr.12349; Jensen-Jarolim E, 2008, ALLERGY, V63, P1255, DOI 10.1111/j.1398-9995.2008.01768.x; Jensen-Jarolim E, 2017, ALLERGY, V72, P866, DOI 10.1111/all.13119; Jensen-Jarolim E, 2016, J ALLERGY CLIN IMMUN, V137, pAB403, DOI 10.1016/j.jaci.2015.12.1248; Karagiannis P, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1032492; Karagiannis P, 2013, CANCER RES, V73, DOI [10.1172/JCI65579, 10.1158/1538-7445.TUMIMM2012-B65]; Mohr A, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1132977; Pali-Scholl I, 2016, CURR OPIN IMMUNOL, V42, P113, DOI 10.1016/j.coi.2016.08.004; Renand A, 2015, J ALLERGY CLIN IMMUN, V136, P1627, DOI 10.1016/j.jaci.2015.07.031; Schwartzbaum J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137503; Stanic B, 2015, J ALLERGY CLIN IMMUN, V135, P771, DOI 10.1016/j.jaci.2014.07.041; van de Veen W, 2016, J ALLERGY CLIN IMMUN, V138, P654, DOI 10.1016/j.jaci.2016.07.006; Wallace ZS, 2016, ARTHRITIS RHEUMATOL, V68, P2283, DOI 10.1002/art.39773; Wulaningsih W, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1154250; Zennaro D, 2011, ALLERGY, V66, P100	18	21	21	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2017	140	4					982	984		10.1016/j.jaci.2017.04.034	http://dx.doi.org/10.1016/j.jaci.2017.04.034			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FI7JL	28526623	Green Published, hybrid			2022-12-18	WOS:000412172900008
J	Kucuk, ZY; Charbonnier, LM; McMasters, RL; Chatila, T; Bleesing, JJ				Kucuk, Zeynep Yesim; Charbonnier, Louis-Marie; McMasters, Richard L.; Chatila, Talal; Bleesing, Jack J.			CTLA-4 haploinsufficiency in a patient with an autoimmune lymphoproliferative disorder	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							T FOLLICULAR HELPER; IMMUNE DYSREGULATION; MUTATIONS; CELLS		[Kucuk, Zeynep Yesim; Bleesing, Jack J.] Cincinnati Childrens Hosp Med Ctr, Div Bone Marrow Transplantat & Immune Deficiency, Cincinnati, OH 45229 USA; [Charbonnier, Louis-Marie; Chatila, Talal] Cincinnati Childrens Hosp Med Ctr, Div Pathol & Lab Med, Cincinnati, OH 45229 USA; [McMasters, Richard L.] Boston Childrens Hosp, Div Allergy & Immunol, Boston, MA USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; Harvard University; Boston Children's Hospital	Kucuk, ZY (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Bone Marrow Transplantat & Immune Deficiency, Cincinnati, OH 45229 USA.	zeynep.kucuk@cchmc.org		Charbonnier, Louis-Marie/0000-0002-4594-7893; Chatila, Talal/0000-0001-7439-2762	National Institutes of Health [R01AI085090]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI085090] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the National Institutes of Health (#R01AI085090 to T.C.).	Charbonnier LM, 2015, J ALLERGY CLIN IMMUN, V135, P217, DOI 10.1016/j.jaci.2014.10.019; Chung Y, 2011, NAT MED, V17, P983, DOI 10.1038/nm.2426; Kuehn HS, 2014, SCIENCE, V345, P1623, DOI 10.1126/science.1255904; Lim MS, 1998, AM J PATHOL, V153, P1541, DOI 10.1016/S0002-9440(10)65742-2; Ma CS, 2015, J ALLERGY CLIN IMMUN, V136, P993, DOI 10.1016/j.jaci.2015.05.036; Oliveira JB, 2010, BLOOD, V116, pE35, DOI 10.1182/blood-2010-04-280347; Sage PT, 2014, IMMUNITY, V41, P1026, DOI 10.1016/j.immuni.2014.12.005; Schubert D, 2014, NAT MED, V20, P1410, DOI 10.1038/nm.3746; Wing K, 2008, SCIENCE, V322, P271, DOI 10.1126/science.1160062	9	21	23	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2017	140	3					862	+		10.1016/j.jaci.2017.02.032	http://dx.doi.org/10.1016/j.jaci.2017.02.032			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FF8CA	28366794	Bronze, Green Accepted			2022-12-18	WOS:000409241500027
J	Dominguez-Huttinger, E; Christodoulides, P; Miyauchi, K; Irvine, AD; Okada-Hatakeyama, M; Kubo, M; Tanaka, RJ				Dominguez-Huttinger, Elisa; Christodoulides, Panayiotis; Miyauchi, Kosuke; Irvine, Alan D.; Okada-Hatakeyama, Mariko; Kubo, Masato; Tanaka, Reiko J.			Mathematical modeling of atopic dermatitis reveals "double-switch" mechanisms underlying 4 common disease phenotypes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; mathematical models; double switch; disease progression; disease phenotypes; preventive treatment	PERMEABILITY BARRIER HOMEOSTASIS; STRATUM-CORNEUM; SKIN BARRIER; EPIDERMAL PERMEABILITY; MURINE MODEL; FILAGGRIN; EXPRESSION; GENE; CELLS; GATA-3	Background: The skin barrier acts as the first line of defense against constant exposure to biological, microbial, physical, and chemical environmental stressors. Dynamic interplay between defects in the skin barrier, dysfunctional immune responses, and environmental stressors are major factors in the development of atopic dermatitis (AD). A systems biology modeling approach can yield significant insights into these complex and dynamic processes through integration of prior biological data. Objective: We sought to develop a multiscale mathematical model of AD pathogenesis that describes the dynamic interplay between the skin barrier, environmental stress, and immune dysregulation and use it to achieve a coherent mechanistic understanding of the onset, progression, and prevention of AD. Methods: We mathematically investigated synergistic effects of known genetic and environmental risk factors on the dynamic onset and progression of the AD phenotype, froma mostly asymptomatic mild phenotype to a severe treatment-resistant form. Results: Our model analysis identified a "double switch," with 2 concatenated bistable switches, as a key network motif that dictates AD pathogenesis: the first switch is responsible for the reversible onset of inflammation, and the second switch is triggered by long-lasting or frequent activation of the first switch, causing irreversible onset of systemic T(H)2 sensitization and worsening of AD symptoms. Conclusions: Our mathematical analysis of the bistable switch predicts that genetic risk factors decrease the threshold of environmental stressors to trigger systemic T(H)2 sensitization. This analysis predicts and explains 4 common clinical AD phenotypes from a mild and reversible phenotype through to severe and recalcitrant disease and provides a mechanistic explanation for clinically demonstrated preventive effects of emollient treatments against development of AD.	[Dominguez-Huttinger, Elisa; Christodoulides, Panayiotis; Tanaka, Reiko J.] Imperial Coll London, Dept Bioengn, London SW7 2AZ, England; [Dominguez-Huttinger, Elisa] Univ Nacl Autonoma Mexico, Inst Ecol, Mexico City, DF, Mexico; [Miyauchi, Kosuke; Okada-Hatakeyama, Mariko; Kubo, Masato] RIKEN, Ctr Integrat Med Sci, Yokohama, Kanagawa, Japan; [Irvine, Alan D.] Our Ladys Childrens Hosp Crumlin, Natl Childrens Res Ctr & Paediat Dermatol, Dublin, Ireland; [Irvine, Alan D.] Trinity Coll Dublin, Med Clin, Dublin, Ireland; [Kubo, Masato] Tokyo Univ Sci, Res Inst Biomed Sci, Tokyo, Japan	Imperial College London; Universidad Nacional Autonoma de Mexico; RIKEN; National Children's Research Centre (NCRC); Our Ladys Children Hospital Crumlin; Trinity College Dublin; Tokyo University of Science	Tanaka, RJ (corresponding author), Imperial Coll London, Dept Bioengn, London SW7 2AZ, England.	r.tanaka@imperial.ac.uk	Irvine, Alan D/A-3982-2008	Irvine, Alan D/0000-0002-9048-2044; Dominguez Huttinger, Elisa/0000-0002-9086-099X; Tanaka, Reiko/0000-0002-0769-9382	Engineering and Physical Sciences Research Council of the United Kingdom [EP/G007446/1]; Mexican Council for Science and Technology [212800]; National Autonomous University of Mexico; EPSRC [EP/G007446/1] Funding Source: UKRI; Engineering and Physical Sciences Research Council [EP/G007446/1] Funding Source: researchfish; National Centre for the Replacement [NC/P00217X/1] Funding Source: researchfish; Grants-in-Aid for Scientific Research [15H01267] Funding Source: KAKEN	Engineering and Physical Sciences Research Council of the United Kingdom(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Mexican Council for Science and Technology; National Autonomous University of Mexico(Universidad Nacional Autonoma de Mexico); EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); National Centre for the Replacement; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	Supported by the Engineering and Physical Sciences Research Council of the United Kingdom (EP/G007446/1 to R.J.T.), the Mexican Council for Science and Technology (PhD scholarship 212800 to E.D.-H.), and the National Autonomous University of Mexico (postdoctoral scholarship to E.D.-H.).	Aberg KM, 2008, J INVEST DERMATOL, V128, P917, DOI 10.1038/sj.jid.5701099; Ahmad-Nejad P, 2004, J ALLERGY CLIN IMMUN, V113, P565, DOI 10.1016/j.jaci.2003.12.583; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Bergman JN, 2014, J AM ACAD DERMATOL, V70, P338; Bieber T, 2016, ALLERGY, V71, P588, DOI 10.1111/all.12857; Briot A, 2009, J EXP MED, V206, P1135, DOI 10.1084/jem.20082242; Brown SJ, 2012, J INVEST DERMATOL, V132, P98, DOI 10.1038/jid.2011.342; Celli S, 2012, BLOOD, V120, P3945, DOI 10.1182/blood-2012-01-408260; Cenac N, 2004, J PHYSIOL-LONDON, V558, P913, DOI 10.1113/jphysiol.2004.061721; Chen LN, 2012, SCI REP-UK, V2, DOI 10.1038/srep00342; Chen M, 2007, MOL IMMUNOL, V44, P2558, DOI 10.1016/j.molimm.2006.12.020; Cork MJ, 2006, J ALLERGY CLIN IMMUN, V118, P3, DOI 10.1016/j.jaci.2006.04.042; Danby SG, 2014, BRIT J DERMATOL, V170, P914, DOI 10.1111/bjd.12778; Das J, 2001, NAT IMMUNOL, V2, P45, DOI 10.1038/83158; Dominguez-Huttinger E, 2013, INTERFACE FOCUS, V3, DOI 10.1098/rsfs.2012.0090; Dommisch H, 2007, INFECT IMMUN, V75, P4326, DOI 10.1128/IAI.00455-07; Duckney Patrick, 2013, BMC Res Notes, V6, P474, DOI 10.1186/1756-0500-6-474; Elias PM, 2014, J ALLERGY CLIN IMMUN, V134, P781, DOI 10.1016/j.jaci.2014.05.048; Fallon PG, 2009, NAT GENET, V41, P602, DOI 10.1038/ng.358; Galli SJ, 2008, NATURE, V454, P445, DOI 10.1038/nature07204; Gittler JK, 2012, J ALLERGY CLIN IMMUN, V130, P1344, DOI 10.1016/j.jaci.2012.07.012; Hachem JP, 2003, J INVEST DERMATOL, V121, P345, DOI 10.1046/j.1523-1747.2003.12365.x; Hams E, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00597; Hirata Y, 2010, CHAOS, V20, DOI 10.1063/1.3526968; Hofer T, 2002, P NATL ACAD SCI USA, V99, P9364, DOI 10.1073/pnas.142284699; Hoffman DR, 2015, SKIN RES TECHNOL, V21, P366, DOI 10.1111/srt.12201; Hoffman DR, 2014, INT J COSMETIC SCI, V36, P93, DOI 10.1111/ics.12101; Holland SM, 2007, NEW ENGL J MED, V357, P1608, DOI 10.1056/NEJMoa073687; Horimukai K, 2014, J ALLERGY CLIN IMMUN, V134, P824, DOI 10.1016/j.jaci.2014.07.060; Howell MD, 2007, J ALLERGY CLIN IMMUN, V120, P150, DOI 10.1016/j.jaci.2007.04.031; Imai Y, 2013, P NATL ACAD SCI USA, V110, P13921, DOI 10.1073/pnas.1307321110; Irvine AD, 2011, NEW ENGL J MED, V365, P1315, DOI 10.1056/NEJMra1011040; Jinnestal CL, 2014, INT J DERMATOL, V53, P27, DOI 10.1111/ijd.12198; Kawasaki H, 2012, J ALLERGY CLIN IMMUN, V129, P1538, DOI 10.1016/j.jaci.2012.01.068; Kezic S, 2012, J ALLERGY CLIN IMMUN, V129, P1031, DOI 10.1016/j.jaci.2011.12.989; Kong HDH, 2012, GENOME RES, V22, P850, DOI 10.1101/gr.131029.111; Leung DYM, 2014, J ALLERGY CLIN IMMUN, V134, P769, DOI 10.1016/j.jaci.2014.08.008; Man MQ, 2008, J INVEST DERMATOL, V128, P79, DOI 10.1038/sj.jid.5701011; McAleer MA, 2013, J ALLERGY CLIN IMMUN, V131, P280, DOI 10.1016/j.jaci.2012.12.668; McGirt LY, 2006, J ALLERGY CLIN IMMUN, V118, P202, DOI 10.1016/j.jaci.2006.04.033; Nakamura Y, 2013, NATURE, V503, P397, DOI 10.1038/nature12655; Nemoto-Hasebe I, 2009, J INVEST DERMATOL, V129, P682, DOI 10.1038/jid.2008.280; Okuma A, 2013, IMMUNITY, V38, P450, DOI 10.1016/j.immuni.2012.11.016; Oyarzun DA, 2012, J THEOR BIOL, V295, P139, DOI 10.1016/j.jtbi.2011.11.017; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Paternoster L, 2015, NAT GENET, V47, P1449, DOI 10.1038/ng.3424; Reynolds NJ, 2014, BRIT J DERMATOL, V171, P1279, DOI 10.1111/bjd.13447; Sano S, 1999, EMBO J, V18, P4657, DOI 10.1093/emboj/18.17.4657; Sasaki T, 2013, J ALLERGY CLIN IMMUN, V132, P1111, DOI 10.1016/j.jaci.2013.08.027; Saunders SP, 2013, J ALLERGY CLIN IMMUN, V132, P1121, DOI 10.1016/j.jaci.2013.08.046; Scharschmidt TC, 2009, J ALLERGY CLIN IMMUN, V124, P496, DOI 10.1016/j.jaci.2009.06.046; Schoepe S, 2006, EXP DERMATOL, V15, P406, DOI 10.1111/j.0906-6705.2006.00435.x; Shouval R, 2014, BONE MARROW TRANSPL, V49, P332, DOI 10.1038/bmt.2013.146; Simpson EL, 2014, J ALLERGY CLIN IMMUN, V134, P818, DOI 10.1016/j.jaci.2014.08.005; Spergel JM, 2010, IMMUNOL ALLERGY CLIN, V30, P269, DOI 10.1016/j.iac.2010.06.003; Sugiura A, 2014, ARCH DERMATOL RES, V306, P427, DOI 10.1007/s00403-013-1430-x; Taieb A, 2012, J DTSCH DERMATOL GES, V10, P174, DOI 10.1111/j.1610-0387.2011.07760.x; Tanaka RJ, 2013, J INVEST DERMATOL, V133, P1472, DOI 10.1038/jid.2013.69; Tanaka RJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019895; Tang TS, 2014, J ALLERGY CLIN IMMUN, V133, P1615, DOI 10.1016/j.jaci.2013.12.1079; Vakirlis E, 2011, J EUR ACAD DERMATOL, V25, P409, DOI 10.1111/j.1468-3083.2010.03800.x; van Logtestijn MDA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117292; Weidinger S, 2016, LANCET, V387, P1109, DOI 10.1016/S0140-6736(15)00149-X; Williams MR, 2015, CURR ALLERGY ASTHM R, V15, DOI 10.1007/s11882-015-0567-4; Wollenberg A, 2012, ANN DERMATOL, V24, P253, DOI 10.5021/ad.2012.24.3.253; Yamane H, 2005, J EXP MED, V202, P793, DOI 10.1084/jem.20051304; Yamasaki K, 2011, J INVEST DERMATOL, V131, P688, DOI 10.1038/jid.2010.351; Yasuda T, 2016, J CLIN INVEST, V126, P2064, DOI 10.1172/JCI82887; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a; Zhang ZH, 2009, PROCEEDINGS OF 2009 INTERNATIONAL CONFERENCE ON ADVANCED FIBERS AND POLYMER MATERIALS, VOLS 1 AND 2, P119; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8	71	21	21	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2017	139	6					1861	+		10.1016/j.jaci.2016.10.026	http://dx.doi.org/10.1016/j.jaci.2016.10.026			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EW7VG	27931974	hybrid, Green Submitted			2022-12-18	WOS:000402724600017
J	Leung, DYM; Guttman-Yassky, E				Leung, Donald Y. M.; Guttman-Yassky, Emma			Assessing the current treatment of atopic dermatitis: Unmet needs Preface	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Atopic dermatitis; eczema; immune; therapy	EXPRESSION		[Leung, Donald Y. M.] Natl Jewish Hlth, Dept Pediat, Denver, CO USA; [Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA; [Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Lab Inflammatory Skin Dis, New York, NY 10029 USA	National Jewish Health; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Leung, DYM (corresponding author), Natl Jewish Hlth, 1400 Jackson St,Rm K926i, Denver, CO 80206 USA.	leungd@njhealth.org			Omnia-Prova Education Collaborative; MedImmune; Regeneron; Celgene; BMS; Janssen; Dermira; Leo Pharma; Merck; Novartis; UCB	Omnia-Prova Education Collaborative; MedImmune(AstraZenecaMedimmune); Regeneron(Regeneron); Celgene(Bristol-Myers SquibbCelgene Corporation); BMS(Bristol-Myers Squibb); Janssen(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Dermira; Leo Pharma(LEO Pharma); Merck(Merck & Company); Novartis(Novartis); UCB(UCB Pharma SA)	D. Y. M. Leung receives grant support form MedImmune; serves as a consultant for Novartis, Regeneron, and Sanofi-Aventis; and receives payments for reviewing from Omnia-Prova Education Collaborative. E. Guttman-Yassky serves on the board for Sanofi-Aventis, Regeneron, Stiefel/Glaxo-SmithKline, MedImmune, Celgene, Anacor, Leo Pharma, AnaptysBio, Celsus, Dermira, Galderma, Novartis, Pfizer, Vitae, Glenmark, AbbVie, and Asana Biosciences; serves as a consultant for Regeneron, Sanofi-Aventis, MedImmune, Celgene, Stiefel/GlaxoSmithKline, Celsus, BMS, Amgen, Drais, AbbVie, Anacor, AnaptysBio, Dermira, Galderma, Leo Pharma, Novartis, Pfizer, Vitae Mitsubishi Tanabe, Eli Lilly, Glenmark, and Asana Biosciences; and receives grant support from Regeneron, Celgene, BMS, Janssen, Dermira, Leo Pharma, Merck, Novartis, and UCB.	Bieber T, 2017, J ALLERGY CLIN IMMUN, V139, pS58, DOI 10.1016/j.jaci.2017.01.008; Brunner PM, 2017, J ALLERGY CLIN IMMUN, V139, pS65, DOI 10.1016/j.jaci.2017.01.011; Brunner PM, 2017, J INVEST DERMATOL, V137, P18, DOI 10.1016/j.jid.2016.08.022; Eichenfield LF, 2017, J ALLERGY CLIN IMMUN, V139, pS49, DOI 10.1016/j.jaci.2017.01.009; Hamid Q, 1996, J ALLERGY CLIN IMMUN, V98, P225, DOI 10.1016/S0091-6749(96)70246-4; HAMID Q, 1994, J CLIN INVEST, V94, P870, DOI 10.1172/JCI117408; Hanifin IM, 2007, DERMATITIS, V18, P82, DOI 10.2310/6620.2007.06034; Oliva M, 2016, CURR OPIN ALLERGY CL, V16, P469, DOI 10.1097/ACI.0000000000000306; Silverberg JI, 2014, DERMATITIS, V25, P107, DOI 10.1097/DER.0000000000000034; Thaci D, 2016, LANCET, V387, P40, DOI 10.1016/S0140-6736(15)00388-8; Werfel T, 2016, J ALLERGY CLIN IMMUN, V138, P336, DOI 10.1016/j.jaci.2016.06.010	11	21	21	2	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2017	139	4		S			S47	S48		10.1016/j.jaci.2017.01.010	http://dx.doi.org/10.1016/j.jaci.2017.01.010			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ER4LN	28390476	Bronze			2022-12-18	WOS:000398771400001
J	Yu, HS; Zheng, MM; Zhang, LJ; Li, H; Zhu, YY; Cheng, L; Li, L; Deng, BL; Kijlstra, A; Yang, PZ				Yu, Hongsong; Zheng, Minming; Zhang, Lijun; Li, Hua; Zhu, Yunyun; Cheng, Ling; Li, Lin; Deng, Bolin; Kijlstra, Aize; Yang, Peizeng			Identification of susceptibility SNPs in IL10 and IL23R-IL12RB2 for Behcet's disease in Han Chinese	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL23R; IL12RB2; IL10; BD; susceptibility	GENOME-WIDE ASSOCIATION; KOYANAGI-HARADA SYNDROME; GENE POLYMORPHISMS; VKH SYNDROME; POPULATION; CELLS; PROMOTES; UVEITIS; IL-23; IL23R	Background: Although previous genome-wide association studies in various cohorts have identified several susceptibility loci underlying Behc,et's disease (BD), this has not yet led to a breakthrough in the management of BD. Objective: This study aimed to further investigate the association of 26 candidate single nucleotide polymorphisms with previous genome-wide association studies-identified nearly positive P values (5.0 x 10(-8) < P < 1.0 x 10(-5)) in Chinese Han patients with BD. Methods: A case-control association study was performed in 1206 patients with BD and 2475 healthy controls. Genotyping was performed using iPLEX Gold genotyping assay. Gene expression and cytokine production was quantified by real-time PCR and ELISA. Results: The results showed that significantly higher frequencies of the IL23R-IL12RB2/rs924080 TT genotype (P = 2.03 x 10(-8); odds ratio [OR] = 1.50), IL23R-IL12RB2/rs12141431 CC genotype (P = 2.18 x 10(-8); OR = 1.53), IL10/rs1800871 TT genotype (P = 5.88 s 10(-8); OR = 1.47), and IL10/rs3024490 TT genotype (P = 2.80 x 10(-5); OR = 1.34) were found in BD. Functional experiments showed an increased IL23R expression and IL-17 production in rs12141431/CC genotype carriers compared with GG genotype carriers. A decreased IL10 expression and IL-10 production was observed in rs3024490/TT genotype carriers as compared with GG genotype carriers. Conclusions: Our findings not only confirmed the association of IL10/rs1800871 and IL23R-IL12RB2/rs924080 with BD but also identified 2 susceptibility single nucleotide polymorphisms in IL10 and IL23R-IL12RB2 (rs3024490 and rs12141431) with BD in Han Chinese.	[Yu, Hongsong; Zheng, Minming; Zhang, Lijun; Li, Hua; Zhu, Yunyun; Cheng, Ling; Li, Lin; Deng, Bolin; Yang, Peizeng] Chongqing Med Univ, Affiliated Hosp 1, Chongqing Key Lab Ophthalmol, Chongqing 400016, Peoples R China; [Yu, Hongsong; Zheng, Minming; Zhang, Lijun; Li, Hua; Zhu, Yunyun; Cheng, Ling; Li, Lin; Deng, Bolin; Yang, Peizeng] Chongqing Med Univ, Affiliated Hosp 1, Chongqing Eye Inst, Chongqing 400016, Peoples R China; [Kijlstra, Aize] Univ Eye Clin Maastricht, Maastricht, Netherlands	Chongqing Medical University; Chongqing Medical University; Maastricht University; Maastricht University Medical Centre (MUMC)	Yang, PZ (corresponding author), Chongqing Med Univ, Affiliated Hosp 1, Chongqing Key Lab Ophthalmol, Chongqing 400016, Peoples R China.; Yang, PZ (corresponding author), Chongqing Med Univ, Affiliated Hosp 1, Chongqing Eye Inst, Chongqing 400016, Peoples R China.	peizengycmu@126.com	Yu, Hongsong/J-9106-2014	Yu, Hongsong/0000-0002-1209-2104	Natural Science Foundation Major International (Regional) Joint Research Project [81320108009]; Key Project of Natural Science Foundation [81130019]; National Natural Science Foundation Project [31370893, 81200678]; Basic Research Program of Chongqing [cstc2013jcyjC10001]; Fundamental and Advanced Research Program of Chongqing [cstc2015jcyjA10022]; Science and Technology Project of Chongqing Municipal Education Commission [KJ1500236]; Scientific Research Program of Science and Technology Commission of Yuzhong District of Chongqing [20150102]; Chongqing Key Laboratory of Ophthalmology (CSTC) [2008CA5003]; National Key Clinical Specialties Construction Program of China; Key Project of Health Bureau of Chongqing [2012-1-003]; Research Fund for Traditional Chinese Medicine of Chongqing Health and Family Planning Commission [ZY201401013]; Chongqing Science & Technology Platform and Base Construction Program [cstc2014pt-sy10002]	Natural Science Foundation Major International (Regional) Joint Research Project; Key Project of Natural Science Foundation; National Natural Science Foundation Project(National Natural Science Foundation of China (NSFC)); Basic Research Program of Chongqing; Fundamental and Advanced Research Program of Chongqing; Science and Technology Project of Chongqing Municipal Education Commission; Scientific Research Program of Science and Technology Commission of Yuzhong District of Chongqing; Chongqing Key Laboratory of Ophthalmology (CSTC)(Natural Science Foundation Project of CQ CSTC); National Key Clinical Specialties Construction Program of China; Key Project of Health Bureau of Chongqing; Research Fund for Traditional Chinese Medicine of Chongqing Health and Family Planning Commission; Chongqing Science & Technology Platform and Base Construction Program	This work was supported by Natural Science Foundation Major International (Regional) Joint Research Project (grant no. 81320108009), Key Project of Natural Science Foundation (grant no. 81130019), National Natural Science Foundation Project (grant nos. 31370893 and 81200678), Basic Research Program of Chongqing (cstc2013jcyjC10001), Fundamental and Advanced Research Program of Chongqing (grant no. cstc2015jcyjA10022), Science and Technology Project of Chongqing Municipal Education Commission (grant no. KJ1500236), Scientific Research Program of Science and Technology Commission of Yuzhong District of Chongqing (grant no. 20150102), Chongqing Key Laboratory of Ophthalmology (CSTC, grant no. 2008CA5003), National Key Clinical Specialties Construction Program of China, Key Project of Health Bureau of Chongqing (2012-1-003), Research Fund for Traditional Chinese Medicine of Chongqing Health and Family Planning Commission (grant no. ZY201401013), and Chongqing Science & Technology Platform and Base Construction Program (cstc2014pt-sy10002).	Aggarwal S, 2003, J BIOL CHEM, V278, P1910, DOI 10.1074/jbc.M207577200; Beaudoin M, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003723; Cargill M, 2007, AM J HUM GENET, V80, P273, DOI 10.1086/511051; Chi W, 2008, INVEST OPHTH VIS SCI, V49, P3058, DOI 10.1167/iovs.07-1390; Davidson SI, 2013, ARTHRITIS RHEUM-US, V65, P1747, DOI 10.1002/art.37976; Di Meglio P, 2013, J INVEST DERMATOL, V133, P2381, DOI 10.1038/jid.2013.170; Duhen T, 2014, J IMMUNOL, V193, P120, DOI 10.4049/jimmunol.1302734; Fang J, 2014, AM J OPHTHALMOL, V157, P488, DOI 10.1016/j.ajo.2013.10.010; FIORENTINO DF, 1991, J IMMUNOL, V146, P3444; Hamzaoui K, 2011, MED SCI MONITOR, V17, pCR227, DOI 10.12659/MSM.881720; Hou SP, 2012, ARTHRITIS RHEUM-US, V64, P4104, DOI 10.1002/art.37708; Hu JM, 2015, MOL VIS, V21, P589; International Study Group for Beh~et's Disease, 1990, LANCET, V335, P1078, DOI DOI 10.1016/0140-; Jiang ZX, 2010, ANN RHEUM DIS, V69, P1325, DOI 10.1136/ard.2009.119420; Kirino Y, 2013, NAT GENET, V45, P202, DOI 10.1038/ng.2520; Li X, 2014, SOFT MATER, V12, P1, DOI 10.1080/1539445X.2011.584269; Liu ZJ, 2011, J LEUKOCYTE BIOL, V89, P597, DOI 10.1189/jlb.0810456; Mizuki N, 2010, NAT GENET, V42, P703, DOI 10.1038/ng.624; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Na SY, 2013, CLIN EXP RHEUMATOL, V31, pS32; Parham C, 2002, J IMMUNOL, V168, P5699, DOI 10.4049/jimmunol.168.11.5699; Remmers EF, 2010, NAT GENET, V42, P698, DOI 10.1038/ng.625; SuttorpSchulten MSA, 1996, BRIT J OPHTHALMOL, V80, P844, DOI 10.1136/bjo.80.9.844; Talaat RM, 2014, IMMUNOBIOLOGY, V219, P573, DOI 10.1016/j.imbio.2014.03.004; Verity DH, 1999, TISSUE ANTIGENS, V54, P213, DOI 10.1034/j.1399-0039.1999.540301.x; Wu ZY, 2014, HUM IMMUNOL, V75, P271, DOI 10.1016/j.humimm.2013.11.009; Xavier JM, 2012, ARTHRITIS RHEUM-US, V64, P2761, DOI 10.1002/art.34437; Yang PZ, 2008, OPHTHALMOLOGY, V115, P312, DOI 10.1016/j.ophtha.2007.04.056; Yang PZ, 2005, CURR EYE RES, V30, P943, DOI 10.1080/02713680500263606; Yu HS, 2015, HUM MUTAT, V36, P1064, DOI 10.1002/humu.22829; Yu HS, 2014, J MOL MED, V92, P961, DOI 10.1007/s00109-014-1159-9; Zhang LJ, 2015, INVEST OPHTH VIS SCI, V56, P6029, DOI 10.1167/iovs.15-17544; Zhang TC, 2014, J INFECTION, V69, P75, DOI 10.1016/j.jinf.2014.03.003; Zhao M, 2014, CLIN IMMUNOL, V150, P22, DOI 10.1016/j.clim.2013.10.009; Zheng MM, 2015, INVEST OPHTH VIS SCI, V56, P8280, DOI 10.1167/iovs.15-18035; Zhou QY, 2014, ANN RHEUM DIS, V73, P170, DOI 10.1136/annrheumdis-2012-201627; Zidi S, 2015, CYTOKINE, V76, P343, DOI 10.1016/j.cyto.2015.05.028	37	21	23	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2017	139	2					621	627		10.1016/j.jaci.2016.05.024	http://dx.doi.org/10.1016/j.jaci.2016.05.024			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EO9IM	27464962	Bronze			2022-12-18	WOS:000397002400027
J	Selb, R; Eckl-Dorna, J; Twaroch, TE; Lupinek, C; Teufelberger, A; Hofer, G; Focke-Tejkl, M; Gepp, B; Linhart, B; Breiteneder, H; Ellinger, A; Keller, W; Roux, KH; Valenta, R; Niederberger, V				Selb, Regina; Eckl-Dorna, Julia; Twaroch, Teresa E.; Lupinek, Christian; Teufelberger, Andrea; Hofer, Gerhard; Focke-Tejkl, Margarete; Gepp, Barbara; Linhart, Birgit; Breiteneder, Heimo; Ellinger, Adolf; Keller, Walter; Roux, Kenneth H.; Valenta, Rudolf; Niederberger, Verena			Critical and direct involvement of the CD23 stalk region in IgE binding	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CD23; allergy; IgE; low-affinity IgE receptor; B cell; allergen	FC-EPSILON-RI; PROTEIN SECONDARY STRUCTURE; FACILITATED ALLERGEN PRESENTATION; AFFINITY RECEPTOR; ANTIBODY FRAGMENT; POLLEN ALLERGEN; T-CELLS; VACCINATION; INHIBITION; OMALIZUMAB	Background: The low-affinity receptor for IgE, FceRII (CD23), contributes to allergic inflammation through allergen presentation to T cells, regulation of IgE responses, and enhancement of transepithelial allergen migration. Objective: We sought to investigate the interaction between CD23, chimeric monoclonal human IgE, and the corresponding birch pollen allergen Bet v 1 at a molecular level. Methods: We expressed 4 CD23 variants. One variant comprised the full extracellular portion of CD23, including the stalk and head domain; 1 variant was identical with the first, except for an amino acid exchange in the stalk region abolishing the N-linked glycosylation site; and 2 variants represented the head domain, 1 complete and 1 truncated. The 4 CD23 variants were purified as monomeric and structurally folded proteins, as demonstrated by gel filtration and circular dichroism. By using a human IgE mAb, the corresponding allergen Bet v 1, and a panel of antibodies specific for peptides spanning the CD23 surface, both binding and inhibition assays and negative stain electron microscopy were performed. Results: A hitherto unknown IgE-binding site was mapped on the stalk region of CD23, and the non-N-glycosylated monomeric version of CD23 was superior in IgE binding compared with glycosylated CD23. Furthermore, we demonstrated that a therapeutic anti-IgE antibody, omalizumab, which inhibits IgE binding to FceRI, also inhibited IgE binding to CD23. Conclusion: Our results provide a new model for the CD23-IgE interaction. We show that the stalk region of CD23 is crucially involved in IgE binding and that the interaction can be blocked by the therapeutic anti-IgE antibody omalizumab.	[Selb, Regina; Eckl-Dorna, Julia; Niederberger, Verena] Med Univ Vienna, Dept Otorhinolaryngol, Vienna, Austria; [Twaroch, Teresa E.; Lupinek, Christian; Focke-Tejkl, Margarete; Linhart, Birgit; Valenta, Rudolf] Med Univ Vienna, Div Immunopathol, Dept Pathophysiol & Allergy Res, Ctr Pathophysiol Infectiol & Immunol, A-1090 Vienna, Austria; [Teufelberger, Andrea; Hofer, Gerhard] Karl Franzens Univ Graz, Inst Mol Biosci, Graz, Austria; [Gepp, Barbara; Breiteneder, Heimo] Med Univ Vienna, Dept Pathophysiol & Allergy Res, Ctr Pathophysiol Infectiol & Immunol, Div Med Biotechnol, Vienna, Austria; [Ellinger, Adolf] Med Univ Vienna, Dept Cell Biol & Ultrastruct Res, Ctr Anat & Cell Biol, Vienna, Austria; [Roux, Kenneth H.] Florida State Univ, Dept Biol Sci, B-157, Tallahassee, FL 32306 USA; [Teufelberger, Andrea] Univ Hosp Ghent, Upper Airway Res Lab, Ghent, Belgium	Medical University of Vienna; Medical University of Vienna; University of Graz; Medical University of Vienna; Medical University of Vienna; State University System of Florida; Florida State University; Ghent University; Ghent University Hospital	Valenta, R (corresponding author), Med Univ Vienna, Div Immunopathol, Dept Pathophysiol & Allergy Res, Ctr Pathophysiol Infectiol & Immunol, A-1090 Vienna, Austria.	Rudolf.valenta@meduniwien.ac.at	Eckl-Dorna, Julia/AAY-6371-2020; Keller, Walter/AAW-1501-2021; Lupinek, Christian/I-3311-2019	Keller, Walter/0000-0002-2261-958X; Lupinek, Christian/0000-0002-8612-8245; Linhart, Birgit/0000-0001-6857-3049; Breiteneder, Heimo/0000-0003-2022-8689; Eckl-Dorna, Julia/0000-0001-5981-1607; Valenta, Rudolf/0000-0001-5944-3365; Selb, Regina/0000-0001-5531-5198; Hofer, Gerhard/0000-0002-9248-6989; Teufelberger, Andrea/0000-0002-1142-949X	Austrian Science Fund [SFB 4604, SFB 4605, SFB 4613]	Austrian Science Fund(Austrian Science Fund (FWF))	Supported by the Austrian Science Fund (FWF): SFB 4604, SFB 4605, and SFB 4613.	AUBRY JP, 1992, NATURE, V358, P505, DOI 10.1038/358505a0; Bendell CJ, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-82; BETTLER B, 1992, J BIOL CHEM, V267, P185; Buchan DWA, 2013, NUCLEIC ACIDS RES, V41, pW349, DOI 10.1093/nar/gkt381; Campana R, 2011, MOL IMMUNOL, V48, P431, DOI 10.1016/j.molimm.2010.09.016; Chan MA, 2014, AM J RESP CELL MOL, V50, P263, DOI 10.1165/rcmb.2013-0112OC; Chen BH, 2002, IMMUNOLOGY, V107, P373, DOI 10.1046/j.1365-2567.2002.01512.x; Dhaliwal B, 2012, P NATL ACAD SCI USA, V109, P12686, DOI 10.1073/pnas.1207278109; Eggel A, 2014, J ALLERGY CLIN IMMUN, V133, P1709, DOI 10.1016/j.jaci.2014.02.005; Focke M, 2004, CLIN EXP ALLERGY, V34, P1525, DOI 10.1111/j.1365-2222.2004.02081.x; Focke M, 2001, FASEB J, V15, P2042, DOI 10.1096/fj.01-0016fje; Galli SJ, 2012, NAT MED, V18, P693, DOI 10.1038/nm.2755; Garman SC, 2000, NATURE, V406, P259, DOI 10.1038/35018500; GRABER P, 1992, J IMMUNOL METHODS, V149, P215, DOI 10.1016/0022-1759(92)90253-P; Hibbert RG, 2005, J EXP MED, V202, P751, DOI 10.1084/jem.20050811; Holgate ST, 2005, CLIN EXP ALLERGY, V35, P408, DOI 10.1111/j.1365-2222.2005.02191.x; Jensen RK, 2015, ACTA CRYSTALLOGR F, V71, P419, DOI 10.1107/S2053230X15004100; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; Kilmon MA, 2004, J IMMUNOL, V172, P1065, DOI 10.4049/jimmunol.172.2.1065; Klunker S, 2007, J ALLERGY CLIN IMMUN, V120, P688, DOI 10.1016/j.jaci.2007.05.034; Laffer S, 2001, J ALLERGY CLIN IMMUN, V108, P409, DOI 10.1067/mai.2001.117593; Lupinek C, 2009, J IMMUNOL, V182, P4817, DOI 10.4049/jimmunol.0800726; Marlovits TC, 1998, J MOL RECOGNIT, V11, P49, DOI 10.1002/(SICI)1099-1352(199812)11:1/6<49::AID-JMR388>3.0.CO;2-3; Pahr S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111483; Palaniyandi S, 2011, J IMMUNOL, V186, P3484, DOI 10.4049/jimmunol.1002146; Pawankar R, 2012, CURR OPIN ALLERGY CL, V12, P39, DOI 10.1097/ACI.0b013e32834ec13b; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Reginald K, 2013, IMMUNOL CELL BIOL, V91, P167, DOI 10.1038/icb.2012.70; Roux Kenneth H., 1996, Methods (Orlando), V10, P247, DOI 10.1006/meth.1996.0099; ROUX KH, 1989, METHOD ENZYMOL, V178, P130; Sanner MF, 1996, BIOPOLYMERS, V38, P305, DOI 10.1002/(SICI)1097-0282(199603)38:3<305::AID-BIP4>3.3.CO;2-8; Schulz O, 1997, EUR J IMMUNOL, V27, P584, DOI 10.1002/eji.1830270303; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; Tu Y, 2005, GASTROENTEROLOGY, V129, P928, DOI 10.1053/j.gastro.2005.06.014; van Neerven RJJ, 1999, J IMMUNOL, V163, P2944; van Neerven RJJ, 2001, INT ARCH ALLERGY IMM, V124, P400, DOI 10.1159/000053770; VANDERHEIJDEN FL, 1993, J IMMUNOL, V150, P3643; Whitmore L, 2004, NUCLEIC ACIDS RES, V32, pW668, DOI 10.1093/nar/gkh371; Wright JD, 2015, SCI REP-UK, V5, DOI 10.1038/srep11581; Wurzburg BA, 2006, STRUCTURE, V14, P1049, DOI 10.1016/j.str.2006.03.017	40	21	21	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2017	139	1					281	+		10.1016/j.jaci.2016.04.015	http://dx.doi.org/10.1016/j.jaci.2016.04.015			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EK5WM	27343203	Green Accepted, hybrid			2022-12-18	WOS:000393996800029
J	Bachert, C; Gevaert, E				Bachert, Claus; Gevaert, Elien			Advances in rhinitis and rhinosinusitis in 2015	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic rhinitis; allergen components; allergen-specific immunotherapy; house dust mite; chronic rhinosinusitis; endotype; type 2 cytokines	EOSINOPHILIC CHRONIC RHINOSINUSITIS; ADULT CHRONIC RHINOSINUSITIS; 5-GRASS POLLEN TABLET; ALLERGEN IMMUNOTHERAPY; NASAL POLYPS; EPITHELIAL-CELLS; IGE RESPONSES; ASTHMA; EXPRESSION; RHINOCONJUNCTIVITIS	The last year has seen great progress in the understanding of upper airway disease and in its management. For allergic rhinitis, authors focused on the prediction of and effect on the natural course of disease. New evidence was published for the disease-modifying effect of allergen immunotherapy in terms of avoidance of new sensitizations and prevention of asthma in either randomized or real-life studies. Specifically, for patients with house dust mite allergies, which are often underestimated and difficult to diagnose, the efficacy of SQ house dust mite sublingual immunotherapy tablets has been demonstrated in patients with allergic rhinitis and asthma. For the first time, allergen immunotherapy significantly reduced asthma exacerbations. In patients with chronic rhinosinusitis, a novel endotyping approach purely based on T helper cell biomarkers has been developed and has shown clinical relevance through associations with asthma comorbidity and recurrence after surgery. Severe nasal polyposis with high risk for asthma comorbidity and disease recurrence is characterized by type 2 inflammatory patterns, including IgE antibodies to staphylococcal superantigens; several studies using biologic agents have targeted exactly this spectrum of mediators. This goes in parallel with new knowledge on even more type 2 mediators derived from epithelial cells, which will expand the number of possible candidates for innovative intervention.	[Bachert, Claus; Gevaert, Elien] Ghent Univ Hosp, Upper Airways Res Lab, Ghent, Belgium; [Bachert, Claus; Gevaert, Elien] Ghent Univ Hosp, ENT Dept, Ghent, Belgium; [Bachert, Claus] Univ Stockholm, CLINTEC, Karolinska Inst, Div ENT Dis, S-10691 Stockholm, Sweden	Ghent University; Ghent University Hospital; Ghent University; Ghent University Hospital; Karolinska Institutet; Stockholm University	Bachert, C (corresponding author), Univ Ghent, Upper Airways Res Lab, Pintelaan 185, B-9000 Ghent, Belgium.; Bachert, C (corresponding author), Univ Ghent, ENT Dept, Pintelaan 185, B-9000 Ghent, Belgium.	Claus.Bachert@ugent.be	Bachert, Claus/J-8825-2012		Sanofi; Novartis; GlaxoSmithKline	Sanofi(Sanofi-Aventis); Novartis(Novartis); GlaxoSmithKline(GlaxoSmithKline)	C. Bachert has received consulting fees or honoraria from Sanofi, Novartis, and GlaxoSmithKline. E. Gevaert declares no relevant conflicts of interest.	Akdis CA, 2013, J ALLERGY CLIN IMMUN, V131, P1479, DOI 10.1016/j.jaci.2013.02.036; Bachert C, 2016, JAMA-J AM MED ASSOC, V315, P469, DOI 10.1001/jama.2015.19330; Bachert C, 2016, J ALLER CL IMM-PRACT, V4, P621, DOI 10.1016/j.jaip.2016.05.004; Bachert C, 2016, J ALLER CL IMM-PRACT, V4, P629, DOI 10.1016/j.jaip.2015.12.008; Bachert C, 2015, J ALLERGY CLIN IMMUN, V136, P1431, DOI 10.1016/j.jaci.2015.10.010; Bachert C, 2015, WORLD ALLERGY ORGAN, V8, DOI 10.1186/s40413-015-0078-8; Buchheit KM, 2016, J ALLERGY CLIN IMMUN, V137, P1566, DOI 10.1016/j.jaci.2015.10.020; Calderon MA, 2015, J ALLERGY CLIN IMMUN, V136, P38, DOI 10.1016/j.jaci.2014.10.012; Chalermwatanachai T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136068; Custovic A, 2015, J ALLERGY CLIN IMMUN, V136, P1645, DOI 10.1016/j.jaci.2015.03.041; Demoly P, 2016, J ALLERGY CLIN IMMUN, V137, P444, DOI 10.1016/j.jaci.2015.06.036; Didier A, 2015, CLIN TRANSL ALLERGY, V5, DOI 10.1186/s13601-015-0057-8; Didier A, 2015, EXPERT OPIN DRUG SAF, V14, P777, DOI 10.1517/14740338.2015.1017468; Dixon AE, 2015, J ALLERGY CLIN IMMUN, V135, P701, DOI 10.1016/j.jaci.2014.06.038; Durham SR, 2016, J ALLERGY CLIN IMMUN, V137, P339, DOI 10.1016/j.jaci.2015.12.1298; Focke-Tejkl M, 2015, J ALLERGY CLIN IMMUN, V135, P1207, DOI 10.1016/j.jaci.2014.09.012; Grabenhenrich LB, 2015, J ALLERGY CLIN IMMUN, V136, P932, DOI 10.1016/j.jaci.2015.03.040; Hansen TE, 2013, ACTA PAEDIATR, V102, P47, DOI 10.1111/apa.12030; Hastan D, 2011, ALLERGY, V66, P1216, DOI 10.1111/j.1398-9995.2011.02646.x; Hayes SM, 2015, J ALLERGY CLIN IMMUN, V135, P1648, DOI 10.1016/j.jaci.2014.12.1929; Henriksen L, 2015, J ALLERGY CLIN IMMUN, V136, P360, DOI 10.1016/j.jaci.2015.02.003; Ho J, 2015, CLIN EXP ALLERGY, V45, P394, DOI 10.1111/cea.12462; Humbert M, 2014, J ALLER CL IMM-PRACT, V2, P525, DOI 10.1016/j.jaip.2014.03.010; Jia Y, 2015, J ALLERGY CLIN IMMUN, V135, P799, DOI 10.1016/j.jaci.2015.01.004; Kashani S, 2015, J ALLER CL IMM-PRACT, V3, P236, DOI 10.1016/j.jaip.2014.09.022; Kruse K, 2015, J ALLER CL IMM-PRACT, V3, P381, DOI 10.1016/j.jaip.2014.10.015; Lam EPS, 2016, J ALLERGY CLIN IMMUN, V137, P1514, DOI 10.1016/j.jaci.2015.10.019; Lam M, 2015, AM J RHINOL ALLERGY, V29, P175, DOI 10.2500/ajra.2015.29.4176; Liao B, 2015, ALLERGY, V70, P1169, DOI 10.1111/all.12667; Long A, 2014, J ALLERGY CLIN IMMUN, V134, P560, DOI 10.1016/j.jaci.2014.02.007; Lou HF, 2015, AM J RHINOL ALLERGY, V29, P350, DOI 10.2500/ajra.2015.29.4231; Milara J, 2015, J ALLERGY CLIN IMMUN, V135, P470, DOI 10.1016/j.jaci.2014.07.011; Nelson H, 2015, J ALLER CL IMM-PRACT, V3, P256, DOI 10.1016/j.jaip.2014.09.018; Nolte H, 2015, J ALLERGY CLIN IMMUN, V135, P1494, DOI 10.1016/j.jaci.2014.12.1911; Normansell R, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011293.pub2; Okano M, 2015, J ALLERGY CLIN IMMUN, V136, P343, DOI 10.1016/j.jaci.2014.10.058; Philpott C, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-006680; Pleis John R, 2009, Vital Health Stat 10, P1; Pothoven KL, 2015, J ALLERGY CLIN IMMUN, V136, P737, DOI 10.1016/j.jaci.2015.01.043; Rajan JP, 2015, J ALLERGY CLIN IMMUN, V135, P676, DOI 10.1016/j.jaci.2014.08.020; Ramakrishnan VR, 2015, J ALLERGY CLIN IMMUN, V136, P334, DOI 10.1016/j.jaci.2015.02.008; Rosner-Friese K, 2015, J ALLERGY CLIN IMMUN, V135, P636, DOI 10.1016/j.jaci.2014.10.045; Rudmik L, 2015, J ALLERGY CLIN IMMUN, V136, P1532, DOI 10.1016/j.jaci.2015.10.012; Schmitt J, 2015, J ALLERGY CLIN IMMUN, V136, P1511, DOI 10.1016/j.jaci.2015.07.038; Schwitzguebel AJP, 2015, J ALLERGY CLIN IMMUN, V136, P1523, DOI 10.1016/j.jaci.2015.07.016; Seshadri S, 2015, J ALLERGY CLIN IMMUN, V136, P1548; Seshadri S, 2015, J ALLERGY CLIN IMMUN, V136, P1548, DOI 10.1016/j.jaci.2015.05.024; Shamji MH, 2015, J ALLERGY CLIN IMMUN, V135, P913, DOI 10.1016/j.jaci.2014.09.049; Shin HW, 2015, J ALLERGY CLIN IMMUN, V135, P1476, DOI 10.1016/j.jaci.2015.01.003; Simpson A, 2015, J ALLERGY CLIN IMMUN, V136, P1224, DOI 10.1016/j.jaci.2015.03.027; Stevens WW, 2015, J ALLERGY CLIN IMMUN, V136, P1442, DOI 10.1016/j.jaci.2015.10.009; Tomassen P, 2016, J ALLERGY CLIN IMMUN, V137, P1449, DOI 10.1016/j.jaci.2015.12.1324; Ueki S, 2016, J ALLERGY CLIN IMMUN, V137, P258, DOI 10.1016/j.jaci.2015.04.041; Van Zele T, 2014, AM J RHINOL ALLERGY, V28, P192, DOI 10.2500/ajra.2014.28.4033; Virchow JC, 2016, JAMA-J AM MED ASSOC, V315, P1715, DOI 10.1001/jama.2016.3964; Wang CS, 2015, J ALLERGY CLIN IMMUN, V135, P922, DOI 10.1016/j.jaci.2014.10.018; Wang M, 2015, J ALLERGY CLIN IMMUN, V136, P1700, DOI 10.1016/j.jaci.2015.09.005; Wang XD, 2016, ALLERGY, V71, P1170, DOI 10.1111/all.12874; Wen WP, 2012, J ALLERGY CLIN IMMUN, V129, P1522, DOI 10.1016/j.jaci.2012.01.079; Westman M, 2015, J ALLERGY CLIN IMMUN, V136, P512, DOI 10.1016/j.jaci.2015.02.019; Westman M, 2015, J ALLERGY CLIN IMMUN, V135, P1199, DOI 10.1016/j.jaci.2014.10.042; Zhang N, 2016, ALLERGY, V71, P295, DOI 10.1111/all.12809; Zhang Y, 2015, ALLERGY ASTHMA IMMUN, V7, P367, DOI 10.4168/aair.2015.7.4.367; Zolkipli Z, 2015, J ALLERGY CLIN IMMUN, V136, P1541, DOI 10.1016/j.jaci.2015.04.045	64	21	25	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2016	138	5					1277	1283		10.1016/j.jaci.2016.09.008	http://dx.doi.org/10.1016/j.jaci.2016.09.008			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EE4AA	27817798	Bronze			2022-12-18	WOS:000389542700004
J	Jang, HY; Gu, S; Lee, SM; Park, BH				Jang, Hyun-Young; Gu, Suna; Lee, Sang-Myeong; Park, Byung-Hyun			Overexpression of sirtuin 6 suppresses allergic airway inflammation through deacetylation of GATA3	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							OBSTRUCTIVE PULMONARY-DISEASE; EOSINOPHIL ADHESION; ASTHMA; LEUKOTRIENE-D-4; DEGRANULATION; GENERATION		[Jang, Hyun-Young; Park, Byung-Hyun] Chonbuk Natl Univ, Sch Med, Dept Biochem, Jeonju, Jeonbuk, South Korea; [Gu, Suna; Lee, Sang-Myeong] Chonbuk Natl Univ, Coll Environm & Bioresource Sci, Div Biotechnol, Iksan, Jeonbuk, South Korea	Jeonbuk National University; Jeonbuk National University	Lee, SM (corresponding author), Chonbuk Natl Univ, Coll Environm & Bioresource Sci, Div Biotechnol, Iksan, Jeonbuk, South Korea.	leesangm@jbnu.ac.kr; bhpark@jbnu.ac.kr						Aoshiba K, 2004, CLIN REV ALLERG IMMU, V27, P35, DOI 10.1385/CRIAI:27:1:035; Barnes PJ, 2008, J CLIN INVEST, V118, P3546, DOI 10.1172/JCI36130; Bhavsar P, 2008, J ALLERGY CLIN IMMUN, V121, P580, DOI 10.1016/j.jaci.2007.12.1156; Cosio BG, 2004, AM J RESP CRIT CARE, V170, P141, DOI 10.1164/rccm.200305-659OC; Kobayashi T, 2008, EUR RESPIR J, V32, P1540, DOI 10.1183/09031936.00059507; Kobayashi T, 2010, J IMMUNOL, V184, P6350, DOI 10.4049/jimmunol.0902673; Kugel S, 2014, TRENDS BIOCHEM SCI, V39, P72, DOI 10.1016/j.tibs.2013.12.002; Nagata M, 2002, J ALLERGY CLIN IMMUN, V109, P676, DOI 10.1067/mai.2002.122841; Noguchi T, 2015, ALLERGOL INT, V64, pS46, DOI 10.1016/j.alit.2015.05.009; Saito K, 2004, ANN ALLERG ASTHMA IM, V93, P594, DOI 10.1016/S1081-1206(10)61269-0; Takaku Y, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-138; Yamagata T, 2000, EMBO J, V19, P4676, DOI 10.1093/emboj/19.17.4676; Zhu JF, 2004, NAT IMMUNOL, V5, P1157, DOI 10.1038/ni1128	13	21	21	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2016	138	5					1452	+		10.1016/j.jaci.2016.05.019	http://dx.doi.org/10.1016/j.jaci.2016.05.019			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EE4AA	27421859	Bronze			2022-12-18	WOS:000389542700030
J	Aubier, M; Thabut, G; Hamidi, F; Guillou, N; Brard, J; Dombret, MC; Borensztajn, K; Aitilalne, B; Poirier, I; Roland-Nicaise, P; Taille, C; Pretolani, M				Aubier, Michel; Thabut, Gabriel; Hamidi, Fatima; Guillou, Noelline; Brard, Julien; Dombret, Marie-Christine; Borensztajn, Keren; Aitilalne, Brahim; Poirier, Isabelle; Roland-Nicaise, Pascale; Taille, Camille; Pretolani, Marina			Airway smooth muscle enlargement is associated with protease-activated receptor 2/ligand overexpression in patients with difficult-to-control severe asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Airway remodeling; asthma control; mast cells; tryptase; protease-activated receptor 2; kallikreins	BLOOD EOSINOPHIL COUNT; CELL-PROLIFERATION; UP-REGULATION; GENE-EXPRESSION; MODERATE ASTHMA; INFLAMMATION; TRYPTASE; EXACERBATIONS; COAGULATION; MEPOLIZUMAB	Background: Asthma is a complex disease with heterogeneous features of airway inflammation and remodeling. The increase in airway smooth muscle (ASM) mass is an essential component of airway remodeling in patients with severe asthma, yet the pathobiological mechanisms and clinical outcomes associated with ASM enlargement remain elusive. Objective: We sought to compare ASM area in control subjects and patients with mild-to-moderate or severe asthma and to identify specific clinical and pathobiological characteristics associated with ASM enlargement. Methods: Bronchial biopsy specimens from 12 control subjects, 24 patients with mild-to-moderate asthma, and 105 patients with severe asthma were analyzed for ASM area, basement membrane thickness, vessels, eosinophils, neutrophils, T lymphocytes, mast cells, and protease-activated receptor 2 (PAR-2). In parallel, the levels of severalASMmitogenic factors, including the PAR-2 ligands, mast cell tryptase, trypsin, tissue factor, and kallikrein (KLK) 5 and KLK14, were assessed in bronchoalveolar lavage fluid. Data were correlated with asthma severity and control both at inclusion and after 12 to 18 months of optimal management and therapy. Results: Analyses across ASM quartiles in patients with severe asthma demonstrated that patients with the highest ASM quartile (median value of ASM area, 26.3%) were younger (42.5 vs >= 50 years old in the other groups, P <= .04) and had lower asthma control after 1 year of optimal management (P <= .006). ASM enlargement occurred independently of features of airway inflammation and remodeling, whereas it was associated with PAR-2 overexpression and higher alveolar tryptase (P <= .02) and KLK14 (P <= .03) levels. Conclusion: Increase in ASM mass, possibly involving aberrant expression and activation of PAR-2-mediated pathways, characterizes younger patients with severe asthma with poor asthma control.	[Aubier, Michel; Thabut, Gabriel; Hamidi, Fatima; Guillou, Noelline; Brard, Julien; Dombret, Marie-Christine; Borensztajn, Keren; Aitilalne, Brahim; Poirier, Isabelle; Taille, Camille; Pretolani, Marina] Inserm UMR1152, Physiopathol & Epidemiol Malad Resp, Paris, France; [Aubier, Michel; Thabut, Gabriel; Hamidi, Fatima; Guillou, Noelline; Brard, Julien; Dombret, Marie-Christine; Borensztajn, Keren; Aitilalne, Brahim; Poirier, Isabelle; Roland-Nicaise, Pascale; Taille, Camille; Pretolani, Marina] Univ Paris Diderot, Fac Med, Site Bichat, Paris, France; [Aubier, Michel; Dombret, Marie-Christine; Roland-Nicaise, Pascale; Taille, Camille] Grp Hosp Univ Nord Bichat Claude Bernard, Dept Pneumol A, Paris, France; [Thabut, Gabriel] Grp Hosp Univ Nord Bichat Claude Bernard, Dept Pneumol B, Paris, France; [Aubier, Michel; Dombret, Marie-Christine; Taille, Camille] Grp Hosp Univ Nord Bichat Claude Bernard, Dept Hematol Immunol, Paris, France; [Aubier, Michel; Thabut, Gabriel; Dombret, Marie-Christine; Roland-Nicaise, Pascale; Taille, Camille] AP HP, Paris, France; [Aitilalne, Brahim] Grp Hosp Univ Nord Bichat Claude Bernard, Ctr Invest Clin, Paris, France; [Aubier, Michel; Thabut, Gabriel; Hamidi, Fatima; Guillou, Noelline; Brard, Julien; Dombret, Marie-Christine; Borensztajn, Keren; Aitilalne, Brahim; Poirier, Isabelle; Taille, Camille; Pretolani, Marina] Univ Sorbonne Paris Cite, INFLAMEX, Lab Excellence, Paris, France; [Aubier, Michel; Thabut, Gabriel; Hamidi, Fatima; Guillou, Noelline; Brard, Julien; Dombret, Marie-Christine; Borensztajn, Keren; Aitilalne, Brahim; Poirier, Isabelle; Taille, Camille; Pretolani, Marina] Dept Hosp Univ FIRE, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Assistance Publique Hopitaux Paris (APHP); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Pretolani, M (corresponding author), Univ Diderot, Fac Med, Inserm UMR1152, Site Bichat,16 Rue Henri Huchard, F-75018 Paris, France.	marina.pretolani@inserm.fr	Borensztajn, Keren S/M-7002-2018; Pretolani, Marina/G-6643-2017; Taille, Camille/J-3751-2017		MedImmune, Gaithersburg, Md	MedImmune, Gaithersburg, Md	Supported in part by MedImmune, Gaithersburg, Md.	Adam RM, 2004, PHYSIOL GENOMICS, V20, P36, DOI 10.1152/physiolgenomics.00181.2004; Ahmad S, 2013, AM J RESP CELL MOL, V48, P94, DOI 10.1165/rcmb.2012-0189OC; Alagha K, 2015, RESP MED, V109, P180, DOI 10.1016/j.rmed.2014.12.008; Allard B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086945; Amin K, 2005, ALLERGY, V60, P1241, DOI 10.1111/j.1398-9995.2005.00823.x; Bara I, 2012, AM J RESP CRIT CARE, V185, P715, DOI 10.1164/rccm.201105-0915OC; Baraldo S, 2011, EUR RESPIR J, V38, P575, DOI 10.1183/09031936.00168210; Benayoun L, 2003, AM J RESP CRIT CARE, V167, P1360, DOI 10.1164/rccm.200209-1030OC; Berger P, 2001, J APPL PHYSIOL, V91, P1372, DOI 10.1152/jappl.2001.91.3.1372; Black JL, 2002, CURR OPIN ALLERGY CL, V2, P47, DOI 10.1097/00130832-200202000-00008; Borensztajn K, 2010, AM J PATHOL, V177, P2753, DOI 10.2353/ajpath.2010.091107; Bosse Y, 2006, AM J RESP CELL MOL, V34, P746, DOI 10.1165/rcmb.2005-0309OC; Bradding P, 2007, EUR RESPIR J, V29, P827, DOI 10.1183/09031936.00017707; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; Brown JK, 2001, AM J RESP CELL MOL, V24, P146, DOI 10.1165/ajrcmb.24.2.4165; Campo P, 2013, J INVEST ALLERG CLIN, V23, P76; Cerutis DR, 1997, AM J PHYSIOL-LUNG C, V273, pL10, DOI 10.1152/ajplung.1997.273.1.L10; Chambers LS, 2001, AM J PHYSIOL-LUNG C, V281, pL1369, DOI 10.1152/ajplung.2001.281.6.L1369; Chhabra J, 2007, EUR RESPIR J, V29, P861, DOI 10.1183/09031936.00106306; Chung Kian Fan, 2013, Ann Am Thorac Soc, V10 Suppl, pS109, DOI 10.1513/AnnalsATS.201304-087AW; Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013; Damera G, 2009, PULM PHARMACOL THER, V22, P353, DOI 10.1016/j.pupt.2008.12.006; de Boer JD, 2012, BLOOD, V119, P3236, DOI 10.1182/blood-2011-11-391532; Fahy John V, 2009, Proc Am Thorac Soc, V6, P256, DOI 10.1513/pats.200808-087RM; Freund-Michel V, 2006, FUND CLIN PHARMACOL, V20, P351, DOI 10.1111/j.1472-8206.2006.00418.x; Global Initiative for Asthma (GINA), 2012, GLOB IN ASTHM GINA R; GOLDSTEIN RA, 1985, AM REV RESPIR DIS, V132, P180; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Hassan M, 2010, J ALLERGY CLIN IMMUN, V125, P1037, DOI 10.1016/j.jaci.2010.02.031; Hirota N, 2013, CHEST, V144, P1026, DOI 10.1378/chest.12-3073; Hirst SJ, 2004, J ALLERGY CLIN IMMUN, V114, P2, DOI [10.1016/j.jaci.2004.04.039, DOI 10.1016/J.JACI.2004.04.039]; Hollenberg MD, 2008, BIOL CHEM, V389, P643, DOI 10.1515/BC.2008.077; Humbert M, 2014, J ALLER CL IMM-PRACT, V2, P525, DOI 10.1016/j.jaip.2014.03.010; Johnson PRA, 2001, AM J RESP CRIT CARE, V164, P474, DOI 10.1164/ajrccm.164.3.2010109; Kaminska M, 2009, J ALLERGY CLIN IMMUN, V124, P45, DOI 10.1016/j.jaci.2009.03.049; Katz Lynn E, 2014, Ann Am Thorac Soc, V11, P531, DOI 10.1513/AnnalsATS.201310-354OC; Knight DA, 2001, J ALLERGY CLIN IMMUN, V108, P797, DOI 10.1067/mai.2001.119025; Lemiere C, 2006, J ALLERGY CLIN IMMUN, V118, P1033, DOI 10.1016/j.jaci.2006.08.003; Macedo P, 2009, CLIN EXP ALLERGY, V39, P1668, DOI 10.1111/j.1365-2222.2009.03319.x; Malmstrom K, 2013, CURR OPIN ALLERGY CL, V13, P203, DOI 10.1097/ACI.0b013e32835e122c; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; O'Reilly R, 2013, J ALLERGY CLIN IMMUN, V131, P1024, DOI 10.1016/j.jaci.2012.08.044; Pepe C, 2005, J ALLERGY CLIN IMMUN, V116, P544, DOI 10.1016/j.jaci.2005.06.011; Prakash YS, 2013, AM J PHYSIOL-LUNG C, V305, pL912, DOI 10.1152/ajplung.00259.2013; Qiu YS, 2007, THORAX, V62, P475, DOI 10.1136/thx.2006.066670; Ramachandran R, 2012, BIOL CHEM, V393, P421, DOI 10.1515/hsz-2011-0251; Schor AM, 1998, HISTOCHEM J, V30, P849, DOI 10.1023/A:1003437619956; Schuliga M, 2016, AM J RESP CELL MOL, V54, P200, DOI 10.1165/rcmb.2014-0419OC; Siddiqui S, 2008, J ALLERGY CLIN IMMUN, V122, P335, DOI 10.1016/j.jaci.2008.05.020; Tran TN, 2014, ANN ALLERG ASTHMA IM, V113, P19, DOI 10.1016/j.anai.2014.04.011; Trudel D, 2014, MODERN PATHOL, V27, P1394, DOI 10.1038/modpathol.2014.32; Walker TR, 1998, MOL PHARMACOL, V54, P1007, DOI 10.1124/mol.54.6.1007; Wallin A, 2003, J ALLERGY CLIN IMMUN, V112, P72, DOI 10.1067/mai.2003.1518; Woodruff PG, 2004, AM J RESP CRIT CARE, V169, P1001, DOI 10.1164/rccm.200311-1529OC; Xiang Y, 2006, OSTEOARTHR CARTILAGE, V14, P1163, DOI 10.1016/j.joca.2006.04.015; Zuyderduyn S, 2000, EUR RESPIR J, V32, P265; 2014, EUR RESPIR J, V43, P343, DOI DOI 10.1183/09031936.00202013	58	21	25	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2016	138	3					729	+		10.1016/j.jaci.2015.12.1332	http://dx.doi.org/10.1016/j.jaci.2015.12.1332			22	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DY9ZM	27001157	Bronze			2022-12-18	WOS:000385496000008
J	Schultz, ES; Hallberg, J; Gustafsson, PM; Bottai, M; Bellander, T; Bergstrom, A; Kull, I; Gruzieva, O; Thunqvist, P; Pershagen, G; Melen, E				Schultz, Erica S.; Hallberg, Jenny; Gustafsson, Per M.; Bottai, Matteo; Bellander, Tom; Bergstrom, Anna; Kull, Inger; Gruzieva, Olena; Thunqvist, Per; Pershagen, Goran; Melen, Erik			Early life exposure to traffic-related air pollution and lung function in adolescence assessed with impulse oscillometry	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							DEPOSITION; ASTHMA		[Schultz, Erica S.; Hallberg, Jenny; Bottai, Matteo; Bellander, Tom; Bergstrom, Anna; Gruzieva, Olena; Thunqvist, Per; Pershagen, Goran; Melen, Erik] Karolinska Inst, Inst Environm Med, Stockholm, Sweden; [Hallberg, Jenny; Kull, Inger; Thunqvist, Per; Melen, Erik] Sachs Childrens Hosp, Sodersjukhuset, Stockholm, Sweden; [Gustafsson, Per M.] Univ Gothenburg, Sahlgrenska Acad, Gothenburg, Sweden; [Gustafsson, Per M.] Cent Hosp Skovde, Dept Paediat, Skovde, Sweden; [Bellander, Tom; Pershagen, Goran; Melen, Erik] Stockholm Cty Council, Ctr Occupat & Environm Med, Stockholm, Sweden; [Kull, Inger] Soder Sjukhuset, Dept Clin Sci & Educ, Stockholm, Sweden	Karolinska Institutet; Sodersjukhuset Hospital; University of Gothenburg; Stockholm County Council; Sodersjukhuset Hospital	Schultz, ES (corresponding author), Karolinska Inst, Inst Environm Med, Stockholm, Sweden.	Erica.Schultz@ki.se		Gruzieva, Olena/0000-0003-4147-5654; Kull, Inger/0000-0001-6096-3771				Chalupa DC, 2004, ENVIRON HEALTH PERSP, V112, P879, DOI 10.1289/ehp.6851; Gazendam RP, 2014, BLOOD, V124, P590, DOI 10.1182/blood-2014-01-551473; Goldman MD, 2005, RESP PHYSIOL NEUROBI, V148, P179, DOI 10.1016/j.resp.2005.05.026; Hallberg J, 2015, ALLERGY, V20, P12598; Jaques PA, 2000, INHAL TOXICOL, V12, P715; Kuehl PJ, 2012, INHAL TOXICOL, V24, P27, DOI 10.3109/08958378.2011.632787; Lipworth B, 2014, LANCET RESP MED, V2, P497, DOI 10.1016/S2213-2600(14)70103-1; Quanjer PH, 2014, EUR RESPIR J, V43, P1051, DOI 10.1183/09031936.00128113; Roos D, 2014, CLIN EXP IMMUNOL, V175, P139, DOI 10.1111/cei.12202; Schultzl ES, 2016, AM J RESP CRIT CARE, V193, P171, DOI 10.1164/rccm.201505-0928OC; van Bruggen R, 2010, J INNATE IMMUN, V2, P280, DOI 10.1159/000268288; van der Wiel E, 2013, J ALLERGY CLIN IMMUN, V131, P646, DOI 10.1016/j.jaci.2012.12.1567	12	21	22	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2016	138	3					930	+		10.1016/j.jaci.2016.04.014	http://dx.doi.org/10.1016/j.jaci.2016.04.014			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DY9ZM	27297996	hybrid			2022-12-18	WOS:000385496000040
J	Jabbal, S; Manoharan, A; Lipworth, J; Lipworth, B				Jabbal, Sunny; Manoharan, Arvind; Lipworth, Joseph; Lipworth, Brian			Utility of impulse oscillometry in patients with moderate to severe persistent asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CONTROL QUESTIONNAIRE		[Jabbal, Sunny; Manoharan, Arvind; Lipworth, Joseph; Lipworth, Brian] Univ Dundee, Scottish Ctr Resp Res, Ninewells Hosp & Med Sch, Dundee, Scotland	University of Dundee	Lipworth, B (corresponding author), Univ Dundee, Scottish Ctr Resp Res, Ninewells Hosp & Med Sch, Dundee, Scotland.	b.j.lipworth@dundee.ac.uk		Jabbal, Sunny/0000-0002-9604-9807				Juniper EF, 2006, RESP MED, V100, P616, DOI 10.1016/j.rmed.2005.08.012; Juniper EF, 2005, RESP MED, V99, P553, DOI 10.1016/j.rmed.2004.10.008; Lipworth B, 2014, LANCET RESP MED, V2, P497, DOI 10.1016/S2213-2600(14)70103-1; Manoharan A, 2015, LUNG, V193, P47, DOI 10.1007/s00408-014-9674-6; Manoharan A, 2014, EUR RESPIR J, V44, P1353, DOI 10.1183/09031936.00082314; Martin RJ, 2014, NPJ PRIM CARE RESP M, V24, DOI 10.1038/npjpcrm.2014.81; McFadden ER, 2010, J ALLERGY CLIN IMMUN, V126, P535, DOI 10.1016/j.jaci.2010.06.035; Meltzer EO, 2011, J ALLERGY CLIN IMMUN, V127, P167, DOI 10.1016/j.jaci.2010.08.042; Orange JS, 2001, CLIN IMMUNOL, V99, P53, DOI 10.1006/clim.2001.5002; Shi YX, 2012, J ALLERGY CLIN IMMUN, V129, P671, DOI 10.1016/j.jaci.2011.11.002	10	21	21	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2016	138	2					601	603		10.1016/j.jaci.2015.12.1336	http://dx.doi.org/10.1016/j.jaci.2015.12.1336			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DS5PY	27016797	Green Submitted, Bronze			2022-12-18	WOS:000380835800037
J	Licciardi, PV; Toh, ZQ; Clutterbuck, EA; Balloch, A; Marimla, RA; Tikkanen, L; Lamb, KE; Bright, KJ; Rabuatoka, U; Tikoduadua, L; Boelsen, LK; Dunne, EM; Satzke, C; Cheung, YB; Pollard, AJ; Russell, FM; Mulholland, EK				Licciardi, Paul V.; Toh, Zheng Quan; Clutterbuck, Elizabeth A.; Balloch, Anne; Marimla, Rachel A.; Tikkanen, Leena; Lamb, Karen E.; Bright, Kathryn J.; Rabuatoka, Uraia; Tikoduadua, Lisi; Boelsen, Laura K.; Dunne, Eileen M.; Satzke, Catherine; Cheung, Yin Bun; Pollard, Andrew J.; Russell, Fiona M.; Mulholland, Edward K.			No long-term evidence of hyporesponsiveness after use of pneumococcal conjugate vaccine in children previously immunized with pneumococcal polysaccharide vaccine	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Pneumococcal polysaccharide vaccine; 23vPPV; hyporesponsiveness; memory B cell; opsonophagocytosis; antibody	STREPTOCOCCUS-PNEUMONIAE; ANTIBODY-RESPONSES; B-CELLS; ADULTS; REVACCINATION; IMMUNOGENICITY; GENERATION; SCHEDULES; CARRIAGE; DISEASE	Background: A randomized controlled trial in Fiji examined the immunogenicity and effect on nasopharyngeal carriage after 0, 1, 2, or 3 doses of 7-valent pneumococcal conjugate vaccine (PCV7; Prevnar) in infancy followed by 23-valent pneumococcal polysaccharide vaccine (23vPPV; Pneumovax) at 12 months of age. At 18 months of age, children given 23vPPV exhibited immune hyporesponsiveness to a micro-23vPPV (20%) challenge dose in terms of serotype-specific IgG and opsonophagocytosis, while 23vPPV had no effect on vaccine-type carriage. Objective: This follow-up study examined the long-term effect of the 12-month 23vPPV dose by evaluating the immune response to 13-valent pneumococcal conjugate vaccine (PCV13) administration 4 to 5 years later. Methods: Blood samples from 194 children (now 5-7 years old) were taken before and 28 days after PCV13 booster immunization. Nasopharyngeal swabs were taken before PCV13 immunization. We measured levels of serotype-specific IgG to all 13 vaccine serotypes, opsonophagocytosis for 8 vaccine serotypes, and memory B-cell responses for 18 serotypes before and after PCV13 immunization. Results: Paired samples were obtained from 185 children. There were no significant differences in the serotype-specific IgG, opsonophagocytosis, or memory B-cell response at either time point between children who did or did not receive 23vPPV at 12 months of age. Nasopharyngeal carriage of PCV7 and 23vPPV serotypes was similar among the groups. Priming with 1, 2, or 3 PCV7 doses during infancy did not affect serotype-specific immunity or carriage. Conclusion: Immune hyporesponsiveness induced by 23vPPV in toddlers does not appear to be sustained among preschool children in this context and does not affect the pneumococcal carriage rate in this age group.	[Licciardi, Paul V.; Toh, Zheng Quan; Balloch, Anne; Marimla, Rachel A.; Tikkanen, Leena; Bright, Kathryn J.; Boelsen, Laura K.; Dunne, Eileen M.; Satzke, Catherine; Mulholland, Edward K.] Murdoch Childrens Res Inst, Pneumococcal Res, Melbourne, Vic, Australia; [Lamb, Karen E.] Murdoch Childrens Res Inst, Clin Epidemiol & Biostat Unit, Melbourne, Vic, Australia; [Russell, Fiona M.] Murdoch Childrens Res Inst, Ctr Int Child Hlth, Melbourne, Vic, Australia; [Licciardi, Paul V.; Lamb, Karen E.; Boelsen, Laura K.; Satzke, Catherine; Russell, Fiona M.] Univ Melbourne, Peter Doherty Inst Infect & Immun, Dept Paediat, Parkville, Vic 3052, Australia; [Satzke, Catherine] Univ Melbourne, Peter Doherty Inst Infect & Immun, Dept Microbiol & Immunol, Parkville, Vic 3052, Australia; [Clutterbuck, Elizabeth A.; Pollard, Andrew J.] Univ Oxford, Dept Paediat, Oxford, England; [Clutterbuck, Elizabeth A.; Pollard, Andrew J.] NIHR Oxford Biomed Res Ctr, Oxford, England; [Rabuatoka, Uraia] Natl Ctr Communicable Dis Res, Mataika House, Suva, Fiji; [Tikoduadua, Lisi] ColonialWar Mem Hosp, Suva, Fiji; [Cheung, Yin Bun] Duke NUS Grad Med Sch, Ctr Quantitat Med, Singapore, Singapore; [Cheung, Yin Bun] Univ Tampere, Dept Int Hlth, FIN-33101 Tampere, Finland; [Mulholland, Edward K.] Menzies Sch Hlth Res, Darwin, NT, Australia; [Mulholland, Edward K.] London Sch Hyg & Trop Med, London WC1, England	Murdoch Children's Research Institute; Murdoch Children's Research Institute; Murdoch Children's Research Institute; University of Melbourne; University of Melbourne; University of Oxford; University of Oxford; National University of Singapore; Tampere University; Charles Darwin University; Menzies School of Health Research; University of London; London School of Hygiene & Tropical Medicine	Licciardi, PV (corresponding author), Murdoch Childrens Res Inst, Pneumococcal Res, Melbourne, Vic, Australia.	paul.licciardi@mcri.edu.au	Satzke, Catherine/D-6501-2013; Dunne, Eileen M/M-3203-2019; Lamb, Karen/P-4988-2016; Boelsen, Laura Kate/ABA-7442-2021	Satzke, Catherine/0000-0003-3164-8849; Dunne, Eileen M/0000-0001-5542-0780; Lamb, Karen/0000-0001-9782-8450; Boelsen, Laura Kate/0000-0002-2480-0753	National Institutes of Allergy and Infectious Disease grant [1R01AI085198-01A1]; Australian National Health and Medical Research Council (NHMRC) Early Career Fellowship; National Research Foundation, Singapore under its Clinician Scientist Award [NMRC/CSA/039/2011]; NIHR Oxford Biomedical Research Centre; Victorian Government's Operational Infrastructure Support Program; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI085198] Funding Source: NIH RePORTER	National Institutes of Allergy and Infectious Disease grant; Australian National Health and Medical Research Council (NHMRC) Early Career Fellowship(National Health and Medical Research Council (NHMRC) of Australia); National Research Foundation, Singapore under its Clinician Scientist Award; NIHR Oxford Biomedical Research Centre(National Institute for Health Research (NIHR)); Victorian Government's Operational Infrastructure Support Program; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by a National Institutes of Allergy and Infectious Disease grant (1R01AI085198-01A1). P.V.L. is a recipient of an Australian National Health and Medical Research Council (NHMRC) Early Career Fellowship. Y.B.C. was supported by the National Research Foundation, Singapore, under its Clinician Scientist Award (award no. NMRC/CSA/039/2011) administered by the Singapore Ministry of Health's National Medical Research Council. E.A.C. was supported by the NIHR Oxford Biomedical Research Centre. A.J.P. is a Jenner Institute Investigator and a James Martin Senior Fellow. We also acknowledge the support of the Victorian Government's Operational Infrastructure Support Program. The views expressed in this manuscript do not necessarily reflect the views of the UK Department of Health or Joint Committee on Vaccination and Immunisation.	Andrews NJ, 2012, VACCINE, V30, P6802, DOI 10.1016/j.vaccine.2012.09.019; [Anonymous], 1997, MMWR Recomm Rep, V46, P1; Balloch A, 2010, VACCINE, V28, P1333, DOI 10.1016/j.vaccine.2009.11.011; Bjarnarson SP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072588; Borrow R, 2000, VACCINE, V19, P1129, DOI 10.1016/S0264-410X(00)00317-0; Brynjolfsson SF, 2012, J INFECT DIS, V205, P422, DOI 10.1093/infdis/jir750; Burton RL, 2006, CLIN VACCINE IMMUNOL, V13, P1004, DOI 10.1128/CVI.00112-06; Clutterbuck EA, 2008, CLIN VACCINE IMMUNOL, V15, P182, DOI 10.1128/CVI.00336-07; Clutterbuck EA, 2012, J INFECT DIS, V205, P1408, DOI 10.1093/infdis/jis212; Feldman C, 2014, J INFECTION, V69, P309, DOI 10.1016/j.jinf.2014.06.006; Granoff DM, 2007, PEDIATR INFECT DIS J, V26, P716, DOI 10.1097/INF.0b013e3180cc2c25; Henriques-Normark B, 2013, COLD SPRING HARB PER, V3; Hull B, 2013, COMMUN DIS INTELL, V37, pE21; Jackson LA, 2013, VACCINE, V31, P3594, DOI 10.1016/j.vaccine.2013.04.084; Lazarus R, 2011, CLIN INFECT DIS, V52, P736, DOI 10.1093/cid/cir003; Manoff SB, 2010, J INFECT DIS, V201, P525, DOI 10.1086/651131; Moberley S, 2010, VACCINE, V28, P2296, DOI 10.1016/j.vaccine.2009.12.066; Moberley SA, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000422.pub2; MUFSON MA, 1991, VACCINE, V9, P403, DOI 10.1016/0264-410X(91)90126-Q; Musher DM, 2011, HUM VACCINES, V7, P919, DOI 10.4161/hv.7.9.15996; O'Brien KL, 2007, LANCET INFECT DIS, V7, P597, DOI 10.1016/S1473-3099(07)70210-4; O'Brien KL, 2009, LANCET, V374, P893, DOI 10.1016/S0140-6736(09)61204-6; O'Grady KAF, 2010, CLIN INFECT DIS, V50, P970, DOI 10.1086/651079; Poolman J, 2011, EXPERT REV VACCINES, V10, P307, DOI [10.1586/ERV.11.8, 10.1586/erv.11.8]; Porter BD, 2014, J VIS EXP, P51747; RILEY ID, 1986, LANCET, V2, P877; Russell FM, 2010, CLIN VACCINE IMMUNOL, V17, P1970, DOI 10.1128/CVI.00117-10; Russell FM, 2010, VACCINE, V28, P3086, DOI 10.1016/j.vaccine.2010.02.065; Satzke C, 2013, VACCINE, V32, P165, DOI 10.1016/j.vaccine.2013.08.062; Sigurdardottir ST, 2014, VACCINE, V32, P417, DOI 10.1016/j.vaccine.2013.11.029; WHO Publication, 2012, VACCINE, V30, P4717, DOI 10.1016/j.vaccine.2012.04.093	31	21	21	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2016	137	6					1772	+		10.1016/j.jaci.2015.12.1303	http://dx.doi.org/10.1016/j.jaci.2015.12.1303			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DO1GT	26825000	Green Accepted, Bronze, Green Submitted			2022-12-18	WOS:000377527200018
J	Bernth-Jensen, JM; Holm, M; Christiansen, M				Bernth-Jensen, Jens Magnus; Holm, Mette; Christiansen, Mette			Neonatal-onset T-B-NK+ severe combined immunodeficiency and neutropenia caused by mutated phosphoglucomutase 3	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							GLYCOSYLATION		[Bernth-Jensen, Jens Magnus; Christiansen, Mette] Aarhus Univ Hosp, Dept Clin Immunol, DK-8000 Aarhus, Denmark; [Holm, Mette] Aarhus Univ Hosp, Dept Pediat, DK-8000 Aarhus, Denmark	Aarhus University; Aarhus University	Bernth-Jensen, JM (corresponding author), Aarhus Univ Hosp, Dept Clin Immunol, DK-8000 Aarhus, Denmark.	jejensen@rm.dk	Bernth-Jensen, Jens Magnus/H-6694-2019	Christiansen, Mette/0000-0001-5158-3670; Bernth Jensen, Jens Magnus/0000-0002-5004-7822				Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; Appay V, 2008, CYTOM PART A, V73A, P975, DOI 10.1002/cyto.a.20643; BUCKLEY RH, 1972, PEDIATRICS, V49, P59; Hochberg MC, 1997, ARTHRITIS RHEUM, V40, P1725, DOI 10.1002/art.1780400928; Ng PC, 2003, NUCLEIC ACIDS RES, V31, P3812, DOI 10.1093/nar/gkg509; Pang H, 2002, ANN HUM GENET, V66, P139, DOI 10.1017/S0003480002001033; Sassi A, 2014, J ALLERGY CLIN IMMUN, V133, P1410, DOI 10.1016/j.jaci.2014.02.025; Sottini A, 2010, CLIN IMMUNOL, V136, P217, DOI 10.1016/j.clim.2010.04.005; Stray-Pedersen A, 2014, AM J HUM GENET, V95, P96, DOI 10.1016/j.ajhg.2014.05.007; Zhang Y, 2014, J ALLERGY CLIN IMMUN, V133, pe1; Zhang Y, 2014, J ALLERGY CLIN IMMUN, V133, P1400, DOI 10.1016/j.jaci.2014.02.013	11	21	22	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2016	137	1					321	324		10.1016/j.jaci.2015.07.047	http://dx.doi.org/10.1016/j.jaci.2015.07.047			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DA3UK	26409661	Bronze			2022-12-18	WOS:000367724300030
J	Crestani, E; Volpi, S; Candotti, F; Giliani, S; Notarangelo, LD; Chu, J; Becerra, JCA; Buchbinder, D; Chou, J; Geha, RS; Kanariou, M; King, A; Mazza, C; Moratto, D; Sokolic, R; Garabedian, E; Porta, F; Putti, MC; Wakim, RH; Tsitsikov, E; Pai, SY; Notarangelo, LD				Crestani, Elena; Volpi, Stefano; Candotti, Fabio; Giliani, Silvia; Notarangelo, Lucia Dora; Chu, Julia; Becerra, Juan Carlos Aldave; Buchbinder, David; Chou, Janet; Geha, Raif S.; Kanariou, Maria; King, Alejandra; Mazza, Cinzia; Moratto, Daniele; Sokolic, Robert; Garabedian, Elizabeth; Porta, Fulvio; Putti, Maria Caterina; Wakim, Rima H.; Tsitsikov, Erdyni; Pai, Sung-Yun; Notarangelo, Luigi D.			Broad spectrum of autoantibodies in patients with Wiskott-Aldrich syndrome and X-linked thrombocytopenia	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							SYNDROME PROTEIN-DEFICIENCY; AUTOIMMUNITY; HUMANS; CELLS		[Crestani, Elena; Volpi, Stefano; Chou, Janet; Geha, Raif S.; Notarangelo, Luigi D.] Boston Childrens Hosp, Div Immunol, Boston, MA 02115 USA; [Chu, Julia; Pai, Sung-Yun] Boston Childrens Hosp, Div Hematol Oncol, Boston, MA USA; [Tsitsikov, Erdyni] Boston Childrens Hosp, Dept Lab Med, Boston, MA USA; [Volpi, Stefano] Univ Genoa, Dept Neurosci Rehabil Ophthalmol Genet Maternal &, Genoa, Italy; [Candotti, Fabio; Sokolic, Robert; Garabedian, Elizabeth] NHGRI, Genet & Mol Biol Branch, NIH, Bethesda, MD 20892 USA; [Giliani, Silvia; Mazza, Cinzia; Moratto, Daniele] Univ Brescia, Angelo Nocivelli Inst Mol Med, Brescia, Italy; [Notarangelo, Lucia Dora; Porta, Fulvio] Spedali Civil Brescia, Pediat Hematol Oncol Unit, I-25125 Brescia, Italy; [Becerra, Juan Carlos Aldave] Rebagliati Martins Natl Hosp, Div Allergy & Clin Immunol, Lima, Peru; [Buchbinder, David] Univ Calif Irvine, Childrens Hosp Orange Cty, Div Pediat Hematol, Irvine, CA USA; [Kanariou, Maria] Aghia Sophia Childrens Hosp, Dept Immunol, Athens, Greece; [King, Alejandra] Hosp Ninos Luis Calvo Mackenna, Div Pediat Immunol, Santiago, Chile; [Putti, Maria Caterina] Univ Hosp, Dept Woman & Child Hlth, Clin Pediat Hematol Oncol, Padua, Italy; [Wakim, Rima H.] Amer Univ Beirut, Dept Pediat & Adolescent Med, Beirut, Lebanon	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; University of Genoa; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Brescia; Hospital Spedali Civili Brescia; Seguro Social de Salud del Peru; Childrens Hospital of Orange County; University of California System; University of California Irvine; The Aghia Sophia Children's Hospital; Universidad de Chile; University of Padua; Azienda Ospedaliera - Universita di Padova; American University of Beirut	Crestani, E (corresponding author), Boston Childrens Hosp, Div Immunol, Boston, MA 02115 USA.	luigi.notarangelo@childrens.harvard.edu	Notarangelo, Luigi D/F-9718-2016; Giliani, Silvia/AAX-8843-2020; Pai, Sung-Yun/AAH-7762-2019; Sokolic, Robert/E-6224-2017; Volpi, Stefano/O-3717-2014	Notarangelo, Luigi D/0000-0002-8335-0262; Giliani, Silvia/0000-0001-8137-4642; Pai, Sung-Yun/0000-0002-0158-8147; Sokolic, Robert/0000-0002-3399-7893; Volpi, Stefano/0000-0002-7129-868X; Aldave, Juan/0000-0003-3548-0385; Candotti, Fabio/0000-0001-6399-6042	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL059561, T32HL007574] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007512] Funding Source: NIH RePORTER; NHLBI NIH HHS [5P01HL059561-13, 5T32HL007574-33, P01 HL059561] Funding Source: Medline; NIAID NIH HHS [T32 AI007512, 5T32AI007512] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Albert MH, 2010, BLOOD, V115, P3231, DOI 10.1182/blood-2009-09-239087; Castiello MC, 2014, J AUTOIMMUN, V50, P42, DOI 10.1016/j.jaut.2013.10.006; Catucci M, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00209; Du HQ, 2015, SCAND J IMMUNOL, V81, P483, DOI 10.1111/sji.12282; Dupuis-Girod S, 2003, PEDIATRICS, V111, pE622, DOI 10.1542/peds.111.5.e622; Fernandez-Boyanapalli R, 2010, BLOOD, V116, P4512, DOI 10.1182/blood-2010-02-272005; Fernandez-Boyanapalli RF, 2015, J ALLERGY CLIN IMMUN, V135, P517, DOI 10.1016/j.jaci.2014.10.034; Kiss M, 2013, J ALLERGY CLIN IMMUN, V132, P264, DOI 10.1016/j.jaci.2013.05.044; Li QZ, 2007, CLIN EXP IMMUNOL, V147, P60, DOI 10.1111/j.1365-2249.2006.03251.x; Ochs HD, 2006, J ALLERGY CLIN IMMUN, V117, P725, DOI 10.1016/j.jaci.2006.02.005; Prete F, 2013, J EXP MED, V210, P355, DOI 10.1084/jem.20120363; Simon KL, 2014, J ALLERGY CLIN IMMUN, V133, P896, DOI 10.1016/j.jaci.2013.08.050	12	21	23	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2015	136	5					1401	1404		10.1016/j.jaci.2015.08.010	http://dx.doi.org/10.1016/j.jaci.2015.08.010			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CW1YE	26409660	Green Accepted			2022-12-18	WOS:000364787200032
J	Fernandez-Boyanapalli, RF; Falcone, EL; Zerbe, CS; Marciano, BE; Frasch, SC; Henson, PM; Holland, SM; Bratton, DL				Fernandez-Boyanapalli, Ruby F.; Falcone, Emilia Liana; Zerbe, Christa S.; Marciano, Beatriz E.; Frasch, S. Courtney; Henson, Peter M.; Holland, Steven M.; Bratton, Donna L.			Impaired efferocytosis in human chronic granulomatous disease is reversed by pioglitazone treatment	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							STERILE INFLAMMATION; MACROPHAGE; CGD		[Fernandez-Boyanapalli, Ruby F.; Frasch, S. Courtney; Henson, Peter M.; Bratton, Donna L.] Natl Jewish Hlth, Dept Pediat, Denver, CO 80206 USA; [Falcone, Emilia Liana; Zerbe, Christa S.; Marciano, Beatriz E.; Holland, Steven M.] NIAID, Lab Clin Infect Dis, NIH, Bethesda, MD 20892 USA	National Jewish Health; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Fernandez-Boyanapalli, RF (corresponding author), Natl Jewish Hlth, Dept Pediat, Denver, CO 80206 USA.	brattond@njhealth.org			Intramural NIH HHS Funding Source: Medline; NHLBI NIH HHS [R01 HL114381, HL114381, P01 HL034303] Funding Source: Medline; NIAID NIH HHS [R01 AI058228, AI110408, R01 AI110408, AI058228, R56 AI058228] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL114381, P01HL034303] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI058228, ZIAAI001216, R01AI110408, R56AI058228] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Annese V, 2012, PPAR RES, V2012, DOI 10.1155/2012/620839; Brown JR, 2003, J LEUKOCYTE BIOL, V73, P591, DOI 10.1189/jlb.1202599; Brown KL, 2008, CLIN IMMUNOL, V129, P90; Fernandez-Boyanapalli R, 2010, BLOOD, V116, P4512, DOI 10.1182/blood-2010-02-272005; Fernandez-Boyanapalli RF, 2015, J ALLERGY CLIN IMMUN, V135, P517, DOI 10.1016/j.jaci.2014.10.034; Holland SM, 2010, CLIN REV ALLERG IMMU, V38, P3, DOI 10.1007/s12016-009-8136-z; Kiss M, 2013, J ALLERGY CLIN IMMUN, V132, P264, DOI 10.1016/j.jaci.2013.05.044; Olefsky JM, 2010, ANNU REV PHYSIOL, V72, P219, DOI 10.1146/annurev-physiol-021909-135846; Sanmun D, 2009, AM J PHYSIOL-CELL PH, V297, pC621, DOI 10.1152/ajpcell.00651.2008; Zeng MY, 2013, BLOOD, V121, P3473, DOI 10.1182/blood-2012-10-461913	10	21	22	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2015	136	5					1399	1401		10.1016/j.jaci.2015.07.034	http://dx.doi.org/10.1016/j.jaci.2015.07.034			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CW1YE	26386811	Green Accepted			2022-12-18	WOS:000364787200031
J	Taylan, F; Nilsson, D; Asad, S; Lieden, A; Wahlgren, CF; Winge, MCG; Bilcha, KD; Nordenskjold, M; Bradley, M				Taylan, Fulya; Nilsson, Daniel; Asad, Samina; Lieden, Agne; Wahlgren, Carl-Fredrik; Winge, Marten C. G.; Bilcha, Kassahun Desalegn; Nordenskjold, Magnus; Bradley, Maria			Whole-exome sequencing of Ethiopian patients with ichthyosis vulgaris and atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							FILAGGRIN; ASSOCIATION; MUTATIONS; VARIANT		[Taylan, Fulya; Nilsson, Daniel; Asad, Samina; Lieden, Agne; Winge, Marten C. G.; Nordenskjold, Magnus; Bradley, Maria] Karolinska Univ Hosp Solna, Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden; [Taylan, Fulya; Nilsson, Daniel; Asad, Samina; Lieden, Agne; Winge, Marten C. G.; Nordenskjold, Magnus; Bradley, Maria] Karolinska Univ Hosp Solna, Karolinska Inst, Ctr Mol Med, Stockholm, Sweden; [Wahlgren, Carl-Fredrik; Bradley, Maria] Karolinska Univ Hosp Solna, Karolinska Inst, Dept Med Solna, Dermatol Unit, Stockholm, Sweden; [Taylan, Fulya; Nilsson, Daniel] Karolinska Inst, Sci Life Lab, Solna, Sweden; [Bilcha, Kassahun Desalegn] Gondar Univ, Fac Med, Dept Dermatovenereol, Gondar, Ethiopia	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; University of Gondar	Taylan, F (corresponding author), Karolinska Univ Hosp Solna, Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden.	fulya.taylan@ki.se	Nilsson, Daniel/B-8365-2009; Taylan, Fulya/V-7121-2019	Nilsson, Daniel/0000-0001-5831-385X; Taylan, Fulya/0000-0002-2907-0235; Bradley, Maria/0000-0001-7192-5041; Nordenskjold, Magnus/0000-0002-4974-425X; Winge, Marten/0000-0001-6119-6009				Fortugno P, 2012, HUM MOL GENET, V21, P4187, DOI 10.1093/hmg/dds243; Kato A, 2003, BRIT J DERMATOL, V148, P665, DOI 10.1046/j.1365-2133.2003.05243.x; Marenholz I, 2011, J INVEST DERMATOL, V131, P1644, DOI 10.1038/jid.2011.90; Margolis DJ, 2014, J INVEST DERMATOL, V134, P2272, DOI 10.1038/jid.2014.126; Polcari I, 2014, PEDIATR DERMATOL, V31, P489, DOI 10.1111/pde.12355; Smith FJD, 2006, NAT GENET, V38, P337, DOI 10.1038/ng1743; Winge MCG, 2011, BRIT J DERMATOL, V165, P1074, DOI 10.1111/j.1365-2133.2011.10475.x	7	21	22	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2015	136	2					507	+		10.1016/j.jaci.2015.02.010	http://dx.doi.org/10.1016/j.jaci.2015.02.010			23	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CO2RS	25819062				2022-12-18	WOS:000359004900042
J	Pomes, A; Chruszcz, M; Gustchina, A; Minor, W; Mueller, GA; Pedersen, LC; Wlodawer, A; Chapman, MD				Pomes, Anna; Chruszcz, Maksymilian; Gustchina, Alla; Minor, Wladek; Mueller, Geoffrey A.; Pedersen, Lars C.; Wlodawer, Alexander; Chapman, Martin D.			100 Years later: Celebrating the contributions of x-ray crystallography to allergy and clinical immunology	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergens; allergy; function; structure; cross-reactivity; x-ray crystallography	HOUSE-DUST MITE; ARA H 1; 3-DIMENSIONAL FOURIER SYNTHESIS; BET V 1; CRYSTAL-STRUCTURE; MAJOR ALLERGEN; BIRCH POLLEN; STRUCTURAL BIOLOGY; CROSS-REACTIVITY; PEANUT ALLERGY	Current knowledge of molecules involved in immunology and allergic disease results from the significant contributions of x-ray crystallography, a discipline that just celebrated its 100th anniversary. The histories of allergens and x-ray crystallography are intimately intertwined. The first enzyme structure to be determined was lysozyme, also known as the chicken food allergen Gal d 4. Crystallography determines the exact 3-dimensional positions of atoms in molecules. Structures of molecular complexes in the disciplines of immunology and allergy have revealed the atoms involved in molecular interactions and mechanisms of disease. These complexes include peptides presented by MHC class II molecules, cytokines bound to their receptors, allergenantibody complexes, and innate immune receptors with their ligands. The information derived from crystallographic studies provides insights into the function of molecules. Allergen function is one of the determinants of environmental exposure, which is essential for IgE sensitization. Proteolytic activity of allergens or their capacity to bind LPSs can also contribute to allergenicity. The atomic positions define the molecular surface that is accessible to antibodies. In turn, this surface determines antibody specificity and cross-reactivity, which are important factors for the selection of allergen panels used for molecular diagnosis and the interpretation of clinical symptoms. This review celebrates the contributions of x-ray crystallography to clinical immunology and allergy, focusing on new molecular perspectives that influence the diagnosis and treatment of allergic diseases.	[Pomes, Anna; Chapman, Martin D.] INDOOR Biotechnol, Basic Res, Charlottesville, VA 22903 USA; [Chruszcz, Maksymilian] Univ S Carolina, Dept Chem & Biochem, Columbia, SC 29208 USA; [Gustchina, Alla; Wlodawer, Alexander] NCI, Macromol Crystallog Lab, Frederick, MD 21701 USA; [Minor, Wladek] Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA USA; [Mueller, Geoffrey A.; Pedersen, Lars C.] NIEHS, Genome Integr & Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA	INDOOR Biotechnologies; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Virginia; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Pomes, A (corresponding author), INDOOR Biotechnol, 1216 Harris St, Charlottesville, VA 22903 USA.	apomes@inbio.com	Chruszcz, Maksymilian/E-6407-2011; Pomés, Anna/H-7010-2019; Mueller, Geoffrey A/I-2909-2017; Pedersen, Lars/C-6173-2019; Minor, Wladek/F-3096-2014	Chruszcz, Maksymilian/0000-0001-7521-5485; Pomés, Anna/0000-0002-8729-1829; Mueller, Geoffrey A/0000-0001-8361-5323; Pedersen, Lars/0000-0002-4488-4077; Minor, Wladek/0000-0001-7075-7090; Chapman, Martin/0000-0002-0845-3632	National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH) [R01AI077653]; Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research; Intramural Research Program of the NIH, National Institute of Environmental Health Sciences Research [Z01-ES050147, ZIA ES102645]; NATIONAL CANCER INSTITUTE [ZIABC010348] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI077653] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES102906, ZIAES102645] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural Research Program of the NIH, National Institute of Environmental Health Sciences Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH; award no. R01AI077653; A.P. contact PI), the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research, and the Intramural Research Program of the NIH, National Institute of Environmental Health Sciences Research (project no. Z01-ES050147 to G.A.M. and ZIA ES102645 to L.C.P.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Aalberse RC, 2006, CHEM IMMUNOL ALLERGY, V91, P134; Aalberse RC, 2001, ALLERGY, V56, P478, DOI 10.1034/j.1398-9995.2001.056006478.x; Afonine PV, 2012, ACTA CRYSTALLOGR D, V68, P352, DOI 10.1107/S0907444912001308; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkt1223, 10.1093/nar/gkr1065, 10.1093/nar/gkp985]; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bernal JD, 1934, NATURE, V133, P794, DOI 10.1038/133794b0; BLAKE CCF, 1965, NATURE, V206, P757, DOI 10.1038/206757a0; BOCSKEI Z, 1992, NATURE, V360, P186, DOI 10.1038/360186a0; Botos I, 2011, STRUCTURE, V19, P447, DOI 10.1016/j.str.2011.02.004; Bublin M, 2014, J ALLERGY CLIN IMMUN, V134, P521, DOI 10.1016/j.jaci.2014.04.015; Bublin M, 2013, J ALLERGY CLIN IMMUN, V132, P118, DOI 10.1016/j.jaci.2013.01.022; Chapman MD, 2007, CURR ALLERGY ASTHM R, V7, P363, DOI 10.1007/s11882-007-0055-6; Chapman MD, 2007, J ALLERGY CLIN IMMUN, V119, P414, DOI 10.1016/j.jaci.2006.11.001; Chruszcz M, 2008, BIOPHYS J, V95, P1, DOI 10.1529/biophysj.108.131789; Chruszcz M, 2013, J ALLERGY CLIN IMMUN, V131, pAB15, DOI 10.1016/j.jaci.2012.12.732; Chruszcz M, 2012, J ALLERGY CLIN IMMUN, V130, P241, DOI 10.1016/j.jaci.2012.03.047; Chruszcz M, 2012, J BIOL CHEM, V287, P7388, DOI 10.1074/jbc.M111.311159; Chruszcz M, 2011, J BIOL CHEM, V286, P39318, DOI 10.1074/jbc.M111.270132; Chruszcz M, 2009, ADV PROTEIN CHEM STR, V77, P23, DOI 10.1016/S1876-1623(09)77002-6; Chruszcz M, 2009, J MOL BIOL, V386, P520, DOI 10.1016/j.jmb.2008.12.049; Coontz R, 2014, SCIENCE, V343, P1091, DOI 10.1126/science.343.6175.1091; Cormack BP, 1997, MICROBIOL-UK, V143, P303, DOI 10.1099/00221287-143-2-303; Cromwell O, 2011, J ALLERGY CLIN IMMUN, V127, P865, DOI 10.1016/j.jaci.2011.01.047; Cymborowski M., 2010, Journal of Structural and Functional Genomics, V11, P211, DOI 10.1007/s10969-010-9092-9; D'Avino R, 2011, ALLERGY, V66, P870, DOI 10.1111/j.1398-9995.2011.02555.x; Dang TD, 2012, J ALLERGY CLIN IMMUN, V129, P1056, DOI 10.1016/j.jaci.2012.01.056; Dauter Z, 2014, IUCRJ, V1, P179, DOI 10.1107/S2052252514005442; Dauter Z, 2010, J SYNCHROTRON RADIAT, V17, P433, DOI 10.1107/S0909049510011611; de Halleux S, 2006, J ALLERGY CLIN IMMUN, V117, P571, DOI 10.1016/j.jaci.2005.11.032; Derewenda U, 2002, J MOL BIOL, V318, P189, DOI 10.1016/S0022-2836(02)00027-X; Derewenda ZS, 2004, STRUCTURE, V12, P529, DOI 10.1016/j.str.2004.03.008; Dhaliwal B, 2012, P NATL ACAD SCI USA, V109, P12686, DOI 10.1073/pnas.1207278109; Drinkwater N, 2014, NAT STRUCT MOL BIOL, V21, P397, DOI 10.1038/nsmb.2795; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Fischer N, 2015, NATURE, V520, P567, DOI 10.1038/nature14275; Flower DR, 1996, BIOCHEM J, V318, P1; Gajhede M, 1996, NAT STRUCT BIOL, V3, P1040, DOI 10.1038/nsb1296-1040; Glesner J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022223; Gustchina A, 2005, J MOL BIOL, V348, P433, DOI 10.1016/j.jmb.2005.02.062; Hamiaux C, 2014, J STRUCT BIOL, V187, P276, DOI 10.1016/j.jsb.2014.07.005; Hazebrouck S, 2014, CLIN EXP ALLERGY, V44, P602, DOI 10.1111/cea.12261; Henzl MT, 2013, PROTEINS, V81, P300, DOI 10.1002/prot.24186; HEWITT CRA, 1995, J EXP MED, V182, P1537, DOI 10.1084/jem.182.5.1537; Hindley J, 2006, J ALLERGY CLIN IMMUN, V117, P1389, DOI 10.1016/j.jaci.2006.02.017; Holdom MD, 2011, NAT STRUCT MOL BIOL, V18, P571, DOI 10.1038/nsmb.2044; Huang SR, 2012, J LIPID RES, V53, P2002, DOI 10.1194/jlr.D029546; Kaiser L, 2003, J BIOL CHEM, V278, P37730, DOI 10.1074/jbc.M304740200; Kaiser L, 2007, J MOL BIOL, V370, P714, DOI 10.1016/j.jmb.2007.04.074; Karp CL, 2010, J ALLERGY CLIN IMMUN, V125, P955, DOI 10.1016/j.jaci.2010.03.002; KENDREW JC, 1958, NATURE, V181, P662, DOI 10.1038/181662a0; King C, 1998, J IMMUNOL, V161, P3645; Klemans RJB, 2015, CLIN EXP ALLERGY, V45, P720, DOI 10.1111/cea.12412; Kupitz C, 2014, NATURE, V513, P261, DOI 10.1038/nature13453; Kusano S, 2014, J MOL BIOL, V426, P3016, DOI 10.1016/j.jmb.2014.06.020; LaPorte SL, 2008, CELL, V132, P259, DOI 10.1016/j.cell.2007.12.030; Le TM, 2013, J ALLERGY CLIN IMMUN, V131, P164, DOI 10.1016/j.jaci.2012.09.009; Li M, 2008, J BIOL CHEM, V283, P22806, DOI 10.1074/jbc.M800937200; Li M, 2011, J IMMUNOL, V186, P333, DOI 10.4049/jimmunol.1002318; Lieberman JA, 2013, J ALLER CL IMM-PRACT, V1, P75, DOI 10.1016/j.jaip.2012.11.002; Llewellyn R, 2008, P NATL ACAD SCI USA, V105, P17700, DOI 10.1073/pnas.0809583105; Maleki SJ, 2000, J IMMUNOL, V164, P5844, DOI 10.4049/jimmunol.164.11.5844; Martin AC, 1998, STRUCTURE, V6, P875, DOI 10.1016/S0969-2126(98)00089-6; McSweeney S, 2014, NATURE, V505, P620, DOI 10.1038/505620a; Meno K, 2005, J IMMUNOL, V175, P3835, DOI 10.4049/jimmunol.175.6.3835; Meyer W, 2013, ALLERGY, V68, P724, DOI 10.1111/all.12148; Minor W, 2000, STRUCTURE, V8, pR105, DOI 10.1016/S0969-2126(00)00139-8; Minor W, 2006, ACTA CRYSTALLOGR D, V62, P859, DOI 10.1107/S0907444906019949; Mirza O, 2000, J IMMUNOL, V165, P331, DOI 10.4049/jimmunol.165.1.331; Mueller GA, 2011, ALLERGY, V66, P878, DOI 10.1111/j.1398-9995.2010.02532.x; Mueller GA, 2015, J ALLERGY CLIN IMMUN, V136, P1369, DOI 10.1016/j.jaci.2015.03.015; Mueller GA, 2013, J ALLERGY CLIN IMMUN, V132, P1420, DOI 10.1016/j.jaci.2013.06.014; Mueller GA, 2010, J BIOL CHEM, V285, P25394, DOI 10.1074/jbc.M110.128306; Mueller GA, 2010, J ALLERGY CLIN IMMUN, V125, P909, DOI 10.1016/j.jaci.2009.12.016; Nicolaou N, 2011, J ALLERGY CLIN IMMUN, V127, P684, DOI 10.1016/j.jaci.2010.12.012; Niemi M, 2007, STRUCTURE, V15, P1413, DOI 10.1016/j.str.2007.09.012; NISHIYAMA C, 1994, INT ARCH ALLERGY IMM, V105, P62, DOI 10.1159/000236804; Osinski T, 2015, J IMMUNOL IN PRESS; Padavattan S, 2007, J MOL BIOL, V368, P742, DOI 10.1016/j.jmb.2007.02.036; Padavattan S, 2009, J IMMUNOL, V182, P2141, DOI 10.4049/jimmunol.0803018; Park BS, 2009, NATURE, V458, P1191, DOI 10.1038/nature07830; Passalacqua G, 2006, ALLERGY, V61, P849, DOI 10.1111/j.1398-9995.2006.01095.x; PERUTZ MF, 1960, NATURE, V185, P416, DOI 10.1038/185416a0; Piggott DA, 2005, J CLIN INVEST, V115, P459, DOI 10.1172/JCI200522462; Pomes A, 1998, J BIOL CHEM, V273, P30801, DOI 10.1074/jbc.273.46.30801; Pomes A, 2002, AM J RESP CRIT CARE, V165, P391, DOI 10.1164/ajrccm.165.3.2104027; Power TD, 2013, PROTEINS, V81, P545, DOI 10.1002/prot.24239; Radauer C, 2014, ALLERGY, V69, P413, DOI 10.1111/all.12348; Radauer C, 2008, J ALLERGY CLIN IMMUN, V121, P847, DOI 10.1016/j.jaci.2008.01.025; Randall TA, 2013, GENOME BIOL EVOL, V5, P2344, DOI 10.1093/gbe/evt182; Redecke V, 2004, J IMMUNOL, V172, P2739, DOI 10.4049/jimmunol.172.5.2739; Romeo MJ, 2014, J ALLERGY CLIN IMMUN, V133, P952, DOI 10.1016/j.jaci.2013.08.006; Saarelainen S, 2008, CLIN EXP ALLERGY, V38, P374, DOI 10.1111/j.1365-2222.2007.02895.x; Sastre J, 2012, ALLERGY, V67, P709, DOI 10.1111/j.1398-9995.2012.02808.x; Schmidt A, 2011, ACTA CRYSTALLOGR F, V67, P424, DOI 10.1107/S1744309110052607; SCHULZ O, 1995, EUR J IMMUNOL, V25, P3191, DOI 10.1002/eji.1830251131; Scott CA, 1998, IMMUNITY, V8, P319, DOI 10.1016/S1074-7613(00)80537-3; Shakib F, 2008, TRENDS IMMUNOL, V29, P633, DOI 10.1016/j.it.2008.08.007; Shimamura T, 2011, NATURE, V475, P65, DOI 10.1038/nature10236; Smith A, 1998, DANCE MAG, V72, P101; Spangfort MD, 2003, J IMMUNOL, V171, P3084, DOI 10.4049/jimmunol.171.6.3084; Stringari G, 2014, J ALLERGY CLIN IMMUN, V134, P75, DOI 10.1016/j.jaci.2014.01.042; Takai T, 1997, NAT BIOTECHNOL, V15, P754, DOI 10.1038/nbt0897-754; Tripodi S, 2012, J ALLERGY CLIN IMMUN, V129, P834, DOI 10.1016/j.jaci.2011.10.045; Trompette A, 2009, NATURE, V457, P585, DOI 10.1038/nature07548; Valenta R, 1998, INT ARCH ALLERGY IMM, V117, P160, DOI 10.1159/000024005; Vance SJ, 2013, J R SOC INTERFACE, V10, DOI 10.1098/rsif.2013.0453; Verdino P, 2002, EMBO J, V21, P5007, DOI 10.1093/emboj/cdf526; Vinogradova MV, 2005, P NATL ACAD SCI USA, V102, P5038, DOI 10.1073/pnas.0408882102; von Laue M., 1912, INTERFERENZ ERSCHEIN, p303?322; Wagner S, 2008, J ALLERGY CLIN IMMUN, V121, P246, DOI 10.1016/j.jaci.2007.08.006; Wallner M, 2011, J ALLERGY CLIN IMMUN, V127, P1571, DOI 10.1016/j.jaci.2011.01.064; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; Westman M, 2015, J ALLERGY CLIN IMMUN, V135, P1199, DOI 10.1016/j.jaci.2014.10.042; Wlodawer A, 2008, FEBS J, V275, P1, DOI 10.1111/j.1742-4658.2007.06178.x; Yuan DP, 2013, J BIOL CHEM, V288, P21667, DOI 10.1074/jbc.M113.480657; Zheng HP, 2014, EXPERT OPIN DRUG DIS, V9, P125, DOI 10.1517/17460441.2014.872623; Zheng HP, 2014, NAT PROTOC, V9, P156, DOI 10.1038/nprot.2013.172; Zimmerman MD, 2014, METHODS MOL BIOL, V1140, P1, DOI 10.1007/978-1-4939-0354-2_1	118	21	21	0	25	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2015	136	1					29	37		10.1016/j.jaci.2015.05.016	http://dx.doi.org/10.1016/j.jaci.2015.05.016			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CM2WE	26145985	Green Accepted			2022-12-18	WOS:000357542200004
J	Lee, JJ; Protheroe, CA; Luo, H; Ochkur, SI; Scott, GD; Zellner, KR; Raish, RJ; Dahl, MV; Vega, ML; Conley, O; Condjella, RM; Kloeber, JA; Neely, JL; Patel, YS; Maizer, P; Mazzolini, A; Fryer, AD; Jacoby, NW; Jacoby, DB; Lee, NA				Lee, James J.; Protheroe, Cheryl A.; Luo, Huijun; Ochkur, Sergei I.; Scott, Gregory D.; Zellner, Katie R.; Raish, Randall J.; Dahl, Mark V.; Vega, Miriam L.; Conley, Olivia; Condjella, Rachel M.; Kloeber, Jake A.; Neely, Joseph L.; Patel, Yash S.; Maizer, Patty; Mazzolini, Andrew; Fryer, Allison D.; Jacoby, Noah W.; Jacoby, David B.; Lee, Nancy A.			Eosinophil-dependent skin innervation and itching following contact toxicant exposure in mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Contact hypersensitivity; eosinophil-deficient; sensory nerve; degranulation	ATOPIC-DERMATITIS; MOUSE MODEL; MAST-CELLS; NEUROPEPTIDES; RESPONSES; RECEPTOR; ALLERGY; ASTHMA; NERVES	Background: Contact toxicant reactions are accompanied by localized skin inflammation and concomitant increases in site-specific itch responses. The role(s) of eosinophils in these reactions is poorly understood. However, previous studies have suggested that localized eosinophil-nerve interactions at sites of inflammation significantly alter tissue innervation. Objective: To define a potential mechanistic link between eosinophils and neurosensory responses in the skin leading to itching. Methods: BALB/cJ mice were exposed to different contact toxicants, identifying trimellitic anhydride (TMA) for further study on the basis of inducing a robust eosinophilia accompanied by degranulation. Subsequent studies using TMA were performed with wild type versus eosinophil-deficient PHIL mice, assessing edematous responses and remodeling events such as sensory nerve innervation of the skin and induced pathophysiological responses (ie, itching). Results: Exposure to TMA, but not dinitrofluorobenzene, resulted in a robust eosinophil skin infiltrate accompanied by significant levels of degranulation. Follow-up studies using TMA with wild type versus eosinophil-deficient PHIL mice showed that the induced edematous responses and histopathology were, in part, causatively linked with the presence of eosinophils. Significantly, these data also demonstrated that eosinophil-mediated events correlated with a significant increase in substance P content of the cutaneous nerves and an accompanying increase in itching, both of which were abolished in the absence of eosinophils. Conclusions: Eosinophil-mediated events following TMA contact toxicant reactions increase skin sensory nerve substance P and, in turn, increase itching responses. Thus, eosinophil-nerve interactions provide a potential mechanistic link between eosinophil-mediated events and neurosensory responses following exposure to some contact toxicants.	[Lee, James J.; Luo, Huijun; Ochkur, Sergei I.; Zellner, Katie R.] Mayo Clin Arizona, Div Pulm Med, Scottsdale, AZ 85259 USA; [Protheroe, Cheryl A.; Conley, Olivia; Condjella, Rachel M.; Lee, Nancy A.] Mayo Clin Arizona, Dept Biochem & Mol Biol, Div Hematol & Oncol, Scottsdale, AZ USA; [Scott, Gregory D.; Jacoby, Noah W.; Jacoby, David B.] Oregon Hlth & Sci Univ, Div Pulm & Crit Care Med, Portland, OR 97201 USA; [Raish, Randall J.] Mayo Clin Arizona, Media Support Serv, Scottsdale, AZ USA; [Dahl, Mark V.; Vega, Miriam L.] Mayo Clin Arizona, Dept Dermatol, Scottsdale, AZ USA; [Kloeber, Jake A.; Neely, Joseph L.; Patel, Yash S.; Maizer, Patty; Mazzolini, Andrew] Brophy Coll Preparatory, Dept Sci, Phoenix, AZ USA; [Fryer, Allison D.] Oregon Hlth & Sci Univ, Dept Physiol & Pharmacol, Portland, OR 97201 USA	Mayo Clinic; Mayo Clinic Phoenix; Mayo Clinic; Mayo Clinic Phoenix; Oregon Health & Science University; Mayo Clinic; Mayo Clinic Phoenix; Mayo Clinic; Mayo Clinic Phoenix; Oregon Health & Science University	Lee, JJ (corresponding author), Mayo Clin Arizona, Div Pulm Med, MCCRB RESEARCH, CR 2-213,13400 E Shea Blvd, Scottsdale, AZ 85259 USA.	jjlee@mayo.edu		Jacoby, David/0000-0003-2195-9512; Kloeber, Jake/0000-0002-6646-564X; Fryer, Allison/0000-0003-1712-9831	United States National Institutes of Health (NIH) [HL065228, RR0109709, HL058723, HL113023, ES017592, ES014601, AR061567]; NATIONAL CENTER FOR RESEARCH RESOURCES [K26RR019709] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F30HL106930, R01HL058723, R01HL065228, R01HL113023, R56HL058723] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR061567] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES014601, R01ES017592] Funding Source: NIH RePORTER	United States National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	The performance of these studies, including data analysis and manuscript preparation, was supported by resources from the Mayo Foundation and a grant from the United States National Institutes of Health (NIH; to J.J.L. [HL065228, RR0109709], to N.A.L. [HL058723], to D.B.J. [HL113023], to A. D. F. [ES017592 and ES014601] and to J.J.L. and D.B.J. [AR061567]). These funding sources had no involvement in study design, data collection (including analysis and interpretation), the writing of the manuscript, or the decision to submit for publication.	Acharya KR, 2014, J BIOL CHEM, V289, P17406, DOI 10.1074/jbc.R113.546218; Cashman MW, 2012, DERMATOL CLIN, V30, P87, DOI 10.1016/j.det.2011.08.004; Cho JY, 2004, J CLIN INVEST, V113, P551, DOI 10.1172/JCI200419133; Chong SZ, 2014, J INVEST DERMATOL, V134, P666, DOI 10.1038/jid.2013.403; Coenraads P-J, 2007, Eur J Dermatol, V17, P564; De Jongh CM, 2008, CONTACT DERMATITIS, V58, P269, DOI 10.1111/j.1600-0536.2008.01317.x; DEARMAN RJ, 1992, INT ARCH ALLERGY IMM, V97, P315, DOI 10.1159/000236139; Dellon ES, 2011, AM J GASTROENTEROL, V106, P264, DOI 10.1038/ajg.2010.412; Foley SC, 2007, J ALLERGY CLIN IMMUN, V119, P1563, DOI 10.1016/j.jaci.2007.03.040; Foster EL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022029; He DG, 2009, J IMMUNOL, V183, P1463, DOI 10.4049/jimmunol.0804108; Inagaki N, 2010, EUR J PHARMACOL, V626, P283, DOI 10.1016/j.ejphar.2009.09.043; Jacobsen EA, 2011, J IMMUNOL, V187, P6059, DOI 10.4049/jimmunol.1102299; Jarvikallio A, 2003, ARCH DERMATOL RES, V295, P2, DOI 10.1007/s00403-002-0378-z; Lee JJ, 2005, CLIN EXP ALLERGY, V35, P986, DOI 10.1111/j.1365-2222.2005.02302.x; Lee JJ, 2004, SCIENCE, V305, P1773, DOI 10.1126/science.1099472; Lee NA, 1997, J IMMUNOL, V158, P1332; LEIFERMAN KM, 1985, NEW ENGL J MED, V313, P282, DOI 10.1056/NEJM198508013130502; Masterson JC, 2011, AM J PATHOL, V179, P2302, DOI 10.1016/j.ajpath.2011.07.039; MOLINA FA, 1992, BRIT J DERMATOL, V127, P344, DOI 10.1111/j.1365-2133.1992.tb00452.x; Nunez-Nateras R, 2014, UROL ONCOL, V32; O'Leary JG, 2006, NAT IMMUNOL, V7, P507, DOI 10.1038/ni1332; Ochkur SI, 2013, AM J RESP CELL MOL, V49, P1074, DOI 10.1165/rcmb.2013-0009OC; Protheroe C, 2009, CLIN GASTROENTEROL H, V7, P749, DOI 10.1016/j.cgh.2009.03.022; Rose L, 2012, EXP DERMATOL, V21, P25, DOI 10.1111/j.1600-0625.2011.01395.x; Schmidt M, 2010, NAT IMMUNOL, V11, P814, DOI 10.1038/ni.1919; Schneider C, 2009, J INVEST DERMATOL, V129, P899, DOI 10.1038/jid.2008.307; Scott GD, 2013, AM J RESP CELL MOL, V48, P10, DOI 10.1165/rcmb.2012-0290MA; Simon D, 2013, EOSINOPHILS IN HEALTH AND DISEASE, P442; Stander S, 2010, PLOS ONE, V4, P5; Suga H, 2013, J IMMUNOL, V190, P6059, DOI 10.4049/jimmunol.1201606; Sugiura H, 1997, ARCH DERMATOL RES, V289, P125, DOI 10.1007/s004030050167; TOBIN D, 1992, J ALLERGY CLIN IMMUN, V90, P613, DOI 10.1016/0091-6749(92)90134-N; Turner MJ, 2014, TRENDS IMMUNOL, V35, P49, DOI 10.1016/j.it.2013.12.001; Weidinger S, 2008, J ALLERGY CLIN IMMUN, V121, P1203, DOI 10.1016/j.jaci.2008.02.014; Xu GY, 2001, BRAIN RES, V923, P112, DOI 10.1016/S0006-8993(01)03203-6	36	21	21	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2015	135	2					477	U643		10.1016/j.jaci.2014.07.003	http://dx.doi.org/10.1016/j.jaci.2014.07.003			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CB1FL	25129680	Green Accepted			2022-12-18	WOS:000349372300021
J	Sampson, HA; Agbotounou, W; Thebault, C; Charles, R; Martin, L; Yang, WH; Sussman, GL; Brown-Whitehorn, TF; Nadeau, KC; Cheema, AS; Leonard, SA; Pongracic, JA; Sauvage, C; Assa'ad, AH; de Blay, F; Bird, JA; Tilles, SA; Boralevi, F; Bourrier, T; Shreffler, WG; Hebert, J; Green, TD; van Wijk, RG; Knulst, AC; Kanny, G; Kowalski, ML; Schneider, LC; Benhamou, PH; Dupont, C				Sampson, Hugh A.; Agbotounou, Wence; Thebault, Claude; Charles, Ruban; Martin, Laurent; Yang, William H.; Sussman, Gordon L.; Brown-Whitehorn, Terri F.; Nadeau, Kari C.; Cheema, Amarjit Singh; Leonard, Stephanie A.; Pongracic, Jacqueline A.; Sauvage, Christine; Assa'ad, Amal H.; de Blay, Frederic; Bird, J. Andrew; Tilles, Stephen A.; Boralevi, Franck; Bourrier, Thierry; Shreffler, Wayne G.; Hebert, Jacques; Green, Todd David; van Wijk, Roy Gerth; Knulst, Andre C.; Kanny, Gisele; Kowalski, Marek L.; Schneider, Lynda C.; Benhamou, Pierre Henri; Dupont, Christophe			Epicutaneous Immunotherapy (EPIT) Is Effective and Safe to Treat Peanut Allergy: A Multi-National Double-Blind PlaceboControlled Randomized Phase IIb Trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract	Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology (AAAAI)	FEB 20-24, 2015	Houston, TX	Amer Acad Allergy, Asthma & Immunol					[Sampson, Hugh A.] Icahn Sch Med Mt Sinai, Dept Pediat, New York, NY 10029 USA; [Agbotounou, Wence; Thebault, Claude; Charles, Ruban; Martin, Laurent; Benhamou, Pierre Henri] DBV Technol, Bagneux, France; [Yang, William H.] Univ Ottawa, Sch Med, Ottawa, ON K1N 6N5, Canada; [Sussman, Gordon L.] Univ Toronto, Fac Med, Toronto, ON, Canada; [Brown-Whitehorn, Terri F.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; [Nadeau, Kari C.] Stanford Univ, Pediat Allergy Immunol, Stanford, CA 94305 USA; [Cheema, Amarjit Singh] Alpha Med Res, Mississauga, ON, Canada; [Leonard, Stephanie A.] Univ Calif San Diego, Rady Childrens Hosp, San Diego, CA USA; [Pongracic, Jacqueline A.] Ann & Robert H Lurie Childrens Hosp Chicago, Chicago, IL USA; [Sauvage, Christine] St Vincent de Paul Hosp, Lille, France; [Assa'ad, Amal H.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA; [de Blay, Frederic] CHRU Strasbourg, Strasbourg, France; [Bird, J. Andrew] UT Southwestern Med Ctr, Dallas, TX USA; [Tilles, Stephen A.] Northwest Asthma & Allergy Ctr, Seattle, WA USA; [Boralevi, Franck] Hop Pellegrin Enfants, Bordeaux, France; [Bourrier, Thierry] Lenval Hosp, Nice, France; [Shreffler, Wayne G.] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Hebert, Jacques] Ctr Rech Appl Allergie Quebec, Quebec City, PQ, Canada; [Green, Todd David] UPMC, Childrens Hosp Pittsburgh, Pittsburgh, PA USA; [van Wijk, Roy Gerth] Erasmus MC, Rotterdam, Netherlands; [Knulst, Andre C.] Univ Med Ctr, Utrecht, Netherlands; [Kanny, Gisele] CHU Nancy Hop Cent, Nancy, France; [Kowalski, Marek L.] Med Univ Lodz, Lodz, Poland; [Schneider, Lynda C.] Boston Childrens Hosp, Boston, MA USA; [Dupont, Christophe] Hop Necker Enfants Malad, Paris, France	Icahn School of Medicine at Mount Sinai; University of Ottawa; University of Toronto; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Stanford University; Rady Childrens Hospital San Diego; University of California System; University of California San Diego; Ann & Robert H. Lurie Children's Hospital of Chicago; Cincinnati Children's Hospital Medical Center; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Texas System; University of Texas Southwestern Medical Center Dallas; CHU Bordeaux; CHU Nice; Harvard University; Massachusetts General Hospital; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Erasmus University Rotterdam; Erasmus MC; Utrecht University; Utrecht University Medical Center; CHU de Nancy; Medical University Lodz; Harvard University; Boston Children's Hospital; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite			Kanny, Gisèle/AHA-8910-2022	boralevi, franck/0000-0002-0477-5909					0	21	21	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2015	135	2		S		L28	AB390	AB390		10.1016/j.jaci.2014.12.1901	http://dx.doi.org/10.1016/j.jaci.2014.12.1901			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	CR2BN					2022-12-18	WOS:000361129600947
J	Walter, JE; Lo, MS; Kis-Toth, K; Tirosh, I; Frugoni, F; Lee, YN; Csomos, K; Chen, K; Pillai, S; Dunham, J; Tsokos, GC; Prak, ETL; Notarangelo, LD				Walter, Jolan E.; Lo, Mindy S.; Kis-Toth, Katalin; Tirosh, Irit; Frugoni, Francesco; Lee, Yu Nee; Csomos, Krisztian; Chen, Karin; Pillai, Shiv; Dunham, Jonathan; Tsokos, George C.; Prak, Eline T. Luning; Notarangelo, Luigi D.			Impaired receptor editing and heterozygous RAG2 mutation in a patient with systemic lupus erythematosus and erosive arthritis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							OMENN-SYNDROME; IMMUNODEFICIENCY; DEFECTS; DISEASE; CELLS		[Walter, Jolan E.; Lo, Mindy S.; Tirosh, Irit; Frugoni, Francesco; Lee, Yu Nee; Notarangelo, Luigi D.] Boston Childrens Hosp, Div Immunol, Boston, MA 02115 USA; [Walter, Jolan E.; Csomos, Krisztian] Massachusetts Gen Hosp Children, Div Pediat Allergy Immunol, Boston, MA USA; [Kis-Toth, Katalin] Beth Israel Deaconess Med Ctr, Div Rheumatol, Boston, MA 02215 USA; [Chen, Karin] Univ Utah, Sch Med, Dept Pediat, Div Rheumatol Allergy & Immunol, Salt Lake City, UT USA; [Pillai, Shiv] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA; [Dunham, Jonathan] Univ Penn, Div Rheumatol, Philadelphia, PA 19104 USA; [Prak, Eline T. Luning] Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA 19104 USA; [Notarangelo, Luigi D.] Boston Childrens Hosp, Manton Ctr Orphan Dis Res, Boston, MA USA; [Notarangelo, Luigi D.] Harvard Stem Cell Inst, Boston, MA USA	Harvard University; Boston Children's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Utah System of Higher Education; University of Utah; Harvard University; Massachusetts General Hospital; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Harvard University; Boston Children's Hospital; Harvard University	Walter, JE (corresponding author), Boston Childrens Hosp, Div Immunol, Boston, MA 02115 USA.	jewalter@partners.org	tsokos, george C/O-3360-2013; Notarangelo, Luigi D/F-9718-2016; Lee, Yu Nee/T-2360-2017	tsokos, george C/0000-0001-9589-2360; Notarangelo, Luigi D/0000-0002-8335-0262; Lee, Yu Nee/0000-0001-8648-5253; Frugoni, Francesco/0000-0002-1769-8121	NIAID NIH HHS [5K08AI103035, K08 AI103035, R01 AI42269, 5P01AI076210-04, U54AI082973] Funding Source: Medline; NIDDK NIH HHS [P30 DK040561] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U54AI082973, R01AI042269, P01AI076210, K08AI103035] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK040561] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Chen K, 2014, J ALLERGY CLIN IMMUN, V133, P880, DOI 10.1016/j.jaci.2013.11.038; Cohen MR, 1998, BRIT J RHEUMATOL, V37, P421; Giblin W, 2009, BLOOD, V113, P2965, DOI 10.1182/blood-2008-07-165167; Odendahl M, 2000, J IMMUNOL, V165, P5970, DOI 10.4049/jimmunol.165.10.5970; Panigrahi AK, 2008, J EXP MED, V205, P2985, DOI 10.1084/jem.20082053; Poliani PL, 2009, BLOOD, V114, P105, DOI 10.1182/blood-2009-03-211029; Schuetz C, 2008, NEW ENGL J MED, V358, P2030, DOI 10.1056/NEJMoa073966; Simon JA, 2002, LUPUS, V11, P287, DOI 10.1191/0961203302lu189oa; Stohl W, 2011, CURR OPIN RHEUMATOL, V23, P305, DOI 10.1097/BOR.0b013e328344c15e; Villa A, 1998, CELL, V93, P885, DOI 10.1016/S0092-8674(00)81448-8; Walter JE, 2010, J EXP MED, V207, P1541, DOI 10.1084/jem.20091927	11	21	22	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2015	135	1					272	273		10.1016/j.jaci.2014.07.063	http://dx.doi.org/10.1016/j.jaci.2014.07.063			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AY0PG	25312763	Green Accepted			2022-12-18	WOS:000347298200036
J	Badalyan, V; Thompson, R; Addo, K; Borthwick, LA; Fisher, AJ; Ort, T; Myers, TG; Wynn, TA; Ramalingam, TR				Badalyan, Vahe; Thompson, Robert; Addo, Kezia; Borthwick, Lee A.; Fisher, Andrew J.; Ort, Tatiana; Myers, Timothy G.; Wynn, Thomas A.; Ramalingam, Thirumalai R.			TNF-alpha/IL-17 synergy inhibits IL-13 bioactivity via IL-13R alpha 2 induction	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							RECEPTOR ALPHA-2; FIBROBLASTS; REVEALS; ASTHMA		[Badalyan, Vahe; Thompson, Robert; Addo, Kezia; Wynn, Thomas A.; Ramalingam, Thirumalai R.] NIAID, Immunopathogenesis Sect, Bethesda, MD 20892 USA; [Badalyan, Vahe] Childrens Natl Med Ctr, Div Gastroenterol Hepatol & Nutr, Washington, DC 20010 USA; [Borthwick, Lee A.; Fisher, Andrew J.] Newcastle Univ, Inst Cellular Med, Tissue Fibrosis & Repair Grp, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Ort, Tatiana] Janssen R&D Companies Johnson & Johnson, Spring House, PA USA; [Myers, Timothy G.] NIAID, Genom Technol Sect, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Children's National Health System; Newcastle University - UK; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Badalyan, V (corresponding author), NIAID, Immunopathogenesis Sect, 9000 Rockville Pike, Bethesda, MD 20892 USA.	ramalingamt@niaid.nih.gov	Fisher, Andrew J/A-2160-2012; Wynn, Thomas A/AAO-3523-2021	Wynn, Thomas A/0000-0002-7244-8731; Myers, Timothy Gene/0000-0002-7059-5906; Borthwick, Lee/0000-0003-2885-3382	Intramural NIH HHS [Z99 AI999999] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZICAI001051, ZIAAI001194, ZIAAI000829, ZIAAI001019] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Campbell-Harding G, 2013, J ALLERGY CLIN IMMUN, V131, P849, DOI 10.1016/j.jaci.2012.08.030; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Fichtner-Feigl S, 2006, NAT MED, V12, P99, DOI 10.1038/nm1332; Newcomb DC, 2011, J ALLERGY CLIN IMMUN, V127, P1006, DOI 10.1016/j.jaci.2010.11.043; Newcomb DC, 2011, J ALLERGY CLIN IMMUN, V127, pe1; O'Toole M, 2008, CLIN EXP ALLERGY, V38, P594, DOI 10.1111/j.1365-2222.2007.02921.x; Ramalingam TR, 2008, NAT IMMUNOL, V9, P25, DOI 10.1038/ni1544; Seys SF, 2013, CLIN EXP ALLERGY, V43, P1009, DOI 10.1111/cea.12125; Tabata Y, 2007, CURR ALLERGY ASTHM R, V7, P338, DOI 10.1007/s11882-007-0051-x; Wynn TA, 2003, ANNU REV IMMUNOL, V21, P425, DOI 10.1146/annurev.immunol.21.120601.141142; Yoshikawa M, 2003, BIOCHEM BIOPH RES CO, V312, P1248, DOI 10.1016/j.bbrc.2003.11.077	11	21	21	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2014	134	4					975	978		10.1016/j.jaci.2014.05.019	http://dx.doi.org/10.1016/j.jaci.2014.05.019			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AQ9GC	24954262	Green Accepted, Green Published			2022-12-18	WOS:000343155700033
J	Gomez-Casado, C; Garrido-Arandia, M; Pereira, C; Catarino, M; Parro, V; Armentia, A; Quirce, S; Armentia, B; Barranco, P; Blanca, M; Campo, P; Diaz-Perales, A				Gomez-Casado, Cristina; Garrido-Arandia, Maria; Pereira, Catia; Catarino, Manuela; Parro, Victor; Armentia, Alicia; Quirce, Santiago; Armentia, Blanca; Barranco, Paloma; Blanca, Miguel; Campo, Paloma; Diaz-Perales, Araceli			Component-resolved diagnosis of wheat flour allergy in baker's asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							RESPIRATORY ALLERGY; IGE; DETERMINANTS; PHENOTYPES		[Gomez-Casado, Cristina; Garrido-Arandia, Maria; Diaz-Perales, Araceli] UPM, Ctr Plant Biotechnol & Genom, INIA, Madrid, Spain; [Pereira, Catia; Catarino, Manuela] Univ Lisbon, Fac Pharm, P-1699 Lisbon, Portugal; [Parro, Victor] CSIC, INTA, Astrobiol Ctr, Mol Evolut Lab, Madrid, Spain; [Armentia, Alicia; Armentia, Blanca] Rio Hortega Univ Hosp, Dept Allergy, Valladolid, Spain; [Quirce, Santiago; Barranco, Paloma] Hosp La Paz, Inst Hlth Res IdiPAZ, Dept Allergy, Madrid, Spain; [Blanca, Miguel; Campo, Paloma] Civil Hosp Malaga, Dept Allergy, Malaga, Spain	Universidad Politecnica de Madrid; Centro de Investigacion en Biotecnologia Genomica de Plantas (CBGP); Universidade de Lisboa; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Astrobiologia (INTA); Hospital del Rio Hortega; Hospital Universitario La Paz	Gomez-Casado, C (corresponding author), UPM, Ctr Plant Biotechnol & Genom, INIA, Campus Montegancedo, Madrid, Spain.	cristina.gcasado@upm.es	Díaz-Perales, Araceli/D-8433-2016; Armentia, Alicia/GLS-3358-2022; Gomez-Casado, Cristina/AAE-4826-2021; Parro, Victor/K-3788-2014; Garrido-Arandia, Maria/ABG-9760-2020; s, q/AAD-7171-2020; Gomez-Casado, Cristina/K-4031-2016	Díaz-Perales, Araceli/0000-0002-1093-3627; Garrido Arandia, Maria/0000-0001-6114-5754; Parro, Victor/0000-0003-3738-0724; Gomez-Casado, Cristina/0000-0002-7707-6367; ARMENTIA, ALICIA/0000-0002-4165-4305				Baatjies R, 2009, EUR RESPIR J, V34, P825, DOI 10.1183/09031936.00164408; Constantin C, 2009, ALLERGY, V64, P1030, DOI 10.1111/j.1398-9995.2009.01955.x; Olivieri M, 2013, OCCUP ENVIRON MED, V70, P617, DOI 10.1136/oemed-2012-101112; Pahr S, 2012, CLIN EXP ALLERGY, V42, P597, DOI 10.1111/j.1365-2222.2012.03961.x; Palacin A, 2007, J ALLERGY CLIN IMMUN, V120, P1132, DOI 10.1016/j.jaci.2007.07.008; Palacin A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050799; Salcedo G, 2011, J INVEST ALLERG CLIN, V21, P81; Sander I, 2011, ALLERGY, V66, P1208, DOI 10.1111/j.1398-9995.2011.02636.x; Sotkovsky P, 2008, PROTEOMICS, V8, P1677, DOI 10.1002/pmic.200700347; van Kampen V, 2009, CLIN EXP ALLERGY, V39, P1896, DOI 10.1111/j.1365-2222.2009.03342.x; Wiszniewska M, 2011, ALLERGY ASTHMA PROC, V32, P111, DOI 10.2500/aap.2011.32.3422	11	21	21	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2014	134	2					480	483		10.1016/j.jaci.2014.03.016	http://dx.doi.org/10.1016/j.jaci.2014.03.016			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AO5GB	24794683	Green Accepted			2022-12-18	WOS:000341370800032
J	Hamilton, RG				Hamilton, Robert G.			Allergic sensitization is a key risk factor for but not synonymous with allergic disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						IgE; prevalence; sensitization; atopy; National Health and Nutrition Examination Survey			Johns Hopkins Univ, Sch Med, Baltimore, MD 21224 USA	Johns Hopkins University	Hamilton, RG (corresponding author), Johns Hopkins Univ, Sch Med, Baltimore, MD 21224 USA.	rhamilto@jhmi.edu						Bernstein IL, 2008, ANN ALLERG ASTHMA IM, V100, pS1, DOI 10.1016/S1081-1206(10)60305-5; Hamilton RG, 2013, MIDDLETONS ALLERGY P; Linden CC, 2011, ANN ALLERG ASTHMA IM, V106, P153, DOI 10.1016/j.anai.2010.11.004; Salo PM, 2014, J ALLERGY CLIN IMMUN, V134, P350, DOI 10.1016/j.jaci.2013.12.1071; Salo PM, 2011, J ALLERGY CLIN IMMUN, V127, P1226, DOI 10.1016/j.jaci.2010.12.1106	5	21	22	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2014	134	2					360	361		10.1016/j.jaci.2014.02.022	http://dx.doi.org/10.1016/j.jaci.2014.02.022			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AO5GB	24698318	Bronze			2022-12-18	WOS:000341370800015
J	Shaheen, SO; Rutterford, C; Zuccolo, L; Ring, SM; Smith, GD; Holloway, JW; Henderson, AJ				Shaheen, Seif O.; Rutterford, Clare; Zuccolo, Luisa; Ring, Susan M.; Smith, George Davey; Holloway, John W.; Henderson, A. John			Prenatal alcohol exposure and childhood atopic disease: A Mendelian randomization approach	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Alcohol; ADH1B; Mendelian randomization; prenatal exposure; ALSPAC; pregnancy; birth cohort; asthma; atopy	ALLERGIC SENSITIZATION; ETHANOL EXPOSURE; IMMUNOGLOBULIN-E; CONSUMPTION; PREGNANCY; RISK; ADH; ASSOCIATIONS; ALTERS; SAMPLE	Background: Alcohol consumption in western pregnant women is not uncommon and could be a risk factor for childhood atopic disease. However, reported alcohol intake may be unreliable, and associations are likely to be confounded. Objective: We aimed to study the relation between prenatal alcohol exposure and atopic phenotypes in a large population-based birth cohort with the use of a Mendelian randomization approach to minimize bias and confounding. Methods: In white mothers and children in the Avon Longitudinal Study of Parents and Children (ALSPAC) we first analyzed associations between reported maternal alcohol consumption during pregnancy and atopic outcomes in the offspring measured at 7 years of age (asthma, wheezing, hay fever, eczema, atopy, and total IgE). We then analyzed the relation of maternal alcohol dehydrogenase (ADH) 1B genotype (rs1229984) with these outcomes (the A allele is associated with faster metabolism and reduced alcohol consumption and, among drinkers, would be expected to reduce fetal exposure to ethanol). Results: After controlling for confounders, reported maternal drinking in late pregnancy was negatively associated with childhood asthma and hay fever (adjusted odds ratio [OR] per category increase in intake: 0.91 [95% CI, 0.82-1.01] and 0.87 [95% CI, 0.78-0.98], respectively). However, maternal ADH1B genotype was not associated with asthma comparing carriers of A allele with persons homozygous for G allele (OR, 0.98 [95% CI, 0.66-1.47]) or hay fever (OR, 1.11 [95% CI, 0.71-1.72]), nor with any other atopic outcome. Conclusion: We have found no evidence to suggest that prenatal alcohol exposure increases the risk of asthma or atopy in childhood.	[Shaheen, Seif O.; Rutterford, Clare] Barts & London Queen Marys Sch Med & Dent, Ctr Primary Care & Publ Hlth, London E1 2AB, England; [Zuccolo, Luisa; Ring, Susan M.; Smith, George Davey; Henderson, A. John] Univ Bristol, Sch Social & Community Med, Bristol BS8 1TH, Avon, England; [Zuccolo, Luisa; Smith, George Davey] Univ Bristol, MRC, Ctr Causal Anal Translat Epidemiol, Bristol BS8 1TH, Avon, England; [Holloway, John W.] Univ Southampton, Fac Med, Southampton SO9 5NH, Hants, England	University of London; Queen Mary University London; University of Bristol; University of Bristol; University of Southampton	Shaheen, SO (corresponding author), Barts & London Queen Marys Sch Med & Dent, Blizard Inst, Ctr Primary Care & Publ Hlth, 58 Turner St, London E1 2AB, England.	s.shaheen@qmul.ac.uk	Holloway, John W/B-5424-2009; Davey Smith, George/A-7407-2013	Holloway, John W/0000-0001-9998-0464; Davey Smith, George/0000-0002-1407-8314; Venkatasubramanian, Siddharth/0000-0002-5860-0768; Henderson, Alexander John/0000-0001-9650-231X; Zuccolo, Luisa/0000-0002-7049-3037; s, hema/0000-0002-3440-9475; Robinson, Clare/0000-0002-2673-2205	UK Medical Research Council; Wellcome Trust [092731]; Medical Research Council [G0902144, G0600705]; MRC [G0600705, G0902144, MC_UU_12013/1] Funding Source: UKRI; Medical Research Council [G9815508, MC_PC_15018, MC_UU_12013/1] Funding Source: researchfish	UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	Supported by the UK Medical Research Council, Wellcome Trust grant 092731, and the University of Bristol who provided core support for ALSPAC. L.Z. was funded by a Medical Research Council Population Health Scientist fellowship (grant G0902144). L.Z. and G. D. S. work in a center that receives funding from the MRC (grant G0600705).	Andersen AMN, 2012, INT J EPIDEMIOL, V41, P405, DOI 10.1093/ije/dyr189; [Anonymous], SAF SENS SOC NEXT ST; [Anonymous], 2007, STAT ALC ENGL 2007; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Birley AJ, 2009, HUM MOL GENET, V18, P1533, DOI 10.1093/hmg/ddp060; Bisgaard H, 2009, J ALLERGY CLIN IMMUN, V123, P1355, DOI 10.1016/j.jaci.2009.03.046; Bjerke T, 1994, Pediatr Allergy Immunol, V5, P88, DOI 10.1111/j.1399-3038.1994.tb00223.x; Boyd A, 2013, INT J EPIDEMIOL, V42, P111, DOI 10.1093/ije/dys064; Brennan P, 2004, AM J EPIDEMIOL, V159, P1, DOI 10.1093/aje/kwh003; Colvin L, 2007, ALCOHOL CLIN EXP RES, V31, P276, DOI 10.1111/j.1530-0277.2006.00303.x; Ethen M, 2009, MATERN CHILD HLTH J, V13, P274, DOI 10.1007/s10995-008-0328-2; Fraser A, 2013, INT J EPIDEMIOL, V42, P97, DOI 10.1093/ije/dys066; Giliberti D, 2013, PAEDIATR RESPIR REV, V14, P17, DOI 10.1016/j.prrv.2012.05.005; Gonzalez-Quintela A, 2003, CLIN EXP ALLERGY, V33, P199, DOI 10.1046/j.1365-2222.2003.01582.x; Goransson M, 2003, ADDICTION, V98, P1513, DOI 10.1046/j.1360-0443.2003.00498.x; Hashibe M, 2008, NAT GENET, V40, P707, DOI 10.1038/ng.151; INSELMAN LS, 1985, PEDIATR RES, V19, P12, DOI 10.1203/00006450-198501000-00004; Kelly YJ, 2012, J EPIDEMIOL COMMUN H, V66, P41, DOI 10.1136/jech.2009.103002; Lawlor DA, 2004, LANCET, V363, P1724, DOI 10.1016/S0140-6736(04)16260-0; Lewis SJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049407; Linneberg A, 2004, CLIN EXP ALLERGY, V34, P1678, DOI 10.1111/j.1365-2222.2004.02101.x; Linneberg A, 2003, CLIN EXP ALLERGY, V33, P192, DOI 10.1046/j.1365-2222.2003.01515.x; Linneberg A, 2001, CLIN EXP ALLERGY, V31, P1409, DOI 10.1046/j.1365-2222.2001.01178.x; Macgregor S, 2009, HUM MOL GENET, V18, P580, DOI 10.1093/hmg/ddn372; Mukhejee RAS, 2005, BMJ-BRIT MED J, V330, P375, DOI 10.1136/bmj.330.7488.375; Oldenburg PJ, 2012, AM J PHYSIOL-LUNG C, V302, pL308, DOI 10.1152/ajplung.00077.2011; Qi L, 2009, NUTR REV, V67, P439, DOI 10.1111/j.1753-4887.2009.00218.x; Roberts G, 2005, CLIN EXP ALLERGY, V35, P933, DOI 10.1111/j.1365-2222.2005.02280.x; Smith GD, 2003, INT J EPIDEMIOL, V32, P1, DOI 10.1093/ije/dyg070; Smith GD, 2008, BASIC CLIN PHARMACOL, V102, P245, DOI 10.1111/j.1742-7843.2007.00191.x; Smith GD, 2011, GENES NUTR, V6, P27, DOI 10.1007/s12263-010-0181-y; Smith GD, 2010, PERSPECT PSYCHOL SCI, V5, P527, DOI 10.1177/1745691610383505; Sozo F, 2009, AM J PHYSIOL-LUNG C, V296, pL510, DOI 10.1152/ajplung.90532.2008; Starkenburg S, 2001, ALCOHOL CLIN EXP RES, V25, P1221, DOI 10.1097/00000374-200108000-00019; Waltenbaugh C, 1998, ALCOHOL CLIN EXP RES, V22, p220S, DOI 10.1111/j.1530-0277.1998.tb04006.x; Wang X, 2007, AM J OBSTET GYNECOL, V197, pS157, DOI 10.1016/j.ajog.2007.10.544; Wurst FM, 2008, AM J OBSTET GYNECOL, V198, DOI 10.1016/j.ajog.2007.10.801; Yuan W, 2004, ALCOHOL CLIN EXP RES, V28, P765, DOI 10.1097/01.ALC.0000125348.23133.88; Zuccolo L, 2009, HUM MOL GENET, V18, P4457, DOI 10.1093/hmg/ddp388	39	21	21	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2014	133	1					225	+		10.1016/j.jaci.2013.04.051	http://dx.doi.org/10.1016/j.jaci.2013.04.051			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	281MM	23806636	hybrid, Green Published, Green Accepted			2022-12-18	WOS:000329105700030
J	Collmann, E; Bohnacker, T; Marone, R; Dawson, J; Rehberg, M; Stringer, R; Krombach, F; Burkhart, C; Hirsch, E; Hollingworth, GJ; Thomas, M; Wymann, MP				Collmann, Emilie; Bohnacker, Thomas; Marone, Romina; Dawson, Janet; Rehberg, Markus; Stringer, Rowan; Krombach, Fritz; Burkhart, Christoph; Hirsch, Emilio; Hollingworth, Gregory J.; Thomas, Matthew; Wymann, Matthias P.			Transient targeting of phosphoinositide 3-kinase acts as a roadblock in mast cells' route to allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mast cells; recruitment; migration; phosphoinositide 3-kinase; anaphylaxis; inflammation; allergy	FC-EPSILON-RI; STEEL FACTOR; IGE; ACTIVATION; RECEPTOR; ADHESION; KINASE; GAMMA; INFLAMMATION; PROGENITORS	Background: Tissue mast cellnumbers are dynamically regulated by recruitment of progenitors from the vasculature. It is unclear whether progenitors are recruited during allergic sensitization and whether recruitment promotes allergic responses. Objective: We sought to (1) determine the effect of mast cell recruitment on acute allergic responses and (2) to define the role of phosphoinositide 3-kinase (PI3K) isoforms in sequential steps to allergic responses. Methods: Gene-targeted mice for PI3K gamma or PI3K delta or mice treated with isoform-specific PI3K inhibitors (a novel PI3K gamma-specific inhibitor [NVS-PI3-4] and the PI3Kd inhibitor IC87114) were used to monitor IgE-mediated mast cell recruitment, migration, adhesion by means of intravital microscopy, degranulation, TNF-alpha release, and subsequent endothelial cell activation in vivo or in bone marrow-derived mast cells. Results: Functional PI3Kg, but not PI3Kd, was crucial for mast cell accumulation in IgE-challenged skin, TNF-alpha release from IgE/antigen-stimulated mast cells, and mast cell/endothelial interactions and chemotaxis. PI3Kg-deficient bone marrow-derived mast cells did not adhere to the endothelium in TNF-alpha-treated cremaster muscle, whereas PI3Kd was not required. Depletion of TNF-alpha blocked IgE-induced mast cell recruitment, which links tissue mast cell-derived cytokine release to endothelial activation and mast cell recruitment. Interference with mast cell recruitment protected against anaphylaxis and was superior to blockage of tissue mast cell degranulation. Conclusions: Interference with mast cell recruitment to exacerbated tissues provides a novel strategy to alleviate allergic reactions and surpassed attenuation of tissue mast cell degranulation. This results in prolonged drug action and allows for reduction of drug doses required to block anaphylaxis, an important feature for drugs targeting inflammatory disease in general.	[Collmann, Emilie; Bohnacker, Thomas; Marone, Romina; Wymann, Matthias P.] Univ Basel, Inst Biochem & Genet, Dept Biomed, Basel, Switzerland; [Dawson, Janet; Burkhart, Christoph] Novartis Inst BioMed Res, Basel, Switzerland; [Rehberg, Markus; Krombach, Fritz] LMU Munchen, Walter Brendel Ctr Expt Med, Munich, Germany; [Stringer, Rowan; Hollingworth, Gregory J.; Thomas, Matthew] Novartis Inst BioMed Res, Horsham, W Sussex, England; [Hirsch, Emilio] Univ Turin, Dept Genet Biol & Biochem, Ctr Mol Biotechnol, I-10124 Turin, Italy	University of Basel; Novartis; University of Munich; Novartis; University of Turin	Wymann, MP (corresponding author), Inst Biochem & Genet, Dept Biomed, Mattenstr 28, CH-4058 Basel, Switzerland.	Matthias.Wymann@UniBas.CH	Wymann, Matthias P/C-3227-2008; Hirsch, Emilio/F-4848-2013; STRINGER, ROWAN/U-3634-2019	Wymann, Matthias P/0000-0003-3349-4281; Hirsch, Emilio/0000-0002-9073-6024; Bohnacker, Thomas/0000-0001-5769-4478; Rehberg, Markus/0000-0001-7314-6332; Dawson, Janet/0000-0003-4615-4091; Marone, Romina/0000-0003-1474-1689; Thomas, Matthew/0000-0003-3472-3904	Swiss National Science Foundation [310030_127574, 31EM30-126143]; Leducq Foundation	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Leducq Foundation(Leducq Foundation)	Supported by the Swiss National Science Foundation (310030_127574 and 31EM30-126143).; Disclosure of potential conflict of interest: J. Dawson, C. Burkhart, and M. Thomas are employed by and own stock/stock options in Novartis Pharma AG. E. Hirsch has been supported by one or more grants from the Leducq Foundation, is a Board member for and owns stock/stock options in Kither Biotech, and has received one or more grants from or has one or more grants pending with AIRC, MIUR, CSP, and Leducq. M. P. Wymann has been supported by one or more grants from the Swiss National Science Foundation, is a Board member for and owns stock/stock options in PIQUR Therapeutics, is employed by the University of Basel, and has received payments for travel/accommodations/meeting expenses from various entities.	Abonia JP, 2006, BLOOD, V108, P1588, DOI 10.1182/blood-2005-12-012781; Abramson J, 2007, IMMUNOL REV, V217, P231, DOI 10.1111/j.1600-065X.2007.00518.x; Ali K, 2004, NATURE, V431, P1007, DOI 10.1038/nature02991; Ali K, 2008, J IMMUNOL, V180, P2538, DOI 10.4049/jimmunol.180.4.2538; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Asai K, 2001, IMMUNITY, V14, P791, DOI 10.1016/S1074-7613(01)00157-1; Bischoff SC, 2007, NAT REV IMMUNOL, V7, P93, DOI 10.1038/nri2018; Bohnacker T, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000259; Boyce JA, 2002, BLOOD, V99, P2890, DOI 10.1182/blood.V99.8.2890; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; Brown JM, 2008, CLIN EXP ALLERGY, V38, P4, DOI 10.1111/j.1365-2222.2007.02886.x; Bruce I, 2012, BIOORG MED CHEM LETT, V22, P5445, DOI 10.1016/j.bmcl.2012.07.042; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chen CC, 2005, P NATL ACAD SCI USA, V102, P11408, DOI 10.1073/pnas.0504197102; Fukao T, 2002, NAT IMMUNOL, V3, P295, DOI 10.1038/ni768; Genovese T, 2006, J PHARMACOL EXP THER, V316, P1006, DOI 10.1124/jpet.105.097188; Gu HH, 2001, NATURE, V412, P186, DOI 10.1038/35084076; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Houtman R, 2001, CLIN EXP ALLERGY, V31, P817, DOI 10.1046/j.1365-2222.2001.01104.x; Huang B, 2008, BLOOD, V112, P1269, DOI 10.1182/blood-2008-03-147033; Kalesnikoff J, 2001, IMMUNITY, V14, P801, DOI 10.1016/S1074-7613(01)00159-5; Kalesnikoff J, 2008, NAT IMMUNOL, V9, P1215, DOI 10.1038/ni.f.216; Kim MS, 2008, TRENDS IMMUNOL, V29, P493, DOI 10.1016/j.it.2008.07.004; KINASHI T, 1994, BLOOD, V83, P1033; Kitaura J, 2005, BLOOD, V105, P3222, DOI 10.1182/blood-2004-11-4205; Kitaura J, 2005, J IMMUNOL, V174, P4495, DOI 10.4049/jimmunol.174.8.4495; Kitaura J, 2003, P NATL ACAD SCI USA, V100, P12911, DOI 10.1073/pnas.1735525100; Kraft S, 2007, NAT REV IMMUNOL, V7, P365, DOI 10.1038/nri2072; Laffargue M, 2002, IMMUNITY, V16, P441, DOI 10.1016/S1074-7613(02)00282-0; Lam V, 2003, BLOOD, V102, P1405, DOI 10.1182/blood-2002-10-3176; Lu-Kuo JM, 2000, J BIOL CHEM, V275, P6022, DOI 10.1074/jbc.275.8.6022; Makowska Joanna S, 2009, BMC Pulm Med, V9, P27, DOI 10.1186/1471-2466-9-27; MENG H, 1995, J CELL PHYSIOL, V165, P40, DOI 10.1002/jcp.1041650106; Metcalfe DD, 1997, PHYSIOL REV, V77, P1033, DOI 10.1152/physrev.1997.77.4.1033; Nadler M J, 2000, Adv Immunol, V76, P325; Nigrovic PA, 2010, ARTHRITIS RHEUM-US, V62, P3322, DOI 10.1002/art.27659; Okkenhaug K, 2002, SCIENCE, V297, P1031; Okkenhaug K, 2010, CURR TOP MICROBIOL, V346, P57, DOI 10.1007/82_2010_45; Olsson N, 2000, J ALLERGY CLIN IMMUN, V105, P455, DOI 10.1067/mai.2000.104380; Parravicini V, 2002, NAT IMMUNOL, V3, P741, DOI 10.1038/ni817; Patrucco E, 2004, CELL, V118, P375, DOI 10.1016/j.cell.2004.07.017; RA CS, 1994, J ALLERGY CLIN IMMUN, V94, P625, DOI 10.1016/0091-6749(94)90139-2; Rivera J, 2006, J ALLERGY CLIN IMMUN, V117, P1214, DOI 10.1016/j.jaci.2006.04.015; Rommel C, 2007, NAT REV IMMUNOL, V7, P191, DOI 10.1038/nri2036; Sadhu C, 2003, J IMMUNOL, V170, P2647, DOI 10.4049/jimmunol.170.5.2647; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Suire S, 2005, CURR BIOL, V15, P566, DOI 10.1016/j.cub.2005.02.020; Vanhaesebroeck B, 2010, NAT REV MOL CELL BIO, V11, P329, DOI 10.1038/nrm2882; Walser R, 2013, PLOS BIOL IN PRESS, DOI [10.1371/journal.pbio.1001587, DOI 10.1371/J0URNAL.PBI0.1001587]; Wedemeyer J, 2000, CURR OPIN IMMUNOL, V12, P624, DOI 10.1016/S0952-7915(00)00154-0; Wymann MP, 2003, TRENDS PHARMACOL SCI, V24, P366, DOI 10.1016/S0165-6147(03)00163-9; Wymann MP, 1996, MOL CELL BIOL, V16, P1722	53	21	22	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2013	132	4					959	968		10.1016/j.jaci.2013.03.008	http://dx.doi.org/10.1016/j.jaci.2013.03.008			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	227FR	23683463	Bronze			2022-12-18	WOS:000325096500024
J	Vidal, C; Porras-Hurtado, L; Cruz, R; Quiralte, J; Cardona, V; Colas, C; Castillo, LF; Marcos, C; Soto, T; Lopez-Abad, R; Hernandez, D; Audicana, MT; Armisen, M; Rodriguez, V; Perez-Carral, C; Moreno, E; Cabanes, R; Corominas, M; Parra, A; Lobera, T; Quinones, D; Ojeda, P; Luna, I; Torres, M; Carracedo, A				Vidal, Carmen; Porras-Hurtado, Liliana; Cruz, Raquel; Quiralte, Joaquin; Cardona, Victoria; Colas, Carlos; Castillo, Luisa F.; Marcos, Carmen; Soto, Teresa; Lopez-Abad, Raquel; Hernandez, Dolores; Teresa Audicana, Maria; Armisen, Margarita; Rodriguez, Virginia; Perez-Carral, Celsa; Moreno, Esther; Cabanes, Rosario; Corominas, Merce; Parra, Antonio; Lobera, Teofilo; Quinones, Dolores; Ojeda, Pedro; Luna, Ildefonso; Torres, Maria; Carracedo, Angel			Association of thromboxane A1 synthase (TBXAS1) gene polymorphism with acute urticaria induced by nonsteroidal anti-inflammatory drugs	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Vidal, Carmen; Armisen, Margarita; Rodriguez, Virginia; Luna, Ildefonso] Complejo Hosp Univ Santiago, Dept Allergy, Santiago De Compostela, Spain; [Porras-Hurtado, Liliana; Castillo, Luisa F.; Carracedo, Angel] Galician Fdn Genom Med SERGAS IDIS Santiago de Co, Santiago De Compostela, Spain; [Cruz, Raquel; Carracedo, Angel] Univ Santiago de Compostela, Grp Med Xenom, CIBERER, Santiago De Compostela, Spain; [Quiralte, Joaquin] Hosp Univ Virgen Rocio, Dept Allergy, Seville, Spain; [Cardona, Victoria] Hosp Univ Vall Hebron, Dept Allergy, Barcelona, Spain; [Colas, Carlos] Hosp Clin, Dept Allergy, Inst Invest Sanit Aragon, Zaragoza, Spain; [Marcos, Carmen] Complejo Hosp Univ Vigo, Dept Allergy, Vigo, Spain; [Soto, Teresa] Complejo Hosp Pontevedra, Dept Allergy, Pontevedra, Spain; [Lopez-Abad, Raquel] Complejo Hosp Univ Ferrol, Dept Allergy, Ferrol, Spain; [Hernandez, Dolores] Hosp Univ Politecn La Fe, Dept Allergy, Valencia, Spain; [Teresa Audicana, Maria] Hosp Univ Araba, Dept Allergy, Vitoria, Spain; [Perez-Carral, Celsa] Hosp Costa, Dept Allergy, Lugo, Spain; [Moreno, Esther] Complejo Asistencial Univ Salamanca, Dept Allergy, Salamanca, Spain; [Cabanes, Rosario] Hosp La Paz Inst Hlth Res IdiPAZ, Dept Allergy, Madrid, Spain; [Corominas, Merce] Hosp Llobregat, Hosp Univ, Dept Allergy, Barcelona, Spain; [Parra, Antonio] Complejo Hosp Univ A Coruna, Allergy Dept, La Coruna, Spain; [Lobera, Teofilo] Hosp San Pedro, Dept Allergy, Logrono, Spain; [Quinones, Dolores] Hosp Monte Naranco, Dept Allergy, Oviedo, Spain; [Ojeda, Pedro] Clin Asma & Alergia Dres Ojeda, Dept Allergy, Madrid, Spain; [Torres, Maria] Natl Genotyping Ctr CeGenISCIII, Santiago De Compostela, Spain	Complexo Hospitalario Universitario de Santiago de Compostela; CIBER - Centro de Investigacion Biomedica en Red; CIBERER; Universidade de Santiago de Compostela; Virgen del Rocio University Hospital; Hospital Universitari Vall d'Hebron; Complexo Hospitalario Universitario de Vigo; Complexo Hospitalario Universitario de Pontevedra; Complejo Hospitalario Universitario de Ferrol; Hospital Universitari i Politecnic La Fe; University Hospital of Araba; University of Barcelona; University of Sevilla; Complejo Hospitalario Universitario A Coruna; Universidade da Coruna	Vidal, C (corresponding author), Complejo Hosp Univ Santiago, Dept Allergy, Santiago De Compostela, Spain.	carmen.vidal.pan@sergas.es	Carracedo, Angel/D-4257-2012; Torres, Maria/R-5162-2019; IBIS, ALERGICAS/C-1733-2016; Cardona, Victoria/GRX-4196-2022	Carracedo, Angel/0000-0003-1085-8986; Torres, Maria/0000-0002-2658-0133; Castillo, Luisa Fernanda/0000-0002-6529-413X; CRUZ, RAQUEL/0000-0002-6964-8898; Cardona, Victoria/0000-0003-2197-9767; Audicana, Maria Teresa/0000-0003-4008-0482; hernandez, Dolores/0000-0001-8427-6845; MORENO, ESTHER/0000-0003-0953-3025				CHASE MB, 1993, GENOMICS, V16, P771, DOI 10.1006/geno.1993.1264; Chaudhry T, 2012, INTERN MED J, V42, P665, DOI 10.1111/j.1445-5994.2011.02601.x; Dona I, 2011, CLIN EXP ALLERGY, V41, P86, DOI 10.1111/j.1365-2222.2010.03651.x; Kowalski ML, 2011, ALLERGY, V66, P818, DOI 10.1111/j.1398-9995.2011.02557.x; MIYATA A, 1994, EUR J BIOCHEM, V224, P273, DOI 10.1111/j.1432-1033.1994.00273.x; Oh SH, 2011, PHARMACOGENOMICS, V12, P351, DOI [10.2217/PGS.10.181, 10.2217/pgs.10.181]; Palikhe NS, 2011, CLIN EXP ALLERGY, V41, P179, DOI 10.1111/j.1365-2222.2010.03642.x; Stevenson DD, 2001, ANN ALLERG ASTHMA IM, V87, P177, DOI 10.1016/S1081-1206(10)62221-1; Vidal C, 2005, J INVEST ALLERG CLIN, V15, P124	9	21	21	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2013	132	4					989	+		10.1016/j.jaci.2013.04.045	http://dx.doi.org/10.1016/j.jaci.2013.04.045			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	227FR	23763970				2022-12-18	WOS:000325096500033
J	Bentley, JK; Sajjan, US; Dzaman, MB; Jarjour, NN; Lee, WM; Gern, JE; Hershenson, MB				Bentley, J. Kelley; Sajjan, Uma S.; Dzaman, Marta B.; Jarjour, Nizar N.; Lee, Wai-Ming; Gern, James E.; Hershenson, Marc B.			Rhinovirus colocalizes with CD68-and CD11b-positive macrophages following experimental infection in humans	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							INFLAMMATION; EXPRESSION; ASTHMA; MODEL		[Bentley, J. Kelley; Sajjan, Uma S.; Hershenson, Marc B.] Univ Michigan, Sch Med, Dept Pediat & Communicable Dis, Ann Arbor, MI 48109 USA; [Dzaman, Marta B.] Univ Michigan, Sch Med, Dept Neurosurg, Ann Arbor, MI USA; [Jarjour, Nizar N.; Gern, James E.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA; [Lee, Wai-Ming] Biol Mimet, Frederick, MD USA; [Hershenson, Marc B.] Univ Michigan, Sch Med, Dept Mol & Integrat Physiol, Ann Arbor, MI USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Wisconsin System; University of Wisconsin Madison; University of Michigan System; University of Michigan	Bentley, JK (corresponding author), Univ Michigan, Sch Med, Dept Pediat & Communicable Dis, Ann Arbor, MI 48109 USA.	mhershen@umich.edu		Bentley, John Kelley/0000-0001-8865-7979	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL081420] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL081420, HL081420] Funding Source: Medline; NIAID NIH HHS [U19 AI070503] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Gern JE, 1996, J IMMUNOL, V156, P621; Melgert BN, 2011, J ALLERGY CLIN IMMUN, V127, P831, DOI 10.1016/j.jaci.2010.10.045; Message SD, 2008, P NATL ACAD SCI USA, V105, P13562, DOI 10.1073/pnas.0804181105; Moon KA, 2007, INT IMMUNOL, V19, P1371, DOI 10.1093/intimm/dxm108; Mosser AG, 2005, AM J RESP CRIT CARE, V171, P645, DOI 10.1164/rccm.200407-970OC; Nagarkar DR, 2010, J IMMUNOL, V185, P2525, DOI 10.4049/jimmunol.1000286; Proud D, 2008, AM J RESP CRIT CARE, V178, P962, DOI 10.1164/rccm.200805-670OC; Schneider D, 2013, AM J PHYSIOL-LUNG C, V304, pL162, DOI 10.1152/ajplung.00182.2012; Travaglione S, 2002, TOXICOL IN VITRO, V16, P405, DOI 10.1016/S0887-2333(02)00028-0	9	21	22	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2013	132	3					758	761		10.1016/j.jaci.2013.04.020	http://dx.doi.org/10.1016/j.jaci.2013.04.020			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207OS	23727038	Green Accepted			2022-12-18	WOS:000323612000036
J	Kyoh, S; Venkatesan, N; Poon, AH; Nishioka, M; Lin, TY; Baglole, CJ; Eidelman, DH; Hamid, Q				Kyoh, Shigenori; Venkatesan, Narayanan; Poon, Audrey H.; Nishioka, Michiyoshi; Lin, Ting-Yu; Baglole, Carolyn J.; Eidelman, David H.; Hamid, Qutayba			Are leukocytes in asthmatic patients aging faster? A study of telomere length and disease severity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							OBSTRUCTIVE PULMONARY-DISEASE		[Kyoh, Shigenori; Venkatesan, Narayanan; Poon, Audrey H.; Nishioka, Michiyoshi; Lin, Ting-Yu; Baglole, Carolyn J.; Eidelman, David H.; Hamid, Qutayba] McGill Univ, Meakins Christie Labs, Ctr Hlth, Montreal, PQ, Canada	McGill University	Kyoh, S (corresponding author), McGill Univ, Meakins Christie Labs, Ctr Hlth, Montreal, PQ, Canada.	qutayba.hamid@mcgill.ca			Canadian Institutes of Health Research Funding Source: Medline	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))		Calado RT, 2009, NEW ENGL J MED, V361, P2353, DOI 10.1056/NEJMra0903373; de Leon AD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010680; Houben JMJ, 2008, FREE RADICAL BIO MED, V44, P235, DOI 10.1016/j.freeradbiomed.2007.10.001; Kirkwood TBL, 2005, CELL, V120, P437, DOI 10.1016/j.cell.2005.01.027; Martinez P, 2011, NAT REV CANCER, V11, P161, DOI 10.1038/nrc3025; McHugh MK, 2009, J ASTHMA, V46, P759, DOI 10.3109/02770900903067895; Mui TSY, 2009, J AM GERIATR SOC, V57, P2372, DOI 10.1111/j.1532-5415.2009.02589.x; O'Callaghan NJ, 2011, BIOL PROCED ONLINE, V13, DOI 10.1186/1480-9222-13-3; Savale L, 2009, AM J RESP CRIT CARE, V179, P566, DOI 10.1164/rccm.200809-1398OC	9	21	21	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2013	132	2					480	482		10.1016/j.jaci.2013.02.010	http://dx.doi.org/10.1016/j.jaci.2013.02.010			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	194KL	23534972				2022-12-18	WOS:000322631700029
J	van Leeuwen, JC; Driessen, JMM; de Jongh, FHC; Anderson, SD; Thio, BJ				van Leeuwen, Janneke C.; Driessen, Jean M. M.; de Jongh, Frans H. C.; Anderson, Sandra D.; Thio, Boony J.			Measuring breakthrough exercise-induced bronchoconstriction in young asthmatic children using a jumping castle	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CHILDHOOD ASTHMA; PULMONARY-FUNCTION; CHALLENGE		[van Leeuwen, Janneke C.; Driessen, Jean M. M.; Thio, Boony J.] Med Spectrum Twente, Dept Pediat, Enschede, Netherlands; [de Jongh, Frans H. C.] Med Spectrum Twente, Dept Pulmonol, Enschede, Netherlands; [Driessen, Jean M. M.] Tjongerschans Hosp, Dept Sports Med, Heerenveen, Netherlands; [Anderson, Sandra D.] Royal Prince Alfred Hosp, Dept Resp & Sleep Med, Camperdown, NSW 2050, Australia	Medical Spectrum Twente; Medical Spectrum Twente; University of Sydney	van Leeuwen, JC (corresponding author), Med Spectrum Twente, Dept Pediat, Enschede, Netherlands.	vanleeuwen.janneke@gmail.com	de Jongh, Frans/N-7739-2013	van Leeuwen, Janneke/0000-0002-1010-8109; Anderson, Sandra/0000-0002-6308-8770; Driessen, Jean/0000-0001-6586-8757				Anderson SD, 2000, J ALLERGY CLIN IMMUN, V106, P453, DOI 10.1067/mai.2000.109822; Chinellato I, 2012, PEDIATR PULM, V47, P226, DOI 10.1002/ppul.21542; GODFREY S, 1991, THORAX, V46, P488, DOI 10.1136/thx.46.7.488; Godfrey S, 1999, EUR RESPIR J, V14, P659, DOI 10.1034/j.1399-3003.1999.14c28.x; Gotshall RW, 2006, SPORTS MED, V36, P513, DOI 10.2165/00007256-200636060-00005; HABY MM, 1995, EUR RESPIR J, V8, P729; HOFSTRA WB, 1995, PEDIATR PULM, V20, P177, DOI 10.1002/ppul.1950200309; Koolen BB, 2011, EUR RESPIR J, V38, P561, DOI 10.1183/09031936.00173710; Koopman M, 2011, RESP MED, V105, P15, DOI 10.1016/j.rmed.2010.07.020; Liu AH, 2007, J ALLERGY CLIN IMMUN, V119, P817, DOI 10.1016/j.jaci.2006.12.662; Merikallio VJ, 2005, PEDIAT ALLERG IMM-UK, V16, P332, DOI 10.1111/j.1399-3038.2005.00286.x; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Panditi S, 2003, ARCH DIS CHILD, V88, P807, DOI 10.1136/adc.88.9.807; Rundell KW, 2001, MED SCI SPORT EXER, V33, P208; Vahlkvist S, 2010, ALLERGY, V65, P1464, DOI 10.1111/j.1398-9995.2010.02406.x; van Leeuwen JC, 2011, ARCH DIS CHILD, V96, P664, DOI 10.1136/adc.2010.209411; Vilozni D, 2007, CHEST, V132, P497, DOI 10.1378/chest.07-0052; Vilozni D, 2009, RESP MED, V103, P1456, DOI 10.1016/j.rmed.2009.04.028	18	21	22	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2013	131	5					1427	U276		10.1016/j.jaci.2012.10.014	http://dx.doi.org/10.1016/j.jaci.2012.10.014			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	144AU	23199614				2022-12-18	WOS:000318912200025
J	Wang, XW; Lin, ZM; Gao, LJ; Wang, AP; Wan, Z; Chen, W; Yang, Y; Li, RY				Wang, Xiaowen; Lin, Zhimiao; Gao, Lujuan; Wang, Aiping; Wan, Zhe; Chen, Wei; Yang, Yong; Li, Ruoyu			Exome sequencing reveals a signal transducer and activator of transcription 1 (STAT1) mutation in a child with recalcitrant cutaneous fusariosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CHRONIC MUCOCUTANEOUS CANDIDIASIS; IMMUNITY		[Wang, Xiaowen; Lin, Zhimiao; Gao, Lujuan; Wang, Aiping; Wan, Zhe; Chen, Wei; Yang, Yong; Li, Ruoyu] Peking Univ, Hosp 1, Dept Dermatol, Beijing 100871, Peoples R China; [Wang, Xiaowen; Gao, Lujuan; Wang, Aiping; Wan, Zhe; Chen, Wei; Li, Ruoyu] Peking Univ, Res Ctr Med Mycol, Beijing 100871, Peoples R China; [Wang, Xiaowen; Lin, Zhimiao; Gao, Lujuan; Wang, Aiping; Wan, Zhe; Chen, Wei; Yang, Yong; Li, Ruoyu] Beijing Key Lab Mol Diag Dermatoses, Beijing, Peoples R China; [Yang, Yong] Peking Tsinghua Ctr Life Sci, Beijing, Peoples R China	Peking University; Peking University	Wang, XW (corresponding author), Peking Univ, Hosp 1, Dept Dermatol, Beijing 100871, Peoples R China.	lry0660@gmail.com						Boisson-Dupuis S, 2012, CURR OPIN IMMUNOL, V24, P364, DOI 10.1016/j.coi.2012.04.011; Dignani MC, 2004, CLIN MICROBIOL INFEC, V10, P67, DOI 10.1111/j.1470-9465.2004.00845.x; Liu LY, 2011, J EXP MED, V208, P1635, DOI 10.1084/jem.20110958; Lynch M, 2010, P NATL ACAD SCI USA, V107, P961, DOI 10.1073/pnas.0912629107; Najjar I, 2010, BIOCHIMIE, V92, P425, DOI 10.1016/j.biochi.2010.02.009; Nucci M, 2002, CLIN INFECT DIS, V35, P909, DOI 10.1086/342328; Romani L, 2011, NAT REV IMMUNOL, V11, P275, DOI 10.1038/nri2939; Smeekens SP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029248; van de Veerdonk FL, 2011, NEW ENGL J MED, V365, P54, DOI 10.1056/NEJMoa1100102	9	21	22	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2013	131	4					1242	1243		10.1016/j.jaci.2012.11.005	http://dx.doi.org/10.1016/j.jaci.2012.11.005			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	120QT	23245795	Bronze			2022-12-18	WOS:000317187200040
J	Zetstra-van der Woude, PA; Vroegop, JS; Bos, HJ; de Jong-van den Berg, LTW				Zetstra-van der Woude, Priscilla A.; Vroegop, J. Sebastiaan; Bos, H. Jens; de Jong-van den Berg, Lolkje T. W.			A population analysis of prescriptions for asthma medications during pregnancy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Drug use; asthma medication; asthma guidelines; pregnancy	DRUGS; WOMEN; RISK	Background: It is important to control asthma during pregnancy. However, some studies indicate that women stop or change their asthma medications when they become pregnant. Objective: We used a population database to analyze changes in prescriptions for asthma medications to patients before, during, and after pregnancy. Methods: We collected information from a pregnancy database that is part of the population-based pharmacy prescription InterAction Database from the northern Netherlands. Our study cohort comprised 25,709 pregnancies for which prescription data were available. We collected data over a study period of 1 year before pregnancy until 6 months after birth and analyzed data from pregnant women who received at least 1 prescription for asthma medication during the study period (n = 2072), identifying all prescriptions for asthma medication and oral corticosteroids. Results: Prescriptions for asthma medications did not change during pregnancies from 1994-2003. However, during the 2004-2009 period, there was a significant decrease (P = .017) in prescriptions for asthma medications during the first months of pregnancy compared with the months before pregnancy, especially prescriptions of long-acting bronchodilators. Although most asthma prescriptions continued throughout pregnancy, prescriptions for controller therapies were reduced by 30% during the first months of pregnancy. Conclusions: Many women stop or reduce their use of asthma medications when they become pregnant. Strategies to safely control asthma during pregnancy are needed. (J Allergy Clin Immunol 2013;131:711-7.)	[Zetstra-van der Woude, Priscilla A.; Bos, H. Jens; de Jong-van den Berg, Lolkje T. W.] Univ Groningen, Unit Pharmacoepidemiol & Pharmacoecon, Dept Pharm, Groningen, Netherlands; [Vroegop, J. Sebastiaan] Martini Ziekenhuis, Dept Pulm Dis, Groningen, Netherlands	University of Groningen; Martini Hospital	Zetstra-van der Woude, PA (corresponding author), Antonius Deusinglaan 1, NL-9713 AV Groningen, Netherlands.	a.p.zetstra-van.der.woude@rug.nl						[Anonymous], 2005, J ALLERGY CLIN IMMUN, V115, P34, DOI 10.1016/j.jaci.2004.10.023; Bakker MK, 2006, BJOG-INT J OBSTET GY, V113, P559, DOI 10.1111/j.1471-0528.2006.00927.x; Blais L, 2007, THORAX, V62, P320, DOI 10.1136/thx.2006.062950; Chambers Karen, 2003, Case Manager, V14, P58, DOI 10.1016/j.casemgr.2003.09.003; College voor zorgverzekeringen, FARM KOMP 2011; Engeland A, 2008, BRIT J CLIN PHARMACO, V65, P653, DOI 10.1111/j.1365-2125.2008.03102.x; Enriquez R, 2006, AM J OBSTET GYNECOL, V195, P149, DOI 10.1016/j.ajog.2006.01.065; Geijer RM, 2007, HUISARTS WET, V50, P537; Global Initiative for Asthma, GLOB STRAT ASTHM MAN; Kwon HL, 2003, ANN EPIDEMIOL, V13, P317, DOI 10.1016/S1047-2797(03)00008-5; Lim AS, 2011, BMC FAM PRACT, V12, DOI 10.1186/1471-2296-12-121; Malm H, 2003, EUR J CLIN PHARMACOL, V59, P127, DOI 10.1007/s00228-003-0584-4; Murphy VE, 2011, CLIN CHEST MED, V32, P93, DOI 10.1016/j.ccm.2010.10.001; Sanz E, 2001, EUR J OBSTET GYN R B, V95, P127, DOI 10.1016/S0301-2115(00)00375-4; Schatz M, 2005, ANN ALLERG ASTHMA IM, V95, P234, DOI 10.1016/S1081-1206(10)61219-7; SCHATZ M, 1988, Journal of Allergy and Clinical Immunology, V81, P509, DOI 10.1016/0091-6749(88)90187-X; Schirm E, 2004, J CLIN EPIDEMIOL, V57, P737, DOI 10.1016/j.jclinepi.2002.12.001; Vroegop JS, 2009, NED TIJDSCHR GENEES, V153, pB361; Webster WS, 2003, EXPERT OPIN PHARMACO, V4, P949, DOI 10.1517/eoph.4.6.949.22192; WHO Collaborating Centre for Drug Statistics Methodology, ATC DDD IND 2011; Yawn B, 2007, J AM BOARD FAM MED, V20, P289, DOI 10.3122/jabfm.2007.03.060144	21	21	21	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2013	131	3					711	717		10.1016/j.jaci.2012.08.027	http://dx.doi.org/10.1016/j.jaci.2012.08.027			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	098ZM	23063582				2022-12-18	WOS:000315587800011
J	Alexis, NE; Lay, JC; Zhou, HB; Kim, CS; Hernandez, ML; Kehrl, H; Hazucha, MJ; Devlin, RB; Diaz-Sanchez, D; Peden, DB				Alexis, Neil E.; Lay, John C.; Zhou, Haibo; Kim, Chong S.; Hernandez, Michelle L.; Kehrl, Howard; Hazucha, Milan J.; Devlin, Robert B.; Diaz-Sanchez, David; Peden, David B.			The glutathione-S-transferase mu 1 (GSTM1) null genotype and increased neutrophil response to low-level ozone (0.06 ppm)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							INDUCED AIRWAY INFLAMMATION; HEALTHY; ANTAGONIST; ACTIVATION; MARKERS; HUMANS		[Alexis, Neil E.; Lay, John C.; Zhou, Haibo; Hernandez, Michelle L.; Hazucha, Milan J.; Peden, David B.] Univ N Carolina, Ctr Environm Med Asthma & Lung Biol, Chapel Hill, NC 27515 USA; [Kim, Chong S.; Kehrl, Howard; Devlin, Robert B.; Diaz-Sanchez, David] US EPA, Environm Publ Hlth Div MD 58B, Natl Hlth & Environm Effects Res Lab, Res Triangle Pk, NC 27711 USA	University of North Carolina; University of North Carolina Chapel Hill; United States Environmental Protection Agency	Alexis, NE (corresponding author), Univ N Carolina, Ctr Environm Med Asthma & Lung Biol, Chapel Hill, NC 27515 USA.	Neil_Alexis@med.unc.edu	ZHOU, Haibo/M-7373-2017	Peden, David/0000-0003-4526-4627	NHLBI NIH HHS [P50 HL084934] Funding Source: Medline; NIAID NIH HHS [U19 AI077437, U19AI077437] Funding Source: Medline; NIEHS NIH HHS [P30 ES010126, R01 ES012706, RC1 ES018417, RC1ES018417, R01ES012706] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL084934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI077437] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES010126, R01ES012706, RC1ES018417] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alexis NE, 2008, ENVIRON HEALTH PERSP, V116, P799, DOI 10.1289/ehp.10981; Alexis NE, 2010, INHAL TOXICOL, V22, P593, DOI 10.3109/08958371003596587; Alexis NE, 2009, J ALLERGY CLIN IMMUN, V124, P1222, DOI 10.1016/j.jaci.2009.07.036; Garantziotis S, 2009, J BIOL CHEM, V284, P11309, DOI 10.1074/jbc.M802400200; Hernandez ML, 2010, J ALLERGY CLIN IMMUN, V126, P537, DOI 10.1016/j.jaci.2010.06.043; Holz O, 2010, EUR RESPIR J, V35, P564, DOI 10.1183/09031936.00048509; Kim CS, 2011, AM J RESP CRIT CARE, V183, P1215, DOI 10.1164/rccm.201011-1813OC; Lay JC, 2007, J ALLERGY CLIN IMMUN, V120, P719, DOI 10.1016/j.jaci.2007.05.005; Lazaar AL, 2011, BRIT J CLIN PHARMACO, V72, P282, DOI 10.1111/j.1365-2125.2011.03968.x	9	21	21	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2013	131	2					610	612		10.1016/j.jaci.2012.07.005	http://dx.doi.org/10.1016/j.jaci.2012.07.005			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	086CT	22921799	Green Accepted			2022-12-18	WOS:000314661500051
J	Azad, MB; Becker, AB; Guttman, DS; Sears, MR; Scott, JA; Kozyrskyj, AL				Azad, Meghan B.; Becker, Allan B.; Guttman, David S.; Sears, Malcolm R.; Scott, James A.; Kozyrskyj, Anita L.		Canadian Healthy Infant Longitudin	Gut microbiota diversity and atopic disease: Does breast-feeding play a role?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							INFANTS; ECZEMA		[Azad, Meghan B.; Kozyrskyj, Anita L.] Univ Alberta, Edmonton, AB, Canada; [Becker, Allan B.] Univ Manitoba, Winnipeg, MB, Canada; [Guttman, David S.] Univ Toronto, Ctr Anal Genome Evolut & Funct, Toronto, ON, Canada; [Sears, Malcolm R.] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada; [Scott, James A.] McMaster Univ, Dept Med, Hamilton, ON, Canada	University of Alberta; University of Manitoba; University of Toronto; University of Toronto; McMaster University	Azad, MB (corresponding author), Univ Alberta, Edmonton, AB, Canada.	kozyrsky@ualberta.ca	Scott, James A/A-8598-2011; Scott, James A/AAN-4011-2021; Guttman, David S/A-7839-2011; Azad, Meghan/H-7226-2019	Scott, James A/0000-0002-5073-0832; Scott, James A/0000-0002-5073-0832; Guttman, David S/0000-0001-8479-3869; Azad, Meghan/0000-0002-5942-4444; Hegele, Richard/0000-0003-1073-8044	Canadian Institutes of Health Research Funding Source: Medline	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))		Abrahamsson TR, 2007, J ALLERGY CLIN IMMUN, V119, P1174, DOI 10.1016/j.jaci.2007.01.007; Abrahamsson TR, 2012, J ALLERGY CLIN IMMUN, V129, P434, DOI 10.1016/j.jaci.2011.10.025; Bezirtzoglou E, 2011, ANAEROBE, V17, P478, DOI 10.1016/j.anaerobe.2011.03.009; Gronlund MM, 2007, CLIN EXP ALLERGY, V37, P1764, DOI 10.1111/j.1365-2222.2007.02849.x; Kramer Michael S, 2011, Ann Nutr Metab, V59 Suppl 1, P20, DOI 10.1159/000334148; Marcobal A, 2010, J AGR FOOD CHEM, V58, P5334, DOI 10.1021/jf9044205; Wright AL, 2000, ADV EXP MED BIOL, V478, P131	7	21	21	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2013	131	1					247	248		10.1016/j.jaci.2012.10.044	http://dx.doi.org/10.1016/j.jaci.2012.10.044			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	062YR	23199602				2022-12-18	WOS:000312961200046
J	Sibilano, R; Frossi, B; Suzuki, R; D'Inca, F; Gri, G; Piconese, S; Colombo, MP; Rivera, J; Pucillo, CE				Sibilano, Riccardo; Frossi, Barbara; Suzuki, Ryo; D'Inca, Federica; Gri, Giorgia; Piconese, Silvia; Colombo, Mario P.; Rivera, Juan; Pucillo, Carlo E.			Modulation of Fc epsilon RI-dependent mast cell response by OX40L via Fyn, PI3K, and RhoA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						OX40L; Fyn; PI3K; mast cell; degranulation; anaphylaxis	REGULATORY T-CELLS; AFFINITY IGE RECEPTOR; ALLERGIC RESPONSES; CROSS-TALK; DEGRANULATION; ACTIVATION; KINASE; IMMUNITY; LIGAND; COSTIMULATION	Background: The interaction of mast cells (MCs) with regulatory T cells through the OX40 ligand (OX40L):OX40 axis downregulates Fc epsilon RI-dependent immediate hypersensitivity responses both in vitro and in vivo. Little is known on OX40L-mediated intracellular signaling or on the mechanism by which OX40L engagement suppresses MC degranulation. Objective: We explored the role of OX40L engagement on IgE/antigen-triggered MCs both in vitro and in vivo. Methods: The soluble form of OX40 molecule was used to selectively trigger OX40L on MCs in vitro and was used to dissect OX40L contribution in an in vivo model of systemic anaphylaxis. Results: OX40L: OX40 interaction led to the recruitment of C-terminal src kinase into lipid rafts, causing a preferential suppression of Fyn kinase activity and subsequent reduction in the phosphorylation of Gab2, the phosphatidylinositol 3-OH kinase regulatory subunit p85, and Akt, without affecting the Lyn pathway. Dampening of Fyn kinase activity also inhibited RhoA activation and microtubule nucleation, key regulators of MC degranulation. The in vivo administration of a blocking antibody to OX40L in wild-type mice caused enhanced immediate hypersensitivity, whereas the administration of soluble OX40 to regulatory T-cell-depleted or OX40-deficient mice reduced MC degranulation. Conclusions: The engagement of OX40L selectively suppresses Fyn-initiated signals required for MC degranulation and serves to limit immediate hypersensitivity. Our data suggest that soluble OX40 can restore the aberrant or absent regulatory T-cell activity, revealing a previously unappreciated homeostatic role for OX40L in setting the basal threshold of MC response. (J Allergy Clin Immunol 2012;130:751-60.)	[Sibilano, Riccardo; Frossi, Barbara; D'Inca, Federica; Gri, Giorgia; Pucillo, Carlo E.] Univ Udine, Dept Med & Biol Sci, I-33100 Udine, Italy; [Suzuki, Ryo; Rivera, Juan] NIAMSD, Immunogenet Mol Lab, NIH, Bethesda, MD 20892 USA; [Piconese, Silvia; Colombo, Mario P.] Fdn IRCCS Ist Nazl Tumori, Mol Immunol Unit, Dept Expt Oncol & Mol Med, Milan, Italy	University of Udine; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Fondazione IRCCS Istituto Nazionale Tumori Milan	Frossi, B (corresponding author), Univ Udine, Dept Med & Biol Sci, Ple Kolbe 4, I-33100 Udine, Italy.	barbara.frossi@uniud.it	Colombo, Mario P./V-7166-2017; Frossi, Barbara/AFL-0800-2022; Pucillo, Carlo/A-5515-2008	Colombo, Mario P./0000-0003-0042-7955; Frossi, Barbara/0000-0001-9855-2396; Pucillo, Carlo/0000-0002-4872-6156; GRI, Giorgia/0000-0002-2826-0459; Piconese, Silvia/0000-0002-9685-5227	Italian Ministry of Health; AIRC (Associazione Italiana Ricerca sul Cancro); Ministero dell'Istruzione; Universita e Ricerca (PRIN); Fondazione Compagnia di San Paolo, Turin, Italy; National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health (Bethesda, Md); My First AIRC Grant [8726]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [ZIAAR041155] Funding Source: NIH RePORTER	Italian Ministry of Health(Ministry of Health, Italy); AIRC (Associazione Italiana Ricerca sul Cancro)(Fondazione AIRC per la ricerca sul cancro); Ministero dell'Istruzione(Ministry of Education, Universities and Research (MIUR)); Universita e Ricerca (PRIN)(Ministry of Education, Universities and Research (MIUR)); Fondazione Compagnia di San Paolo, Turin, Italy(Compagnia di San Paolo); National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health (Bethesda, Md); My First AIRC Grant(Fondazione AIRC per la ricerca sul cancro); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Supported by the Italian Ministry of Health, AIRC (Associazione Italiana Ricerca sul Cancro), Ministero dell'Istruzione, Universita e Ricerca (PRIN 2009), Fondazione Compagnia di San Paolo, Turin, Italy, and the Intramural Research Program of the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health (Bethesda, Md). S.P. was supported by a My First AIRC Grant (8726).	Akdis CA, 2009, J ALLERGY CLIN IMMUN, V123, P735, DOI 10.1016/j.jaci.2009.02.030; Alvarez-Errico D, 2009, IMMUNOL REV, V232, P195, DOI 10.1111/j.1600-065X.2009.00834.x; Bachelet I, 2006, J BIOL CHEM, V281, P27190, DOI 10.1074/jbc.M602359200; Bjorgo E, 2010, MOL CELL BIOL, V30, P1660, DOI 10.1128/MCB.00696-09; Croft M, 2010, ANNU REV IMMUNOL, V28, P57, DOI 10.1146/annurev-immunol-030409-101243; Croft M, 2009, NAT REV IMMUNOL, V9, P271, DOI 10.1038/nri2526; Frossi B, 2007, J IMMUNOL, V178, P2549, DOI 10.4049/jimmunol.178.4.2549; Fukao T, 2002, NAT IMMUNOL, V3, P295, DOI 10.1038/ni768; Gilfillan AM, 2009, IMMUNOL REV, V228, P149, DOI 10.1111/j.1600-065X.2008.00742.x; Gimborn K, 2005, J IMMUNOL, V174, P507, DOI 10.4049/jimmunol.174.1.507; Gonzalez-Espinosa C, 2003, J EXP MED, V197, P1453, DOI 10.1084/jem.20021806; Gri G, 2008, IMMUNITY, V29, P771, DOI 10.1016/j.immuni.2008.08.018; Gu HH, 2001, NATURE, V412, P186, DOI 10.1038/35084076; Han SJ, 2006, EMBO J, V25, P5716, DOI 10.1038/sj.emboj.7601431; Inamura N, 1998, J IMMUNOL, V160, P4026; Ishii N, 2010, ADV IMMUNOL, V105, P63, DOI 10.1016/S0065-2776(10)05003-0; Kalesnikoff J, 2008, NAT IMMUNOL, V9, P1215, DOI 10.1038/ni.f.216; Kashiwakura J, 2004, J IMMUNOL, V173, P5247, DOI 10.4049/jimmunol.173.8.5247; Kohm AP, 2006, J IMMUNOL, V176, P3301, DOI 10.4049/jimmunol.176.6.3301; Kovarova M, 2006, J EXP MED, V203, P1161, DOI 10.1084/jem.20051701; LIU FT, 1980, J IMMUNOL, V124, P2728; Metz M, 2009, CURR OPIN IMMUNOL, V21, P687, DOI 10.1016/j.coi.2009.09.009; Nishida K, 2005, J CELL BIOL, V170, P115, DOI 10.1083/jcb.200501111; Nishida K, 2011, J IMMUNOL, V187, P932, DOI 10.4049/jimmunol.1100360; Nishimoto H, 2005, BLOOD, V106, P4241, DOI 10.1182/blood-2005-04-1358; Odom S, 2004, J EXP MED, V199, P1491, DOI 10.1084/jem.20040382; Parravicini V, 2002, NAT IMMUNOL, V3, P741, DOI 10.1038/ni817; Piconese S, 2008, J EXP MED, V205, P825, DOI 10.1084/jem.20071341; PRICE LS, 1995, CURR BIOL, V5, P68, DOI 10.1016/S0960-9822(95)00018-2; Rao KN, 2008, ANN NY ACAD SCI, V1143, P83, DOI 10.1196/annals.1443.023; Rivera J, 2005, TRENDS IMMUNOL, V26, P119, DOI 10.1016/j.it.2005.01.001; Rivera J, 2008, ADV IMMUNOL, V98, P85, DOI 10.1016/S0065-2776(08)00403-3; Rivera J, 2006, J ALLERGY CLIN IMMUN, V117, P1214, DOI 10.1016/j.jaci.2006.04.015; Samayawardhena LA, 2010, J IMMUNOL, V185, P5993, DOI 10.4049/jimmunol.1001261; Sayed BA, 2008, ANNU REV IMMUNOL, V26, P705, DOI 10.1146/annurev.immunol.26.021607.090320; Sibilano R, 2011, J LEUKOCYTE BIOL, V90, P831, DOI 10.1189/jlb.1210651; Simon AK, 2007, EUR J IMMUNOL, V37, P758, DOI 10.1002/eji.200636593; Sulimenko V, 2006, J IMMUNOL, V176, P7243, DOI 10.4049/jimmunol.176.12.7243; Suzuki R, 2010, J LEUKOCYTE BIOL, V88, P863, DOI 10.1189/jlb.0510253; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Yamashita T, 2008, J BIOL CHEM, V283, P28584, DOI 10.1074/jbc.M802679200; Zhang SQ, 2004, MOL CELL, V13, P341, DOI 10.1016/S1097-2765(04)00050-4	42	21	21	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2012	130	3					751	+		10.1016/j.jaci.2012.03.032	http://dx.doi.org/10.1016/j.jaci.2012.03.032			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	001LZ	22564682				2022-12-18	WOS:000308463500026
J	Price, JB; Divjan, A; Montfort, WR; Stansfield, KH; Freyer, GA; Perzanowski, MS				Price, Jason B.; Divjan, Adnan; Montfort, William R.; Stansfield, Kirstie H.; Freyer, Greg A.; Perzanowski, Matthew S.			IgE against bed bug (Cimex lectularius) allergens is common among adults bitten by bed bugs	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							SALIVARY NITROPHORIN		[Price, Jason B.] Columbia Univ, Dept Pediat, Coll Phys & Surg, New York, NY 10027 USA; [Divjan, Adnan; Stansfield, Kirstie H.; Freyer, Greg A.; Perzanowski, Matthew S.] Columbia Univ, Dept Environm Hlth Sci, Mailman Sch Publ Hlth, New York, NY USA; [Montfort, William R.] Univ Arizona, Dept Chem & Biochem, Tucson, AZ USA	Columbia University; Columbia University; University of Arizona	Price, JB (corresponding author), Columbia Univ, Dept Pediat, Coll Phys & Surg, New York, NY 10027 USA.	mp2217@columbia.edu		Divjan, Adnan/0000-0002-8895-5965	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062969] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES009089] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL062969, R01HL062969] Funding Source: Medline; NIEHS NIH HHS [P30 ES009089-14, P30 ES009089, P30 ES09089] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abou Gamra E M, 1991, J Egypt Soc Parasitol, V21, P735; Boase C., 2001, Pesticide Outlook, V12, P159, DOI 10.1039/b106301b; Erwin EA, 2005, J ALLERGY CLIN IMMUN, V115, P1029, DOI 10.1016/j.jaci.2004.12.1131; Leverkus M, 2006, J INVEST DERMATOL, V126, P91, DOI 10.1038/sj.jid.5700012; Maeda Yuji, 2008, Allergol Int, V57, P79, DOI 10.2332/allergolint.O-07-496; New York City Bed Bug Advisory Board, 2010, REC MAN BED BUGS NEW; PARSONS D J, 1955, Ohio State Med J, V51, P669; Valenzuela JG, 1998, J EXP BIOL, V201, P2659; Walker FA, 2005, J INORG BIOCHEM, V99, P216, DOI 10.1016/j.jinorgbio.2004.10.009; Weichsel A, 2005, P NATL ACAD SCI USA, V102, P594, DOI 10.1073/pnas.0406549102	10	21	22	1	45	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2012	129	3					863	865		10.1016/j.jaci.2012.01.034	http://dx.doi.org/10.1016/j.jaci.2012.01.034			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	904IW	22305681	Green Accepted			2022-12-18	WOS:000301189300041
J	van de Ven, AAJM; Compeer, EB; Bloem, AC; van de Corput, L; van Gijn, M; van Montfrans, JM; Boes, M				van de Ven, Annick A. J. M.; Compeer, Ewoud B.; Bloem, Andries C.; van de Corput, Lisette; van Gijn, Marielle; van Montfrans, Joris M.; Boes, Marianne			Defective calcium signaling and disrupted CD20-B-cell receptor dissociation in patients with common variable immunodeficiency disorders	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						B cells; common variable immunodeficiency; CD20; B-cell receptor	CELL ANTIGEN RECEPTOR; STAPHYLOCOCCUS-AUREUS; B-LYMPHOCYTES; TYROSINE RESIDUES; PROTEIN-A; CD20; ACTIVATION; KINASE; PROLIFERATION; DEFICIENCY	Background: B cells of patients with common variable immunodeficiency (CVID) disorders display impairment in production of immunoglobulin class-switched antibodies, which is possibly contributed to by defects in early B-cell activation. On resting B cells, B-cell receptors (BCRs) are organized in oligomers that are signaling inactive. Their triggering by cognate antigen causes the lateral reorganization of BCRs and associated proteins into signalosomes, resulting in BCR-activated calcium entry. In resting cells the B-cell surface antigen CD20 is associated with the BCR but dissociates on signalosome formation. Objective: We sought to determine whether CD20 dissociation from the BCR during early B-cell activation might contribute to the development of CVID disorders. Methods: We evaluated BCR signalosome formation, internalization, and signaling in primary B cells of pediatric patients with CVID disorders and healthy control subjects. Results: In many pediatric patients with CVID disorders, B cells exhibit significant deficits in BCR triggering-mediated calcium entry in the cytosol, which correlates with impaired plasmablast differentiation in vitro. These alterations did not originate from upregulation of CD22 or defects in calcium channels and did not involve gene mutations in phospholipase C gamma 2 or Bruton tyrosine kinase. Instead, B cells from patients with CVID disorders exhibited reduced BCR dissociation from CD20. BCR or CD20 cross-linking induced less BCR internalization, and antibody-mediated CD20 triggering elicited less BCR downstream signaling, as measured based on secondary fluxes. Conclusions: We propose that CD20 dissociation from the BCR signalosome is pivotal to BCR-mediated calcium mobilization in the cytosol. Defects in CD20/BCR signalosome conformation might predispose to the spectrum of CVID disorders. (J Allergy Clin Immunol 2012; 129: 755-61.)	[van de Ven, Annick A. J. M.; Compeer, Ewoud B.; van Montfrans, Joris M.; Boes, Marianne] Univ Med Ctr Utrecht, Dept Pediat Immunol & Infect Dis, NL-3584 EA Utrecht, Netherlands; [van de Ven, Annick A. J. M.; Compeer, Ewoud B.; van Montfrans, Joris M.; Boes, Marianne] Wilhelmina Childrens Hosp, NL-3584 EA Utrecht, Netherlands; [Bloem, Andries C.; van de Corput, Lisette] Univ Med Ctr Utrecht, Dept Med Immunol, NL-3584 EA Utrecht, Netherlands; [van Gijn, Marielle] Univ Med Ctr Utrecht, Dept Genet, NL-3584 EA Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Wilhelmina Kinderziekenhuis; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	Boes, M (corresponding author), Univ Med Ctr Utrecht, Dept Pediat Immunol, Lundlaan 6,Post Box 85090,KC-01-069-0, NL-3584 EA Utrecht, Netherlands.	M.L.Boes@umcutrecht.nl	Compeer, Ewoud Bernardus/E-8553-2015	Compeer, Ewoud Bernardus/0000-0002-3050-7633; Boes, Marianne/0000-0003-2590-1692	Baxter Bioscience; Marie Curie International Reintegration grant	Baxter Bioscience; Marie Curie International Reintegration grant(European Commission)	Supported by an educational grant from Baxter Bioscience (to A. v. d. V.) and in part by a Marie Curie International Reintegration grant (to M.B.).	BRAUN J, 1979, J CELL BIOL, V82, P755, DOI 10.1083/jcb.82.3.755; BUBIEN JK, 1993, J CELL BIOL, V121, P1121, DOI 10.1083/jcb.121.5.1121; Chapel H, 2008, BLOOD, V112, P277, DOI 10.1182/blood-2007-11-124545; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; European Society for Immunodeficiencies, 2005, DIAGN CRIT PID COMM; FALKOFF RJM, 1982, J IMMUNOL, V129, P97; Feske S, 2006, NATURE, V441, P179, DOI 10.1038/nature04702; Foerster C, 2010, J IMMUNOL, V184, P7305, DOI 10.4049/jimmunol.1000434; Franke A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016596; Guo SL, 2004, P NATL ACAD SCI USA, V101, P14180, DOI 10.1073/pnas.0405878101; Healy JI, 1997, IMMUNITY, V6, P419, DOI 10.1016/S1074-7613(00)80285-X; INGANAS M, 1980, SCAND J IMMUNOL, V12, P23, DOI 10.1111/j.1365-3083.1980.tb00037.x; Kheirallah S, 2010, BLOOD, V115, P985, DOI 10.1182/blood-2009-08-237537; KLEIN G, 1974, INTERVIROLOGY, V3, P232, DOI 10.1159/000149760; Kuijpers TW, 2010, J CLIN INVEST, V120, P214, DOI 10.1172/JCI40231; Li HD, 2003, J BIOL CHEM, V278, P42427, DOI 10.1074/jbc.M308802200; Minegishi Y, 1999, J CLIN INVEST, V104, P1115, DOI 10.1172/JCI7696; Minegishi Y, 1999, SCIENCE, V286, P1954, DOI 10.1126/science.286.5446.1954; Park MA, 2008, LANCET, V372, P489, DOI 10.1016/S0140-6736(08)61199-X; Petrie RJ, 2002, J IMMUNOL, V169, P2886, DOI 10.4049/jimmunol.169.6.2886; Picard C, 2009, NEW ENGL J MED, V360, P1971, DOI 10.1056/NEJMoa0900082; Polyak MJ, 2008, J BIOL CHEM, V283, P18545, DOI 10.1074/jbc.M800784200; Rodriguez R, 2001, J BIOL CHEM, V276, P47982, DOI 10.1074/jbc.M107577200; ROMAGNANI S, 1981, J IMMUNOL, V127, P1307; Salzer U, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-3; Smith MR, 2003, ONCOGENE, V22, P7359, DOI 10.1038/sj.onc.1206939; STASHENKO P, 1980, J IMMUNOL, V125, P1678; Strehler EE, 2004, CURR MOL MED, V4, P323, DOI 10.2174/1566524043360735; TEDDER TE, 1994, IMMUNOL TODAY, V15, P450, DOI 10.1016/0167-5699(94)90276-3; Treanor B, 2010, IMMUNITY, V32, P187, DOI 10.1016/j.immuni.2009.12.005; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; van De Ven AAJM, 2010, CHEST, V138, P371, DOI 10.1378/chest.09-2398; van de Ven AAJM, 2010, CLIN IMMUNOL, V135, P63, DOI 10.1016/j.clim.2009.11.010; van Gent R, 2009, CLIN IMMUNOL, V133, P95, DOI 10.1016/j.clim.2009.05.020; van Zelm MC, 2006, NEW ENGL J MED, V354, P1901, DOI 10.1056/NEJMoa051568; van Zelm MC, 2010, J CLIN INVEST, V120, P1265, DOI 10.1172/JCI39748; Walshe CA, 2008, J BIOL CHEM, V283, P16971, DOI 10.1074/jbc.M708459200; Watanabe D, 2001, J BIOL CHEM, V276, P38595, DOI 10.1074/jbc.M103675200; Yang JY, 2010, NATURE, V467, P465, DOI 10.1038/nature09357	40	21	23	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2012	129	3					755	U235		10.1016/j.jaci.2011.10.020	http://dx.doi.org/10.1016/j.jaci.2011.10.020			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	904IW	22130422	Bronze			2022-12-18	WOS:000301189300022
J	Olivieri, M; Zock, JP; Accordini, S; Heinrich, J; Jarvis, D; Kunzli, N; Anto, JM; Norback, D; Svanes, C; Verlato, G				Olivieri, Mario; Zock, Jan-Paul; Accordini, Simone; Heinrich, Joachim; Jarvis, Deborah; Kuenzli, Nino; Anto, Josep M.; Norback, Dan; Svanes, Cecilie; Verlato, Giuseppe		European Community Resp Hlth	Risk factors for new-onset cat sensitization among adults: A population-based international cohort study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Sensitization; cat allergen; cat ownership; epidemiology; adulthood	RESPIRATORY-HEALTH-SURVEY; ALLERGIC RHINITIS; SURVEY-II; ASTHMA; EXPOSURE; COMMUNITY; CHILDREN; CHILDHOOD; PETS; OWNERSHIP	Background: Cat exposure during childhood has been shown to increase the risk of developing cat sensitization, while the effect of cat exposure in adulthood has not yet been established. Objective: To evaluate new-onset sensitization to cat in adulthood in relation to changes in cat keeping. Methods: A total of 6292 European Community Respiratory Health Survey I (ECRHS I) participants aged 20 to 44 years from 28 European centers, who were not sensitized to cat, were reevaluated 9 years later in ECRHS II. Present and past cat ownership and total and specific IgE levels were assessed in both surveys. Allergen-specific sensitization was defined as a specific serum IgE level of 0.35 kU/L or more. Results: A total of 4468 subjects did not have a cat in ECRHS I or ECRHS II, 473 had a cat only at baseline, 651 acquired a cat during the follow-up, and 700 had a cat at both evaluations. Two hundred thirty-one subjects (3.7%) became sensitized to cat. In a 2-level multivariable Poisson regression model, cat acquisition during follow-up was significantly associated with new-onset cat sensitization (relative risk = 1.85, 95% CI 1.23-2.78) when compared with those without a cat at both surveys. Preexisting sensitization to other allergens, a history of asthma, nasal allergies and eczema, and high total IgE level were also significant risk factors for developing cat sensitization, while cat ownership in childhood was a significant protective factor. Conclusion: Our data support that acquiring a cat in adulthood nearly doubles the risk of developing cat sensitization. Hence, cat avoidance should be considered in adults, especially in those sensitized to other allergens and reporting a history of allergic diseases. (J Allergy Clin Immunol 2012;129:420-5.)	[Verlato, Giuseppe] Univ Verona, Sez Epidemiol & Stat Med, Inst Biol 2, Unit Epidemiol & Med Stat, I-37134 Verona, Italy; [Olivieri, Mario] Univ Hosp Verona, Unit Occupat Med, Verona, Italy; [Zock, Jan-Paul; Anto, Josep M.] Ctr Res Environm Epidemiol CREAL, Barcelona, Spain; [Zock, Jan-Paul; Anto, Josep M.] Hosp del Mar Res Inst IMIM, Barcelona, Spain; [Zock, Jan-Paul; Anto, Josep M.] Ctr Invest Biomed Red Epidemiol & Salud Publ CIBE, Barcelona, Spain; [Heinrich, Joachim] GSF Natl Res Ctr Environm & Hlth, Inst Epidemiol, Neuherberg, Germany; [Jarvis, Deborah] Univ London Imperial Coll Sci Technol & Med, Resp Epidemiol & Publ Hlth Grp, London, England; [Kuenzli, Nino] Swiss Trop & Publ Hlth Inst, Basel, Switzerland; [Anto, Josep M.] Univ Pompeu Fabra, Dept Hlth & Expt Sci, Barcelona, Spain; [Kuenzli, Nino] Univ Basel, Basel, Switzerland; [Norback, Dan] Uppsala Univ, Dept Med Sci Occupat & Environm Med, Uppsala, Sweden; [Svanes, Cecilie] Univ Bergen, Dept Thorac Med, Inst Med, Bergen, Norway	University of Verona; Pompeu Fabra University; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Imperial College London; University of Basel; Swiss Tropical & Public Health Institute; Pompeu Fabra University; University of Basel; Uppsala University; University of Bergen	Verlato, G (corresponding author), Univ Verona, Sez Epidemiol & Stat Med, Inst Biol 2, Unit Epidemiol & Med Stat, Str Le Grazie 8, I-37134 Verona, Italy.	giuseppe.verlato@univr.it	Svanes, Cecilie/N-7556-2017; Heinrich, Joachim/N-1720-2013; Sunyer, Jordi/G-6909-2014; Zock, Jan-Paul/P-5034-2018; Anto, J M/H-2676-2014; Jarvis, Deborah/E-6494-2011; Kuenzli, Nino/F-7195-2014	Svanes, Cecilie/0000-0001-8512-5192; Heinrich, Joachim/0000-0002-9620-1629; Sunyer, Jordi/0000-0002-2602-4110; Zock, Jan-Paul/0000-0002-2941-6259; Anto, J M/0000-0002-4736-8529; Kuenzli, Nino/0000-0001-8360-080X; Jarvis, Deborah/0000-0002-1753-3896; Norback, Dan/0000-0002-5174-6668; Leynaert, Benedicte/0000-0001-5045-2492	European Commission; European Union; FIS-Health Research Fund, Spain; MRC [G0901214] Funding Source: UKRI; Medical Research Council [G0901214, G0801056B] Funding Source: researchfish	European Commission(European CommissionEuropean Commission Joint Research Centre); European Union(European Commission); FIS-Health Research Fund, Spain; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	The coordination of ECRHS II was supported by the European Commission as part of its Quality of Life program. Funding for the individual centers is listed at http://www.ecrhs.org.; D. Jarvis has received grants from the European Union to coordinate ECRHS and to perform the Indoor study. J.-P. Zock and J.M. Anto have received grants from the FIS-Health Research Fund, Spain, to support the ECRHS II study in Spanish centers. The rest of the authors declare that they have no relevant conflicts of interest.	Almqvist C, 2003, CLIN EXP ALLERGY, V33, P1190, DOI 10.1046/j.1365-2222.2003.01764.x; Anto JM, 2010, ALLERGY, V65, P1021, DOI 10.1111/j.1398-9995.2009.02301.x; Boulet LP, 1997, CLIN EXP ALLERGY, V27, P52, DOI 10.1111/j.1365-2222.1997.tb00672.x; Brozek JL, 2010, J ALLERGY CLIN IMMUN, V126, P466, DOI 10.1016/j.jaci.2010.06.047; BRUNEKREEF B, 1992, INT J EPIDEMIOL, V21, P338, DOI 10.1093/ije/21.2.338; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954, DOI 10.1183/09031936.94.07050954; Chen CM, 2007, J ALLERGY CLIN IMMUN, V119, P1148, DOI 10.1016/j.jaci.2007.02.017; Chen CM, 2010, INT J HYG ENVIR HEAL, V213, P1, DOI 10.1016/j.ijheh.2009.12.003; de Meer G, 2004, J ALLERGY CLIN IMMUN, V113, P433, DOI 10.1016/j.jaci.2003.10.008; DELACOURT C, 1994, ALLERGY, V49, P843, DOI 10.1111/j.1398-9995.1994.tb00785.x; Goldstein H., 2011, MULTILEVEL STAT MODE; Heinrich J, 2006, J ALLERGY CLIN IMMUN, V118, P674, DOI 10.1016/j.jaci.2006.06.012; Heissenhuber A, 2003, ALLERGY, V58, P154, DOI 10.1034/j.1398-9995.2003.00037.x; Jarvis D, 2005, J ALLERGY CLIN IMMUN, V116, P675, DOI 10.1016/j.jaci.2005.05.009; Jarvis D, 2002, EUR RESPIR J, V20, P1071, DOI 10.1183/09031936.02.00046802; Linneberg A, 2003, ALLERGY, V58, P21, DOI 10.1034/j.1398-9995.2003.23639.x; Litonjua AA, 1997, AM J RESP CRIT CARE, V156, P23, DOI 10.1164/ajrccm.156.1.9608072; Melen E, 2001, ALLERGY, V56, P646, DOI 10.1034/j.1398-9995.2001.00387.x; MUNIR AKM, 1993, ALLERGY, V48, P158, DOI 10.1111/j.1398-9995.1993.tb00706.x; MURRAY AB, 1983, J ALLERGY CLIN IMMUN, V72, P145, DOI 10.1016/0091-6749(83)90522-5; Oryszczyn MP, 2003, ALLERGY, V58, P1136, DOI 10.1046/j.1398-9995.2003.00314.x; Perzanowski MS, 2008, J ALLERGY CLIN IMMUN, V121, P1047, DOI 10.1016/j.jaci.2008.02.005; Perzanowski MS, 1999, J ALLERGY CLIN IMMUN, V103, P1018, DOI 10.1016/S0091-6749(99)70173-9; Perzanowski MS, 2002, AM J RESP CRIT CARE, V166, P696, DOI 10.1164/rccm.2201035; Ronmark E, 2003, J ALLERGY CLIN IMMUN, V112, P747, DOI 10.1016/S0091-6749(03)01866-9; Roost HP, 1999, J ALLERGY CLIN IMMUN, V104, P941, DOI 10.1016/S0091-6749(99)70072-2; Svanes C, 2008, INDOOR AIR, V18, P84, DOI 10.1111/j.1600-0668.2008.00523.x; Svanes C, 2003, J ALLERGY CLIN IMMUN, V112, P289, DOI 10.1067/mai.2003.1596; Svanes C, 2006, J ALLERGY CLIN IMMUN, V118, P691, DOI 10.1016/j.jaci.2006.06.017; Torrent M, 2007, AM J RESP CRIT CARE, V176, P446, DOI 10.1164/rccm.200607-916OC; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	31	21	22	0	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2012	129	2					420	425		10.1016/j.jaci.2011.10.044	http://dx.doi.org/10.1016/j.jaci.2011.10.044			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	887TC	22168997				2022-12-18	WOS:000299951700019
J	Hanna, S; Etzoni, A				Hanna, Suheir; Etzoni, Amos			New host defense mechanisms against Candida species clarify the basis of clinical phenotypes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic mucocutaneous candidiasis; T(H)17 cells; IL-17; IL-22	CHRONIC MUCOCUTANEOUS CANDIDIASIS; HYPER-IGE SYNDROME; TH17-ASSOCIATED CYTOKINES; CELL-DIFFERENTIATION; FUNGAL-INFECTIONS; T-CELLS; ALBICANS; T(H)17; SUSCEPTIBILITY; IMMUNITY	Chronic Candida species infection of the skin and mucosal membranes is viewed as a group of disorders all sharing a similar clinical condition, the susceptibility to localized fungal infections, which can be isolated or as a feature associated with various other entities. Although the pathogenesis underlying such a tendency had previously been poorly understood, the last decade has witnessed significant progress in revealing the molecular and immunologic mechanisms involved in antifungal immunity. T(H)17 cells and their specific cytokines (IL-17A and IL-17F cytokines and IL-22) are the main players in conferring antifungal protection. Autoimmune polyendocrinopathy and ectodermal dystrophy and hyper-IgE syndrome are 2 entities caused by different genetic mutations affecting distinct immune pathways but eventually share a similar clinical phenotype of Candida species infection. Impaired T(H)17 responses, although mediated by different mechanisms, seem to underlie this common feature: neutralizing autoantibodies against IL-17A and 1L-22 are involved in patients with autoimmune polyendocrinopathy and ectodermal dystrophy syndrome, whereas abnormal T(H)17 proliferation and IL-17 production are observed in the latter. Although various degrees of T(H)17 dysfunction were also observed in most cases of isolated chronic mucocutaneous candidiasis, only in very few families was a distinct mutation detected (caspase recruitment domain family, member 9 [CARD9]), thus indicating certain forms of chronic mucocutaneous candidiasis as monogenic with a Mendelian pattern of inheritance. Hopefully, these data will open the way for further searches for other genes and for introducing new treatment modalities. (J Allergy Clin Immunol 2011;127:1433-7.)	[Hanna, Suheir; Etzoni, Amos] Technion Israel Inst Technol, Meyers Childrens Hosp, Rappaport Fac Med, IL-31096 Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Etzoni, A (corresponding author), Technion Israel Inst Technol, Meyers Childrens Hosp, Rappaport Fac Med, Rambam Med Hlth Campus, IL-31096 Haifa, Israel.	etzioni@rambam.health.gov.il						Beaucoudrey L, 2010, MEDICINE, V89, P381; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Conti HR, 2010, MICROBES INFECT, V12, P518, DOI 10.1016/j.micinf.2010.03.013; Conti HR, 2011, MUCOSAL IMMUNOL; Drummond RA, 2011, EUR J IMMUNOL, V41, P276, DOI 10.1002/eji.201041252; Eyerich K, 2008, J INVEST DERMATOL, V128, P2640, DOI 10.1038/jid.2008.139; Farah CS, 2006, ORAL MICROBIOL IMMUN, V21, P252, DOI 10.1111/j.1399-302X.2006.00288.x; Ferwerda B, 2009, NEW ENGL J MED, V361, P1760, DOI 10.1056/NEJMoa0901053; Gaffen SL, 2009, NAT REV IMMUNOL, V9, P556, DOI 10.1038/nri2586; Glocker E, 2010, CURR OPIN ALLERGY CL, V10, P542, DOI 10.1097/ACI.0b013e32833fd74f; Glocker EO, 2009, NEW ENGL J MED, V361, P1727, DOI 10.1056/NEJMoa0810719; Kisand K, 2010, J EXP MED, V207, P299, DOI 10.1084/jem.20091669; Kroetz DN, 2010, J IMMUNOL, V184, P5224, DOI 10.4049/jimmunol.1000032; Gil ML, 2009, FRONT BIOSCI-LANDMRK, V14, P570, DOI 10.2741/3263; Milner JD, 2008, NATURE, V452, P773, DOI 10.1038/nature06764; Minegishi Y, 2007, NATURE, V448, P1058, DOI 10.1038/nature06096; Netea MG, 2010, TRENDS IMMUNOL, V31, P346, DOI 10.1016/j.it.2010.06.007; Ng WF, 2010, J ALLERGY CLIN IMMUN, V126, P1006, DOI 10.1016/j.jaci.2010.08.027; Palm NW, 2007, NAT IMMUNOL, V8, P549, DOI 10.1038/ni0607-549; Puel A, 2011, SCIENCE, V332, P65, DOI 10.1126/science.1200439; Puel A, 2010, CURR OPIN IMMUNOL, V22, P467, DOI 10.1016/j.coi.2010.06.009; Puel A, 2010, J EXP MED, V207, P291, DOI 10.1084/jem.20091983; Saijo S, 2010, IMMUNITY, V32, P681, DOI 10.1016/j.immuni.2010.05.001; Tessarolli V, 2010, MED MYCOL, V48, P129, DOI 10.3109/13693780902964339; Thorpe E, 1929, AM J DIS CHILD, V38, P228	25	21	25	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2011	127	6					1433	1437		10.1016/j.jaci.2011.03.026	http://dx.doi.org/10.1016/j.jaci.2011.03.026			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	769WH	21497889	Bronze			2022-12-18	WOS:000291048500018
J	McKinney, KK; Webb, L; Petersen, M; Nelson, M; Laubach, S				McKinney, Kristi K.; Webb, Luke; Petersen, Maureen; Nelson, Michael; Laubach, Susan			Ovalbumin content of 2010-2011 influenza vaccines	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[McKinney, Kristi K.; Webb, Luke; Petersen, Maureen; Nelson, Michael; Laubach, Susan] Walter Reed Army Med Ctr, Dept Allergy Immunol, Washington, DC 20307 USA	United States Department of Defense; United States Army; Walter Reed National Military Medical Center	McKinney, KK (corresponding author), Walter Reed Army Med Ctr, Dept Allergy Immunol, Washington, DC 20307 USA.	Kristi.mckinney@us.army.mil	Nelson, Michael Shawn/GXF-4934-2022					[Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; GREENHAWT MJ, ADM INFLUENZA VACCIN; James JM, 1998, J PEDIATR-US, V133, P624, DOI 10.1016/S0022-3476(98)70101-5; Kelso JM, 2010, J ALLERGY CLIN IMMUN, V125, P800, DOI 10.1016/j.jaci.2010.02.013; Kelso JM, 2009, ANN ALLERG ASTHMA IM, V103, pS1, DOI 10.1016/S1081-1206(10)60350-X; Li JT, 2010, J ALLERGY CLIN IMMUN, V125, P1412, DOI 10.1016/j.jaci.2010.03.009; Liu AH, 2010, J ALLERGY CLIN IMMUN, V126, P798, DOI 10.1016/j.jaci.2010.07.026; Waibel KH, 2010, J ALLERGY CLIN IMMUN, V125, P749, DOI 10.1016/j.jaci.2009.12.015; Zeiger RS, 2002, J ALLERGY CLIN IMMUN, V110, P834, DOI 10.1067/mai.2002.129372	9	21	23	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2011	127	6					1629	1632		10.1016/j.jaci.2011.02.003	http://dx.doi.org/10.1016/j.jaci.2011.02.003			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	769WH	21397313				2022-12-18	WOS:000291048500049
J	Bacchelli, C; Buckland, KF; Buckridge, S; Salzer, U; Schneider, P; Thrasher, AJ; Gaspar, HB				Bacchelli, Chiara; Buckland, Karen F.; Buckridge, Sylvie; Salzer, Ulrich; Schneider, Pascal; Thrasher, Adrian J.; Gaspar, H. Bobby			The C76R transmembrane activator and calcium modulator cyclophilin ligand interactor mutation disrupts antibody production and B-cell homeostasis in heterozygous and homozygous mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Hypogammaglobulinemia; B cell; common variable immunodeficiency; primary immunodeficiency; transmembrane activator and calcium modulator cyclophilin ligand; a proliferation-inducing ligand; lymphoproliferation	COMMON VARIABLE IMMUNODEFICIENCY; IGA DEFICIENCY; TACI; RECEPTOR; BAFF; APRIL; DISEASE; VARIANTS; SURVIVAL; BINDING	Background: Mutations in TNFRSF13B, the gene encoding transmembrane activator and calcium modulator cyclophilin ligand interactor (TACI), are found in 10% of patients with common variable immunodeficiency. However, the most commonly detected mutation is the heterozygous change C104R, which is also found in 0.5% to 1% of healthy subjects. The contribution of the C104R mutation to the B-cell defects observed in patients with common variable immunodeficiency therefore remains unclear. Objective: We sought to define the functional consequences of the C104R mutation on B-cell function. Methods: We performed in vitro studies of TACI C104R expression and signaling. A knock-in mouse with the equivalent mutation murine TACI (mTACI) C76R was generated as a physiologically relevant model of human disease. We examined homozygous and heterozygous C76R mutant mice alongside wildtype littermates and studied specific B-cell lineages and antibody responses to T cell-independent and T cell-dependent challenge. Results: C104R expression and ligand binding are significantly diminished when the mutant protein is expressed in 293T cells or in patients' cell lines. This leads to defective nuclear factor kappa B activation, which is proportionally restored by reintroduction of wild-type TACI. Mice heterozygous and homozygous for mTACI C76R exhibit significant B-cell dysfunction with splenomegaly, marginal zone B-cell expansion, diminished immunoglobulin production and serological responses to T cell-independent antigen, and abnormal immunoglobulin synthesis. Conclusions: These data show that the C104R mutation and its murine equivalent, C76R, can significantly disrupt TACI function, probably through haploinsufficiency. Furthermore, the heterozygous C76R mutation alone is sufficient to disturb B-cell function with lymphoproliferation and immunoglobulin production defects. (J Allergy Clin Immunol 2011;127:1253-9.)	[Bacchelli, Chiara; Buckland, Karen F.; Buckridge, Sylvie; Thrasher, Adrian J.; Gaspar, H. Bobby] UCL Inst Child Hlth, Mol Immunol Unit, Ctr Immunodeficiency, London WC1N 1EH, England; [Salzer, Ulrich] Univ Med Ctr Freiburg, Ctr Chron Immunodeficiency, Freiburg, Germany; [Salzer, Ulrich] Univ Freiburg, Freiburg, Germany; [Schneider, Pascal] Univ Lausanne, Dept Biochem, CH-1066 Epalinges, Switzerland; [Thrasher, Adrian J.; Gaspar, H. Bobby] Great Ormond St Hosp NHS Trust, Dept Clin Immunol, London, England	University of London; University College London; University of Freiburg; University of Freiburg; University of Lausanne; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	Gaspar, HB (corresponding author), UCL Inst Child Hlth, Mol Immunol Unit, Ctr Immunodeficiency, 30 Guilford St, London WC1N 1EH, England.	h.gaspar@ich.ucl.ac.uk		Schneider, Pascal/0000-0003-0677-9409; Buckland, Karen/0000-0001-6989-2228; Thrasher, Adrian/0000-0002-6097-6115	Medical Research Council (United Kingdom); EURO-PAD-net; Primary Immunodeficiency Association (United Kingdom); Swiss National Science Foundation; European Commission; Wellcome Trust; Great Ormond Street Hospital NIHR Biomedical Research Centre; MRC [G0501468] Funding Source: UKRI; Medical Research Council [G0501468] Funding Source: researchfish; Great Ormond Street Hospital Childrens Charity [V1223, V1242] Funding Source: researchfish	Medical Research Council (United Kingdom)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); EURO-PAD-net; Primary Immunodeficiency Association (United Kingdom); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); European Commission(European CommissionEuropean Commission Joint Research Centre); Wellcome Trust(Wellcome TrustEuropean Commission); Great Ormond Street Hospital NIHR Biomedical Research Centre; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Great Ormond Street Hospital Childrens Charity	Supported by the Medical Research Council (United Kingdom), EURO-PAD-net, the Primary Immunodeficiency Association (United Kingdom), the Swiss National Science Foundation, the European Commission 7th EU Framework grant, the Wellcome Trust, and the Great Ormond Street Hospital NIHR Biomedical Research Centre.	Bishop GA, 2002, J LEUKOCYTE BIOL, V72, P19; Bossen C, 2008, BLOOD, V111, P1004, DOI 10.1182/blood-2007-09-110874; Carsetti R, 2005, J ALLERGY CLIN IMMUN, V115, P412, DOI 10.1016/j.jaci.2004.10.048; Castigli E, 2005, NAT GENET, V37, P829, DOI 10.1038/ng1601; Castigli E, 2004, P NATL ACAD SCI USA, V101, P3903, DOI 10.1073/pnas.0307348101; Cunningham-Rundles C, 2008, J CLIN IMMUNOL, V28, pS42, DOI 10.1007/s10875-008-9182-7; Darce JR, 2007, J IMMUNOL, V179, P7276, DOI 10.4049/jimmunol.179.11.7276; Garibyan L, 2007, J CLIN INVEST, V117, P1550, DOI 10.1172/JCI31023; Hymowitz SG, 2005, J BIOL CHEM, V280, P7218, DOI 10.1074/jbc.M411714200; Kruetzmann S, 2003, J EXP MED, V197, P939, DOI 10.1084/jem.20022020; Lee JJ, 2010, J ALLERGY CLIN IMMUN, V126, P1234, DOI 10.1016/j.jaci.2010.08.017; Lee JJ, 2009, BLOOD, V114, P2254, DOI 10.1182/blood-2008-11-189720; Lopez-Mejias R, 2009, TISSUE ANTIGENS, V74, P42, DOI 10.1111/j.1399-0039.2009.01253.x; Pan-Hammarstrom Q, 2007, NAT GENET, V39, P429, DOI 10.1038/ng0407-429; Poodt AEJ, 2009, CLIN EXP IMMUNOL, V156, P35, DOI 10.1111/j.1365-2249.2008.03863.x; Salzer U, 2005, NAT GENET, V37, P820, DOI 10.1038/ng1600; Salzer U, 2009, BLOOD, V113, P1967, DOI 10.1182/blood-2008-02-141937; Sasaki Y, 2004, J IMMUNOL, V173, P2245, DOI 10.4049/jimmunol.173.4.2245; Schiemann B, 2001, SCIENCE, V293, P2111, DOI 10.1126/science.1061964; Schneider P, 2005, CURR OPIN IMMUNOL, V17, P282, DOI 10.1016/j.coi.2005.04.005; Seshasayee D, 2003, IMMUNITY, V18, P279, DOI 10.1016/S1074-7613(03)00025-6; Shulga-Morskaya S, 2004, J IMMUNOL, V173, P2331, DOI 10.4049/jimmunol.173.4.2331; von Bulow GU, 2001, IMMUNITY, V14, P573, DOI 10.1016/S1074-7613(01)00130-3; Warnatz K, 2009, P NATL ACAD SCI USA, V106, P13945, DOI 10.1073/pnas.0903543106; Weller S, 2004, BLOOD, V104, P3647, DOI 10.1182/blood-2004-01-0346; Yan MH, 2001, CURR BIOL, V11, P1547, DOI 10.1016/S0960-9822(01)00481-X	26	21	21	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2011	127	5					1253	U259		10.1016/j.jaci.2011.02.037	http://dx.doi.org/10.1016/j.jaci.2011.02.037			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	756NG	21458042				2022-12-18	WOS:000290018600021
J	Massaad, MJ; Ramesh, N; Le Bras, S; Giliani, S; Notarangelo, LD; Al-Herz, W; Notarangelo, LD; Geha, RS				Massaad, Michel J.; Ramesh, Narayanaswamy; Le Bras, Severine; Giliani, Silvia; Notarangelo, Lucia D.; Al-Herz, Waleed; Notarangelo, Luigi D.; Geha, Raif S.			A peptide derived from the Wiskott-Aldrich syndrome (WAS) protein-interacting protein (WIP) restores WAS protein level and actin cytoskeleton reorganization in lymphocytes from patients with WAS mutations that disrupt WIP binding	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Wiskott-Aldrich syndrome; WASP; WIP; T cells; actin cytoskeleton	X-LINKED THROMBOCYTOPENIA; T-CELLS; WASP; POLYMERIZATION; ACTIVATION; EXPRESSION; ROLES	Background: The Wiskott-Aldrich syndrome (WAS) and X-linked thrombocytopenia (XLT) are caused by mutations in WAS, which encodes for WAS protein (WASP). The WASP-interacting protein (WIP) stabilizes WASP, as evidenced by severely decreased WASP levels in T cells from WIP-deficient mice. The majority of missense mutations in patients with WAS/XLT are located in the WIP-binding domain of WASP and might result in dissociation of the WASP-WIP complex and WASP degradation. Objective: To restore WASP levels and correct T-cell function in WAS/XLT patients with mutations in the WIP-binding domain of WASP. Methods: WIP, and a WIP-derived 41-amino acid-long peptide, which interacts with WASP and was designated nanoWIP (nWIP), were fused to enhanced green fluorescent protein and introduced by electroporation into EBV-transformed B cells, and by retroviral transduction into purified blood T cells from patients with WAS. WASP levels were measured by intracellular fluorescence-activated cell sorting staining. The actin cytoskeleton was visualized by intracellular phalloidin staining. Results: Introduction of WIP and nWIP restored WASP levels to normal in EBV-transformed B-cell lines from XLT patients with missense mutations in the WIP-binding domain of WASP and residual WASP levels, and corrected the defective spreading and pseudopodia formation of their T cells in response to immobilized anti-CD3. Conclusion: AWASP-binding WIP-derived peptide stabilizes WASP in cells from XLT patients with missense mutations that disrupt WIP binding, and corrects their T-cell actin cytoskeleton defect. This may provide a novel therapeutic strategy for these patients. (J Allergy Clin Immunol 2011;127:998-1005.)	[Massaad, Michel J.; Ramesh, Narayanaswamy; Le Bras, Severine; Notarangelo, Luigi D.; Geha, Raif S.] Childrens Hosp, Div Immunol, Boston, MA 02115 USA; [Massaad, Michel J.; Ramesh, Narayanaswamy; Le Bras, Severine; Notarangelo, Luigi D.; Geha, Raif S.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; [Giliani, Silvia] Univ Brescia, Dept Pediat, Angelo Nocivelli Inst Mol Med, Brescia, Italy; [Notarangelo, Lucia D.] Spedali Civil Brescia, Dept Pediat Hematooncol, I-25125 Brescia, Italy; [Al-Herz, Waleed] Al Sabah Hosp, Allergy & Clin Immunol Unit, Dept Pediat, Kuwait, Kuwait	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; University of Brescia; Hospital Spedali Civili Brescia; Al Sabah Hospital	Massaad, MJ (corresponding author), Childrens Hosp, Div Immunol, Karp Bldg,10th Floor,1 Blackfan Circle, Boston, MA 02115 USA.	michel.massaad@childrens.harvard.edu	Giliani, Silvia/AAX-8843-2020; Notarangelo, Luigi D/F-9718-2016	Giliani, Silvia/0000-0001-8137-4642; Notarangelo, Luigi D/0000-0002-8335-0262	Perkin fund; National Institutes of Health [5PO1HL059561]; Dubai Harvard Foundation for Medical Research; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL059561] Funding Source: NIH RePORTER	Perkin fund; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Dubai Harvard Foundation for Medical Research; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by the Perkin fund (M.J.M.), National Institutes of Health grant no. 5PO1HL059561 (R. S. G.), and the Dubai Harvard Foundation for Medical Research.	Albert MH, 2010, BLOOD, V115, P3231, DOI 10.1182/blood-2009-09-239087; Anton IM, 2002, IMMUNITY, V16, P193, DOI 10.1016/S1074-7613(02)00268-6; CANALES L, 1967, NEW ENGL J MED, V277, P899, DOI 10.1056/NEJM196710262771703; Cannon JL, 2004, J IMMUNOL, V173, P1658, DOI 10.4049/jimmunol.173.3.1658; Carman CV, 2007, IMMUNITY, V26, P784, DOI 10.1016/j.immuni.2007.04.015; Cianferoni A, 2005, J ALLERGY CLIN IMMUN, V116, P1364, DOI 10.1016/j.jaci.2005.09.006; de la Fuente MA, 2007, P NATL ACAD SCI USA, V104, P926, DOI 10.1073/pnas.0610275104; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; Gallego MD, 2006, INT IMMUNOL, V18, P221, DOI 10.1093/intimm/dxh310; Gallego MD, 1997, BLOOD, V90, P3089, DOI 10.1182/blood.V90.8.3089; Haddad E, 2001, BLOOD, V97, P33, DOI 10.1182/blood.V97.1.33; Jin YZ, 2004, BLOOD, V104, P4010, DOI 10.1182/blood-2003-05-1592; Koduru S, 2007, BIOCHEM BIOPH RES CO, V353, P875, DOI 10.1016/j.bbrc.2006.12.079; MOLINA IJ, 1993, J IMMUNOL, V151, P4383; MURPHY S, 1969, NEW ENGL J MED, V281, P857, DOI 10.1056/NEJM196910162811601; Ochs HD, 2006, J ALLERGY CLIN IMMUN, V117, P725, DOI 10.1016/j.jaci.2006.02.005; Peterson FC, 2007, J BIOL CHEM, V282, P8446, DOI 10.1074/jbc.M609902200; Rajmohan R, 2009, FEMS YEAST RES, V9, P1226, DOI 10.1111/j.1567-1364.2009.00581.x; Ramesh N, 1997, P NATL ACAD SCI USA, V94, P14671, DOI 10.1073/pnas.94.26.14671; ROZDZIAL MM, 1995, IMMUNITY, V3, P623, DOI 10.1016/1074-7613(95)90133-7; Snapper SB, 1998, IMMUNITY, V9, P81, DOI 10.1016/S1074-7613(00)80590-7; Stewart DM, 1999, J IMMUNOL, V162, P5019; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; VESTERMARK B, 1964, ACTA PAEDIATR, V53, P365, DOI 10.1111/j.1651-2227.1964.tb07790.x; VILLA A, 1995, NAT GENET, V9, P414, DOI 10.1038/ng0495-414; Volkman BF, 2002, CELL, V111, P565, DOI 10.1016/S0092-8674(02)01076-0; Zhang J, 1999, J EXP MED, V190, P1329, DOI 10.1084/jem.190.9.1329; ZHU QL, 1995, BLOOD, V86, P3797, DOI 10.1182/blood.V86.10.3797.bloodjournal86103797; Zhu QL, 1997, BLOOD, V90, P2680, DOI 10.1182/blood.V90.7.2680.2680_2680_2689	29	21	22	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2011	127	4					998	U254		10.1016/j.jaci.2011.01.015	http://dx.doi.org/10.1016/j.jaci.2011.01.015			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	743YL	21376381	Green Accepted			2022-12-18	WOS:000289055800022
J	Le, TM; Fritsche, P; Bublin, M; Oberhuber, C; Bulley, S; van Hoffen, E; Ballmer-Weber, BK; Knulst, AC; Hoffmann-Sommergruber, K				Le, Thuy-My; Fritsche, Philipp; Bublin, Merima; Oberhuber, Christina; Bulley, Sean; van Hoffen, Els; Ballmer-Weber, Barbara K.; Knulst, Andre C.; Hoffmann-Sommergruber, Karin			Differences in the allergenicity of 6 different kiwifruit cultivars analyzed by prick-to-prick testing, open food challenges, and ELISA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ACTINIDIA-CHINENSIS; KIWI; ALLERGY; FRUIT; GREEN		[Le, Thuy-My; van Hoffen, Els; Knulst, Andre C.] Univ Med Ctr Utrecht, Dept Dermatol Allergol, Utrecht, Netherlands; [Fritsche, Philipp; Ballmer-Weber, Barbara K.] Univ Zurich Hosp, Allergy Unit, Dept Dermatol, CH-8091 Zurich, Switzerland; [Bublin, Merima; Hoffmann-Sommergruber, Karin] Med Univ Vienna, Dept Pathophysiol & Allergy Res, Vienna, Austria; [Oberhuber, Christina] Biomay AG, Vienna, Austria; [Bulley, Sean] Plant & Food Res Inst New Zealand, Auckland, New Zealand	Utrecht University; Utrecht University Medical Center; University of Zurich; University Zurich Hospital; Medical University of Vienna; New Zealand Institute for Plant & Food Research Ltd	Le, TM (corresponding author), Univ Med Ctr Utrecht, Dept Dermatol Allergol, Utrecht, Netherlands.	Karin.Hoffmann@meduniwien.ac.at	Bulley, Sean M/B-3989-2008; Bulley, Sean/Q-9747-2019	Bulley, Sean M/0000-0001-6142-5414; Bulley, Sean/0000-0001-6142-5414; Bublin, Merima/0000-0002-7191-9431; Knulst, Andre/0000-0002-1056-3179; Hoffmann-Sommergruber, Karin/0000-0002-8830-058X				Aleman A, 2004, J ALLERGY CLIN IMMUN, V113, P543, DOI 10.1016/j.jaci.2003.11.043; Bublin M, 2004, J ALLERGY CLIN IMMUN, V114, P1169, DOI 10.1016/j.jaci.2004.07.016; Chen LY, 2006, FOOD CHEM TOXICOL, V44, P1100, DOI 10.1016/j.fct.2006.01.005; Santana AH, 2008, ALLERGOL IMMUNOPATH, V36, P366, DOI 10.1016/S0301-0546(08)75870-1; Lucas JSA, 2005, PEDIAT ALLERG IMM-UK, V16, P647, DOI 10.1111/j.1399-3038.2005.00330.x; Lucas JSA, 2003, PEDIAT ALLERG IMM-UK, V14, P420, DOI 10.1046/j.0905-6157.2003.00095.x; Mattila L, 2003, CLIN EXP ALLERGY, V33, P600, DOI 10.1046/j.1365-2222.2003.01661.x	7	21	21	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2011	127	3					677	679		10.1016/j.jaci.2010.10.003	http://dx.doi.org/10.1016/j.jaci.2010.10.003			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	730FG	21094995				2022-12-18	WOS:000288018400018
J	Abonia, JP; Franciosi, JP; Rothenberg, ME				Abonia, J. Pablo; Franciosi, James P.; Rothenberg, Marc E.			TGF-eta 1: Mediator of a feedback loop in eosinophilic esophagitis-or should we really say mastocytic esophagitis?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Mast cells; eosinophilic esophagitis; human	GROWTH-FACTOR-BETA; THYMIC STROMAL LYMPHOPOIETIN; TGF-BETA; CONTROLLED-TRIAL; MARFAN-SYNDROME; MAST-CELLS; FIBROSIS; ASTHMA; EXPRESSION; PHENOTYPE		[Abonia, J. Pablo; Rothenberg, Marc E.] Univ Cincinnati, Div Allergy & Immunol, Coll Med, Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA; [Franciosi, James P.] Univ Cincinnati, Div Gastroenterol Hepatol & Nutr, Dept Pediat, Cincinnati Childrens Hosp Med Ctr,Coll Med, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Rothenberg, ME (corresponding author), Univ Cincinnati, Div Allergy & Immunol, Coll Med, Cincinnati Childrens Hosp Med Ctr, 3333 Burnet Ave,ML7028, Cincinnati, OH 45229 USA.	rothenberg@cchmc.org		Abonia, Juan/0000-0003-3788-6485	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI045898, U19AI070235, R01AI045898] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK076893] Funding Source: NIH RePORTER; NIAID NIH HHS [R37 AI045898-12, R37 AI045898, U19 AI070235, R01 AI045898, AI045898, U19 AI070235-07] Funding Source: Medline; NIDDK NIH HHS [DK076893, R01 DK076893, R01 DK076893-05] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abonia JP, 2010, J ALLERGY CLIN IMMUN, V126, P140, DOI 10.1016/j.jaci.2010.04.009; Aceves SS, 2010, J ALLERGY CLIN IMMUN, V126, P1198, DOI 10.1016/j.jaci.2010.08.050; Aceves SS, 2007, J ALLERGY CLIN IMMUN, V119, P206, DOI 10.1016/j.jaci.2006.10.016; Ahimastos AA, 2007, JAMA-J AM MED ASSOC, V298, P1539, DOI 10.1001/jama.298.13.1539; Ahimastos AA, 2010, ATHEROSCLEROSIS, V209, P211, DOI 10.1016/j.atherosclerosis.2009.08.003; Aloysius A, 2008, EUR J PAEDIATR NEURO, V12, P239, DOI 10.1016/j.ejpn.2007.08.009; Attias D, 2009, CIRCULATION, V120, P2541, DOI 10.1161/CIRCULATIONAHA.109.887042; Bernasconi P, 1999, NEUROMUSCULAR DISORD, V9, P28, DOI 10.1016/S0960-8966(98)00093-5; Blanchard C, 2006, J CLIN INVEST, V116, P536, DOI 10.1172/JCI26679; Blanchard C, 2008, MUCOSAL IMMUNOL, V1, P289, DOI 10.1038/mi.2008.15; BLANCHARD C, 2011, J ALLERGY C IN PRESS; Branton MH, 1999, MICROBES INFECT, V1, P1349, DOI 10.1016/S1286-4579(99)00250-6; Chakir J, 2003, J ALLERGY CLIN IMMUN, V111, P1293, DOI 10.1067/mai.2003.1557; Chehade M, 2007, J PEDIATR GASTR NUTR, V45, P319, DOI 10.1097/MPG.0b013e31806ab384; Dardalhon V, 2008, NAT IMMUNOL, V9, P1347, DOI 10.1038/ni.1677; Dougherty RH, 2010, J ALLERGY CLIN IMMUN, V125, P1046, DOI 10.1016/j.jaci.2010.03.003; Fuentebella J, 2010, J PEDIATR GASTR NUTR, V51, P283, DOI 10.1097/MPG.0b013e3181e0817b; HULTNER L, 1990, EUR J IMMUNOL, V20, P1413, DOI 10.1002/eji.1830200632; Kirsch R, 2007, J PEDIATR GASTR NUTR, V44, P20, DOI 10.1097/MPG.0b013e31802c0d06; Konikoff MR, 2006, GASTROENTEROLOGY, V131, P1381, DOI 10.1053/j.gastro.2006.08.033; KWIATEK MA, 2010, GASTROENTEROLOGY; Lucendo AJ, 2007, AM J SURG PATHOL, V31, P598, DOI 10.1097/01.pas.0000213392.49698.8c; Mishra A, 2008, GASTROENTEROLOGY, V134, P204, DOI 10.1053/j.gastro.2007.10.002; Rothenberg ME, 2010, NAT GENET, V42, P289, DOI 10.1038/ng.547; Sheehan NJ, 2008, RHEUMATOLOGY, V47, P746, DOI 10.1093/rheumatology/ken029; Sherrill JD, 2010, J ALLERGY CLIN IMMUN, V126, P160, DOI 10.1016/j.jaci.2010.04.037; Sidhu SS, 2010, P NATL ACAD SCI USA, V107, P14170, DOI 10.1073/pnas.1009426107; Straumann A, 2001, J ALLERGY CLIN IMMUN, V108, P954, DOI 10.1067/mai.2001.119917; Straumann A, 2010, GUT, V59, P21, DOI 10.1136/gut.2009.178558; Veldhoen M, 2008, NAT IMMUNOL, V9, P1341, DOI 10.1038/ni.1659; Vicario M, 2010, GUT, V59, P12, DOI 10.1136/gut.2009.178020; Zeuthen LH, 2008, IMMUNOLOGY, V123, P197, DOI 10.1111/j.1365-2567.2007.02687.x; Zhu X, 2009, AM J PHYSIOL-GASTR L, V297, pG550, DOI 10.1152/ajpgi.00148.2009	33	21	21	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2010	126	6					1205	1207		10.1016/j.jaci.2010.10.031	http://dx.doi.org/10.1016/j.jaci.2010.10.031			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	689RZ	21134572	Green Accepted			2022-12-18	WOS:000284947800019
J	Ananworanich, J; Apornpong, T; Kosalaraksa, P; Jaimulwong, T; Hansudewechakul, R; Pancharoen, C; Bunupuradah, T; Chandara, M; Puthanakit, T; Ngampiyasakul, C; Wongsawat, J; Kanjanavanit, S; Luesomboon, W; Klangsinsirikul, P; Ngo-Giang-Huong, N; Kerr, SJ; Ubolyam, S; Mengthaisong, T; Gelman, RS; Pattanapanyasat, K; Saphonn, V; Ruxrungtham, K; Shearer, WT				Ananworanich, Jintanat; Apornpong, Tanakorn; Kosalaraksa, Pope; Jaimulwong, Tanyathip; Hansudewechakul, Rawiwan; Pancharoen, Chitsanu; Bunupuradah, Torsak; Chandara, Mom; Puthanakit, Thanyawee; Ngampiyasakul, Chaiwat; Wongsawat, Jurai; Kanjanavanit, Suparat; Luesomboon, Wicharn; Klangsinsirikul, Phennapha; Ngo-Giang-Huong, Nicole; Kerr, Stephen J.; Ubolyam, Sasiwimol; Mengthaisong, Tawan; Gelman, Rebecca S.; Pattanapanyasat, Kovit; Saphonn, Vonthanak; Ruxrungtham, Kiat; Shearer, William T.		PREDICT Study Grp	Characteristics of lymphocyte subsets in HIV-infected, long-term nonprogressor, and healthy Asian children through 12 years of age	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						HIV; children; lymphocyte; monocyte; phenotyping; long-term nonprogressors; antiretroviral therapy; Asia; disease progression; pediatric AIDS	ACTIVE ANTIRETROVIRAL THERAPY; CD4(+) T-CELLS; HIV-1-INFECTED CHILDREN; UNINFECTED CHILDREN; PREDICTORS; MARKERS; IMMUNODEFICIENCY; ACTIVATION; HAART; REPLICATION	Background: There are limited data on the immune profiles of HIV-positive children compared with healthy controls, and no such data for Asian children. Objectives: To immunophenotype HIV-positive Asian children, including long-term nonprogressors (LTNPs), compared with age-matched healthy controls. Methods: We used flow cytometry to analyze 13 lymphocyte and monocyte subsets from 222 untreated, HIV-positive children with 15% to 24% CD4(+) T cells and no AIDS-related illnesses and 142 healthy children (controls). Data were compared among age categories. Profiles from LTNPs (n = 50), defined as children >= 8 years old with CD4(+) T-cell counts >= 350 cells/mm(3), were compared with data from age-matched non-LTNPs (n = 17) and controls (n = 53). Results: Compared with controls, HIV-positive children had lower values (cell count per mm(3) and percent distribution) for T-H cells and higher values for cytotoxic T cells, with reductions in populations of naive T-H and cytotoxic T cells, B cells, and natural killer (NK) cells. HIV-positive children had high values for activated T-H and cytotoxic T cells. Compared with non-LTNPs, LTNPs had higher values of T-H and cytotoxic T cells, naive and memory T-cell subsets, and B and NK cells. Surprisingly, counts of activated T-H and cytotoxic T cells were also higher among LTNPs. LNTPs were more frequently male. Conclusion: Untreated, HIV-infected Asian children have immune profiles that differ from those of controls, characterized by low values for T-H cells, naive T cells, B cells, and NK cells but high values for cytotoxic, activated T-H, and cytotoxic T cells. The higher values for activated T cells observed in LTNPs require confirmation in longitudinal studies. (J Allergy Clin Immunol 2010;126:1294-301.)	[Ananworanich, Jintanat; Apornpong, Tanakorn; Jaimulwong, Tanyathip; Bunupuradah, Torsak; Puthanakit, Thanyawee; Kerr, Stephen J.; Ubolyam, Sasiwimol; Mengthaisong, Tawan; Ruxrungtham, Kiat] HIV Netherlands Australia Thailand Res Collaborat, Thai Red Cross AIDS Res Ctr, Bangkok, Thailand; [Ananworanich, Jintanat] SE Asia Res Collaborat Hawaii, Bangkok, Thailand; [Ananworanich, Jintanat; Pancharoen, Chitsanu; Puthanakit, Thanyawee; Ruxrungtham, Kiat] Chulalongkorn Univ, Fac Med, Bangkok 10330, Thailand; [Kosalaraksa, Pope] Khon Kaen Univ, Khon Kaen, Thailand; [Hansudewechakul, Rawiwan] Chiangrai Prachanukroh Hosp, Chiang Rai, Thailand; [Chandara, Mom; Saphonn, Vonthanak] Natl Inst Publ Hlth, Phnom Penh, Cambodia; [Ngampiyasakul, Chaiwat] Prapokklao Hosp, Chanthaburi, Thailand; [Wongsawat, Jurai] Bamrasnaradura Infect Dis Inst, Nonthaburi, Thailand; [Kanjanavanit, Suparat] Nakornping Hosp, Chiang Mai, Thailand; [Luesomboon, Wicharn] Queen Savang Vadhana Mem Hosp, Chon Buri, Thailand; [Klangsinsirikul, Phennapha] Chiang Mai Univ, Fac Associated Med Sci, Chiang Mai, Thailand; [Ngo-Giang-Huong, Nicole] IRD U174 Program HIV Prevent & Treatment, Chiang Mai, Thailand; [Kerr, Stephen J.] Natl Ctr HIV Epidemiol & Clin Res, Sydney, NSW, Australia; [Gelman, Rebecca S.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; [Gelman, Rebecca S.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Pattanapanyasat, Kovit] Mahidol Univ, Fac Med, Siriraj Hosp, Bangkok 10700, Thailand; [Saphonn, Vonthanak] Natl Ctr HIV AIDS Dermatol & STDs, Phnom Penh, Cambodia; [Shearer, William T.] Baylor Coll Med, Houston, TX 77030 USA	Thai Red Cross Society; Chulalongkorn University; Khon Kaen University; Chiang Mai University; University of New South Wales Sydney; Kirby Institute; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Dana-Farber Cancer Institute; Mahidol University; Baylor College of Medicine	Ananworanich, J (corresponding author), HIV NAT, Thai Red Cross AIDS Res Ctr, 104 Rajdumri Rd, Bangkok 10330, Thailand.	jintanat.a@hivnat.org	Ngo-Giang-Huong, Nicole/G-2860-2017; Kerr, Stephen/J-6126-2012; Ananworanich, Jintanat/AAC-6348-2021	Ngo-Giang-Huong, Nicole/0000-0001-8950-3234; Kerr, Stephen/0000-0002-1919-4525; Ananworanich, Jintanat/0000-0003-1369-3224; Puthanakit, Thanywee/0000-0003-1873-1867; Shearer, William/0000-0002-2483-2130	National Institute of Allergy and Infectious Diseases [U19 AI053741, 1R01AI075408-0]; Clinical trial.gov [NCT00234091]; Thai Research Council; Division of AIDS, National Institute of Allergy and Infectious Disease, NIH; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI053741, R01AI075408] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH089722] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Clinical trial.gov; Thai Research Council; Division of AIDS, National Institute of Allergy and Infectious Disease, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	The PREDICT study was sponsored by the National Institute of Allergy and Infectious Diseases, grant no. U19 AI053741, Clinical trial.gov identification number NCT00234091. The lymphocyte subset study in HIV-positive children was sponsored by the National Institute of Allergy and Infectious Disease, grant no. 1R01AI075408-0. The Thai Research Council sponsored the study in healthy children. K.P. is a Thailand Research Fund-Senior Research Scholar. Antiretroviral therapy for PREDICT was provided by GlaxoSmithKline, Boehringer Ingelheim, Merck, Abbott, and Roche.; K. Ruxrungtham has received research support from the Division of AIDS, National Institute of Allergy and Infectious Disease, NIH. The rest of the authors have declared that they have no conflict of interest.	Ananworanich J, 2004, ASIAN PAC J ALLERGY, V22, P165; Benito DM, 2005, JAIDS-J ACQ IMM DEF, V38, P373, DOI 10.1097/01.qai.0000153105.42455.c2; Bunders M, 2005, AIDS, V19, P1071, DOI 10.1097/01.aids.0000174454.63250.22; Cagigi A, 2010, AIDS, V24, P2075, DOI 10.1097/QAD.0b013e32833c3298; Chearskul S, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.2.e25; Chinen J, 2010, J ALLERGY CLIN IMMUN, V125, pS195, DOI 10.1016/j.jaci.2009.08.040; Douek DC, 2009, ANNU REV MED, V60, P471, DOI 10.1146/annurev.med.60.041807.123549; Ford ES, 2009, CURR OPIN HIV AIDS, V4, P206, DOI 10.1097/COH.0b013e328329c68c; GELMAN R, 1993, CLIN IMMUNOL IMMUNOP, V66, P150, DOI 10.1006/clin.1993.1019; Giaquinto C, 2005, PEDIATR INFECT DIS J, V24, P595, DOI 10.1097/01.inf.0000168835.01233.64; Hazenberg MD, 2004, BLOOD, V104, P3513, DOI 10.1182/blood-2004-03-0805; Hofer CB, 2009, BRAZ J INFECT DIS, V13, P276, DOI 10.1590/S1413-86702009000400007; Kim WK, 2006, AM J PATHOL, V168, P822, DOI 10.2353/ajpath.2006.050215; Kupka R, 2009, J TROP PEDIATRICS, V55, P290, DOI 10.1093/tropej/fmn118; Mandala WL, 2010, J ALLERGY CLIN IMMUN, V125, P203, DOI 10.1016/j.jaci.2009.10.010; Migueles SA, 2009, J VIROL, V83, P11876, DOI 10.1128/JVI.01153-09; Miura T, 2010, J VIROL, V84, P7581, DOI 10.1128/JVI.00286-10; Navarro J, 2001, AIDS RES HUM RETROV, V17, P525, DOI 10.1089/08892220151126607; Ono E, 2008, BRAZ J MED BIOL RES, V41, P700, DOI 10.1590/S0100-879X2008000800011; Paul ME, 2005, J ALLERGY CLIN IMMUN, V115, P848, DOI 10.1016/j.jaci.2004.11.054; Paul ME, 2001, J ALLERGY CLIN IMMUN, V108, P258, DOI 10.1067/mai.2001.117179; Pereyra F, 2008, J INFECT DIS, V197, P563, DOI 10.1086/526786; Ratto-Kim S, 2008, J NEUROIMMUNOL, V195, P100, DOI 10.1016/j.jneuroim.2007.11.021; Resino S, 2006, CLIN INFECT DIS, V42, P862, DOI 10.1086/500412; Resino S, 2003, CLIN EXP IMMUNOL, V131, P130, DOI 10.1046/j.1365-2249.2003.02034.x; Resino S, 2001, CLIN EXP IMMUNOL, V125, P266, DOI 10.1046/j.1365-2249.2001.01612.x; Resino S, 2006, JAIDS-J ACQ IMM DEF, V42, P269, DOI 10.1097/01.qai.0000222287.90201.d7; Saag M, 2010, CLIN INFECT DIS, V51, P239, DOI 10.1086/653678; Sanchez-Ramon S, 2003, PEDIATRICS, V111, DOI 10.1542/peds.111.2.e168; Scott-Algara D, 2010, JAIDS-J ACQ IMM DEF, V53, P553, DOI 10.1097/QAI.0b013e3181cf060f; Shearer WT, 2003, J ALLERGY CLIN IMMUN, V112, P973, DOI 10.1016/j.jaci.2003.07.003; Streeck H, 2009, J VIROL, V83, P7641, DOI 10.1128/JVI.00182-09; *UNAIDS, 2009, AIDS EP UPD; van Gent R, 2009, CLIN IMMUNOL, V133, P95, DOI 10.1016/j.clim.2009.05.020	34	21	22	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2010	126	6					1294	U352		10.1016/j.jaci.2010.09.038	http://dx.doi.org/10.1016/j.jaci.2010.09.038			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	689RZ	21134574	Green Accepted			2022-12-18	WOS:000284947800030
J	Makino, Y; Noguchi, E; Takahashi, N; Matsumoto, Y; Kubo, S; Yamada, T; Imoto, Y; Ito, Y; Osawa, Y; Shibasaki, M; Uchida, K; Meno, K; Suzuki, H; Okubo, K; Arinami, T; Fujieda, S				Makino, Yuka; Noguchi, Emiko; Takahashi, Noboru; Matsumoto, Yuri; Kubo, Seita; Yamada, Takechiyo; Imoto, Yoshimasa; Ito, Yumi; Osawa, Yoko; Shibasaki, Masanao; Uchida, Kazuhiko; Meno, Kohji; Suzuki, Hideaki; Okubo, Kimihiro; Arinami, Tadao; Fujieda, Shigeharu			Apolipoprotein A-IV is a candidate target molecule for the treatment of seasonal allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Sublingual immunotherapy; apoA-IV; HNF4A; proteome	HEPATOCYTE NUCLEAR FACTOR-4-ALPHA; IMMUNOTHERAPY; EXPRESSION; ACTIVATION; PLACEBO; UPDATE; IMPACT; CELLS; GENE	Background: Allergic rhinitis is a global health problem that causes major illnesses and disability worldwide. Allergen-specific immunotherapy (SIT) is the only available treatment that can alter the natural course of allergic disease. However, the precise mechanism underlying allergen-SIT is not well understood. Objective: The aim of the current study was to identify protein expression signatures reflective of allergen-SIT-more specifically, sublingual immunotherapy (SLIT). Methods: Serum was taken twice from patients with seasonal allergic rhinitis caused by Japanese cedar: once before the pollen season and once during the season. A total of 25 patients was randomly categorized into a placebo-treated group and an active-treatment group. Their serum protein profiles were analyzed by 2-dimensional electrophoresis. Results: Sixteen proteins were found to be differentially expressed during the pollen season. Among the differentially expressed proteins, the serum levels of complement C4A, apolipoprotein A-IV (apoA-IV), and transthyretin were significantly increased in SLIT-treated patients but not in placebo-treated patients. Among these proteins, the serum levels of apoA-IV correlated with the clinical symptom-medication scores (r = -0.635; P < .05) and with quality of life scores (r = -0.516; P < .05) in the case of SLIT-treated patients. The amount of histamine released from the basophils in vitro was greatly reduced after the addition of recombinant apoA-IV in the medium (P < .01). Conclusion: Our data will increase the understanding of the mechanism of SLIT and may provide novel insights into the treatment of allergic rhinitis. (J Allergy Clin Immunol 2010;126:1163-9.)	[Makino, Yuka; Noguchi, Emiko; Matsumoto, Yuri; Arinami, Tadao] Univ Tsukuba, Grad Sch Comprehens Human Sci, Dept Med Genet, Tsukuba, Ibaraki, Japan; [Uchida, Kazuhiko; Meno, Kohji; Suzuki, Hideaki] Univ Tsukuba, Grad Sch Comprehens Human Sci, Dept Mol Biol Oncol, Tsukuba, Ibaraki, Japan; [Takahashi, Noboru; Kubo, Seita; Yamada, Takechiyo; Imoto, Yoshimasa; Ito, Yumi; Osawa, Yoko; Fujieda, Shigeharu] Univ Fukui, Dept Otorhinolaryngol Head & Neck Surg, Fac Med Sci, Fukui 910, Japan; [Shibasaki, Masanao] Tsukuba Univ Technol, Dept Pediat, Tsukuba, Ibaraki, Japan; [Okubo, Kimihiro] Nippon Med Sch, Dept Otorhinolaryngol, Tokyo 113, Japan	University of Tsukuba; University of Tsukuba; University of Fukui; Tsukuba University of Technology; Nippon Medical School	Noguchi, E (corresponding author), Univ Tsukuba, Grad Sch Comprehens Human Sci, Dept Med Genet, 1-1-1 Tennodai, Tsukuba, Ibaraki, Japan.	enoguchi@md.tsukuba.ac.jp			Ministry of Health and Welfare, Japan [H17-Genome-001, H17-Immunology-001, H20-Immunology-001, -004]; Ministry of Education, Science and Culture of Japan [17390458, 18591097, 20390441]	Ministry of Health and Welfare, Japan(Ministry of Health, Labour and Welfare, Japan); Ministry of Education, Science and Culture of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	Supported by a Grant-in-Aid for Scientific Research from the Ministry of Health and Welfare, Japan (H17-Genome-001, H17-Immunology-001, H20-Immunology-001, -004) and from the Ministry of Education, Science and Culture of Japan (17390458, 18591097, 20390441).	ANDERSSON M, 1994, ALLERGY, V49, P242, DOI 10.1111/j.1398-9995.1994.tb02656.x; Bohle B, 2007, J ALLERGY CLIN IMMUN, V120, P707, DOI 10.1016/j.jaci.2007.06.013; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; CALDERON MA, 2007, COCHRANE DB SYST REV, V7; Cohen RD, 1997, J CLIN INVEST, V99, P1906, DOI 10.1172/JCI119358; Compalati E, 2009, ANN ALLERG ASTHMA IM, V102, P22, DOI 10.1016/S1081-1206(10)60103-2; De Blay F, 2007, ANN ALLERG ASTHMA IM, V99, P453, DOI 10.1016/S1081-1206(10)60571-6; Duverger N, 1996, SCIENCE, V273, P966, DOI 10.1126/science.273.5277.966; DVORIN E, 1986, J BIOL CHEM, V261, P5714; ELSHOURBAGY NA, 1987, J BIOL CHEM, V262, P7973; Frew AJ, 2008, NEW ENGL J MED, V358, P2259, DOI 10.1056/NEJMct0708337; GOLDBERG IJ, 1990, J BIOL CHEM, V265, P4266; Hyo S, 2005, ANN ALLERG ASTHMA IM, V94, P457, DOI 10.1016/S1081-1206(10)61116-7; Juniper EF, 1999, J ALLERGY CLIN IMMUN, V104, P364, DOI 10.1016/S0091-6749(99)70380-5; KTISTAKI E, 1994, NUCLEIC ACIDS RES, V22, P4689, DOI 10.1093/nar/22.22.4689; Lee SH, 2006, AM J RESP CRIT CARE, V173, P370, DOI 10.1164/rccm.200505-740OC; Naiki T, 2002, J BIOL CHEM, V277, P14011, DOI 10.1074/jbc.M105403200; Nishima Sankei, 2009, Allergology International, V58, P37, DOI 10.2332/allergolint.O-08-550; Nishioka T, 2008, PROTEOM CLIN APPL, V2, P46, DOI 10.1002/prca.200780065; Okubo Kimihiro, 2008, Allergol Int, V57, P265, DOI 10.2332/allergolint.O-07-514; Passalacqua G, 2007, J ALLERGY CLIN IMMUN, V119, P881, DOI 10.1016/j.jaci.2007.01.045; Recalde D, 2004, ARTERIOSCL THROM VAS, V24, P756, DOI 10.1161/01.ATV.0000119353.03690.22; Rhee J, 2006, J BIOL CHEM, V281, P14683, DOI 10.1074/jbc.M512636200; Sakashita M, 2010, INT ARCH ALLERGY IMM, V151, P255, DOI 10.1159/000242363; Samano Eliana Sueco Tibana, 2004, Rev. Hosp. Clin., V59, P138, DOI 10.1590/S0041-87812004000300009; Spath GF, 1997, MOL CELL BIOL, V17, P1913; Tso P, 2004, PHYSIOL BEHAV, V83, P631, DOI 10.1016/j.physbeh.2004.07.032; Vowinkel T, 2004, J CLIN INVEST, V114, P260, DOI 10.1172/JCI200421233; Wang Y, 2007, J BIOL CHEM, V282, P31826, DOI 10.1074/jbc.M704894200; Wang ZY, 2007, J MOL BIOL, V371, P323, DOI 10.1016/j.jmb.2007.05.049	30	21	22	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2010	126	6					1163	U151		10.1016/j.jaci.2010.06.031	http://dx.doi.org/10.1016/j.jaci.2010.06.031			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	689RZ	20810159				2022-12-18	WOS:000284947800012
J	Marodi, L; Casanova, JL				Marodi, Laszlo; Casanova, Jean-Laurent			Primary immunodeficiencies may reveal potential infectious diseases associated with immune-targeting mAb treatments	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Primary immunodeficiency diseases; monoclonal antibody therapy; infections	SYSTEMIC-LUPUS-ERYTHEMATOSUS; INHERITED INTERLEUKIN-12 DEFICIENCY; CHRONIC MUCOCUTANEOUS CANDIDIASIS; NECROSIS FACTOR THERAPY; NON-HODGKINS-LYMPHOMA; HYPER-IGM SYNDROME; SYNDROME TYPE-I; RHEUMATOID-ARTHRITIS; IFN-GAMMA; ENTEROVIRAL MENINGOENCEPHALITIS	mAbs directed against immunologic molecules have emerged as a new class of drugs for treating patients with various immunologic conditions. However, mAb-based treatments may confer a predisposition to various infections. The authors argue that infections in individuals treated with mAbs directed against molecules of the immune system may display some similarities to those in patients with primary immunodeficiency of the corresponding mAb target. A comprehensive dissection of the tremendously diverse human primary immunodeficiencies and the careful description of their clinical features in different populations living in diverse environments thus represents an original, neglected, but promising approach to assessing the potential risk of infection associated with therapeutic mAbs, or with any therapeutic compound inhibiting a specific immunologic molecule. (J Allergy Clin Immunol 2010; 126:910-7.)	[Marodi, Laszlo] Univ Debrecen, Dept Infect & Pediat Immunol, H-4032 Debrecen, Hungary; [Casanova, Jean-Laurent] Rockefeller Univ, Rockefeller Univ Hosp, Rockefeller Branch, Lab Human Genet Infect Dis, New York, NY 10021 USA; [Casanova, Jean-Laurent] Paris Descartes Univ, Necker Branch, INSERM, Necker Med Sch,U550, Paris, France	University of Debrecen; Rockefeller University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Marodi, L (corresponding author), Univ Debrecen, Dept Infect & Pediat Immunol, Nagyerdei Krt 98, H-4032 Debrecen, Hungary.	lmarodi@dote.hu	Casanova, Jean-Laurent/I-3418-2017; Marodi, Laszlo/AAU-9915-2020	Casanova, Jean-Laurent/0000-0002-7782-4169	TAMOP [4.2.2-08/1/2008-0015, 4.2.1/B-09/1/KONV-2010-0007]	TAMOP	Supported by TAMOP grants (4.2.2-08/1/2008-0015 and 4.2.1/B-09/1/KONV-2010-0007) to L.M.	Altare F, 1998, J CLIN INVEST, V102, P2035, DOI 10.1172/JCI4950; Archimbaud C, 2003, J CLIN MICROBIOL, V41, P4605, DOI 10.1128/JCM.41.10.4605-4610.2003; Aschermann Z, 2007, ARCH NEUROL-CHICAGO, V64, P273, DOI 10.1001/archneur.64.2.273; Banchereau J, 2006, IMMUNITY, V25, P383, DOI 10.1016/j.immuni.2006.08.010; Barkholt L, 2005, TRANSPL INT, V18, P835, DOI 10.1111/j.1432-2277.2005.00145.x; Brinkmann MM, 2007, J CELL BIOL, V177, P265, DOI 10.1083/jcb.200612056; Burra P, 2006, EUR J GASTROEN HEPAT, V18, P1065, DOI 10.1097/01.meg.0000231752.50587.ae; Bustarnante J, 2008, CURR OPIN IMMUNOL, V20, P39, DOI 10.1016/j.coi.2007.10.005; Cardenes M, 2010, J MED GENET, V47, P635, DOI 10.1136/jmg.2009.071910; Carrasco Ruy, 2004, Paediatr Drugs, V6, P137, DOI 10.2165/00148581-200406030-00001; Carson KR, 2009, LANCET ONCOL, V10, P816, DOI 10.1016/S1470-2045(09)70161-5; Casanova JL, 2007, SCIENCE, V317, P617, DOI 10.1126/science.1142963; Casrouge A, 2006, SCIENCE, V314, P308, DOI 10.1126/science.1128346; Chapgier A, 2009, J CLIN INVEST, V119, P1502, DOI 10.1172/JCI37083; Cohen SB, 2006, ARTHRITIS RHEUM-US, V54, P2793, DOI 10.1002/art.22025; Coles AJ, 2008, NEW ENGL J MED, V359, P1786, DOI 10.1056/NEJMoa0802670; Cornely Oliver A, 2004, Wien Med Wochenschr, V154, P209, DOI 10.1007/s10354-004-0067-y; Dall'Era M, 2007, ARTHRITIS RHEUM, V56, P4142, DOI 10.1002/art.23047; Desai SB, 2006, BEST PRACT RES CL RH, V20, P757, DOI 10.1016/j.berh.2006.06.002; Dorner T, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1942; Dorner T, 2009, NAT REV RHEUMATOL, V5, P433, DOI 10.1038/nrrheum.2009.141; Doffinger R, 2004, CLIN INFECT DIS, V38, pE10, DOI 10.1086/380453; Dong C, 2008, NAT REV IMMUNOL, V8, P337, DOI 10.1038/nri2295; Donnithorne KJ, 2009, J PEDIATR-US, V155, P136, DOI 10.1016/j.jpeds.2008.12.049; Dupuis S, 2003, NAT GENET, V33, P388, DOI 10.1038/ng1097; Erdos M, 2005, IMMUNOL LETT, V97, P1, DOI 10.1016/j.imlet.2004.09.021; Erdos M, 2008, CLIN IMMUNOL, V129, P455, DOI 10.1016/j.clim.2008.08.005; Ford ML, 2009, IMMUNOL REV, V229, P294, DOI 10.1111/j.1600-065X.2009.00776.x; Ganjoo KN, 2009, LEUKEMIA LYMPHOMA, V50, P673, DOI 10.1080/10428190902782210; Geha RS, 2007, J ALLERGY CLIN IMMUN, V120, P776, DOI 10.1016/j.jaci.2007.08.053; Hauser SL, 2008, NEW ENGL J MED, V358, P676, DOI 10.1056/NEJMoa0706383; Hoflich C, 2004, BLOOD, V103, P673, DOI 10.1182/blood-2003-04-1065; Husebye ES, 2009, J INTERN MED, V265, P514, DOI 10.1111/j.1365-2796.2009.02090.x; Kampmann B, 2005, J CLIN INVEST, V115, P2480, DOI 10.1172/JCI19316; Kanbayashi Y, 2009, EUR J HAEMATOL, V82, P26, DOI 10.1111/j.1600-0609.2008.01165.x; Katchamart W, 2010, ARTHRIT CARE RES, V62, P1128, DOI 10.1002/acr.20188; Kenyon NS, 1999, DIABETES, V48, pA59; Kiani-Alikhan S, 2009, BRIT J HAEMATOL, V146, P333, DOI 10.1111/j.1365-2141.2009.07748.x; Kimby E, 2005, CANCER TREAT REV, V31, P456, DOI 10.1016/j.ctrv.2005.05.007; KINDLER V, 1989, CELL, V56, P731, DOI 10.1016/0092-8674(89)90676-4; Kirk AD, 1999, NAT MED, V5, P686, DOI 10.1038/9536; Kisand K, 2010, J EXP MED, V207, P299, DOI 10.1084/jem.20091669; Kishimoto T, 2005, ANNU REV IMMUNOL, V23, P1, DOI 10.1146/annurev.immunol.23.021704.115806; Lachmann HJ, 2009, NEW ENGL J MED, V360, P2416, DOI 10.1056/NEJMoa0810787; Li XX, 2008, EUR J IMMUNOL, V38, P614, DOI 10.1002/eji.200838161; Major EO, 2009, NEW ENGL J MED, V361, P1041, DOI 10.1056/NEJMp0906248; Marodi L, 2007, NAT REV IMMUNOL, V7, P851, DOI 10.1038/nri2195; Marodi L, 2007, NAT IMMUNOL, V8, P323, DOI 10.1038/ni0407-323; Marodi L, 2010, NAT REV IMMUNOL, V10, P298, DOI 10.1038/nri2764; Marodi L, 2009, LANCET, V373, P2179, DOI 10.1016/S0140-6736(09)61171-5; Martin-Mola E, 2009, RHEUM DIS CLIN N AM, V35, P183, DOI 10.1016/j.rdc.2009.03.009; Martinez-Moczygemba M, 2008, J EXP MED, V205, P2711, DOI 10.1084/jem.20080759; Mertens M, 2009, J RHEUMATOL, V36, P1118, DOI 10.3899/jrheum.090074; Minegishi Y, 2007, NATURE, V448, P1058, DOI 10.1038/nature06096; Minegishi Y, 2009, J EXP MED, V206, P1291, DOI 10.1084/jem.20082767; Netea MG, 2010, TRENDS IMMUNOL, V31, P346, DOI 10.1016/j.it.2010.06.007; Notarangelo LD, 2009, CURR OPIN IMMUNOL, V21, P461, DOI 10.1016/j.coi.2009.09.002; O'Neill JL, 2009, BIOL-TARGETS THER, V3, P159; Oldfield V, 2009, DRUGS, V69, P609, DOI 10.2165/00003495-200969050-00007; Padate BP, 2006, CLIN LAB HAEMATOL, V28, P69, DOI 10.1111/j.1365-2257.2006.00751.x; PARKER DC, 1995, P NATL ACAD SCI USA, V92, P9560, DOI 10.1073/pnas.92.21.9560; Patel SY, 2005, J IMMUNOL, V175, P4769, DOI 10.4049/jimmunol.175.7.4769; Picard C, 2002, AM J HUM GENET, V70, P336, DOI 10.1086/338625; PICARD C, 2010, MEDICINE IN PRESS; Plater-Zyberk C, 2009, ANN RHEUM DIS, V68, P721, DOI 10.1136/ard.2007.085431; Puel A, 2008, J IMMUNOL, V180, P647, DOI 10.4049/jimmunol.180.1.647; Puel A, 2010, J EXP MED, V207, P291, DOI 10.1084/jem.20091983; Quartier P, 2003, CLIN INFECT DIS, V36, pE47, DOI 10.1086/345746; Ram R, 2009, LEUKEMIA LYMPHOMA, V50, P1083, DOI 10.1080/10428190902934944; Rauch M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005456; Reinisch W, 2010, INFLAMM BOWEL DIS, V16, P233, DOI 10.1002/ibd.21038; Ruperto N, 2007, ARTHRITIS RHEUM-US, V56, P3096, DOI 10.1002/art.22838; Salliot C, 2009, ANN RHEUM DIS, V68, P25, DOI 10.1136/ard.2007.083188; Sasaki Y, 2004, J IMMUNOL, V173, P2245, DOI 10.4049/jimmunol.173.4.2245; Schiemann B, 2001, SCIENCE, V293, P2111, DOI 10.1126/science.1061964; Sevmis S, 2005, TRANSPL P, V37, P3016, DOI 10.1016/j.transproceed.2005.07.052; Shortt J, 2006, BONE MARROW TRANSPL, V38, P433, DOI 10.1038/sj.bmt.1705463; Suzuki T, 2008, J EXP MED, V205, P2703, DOI 10.1084/jem.20080990; Toth B, 2010, CLIN ENDOCRINOL, V72, P641, DOI 10.1111/j.1365-2265.2009.03740.x; Toth B, 2009, MOL IMMUNOL, V46, P2140, DOI 10.1016/j.molimm.2009.03.012; Toyoda H, 2010, J MED GENET, V47, P631, DOI 10.1136/jmg.2009.072108; Vogt G, 2008, J EXP MED, V205, P1729, DOI 10.1084/jem.20071987; von Bernuth H, 2008, SCIENCE, V321, P691, DOI 10.1126/science.1158298; Wallis RS, 2009, CURR OPIN INFECT DIS, V22, P403, DOI 10.1097/QCO.0b013e32832dda55; Wang ZL, 2009, CURR TOP MED CHEM, V9, P724, DOI 10.2174/156802609789044407; Yao YH, 2009, ARTHRITIS RHEUM, V60, P1785, DOI 10.1002/art.24557; Young JD, 2005, NEW ENGL J MED, V353, P1530, DOI 10.1056/NEJMc051556; Zhang SY, 2008, IMMUNOL REV, V226, P29, DOI 10.1111/j.1600-065X.2008.00698.x; Zhang SY, 2007, SCIENCE, V317, P1522, DOI 10.1126/science.1139522	89	21	21	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2010	126	5					910	917		10.1016/j.jaci.2010.08.009	http://dx.doi.org/10.1016/j.jaci.2010.08.009			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	674HB	20943260				2022-12-18	WOS:000283727100003
J	Baumgrass, R; Brandt, C; Wegner, F; Abdollahnia, M; Worm, M				Baumgrass, Ria; Brandt, Claudia; Wegner, Fanny; Abdollahnia, Mandana; Worm, Margitta			Low-dose, but not high-dose, cyclosporin A promotes regulatory T-cell induction, expansion, or both	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Baumgrass, Ria; Brandt, Claudia; Wegner, Fanny] DRFZ, Berlin, Germany; [Abdollahnia, Mandana; Worm, Margitta] Allergy Ctr Charite, Dept Dermatol & Allergy, Berlin, Germany	Deutsches Rheuma-Forschungszentrum (DRFZ); Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Baumgrass, R (corresponding author), DRFZ, Berlin, Germany.	baumgrass@drfz.de		Wegner, Fanny/0000-0003-4348-5872; Baumgrass, Ria/0000-0002-3289-1608; Worm, Margitta/0000-0002-3449-1245				Brandt C, 2009, ALLERGY, V64, P1588, DOI 10.1111/j.1398-9995.2009.02054.x; BRANDT C, 2010, CYTOMETRY A IN PRESS; Coenen JJA, 2007, BONE MARROW TRANSPL, V39, P537, DOI 10.1038/sj.bmt.1705628; Ekberg H, 2007, NEW ENGL J MED, V357, P2562, DOI 10.1056/NEJMoa067411; Filantenkov A, 2002, TRANSPLANT P, V34, P2895, DOI 10.1016/S0041-1345(02)03551-0; Hijnen D, 2009, J ALLERGY CLIN IMMUN, V124, P856, DOI 10.1016/j.jaci.2009.07.056; Wang HJ, 2006, TRANSPLANTATION, V82, P1484, DOI 10.1097/01.tp.0000246312.89689.17	7	21	23	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2010	126	1					183	184		10.1016/j.jaci.2010.04.032	http://dx.doi.org/10.1016/j.jaci.2010.04.032			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	627SE	20542321				2022-12-18	WOS:000280061800041
J	Tedder, TF; Matsushita, T				Tedder, Thomas F.; Matsushita, Takashi			Regulatory B cells that produce IL-10: A breath of fresh air in allergic airway disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Asthma; IL-10; regulatory B cell	B10 CELLS; AUTOIMMUNITY; IMMUNOLOGY; SUBSET; MICE		[Tedder, Thomas F.; Matsushita, Takashi] Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27710 USA	Duke University	Tedder, TF (corresponding author), Duke Univ, Med Ctr, Dept Immunol, Box 3010,Room 353 Jones Bldg,Res Dr, Durham, NC 27710 USA.	thomas.tedder@duke.edu	Matsushita, Takashi/C-4750-2015	Matsushita, Takashi/0000-0002-1617-086X	NIAID NIH HHS [U19 AI056363-067521, AI057157, AI56363, U54 AI057157-075808, U54 AI057157-085808, U54 AI057157, U19 AI056363] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI056363, U54AI057157] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Amu S, 2010, J ALLERGY CLIN IMMUN, V125, P1114, DOI 10.1016/j.jaci.2010.01.018; Boyce JA, 2009, J ALLERGY CLIN IMMUN, V123, P569, DOI 10.1016/j.jaci.2009.01.041; DiLillo DJ, 2010, ANN NY ACAD SCI, V1183, P38, DOI 10.1111/j.1749-6632.2009.05137.x; Fillatreau S, 2002, NAT IMMUNOL, V3, P944, DOI 10.1038/ni833; HAAS KM, 2010, J IMMUNOL IN PRESS; Mangan NE, 2004, J IMMUNOL, V173, P6346, DOI 10.4049/jimmunol.173.10.6346; Matsushita T, 2008, J CLIN INVEST, V118, P3420, DOI 10.1172/JCI36030; Mauri C, 2003, J EXP MED, V197, P489, DOI 10.1084/jem.20021293; Mizoguchi A, 2002, IMMUNITY, V16, P219, DOI 10.1016/S1074-7613(02)00274-1; Simon D, 2008, J ALLERGY CLIN IMMUN, V121, P122, DOI 10.1016/j.jaci.2007.11.016; WATANABE R, 2010, J IMMUNOL IN PRESS; Yanaba K, 2008, IMMUNOL REV, V223, P284, DOI 10.1111/j.1600-065X.2008.00646.x; Yanaba K, 2008, IMMUNITY, V28, P639, DOI 10.1016/j.immuni.2008.03.017; Yanaba K, 2009, J IMMUNOL, V182, P7459, DOI 10.4049/jimmunol.0900270; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490	15	21	22	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2010	125	5					1125	1127		10.1016/j.jaci.2010.03.024	http://dx.doi.org/10.1016/j.jaci.2010.03.024			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	596LO	20451042	Green Accepted, Bronze			2022-12-18	WOS:000277686700023
J	Peric, M; Lehmann, B; Vashina, G; Dombrowski, Y; Koglin, S; Meurer, M; Ruzicka, T; Schauber, J				Peric, Mark; Lehmann, Bodo; Vashina, Gabriela; Dombrowski, Yvonne; Koglin, Sarah; Meurer, Michael; Ruzicka, Thomas; Schauber, Juergen			UV-B-triggered induction of vitamin D3 metabolism differentially affects antimicrobial peptide expression in keratinocytes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							SKIN		[Peric, Mark; Dombrowski, Yvonne; Koglin, Sarah; Ruzicka, Thomas; Schauber, Juergen] Univ Munich, Dept Dermatol & Allergol, Munich, Germany; [Lehmann, Bodo; Vashina, Gabriela; Meurer, Michael] Tech Univ Dresden, Dept Dermatol, Carl Gustav Carus Med Sch, Dresden, Germany	University of Munich; Technische Universitat Dresden	Peric, M (corresponding author), Univ Munich, Dept Dermatol & Allergol, Munich, Germany.	juergen.schauber@med.uni-muenchen.de	Dombrowski, Yvonne/N-7020-2019	Dombrowski, Yvonne/0000-0003-1732-6288				Glasser R, 2009, J ALLERGY CLIN IMMUN, V123, P1117, DOI 10.1016/j.jaci.2009.01.043; Koczulla R, 2003, J CLIN INVEST, V111, P1665, DOI 10.1172/JCI200317545; Lehmann B, 2009, EXP DERMATOL, V18, P97, DOI 10.1111/j.1600-0625.2008.00810.x; Mallbris L, 2005, J INVEST DERMATOL, V125, P1072, DOI 10.1111/j.0022-202X.2005.23872.x; NEMANIC MK, 1985, BIOCHIM BIOPHYS ACTA, V841, P267, DOI 10.1016/0304-4165(85)90068-6; Peric M, 2008, J IMMUNOL, V181, P8504, DOI 10.4049/jimmunol.181.12.8504; Schauber J, 2009, J ALLERGY CLIN IMMUN, V124, pR13, DOI 10.1016/j.jaci.2009.07.014; Schauber J, 2006, IMMUNOLOGY, V118, P509, DOI 10.1111/j.1365-2567.2006.02399.x; Schuessler M, 2001, STEROIDS, V66, P399, DOI 10.1016/S0039-128X(00)00229-4; Vantieghem K, 2006, J CELL BIOCHEM, V98, P81, DOI 10.1002/jcb.20756	10	21	22	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2010	125	3					746	749		10.1016/j.jaci.2009.12.933	http://dx.doi.org/10.1016/j.jaci.2009.12.933			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	573BK	20226307				2022-12-18	WOS:000275883200036
J	Summers, RW; Elliott, DE; Weinstock, JV				Summers, Robert W.; Elliott, David E.; Weinstock, Joel V.			Trichuris suis might be effective in treating allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							THERAPY		[Summers, Robert W.; Elliott, David E.] Univ Iowa, Dept Internal Med, Carver Coll Med, Iowa City, IA 52242 USA; [Weinstock, Joel V.] Tufts Univ New England Med Ctr, Dept Internal Med, Boston, MA USA	University of Iowa; Tufts Medical Center	Summers, RW (corresponding author), Univ Iowa, Dept Internal Med, Carver Coll Med, Iowa City, IA 52242 USA.	david-elliott@uiowa.edu		Elliott, David/0000-0002-5359-7125				Bager P, 2010, J ALLERGY CLIN IMMUN, V125, P123, DOI 10.1016/j.jaci.2009.08.006; Kitagaki K, 2006, J IMMUNOL, V177, P1628, DOI 10.4049/jimmunol.177.3.1628; Summers RW, 2005, GASTROENTEROLOGY, V128, P825, DOI 10.1053/j.gastro.2005.01.005; Summers RW, 2005, GUT, V54, P87, DOI 10.1136/gut.2004.041749; Wilson MS, 2005, J EXP MED, V202, P1199, DOI 10.1084/jem.20042572	5	21	22	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2010	125	3					766	767		10.1016/j.jaci.2009.12.937	http://dx.doi.org/10.1016/j.jaci.2009.12.937			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	573BK	20153033				2022-12-18	WOS:000275883200047
J	Frank, MM				Frank, Michael M.			Complement disorders and hereditary angioedema	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Complement; complement deficiencies; hereditary angioedema; atypical hemolytic uremic syndrome	C5A ANAPHYLATOXIN; INNATE; PATHWAY; IMMUNOLOGY; ACTIVATION; IMMUNITY; BIOLOGY; PROTEIN; DISEASE; SYSTEM	The term complement was introduced more than 100 years ago to refer to a group of plasma factors important in host defense and in the destruction of microorganisms. We now know that there are 3 separate activation pathways that appeared at different times in evolution: the classical, alternative, and lectin pathways. Two of these appear before the evolution of the adaptive immune system and do not require antibody for initiation. All pathways come together to activate C3, the principle opsonic protein of the complement cascade, and all continue together to the generation of biologically active factors, such as C5a, and to lysis of cells and microbes. In general, complete deficiencies of complement proteins are rare, although partial or complete deficiencies of one of the proteins that initiates the lectin pathway, mannose-binding lectin, are far more common. Although genetically controlled complement defects are rare, defects in the proteins in the circulation and on cell membranes that downregulate complement so as to limit uncontrolled inflammation are more common. A number of these are discussed, and because new methods of treatment are currently being introduced, one of these defects, CI inhibitor deficiency associated with hereditary angioedema, is discussed in some detail. (J Allergy Clin Immunol 2010;125:S262-71.)	Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27710 USA	Duke University	Frank, MM (corresponding author), Duke Univ, Med Ctr, Dept Pediat, Box 2611,Room 131 MSRB, Durham, NC 27710 USA.	frank007@mc.duke.edu						Barilla-LaBarca ML, 2002, J IMMUNOL, V168, P6298, DOI 10.4049/jimmunol.168.12.6298; Blom AM, 2004, MOL IMMUNOL, V40, P1333, DOI 10.1016/j.molimm.2003.12.002; Carroll MC, 2005, ADV IMMUNOL, V86, P137, DOI 10.1016/S0065-2776(04)86004-8; Carroll MC, 2004, NAT IMMUNOL, V5, P981, DOI 10.1038/ni1113; Carroll MC, 1998, ANNU REV IMMUNOL, V16, P545, DOI 10.1146/annurev.immunol.16.1.545; Davis A. E., 1998, HUMAN COMPLEMENT SYS, P455; Dempsey PW, 1996, SCIENCE, V271, P348, DOI 10.1126/science.271.5247.348; Fang CJ, 2008, BRIT J HAEMATOL, V143, P336, DOI 10.1111/j.1365-2141.2008.07324.x; FIGUEROA JE, 1991, CLIN MICROBIOL REV, V4, P359, DOI 10.1128/CMR.4.3.359-395.1991; Frank M. M., 1998, HUMAN COMPLEMENT SYS, P1; Frank MM, 2006, IMMUNOL ALLERGY CLIN, V26, P653, DOI 10.1016/j.iac.2006.09.005; Frank MM, 2000, PEDIATR CLIN N AM, V47, P1339, DOI 10.1016/S0031-3955(05)70274-1; Fujita T, 2004, IMMUNOL REV, V198, P185, DOI 10.1111/j.0105-2896.2004.0123.x; Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359; He JQ, 2008, MOL IMMUNOL, V45, P4041, DOI 10.1016/j.molimm.2008.07.011; Hillmen P, 2006, NEW ENGL J MED, V355, P1233, DOI 10.1056/NEJMoa061648; Holers VM, 2000, IMMUNOPHARMACOLOGY, V49, P125, DOI 10.1016/S0162-3109(00)80298-2; HUGLI T E, 1986, Complement, V3, P111; Jensenius JC, 2005, ADV EXP MED BIOL, V564, P21; JOINER KA, 1984, ANNU REV IMMUNOL, V2, P461, DOI 10.1146/annurev.immunol.2.1.461; Kim DD, 2006, CLIN IMMUNOL, V118, P127, DOI 10.1016/j.clim.2005.10.014; Kohl J, 2006, J CLIN INVEST, V116, P783, DOI 10.1172/JCI26582; Liszewski M.K., 1998, HUMAN COMPLEMENT SYS, P149; Luzzatto L, 2006, CURR OPIN GENET DEV, V16, P317, DOI 10.1016/j.gde.2006.04.015; Manderson AP, 2004, ANNU REV IMMUNOL, V22, P431, DOI 10.1146/annurev.immunol.22.012703.104549; NONAKA M, 1998, HUMAN COMPLEMENT SYS, P203; Nordahl EA, 2004, P NATL ACAD SCI USA, V101, P16879, DOI 10.1073/pnas.0406678101; Peng T, 2005, J CLIN INVEST, V115, P1590, DOI 10.1172/JCI22906; Shushakova N, 2002, J CLIN INVEST, V110, P1823, DOI 10.1172/JCI200216577; Sjoholm AG, 2006, MOL IMMUNOL, V43, P78, DOI 10.1016/j.molimm.2005.06.025; Staunton DE, 2006, ADV IMMUNOL, V91, P111, DOI 10.1016/S0065-2776(06)91003-7; Thurman JM, 2006, J IMMUNOL, V176, P1305, DOI 10.4049/jimmunol.176.3.1305; Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406; Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506; Walport MJ, 1998, IMMUNOBIOLOGY, V199, P265, DOI 10.1016/S0171-2985(98)80032-6; Zuraw BL, 2008, NEW ENGL J MED, V359, P1027, DOI 10.1056/NEJMcp0803977	36	21	24	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2010	125	2		2			S262	S271		10.1016/j.jaci.2009.10.063	http://dx.doi.org/10.1016/j.jaci.2009.10.063			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	629CC	20176263				2022-12-18	WOS:000280170600024
J	Werfel, T				Werfel, Thomas			Epicutaneous allergen administration: A novel approach for allergen-specific immunotherapy?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Specific immunotherapy; rhinitis; grass pollen; epicutaneous application; patch test	ATOPIC-DERMATITIS; SUBLINGUAL IMMUNOTHERAPY		Hannover Med Sch, Div Immunodermatol & Expt Allergy, Dept Dermatol & Allergy, D-30449 Hannover, Germany	Hannover Medical School	Werfel, T (corresponding author), Hannover Med Sch, Div Immunodermatol & Expt Allergy, Dept Dermatol & Allergy, Ricklinger Str 5, D-30449 Hannover, Germany.	Werfel.Thomas@MH-Hannover.de	Werfel, Thomas/B-6921-2012					BLAMOUTIER P, 1959, PRESSE MED, V67, P2299; Bussmann C, 2006, J ALLERGY CLIN IMMUN, V118, P1292, DOI 10.1016/j.jaci.2006.07.054; Carnes J, 2008, RECENT PATENTS INFLA, V2, P92, DOI 10.2174/187221308784543610; Compalati E, 2009, ANN ALLERG ASTHMA IM, V102, P22, DOI 10.1016/S1081-1206(10)60103-2; Corsini E, 2000, TOXICOLOGY, V142, P203, DOI 10.1016/S0300-483X(99)00145-6; Cumberbatch M, 2001, IMMUNOLOGY, V102, P323, DOI 10.1046/j.1365-2567.2001.01187.x; Frew AJ, 2008, NEW ENGL J MED, V358, P2259, DOI 10.1056/NEJMct0708337; More DR, 2002, ANN ALLERG ASTHMA IM, V88, P391, DOI 10.1016/S1081-1206(10)62370-8; Pajno GB, 2007, J ALLERGY CLIN IMMUN, V120, P164, DOI 10.1016/j.jaci.2007.04.008; Senti G, 2009, J ALLERGY CLIN IMMUN, V124, P997, DOI 10.1016/j.jaci.2009.07.019; Skripak JM, 2008, CURR OPIN IMMUNOL, V20, P690, DOI 10.1016/j.coi.2008.09.002; Turjanmaa K, 2006, ALLERGY, V61, P1377, DOI 10.1111/j.1398-9995.2006.01136.x; Werfel T, 2006, ALLERGY, V61, P202, DOI 10.1111/j.1398-9995.2006.00974.x	13	21	22	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2009	124	5					1003	1004		10.1016/j.jaci.2009.09.049	http://dx.doi.org/10.1016/j.jaci.2009.09.049			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	523XI	19895988	Bronze			2022-12-18	WOS:000272108000019
J	Greenhawt, MJ; McMorris, MS; Furlong, TJ				Greenhawt, Matthew J.; McMorris, Marc S.; Furlong, Terence J.			Self-reported allergic reactions to peanut and tree nuts occurring on commercial airlines	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Greenhawt, Matthew J.; McMorris, Marc S.] Univ Michigan Hlth Syst, Div Allergy & Clin Immunol, Ann Arbor, MI USA; [Furlong, Terence J.] Food Allergy & Anaphylaxis Network, Fairfax, VA USA	University of Michigan System; University of Michigan	Greenhawt, MJ (corresponding author), Univ Michigan Hlth Syst, Div Allergy & Clin Immunol, Ann Arbor, MI USA.	mgreenha@med.umich.edu		Greenhawt, Matthew/0000-0002-2365-9372				Comstock SS, 2008, ANN ALLERG ASTHMA IM, V101, P51, DOI 10.1016/S1081-1206(10)60835-6; DeJohn CA, 2000, EVALUATION IN FLIGHT; Delaune EF, 2003, AVIAT SPACE ENVIR MD, V74, P62; GILLIS A, COMP AIRLINES ALLERG; Jones R. T., 1996, Journal of Allergy and Clinical Immunology, V97, P423, DOI 10.1016/S0091-6749(96)81179-1; Perry TT, 2004, J ALLERGY CLIN IMMUN, V113, P973, DOI 10.1016/j.jaci.2004.02.035; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V104, P186, DOI 10.1016/S0091-6749(99)70133-8; Simonte SJ, 2003, J ALLERGY CLIN IMMUN, V112, P180, DOI 10.1067/mai.2003.1486	9	21	22	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2009	124	3					598	599		10.1016/j.jaci.2009.06.039	http://dx.doi.org/10.1016/j.jaci.2009.06.039			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	552TG	19733300				2022-12-18	WOS:000274315900028
J	Koetzler, R; Zaheer, RS; Newton, R; Proud, D				Koetzler, Rommy; Zaheer, Raza S.; Newton, Robert; Proud, David			Nitric oxide inhibits IFN regulatory factor 1 and nuclear factor-kappa B pathways in rhinovirus-infected epithelial cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Human rhinovirus; asthma; airway epithelial cells; CXCL10; nitric oxide; IFN regulatory factors; nuclear factor-kappa B	GENE-EXPRESSION; PROTEIN-KINASE; IN-VIVO; TRANSCRIPTION FACTORS; CYTOKINE PRODUCTION; HOST-DEFENSE; ASTHMA; SYNTHASE; DISEASE; CXCL10	Background: Nitric oxide (NO) has previously been shown to inhibit human rhinovirus (HRV) replication in airway epithelial cells and to inhibit rhinovirus-induced epithelial cytokine and chemokine production independently of its effects on viral replication by modulating nuclear translocation and binding of transcription factors. Objective: To define the molecular mechanisms by which NO inhibits HRV-16-induced epithelial production of CXCL10 by affecting nuclear translocation and binding of nuclear factor-kappa B (NF-kappa B) and IFN regulatory factor 1 (IRF-1). Methods: Cultured human airway epithelial cells were infected with HRV-16 in the absence or presence of a NO donor, or were preincubated with 2 highly selective inhibitors of inhibitor of kappa B kinase (IKK)beta and then infected with HRV-16. Effects on the NF-kappa B and IRF-1 pathways were examined by using electrophoretic mobility shift assays, Western blotting, and real-time RT-PCR. Results: Nitric oxide directly inhibited the binding of both recombinant NF-kappa B p50 protein and recombinant IRF-1 to their recognition sequences from the CXCL10 promoter. NO also inhibited phosphorylation of the NF-kappa B inhibitor, I kappa B alpha, in HRV-16-infected cells. In addition, both NO and inhibitors of IKK beta inhibited viral induction of IRF-1 mRNA and protein. Conclusions: Nitric oxide blocks rhinovirus-mediated activation and nuclear translocation of both NF-kappa B and IRF-1. NO also directly inhibits the binding of each of these transcription factors to their respective recognition sites in the CXCL10 promoter. In addition, the ability of HRV- 16 to induce epithelial expression of IRF-1 is dependent, at least in part, on viral activation of NF-kappa B. (J Allergy Clin Immunol 2009;124:551-7.)	[Proud, David] Univ Calgary, Fac Med, Dept Physiol & Pharmacol, Airway Inflammat Grp,Inst Infect Immun & Inflamma, Calgary, AB T2N 4N1, Canada	University of Calgary	Proud, D (corresponding author), Univ Calgary, Fac Med, Dept Physiol & Pharmacol, Airway Inflammat Grp,Inst Infect Immun & Inflamma, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	dproud@ucalgary.ca	Newton, Robert/C-6814-2012	Newton, Robert/0000-0002-4919-8498	Canadian Institutes of Health Research [43923]; American Academy of Allergy, Asthma Immunology; Lung Association of Alberta and Northwest Territories	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); American Academy of Allergy, Asthma Immunology; Lung Association of Alberta and Northwest Territories	Supported by grant no. 43923 from the Canadian Institutes of Health Research. D. P. is a Canada Research Chair in Inflammatory Airway Diseases. R. K. was the recipient of a ST*AR award from the American Academy of Allergy, Asthma & Immunology. R. K. and R.S.Z. are recipients of studentship awards from the Lung Association of Alberta and Northwest Territories. R.N. is an Alberta Heritage Foundation for Medical Research (AHFMR) Scholar and Canadian Institutes of Health Research (CIHR) New Investigator.	Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797; CHURCHILL L, 1989, AM REV RESPIR DIS, V140, P449, DOI 10.1164/ajrccm/140.2.449; Edwards MR, 2007, MOL IMMUNOL, V44, P1587, DOI 10.1016/j.molimm.2006.08.014; Genin P, 2000, J IMMUNOL, V164, P5352, DOI 10.4049/jimmunol.164.10.5352; Hiscott J, 2006, ONCOGENE, V25, P6844, DOI 10.1038/sj.onc.1209941; Khetsuriani N, 2007, J ALLERGY CLIN IMMUN, V119, P314, DOI 10.1016/j.jaci.2006.08.041; Koetzler R, 2009, J ALLERGY CLIN IMMUN, V123, P201, DOI 10.1016/j.jaci.2008.09.041; Leigh R, 2008, J ALLERGY CLIN IMMUN, V121, P1238, DOI 10.1016/j.jaci.2008.01.067; Matthews JR, 1996, NUCLEIC ACIDS RES, V24, P2236, DOI 10.1093/nar/24.12.2236; Message SD, 2004, J LEUKOCYTE BIOL, V75, P5, DOI 10.1189/jlb.0703315; Moschonas A, 2008, MOL CELL BIOL, V28, P6208, DOI 10.1128/MCB.00611-08; Mosser AG, 2005, AM J RESP CRIT CARE, V171, P645, DOI 10.1164/rccm.200407-970OC; Newton R, 2007, J PHARMACOL EXP THER, V321, P734, DOI 10.1124/jpet.106.118125; Paludan SR, 2001, EUR CYTOKINE NETW, V12, P297; Proud D, 2004, J IMMUNOL, V172, P4637, DOI 10.4049/jimmunol.172.7.4637; Proud D, 2008, AM J RESP CRIT CARE, V178, P962, DOI 10.1164/rccm.200805-670OC; Proud D, 2006, AM J RESP CELL MOL, V35, P513, DOI 10.1165/rcmb.2006-0199TR; Reynaert NL, 2004, P NATL ACAD SCI USA, V101, P8945, DOI 10.1073/pnas.0400588101; Sanders SP, 1998, J VIROL, V72, P934, DOI 10.1128/JVI.72.2.934-942.1998; Sanders SP, 2004, J ALLERGY CLIN IMMUN, V113, P697, DOI 10.1016/j.jaci.2004.01.755; Sanders SP, 2001, J ALLERGY CLIN IMMUN, V107, P235, DOI 10.1067/mai.2001.112028; Sanders SP, 2001, AM J RESP CELL MOL, V24, P317, DOI 10.1165/ajrcmb.24.3.4131; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; Traves SL, 2007, CURR OPIN PHARMACOL, V7, P252, DOI 10.1016/j.coph.2006.11.010; Uetani K, 2000, J IMMUNOL, V165, P988, DOI 10.4049/jimmunol.165.2.988; Wedzicha Jadwiga A, 2003, Respir Care, V48, P1204; Wen DY, 2006, J PHARMACOL EXP THER, V317, P989, DOI 10.1124/jpet.105.097584; WU CQ, 1994, J INTERFERON RES, V14, P357, DOI 10.1089/jir.1994.14.357; Zaheer RS, 2009, J IMMUNOL, V182, P4854, DOI 10.4049/jimmunol.0802401	29	21	21	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2009	124	3					551	557		10.1016/j.jaci.2009.04.041	http://dx.doi.org/10.1016/j.jaci.2009.04.041			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	552TG	19541350				2022-12-18	WOS:000274315900022
J	O'Byrne, PM; Gauvreau, GM; Murphy, DM				O'Byrne, Paul M.; Gauvreau, Gail M.; Murphy, Desmond M.			Efficacy of leukotriene receptor antagonists and synthesis inhibitors in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Asthma; treatment; leukotrienes; antagonists; synthesis inhibitors; treatment guidelines	EXERCISE-INDUCED BRONCHOCONSTRICTION; ALLERGEN-INDUCED BRONCHOCONSTRICTION; 5-LIPOXYGENASE INHIBITOR; DOUBLE-BLIND; INHALED CORTICOSTEROIDS; FLUTICASONE PROPIONATE; AIRWAY RESPONSIVENESS; BRONCHIAL BIOPSIES; CONTROLLED-TRIAL; C-4 SYNTHASE	Cysteinyl leukotrienes are important mediators of asthmatic responses. They are the most potent bronchoconstrictors known; their release is triggered by exposure to inhaled allergens after exercise and after aspirin ingestion by subjects with aspirin-sensitive asthma. The cysteinyl leukotrienes promote inflammatory cell migration into the airways, as well as bone marrow eosinophilopoiesis after allergen inhalation. Leukotriene inhibitors are effective at attenuating asthmatic responses to all of these stimuli and are also effective at treating persistent asthma. These drugs are a viable alternative to low-dose inhaled corticosteroid (ICS) treatment but should be reserved for patients who cannot or will not use ICSs, often because of concerns about potential side effects of ICS treatment, which limits their use, particularly in children. Leukotriene receptor antagonists are also alternatives to long-acting inhaled beta(2)-agonists as add-on therapy to ICSs, but their efficacy together with ICSs is less than that of ICS/long-acting inhaled beta(2)-agonist combinations. Leukotriene receptor antagonists have an excellent safety profile. (J Allergy Clin Immunol 2009; 124: 397-403.)	[O'Byrne, Paul M.] McMaster Univ, Firestone Inst Resp Hlth, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Med, Hamilton, ON L8N 3Z5, Canada	McMaster University; McMaster University	O'Byrne, PM (corresponding author), McMaster Univ, Firestone Inst Resp Hlth, HSC 3W10,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	obyrnep@mcmaster.ca		O'Byrne, Paul/0000-0003-0979-281X	AstraZeneca; GlaxoSmithKline; Merck; Wyeth; Schering- Plough; Alexion	AstraZeneca(AstraZeneca); GlaxoSmithKline(GlaxoSmithKline); Merck(Merck & Company); Wyeth(Wyeth); Schering- Plough(Merck & CompanySchering Plough Corporation); Alexion	Disclosure of potential conflict of interest: P. M. O'Byrne is on advisory boards for AstraZeneca, GlaxoSmithKline, Topigen, Wyeth, and Schering-Plough; has received speakers' honoraria from AstraZeneca and GlaxoSmithKline; and has received research support from AstraZeneca, GlaxoSmithKline, Merck, Wyeth, Schering- Plough, and Alexion. The rest of the authors have declared that they have no conflict of interest.	Adelroth E, 1997, J ALLERGY CLIN IMMUN, V99, P210, DOI 10.1016/S0091-6749(97)70098-8; Anderson SD, 2000, J ALLERGY CLIN IMMUN, V106, P453, DOI 10.1067/mai.2000.109822; Austen KF, 2009, J ALLERGY CLIN IMMUN, V124, P406, DOI 10.1016/j.jaci.2009.05.046; Barnes NC, 1997, THORAX, V52, P523, DOI 10.1136/thx.52.6.523; Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707; Bleecker ER, 2000, J ALLERGY CLIN IMMUN, V105, P1123, DOI 10.1067/mai.2000.106043; Busse W, 2001, J ALLERGY CLIN IMMUN, V107, P461, DOI 10.1067/mai.2001.114657; Calhoun WJ, 1998, AM J RESP CRIT CARE, V157, P1381, DOI 10.1164/ajrccm.157.5.9609014; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; CHRISTIE PE, 1991, AM REV RESPIR DIS, V144, P957, DOI 10.1164/ajrccm/144.4.957; COHEN P, 1995, AM J PHYSIOL-LUNG C, V269, pL151, DOI 10.1152/ajplung.1995.269.2.L151; COLES SJ, 1983, PROSTAGLANDINS, V25, P155, DOI 10.1016/0090-6980(83)90101-6; Cowburn AS, 1998, J CLIN INVEST, V101, P834, DOI 10.1172/JCI620; DAHLEN B, 1993, EUR RESPIR J, V6, P1018; DAHLEN B, 1993, THORAX, V48, P1205, DOI 10.1136/thx.48.12.1205; Dahlen SE, 2002, AM J RESP CRIT CARE, V165, P9, DOI 10.1164/ajrccm.165.1.2010080; DAHLEN SE, 1980, NATURE, V288, P484, DOI 10.1038/288484a0; DAHLEN SE, 1981, P NATL ACAD SCI-BIOL, V78, P3887, DOI 10.1073/pnas.78.6.3887; Davis BE, 2009, EUR RESPIR J, V33, P1302, DOI 10.1183/09031936.00169008; DIAMANT Z, 1995, J ALLERGY CLIN IMMUN, V95, P42, DOI 10.1016/S0091-6749(95)70151-6; Edelman JM, 2000, ANN INTERN MED, V132, P97, DOI 10.7326/0003-4819-132-2-200001180-00002; Ferreira M B, 2001, Allerg Immunol (Paris), V33, P315; FINNERTY JP, 1992, AM REV RESPIR DIS, V145, P746, DOI 10.1164/ajrccm/145.4_Pt_1.746; GADDY JN, 1992, AM REV RESPIR DIS, V146, P358, DOI 10.1164/ajrccm/146.2.358; Gauvreau GM, 1999, AM J RESP CRIT CARE, V160, P640, DOI 10.1164/ajrccm.160.2.9809130; Gauvreau GM, 2001, AM J RESP CRIT CARE, V164, P1495, DOI 10.1164/ajrccm.164.8.2102033; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Hamilton A, 1998, J ALLERGY CLIN IMMUN, V102, P177, DOI 10.1016/S0091-6749(98)70083-1; Hamilton AL, 1997, THORAX, V52, P348, DOI 10.1136/thx.52.4.348; HAMMARSTROM S, 1980, BIOCHEM BIOPH RES CO, V92, P946, DOI 10.1016/0006-291X(80)90794-9; Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200; Hoshino M, 2001, CLIN EXP ALLERGY, V31, P722, DOI 10.1046/j.1365-2222.2001.01071.x; Israel E, 1996, JAMA-J AM MED ASSOC, V275, P931, DOI 10.1001/jama.275.12.931; ISRAEL E, 1990, NEW ENGL J MED, V323, P1740, DOI 10.1056/NEJM199012203232505; ISRAEL E, 1993, AM REV RESPIR DIS, V148, P1447, DOI 10.1164/ajrccm/148.6_Pt_1.1447; Johnston NW, 2007, PEDIATRICS, V120, pE702, DOI 10.1542/peds.2006-3317; JUNIPER EF, 1990, EUR RESPIR J, V3, P1122; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Kane GC, 1996, J ALLERGY CLIN IMMUN, V97, P646, DOI 10.1016/S0091-6749(96)70310-X; Kanniess F, 2002, EUR RESPIR J, V20, P853, DOI 10.1183/09031936.02.00244602; Kellaway CH, 1940, Q J EXP PHYSIOL CMS, V30, P121; KIKAWA Y, 1992, J ALLERGY CLIN IMMUN, V89, P1111, DOI 10.1016/0091-6749(92)90294-C; LAITINEN LA, 1992, J ALLERGY CLIN IMMUN, V90, P32, DOI 10.1016/S0091-6749(06)80008-4; LAITINEN LA, 1993, LANCET, V341, P989, DOI 10.1016/0140-6736(93)91073-U; LAM BK, 1992, P NATL ACAD SCI USA, V89, P11598, DOI 10.1073/pnas.89.23.11598; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; Leff JA, 1998, NEW ENGL J MED, V339, P147, DOI 10.1056/NEJM199807163390302; Leigh R, 2002, AM J RESP CRIT CARE, V166, P1212, DOI 10.1164/rccm.200206-509OC; Lynch KR, 1999, NATURE, V399, P789; Maekawa A, 2008, P NATL ACAD SCI USA, V105, P16695, DOI 10.1073/pnas.0808993105; MANNING PJ, 1990, NEW ENGL J MED, V323, P1736, DOI 10.1056/NEJM199012203232504; MANNING PJ, 1990, J ALLERGY CLIN IMMUN, V86, P211, DOI 10.1016/S0091-6749(05)80068-5; Masuda K, 1999, BIOCHEM J, V342, P79, DOI 10.1042/0264-6021:3420079; Meltzer SS, 1996, AM J RESP CRIT CARE, V153, P931, DOI 10.1164/ajrccm.153.3.8630575; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; NASSER SMS, 1994, THORAX, V49, P749, DOI 10.1136/thx.49.8.743; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Nelson HS, 2000, J ALLERGY CLIN IMMUN, V106, P1088, DOI 10.1067/mai.2000.110920; OBYRNE PM, 1987, AM REV RESPIR DIS, V136, P740, DOI 10.1164/ajrccm/136.3.740; Parameswaran K, 2004, AM J RESP CRIT CARE, V169, P915, DOI 10.1164/rccm.200312-1645OC; Parameswaran K, 2004, J ALLERGY CLIN IMMUN, V114, P73, DOI 10.1016/j.jaci.2004.03.054; RADMARK O, 1980, BIOCHEM BIOPH RES CO, V92, P954, DOI 10.1016/0006-291X(80)90795-0; Ram FS, 2005, COCHRANE DB SYST REV; RASMUSSEN JB, 1992, J ALLERGY CLIN IMMUN, V90, P193, DOI 10.1016/0091-6749(92)90071-9; Reiss TF, 1998, ARCH INTERN MED, V158, P1213, DOI 10.1001/archinte.158.11.1213; Reiss TF, 1997, THORAX, V52, P45, DOI 10.1136/thx.52.1.45; Sampson AP, 1997, INT ARCH ALLERGY IMM, V113, P355, DOI 10.1159/000237600; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SAMUELSSON B, 1980, PROSTAGLANDINS, V19, P645, DOI 10.1016/0090-6980(80)90099-4; SEARS MR, 1993, CLIN EXP ALLERGY, V23, P941, DOI 10.1111/j.1365-2222.1993.tb00279.x; SPECTOR SL, 1994, AM J RESP CRIT CARE, V150, P618, DOI 10.1164/ajrccm.150.3.8087328; Stevenson DD, 2006, J ALLERGY CLIN IMMUN, V118, P773, DOI 10.1016/j.jaci.2006.07.024; Szczeklik A, 1999, J ALLERGY CLIN IMMUN, V104, P5, DOI 10.1016/S0091-6749(99)70106-5; Szefler SJ, 2005, J ALLERGY CLIN IMMUN, V115, P233, DOI 10.1016/j.jaci.2004.11.014; TAYLOR IK, 1991, LANCET, V337, P690, DOI 10.1016/0140-6736(91)90277-V; TRIGG CJ, 1994, AM J RESP CRIT CARE, V150, P17, DOI 10.1164/ajrccm.150.1.8025745; Watkins PB, 2007, DRUG SAFETY, V30, P805, DOI 10.2165/00002018-200730090-00006; Wechsler ME, 1998, JAMA-J AM MED ASSOC, V279, P455, DOI 10.1001/jama.279.6.455; Wechsler ME, 2000, CHEST, V117, P708, DOI 10.1378/chest.117.3.708; WEISS JW, 1982, SCIENCE, V216, P196, DOI 10.1126/science.7063880; Yokomizo T, 2000, J EXP MED, V192, P421, DOI 10.1084/jem.192.3.421	82	21	21	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2009	124	3					397	405		10.1016/j.jaci.2009.05.029	http://dx.doi.org/10.1016/j.jaci.2009.05.029			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	552TG	19608262				2022-12-18	WOS:000274315900001
J	MacGlashan, D				MacGlashan, Donald, Jr.			Therapeutic efficacy of omalizumab	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						IgE; basophils; mast cells; asthma	FC-EPSILON-RI; EXPRESSION; BASOPHILS; IGE		Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine	MacGlashan, D (corresponding author), Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD 21224 USA.	dmacglas@jhmi.edu						Beck LA, 2004, J ALLERGY CLIN IMMUN, V114, P527, DOI 10.1016/j.jaci.2004.06.032; Erwin EA, 2007, J ALLERGY CLIN IMMUN, V119, P359, DOI 10.1016/j.jaci.2006.12.648; MACGLASHAN DW, 1993, J ALLERGY CLIN IMMUN, V91, P605, DOI 10.1016/0091-6749(93)90266-I; Saini SS, 2000, J ALLERGY CLIN IMMUN, V106, P514, DOI 10.1067/mai.2000.108431; Slavin RG, 2009, J ALLERGY CLIN IMMUN, V123, P107, DOI 10.1016/j.jaci.2008.09.050	5	21	21	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2009	123	1					114	115		10.1016/j.jaci.2008.10.053	http://dx.doi.org/10.1016/j.jaci.2008.10.053			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	399IP	19130932				2022-12-18	WOS:000262793900018
J	Notarangelo, LD; Sorensen, R				Notarangelo, Luigi D.; Sorensen, Ricardo			Is it necessary to identify molecular defects in primary immunodeficiency disease?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Primary immunodeficiency; mutation analysis; gene; prenatal diagnosis; carrier detection	MUTATIONS	The identification or the molecular bases of more than 130 primary immunodeficiency diseases has prompted the use of mutation analysis in the diagnostic approach to these patients. Here we discuss the importance of and the limitations associated with molecular diagnosis of these disorders and emphasize the need that mutation analysis be accompanied by appropriate evidence that the identified genetic defect has pathologic consequences on RNA/protein expression and function. U Allergy Clin Immunol 2008;122:1069-73.)	[Sorensen, Ricardo] Childrens Hosp, LSU Hlth Sci Ctr, Dept Pediat, New Orleans, LA 70118 USA; [Notarangelo, Luigi D.] Harvard Univ, Childrens Hosp, Sch Med, Div Immunol, Boston, MA 02115 USA	Children's Hospital of New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Harvard University; Boston Children's Hospital; Harvard Medical School	Sorensen, R (corresponding author), Childrens Hosp, LSU Hlth Sci Ctr, Dept Pediat, RIC Bldg,Room 4229,200 Henry Clay Ave, New Orleans, LA 70118 USA.	Rsoren@lsuhsc.edu	Notarangelo, Luigi D/F-9718-2016	Notarangelo, Luigi D/0000-0002-8335-0262				Bashyam H, 2007, J EXP MED, V204, P2245, DOI 10.1084/jem.20071995; Brugnoni D, 1996, IMMUNOL LETT, V52, P61; BRUGNONI D, 1996, J IMMUNOL LETT, V49, P27; Conley ME, 1999, CLIN IMMUNOL, V93, P190, DOI 10.1006/clim.1999.4799; Fleisher TA, 2008, CLIN IMMUNOL, V128, P285, DOI 10.1016/j.clim.2008.04.013; Gaspar HB, 2002, BRIT J HAEMATOL, V119, P585, DOI 10.1046/j.1365-2141.2002.03851.x; Geha RS, 2007, J ALLERGY CLIN IMMUN, V120, P776, DOI 10.1016/j.jaci.2007.08.053; Hacein-Bey-Abina S, 2008, J CLIN INVEST, V118, P3132, DOI 10.1172/JCI35700; Hachwell E, 2007, TRENDS GENET, V23, P588, DOI 10.1016/j.tig.2007.08.010; Holliday R, 2006, EPIGENETICS-US, V1, P76, DOI 10.4161/epi.1.2.2762; Jin YZ, 2004, BLOOD, V104, P4010, DOI 10.1182/blood-2003-05-1592; JORDAN MB, 2008, BONE MARROW TRANSPLA; KINNON C, 2002, MANUAL CLIN LAB IMMU, P810; Lebet T, 2008, GENET MED, V10, P575, DOI [10.1097/GIM.0b013e31818063bc, 10.1097GIM.0b013e31818063bc]; Matthijs G, 2004, BRIT MED J, V329, P1358, DOI 10.1136/bmj.329.7479.1358; OLIVEIRA JB, 2008, CURR OPIN A IN PRESS; Pan-Hammarstrom Q, 2007, NAT GENET, V39, P429, DOI 10.1038/ng0407-429; Schuetz C, 2008, NEW ENGL J MED, V358, P2030, DOI 10.1056/NEJMoa073966; Villa A, 2008, CURR OPIN IMMUNOL, V20, P318, DOI 10.1016/j.coi.2008.02.001	19	21	23	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2008	122	6					1069	1073		10.1016/j.jaci.2008.08.038	http://dx.doi.org/10.1016/j.jaci.2008.08.038			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	383ZA	18992927	Bronze			2022-12-18	WOS:000261711800004
J	Jun, SW; Kim, TH; Lee, HM; Lee, SH; Kim, WJ; Park, SJ; Kim, YS; Lee, SH				Jun, Sung Whan; Kim, Tae Hoon; Lee, Heung Man; Lee, Seung Hoon; Kim, Woo Joo; Park, Se Jin; Kim, Yang Soo; Lee, Sang Hag			Overexpression of the anaphylatoxin receptors, complement anaphylatoxin 3a receptor and complement anaphylatoxin 5a receptor, in the nasal mucosa of patients with mild and severe persistent allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						C3aR; C5aR; normal nasal mucosa; allergic nasal mucosa	C3A RECEPTOR; C5A ANAPHYLATOXIN; INFERIOR TURBINATE; EXPRESSION; ACTIVATION; ASTHMA; CELLS; INFECTION; RESPONSES; PROTEINS	Background: Although the complement anaphylatoxin peptides, complement anaphylatoxin 3a (C3a) and complement anaphylatoxin 5a (C5a), are implicated in the inflammatory process in allergic rhinitis, a direct interaction between allergic mucosa and complement receptors has not been demonstrated. Objective: We investigated the expressional levels and distributional patterns of the C3a receptor (C3aR) and C5a receptor (C5aR) in normal, mild, and severe persistent allergic nasal mucosa. Methods: Immunohistochemistry and Western blotting using C3aR and C5aR antibodies were applied to normal nasal, mild, and severe persistent allergic nasal mucosa. Results: Complement anaphylatoxin 5a receptor was detected in the inflammatory cells of normal and allergic nasal mucosa, and its expression level was significantly higher in allergic nasal mucosa than normal nasal mucosa. C3aR in normal and allergic nasal mucosa was commonly expressed in nonmyeloid cells such as epithelial cells, submucosal glands, and nerve fibers. In addition, C3aR was expressed in the endothelium of cavernous sinuses and the surrounding perivascular muscle layer in severe persistent allergic nasal mucosa, but not in normal and mild allergic nasal mucosa. Western blotting demonstrated that the expression level of C3aR was significantly increased in severe persistent allergic nasal mucosa compared with normal and mild nasal mucosa. Conclusion: On the basis of the location of C3aR and C5aR, C5aR may play a role inactivation of inflammatory cells, whereas C3aR may mediate mucus secretion and mucosal swelling in allergic nasal mucosa, especially severe persistent allergic nasal mucosa.	[Jun, Sung Whan] Natl Med Ctr, Dept Otorhinolaryngol Head & Neck Surg, Seoul, South Korea; [Kim, Tae Hoon; Lee, Heung Man; Lee, Seung Hoon; Kim, Woo Joo; Park, Se Jin; Kim, Yang Soo; Lee, Sang Hag] Korea Univ, Dept Otorhinolaryngol Head & Neck Surg, Coll Med, Seoul 136705, South Korea	National Medical Center - Korea; Korea University; Korea University Medicine (KU Medicine)	Lee, SH (corresponding author), Korea Univ, Dept Otorhinolaryngol Head & Neck Surg, Coll Med, 126-1 5 Ka,Anam Dong, Seoul 136705, South Korea.	sanghag@kumc.or.kr	LEE, Seung Hoon/GLN-6169-2022; Kim, Woo Joo/D-2733-2015	Kim, Woo Joo/0000-0002-4546-3880				Abe K, 2001, KIDNEY INT, V60, P137, DOI 10.1046/j.1523-1755.2001.00780.x; Ames RS, 1996, J BIOL CHEM, V271, P20231, DOI 10.1074/jbc.271.34.20231; ANDERSSON M, 1994, ALLERGY, V49, P242, DOI 10.1111/j.1398-9995.1994.tb02656.x; BELL DY, 1981, AM REV RESPIR DIS, V124, P72; Berger G, 2006, ARCH OTOLARYNGOL, V132, P588, DOI 10.1001/archotol.132.6.588; Berger G, 2007, ARCH OTOLARYNGOL, V133, P78, DOI 10.1001/archotol.133.1.78; BJORNSON AB, 1991, AM REV RESPIR DIS, V143, P1062, DOI 10.1164/ajrccm/143.5_Pt_1.1062; Braun MC, 2004, J IMMUNOL, V173, P4190, DOI 10.4049/jimmunol.173.6.4190; Chiba Y, 2006, AM J RHINOL, V20, P477, DOI 10.2500/ajr.2006.20.2875; Drouin SM, 2001, J IMMUNOL, V166, P2025, DOI 10.4049/jimmunol.166.3.2025; Fregonese L, 2005, J ALLERGY CLIN IMMUN, V115, P1148, DOI 10.1016/j.jaci.2005.01.068; Frieri M, 2005, ALLERGY ASTHMA PROC, V26, P163; GASQUE P, 1995, J IMMUNOL, V155, P4882; GERARD NP, 1989, J BIOL CHEM, V264, P1760; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; HAVILAND DL, 1995, J IMMUNOL, V154, P1861; Hidvegi T, 1995, IMMUNOL LETT, V48, P65, DOI 10.1016/0165-2478(95)02445-X; Huang TW, 2006, ARCH OTOLARYNGOL, V132, P990, DOI 10.1001/archotol.132.9.990; Ikeda K, 2006, ACTA OTO-LARYNGOL, V126, P739, DOI 10.1080/00016480500472853; KEW RR, 1985, J CLIN INVEST, V75, P1000, DOI 10.1172/JCI111760; KRETZSCHMAR T, 1993, EUR J IMMUNOL, V23, P558, DOI 10.1002/eji.1830230239; MAROM Z, 1985, J EXP MED, V161, P657, DOI 10.1084/jem.161.4.657; Martin U, 1997, J EXP MED, V186, P199, DOI 10.1084/jem.186.2.199; Mezei G, 2001, PEDIAT ALLERG IMM-UK, V12, P201, DOI 10.1034/j.1399-3038.2001.012004201.x; MORGAN BP, 1989, COMPLEMENT INFLAMMAT, V6, P104, DOI 10.1159/000463082; MULLEREBERHARD HJ, 1988, ANNU REV BIOCHEM, V57, P321, DOI 10.1146/annurev.biochem.57.1.321; Neumann E, 2002, ARTHRITIS RHEUM, V46, P934, DOI 10.1002/art.10183; Onuma H, 2002, RHEUMATOL INT, V22, P52, DOI 10.1007/s00296-002-0199-6; PANGBURN MK, 1988, CYTOLYTIC LYMPHOCYTE, P42; Tosi MF, 2005, J ALLERGY CLIN IMMUN, V116, P241, DOI 10.1016/j.jaci.2005.05.036; VANDEGRAAF EA, 1992, J IMMUNOL METHODS, V147, P241, DOI 10.1016/S0022-1759(12)80014-7; Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406; Zwirner J, 1999, IMMUNOLOGY, V97, P166	33	21	22	1	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2008	122	1					119	125		10.1016/j.jaci.2008.04.028	http://dx.doi.org/10.1016/j.jaci.2008.04.028			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	325RD	18538384	Bronze			2022-12-18	WOS:000257605100020
J	Koplin, J; Dharmage, SC; Gurrin, L; Osborne, N; Tang, MLK; Lowe, AJ; Hosking, C; Hill, D; Allen, KJ				Koplin, Jennifer; Dharmage, Shyamali C.; Gurrin, Lyle; Osborne, Nicholas; Tang, Mimi L. K.; Lowe, Adrian J.; Hosking, Cliff; Hill, David; Allen, Katrina J.			Soy consumption is not a risk factor for peanut sensitization	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						skin prick test; peanut allergy; soy formula; soy milk; risk factors; sensitization	ATOPIC-DERMATITIS; FOOD ALLERGY; PREVALENCE; CHILDREN; INFANCY; MILK	Background: A recent cohort study suggested that intake of soy milk or soy formula was associated with peanut allergy. If this finding is confirmed, it suggests an avenue for modification of diet as a peanut allergy prevention strategy. Objective: To investigate the relationship between soy consumption and peanut sensitization in a prospective cohort study of children. Methods: A total of 620 babies with a family history of allergic disease were recruited. Dietary information was obtained from telephone interviews every 4 weeks from birth until 15 months and then again at 18 months and 2 years. Skin prick tests to peanut, milk, and egg were performed at 6, 12, and 24 months. A wheal size >= 3 mm was considered positive for sensitization. Results: Children whose parents elected to introduce soy formula or soy milk into their children's diet were more likely to be sensitized to peanuts at 2 years (odds ratio, 2.02; 95% CI, 1.04-3.92; P=.039). However, this relationship was explained by feeding of soy to children who had siblings with milk allergy or were themselves sensitized to milk. After adjusting for these factors, there was no evidence of an association between soy consumption and peanut sensitization (odds ratio, 1.34; 95% CI, 0.64-2.79; P=.434). Conclusion: The association between soy consumption and peanut sensitization is not causal but merely a result of preferential use of soy milk in infants with a personal or family history of cow's milk allergy. Future studies should take the confounding effects related to dietary modifications by parents into account when investigating the association between diet and childhood allergic diseases.	[Dharmage, Shyamali C.] Univ Melbourne, Fac Med Dent & Hlth Sci, Sch Populat Hlth, Ctr Mol Environm Genet & Analyt Epidemiol, Melbourne, Vic 3053, Australia; [Koplin, Jennifer; Osborne, Nicholas; Tang, Mimi L. K.; Hill, David; Allen, Katrina J.] Murdoch Childrens Res Inst, Murdoch, WA, Australia; [Koplin, Jennifer; Osborne, Nicholas; Tang, Mimi L. K.; Allen, Katrina J.] Univ Melbourne, Dept Pediat, Melbourne, Vic 3053, Australia; [Tang, Mimi L. K.; Allen, Katrina J.] Royal Childrens Hosp, Dept Allergy & Immunol, Melbourne, Vic, Australia; [Hosking, Cliff] John Hunter Childrens Hosp, Newcastle, NSW, Australia	University of Melbourne; Murdoch Children's Research Institute; University of Melbourne; Royal Children's Hospital Melbourne	Dharmage, SC (corresponding author), Univ Melbourne, Fac Med Dent & Hlth Sci, Sch Populat Hlth, Ctr Mol Environm Genet & Analyt Epidemiol, Melbourne, Vic 3053, Australia.	s.dharmage@unimelb.edu.au	Osborne, Nicholas/D-2086-2011; Tang, Mimi/ABD-8350-2020; Allen, Katrina/I-4361-2018	Osborne, Nicholas/0000-0002-6700-2284; Tang, Mimi/0000-0002-3839-5293; Allen, Katrina/0000-0002-1921-4493; Lowe, Adrian/0000-0002-4691-8162; Gurrin, Lyle/0000-0001-7052-1969; Koplin, Jennifer/0000-0002-7576-5142				Grundy J, 2002, J ALLERGY CLIN IMMUN, V110, P784, DOI 10.1067/mai.2002.128802; Hill DJ, 2000, J PEDIATR-US, V137, P475, DOI 10.1067/mpd.2000.108207; Hill DJ, 2004, PEDIAT ALLERG IMM-UK, V15, P421, DOI 10.1111/j.1399-3038.2004.00178.x; Khakoo GA, 2004, ARCH DIS CHILD, V89, P295, DOI 10.1136/adc.2003.039016; Klemola T, 2005, PEDIAT ALLERG IMM-UK, V16, P641, DOI 10.1111/j.1399-3038.2005.00326.x; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; Lowe AJ, 2006, J ALLERGY CLIN IMMUN, V117, P682, DOI 10.1016/j.jaci.2005.10.027; Sicherer SH, 2007, J ALLERGY CLIN IMMUN, V120, P491, DOI 10.1016/j.jaci.2007.07.015; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8; Sporik R, 2000, CLIN EXP ALLERGY, V30, P1540, DOI 10.1046/j.1365-2222.2000.00928.x; van Wijk F, 2007, BIOMED PHARMACOTHER, V61, P8, DOI 10.1016/j.biopha.2006.11.003; Venter C, 2006, J ALLERGY CLIN IMMUN, V117, P1118, DOI 10.1016/j.jaci.2005.12.1352	12	21	35	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2008	121	6					1455	1459		10.1016/j.jaci.2008.03.017	http://dx.doi.org/10.1016/j.jaci.2008.03.017			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	313WW	18436294	Bronze			2022-12-18	WOS:000256771700023
J	Sicherer, SH; Leung, DYM				Sicherer, Scott H.; Leung, Donald Y. M.			Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects in 2007	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						dermatology; skin disease; urticaria; atopic dermatitis; anaphylaxis; allergy; hypersensitivity disorders; food; drug; insect venom	PLACEBO-CONTROLLED TRIAL; STEVENS-JOHNSON-SYNDROME; COWS MILK ALLERGY; ATOPIC-DERMATITIS; EOSINOPHILIC ESOPHAGITIS; DOUBLE-BLIND; SUBLINGUAL IMMUNOTHERAPY; HEREDITARY ANGIOEDEMA; CHRONIC URTICARIA; NATURAL-HISTORY	This review highlights some of the research advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects that were reported primarily in the journal in 2007. Advances in diagnosis include possible biomarkers for anaphylaxis, improved understanding of the relevance of food-specific serum IgE tests, identification of possibly discriminatory T-cell responses for drug allergy, and an elucidation of irritant responses for vaccine allergy diagnostic skin tests. Mechanistic studies are discerning T-cell and cytokine responses central to eosinophilic gastroenteropathies and food allergy, including the identification of multiple potential therapeutic targets. Regarding treatment, clinical studies of oral immunotherapy and allergen vaccination strategies show promise, whereas several clinical studies raise questions about whether oral allergen avoidance reduces atopic risks and whether probiotics can prevent or treat atopic disease. The importance of skin barrier dysfunction has been highlighted in the pathogenesis of atopic dermatitis (AD), particularly as it relates to allergen sensitization and eczema severity. Research has also continued to identify immunologic defects that contribute to the propensity of patients with AD to have viral and bacterial infections. New therapeutic approaches to AD, urticaria, and angioedema have been reported, including use of sublingual immunotherapy, anti-IgE, and a kallikrein inhibitor.	[Sicherer, Scott H.] Mt Sinai Sch Med, Dept Pediat, Div Allergy & Immunol, Elliot & Rosyln Jaffe Food Allergy Inst, New York, NY USA; [Leung, Donald Y. M.] Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA; [Leung, Donald Y. M.] Natl Jewish Med & Res Ctr, Div Pediat Allergy Immunol, Denver, CO USA	Icahn School of Medicine at Mount Sinai; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Jewish Health	Sicherer, SH (corresponding author), Mt Sinai Hosp, Div Allergy Immunol, Box 1198,1 Gustave L Levy Pl, New York, NY 10029 USA.	scott.sicherer@mssm.edu						Abrahamsson TR, 2007, J ALLERGY CLIN IMMUN, V119, P1174, DOI 10.1016/j.jaci.2007.01.007; Aceves SS, 2007, J ALLERGY CLIN IMMUN, V119, P206, DOI 10.1016/j.jaci.2006.10.016; Ando T, 2007, J ALLERGY CLIN IMMUN, V120, P916, DOI 10.1016/j.jaci.2007.05.023; Arshad SH, 2007, J ALLERGY CLIN IMMUN, V119, P307, DOI 10.1016/j.jaci.2006.12.621; Asero R, 2006, J ALLERGY CLIN IMMUN, V117, P1113, DOI 10.1016/j.jaci.2005.12.1343; Asero R, 2007, J ALLERGY CLIN IMMUN, V119, P705, DOI 10.1016/j.jaci.2006.08.043; Assa'ad AH, 2007, J ALLERGY CLIN IMMUN, V119, P731, DOI 10.1016/j.jaci.2006.10.044; Bae JS, 2007, J ALLERGY CLIN IMMUN, V119, P449, DOI 10.1016/j.jaci.2006.10.006; Ballmer-Weber BK, 2007, J ALLERGY CLIN IMMUN, V119, P1489, DOI 10.1016/j.jaci.2007.01.049; Baurecht H, 2007, J ALLERGY CLIN IMMUN, V120, P1406, DOI 10.1016/j.jaci.2007.08.067; Belloni B, 2007, J ALLERGY CLIN IMMUN, V120, P1223, DOI 10.1016/j.jaci.2007.08.060; Blanchard C, 2007, J ALLERGY CLIN IMMUN, V120, P1292, DOI 10.1016/j.jaci.2007.10.024; Bock SA, 2007, J ALLERGY CLIN IMMUN, V119, P1016, DOI 10.1016/j.jaci.2006.12.622; Bork K, 2007, J ALLERGY CLIN IMMUN, V119, P1497, DOI 10.1016/j.jaci.2007.02.012; Buchanan AD, 2007, J ALLERGY CLIN IMMUN, V119, P199, DOI 10.1016/j.jaci.2006.09.016; Camargo CA, 2007, J ALLERGY CLIN IMMUN, V120, P131, DOI 10.1016/j.jaci.2007.03.049; Carter MC, 2007, J ALLERGY CLIN IMMUN, V119, P1550, DOI 10.1016/j.jaci.2007.03.032; Chan-Yeung M, 2007, J ALLERGY CLIN IMMUN, V120, P1221, DOI 10.1016/j.jaci.2007.08.025; Cork MJ, 2006, J ALLERGY CLIN IMMUN, V118, P3, DOI 10.1016/j.jaci.2006.04.042; Cox L, 2007, J ALLERGY CLIN IMMUN, V120, P1373, DOI 10.1016/j.jaci.2007.09.032; Dean T, 2007, J ALLERGY CLIN IMMUN, V120, P1166, DOI 10.1016/j.jaci.2007.06.042; Dunford PJ, 2007, J ALLERGY CLIN IMMUN, V119, P176, DOI 10.1016/j.jaci.2006.08.034; Finkelman FD, 2007, J ALLERGY CLIN IMMUN, V120, P506, DOI 10.1016/j.jaci.2007.07.033; Foroughi S, 2007, J ALLERGY CLIN IMMUN, V120, P594, DOI 10.1016/j.jaci.2007.06.015; Frossard CP, 2007, J ALLERGY CLIN IMMUN, V119, P952, DOI 10.1016/j.jaci.2006.12.615; Furuta GT, 2007, GASTROENTEROLOGY, V133, P1342, DOI 10.1053/j.gastro.2007.08.017; Garvey LH, 2007, J ALLERGY CLIN IMMUN, V120, P409, DOI 10.1016/j.jaci.2007.04.029; Gober LM, 2007, J ALLERGY CLIN IMMUN, V119, P1181, DOI 10.1016/j.jaci.2007.01.008; Greenberger PA, 2007, J ALLERGY CLIN IMMUN, V120, P1466, DOI 10.1016/j.jaci.2007.08.055; Greer FR, 2008, PEDIATRICS, V121, P183, DOI 10.1542/peds.2007-3022; Guttman-Yassky E, 2007, J ALLERGY CLIN IMMUN, V119, P1210, DOI 10.1016/j.jaci.2007.03.006; Hare ND, 2007, J ALLERGY CLIN IMMUN, V120, P716, DOI 10.1016/j.jaci.2007.06.008; Hefle SL, 2007, J ALLERGY CLIN IMMUN, V120, P171, DOI 10.1016/j.jaci.2007.04.013; Hourihane JO, 2007, J ALLERGY CLIN IMMUN, V119, P1197, DOI 10.1016/j.jaci.2006.12.670; Howell MD, 2007, J ALLERGY CLIN IMMUN, V120, P150, DOI 10.1016/j.jaci.2007.04.031; Howell MD, 2007, J ALLERGY CLIN IMMUN, V119, P1022, DOI 10.1016/j.jaci.2007.01.044; Jenkins JA, 2007, J ALLERGY CLIN IMMUN, V120, P1399, DOI 10.1016/j.jaci.2007.08.019; Kalliomaki M, 2007, J ALLERGY CLIN IMMUN, V119, P1019, DOI 10.1016/j.jaci.2006.12.608; Kim BE, 2007, J ALLERGY CLIN IMMUN, V119, P457, DOI 10.1016/j.jaci.2006.10.005; Kinaciyan T, 2007, J ALLERGY CLIN IMMUN, V119, P937, DOI 10.1016/j.jaci.2006.11.010; Komata T, 2007, J ALLERGY CLIN IMMUN, V119, P1272, DOI 10.1016/j.jaci.2007.01.038; Kukkonen K, 2007, J ALLERGY CLIN IMMUN, V119, P192, DOI 10.1016/j.jaci.2006.09.009; Lee TTT, 2007, J ALLERGY CLIN IMMUN, V119, P746, DOI 10.1016/j.jaci.2006.11.011; Leguy-Seguin V, 2007, J ALLERGY CLIN IMMUN, V119, P726, DOI 10.1016/j.jaci.2006.11.640; Lerch M, 2007, J ALLERGY CLIN IMMUN, V119, P1529, DOI 10.1016/j.jaci.2007.02.007; Li XM, 2007, J ALLERGY CLIN IMMUN, V120, P25, DOI 10.1016/j.jaci.2007.04.030; Liem JJ, 2007, J ALLERGY CLIN IMMUN, V119, P1203, DOI 10.1016/j.jaci.2006.12.671; Limb SL, 2007, J ALLERGY CLIN IMMUN, V120, P1378, DOI 10.1016/j.jaci.2007.09.022; Magerl M, 2007, J ALLERGY CLIN IMMUN, V119, P752, DOI 10.1016/j.jaci.2006.12.658; Marenholz I, 2006, J ALLERGY CLIN IMMUN, V118, P866, DOI 10.1016/j.jaci.2006.07.026; Matheson MC, 2007, J ALLERGY CLIN IMMUN, V120, P1051, DOI 10.1016/j.jaci.2007.06.030; McGirt LY, 2006, J ALLERGY CLIN IMMUN, V118, P202, DOI 10.1016/j.jaci.2006.04.033; Meller S, 2007, J ALLERGY CLIN IMMUN, V119, P1470, DOI 10.1016/j.jaci.2006.12.654; Niederberger V, 2007, J ALLERGY CLIN IMMUN, V119, P1013, DOI 10.1016/j.jaci.2006.12.661; Nomura T, 2007, J ALLERGY CLIN IMMUN, V119, P434, DOI 10.1016/j.jaci.2006.12.646; Pajno GB, 2007, J ALLERGY CLIN IMMUN, V120, P164, DOI 10.1016/j.jaci.2007.04.008; Palmer CNA, 2007, J ALLERGY CLIN IMMUN, V120, P64, DOI 10.1016/j.jaci.2007.04.001; Palomares O, 2007, J ALLERGY CLIN IMMUN, V119, P1189, DOI 10.1016/j.jaci.2007.01.027; Peeters KABM, 2007, J ALLERGY CLIN IMMUN, V120, P647, DOI 10.1016/j.jaci.2007.05.032; Pilette C, 2007, J ALLERGY CLIN IMMUN, V120, P972, DOI 10.1016/j.jaci.2007.06.038; Poulos LM, 2007, J ALLERGY CLIN IMMUN, V120, P878, DOI 10.1016/j.jaci.2007.07.040; Prescott SL, 2007, J ALLERGY CLIN IMMUN, V120, P255, DOI 10.1016/j.jaci.2007.04.027; Prieto A, 2007, J ALLERGY CLIN IMMUN, V119, P960, DOI 10.1016/j.jaci.2006.12.616; Pumphrey RSH, 2007, J ALLERGY CLIN IMMUN, V119, P1018, DOI 10.1016/j.jaci.2007.01.021; Radauer C, 2007, J ALLERGY CLIN IMMUN, V120, P518, DOI 10.1016/j.jaci.2007.07.024; Reefer AJ, 2007, J ALLERGY CLIN IMMUN, V120, P156, DOI 10.1016/j.jaci.2007.03.042; Reese G, 2007, J ALLERGY CLIN IMMUN, V119, P944, DOI 10.1016/j.jaci.2006.11.699; Rogers AJ, 2007, J ALLERGY CLIN IMMUN, V120, P1332, DOI 10.1016/j.jaci.2007.09.037; Rona RJ, 2007, J ALLERGY CLIN IMMUN, V120, P638, DOI 10.1016/j.jaci.2007.05.026; Rowe J, 2007, J ALLERGY CLIN IMMUN, V119, P1164, DOI 10.1016/j.jaci.2007.02.016; Salt BH, 2007, J ALLERGY CLIN IMMUN, V119, P508, DOI 10.1016/j.jaci.2006.11.006; Sands MF, 2007, J ALLERGY CLIN IMMUN, V120, P979, DOI 10.1016/j.jaci.2007.07.041; Savage JH, 2007, J ALLERGY CLIN IMMUN, V120, P1413, DOI 10.1016/j.jaci.2007.09.040; Savage JH, 2007, J ALLERGY CLIN IMMUN, V120, P717, DOI 10.1016/j.jaci.2007.07.027; Schmitt J, 2007, J ALLERGY CLIN IMMUN, V120, P1389, DOI 10.1016/j.jaci.2007.08.011; Schneider L, 2007, J ALLERGY CLIN IMMUN, V120, P416, DOI 10.1016/j.jaci.2007.04.028; Scott JE, 2007, J ALLERGY CLIN IMMUN, V120, P1382, DOI 10.1016/j.jaci.2007.08.004; Sicherer SH, 2007, J ALLERGY CLIN IMMUN, V120, P491, DOI 10.1016/j.jaci.2007.07.015; Sicherer SH, 2007, J ALLERGY CLIN IMMUN, V119, P1462, DOI 10.1016/j.jaci.2007.02.013; Simons FER, 2007, J ALLERGY CLIN IMMUN, V120, pS2, DOI [10.1016/j.jaci.2007.05.001, 10.1016/j.jaci.2007.05.016]; Simons FER, 2007, J ALLERGY CLIN IMMUN, V120, P537, DOI 10.1016/j.jaci.2007.06.025; Skripak JM, 2007, J ALLERGY CLIN IMMUN, V120, P1172, DOI 10.1016/j.jaci.2007.08.023; Sloane DE, 2007, J ALLERGY CLIN IMMUN, V120, P654, DOI 10.1016/j.jaci.2007.06.037; Spergel JM, 2007, J ALLERGY CLIN IMMUN, V119, P509, DOI 10.1016/j.jaci.2006.11.016; Staden U, 2007, ALLERGY, V62, P1261, DOI 10.1111/j.1398-9995.2007.01501.x; Taylor AL, 2007, J ALLERGY CLIN IMMUN, V119, P184, DOI 10.1016/j.jaci.2006.08.036; Ternblay JN, 2007, J ALLERGY CLIN IMMUN, V120, P659, DOI 10.1016/j.jaci.2007.04.044; Ueta M, 2007, J ALLERGY CLIN IMMUN, V120, P1457, DOI 10.1016/j.jaci.2007.07.048; Untersmayr E, 2007, J ALLERGY CLIN IMMUN, V119, P711, DOI 10.1016/j.jaci.2006.10.039; Vadas P, 2008, NEW ENGL J MED, V358, P28, DOI 10.1056/NEJMoa070030; Vierk KA, 2007, J ALLERGY CLIN IMMUN, V119, P1504, DOI 10.1016/j.jaci.2007.03.011; von Berg A, 2007, J ALLERGY CLIN IMMUN, V119, P718, DOI 10.1016/j.jaci.2006.11.017; Vonakis BM, 2007, J ALLERGY CLIN IMMUN, V119, P441, DOI 10.1016/j.jaci.2006.09.035; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P214, DOI 10.1016/j.jaci.2006.05.004; Wood RA, 2007, J ALLERGY CLIN IMMUN, V120, P478, DOI 10.1016/j.jaci.2007.04.035; Wu Y, 2007, J ALLERGY CLIN IMMUN, V119, P973, DOI 10.1016/j.jaci.2006.12.617; Yang CWO, 2007, J ALLERGY CLIN IMMUN, V120, P870, DOI 10.1016/j.jaci.2007.06.017; Ying S, 2006, J ALLERGY CLIN IMMUN, V118, P1386, DOI 10.1016/j.jaci.2006.08.030; Zhu FG, 2007, J ALLERGY CLIN IMMUN, V120, P631, DOI 10.1016/j.jaci.2007.05.015	99	21	22	1	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2008	121	6					1351	1358		10.1016/j.jaci.2008.01.032	http://dx.doi.org/10.1016/j.jaci.2008.01.032			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	313WW	18325575				2022-12-18	WOS:000256771700008
J	Tichenor, WS; Adinoff, A; Smart, B; Hamilos, DL				Tichenor, Wellington S.; Adinoff, Allen; Smart, Brian; Hamilos, Daniel L.			Nasal and sinus endoscopy for medical management of resistant rhinosinusitis, including postsurgical patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						sinusitis; rhinosinusitis; endoscopy; sinus; nasal; surgery; FESS; maxillary; ethmoid; culture	MIDDLE TURBINATE RESECTION; IMAGE-GUIDED SURGERY; ADENOID HYPERTROPHY; DIAGNOSIS; CULTURE; MICROBIOLOGY; ADULTS; AIRWAY; MUCUS; PCR	Nasal endoscopy has been practiced by allergists since the early 1980s; however, allergists in general have not embraced endoscopic evaluation of patients with sinus disease, either before or after surgery. Allergists are in a unique position to render medical (as opposed to surgical) care of patients with sinusitis. There has been a growing realization that endoscopy is a valuable procedure for the evaluation and medical treatment of patients with difficult sinusitis. This has resulted in the need for a resource to allow allergists to understand the nature of endoscopic findings in patients with sinusitis, either preoperatively or postoperatively. This article introduces the findings at endoscopy that are common in patients with sinusitis, including those that may be seen after surgery. The findings include perforation of the septum, retained secretions, small surgical ostium caused by postoperative ostial stenosis, previous Caldwell Luc procedure, recirculation of mucus, hyperplastic nasal disease, synechiae, recurrent disease in previously unaffected sinuses, empty nose syndrome, frontal sinus disease, dental disease, and other, more complicated entities.	[Tichenor, Wellington S.] Ctr Allergy Asthma & Sinusitis, New York, NY USA; [Tichenor, Wellington S.] New York Med Coll, Valhalla, NY 10595 USA; [Adinoff, Allen] Univ Colorado, Hlth Sci Ctr, Denver, CO USA; [Adinoff, Allen] Colorado Allergy & Asthma Ctr, Denver, CO USA; [Hamilos, Daniel L.] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Smart, Brian] DuPage Med Grp, Glen Ellyn, IL USA; [Hamilos, Daniel L.] Harvard Univ, Sch Med, Boston, MA USA	New York Medical College; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Tichenor, WS (corresponding author), 642 Pk Ave, New York, NY 10021 USA.	wtichenor@sinuses.com						ANAND VK, 1993, PRACTICAL ENDOSCOPIC, P87; ANON JB, 1996, ANATOMY PARANASAL SI, P18; Aukema Albertien A C, 2004, Treat Respir Med, V3, P97, DOI 10.2165/00151829-200403020-00004; BAKER HL, 1993, J NATL MED ASSOC, V85, P773; Benninger MS, 2002, OTOLARYNG HEAD NECK, V127, P7, DOI 10.1067/mhn.2002.124847; Bolger W., 2001, DIS SINUSES DIAGNOSI, P1; BOLGER W, 1994, SINUSITIS PATHOPHYSI, P107; Bolger WE, 1999, LARYNGOSCOPE, V109, P1852, DOI 10.1097/00005537-199911000-00025; Brook I, 2004, OTOLARYNG CLIN N AM, V37, P253, DOI 10.1016/S0030-6665(03)00155-5; Brook I, 1996, ARCH OTOLARYNGOL, V122, P418; Cassano P, 2003, INT J PEDIATR OTORHI, V67, P1303, DOI 10.1016/j.ijporl.2003.07.018; Catalano PJ, 2003, OTOLARYNG HEAD NECK, V128, P875, DOI 10.1016/S0194-5998(03)00469-8; CHOW J, 2002, CURR OPIN OTOLARYNGO, V10, P33; Cutler JL, 2003, LARYNGOSCOPE, V113, P2148, DOI 10.1097/00005537-200312000-00018; Dalziel K, 2004, HEALTH TECHNOL ASSES, V8, P1; DESAI SD, 1992, OTOLARYNG HEAD NECK, V107, P755, DOI 10.1177/019459988910700608.1; Desrosiers M, 2004, CURR ALLERGY ASTHM R, V4, P200, DOI 10.1007/s11882-004-0027-z; DRUCE HM, 1992, J ALLERGY CLIN IMMUN, V90, P436, DOI 10.1016/0091-6749(92)90165-X; Fischer Y, 2000, AM J RHINOL, V14, P355, DOI 10.2500/105065800779954257; GEORGITIS JW, 1993, J ALLERGY CLIN IMMUN, V91, P961, DOI 10.1016/0091-6749(93)90355-J; GILL V, 2000, PRINCIPLES PRACTICE, P184; Gold SM, 1997, LARYNGOSCOPE, V107, P1586, DOI 10.1097/00005537-199712000-00002; Hendolin PH, 2000, J CLIN MICROBIOL, V38, P4186, DOI 10.1128/JCM.38.11.4186-4192.2000; Hwang PH, 1999, OTOLARYNG HEAD NECK, V120, P678, DOI 10.1053/hn.1999.v120.a93047; Hytonen M, 2000, ACTA OTO-LARYNGOL, P154; Jiang RS, 2002, ANN OTO RHINOL LARYN, V111, P155, DOI 10.1177/000348940211100208; Kane KJ, 1997, AM J RHINOL, V11, P361, DOI 10.2500/105065897781286034; Kennedy D W, 1992, Laryngoscope, V102, P1; Kennedy DW, 1997, OTOLARYNG CLIN N AM, V30, P313; Kennedy DW, 1998, ARCH OTOLARYNGOL, V124, P107, DOI 10.1001/archotol.124.1.107; Kingdom TT, 2004, OTOLARYNG CLIN N AM, V37, P381, DOI 10.1016/S0030-6665(03)00158-0; Koele W, 2002, RHINOLOGY, V40, P1; Kopp W, 1991, FUNCTIONAL ENDOSCOPI; Kuhn FA, 2001, OTOLARYNG CLIN N AM, V34, P59, DOI 10.1016/S0030-6665(05)70295-4; Kulacz R, 2004, OPER TECHN OTOLARYNG, V15, P2; Lavigne F, 2000, J ALLERGY CLIN IMMUN, V105, P746, DOI 10.1067/mai.2000.105218; LEVINE HL, 1990, LARYNGOSCOPE, V100, P79; Lipworth BJ, 2000, THORAX, V55, P878, DOI 10.1136/thorax.55.10.878; LOFCHY N, 1998, OTOLARYNGOLOGY HEAD, P1173; Ludwick JJ, 2002, J COMPUT ASSIST TOMO, V26, P317, DOI 10.1097/00004728-200203000-00026; LUSK R, 1994, SINUSITIS PATHOPHYSI, P129; Messerklinger W., 1978, ENDOSCOPY NOSE; Moore EJ, 2001, AM J RHINOL, V15, P355, DOI 10.1177/194589240101500601; Orlandi RR, 2001, OTOLARYNG CLIN N AM, V34, P77, DOI 10.1016/S0030-6665(05)70296-6; OROBELLO PW, 1991, ARCH OTOLARYNGOL, V117, P980; Parsons DS, 1996, OTOLARYNG CLIN N AM, V29, P169; PFLEIDERER AG, 1987, J LARYNGOL OTOL, V101, P1035, DOI 10.1017/S0022215100103184; Polzehl D, 2005, J MED MICROBIOL, V54, P31, DOI 10.1099/jmm.0.45881-0; Ponikau JU, 2005, J ALLERGY CLIN IMMUN, V116, P362, DOI 10.1016/j.jaci.2005.03.049; POOLE MD, 1992, OTOLARYNGOL HEAD NEC, V107, P272; Price DL, 2003, ARCH OTOLARYNGOL, V129, P1236, DOI 10.1001/archotol.129.11.1236; Ramadan HH, 1999, LARYNGOSCOPE, V109, P27, DOI 10.1097/00005537-199901000-00006; Richtsmeier WJ, 2001, LARYNGOSCOPE, V111, P1952, DOI 10.1097/00005537-200111000-00015; Ridenour BD, 1998, OTOLARYNGOLOGY HEAD, P921; ROHR A, 1983, ANN ALLERGY, V50, P380; Romo T, 1999, PLAST RECONSTR SURG, V103, P66, DOI 10.1097/00006534-199901000-00012; Rosanowski F, 2001, LARYNGO RHINO OTOL, V80, P487, DOI 10.1055/s-2001-16430; Selivanova O, 2003, AM J RHINOL, V17, P197, DOI 10.1177/194589240301700404; SELNER JC, 1988, J ALLERGY CLIN IMMUN, V82, P909, DOI 10.1016/0091-6749(88)90033-4; SELNER JC, 1985, ANN ALLERGY, V54, P479; Senior BA, 1998, LARYNGOSCOPE, V108, P151, DOI 10.1097/00005537-199802000-00001; Setliff RC, 1997, OTOLARYNG CLIN N AM, V30, P341; SPRING P, 1958, ENT-EAR NOSE THROAT, V78, P362; STANKIEWICZ JA, 1989, OTOLARYNG CLIN N AM, V22, P749; SWANSON PB, 1995, AM J RHINOL, V9, P191, DOI 10.2500/105065895781873737; Taylor MJ, 2002, OTOLARYNG HEAD NECK, V127, P377, DOI 10.1067/mhn.2002.128896; TERRELL JE, 1998, OTOLARYNGOLOGY HEAD, P1145; Tuncer U, 2004, AM J OTOLARYNG, V25, P5, DOI 10.1016/j.amjoto.2003.10.003; Vogan JC, 2000, OTOLARYNG HEAD NECK, V122, P370, DOI 10.1016/S0194-5998(00)70051-9; WITTERICK K, 2004, IMMUNOL ALLERGY CLIN, P199	70	21	21	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2008	121	4					917	927		10.1016/j.jaci.2007.08.065	http://dx.doi.org/10.1016/j.jaci.2007.08.065			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	286YY	17981318	Bronze			2022-12-18	WOS:000254884000016
J	Horner, WE; Barnes, C; Codina, R; Levetin, E				Horner, W. Elliott; Barnes, Charles; Codina, Rosa; Levetin, Estelle			Guide for interpreting reports from inspections/investigations of indoor mold	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mold; testing; indoor air; investigation; inspection		Inspections and testing of indoor environments for mold growth increased dramatically in the past decade. Allergists can now be presented copies of reports and laboratory data and asked to provide an interpretation, although allergists are seldom trained to review environmental data. There is no single sampling method that is both specific for mold growth and robust enough to reliably detect mold growth. There is no standard method for these inspections or testing and no widely recognized credential for investigators, and therefore reports also vary in quality, objectives, and thoroughness. Despite these issues, observations from informed inspections coupled with results from qualified analyses of samples that are collected with a useful strategy can usually indicate whether mold growth is present in a building, but the nature of the report should be assessed before any interpretation of the results and data are attempted. This rostrum discusses objectives of inspections, describes qualifications for investigators, outlines the limitations of various sampling methods applicable to mold and to some degree endotoxin, and provides guidance for data interpretation.	[Horner, W. Elliott] Air Qual Sci, Atlanta, GA USA; [Barnes, Charles] Childrens Mercy Hosp, Kansas City, KS USA; [Levetin, Estelle] Univ Tulsa, Tulsa, OK 74104 USA	University of Tulsa	Horner, WE (corresponding author), Air Qual Sci, 2211 Newmarket Pkwy, Marietta, GA 30067 USA.	ehorner@aqs.com		Levetin, Estelle/0000-0002-2409-5142				*COMM DAMP IND SPA, 2004, DAMP IND SPAC HLTH; Cox-Ganser JM, 2005, ENVIRON HEALTH PERSP, V113, P485, DOI 10.1289/ehp.7559; Flannigan B, 2011, MICROORGANISMS IN HOME AND INDOOR WORK ENVIRONMENTS: DIVERSITY, HEALTH IMPACTS, INVESTIGATION AND CONTROL, 2ND EDITION; Green BJ, 2005, J ALLERGY CLIN IMMUN, V115, P1043, DOI 10.1016/j.jaci.2005.02.009; Horner WE, 2004, APPL ENVIRON MICROB, V70, P6394, DOI 10.1128/AEM.70.11.6394-6400.2004; Jaakkola JJK, 2005, ENVIRON HEALTH PERSP, V113, P357, DOI 10.1289/ehp.7242; Kendrick B., 2000, 5 KINGDOM; Levetin E., 2002, FUNGAL ALLERGY PATHO; Macher J., 1999, AM C GOV IND HYG; Miller JD, 2003, MED MYCOL, V41, P271, DOI 10.1080/1369378031000137350; Pasanen AL, 2001, INDOOR AIR, V11, P87, DOI 10.1034/j.1600-0668.2001.110203.x; Portnoy JM, 2004, J ALLERGY CLIN IMMUN, V113, P189, DOI 10.1016/j.jaci.2003.11.021; Rao CY, 1996, J AIR WASTE MANAGE, V46, P899, DOI 10.1080/10473289.1996.10467526; Sam Z, 2006, ENVIRON HEALTH PERSP, V114, P1099, DOI 10.1289/ehp.8854; *US EPA, 2001, 402K01001 EPA	15	21	24	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2008	121	3					592	597		10.1016/j.jaci.2007.11.020	http://dx.doi.org/10.1016/j.jaci.2007.11.020			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	273GR	18243284	Bronze			2022-12-18	WOS:000253918900006
J	Hulse, KE; Reefer, AJ; Engelhard, VH; Satinover, SM; Patrie, JT; Chapman, MD; Woodfolk, JA				Hulse, Kathryn E.; Reefer, Amanda J.; Engelhard, Victor H.; Satinover, Shama M.; Patrie, James T.; Chapman, Martin D.; Woodfolk, Judith A.			Targeting Fel d 1 to Fc gamma RI induces a novel variation of the T(H)2 response in subjects with cat allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CD64; IL-10; IL-5; IFN-gamma; H22-Fel d 1; dendritic cells; CD4(+) T cells; regulatory T cells; immunotherapy	MODIFIED TH2 RESPONSE; DENDRITIC CELLS; EFFICIENT PRESENTATION; REGULATORY CELLS; T-CELLS; ANTIGEN; IMMUNOTHERAPY; INDUCTION; IGE; PREVENTION	Background: Induction of CD4(+) T cells that produce IL-10 or IFN-gamma is central to the protective effects of conventional allergen immunotherapy. Objective: We examined the T-cell modulatory capacity of a fusion protein (H22-Fel d 1) that targets Fel d 1 to the high-affinity IgG receptor (Fc gamma RI) on antigen-presenting cells. Methods: Monocyte-derived dendritic cells pulsed with H22-Fel d 1 were analyzed for surface phenotype and cytokine secretion by flow cytometry and cytometric bead assay, respectively. CD4(+) T cells generated after coculture with H22-Fel d 1-pulsed dendritic cells were analyzed at the single-cell level by flow cytometry after intracellular cytokine staining. The T-cell repertoire was compared for subjects with (IgE(+)) and without cat allergy (IgE(neg)IgG(neg)), including subjects with a modified T(H)2 response (IgE(neg)IgG(+)). Results: H22-Fel d 1 induced a semimature phenotype in dendritic cells in conjunction with a selective increase in IL-5(+) and IL-10(+) CD4(+) T cells compared with nonreceptor-targeted Fel d 1. Amplified T cells included diverse subtypes characteristic of THO (IL-5(+)IFN-gamma(+)), regulatory T(H)1 (IL-10(+)IFN-gamma(+)) and regulatory T(H)2 (IL-10(+)IL-5(+)) cells. T-cell qualitative changes were restricted to subjects with allergy and were distinct from a modified T(H)2 response. Blocking IL-10 induced by H22-Fel d 1 selectively increased IL-5(+) CD4(+) T cells, suggesting that T(H)2 responses were controlled. Conclusion: Targeting Fel d 1 to Fc gamma RI induces a novel variation of the T(H)2 response that incorporates major elements of a protective T-cell response.	[Hulse, Kathryn E.; Reefer, Amanda J.; Satinover, Shama M.; Woodfolk, Judith A.] Univ Virginia Hlth Syst, Div Allergy, Asthma & Allerg Dis Ctr, Charlottesville, VA 22908 USA; [Engelhard, Victor H.] Univ Virginia Hlth Syst, Dept Microbiol, Charlottesville, VA 22908 USA; [Patrie, James T.] Univ Virginia Hlth Syst, Dept Hlth Evaluat Sci, Charlottesville, VA 22908 USA; [Chapman, Martin D.] Indoor Biotechnol Inc, Charlottesville, VA USA	University of Virginia; University of Virginia; University of Virginia; INDOOR Biotechnologies	Woodfolk, JA (corresponding author), Univ Virginia Hlth Syst, Div Allergy, Asthma & Allerg Dis Ctr, POB 801355, Charlottesville, VA 22908 USA.	jaw4m@virginia.edu		Engelhard, Victor/0000-0002-1741-0925; Chapman, Martin/0000-0002-0845-3632; Hulse, Kathryn/0000-0003-0969-999X	NIAID NIH HHS [R01AI-020565, U19AI 070364, R01AI-052196] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020565, R01AI052196, U19AI070364] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Akdis CA, 1998, EUR J IMMUNOL, V28, P914, DOI 10.1002/(SICI)1521-4141(199803)28:03<914::AID-IMMU914>3.0.CO;2-C; Akdis M, 2006, CHEM IMMUNOL ALLERGY, V91, P159; Erwin EA, 2005, J ALLERGY CLIN IMMUN, V115, P1029, DOI 10.1016/j.jaci.2004.12.1131; Francis JN, 2003, J ALLERGY CLIN IMMUN, V111, P1255, DOI 10.1067/mai.2003.1570; GOSSELIN EJ, 1992, J IMMUNOL, V149, P3477; Guyre PM, 1997, CANCER IMMUNOL IMMUN, V45, P146, DOI 10.1007/s002620050418; Hochreiter R, 2003, EUR J IMMUNOL, V33, P1667, DOI 10.1002/eji.200323377; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; Liu CL, 1996, J CLIN INVEST, V98, P2001, DOI 10.1172/JCI119004; Macaubas C, 2006, J IMMUNOL, V176, P5069, DOI 10.4049/jimmunol.176.8.5069; Meissner N, 1999, CLIN EXP ALLERGY, V29, P618; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Reefer AJ, 2004, J IMMUNOL, V172, P2763, DOI 10.4049/jimmunol.172.5.2763; ROWNTREE S, 1987, J ALLERGY CLIN IMMUN, V80, P622, DOI 10.1016/0091-6749(87)90017-0; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Stock P, 2004, NAT IMMUNOL, V5, P1149, DOI 10.1038/ni1122; Tighe H, 2000, J ALLERGY CLIN IMMUN, V106, P124, DOI 10.1067/mai.2000.107927; Vailes LD, 2002, J ALLERGY CLIN IMMUN, V110, P757, DOI 10.1067/mai.2002.129035; van Duivenvoorde LM, 2006, IMMUNOBIOLOGY, V211, P627, DOI 10.1016/j.imbio.2006.05.014; Wang YH, 2006, IMMUNITY, V24, P827, DOI 10.1016/j.immuni.2006.03.019; Woodfolk JA, 2001, J IMMUNOL, V167, P5412, DOI 10.4049/jimmunol.167.9.5412; Zhu DC, 2005, NAT MED, V11, P446, DOI 10.1038/nm1219	24	21	23	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2008	121	3					756	762		10.1016/j.jaci.2007.10.016	http://dx.doi.org/10.1016/j.jaci.2007.10.016			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	273GR	18086491				2022-12-18	WOS:000253918900034
J	Foley, SC; Prefontaine, D; Hamid, Q				Foley, Susan C.; Prefontaine, David; Hamid, Qutayba			Images in Allergy and Immunology - Role of eosinophils in airway remodeling	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							SEVERE ASTHMA; EXPRESSION; MATRIX-METALLOPROTEINASE-9; INFLAMMATION; DEPOSITION; FIBROSIS					qutayba.hamid@mcgill.ca						Aceves SS, 2007, J ALLERGY CLIN IMMUN, V119, P206, DOI 10.1016/j.jaci.2006.10.016; Flood-Page P, 2003, J CLIN INVEST, V112, P1029, DOI 10.1172/JCI200317974; Hoshino M, 1998, J ALLERGY CLIN IMMUN, V102, P783, DOI 10.1016/S0091-6749(98)70018-1; Leung SY, 2005, J ALLERGY CLIN IMMUN, V115, P989, DOI 10.1016/j.jaci.2005.01.036; Minshall E, 2000, J ALLERGY CLIN IMMUN, V105, P232, DOI 10.1016/S0091-6749(00)90070-8; Minshall EM, 1997, AM J RESP CELL MOL, V17, P326, DOI 10.1165/ajrcmb.17.3.2733; Phipps S, 2004, J INVEST DERMATOL, V122, P1406, DOI 10.1111/j.0022-202X.2004.22619.x; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001, DOI 10.1164/ajrccm.160.3.9812110; Wiehler S, 2004, BIOCHEM BIOPH RES CO, V315, P463, DOI 10.1016/j.bbrc.2004.01.078	9	21	23	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2007	119	6					1563	1566		10.1016/j.jaci.2007.03.040	http://dx.doi.org/10.1016/j.jaci.2007.03.040			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	178PO	17481718				2022-12-18	WOS:000247232800049
J	Giavina-Bianchi, P; Giavina-Bianchi, M; Agondi, R; Kalil, J				Giavina-Bianchi, Pedro; Giavina-Bianchi, Mara; Agondi, Rosana; Kalil, Jorge			Three months' administration of anti-IgE to a patient with Churg-Strauss syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ALLERGIC-ASTHMA; OMALIZUMAB		Univ Sao Paulo, Div Clin Immunol & Allergy, Sao Paulo, Brazil	Universidade de Sao Paulo	Giavina-Bianchi, P (corresponding author), Univ Sao Paulo, Div Clin Immunol & Allergy, Sao Paulo, Brazil.	saudesos@saudesos.com.br	Giavina-Bianchi, Pedro/I-3112-2014; KALIL, JORGE/C-8029-2012; Agondi, Rosana/AAV-7531-2021	Giavina-Bianchi, Pedro/0000-0002-1034-7580; KALIL, JORGE/0000-0001-8415-4274; 				Djukanovic R, 2004, AM J RESP CRIT CARE, V170, P583, DOI 10.1164/rccm.200312-1651OC; Humbert M, 2005, ALLERGY, V60, P309, DOI 10.1111/j.1398-9995.2004.00772.x; Keogh KA, 2006, SEMIN RESP CRIT CARE, V27, P148, DOI 10.1055/s-2006-939518; Noga O, 2003, INT ARCH ALLERGY IMM, V131, P46, DOI 10.1159/000070434; Noga O, 2006, J ALLERGY CLIN IMMUN, V117, P1493, DOI 10.1016/j.jaci.2006.02.028; Winchester DE, 2006, NEW ENGL J MED, V355, P1281	6	21	21	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2007	119	5					1279	1279		10.1016/j.jaci.2007.01.041	http://dx.doi.org/10.1016/j.jaci.2007.01.041			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	167CB	17349685				2022-12-18	WOS:000246427200038
J	Palomares, O; Vereda, A; Cuesta-Herranz, J; Vilialba, M; Rodriguez, R				Palomares, Oscar; Vereda, Andrea; Cuesta-Herranz, Javier; Vilialba, Mayte; Rodriguez, Rosalia			Cloning, sequencing, and recombinant production of Sin a 2, an allergenic 11S globulin from yellow mustard seeds	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mustard allergy; cupin superfamily; 11S globulin; Sin a 2; recombinant allergen; cross-reactivity	MAJOR ALLERGEN; CROSS-REACTIVITY; PEANUT ALLERGEN; 11S GLOBULIN; FOOD ALLERGY; PROTEINS; POLLEN; HYPERSENSITIVITY; IDENTIFICATION; ANAPHYLAXIS	Background: Among allergenic spices, mustard represents I of the most important in terms of allergenic potency and widespread use. An I IS globulin (Sin a 2) has been isolated from yellow mustard seeds and identified as a new major allergen. Objective: Cloning and sequencing a cDNA encoding a Sin a 2 subunit and producing the allergen as a recombinant protein. Methods: Sin a 2 subunit-encoding cDNA was amplified by polymerase chain reaction, cloned, and sequenced. The allergen was produced as a recombinant protein in Escherichia coli and used for enzyme-linked immunosorbent assay, immunoblotting, and inhibition experiments. Sera from patients with mustard allergy and an anti-polyhistidine monoclonal antibody were used. Results: Sin a 2-specific cDNA comprises an open reading frame that encodes a protein of 510 amino acids, in which the first 23 residues correspond to the signal peptide. Sequence alignment with other allergenic IIS globulins showed levels of sequence identity ranging between 27% and 38%. Three peptides described as epitopes in Ara h 3 were moderately conserved in Sin a 2. Approximately 87% of the IgE binding to natural Sin a 2 was inhibited by the recombinant allergen using sera from patients with mustard allergy. Conclusion: The recombinant 11S globulin from yellow mustard seeds produced in E coli retained the IgE-binding capability of the natural allergen. Clinical implications: The availability of Sin a 2 sequence and its recombinant production could help to develop future therapeutic approaches and might well open new investigation lines to resolve whether 11S globulins are proteins implicated in cross-reactivity processes involving mustard seeds.	Univ Complutense, Fac Quim, Dept Bioquim & Biol Mol, E-28040 Madrid, Spain; Fdn Jimenez Diaz, Serv Alergia, E-28040 Madrid, Spain	Complutense University of Madrid	Rodriguez, R (corresponding author), Univ Complutense, Fac Quim, Dept Bioquim & Biol Mol, E-28040 Madrid, Spain.	rrg@bbm1.ucm.es	RODRIGUEZ, ROSALIA/K-4993-2014; Villalba, María Teresa/AAW-1067-2020; Villalba, Mayte/K-5365-2014; Palomares, Oscar/ABG-5229-2020	RODRIGUEZ, ROSALIA/0000-0002-4280-3691; Villalba, María Teresa/0000-0002-0042-9953; Palomares, Oscar/0000-0003-4516-0369				Adachi M, 2001, J MOL BIOL, V305, P291, DOI 10.1006/jmbi.2000.4310; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Barderas R, 2004, J ALLERGY CLIN IMMUN, V113, P1192, DOI 10.1016/j.jaci.2003.12.587; Beyer K, 2002, J ALLERGY CLIN IMMUN, V110, P517, DOI 10.1067/mai.2002.127434; BURKS AW, 1992, J ALLERGY CLIN IMMUN, V90, P962, DOI 10.1016/0091-6749(92)90469-I; Caballero T, 2002, ANN ALLERG ASTHMA IM, V89, P166, DOI 10.1016/S1081-1206(10)61933-3; ClareMills EN, 2004, PLANT FOOD ALLERGENS, P141, DOI 10.1017/CBO9781107415324.004; Dunwell JM, 2001, TRENDS BIOCHEM SCI, V26, P740, DOI 10.1016/S0968-0004(01)01981-8; Figueroa J, 2005, ALLERGY, V60, P48, DOI 10.1111/j.1398-9995.2005.00644.x; Helm RM, 2000, INT ARCH ALLERGY IMM, V123, P213, DOI 10.1159/000024446; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Huecas S, 1999, EUR J BIOCHEM, V261, P539, DOI 10.1046/j.1432-1327.1999.00307.x; KANNY G, 1995, ANN ALLERG ASTHMA IM, V75, P340; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MENENDEZARIAS L, 1988, EUR J BIOCHEM, V177, P159, DOI 10.1111/j.1432-1033.1988.tb14357.x; Mills ENC, 2005, BIOTECHNOL ADV, V23, P409, DOI 10.1016/j.biotechadv.2005.05.006; MONREAL P, 1992, ANN ALLERGY, V69, P317; Monsalve RI, 1997, CLIN EXP ALLERGY, V27, P833, DOI 10.1046/j.1365-2222.1997.660843.x; NIINIMAKI A, 1981, ALLERGY, V36, P487, DOI 10.1111/j.1398-9995.1981.tb01860.x; Palomares O, 2005, ANN ALLERG ASTHMA IM, V94, P586, DOI 10.1016/S1081-1206(10)61138-6; PANCONESI E, 1980, CONTACT DERMATITIS, V6, P294, DOI 10.1111/j.1600-0536.1980.tb04943.x; Pastorello EA, 1998, J ALLERGY CLIN IMMUN, V102, P1021, DOI 10.1016/S0091-6749(98)70341-0; Rabjohn P, 1999, J CLIN INVEST, V103, P535, DOI 10.1172/JCI5349; Rance F, 1999, PEDIAT ALLERG IMM-UK, V10, P33, DOI 10.1034/j.1399-3038.1999.101008.x; Sanchez-Monge R, 2004, CLIN EXP ALLERGY, V34, P1747, DOI 10.1111/j.1365-2222.2004.02085.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sicherer SH, 2006, J ALLERGY CLIN IMMUN, V117, pS470, DOI 10.1016/j.jaci.2005.05.048; STRICKER WE, 1986, J ALLERGY CLIN IMMUN, V77, P516, DOI 10.1016/0091-6749(86)90188-0; Teuber SS, 1999, J ALLERGY CLIN IMMUN, V103, P1180, DOI 10.1016/S0091-6749(99)70196-X; Teuber SS, 2002, J AGR FOOD CHEM, V50, P6543, DOI 10.1021/jf025757j; TOBIAS JW, 1991, SCIENCE, V254, P1374, DOI 10.1126/science.1962196; Valenta R, 1999, CLIN EXP ALLERGY, V29, P896; VILLALBA M, 1994, J BIOL CHEM, V269, P15217; WIDSTROM L, 1986, ACTA DERM-VENEREOL, V66, P70	35	21	21	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2007	119	5					1189	1196		10.1016/j.jaci.2007.01.027	http://dx.doi.org/10.1016/j.jaci.2007.01.027			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	167CB	17349683				2022-12-18	WOS:000246427200020
J	Baynam, G; Khoo, SK; Rowe, J; Zhang, GC; Laing, I; Hayden, C; Kusel, M; DeKlerk, N; Sly, P; Goldblatt, J; Holt, P; LeSouef, P				Baynam, Gareth; Khoo, Siew-Kim; Rowe, Julie; Zhang, Guicheng; Laing, Ingrid; Hayden, Catherine; Kusel, Merci; DeKlerk, Nick; Sly, Peter; Goldblatt, Jack; Holt, Patrick; LeSouef, Peter			Parental smoking impairs vaccine responses in children with atopic genotypes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						genetics; environmental exposure; atopy; public health; smoking; toxicology	IMMUNOLOGICAL FUNCTION; POSTNATAL MATURATION; CIGARETTE-SMOKING; PERTUSSIS VACCINE; IMMUNE-RESPONSES; ASTHMA; GENE; ENVIRONMENT; DIPHTHERIA; TETANUS	Background: Gene-environment interactions play central roles in controlling postnatal maturation of immune function, but their effects on infant vaccine responses are unknown. Genetic variants associated with atopy and the environmental factor of exposure to parental smoking (PS) of tobacco independently alter immune responses. Objective: We sought to investigate the hypothesis that genetic variants associated with atopy and their interaction with PS influence infant vaccine responsiveness. Methods: In 200 infants with parental atopic history, relationships were sought between polymorphisms in the IL-4, IL-4 receptor alpha (IL-4R alpha), and IL-13 genes; PS; and immune responses to diphtheria/tetanus vaccination. Results: Analyses stratified by PS unmasked negative associations between atopic alleles of these genes and vaccine outcomes. The most consistent involved the IL-4R alpha 551 QR/QQ genotypes, which were associated with reduced IgG levels (P = .02) and T-cell responses (IFN-gamma, P = .002; IL-10, P = .01; IL-13, P = .01; IL-5, P = .06) to tetanus toxoid and parallel reductions in polyclonal T-cell responses and innate immune responses in PS-exposed infants. Conclusion: PS potentiates suppressive effects of variants in immune response genes in children. These effects are not observed in the absence of this exposure. Ultimately, this finding might have implications for infant vaccination in countries with high smoking rates. It might also have broader implications in relation to environmental toxicology because it demonstrates specific mechanisms through which the developing immune system might be differentially sensitive to low-level toxicant exposures. Clinical implications: PS interacts with genes associated with atopy to impair vaccine responses. These interactions might have vaccine design and public health implications.	Telethon Inst Child Hlth Res, Perth, WA 6008, Australia; Univ Western Australia, Sch Paediat & Child Hlth, Nedlands, WA 6009, Australia; Univ Western Australia, Ctr Child Hlth Res, Nedlands, WA 6009, Australia	Telethon Kids Institute; University of Western Australia; University of Western Australia; University of Western Australia	Baynam, G (corresponding author), Telethon Inst Child Hlth Res, 100 Roberts Rd, Perth, WA 6008, Australia.	garethb@ichr.uwa.edu.au	Khoo, Siew-Kim/B-6493-2012; de Klerk, Nicholas H/D-8388-2016; Holt, Patrick G/H-1548-2011; Sly, Peter D/F-1486-2010; Khoo, Siew-Kim/D-7655-2016; Laing, Ingrid/I-7092-2013; Le Souef, Peter N/H-5256-2014; Zhang, Brad/AAF-8719-2021	de Klerk, Nicholas H/0000-0001-9223-0767; Holt, Patrick G/0000-0003-1193-0935; Sly, Peter D/0000-0001-6305-2201; Laing, Ingrid/0000-0002-1641-9899; Zhang, Guicheng/0000-0001-9888-5385; Le Souef, Peter/0000-0003-0930-1654				ALLANSMITH M, 1969, J IMMUNOL, V102, P1504; Arkwright PD, 2000, CLIN EXP IMMUNOL, V122, P16, DOI 10.1046/j.1365-2249.2000.01338.x; Basehore MJ, 2004, J ALLERGY CLIN IMMUN, V114, P80, DOI 10.1016/j.jaci.2004.05.035; Bryce J, 2005, LANCET, V365, P1147, DOI 10.1016/S0140-6736(05)71877-8; Callard RE, 2002, CLIN EXP ALLERGY, V32, P990, DOI 10.1046/j.1365-2222.2002.01414.x; Choudhry S, 2005, AM J RESP CRIT CARE, V172, P173, DOI 10.1164/rccm.200409-1232OC; Colilla S, 2003, J ALLERGY CLIN IMMUN, V111, P840, DOI 10.1067/mai.2003.170; Heaton T, 2005, LANCET, V365, P142, DOI 10.1016/S0140-6736(05)17704-6; Hoffjan S, 2005, AM J HUM GENET, V76, P696, DOI 10.1086/429418; Hoffjan S, 2003, RESP RES, V4, DOI 10.1186/1465-9921-4-14; Hohler T, 2002, LANCET, V360, P991, DOI 10.1016/S0140-6736(02)11083-X; Holt PG, 2000, J ALLERGY CLIN IMMUN, V105, P1117, DOI 10.1067/mai.2000.105804; HOLT PG, 1979, ENVIRON RES, V19, P154, DOI 10.1016/0013-9351(79)90043-4; HOLT PG, 1977, BACTERIOL REV, V41, P205, DOI 10.1128/MMBR.41.1.205-216.1977; HOLT PG, 1995, PEDIAT ALLERG IMM-UK, V6, P59, DOI 10.1111/j.1399-3038.1995.tb00261.x; Kelly-Welch AE, 2003, SCIENCE, V300, P1527, DOI 10.1126/science.1085458; Kusel MMH, 2005, J ALLERGY CLIN IMMUN, V116, P1067, DOI 10.1016/j.jaci.2005.06.038; Lohning M, 2002, ADV IMMUNOL, V80, P115, DOI 10.1016/S0065-2776(02)80014-1; Luoni G, 2001, GENES IMMUN, V2, P411, DOI 10.1038/sj.gene.6363797; Mackay J, 2002, TOBACCO ATLAS; MACKENZIE JS, 1976, J HYG-CAMBRIDGE, V77, P409, DOI 10.1017/S0022172400055790; Mancini D A, 1998, Boll Chim Farm, V137, P21; McQuillan GM, 2002, ANN INTERN MED, V136, P660, DOI 10.7326/0003-4819-136-9-200205070-00008; Messi M, 2003, NAT IMMUNOL, V4, P78, DOI 10.1038/ni872; Newport MJ, 2004, GENES IMMUN, V5, P122, DOI 10.1038/sj.gene.6364051; O'Donnell AR, 2004, AM J RESP CRIT CARE, V169, P615, DOI 10.1164/rccm.200302-278OC; OBER C, 2000, COMPLEX TRIAT MAPPIN; OEFNER P, 1998, CURRENT PROTOCOLS HU; Ovsyannikova IG, 2004, PHARMACOGENOMICS, V5, P417, DOI 10.1517/14622416.5.4.417; PANDEY JP, 1981, J CLIN INVEST, V68, P1378, DOI 10.1172/JCI110387; Perneger TV, 1998, BRIT MED J, V316, P1236, DOI 10.1136/bmj.316.7139.1236; Plotkin SA, 2005, NAT MED, V11, pS5, DOI 10.1038/nm1209; Poland Gregory A., 1998, Current Opinion in Pediatrics, V10, P208; Rothman KJ., 1986, MODERN EPIDEMIOLOGY; Rowe J, 2004, J ALLERGY CLIN IMMUN, V113, P710, DOI 10.1016/j.jaci.2003.12.585; Rowe J, 2001, J INFECT DIS, V184, P80, DOI 10.1086/320996; Tan PL, 2001, VACCINE, V19, P2434, DOI 10.1016/S0264-410X(00)00468-0; THOMAS W, 1973, NATURE, V243, P240, DOI 10.1038/243240a0; Wang CB, 2004, HEPATOLOGY, V39, P978, DOI 10.1002/hep.20142; WOOD RC, 1993, JAMA-J AM MED ASSOC, V270, P2935, DOI 10.1001/jama.270.24.2935	40	21	22	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2007	119	2					366	374		10.1016/j.jaci.2006.09.018	http://dx.doi.org/10.1016/j.jaci.2006.09.018			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	137YB	17291854				2022-12-18	WOS:000244327900014
J	Salt, BH; Boguniewicz, M; Leung, DYM				Salt, Bryn H.; Boguniewicz, Mark; Leung, Donald Y. M.			Severe refractory atopic dermatitis in adults is highly atopic	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							FILAGGRIN; PREDISPOSE		Natl Jewish Med & Res Ctr, Dept Pediat Allergy & Immunol, Denver, CO USA	National Jewish Health	Salt, BH (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat Allergy & Immunol, Denver, CO USA.	leungd@njc.org						BARKER JN, 2006, J INVEST DERMAT 0921; Cork MJ, 2006, J ALLERGY CLIN IMMUN, V118, P3, DOI 10.1016/j.jaci.2006.04.042; Howell MD, 2007, J ALLERGY CLIN IMMUN, V119, pS283, DOI 10.1016/j.jaci.2006.12.479; Marenholz I, 2006, J ALLERGY CLIN IMMUN, V118, P866, DOI 10.1016/j.jaci.2006.07.026; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; RAJKA G, 1989, ACTA DERM-VENEREOL, P13; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P214, DOI 10.1016/j.jaci.2006.05.004	7	21	21	1	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2007	119	2					508	509		10.1016/j.jaci.2006.11.006	http://dx.doi.org/10.1016/j.jaci.2006.11.006			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	137YB	17194471	Bronze			2022-12-18	WOS:000244327900037
J	Bukstein, D; Kraft, M; Liu, AH; Peters, SP				Bukstein, Don; Kraft, Monica; Liu, Andrew H.; Peters, Stephen P.			Asthma end points and outcomes: What have we learned?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						asthma; asthma treatment; lung function measures; clinical outcomes	EXHALED NITRIC-OXIDE; INHALED CORTICOSTEROIDS; PERSISTENT ASTHMA; LUNG-FUNCTION; AIRWAY HYPERRESPONSIVENESS; ALVEOLAR TISSUE; INFLAMMATION; MONTELUKAST; CHILDREN; FLUTICASONE	In spite of the wide prevalence of asthma and its substantial consequences, the diagnosis and assessment of asthma has not been standardized, and the goals of therapy currently are not being achieved. Our purpose is to help delineate what the most important asthma end points are and what kinds of strategies we should use to guide therapy. Comparison of numerous studies reveals that asthma measures used routinely in the clinic, such as spirometric lung function, do not uniformly correlate with asthma control. We cannot improve outcomes until we determine which measures reveal the underlying disease process most clearly and at the same time offer ease of performance during routine office visits. We propose that by standardizing the way we collect and analyze data from our daily practice, we can better define which measures reflect true asthma control. Such measures most likely address a spectrum of changes occurring in the pathophysiology of asthma, notably distal airway inflammation and hyperresponsiveness. Inflammation may provide the best opportunity for assessment and treatment, because if it is adequately addressed, airway sensitivity may improve, thereby reducing airway obstruction and subsequently minimizing exacerbations. The fraction of exhaled nitric oxide as a measure of inflammation is suggested as offering the best combination of disease evaluation and practical implementation for improved asthma outcomes.	Univ Wisconsin, Sch Med, Dept Pediat & Family Practice, Dean Med Ctr, Madison, WI 53706 USA; Duke Univ, Med Ctr, Dept Med, Duke Asthma Allergy & Airway Ctr, Durham, NC 27710 USA; Natl Jewish Med & Res Ctr, Dept Pediat, Dept Allergy & Immunol, Denver, CO USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Med, Sect Pulm Crit Care Allergy & Clin Immunol, Winston Salem, NC 27103 USA; Wake Forest Univ, Bowman Gray Sch Med, Ctr Human Genom, Winston Salem, NC 27103 USA	University of Wisconsin System; University of Wisconsin Madison; Duke University; National Jewish Health; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center	Bukstein, D (corresponding author), Amer Acad Allergy Asthma & Immunol, 611 E Wells St, Milwaukee, WI 53202 USA.							Alving K, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-67; *AM LUNG ASS EP ST, 2005, TRENDS ASTHM MORB MO; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Bender B, 2003, J ALLERGY CLIN IMMUN, V112, P489, DOI 10.1067/mai.2003.1680; Buchvald F, 2005, CHEST, V128, P1964, DOI 10.1378/chest.128.4.1964; Buchvald F, 2005, J ALLERGY CLIN IMMUN, V115, P1130, DOI 10.1016/j.jaci.2005.03.020; Bukstein DA, 2001, J ALLERGY CLIN IMMUN, V107, pS244; BUKSTEIN DA, 2001, ANN M AM THOR SOC MA; Busse WW, 2006, ANN ALLERG ASTHMA IM, V96, P60, DOI 10.1016/S1081-1206(10)61041-1; Calhoun WJ, 2003, J ALLERGY CLIN IMMUN, V112, P1088, DOI 10.1016/j.jaci.2003.09.044; Cherniack R, 1999, CONTROL CLIN TRIALS, V20, P91; *CHILDH ASTHM MAN, 2000, NEW ENGLAND J MED, V0343; Covar RA, 2004, AM J RESP CRIT CARE, V170, P234, DOI 10.1164/rccm.200308-1174OC; Crimi E, 1998, AM J RESP CRIT CARE, V157, P4, DOI 10.1164/ajrccm.157.1.9703002; DRAZEN JM, 2000, CECIL TXB MED, P387; *GLAX SMITH KLIN, ASTHM AM LANDM SURV; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Hamid Q, 1997, J ALLERGY CLIN IMMUN, V100, P44, DOI 10.1016/S0091-6749(97)70193-3; Israel E, 2001, NEW ENGL J MED, V345, P941, DOI 10.1056/NEJMoa002304; Israel E, 2004, LANCET, V364, P1505, DOI 10.1016/S0140-6736(04)17273-5; Jatakanon A, 1998, THORAX, V53, P91, DOI 10.1136/thx.53.2.91; Kavuru M, 2000, J ALLERGY CLIN IMMUN, V105, P1108, DOI 10.1067/mai.2000.105711; Kraft M, 1999, AM J RESP CRIT CARE, V159, P228, DOI 10.1164/ajrccm.159.1.9804033; Kraft M, 1996, AM J RESP CRIT CARE, V154, P1505, DOI 10.1164/ajrccm.154.5.8912772; KRAFT M, 2006, IN PRESS CHEST; LAITINEN LA, 1993, AM REV RESPIR DIS, V147, P697, DOI 10.1164/ajrccm/147.3.697; Laviolette M, 1999, AM J RESP CRIT CARE, V160, P1862, DOI 10.1164/ajrccm.160.6.9803042; Lazarus SC, 2001, JAMA-J AM MED ASSOC, V285, P2583, DOI 10.1001/jama.285.20.2583; Lemanske RF, 2001, JAMA-J AM MED ASSOC, V285, P2594, DOI 10.1001/jama.285.20.2594; Malmberg LP, 2005, ALLERGY, V60, P464, DOI 10.1111/j.1398-9995.2005.00740.x; Malmberg LP, 2003, THORAX, V58, P494, DOI 10.1136/thorax.58.6.494; Malmstrom K, 1999, ANN INTERN MED, V130, P487, DOI 10.7326/0003-4819-130-6-199903160-00005; Moy ML, 2001, AM J RESP CRIT CARE, V163, P924, DOI 10.1164/ajrccm.163.4.2008014; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; Nelson HS, 2000, J ALLERGY CLIN IMMUN, V106, P1088, DOI 10.1067/mai.2000.110920; *NIAID, 2005, ICAC02 DAIT NIAID; O'Byrne PM, 2001, AM J RESP CRIT CARE, V164, P1392, DOI 10.1164/ajrccm.164.8.2104102; Patel Pankaj H, 2004, Dis Manag, V7, P102, DOI 10.1089/1093507041253235; Payne DNR, 2001, AM J RESP CRIT CARE, V164, P1376, DOI 10.1164/ajrccm.164.8.2101145; Pijnenburg MW, 2005, THORAX, V60, P215, DOI 10.1136/thx.2004.023374; Pijnenburg MW, 2005, AM J RESP CRIT CARE, V172, P831, DOI 10.1164/rccm.200503-458OC; Shingo S, 2001, EUR RESPIR J, V17, P220, DOI 10.1183/09031936.01.17202200; Smith AD, 2004, AM J RESP CRIT CARE, V169, P473, DOI 10.1164/rccm.200310-1376OC; Smith AD, 2005, NEW ENGL J MED, V352, P2163, DOI 10.1056/NEJMoa043596; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043, DOI 10.1164/ajrccm.159.4.9806052; Suissa S, 2002, THORAX, V57, P880, DOI 10.1136/thorax.57.10.880; Sutherland ER, 2004, J ALLERGY CLIN IMMUN, V113, P1046, DOI 10.1016/j.jaci.2004.03.016; Szefler SJ, 2001, J ALLERGY CLIN IMMUN, V107, pS456, DOI 10.1067/mai.2001.114947; 't Veen JCCMI, 2000, AM J RESP CRIT CARE, V161, P1902; Tantisira KG, 2004, HUM MOL GENET, V13, P1353, DOI 10.1093/hmg/ddh149; Wagner EM, 1998, AM J RESP CRIT CARE, V157, P447, DOI 10.1164/ajrccm.157.2.9611043; WAGNER EM, 1990, AM REV RESPIR DIS, V141, P584, DOI 10.1164/ajrccm/141.3.584; Williams LK, 2004, J ALLERGY CLIN IMMUN, V114, P1288, DOI 10.1016/j.jaci.2004.09.028; Yawn BP, 2006, RESP MED, V100, P26, DOI 10.1016/j.rmed.2005.04.010; Zeiger RS, 2006, J ALLERGY CLIN IMMUN, V117, P45, DOI 10.1016/j.jaci.2005.10.012; 2006, NAT C STAT LEG WASH; [No title captured]	57	21	22	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2006	118	4		S			S1	S15		10.1016/j.jaci.2006.08.002	http://dx.doi.org/10.1016/j.jaci.2006.08.002			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	098EG	17027530				2022-12-18	WOS:000241503200001
J	Fuhlbrigge, AL; Bae, SJ; Weiss, ST; Kuntz, KM; Paltiel, AD				Fuhlbrigge, AL; Bae, SJ; Weiss, ST; Kuntz, KM; Paltiel, AD			Cost-effectiveness of inhaled steroids in asthma: Impact of effect on bone mineral density	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; inhaled corticosteroids; cost-effectiveness; drug toxicity; bonedensity; osteoporosis; hip fracture; treatment outcome; Markov models	FLUTICASONE PROPIONATE; CORTICOSTEROID TREATMENT; FRACTURE RISK; HIP FRACTURE; DOUBLE-BLIND; BECLOMETHASONE; DISEASE; GLUCOCORTICOIDS; BUDESONIDE; MODERATE	Background: The effects of inhaled corticosteroid (ICS) preparations on bone health have been debated. Multiple analyses have been published examining the question, with mixed results. Objectives: We examined how assumptions about the effect of ICS on bone mineral density (BMD) influence the cost-effectiveness of ICS in asthma. Methods: We developed a mathematical simulation model to estimate clinical outcomes and costs for a cohort with mild/moderate asthma. The analysis conformed to reference case recommendations of the US Panel on Cost-Effectiveness in Health and Medicine. Sensitivity analysis evaluated the stability of our results to uncertainty in treatment duration, age at treatment, and ICS dose. Results: Assuming a dose of 200 mu g twice per day of ICS, a literature-based average effect of ICS on BMD and a 10-year time horizon, we observed a minimal increase in the costs attributed to hip fracture and incremental cost effectiveness ratio of $26,000 per quality-adjusted life-year and $14.00 per symptom-free day gained. Over an extended the time horizon (lifetime), the incremental cost effectiveness ratio increased to $42,000/quality-adjusted life-year. Only under a scenario of high-dose ICS, a lifetime horizon, and a large effect of ICS on BMD did the potential impact of ICS on BMD dramatically affect the economic attractiveness of therapy. Conclusion: To minimize any potential impact, use of the lowest effective dose of ICS and measures to target and intervene in high-risk individuals are warranted. However, ICS therapy in mild/moderate asthma compares favorably with commonly accepted interventions over a wide range of assumptions regarding this treatment and its effects on BMD.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Channing Lab, Boston, MA USA; Yale Sch Med, New Haven, CT USA; Harvard Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Yale University; Harvard University; Harvard T.H. Chan School of Public Health	Fuhlbrigge, AL (corresponding author), Channing Labs, 181 Longwood Ave, Boston, MA 02115 USA.	anne.fuhlbrigge@channing.harvard.edu	Bae, SeungJin/J-6011-2016	Bae, SeungJin/0000-0002-8993-8884; Paltiel, A. David/0000-0002-4861-3290	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003910] Funding Source: NIH RePORTER; NHLBI NIH HHS [1 R01 HL0068201-01, 1 K08 HL003910] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS N, 2002, BUDESONIDE CHRONIC A; Adams RJ, 2001, ARCH PEDIAT ADOL MED, V155, P501, DOI 10.1001/archpedi.155.4.501; Allen David B, 2003, J Allergy Clin Immunol, V112, pS1, DOI 10.1016/S0091-6749(03)01859-1; Altose MD, 2000, NEW ENGL J MED, V343, P1902; Berg AO, 2002, ANN INTERN MED, V137, P526, DOI 10.7326/0003-4819-137-6-200209170-00014; *BUR LAB STAT, 2004, CONS PRIC IND CPI DE; COOPER C, 1992, TRENDS ENDOCRIN MET, V3, P224, DOI 10.1016/1043-2760(92)90032-V; Egan JJ, 1999, EUR RESPIR J, V13, P1267, DOI 10.1183/09031936.99.13612769; FUHLBRIGGE A, 2003, AM J RESP CRIT CARE, V167, pA38; Fuhlbrigge AL, 2002, AM J RESP CRIT CARE, V166, P1044, DOI 10.1164/rccm.2107057; Gershman NH, 2000, EUR RESPIR J, V15, P11, DOI 10.1183/09031936.00.15101100; Gold MR, 1996, COST EFFECTIVENESS H; Halpern MT, 2004, ANN ALLERG ASTHMA IM, V92, P201, DOI 10.1016/S1081-1206(10)61548-7; *HARV CTR RISK ANA, 2005, CEA REG STAND METH P; Hay J, 1999, Value Health, V2, P78, DOI 10.1046/j.1524-4733.1999.02203.x; Hubbard RB, 2002, AM J RESP CRIT CARE, V166, P1563, DOI 10.1164/rccm.200206-606OC; Hughes JA, 1999, THORAX, V54, P223, DOI 10.1136/thx.54.3.223; Israel E, 2001, NEW ENGL J MED, V345, P941, DOI 10.1056/NEJMoa002304; Jones A, 2002, Cochrane Database Syst Rev, pCD003537, DOI 10.1002/14651858.CD003537; Kemp JP, 2004, MAYO CLIN PROC, V79, P458, DOI 10.4065/79.4.458; Krahn MD, 1997, MED DECIS MAKING, V17, P142, DOI 10.1177/0272989X9701700204; Li JTC, 1999, J ALLERGY CLIN IMMUN, V103, P1062, DOI 10.1016/S0091-6749(99)70180-6; LOCASCIO V, 1990, BONE MINER, V8, P39, DOI 10.1016/0169-6009(91)90139-Q; Martin RJ, 2002, AM J RESP CRIT CARE, V165, P1377, DOI 10.1164/rccm.2105013; Medici TC, 2000, THORAX, V55, P375, DOI 10.1136/thorax.55.5.375; MELTON LJ, 1988, J CLIN EPIDEMIOL, V41, P985; Moy ML, 2004, ANN ALLERG ASTHMA IM, V92, P329, DOI 10.1016/S1081-1206(10)61570-0; *NIH, 1997, PUB NIH; Paltiel AD, 2001, DRUG INF J, V35, P131, DOI 10.1177/009286150103500114; Paltiel AD, 2001, J ALLERGY CLIN IMMUN, V108, P39, DOI 10.1067/mai.2001.116289; PASHOS CL, 1998, ISPOR LEXICON; PAUKER SG, 1980, NEW ENGL J MED, V302, P1109, DOI 10.1056/NEJM198005153022003; Pauwels RA, 1998, AM J RESP CRIT CARE, V157, P827, DOI 10.1164/ajrccm.157.3.9610009; Pauwels RA, 1999, NEW ENGL J MED, V340, P1948, DOI 10.1056/NEJM199906243402503; POWELL H, 2005, COCHRANE DB SYST REV, P4; RAMSEY SD, 2004, SURG ENDOSCOPIC THER; RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605; Solomon DH, 2000, ARTHRITIS RHEUM-US, V43, P1967, DOI 10.1002/1529-0131(200009)43:9<1967::AID-ANR7>3.0.CO;2-W; Sorkness CA, 1998, J ALLERGY CLIN IMMUN, V102, pS52, DOI 10.1016/S0091-6749(98)70005-3; Struijs A, 1997, NETH J MED, V50, P233, DOI 10.1016/S0300-2977(96)00081-2; Suissa S, 2004, AM J RESP CRIT CARE, V169, P83, DOI 10.1164/rccm.200305-640OC; Tattersfield AE, 2001, THORAX, V56, P272, DOI 10.1136/thorax.56.4.272; Todd GRG, 2002, EUR RESPIR J, V19, P1207, DOI 10.1183/09031936.02.00274402; Tosteson ANA, 2001, OSTEOPOROSIS INT, V12, P1042, DOI 10.1007/s001980170015; van Staa TP, 2000, RHEUMATOLOGY, V39, P1383, DOI 10.1093/rheumatology/39.12.1383; van Staa TP, 2001, J BONE MINER RES, V16, P581, DOI 10.1359/jbmr.2001.16.3.581; WASNICH RD, 1999, PRIMER METABOLIC BON, P257; WEINSTEIN MC, 1987, AM J PUBLIC HEALTH, V77, P1417, DOI 10.2105/AJPH.77.11.1417; Wong CA, 2000, LANCET, V355, P1399, DOI 10.1016/S0140-6736(00)02138-3; Wong CA, 2002, CURR OPIN PULM MED, V8, P39, DOI 10.1097/00063198-200201000-00007	50	21	21	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2006	117	2					359	366		10.1016/j.jaci.2005.10.036	http://dx.doi.org/10.1016/j.jaci.2005.10.036			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IM	16461137				2022-12-18	WOS:000235687300019
J	Asero, R; Orsatti, A; Tedeschi, A; Lorini, M				Asero, R; Orsatti, A; Tedeschi, A; Lorini, M			Autoimmune chronic urticaria associated with type 1 diabetes and Graves' disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							THYROID AUTOIMMUNITY; AUTOANTIBODIES		Clin San Carlo, Ambulatorio Allergol, I-20037 Paderno Dugnano, MI, Italy; Univ Milan, Osped Maggiore Policlin, IRCCS, Div Internal Med 1, Milan, Italy	IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan	Asero, R (corresponding author), Clin San Carlo, Ambulatorio Allergol, Via Osped 21, I-20037 Paderno Dugnano, MI, Italy.							Asero R, 2001, CLIN EXP ALLERGY, V31, P1105, DOI 10.1046/j.1365-2222.2001.01131.x; Asero R, 2003, J ALLERGY CLIN IMMUN, V111, P1129, DOI 10.1067/mai.2003.1389; Barlow ABT, 1996, CLIN ENDOCRINOL, V44, P73, DOI 10.1046/j.1365-2265.1996.634454.x; Chuang LM, 1996, CLIN ENDOCRINOL, V45, P631, DOI 10.1046/j.1365-2265.1996.00857.x; Greaves M, 2000, J ALLERGY CLIN IMMUN, V105, P664, DOI 10.1067/mai.2000.105706; Irani C, 2001, J ALLERGY CLIN IMMUN, V108, P874, DOI 10.1067/mai.2001.119161; IRWIN WJ, 1980, RECENT PROG HORM RES, V36, P509; Kaplan AP, 2004, J ALLERGY CLIN IMMUN, V114, P465, DOI 10.1016/j.jaci.2004.02.049; KAWASAKI E, 1994, DIABETES, V43, P80, DOI 10.2337/diabetes.43.1.80; ROBLES DT, 2001, CLIN IMMUNOLOGY PRIN; Sabroe RA, 1999, BRIT J DERMATOL, V140, P446; SMALL P, 1981, ANN ALLERGY, V46, P256; WEETMAN AP, 1994, ENDOCR REV, V15, P788, DOI 10.1210/er.15.6.788	13	21	21	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2005	115	5					1088	1089		10.1016/j.jaci.2004.12.009	http://dx.doi.org/10.1016/j.jaci.2004.12.009			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	925LR	15867871				2022-12-18	WOS:000229055100029
J	Bergeron, C; Boulet, LP; Hamid, Q				Bergeron, C; Boulet, LP; Hamid, Q			Obesity, allergy and immunology	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							BODY-MASS INDEX; ASTHMA; CHILDREN; LEPTIN		McGill Univ, Meakins Christie Labs, Montreal, PQ H2X 2P2, Canada; Univ Laval, Hop Laval, Ctr Rech Pneumol, Quebec City, PQ, Canada	McGill University; Laval University	Hamid, Q (corresponding author), McGill Univ, Meakins Christie Labs, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.	qutayba.hamid@mcgill.ca						Chinn S, 2002, THORAX, V57, P1028, DOI 10.1136/thorax.57.12.1028; Guerra S, 2002, CHEST, V122, P1256, DOI 10.1378/chest.122.4.1256; Hancox RJ, 2005, AM J RESP CRIT CARE, V171, P440, DOI 10.1164/rccm.200405-623OC; Hedberg A, 2000, INT J OBESITY, V24, P1217, DOI 10.1038/sj.ijo.0801382; Mai XM, 2004, PEDIAT ALLERG IMM-UK, V15, P523, DOI 10.1111/j.1399-3038.2004.00195.x; Mokdad AH, 1999, JAMA-J AM MED ASSOC, V282, P1519, DOI 10.1001/jama.282.16.1519; Schachter LM, 2003, THORAX, V58, P1031, DOI 10.1136/thorax.58.12.1031; Shore SA, 2005, J ALLERGY CLIN IMMUN, V115, P103, DOI 10.1016/j.jaci.2004.10.007; Simard B, 2004, OBES SURG, V14, P1381, DOI 10.1381/0960892042584021; Tantisira KG, 2003, THORAX, V58, P1036, DOI 10.1136/thorax.58.12.1036; TURCOTTE H, 2004, AM J RESP CRIT CARE, V169, pA246; Wajchenberg BL, 2000, ENDOCR REV, V21, P697, DOI 10.1210/er.21.6.697; Wickens K, 2005, THORAX, V60, P7, DOI 10.1136/thx.2002.001529	13	21	21	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2005	115	5					1102	1104		10.1016/j.jaci.2005.03.018	http://dx.doi.org/10.1016/j.jaci.2005.03.018			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	925LR	15867879	Bronze			2022-12-18	WOS:000229055100040
J	Israel, E				Israel, E			Genetics and the variability of treatment response in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; treatment response variability; pharmacogenomics; leukotrienes; beta-agonists	BETA(2)-ADRENERGIC RECEPTOR; PROMOTER GENOTYPE; BETA-AGONIST; ALBUTEROL; EXACERBATIONS; MUTATIONS; PLACEBO; TRIAL	Pharmacogenetics is the study of how genetic differences influence the variability in patients' responses to therapy. Using specific examples in asthma, I will define the concepts of variability in response to therapy in asthma. I will then use the relationship between specific genetic polymorphisms and the response to beta-adrenergic agonists and leukotriene modifiers to illustrate pharmacogenetic interactions and to acquaint the reader with the applicability of these findings to clinical practice.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Pulm & Crit Care Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Israel, E (corresponding author), Amer Acad Allergy Asthma & Immunol, 611 E Wells St, Milwaukee, WI 53202 USA.							Drazen JM, 1996, NEW ENGL J MED, V335, P841, DOI 10.1056/NEJM199609193351202; Drazen JM, 1999, NAT GENET, V22, P168, DOI 10.1038/9680; Drysdale CM, 2000, P NATL ACAD SCI USA, V97, P10483, DOI 10.1073/pnas.97.19.10483; Dwyer JH, 2004, NEW ENGL J MED, V350, P29, DOI 10.1056/NEJMoa025079; HOSHIKO S, 1990, P NATL ACAD SCI USA, V87, P9073, DOI 10.1073/pnas.87.23.9073; In KH, 1997, J CLIN INVEST, V99, P1130, DOI 10.1172/JCI119241; Israel E, 2001, NEW ENGL J MED, V345, P941, DOI 10.1056/NEJMoa002304; Israel E, 2004, LANCET, V364, P1505, DOI 10.1016/S0140-6736(04)17273-5; Israel E, 2000, AM J RESP CRIT CARE, V162, P75, DOI 10.1164/ajrccm.162.1.9907092; Malmstrom K, 1999, ANN INTERN MED, V130, P487, DOI 10.7326/0003-4819-130-6-199903160-00005; Palmer LJ, 2002, AM J RESP CRIT CARE, V165, P861, DOI 10.1164/ajrccm.165.7.2109096; REIHSAUS E, 1993, AM J RESP CELL MOL, V8, P334, DOI 10.1165/ajrcmb/8.3.334; Sampson AP, 2000, THORAX, V55, pS28, DOI 10.1136/thorax.55.suppl_2.S28; Szefler SJ, 2002, J ALLERGY CLIN IMMUN, V109, P410, DOI 10.1067/mai.2002.122635; Taylor DR, 2000, THORAX, V55, P762, DOI 10.1136/thorax.55.9.762; TAYLOR DR, 1993, THORAX, V48, P134, DOI 10.1136/thx.48.2.134	16	21	22	1	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2005	115	4		S			S532	S538		10.1016/j.jaci.2005.01.029	http://dx.doi.org/10.1016/j.jaci.2005.01.029			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	918FS	15806036				2022-12-18	WOS:000228528300003
J	Lilly, CM				Lilly, CM			Diversity of asthma: Evolving concepts of pathophysiology and lessons from genetics	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; genetics; disease mechanisms; leukotriene; prostaglandin	POSITIONAL CLONING; ALLERGIC DISEASES; 2 PARTS; IMMUNOLOGY; RECEPTORS; MICE	Asthma is a complex respiratory disorder characterized by reversible airflow obstruction and bronchial hyperreactivity. In recent years, our understanding of the mechanisms underlying allergic asthma has grown, and this has resulted in complex paradigms to define the immunobiology of the disorder. These paradigms conceive of asthma as a disorder with complex genetic and environmental interactions that affect the developing immune system and ultimately result in the episodic release of procontractile mediators, including leukotrienes; and prostaglandins, causing susceptible individuals to wheeze. Genetic studies seek to advance our knowledge by identifying the differences in our genetic make-up that cause us to be susceptible. Surprisingly few of the verified asthma genes involve known asthma mediators. This article reviews several of the best-established asthma genes, including a disintegrin and metalloprotease 33, dipeptidyl peptidase 10, PHD finger protein 11 (PHF11), and the prostanoid DP1 receptor. Identification of these unsuspected genes is leading to models of asthma pathogenesis that go beyond our conception of asthma as a disease of smooth muscle abnormalities, inflammatory cell presence, and airway structural changes.	Amer Acad Allergy Asthma & Immunol, Milwaukee, WI 53202 USA; Brigham & Womens Hosp, Med Intens Care Unit, Div Pulm, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Lilly, CM (corresponding author), Amer Acad Allergy Asthma & Immunol, 611 E Wells St, Milwaukee, WI 53202 USA.							Allen M, 2003, NAT GENET, V35, P258, DOI 10.1038/ng1256; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507; *CDCP, 2004, MMWR-MORBID MORTAL W, V53, P145; Drazen JM, 2003, ADV EXP MED BIOL, V525, P1; Finotto S, 2004, SPRINGER SEMIN IMMUN, V25, P281, DOI 10.1007/s00281-003-0143-1; Fiore B J, 2000, WMJ, V99, P52; Gervais FG, 2001, J ALLERGY CLIN IMMUN, V108, P982, DOI 10.1067/mai.2001.119919; Hartert T V, 2000, Curr Opin Pulm Med, V6, P4, DOI 10.1097/00063198-200001000-00002; Holgate Stephen T., 2003, Journal of Allergy and Clinical Immunology, V111, pS18, DOI 10.1067/mai.2003.25; ISRAEL E, 1992, American Review of Respiratory Disease, V145, pA16; Kay AB, 2001, NEW ENGL J MED, V344, P30, DOI 10.1056/NEJM200101043440106; Kay AB, 2001, NEW ENGL J MED, V344, P109, DOI 10.1056/NEJM200101113440206; Kobayashi T, 2002, PROSTAG OTH LIPID M, V68-9, P557, DOI 10.1016/S0090-6980(02)00055-2; Kussin P S, 1995, Respir Care Clin N Am, V1, P163; Malmstrom K, 1999, ANN INTERN MED, V130, P487, DOI 10.7326/0003-4819-130-6-199903160-00005; Matsuoka T, 2000, SCIENCE, V287, P2013, DOI 10.1126/science.287.5460.2013; Moorman JE, 2001, J ASTHMA, V38, P65, DOI 10.1081/JAS-100000023; Shapiro SD, 2002, NEW ENGL J MED, V347, P936, DOI 10.1056/NEJMcibr022144; Sheller JR, 2000, J APPL PHYSIOL, V88, P2214, DOI 10.1152/jappl.2000.88.6.2214; Tilley SL, 2003, AM J PHYSIOL-LUNG C, V284, pL599, DOI 10.1152/ajplung.00324.2002; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; Weiss KB, 2001, J ALLERGY CLIN IMMUN, V107, P3, DOI 10.1067/mai.2001.112262; Weiss KB, 2000, J ALLERGY CLIN IMMUN, V106, P493, DOI 10.1067/mai.2000.109426; WIGGS BR, 1992, AM REV RESPIR DIS, V145, P1251, DOI 10.1164/ajrccm/145.6.1251; Wood LG, 2003, EUR RESPIR J, V21, P177, DOI 10.1183/09031936.03.00017003a; Zhang YM, 2003, NAT GENET, V34, P181, DOI 10.1038/ng1166	28	21	25	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2005	115	4		S			S526	S531		10.1016/j.jaci.2005.01.028	http://dx.doi.org/10.1016/j.jaci.2005.01.028			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	918FS	15806035				2022-12-18	WOS:000228528300002
J	Bogen, D; Apter, AJ				Bogen, D; Apter, AJ			Adherence logger for a dry powder inhaler: A new device for medical adherence research	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; adherence; inhaled corticosteroids; clinical research	CLINICAL-TRIAL; ASTHMA; CORTICOSTEROIDS; STEROIDS	Background: Adherence to inhaled steroid regimens is frequently poor. Finding ways to improve adherence depends on the ability to measure time and date of inhaler use reliably and to detect deliberate dose dumping. There is no such monitor for the popular new dry powder inhalers. Objective: To develop and test an electronic monitor for a dry powder inhaler that will provide information on the time and date of use. Methods: An electronic adherence monitor for the Advair Diskus dry powder inhaler was developed and tested. In this device, inhaler use is determined by detecting and recording the motion of the drug delivery lever in the inhaler with a magnetic sensor. An additional electronic interface and software were also developed to allow the adherence data to be uploaded to a computer for display and analysis. Results: System and reliability tests involving multiple-day and repeated-use tests of the adherence monitor demonstrate the overall performance and reliability of the device, and specifically its ability to record the time and date of dose delivery. In the repeated-use test, 300 successive actuations of the dose delivery lever were correctly sensed and recorded without error. Conclusion: The simple-to-use, low-cost, reusable adherence monitor accurately records time and date of inhaler use and thus allows clinical monitoring and adherence studies in patients using the Advair Diskus dry powder inhaler. The same technology should be adaptable to other dry powder inhalers, including the Pulmicort Tubuhaler and the Symbicort Tubuhaler.	Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; Univ Penn, Div Pulm & Crit Care Med, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine	Bogen, D (corresponding author), Univ Penn, Dept Bioengn, 120 Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.	dan@seas.upenn.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL004337] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL04337-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Apter AJ, 1998, AM J RESP CRIT CARE, V157, P1810, DOI 10.1164/ajrccm.157.6.9712007; Apter AJ, 2003, J ALLERGY CLIN IMMUN, V111, P1219, DOI 10.1067/mai.2003.1479; Bender B, 2003, J ALLERGY CLIN IMMUN, V112, P489, DOI 10.1067/mai.2003.1680; Diette GB, 1999, ARCH INTERN MED, V159, P2697, DOI 10.1001/archinte.159.22.2697; GOTTLIEB DJ, 1995, CHEST, V108, P28, DOI 10.1378/chest.108.1.28; *I MED, UN TREATM CONFR RAC; Milgrom H, 1996, J ALLERGY CLIN IMMUN, V98, P1051, DOI 10.1016/S0091-6749(96)80190-4; Partridge MR, 1998, EUR RESPIR J, V11, P1006, DOI 10.1183/09031936.98.11051006; RAND CS, 1995, AM J RESP CRIT CARE, V152, P580, DOI 10.1164/ajrccm.152.2.7633711; RAND CS, 1992, AM REV RESPIR DIS, V146, P1559, DOI 10.1164/ajrccm/146.6.1559; RAND CS, 1993, AM J CARDIOL, V72, pD68, DOI 10.1016/0002-9149(93)90014-4; Suissa S, 2001, J ALLERGY CLIN IMMUN, V107, P937, DOI 10.1067/mai.2001.115653	12	21	21	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2004	114	4					863	868		10.1016/j.jaci.2004.07.017	http://dx.doi.org/10.1016/j.jaci.2004.07.017			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	861SO	15480328				2022-12-18	WOS:000224439100022
J	Kollmeier, AP; Eddleston, J; Zuraw, BL; Christiansen, SC				Kollmeier, AP; Eddleston, J; Zuraw, BL; Christiansen, SC			Recurrent anaphylaxis linked to pantoprazole	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							S-MEPHENYTOIN; OMEPRAZOLE; POLYMORPHISM; PHENOTYPE		Scripps Clin, Dept Asthma Allergy & Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA USA; Kaiser Permanente, Dept Allergy & Immunol, San Diego, CA USA	Scripps Research Institute; Scripps Research Institute; Kaiser Permanente	Kollmeier, AP (corresponding author), Scripps Clin, Dept Asthma Allergy & Immunol, N Torrey Pines Rd,Mail Drop W205, La Jolla, CA 92037 USA.	alexakol@yahoo.com		Zuraw, Bruce/0000-0003-0640-6768				BOWLBY HA, 1994, PHARMACOTHERAPY, V14, P119, DOI 10.1002/j.1875-9114.1994.tb02796.x; DEMORAIS SMF, 1994, J BIOL CHEM, V269, P15419; Fardet L, 2002, AM J GASTROENTEROL, V97, P1578, DOI 10.1016/S0002-9270(02)04116-3; Galindo PA, 1999, ANN ALLERG ASTHMA IM, V82, P52, DOI 10.1016/S1081-1206(10)62660-9; Gonzalez P, 2002, Allergol Immunopathol (Madr), V30, P342; Ibeanu GC, 1999, J PHARMACOL EXP THER, V290, P635; Natsch S, 2000, ANN PHARMACOTHER, V34, P474; Ottervanger JP, 1996, J ALLERGY CLIN IMMUN, V97, P1413, DOI 10.1016/S0091-6749(96)70212-9; Tanaka M, 1997, CLIN PHARMACOL THER, V62, P619, DOI 10.1016/S0009-9236(97)90081-3	9	21	22	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2004	114	4					975	977		10.1016/j.jaci.2004.05.068	http://dx.doi.org/10.1016/j.jaci.2004.05.068			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	861SO	15480345				2022-12-18	WOS:000224439100039
J	Milanese, M; Peroni, D; Costella, S; Aralla, R; Loiacono, A; Barp, C; Boner, A; Brusasco, V				Milanese, M; Peroni, D; Costella, S; Aralla, R; Loiacono, A; Barp, C; Boner, A; Brusasco, V			Improved bronchodilator effect of deep inhalation after allergen avoidance in asthmatic children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						respiratory resistance; forced oscillation technique; eosinophils; methacholine challenge	AIRWAY SMOOTH-MUSCLE; LUNG-MECHANICS; HIGH-ALTITUDE; INFLAMMATION; RESPONSIVENESS; HYSTERESIS; HYPERRESPONSIVENESS; METHACHOLINE; OBSTRUCTION	Background: In healthy adults and children, deep inhalation (DI) is able to reverse induced bronchoconstriction. This ability is impaired in asthma, but the reasons are still to be elucidated. Objectives: This study investigated whether the bronchodilator effect of DI during methacholine-induced bronchoconstriction can be improved by allergen avoidance in asthmatic children, and its relationship with airway inflammation. Methods: The effect of DI on methacholine-induced bronchoconstriction was studied at the beginning and the end of a 3-month allergen avoidance period at high altitude in 14 allergic asthmatic children who had severe asthma attacks. Changes in airway caliber were inferred from the respiratory resistance (Rrs) measured by a forced oscillation technique. Results were related to the percentage of eosinophils in induced sputum and compared with those obtained in 9 age-matched nonasthmatic children. Results: In asthmatic subjects, DI had no significant effect on methacholine-induced increase in Rrs before (P = .62) but significantly reversed it after (P < .01) allergen avoidance. However, the ability of DI to reverse a methacholine-induced increase in Rrs tended to remain less in asthmatic than nonasthmatic children even after allergen avoidance (P = .05). In the asthmatic children, the percentage of eosinophils in induced sputum was decreased at the end of the allergen avoidance period (P < .001), without any significant correlation between sputum eosinophils and airway responsiveness to methacholine or effect of DI. Conclusion: A short period of allergen avoidance may improve the ability of DI to reverse induced bronchoconstriction in some asthmatic children. This effect is associated, yet not correlated, with a reduction in airway inflammation.	Univ Genoa, Dipartimento Med Interna, I-16132 Genoa, Italy; Univ Verona, Pediat Clin, I-37100 Verona, Italy	University of Genoa; University of Verona	Brusasco, V (corresponding author), Univ Genoa, Dipartimento Med Interna, Viale Benedetto XV,6, I-16132 Genoa, Italy.	Vito.Brusasco@unige.it	Peroni, Diego G/K-4002-2018; Peroni, Diego/K-8795-2016	MILANESE, Manlio/0000-0001-9626-6230; Peroni, Diego/0000-0002-0234-1373				[Anonymous], 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; Barbato A, 2003, AM J RESP CRIT CARE, V168, P798, DOI 10.1164/rccm.200305-650OC; BRUSASCO V, 1992, J APPL PHYSIOL, V72, P2075, DOI 10.1152/jappl.1992.72.6.2075; Brusasco V, 1999, J APPL PHYSIOL, V87, P567, DOI 10.1152/jappl.1999.87.2.567; Brusasco V, 1998, THORAX, V53, P992, DOI 10.1136/thx.53.11.992; Brusasco V., 1994, EUR RESPIR REV, V4, P118; BURNS CB, 1985, J APPL PHYSIOL, V59, P1590, DOI 10.1152/jappl.1985.59.5.1590; FISH JE, 1981, J APPL PHYSIOL, V50, P1079, DOI 10.1152/jappl.1981.50.5.1079; Fredberg JJ, 1997, AM J RESP CRIT CARE, V156, P1752, DOI 10.1164/ajrccm.156.6.9611016; FROEB HF, 1968, J APPL PHYSIOL, V25, P244, DOI 10.1152/jappl.1968.25.3.244; HIBBERT ME, 1989, PEDIATR PULM, V7, P101, DOI 10.1002/ppul.1950070209; JAMES AL, 1989, AM REV RESPIR DIS, V139, P242, DOI 10.1164/ajrccm/139.1.242; Jenkins HA, 2003, CHEST, V124, P32, DOI 10.1378/chest.124.1.32; LAMBERT RK, 1994, J APPL PHYSIOL, V77, P1206, DOI 10.1152/jappl.1994.77.3.1206; LIM TK, 1987, AM REV RESPIR DIS, V135, P591; Macklem PT, 1996, AM J RESP CRIT CARE, V153, P83, DOI 10.1164/ajrccm.153.1.8542167; Marchal F, 1997, EUR RESP MON, V5, P58; Milanese M, 2001, J APPL PHYSIOL, V91, P1035, DOI 10.1152/jappl.2001.91.3.1035; MITCHELL RW, 1994, AM J PHYSIOL, V267, pL218, DOI 10.1152/ajplung.1994.267.2.L218; MORENO RH, 1986, AM REV RESPIR DIS, V133, P1171; Pellegrino R, 1996, J APPL PHYSIOL, V81, P964, DOI 10.1152/jappl.1996.81.2.964; Pellegrino R, 2003, J APPL PHYSIOL, V95, P728, DOI 10.1152/japplphysiol.00310.2003; PELLEGRINO R, 1990, AM REV RESPIR DIS, V142, P822, DOI 10.1164/ajrccm/142.4.822; Pellegrino R, 1996, AM J RESP CRIT CARE, V153, P115, DOI 10.1164/ajrccm.153.1.8542103; PELLEGRINO R, 1993, J APPL PHYSIOL, V74, P2681, DOI 10.1152/jappl.1993.74.6.2681; PERONI DG, 1994, AM J RESP CRIT CARE, V149, P1442, DOI 10.1164/ajrccm.149.6.8004296; PIN I, 1992, THORAX, V47, P25, DOI 10.1136/thx.47.1.25; PLISS LB, 1989, J APPL PHYSIOL, V66, P2298, DOI 10.1152/jappl.1989.66.5.2298; SACKNER MA, 1989, J APPL PHYSIOL, V66, P410, DOI 10.1152/jappl.1989.66.1.410; SASAKI H, 1979, J APPL PHYSIOL, V47, P1251, DOI 10.1152/jappl.1979.47.6.1251; vanVelzen E, 1996, THORAX, V51, P582, DOI 10.1136/thx.51.6.582	31	21	21	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2004	114	3					505	511		10.1016/j.jaci.2004.05.041	http://dx.doi.org/10.1016/j.jaci.2004.05.041			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	853AX	15356548				2022-12-18	WOS:000223799600005
J	Lora, JM; Al-Garawi, A; Pickard, MD; Price, KS; Bagga, S; Sicoli, J; Hodge, MR; Gutierrez-Ramos, JC; Briskin, MJ; Boyce, JA				Lora, JM; Al-Garawi, A; Pickard, MD; Price, KS; Bagga, S; Sicoli, J; Hodge, MR; Gutierrez-Ramos, JC; Briskin, MJ; Boyce, JA			Fc epsilon-RI-dependent gene expression in human mast cells is differentially controlled by T helper type 2 cytokines	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cytokines; activation; mast cells; asthma	RECEPTOR CROSS-LINKING; CONNECTIVE TISSUE-TYPE; TRICHINELLA-SPIRALIS; INTERLEUKIN-3 IL-3; MEDIATOR RELEASE; TRANSGENIC MICE; IGE; GROWTH; PROLIFERATION; INFLAMMATION	Background: Mast cells (MCs) proliferate in response to T(H)2 cytokines and express genes de novo after activation. Limited information is available concerning the interplay between these events. Objective: We explored the potential for T(H)2 cytokines to alter activation-dependent gene expression by MCs. Methods: Cord blood-derived human (h)MCs maintained in stem cell factor (SCF) alone were compared with replicates treated with IL-4, IL-5, or IL-9, respectively, for their patterns of FeepsilonRI-dependent gene induction using microarray technology. Results: Activation of SCF-treated hMCs upregulated their expression of roughly 140 transcripts at 2 hours, including genes involved in cell cycle progression and arrest. Each cytokine substantially modified this profile; similar to800 inducible genes apiece were controlled by IL-5 or IL-9, whereas 169 inducible genes were controlled by IL-4. IL-4 favored the induction of cytokines and of genes associated with cell growth arrest (GADD34, GAS-1, CIDE-A, INK4D, and BAX) and completely abolished the enhanced proliferation observed in the other 3 groups after activation. Conversely, IL-5 priming induced preferential upregulation of genes involved in cell proliferation and did not abolish thymidine incorporation. Conclusions: T(H)2 cytokines differentially modulate gene induction in hMCs after FcepsilonRI cross-linkage. IL-4 uniquely controls cytokine gene expression by hMCs and might also limit their activation-driven proliferation.	Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA; Millennium Pharmaceut Inc, Dept Immunobiol & Inflammat, Cambridge, MA USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA USA; Partners Asthma Ctr, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Boyce, JA (corresponding author), Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, S Res Bldg,1 Jimmy Fund Way, Boston, MA 02115 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI031599, R56AI052353, U19AI031599, R01AI052353, R01AI048802] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-36110] Funding Source: Medline; NIAID NIH HHS [AI-52353, AI-31599, AI-48802] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Amin K, 2001, J ALLERGY CLIN IMMUN, V107, P249, DOI 10.1067/mai.2001.112266; Anderson DF, 1997, CLIN EXP ALLERGY, V27, P1060, DOI 10.1111/j.1365-2222.1997.tb01258.x; Bischoff SC, 2001, INT ARCH ALLERGY IMM, V124, P151, DOI 10.1159/000053695; Bischoff SC, 1999, P NATL ACAD SCI USA, V96, P8080, DOI 10.1073/pnas.96.14.8080; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; CASALE TB, 1987, J CLIN INVEST, V80, P1507, DOI 10.1172/JCI113234; DELSAL G, 1994, P NATL ACAD SCI USA, V91, P1848, DOI 10.1073/pnas.91.5.1848; Finkelman FD, 1997, ANNU REV IMMUNOL, V15, P505, DOI 10.1146/annurev.immunol.15.1.505; Friend DS, 1998, J IMMUNOL, V160, P5537; Gebhardt T, 2002, EUR J IMMUNOL, V32, P2308, DOI 10.1002/1521-4141(200208)32:8<2308::AID-IMMU2308>3.0.CO;2-X; Godfraind C, 1998, J IMMUNOL, V160, P3989; GORDON JR, 1990, NATURE, V346, P274, DOI 10.1038/346274a0; Hsieh FH, 2001, J EXP MED, V193, P123, DOI 10.1084/jem.193.1.123; Huang CF, 1998, J CLIN IMMUNOL, V18, P169, DOI 10.1023/A:1020574820797; Inohara N, 1998, EMBO J, V17, P2526, DOI 10.1093/emboj/17.9.2526; IRANI AMA, 1991, J IMMUNOL, V147, P247; IRANI AMA, 1987, J IMMUNOL, V138, P4381; KITAMURA Y, 1978, BLOOD, V52, P447; KITAMURA Y, 1979, BLOOD, V53, P492; KOBAYASI T, 1969, ACTA DERM-VENEREOL, V49, P369; LAITINEN LA, 1993, AM REV RESPIR DIS, V147, P697, DOI 10.1164/ajrccm/147.3.697; Lantz CS, 1998, NATURE, V392, P90, DOI 10.1038/32190; LEVISCHAFFER F, 1993, CELL IMMUNOL, V148, P435, DOI 10.1006/cimm.1993.1124; Lorentz A, 2000, J IMMUNOL, V164, P43, DOI 10.4049/jimmunol.164.1.43; MADDEN KB, 1991, J IMMUNOL, V147, P1387; Manji GA, 2002, J BIOL CHEM, V277, P11570, DOI 10.1074/jbc.M112208200; Matsuzawa S, 2003, J IMMUNOL, V170, P3461, DOI 10.4049/jimmunol.170.7.3461; Mellor EA, 2002, J EXP MED, V195, P583, DOI 10.1084/jem.20020044; Nakajima T, 2002, BLOOD, V100, P3861, DOI 10.1182/blood-2002-02-0602; Ochi H, 2000, P NATL ACAD SCI USA, V97, P10509, DOI 10.1073/pnas.180318697; Ochi H, 1999, J EXP MED, V190, P267, DOI 10.1084/jem.190.2.267; OLTAVI ZN, 1993, CELL, V74, P609; Oskeritzian CA, 1999, J IMMUNOL, V163, P5105; Pesce M, 1997, MECH DEVELOP, V68, P37, DOI 10.1016/S0925-4773(97)00120-2; PESCI A, 1993, AM REV RESPIR DIS, V147, P684, DOI 10.1164/ajrccm/147.3.684; PLANT M, 1989, NATURE, V339, P64; RENNICK D, 1995, BLOOD, V85, P57, DOI 10.1182/blood.V85.1.57.bloodjournal85157; RUITENBER EJ, 1976, NATURE, V264, P258, DOI 10.1038/264258a0; SAYAMA K, 2002, BMC IMMUNOL, V3, P3; SCHECHTER NM, 1990, J IMMUNOL, V145, P2652; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Straumann A, 2001, J ALLERGY CLIN IMMUN, V108, P954, DOI 10.1067/mai.2001.119917; TAKAGI M, 1989, J EXP MED, V170, P233, DOI 10.1084/jem.170.1.233; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; Temann UA, 1998, J EXP MED, V188, P1307, DOI 10.1084/jem.188.7.1307; Toru H, 1998, J ALLERGY CLIN IMMUN, V102, P491, DOI 10.1016/S0091-6749(98)70140-X; Toru H, 1996, INT IMMUNOL, V8, P1367; URATA H, 1991, J BIOL CHEM, V266, P17173; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wong GW, 2001, J BIOL CHEM, V276, P49169, DOI 10.1074/jbc.M108677200; Xiang Z, 2001, J EXP MED, V194, P1561, DOI 10.1084/jem.194.11.1561; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YANAGIDA M, 1995, BLOOD, V86, P3705, DOI 10.1182/blood.V86.10.3705.bloodjournal86103705; YOWE D, 2002, IMMUNOLOGY INFECT, P521; Zhang C, 1997, J BIOL CHEM, V272, P13397, DOI 10.1074/jbc.272.20.13397	55	21	22	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2003	112	6					1119	1126		10.1016/j.jaci.2003.08.042	http://dx.doi.org/10.1016/j.jaci.2003.08.042			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	752HC	14657870	Bronze			2022-12-18	WOS:000187154200014
J	Sutherland, ER; Ellison, MC; Kraft, M; Martin, RJ				Sutherland, ER; Ellison, MC; Kraft, M; Martin, RJ			Altered pituitary-adrenal interaction in nocturnal asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						corticotropin; cortisol; inflammation; nocturnal asthma	DECREASED STEROID RESPONSIVENESS; ALVEOLAR TISSUE; SERUM CORTISOL; LUNG-FUNCTION; ADRENOCORTICOTROPIN; INFLAMMATION; EPINEPHRINE; EOSINOPHILS; HISTAMINE; RECEPTOR	Background: Increased airway inflammation at night contributes to the nocturnal worsening of asthma, but the mechanisms regulating circadian variations in airway inflammation are unknown. Objective: We hypothesized that altered hypothalamic-pituitary-adrenal axis function serves as an endogenous controller of inflammation in nocturnal asthma. Methods: Patients with nocturnal asthma (n = 7), patients with nonnocturnal asthma (n = 13), and healthy control subjects (n = 11) adhered to a regular sleep-wake cycle for 1 week. Corticotropin and cortisol levels were assayed every 2 hours for 24 hours. Low-dose' corticotropin stimulation was performed. Circadian hormonal flux was analyzed by means of cosinor modeling and calculation of the area under the 24-hour curve. Results: Corticotropin peak levels and areas under the 24-hour curve were significantly increased in patients with nocturnal asthma versus values in patients with nonnocturnal asthma and control subjects. Patients with nonnocturnal asthma demonstrated significantly increased areas under the 24-hour cortisol curve when compared with control subjects, but peak cortisol levels did not differ between groups. Cortisol levels after low-dose corticotropin stimulation did not differ between groups. Corticotropin and cortisol levels were not correlated with the degree of physiologic impairment. Conclusion: Nocturnal asthma is marked by increased corticotropin levels that are not accompanied by commensurate increases in cortisol levels. This observation might indicate blunted adrenal responsiveness in the nocturnal asthma phenotype. Conversely, adrenal response to corticotropin might be enhanced in nonnocturnal asthma, attenuating nocturnal worsening of airway inflammation.	Natl Jewish Med & Res Ctr, Dept Med, Denver, CO USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Prevent Med & Biometr, Denver, CO USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Martin, RJ (corresponding author), 1400 Jackson St, Denver, CO 80206 USA.		Sutherland, Everett Rand/B-7666-2008		NHLBI NIH HHS [R01 HL64804, K23 HL04385] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064804, K23HL004385] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARNES P, 1980, NEW ENGL J MED, V303, P263, DOI 10.1056/NEJM198007313030506; BEAM WR, 1992, AM REV RESPIR DIS, V146, P1524, DOI 10.1164/ajrccm/146.6.1524; Bornstein SR, 1999, J CLIN ENDOCR METAB, V84, P1729; BROIDE J, 1995, J CLIN ENDOCR METAB, V80, P1243, DOI 10.1210/jc.80.4.1243; CALHOUN WJ, 1992, AM REV RESPIR DIS, V145, P577, DOI 10.1164/ajrccm/145.3.577; Cunningham S.J., 1997, EMERG PEDIAT, V10, P33; CZEISLER CA, 1986, SCIENCE, V233, P667, DOI 10.1126/science.3726555; FRICK WE, 1989, AM REV RESPIR DIS, V139, P1401, DOI 10.1164/ajrccm/139.6.1401; Georges G, 1998, J ASTHMA, V35, P261, DOI 10.3109/02770909809068216; HAEN E, 1991, CHEST, V100, P1239, DOI 10.1378/chest.100.5.1239; Halberg F., 1967, CELLULAR ASPECTS BIO, P20, DOI DOI 10.1007/978-3-642-88394-1; HELLMAN L, 1970, J CLIN ENDOCR METAB, V30, P411, DOI 10.1210/jcem-30-4-411; Kraft M, 2001, AM J RESP CRIT CARE, V163, P1219, DOI 10.1164/ajrccm.163.5.2002058; Kraft M, 1999, J ALLERGY CLIN IMMUN, V103, P66, DOI 10.1016/S0091-6749(99)70527-0; Kraft M, 1999, AM J RESP CRIT CARE, V159, P228, DOI 10.1164/ajrccm.159.1.9804033; Kraft M, 1996, AM J RESP CRIT CARE, V154, P1505, DOI 10.1164/ajrccm.154.5.8912772; Kraft M, 1998, CHRONOBIOL INT, V15, P85, DOI 10.3109/07420529808998672; Landstra AM, 2002, AM J RESP CRIT CARE, V165, P708, DOI 10.1164/ajrccm.165.5.2102115; LAUE L, 1991, J CLIN ENDOCR METAB, V73, P380, DOI 10.1210/jcem-73-2-380; MARTIN RJ, 1990, AM REV RESPIR DIS, V141, P33, DOI 10.1164/ajrccm/141.1.33; Martin RJ, 1999, CHRONOBIOL INT, V16, P623, DOI 10.3109/07420529908998731; MORRISH DW, 1979, CHEST, V75, P161, DOI 10.1378/chest.75.2.161; PINCUS DJ, 1995, J ALLERGY CLIN IMMUN, V95, P1172, DOI 10.1016/S0091-6749(95)70073-0; *SAS I INC, 1999, SAS STAT US GUID VER, P2419; Spengler CM, 2000, AM J RESP CRIT CARE, V162, P1038, DOI 10.1164/ajrccm.162.3.9911107; SZEFLER SJ, 1991, CLIN PHARMACOL THER, V49, P59, DOI 10.1038/clpt.1991.11; TURKI J, 1995, J CLIN INVEST, V95, P1635, DOI 10.1172/JCI117838; VanKeimpema ARJ, 1997, RESPIRATION, V64, P29	28	21	22	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2003	112	1					52	57		10.1067/mai.2003.1608	http://dx.doi.org/10.1067/mai.2003.1608			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	698QQ	12847479	Bronze			2022-12-18	WOS:000184010600009
J	Liccardi, G; Salzillo, A; Spadaro, G; Senna, G; Canonica, WG; D'Amato, G; Passalacqua, G				Liccardi, G; Salzillo, A; Spadaro, G; Senna, G; Canonica, WG; D'Amato, G; Passalacqua, G			Anaphylaxis caused by skin prick testing with aeroallergens: Case report and evaluation of the risk in Italian allergy services	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									A Cardarelli Hosp, Div Pneumol & Allergol, Naples, Italy; Univ Naples Federico II, Div Clin Immunol & Allergy, Naples, Italy; Verona Gen Hosp, Allergy Serv, Verona, Italy; Univ Genoa, Dept Internal Med, I-16132 Genoa, Italy	Antonio Cardarelli Hospital; University of Naples Federico II; University of Genoa	Liccardi, G (corresponding author), A Cardarelli Hosp, Div Pneumol & Allergol, Naples, Italy.		Senna, Gianenrico/AAC-5201-2022; canonica, giorgio walter/ABF-2037-2020	Senna, Gianenrico/0000-0003-4172-3216; canonica, giorgio walter/0000-0001-8467-2557; Ziyadullaev, Shukhrat/0000-0002-9309-3933				*AM AC ALL IMM, 1993, J ALLERGY CLIN IMMUN, V92, P6; [Anonymous], 1989, ALLERGY S10, V10, P1; Devenney I, 2000, ANN ALLERG ASTHMA IM, V85, P455, DOI 10.1016/S1081-1206(10)62571-9; Dreborg S, 1996, ALLERGY, V51, P60, DOI 10.1111/j.1398-9995.1996.tb04552.x; LIN MS, 1993, ANN ALLERGY, V71, P557; LOCKEY RF, 1987, J ALLERGY CLIN IMMUN, V79, P660, DOI 10.1016/S0091-6749(87)80164-1; NOVEMBRE E, 1995, ALLERGY, V50, P511, DOI 10.1111/j.1398-9995.1995.tb01187.x; TURKELTAUB PC, 1989, J ALLERGY CLIN IMMUN, V84, P886, DOI 10.1016/0091-6749(89)90384-9; Valyasevi MA, 1999, ANN ALLERG ASTHMA IM, V83, P132, DOI 10.1016/S1081-1206(10)62624-5; Vanin E, 2002, PEDIATR ALLERGY IMMU, V13, P227, DOI 10.1034/j.1399-3038.2002.01035.x	10	21	22	1	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2003	111	6					1410	1412		10.1067/mai.2003.1521	http://dx.doi.org/10.1067/mai.2003.1521			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	688FZ	12789249				2022-12-18	WOS:000183424700037
J	Matsukura, S; Kokubu, F; Kuga, H; Kawaguchi, M; Ieki, K; Odaka, M; Suzuki, S; Watanabe, S; Takeuchi, H; Adachi, M; Stellato, C; Schleimer, RP				Matsukura, S; Kokubu, F; Kuga, H; Kawaguchi, M; Ieki, K; Odaka, M; Suzuki, S; Watanabe, S; Takeuchi, H; Adachi, M; Stellato, C; Schleimer, RP			Differential regulation of eotaxin expression by IFN-gamma in airway epithelial cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eotaxin; IFN-gamma; epithelial cells; asthma	NF-KAPPA-B; INTERFERON-GAMMA; IN-VITRO; GENOMIC ORGANIZATION; MESSENGER-RNA; DNA-BINDING; ASTHMA; GENE; TRANSCRIPTION; INFLAMMATION	Background: Eotaxin is a chemokine that binds with high affinity and specificity to the chemokine receptor CCR3 and plays an important role in the pathogenesis of allergic disease. Objective: We studied the regulation of eotaxin expression by the T(H)1 cytokine IFN-gamma and analyzed its molecular mechanisms. Methods: Levels of eotaxin mRNA and protein expression in the airway epithelial cell line BEAS-2B were determined with RT-PCR and ELISA. Mechanisms of transcriptional regulation were assessed by means of electrophoretic mobility shift assays and luciferase assay with eotaxin promoter-luciferase reporter plasmids. Results: Although IFN-gamma did not directly induce the expression of eotaxin protein, it increased the induction by TNF-alpha when these cytokines were added simultaneously. In contrast, preincubation of cells with IFN-gamma for 24 hours profoundly inhibited the production induced by TNF-alpha. IFN-gamma did not influence the TNF-alpha-induced binding of nuclear factor kappaB to a DNA probe derived from the eotaxin promoter. IFN-gamma did not increase the ability of TNF-a to activate the eotaxin promoter. Studies of eotaxin mRNA levels indicate that IFN-gamma combined with TNF-alpha increased the expression of eotaxin mRNA. When cells were preincubated with IFN-gamma, there was no inhibition of the appearance of eotaxin mRNA. Conclusion: These studies demonstrate that IFN-gamma enhances eotaxin expression when added in combination with TNF-alpha and profoundly inhibits eotaxin expression after preincubation. In both cases the available data indicate that the effect is mediated by a posttranscriptional mechanism. (J Allergy Clin Immunol 2003;111:1337-44.).	Showa Univ, Dept Internal Med 1, Sch Med, Shinagawa Ku, Tokyo 1428666, Japan; Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD USA	Showa University; Johns Hopkins University; Johns Hopkins Medicine	Matsukura, S (corresponding author), Showa Univ, Dept Internal Med 1, Sch Med, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428666, Japan.		Stellato, Cristiana/P-3001-2015	Stellato, Cristiana/0000-0002-1294-8355	NHLBI NIH HHS [HL 68546] Funding Source: Medline; NIAID NIH HHS [AI 44885] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL068546, R01HL068546] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044885] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Ben-Asouli Y, 2002, CELL, V108, P221, DOI 10.1016/S0092-8674(02)00616-5; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Castro M, 2000, AM J RESP CELL MOL, V22, P143, DOI 10.1165/ajrcmb.22.2.f174; CORRIGAN CJ, 1991, INT ARCH ALLER A IMM, V94, P270, DOI 10.1159/000235380; Daugherty BL, 1996, J EXP MED, V183, P2349, DOI 10.1084/jem.183.5.2349; Ehret GB, 2001, J BIOL CHEM, V276, P6675, DOI 10.1074/jbc.M001748200; FLOLKERTS G, 1998, AM J RESP CRIT CARE, V157, P1708; GarciaZepeda EA, 1997, GENOMICS, V41, P471, DOI 10.1006/geno.1997.4656; GarciaZepeda EA, 1996, NAT MED, V2, P449, DOI 10.1038/nm0496-449; Hein H, 1997, BIOCHEM BIOPH RES CO, V237, P537, DOI 10.1006/bbrc.1997.7169; Hoeck J, 2001, J IMMUNOL, V166, P4507, DOI 10.4049/jimmunol.166.7.4507; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; Kawaguchi M, 2000, INT ARCH ALLERGY IMM, V122, P44, DOI 10.1159/000053632; Lamkhioued B, 1997, J IMMUNOL, V159, P4593; LILLY CM, 1997, J CLIN INVEST, V99, P1763; Matsukura S, 2001, AM J RESP CELL MOL, V24, P755, DOI 10.1165/ajrcmb.24.6.4351; Matsukura S, 1999, J IMMUNOL, V163, P6876; Mazumder B, 1999, MOL CELL BIOL, V19, P6898; Miyamasu M, 1999, INT IMMUNOL, V11, P1001, DOI 10.1093/intimm/11.6.1001; Mochizuki M, 1998, J IMMUNOL, V160, P60; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Ochi H, 1999, J EXP MED, V190, P267, DOI 10.1084/jem.190.2.267; REDDEL RR, 1988, CANCER RES, V48, P1904; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; Stellato C, 1999, J IMMUNOL, V163, P5624; Stellato C, 1997, J CLIN INVEST, V99, P926, DOI 10.1172/JCI119257; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; Teran LM, 1999, AM J RESP CELL MOL, V20, P777, DOI 10.1165/ajrcmb.20.4.3508; von Hertzen LC, 2000, AM J RESP CELL MOL, V22, P139, DOI 10.1165/ajrcmb.22.2.3753; Yamada H, 1997, BIOCHEM BIOPH RES CO, V231, P365, DOI 10.1006/bbrc.1997.6100; YANG Z, 1990, P NATL ACAD SCI USA, V87, P9226, DOI 10.1073/pnas.87.23.9226; Ying S, 1997, EUR J IMMUNOL, V27, P3507, DOI 10.1002/eji.1830271252	35	21	21	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2003	111	6					1337	1344		10.1067/mai.2003.1513	http://dx.doi.org/10.1067/mai.2003.1513			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	688FZ	12789237	Bronze			2022-12-18	WOS:000183424700025
J	Feuchtinger, T; Bartz, H; von Berg, A; Riedinger, F; Brauburger, J; Stenglein, S; Wahn, U; Schaur, U				Feuchtinger, T; Bartz, H; von Berg, A; Riedinger, F; Brauburger, J; Stenglein, S; Wahn, U; Schaur, U			Treatment with omalizumab normalizes the number of myeloid dendritic cells during the grass pollen season	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							FC-EPSILON-RI; IGE		Ruhr Univ Bochum, Childrens Hosp, Bochum, Germany; Marien Hosp, Wesel, Germany; Novartis Pharma GmbH, Nurnberg, Germany; Humboldt Univ, Charite, Dept Pediat Pneumol & Immunol, Berlin, Germany	Ruhr University Bochum; St. Marien Hospital; Novartis; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Feuchtinger, T (corresponding author), Ruhr Univ Bochum, Childrens Hosp, Bochum, Germany.		Feuchtinger, Tobias/AAS-3869-2021	Feuchtinger, Tobias/0000-0002-8517-9681				Babu KS, 2001, ALLERGY, V56, P1121, DOI 10.1034/j.1398-9995.2001.00019.x; Chang TW, 2000, NAT BIOTECHNOL, V18, P157, DOI 10.1038/72601; Coyle AJ, 1996, J EXP MED, V183, P1303, DOI 10.1084/jem.183.4.1303; Heusser C, 1997, CURR OPIN IMMUNOL, V9, P805, DOI 10.1016/S0952-7915(97)80182-3; Katoh N, 2000, J CLIN INVEST, V105, P183, DOI 10.1172/JCI6895; Kuehr J, 2002, J ALLERGY CLIN IMMUN, V109, P274, DOI 10.1067/mai.2002.121949; Liu YJ, 2001, NAT IMMUNOL, V2, P585, DOI 10.1038/89726; Pawankar R, 1997, J CLIN INVEST, V99, P1492, DOI 10.1172/JCI119311; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Teig N, 2002, SCAND J IMMUNOL, V55, P453, DOI 10.1046/j.1365-3083.2002.01068.x	10	21	21	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2003	111	2					428	430		10.1067/mai.2003.56	http://dx.doi.org/10.1067/mai.2003.56			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	644WF	12589369				2022-12-18	WOS:000180942700033
J	Matsui, E; Kagey-Sobotka, A; Chichester, K; Eggleston, PA				Matsui, E; Kagey-Sobotka, A; Chichester, K; Eggleston, PA			Allergic potency of recombinant Fel d 1 is reduced by low concentrations of chlorine bleach	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Fel d 1; sodium hypochlorite; basophil histamine release	INNER-CITY HOMES; COCKROACH ALLERGEN; MONOCLONAL-ANTIBODIES; SODIUM-HYPOCHLORITE; SEQUENCE-ANALYSIS; D-I; DUST; CAT; EXTERMINATION; EXPOSURE	Background: Sodium hypochlorite (NaOCl), the primary component of household bleach, has been shown to alter the purified mouse allergen Mus m 1, such that antibody recognition, or immunogenicity, is lost. Results of initial experiments suggest that antibody recognition is lost at lower concentrations of NaOCl than those required to fragment Mus m 1. Objective: We sought to determine whether NaOCl had similar effects on recombinant (r)Fel d 1 and whether the loss of antibody recognition correlated with the loss of biologic activity, as measured with a basophil histamine release assay. Methods: Recombinant Fel d 1 was treated with increasing amounts of NaOCl, and the product of the reaction was analyzed by using SDS-PAGE, Western blotting, and ELISA. The biologic activity of NaOCl-treated rFel d 1 was analyzed with a basophil histamine release assay. Results: The protein fragmented at an NaOCl/rFel d 1 molar ratio of 7000, whereas cat-specific IgG recognition was lost at a lower molar ratio of 560. Basophil histamine release assays were performed to determine the effect of NaOCl on the biologic activity of rFel d 1. An NaOCl/protein molar ratio of 70 caused a significant reduction in histamine release from basophils of subjects with cat allergy. A molar ratio of 140 further inhibited histamine release by rFel d 1, suggesting a dose-response relationship between NaOCl and loss of biologic activity. Conclusions: NaOCl modifies rFel d 1, resulting in loss of immunogenicity and attenuation of biologic activity, as measured by its ability to stimulate basophil histamine release.	Johns Hopkins Sch Med, Dept Pediat, Baltimore, MD USA; Johns Hopkins Sch Med, Dept Med, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Matsui, E (corresponding author), Johns Hopkins Univ Hosp, CMSC 1102,600 N Wolfe St, Baltimore, MD 21287 USA.			Matsui, Elizabeth/0000-0001-8134-5593	NIEHS NIH HHS [ES 09606, ES 07527] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R55ES007527, P01ES009606, R01ES007527] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		*AM PUBL HLTH ASS, 1907, AM PUBL HLTH ASS STA, P316; *CDC, 1987, MMWR-MORBID M    S2S, V36, pS9; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; Chen P, 2001, CLIN EXP ALLERGY, V31, P1086, DOI 10.1046/j.1365-2222.2001.01127.x; Eggleston PA, 1999, J ALLERGY CLIN IMMUN, V104, P842, DOI 10.1016/S0091-6749(99)70296-4; EHNERT B, 1992, J ALLERGY CLIN IMMUN, V90, P135, DOI 10.1016/S0091-6749(06)80024-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LICHTENSTEIN LM, 1971, ANN INTERN MED, V75, P663, DOI 10.7326/0003-4819-75-5-663; MORGENSTERN JP, 1991, P NATL ACAD SCI USA, V88, P9690, DOI 10.1073/pnas.88.21.9690; PERIERA WE, 1973, BIOCHIM BIOPHYS ACTA, V313, P170; Sarpong SB, 1996, ANN ALLERG ASTHMA IM, V76, P257, DOI 10.1016/S1081-1206(10)63437-0; SEHULSTER LM, 1981, APPL ENVIRON MICROB, V42, P762, DOI 10.1128/AEM.42.5.762-767.1981; Vailes LD, 2002, J ALLERGY CLIN IMMUN, V110, P757, DOI 10.1067/mai.2002.129035; VANMILLIGEN FJ, 1992, INT ARCH ALLERGY IMM, V99, P63, DOI 10.1159/000236337; WOOD RA, 1989, J ALLERGY CLIN IMMUN, V83, P730, DOI 10.1016/0091-6749(89)90006-7; Wood RA, 2001, ANN ALLERG ASTHMA IM, V87, P60, DOI 10.1016/S1081-1206(10)62324-1	16	21	24	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2003	111	2					396	401		10.1067/mai.2003.11	http://dx.doi.org/10.1067/mai.2003.11			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	644WF	12589362				2022-12-18	WOS:000180942700026
J	Elmstahl, S; Ekstrom, H; Galvard, H; Johnell, O; de Verdier, MG; Norjavaara, E				Elmstahl, S; Ekstrom, H; Galvard, H; Johnell, O; de Verdier, MG; Norjavaara, E			Is there an association between inhaled corticosteroids and bone density in postmenopausal women?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						bone mineral density; cohort study; inhaled corticosteroids; postmenopausal	DIET HISTORY METHOD; MINERAL DENSITY; MALMO FOOD; ASTHMA; RISK; QUESTIONNAIRE; THERAPY; FRACTURE	Background: During the last decades, there has been increased concern about the association between oral corticosteroid (OC) therapy and osteoporosis. Objective: The question currently discussed is whether inhaled corticosteroids (ICs) in recommended doses have any clinically relevant effects on bone mineral density (BMD). Methods: We compared BMD in postmenopausal women exposed to corticosteroids only in inhaled form (IC group, n 106) with that in women not exposed to corticosteroids (unexposed group, n = 674). BMD was also studied in 49 women exposed to OCs, intra-articular injections, or both in addition to ICs (OC group). The women were recruited from a population-based prospective cohort study. Methods: We used a dietary survey, bone density measurement of the forearm, and a health questionnaire including an interview about past and present medication use. Results: Mean BMD did not significantly differ between the IC group (0.434 g/cm(2)) and the unexposed group (0.429 g/cm(2)). The mean duration and dose of lCs was 8.2 +/- 5.03 years and 853 mug daily. Within the IC group, BMD stratified for cumulative dose of IC, duration, or current dose greater than or less than 1000 mug did not differ. BMD in the OC group was lower than that in the IC group (0.408 vs 0.434 g/cm(2)). Conclusion: No difference in BMD was noted between the IC group and unexposed control subjects, nor was any dose response relationship observed between IC therapy and BMD.	Univ Gothenburg, Paediat Growth Res Ctr, Gothenburg, Sweden; AstraZeneca, Lund, Sweden; Lund Univ, Dept Orthopaed, Malmo, Sweden; Lund Univ, Dept Community Med, Div Geriatr Med, Malmo, Sweden	University of Gothenburg; AstraZeneca; Lund University; Lund University	Elmstahl, S (corresponding author), Malmo Univ Hosp, Dept Community Med, SE-20502 Malmo, Sweden.			Norjavaara, Ensio/0000-0003-0415-4843				Augat P, 1998, OSTEOPOROSIS INT, V8, P299, DOI 10.1007/s001980050068; Bonay M, 2002, DRUG SAFETY, V25, P57, DOI 10.2165/00002018-200225010-00005; BOYD G, 1994, RESP MED, V88, P45, DOI 10.1016/S0954-6111(05)80040-X; Cave A, 1999, PHARMACOL THERAPEUT, V83, P153, DOI 10.1016/S0163-7258(99)00019-4; Ebeling PR, 1998, J BONE MINER RES, V13, P1283, DOI 10.1359/jbmr.1998.13.8.1283; Elmstahl S, 1996, EUR J CLIN NUTR, V50, P143; Elmstahl S, 1996, EUR J CLIN NUTR, V50, P134; IP M, 1994, CHEST, V105, P1722, DOI 10.1378/chest.105.6.1722; Israel E, 2001, NEW ENGL J MED, V345, P941, DOI 10.1056/NEJMoa002304; Jackson L D, 1999, Can J Clin Pharmacol, V6, P26; JONES A, 2002, COCHRANE DATABASE SY; Lane NE, 1998, ENDOCRIN METAB CLIN, V27, P465, DOI 10.1016/S0889-8529(05)70017-7; Li JTC, 1999, J ALLERGY CLIN IMMUN, V103, P1062, DOI 10.1016/S0091-6749(99)70180-6; Lipworth BJ, 1999, ARCH INTERN MED, V159, P941, DOI 10.1001/archinte.159.9.941; Luengo M, 1997, EUR RESPIR J, V10, P2110, DOI 10.1183/09031936.97.10092110; LUKASKI HC, 1985, AM J CLIN NUTR, V41, P810, DOI 10.1093/ajcn/41.4.810; Marshall D, 1996, BRIT MED J, V312, P1254, DOI 10.1136/bmj.312.7041.1254; MAXWELL DL, 1990, BIOMED PHARMACOTHER, V44, P421, DOI 10.1016/0753-3322(90)90047-D; MEERAN K, 1995, AM J RESP CRIT CARE, V151, P333, DOI 10.1164/ajrccm.151.2.7842187; Melton LJ, 1998, J BONE MINER RES, V13, P1915, DOI 10.1359/jbmr.1998.13.12.1915; Pauwels RA, 1999, NEW ENGL J MED, V340, P1948, DOI 10.1056/NEJM199906243402503; SAAG KG, 1999, THORAX S2, V54, P552; STEEN B, 1986, COMPREHENSIVE GERO A, V1, P102; Storms WW, 1998, ANN ALLERG ASTHMA IM, V80, P391, DOI 10.1016/S1081-1206(10)62989-4; Tattersfield AE, 2001, THORAX, V56, P272, DOI 10.1136/thorax.56.4.272; TAYLOR HL, 1978, J CHRON DIS, V31, P741, DOI 10.1016/0021-9681(78)90058-9; Toogood JH, 1998, J ALLERGY CLIN IMMUN, V102, P705, DOI 10.1016/S0091-6749(98)70007-7; TOOGOOD JH, 1995, J ALLERGY CLIN IMMUN, V96, P157, DOI 10.1016/S0091-6749(95)70003-X; van Staa TP, 2001, J BONE MINER RES, V16, P581, DOI 10.1359/jbmr.2001.16.3.581; Van Staa TP, 2000, J BONE MINER RES, V15, P993, DOI 10.1359/jbmr.2000.15.6.993; Wong CA, 2000, LANCET, V355, P1399, DOI 10.1016/S0140-6736(00)02138-3; Wong CA, 2002, CURR OPIN PULM MED, V8, P39, DOI 10.1097/00063198-200201000-00007	32	21	23	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2003	111	1					91	96		10.1067/mai.2003.4	http://dx.doi.org/10.1067/mai.2003.4			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	636PR	12532102				2022-12-18	WOS:000180465500014
J	Tomkinson, A; Duez, C; Lahn, M; Gelfand, EW				Tomkinson, A; Duez, C; Lahn, M; Gelfand, EW			Adoptive transfer of T cells induces airway hyperresponsiveness independently of airway eosinophilia but in a signal transducer and activator of transcription 6-dependent manner	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						airway hyperresponsiveness; T lymphocyte; STAT6; eosinophilia	MURINE MODEL; LUNG DAMAGE; BRONCHIAL BIOPSIES; DEFICIENT MICE; ATOPIC ASTHMA; MESSENGER-RNA; MAST-CELLS; TH2 CELLS; HYPERREACTIVITY; INTERLEUKIN-5	Background: Activated T cells, through the release of specific cytokines (ie, IL-4, IL-5, and IL-13), regulate effector cell recruitment and function. In this way T cells orchestrate the inflammatory response, which leads to airway hyperresponsiveness (AHR), a cardinal feature of allergic asthma. Objective: In the present study the direct role of T cells and, in particular, the importance of signal transducer and activator of transcription 6 (STAT6) in T cells was investigated in the development of AHR. Methods: In a murine model of allergen-driven AHR, the effects of adoptive transfer of STAT6-containing (STAT6+/+) and STAT6-deficient (STAT6-/-) T cells from sensitized mice into allergen-challenged mice were tested. Results: Although greater in STAT6+/+ mice, both allergen-challenged STAT6+/+ and STAT6-/- mice had AHR after transfer of T cells from sensitized STAT6+/+ mice. In contrast, AHR did not develop in allergen-challenged STAT6-/- mice after transfer of T cells from sensitized STAT6-/- mice. Reconstitution of AHR after T-cell transfer was not associated with airway eosinophilia. Conclusions: The data indicate that the STAT6 status of the donor mice is critical to the development of AHR. Although not critical for the development of AHR, the STAT6 status of the recipient mice might play a contributory-regulatory role in the AHR response. The results identify a STAT6-dependent T-cell pathway capable of modulating airway responsiveness, even in the absence of a significant airway eosinophilia.	Natl Jewish Med & Res Ctr, Dept Pediat, Div Cell Biol, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Dept Immunol, Div Cell Biol, Denver, CO 80206 USA	National Jewish Health; National Jewish Health	Gelfand, EW (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Div Cell Biol, Denver, CO 80206 USA.		Duez, Catherine/B-8425-2018	Duez, Catherine/0000-0002-2327-1095	NHLBI NIH HHS [HL-36577, HL-61005] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061005, P01HL036577] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BRADLEY BL, 1991, J ALLERGY CLIN IMMUN, V88, P661, DOI 10.1016/0091-6749(91)90160-P; Cohn L, 1998, J IMMUNOL, V161, P3813; Corry DB, 1996, J EXP MED, V183, P109, DOI 10.1084/jem.183.1.109; Corry DB, 1998, MOL MED, V4, P344, DOI 10.1007/BF03401741; de Vries JE, 1998, J ALLERGY CLIN IMMUN, V102, P165, DOI 10.1016/S0091-6749(98)70080-6; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; GAVETT SH, 1994, AM J RESP CELL MOL, V10, P587, DOI 10.1165/ajrcmb.10.6.8003337; GONZALEZ MC, 1987, AM REV RESPIR DIS, V136, P600, DOI 10.1164/ajrccm/136.3.600; Hamelmann E, 1996, J EXP MED, V183, P1719, DOI 10.1084/jem.183.4.1719; Hamelmann E, 1997, AM J RESP CRIT CARE, V155, P819, DOI 10.1164/ajrccm.155.3.9117011; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Henderson WR, 1996, J EXP MED, V184, P1483, DOI 10.1084/jem.184.4.1483; Hogan SP, 1997, J CLIN INVEST, V99, P1329, DOI 10.1172/JCI119292; Hogan SP, 1998, J IMMUNOL, V161, P1501; Hogan SP, 1998, AM J RESP CRIT CARE, V157, P210, DOI 10.1164/ajrccm.157.1.9702074; HUANG SK, 1995, J IMMUNOL, V155, P2688; Kaminuma O, 1997, AM J RESP CELL MOL, V16, P448, DOI 10.1165/ajrcmb.16.4.9115756; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; Li XM, 1998, J IMMUNOL, V160, P1378; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; MCFADDEN ER, 1994, AM J RESP CRIT CARE, V150, pS23, DOI 10.1164/ajrccm/150.5_Pt_2.S23; ROBINSON D, 1993, J ALLERGY CLIN IMMUN, V92, P313, DOI 10.1016/0091-6749(93)90175-F; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Takeda K, 2001, AM J PHYSIOL-LUNG C, V281, pL394, DOI 10.1152/ajplung.2001.281.2.L394; Takeda K, 1997, J EXP MED, V186, P449, DOI 10.1084/jem.186.3.449; Tomkinson A, 1999, AM J RESP CRIT CARE, V160, P1283, DOI 10.1164/ajrccm.160.4.9809065; WALKER C, 1991, J IMMUNOL, V146, P1829; YAMAGUCHI Y, 1988, J EXP MED, V167, P43, DOI 10.1084/jem.167.1.43; Ying S, 1997, J IMMUNOL, V158, P3539; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909	34	21	22	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2002	109	5					810	816		10.1067/mai.2002.123531	http://dx.doi.org/10.1067/mai.2002.123531			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	553QW	11994705	Bronze			2022-12-18	WOS:000175687800011
J	Bacharier, LB; Mauger, DT; Lemanske, RF; Schend, V; Sorkness, C; Strunk, RC				Bacharier, LB; Mauger, DT; Lemanske, RF; Schend, V; Sorkness, C; Strunk, RC			Classifying asthma severity in children: Is measuring lung function helpful?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract									Washington Univ, Sch Med, St Louis, MO USA; Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Hershey, PA 17033 USA; Univ Wisconsin, Madison, WI 53706 USA	Washington University (WUSTL); Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of Wisconsin System; University of Wisconsin Madison									0	21	21	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2002	109	1		S		811	S266	S266		10.1016/S0091-6749(02)81946-7	http://dx.doi.org/10.1016/S0091-6749(02)81946-7			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	519UX					2022-12-18	WOS:000173744800808
J	Broide, DH; Stachnick, G; Castaneda, D; Nayar, J; Miller, M; Cho, J; Rodriquez, M; Roman, M; Raz, E				Broide, DH; Stachnick, G; Castaneda, D; Nayar, J; Miller, M; Cho, J; Rodriquez, M; Roman, M; Raz, E			Immunostimulatory DNA mediates inhibition of eosinophilic inflammation and airway hyperreactivity independent of natural killer cells in vivo	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; eosinophil; natural killer cell; IFN-gamma	CPG OLIGODEOXYNUCLEOTIDES; BACTERIAL-DNA; MURINE MODEL; SYNTHETIC OLIGONUCLEOTIDES; IFN-GAMMA; IMMUNOGLOBULIN-E; MOUSE MODEL; TH2 CELLS; SEQUENCES; HYPERRESPONSIVENESS	Background: Immunostimulatory DNA sequences (ISS) inhibit eosinophilic inflammation and airway hyperreactivity in mouse models of asthma. In vitro ISS activate natural killer (NK) cells to secrete IFN-gamma, and this cytokine is hypothesized to contribute to the antiallergic effect of ISS in vivo. Objective: We investigated whether ISS activation of NK cells is important in mediating the reduction in airway hyperreactivity and the antieosinophilic effect of ISS in vivo. Methods: We assessed whether ISS modulated the development of eosinophilic airway inflammation and airway hyperreactivity to methacholine in ovalbumin (OVA)-sensitized and OVA allergen-challenged mice pretreated with an antibody to deplete NK cells. Results: Mice sensitized and challenged with OVA had significant bronchoalveolar lavage and lung eosinophilia, as well as airway hyperresponsiveness. ISS induced significant inhibition of bronchoalveolar lavage and lung eosinophilia, as well as airway hyperresponsiveness, in OVA-sensitized mice pretreated before OVA challenge with an NK cell-depleting antibody (NK-mice), as well as in mice pretreated with a control non-NK cell-depleting antibody (NK+ mice). The NK cell-depleting antibody inhibited ISS-induced IFN-gamma production by spleen cells. Conclusion: These studies demonstrate that depletion of NK cells has no significant effect on ISS-mediated inhibition of airway eosinophilia and airway hyperresponsiveness in vivo, suggesting that non-NK cells and cytokines other than IFN-gamma derived from NK cells mediate the majority of the ISS-inhibitory effect on eosinophilic inflammation and airway hyperresponsiveness in vivo.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Broide, DH (corresponding author), Univ Calif San Diego, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.			Broide, David/0000-0001-8405-9090	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI038425, R01AI038425, R01AI033977, P01AI040682] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 40682, AI 38425, AI 33977] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ballas ZK, 1996, J IMMUNOL, V157, P1840; Broide D, 1999, INT ARCH ALLERGY IMM, V118, P453, DOI 10.1159/000024162; Broide D, 1998, J IMMUNOL, V161, P7054; Broide DH, 2001, AM J RESP CELL MOL, V24, P304, DOI 10.1165/ajrcmb.24.3.4071; Broide DH, 2001, J CLIN IMMUNOL, V21, P175, DOI 10.1023/A:1011078930363; Broide DH, 2000, BLOOD, V95, P263; Brusselle GG, 1997, AM J RESP CELL MOL, V17, P767, DOI 10.1165/ajrcmb.17.6.2820; Chace JH, 1997, CLIN IMMUNOL IMMUNOP, V84, P185, DOI 10.1006/clin.1997.4380; Halpern MD, 1996, CELL IMMUNOL, V167, P72, DOI 10.1006/cimm.1996.0009; Hamelmann E, 2000, AM J RESP CELL MOL, V23, P327, DOI 10.1165/ajrcmb.23.3.3796; Hamelmann E, 1999, AM J RESP CELL MOL, V21, P480, DOI 10.1165/ajrcmb.21.4.3659; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; IWAMOTO I, 1993, J EXP MED, V177, P573, DOI 10.1084/jem.177.2.573; Keane-Myers A, 1998, J IMMUNOL, V161, P919; Kline JN, 1999, J ALLERGY CLIN IMMUN, V104, P1258, DOI 10.1016/S0091-6749(99)70022-9; Kline JN, 1998, J IMMUNOL, V160, P2555; Korsgren M, 1999, J EXP MED, V189, P553, DOI 10.1084/jem.189.3.553; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Li XM, 1996, J IMMUNOL, V157, P3216; NAKAJIMA H, 1993, AM REV RESPIR DIS, V148, P1102, DOI 10.1164/ajrccm/148.4_Pt_1.1102; Randolph DA, 1999, J CLIN INVEST, V104, P1021, DOI 10.1172/JCI7631; Roman M, 1997, NAT MED, V3, P849, DOI 10.1038/nm0897-849; Sato Y, 1996, SCIENCE, V273, P352, DOI 10.1126/science.273.5273.352; Serebrisky D, 2000, J IMMUNOL, V165, P5906, DOI 10.4049/jimmunol.165.10.5906; Shirota H, 2000, J IMMUNOL, V164, P5575, DOI 10.4049/jimmunol.164.11.5575; Sur S, 1999, J IMMUNOL, V162, P6284; TOKUNAGA T, 1992, MICROBIOL IMMUNOL, V36, P55, DOI 10.1111/j.1348-0421.1992.tb01642.x; Trinchieri G, 1995, Semin Immunol, V7, P83, DOI 10.1006/smim.1995.0012; VanHeyningen TK, 1997, J IMMUNOL, V158, P330; Walker C, 1998, J IMMUNOL, V161, P1962; Wang JM, 2000, J IMMUNOL, V165, P4051, DOI 10.4049/jimmunol.165.7.4051; Wang MD, 1998, J IMMUNOL, V160, P1098; YAMAMOTO S, 1992, J IMMUNOL, V148, P4072; YAMAMOTO T, 1994, JPN J CANCER RES, V85, P775, DOI 10.1111/j.1349-7006.1994.tb02947.x; Yi AK, 1996, J IMMUNOL, V157, P5394	36	21	22	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2001	108	5					759	763		10.1067/mai.2001.118795	http://dx.doi.org/10.1067/mai.2001.118795			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	498RG	11692101	Bronze			2022-12-18	WOS:000172523800016
J	Matsuse, H; Shimoda, T; Fukushima, C; Mitsuta, K; Kawano, T; Tomari, S; Saeki, S; Kondoh, Y; Machida, I; Obase, Y; Asai, S; Kohno, S				Matsuse, H; Shimoda, T; Fukushima, C; Mitsuta, K; Kawano, T; Tomari, S; Saeki, S; Kondoh, Y; Machida, I; Obase, Y; Asai, S; Kohno, S			Screening for acetaldehyde dehydrogenase 2 genotype in alcohol-induced asthma by using the ethanol patch test	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						alcohol-induced asthma; acetaldehyde dehydrogenase 2; ethanol patch test; questionnaire; polymerase chain reaction	ALDEHYDE DEHYDROGENASE; DEFICIENCY; JAPANESE	Background: We have previously reported that alcohol-induced asthma in Japanese patients is caused by increased blood acetaldehyde concentration resulting from abnormalities of acetaldehyde dehydrogenase 2 (ALDH2) enzyme activity on the basis of ALDH2 genotype differences. Objectives: The purpose of the present study was to determine whether the ethanol patch test could predict the ALDH2 genotype in Japanese asthmatic subjects. Methods: An ethanol patch test on the upper arm and a questionnaire survey addressing the past history of alcohol-induced asthma were administered to 148 adult Japanese asthmatic subjects. The ALDH2 genotypes in these 148 subjects were also determined by means of PCR. Results: The genotype distribution of ALDH2 determined by PCR in 68 subjects with positive ethanol patch test results was 4 (5.9%), 56 (82.4%), and 8 (11.8%) for genotypes NN (normal homozygote), NM (mutant heterozygote), and MM (mutant homozygote). The ALDH2 genotype in 80 subjects with a negative test result was only NN. The distribution of ALDH2 genotype in 78 (52.7%) subjects who had experienced alcohol-induced asthma symptoms on the basis of the questionnaire was 27 (34.6%), 44 (56.4%), and 7 (9.0%) for genotypes NN, NM, and MM, respectively. On the other hand, 70 subjects had never experienced alcohol-induced asthma symptoms. In these subjects the ALDH2 genotype was NN in 51 (72.9%), N in (25.7%), and MM in 1 (1.4%). Conclusions: Our results indicate that the results of ethanol patch testing correlate well with ALDH2 genotype, as determined by means of PCR, suggesting that the ethanol patch test is useful for the screening of alcohol-induced asthma.	Nagasaki Univ, Sch Med, Dept Internal Med 2, Nagasaki 8528501, Japan; Sasebo City Gen Hosp, Dept Internal Med, Sasebo, Japan	Nagasaki University	Matsuse, H (corresponding author), Nagasaki Univ, Sch Med, Dept Internal Med 2, 1-7-1 Sakamoto, Nagasaki 8528501, Japan.							AYRES JG, 1983, BRIT J DIS CHEST, V77, P370, DOI 10.1016/0007-0971(83)90072-4; BRESLIN A B X, 1973, Clinical Allergy, V3, P71, DOI 10.1111/j.1365-2222.1973.tb01311.x; DAHL R, 1986, J ALLERGY CLIN IMMUN, V78, P1126, DOI 10.1016/0091-6749(86)90261-7; *DEP HLTH HUM SERV, 1997, NIH PUBL; ENOMOTO N, 1990, J CLIN EXP MED, V154, P823; GEPPERT EF, 1978, AM REV RESPIR DIS, V118, P135; GOEDDE HW, 1979, CLIN GENET, V16, P29; GONG H, 1981, CHEST, V80, P167, DOI 10.1378/chest.80.2.167; HARADA S, 1982, LANCET, V2, P827, DOI 10.1016/s0140-6736(82)92722-2; HARADA S, 1980, AM J HUM GENET, V32, P8; HARADA S, 1981, LANCET, V2, P982; HARADA S, 1990, J CLIN EXP MED, V154, P817; HIGUCHI S, 1987, LANCET, V1, P629; MATSUSE H, 1995, ANN ALLERG ASTHMA IM, V75, P267; MORROWBROWN H, 1987, PRACTITIONER, V231, P684; MURAMATSU T, 1989, ALCOHOL CLIN EXP RES, V13, P229, DOI 10.1111/j.1530-0277.1989.tb00317.x; Shimoda T, 1996, J ALLERGY CLIN IMMUN, V97, P74, DOI 10.1016/S0091-6749(96)70285-3; Takao A, 1998, J ALLERGY CLIN IMMUN, V101, P576, DOI 10.1016/S0091-6749(98)70162-9; Takao A, 1999, ANN ALLERG ASTHMA IM, V82, P390, DOI 10.1016/S1081-1206(10)63289-9; Vally H, 2000, J ALLERGY CLIN IMMUN, V105, P462, DOI 10.1067/mai.2000.104548; WALLS AF, 1992, CLIN EXP ALLERGY, V22, P1, DOI 10.1111/j.1365-2222.1992.tb00106.x; WOLFF PH, 1972, SCIENCE, V175, P449, DOI 10.1126/science.175.4020.449	22	21	21	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2001	108	5					715	719		10.1067/mai.2001.118791	http://dx.doi.org/10.1067/mai.2001.118791			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	498RG	11692094				2022-12-18	WOS:000172523800009
J	Duez, C; Tornkinson, A; Shultz, LD; Bratton, DL; Gelfand, EW				Duez, C; Tornkinson, A; Shultz, LD; Bratton, DL; Gelfand, EW			Fas deficiency delays the resolution of airway hyperresponsiveness after allergen sensitization and challenge	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						lung; eosinophils; apoptosis; inflammation; in vivo animal models	EOSINOPHIL APOPTOSIS; MURINE MODEL; INBRED MICE; ASTHMA; INFLAMMATION; LUNG; HYPERREACTIVITY; INTERLEUKIN-5; RESPONSIVENESS; EPITHELIUM	Background: In asthma, persistent inflammation might be the result of (1) an impaired ability to clear inflammatory cells from the airways and/or (2) impaired apoptotic responses. Objective: In a mouse model, we investigated the regulatory role of Fas (CD95)-induced apoptosis in the development and resolution of airway inflammation and airway hyperresponsiveness (AHR). Methods: Mice that were either Fas-sufficient (wild-type; WT) or Fas-deficient (lpr) were sensitized by intraperitoneal injections of ovalbumin (OVA) and challenged once intranasally with OVA (IP-IN mice). Control (IN) mice were challenged only. Results: IP-IN WT mice developed AHR at 48 hours; changes in airway resistance resolved by 96 hours. Airway responsiveness at 48 hours in IP-IN lpr mice was sin-Alar to that in IP-IN WT mice. However, in contrast to WT mice, IP-IN lpr mice sustained significant AHR at 96 hours in comparison with IN lpr mice; the AHR resolved by 6 days. Bronchoalveolar lavage fluid cell composition was similar in all of the different groups at 48 hours and 96 hours. Both IP-IN WT mice and lpr mice exhibited similar tissue eosinophilia, whereas IP-IN lpr mice had significantly lower numbers of TdT-mediated dUTP nick end labeling (TUNEL)-positive cells in comparison with IP-IN WT mice at 48 hours. Anti-IL-5 antibody given to IP-IN lpr mice 48 hours and 72 hours after the challenge significantly decreased AHR and eosinophilic inflammation and increased TUNEL-positive cell numbers at 96 hours. Conclusion: These results suggest that Fas expression can regulate the onset and resolution of AHR through an increase in eosinophil apoptosis.	Natl Jewish Med & Res Ctr, Dept Pediat, Div Cell Biol, Denver, CO 80206 USA; Jackson Lab, Bar Harbor, ME 04609 USA	National Jewish Health; Jackson Laboratory	Gelfand, EW (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Div Cell Biol, 1400 Jackson St, Denver, CO 80206 USA.		Duez, Catherine/B-8425-2018	Duez, Catherine/0000-0002-2327-1095	NATIONAL CANCER INSTITUTE [R01CA020408] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036577, R01HL061005] Funding Source: NIH RePORTER; NCI NIH HHS [CA-20408] Funding Source: Medline; NHLBI NIH HHS [HL-36577, HL-61005] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Brewer JP, 1999, AM J RESP CRIT CARE, V160, P1150, DOI 10.1164/ajrccm.160.4.9806034; Chung KF, 1999, THORAX, V54, P825, DOI 10.1136/thx.54.9.825; CORRIGAN CJ, 1992, IMMUNOL TODAY, V13, P501, DOI 10.1016/0167-5699(92)90026-4; De Sanctis GT, 1999, AM J PHYSIOL-LUNG C, V277, pL1118, DOI 10.1152/ajplung.1999.277.6.L1118; Druilhe A, 1998, AM J RESP CELL MOL, V19, P747, DOI 10.1165/ajrcmb.19.5.3166; Duguet A, 2000, AM J RESP CRIT CARE, V161, P839, DOI 10.1164/ajrccm.161.3.9906054; Eum SY, 1995, P NATL ACAD SCI USA, V92, P12290, DOI 10.1073/pnas.92.26.12290; Ewart SL, 2000, AM J RESP CELL MOL, V23, P537, DOI 10.1165/ajrcmb.23.4.4199; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; Hamelmann E, 1999, INT ARCH ALLERGY IMM, V120, P8, DOI 10.1159/000024215; Hamelmann E, 1997, AM J RESP CRIT CARE, V155, P819, DOI 10.1164/ajrccm.155.3.9117011; Hogan SP, 1998, J IMMUNOL, V161, P1501; Ishii T, 1997, ARCH HISTOL CYTOL, V60, P65, DOI 10.1679/aohc.60.65; Kankaanranta H, 2000, J ALLERGY CLIN IMMUN, V106, P77; Kodama T, 1998, CLIN EXP ALLERGY, V28, P1435; Lee JJ, 1997, J EXP MED, V185, P2143, DOI 10.1084/jem.185.12.2143; MATSUMOTO K, 1995, BLOOD, V86, P1437, DOI 10.1182/blood.V86.4.1437.bloodjournal8641437; Nagata S, 1999, ANNU REV GENET, V33, P29, DOI 10.1146/annurev.genet.33.1.29; NAKAMURA M, 1995, ARCH HISTOL CYTOL, V58, P249, DOI 10.1679/aohc.58.249; Shardonofsky FR, 1999, J ALLERGY CLIN IMMUN, V104, P215, DOI 10.1016/S0091-6749(99)70138-7; Simon HU, 1997, J IMMUNOL, V158, P3902; Takeda K, 1997, J EXP MED, V186, P449, DOI 10.1084/jem.186.3.449; TANAKA H, 1998, LIFE SCI, V62, pL169; Tomkinson A, 2001, AM J RESP CRIT CARE, V163, P721, DOI 10.1164/ajrccm.163.3.2005010; Tsuyuki S, 1995, J CLIN INVEST, V96, P2924, DOI 10.1172/JCI118364; VANOOSTERHOUT AJM, 1995, J ALLERGY CLIN IMMUN, V96, P104, DOI 10.1016/S0091-6749(95)70039-0; Vignola AM, 1999, J ALLERGY CLIN IMMUN, V103, P563, DOI 10.1016/S0091-6749(99)70225-3; Walsh GM, 1997, CLIN EXP ALLERGY, V27, P482, DOI 10.1111/j.1365-2222.1997.tb00735.x; Woolley KL, 1996, AM J RESP CRIT CARE, V154, P237, DOI 10.1164/ajrccm.154.1.8680686; Yamashita N, 2000, INT ARCH ALLERGY IMM, V122, P40, DOI 10.1159/000053631	31	21	23	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2001	108	4					547	556						10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	485NK	11590380				2022-12-18	WOS:000171760300013
J	Vercellotti, GM				Vercellotti, GM			Overview of infections and cardiovascular diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	IVIG Advisory Meeting	OCT 26-29, 2000	SANTA BARBARA, CA	Bayer Biol		atherosclerosis; microbes; myocardial infarction; viruses	CORONARY-ARTERY-DISEASE; CHLAMYDIA-PNEUMONIAE; HEART-DISEASE; ENDOTHELIAL-CELLS; HUMAN CYTOMEGALOVIRUS; POTENTIAL ROLE; ATHEROSCLEROSIS; VIRUS; RISK; ASSOCIATION	Microbes have been proposed as inciting agents of tissue injury and inflammation, both of which underlie the pathogenesis of atherosclerosis. Viruses, including the herpes simplex virus and cytomegalovirus, as well as bacteria such as Chlamydia pneumoniae, have been Implicated in the process. In vitro, these agents promote a proinflammatory and a procoagulant phenotype in vascular cells. Viruses augment cell accumulation through alterations of apoptosis. Infectious agents may play a role in pathogenesis of atherosclerosis by triggering an autoimmune response due to microbial molecular mimicry. It is unlikely that a single agent is the sole cause or modulator of this heterogeneous disease. Contradictory epidemiological studies may be reconciled with a new construct suggesting that multiple pathogens infecting an individual in aggregate may promote an inflammatory and procoagulant environment that underlies the pathogenesis of atherosclerosis.	Univ Minnesota, Sch Med, Dept Med, Div Hematol Oncol & Bone Marrow Transplant, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Vercellotti, GM (corresponding author), Univ Minnesota, Sch Med, Dept Med, Div Hematol Oncol & Bone Marrow Transplant, 420 Delaware St SE, Minneapolis, MN 55455 USA.							BAINTON D, 1978, INT J EPIDEMIOL, V7, P231, DOI 10.1093/ije/7.3.231; Beck J, 1996, J PERIODONTOL, V67, P1123, DOI 10.1902/jop.1996.67.10s.1123; BENDITT EP, 1973, P NATL ACAD SCI USA, V70, P1753, DOI 10.1073/pnas.70.6.1753; BENDITT EP, 1983, P NATL ACAD SCI-BIOL, V80, P6386, DOI 10.1073/pnas.80.20.6386; Blum A, 1998, AM J CARDIOL, V81, P866, DOI 10.1016/S0002-9149(98)00019-8; Burns LJ, 1999, TRANSPLANTATION, V67, P137, DOI 10.1097/00007890-199901150-00023; Danesh J, 1997, LANCET, V350, P430, DOI 10.1016/S0140-6736(97)03079-1; Danesh J, 1998, Expert Opin Investig Drugs, V7, P691, DOI 10.1517/13543784.7.5.691; Epstein SE, 1999, CIRCULATION, V100, pE20, DOI 10.1161/01.CIR.100.4.e20; Epstein SE, 2000, ARTERIOSCL THROM VAS, V20, P1417, DOI 10.1161/01.ATV.20.6.1417; ETINGIN OR, 1991, P NATL ACAD SCI USA, V88, P7200, DOI 10.1073/pnas.88.16.7200; ETINGIN OR, 1990, CELL, V61, P657, DOI 10.1016/0092-8674(90)90477-V; FABRICANT CG, 1978, J EXP MED, V148, P335, DOI 10.1084/jem.148.1.335; Fortunato EA, 1998, J VIROL, V72, P2033, DOI 10.1128/JVI.72.3.2033-2039.1998; GRAYSTON JT, 1995, CIRCULATION, V92, P3397, DOI 10.1161/01.CIR.92.12.3397; Gupta S, 1997, CIRCULATION, V96, P404; Gurfinkel E, 1997, LANCET, V350, P404, DOI 10.1016/S0140-6736(97)07201-2; HAJJAR DP, 1986, AM J PATHOL, V122, P62; Jones NW, 1935, ANN INTERN MED, V8, P834, DOI 10.7326/0003-4819-8-7-834; Karsner HT, 1934, AM HEART J, V9, P557, DOI 10.1016/S0002-8703(34)90440-3; KEY NS, 1990, P NATL ACAD SCI USA, V87, P7095, DOI 10.1073/pnas.87.18.7095; KOL A, 1995, CIRCULATION, V91, P1910, DOI 10.1161/01.CIR.91.7.1910; Kol A, 1998, CIRCULATION, V98, P300, DOI 10.1161/01.CIR.98.4.300; Kovacs A, 1996, AM J PATHOL, V149, P1531; KUO CC, 1993, J INFECT DIS, V167, P841, DOI 10.1093/infdis/167.4.841; KUO CC, 1993, ARTERIOSCLER THROMB, V13, P1501, DOI 10.1161/01.ATV.13.10.1501; Libby P, 1997, CIRCULATION, V96, P4095; MACCALLUM WG, 1933, ARTERIOSCLEROSIS, P355; MATTILA KJ, 1989, J INTERN MED, V225, P293, DOI 10.1111/j.1365-2796.1989.tb00084.x; Mattila KJ, 1998, CLIN INFECT DIS, V26, P719, DOI 10.1086/514570; MCDONALD K, 1989, AM J CARDIOL, V64, P359, DOI 10.1016/0002-9149(89)90535-3; Mehta JL, 1998, J AM COLL CARDIOL, V31, P1217, DOI 10.1016/S0735-1097(98)00093-X; MELNICK JL, 1983, LANCET, V2, P644; Muhlestein JB, 2000, CIRCULATION, V102, P1755; Muhlestein JB, 1998, CIRCULATION, V97, P633, DOI 10.1161/01.CIR.97.7.633; NICHOLLS AC, 1977, LANCET, V1, P883; Nieto FJ, 1998, AM J EPIDEMIOL, V148, P937, DOI 10.1093/oxfordjournals.aje.a009570; OLDSTONE MB, 1994, ADV PARASIT, V34, P81; OSLER W, 1908, MODERN MED ITS THEOR, P426; PATEL P, 1995, BRIT MED J, V311, P711, DOI 10.1136/bmj.311.7007.711; PATON P, 1993, RES VIROLOGY, V144, P225, DOI 10.1016/S0923-2516(06)80033-6; PRYZDIAL ELG, 1994, BLOOD, V84, P3749, DOI 10.1182/blood.V84.11.3749.bloodjournal84113749; Ridker PM, 1999, CIRCULATION, V99, P1161, DOI 10.1161/01.CIR.99.9.1161; ROKITANSKY C, 1855, MANUAL PATHOLOGICAL, V4, P201; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SAIKKU P, 1988, LANCET, V2, P983, DOI 10.1016/S0140-6736(88)90741-6; Saikku P, 1997, SCAND J INFECT DIS, P53; Shahgasempour S, 1997, MICROBIOL IMMUNOL, V41, P121, DOI 10.1111/j.1348-0421.1997.tb01177.x; SHOR A, 1992, S AFR MED J, V82, P158; SORLIE PD, 1994, J MED VIROL, V42, P33, DOI 10.1002/jmv.1890420107; SPEIR E, 1994, SCIENCE, V265, P391, DOI 10.1126/science.8023160; Streblow DN, 1999, CELL, V99, P511, DOI 10.1016/S0092-8674(00)81539-1; Vercellotti GM, 1998, J INVEST MED, V46, P403; VERCELLOTTI GM, 1995, TRENDS CARDIOVAS MED, V5, P128, DOI 10.1016/1050-1738(95)00052-B; VERCELLOTTI GM, 2000, IN PRESS T AM CLIN C; VISSER MR, 1989, LAB INVEST, V60, P296; VISSER MR, 1988, P NATL ACAD SCI USA, V85, P8227, DOI 10.1073/pnas.85.21.8227; YUROCHKO AD, 1995, J VIROL, V69, P5391, DOI 10.1128/JVI.69.9.5391-5400.1995; Zhou YF, 1996, NEW ENGL J MED, V335, P624, DOI 10.1056/NEJM199608293350903; Zhu JH, 2000, AM J CARDIOL, V85, P140, DOI 10.1016/S0002-9149(99)00653-0	60	21	23	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2001	108	4		S			S117	S120		10.1067/mai.2001.117976	http://dx.doi.org/10.1067/mai.2001.117976			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	487KL	11586278				2022-12-18	WOS:000171874200008
J	Laffer, S; Hogbom, E; Roux, KH; Sperr, WR; Valent, P; Bankl, HC; Vangelista, L; Kricek, F; Kraft, D; Gronlund, H; Valenta, R				Laffer, S; Hogbom, E; Roux, KH; Sperr, WR; Valent, P; Bankl, HC; Vangelista, L; Kricek, F; Kraft, D; Gronlund, H; Valenta, R			A molecular model of type I allergy: Identification and characterization of a nonanaphylactic anti-human IgE antibody fragment that blocks the IgE-Fc epsilon RI interaction and reacts with receptor-bound IgE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy asthma; IgE; Fc epsilon RI; competitor; therapy	HIGH-AFFINITY RECEPTOR; BIRCH POLLEN ALLERGEN; HIGH-LEVEL EXPRESSION; IMMUNOELECTRON MICROSCOPY; MONOCLONAL-ANTIBODY; BINDING-SITES; COMPLEXES; CELLS; CHAIN; BASOPHILS	Background: The IgE-mediated activation of effector cells and antigen-presenting cells through the high-affinity receptor for IgE (Fc epsilon RI) represents a key pathomechanism in type 1 allergy and many forms of asthma. Objective: We sought to establish an in vitro molecular model for the interaction of human Fc epsilon RI, IgE, and the corresponding allergen and to identify monoclonal anti-human IgE antibodies with a therapeutic profile different from previously established anti-IgE antibodies. Methods: Human Fc epsilon RI alpha chain, a human monoclonal allergen-specific IgE antibody (chimeric Bip 1), and the corresponding allergen, the major birch pollen allergen Bet v 1, were produced as recombinant proteins and analyzed by means of circular dichroism and native overlays, respectively. Using this molecular model, as well as negative stain immunoelectron microscopic analysis, and in vitro cultivated human basophils, we characterized mouse anti-human IgE antibodies. Results: We established a molecular model for the interaction of human IgE with FeeRl. Using this molecular model, we identified a nonanaphylactic anti-human IgE antibody fragment (Fab12), which blocked the IgE-Fe epsilon RI interaction and reacted with effector cell-bound IgE. Conclusion: Fab12 represents a candidate molecule for therapy of atopy and asthma because it can be used for the depletion of circulating IgE antibodies, as well as for the depletion of IgE-bearing cells.	Univ Vienna, AKH, Dept Pathophysiol, Mol Immunopathol Grp, A-1090 Vienna, Austria; Pharmacia Diagnost AB, S-75182 Uppsala, Sweden; Florida State Univ, Biol Unit 1, Dept Biol Sci, Tallahassee, FL 32306 USA; Univ Vienna, AKH, Dept Internal Med 1, Div Hematol, A-1090 Vienna, Austria; Univ Vienna, AKH, Dept Pathol, A-1090 Vienna, Austria; EMBL, Struct Biol Grp, Heidelberg, Germany; Novartis Res Ctr, Vienna, Austria	University of Vienna; Pfizer; Pharmacia Corporation; State University System of Florida; Florida State University; University of Vienna; University of Vienna; European Molecular Biology Laboratory (EMBL); Novartis	Valenta, R (corresponding author), Univ Vienna, AKH, Dept Pathophysiol, Mol Immunopathol Grp, Waehringer Guertel 18-20, A-1090 Vienna, Austria.		Test, Test/Y-7921-2019; Sperr, Mast/V-4767-2019; Test, PV/U-9451-2019; Valent, Peter/B-8533-2016; Gamperl, Susi/V-2715-2019	Sperr, Mast/0000-0002-7778-5219; Valent, Peter/0000-0003-0456-5095; Gamperl, Susi/0000-0003-0456-5095; Gronlund, Hans/0000-0003-4882-7624; Sperr, Wolfgang/0000-0003-3288-8027; Valenta, Rudolf/0000-0001-5944-3365; Vangelista, Luca/0000-0003-0764-5031				BEAVEN MA, 1993, IMMUNOL TODAY, V14, P222, DOI 10.1016/0167-5699(93)90167-J; Bennich H, 1971, Adv Immunol, V13, P1; Bieber T, 1996, CURR OPIN IMMUNOL, V8, P773, DOI 10.1016/S0952-7915(96)80003-3; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; DEWECK AL, 1993, MOLECULAR BIOLOGY AND IMMUNOLOGY OF ALLERGENS, P101; GOUNNI AS, 1994, NATURE, V367, P183, DOI 10.1038/367183a0; Helm BA, 1997, ALLERGY, V52, P1155, DOI 10.1111/j.1398-9995.1997.tb02518.x; HoffmannSommergruber K, 1997, PROTEIN EXPRES PURIF, V9, P33, DOI 10.1006/prep.1996.0671; Joseph M, 1997, EUR J IMMUNOL, V27, P2212, DOI 10.1002/eji.1830270914; Keown MB, 1997, EUR BIOPHYS J BIOPHY, V25, P471, DOI 10.1007/s002490050062; KEOWN MB, 1995, P NATL ACAD SCI USA, V92, P1841, DOI 10.1073/pnas.92.6.1841; Keown MB, 1998, BIOCHEMISTRY-US, V37, P8863, DOI 10.1021/bi972354h; Laffer S, 1996, J IMMUNOL, V157, P4953; LEBEDIN YS, 1991, INT J ARTIF ORGANS, V14, P508, DOI 10.1177/039139889101400809; MAURER D, 1995, J IMMUNOL, V154, P6285; Maurer D, 1996, J IMMUNOL, V157, P607; Milgrom H, 1999, NEW ENGL J MED, V341, P1966, DOI 10.1056/NEJM199912233412603; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; Roux Kenneth H., 1996, Methods (Orlando), V10, P247, DOI 10.1006/meth.1996.0099; ROUX KH, 1983, J IMMUNOL, V131, P2411; ROUX KH, 1989, METHOD ENZYMOL, V178, P130; Roux KH, 1998, J IMMUNOL, V161, P4083; ROUX KH, 1987, P NATL ACAD SCI USA, V84, P4984, DOI 10.1073/pnas.84.14.4984; Rudolf MP, 1996, J IMMUNOL, V157, P5646; Sambrook J, 1989, MOL CLONING LAB MANU, V1, P1; Sechi S, 1996, J BIOL CHEM, V271, P19256, DOI 10.1074/jbc.271.32.19256; VALENT P, 1989, P NATL ACAD SCI USA, V86, P5542, DOI 10.1073/pnas.86.14.5542; VALENT P, 1989, BLOOD, V73, P1778; VALENTA R, 1993, J ALLERGY CLIN IMMUN, V91, P88, DOI 10.1016/0091-6749(93)90300-5; Vangelista L, 1999, J CLIN INVEST, V103, P1571, DOI 10.1172/JCI6551; Wiedemann P, 1996, J BIOL CHEM, V271, P29915, DOI 10.1074/jbc.271.47.29915; YAGI S, 1994, EUR J BIOCHEM, V220, P593, DOI 10.1111/j.1432-1033.1994.tb18660.x	32	21	21	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2001	108	3					409	416		10.1067/mai.2001.117593	http://dx.doi.org/10.1067/mai.2001.117593			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	476FK	11544461				2022-12-18	WOS:000171215400013
J	Szefler, SJ				Szefler, SJ			Challenges in assessing outcomes for pediatric asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						chronic inflammation; pulmonary function; natural history; inhaled glucocorticoids; nonsteroid controller medication; surrogate markers	MANAGEMENT PROGRAM CAMP; INHALED CORTICOSTEROIDS; PULMONARY-FUNCTION; CHILDHOOD ASTHMA; TERM TREATMENT; MILD ASTHMA; INFLAMMATION; PHARMACOGENETICS; MUTATIONS; CHILDREN	Although progress has been made in understanding asthma, much remains unknown; as a result, diagnosis and treatment are not optimal, Information is still needed about the natural history of asthma to better understand which patients are at risk of inflammation and at what point during their disease that inflammation occurs. In the case of children, a greater understanding of the disease's natural history is needed to establish criteria for early diagnosis and to evaluate progressive aspects of the disease so that appropriate measures of progression ran be defined, The safety of various medications used as long-term controllers must also be evaluated, The growing information about medication effects on asthma provides unique opportunities to design studies that will guide improvement in asthma care. A number of disease outcomes can be used as surrogate markers of clinically significant endpoints, and a number of adverse effects may serve as surrogate markers. The consequences of poor control of pediatric asthma can be observed in a variety of clinical markers, including clinical features of the disease that worsen as it progresses, pulmonary function deterioration, lung hyperexpansion, and inflammation increases, The Childhood Asthma Management Program is an ongoing clinical trial designed to improve the diagnosis and treatment of asthma in children. Its hypothesis is that anti-inflammatory treatment of childhood asthma will not only relieve morbidity but will also improve lung growth.	Natl Jewish Med & Res Ctr, Dept Pediat, Pharmacokinet Div Clin Pharmacol, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Dept Pediat, Pharmacokinet Div Allergy & Immunol, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Pediat & Pharmacol, Denver, CO USA	National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Szefler, SJ (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Pharmacokinet Div Clin Pharmacol, 1400 Jackson St,Room J209, Denver, CO 80206 USA.				NCRR NIH HHS [5MO1 RR00051] Funding Source: Medline; NHLBI NIH HHS [HL 51834, HL 36577, 1NO1-HR-16048] Funding Source: Medline; DIVISION OF LUNG DISEASES [N01HR016048] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000051] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL051834, P01HL036577] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGERTOFT L, 1994, RESP MED, V88, P373, DOI 10.1016/0954-6111(94)90044-2; DuBuske LM, 1997, AM J MANAG C, V3, P633; *GLOB IN ASTHM, 1998, NIH PUBL; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; In KH, 1997, J CLIN INVEST, V99, P1130, DOI 10.1172/JCI119241; Kemp J, 1999, ANN ALLERG ASTHMA IM, V82, P463, DOI 10.1016/S1081-1206(10)62722-6; Kennis T, 1998, ANN ALLERG ASTHMA IM, V81, P406, DOI 10.1016/S1081-1206(10)63137-7; Laitinen A, 1997, AM J RESP CRIT CARE, V156, P951, DOI 10.1164/ajrccm.156.3.9610084; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; Larsen GL, 1999, J ALLERGY CLIN IMMUN, V103, P371, DOI 10.1016/S0091-6749(99)70458-6; Lee T, 1996, AM J RESP CRIT CARE, V154, pS1, DOI 10.1164/ajrccm/154.2_Pt_2.S1; Leeder JS, 1997, PEDIATR CLIN N AM, V44, P55, DOI 10.1016/S0031-3955(05)70463-6; LEUNG DYM, 1995, J EXP MED, V181, P33, DOI 10.1084/jem.181.1.33; *NAT ASTHM ED PREV, 1997, NIH PUBL; Olivieri D, 1997, AM J RESP CRIT CARE, V155, P1864, DOI 10.1164/ajrccm.155.6.9196087; Overbeek SE, 1996, CHEST, V110, P35, DOI 10.1378/chest.110.1.35; Peat JK, 1998, J ASTHMA, V35, P235, DOI 10.3109/02770909809068213; REIHSAUS E, 1993, AM J RESP CELL MOL, V8, P334, DOI 10.1165/ajrcmb/8.3.334; Roses AD, 2000, LANCET, V355, P1358, DOI 10.1016/S0140-6736(00)02126-7; SELROOS O, 1995, CHEST, V108, P1228, DOI 10.1378/chest.108.5.1228; Szefler S, 2000, NEW ENGL J MED, V343, P1054; Szefler S J, 2000, Adv Pediatr, V47, P273; Szefler SJ, 1998, ANN ALLERG ASTHMA IM, V81, P571; Vrugt B, 1999, EUR RESPIR J, V13, P1245, DOI 10.1183/09031936.99.13612539; Wanner A, 1997, AM J RESP CRIT CARE, V156, pS67; WEISS ST, 1995, EUR RESPIR REV, V5, P303; Wenzel SE, 1997, AM J RESP CRIT CARE, V156, P737, DOI 10.1164/ajrccm.156.3.9610046; Zeiger RS, 1999, J ALLERGY CLIN IMMUN, V103, P376, DOI 10.1016/S0091-6749(99)70460-4	28	21	22	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2001	107	5		S			S456	S464		10.1067/mai.2001.114947	http://dx.doi.org/10.1067/mai.2001.114947			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	435RD	11344375				2022-12-18	WOS:000168894200004
J	Scala, E; Giani, M; Pirrotta, L; Guerra, EC; Locanto, M; De Pita, O; Puddu, P				Scala, E; Giani, M; Pirrotta, L; Guerra, EC; Locanto, M; De Pita, O; Puddu, P			Selective severe anaphylactic reaction due to ketorolac tromethamine without nonsteroidal anti-inflammatory drug intolerance	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									Ist Dermopat Immacolata, Dept Immunodermatol Allergy & Clin Immunol, Rome, Italy	IRCCS Istituto Dermopatico dell'Immacolata (IDI)	Scala, E (corresponding author), Ist Dermopat Immacolata, Dept Immunodermatol Allergy & Clin Immunol, Rome, Italy.		Scala, Enrico/H-6997-2012	Scala, Enrico/0000-0002-9391-9168				Chen A H, 1994, Anesth Prog, V41, P102; GOETZ CM, 1996, ANN PHARM, V26, P1237; HERBERT WG, 1994, SOUTH MED J, V87, P282; ITENGA GL, 1996, OPHTHALMOLOGY, V103, P890; SHAPIRO N, 1994, J ORAL MAXIL SURG, V52, P626, DOI 10.1016/0278-2391(94)90103-1	5	21	21	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2001	107	3					557	557		10.1067/mai.2001.113241	http://dx.doi.org/10.1067/mai.2001.113241			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	416RE	11240963				2022-12-18	WOS:000167793300024
J	Tournoy, KG; Kips, JC; Pauwels, RA				Tournoy, KG; Kips, JC; Pauwels, RA			Counterbalancing of T(H)2-driven allergic airway inflammation by IL-12 does not require IL-10	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-10; IL-12; allergen; airway inflammation; airway responsiveness; T(H)1; T(H)2; eosinophil; IgE; asthma	RESPONSES IN-VIVO; IMMUNE-RESPONSES; INTERFERON-GAMMA; IFN-GAMMA; ANTIBODY-PRODUCTION; SENSITIZED MICE; CELL CLONES; TH2 CELLS; INTERLEUKIN-12; ANTIGEN	Background: Asthma is characterized by allergen-induced airway inflammation orchestrated by T(H)2 cells. The T(H)1-promoting cytokine IL-12 is capable of inhibiting the T(H)2-driven allergen-induced airway changes in mice and is therefore regarded as an interesting strategy for treating asthma. Objective: The antiallergic effects of IL-12 are only partially dependent of IFN-gamma, Because IL-12 is a potent inducer of the anti-inflammatory cytokine IL-10, the aim of the present study was to investigate in vivo whether the antiallergic effects of IL-12 are mediated through IL-10. Methods: C57BL/6J-IL-10 knock-out IL-10(-/-)) mice were sensitized intraperitoneally to ovalbumin (OVA) and subsequently exposed from day 14 to day 21 to aerosolized OVA (1%). IL-12 was administered intraperitoneally during sensitization, subsequent OVA exposure, or both. Results: IL-12 inhibited the OVA-induced airway eosinophilia, despite the absence of IL-10. Moreover, a shift from a T(H)2 inflammatory pattern toward a T(H)1 reaction was observed, with concomitant pronounced mononuclear peribronchial inflammation after IL-12 treatment. Allergen-specific IgE synthesis was completely suppressed only when IL-12 was administered along with the allergen sensitization. Furthermore, treating the animals with IL-12 at the time of the secondary allergen challenge resulted not only in a significant suppression of the airway responsiveness but also in an important IFN-gamma -associated toxicity. Conclusions: These results indicate that IL-12 is able to inhibit allergen-induced airway changes, even in the absence of IL-10, In addition, our results raise concerns regarding the redirection of T(H)2 inflammation by T(H)1-inducing therapies because treatment with IL-12 resulted not only in a disappearance of the T(H)2 inflammation but also in a T(H)1-driven inflammatory pulmonary pathology.	State Univ Ghent Hosp, Dept Resp Dis, B-9000 Ghent, Belgium	Ghent University; Ghent University Hospital	Tournoy, KG (corresponding author), State Univ Ghent Hosp, Dept Resp Dis, De Pintelaan 185 7 K12 I-E, B-9000 Ghent, Belgium.							Bliss J, 1996, J IMMUNOL, V156, P887; Brusselle GG, 1997, AM J RESP CELL MOL, V17, P767, DOI 10.1165/ajrcmb.17.6.2820; Car BD, 1999, TOXICOL PATHOL, V27, P58, DOI 10.1177/019262339902700112; Chung KF, 1999, THORAX, V54, P825, DOI 10.1136/thx.54.9.825; ENK AH, 1993, J IMMUNOL, V151, P2390; Galbiati F, 1998, EUR J IMMUNOL, V28, P209, DOI 10.1002/(SICI)1521-4141(199801)28:01<209::AID-IMMU209>3.0.CO;2-S; GATELY MK, 1994, INT IMMUNOL, V6, P157, DOI 10.1093/intimm/6.1.157; Gately MK, 1998, ANNU REV IMMUNOL, V16, P495, DOI 10.1146/annurev.immunol.16.1.495; GAVETT SH, 1995, J EXP MED, V182, P1527, DOI 10.1084/jem.182.5.1527; Gerosa F, 1996, J EXP MED, V183, P2559, DOI 10.1084/jem.183.6.2559; Guler ML, 1997, J IMMUNOL, V159, P1767; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Hofstra CL, 1998, J IMMUNOL, V161, P5054; John M, 1998, AM J RESP CRIT CARE, V157, P256, DOI 10.1164/ajrccm.157.1.9703079; Kips JC, 1996, AM J RESP CRIT CARE, V153, P535, DOI 10.1164/ajrccm.153.2.8564093; Kips JC, 2000, AM J RESP CRIT CARE, V162, pS66, DOI 10.1164/ajrccm.162.supplement_2.ras-2; Koulis A, 2000, CLIN EXP ALLERGY, V30, P747; Launois P, 1995, EUR J IMMUNOL, V25, P3298, DOI 10.1002/eji.1830251215; Lee YL, 1999, SCAND J IMMUNOL, V49, P229; Lim S, 1998, LANCET, V352, P113, DOI 10.1016/S0140-6736(98)85018-6; MANETTI R, 1994, J EXP MED, V179, P1273, DOI 10.1084/jem.179.4.1273; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; MCKNIGHT AJ, 1994, J IMMUNOL, V152, P2172; Peritt D, 1996, ANN NY ACAD SCI, V795, P387, DOI 10.1111/j.1749-6632.1996.tb52701.x; Randolph DA, 1999, J IMMUNOL, V162, P2375; Rempel JD, 1997, J IMMUNOL, V159, P1490; Schwarze J, 1998, J ALLERGY CLIN IMMUN, V102, P86, DOI 10.1016/S0091-6749(98)70058-2; Sur S, 1996, J IMMUNOL, V157, P4173; Szabo SJ, 1997, J EXP MED, V185, P817, DOI 10.1084/jem.185.5.817; Tournoy KG, 2000, CLIN EXP ALLERGY, V30, P775; van Scott MR, 2000, AM J PHYSIOL-LUNG C, V278, pL667, DOI 10.1152/ajplung.2000.278.4.L667; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; Wills-Karp M, 1998, ALLERGY, V53, P113, DOI 10.1111/j.1398-9995.1998.tb03858.x; Wu CY, 1997, EUR J IMMUNOL, V27, P147, DOI 10.1002/eji.1830270122; Wynn TA, 1997, J IMMUNOL, V159, P5014; ZUANYAMORIM C, 1995, J CLIN INVEST, V95, P2644, DOI 10.1172/JCI117966	36	21	23	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2001	107	3					483	491		10.1067/mai.2001.112693	http://dx.doi.org/10.1067/mai.2001.112693			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	416RE	11240949	Bronze			2022-12-18	WOS:000167793300010
J	Liu, LY; Swensen, CA; Kelly, EAB; Kita, H; Busse, WW				Liu, LY; Swensen, CA; Kelly, EAB; Kita, H; Busse, WW			The relationship of sputum eosinophilia and sputum cell generation of IL-5	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; eosinophil; IL-5; sputum induction	SEGMENTAL ANTIGEN CHALLENGE; MESSENGER-RNA EXPRESSION; ALLERGEN CHALLENGE; BRONCHOALVEOLAR LAVAGE; AIRWAY HYPERREACTIVITY; ASTHMATIC SUBJECTS; INTERLEUKIN-5; EOTAXIN; INFLAMMATION; INCREASES	Background: Eosinophil recruitment to the airway after antigen challenge is regulated by many factors, including airway cell generation of cytokines. Objectives: The purpose of this study was to determine the relationship between sputum cell generation of IL-5 and the appearance of eosinophils in the sputum after antigen challenge. Methods: Sputum samples from 11 allergic subjects were collected before and again 4 and 24 hours after antigen challenge. In 6 of these subjects, induced sputum samples were also obtained 48 hours and 7 days after challenge. Sputum leukocyte differential and cell counts and eosinophil-derived neurotoxin levels were determined. Sputum cells were then cultured with PHA (10 mug/mL) to stimulate IL-5 and IFN-gamma, which were measured in culture supernatants. Results: An increase in sputum eosinophils and eosinophil-derived neurotoxin levels was detected at 4 hours after antigen challenge, with peak values at 24 hours. In contrast, significant increases in ex vivo generation of IL-5 by sputum cells was not seen until 24 hours after challenge. At 24 hours, PHA-induced IL-5 correlated with airspace eosinophil values (r(s) = 0.78, P < .01). In addition, the ratio of IFN-<gamma>/IL-5 decreased at 24 hours (P < .05) and had an inverse correlation with sputum eosinophils (r(s) = -0.68, P < .05). Conclusion: Although eosinophils are increased in the airway lumen as early as 4 hours, the ex vivo generation of IL-5 by sputum cells is first noted in samples obtained 24 hours after antigen challenge, This suggests that the early (4 hours) recruitment of eosinophils to the airway lumen may be regulated by factors other than IL-5 or that mucosal cells (rather than airspace cells) contribute to the IL-5 generation at this time point, Furthermore, IL-5 generation by airspace cells may be more responsible for either eosinophil recruitment or retention at later time points.	Univ Wisconsin, Sect Allergy & Immunol, Madison, WI 53792 USA; Univ Wisconsin, Pulm & Crit Care Med Sect, Madison, WI 53792 USA; Univ Wisconsin, Dept Med, Madison, WI 53792 USA; Mayo Clin & Mayo Fdn, Dept Internal Med, Rochester, MN 55905 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Mayo Clinic	Busse, WW (corresponding author), Univ Wisconsin, Sect Allergy & Immunol, 600 Highland Ave,CSC H6-367, Madison, WI 53792 USA.			Kelly, Elizabeth/0000-0001-7335-6698	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056396] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56396] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABUGHAZALEH RI, 1989, J IMMUNOL, V142, P2393; ALAM R, 1993, J IMMUNOL, V150, P3442; FAHY JV, 1993, AM REV RESPIR DIS, V147, P1126, DOI 10.1164/ajrccm/147.5.1126; Gauvreau GM, 1999, AM J RESP CRIT CARE, V160, P640, DOI 10.1164/ajrccm.160.2.9809130; JARJOUR NN, 1997, AM J RESP CRIT CARE, V155, P1421; Jatakanon A, 1999, AM J RESP CRIT CARE, V160, P1532, DOI 10.1164/ajrccm.160.5.9806170; Keatings VM, 1997, J ALLERGY CLIN IMMUN, V99, P693, DOI 10.1016/S0091-6749(97)70032-0; Kelly EAB, 1997, AM J RESP CRIT CARE, V156, P1421, DOI 10.1164/ajrccm.156.5.9703054; Konno S, 1996, INT ARCH ALLERGY IMM, V109, P73, DOI 10.1159/000237234; Lamkhioued B, 1997, J IMMUNOL, V159, P4593; Lampinen M, 1999, CLIN EXP ALLERGY, V29, P314; MAUSER PJ, 1995, AM J RESP CRIT CARE, V152, P467, DOI 10.1164/ajrccm.152.2.7633694; Meerschaert J, 1999, AM J RESP CRIT CARE, V159, P619, DOI 10.1164/ajrccm.159.2.9806053; Mould AW, 2000, J IMMUNOL, V164, P2142, DOI 10.4049/jimmunol.164.4.2142; Mould AW, 1997, J CLIN INVEST, V99, P1064, DOI 10.1172/JCI119234; OHNISHI T, 1993, AM REV RESPIR DIS, V147, P901, DOI 10.1164/ajrccm/147.4.901; Olivenstein R, 1999, J ALLERGY CLIN IMMUN, V103, P238, DOI 10.1016/S0091-6749(99)70497-5; Pizzichini E, 1996, AM J RESP CRIT CARE, V154, P308, DOI 10.1164/ajrccm.154.2.8756799; Pizzichini MMM, 1997, AM J RESP CRIT CARE, V155, P1501, DOI 10.1164/ajrccm.155.5.9154849; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROSSI GA, 1991, AM REV RESPIR DIS, V144, P379, DOI 10.1164/ajrccm/144.2.379; SEDGWICK JB, 1991, AM REV RESPIR DIS, V144, P1274, DOI 10.1164/ajrccm/144.6.1274; Shi HZ, 1998, AM J RESP CRIT CARE, V157, P204, DOI 10.1164/ajrccm.157.1.9703027; Sulakvelidze I, 1998, EUR RESPIR J, V11, P821, DOI 10.1183/09031936.98.11040821; Sur S, 1996, J ALLERGY CLIN IMMUN, V97, P1272, DOI 10.1016/S0091-6749(96)70195-1; Taha RA, 1999, J ALLERGY CLIN IMMUN, V103, P476, DOI 10.1016/S0091-6749(99)70474-4; Uguccioni M, 1996, J EXP MED, V183, P2379, DOI 10.1084/jem.183.5.2379; VANOOSTERHOUT AJM, 1993, AM REV RESPIR DIS, V147, P548, DOI 10.1164/ajrccm/147.3.548; WARRINGA RAJ, 1992, AM J RESP CELL MOL, V7, P631, DOI 10.1165/ajrcmb/7.6.631; Zeibecoglou K, 1999, ALLERGY, V54, P730, DOI 10.1034/j.1398-9995.1999.00058.x	30	21	21	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2000	106	6					1063	1069						7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	384ER	11112887				2022-12-18	WOS:000165930300006
J	Kelso, JM; Fox, RW; Jones, RT; Yunginger, JW				Kelso, JM; Fox, RW; Jones, RT; Yunginger, JW			Allergy to iguana	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; allergic rhinitis; allergic asthma; aeroallergens; iguana; lizard; reptile; pets	ASTHMA; HOMES	Background: Furry animals produce allergens that can cause allergic rhinitis and asthma, In contrast, scaly animals, such as lizards, are assumed not to be allergenic, Objective: We sought to evaluate a 32-year-old man who complained of allergic rhinitis and asthma symptoms that occurred exclusively in his own home. He had dogs and cats at home but denied any increase in symptoms specifically associated with these pets, Skin prick testing initially performed to 42 common aeroallergens, including cat, dog, and house dust mite, elicited negative results. He later reported that the symptoms were worse on exposure to his pet iguanas, Methods: Skin prick tests were subsequently performed to an extract made from scales from his pet iguana, Extracts were also prepared from several zoo reptiles, Immunoassays for IgE antibody, as well as IgE immunoblots, were performed by using these extracts and the patient's serum. Results: The skin prick test result with the pet iguana scale extract was positive, The patient's serum contained IgE antibody to his own pet iguana and to a zoo iguana, Conclusion: Our patient's history, skin test results, and in vitro studies clearly demonstrate that he is allergic to iguana, Physicians should be aware that such allergy to scaly pets may occur and should not restrict history taking to questions about furry pets.	USN, Dept Clin Invest, Naval Med Ctr, San Diego, CA 92134 USA; USN, Dept Internal Med, Naval Med Ctr, Div Allergy, San Diego, CA 92134 USA; Univ S Florida, Hlth Sci Ctr, Dept Environm & Occupat Hlth, Div Allergy & Immunol, Tampa, FL USA; Mayo Clin & Mayo Fdn, Allerg Dis Res Lab, Rochester, MN 55905 USA	United States Department of Defense; United States Navy; Naval Medical Center San Diego; United States Department of Defense; United States Navy; Naval Medical Center San Diego; State University System of Florida; University of South Florida; Mayo Clinic	Kelso, JM (corresponding author), USN, Dept Clin Invest, Naval Med Ctr, San Diego, CA 92134 USA.							Boulet LP, 1997, CLIN EXP ALLERGY, V27, P52, DOI 10.1111/j.1365-2222.1997.tb00672.x; Bryant DH, 1995, MED J AUSTRALIA, V163, P415, DOI 10.5694/j.1326-5377.1995.tb124657.x; Custovic A, 1998, THORAX, V53, P33, DOI 10.1136/thx.53.1.33; Custovic A, 1997, AM J RESP CRIT CARE, V155, P94, DOI 10.1164/ajrccm.155.1.9001295; Hollander A, 1998, SCAND J WORK ENV HEA, V24, P228, DOI 10.5271/sjweh.303; RICHMAN PG, 1988, J BIOL STAND, V16, P225, DOI 10.1016/0092-1157(88)90010-8; SUTTON R, 1982, J IMMUNOL METHODS, V52, P183, DOI 10.1016/0022-1759(82)90044-8; UHL B, 1985, HAUTARZT, V36, P165; YUNGINGER JW, 1997, MANUAL CLIN LAB IMMU, P868	9	21	24	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2000	106	2					369	372						4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	343NH	10932082				2022-12-18	WOS:000088708100021
J	Corren, J				Corren, J			Allergic rhinitis: Treating the adult	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Conference on Advances in Allergic Diseases - An Update for the New Millennium	FEB 11, 1999	WASHINGTON, D.C.			allergic rhinitis; antihistamine; decongestant; intranasal corticosteroid; pharmacotherapy; specific-allergen immunotherapy	HOUSE-DUST MITE; COCKROACH ALLERGEN; PERENNIAL RHINITIS; CLINICAL EFFICACY; ASTHMA; CORTICOSTEROIDS; MEDICATIONS; LORATADINE; PREVALENCE; RELEASE	Allergic rhinitis is now recognized as a chronic medical condition that markedly affects patient quality of life and is a cause of substantial medical care expenditures. Effective treatment of adults with allergic rhinitis usually requires an integrated regimen that combines allergen avoidance measures, pharmacotherapy, and possible specific-allergen immunotherapy, This approach can control bothersome symptoms with minimal adverse effects in most patients. New medications, such as anti-immunoglobulin E therapy and cytokine antagonists, may provide relief to patients who are refractory to or do not tolerate currently available treatments.	Univ Calif Los Angeles, Dept Med & Pediat, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles	Corren, J (corresponding author), Allergy Res Fdn Inc, 11620 Wilshire Blvd,Suite 200, Los Angeles, CA 90025 USA.							Borish LC, 1998, J ALLERGY CLIN IMMUN, V101, pS8; BOUSQUET J, 1990, J ALLERGY CLIN IMMUN, V86, P248, DOI 10.1016/S0091-6749(05)80072-7; Caballero R, 1997, BRIT J PHARMACOL, V122, P796, DOI 10.1038/sj.bjp.0701468; Casale TB, 1999, ALLERGY ASTHMA PROC, V20, P193, DOI 10.2500/108854199778553046; Corren J, 1999, J ALLERGY CLIN IMMUN, V104, pS144, DOI 10.1016/S0091-6749(99)70310-6; Corren J, 1998, J ALLERGY CLIN IMMUN, V101, pS105; Corren J, 1996, J ALLERGY CLIN IMMUN, V97, P251; CRETICOS PS, 1984, NEW ENGL J MED, V310, P1626, DOI 10.1056/NEJM198406213102502; DEBLAY F, 1991, AM REV RESPIR DIS, V143, P1334, DOI 10.1164/ajrccm/143.6.1334; DONNELLY AL, 1995, AM J RESP CRIT CARE, V151, P1734, DOI 10.1164/ajrccm.151.6.7767514; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Galant S, 1998, ANN ALLERG ASTHMA IM, V81, P203, DOI 10.1016/S1081-1206(10)62813-X; Gergen PJ, 1999, J ALLERGY CLIN IMMUN, V103, P501, DOI 10.1016/S0091-6749(99)70477-X; Gilmore TM, 1996, AM J IND MED, V30, P234; Graf P, 1997, ALLERGY, V52, P28, DOI 10.1111/j.1398-9995.1997.tb04881.x; GROSSMAN J, 1995, J ALLERGY CLIN IMMUN, V95, P1123, DOI 10.1016/S0091-6749(95)70216-4; Hill DJ, 1997, J ALLERGY CLIN IMMUN, V99, P323, DOI 10.1016/S0091-6749(97)70049-6; Howarth PH, 1999, CLIN EXP ALLERGY, V29, P87; JAAKKOLA JJK, 1993, J EXPO ANAL ENV EPID, V3, P129; JUNIPER EF, 1993, J ALLERGY CLIN IMMUN, V92, P66, DOI 10.1016/0091-6749(93)90039-I; KANFER I, 1993, PHARMACOTHERAPY, V13, pS116; Kay GG, 1997, AM J MANAG CARE, V3, P1843; Kay GG, 1999, J ALLERGY CLIN IMMUN, V103, pS254; KIVITY S, 1989, ALLERGY, V44, P291, DOI 10.1111/j.1398-9995.1989.tb01072.x; KNIGHT A, 1976, J ALLERGY CLIN IMMUN, V58, P278, DOI 10.1016/0091-6749(76)90132-9; Lu S, 1999, J ALLERGY CLIN IMMUN, V103, pS135; Mazzotta P, 1999, DRUG SAFETY, V20, P361, DOI 10.2165/00002018-199920040-00005; Meltzer EO, 1997, ALLERGY, V52, P33, DOI 10.1111/j.1398-9995.1997.tb04820.x; Munir A K, 1993, Pediatr Allergy Immunol, V4, P136, DOI 10.1111/j.1399-3038.1993.tb00082.x; OHANLON JF, 1995, ALLERGY, V50, P234, DOI 10.1111/j.1398-9995.1995.tb01140.x; Onrust SV, 1998, DRUGS, V56, P725, DOI 10.2165/00003495-199856040-00018; PETRULIS AS, 1991, J GEN INTERN MED, V6, P503, DOI 10.1007/BF02598217; PIPKORN U, 1987, NEW ENGL J MED, V316, P1506, DOI 10.1056/NEJM198706113162403; Ray NF, 1999, J ALLERGY CLIN IMMUN, V103, P401, DOI 10.1016/S0091-6749(99)70463-X; REISMAN RE, 1990, J ALLERGY CLIN IMMUN, V85, P1050, DOI 10.1016/0091-6749(90)90050-E; Sly RM, 1999, ANN ALLERG ASTHMA IM, V82, P233, DOI 10.1016/S1081-1206(10)62603-8; Sporik R, 1998, J ALLERGY CLIN IMMUN, V101, P451, DOI 10.1016/S0091-6749(98)70352-5; TAN R, 1995, DRUG AGING, V7, P168, DOI 10.2165/00002512-199507030-00002; TOGIAS A, 1998, J ALLERGY CLIN IMMUN, V101, pA706; Torfs CP, 1996, TERATOLOGY, V54, P84, DOI 10.1002/(SICI)1096-9926(199606)54:2<84::AID-TERA4>3.0.CO;2-4; van Neerven RJJ, 1999, J IMMUNOL, V163, P2944; Wiseman LR, 1997, DRUGS, V53, P885, DOI 10.2165/00003495-199753050-00014; WOOD RA, 1989, J ALLERGY CLIN IMMUN, V83, P730, DOI 10.1016/0091-6749(89)90006-7; Wood RA, 1998, AM J RESP CRIT CARE, V158, P115, DOI 10.1164/ajrccm.158.1.9712110; YANAI K, 1995, BRIT J PHARMACOL, V116, P1649, DOI 10.1111/j.1476-5381.1995.tb16386.x	45	21	22	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2000	105	6	2	S			S610	S615		10.1067/mai.2000.106151	http://dx.doi.org/10.1067/mai.2000.106151			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	328QU	10856166	Bronze			2022-12-18	WOS:000087862200004
J	Davies, JM; O'Hehir, RE; Suphioglu, C				Davies, JM; O'Hehir, RE; Suphioglu, C			Use of phage display technology to investigate allergen-antibody interactions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						phage display; IgE; FAb; allergen; epitope	GRASS-POLLEN ALLERGEN; MONOCLONAL-ANTIBODIES; PEPTIDE LIBRARIES; ESCHERICHIA-COLI; IGE; SPECIFICITY; BINDING; PROTEIN; EXPRESSION; PROFILIN	Phage display is an advanced technology that can be used to characterize the interactions of antibody with antigen at the molecular level, It provides valuable data when applied to the investigation of IgE interaction with allergens. The aim of this rostrum article is to provide an explanation of the potential of phage display for increasing the understanding of allergen-IgE interaction, the discovery of diagnostic reagents, and the development of novel therapeutics for the treatment of allergic disease. The significance of initial studies that have applied phage display technology in allergy research will be highlighted. Phage display has been used to clone human IgE to timothy grass pollen allergen Phl p 5, to characterize the epitopes for murine and human antibodies to a birch pollen allergen Bet v 1, and to elucidate the epitopes of a murine mAb to the house dust mite allergen Der p 1, The technology has identified peptides that functionally mimic sites of human IgE constant domains and that were used to raise antiserum for blocking binding of IgE to the Fc epsilon RI on basophils and subsequent release of histamine. Phage display has also been used to characterize novel peanut and fungal allergens, The method has been used to increase our understanding of the molecular basis of allergen-IgE interactions and to develop clinically relevant reagents with the pharmacologic potential to block the effector phase of allergic reactions. Many advances from these early studies are likely as phage display technology evolves and allergists gain expertise in its research applications.	Alfred Hosp, Dept Allergy Asthma & Clin Immunol, Prahran, Vic 3181, Australia; Monash Univ, Sch Med, Prahran, Vic 3181, Australia	Florey Institute of Neuroscience & Mental Health; Monash University	Davies, JM (corresponding author), Alfred Hosp, Dept Allergy Asthma & Clin Immunol, Commercial Rd, Prahran, Vic 3181, Australia.		O'Hehir, Robyn E/H-3627-2011; Davies, Janet/C-7989-2009	O'Hehir, Robyn E/0000-0002-3489-7595; Davies, Janet/0000-0002-6378-4119				BARBAS CF, 1991, P NATL ACAD SCI USA, V88, P7978, DOI 10.1073/pnas.88.18.7978; Crameri R, 1998, INT IMMUNOL, V10, P1211, DOI 10.1093/intimm/10.8.1211; Crameri R, 1996, INT ARCH ALLERGY IMM, V110, P41, DOI 10.1159/000237308; Davies JM, 1999, IMMUNOL CELL BIOL, V77, P483, DOI 10.1046/j.1440-1711.1999.00846.x; DeLalla C, 1996, MOL IMMUNOL, V33, P1049, DOI 10.1016/S0161-5890(96)00061-2; DROUPADI PR, 1994, MOL IMMUNOL, V31, P537, DOI 10.1016/0161-5890(94)90041-8; Furmonaviciene R, 1999, CLIN EXP ALLERGY, V29, P1563, DOI 10.1046/j.1365-2222.1999.00686.x; GRIFFITHS AD, 1994, EMBO J, V13, P3245, DOI 10.1002/j.1460-2075.1994.tb06626.x; Houshmand H, 1999, ANAL BIOCHEM, V268, P363, DOI 10.1006/abio.1998.3076; Jensen-Jarolim E, 1998, FASEB J, V12, P1635, DOI 10.1096/fasebj.12.15.1635; KANG AS, 1991, P NATL ACAD SCI USA, V88, P4363, DOI 10.1073/pnas.88.10.4363; Kleber-Janke T, 1999, INT ARCH ALLERGY IMM, V119, P265, DOI 10.1159/000024203; Knox B, 1996, TRENDS PLANT SCI, V1, P156, DOI 10.1016/S1360-1385(96)80051-3; Kricek F, 1999, INT ARCH ALLERGY IMM, V118, P222, DOI 10.1159/000024077; Leitner A, 1998, EUR J IMMUNOL, V28, P2921, DOI 10.1002/(SICI)1521-4141(199809)28:09<2921::AID-IMMU2921>3.0.CO;2-D; Li Z D, 1997, Cell Res, V7, P171; Li Z D, 1997, Cell Res, V7, P161; Low NM, 1996, J MOL BIOL, V260, P359, DOI 10.1006/jmbi.1996.0406; LU ZJ, 1995, BIO-TECHNOL, V13, P366, DOI 10.1038/nbt0495-366; MAKOWSKI L, 1993, GENE, V128, P5, DOI 10.1016/0378-1119(93)90146-T; Malik P, 1996, J MOL BIOL, V260, P9, DOI 10.1006/jmbi.1996.0378; Mayer C, 1999, J EXP MED, V189, P1507, DOI 10.1084/jem.189.9.1507; MCCAFFERTY J, 1990, NATURE, V348, P552, DOI 10.1038/348552a0; PERSSON MAA, 1991, P NATL ACAD SCI USA, V88, P2432, DOI 10.1073/pnas.88.6.2432; Rolland J, 1998, CURR OPIN IMMUNOL, V10, P640, DOI 10.1016/S0952-7915(98)80082-4; Rudolf MP, 1998, J IMMUNOL, V160, P3315; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; Smith GP, 1997, CHEM REV, V97, P391, DOI 10.1021/cr960065d; Steinberger P, 1997, INT ARCH ALLERGY IMM, V113, P258, DOI 10.1159/000237564; Steinberger P, 1996, J BIOL CHEM, V271, P10967, DOI 10.1074/jbc.271.18.10967; Wang Y, 1996, IMMUNOLOGY, V89, P316, DOI 10.1046/j.1365-2567.1996.d01-761.x; WATERHOUSE P, 1993, NUCLEIC ACIDS RES, V21, P2265, DOI 10.1093/nar/21.9.2265; Wiedemann P, 1996, J BIOL CHEM, V271, P29915, DOI 10.1074/jbc.271.47.29915; Zhao J, 1999, J EXP MED, V190, P101, DOI 10.1084/jem.190.1.101	34	21	26	1	9	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2000	105	6	1				1085	1092		10.1067/mai.2000.107040	http://dx.doi.org/10.1067/mai.2000.107040			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	327EX	10856140				2022-12-18	WOS:000087781800007
J	Wang, CH; Hsieh, WY; Shih, LY; Lin, HC; Liu, CY; Chung, KF; Kuo, HP				Wang, CH; Hsieh, WY; Shih, LY; Lin, HC; Liu, CY; Chung, KF; Kuo, HP			Increased progenitor cell proliferation in the peripheral blood of patients with bronchial asthma: The role of nitric oxide	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; progenitor cells; nitric oxide; cytokines; nitric oxide synthase	MESSENGER-RNA; CIRCULATING EOSINOPHILS; SYNTHASE; INTERLEUKIN-5; EXPRESSION; PROTEINS; NITROSYLATION; INFLAMMATION; ACTIVATION; BASOPHILS	Background: Asthma exacerbation is associated with increased numbers of circulating CD34(+) progenitor cells, which may migrate to airways and develop into mature cells under the effects of cytokines and hematopoietic factors. Nitric oxide (NO) generation is enhanced in asthma and is known to suppress human hematopoiesis. Objectives: We studied circulating progenitor cells in the blood of patients with varying severity of asthma and examined the contribution of NO to their proliferation into eosinophil-forming colonies ex vivo, Methods: With use of multiparameter flow cytometric analyses, the cell numbers and intracellular inducible NO synthase (iNOS) immunoreactivity of circulating CD34(+) cells in peripheral blood was measured. The serum level of GM-CSF or IL-5 was also determined, The colonies grown from progenitor cells were cultured in methylcellulose either in the presence or absence of growth factors, including GM-CSF, stem cell factor, and IL-3. Results: A significantly greater number of circulating CD34(+) cells increased together with higher intracellular iNOS immunoreactivity in moderate asthmatics compared with mild intermittent asthmatics and healthy subjects. There was no significant difference in iNOS immunoreactivities or CD34(+) progenitor cell numbers between healthy subjects and those with mild intermittent asthma. Serum levels of GM-CSF or IL-5 mere significantly higher in all asthmatics compared with healthy subjects and correlated with circulating CD34+ cells. A greater number of colonies was grown either in the presence or absence of growth factors with a higher percentage of cells of eosinophil lineage in asthmatics than in health subjects. N-G-nitro-L-arginine methyl ester potentiated and sodium nitroprusside inhibited the colony growth in both asthmatic and healthy subjects without a significant change in the percentage of eosinophil lineage, Conclusions: The production of NO from progenitor cells or other circulating cells may act in an autocrine or paracrine fashion to regulate progenitor cell growth and colony formation. However, this is not sufficient to control the increased proliferation of progenitor cells observed in asthma.	Chang Gung Mem Hosp, Dept Thorac Med 2, Taipei 10591, Taiwan; Chang Gung Mem Hosp, Dept Hematol, Taipei 10591, Taiwan; Natl Heart & Lung Inst, Dept Thorac Med, London, England	Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Imperial College London	Kuo, HP (corresponding author), Chang Gung Mem Hosp, Dept Thorac Med 2, 199 Tung Hwa N Rd, Taipei 10591, Taiwan.		Chung, Kian Fan/I-8456-2019; Chung, Kian Fan/B-1872-2012; Wang, Chun-Hua/V-9861-2019; Wang, Chun-Hua/C-1488-2016	Chung, Kian Fan/0000-0001-7101-1426; Chung, Kian Fan/0000-0001-7101-1426; Wang, Chun-Hua/0000-0002-3514-9353; 				ALVING K, 1993, EUR RESPIR J, V6, P1268; BACH MK, 1991, J IMMUNOL METHODS, V142, P243, DOI 10.1016/0022-1759(91)90112-S; BERDEAUX A, 1993, FUND CLIN PHARMACOL, V7, P401, DOI 10.1111/j.1472-8206.1993.tb01037.x; Berkman N, 1996, AM J RESP CRIT CARE, V154, P1804, DOI 10.1164/ajrccm.154.6.8970374; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BRUNE B, 1994, LIFE SCI, V54, P61, DOI 10.1016/0024-3205(94)00775-6; BRUNE B, 1990, ARCH BIOCHEM BIOPHYS, V279, P286, DOI 10.1016/0003-9861(90)90493-I; Civin C. L., 1989, LEUKOCYTE TYPING, P818; CLUTTERBUCK EJ, 1989, BLOOD, V73, P1504; CORRIGAN CJ, 1993, AM REV RESPIR DIS, V147, P540, DOI 10.1164/ajrccm/147.3.540; delPozo V, 1997, J IMMUNOL, V158, P859; DENBURG JA, 1985, J ALLERGY CLIN IMMUN, V76, P466, DOI 10.1016/0091-6749(85)90728-6; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; FEHSEL K, 1993, DIABETES, V42, P496, DOI 10.2337/diabetes.42.3.496; Flak TA, 1996, AM J RESP CRIT CARE, V154, pS202, DOI 10.1164/ajrccm/154.4_Pt_2.S202; GIBSON PG, 1991, AM REV RESPIR DIS, V143, P331, DOI 10.1164/ajrccm/143.2.331; GIBSON PG, 1990, CLIN EXP ALLERGY, V20, P661, DOI 10.1111/j.1365-2222.1990.tb02705.x; HAMID Q, 1993, LANCET, V342, P1510, DOI 10.1016/S0140-6736(05)80083-2; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; Inman MD, 1996, AM J RESP CELL MOL, V15, P305, DOI 10.1165/ajrcmb.15.3.8924277; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745, DOI 10.1164/ajrccm/140.6.1745; Kharitonov SA, 1997, J ALLERGY CLIN IMMUN, V99, P58; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; MACIEJEWSKI JP, 1995, J CLIN INVEST, V96, P1085, DOI 10.1172/JCI118094; MARAGOS CM, 1993, CANCER RES, V53, P564; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; *NAT HEART LUNG BL, 1998, GLOB IN ASTHM PRACT; NGYYEN T, 1992, P NATL ACAD SCI USA, V89, P3030; RADI R, 1993, ARCH BIOCHEM BIOPHYS, V300, P409, DOI 10.1006/abbi.1993.1055; Robinson DS, 1999, AM J RESP CELL MOL, V20, P9, DOI 10.1165/ajrcmb.20.1.3449; SARIH M, 1993, BIOCHEM BIOPH RES CO, V191, P503, DOI 10.1006/bbrc.1993.1246; SCHMIDT HHHW, 1993, BIOCHIM BIOPHYS ACTA, V1178, P153, DOI 10.1016/0167-4889(93)90006-B; Sehmi R, 1996, AM J RESP CELL MOL, V15, P645, DOI 10.1165/ajrcmb.15.5.8918371; Sehmi R, 1997, J CLIN INVEST, V100, P2466, DOI 10.1172/JCI119789; SHALIT M, 1995, CELL IMMUNOL, V160, P50, DOI 10.1016/0008-8749(95)80008-7; SHIH LY, 1994, BLOOD, V83, P744; SOUSA AR, 1993, AM REV RESPIR DIS, V147, P1557, DOI 10.1164/ajrccm/147.6_Pt_1.1557; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; Sutherland D R, 1992, J Hematother, V1, P115, DOI 10.1089/scd.1.1992.1.115; SUTHERLAND DR, 1994, EXP HEMATOL, V22, P1003; TEN RM, 1989, J EXP MED, V169, P1757, DOI 10.1084/jem.169.5.1757; Wang CH, 1998, EUR RESPIR J, V11, P809, DOI 10.1183/09031936.98.11040809; WINK DA, 1993, ARCH BIOCHEM BIOPHYS, V300, P115, DOI 10.1006/abbi.1993.1016; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500	45	21	21	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1999	104	4	1				803	810		10.1016/S0091-6749(99)70291-5	http://dx.doi.org/10.1016/S0091-6749(99)70291-5			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	248NG	10518825				2022-12-18	WOS:000083281200012
J	Wurtzen, PA; Wissenbach, M; Ipsen, H; Bufe, A; Arnved, J; van Neerven, RJJ				Wurtzen, PA; Wissenbach, M; Ipsen, H; Bufe, A; Arnved, J; van Neerven, RJJ			Highly heterogeneous Phl p 5-specific T cells from patients with allergic rhinitis differentially recognize recombinant Phl p 5 isoallergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T lymphocytes; allergy; Poaceae grasses; isoallergens; HLA; cytokines	BIRCH POLLEN ALLERGEN; GROUP-V ALLERGENS; MESSENGER-RNA EXPRESSION; HOUSE-DUST MITE; TIMOTHY-GRASS; MAJOR ALLERGEN; ATOPIC PATIENTS; PRATENSE POLLEN; CYTOKINE PRODUCTION; LYMPHOCYTES-T	Background: The prevalence of atopic allergy to Poaceae grasses poses a serious health problem. Objective: To evaluate the T cell-activating capacity of recombinant grass pollen allergens suggested for immunotherapy, we characterized the T-cell response of allergic patients to the Phleum pratense (Phl p) major allergen, Phl p 5. Methods: Thirty-eight Phl p 5-specific CD4(+) T-cell clones (TCCs) were isolated from the peripheral blood of 3 patients with allergic rhinitis and were characterized with respect to cross-reactivity, HLA restriction, cytokine profiles, and isoallergen specificity when tested with natural Phl p 5 and 5 rPhl p 5 isoallergens (4 Phl p 5a and 1 Phl p 5b). Results: The TCCs were highly cross-reactive with group 5 allergens of related grasses, and the different cross-reactivity patterns found indicate that several T-cell epitopes are present in Phl p 5, Most TCCs displayed a T-H0-like cytokine profile, whereas a few TCCs belonged to the T-H2 or T-H1 subset. The TCCs were restricted by HCA-DR (24/38 TCCs), HLA-DQ (11/38 TCCs), or HLA-DP (3/38 TCCs), Interestingly, 4 of the 34 TCCs tested reacted exclusively with the 4 rPhl p 5a isoforms; 8 of 34 TCCs were rPhl p 5b specific, and 3 of 34 TCCs reacted with all isoforms; 19 of 34 TCCs did not react with any of the rPhl p 5 isoallergens. Moreover, the overall isoform recognition pattern differed considerably among patients. Conclusion: These results demonstrate that Phl p 5-specific T cells are highly heterogeneous and that individual TCCs, and individual patients, differentially recognize isoallergens. The differential isoallergen recognition for Phl p 5-specific T cells suggests, if confirmed in larger patient groups, that a combination of 2 or more rPhl p 5 isoallergens may be needed to replace the natural grass allergen for immunotherapy.	ALK Abello, Horsholm, Denmark; Forschungszentrum Borstel, Borstel, Germany; Lunge & Allergiklinikken, Copenhagen, Denmark	ALK-Abello AS; Forschungszentrum Borstel	Wurtzen, PA (corresponding author), Univ Copenhagen, Panum Inst, Dept Med Anat, Blegdamsvej 3, DK-2200 Copenhagen, Denmark.		van Neerven, Joost/GWZ-3214-2022	Bufe, Albrecht/0000-0001-7335-9362; van Neerven, R.J.Joost/0000-0002-3991-5297				Blaher B, 1996, J ALLERGY CLIN IMMUN, V98, P124, DOI 10.1016/S0091-6749(96)70234-8; BREITENEDER H, 1993, EUR J BIOCHEM, V552, P1; BRINER TJ, 1993, P NATL ACAD SCI USA, V90, P7608, DOI 10.1073/pnas.90.16.7608; BUFE A, 1995, FEBS LETT, V363, P6, DOI 10.1016/0014-5793(95)00259-C; CORRIGAN CJ, 1992, IMMUNOL TODAY, V13, P501, DOI 10.1016/0167-5699(92)90026-4; EBNER C, 1995, J IMMUNOL, V154, P1932; Ferreira F, 1996, J EXP MED, V183, P599, DOI 10.1084/jem.183.2.599; Gehlhar K, 1997, EUR J BIOCHEM, V247, P217, DOI 10.1111/j.1432-1033.1997.00217.x; GodnicCvar J, 1997, J ALLERGY CLIN IMMUN, V99, P354, DOI 10.1016/S0091-6749(97)70053-8; IPSEN H, 1991, MOL IMMUNOL, V28, P1279, DOI 10.1016/0161-5890(91)90015-C; JUTEL M, 1995, J IMMUNOL, V154, P4187; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; LARSEN JN, 1995, ACI NEWS, V7, P141; Leonard C, 1997, AM J RESP CELL MOL, V17, P368, DOI 10.1165/ajrcmb.17.3.2797; LOWENSTEIN H, 1986, CLIN REV ALLERG, V4, P405; MAGGI E, 1988, EUR J IMMUNOL, V18, P1045, DOI 10.1002/eji.1830180712; MAGGI E, 1991, J IMMUNOL, V146, P1169; MATTHIESEN F, 1991, CLIN EXP ALLERGY, V21, P309, DOI 10.1111/j.1365-2222.1991.tb01662.x; MATTHIESEN F, 1991, CLIN EXP ALLERGY, V21, P297, DOI 10.1111/j.1365-2222.1991.tb01661.x; Menz G, 1996, CLIN EXP ALLERGY, V26, P50, DOI 10.1111/j.1365-2222.1996.tb00056.x; MULLER WD, 1994, INT ARCH ALLERGY IMM, V105, P391, DOI 10.1159/000236789; Muller WD, 1996, INT ARCH ALLERGY IMM, V109, P352, DOI 10.1159/000237262; Norman PS, 1996, AM J RESP CRIT CARE, V154, P1623, DOI 10.1164/ajrccm.154.6.8970345; OHEHIR RE, 1989, IMMUNOLOGY, V66, P499; PARRONCHI P, 1991, P NATL ACAD SCI USA, V88, P4538, DOI 10.1073/pnas.88.10.4538; Pauli G, 1996, J ALLERGY CLIN IMMUN, V97, P1100, DOI 10.1016/S0091-6749(96)70264-6; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Sallusto F, 1996, J ALLERGY CLIN IMMUN, V97, P627, DOI 10.1016/S0091-6749(96)70308-1; SCHEINER O, 1995, ALLERGY, V50, P384, DOI 10.1111/j.1398-9995.1995.tb01167.x; SCHENK S, 1994, EUR J BIOCHEM, V224, P717, DOI 10.1111/j.1432-1033.1994.00717.x; Schenk S, 1995, J ALLERGY CLIN IMMUN, V96, P986, DOI 10.1016/S0091-6749(95)70237-7; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; SMITH PM, 1994, MOL IMMUNOL, V31, P491, DOI 10.1016/0161-5890(94)90068-X; Sparholt SH, 1997, CLIN EXP ALLERGY, V27, P932; SPIEGELBERG HL, 1994, J IMMUNOL, V152, P4706; Till S, 1997, J ALLERGY CLIN IMMUN, V99, P563, DOI 10.1016/S0091-6749(97)70085-X; VALENTA R, 1992, INT ARCH ALLERGY IMM, V97, P287, DOI 10.1159/000236135; VANDERHEIJDEN FL, 1991, J INVEST DERMATOL, V97, P389, DOI 10.1111/1523-1747.ep12480966; VANNEERVEN RJJ, 1994, J IMMUNOL, V152, P4203; VANNEERVEN RJJ, 1993, J IMMUNOL, V151, P2326; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633; VRTALA S, 1993, J IMMUNOL, V151, P4773; Vrtala S, 1996, J ALLERGY CLIN IMMUN, V97, P781, DOI 10.1016/S0091-6749(96)80156-4; WIERENGA EA, 1990, J IMMUNOL, V144, P4651	44	21	22	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1999	104	1					115	122		10.1016/S0091-6749(99)70122-3	http://dx.doi.org/10.1016/S0091-6749(99)70122-3			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	221QZ	10400848				2022-12-18	WOS:000081738900017
J	Gentile, DA; Patel, A; Ollila, C; Fireman, P; Zeevi, A; Doyle, WJ; Skoner, DP				Gentile, DA; Patel, A; Ollila, C; Fireman, P; Zeevi, A; Doyle, WJ; Skoner, DP			Diminished IL-10 production in subjects with allergy after infection with influenza A virus	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic rhinitis; asthma; influenza A infection	RESPIRATORY SYNCYTIAL VIRUS; CYTOKINE PRODUCTION; ASTHMA; INTERLEUKIN-10; CELLS; PROLIFERATION; EXACERBATIONS; INFLAMMATION; INHIBITION; EXPRESSION	Background: Recent studies have documented a link between respiratory viral infections and the expression of asthma and other allergic disorders. Results from other studies have suggested that diminished production of IL-10, an anti-inflammatory cytokine, may contribute to the pathophysiologic features of these diseases. Objective: The objective of this study was to determine whether diminished IL-10 production and T-H2 cytokine skewing occur in allergic, as compared with nonallergic, subjects after experimental infection with the influenza A virus. Methods: PBMCs were isolated from 11 subjects with allergy and 14 subjects with no allergy before and after influenza A infection and stimulated with either mitogen (PHA) or antigen (influenza A). Supernatants were assayed for IL-10, IL-4, and IFN-gamma by ELISA. Results: PBMC IL-10 production was significantly diminished in subjects with allergy, as compared with subjects with no allergy, after experimental infection with influenza A virus. However, significant T-H2 skewing and enhanced airway symptoms were not observed in these same subjects. Conclusions: These data provide further support that subjects with allergy have an intrinsic inability to upregulate IL-10 production in response to inflammatory stimuli and extend this observation to include respiratory viral infections. Future studies in this area could lead to a better understanding of the pathogenesis of asthma and other allergic disorders.	Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Dept Otolaryngol, Pittsburgh, PA 15260 USA; Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Gentile, DA (corresponding author), 3705 5th Ave, Pittsburgh, PA 15213 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000084] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019262] Funding Source: NIH RePORTER; NCRR NIH HHS [5MO1RR00084] Funding Source: Medline; NIAID NIH HHS [AI19262] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON LJ, 1994, J INFECT DIS, V170, P1201, DOI 10.1093/infdis/170.5.1201; Borish L, 1996, J ALLERGY CLIN IMMUN, V97, P1288, DOI 10.1016/S0091-6749(96)70197-5; CALHOUN WJ, 1994, J CLIN INVEST, V94, P2200, DOI 10.1172/JCI117581; DEL PG, 1993, J IMMUNOL, V150, P353; DELPRETE G, 1993, J IMMUNOL, V150, P353; DOWDLE W, 1979, PROC VIRAL RICKETTSI, P585; DOYLE WJ, 1994, ANN OTO RHINOL LARYN, V103, P59, DOI 10.1177/000348949410300111; ENK AH, 1993, J IMMUNOL, V151, P2390; FRAENKEL DJ, 1995, AM J RESP CRIT CARE, V151, P879; Gentile DA, 1997, ANN ALLERG ASTHMA IM, V78, P466, DOI 10.1016/S1081-1206(10)63233-4; Hussell T, 1996, J GEN VIROL, V77, P2447, DOI 10.1099/0022-1317-77-10-2447; John M, 1998, AM J RESP CRIT CARE, V157, P256, DOI 10.1164/ajrccm.157.1.9703079; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Koning H, 1997, CYTOKINE, V9, P427, DOI 10.1006/cyto.1996.0185; Lim S, 1998, LANCET, V352, P113, DOI 10.1016/S0140-6736(98)85018-6; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; PUNNONEN J, 1993, J IMMUNOL, V151, P1280; Renzi PM, 1997, J PEDIATR-US, V130, P584, DOI 10.1016/S0022-3476(97)70243-9; Roman M, 1997, AM J RESP CRIT CARE, V156, P190, DOI 10.1164/ajrccm.156.1.9611050; Rosenwasser LJ, 1997, AM J RESP CRIT CARE, V156, pS152, DOI 10.1164/ajrccm.156.4.12tac-14; Sanchez-Guerrero I, 1997, Allergol Immunopathol (Madr), V25, P98; TAKANASKI S, 1994, J EXP MED, V180, P711, DOI 10.1084/jem.180.2.711; TANG YW, 1994, J CLIN INVEST, V94, P1953, DOI 10.1172/JCI117546; TOBITA K, 1975, MED MICROBIOL IMMUN, V162, P9, DOI 10.1007/BF02123572; WELLIVER RC, 1981, NEW ENGL J MED, V5, P48	25	21	23	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1999	103	6					1045	1048		10.1016/S0091-6749(99)70177-6	http://dx.doi.org/10.1016/S0091-6749(99)70177-6			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207GT	10359884				2022-12-18	WOS:000080929500011
J	Hisauchi-Kojima, K; Sumi, Y; Miyashita, Y; Miyake, S; Toyoda, H; Kurup, VP; Yoshizawa, Y				Hisauchi-Kojima, K; Sumi, Y; Miyashita, Y; Miyake, S; Toyoda, H; Kurup, VP; Yoshizawa, Y			Purification of the antigenic components of pigeon dropping extract, the responsible agent for cellular immunity in pigeon breeder's disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						pigeon breeder's disease; antigen purification; sodium dodecylsulfate-polyacrylamide gel electrophoresis; 2-dimensional electrophoresis; immunoblotting; cellular immune response; N-terminal sequence of peptide; synthetic peptides	HYPERSENSITIVITY PNEUMONITIS; TRICHOSPORON-CUTANEUM; INTESTINAL MUCIN; AVIAN ANTIGENS; LUNG; PROTEINS; MECHANISMS; ANTIBODIES; CELLS; IGA	Background: Pigeon breeder's disease (PBD) is a lung disease caused by inhalation of antigens derived from pigeons. Objective: This study was undertaken to characterize the responsible component of pigeon dropping extract (PDE) for PBD. Methods: First, crude PDE was applied to SDS-PAGE followed by immunoblotting by using antibodies in bronchoalveolar lavage (BAL) fluid. Second, 9 bands of PDE were separated by SDS-PAGE and used for antigen-induced PBMCs. Finally, amino-terminal sequencing was conducted on an isolated 21-kd protein by 2-dimensional electrophoresis. Results: Immunoblots with BAL fluid from patients with PBD identified 9 bands. Similar patterns were observed by using BAL fluid from 10 control patients (9 with summer-type hypersensitivity pneumonitis of idiopathic pulmonary fibrosis and 1 asymptomatic breeder), except for the 21-kd protein, which was detected in 10 patients with PBD and 1 asymptomatic breeder. The stimulation indices of PBMCs determined by using proteins electroeluted from the 9 bands were higher in patients with PBD than in the 10 control patients. The 21-kd protein was separated into 5 spots by 2-dimensional electrophoresis; these spots were all reactive with BAL fluid from patients with PBD as determined by immunoblotting. The sequence of the 21-kd protein had 57% identity to a Saccharomyces cerevisiae chromosome X reading frame. A synthetic peptide, derived from the amino acid sequence of the N-terminal of the native protein, induced significant proliferation of PBMCs obtained from 5 patients with PBD, but not with PBMCs obtained from control patients. Conclusion: The 21-kd protein is the only protein that identified individuals exposed to pigeons by immunoblotting. Only PBMCs from patients with PBD showed significant proliferation to the 21-kd protein and to the synthetic peptide on the basis of the N-terminal sequence of the native peptide. The 21-kd protein will be an important antigen for studies on the epidemiology, diagnosis, and pathogenesis of PBD.	Tokyo Med & Dent Univ, Dept Pulm Med, Bunkyo Ku, Tokyo 1138519, Japan; Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Div Med Genet, Los Angeles, CA USA; Med Coll Wisconsin, VAMC, Dept Med, Milwaukee, WI 53226 USA	Tokyo Medical & Dental University (TMDU); Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Medical College of Wisconsin	Yoshizawa, Y (corresponding author), Tokyo Med & Dent Univ, Dept Pulm Med, Bunkyo Ku, 5-45 Yushima 1 Chome, Tokyo 1138519, Japan.							BARRIOS R, 1986, LUNG, V164, P55, DOI 10.1007/BF02713629; BOURKE SJ, 1989, THORAX, V44, P415, DOI 10.1136/thx.44.5.415; CALDWELL JR, 1973, J ALLERGY CLIN IMMUN, V52, P225, DOI 10.1016/0091-6749(73)90060-2; CALVANICO NJ, 1986, ALLERGY CLIN IMMUNOL, V77, P79; DEBEER PM, 1990, INT ARCH ALLER A IMM, V91, P343, DOI 10.1159/000235139; FINK JN, 1975, INT ARCH ALLER A IMM, V49, P831, DOI 10.1159/000231466; FINK JN, 1969, J IMMUNOL, V103, P244; FINK JN, 1969, J LAB CLIN MED, V74, P325; GUEHO E, 1992, ANTON LEEUW INT J G, V61, P285, DOI 10.1007/BF00713937; HANSEN PJ, 1974, INT ARCH ALLER A IMM, V47, P498, DOI 10.1159/000231244; KALTREIDER HB, 1976, AM REV RESPIR DIS, V113, P347; KURUP VP, 1975, J CLIN MICROBIOL, V2, P55; KURUP VP, 1979, INT ARCH ALLER A IMM, V60, P140, DOI 10.1159/000232335; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCCORMICK DJ, 1982, IMMUNOLOGY, V129, P1493; MENDEZSAMPERIO P, 1989, J IMMUNOL, V142, P3599; Mendoza F, 1996, J LAB CLIN MED, V127, P23, DOI 10.1016/S0022-2143(96)90162-6; MIZOBE T, 1995, CLIN EXP ALLERGY, V25, P265, DOI 10.1111/j.1365-2222.1995.tb01039.x; MOORE VL, 1980, J ALLERGY CLIN IMMUN, V65, P365, DOI 10.1016/0091-6749(80)90214-6; MOORE VL, 1975, J LAB CLIN MED, V85, P540; Mundt C, 1996, J ALLERGY CLIN IMMUN, V98, P441, DOI 10.1016/S0091-6749(96)70169-0; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OHTSUKA M, 1994, AM J RESP CRIT CARE, V149, P455, DOI 10.1164/ajrccm.149.2.8306045; PerezPadilla R, 1996, CHEST, V110, P371, DOI 10.1378/chest.110.2.371; ROBERTS RC, 1977, AM REV RESPIR DIS, V116, P1075; SHIMAZU K, 1984, AM REV RESPIR DIS, V130, P407; TODD A, 1993, CLIN EXP IMMUNOL, V92, P494; TODD A, 1991, CLIN EXP IMMUNOL, V85, P453; TOWBIN H, 1984, J IMMUNOL METHODS, V72, P313, DOI 10.1016/0022-1759(84)90001-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; YOSHIZAWA Y, 1989, ANN INTERN MED, V110, P31, DOI 10.7326/0003-4819-110-1-31; YOSHIZAWA Y, 1995, J ALLERGY CLIN IMMUN, V96, P122, DOI 10.1016/S0091-6749(95)70041-2; YOSHIZAWA Y, 1995, CLIN EXP IMMUNOL, V100, P395	33	21	22	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1999	103	6					1158	1165		10.1016/S0091-6749(99)70193-4	http://dx.doi.org/10.1016/S0091-6749(99)70193-4			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207GT	10359900				2022-12-18	WOS:000080929500027
J	Bellinghausen, I; Brand, U; Enk, AH; Knop, J; Saloga, J				Bellinghausen, I; Brand, U; Enk, AH; Knop, J; Saloga, J			Signals involved in the early T-H1/T-H2 polarization of an immune response depending on the type of antigen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						protein allergen; hapten; epidermal cells; cytokines; IL-10	INTERFERON-GAMMA-PRODUCTION; CD4+ T-CELLS; IFN-GAMMA; CONTACT SENSITIVITY; CYTOKINE PRODUCTION; PHENOTYPE DEVELOPMENT; PRESENTING CELL; TH1 CELLS; IN-VIVO; INDUCTION	Background: The early production of distinct cytokines by epidermal cells (ECs) in response to antigen exposure may govern the development of T-H1-like immune responses, such as contact sensitivity, or T-H2-like immune responses, such as IgE-dependent allergies of the immediate type, depending on the type of antigen. Objective: The aim of this study was to compare the signals induced by protein allergens with those induced by haptens in ECs and subsequently in local draining lymph node cells (LNCs) or splenocytes. Methods: BALB/c mice mere primed in vivo with the protein allergens ovalbumin or birch pollen or the haptens 2,4-dinitrofluorobenzene or trinitrochlorbenzene, respectively, and cytokine and immunoglobulin secretions of responding splenocytes were measured by ELISA after in vitro coculture with ECs. Induction of cytokine mRNA expression in ECs and LNCs was analyzed by reverse transcriptase-PCR. Results: In the presence of protein allergens, ECs enhance the induction of a T-H2 immune response (IL-4 and IgE production of splenocytes), whereas a T-H1 immune response (IFN-gamma and IgG(2a) production) was only induced in the context of haptens. Heat inactivation of ovalbumin did not diminish the development of a T-H2 immune response. One direct effect of antigen on ECs was the earlier expression of IL-10 mRNA after stimulation with protein allergens (30 minutes) than with haptens (2 hours) in vitro. By using an in vivo approach, sensitization of the skin with trinitrochlorbenzene, but not with ovalbumin, resulted in an early induction of IL-1 beta, IL-12p40, and IFN-gamma mRNA in LNCs,,whereas IL-18 was induced by both. Conclusion: These data indicate that the type of antigen strongly influences the type of immune response by eliciting distinct signals already in the epithelium.	Univ Mainz, Hautklin, Dept Dermatol, Clin Res Grp, D-55131 Mainz, Germany	Johannes Gutenberg University of Mainz	Saloga, J (corresponding author), Univ Mainz, Hautklin, Dept Dermatol, Clin Res Grp, Langenbeckstr 1, D-55131 Mainz, Germany.							Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Bellinghausen I, 1996, J INVEST DERMATOL, V107, P582, DOI 10.1111/1523-1747.ep12582825; Catalina MD, 1996, J EXP MED, V184, P2341, DOI 10.1084/jem.184.6.2341; Constant SL, 1997, ANNU REV IMMUNOL, V15, P297, DOI 10.1146/annurev.immunol.15.1.297; DANDREA A, 1993, J EXP MED, V178, P1041, DOI 10.1084/jem.178.3.1041; DEKRUYFF RH, 1992, J IMMUNOL, V149, P3468; ENK AH, 1995, J INVEST DERMATOL, V105, pS80, DOI 10.1111/1523-1747.ep12316112; ENK AH, 1992, J IMMUNOL, V149, P92; ENK AH, 1994, J EXP MED, V179, P1397, DOI 10.1084/jem.179.4.1397; ENK AH, 1993, J IMMUNOL, V151, P2390; ENK AH, 1993, J IMMUNOL, V150, P3698; ENK AH, 1992, P NATL ACAD SCI USA, V89, P1398, DOI 10.1073/pnas.89.4.1398; FINKELMAN FD, 1988, J IMMUNOL, V141, P2335; FIORENTINO DF, 1991, J IMMUNOL, V146, P3444; FONG TAT, 1989, J IMMUNOL, V143, P2887; Heufler C, 1996, EUR J IMMUNOL, V26, P659, DOI 10.1002/eji.1830260323; HOSKEN NA, 1995, J EXP MED, V182, P1579, DOI 10.1084/jem.182.5.1579; HSIEH CS, 1992, P NATL ACAD SCI USA, V89, P6065, DOI 10.1073/pnas.89.13.6065; KAPSENBERG ML, 1992, J INVEST DERMATOL, V98, P59, DOI 10.1111/1523-1747.ep12494841; Kuhn U, 1998, J IMMUNOL, V160, P667; MAGGI E, 1992, J IMMUNOL, V148, P2142; Marth T, 1996, J IMMUNOL, V157, P2348; METCALFE DD, 1985, CLIN REV ALLERG, V3, P331, DOI 10.1007/BF02992999; Micallef MJ, 1996, EUR J IMMUNOL, V26, P1647, DOI 10.1002/eji.1830260736; Mosmann TR, 1996, IMMUNOL TODAY, V17, P138, DOI 10.1016/0167-5699(96)80606-2; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MULLER G, 1995, J IMMUNOL, V155, P4661; Nakamura T, 1997, J IMMUNOL, V158, P2648; OKAMURA H, 1995, NATURE, V378, P88, DOI 10.1038/378088a0; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; ROBINSON DS, 1993, SPRINGER SEMIN IMMUN, V15, P17; SALOGA J, 1994, AM J RESP CRIT CARE, V149, P65, DOI 10.1164/ajrccm.149.1.8111600; SEDER RA, 1993, P NATL ACAD SCI USA, V90, P10188, DOI 10.1073/pnas.90.21.10188; Stoll S, 1997, J IMMUNOL, V159, P298; TRINCHIERI G, 1993, IMMUNOL TODAY, V14, P335, DOI 10.1016/0167-5699(93)90230-I; Umetsu DT, 1997, P SOC EXP BIOL MED, V215, P11; VANDERHEIJDEN FL, 1991, J INVEST DERMATOL, V97, P389, DOI 10.1111/1523-1747.ep12480966; Wang LF, 1996, J IMMUNOL, V156, P4079; Xu H, 1996, J EXP MED, V183, P1001, DOI 10.1084/jem.183.3.1001	39	21	25	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1999	103	2	1				298	306		10.1016/S0091-6749(99)70505-1	http://dx.doi.org/10.1016/S0091-6749(99)70505-1			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	167JW	9949322				2022-12-18	WOS:000078630100018
J	Levy, AM; Kita, H; Phillips, SF; Schkade, PA; Dyer, PD; Gleich, GJ; Dubravec, VA				Levy, AM; Kita, H; Phillips, SF; Schkade, PA; Dyer, PD; Gleich, GJ; Dubravec, VA			Eosinophilia and gastrointestinal symptoms after ingestion of shiitake mushrooms	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						shiitake mushroom; eosinophilia; eosinophil major basic protein; eosinophil-derived neurotoxin; gastrointestinal symptoms; IL-5	MAJOR BASIC-PROTEIN; GRANULE PROTEINS; DEPOSITION; GASTROENTERITIS; DERMATITIS; LENTINAN; CYTOKINE; DISEASE; TISSUES; ASTHMA	Background: Shiitake mushrooms are a dietary staple in Asia and are increasingly popular worldwide. A cholesterol-lowering study with shiitake showed that 17 of 49 participants withdrew because of rash or abdominal discomfort, and two had marked eosinophilia. One of these latter participants was subsequently challenged for 14 days with shiitake powder and again had eosinophilia. Objective: We investigated whether ingestion of shiitake mushroom powder induces eosinophilia or symptoms. Methods: We studied 10 normal persons. Each participant ingested 4 gm shiitake powder (open label) daily for 10 weeks (trial 1), and the protocol was repeated in these same subjects after 3 to 6 months (trial 2). Blood counts and serum samples were obtained biweekly (trial I) or weekly along with stool spec imens (trial 2). Eosinophil major basic protein and IL-5, IgE, and IgG antishiitake antibodies were measured in sera. Eosinophil-derived neurotoxin was measured in stool extracts. We defined responders as subjects having peak eosinophil counts four or more times their average baseline counts. Results: Each trial had four responders, and trial 2 had one new and three repeat responders. Eosinophilia ranged from 400 to 3900/mm(3). Responders had increased blood eosinophils, serum major basic protein, stool eosinophil-derived neurotoxin, and factors that enhanced eosinophil viability. Antishiitake IgE was not detected, and antishiitake IgG increased in two responders. Gastrointestinal symptoms coincided with eosinophilia in two subjects. Symptoms and eosinophilia resolved after discontinuing shiitake ingestion. Conclusions: Daily ingestion of shiitake mushroom powder in five of 10 healthy persons provoked blood eosinophilia, increased eosinophil granule proteins in serum and stool, and increased gastrointestinal symptoms. Shiitake ingestion suggests a model to study the eosinophil's role in the blood and gastrointestinal tract. Finally, our report raises concerns of possible adverse systemic reactions to this increasingly popular food.	Mayo Clin & Mayo Fdn, Dept Immunol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Gastroenterol & Hepatol & Internal Med, Rochester, MN 55905 USA; Fitzsimons Army Med Ctr, Denver, CO USA	Mayo Clinic; Mayo Clinic	Gleich, GJ (corresponding author), Mayo Clin & Mayo Fdn, Dept Immunol, Rochester, MN 55905 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015231, U19AI034577, R37AI015231, R01AI009728, U01AI034577, R37AI009728] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 15231, AI 34577, AI 09728] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABUGHAZALEH RI, 1992, J LEUKOCYTE BIOL, V52, P611, DOI 10.1002/jlb.52.6.611; BEESON PB, 1977, MAJOR PROBLEMS INTER, V14, P10; BENJMAIN DR, 1995, MUSHROOMS POISONS PA, P75; FILLEY WV, 1982, LANCET, V2, P11; HERBERMEN RB, 1981, MANIPULATION HOST DE, P188; HOKAMA Y, 1981, RES COMMUN CHEM PATH, V31, P177; IDE M, 1994, J IMMUNOL METHODS, V168, P187, DOI 10.1016/0022-1759(94)90054-X; JONG SC, 1993, ADV APPL MICROBIOL, V39, P153, DOI 10.1016/S0065-2164(08)70595-1; KEPHART GM, 1984, LAB INVEST, V50, P51; KESHAVARZIAN A, 1985, GASTROENTEROLOGY, V88, P1041, DOI 10.1016/S0016-5085(85)80026-3; LEIFERMAN KM, 1985, NEW ENGL J MED, V313, P282, DOI 10.1056/NEJM198508013130502; Levy AM, 1997, MAYO CLIN PROC, V72, P117, DOI 10.4065/72.2.117; LEVY AM, 1996, GASTROENTEROLOGY, V110, P950; LEVY AM, 1996, GASTROENTEROLOGY, V110, P949; MORGAN C, 1992, SHIITAKE MUSHROOM PR, V13, P16; MORI K, 1974, MUSHROOMS HLTH FOODS; OHNISHI T, 1993, AM REV RESPIR DIS, V147, P901, DOI 10.1164/ajrccm/147.4.901; OKA M, 1992, BIOTHERAPY, V5, P107, DOI 10.1007/BF02171695; ROSS R, 1966, J EXP MED, V124, P653, DOI 10.1084/jem.124.4.653; RUD FINN, 1947, ACTA PSYCHIAT ET NEUROL [COPENHAGEN], V40, P1; SASTRE J, 1990, CLIN EXP ALLERGY, V20, P13, DOI 10.1111/j.1365-2222.1990.tb02769.x; SUZUKI M, 1990, INT J IMMUNOPHARMACO, V12, P613, DOI 10.1016/0192-0561(90)90098-8; SWANSON MC, 1987, J INFECT DIS, V155, P909, DOI 10.1093/infdis/155.5.909; Taguchi T, 1987, Cancer Detect Prev Suppl, V1, P333; TAI PC, 1987, LANCET, V1, P643; TALLEY NJ, 1992, GASTROENTEROLOGY, V103, P137, DOI 10.1016/0016-5085(92)91106-E; TARVAINEN K, 1991, J AM ACAD DERMATOL, V24, P64, DOI 10.1016/0190-9622(91)70011-P; TEIR H, 1963, ACTA PATHOL MIC SC, V59, P311; UEDA A, 1992, CONTACT DERMATITIS, V26, P228, DOI 10.1111/j.1600-0536.1992.tb00234.x; WAGNER JM, 1993, PLACENTA, V14, P671, DOI 10.1016/S0143-4004(05)80384-4; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62; Weiler CR, 1996, J LEUKOCYTE BIOL, V60, P493, DOI 10.1002/jlb.60.4.493; WELLER PF, 1991, NEW ENGL J MED, V324, P1110; Yunginger JW, 1992, MANUAL CLIN LAB IMMU, V4th, P678	34	21	21	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1998	101	5					613	620		10.1016/S0091-6749(98)70168-X	http://dx.doi.org/10.1016/S0091-6749(98)70168-X			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZN926	9600497				2022-12-18	WOS:000073697400008
J	Szepfalusi, Z; Nentwich, I; Jost, E; Gerstmayr, M; Ebner, C; Frischer, T; Urbanek, R				Szepfalusi, Z; Nentwich, I; Jost, E; Gerstmayr, M; Ebner, C; Frischer, T; Urbanek, R			Cord blood mononuclear cells and milk-specific T-cell clones are tools to evaluate the residual immunogenicity of hydrolyzed milk formulas	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cold blood cells; hydrolyzed milk formulas; proliferative response; milk proteins; T-cell clones; cytokines	BIRCH POLLEN ALLERGEN; COWS MILK; LYMPHOCYTE-PROLIFERATION; PROTEIN FORMULAS; IN-VITRO; EPITOPES; INTERLEUKIN-4; ANAPHYLAXIS; SECRETION; BET-V-1	Background: Hydrolyzed milk formulas (HFs) are given to infants allergic to cow's milk proteins and, For preventive reasons, to atopy-prone newborns for which breast feeding is not feasible, The ultimate properties of HFs are not only a reduced allergenicity but also decreased immunogenic capacity combined with good taste and caloric value. No information is available concerning the capacity of HFs to induce immune responses. Objective: We sought to determine the residual immunogenic capacity of partially (pHF) and extensively hydrolyzed milk formula (eHF), and we studied the cellular reactivity of cord blood-derived (n = 71) mononuclear cells induced by 10 different HFs. Methods: To test the effect of HF on T-helper cells, beta-casein-specific T-cell clones (TCCs, n = 21) from individuals allergic to milk were established, and T-cell proliferation and cytokine profiles (interferon-gamma and IL-4) were determined on stimulation with HF. Results: We found significantly reduced proliferative responses of eHF compared with milk proteins. Whey-based pHF displayed the same proliferative capacity as unmodified milk proteins. As expected, extensively processed whey products displayed lower cellular responses compared with partially hydrolyzed products (pHF whey vs eHF whey, p < 0.0001). No difference in cellular response was found between casein-based eHF and casein-based eHF. beta-Casein-specific TCCs (n = 21) proliferated in response to casein-derived hydrolysates (14% with casein/whey-based pHF), 4% with casein-based pHF, and 0% with casein-based eHF). Whey-based pHF was also found to induce proliferation in beta-casein-specific TCCs, indicating the presence or the generation of peptides displaying cross-reactivity with these whey-derived hydrolysates. TCCs stimulated with whey- or casein-bhased pHF or eHF produced the same amount of cytokines (IL-4, interferon-gamma) as the same clones stimulated with unmodified products. Conclusion: Our data indicate that whey- and casein-derived eHFs display highly reduced immunogenic properties at the T-celI level. In contrast, pHFs display residual immunogenic properties detectable at the T cell level, reflecting a potential for the induction of pathogenetically important T-cell responses.	Univ Vienna, Dept Pediat, Vienna, Austria; Univ Vienna, Dept Gen & Expt Pathol, Vienna, Austria	University of Vienna; University of Vienna	Szepfalusi, Z (corresponding author), AKH Vienna, Dept Pediat, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.			Szepfalusi, Zsolt/0000-0003-4852-3102				Brown MA, 1997, CLIN EXP ALLERGY, V27, P4, DOI 10.1046/j.1365-2222.1997.d01-430.x; DAVIS NC, 1955, METHOD BIOCHEM ANAL, P215; DEAN TP, 1993, CLIN EXP ALLERGY, V23, P205, DOI 10.1111/j.1365-2222.1993.tb00883.x; EBNER C, 1993, J IMMUNOL, V150, P1047; EBNER C, 1995, J IMMUNOL, V154, P1932; EIGENMANN PA, 1995, J ALLERGY CLIN IMMUN, V96, P549, DOI 10.1016/S0091-6749(95)70300-4; ELLIS MH, 1991, J PEDIATR-US, V118, P74, DOI 10.1016/S0022-3476(05)81849-9; Ferreira F, 1996, J EXP MED, V183, P599, DOI 10.1084/jem.183.2.599; GAUCHAT JF, 1990, J EXP MED, V172, P463, DOI 10.1084/jem.172.2.463; HOLT PG, 1994, IMMUNOL TODAY, V15, P484, DOI 10.1016/0167-5699(94)90194-5; HOLT PG, 1990, PEDIATR ALLERGY IMMU, V1, P3; LAVER WG, 1990, CELL, V61, P553, DOI 10.1016/0092-8674(90)90464-P; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; OLDAEUS G, 1991, PEDIATR ALLERGY IMMU, V4, P156; RESTANI P, 1995, CLIN EXP ALLERGY, V25, P651, DOI 10.1111/j.1365-2222.1995.tb01113.x; Rothbard J B, 1989, Int Immunol, V1, P479, DOI 10.1093/intimm/1.5.479; SAYLOR JD, 1991, J PEDIATR-US, V118, P71, DOI 10.1016/S0022-3476(05)81848-7; SCHWARTZ RH, 1985, ANNU REV IMMUNOL, V3, P237, DOI 10.1146/annurev.iy.03.040185.001321; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SNYDER SL, 1975, ANAL BIOCHEM, V64, P284, DOI 10.1016/0003-2697(75)90431-5; Sutas Y, 1996, J ALLERGY CLIN IMMUN, V98, P216, DOI 10.1016/S0091-6749(96)70245-2; Szepfalusi Z, 1997, CLIN EXP ALLERGY, V27, P28, DOI 10.1046/j.1365-2222.1997.d01-417.x; TANG MLK, 1994, LANCET, V344, P983, DOI 10.1016/S0140-6736(94)91641-1; Vaarala O, 1995, J ALLERGY CLIN IMMUN, V96, P917, DOI 10.1016/S0091-6749(95)70229-6; vanNeerven RJJ, 1996, IMMUNOL TODAY, V17, P526, DOI 10.1016/0167-5699(96)10058-X; WAHN U, 1992, J PEDIATR-US, V121, pS80, DOI 10.1016/S0022-3476(05)81412-X	27	21	21	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1998	101	4	1				514	520		10.1016/S0091-6749(98)70359-8	http://dx.doi.org/10.1016/S0091-6749(98)70359-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZH469	9564805				2022-12-18	WOS:000073113500014
J	Platts-Mills, TAE				Platts-Mills, TAE			The role of allergens in allergic airway disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	21st Century Management of Upper Respiratory Allergic Diseases - a Focus on Allergy and Asthma	JAN 13-14, 1997	CHICAGO, ILLINOIS				ASTHMA		Univ Virginia, Med Ctr, Dept Med, Div Asthma & Allerg Dis, Charlottesville, VA 22908 USA	University of Virginia	Platts-Mills, TAE (corresponding author), Univ Virginia, Med Ctr, Dept Med, Div Asthma & Allerg Dis, MR4 Bldg,Room 5086,Lane Rd, Charlottesville, VA 22908 USA.			Platts-Mills, Thomas/0000-0002-1263-329X				CANONICA GW, 1995, INT ARCH ALLERGY IMM, V107, P99, DOI 10.1159/000236943; DUFF AL, 1993, PEDIATRICS, V92, P535; Platts-Mills Thomas A. E., 1997, Journal of Allergy and Clinical Immunology, V100, pS1; POLLART SM, 1988, J ALLERGY CLIN IMMUN, V82, P224, DOI 10.1016/0091-6749(88)91003-2; RONMARK E, 1998, J ALLERGY CLIN IMM 2, V101; SEATON A, 1994, THORAX, V49, P171, DOI 10.1136/thx.49.2.171; Squillace SP, 1997, AM J RESP CRIT CARE, V156, P1760, DOI 10.1164/ajrccm.156.6.9704026; WICKMAN M, 1993, AM REV RESPIR DIS, V148, P58, DOI 10.1164/ajrccm/148.1.58	8	21	21	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1998	101	2	2	S			S364	S366		10.1016/S0091-6749(98)70221-0	http://dx.doi.org/10.1016/S0091-6749(98)70221-0			3	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZA245	9500729				2022-12-18	WOS:000072343900005
J	Vignola, AM; Gjomarkaj, M; Arnoux, B; Bousquet, J				Vignola, AM; Gjomarkaj, M; Arnoux, B; Bousquet, J			Monocytes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							DISEASE		Hop Arnaud Villeneuve, Clin Malad Resp, F-34295 Montpellier 5, France; Hop Arnaud Villeneuve, INSERM, U 454, IFR 3, F-34295 Montpellier 5, France; CNR, Ist Fisiopatol Resp, Palermo, Italy	Universite de Montpellier; CHU de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier; Consiglio Nazionale delle Ricerche (CNR)	Bousquet, J (corresponding author), Hop Arnaud Villeneuve, Clin Malad Resp, F-34295 Montpellier 5, France.		Bousquet, Jean/O-4221-2019	CHIAPPARA, GIUSEPPINA/0000-0002-7226-5660				BAGGIOLINI M, 1994, IMMUNOL TODAY, V15, P127, DOI 10.1016/0167-5699(94)90156-2; DEVRIES JE, 1995, INT ARCH ALLERGY IMM, V106, P175, DOI 10.1159/000236842; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; DOHERTY TM, 1995, CURR OPIN IMMUNOL, V7, P400; HAMILTON JA, 1993, IMMUNOL TODAY, V14, P18, DOI 10.1016/0167-5699(93)90319-G; MALEFYT RD, 1992, CURR OPIN IMMUNOL, V4, P314, DOI 10.1016/0952-7915(92)90082-P; MAURER D, 1994, J EXP MED, V179, P745, DOI 10.1084/jem.179.2.745; PATARROYO M, 1994, IMMUNOBIOLOGY, V191, P474, DOI 10.1016/S0171-2985(11)80453-5; Taub Dennis D., 1996, Cytokine and Growth Factor Reviews, V7, P355, DOI 10.1016/S1359-6101(97)89237-4; Trinchieri G, 1997, CURR OPIN IMMUNOL, V9, P17, DOI 10.1016/S0952-7915(97)80154-9; Trinchieri G, 1996, J LEUKOCYTE BIOL, V59, P505, DOI 10.1002/jlb.59.4.505; ZIEGLERHEITBROCK HWL, 1993, IMMUNOL TODAY, V14, P121, DOI 10.1016/0167-5699(93)90212-4	12	21	21	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1998	101	2	1				149	152		10.1016/S0091-6749(98)70378-1	http://dx.doi.org/10.1016/S0091-6749(98)70378-1			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YZ342	9500745				2022-12-18	WOS:000072244800001
J	Wurtzen, PA; van Neerven, RJJ; Arnved, J; Ipsen, H; Sparholt, SH				Wurtzen, PA; van Neerven, RJJ; Arnved, J; Ipsen, H; Sparholt, SH			Dissection of the grass allergen-specific immune response in patients with allergies and control subjects: T-cell proliferation in patients does not correlate with specific serum IgE and skin reactivity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T cells; Poacea grasses; grass group 5 allergens; cross-reactivity; skin prick test; IgE	HOUSE DUST MITE; GROUP-V ALLERGENS; RAGWEED ANTIGEN-E; PURIFIED MAJOR ALLERGENS; DERMATOPHAGOIDES-PTERONYSSINUS; SENSITIVE PATIENTS; POLLEN ALLERGENS; LYMPHOCYTES-T; NONATOPIC INDIVIDUALS; PHLEUM-PRATENSE	Background: Pollinosis, caused by grasses of the Poaceae family, is a problem worldwide. The relative importance of grass groups 1 and 5 major allergens is well established. However, not much is known about the recognition of these allergens by T cells and whether this T-cell reactivity correlates with skin reactivity and serum IgE levels. Objectives: The aim of this study was to characterize the cross-reactive, grass allergen-specific T-cell responses from patients allergic to grass and nonatopic individuals and to investigate whether these responses correlate with grass-specific IgE and skin reactivity. Methods: Skin prick test wheal areas and grass-specific serum IgE levels were determined in all patients (n = 21) and nonallergic control donors (n = 20). Peripheral blood mononuclear cells were isolated and stimulated with grass allergen extracts (Phleum pratense, Poa pratensis, Lolium perenne) and immunoaffinity-purified group 5 allergens, and the production of type 1 and type 2 cytokines was determined in the patient group. Results: Donors allergic to grass showed increased T-cell-proliferative responses to grass allergens compared with nonatopic control subjects, We find it interesting that the magnitude of the patients' T-cell responses could not be correlated with the individual skin prick test areas and specific serum IgE levels, and several patients with allergies to grass had group 5-specific T-cell responses in the absence of group 5-specific IgE. The absence of a correlation between T-cell proliferation and IgE levels or skin prick test results may in part be explained by the finding that patients predominantly produced IL-5 in response to Phl p 5, the major allergen, and predominantly IFN-gamma in response to Phl p extract. In general, all donors responded equally well to all three grasses. Additional experiments with Phl p 5-specific T-cell lines indicated that the equal proliferation of peripheral blood mononuclear cells to all three species is the direct result of cross-reactivity. Conclusions: Grass allergen-specific T-cell responses are highly cross-reactive, and patients with allergies exhibit higher responses than nonallergic donors, suggesting that T cells are involved in the allergic reaction to grass group 5 allergens. However, group 5-specific T-cell responses are also found in donors without group 5-specific IgE, and the patients' grass-specific T-cell responses and cytokine production do not correlate to skin reactivity or to concentrations of grass-specific IgE.	ALK ABELLO Grp, DK-2970 Horsholm, Denmark; Lunge & Allergiklin, Copenhagen, Denmark	ALK-Abello AS	Wurtzen, PA (corresponding author), ALK ABELLO Grp, Boge Alle 10-12, DK-2970 Horsholm, Denmark.		van Neerven, Joost/GWZ-3214-2022	van Neerven, R.J.Joost/0000-0002-3991-5297				AALBERSE RC, 1973, INT ARCH ALLER A IMM, V45, P46, DOI 10.1159/000230999; AXELSEN NH, 1984, SCAND J IMMUNOL, V17, P103; BUCKLEY RH, 1977, J ALLERGY CLIN IMMUN, V59, P70, DOI 10.1016/0091-6749(77)90180-4; BURASTERO SE, 1993, J ALLERGY CLIN IMMUN, V91, P1075, DOI 10.1016/0091-6749(93)90222-2; BUSINCO L, 1979, CLIN ALLERGY, V9, P459, DOI 10.1111/j.1365-2222.1979.tb02509.x; CRETICOS PS, 1987, ALLERGY INT TXB, P617; DIFELICE G, 1989, ALLERGY, V44, P322; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; EIKEN P, 1992, ALLERGY, V47, P495, DOI 10.1111/j.1398-9995.1992.tb00671.x; EISENBREY AB, 1985, J ALLERGY CLIN IMMUN, V75, P84; GATIEN JG, 1975, CLIN IMMUNOL IMMUNOP, V4, P32, DOI 10.1016/0090-1229(75)90036-7; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; HIRATANI M, 1981, J ALLERGY CLIN IMMUN, V68, P205, DOI 10.1016/0091-6749(81)90185-8; JUTEL M, 1995, J IMMUNOL, V154, P4187; KAPSENBERG ML, 1988, EUR J IMMUNOL, V18, P977, DOI 10.1002/eji.1830180702; KIMURA JY, 1990, IMMUNOLOGY, V70, P385; KLYSNER S, 1992, CLIN EXP ALLERGY, V22, P491, DOI 10.1111/j.1365-2222.1992.tb00152.x; LOWENSTEIN H, 1986, CLIN REV ALLERG, V4, P405; MARSHALL JD, 1993, CELL IMMUNOL, V152, P18, DOI 10.1006/cimm.1993.1264; MATTHIESEN F, 1991, CLIN EXP ALLERGY, V21, P309, DOI 10.1111/j.1365-2222.1991.tb01662.x; MAURER D, 1995, J IMMUNOL, V154, P6285; MOXNES A, 1984, ALLERGY, V39, P339, DOI 10.1111/j.1398-9995.1984.tb01951.x; MULLER WD, 1994, INT ARCH ALLERGY IMM, V105, P391, DOI 10.1159/000236789; NAGAYA H, 1977, ANN ALLERGY, V39, P246; OBRIEN RM, 1992, J ALLERGY CLIN IMMUN, V89, P1021, DOI 10.1016/0091-6749(92)90225-Q; OHEHIR RE, 1987, IMMUNOLOGY, V62, P635; OWNBY DR, 1979, J ALLERGY CLIN IMMUN, V63, P65, DOI 10.1016/0091-6749(79)90164-7; PARRONCHI P, 1991, P NATL ACAD SCI USA, V88, P4538, DOI 10.1073/pnas.88.10.4538; PECQUET C, 1989, ALLERGY, V44, P427, DOI 10.1111/j.1398-9995.1989.tb04174.x; PETERSEN A, 1993, BIOL CHEM H-S, V374, P855, DOI 10.1515/bchm3.1993.374.7-12.855; RAWLE FC, 1983, CLIN ALLERGY, V13, P409, DOI 10.1111/j.1365-2222.1983.tb02616.x; RAWLE FC, 1984, J IMMUNOL, V133, P195; ROCKLIN RE, 1974, J CLIN INVEST, V53, P735, DOI 10.1172/JCI107612; SALLUSTO F, 1993, ALLERGY, V48, P37, DOI 10.1111/j.1398-9995.1993.tb02172.x; Schenk S, 1995, J ALLERGY CLIN IMMUN, V96, P986, DOI 10.1016/S0091-6749(95)70237-7; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; SMITH PM, 1994, MOL IMMUNOL, V31, P491, DOI 10.1016/0161-5890(94)90068-X; Sparholt SH, 1997, CLIN EXP ALLERGY, V27, P932; SPIEGELBERG HL, 1994, J IMMUNOL, V152, P4706; STENIUS B, 1971, Clinical Allergy, V1, P37, DOI 10.1111/j.1365-2222.1971.tb02446.x; Till S, 1997, J ALLERGY CLIN IMMUN, V99, P563, DOI 10.1016/S0091-6749(97)70085-X; Till S, 1997, IMMUNOLOGY, V91, P53, DOI 10.1046/j.1365-2567.1997.00218.x; VANDERHEIJDEN FL, 1993, J IMMUNOL, V150, P3643; VANDERHEIJDEN FL, 1995, CLIN EXP IMMUNOL, V99, P289; VANDERZEE JS, 1988, J ALLERGY CLIN IMMUN, V82, P270, DOI 10.1016/0091-6749(88)91011-1; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633; VRTALA S, 1993, J IMMUNOL, V151, P4773; WALKER CA, 1989, CLIN EXP IMMUNOL, V76, P34; WIERENGA EA, 1990, J IMMUNOL, V144, P4651; Witteman AM, 1996, J ALLERGY CLIN IMMUN, V97, P16, DOI 10.1016/S0091-6749(96)70278-6; WURTZEN PA, 1995, ALLERGY, V50, P489, DOI 10.1111/j.1398-9995.1995.tb01184.x	51	21	23	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1998	101	2	1				241	249						9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YZ342	9500758				2022-12-18	WOS:000072244800014
J	Metzger, WJ; Fick, RB				Metzger, WJ; Fick, RB		E25 Asthma Study Grp	Corticosteroid (CS) withdrawal in a study of recombinant humanized monoclonal antibody to IgE (rhuMAb25).	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract									E Carolina Univ, Greenville, NC USA; Genentech Inc, S San Francisco, CA 94080 USA	University of North Carolina; East Carolina University; Roche Holding; Genentech									0	21	21	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1998	101	1	2			960	S231	S231						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YW339					2022-12-18	WOS:000071924800956
J	Bacot, BK; Paul, ME; Navarro, M; Abramson, SL; Kline, MW; Hanson, IC; Rosenblatt, HM; Shearer, WT				Bacot, BK; Paul, ME; Navarro, M; Abramson, SL; Kline, MW; Hanson, IC; Rosenblatt, HM; Shearer, WT			Objective measures of allergic disease in children with human immunodeficiency virus infection	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						pediatric human immunodeficiency virus; serum IgE; allergy; skin test reactivity; eosinophil count	HIV-INFECTION; SERUM IGE; SINUSITIS; ELEVATION	Background: Available information suggests that IgE levels are elevated in adults infected with human immunodeficiency virus (HIV), and that increased IgE levels correlate with allergic disease, with decreased CD4 counts, and with a poor prognosis. Data with respect to these factors in children are scant. Objective: We investigated whether serum IgE levels are elevated in children with HIV and, if so, whether the serum IgE level correlates with the degree of immunodeficiency and/or objective indicators of allergic disease. Methods: Serum IgE levels, CD4 counts, absolute eosinophil counts, and immediate hypersensitivity skin test (IHST) results were collected from 43 children with symptomatic HIV infection (mean age 7.2 years). Associations between serum IgE levels, CD4 counts, and eosinophil counts were investigated by multiple stepwise linear regression analysis. Data were stratified according to IHST positivity, and analysis of variance was used to compare mean values for age, CD4 counts, IgE levels, and eosinophil counts between the two groups. Results: Serum IgE values were elevated more than 2 SDs above control age-matched mean values in 17 of 43 patients (40%). IHST results were positive in 12 of 43 patients (28%). CD4 counts were less than 200/mm(3) in 17 of 43 patients (40%). Stepwise linear regression failed to demonstrate any correlation between serum IgE levels and either CD? or eosinophil counts. With data divided into two groups according to MST results (positive vs negative), analysis of variance failed to reveal significant differences between means for patient age, CD4 counts, IgE levels, or eosinophil counts. Conclusions: Our findings confirm that serum IgE levels are increased in children infected with HIV,just as in adults. However, an elevated serum IgE level did not correlate with allergic disease as measured by IHST results and eosinophil counts, nor with the degree of immune dysfunction as approximated by CD4 counts. The mechanism and significance of elevated serum IgE levels remain unclear in children with HIV, and warrant further investigation.	TEXAS CHILDRENS HOSP,HOUSTON,TX 77030; BAYLOR COLL MED,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine			Paul, Mary/AAA-2722-2021	Shearer, William/0000-0002-2483-2130	NCRR NIH HHS [RR 00188] Funding Source: Medline; NIAID NIH HHS [AI 07456, AI 32466-0351] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032466] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARBEE RA, 1976, ANN INTERN MED, V84, P129, DOI 10.7326/0003-4819-84-2-129; CARR A, 1991, J CLIN IMMUNOL, V11, P55, DOI 10.1007/BF00917741; CLERICI M, 1993, IMMUNOL TODAY, V14, P107, DOI 10.1016/0167-5699(93)90208-3; Cserhati E, 1983, Acta Paediatr Hung, V24, P189; DIKEACOU T, 1992, INT ARCH ALLERGY IMM, V102, P408; ELLAURIE M, 1995, ANN ALLERG ASTHMA IM, V75, P332; GREENBERG M, 1970, BMJ-BRIT MED J, V2, P629, DOI 10.1136/bmj.2.5710.629; GREENBERGER PA, 1987, J ALLERGY CLIN IMMUN, V79, P484, DOI 10.1016/0091-6749(87)90366-6; GREICO MH, 1989, J ALLERGY CLIN IMMUN, V84, P1; HAGY GW, 1966, J ALLERGY, V37, P107; ISRAELBIET D, 1992, J ALLERGY CLIN IMMUN, V89, P68, DOI 10.1016/S0091-6749(05)80042-9; LIM DT, 1988, ANN ALLERGY, V61, P175; MAZZA DS, 1995, ANN ALLERG ASTHMA IM, V74, P411; MCNICHOL KN, 1969, BRIT MED J, V4, P321; NAKAJIMA K, 1989, J IMMUNOL, V142, P531; PATKE CL, 1995, 11 INT C AIDS, P74; PEDERSON M, 1988, 4 INT C AIDS STOCKH, P189; RHYNE MB, 1971, DETERMINATION PREVAL; RUSSI JC, 1993, J CLIN MICROBIOL, V31, P819, DOI 10.1128/JCM.31.4.819-823.1993; SMALL CB, 1993, J INFECT DIS, V167, P283, DOI 10.1093/infdis/167.2.283; VIGANO A, 1995, J ALLERGY CLIN IMMUN, V95, P627, DOI 10.1016/S0091-6749(95)70326-8; WELLIVER RC, 1993, PEDIATR PULM, V15, P19, DOI 10.1002/ppul.1950150104; WRIGHT DN, 1990, J ALLERGY CLIN IMMUN, V85, P445, DOI 10.1016/0091-6749(90)90154-V; ZURLO JJ, 1992, AM J MED, V93, P157, DOI 10.1016/0002-9343(92)90045-D	24	21	22	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1997	100	5					707	711		10.1016/S0091-6749(97)70177-5	http://dx.doi.org/10.1016/S0091-6749(97)70177-5			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YG202	9389303				2022-12-18	WOS:A1997YG20200020
J	McDowell, SL; Fleck, SJ; Storms, WW				McDowell, SL; Fleck, SJ; Storms, WW			The effects of salmeterol on power output in nonasthmatic athletes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Salmeterol; performance; track cyclists; Wingate	ACUTE INHALATION; ALBUTEROL; ASTHMA; SALBUTAMOL; BRONCHODILATOR; PERFORMANCE; EXERCISE; AGONIST	Background: Salmeterol xinafoate is a new aerosol inhalant that is used in the treatment of asthma. It is currently banned by the International Olympic Committee because of the concern that it may lend an unfair competitive advantage to the user. Objective: The purpose of this study was to determine whether salmeterol improves short-term anaerobic performance in elite nonasthmatic track cyclists, Methods: Eleven elite track cyclists volunteered to perform a 30-second all-out cycle ergometer test 3 hours after receiving either 42 mu g of salmeterol xinafoate or placebo applied in a double-blind crossover procedure, During the ergometer test, peak power output, total work, time to peak power, and percent fatigue (decline in power output) were measured, Pulmonary measurements were also taken before and at various time points after inhalation and the ergometer test. A methacholine challenge was administered to each subject before participation in the study to ensure that none of the subjects had any reactive airway diseases, Results: There were no significant differences (p > 0.05) between the placebo and salmeterol trials for peak power output, total work performed during the 30-second test, percent fatigue, and time to peak power, No differences between trials were observed for the pulmonary function test variables at any of the time points, Blood lactate concentrations before and after administration of drug or placebo were also not significantly different between trials, Additionally, salmeterol did not affect the maximal heart rate achieved during the test as compared with the placebo, Conclusion: Short-term salmeterol use within the prescribed dosage was not shown to increase short-term power output in nonasthmatic cyclists.	INST HLTH & HUMAN PERFORMANCE INC,COLORADO SPRINGS,CO; FLECKS RX INC,COLORADO SPRINGS,CO; ALLERGY ASSOCIATES,COLORADO SPRINGS,CO									*ALL HANB GLAX INC, 1994, PRESCR INF; BALL DI, 1991, BRIT J PHARMACOL, V104, P665, DOI 10.1111/j.1476-5381.1991.tb12486.x; BEDI JF, 1988, CAN J SPORT SCI, V13, P144; BUTLER J, 1982, NATURE, V298, P60, DOI 10.1038/298060a0; BUTLER J, 1983, J PHYSIOL-LONDON, V344, P113, DOI 10.1113/jphysiol.1983.sp014927; CASTLE W, 1993, BRIT MED J, V306, P1034, DOI 10.1136/bmj.306.6884.1034; CASWELL AH, 1983, J BIOL CHEM, V253, P3049; DALONZO GE, 1994, JAMA-J AM MED ASSOC, V271, P1412, DOI 10.1001/jama.271.18.1412; DEROM E, 1990, AM REV RESPIR DIS, V43, pA469; DOTAN R, 1985, EUR J APPL PHYSL, V51, P409; FLECK SJ, 1993, INT J SPORTS MED, V14, P239, DOI 10.1055/s-2007-1021170; JOHNSON M, 1993, LIFE SCI, V52, P2131, DOI 10.1016/0024-3205(93)90728-L; KATZ RM, 1983, ANN ALLERGY, V51, P153; KEMP JP, 1994, AM J RESP CRIT CARE, V150, P1612, DOI 10.1164/ajrccm.150.6.7952623; LEMMER JT, 1995, INT J SPORTS MED, V16, P243, DOI 10.1055/s-2007-972999; MACONOSHIE JG, 1988, BR J CLIN PHARM, V25; MALO JL, 1992, J ALLERGY CLIN IMMUN, V89, P567, DOI 10.1016/0091-6749(92)90324-U; MARTIN DE, 1988, RESP ANATOMY PHYSL, P116; MCKENZIE DC, 1983, MED SCI SPORT EXER, V15, P520; MEEUWISSE WH, 1992, MED SCI SPORT EXER, V24, P1161; Morton AR, 1992, CLIN J SPORT MED, V2, P93; PATTON JF, 1985, INT J SPORTS MED, V6, P82, DOI 10.1055/s-2008-1025818; PEARLMAN DS, 1992, NEW ENGL J MED, V327, P1420, DOI 10.1056/NEJM199211123272004; REED CE, 1978, CHEST, V73, P914, DOI 10.1378/chest.73.6_Supplement.914; ROSENTHAL RR, 1989, ALLERGY PROC, V10, P301, DOI 10.2500/108854189778959867; SIGNORILE J, 1989, MED SCI EXERC, V20, pS16; SIGNORILE JF, 1992, MED SCI SPORT EXER, V24, P638; TWENTYMAN OP, 1990, LANCET, V336, P1338, DOI 10.1016/0140-6736(90)92894-N; *US OL COMM DIV SP, 1995, GUID BANN MED	29	21	22	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1997	99	4					443	449		10.1016/S0091-6749(97)70068-X	http://dx.doi.org/10.1016/S0091-6749(97)70068-X			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WU274	9111486				2022-12-18	WOS:A1997WU27400004
J	Boulet, LP; Laviolette, M; Boucher, S; Knight, A; Hebert, J; Chapman, KR				Boulet, LP; Laviolette, M; Boucher, S; Knight, A; Hebert, J; Chapman, KR			A twelve-week comparison of salmeterol and salbutamol in the treatment of mild-to-moderate asthma: A Canadian multicenter study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; salmeterol; salbutamol; beta(2)-agonists	INHALED BETA-AGONIST; INDUCED BRONCHOCONSTRICTION; ADRENOCEPTOR AGONIST; AIRWAYS DISEASE; STABLE ASTHMA; PROTECTION; DURATION; ALLERGEN; HYPERVENTILATION; RESPONSIVENESS	Background: A long-acting inhaled bronchodilator that is both well tolerated and effective could allow for improved cona ol of both daytime and nighttime symptoms in patients with asthma who use frequent as-needed short-acting bronchodilators despite antiinflammatory treatment. Objective and methods: We compared the efficacy and safety of inhaled salmeterol, 50 mu g twice daily, with inhaled salbutamol, 200 mu g four times daily, delivered through a metered-dose inhaler for 3 months in a multicenter, randomized double-blind, parallel-group study of 228 patients (aged 12 to 76 years) with mild-to-moderate asthma. Results: A single morning dose of salmeterol produced improvement in FEV(1) that was significantly greater (p less than or equal to 0.012) than that produced by two doses of salbutamol (taken 6 hours apart) when patients were assessed 3 to 6 hours and 10 to 12 hours after the dose. This greater bronchodilation was present on day 1 of the study and after 4, 8, and 12 weeks of regular treatment. Over the 12 weeks, compared with salbutamol, salmeterol treatment was associated with a greater mean improvement in morning peak expiratory flow (35 L/min vs -3 L/min, p < 0.001), a higher percentage of days with no symptoms (29% vs 15%; p = 0.012), and a higher percentage of nights with no awakenings (14% vs -1%; p < 0.001). Adverse events were similar for both treatments. Conclusions: In this study salmeterol, 50 mu g twice daily, was well tolerated and more effective than salbutamol, 200 mu g four times daily, in improving symptoms and lung function in patients with mild-to-moderate asthma.	HOP ST SACREMENT, Ste Foy, PQ, CANADA; SUNNYBROOK HLTH SCI CTR, TORONTO, ON M4N 3M5, CANADA; UNIV LAVAL, CTR HOSP, Ste Foy, PQ G1K 7P4, CANADA; TORONTO HOSP, WESTERN DIV, TORONTO, ON M5T 2S8, CANADA	Laval University; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Laval University; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Boulet, LP (corresponding author), HOP LAVAL, CTR PNEUMOL, UNITE RECH, Ste Foy, PQ G1V 4G5, CANADA.							ANDERSON SD, 1991, CHEST, V100, P1254, DOI 10.1378/chest.100.5.1254; BOULET LP, 1994, DRUGS, V47, P207, DOI 10.2165/00003495-199447020-00001; BRITTON MG, 1992, EUR RESPIR J, V5, P1062; Brogden R N, 1992, Allergol Immunopathol (Madr), V20, P72; CAMPOSGONGORA H, 1991, AM REV RESPIR DIS, V144, P626; CARTIER A, 1993, J ALLERGY CLIN IMMUN, V92, P488, DOI 10.1016/0091-6749(93)90128-3; CHAPMAN KR, 1994, LANCET, V343, P1379, DOI 10.1016/S0140-6736(94)92520-8; CHEUNG D, 1992, NEW ENGL J MED, V327, P1198, DOI 10.1056/NEJM199210223271703; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; DAHL R, 1991, EUR RESPIR J, V4, P1178; DALONZO GE, 1994, JAMA-J AM MED ASSOC, V271, P1412, DOI 10.1001/jama.271.18.1412; DEROM EY, 1992, J ALLERGY CLIN IMMUN, V89, P811, DOI 10.1016/0091-6749(92)90435-5; ELLULMICALLEF R, 1975, LANCET, V2, P1269; FITZPATRICK MF, 1990, BRIT MED J, V301, P1365, DOI 10.1136/bmj.301.6765.1365; HEINO M, 1994, J ALLERGY CLIN IMMUN, V93, P80, DOI 10.1016/0091-6749(94)90235-6; HUI KKP, 1982, CLIN PHARMACOL THER, V32, P566, DOI 10.1038/clpt.1982.204; JENNE JW, 1981, LUNG, V159, P295, DOI 10.1007/BF02713930; LOTVALL J, 1993, LUNG, V171, P249; LUNDBACK B, 1993, THORAX, V48, P148, DOI 10.1136/thx.48.2.148; NEWNHAM DM, 1993, RESP MED, V87, P439, DOI 10.1016/0954-6111(93)90070-G; NOWAK D, 1992, EUR J CLIN PHARMACOL, V43, P591, DOI 10.1007/BF02284956; PALMER JBD, 1992, RESP MED, V86, P409, DOI 10.1016/S0954-6111(06)80008-9; PALMER JBD, 1991, EUR RESPIR REV, V1, P301; PEARLMAN DS, 1992, NEW ENGL J MED, V327, P1420, DOI 10.1056/NEJM199211123272004; PEDERSEN B, 1993, ALLERGY, V48, P377, DOI 10.1111/j.1398-9995.1993.tb02410.x; Polgar G, 1971, PULMONARY FUNCTION T; SAS Institute Inc, 1989, SAS STAT US GUID VER; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SIMONS FER, 1992, J ALLERGY CLIN IMMUN, V90, P840, DOI 10.1016/0091-6749(92)90110-N; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; TAYLOR DR, 1993, THORAX, V48, P134, DOI 10.1136/thx.48.2.134; TAYLOR IK, 1992, J ALLERGY CLIN IMMUN, V89, P575, DOI 10.1016/0091-6749(92)90325-V; TWENTYMAN OP, 1990, LANCET, V336, P1338, DOI 10.1016/0140-6736(90)92894-N; ULLMAN A, 1988, THORAX, V43, P674, DOI 10.1136/thx.43.9.674; ULLMAN A, 1990, AM REV RESPIR DIS, V142, P571, DOI 10.1164/ajrccm/142.3.571; *US DOE, 1992, IND INN TOM, P1; VANELTEREN P, 1960, B INT STATIST INST, V37, P351; VERBERNE AAPH, 1993, J ALLERGY CLIN IMMUN, V91, P127, DOI 10.1016/0091-6749(93)90305-Y; WILCOXON F, 1946, J ECON ENTOMOL, V39, P269, DOI 10.1093/jee/39.2.269	39	21	21	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1997	99	1	1				13	21		10.1016/S0091-6749(97)81039-1	http://dx.doi.org/10.1016/S0091-6749(97)81039-1			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WD061	9003206				2022-12-18	WOS:A1997WD06100003
J	Ownby, DR				Ownby, DR			Acetaminophen-induced urticaria and tolerance of ibuprofen in an eight-year-old child	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							ASPIRIN				Ownby, DR (corresponding author), HENRY FORD HOSP,DEPT PEDIAT,DIV CLIN IMMUNOL & ALLERGY,2799 W GRAND BLVD,DETROIT,MI 48202, USA.							COLE FOA, 1985, CLIN EXP DERMATOL, V10, P404, DOI 10.1111/j.1365-2230.1985.tb00594.x; DELANEY JC, 1976, CLIN ALLERGY, V6, P177, DOI 10.1111/j.1365-2222.1976.tb01896.x; DOAN T, 1993, ANN ALLERGY, V70, P439; ELLIS M, 1989, J PEDIATR-US, V114, P654, DOI 10.1016/S0022-3476(89)80716-4; FALLIERS CJ, 1983, J ASTHMA, V20, P39, DOI 10.3109/02770908309078051; *MED EC CO, 1996, PHYS DESK REF, P1546; SETTIPANE RA, 1989, J ALLERGY CLIN IMMUN, V84, P26, DOI 10.1016/0091-6749(89)90174-7	7	21	21	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1997	99	1	1				151	152		10.1016/S0091-6749(97)70313-0	http://dx.doi.org/10.1016/S0091-6749(97)70313-0			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WD061	9003224	Bronze			2022-12-18	WOS:A1997WD06100021
J	Desai, K; Hutson, DP; Harriman, GR				Desai, K; Hutson, DP; Harriman, GR			Previously undiagnosed hyper-IgE syndrome in an adult with multiple systemic fungal infections	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									BAYLOR COLL MED,DEPT MED,IMMUNOL SECT,HOUSTON,TX 77030	Baylor College of Medicine				Huston, David/0000-0002-2332-0010				BUCKLEY RH, 1972, PEDIATRICS, V49, P59; BUCKLEY RH, 1996, CLIN IMMUNOLOGY PRIN, V1, P694; DAVIS SD, 1966, LANCET, V1, P1013; DONABEDIAN H, 1983, MEDICINE, V62, P195, DOI 10.1097/00005792-198307000-00001; LEUNG DYM, 1988, HEMATOL ONCOL CLIN N, V2, P81	5	21	21	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1996	98	6	1				1123	1124		10.1016/S0091-6749(96)80202-8	http://dx.doi.org/10.1016/S0091-6749(96)80202-8			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WB378	8977516				2022-12-18	WOS:A1996WB37800020
J	Pastuszak, A; Schick, B; DAlimonte, D; Donnenfeld, A; Koren, G				Pastuszak, A; Schick, B; DAlimonte, D; Donnenfeld, A; Koren, G			The safety of astemizole in pregnancy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HOSP SICK CHILDREN,DIV CLIN PHARMACOL & TOXICOL,MOTHERISK PROGRAM,TORONTO,ON M5G 1X8,CANADA; UNIV TORONTO,DEPT PEDIAT,TORONTO,ON M5S 1A1,CANADA; UNIV TORONTO,DEPT PHARMACOL,TORONTO,ON M5S 1A1,CANADA; UNIV TORONTO,DEPT PHARM,TORONTO,ON M5S 1A1,CANADA; UNIV TORONTO,DEPT MED,TORONTO,ON M5S 1A1,CANADA; UNIV PENN,PREGNANCY HEALTHLINE,PHILADELPHIA,PA 19104	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of Pennsylvania			Koren, Gideon/AAG-7726-2019	Koren, Gideon/0000-0002-9234-0875				EINARSON TR, 1988, DRUG INTEL CLIN PHAR, V22, P813, DOI 10.1177/106002808802201021; JANSSENS MML, 1993, CLIN REV ALLERG, V11, P35; KOREN G, 1994, MATERNAL FETAL TOXIC; KROGH C, 1994, COMPENDIUM PHARM SPE, P556; SCHARDEIN JL, 1993, CHEM INDUCED BIRTH D, P342; SETO A, UNPUB PREGNANCY OUTC	6	21	21	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1996	98	4					748	750		10.1016/S0091-6749(96)70122-7	http://dx.doi.org/10.1016/S0091-6749(96)70122-7			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VM665	8876549				2022-12-18	WOS:A1996VM66500006
J	Lacroix, JS; Mosimann, BL				Lacroix, JS; Mosimann, BL			Attenuation of allergen-evoked nasal responses by local pretreatment with exogenous neuropeptide Y in atopic patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						neuropeptides; neuropeptide Y; allergic rhinitis; nasal secretion; nasal obstruction	VASOACTIVE INTESTINAL POLYPEPTIDE; GENE-RELATED PEPTIDE; SUBSTANCE-P; GUINEA-PIG; VASCULAR-PERMEABILITY; RESPIRATORY-TRACT; MUCOSA; INNERVATION; RESISTANCE; MODULATION	Background: Nasal obstruction and rhinorrhea present in allergic rhinitis are at least partly influenced by neuropeptides released from sensory, parasympathetic, and sympathetic nerves. Neuropeptide Y (NPY) is co-localized with norepinephrine in sympathetic perivascular nerves. NPY is released with norepinephrine on sympathetic nerve stimulation and produces long-lasting vasoconstriction of the nasal vascular bed. In addition to vasoconstriction, there is evidence to suggest that NPY modulates the release of transmitters originating from parasympathetic and sensory nerves by acting on prejunctional receptors. Putative therapeutic application of NPY in rhinitis has been recently suggested because intranasal administration of exogenous NPY in human beings reduces nasal airway resistance and vascular permeability without affecting submucosal gland secretion. Objective: The aim of this study was to determine whether intranasal pretreatment with exogenous NPY could influence the functional responses to subsequent allergen challenge. Methods: A randomized double-blind, three-way, crossover, placebo-controlled study was performed in 13 patients with allergic rhinitis. Pretreatments with NPY (20 nmol), oxymetazoline hydrochloride (20 nmol), or saline solution (NaCl 0.9%) were administered in one nostril 5 minutes before nasal challenge with grass pollen allergen (10,000 standardized quality units). The number of sneezes and the subjective evaluation of nasal itching, obstruction, and rhinorrhea were recorded. Nasal airway resistance was measured by anterior rhinomanometry, and nasal secretions were weighed. Mean arterial pressure and heart rate were recorded by noninvasive methods. Results: The number of sneezes, nasal itching, and subjective rhinorrhea evoked by the allergen were similar after the three pretreatments. Subjective and objective increases in nasal airway resistance and mucus production induced by the allergen were significantly (p < 0.01) reduced after NPY pretreatment when compared with saline solution or oxymetazoline pretreatment. Mean arterial pressure and heart rate were not changed. Conclusions: Local pretreatment with exogenous NPY reduces nasal obstruction and mucus secretion evoked by allergen challenge in allergic patients without modification of local itching and number of sneezes.	POLICLIN MED UNIV,LAUSANNE,SWITZERLAND		Lacroix, JS (corresponding author), UNIV HOSP GENEVA,DEPT OTORHINOLARYNGOL,LAB EXPT RHINOL,CH-1211 GENEVA 14,SWITZERLAND.							ANGGARD A, 1974, ACTA OTO-LARYNGOL, V78, P232, DOI 10.3109/00016487409126349; BARANIUK JN, 1991, AM J RESP CELL MOL, V4, P228, DOI 10.1165/ajrcmb/4.3.228; BARANIUK JN, 1990, J CLIN INVEST, V86, P825, DOI 10.1172/JCI114780; BARANIUK JN, 1992, J APPL PHYSIOL, V73, P1867, DOI 10.1152/jappl.1992.73.5.1867; BARNES PJ, 1991, AM REV RESPIR DIS, V144, P1391, DOI 10.1164/ajrccm/144.6.1391; BARNES PJ, 1991, AM REV RESPIR DIS, V144, P1187, DOI 10.1164/ajrccm/144.5.1187; CHATELAIN C, 1995, EUR ARCH OTO-RHINO-L, V252, P83; EDWINSSON L, 1987, TRENDS PHARMACOL SCI, V8, P231; LACROIX JS, 1994, BRIT J PHARMACOL, V113, P479, DOI 10.1111/j.1476-5381.1994.tb17014.x; LACROIX JS, 1990, CELL TISSUE RES, V259, P119, DOI 10.1007/BF00571436; LACROIX JS, 1989, ACTA PHYSIOL SCAND, V136, P1; LACROIX JS, 1996, IN PRESS BR J PHARM; LACROIX JS, 1994, ASTHMA RHINITIS, V52, P686; LUNDBERG JM, 1990, FUNDAM CLIN PHARM, V4, P373, DOI 10.1111/j.1472-8206.1990.tb00692.x; LUNDBERG JM, 1983, P NATL ACAD SCI-BIOL, V80, P1120, DOI 10.1073/pnas.80.4.1120; LUNDBERG JM, 1981, P NATL ACAD SCI-BIOL, V78, P5255, DOI 10.1073/pnas.78.8.5255; LUNDBERG JM, 1988, AIRWAYS NEURAL CONTR, P417; MALM L, 1980, ACTA OTO-LARYNGOL, V90, P304, DOI 10.3109/00016488009131730; MATRAN R, 1989, EUR J PHARMACOL, V163, P15, DOI 10.1016/0014-2999(89)90390-7; MOSIMANN BL, 1993, J ALLERGY CLIN IMMUN, V92, P95, DOI 10.1016/0091-6749(93)90043-F; NIEBER K, 1992, J ALLERGY CLIN IMMUN, V90, P646, DOI 10.1016/0091-6749(92)90138-R; NUKI C, 1990, JPN J PHARMACOL, V53, P125, DOI 10.1254/jjp.53.125; POTTER EK, 1985, NEUROSCI LETT, V54, P117, DOI 10.1016/S0304-3940(85)80065-3; PROUD D, 1983, J CLIN INVEST, V72, P1678, DOI 10.1172/JCI111127; RAPHAEL GD, 1988, AM J RHINOL, V2, P8; SERTL K, 1988, AM REV RESPIR DIS, V138, P151, DOI 10.1164/ajrccm/138.1.151; STRETTON CD, 1988, BRIT J PHARMACOL, V93, P672, DOI 10.1111/j.1476-5381.1988.tb10325.x; WARNER MR, 1989, CIRC RES, V64, P882, DOI 10.1161/01.RES.64.5.882; WHITE MV, 1989, BIOCH ACUTE ALLERGIC, P83; WIDDICOMBE J, 1988, LUNG BIOL HLTH DIS, V35, P233	30	21	24	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1996	98	3					611	616		10.1016/S0091-6749(96)70095-7	http://dx.doi.org/10.1016/S0091-6749(96)70095-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VJ428	8828539				2022-12-18	WOS:A1996VJ42800018
J	Blaher, B; Suphioglu, C; Knox, RB; Singh, MB; McCluskey, J; Rolland, JM				Blaher, B; Suphioglu, C; Knox, RB; Singh, MB; McCluskey, J; Rolland, JM			Identification of T-cell epitopes of Lol p 9, a major allergen of ryegrass (Lolium perenne) pollen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; T cells; ryegrass pollen; Lol p 9; peptides; MHC	RYE-GRASS POLLEN; HUMAN IMMUNE-RESPONSE; GROUP-V ALLERGENS; HOUSE DUST MITE; SKIN-TEST; REACTIVITY; PROTEIN; CLONING; PEPTIDE; DERMATOPHAGOIDES	T-cell recognition of Lol p 9, a major allergen of ryegrass pollen, was investigated by using a T-cell line and T-cell clones generated from the peripheral blood of an atopic donor. The T-cell line reacted with purified Lol p 9, as well as with crude ryegrass pollen extract, but failed to cross-react with Bermuda grass pollen extract. All of six T-cell clones generated from this line proliferated in response to Lol p 9. Epitope mapping was carried our with a panel of 34 overlapping synthetic peptides, which spanned the entire sequence of the Lol p 9 12R isoform. The T-cell line responded to two of the peptides, Lol p 9 (105-116) and Lol p 9 (193-204), whereas reactivity with one oi other of these peptides was shown by five T-cell clones. These two peptides contained sequences consistent with motifs previously reported for major histocompatibility complex class II-restricted peptides. HLA antibody blocking studies showed that presentation of peptide Lol p 9 (105-116) to one T-cell clone was HLA-DR-restricted; this clone expressed a T helper cell phenotype (CD3(+), CD4(+)) and the T-cell receptor alpha beta. The identification of immunodominant T-cell epitope(s) on allergens is essential for, devising safer and more effective immunotherapy strategies, which can interrupt the chain of events leading to allergic disease.	MONASH UNIV,DEPT PATHOL & IMMUNOL,PRAHRAN,VIC 3181,AUSTRALIA; UNIV MELBOURNE,SCH BOT,PARKVILLE,VIC 3052,AUSTRALIA; FLINDERS MED CTR,BEDFORD PK,SA,AUSTRALIA	Monash University; University of Melbourne; Flinders Medical Centre			Rolland, Jennifer/E-7543-2011; McCluskey, James/A-1291-2007	McCluskey, James/0000-0002-8597-815X; Singh, Mohan/0000-0001-9427-8975				ANSARI AA, 1991, IMMUNOGENETICS, V33, P24; ANSARI AA, 1989, HUM IMMUNOL, V25, P59, DOI 10.1016/0198-8859(89)90070-0; ANSARI AA, 1987, J IMMUNOL, V139, P4034; BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; BLAHER B, 1995, IMMUNOL CELL BIOL, V73, P17, DOI 10.1038/icb.1995.3; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BUSS S, 1986, CELL, V47, P1071; COLE WQ, 1994, J ALLERGY CLIN IMMUN, V93, P250; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; Durham S R, 1991, Clin Exp Allergy, V21 Suppl 1, P206, DOI 10.1111/j.1365-2222.1991.tb01729.x; EBNER C, 1993, J IMMUNOL, V150, P1047; FRASER JD, 1993, IMMUNOL TODAY, V14, P357, DOI 10.1016/0167-5699(93)90236-E; FREIDHOFF LR, 1986, J ALLERGY CLIN IMMUN, V78, P1190, DOI 10.1016/0091-6749(86)90271-X; FREIDHOFF LR, 1988, TISSUE ANTIGENS, V31, P211, DOI 10.1111/j.1399-0039.1988.tb02083.x; GRIFFITH IJ, 1991, FEBS LETT, V279, P210, DOI 10.1016/0014-5793(91)80151-R; KING TP, 1994, INT ARCH ALLERGY IMM, V105, P224, DOI 10.1159/000236761; MARSH DG, 1975, ANTIGENS, P271; MATTHIESEN F, 1991, CLIN EXP ALLERGY, V21, P309, DOI 10.1111/j.1365-2222.1991.tb01662.x; MCCLUSKEY J, 1991, ANTIGEN PROCESSING R, P1; NASERT S, 1994, J ALLERGY CLIN IMMUN, V93, P187; NORMAN PS, 1990, J ALLERGY CLIN IMMUN, V85, P522, DOI 10.1016/0091-6749(90)90165-Z; OHEHIR RE, 1989, IMMUNOLOGY, V66, P499; OHEHIR RE, 1988, IMMUNOLOGY, V64, P627; ONG EK, 1993, GENE, V134, P235, DOI 10.1016/0378-1119(93)90099-O; PEREZ M, 1990, J BIOL CHEM, V265, P16210; RICCI M, 1994, CLIN EXP ALLERGY, V24, P801, DOI 10.1111/j.1365-2222.1994.tb01803.x; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; ROTHBARD JB, 1994, INT ARCH ALLERGY IMM, V105, P1, DOI 10.1159/000236795; RUDENSKY AY, 1992, NATURE, V359, P429, DOI 10.1038/359429a0; SETTE A, 1993, J IMMUNOL, V151, P3163; SINGH MB, 1991, P NATL ACAD SCI USA, V88, P1384, DOI 10.1073/pnas.88.4.1384; SMART IJ, 1983, INT ARCH ALLER A IMM, V72, P243, DOI 10.1159/000234875; SMITH PM, 1994, MOL IMMUNOL, V31, P491, DOI 10.1016/0161-5890(94)90068-X; SPARHOLT SH, 1994, J ALLERGY CLIN IMMUN, V93, P249; STADLER BM, 1993, INT ARCH ALLERGY IMM, V102, P121, DOI 10.1159/000236561; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; SUPHIOGLU C, 1992, LANCET, V339, P569, DOI 10.1016/0140-6736(92)90864-Y; WUTHRICH B, 1989, INT ARCH ALLER A IMM, V79, P434	38	21	25	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1996	98	1					124	132		10.1016/S0091-6749(96)70234-8	http://dx.doi.org/10.1016/S0091-6749(96)70234-8			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VA692	8765826	Bronze			2022-12-18	WOS:A1996VA69200015
J	Knutson, TW; Bengtsson, U; Dannaeus, A; Ahlstedt, S; Knutson, L				Knutson, TW; Bengtsson, U; Dannaeus, A; Ahlstedt, S; Knutson, L			Effects of luminal antigen on intestinal albumin and hyaluronan permeability and ion transport in atopic patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; anaphylaxis; birch; food intolerance; intestinal permeability; ion transport; segmental intestinal perfusion	FOOD HYPERSENSITIVITY; ALLERGIC REACTIONS; JEJUNAL MUCOSA; CELIAC-DISEASE; ANAPHYLAXIS; RAT; RELEASE; LYMPHOCYTES; EXUDATION; MEDIATORS	Background: Increased luminal transport of proteins and fluid is part of the inflammatory reaction in inflammatory disease of the bowel and of the airways in allergic diseases and asthma. The objective of this study was to determine intestinal appearance rates of albumin and hyaluronan in vivo in atopic patients allergic to birch, as well as changes in net jejunal transport of monovalent ions and water induced by the antigen. Methods: Secretion studies were performed with the use of a segmental jejunal perfusion system with a small two-balloon, six-channel tube. The intestinal mucosa was challenged with birch allergen in patients allergic to birch and in matched control subjects (n = 12 in both groups). Results: In patients, but not in control subjects, the luminal antigen induced a net increase in albumin of 2689 +/- 567 mu g/cm/hr and in hyaluronan of 2609 +/- 737 ng/cm/hr (p < 0.01 vs control subjects in both cases). Furthermore, basel net absorption of Cl- ions, Na+ ions, and water was converted to a net secretion after antigen challenge. Conclusion: Exposure to antigen normally acting on the respiratory tract induced increased permeability of the gastrointestinal mucosa. This would suggest less organ specificity and more general allergic recognition shared by several immunocompetent tissues in the body, probably mediated by circulating IgE antibodies.	UNIV UPPSALA HOSP,DEPT SURG,S-75185 UPPSALA,SWEDEN; UNIV UPPSALA HOSP,DEPT PEDIAT,S-75185 UPPSALA,SWEDEN; GOTHENBURG UNIV,SAHLGRENS HOSP,DIV ALLERGOL,S-41345 GOTHENBURG,SWEDEN; PHARMACIA DIAGNOST AB,S-75182 UPPSALA,SWEDEN	Uppsala University; Uppsala University Hospital; Uppsala University; Uppsala University Hospital; Sahlgrenska University Hospital; University of Gothenburg; Pfizer; Pharmacia Corporation								AHRENSTEDT O, 1992, DIGESTION, V52, P6, DOI 10.1159/000200932; ANAND BS, 1981, Q J MED, V197, P83; BARRETT KE, 1988, IMMUNOLOGY GASTROINT, P65; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BOTH CC, 1970, BRIT MED J, V3, P725; BYARS NE, 1976, CLIN EXP IMMUNOL, V24, P352; CASTRO GA, 1987, AM J PHYSIOL, V253, pG540, DOI 10.1152/ajpgi.1987.253.4.G540; CROWE SE, 1990, GASTROENTEROLOGY, V99, P74, DOI 10.1016/0016-5085(90)91232-U; DEWECK AL, 1984, ANN ALLERGY, V53, P583; FIELD M, 1981, PHYSL GASTROINTESTIN, P963; FREEDMAN AR, 1987, J CLIN PATHOL, V40, P741, DOI 10.1136/jcp.40.7.741; GUSTAFSSON B, 1992, SCAND J GASTROENTERO, V27, P587; KLEINMAN RE, 1989, IMMUNOLOGY, V68, P464; KNUTSON L, 1989, AM J GASTROENTEROL, V84, P1278; KNUTSON L, 1993, CLIN TRANSPLANT, V7, P151; KNUTSON TW, 1993, J ALLERGY CLIN IMMUN, V91, P553, DOI 10.1016/0091-6749(93)90261-D; KREJS GJ, 1980, GASTROENTEROLOGY, V78, P722; LAKE AM, 1983, ANN ALLERGY, V51, P226; LAKE AM, 1980, IMMUNOLOGY, V39, P173; LAURENT UBG, 1980, ANN BIOCH, V109, P394; LAVO B, 1990, GUT, V31, P153, DOI 10.1136/gut.31.2.153; MARSH MN, 1980, GASTROENTEROLOGY, V79, P481; MARSH MN, 1985, GASTROENTEROLOGY, V89, P92, DOI 10.1016/0016-5085(85)90749-8; MARSH MN, 1983, J R COLL PHYSICIANS, V197, P205; MATUCHANSKY C, 1973, GASTROENTEROLOGY, V64, P1111; MAY CD, 1985, J ALLERGY CLIN IMMUN, V75, P329, DOI 10.1016/0091-6749(85)90067-3; METCALFE DD, 1989, NEW ENGL J MED, V321, P255, DOI 10.1056/NEJM198907273210410; PERDUE MH, 1986, AM J PHYSIOL, V250, pG427, DOI 10.1152/ajpgi.1986.250.4.G427; PERSSON CGA, 1986, LANCET, V2, P1126; RUSSEL DA, 1987, J IMMUNOL, V138, P1250; SAAVEDRADELGADO AM, 1985, ANN ALLERGY, V55, P694; SAMPSON HA, 1989, NEW ENGL J MED, V321, P228, DOI 10.1056/NEJM198907273210405; SANDERSON IR, 1993, GASTROENTEROLOGY, V104, P622, DOI 10.1016/0016-5085(93)90436-G; SMART HL, 1986, HEPATO-GASTROENTEROL, V33, P47; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; TENGBLAD A, 1986, BIOCHEM J, V236, P521, DOI 10.1042/bj2360521; ZWETCHKENBAUM JF, 1988, AM J GASTROENTEROL, V83, P901	37	21	22	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1996	97	6					1225	1232		10.1016/S0091-6749(96)70189-6	http://dx.doi.org/10.1016/S0091-6749(96)70189-6			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VD607	8648017	Bronze			2022-12-18	WOS:A1996VD60700009
J	Kelso, JM; Keating, RM				Kelso, JM; Keating, RM			Successful desensitization for treatment of a fixed drug eruption to allopurinol	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									USN,MED CTR,DEPT INTERNAL MED,DIV ALLERGY,SAN DIEGO,CA 92134; USN,MED CTR,DEPT INTERNAL MED,DIV RHEUMATOL,SAN DIEGO,CA 92134	United States Department of Defense; United States Navy; United States Department of Defense; United States Navy	Kelso, JM (corresponding author), USN,MED CTR,DEPT CLIN INVEST,SAN DIEGO,CA 92134, USA.							Audicana M., 1990, CIN EXP ALLERGY, V20, P21; FAM AG, 1992, AM J MED, V93, P299, DOI 10.1016/0002-9343(92)90236-5; GAFFOOR PMA, 1990, CUTIS, V45, P242; KANWAR AJ, 1988, DERMATOLOGICA, V177, P274, DOI 10.1159/000248578; SEHGAL VN, 1987, INT J DERMATOL, V26, P67, DOI 10.1111/j.1365-4362.1987.tb00522.x; SHIOHARA T, 1989, ARCH DERMATOL, V125, P1371, DOI 10.1001/archderm.125.10.1371	6	21	22	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1996	97	5					1171	1172		10.1016/S0091-6749(96)70275-0	http://dx.doi.org/10.1016/S0091-6749(96)70275-0			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	UL261	8626998				2022-12-18	WOS:A1996UL26100021
J	Saito, K; Suzuki, K; Matsuda, H; Okumura, K; Ra, C				Saito, K; Suzuki, K; Matsuda, H; Okumura, K; Ra, C			Physical association of Fc receptor gamma chain homodimer with IgA receptor	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	New Trends in Immunopharmacology 1994 Conference	JUL 23, 1994	TOKYO, JAPAN	Sandoz Pharm Ltd		IgA; receptor for the Fc portion of IgA (Fc alpha R); monocyte/macrophage; gamma chain of FcR (FcR gamma); antigen recognition activation motif (ARAM)	HUMAN POLYMORPHONUCLEAR LEUKOCYTES; MAST-CELL RECEPTOR; EPSILON-RI; TRANSFECTED CELLS; IMMUNOGLOBULIN-A; HUMAN-MONOCYTES; EXPRESSION; SUBUNIT; ANTIBODIES; BINDING	The receptor for IgA, Fc alpha R, consists of one IgA-binding alpha chain and a signal-transducing dimeric FcR gamma chain. Immunoprecipitation with an anti-Fc alpha R alpha chain monoclonal antibody from the lysates of U937 cells (human monocytic cell line) revealed an association of 20 kd (unreduced) and 10 kd (reduced) molecules to Fc alpha R alpha chain on sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE). These molecules were confirmed to be FcR gamma chain by immunoblotting probed with anti-FcR gamma chain antibody. A serial immunoprecipitation with both antibodies further ascertained the FcR gamma association with Fc alpha R alpha. The lysates precleared with anti-FcR gamma antibody were subjected to the second immunoprecipitation with an anti-Fc alpha R alpha monoclonal antibody. By this preclearance, FcR gamma disappeared, and the Fc alpha R alpha appealed to be significantly decreased on SDS-PAGE, suggesting that a part of Fca alpha R alpha was co-absorbed with FcR gamma. Therefore, it may be likely that Fc alpha R is expressed in two forms, namely, with or without FcR gamma. We reconstituted the Fc alpha R alpha-FcR gamma association by introducing both chains into host cells. The expression of Fc alpha R alpha was achieved by introducing Fc alpha R alpha alone, and the co-introduction of FcR gamma did not enhance Fc alpha R alpha expression on the cell surface, suggesting again the occurence of the two forms of Fc alpha R.	JUNTENDO UNIV, SCH MED, DEPT IMMUNOL, BUNKYO KU, TOKYO 113, JAPAN; TOKYO MED & DENT UNIV, FAC DENT, DEPT PROSTHODONT 2, TOKYO, JAPAN	Juntendo University; Tokyo Medical & Dental University (TMDU)								ABU GR, 1989, J IMMUNOL, V142, P2393; ALBRECHTSEN M, 1988, IMMUNOLOGY, V64, P201; BEAVEN MA, 1993, IMMUNOL TODAY, V14, P222, DOI 10.1016/0167-5699(93)90167-J; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; CHEVAILLER A, 1989, J IMMUNOL, V142, P2244; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; ERNST LK, 1993, P NATL ACAD SCI USA, V90, P6023, DOI 10.1073/pnas.90.13.6023; FANGER MW, 1980, P NATL ACAD SCI-BIOL, V77, P3640, DOI 10.1073/pnas.77.6.3640; FERRERI NR, 1986, J IMMUNOL, V136, P4188; GUPTA S, 1979, P NATL ACAD SCI USA, V76, P4025, DOI 10.1073/pnas.76.8.4025; KARASUYAMA H, 1990, J EXP MED, V172, P969, DOI 10.1084/jem.172.3.969; KERR MA, 1990, BIOCHEM SOC T, V18, P215, DOI 10.1042/bst0180215; KUROSAKI T, 1992, J EXP MED, V175, P447, DOI 10.1084/jem.175.2.447; LETOURNEUR O, 1991, J IMMUNOL, V147, P2652; MALISZEWSKI CR, 1990, J EXP MED, V172, P1665, DOI 10.1084/jem.172.6.1665; MALISZEWSKI CR, 1985, J IMMUNOL, V135, P3878; METZGER H, 1988, ADV IMMUNOL, V43, P277; MONTEIRO RC, 1992, J IMMUNOL, V148, P1764; MONTEIRO RC, 1990, J EXP MED, V171, P597, DOI 10.1084/jem.171.3.597; ORLOFF DG, 1990, NATURE, V347, P189, DOI 10.1038/347189a0; PFFERKORN LC, 1994, J IMMUNOL, V153, P3228; RA C, 1989, NATURE, V341, P752, DOI 10.1038/341752a0; RA C, 1989, J BIOL CHEM, V264, P15323; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; SCHOLL PR, 1993, P NATL ACAD SCI USA, V90, P8847, DOI 10.1073/pnas.90.19.8847; SHEN L, 1981, CELL IMMUNOL, V59, P75, DOI 10.1016/0008-8749(81)90435-4; SHEN L, 1989, J IMMUNOL, V143, P4117; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; UNDERDOWN BJ, 1986, ANNU REV IMMUNOL, V4, P389, DOI 10.1146/annurev.iy.04.040186.002133; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEISBART RH, 1988, NATURE, V332, P647, DOI 10.1038/332647a0; YEAMAN GR, 1987, CLIN EXP IMMUNOL, V68, P200	33	21	23	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1995	96	6	2	S			1152	1160		10.1016/S0091-6749(95)70200-8	http://dx.doi.org/10.1016/S0091-6749(95)70200-8			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	TQ509	8543772				2022-12-18	WOS:A1995TQ50900011
J	COTTIN, V; TARDY, F; GINDRE, D; VERNET, G; DEVILLER, P; CORDIER, JF				COTTIN, V; TARDY, F; GINDRE, D; VERNET, G; DEVILLER, P; CORDIER, JF			URINARY EOSINOPHIL-DERIVED NEUROTOXIN IN CHURG-STRAUSS-SYNDROME	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note							CATIONIC PROTEIN; ALLERGIC GRANULOMATOSIS; PNEUMONIA		UNIV LYON 1,HOP CARDIOVASC & PNEUMOL LOUIS PRADEL,SERV PNEUMOL,F-69394 LYON 03,FRANCE; UNIV LYON 1,HOP CARDIOVASC & PNEUMOL LOUIS PRADEL,BIOCHIM LAB,F-69394 LYON 03,FRANCE	CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1								DEVILLER P, 1991, CLIN CHIM ACTA, V201, P105, DOI 10.1016/0009-8981(91)90031-7; HERTZMAN PA, 1990, NEW ENGL J MED, V322, P869, DOI 10.1056/NEJM199003293221301; JANIN A, 1993, THORAX, V48, P57, DOI 10.1136/thx.48.1.57; MORITA H, 1992, ACTA DERM-VENEREOL, V72, P201; PETERSON CGB, 1987, BIOCHEM J, V245, P781, DOI 10.1042/bj2450781; TAI PC, 1984, BRIT MED J, V289, P400, DOI 10.1136/bmj.289.6442.400; TARDY F, 1993, CLIN CHEM, V39, P919; WALLEN N, 1991, J IMMUNOL, V147, P3490	8	21	21	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1995	96	2					261	264		10.1016/S0091-6749(95)70018-8	http://dx.doi.org/10.1016/S0091-6749(95)70018-8			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RQ001	7636065	Bronze			2022-12-18	WOS:A1995RQ00100018
J	POPKENHARRIS, P; THOMAS, L; OXVIG, C; SOTTRUPJENSEN, L; KUBO, H; KLEIN, JS; GLEICH, GJ				POPKENHARRIS, P; THOMAS, L; OXVIG, C; SOTTRUPJENSEN, L; KUBO, H; KLEIN, JS; GLEICH, GJ			BIOCHEMICAL-PROPERTIES, ACTIVITIES, AND PRESENCE IN BIOLOGIC FLUIDS OF EOSINOPHIL GRANULE MAJOR BASIC-PROTEIN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							A PAPP-A; HUMAN-PREGNANCY; TRYPANOSOMA-CRUZI; CATIONIC PROTEINS; TRACHEAL EPITHELIUM; HISTAMINE-RELEASE; BRONCHIAL-ASTHMA; HUMAN-PLACENTA; TOXICITY; PURIFICATION		MAYO CLIN & MAYO FDN,DEPT IMMUNOL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT INTERNAL MED,ROCHESTER,MN 55905; RUSH PRESBYTERIAN ST LUKES MED CTR,DEPT IMMUNOL MICROBIOL,CHICAGO,IL 60612; AARHUS UNIV,DEPT MOLEC BIOL,DK-8000 AARHUS,DENMARK	Mayo Clinic; Mayo Clinic; Rush University; Aarhus University				Oxvig, Claus/0000-0002-4715-9719	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI015231, R01AI009728, R37AI009728, R01AI015231] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 09728, AI 15231] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABUGHAZALEH RI, 1992, J MEMBRANE BIOL, V128, P153; BARKER RL, 1991, J CLIN INVEST, V88, P798, DOI 10.1172/JCI115379; BARKER RL, 1988, J EXP MED, V168, P1493, DOI 10.1084/jem.168.4.1493; BISCHOF P, 1979, ARCH GYNECOL, V227, P315, DOI 10.1007/BF02109920; BONNO M, 1994, IN PRESS LAB INVEST; BUTTERWORTH AE, 1979, J IMMUNOL, V122, P221; DAVEY MW, 1983, ANAL BIOCHEM, V131, P18, DOI 10.1016/0003-2697(83)90130-6; FILLEY WV, 1982, LANCET, V2, P11; FISCHKOFF SA, 1984, J EXP MED, V160, P179, DOI 10.1084/jem.160.1.179; FOLKERSEN J, 1981, AM J OBSTET GYNECOL, V139, P910, DOI 10.1016/0002-9378(81)90957-1; FRIGAS E, 1980, LAB INVEST, V42, P35; FRIGAS E, 1986, J ALLERGY CLIN IMMUN, V77, P527, DOI 10.1016/0091-6749(86)90341-6; FRIGAS E, 1981, MAYO CLIN PROC, V56, P345; GLEICH GJ, 1979, J IMMUNOL, V123, P2925; GUNDEL RH, 1991, J CLIN INVEST, V87, P1470, DOI 10.1172/JCI115155; HAMANN KJ, 1987, J PARASITOL, V73, P523, DOI 10.2307/3282130; HAMMAN KJ, 1990, J IMMUNOL, V144, P3166; KIERSZENBAUM F, 1981, AM J TROP MED HYG, V30, P775, DOI 10.4269/ajtmh.1981.30.775; LEHRER RI, 1989, J IMMUNOL, V142, P4428; LIN TM, 1976, SCIENCE, V193, P1249, DOI 10.1126/science.60782; MADDOX DE, 1983, J EXP MED, V158, P1211, DOI 10.1084/jem.158.4.1211; MADDOX DE, 1984, J EXP MED, V160, P29, DOI 10.1084/jem.160.1.29; MCGROGAN M, 1988, J EXP MED, V168, P2295, DOI 10.1084/jem.168.6.2295; MOLINA HA, 1988, AM J TROP MED HYG, V38, P327, DOI 10.4269/ajtmh.1988.38.327; MOTOJIMA S, 1989, AM REV RESPIR DIS, V139, P801, DOI 10.1164/ajrccm/139.3.801; MOY JN, 1990, J IMMUNOL, V145, P2626; ODONNEL MC, 1991, J EXP MED, V157, P1981; OXVIG C, 1993, J BIOL CHEM, V268, P12243; POPKENHARRIS P, 1994, THESIS; ROHRBACH MS, 1900, J EXP MED, V172, P1271; SINOSICH MJ, 1990, BIOCHEM INT, V20, P579; SOTTRUPJENSEN L, 1993, BIOCHEM MOL BIOL INT, V30, P789; SUTCLIFFE RG, 1980, BIOCHEM J, V191, P799, DOI 10.1042/bj1910799; THOMAS LL, 1989, IMMUNOLOGY, V66, P611; TORNEHAVE D, 1984, PLACENTA, V5, P427, DOI 10.1016/S0143-4004(84)80023-5; VILLALTA F, 1984, J IMMUNOL, V132, P2053; WAGNER JM, 1993, PLACENTA, V14, P671, DOI 10.1016/S0143-4004(05)80384-4; WASMOEN TL, 1988, J BIOL CHEM, V263, P12559; WASMOEN TL, 1989, J EXP MED, V170, P2051, DOI 10.1084/jem.170.6.2051; WASMOEN TL, 1987, P NATL ACAD SCI USA, V84, P3029, DOI 10.1073/pnas.84.9.3029; WEILER JM, 1992, J IMMUNOL, V149, P643; WESTERGAARD JG, 1983, ARCH GYNECOL, V233, P211, DOI 10.1007/BF02114602; YOSHIMATSU K, 1992, MOL IMMUNOL, V29, P537; ZHEUTLIN LM, 1984, J IMMUNOL, V133, P2180	44	21	28	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1994	94	6	2	S			1282	1289		10.1016/0091-6749(94)90343-3	http://dx.doi.org/10.1016/0091-6749(94)90343-3			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QA020	7798569				2022-12-18	WOS:A1994QA02000023
J	KOHSAKA, T; ABE, J; ASAHINA, T; KOBAYASHI, N				KOHSAKA, T; ABE, J; ASAHINA, T; KOBAYASHI, N			CLASSICAL PATHWAY COMPLEMENT ACTIVATION IN KAWASAKI SYNDROME	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						KAWASAKI SYNDROME; COMPLEMENT; CYTOKINE; C4D; C3D; MEMBRANE ATTACK COMPLEX; BB; IL-6; CLASSICAL PATHWAY	IMMUNE-COMPLEX; DISEASE; ANTIBODIES; INTERLEUKIN-6; QUANTITATION; FRAGMENTS; ABSENCE	In this study the complement breakdown products C3d, C4d, Bb and membrane attack complex were measured in plasma of patients with Kawasaki syndrome. The results suggested strong activation of the classical activation pathway. However, there was no significant decrease in hemolytic titer or in the concentrations of the intact proteins C3, C4, and B. The relationship between the serum concentrations of cytokines and complement components was examined; increased interleukin-6 concentration on the fifth day after the onset of fever was found to correlate well with the C3 and B concentrations in serum obtained 5 days later We conclude that complement activation occurred in Kawasaki syndrome via the classical pathway but that the inflammatory reaction was accompanied by increased production of complement components. As a result, there was increased formation of activation products without changes in the serum complement levels.			KOHSAKA, T (corresponding author), NATL CHILDRENS HOSP,CHILDRENS MED RES CTR,DEPT IMMUNOL,SETAGAYA KU,3-35-31 TAISHIDO,TOKYO 154,JAPAN.							AREND WP, 1989, J IMMUNOL, V142, P173; BARRON KS, 1990, ARTHRITIS RHEUM, V33, P1371, DOI 10.1002/art.1780330909; KOHSAKA T, 1980, IMMUNOLOGY, V3, P104; KOHSAKA T, 1990, PROG MED, V10, P49; KOLB WP, 1989, COMPLEMENT INFLAMMAT, V6, P175, DOI 10.1159/000463093; KOREN G, 1986, J PEDIATR-US, V108, P388, DOI 10.1016/S0022-3476(86)80878-2; LAXER PM, 1984, PROG CLIN BIOL RES, V250, P175; LEUG DY, 1986, J CLIN INVEST, V77, P1428; LEVIN M, 1985, BRIT MED J, V290, P1456, DOI 10.1136/bmj.290.6480.1456; Levin M, 1987, Prog Clin Biol Res, V250, P227; LIN CY, 1987, ANN ALLERGY, V59, P291; MARDHETT NJ, 1990, J INFECT DIS, V1614, P680; MASON WH, 1985, PEDIATR INFECT DIS J, V4, P48, DOI 10.1097/00006454-198501000-00012; MATUBARA T, 1990, CLIN IMMUNOL IMMUNOP, V56, P29; MCCLURE JE, 1988, MOL CELL PROBE, V2, P305, DOI 10.1016/0890-8508(88)90014-X; MELISH ME, 1989, NATURE, V337, P288, DOI 10.1038/337288a0; MYONES BL, 1986, J RHEUMATOL, V13, P981; MYONES BL, 1990, CLIN IMMUNOL NEW LET, V25, P11; OHSHIO G, 1987, MICROBIOL IMMUNOL, V31, P891, DOI 10.1111/j.1348-0421.1987.tb03150.x; SAVAGE COS, 1989, ARCH DIS CHILD, V64, P360, DOI 10.1136/adc.64.3.360; SHIMAMURA T, 1991, MOL IMMUNOL, V28, P1155; SHOLZ W, 1990, CLIN IMMUNOL IMMUNOP, V57, P297; STEEL DM, 1991, BIOCHEM J, V277, P477, DOI 10.1042/bj2770477; SWRVIS C, 1989, J IMMUNOL, V142, P2207; TIZARD EJ, 1991, ARCH DIS CHILD, V66, P189, DOI 10.1136/adc.66.2.189; UENO Y, 1989, CLIN EXP IMMUNOL, V76, P337; VAARALA O, 1990, ACTA PAEDIATR SCAND, V79, P804, DOI 10.1111/j.1651-2227.1990.tb11558.x; VONESSEN R, 1985, SCAND J RHEUMATOL, V14, P421	28	21	22	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1994	93	2					520	525		10.1016/0091-6749(94)90362-X	http://dx.doi.org/10.1016/0091-6749(94)90362-X			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MY581	8120278	Bronze			2022-12-18	WOS:A1994MY58100014
J	KURUP, VP; KUMAR, A; KELLY, KJ; FINK, JN				KURUP, VP; KUMAR, A; KELLY, KJ; FINK, JN			CHARACTERIZATION OF A MONOCLONAL-ANTIBODY AGAINST LATEX PROTEIN ASSOCIATED WITH LATEX ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						MONOCLONAL ANTIBODY; LATEX PROTEIN; LATEX ALLERGY; RUBBER PLANT EXTRACT	CONTACT URTICARIA; GLOVE CONTACT; RUBBER; ANAPHYLAXIS; ANTIGENS; HYPERSENSITIVITY; ASTHMA	Several hybridomas were produced against antigens extracted from the latex sap of Hevea brasiliensis. One of the monoclonal antibodies (LA-E3) reacted with antigens demonstrating binding to patient sera on crossed enzyme immunoelectrophoresis. This monoclonal reacted with 2 of 10 glove extracts studied and with both Malaysian and Indian law extracts. The antigens purified with monoclonal affinity chromatography demonstrated specific IgE in the sera of patients with later allergy as determined by ELISA. This monoclonal antibody can thus be utilized to obtain reliable antigens useful in the diagnosis of law sensitivity, although additional antigens will likely be necessary to enhance sensitivity and specificity.	VET AFFAIRS MED CTR,RES SERV,MILWAUKEE,WI	US Department of Veterans Affairs; Veterans Health Administration (VHA)	KURUP, VP (corresponding author), MED COLL WISCONSIN,DEPT MED,DIV ALLERGY IMMUNOL,VET AFFAIRS RES SERV 151,MILWAUKEE,WI 53295, USA.			Kelly, Kevin/0000-0002-2954-6117				ALENIUS H, 1991, INT ARCH ALLER A IMM, V96, P376, DOI 10.1159/000235525; AXELSSON JGK, 1987, ALLERGY, V42, P46, DOI 10.1111/j.1398-9995.1987.tb02186.x; BELSITO DV, 1990, DERMATOL CLIN, V8, P61, DOI 10.1016/S0733-8635(18)30523-0; FORSTROM L, 1980, CONTACT DERMATITIS, V6, P33, DOI 10.1111/j.1600-0536.1980.tb03887.x; FROSCH PJ, 1986, CONTACT DERMATITIS, V14, P241, DOI 10.1111/j.1600-0536.1986.tb01233.x; JAEGER D, 1992, J ALLERGY CLIN IMMUN, V89, P759, DOI 10.1016/0091-6749(92)90385-F; KELLY KJ, 1993, J ALLERGY CLIN IMMUN, V91, P1140, DOI 10.1016/0091-6749(93)90316-8; KURUP VP, 1989, J CLIN LAB ANAL, V3, P116, DOI 10.1002/jcla.1860030209; KURUP VP, 1984, MOL IMMUNOL, V21, P214; KURUP VP, 1993, ALLERGY PROC, V13, P329; MARCH PJ, 1988, J AM DENT ASSOC, V117, P590, DOI 10.14219/jada.archive.1988.0046; MONERETVAUTRIN DA, 1990, ANESTHESIOLOGY, V73, P556, DOI 10.1097/00000542-199009000-00032; MORALES C, 1989, CLIN EXP ALLERGY, V19, P425, DOI 10.1111/j.1365-2222.1989.tb02409.x; MRAIHI L, 1991, J ALLERGY CLIN IMMUN, V87, P129, DOI 10.1016/0091-6749(91)90224-C; NUTTER AF, 1979, BRIT J DERMATOL, V101, P597, DOI 10.1111/j.1365-2133.1979.tb15107.x; OWNBY DR, 1991, AM J ROENTGENOL, V156, P903, DOI 10.2214/ajr.156.5.2017949; SCHWARTZ EE, 1984, AM J ROENTGENOL, V143, P103, DOI 10.2214/ajr.143.1.103; SEATON A, 1988, BRIT MED J, V296, P531, DOI 10.1136/bmj.296.6621.531-a; SKJODT K, 1984, J IMMUNOL METHODS, V72, P243, DOI 10.1016/0022-1759(84)90452-6; SLATER JE, 1992, J ALLERGY CLIN IMMUN, V89, P673, DOI 10.1016/0091-6749(92)90373-A; SLATER JE, 1989, NEW ENGL J MED, V320, P1126, DOI 10.1056/NEJM198904273201707; SONDHEIMER JM, 1989, AM J GASTROENTEROL, V84, P975; SPANER D, 1989, J ALLERGY CLIN IMMUN, V83, P1135, DOI 10.1016/0091-6749(89)90457-0; TARLO SM, 1990, J ALLERGY CLIN IMMUN, V85, P626, DOI 10.1016/0091-6749(90)90103-B; TURJANMAA K, 1988, CONTACT DERMATITIS, V19, P241, DOI 10.1111/j.1600-0536.1988.tb02920.x; TURJANMAA K, 1987, CONTACT DERMATITIS, V17, P270, DOI 10.1111/j.1600-0536.1987.tb01476.x	26	21	24	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1993	92	5					638	643		10.1016/0091-6749(93)90005-Z	http://dx.doi.org/10.1016/0091-6749(93)90005-Z			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MG982	8227854				2022-12-18	WOS:A1993MG98200003
J	HAN, SH; CHANG, ZN; CHI, CW; PERNG, HJ; LIU, CC; TSAI, JJ; TAM, MF				HAN, SH; CHANG, ZN; CHI, CW; PERNG, HJ; LIU, CC; TSAI, JJ; TAM, MF			USE OF MONOCLONAL-ANTIBODIES TO ISOLATE AND CHARACTERIZE CYN-D-I, THE MAJOR ALLERGEN OF BERMUDA GRASS-POLLEN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CYN-D-I; PURIFICATION; CHARACTERIZATION; MONOCLONAL ANTIBODY AFFINITY CHROMATOGRAPHY	CYNODON-DACTYLON POLLEN; P-I; IDENTIFICATION; PROTEINS; GEL; ANTIGENS; MEMBRANE	Background: Cyn d I has been found to be the major allergen of Bermuda grass (Cynodon dactylon) pollen, but its exact nature remains to be clarified. Methods: Cyn d I, the major allergen of Bermuda grass (Cynodon dactylon) pollen, was purified by monoclonal antibody (MoAb) affinity chromatography, and its biochemical and immunologic properties were characterized. Anti-Cyn d I MoAb 4-37, which recognizes all of the isoallergens of Cyn d I, was chosen as the immunosorbent. Results: The purified protein has an amino acid composition similar to that of the group I allergens of other grass pollens. It appears as a single 34 kd band or as a mixture of 34 and 29 kd polypeptides in sodium dodecylsulfate-polyacrylamide gel electrophoresis analysis. The hydrophobicity of these two polypeptides is similar because they have the same retention time on a C18 reverse-phase column when a trifluoroacetic acid/H2O/CH3CN buffer system is used. The N-terminal amino acid sequence of the 34 kd component has a 60% homology with residues of 1-25 of Lol p I, whereas that of the 29 kd component has a 68% homology with residues 31-68 of Lol p I. In addition, this 29 kd polypeptide can be recognized by another anti-Cyn d I MoAb 1-61. Conclusions: These results suggest that the 29 kd component is derived from Cyn d I. In spite of the similarity in the amino acid composition between Cyn d I and group I allergens of other grass pollens, none of our four anti-Cyn d I MoAbs cross-reacted with 10 other grass pollens tested, including ryegrass pollen. Despite biochemical similarity with other group I allergens, the B-cell epitopes on Cyn d I are different from those on other grass pollens.	NATL YANG MING MED COLL, SCH MED TECHNOL, TAIPEI, TAIWAN; TAIWAN ALLERGY CTR, TAIPEI, TAIWAN; VET GEN HOSP, DEPT MED RES, TAIPEI, TAIWAN; ACAD SINICA, INST MOL BIOL, TAIPEI 115, TAIWAN	National Yang Ming Chiao Tung University; Academia Sinica - Taiwan	HAN, SH (corresponding author), NATL YANG MING MED COLL, INST MICROBIOL & IMMUNOL, TAIPEI, TAIWAN.							BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chang HN, 1984, CLIN MED J, V34, P376; CHANG LH, 1990, ELECTROPHORESIS, V11, P589, DOI 10.1002/elps.1150110710; CHANG Z-N, 1988, Proceedings of the National Science Council Republic of China Part B Life Sciences, V12, P140; CHANG ZN, 1991, ALLERGY, V46, P520, DOI 10.1111/j.1398-9995.1991.tb00615.x; COTTAM GP, 1986, BIOCHEM J, V234, P305, DOI 10.1042/bj2340305; EKRAMODDOULLAH AKM, 1990, INT ARCH ALLER A IMM, V93, P371, DOI 10.1159/000235268; FORD SA, 1987, J ALLERGY CLIN IMMUN, V79, P711, DOI 10.1016/0091-6749(87)90201-6; HAN SH, 1993, J ALLERGY CLIN IMMUN, V91, P1035, DOI 10.1016/0091-6749(93)90217-4; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HJELMELAND LM, 1979, ANAL BIOCHEM, V95, P201, DOI 10.1016/0003-2697(79)90206-9; HUDSON L, 1980, PRACTICAL IMMUNOLOGY, P223; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIFERMAN KM, 1976, J ALLERGY CLIN IMMUN, V58, P129, DOI 10.1016/0091-6749(76)90148-2; MARSH DG, 1970, J ALLERGY, V46, P107, DOI 10.1016/0021-8707(70)90078-X; MARSH DG, 1988, ALLERGY, V43, P161; MARTIN BG, 1985, ANN ALLERGY, V54, P99; MATTHIESEN F, 1989, J ALLERGY CLIN IMMUN, V83, P1124, DOI 10.1016/0091-6749(89)90456-9; MATTHIESEN F, 1991, J ALLERGY CLIN IMMUN, V88, P763, DOI 10.1016/0091-6749(91)90184-P; MEYERS RL, 1971, J ALLERGY, V47, P100; NIECE RL, 1989, TECHNIQUE PROTEIN CH, V1, P89; ORREN A, 1977, S AFR MED J, V51, P586; PEREZ M, 1990, J BIOL CHEM, V265, P16210; POULSEN K, 1972, P NATL ACAD SCI USA, V69, P2495, DOI 10.1073/pnas.69.9.2495; SCHUMACHER MJ, 1985, ANN ALLERGY, V55, P584; SHEN HD, 1990, ELECTROPHORESIS, V11, P878, DOI 10.1002/elps.1150111018; SHEN HD, 1988, CLIN ALLERGY, V18, P401, DOI 10.1111/j.1365-2222.1988.tb02888.x; TARR GE, 1991, TECHNIQUES PROTEIN C, V2, P139; THORPE R, 1984, J IMMUNOL METHODS, V73, P259, DOI 10.1016/0022-1759(84)90400-9; TRINCA JC, 1962, MED J UST, V49, P696; TSAI LC, 1987, ASIA PAC COMMUN BIOC, V1, P133	31	21	22	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1993	92	4					549	558		10.1016/0091-6749(93)90079-U	http://dx.doi.org/10.1016/0091-6749(93)90079-U			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MC590	8409115	Bronze			2022-12-18	WOS:A1993MC59000007
J	WHITE, MV				WHITE, MV			NASAL CHOLINERGIC HYPERRESPONSIVENESS IN ATOPIC SUBJECTS STUDIED OUT-OF-SEASON	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						NASAL GLANDULAR HYPERRESPONSIVENESS; METHACHOLINE; LACTOFERRIN; ALBUMIN; CHOLINERGIC STIMULATION	PATHO-PHYSIOLOGY; NERVOUS-SYSTEM; HISTAMINE; RESPONSES; RESPONSIVENESS; METHACHOLINE; SECRETIONS; RHINITIS; HYPERREACTIVITY; INCREASES	Background: Atopic individuals have previously been shown to have an autonomic imbalance consisting of heightened cholinergic responsiveness in the lung, skin, and eyes, and beta-adrenergic hyporesponsiveness in the lungs, eyes, and vasculature. This array of abnormalities is often accompanied by nonspecific bronchial hyperresponsiveness, as well as alpha-adrenergic hyperresponsiveness in individuals with asthma. Methods: To determine whether atopic individuals have intrinsic nasal airway hyperresponsiveness to methacholine, 21 nonatopic subjects and 37 subjects with allergic rhinitis were studied. All subjects were studied out of their allergy seasons, and all allergy-related medications were discontinued before the study began. Subjects underwent nasal challenge with methacholine (1 to 25 mg), and lavaged nasal secretions were analyzed for total protein, the plasma marker albumin, and the glandular marker lactoferrin. Results: Atopic subjects demonstrated increased glandular responsiveness to methacholine as evidenced by an increase in the secretion of lactoferrin in response to individual doses of methacholine. Although the maximal lactoferrin secretion did not increase, glandular sensitivity to methacholine was heightened because the dose of methacholine required to induce lactoferrin secretion achievable by 60% of the study population was significantly lower in the atopic group. The volume of lavaged secretions recovered and congestion scores were also higher in the atopic group as compared with the normal control group. Conclusions: These data strongly suggest that atopic individuals have intrinsic nasal glandular hyperresponsiveness to cholinergic stimulation.	NIAID,ALLERG DIS SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)								BARANIUK JN, 1990, J CLIN INVEST, V85, P998, DOI 10.1172/JCI114577; BARANIUK JN, 1990, J CLIN INVEST, V86, P825, DOI 10.1172/JCI114780; BARANIUK JN, 1991, AM J PHYSIOL, V261, pL223, DOI 10.1152/ajplung.1991.261.4.L223; BEDARD PM, 1989, AM J RHINOL, V3, P211; BORUM P, 1983, EUR J RESPIR DIS, V64, P65; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; DOYLE WJ, 1990, J ALLERGY CLIN IMMUN, V86, P924, DOI 10.1016/S0091-6749(05)80156-3; DRUCE HM, 1985, J ALLERGY CLIN IMMUN, V76, P445, DOI 10.1016/0091-6749(85)90725-0; DURHAM SR, 1988, J ALLERGY CLIN IMMUN, V82, P764, DOI 10.1016/0091-6749(88)90077-2; FISH JE, 1976, AM REV RESPIR DIS, V113, P579; GRIECO MH, 1971, J ALLERGY CLIN IMMUN, V48, P143, DOI 10.1016/0091-6749(71)90009-1; HALONEN M, 1984, INT J IMMUNOPHARMACO, V6, P351, DOI 10.1016/0192-0561(84)90054-7; KALINER M, 1982, ANN INTERN MED, V96, P349, DOI 10.7326/0003-4819-96-3-349; KALINER M, 1976, J ALLERGY CLIN IMMUN, V58, P308, DOI 10.1016/0091-6749(76)90136-6; KLEMENTSSON H, 1990, CLIN EXP ALLERGY, V20, P539, DOI 10.1111/j.1365-2222.1990.tb03147.x; LEMANSKE RF, 1989, J CLIN INVEST, V83, P1, DOI 10.1172/JCI113843; MCLEAN JA, 1977, J ALLERGY CLIN IMMUN, V59, P165, DOI 10.1016/0091-6749(77)90220-2; OKAYAMA M, 1992, J ALLERGY CLIN IMMUN, V89, P1144, DOI 10.1016/0091-6749(92)90298-G; OUELLETTE J J, 1967, Journal of Allergy, V39, P160, DOI 10.1016/0021-8707(67)90033-0; RAPHAEL GD, 1988, AM REV RESPIR DIS, V138, P413, DOI 10.1164/ajrccm/138.2.413; RAPHAEL GD, 1991, J ALLERGY CLIN IMMUN, V88, P33, DOI 10.1016/0091-6749(91)90298-3; RAPHAEL GD, 1989, J CLIN INVEST, V84, P1528, DOI 10.1172/JCI114329; RAPHAEL GD, 1989, AM REV RESPIR DIS, V139, P791, DOI 10.1164/ajrccm/139.3.791; SHELHAMER JH, 1980, J ALLERGY CLIN IMMUN, V66, P52, DOI 10.1016/0091-6749(80)90138-4; SKONER DP, 1989, AM J RHINOL, V3, P353; SMITH LJ, 1980, J ALLERGY CLIN IMMUN, V66, P374, DOI 10.1016/0091-6749(80)90116-5; WALDEN SM, 1991, AM REV RESPIR DIS, V144, P642, DOI 10.1164/ajrccm/144.3_Pt_1.642; WHITE MV, 1987, J IMMUNOL, V139, P1624	28	21	21	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1993	92	2					278	287		10.1016/0091-6749(93)90171-B	http://dx.doi.org/10.1016/0091-6749(93)90171-B			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LT469	8349938				2022-12-18	WOS:A1993LT46900008
J	BOCK, SA				BOCK, SA			ANAPHYLAXIS TO CORIANDER - A SLEUTHING STORY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note							SPICES		NATL JEWISH CTR IMMUNOL & RESP MED,DENVER,CO	National Jewish Health								ATKINS FM, 1988, J ALLERGY CLIN IMMUN, V82, P240; GERN JE, 1992, NEW ENGL J MED, V324, P976; JONES RT, 1992, ANN ALLERGY, V68, P223; NIINIMAKI A, 1981, ALLERGY, V36, P487, DOI 10.1111/j.1398-9995.1981.tb01860.x; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; STRICKER WE, 1986, J ALLERGY CLIN IMMUN, V77, P516, DOI 10.1016/0091-6749(86)90188-0; VANTOORENENBERGEN AW, 1985, J ALLERGY CLIN IMMUN, V76, P477, DOI 10.1016/0091-6749(85)90730-4; VANTOORENENBERGEN AW, 1987, J ALLERGY CLIN IMMUN, V79, P108, DOI 10.1016/S0091-6749(87)80024-6; YUNGINGER JW, 1988, JAMA-J AM MED ASSOC, V260, P1450, DOI 10.1001/jama.260.10.1450	9	21	21	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1993	91	6					1232	1233		10.1016/0091-6749(93)90329-E	http://dx.doi.org/10.1016/0091-6749(93)90329-E			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LG740	8509584				2022-12-18	WOS:A1993LG74000018
J	DOHLMAN, AW; HEMSTREET, MPB; ODREZIN, GT; BARTOLUCCI, AA				DOHLMAN, AW; HEMSTREET, MPB; ODREZIN, GT; BARTOLUCCI, AA			SUBACUTE SINUSITIS - ARE ANTIMICROBIALS NECESSARY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						SUBACUTE SINUSITIS; ROENTGENOGRAM; ANTIMICROBIAL; DECONGESTANT; SALINE NASAL SPRAY	MAXILLARY SINUSITIS; RESPIRATORY ALLERGY; CHILDREN; RADIOGRAPHS	Background: The need for antimicrobials in the treatment of subacute sinusitis was evaluated in 96 afebrile children who were prescribed antimicrobial (amoxillin, amoxicillin clavulanate potassium, or trimethoprim-sulfamethoxazole) or no antimicrobial medication in addition to a decongestant and saline nasal spray for 3 weeks. Methods: Response was determined by complete clearing of the initial radiologic abnormalities or in the case of mucosal thickening by a significant decrease in thickness to < 6 mm within the maxillary sinuses associated with improvement of the clinical signs and symptoms of sinusitis. If there was evidence of partial clearing by radiograph, the same therapy was continued for another 3 weeks. Nonresponders demonstrated no change or worsening of clinical and radiologic findings. Results: Sixty-seven of the 96 subjects (70%) responded: 58 (87%) in 3 weeks and 9 (13%) in 6 weeks. Fifty-five of the responders were in the antimicrobial treatment group, and 12 were prescribed no antimicrobial medication. Twenty-nine of the 96 subjects (30%) did not respond to treatment; 22 received an antimicrobial and seven received no antimicrobial medication. Conclusions: The number of responders and nonresponders was similar in the antimicrobial- and nonantimicrobial-treated groups (p = NS), and no single antimicrobial medication demonstrated greater treatment effectiveness.	UNIV ALABAMA,SCH MED,DEPT PEDIAT,DIV CLIN & DEV IMMUNOL,PEDIAT ALLERGY SECT,BIRMINGHAM,AL 35233; UNIV ALABAMA,SCH MED,DEPT RADIOL,BIRMINGHAM,AL 35233; UNIV ALABAMA,SCH MED,DEPT BIOSTAT & BIOMATH,BIRMINGHAM,AL 35233	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham								ARRUDA LK, 1990, PEDIATRICS, V85, P553; AXELSSON A, 1970, ACTA OTO-LARYNGOL, V69, P302, DOI 10.3109/00016487009123368; BLUESTONE CB, 1985, PEDIATR INFECT DIS J, V6, pS49; BUSINCO L, 1981, INT J PEDIATR OTORHI, V3, P287, DOI 10.1016/0165-5876(81)90053-7; Chobot R, 1930, AM J DIS CHILD, V39, P257; DIAMENT MJ, 1987, J COMPUT ASSIST TOMO, V11, P426, DOI 10.1097/00004728-198705000-00011; DIAMENT MJ, 1992, J ALLERGY CLIN IMMUN, V90, P442, DOI 10.1016/0091-6749(92)90166-Y; DRUCE HM, 1984, J APPL PHYSIOL, V57, P1276, DOI 10.1152/jappl.1984.57.4.1276; DRUCE HM, 1987, IMMUNOLOGY ALLERGY C, P117; FIREMAN P, 1992, J ALLERGY CLIN IMMUN, V90, P433, DOI 10.1016/0091-6749(92)90164-W; KOGUTT MS, 1973, PEDIATRICS, V52, P121; KOVATCH AL, 1984, PEDIATRICS, V73, P306; PELIKAN Z, 1990, J ALLERGY CLIN IMMUN, V86, P484, DOI 10.1016/S0091-6749(05)80203-9; RACHELEFSKY GS, 1982, J ALLERGY CLIN IMMUN, V69, P382, DOI 10.1016/0091-6749(82)90150-6; RACHELEFSKY GS, 1978, J ALLERGY CLIN IMMUN, V61, P310, DOI 10.1016/0091-6749(78)90052-0; SHOPFNER CE, 1973, AM J ROENTGENOL, V118, P176, DOI 10.2214/ajr.118.1.176; SILVERMAN FN, 1990, ESSENTIALS CAFFEYS P, P54; SLAVIN RG, 1988, ALLERGY PRINCIPLE PR, P1295; TINKELMAN DG, 1989, AM J DIS CHILD, V143, P938, DOI 10.1001/archpedi.1989.02150200098025; WALD ER, 1989, J PEDIATR-US, V115, P28, DOI 10.1016/S0022-3476(89)80324-5; 1992, J ALLERGY CLIN IMMUN, V90, P555	21	21	21	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1993	91	5					1015	1023						9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LC978	8491934				2022-12-18	WOS:A1993LC97800008
J	KNUTSON, TW; BENGTSSON, U; DANNAEUS, A; AHLSTEDT, S; STALENHEIM, G; HALLGREN, R; KNUTSON, L				KNUTSON, TW; BENGTSSON, U; DANNAEUS, A; AHLSTEDT, S; STALENHEIM, G; HALLGREN, R; KNUTSON, L			INTESTINAL REACTIVITY IN ALLERGIC AND NONALLERGIC PATIENTS - AN APPROACH TO DETERMINE THE COMPLEXITY OF THE MUCOSAL REACTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALBUMIN; ALLERGY; BIRCH; EOSINOPHILS; FOOD INTOLERANCE; HISTAMINE; HYALURONAN; INTESTINAL ANAPHYLAXIS; MAST CELLS; SEGMENTAL INTESTINAL PERFUSION	CELIAC-DISEASE; FOOD HYPERSENSITIVITY; SCHISTOSOMA-MANSONI; MAST-CELLS; EOSINOPHIL; HYALURONATE; CHALLENGE; PROTEIN; DAMAGE	Background: To determine whether inflammatory markers and mediators were released in response to different intestinal antigens, studies were performed in atopic patients allergic to birch, patients allergic to psyllium powder (ispaghula), and patients intolerant to milk. Methods: Allergy to birch and psyllium powder was documented by the presence of circulating IgE antibodies and positive skin tests. Patients intolerant to milk had negative outcomes Of radioallergosorbent tests and skin tests but positive results of double-blind, placebo-controlled tests. Challenge of the intestine with different antigens was achieved by perfusion of a jejunal segment occluded between balloons. Basal and antigen-activated release of mast cell/basophil and eosinophil products and of substances emanating from the plasma and interstitial fluid was compared in perfusate fluid from patients (n = 8) and matched healthy controls (n = 8). Results: Perfusate levels of albumin and hyaluronan (previous name hyaluronic acid) were increased threefold to fivefold by antigen in all patients, but not in controls. Eosinophilic cationic protein increased in patients but also in ispaghula controls. Histamine was released in response to milk, but not in patients allergic to birch or ispaghula. Prostaglandin E2 increased in milk- and birch-sensitive patients. In response to ispaghula, however, it was released in both patients and controls. Conclusions: We conclude that subclinical intestinal challenge with antigen induces an increase in the appearance rate of albumin and hyaluronan in the intestinal lumen both in atopic patients (with target organs such as the lungs or nose and eves) and in patients with intestinal intolerance to milk. These changes in permeation are similar to those reported from other organs such as the lung. They may reflect a common response in early phase I reactions that are either IgE-mediated or occur in response to food antigens without any obvious involvement of an IgE-mediated mechanism. Subclinical provocation with intestinal antigens should prove useful for further elucidation of mechanisms underlying intestinal mucosal reactions to exogenous stimuli.	UNIV HOSP UPPSALA, DEPT SURG, S-75185 UPPSALA, SWEDEN; UNIV HOSP UPPSALA, DEPT PEDIAT, S-75185 UPPSALA, SWEDEN; UNIV HOSP UPPSALA, DEPT INTERNAL MED, S-75185 UPPSALA, SWEDEN; PHARMACIA AB, UPPSALA, SWEDEN; SAHLGRENS UNIV HOSP, DIV ALLERGOL, S-41345 GOTHENBURG, SWEDEN	Uppsala University; Uppsala University Hospital; Uppsala University; Uppsala University Hospital; Uppsala University; Uppsala University Hospital; Pfizer; Pharmacia Corporation; Sahlgrenska University Hospital								ABRAHAMSON DR, 1979, SCIENCE, V206, P567, DOI 10.1126/science.493961; BOCK SA, 1980, AM J DIS CHILD, V134, P973, DOI 10.1001/archpedi.1980.02130220049015; BURKS AW, 1988, J ALLERGY CLIN IMMUN, V81, P417, DOI 10.1016/0091-6749(88)90185-6; BUTTERWORTH AE, 1979, J IMMUNOL, V122, P221; DAVID JR, 1977, FED PROC, V36, P2176; DEWECK AL, 1984, ANN ALLERGY, V53, P583; DOLLBERG L, 1980, ARCH DIS CHILD, V55, P702, DOI 10.1136/adc.55.9.702; ENGSTROMLAURENT A, 1985, SCAND J CLIN LAB INV, V45, P497, DOI 10.3109/00365518509155249; FORBES D, 1988, AM J PHYSIOL, V255, pG201, DOI 10.1152/ajpgi.1988.255.2.G201; FUGNER A, 1989, INT ARCH ALLER A IMM, V88, P225, DOI 10.1159/000234792; GEORGE JD, 1968, GUT, V9, P237, DOI 10.1136/gut.9.2.237; GLEICH GJ, 1980, DIGEST DIS SCI, V25, P321, DOI 10.1007/BF01308054; HOHMANN A, 1983, J IMMUNOL METHODS, V64, P199, DOI 10.1016/0022-1759(83)90398-8; HUBSCHER T, 1975, J IMMUNOL, V114, P1389; HYDEN S, 1956, ANN AGR COLL SWEDEN, V22, P411; KNUTSON L, 1989, AM J GASTROENTEROL, V84, P1278; LAURENT UBG, 1980, ANN BIOCH, V109, P394; LAVO B, 1990, GUT, V31, P153, DOI 10.1136/gut.31.2.153; LAVO B, 1989, AM J MED, V87, P655, DOI 10.1016/0002-9343(89)90726-2; MALUENDA C, 1984, J PEDIATR GASTR NUTR, V3, P349, DOI 10.1097/00005176-198406000-00008; MAY CD, 1985, J ALLERGY CLIN IMMUN, V75, P329, DOI 10.1016/0091-6749(85)90067-3; METCALFE DD, 1989, NEW ENGL J MED, V321, P255, DOI 10.1056/NEJM198907273210410; METCALFE DD, 1984, ANN ALLERGY, V53, P563; PARRILLO JE, 1978, BLOOD, V51, P457; PERDUE MH, 1984, GASTROENTEROLOGY, V86, P391; SHINER M, 1975, LANCET, V1, P136; TENGBLAD A, 1986, BIOCHEM J, V236, P521, DOI 10.1042/bj2360521; VENGE P, 1977, BRIT J HAEMATOL, V37, P331, DOI 10.1111/j.1365-2141.1977.tb01003.x; WALKER WA, 1974, GASTROENTEROLOGY, V67, P531	29	21	22	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1993	91	2					553	559		10.1016/0091-6749(93)90261-D	http://dx.doi.org/10.1016/0091-6749(93)90261-D			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KN548	8436771				2022-12-18	WOS:A1993KN54800003
J	EVANS, R				EVANS, R			ENVIRONMENTAL-CONTROL AND IMMUNOTHERAPY FOR ALLERGIC DISEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	SYMP ON MECHANISMS, DIAGNOSIS, AND TREATMENT OF SINUSITIS IN CHILDREN AND ADULTS	JAN 24-25, 1992	SCOTTSDALE, AZ	ALLEN & HANBURYS		ALLERGY; ANIMAL; ASTHMA; ENVIRONMENT; EXTRACTS; HOUSE DUST MITE; IMMUNOTHERAPY; INSECT BITES AND STINGS; RHINITIS	HOUSE DUST MITE; CLADOSPORIUM-HERBARUM PREPARATION; DOUBLE-BLIND; DERMATOPHAGOIDES-PTERONYSSINUS; CONTROLLED TRIAL; INDUCED ASTHMA; HAY-FEVER; CHILDREN; CAT; PREVALENCE	Treatment for allergic disease can help prevent recurrent sinusitis. Removal of carpeting and feather bedding and use of acaricides can significantly improve symptoms caused by house dust mites or animal dander. To kill mites, wash-water temperature must be at least 58-degrees-C. Patients with severe allergy should use an air-filtering vacuum cleaner and an air cleaner with a HEPA filter. Humidity should be kept at under 50%. If other measures fail, pets may have to be removed. Subcutaneous immunotherapy is effective for patients with anaphylactic reactions to insect stings, allergic rhinitis, and allergic asthma. It is ineffective for food allergy or nonallergic rhinitis or asthma. In children, immunotherapy is reserved for generalized life-threatening airway reactions. Relative indications for immunotherapy include inability to avoid the allergen and poor results or significant side effects from pharmacologic treatment. Efficacy depends on dosage, duration of treatment, and allergen selection. Low initial doses are increased at a set rate until the dose induces appropriate antibody response without significant reactions. Patients should be much improved or symptom-free for 1 to 2 years before immunotherapy is discontinued. Pollen, house dust mite, cat, and some mold spore extracts reduce symptoms and sensitivity to nasal or bronchial provocation. When used appropriately, immunotherapy is safe and effective.	NORTHWESTERN UNIV,SCH MED,CHICAGO,IL 60611	Northwestern University	EVANS, R (corresponding author), CHILDRENS MEM HOSP,DIV ALLERGY,2300 CHILDRENS PLAZA,CHICAGO,IL 60614, USA.							ANDERSEN A, 1989, ALLERGY, V44, P396, DOI 10.1111/j.1398-9995.1989.tb04170.x; [Anonymous], 1989, J ALLERGY CLIN IMMUN, V83, P416; BAUMGARTEN C, 1984, RESPIRATION, V46, P97, DOI 10.1159/000194676; BECK AM, 1987, NEW ENGL REG ALLERGY, V8, P185; BOUSQUET J, 1987, INT ARCH ALLER A IMM, V82, P550, DOI 10.1159/000234277; BROWN HM, 1991, ANN ALLERGY, V67, P25; CHAPMAN MD, 1987, J ALLERGY CLIN IMMUN, V80, P184, DOI 10.1016/0091-6749(87)90128-X; CRETICOS PS, 1987, JAMA-J AM MED ASSOC, V258, P2874, DOI 10.1001/jama.258.20.2874; DOWSE GK, 1985, J ALLERGY CLIN IMMUN, V75, P75, DOI 10.1016/0091-6749(85)90016-8; DREBORG S, 1986, ALLERGY, V41, P131, DOI 10.1111/j.1398-9995.1986.tb00289.x; GERGEN PJ, 1987, J ALLERGY CLIN IMMUN, V80, P669, DOI 10.1016/0091-6749(87)90286-7; HAMILTON RG, 1991, 061 J HOPK U ASTHM A; KARLSSON R, 1986, ALLERGY, V41, P141, DOI 10.1111/j.1398-9995.1986.tb00290.x; KING AG, 1973, RESPIR CARE, V18, P160; KNIEST FM, 1991, CLIN EXP ALLERGY, V21, P39, DOI 10.1111/j.1365-2222.1991.tb00802.x; LICHTENSTEIN LM, 1968, J IMMUNOL, V101, P317; LUCZYNSKA CM, 1990, AM REV RESPIR DIS, V141, P361, DOI 10.1164/ajrccm/141.2.361; MILLER JD, 1989, J ALLERGY CLIN IMMUN, V83, P262; NELSON HS, 1988, J ALLERGY CLIN IMMUN, V82, P661, DOI 10.1016/0091-6749(88)90980-3; Noon L, 1911, LANCET, V1, P1572; NORMAN PS, 1990, J ALLERGY CLIN IMMUN, V85, P88, DOI 10.1016/0091-6749(90)90227-U; NORMAN PS, 1978, J ALLERGY CLIN IMMUN, V61, P384, DOI 10.1016/0091-6749(78)90118-5; NORMAN PS, 1982, J ALLERGY CLIN IMMUN, V70, P248, DOI 10.1016/0091-6749(82)90061-6; NORMAN PS, 1990, HOSP PRACT, V15, P81; OFFERMANN JF, 1984, CONTROL RESPIRABLE P; OHASHI Y, 1989, ANN OTO RHINOL LARYN, V98, P350, DOI 10.1177/000348948909800507; OHMAN JL, 1984, J ALLERGY CLIN IMMUN, V74, P230, DOI 10.1016/0091-6749(84)90251-3; OHMAN JL, 1978, J AM VET MED ASSOC, V172, P1403; ORTOLANI C, 1984, J ALLERGY CLIN IMMUN, V73, P283, DOI 10.1016/S0091-6749(84)80021-4; OWEN S, 1990, LANCET, V335, P396, DOI 10.1016/0140-6736(90)90219-U; PENAUD A, 1977, CLIN ALLERGY, V7, P49, DOI 10.1111/j.1365-2222.1977.tb01424.x; PIENKOWSKI MM, 1985, J ALLERGY CLIN IMMUN, V76, P729, DOI 10.1016/0091-6749(85)90679-7; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V80, P755, DOI 10.1016/S0091-6749(87)80261-0; RAK S, 1988, J ALLERGY CLIN IMMUN, V82, P470, DOI 10.1016/0091-6749(88)90021-8; REID MJ, 1986, J ALLERGY CLIN IMMUN, V78, P590, DOI 10.1016/0091-6749(86)90076-X; REISER J, 1990, CLIN EXP ALLERGY, V20, P561, DOI 10.1111/j.1365-2222.1990.tb03150.x; SWANSON MC, 1985, J ALLERGY CLIN IMMUN, V76, P724, DOI 10.1016/0091-6749(85)90678-5; VANMETRE TE, 1988, J ALLERGY CLIN IMMUN, V82, P1055, DOI 10.1016/0091-6749(88)90144-3; WARNER JO, 1978, LANCET, V2, P912	39	21	21	1	7	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1992	90	3	2	S			462	468		10.1016/0091-6749(92)90170-7	http://dx.doi.org/10.1016/0091-6749(92)90170-7			7	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JP521	1527338				2022-12-18	WOS:A1992JP52100011
J	TARHINI, H; KNANI, J; MICHEL, FB; BOUSQUET, J				TARHINI, H; KNANI, J; MICHEL, FB; BOUSQUET, J			SAFETY OF VENOM IMMUNOTHERAPY ADMINISTERED BY A CLUSTER SCHEDULE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note							HYMENOPTERA VENOM		CHU MONTPELLIER,MALAD RESP CLIN,F-34059 MONTPELLIER,FRANCE	Universite de Montpellier; CHU de Montpellier			Bousquet, Jean/O-4221-2019					BIRNBAUM J, 1986, REV FR ALLERGOL, V26, P212, DOI 10.1016/S0335-7457(86)80037-5; BOUSQUET J, 1987, ALLERGY, V42, P401, DOI 10.1111/j.1398-9995.1987.tb00355.x; BOUSQUET J, 1989, J ALLERGY CLIN IMMUN, V84, P944, DOI 10.1016/0091-6749(89)90393-X; LOCKEY RF, 1990, J ALLERGY CLIN IMMUN, V86, P775, DOI 10.1016/S0091-6749(05)80182-4; MUELLER HL, 1959, PEDIATR CLIN N AM, V6, P917; VANDERZWAN JC, 1983, BRIT MED J, V287, P1329, DOI 10.1136/bmj.287.6402.1329	6	21	21	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1992	89	6					1198	1199		10.1016/0091-6749(92)90306-M	http://dx.doi.org/10.1016/0091-6749(92)90306-M			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HZ748	1607554				2022-12-18	WOS:A1992HZ74800017
J	REDDIGARI, SR; KUNA, P; MIRAGLIOTTA, GF; KORNFELD, D; BAEZA, ML; CASTOR, CW; KAPLAN, AP				REDDIGARI, SR; KUNA, P; MIRAGLIOTTA, GF; KORNFELD, D; BAEZA, ML; CASTOR, CW; KAPLAN, AP			CONNECTIVE TISSUE-ACTIVATING PEPTIDE-III AND ITS DERIVATIVE, NEUTROPHIL-ACTIVATING PEPTIDE-2, RELEASE HISTAMINE FROM HUMAN BASOPHILS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CONNECTIVE TISSUE; NEUTROPHIL; ACTIVATING PEPTIDES; FIBROBLAST GROWTH FACTORS; HISTAMINE RELEASE; BASOPHILS; PROTEIN PURIFICATION	PLATELET BASIC-PROTEIN; GROWTH STIMULATORY ACTIVITY; BETA-THROMBOGLOBULIN; MONONUCLEAR-CELLS; CTAP-III; FACTOR-4; CLEAVAGE; HOMOLOGY; SEQUENCE; BINDING	Connective tissue-activating peptide-III (CTAP-III) is a 9 kd platelet alpha-granule-derived growth factor. It stimulates the synthesis of DNA, hyaluronic acid, glycosaminoglycans, and proteoglycan core protein in human fibroblasts. Human mononuclear cell-derived proteases have been previously demonstrated to digest the N-terminal 15 residues of CTAP-III (total, 85 residues) to produce neutrophil-activating peptide-2 (NAP-2). CTAP-III and NAP-2 belong to a class of proteins (platelet factor 4, interleukin-8/NAP-1, etc.) associated with inflammation and wound repair. In our efforts to purify human mononuclear cells and platelet-derived histamine-releasing factors, we had previously discovered that mixtures of CTAP-III and NAP-2 released histamine from human basophils. We have now developed simple protocols for the purification of CTAP-III and NAP-2, independently, from calcium ionophore (A23187)-stimulated platelet supernatants by affinity chromatography and have established their identity by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and N-terminal sequence analysis. Each of these released histamine between 2 and 10-mu-g/ml, a range identical to that obtained with CTAP-III/NAP-2 mixtures that we reported earlier. Thus, our data suggest that CTAP-III and NAP-2 independently release histamine from human basophils in dose ranges similar to ranges required for fibroblast stimulation by each.	SUNY STONY BROOK, HLTH SCI CTR,SCH MED,DEPT MED,DIV ALLERGY, RHEUMATOL & CLIN IMMUNOL, STONY BROOK, NY 11794 USA; UNIV MICHIGAN, DEPT INTERNAL MED, ANN ARBOR, MI 48109 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Michigan System; University of Michigan				Kuna, Piotr/0000-0003-2401-0070				ALAM R, 1989, J IMMUNOL, V142, P3431; ALAM R, 1989, J IMMUNOL, V142, P3951; BAEZA ML, 1989, J CLIN INVEST, V83, P1204, DOI 10.1172/JCI114002; BAEZA ML, 1990, J CLIN INVEST, V85, P1516, DOI 10.1172/JCI114598; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BEAVEN MA, 1972, CLIN CHIM ACTA, V37, P91, DOI 10.1016/0009-8981(72)90419-6; CASTOR CW, 1987, CLIN RES, V35, pA893; CASTOR CW, 1990, J LAB CLIN MED, V116, P516; CASTOR CW, 1989, BIOCHEM BIOPH RES CO, V163, P1071, DOI 10.1016/0006-291X(89)92330-9; CASTOR CW, 1988, METHOD ENZYMOL, V163, P731; CASTOR CW, 1990, ARTHRITIS RHEUM S9, V33, P42; COLLER BS, 1983, J CLIN INVEST, V72, P325, DOI 10.1172/JCI110973; HAAKFRENDSCHO M, 1988, J CLIN INVEST, V82, P17, DOI 10.1172/JCI113567; HAAKFRENDSCHO M, 1988, CLIN IMMUNOL IMMUNOP, V49, P72, DOI 10.1016/0090-1229(88)90096-7; HAAKFRENDSCHO M, 1988, J ALLERGY CLIN IMMUN, V82, P218, DOI 10.1016/0091-6749(88)91002-0; HOLT JC, 1986, BIOCHEMISTRY-US, V25, P1988, DOI 10.1021/bi00356a023; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; KAPLAN AP, 1985, J IMMUNOL, V135, P2027; KNAUER KA, 1981, NEW ENGL J MED, V304, P1404, DOI 10.1056/NEJM198106043042307; KUNA P, 1991, J IMMUNOL, V147, P1920; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUSTER AD, 1985, NATURE, V315, P672, DOI 10.1038/315672a0; MACDONALD SM, 1987, J IMMUNOL, V139, P506; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MORLEY J, 1984, LANCET, V2, P1142; ORCHARD MA, 1986, J IMMUNOL, V136, P2240; RICHMOND A, 1988, J CELL BIOCHEM, V36, P185, DOI 10.1002/jcb.240360209; RICHMOND A, 1988, EMBO J, V7, P2025, DOI 10.1002/j.1460-2075.1988.tb03042.x; SCHULMAN ES, 1985, AM REV RESPIR DIS, V131, P230; SEDGWICK JD, 1981, CLIN EXP IMMUNOL, V45, P409; SUGANO S, 1987, CELL, V49, P321, DOI 10.1016/0092-8674(87)90284-4; THUESON DO, 1979, J IMMUNOL, V123, P633; THUESON DO, 1979, J IMMUNOL, V123, P626; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALZ A, 1989, J EXP MED, V170, P1745, DOI 10.1084/jem.170.5.1745; WALZ A, 1990, J EXP MED, V171, P449, DOI 10.1084/jem.171.2.449; WASSERMAN SI, 1984, J ALLERGY CLIN IMMUN, V74, P275, DOI 10.1016/0091-6749(84)90258-6; WHITE MV, 1987, J IMMUNOL, V139, P1624; YOSHIMURA T, 1987, P NATL ACAD SCI USA, V84, P9233, DOI 10.1073/pnas.84.24.9233	39	21	21	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1992	89	3					666	672		10.1016/0091-6749(92)90372-9	http://dx.doi.org/10.1016/0091-6749(92)90372-9			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HJ340	1372016				2022-12-18	WOS:A1992HJ34000004
J	SUBIZA, J; SUBIZA, JL; ESCRIBANO, PM; HINOJOSA, M; GARCIA, R; JEREZ, M; SUBIZA, E				SUBIZA, J; SUBIZA, JL; ESCRIBANO, PM; HINOJOSA, M; GARCIA, R; JEREZ, M; SUBIZA, E			OCCUPATIONAL ASTHMA CAUSED BY BRAZIL GINSENG DUST	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALLERGY; ASTHMA; GINSENG; OCCUPATIONAL DISEASE	PFAFFIA-PANICULATA; INHALED HISTAMINE; REACTIVITY	The inhalation of different substances of plant origin can cause immediate and late onset asthma. The list of these agents responsible for such reactions is continuously increasing. We discuss a patient who developed symptoms of asthma after exposure to Pfaffia paniculata root powder used in the manufacturing of Brazil ginseng capsules. Airway hyperreactivity was confirmed by a positive bronchial challenge to methacholine. Sensitivity to this dust was confirmed by immediate skin test reactivity, a positive bronchial challenge (immediate response), and the presence of specific IgE detected by ELISA technique to an aqueous extract. The bronchial response was inhibited by sodium cromoglycate. Unexposed subjects did not exhibit reactivity to this ginseng extract with any of the tests referred to above. The same study performed with Korean ginseng (Panax ginseng) elicited negative results. This study is the first, to our knowledge, that links ginseng-root dust to occupational asthma.	HOSP UNIV SAN CARLOS, SERV INMUNOL, MADRID, SPAIN		SUBIZA, J (corresponding author), CTR ALERGIA & INMUNOL CLIN, GEN PARDINAS 116, E-28006 MADRID, SPAIN.							BERSTEIN DI, 1988, ALLERGY PRINCIPLES P, V2, P1197; BUTCHER BT, 1986, J ALLERGY CLIN IMMUN, V78, P547, DOI 10.1016/0091-6749(86)90068-0; CARTIER A, 1989, J ALLERGY CLIN IMMUN, V84, P823, DOI 10.1016/0091-6749(89)90346-1; CHONG SKF, 1988, POSTGRAD MED J, V64, P841, DOI 10.1136/pgmj.64.757.841; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; HEYWOOD VH, 1985, PLANTAS CON FLORES, P213; HINOJOSA M, 1984, J ALLERGY CLIN IMMUN, V74, P782, DOI 10.1016/0091-6749(84)90179-9; HINOJOSA M, 1987, J ALLERGY CLIN IMMUN, V79, P574, DOI 10.1016/S0091-6749(87)80151-3; HOPKINS MP, 1988, AM J OBSTET GYNECOL, V159, P1121, DOI 10.1016/0002-9378(88)90426-7; JUNIPER EF, 1978, THORAX, V33, P705, DOI 10.1136/thx.33.6.705; LEWIS WH, 1983, AIRBORRNE ALLERGENIC, P1; MOIRA CY, 1986, AM REV RESPIR DIS, V133, P686; NISHIMOTO N, 1984, PHYTOCHEMISTRY, V23, P139, DOI 10.1016/0031-9422(84)83094-0; OUCHTERLONY O, 1953, ACTA PATHOL MIC SC, V32, P231; PALMER BV, 1978, BRIT MED J, V1, P1284, DOI 10.1136/bmj.1.6122.1284; REED CE, 1974, J ALLERGY CLIN IMMUN, V53, P34, DOI 10.1016/0091-6749(74)90097-9; SIEGEL RK, 1979, JAMA-J AM MED ASSOC, V241, P1614, DOI 10.1001/jama.241.15.1614; SUBIZA J, 1989, J ALLERGY CLIN IMMUN, V84, P353, DOI 10.1016/0091-6749(89)90420-X; TAKEMOTO T, 1983, TETRAHEDRON LETT, V24, P1057, DOI 10.1016/S0040-4039(00)81603-2; TARLO SM, 1990, J ALLERGY CLIN IMMUN, V85, P626, DOI 10.1016/0091-6749(90)90103-B	20	21	24	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1991	88	5					731	736		10.1016/0091-6749(91)90179-R	http://dx.doi.org/10.1016/0091-6749(91)90179-R			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GQ452	1955631				2022-12-18	WOS:A1991GQ45200007
J	KHAN, RH; SZEWCZUK, MR; DAY, JH				KHAN, RH; SZEWCZUK, MR; DAY, JH			BEE VENOM ANTIIDIOTYPIC ANTIBODY IS ASSOCIATED WITH PROTECTION IN BEEKEEPERS AND BEE STING SENSITIVE PATIENTS RECEIVING IMMUNOTHERAPY AGAINST ALLERGIC REACTIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						HYMENOPTERA; IMMUNOTHERAPY; ANTIIDIOTYPIC ANTIBODY; ALLERGY	MURINE ANTIBODIES; IGE; ANAPHYLAXIS; SERUM; IMMUNOGLOBULIN-G4; REACTIVITY; PROBES; AB2	Bee venom (BV) anti-idiotypic (anti-Id) antibodies (Abs) were studied in nonreactive beekeepers, patients receiving BV immunotherapy (IT), and in patients with bee-sting hypersensitivity. Detection of serum anti-BV was determined either by the Phadebas RAST test for IgE and IgG concentrations or by isoelectric focusing followed by capillary blotting onto nitrocellulose membranes. Clonotypic analyses of Ab were made with specific probes for BV or BV anti-Id; 13/14 nonreactive multiple-sting beekeepers (93%; p = 0.00006) and 3/3 patients receiving BV IT (100%; p = 0.0026) had detectable amounts of BV anti-Id in serum, whereas five BV-sensitive patients (0%) and four ragweed-sensitive control patients (0%) did not. Beekeeper's serum containing BV anti-Id was found to recognize and bind to IgE anti-BV idiotype from two different patient sources and inhibit their reactions in a Phadebas RAST test in a dose-dependent manner. Nonreactive beekeepers generally had BV-specific IgE levels < 0.35 PRU/ml in serum with detectable BV anti-Id. BV-allergic patients before IT had elevated BV-specific serum IgE levels, even in the presence of BV-specific IgG > 136 U/ml with no BV anti-Id present. These findings provide strong support for a protective role of BV anti-Id against bee sting-allergic reactions.	QUEENS UNIV, DEPT MICROBIOL & IMMUNOL, KINGSTON K7L 3N6, ONTARIO, CANADA; QUEENS UNIV, DEPT MED, DIV ALLERGY & IMMUNOL, KINGSTON K7L 3N6, ONTARIO, CANADA	Queens University - Canada; Queens University - Canada								BLASER K, 1980, J IMMUNOL, V125, P24; BLASER K, 1983, ANN NY ACAD SCI, V418, P330, DOI 10.1111/j.1749-6632.1983.tb18083.x; BOSE R, 1986, CLIN EXP IMMUNOL, V66, P231; BOSE R, 1988, IMMUNOLOGY, V63, P579; BOSE R, 1984, J IMMUNOL, V133, P2474; CASTRACANE JM, 1988, INT ARCH ALLER A IMM, V86, P295, DOI 10.1159/000234587; CASTRACANE JM, 1988, INT ARCH ALLER A IMM, V86, P288, DOI 10.1159/000234586; CHEUNG NKV, 1983, ANN ALLERGY, V50, P155; DAVID MF, 1987, CLIN INVEST MED, V10, pB48; DAY JH, 1985, J ALLERGY CLIN IMMUN, V75, P209, DOI 10.1016/0091-6749(85)90553-6; DAY JH, 1982, CAN FAM PHYSICIAN, V28, P716; DAY JH, 1988, DRUG PROTOCOL, V3, P31; FAGAN DL, 1982, J ALLERGY CLIN IMMUN, V70, P399, DOI 10.1016/0091-6749(82)90031-8; FRANKLAND AW, 1954, LANCET, V1, P1055; GOLDEN DBK, 1982, J ALLERGY CLIN IMMUN, V69, P489, DOI 10.1016/0091-6749(82)90172-5; GOLDEN DBK, 1989, J ALLERGY CLIN IMMUN, V84, P162, DOI 10.1016/0091-6749(89)90320-5; GRANT JA, 1981, J ALLERGY CLIN IMMUN, V68, P112, DOI 10.1016/0091-6749(81)90168-8; HOFFMAN DR, 1983, J ALLERGY CLIN IMMUN, V71, P193, DOI 10.1016/0091-6749(83)90099-4; HUNT KL, 1978, ANN INTERN MED, V85, P56; KEMENY DM, 1988, CLIN ALLERGY, V18, P79, DOI 10.1111/j.1365-2222.1988.tb02846.x; KEMENY DM, 1989, INT ARCH ALLER A IMM, V88, P247, DOI 10.1159/000234799; Lessof M H, 1977, Monogr Allergy, V12, P253; LESSOF MH, 1978, JOHNS HOPKINS MED J, V142, P1; LICHTENS.LM, 1968, AM J MED, V44, P514, DOI 10.1016/0002-9343(68)90052-1; LICHTENSTEIN LM, 1979, J ALLERGY CLIN IMMUN, V64, P5, DOI 10.1016/0091-6749(79)90075-7; LOMNITZER R, 1988, CLIN ALLERGY, V18, P39, DOI 10.1111/j.1365-2222.1988.tb02841.x; LOWELL FC, 1965, NEW ENGL J MED, V273, P675, DOI 10.1056/NEJM196509232731302; MOURAD W, 1988, IMMUNOLOGY, V63, P397; MOURAD W, 1988, MOL IMMUNOL, V25, P899, DOI 10.1016/0161-5890(88)90127-7; NAGPAL S, 1989, J IMMUNOL, V142, P3411; REISMAN RE, 1985, J ALLERGY CLIN IMMUN, V75, P731, DOI 10.1016/0091-6749(85)90103-4; SAINTREMY JMR, 1988, EUR J IMMUNOL, V18, P77, DOI 10.1002/eji.1830180112; SAINTREMY JMR, 1986, EUR J IMMUNOL, V16, P575, DOI 10.1002/eji.1830160520; SAINTREMY JMR, 1988, EUR J IMMUNOL, V18, P83, DOI 10.1002/eji.1830180113; SAINTREMY JMR, 1988, EUR J IMMUNOL, V18, P1009, DOI 10.1002/eji.1830180706; SCHIBECI A, 1986, J IMMUNOL METHODS, V89, P201, DOI 10.1016/0022-1759(86)90358-3; STUCKEY M, 1982, LANCET, V2, P41; VALENTINE MD, 1984, J ALLERGY CLIN IMMUN, V73, P299, DOI 10.1016/0091-6749(84)90397-X; YUNGINGER JW, 1979, J ALLERGY CLIN IMMUN, V63, P340, DOI 10.1016/0091-6749(79)90129-5; ZORA JA, 1988, J ALLERGY CLIN IMMUN, V81, P77, DOI 10.1016/0091-6749(88)90223-0	40	21	21	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1991	88	2					199	208		10.1016/0091-6749(91)90329-M	http://dx.doi.org/10.1016/0091-6749(91)90329-M			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GB225	1880320				2022-12-18	WOS:A1991GB22500008
J	WEGNER, CD; TORCELLINI, CA; CLARKE, CC; LETTS, LG; GUNDEL, RH				WEGNER, CD; TORCELLINI, CA; CLARKE, CC; LETTS, LG; GUNDEL, RH			EFFECTS OF SINGLE AND MULTIPLE INHALATIONS OF ANTIGEN ON AIRWAY RESPONSIVENESS IN MONKEYS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							NONSPECIFIC BRONCHIAL REACTIVITY; ALLERGEN-INDUCED INCREASE; LATE ASTHMATIC RESPONSE; BRONCHOALVEOLAR LAVAGE; OCCUPATIONAL ASTHMA; HISTAMINE; HYPERRESPONSIVENESS; HYPERREACTIVITY; METHACHOLINE; EOSINOPHILIA	Airway hyperresponsiveness is an important and characteristic feature of asthma. In monkeys, we have reported that antigen (Ag) inhalation induces a prolonged airway eosinophilia, that chronic airway eosinophilia is associated with marked airway hyperresponsiveness, and that chronic Ag inhalations induce airway eosinophilia and hyperresponsiveness. In this study we have determined the effects of acute Ag inhalation(s) on airway responsiveness to obtain a protocol for the study of the mechanisms involved. Anesthetized and intubated adult male cynomolgus monkeys with a naturally occurring sensitivity to Ascaris suum extract were studied. Airway responsiveness (provocative concentration of nebulized and inhaled methacholine that induced a 100% increase in respiratory system resistance [Rrs] [PC100]; twofold decrease regarded as significant) and airway cell composition (bronchoalveolar lavage [BAL]) were determined 1 day before and 20 hours after a single inhalation of Ascaris extract, or 3 days before and 3 days after three alternate-day inhalations of Ascaris extract. The single inhalation of Ag (N = 7) caused an acute increase in Rrs (307% +/- 62%), an increase in BAL leukocytes, and a decrease in PC100 in three animals that was moderate (more than eightfold) in two animals. The mean +/- SE change in log PC100 was only - 0.25 +/- 0.24. The multiple inhalations of Ag in the same animals caused acute increases in Rrs (178% +/- 48%, 380% +/- 83%, and 331% +/- 63%, respectively), an increase in BAL granulocytes, and a decrease in PC100 in six of seven animals (mean +/- SE change in log PC100 was - 1.36 +/- 0.34) that was moderate in two and severe (more than 80-fold) in three animals. In summary, multiple (but not single) inhalations of Ag induce an increase (usually more than eightfold) in airway responsiveness in most monkeys.			WEGNER, CD (corresponding author), BOEHRINGER INGELHEIM PHARMACEUT INC,DEPT PHARMACOL,90 E RIDGE,POB 368,RIDGEFIELD,CT 06877, USA.							AIZAWA H, 1985, J APPL PHYSIOL, V59, P1918, DOI 10.1152/jappl.1985.59.6.1918; BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P399, DOI 10.1016/0091-6749(83)90069-6; BOUSHEY HA, 1980, AM REV RESPIR DIS, V121, P389; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; CHANYEUNG M, 1982, AM J MED, V72, P411, DOI 10.1016/0002-9343(82)90497-1; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DURHAM SR, 1987, J ALLERGY CLIN IMMUN, V79, P398, DOI 10.1016/0091-6749(87)90161-8; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; GOLDEN JA, 1978, AM REV RESPIR DIS, V118, P287; GUNDEL R H, 1990, Journal of Allergy and Clinical Immunology, V85, P282; GUNDEL RH, 1989, AM REV RESPIR DIS, V140, P629, DOI 10.1164/ajrccm/140.3.629; GUNDEL RH, 1990, J APPL PHYSIOL, V68, P779, DOI 10.1152/jappl.1990.68.2.779; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; JAMES AL, 1989, AM REV RESPIR DIS, V139, P242, DOI 10.1164/ajrccm/139.1.242; JUNIPER EF, 1981, THORAX, V36, P575, DOI 10.1136/thx.36.8.575; JUNIPER EF, 1982, THORAX, V37, P288, DOI 10.1136/thx.37.4.288; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; LAM S, 1979, J ALLERGY CLIN IMMUN, V63, P28, DOI 10.1016/0091-6749(79)90158-1; LAM S, 1983, J ALLERGY CLIN IMMUN, V72, P134, DOI 10.1016/0091-6749(83)90520-1; LANES S, 1986, J APPL PHYSIOL, V61, P864, DOI 10.1152/jappl.1986.61.3.864; LAZARUS SC, 1986, AM J MED, V81, P2, DOI 10.1016/0002-9343(86)90454-7; MARSH WR, 1985, AM REV RESPIR DIS, V131, P875; METZGER WJ, 1986, CHEST, V89, P477, DOI 10.1378/chest.89.4.477; OBYRNE PM, 1986, CHEST, V90, P575, DOI 10.1378/chest.90.4.575; OBYRNE PM, 1984, PROSTAGLANDINS, V4, P537; RYAN G, 1982, THORAX, V37, P423, DOI 10.1136/thx.37.6.423; SCHULMAN ES, 1986, CHEST, V90, P578, DOI 10.1378/chest.90.4.578; SHEPPARD D, 1986, J APPL PHYSIOL, V60, P1213, DOI 10.1152/jappl.1986.60.4.1213; SOTOMAYOR H, 1984, AM REV RESPIR DIS, V130, P56; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62; WEGNER C D, 1987, American Review of Respiratory Disease, V135, pA222; WEGNER C D, 1987, American Review of Respiratory Disease, V135, pA221; WEGNER CD, 1984, RESP PHYSIOL, V55, P47, DOI 10.1016/0034-5687(84)90116-6	34	21	21	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1991	87	4					835	841		10.1016/0091-6749(91)90130-G	http://dx.doi.org/10.1016/0091-6749(91)90130-G			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FG059	2013678				2022-12-18	WOS:A1991FG05900013
J	REISMAN, RE				REISMAN, RE			VENOM IMMUNOTHERAPY - WHEN IS IT REASONABLE TO STOP	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							ALLERGY				REISMAN, RE (corresponding author), BUFFALO MED GRP PC,50 HIGH ST,SUITE 1102,BUFFALO,NY 14203, USA.							BOUSQUET J, 1989, J ALLERGY CLIN IMMUN, V84, P944, DOI 10.1016/0091-6749(89)90393-X; GOLDEN DBK, 1986, J ALLERGY CLIN IMMUN, V77, P435, DOI 10.1016/0091-6749(86)90177-6; GOLDEN DBK, 1988, J ALLERGY CLIN IMMUN, V81, P202; HAUGAARD L, 1991, J ALLERGY CLIN IMMUN, V87, P699, DOI 10.1016/0091-6749(91)90391-Z; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; LANTNER R, 1989, J ALLERGY CLIN IMMUN, V84, P900, DOI 10.1016/0091-6749(89)90387-4; MULLER U, 1991, J ALLERGY CLIN IMMUN, V87, P702, DOI 10.1016/0091-6749(91)90392-2; REISMAN RE, 1989, ALLERGY PROC, V10, P97, DOI 10.2500/108854189778960991; REISMAN RE, 1989, J ALLERGY CLIN IMMUN, V83, P1049, DOI 10.1016/0091-6749(89)90446-6; SCHUBERTH KC, 1983, J PEDIATR-US, V102, P361, DOI 10.1016/S0022-3476(83)80649-0; SCHUBERTH KC, 1988, J ALLERGY CLIN IMMUN, V81, P200, DOI 10.1016/0091-6749(88)90364-8; VALENTINE MD, 1984, J ALLERGY CLIN IMMUN, V73, P299, DOI 10.1016/0091-6749(84)90397-X; WYPYCH JI, 1979, J ALLERGY CLIN IMMUN, V63, P267, DOI 10.1016/0091-6749(79)90111-8	13	21	21	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1991	87	3					618	620		10.1016/0091-6749(91)90378-2	http://dx.doi.org/10.1016/0091-6749(91)90378-2			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FB801	2005312				2022-12-18	WOS:A1991FB80100002
J	ZWICK, H; POPP, W; SERTL, K; RAUSCHER, H; WANKE, T				ZWICK, H; POPP, W; SERTL, K; RAUSCHER, H; WANKE, T			ALLERGENIC STRUCTURES IN COCKROACH HYPERSENSITIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							BRONCHIAL-ASTHMA; ANTIGENS; DIAGNOSIS; IGE	The tissues from which cockroach allergens were derived were identified by use of serum IgE of five patients with allergic rhinitis and bronchial asthma as a result of hypersensitivity to German cockroach. RAST and skin test results demonstrated four of five patients to be positive to cockroach only, and one patient was tested positive to house dust mite as well. Allergen-specific IgE binding to German cockroach was investigated by cryostat sections by means of immunofluorescent test. In all patients with cockroach hypersensitivity, we found IgE bound to the gastrointestinal epithelium and contents of the intestinal tract. In four cases, IgE was also bound to the Malpighian vessels (equivalent in function to kidneys). In three cases, IgE was also bound to the ovarian cells. All cases revealed cytoplasmic staining.	UNIV VIENNA, DEPT MED, A-1010 VIENNA, AUSTRIA	University of Vienna	POPP, W (corresponding author), KRANKENHAUS STADT VIENNA LAINZ, DEPT PULM, LUDWIG BOLTZMANN FORSCHUNGSSTELLE UMWELTPNEUMOL, A-1130 VIENNA, AUSTRIA.							BERNTON HS, 1970, ANN ALLERGY, V28, P420; BERNTON HS, 1964, J ALLERGY, V35, P506, DOI 10.1016/0021-8707(64)90082-6; HELM RM, 1988, INT ARCH ALLER A IMM, V87, P230, DOI 10.1159/000234678; HULETT AC, 1979, ANN ALLERGY, V42, P160; JOHANSSON SG, 1971, INT ARCH ALLER A IMM, V41, P443, DOI 10.1159/000230538; KANG B, 1978, ANN ALLERGY, V41, P333; KANG B, 1976, J ALLERGY CLIN IMMUN, V58, P357, DOI 10.1016/0091-6749(76)90115-9; KANG B, 1979, J ALLERGY CLIN IMMUN, V63, P80, DOI 10.1016/0091-6749(79)90196-9; LAN JL, 1988, J ALLERGY CLIN IMMUN, V82, P736, DOI 10.1016/0091-6749(88)90072-3; MENDOZA J, 1970, ANN ALLERGY, V28, P159; PERLMAN F, 1961, J ALLERGY, V32, P93, DOI 10.1016/0021-8707(61)90061-2; PERLMAN F, 1958, J ALLERGY, V29, P302, DOI 10.1016/0021-8707(58)90037-6; POPP W, 1988, STAIN TECHNOL, V63, P249, DOI 10.3109/10520298809107191; RICHMAN PG, 1984, J ALLERGY CLIN IMMUN, V73, P590, DOI 10.1016/0091-6749(84)90516-5; STANKUS RP, 1988, J ALLERGY CLIN IMMUN, V81, P548, DOI 10.1016/0091-6749(88)90195-9; STEINBERG DR, 1987, J ALLERGY CLIN IMMUN, V80, P586, DOI 10.1016/0091-6749(87)90012-1; SWANSON MC, 1985, J ALLERGY CLIN IMMUN, V76, P724, DOI 10.1016/0091-6749(85)90678-5; TWAROG FJ, 1977, J ALLERGY CLIN IMMUN, V59, P154, DOI 10.1016/0091-6749(77)90218-4; VORLAENDER KO, 1983, IMMUNOLOGIE; WU CH, 1988, J ALLERGY CLIN IMMUN, V82, P727, DOI 10.1016/0091-6749(88)90071-1	20	21	22	1	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1991	87	3					626	630		10.1016/0091-6749(91)90380-7	http://dx.doi.org/10.1016/0091-6749(91)90380-7			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FB801	2005314				2022-12-18	WOS:A1991FB80100004
J	SKONER, DP; GENTILE, D; EVANS, RW				SKONER, DP; GENTILE, D; EVANS, RW			A CIRCULATING INHIBITOR OF THE PLATELET NA+,K+ ADENOSINE-TRIPHOSPHATASE (ATPASE) ENZYME IN ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							AIRWAY SMOOTH-MUSCLE; ASTHMATIC SUBJECTS; BRONCHIAL-ASTHMA; MAST-CELLS; SODIUM; MEMBRANE; BLOOD; BRAIN; HYPERTENSION; STIMULATION	Previous investigations have documented a reduced activity of the sodium-potassium-stimulated adenosine triphosphatase enzyme (Na+, K+ ATPase) in platelet membranes of allergic subjects. The purpose of this study was to determine if the reduced Na+, K+ ATPase activity was due to an enzyme inhibitor. Na+, K+ ATPase activity of a particulate fraction of sonicated platelets was determined by spectrophotometry in asymptomatic adults with and without allergy. The Na+, K+ ATPase level (mean, nanomoles per microgram of protein per minute; +/- STD) of allergic subjects (0.9 +/- 1.3) was lower (p < 0.001) than that of nonallergic subjects (3.9 +/- 1.6). In contrast, when the same platelet fractions were frozen before assay, Na+, K+ ATPase was higher (p < 0.005) in allergic subjects (6.0 +/- 1.4) than in nonallergic subjects (3.6 +/- 2.0). An inhibitor of canine kidney Na+, K+ ATPase was detected in the buffer in which these platelet fractions were frozen, allergic subjects (0.5% +/- 0.4% inhibition per microgram of protein) compared to nonallergic subjects (0.04% +/- 0.08%; p < 0.005). The level of inhibition correlated positively with the postfreezing increase in platelet membrane Na+, K+ ATPase, suggesting a freezing-induced displacement of an inhibitor from the membrane. Plasma from these same subjects inhibited Na+, K+ ATPase activity of normal platelets, allergic subjects (70% +/- 31% inhibition) compared to nonallergic subjects (13% +/- 16%; p < 0.001). These data suggest that the transport-enzyme defect observed in platelets from allergic subjects was due to a circulating Na+, K+ ATPase inhibitor. In vivo Na+, K+ ATPase inhibition in allergy could have profound effects on intracellular cation concentrations and broad implications for pathogenesis.	UNIV PITTSBURGH,SCH MED,DEPT PEDIAT & ANESTHESIOL,PITTSBURGH,PA 15261; UNIV PITTSBURGH,SCH MED,DEPT CRIT CARE MED,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh								ANDERSON WB, 1977, ARCH BIOCHEM BIOPHYS, V180, P374, DOI 10.1016/0003-9861(77)90051-0; BATTAINI F, 1980, BIOCHEM BIOPH RES CO, V94, P240, DOI 10.1016/S0006-291X(80)80212-9; BIANCO S, 1989, NEW ENGL J MED, V321, P1069, DOI 10.1056/NEJM198910193211602; BRENNAN PJ, 1982, BMJ-BRIT MED J, V285, P919, DOI 10.1136/bmj.285.6346.919; BURNEY PGJ, 1986, BRIT MED J, V292, P1483, DOI 10.1136/bmj.292.6534.1483; CARAFOLI E, 1974, J MOL CELL CARDIOL, V6, P361, DOI 10.1016/0022-2828(74)90077-7; COFFEY RG, 1975, INT ARCH ALLER A IMM, V48, P171, DOI 10.1159/000231303; COFFEY RG, 1974, J CLIN INVEST, V54, P138, DOI 10.1172/JCI107735; EICK RE, 1969, J PHARMACOL EXP THER, V169, P95; FLINT KC, 1985, BRIT MED J, V291, P923, DOI 10.1136/bmj.291.6500.923; FUJITA T, 1984, CIRCULATION, V69, P468, DOI 10.1161/01.CIR.69.3.468; FUKUDA T, 1985, AM REV RESPIR DIS, V132, P981; GIN W, 1985, J ALLERGY CLIN IMMUN, V76, P675, DOI 10.1016/0091-6749(85)90670-0; HAMLYN JM, 1982, NATURE, V300, P650, DOI 10.1038/300650a0; HENDERSON WR, 1979, NEW ENGL J MED, V300, P642, DOI 10.1056/NEJM197903223001203; JOHNSON JD, 1979, BIOPHYS J, V25, pA131; JOIST JH, 1977, BLOOD, V49, P101; KALINER M, 1976, J ALLERGY CLIN IMMUN, V58, P308, DOI 10.1016/0091-6749(76)90136-6; KNAUER KA, 1981, NEW ENGL J MED, V304, P1404, DOI 10.1056/NEJM198106043042307; LICHTSTEIN D, 1982, P NATL ACAD SCI-BIOL, V79, P1453, DOI 10.1073/pnas.79.5.1453; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACCIA CA, 1977, J ALLERGY CLIN IMMUN, V59, P101, DOI 10.1016/0091-6749(77)90210-X; MADONINI E, 1987, J ALLERGY CLIN IMMUN, V79, P358, DOI 10.1016/0091-6749(87)90156-4; MAKINO S, 1977, J ALLERGY CLIN IMMUN, V59, P348, DOI 10.1016/0091-6749(77)90016-1; MARTIN TW, 1979, NATURE, V279, P250, DOI 10.1038/279250a0; MIDDLETON E, 1985, J ALLERGY CLIN IMMUN, V76, P341, DOI 10.1016/0091-6749(85)90651-7; PICHARD AL, 1977, J BIOL CHEM, V252, P4872; SCHWARTZMAN ML, 1987, P NATL ACAD SCI USA, V84, P8125, DOI 10.1073/pnas.84.22.8125; Silber J H, 1987, Pediatr Emerg Care, V3, P13, DOI 10.1097/00006565-198703000-00004; SKONER DP, 1990, J LAB CLIN MED, V115, P535; SNEDDON JM, 1972, NATURE-NEW BIOL, V236, P103, DOI 10.1038/newbio236103a0; SOUHRADA M, 1981, J APPL PHYSIOL, V51, P346, DOI 10.1152/jappl.1981.51.2.346; SOUHRADA M, 1984, SCIENCE, V225, P723, DOI 10.1126/science.6087455; TITUS E, 1956, SCIENCE, V124, P1205, DOI 10.1126/science.124.3233.1205; TSAY YG, 1985, INT S RAPID METHODS, pW20; TURAIHI K, 1989, METABOLISM, V38, P773, DOI 10.1016/0026-0495(89)90065-6; YODA A, 1981, ANAL BIOCHEM, V110, P82, DOI 10.1016/0003-2697(81)90115-9	37	21	21	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1991	87	2					476	482		10.1016/0091-6749(91)90005-9	http://dx.doi.org/10.1016/0091-6749(91)90005-9			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EX987	1847156				2022-12-18	WOS:A1991EX98700004
J	VANDERBREMPT, X; HADDI, E; MICHELNGUYEN, A; FAYON, JP; SOLER, M; CHARPIN, D; VERVLOET, D				VANDERBREMPT, X; HADDI, E; MICHELNGUYEN, A; FAYON, JP; SOLER, M; CHARPIN, D; VERVLOET, D			COMPARISON OF THE ACAREX TEST WITH MONOCLONAL-ANTIBODIES FOR THE QUANTIFICATION OF MITE ALLERGENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note									HOP ST MARGUERITE, DEPT MALAD RESP, BP 29, F-13277 MARSEILLE 9, FRANCE; HOP NORD MARSEILLE, DEPT BACTERIOL, MARSEILLE, FRANCE; HOP ST MARGUERITE, DEPT IMMUNOL, F-13277 MARSEILLE 9, FRANCE	UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille			VAN DER BREMPT, Xavier/GLT-1646-2022					BISCHOFF E, 1985, ALLERGOLOGIE, V8, P97; LEMAO J, 1989, J ALLERGY CLIN IMMUN, V83, P926, DOI 10.1016/0091-6749(89)90107-3; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; PLATTSMILLS TAE, 1989, J ALLERGY CLIN IMMUN, V83, P416, DOI 10.1016/0091-6749(89)90128-0; VANBRONSWIJK JEMH, 1986, J MED ENTOMOL, V23, P217, DOI 10.1093/jmedent/23.2.217	5	21	23	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1991	87	1	1				130	132		10.1016/0091-6749(91)90225-D	http://dx.doi.org/10.1016/0091-6749(91)90225-D			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EX985	1991917				2022-12-18	WOS:A1991EX98500020
J	ATKINS, PC; VONALLMEN, C; VALENZANO, M; OLSON, R; SHALIT, M; ZWEIMAN, B				ATKINS, PC; VONALLMEN, C; VALENZANO, M; OLSON, R; SHALIT, M; ZWEIMAN, B			DETERMINANTS OF INVIVO HISTAMINE-RELEASE IN CUTANEOUS ALLERGIC REACTIONS IN HUMANS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											ATKINS, PC (corresponding author), UNIV PENN,SCH MED,DEPT MED,ALLERGY & IMMUNOL SECT,510 JOHNSON PAVILION,36TH & HAMILTON WALK,PHILADELPHIA,PA 19104, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI014332] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-14332] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ATKINS PC, 1987, J IMMUNOL, V139, P2744; ATKINS PC, 1989, CLIN RES, V37, P238; BANKS JR, 1986, J ALLERGY CLIN IMMUN, V78, P51, DOI 10.1016/0091-6749(86)90114-4; BEDARD PM, 1983, J ALLERGY CLIN IMMUN, V71, P394, DOI 10.1016/0091-6749(83)90068-4; BRUCE CA, 1974, J ALLERGY CLIN IMMUN, V53, P230, DOI 10.1016/0091-6749(74)90085-2; COHEN RW, 1986, J ALLERGY CLIN IMMUN, V77, P802, DOI 10.1016/0091-6749(86)90377-5; CRETICOS PS, 1984, NEW ENGL J MED, V310, P1676; DUNSKY EH, 1979, J ALLERGY CLIN IMMUN, V63, P426, DOI 10.1016/0091-6749(79)90217-3; FRIEDMAN BF, 1986, CLIN RES, V34, pA675; GADDY JN, 1986, AM REV RESPIR DIS, V134, P969, DOI 10.1164/arrd.1986.134.5.969; KIVITY S, 1988, J ALLERGY CLIN IMMUN, V81, P1155, DOI 10.1016/0091-6749(88)90884-6; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; LICHTENSTEIN LM, 1966, J CLIN INVEST, V45, P1126, DOI 10.1172/JCI105419; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; SCHLEIMER RP, 1984, J ALLERGY CLIN IMMUN, V74, P473, DOI 10.1016/0091-6749(84)90381-6; SHALIT M, 1989, J ALLERGY CLIN IMMUN, V83, P691, DOI 10.1016/0091-6749(89)90084-5; SHALIT M, 1988, J IMMUNOL, V141, P821; SHALIT M, 1988, J ALLERGY CLIN IMMUN, V82, P297; SIEGEL S, 1956, MEASURES CORRELATION, P202; STUCKEY MS, 1985, J ALLERGY CLIN IMMUN, V75, P373, DOI 10.1016/0091-6749(85)90074-0; TALBOT SF, 1985, J CLIN INVEST, V76, P650, DOI 10.1172/JCI112018; TALBOT SF, 1984, J ALLERGY CLIN IMMUN, V74, P819, DOI 10.1016/0091-6749(84)90185-4	22	21	21	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1990	86	3	1				371	379		10.1016/S0091-6749(05)80100-9	http://dx.doi.org/10.1016/S0091-6749(05)80100-9			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EA859	1698846	Bronze			2022-12-18	WOS:A1990EA85900011
J	MALO, JL; FU, CLY; LARCHEVEQUE, J; GHEZZO, H; CARTIER, A				MALO, JL; FU, CLY; LARCHEVEQUE, J; GHEZZO, H; CARTIER, A			DURATION OF THE EFFECT OF ASTEMIZOLE ON HISTAMINE-INHALATION TESTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											MALO, JL (corresponding author), HOP SACRE COEUR, DEPT CHEST MED, 5400 W GOUIN BLVD, MONTREAL H4J 1C5, QUEBEC, CANADA.							[Anonymous], 1987, Am Rev Respir Dis, V136, P1285; BANTZ EW, 1987, J ALLERGY CLIN IMMUN, V80, P99, DOI 10.1016/S0091-6749(87)80198-7; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CHAPMAN PH, 1983, BR J CLIN PHARM, V13, P593; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; DAVIES R, 1987, REV ESP ALLERGO IMMU, V2, P79; DEHAUT P, 1983, THORAX, V38, P516, DOI 10.1136/thx.38.7.516; EISER N, 1984, DEV ANTIASTHMA DRUGS, P121; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; HOLGATE ST, 1985, J ALLERGY CLIN IMMUN, V76, P375, DOI 10.1016/0091-6749(85)90657-8; JUNIPER EF, 1978, THORAX, V33, P705, DOI 10.1136/thx.33.6.705; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; LONG WF, 1985, J ALLERGY CLIN IMMUN, V76, P113, DOI 10.1016/0091-6749(85)90813-9; MAGNUSSEN H, 1989, J ALLERGY CLIN IMMUN, V83, P467, DOI 10.1016/0091-6749(89)90135-8; NOGRADY SG, 1978, THORAX, V33, P479, DOI 10.1136/thx.33.4.479; NORMAN PS, 1985, J ALLERGY CLIN IMMUN, V76, P366, DOI 10.1016/0091-6749(85)90655-4; OLLIER S, 1986, J ALLERGY CLIN IMMUN, V78, P358, DOI 10.1016/S0091-6749(86)80090-2; PARTRIDGE MR, 1979, THORAX, V34, P771, DOI 10.1136/thx.34.6.771; VANDERSCHUEREN R, 1986, JDR J DRUG THERAPY R, V11, P432; VANNUETEN JM, 1980, ANTAGONISM HISTAMINE; 1982, AM REV RESPIR DIS, V85, P762	21	21	21	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1990	85	4					729	736		10.1016/0091-6749(90)90191-6	http://dx.doi.org/10.1016/0091-6749(90)90191-6			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DA437	1969870				2022-12-18	WOS:A1990DA43700008
J	BALLOW, M; PARKE, A				BALLOW, M; PARKE, A			THE USES OF INTRAVENOUS IMMUNE GLOBULIN IN COLLAGEN VASCULAR DISORDERS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SUNY BUFFALO, DEPT PEDIAT, DIV ALLERGY & IMMUNOL, BUFFALO, NY 14260 USA; UNIV CONNECTICUT, CTR HLTH, DEPT MED, DIV RHEUMAT DIS, FARMINGTON, CT 06032 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; University of Connecticut	BALLOW, M (corresponding author), CHILDRENS HOSP, DIV ALLERGY & IMMUNOL, 219 BRYANT ST, BUFFALO, NY 14222 USA.							ABDOU NI, 1976, CLIN IMMUNOL IMMUNOP, V6, P192, DOI 10.1016/0090-1229(76)90110-0; BRANCH DW, 1985, NEW ENGL J MED, V313, P1322, DOI 10.1056/NEJM198511213132104; BRESNIHAN B, 1977, J CLIN INVEST, V59, P106, DOI 10.1172/JCI108607; FEHR J, 1982, NEW ENGL J MED, V306, P1254, DOI 10.1056/NEJM198205273062102; IMPACH P, 1981, LANCET, V2, P1228; KAUFMAN DB, 1979, CLIN IMMUNOL IMMUNOP, V13, P9, DOI 10.1016/0090-1229(79)90015-1; LUBBE WF, 1983, LANCET, V1, P1361; NEWBURGER JW, 1986, NEW ENGL J MED, V315, P341, DOI 10.1056/NEJM198608073150601; NEWMAN B, 1979, CLIN IMMUNOL IMMUNOP, V13, P187, DOI 10.1016/0090-1229(79)90063-1; PAGE R, 1988, J PEDIATR-US, V112, P127, DOI 10.1016/S0022-3476(88)80137-9; PARKE A, 1986, J RHEUMATOL, V13, P1178; POLLACK S, 1982, NEW ENGL J MED, V307, P253; RAVECHE ES, 1979, SEMIN HEMATOL, V16, P344; WHITE WB, 1987, AM J MED, V83, P431, DOI 10.1016/0002-9343(87)90752-2	14	21	23	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1989	84	4	2	S			608	612		10.1016/0091-6749(89)90198-X	http://dx.doi.org/10.1016/0091-6749(89)90198-X			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AZ398	2529304				2022-12-18	WOS:A1989AZ39800007
J	KAUFFMAN, HF; KOETER, GH; VANDERHEIDE, S; DEMONCHY, JGR; KLOPROGGE, E; DEVRIES, K				KAUFFMAN, HF; KOETER, GH; VANDERHEIDE, S; DEMONCHY, JGR; KLOPROGGE, E; DEVRIES, K			CELLULAR AND HUMORAL OBSERVATIONS IN A PATIENT WITH ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS DURING A NONASTHMATIC EXACERBATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									STATE UNIV GRONINGEN HOSP,DEPT PULMONOL,9713 EZ GRONINGEN,NETHERLANDS	University of Groningen	KAUFFMAN, HF (corresponding author), STATE UNIV GRONINGEN HOSP,DEPT ALLERGOL,INTERNAL MED CLIN,OOSTERSINGEL 59,9713 EZ GRONINGEN,NETHERLANDS.							AGOSTI JM, 1987, J ALLERGY CLIN IMMUN, V79, P496, DOI 10.1016/0091-6749(87)90368-X; BEAUMONT F, 1984, ALLERGY, V39, P183, DOI 10.1111/j.1398-9995.1984.tb02623.x; CUSS FM, 1986, LANCET, V2, P189; DEMONCHY JGR, 1986, ASTHMA CLIN PHARM TH, P46; DEUTSCHL H, 1974, CLIN EXP IMMUNOL, V16, P401; DEVRIES K, 1962, INT ARCH ALLER A IMM, V20, P93, DOI 10.1159/000229248; EVANS TJ, 1986, CLIN SCI, V71, P1; FRIGAS E, 1986, J ALLERGY CLIN IMMUN, V77, P527, DOI 10.1016/0091-6749(86)90341-6; FUKUDA T, 1985, AM REV RESPIR DIS, V132, P981; GLANCY JJ, 1981, THORAX, V36, P345, DOI 10.1136/thx.36.5.345; GUTT L, 1986, J ALLERGY CLIN IMMUN, V78, P98, DOI 10.1016/0091-6749(86)90120-X; HENDERSON AH, 1968, THORAX, V23, P501, DOI 10.1136/thx.23.5.501; KAUFFMAN HF, 1983, J ALLERGY CLIN IMMUN, V72, P255, DOI 10.1016/0091-6749(83)90029-5; KAUFFMAN HF, 1984, J ALLERGY CLIN IMMUN, V74, P741, DOI 10.1016/0091-6749(84)90239-2; KAUFFMAN HF, 1987, J ALLERGY CLIN IMMUN, V79, P611, DOI 10.1016/S0091-6749(87)80157-4; KAUFFMAN HF, 1984, J ALLERGY CLIN IMMUN, V74, P833; KLOPROGGE E, 1989, J ALLERGY CLIN IMMUN, V83, P393, DOI 10.1016/0091-6749(89)90124-3; McCarthy DS, 1971, CLIN ALLERGY, V1, P261, DOI DOI 10.1111/J.1365-2222.1971.TB; PATTERSON R, 1982, ANN INTERN MED, V96, P286, DOI 10.7326/0003-4819-96-3-286; PRIN L, 1984, CLIN EXP IMMUNOL, V57, P735; ROSENBERG M, 1977, ANN INTERN MED, V86, P405, DOI 10.7326/0003-4819-86-4-405; SAFIRSTEIN BH, 1973, AM REV RESPIR DIS, V108, P450; SHAW RJ, 1985, NATURE, V316, P150, DOI 10.1038/316150a0; SLAVIN RG, 1988, J ALLERGY CLIN IMMUN, V81, P718, DOI 10.1016/0091-6749(88)91044-5; SPRY CJF, 1985, INT ARCH ALLER A IMM, V77, P252, DOI 10.1159/000233803; VANDERGIESSEN M, 1985, SCAND J IMMUNOL, V22, P41; VANDERHEIDE S, 1984, J ALLERGY CLIN IMMUN, V73, P813, DOI 10.1016/0091-6749(84)90452-4	27	21	21	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1989	83	4					829	838		10.1016/0091-6749(89)90022-5	http://dx.doi.org/10.1016/0091-6749(89)90022-5			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	U3420	2708743				2022-12-18	WOS:A1989U342000019
J	ZIMMERMAN, B; FORSYTH, S; GOLD, M				ZIMMERMAN, B; FORSYTH, S; GOLD, M			HIGHLY ATOPIC CHILDREN - FORMATION OF IGE ANTIBODY TO FOOD PROTEIN, ESPECIALLY PEANUT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HOSP SICK CHILDREN,TORONTO M5G 1X8,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)								BOCK SA, 1982, J ALLERGY CLIN IMMUN, V69, P173, DOI 10.1016/0091-6749(82)90096-3; BOCK SA, 1978, J ALLERGY CLIN IMMUN, V62, P327, DOI 10.1016/0091-6749(78)90132-X; GERRARD JW, 1986, ANN ALLERGY, V55, P351; KEMP AS, 1985, CLIN ALLERGY, V15, P73, DOI 10.1111/j.1365-2222.1985.tb02258.x; MARTIN AJ, 1982, AUST PAEDIATR J, V18, P84; NORDLEE JA, 1981, J ALLERGY CLIN IMMUN, V68, P376, DOI 10.1016/0091-6749(81)90136-6; SAMPSON HA, 1984, J ALLERGY CLIN IMMUN, V74, P26, DOI 10.1016/0091-6749(84)90083-6; SAMPSON HA, 1985, J PEDIATR-US, V107, P669, DOI 10.1016/S0022-3476(85)80390-5; UMEMOTO L, 1976, J ALLERGY CLIN IMMUN, V58, P60, DOI 10.1016/0091-6749(76)90107-X; VANASPEREN PP, 1983, ARCH DIS CHILD, V58, P253, DOI 10.1136/adc.58.4.253; ZEIGER RS, 1986, J ALLERGY CLIN IMMUN, V78, P224, DOI 10.1016/0091-6749(86)90016-3; ZIMMERMAN B, 1988, J ALLERGY CLIN IMMUN, V81, P63, DOI 10.1016/0091-6749(88)90221-7; ZIMMERMAN B, 1988, J ALLERGY CLIN IMMUN, V81, P71, DOI 10.1016/0091-6749(88)90222-9	13	21	21	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1989	83	4					764	770		10.1016/0091-6749(89)90012-2	http://dx.doi.org/10.1016/0091-6749(89)90012-2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	U3420	2708736				2022-12-18	WOS:A1989U342000009
J	ATKINS, PC; VALENZANO, M; GOETZL, EJ; RATNOFF, WD; GRAZIANO, FM; ZWEIMAN, B				ATKINS, PC; VALENZANO, M; GOETZL, EJ; RATNOFF, WD; GRAZIANO, FM; ZWEIMAN, B			IDENTIFICATION OF LEUKOTRIENE-B4 AS THE NEUTROPHIL CHEMOTACTIC FACTOR RELEASED BY ANTIGEN CHALLENGE FROM PASSIVELY SENSITIZED GUINEA-PIG LUNGS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF SAN FRANCISCO,HOWARD HUGUES MED INST LABS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV WISCONSIN,SCH MED,DEPT MED,MADISON,WI 53706	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Wisconsin System; University of Wisconsin Madison	ATKINS, PC (corresponding author), UNIV PENN,SCH MED,DEPT MED ALLERGY IMMUNOL,510 JOHNSON PAVILL,36TH HAMILTON WALK,PHILADELPHIA,PA 19104, USA.				NHLBI NIH HHS [HL-31809] Funding Source: Medline; NIAID NIH HHS [AI-19784, AI14332-10] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031809] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI014332, P01AI019784] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ATKINS PC, 1982, J ALLERGY CLIN IMMUN, V69, P39, DOI 10.1016/0091-6749(82)90085-9; ATKINS PC, 1977, ANN INTERN MED, V86, P415, DOI 10.7326/0003-4819-86-4-415; BAKER AR, 1964, J IMMUNOL, V93, P525; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; GOETZL EJ, 1975, P NATL ACAD SCI USA, V72, P4123, DOI 10.1073/pnas.72.10.4123; GOETZL EJ, 1981, PROSTAGLANDINS, V22, P279, DOI 10.1016/0090-6980(81)90042-3; GOETZL EJ, 1983, J EXP MED, V158, P731, DOI 10.1084/jem.158.3.731; GRAZIANO FM, 1984, J CLIN INVEST, V73, P1215, DOI 10.1172/JCI111307; IIJIMA H, 1987, AM REV RESPIR DIS, V136, P922, DOI 10.1164/ajrccm/136.4.922; KAY AB, 1971, J EXP MED, V133, P602, DOI 10.1084/jem.133.3.602; LEE JY, 1984, BIOCHEM BIOPH RES CO, V123, P944, DOI 10.1016/S0006-291X(84)80225-9; LEE TH, 1986, J IMMUNOL, V136, P2575; LEMANSKE RF, 1987, J ALLERGY CLIN IMMUN, V79, P320; LEVISCHAFFER F, 1987, J IMMUNOL, V139, P3431; MARTIN GL, 1980, J ALLERGY CLIN IMMUN, V66, P204, DOI 10.1016/0091-6749(80)90040-8; MARTIN LN, 1982, J IMMUNOL METHODS, V52, P205, DOI 10.1016/0022-1759(82)90046-1; MARTIN TR, 1987, J CLIN INVEST, V80, P1114, DOI 10.1172/JCI113168; METZGER WJ, 1986, J ALLERGY CLIN IMMUN, V78, P282; ODRISCOLL BRC, 1983, J ALLERGY CLIN IMMUN, V72, P695, DOI 10.1016/0091-6749(83)90632-2; OERTEL HL, 1981, J IMMUNOL, V127, P1398; PETERS SP, 1984, J IMMUNOL, V132, P1972; SALARI H, 1986, J ALLERGY CLIN IMMUN, V77, P720, DOI 10.1016/0091-6749(86)90417-3; SCHENKEL E, 1982, J ALLERGY CLIN IMMUN, V70, P321, DOI 10.1016/0091-6749(82)90020-3; SILBAUGH SA, 1987, AM REV RESPIR DIS, V136, P930, DOI 10.1164/ajrccm/136.4.930; SOTER NA, 1976, NEW ENGL J MED, V294, P687, DOI 10.1056/NEJM197603252941302; UNDEM BJ, 1985, AM REV RESPIR DIS, V131, P260	26	21	21	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1989	83	1					136	143		10.1016/0091-6749(89)90488-0	http://dx.doi.org/10.1016/0091-6749(89)90488-0			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T0419	2536412				2022-12-18	WOS:A1989T041900019
J	SAMPLE, S; LENAHAN, GA; SERWONSKA, MH; RANGI, S; SHERMAN, JW; CHERNOFF, DN; HOLLANDER, H; GOETZL, EJ				SAMPLE, S; LENAHAN, GA; SERWONSKA, MH; RANGI, S; SHERMAN, JW; CHERNOFF, DN; HOLLANDER, H; GOETZL, EJ			ALLERGIC DISEASES AND SINUSITIS IN ACQUIRED IMMUNE-DEFICIENCY SYNDROME (AIDS)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	21	22	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1989	83	1					190	190						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T0419					2022-12-18	WOS:A1989T041900096
J	BOXER, MB; BUSH, RK; HARRIS, KE; PATTERSON, R; PRUZANSKY, JJ; YANG, WH				BOXER, MB; BUSH, RK; HARRIS, KE; PATTERSON, R; PRUZANSKY, JJ; YANG, WH			THE LABORATORY EVALUATION OF IGE ANTIBODY TO METABISULFITES IN PATIENTS SKIN-TEST POSITIVE TO METABISULFITES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,CHICAGO,IL 60611; UNIV WISCONSIN,DEPT MED,MADISON,WI 53706; UNIV OTTAWA,SCH MED,DEPT MED,OTTAWA K1N 6N5,ONTARIO,CANADA	Northwestern University; University of Wisconsin System; University of Wisconsin Madison; University of Ottawa					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 11403] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		GRAMMER LC, 1987, ARTIF ORGANS, V11, P97, DOI 10.1111/j.1525-1594.1987.tb02637.x; GRAMMER LC, 1987, J OCCUP ENVIRON MED, V29, P806; JACOBSEN D W, 1984, Journal of Allergy and Clinical Immunology, V73, P135; MEGGS WJ, 1985, J ALLERGY CLIN IMMUN, V76, P840, DOI 10.1016/0091-6749(85)90758-4; PATTERSON R, 1987, INT ARCH ALLER A IMM, V84, P93, DOI 10.1159/000234404; PATTERSON R, 1982, J ALLERGY CLIN IMMUN, V70, P19, DOI 10.1016/0091-6749(82)90196-8; PRENNER BM, 1976, ANN ALLERGY, V37, P180; SEPULVEDA R, 1979, CLIN ALLERGY, V9, P359, DOI 10.1111/j.1365-2222.1979.tb02494.x; SHEPPARD D, 1980, AM REV RESPIR DIS, V122, P873; SIMON RA, 1986, ANN ALLERGY, V56, P281; SIMON RA, 1986, J ALLERGY CLIN IMMUN, V77, P157; VOLLER A, 1976, B WORLD HEALTH ORGAN, V53, P55; YANG WH, 1986, J ALLERGY CLIN IMMUN, V78, P443, DOI 10.1016/0091-6749(86)90031-X; ZEISS CR, 1980, J ALLERGY CLIN IMMUN, V65, P346, DOI 10.1016/0091-6749(80)90211-0	14	21	21	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1988	82	4					622	626		10.1016/0091-6749(88)90974-8	http://dx.doi.org/10.1016/0091-6749(88)90974-8			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	Q6399	3171002	Bronze			2022-12-18	WOS:A1988Q639900014
J	KOENIG, JQ; MARSHALL, SG; VANBELLE, G; MCMANUS, MS; BIERMAN, CW; SHAPIRO, GG; FURUKAWA, CT; PIERSON, WE				KOENIG, JQ; MARSHALL, SG; VANBELLE, G; MCMANUS, MS; BIERMAN, CW; SHAPIRO, GG; FURUKAWA, CT; PIERSON, WE			THERAPEUTIC RANGE CROMOLYN DOSE-RESPONSE INHIBITION AND COMPLETE OBLITERATION OF SO2-INDUCED BRONCHOCONSTRICTION IN ATOPIC ADOLESCENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WASHINGTON,DEPT PEDIAT,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOSTAT,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	KOENIG, JQ (corresponding author), UNIV WASHINGTON,DEPT ENVIRONM HLTH,SC-34,SEATTLE,WA 98195, USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES002366] Funding Source: NIH RePORTER; NIEHS NIH HHS [5 RO1 ES 02366] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADELROTH E, 1986, NEW ENGL J MED, V315, P480, DOI 10.1056/NEJM198608213150803; ADVENIER C, 1983, BRIT J PHARMACOL, V78, P301, DOI 10.1111/j.1476-5381.1983.tb09395.x; ATKINS PC, 1978, J ALLERGY CLIN IMMUN, V62, P149, DOI 10.1016/0091-6749(78)90099-4; BENDOV I, 1983, AM REV RESPIR DIS, V127, P113, DOI 10.1164/arrd.1983.127.1.113; DIAZ P, 1984, J ALLERGY CLIN IMMUN, V74, P41, DOI 10.1016/0091-6749(84)90085-X; DIXON M, 1980, BRIT J PHARMACOL, V70, P11, DOI 10.1111/j.1476-5381.1980.tb10898.x; DUBOIS AB, 1956, J CLIN INVEST, V35, P322, DOI 10.1172/JCI103281; EGGLESTON PA, 1979, J ALLERGY CLIN IMMUN, V64, P642, DOI 10.1016/0091-6749(79)90028-9; FANTA CH, 1981, AM REV RESPIR DIS, V123, P161; FULLER RW, 1984, THORAX, V39, P766, DOI 10.1136/thx.39.10.766; GODDEN D, 1983, THORAX, V38, P226; GOLDMAN M, 1970, J APPL PHYSIOL, V28, P113, DOI 10.1152/jappl.1970.28.1.113; HARRIES MG, 1981, ANN ALLERGY, V46, P156; HARRIES MG, 1981, LANCET, V1, P5; HEGARDT B, 1981, ALLERGY, V36, P115, DOI 10.1111/j.1398-9995.1981.tb04105.x; KITAMURA S, 1984, ARZNEIMITTEL-FORSCH, V34-2, P1002; KOENIG JQ, 1982, J ALLERGY CLIN IMMUN, V69, P339, DOI 10.1016/0091-6749(82)90143-9; KOENIG JQ, 1983, J TOXICOL ENV HEALTH, V11, P129, DOI 10.1080/15287398309530327; KOENIG JQ, 1987, J ALLERGY CLIN IMMUN, V79, P54, DOI 10.1016/S0091-6749(87)80016-7; KOENIG JQ, 1980, ENVIRON RES, V22, P145, DOI 10.1016/0013-9351(80)90126-7; KOENIG JQ, 1981, ENVIRON RES, V25, P340, DOI 10.1016/0013-9351(81)90036-0; LINN WS, 1983, AM REV RESPIR DIS, V127, P278; MYERS DJ, 1986, AM REV RESPIR DIS, V133, P1154; MYERS DJ, 1986, AM REV RESPIR DIS, V133, P1150; NAGY L, 1982, NEW ENGL J MED, V306, P497, DOI 10.1056/NEJM198203043060901; OREHEK J, 1977, AM REV RESPIR DIS, V115, P937; PEPYS J, 1968, LANCET, V2, P134; SHEPPARD D, 1980, AM REV RESPIR DIS, V122, P873; SHEPPARD D, 1981, AM REV RESPIR DIS, V123, P486; SHEPPARD D, 1981, AM REV RESPIR DIS, V124, P257; SNASHALL PD, 1982, THORAX, V37, P118, DOI 10.1136/thx.37.2.118; TAM E, 1983, AM REV RESPIR DIS, V127, P257; TAN WC, 1982, THORAX, V37, P671, DOI 10.1136/thx.37.9.671	33	21	21	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1988	81	5	1				897	901		10.1016/0091-6749(88)90947-5	http://dx.doi.org/10.1016/0091-6749(88)90947-5			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	N7036	3131405				2022-12-18	WOS:A1988N703600019
J	BAKER, JR; MOESSNER, H; GONZALEZ, U; GRABENSTEIN, J; RENARD, R; DENAPOLI, T; SUMMERS, R; SCHUSTER, B				BAKER, JR; MOESSNER, H; GONZALEZ, U; GRABENSTEIN, J; RENARD, R; DENAPOLI, T; SUMMERS, R; SCHUSTER, B			CLINICAL RELEVANCE OF THE SUBSTITUTION OF DIFFERENT BRANDS OF SUSTAINED-RELEASE THEOPHYLLINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									WALTER REED ARMY MED CTR,DEPT ALLERGY IMMUNOL,WASHINGTON,DC 20307; WALTER REED ARMY MED CTR,DEPT PATHOL,WASHINGTON,DC 20307; WALTER REED ARMY INST RES,DIV EXPTL THERAPEUT,WASHINGTON,DC 20307; UNIFORMED SERV UNIV HLTH SCI,DEPT MED,BETHESDA,MD 20814; UNIFORMED SERV UNIV HLTH SCI,DEPT PEDIAT,BETHESDA,MD 20814	United States Department of Defense; United States Army; Walter Reed National Military Medical Center; United States Department of Defense; United States Army; Walter Reed National Military Medical Center; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Uniformed Services University of the Health Sciences - USA; Uniformed Services University of the Health Sciences - USA	BAKER, JR (corresponding author), WALTER REED ARMY MED CTR,DEPT CLIN INVEST,WASHINGTON,DC 20307, USA.							DEDERICH RA, 1981, J ALLERGY CLIN IMMUN, V67, P465, DOI 10.1016/0091-6749(81)90100-7; HENDELES L, 1984, CLIN PHARMACOKINET, V9, P95, DOI 10.2165/00003088-198409020-00001; HENDELES L, 1983, PHARMACOTHERAPY, V3, P2; JACOBS MH, 1976, JAMA-J AM MED ASSOC, V235, P1983, DOI 10.1001/jama.235.18.1983; JENNE JW, 1972, CLIN PHARMACOL THER, V13, P349; LESKO LJ, 1981, IMMUNOL ALLERG PRACT, V3, P15; PECK CC, 1984, PHARMACOKINETIC BASI, P349; PEDERSEN S, 1985, CLIN ALLERGY, V15, P253, DOI 10.1111/j.1365-2222.1985.tb02282.x; ROGERS RJ, 1985, J PEDIATR-US, V106, P496, DOI 10.1016/S0022-3476(85)80690-9; SCOTT PH, 1981, J PEDIATR-US, V99, P476, DOI 10.1016/S0022-3476(81)80354-X; SPECTOR SS, 1986, CHEST, V90, P623, DOI 10.1378/chest.90.4.623-b; TABACHNIK E, 1982, J PEDIATR-US, V100, P489, DOI 10.1016/S0022-3476(82)80467-8; WEINBERG.MM, 1974, J PEDIATR-US, V84, P421; WEINBERGER M, 1981, J PEDIATR-US, V99, P145, DOI 10.1016/S0022-3476(81)80982-1; WEINBERGER M, 1983, NEW ENGL J MED, V308, P760, DOI 10.1056/NEJM198303313081306; WEINBERGER M, 1978, NEW ENGL J MED, V299, P852, DOI 10.1056/NEJM197810192991603; WEINBERGER MM, 1984, PHARMACOTHERAPY, V4, P181; WILLIAMS RL, 1983, J ASTHMA, V20, P27, DOI 10.3109/02770908309070908; 1987, FDA APPROVED DRUG PR, P3	19	21	21	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1988	81	4					664	673		10.1016/0091-6749(88)91036-6	http://dx.doi.org/10.1016/0091-6749(88)91036-6			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	N0650	3356847				2022-12-18	WOS:A1988N065000005
J	CORRADO, OJ; GOMEZ, E; BALDWIN, DL; CLAGUE, JE; DAVIES, RJ				CORRADO, OJ; GOMEZ, E; BALDWIN, DL; CLAGUE, JE; DAVIES, RJ			THE EFFECT OF NEDOCROMIL SODIUM ON NASAL PROVOCATION WITH ALLERGEN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ST BARTHOLOMEWS HOSP,ST BARTHOLOMEWS CTR RES,DEPT RESP MED,LONDON EC1A 7BE,ENGLAND; ST BARTHOLOMEWS HOSP,ST BARTHOLOMEWS CTR RES,DEPT EAR NOSE & THROAT,LONDON EC1A 7BE,ENGLAND	University of London; Queen Mary University London; University of London; Queen Mary University London								ALTOUNYAN REC, 1985, ANN ALLERGY, V55, P256; BORUM P, 1980, J ALLERGY CLIN IMMUN, V66, P25, DOI 10.1016/0091-6749(80)90134-7; BORUM P, 1979, J ALLERGY CLIN IMMUN, V63, P253, DOI 10.1016/0091-6749(79)90109-X; BRITTON MG, 1978, BRIT J CLIN PHARMACO, V6, P51, DOI 10.1111/j.1365-2125.1978.tb01681.x; CONNELL JT, 1979, ANN ALLERGY, V42, P278; CORRADO OJ, IN PRESS BR J CLIN P; EADY RP, 1985, BRIT J PHARMACOL, V85, P323, DOI 10.1111/j.1476-5381.1985.tb08864.x; EADY RP, 1986, EUR J RESPIR DIS, V69, P112; GOMEZ E, 1986, J ALLERGY CLIN IMMUN, V78, P637, DOI 10.1016/0091-6749(86)90082-5; HOLGATE ST, 1985, BRIT MED J, V291, P92, DOI 10.1136/bmj.291.6488.92; HOROWITZ JD, 1980, LANCET, V1, P60; ISHIZAKA T, 1984, PROG ALLERGY, V34, P188; KERN E B, 1977, Rhinology (Utrecht), V15, P115; LAL S, 1984, THORAX, V39, P809, DOI 10.1136/thx.39.11.809; Mygind N., 1979, NASAL ALLERGY; NACLERIO RM, 1983, EUR J RESPIR DIS, V64, P26; PEARCE FL, 1985, INT ARCH ALLER A IMM, V77, P274, DOI 10.1159/000233808; ROBERTS JA, 1985, CLIN ALLERGY, V15, P377, DOI 10.1111/j.1365-2222.1985.tb03006.x; SECHER C, 1983, ALLERGY, V38, P565; SHANAHAN F, 1984, CAN J PHYSIOL PHARM, V62, P734, DOI 10.1139/y84-121; SHAW RJ, 1985, ALLERGY, V50, P1; TAYLOR G, 1971, Clinical Allergy, V1, P189, DOI 10.1111/j.1365-2222.1971.tb03018.x; WONG L, 1981, J ALLERGY CLIN IMMUN, V67, P223, DOI 10.1016/0091-6749(81)90065-8; YOUNGCHAIYUD P, 1986, CLIN ALLERGY, V16, P129, DOI 10.1111/j.1365-2222.1986.tb00756.x; 1981, BR MED J, V283, P808	25	21	22	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1987	80	2					218	222		10.1016/0091-6749(87)90132-1	http://dx.doi.org/10.1016/0091-6749(87)90132-1			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	J6575	3038987				2022-12-18	WOS:A1987J657500014
J	JUNIPER, EF; OCONNOR, J; ROBERTS, RS; EVANS, S; HARGREAVE, FE; DOLOVICH, J				JUNIPER, EF; OCONNOR, J; ROBERTS, RS; EVANS, S; HARGREAVE, FE; DOLOVICH, J			POLYETHYLENE-GLYCOL MODIFIED RAGWEED EXTRACT - COMPARISON OF 2 TREATMENT REGIMENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MCMASTER UNIV,DEPT MED,HAMILTON L8S 4L8,ONTARIO,CANADA; MCMASTER UNIV,DEPT CLIN EPIDEMIOL & BIOSTAT,HAMILTON L8S 4L8,ONTARIO,CANADA; MCMASTER UNIV,DEPT PEDIAT,HAMILTON L8S 4L8,ONTARIO,CANADA	McMaster University; McMaster University; McMaster University	JUNIPER, EF (corresponding author), ST JOSEPHS HOSP,DEPT MED,FIRESTONE REG CHEST & ALLERGY UNIT,50 CHARLTON AVE E,HAMILTON L8N 4A6,ONTARIO,CANADA.							AKERBLOM E, 1983, ARBEITEN P ERHLICH I, V78, P231; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; COCKCROFT DW, 1977, J ALLERGY CLIN IMMUN, V60, P56, DOI 10.1016/0091-6749(77)90083-5; DANTZLER BS, 1980, ANN ALLERGY, V45, P213; FOUCARD T, 1976, CLIN ALLERGY, V6, P429, DOI 10.1111/j.1365-2222.1976.tb01927.x; JUNIPER EF, 1985, J ALLERGY CLIN IMMUN, V75, P578, DOI 10.1016/0091-6749(85)90033-8; LEE WY, 1978, IMMUNOL REV, V41, P200, DOI 10.1111/j.1600-065X.1978.tb01466.x; LICHTENS.LM, 1968, AM J MED, V44, P514, DOI 10.1016/0002-9343(68)90052-1; NORMAN PS, 1972, J ALLERGY CLIN IMMUN, V50, P31, DOI 10.1016/0091-6749(72)90077-2; NORMAN PS, 1980, J ALLERGY CLIN IMMUN, V65, P87, DOI 10.1016/0091-6749(80)90191-8; NORMAN PS, 1984, J ALLERGY CLIN IMMUN, V73, P782, DOI 10.1016/0091-6749(84)90448-2; RICHTER AW, 1983, INT ARCH ALLER A IMM, V70, P124, DOI 10.1159/000233309; RICHTER AW, 1984, INT ARCH ALLER A IMM, V74, P36, DOI 10.1159/000233512; VERVLOET D, 1980, CLIN ALLERGY, V10, P59, DOI 10.1111/j.1365-2222.1980.tb02080.x	14	21	21	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1986	78	5	1				851	856		10.1016/0091-6749(86)90229-0	http://dx.doi.org/10.1016/0091-6749(86)90229-0			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	E9713	3782653	Bronze			2022-12-18	WOS:A1986E971300004
J	MONERETVAUTRIN, DA				MONERETVAUTRIN, DA			FOOD ANTIGENS AND ADDITIVES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											MONERETVAUTRIN, DA (corresponding author), CHU NANCY BRABOIS,SERV MED D IMMUNOALLERGOL,F-54511 VANDOEUVRE NANCY,FRANCE.							ALLEN DH, 1981, N ENGL J MED, V19, P1154; AUGUSTINE GJ, 1980, SCIENCE, V207, P1489, DOI 10.1126/science.6244619; BALDO BA, 1978, CLIN ALLERGY, V8, P109, DOI 10.1111/j.1365-2222.1978.tb00456.x; BARNETT D, 1983, J ALLERGY CLIN IMMUN, V72, P61, DOI 10.1016/0091-6749(83)90053-2; BERRENS L, 1971, INT ARCH ALLER A IMM, V41, P186, DOI 10.1159/000230517; BESSOT JC, 1984, REV FR ALLERGOL, V24, P29, DOI 10.1016/S0335-7457(84)80035-0; BJORKNER B, 1981, CONTACT DERMATITIS, V7, P1, DOI 10.1111/j.1600-0536.1981.tb03949.x; Bleumink E, 1970, World Rev Nutr Diet, V12, P505; BOCK SA, 1982, J ALLERGY CLIN IMMUN, V69, P173, DOI 10.1016/0091-6749(82)90096-3; BOUSQUET J, 1984, ALLERGY, V39, P73, DOI 10.1111/j.1398-9995.1984.tb01936.x; BRUN R, 1979, DERMATOLOGICA, V159, P365, DOI 10.1159/000250641; BUNDGAARD H, 1983, WHO12 REG OFF EUR IN, P222; DANOFF D, 1978, NEW ENGL J MED, V298, P1095; ELSAYED S, 1971, J ALLERGY, V47, P283, DOI 10.1016/S0091-6749(71)80006-4; ELSAYED S, 1983, ALLERGY, V38, P449, DOI 10.1111/j.1398-9995.1983.tb02353.x; FOUSSEREAU J, 1970, ECZEMAS ALLERGIQUES; FREEDMAN BJ, 1977, CLIN ALLERGY, V7, P407, DOI 10.1111/j.1365-2222.1977.tb01471.x; GERBER JG, 1979, J ALLERGY CLIN IMMUN, V63, P289, DOI 10.1016/0091-6749(79)90115-5; GHADIMI H, 1971, BIOCHEM MED METAB B, V5, P447, DOI 10.1016/0006-2944(71)90052-4; GUNN RA, 1980, J FOOD PROTECT, V43, P525, DOI 10.4315/0362-028X-43.7.525; HANNUKSELA M, 1977, CONTACT DERMATITIS, V3, P79, DOI 10.1111/j.1600-0536.1977.tb03603.x; HOFFMAN DR, 1981, ANN ALLERGY, V47, P17; JOHNSTONE DE, 1981, RESPIRATION, V42, P34; JUHLIN L, 1981, BRIT J DERMATOL, V104, P369, DOI 10.1111/j.1365-2133.1981.tb15306.x; KAPSALIS AA, 1978, CLIN EXP IMMUNOL, V33, P150; KENDRICK E, 1980, PEDIATRICS, V3, P470; KING TP, 1976, ADV IMMUNOLOGY, V23, P76; KURISAKI JI, 1981, AGR BIOL CHEM TOKYO, V45, P879, DOI 10.1080/00021369.1981.10864625; LANGELAND T, 1983, ALLERGY, V38, P493, DOI 10.1111/j.1398-9995.1983.tb02358.x; LARSEN JC, 1983, WHO12 REG OFF EUR IN, P162; LAUGHLAN PM, 1981, ARCH DIS CHILD, V56, P165; LINDEMAYR H, 1981, ALLERGY, V36, P471, DOI 10.1111/j.1398-9995.1981.tb01858.x; LOCKEY STEPHEN D., 1959, ANN ALLERGY, V17, P719; MICHAELSSON G, 1973, BRIT J DERMATOL, V88, P525, DOI 10.1111/j.1365-2133.1973.tb08014.x; Moneret-Vautrin D. A., 1983, Clinical reactions to food, P135; MONERETVAUTRIN DA, 1980, ANN NUTR ALIMENT, V34, P1125; MONERETVAUTRIN DA, 1982, ANAESTH INTENS CARE, V10, P156, DOI 10.1177/0310057X8201000214; MONERETVAUTRIN DA, 1978, RISQUE SENSIBILISATI; MONERETVAUTRIN DA, 1983, IMMUNOPATHOLOGIE ALL; MONERETVAUTRIN DA, 1981, ACAD EUROP ALLERGOL, V1, P234; MURRAY JA, 1979, BR J MED, V6204, P1551; NABEL JE, 1977, JAMA, V237, P1594; PAULI G, 1982, REV FR ALLERGOL, V22, P6; PRADALIER A, 1984, REV FR ALLERGOL, V24, P47, DOI 10.1016/S0335-7457(84)80038-6; PRENNER BM, 1976, ANN ALLERGY, V37, P180; ROWLAND IR, 1983, TOXIC HAZARDS FOOD, P183; SACHS MI, 1981, J ALLERGY CLIN IMMUN, V67, P27, DOI 10.1016/0091-6749(81)90041-5; SCHLUMBERGER HD, 1980, PSEUDO ALLERGIC REAC, V1, P125; SCHULZ KH, 1983, WHO12 REG OFF EUR IN, P1; STROBEL S, 1982, TOXICOL LETT, V14, P247, DOI 10.1016/0378-4274(82)90059-5; SWAN G, 1982, ASTHMA, V19, P105; THUNE P, 1975, DERMATOLOGICA, V151, P360, DOI 10.1159/000251361; WAHL JM, 1980, BIOCH PHARM, V29, P195; WUTHRICH B, 1979, RESPIRATION, V37, P224; WUTHRICH B, 1983, PRAXIS, V72, P691	55	21	21	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1986	78	5	2	S			1039	1046		10.1016/0091-6749(86)90301-5	http://dx.doi.org/10.1016/0091-6749(86)90301-5			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	E9719	3537088				2022-12-18	WOS:A1986E971900022
J	JENNE, JW				JENNE, JW			EFFECT OF DISEASE STATES ON THEOPHYLLINE ELIMINATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											JENNE, JW (corresponding author), VET ADM MED CTR, PULM DIS SECT, HINES, IL 60141 USA.							ADERKA D, 1983, RESPIRATION, V44, P77, DOI 10.1159/000194531; AGNIHOTRI SN, 1978, BRIT J CLIN PHARMACO, V5, P275, DOI 10.1111/j.1365-2125.1978.tb01641.x; BAUER LA, 1982, J CLIN PHARMACOL, V22, P65, DOI 10.1002/j.1552-4604.1982.tb05710.x; BAUMAN JH, 1984, ANN ALLERGY, V52, P94; BAUMAN JH, 1985, IMMUNOL ALLERGY PRAC, V7, P259; BUKOWSKYJ M, 1984, AM REV RESPIR DIS, V129, P672, DOI 10.1164/arrd.1984.129.5.672; CHANG KC, 1978, LANCET, V1, P1132; CLOZEL JP, 1981, CHEST, V80, P631, DOI 10.1378/chest.80.5.631; CORNISH HH, 1957, J BIOL CHEM, V228, P315; CUMMING JF, 1976, CLIN PHARMACOL THER, V19, P468; CUMMING JF, 1970, BIOCHEM PHARMACOL, V19, P973, DOI 10.1016/0006-2952(70)90359-X; CUSACK BJ, 1986, AM REV RESPIR DIS, V133, P1110; ELIN RJ, 1975, CLIN PHARMACOL THER, V17, P447; GEORGITIS JW, 1982, ANN ALLERGY, V48, P175; GILLETTE JR, 1971, ANN NY ACAD SCI, V179, P43, DOI 10.1111/j.1749-6632.1971.tb46890.x; GRABOWSKI N, 1985, AM REV RESPIR DIS, V131, P934; GRYGIEL JJ, 1981, CLIN PHARMACOL THER, V30, P491, DOI 10.1038/clpt.1981.193; GRYGIEL JJ, 1980, CLIN PHARMACOL THER, V28, P456, DOI 10.1038/clpt.1980.188; HAWKINS SF, 1971, BIOCHEM PHARMACOL, V20, P2221, DOI 10.1016/0006-2952(71)90221-8; HENDELES L, 1983, PHARMACOTHERAPY, V3, P2; HENDELES L, 1982, AM J HOSP PHARM, V39, P249, DOI 10.1093/ajhp/39.2.249; HEPNER GW, 1978, AM J MED, V65, P271, DOI 10.1016/0002-9343(78)90819-7; ISLES A, 1983, AM REV RESPIR DIS, V127, P417, DOI 10.1164/arrd.1983.127.4.417; JENNE JW, 1977, AM J HOSP PHARM, V34, P408, DOI 10.1093/ajhp/34.4.408; JENNE JW, 1972, CLIN PHARMACOL THER, V13, P349; JONES DP, 1981, BIOCHEM PHARMACOL, V30, P1019, DOI 10.1016/0006-2952(81)90436-6; JUSKO WJ, 1979, J PHARM SCI, V68, P1358, DOI 10.1002/jps.2600681106; KRAEMER MJ, 1982, PEDIATRICS, V69, P476; KRAMER P, 1981, NEW ENGL J MED, V305, P1262, DOI 10.1056/NEJM198111193052106; LANDAY RA, 1978, J ALLERGY CLIN IMMUN, V62, P27, DOI 10.1016/0091-6749(78)90068-4; LARSEN GL, 1980, AM J DIS CHILD, V134, P1143, DOI 10.1001/archpedi.1980.02130240027009; LETARTE L, 1984, AM REV RESPIR DIS, V129, P762, DOI 10.1164/arrd.1984.129.5.762; LOHMANN SM, 1976, J PHARMACOL EXP THER, V196, P213; MANGIONE A, 1978, CHEST, V73, P616, DOI 10.1378/chest.73.5.616; Mannering G J, 1980, Ann N Y Acad Sci, V350, P314; MILLER JL, 1983, IMMUNOL ALLERGY PRAC, V5, P130; MURPHY BR, 1973, J INFECT DIS, V128, P488, DOI 10.1093/infdis/128.4.488; MURPHY JE, 1980, NEW ENGL J MED, V303, P760; OGILVIE RI, 1978, CLIN PHARMACOKINET, V3, P267, DOI 10.2165/00003088-197803040-00002; PIAFSKY KM, 1977, CLIN PHARMACOL THER, V21, P310; PIAFSKY KM, 1977, NEW ENGL J MED, V296, P1495, DOI 10.1056/NEJM197706302962603; POWELL JR, 1978, AM REV RESPIR DIS, V118, P229; RAY CG, 1967, J PEDIATR-US, V71, P27, DOI 10.1016/S0022-3476(67)80226-9; RENTON KW, 1980, CAN MED ASSOC J, V123, P288; RESAR RK, 1979, CHEST, V76, P11, DOI 10.1378/chest.76.1.11; ROTH RA, 1976, DRUG METAB DISPOS, V4, P460; ROWLAND M, 1973, J PHARMACOKINET BIOP, V1, P123, DOI 10.1007/BF01059626; STAIB AH, 1980, INT J CLIN PHARM TH, V18, P500; TANGLIU DDS, 1982, CLIN PHARMACOL THER, V31, P358, DOI 10.1038/clpt.1982.46; THOMSON PD, 1971, AM HEART J, V82, P417, DOI 10.1016/0002-8703(71)90308-5; VALLNER JJ, 1979, AM REV RESPIR DIS, V120, P83; VICUNA N, 1979, BRIT J CLIN PHARMACO, V7, P33, DOI 10.1111/j.1365-2125.1979.tb00893.x; WEINBERGER M, 1977, J PEDIATR-US, V91, P820, DOI 10.1016/S0022-3476(77)81051-2; WESTERFIELD BT, 1981, AM REV RESPIR DIS, V124, P17; WILKINSON GR, 1975, CLIN PHARMACOL THER, V18, P377; WILLIAMS JF, 1979, BIOCHEM PHARMACOL, V28, P2935, DOI 10.1016/0006-2952(79)90589-6; ZWILLICH CW, 1975, ANN INTERN MED, V82, P784, DOI 10.7326/0003-4819-82-6-784; 1980, FDA DRUG B, V10, P4	58	21	22	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1986	78	4	2				727	735		10.1016/0091-6749(86)90053-9	http://dx.doi.org/10.1016/0091-6749(86)90053-9			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	E5684	3534054				2022-12-18	WOS:A1986E568400011
J	SMOLENSKY, MH; SCOTT, PH; KRAMER, WG				SMOLENSKY, MH; SCOTT, PH; KRAMER, WG			CLINICAL-SIGNIFICANCE OF DAY-NIGHT DIFFERENCES IN SERUM THEOPHYLLINE CONCENTRATION WITH SPECIAL REFERENCE TO THEO-DUR	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV TEXAS,HLTH SCI CTR,GRAD SCH BIOMED SCI,HOUSTON,TX 77225; INDIANA UNIV,SCH MED,DEPT PEDIAT,PEDIAT PULMONOL SECT,INDIANAPOLIS,IN 46202; UNIV HOUSTON,COLL PHARM,DEPT PHARMACEUT,HOUSTON,TX 77004	University of Texas System; University of Texas Health Science Center Houston; Indiana University System; Indiana University-Purdue University Indianapolis; University of Houston System; University of Houston	SMOLENSKY, MH (corresponding author), UNIV TEXAS,HLTH SCI CTR,SCH PUBL HLTH,POB 20186,HOUSTON,TX 77225, USA.							COULTHARD KP, 1983, EUR J CLIN PHARMACOL, V25, P667, DOI 10.1007/BF00542356; GIACONA N, 1983, DRUG INTEL CLIN PHAR, V17, P452; HARRIST RB, 1984, ANN REV CHRONOPHARMA, V1, P177; ISLES AT, 1983, SUSTAINED RELEASE TH, P91; JONKMAN JHG, 1984, EUR J CLIN PHARMACOL, V26, P215, DOI 10.1007/BF00630288; KARIM S, 1985, AM PHARM, V25, P132; KELLY HW, 1980, PEDIATRICS, V66, P97; LEEDS NH, 1982, J CLIN PHARMACOL, V22, P196, DOI 10.1002/j.1552-4604.1982.tb02162.x; LESKO LJ, 1980, J PHARM SCI, V69, P357; NEUENKIRCHEN H, 1985, EUR J RESPIR DIS, V66, P196; OSMAN MA, 1983, BIOPHARM DRUG DISPOS, V4, P63, DOI 10.1002/bdd.2510040109; PEDERSEN S, 1981, BRIT J CLIN PHARMACO, V12, P904, DOI 10.1111/j.1365-2125.1981.tb01329.x; PRIMROSE WR, 1983, LANCET, V1, P927; REED RC, 1983, DRUG INTEL CLIN PHAR, V17, P444; REINBERG A, ANN REV CHRONOPHARMA; ROGERS RJ, 1985, J PEDIATR-US, V106, P496, DOI 10.1016/S0022-3476(85)80690-9; SAMAAN SS, 1983, P NE REGIONAL ALLERG, V4, P279; SCHULZ HU, 1984, THERAPIEWOCHE, V34, P536; SCOTT PH, 1981, J PEDIATR-US, V99, P476, DOI 10.1016/S0022-3476(81)80354-X; SEGRESTAA JM, 1984, THERAPIE, V39, P633; SIMONS FER, 1982, AM J DIS CHILD, V136, P790, DOI 10.1001/archpedi.1982.03970450032008; SIPS AP, 1984, EUR J CLIN PHARMACOL, V26, P405, DOI 10.1007/BF00548776; SMOLENSKY MH, 1982, CHRONOPHARMACOLOGY, P225; SMOLENSKY MH, 1986, ANN REV CHRONOPHARMA, V2, P229; STPIERRE M, 1984, ANN REV CHRONOPHARMA, V1, P81; STRAUGHN AB, 1985, SUSTAINED RELEASE TH, P116; THOMPSON PJ, 1983, BRIT J DIS CHEST, V77, P293; THOMPSON PJ, 1981, BRIT J CLIN PHARMACO, V12, P443, DOI 10.1111/j.1365-2125.1981.tb01248.x; THURESSON SO, 1985, SUSTAINED RELEASE TH, P125; WARREN JB, 1985, BRIT J CLIN PHARMACO, V19, P707, DOI 10.1111/j.1365-2125.1985.tb02701.x; WEINBERGER M, 1983, NEW ENGL J MED, V308, P760, DOI 10.1056/NEJM198303313081306	31	21	22	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1986	78	4	2				716	722		10.1016/0091-6749(86)90051-5	http://dx.doi.org/10.1016/0091-6749(86)90051-5			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	E5684	3771961				2022-12-18	WOS:A1986E568400009
J	LEE, TM; GREENBERGER, PA; NAHRWOLD, DL; PATTERSON, R				LEE, TM; GREENBERGER, PA; NAHRWOLD, DL; PATTERSON, R			RECTUS SHEATH HEMATOMA COMPLICATING AN EXACERBATION OF ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV, SCH MED,DEPT MED,ALLERGY IMMUNOL SECT, 303 E CHICAGO AVE, CHICAGO, IL 60611 USA; NORTHWESTERN UNIV, SCH MED, DEPT SURG, CHICAGO, IL 60611 USA	Northwestern University; Northwestern University			Greenberger, Paul/L-2770-2019	Greenberger, Paul/0000-0003-3882-8498	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 11403] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		DELAURENTIS DA, 1966, AM J SURG, V112, P359; Fothergill WE, 1926, BMJ-BRIT MED J, V1926, P941, DOI 10.1136/bmj.1.3413.941; GOCKE JE, 1981, MAYO CLIN PROC, V56, P757; HENZEL JH, 1966, ARCH SURG-CHICAGO, V93, P929; HOBBS FB, 1938, BRIT MED J, V1, P895; MANIER JW, 1972, AM J GASTROENTEROL, V57, P443; Torpin R, 1969, J Med Assoc Ga, V58, P158	7	21	21	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1986	78	2					290	292		10.1016/S0091-6749(86)80078-1	http://dx.doi.org/10.1016/S0091-6749(86)80078-1			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	D7261	2942597				2022-12-18	WOS:A1986D726100008
J	GUTT, L; GREENBERGER, PA; LIOTTA, JL				GUTT, L; GREENBERGER, PA; LIOTTA, JL			SERUM IGA ANTIBODIES TO ASPERGILLUS-FUMIGATUS IN VARIOUS STAGES OF ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,CHICAGO,IL 60611	Northwestern University			Greenberger, Paul/L-2770-2019	Greenberger, Paul/0000-0003-3882-8498	NIAID NIH HHS [AI 11403] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CHANYEUN.M, 1971, CHEST, V59, P33, DOI 10.1378/chest.59.1.33; GEHA RS, 1977, J ALLERGY CLIN IMMUN, V60, P357, DOI 10.1016/0091-6749(77)90066-5; GREENBERGER PA, 1982, J LAB CLIN MED, V99, P288; JOHNSON KJ, 1984, J CLIN INVEST, V74, P358, DOI 10.1172/JCI111431; MARX JJ, 1976, J ALLERGY CLIN IMMUN, V57, P328, DOI 10.1016/0091-6749(76)90089-0; OUCHTERLONY O, 1958, PROG ALLERGY, V5, P1, DOI 10.1159/000273347; PATTERSON R, 1982, ANN INTERN MED, V96, P286, DOI 10.7326/0003-4819-96-3-286; PATTERSON R, 1980, CLIN EXP IMMUNOL, V42, P395; PATTERSON R, 1978, J IMMUNOL, V120, P66; PATTERSON R, 1983, ANN INTERN MED, V99, P18, DOI 10.7326/0003-4819-99-1-18; PATTERSON R, 1973, AM J MED, V54, P16, DOI 10.1016/0002-9343(73)90078-8; Spiegelberg H L, 1974, Adv Immunol, V19, P259, DOI 10.1016/S0065-2776(08)60254-0; VOLLER A, 1976, B WORLD HEALTH ORGAN, V53, P55; WANG JLF, 1978, AM REV RESPIR DIS, V117, P917	14	21	21	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1986	78	1	1				98	101		10.1016/0091-6749(86)90120-X	http://dx.doi.org/10.1016/0091-6749(86)90120-X			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	D2996	3522709				2022-12-18	WOS:A1986D299600015
J	DAVIS, PB; SIMPSON, DM; PAGET, GL; TURI, V				DAVIS, PB; SIMPSON, DM; PAGET, GL; TURI, V			BETA-ADRENERGIC RESPONSES IN DRUG-FREE SUBJECTS WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									VET ADM MED CTR,DIV PULM,MED SERV,CLEVELAND,OH 44106; VET ADM MED CTR,PSYCHIAT SERV,CLEVELAND,OH 44106	US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA)					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028386] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 28386] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AARONS RD, 1980, J CLIN INVEST, V65, P949, DOI 10.1172/JCI109781; AKSELROD S, 1981, SCIENCE, V213, P220, DOI 10.1126/science.6166045; ALSTON WC, 1974, BRIT MED J, V1, P90, DOI 10.1136/bmj.1.5898.90; APOLD J, 1977, J ALLERGY CLIN IMMUN, V59, P343, DOI 10.1016/0091-6749(77)90015-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOKS SM, 1979, J ALLERGY CLIN IMMUN, V63, P401, DOI 10.1016/0091-6749(79)90213-6; BROWN BL, 1971, BIOCHEM J, V121, P561, DOI 10.1042/bj1210561; Colton T., 1974, STAT MED, V1; CONOLLY ME, 1976, J CLIN INVEST, V58, P1307, DOI 10.1172/JCI108586; DAVIS PB, 1983, J CLIN INVEST, V71, P1787, DOI 10.1172/JCI110934; DAVIS PB, 1983, J CHRON DIS, V36, P269, DOI 10.1016/0021-9681(83)90062-0; DAVIS PB, 1985, J LAB CLIN MED, V105, P164; DAVIS PB, 1984, AM REV RESPIR DIS, V129, P911; DUBOIS AB, 1956, J CLIN INVEST, V35, P327, DOI 10.1172/JCI103282; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; FRASER J, 1981, J CLIN INVEST, V67, P1777, DOI 10.1172/JCI110217; GALANT SP, 1980, J CLIN INVEST, V65, P577, DOI 10.1172/JCI109702; GALANT SP, 1981, J LAB CLIN MED, V98, P227; GEDEON A, 1983, MED BIOL ENG COMPUT, V21, P65, DOI 10.1007/BF02446408; GREENACRE JK, 1978, BRIT J CLIN PHARMACO, V5, P199, DOI 10.1111/j.1365-2125.1978.tb01624.x; HAYNES RL, 1976, AM REV RESPIR DIS, V114, P739; HYNDMAN BW, 1974, KYBERNETIK, V15, P227; HYNDMAN BW, 1971, NATURE, V233, P338; IGNARRO LJ, 1974, J EXP MED, V139, P1395, DOI 10.1084/jem.139.6.1395; KALINER M, 1982, ANN INTERN MED, V96, P349, DOI 10.7326/0003-4819-96-3-349; KARIMAN K, 1977, American Review of Respiratory Disease, V115, P61; KATONA PG, 1975, J APPL PHYSIOL, V39, P801, DOI 10.1152/jappl.1975.39.5.801; LEE TP, 1977, J ALLERGY CLIN IMMUN, V59, P408, DOI 10.1016/0091-6749(77)90002-1; LEMANSKE RF, 1980, AM REV RESPIR DIS, V122, P213; MAKINO S, 1970, J ALLERGY, V46, P178, DOI 10.1016/0021-8707(70)90096-1; MAKINO S, 1977, J ALLERGY CLIN IMMUN, V59, P348, DOI 10.1016/0091-6749(77)90016-1; MORRIS HG, 1977, J CYCLIC NUCL PROT, V3, P439; NADEL JA, 1977, AM REV RESPIR DIS, V115, P117; ORANGE RP, 1971, FED PROC, V30, P1725; PARKER CW, 1973, J CLIN INVEST, V52, P48, DOI 10.1172/JCI107173; PAVIA D, 1977, THORAX, V32, P194, DOI 10.1136/thx.32.2.194; PFEIFER MA, 1982, DIABETES, V31, P339, DOI 10.2337/diabetes.31.4.339; Pomeranz B., 1985, CNS NEUROSCI THER, V248, pH151, DOI 10.1152/ajpheart.1985.248.1.H151; PORGES SW, 1982, PERSPECTIVES CARDIOV, P223; SANO Y, 1981, American Review of Respiratory Disease, V123, P55; SAYERS BM, 1973, ERGONOMICS, V16, P85; SETTLES JJ, 1980, P BIOL ENG SOC 20TH, P265; SHELHAMER JH, 1980, J ALLERGY CLIN IMMUN, V66, P52, DOI 10.1016/0091-6749(80)90138-4; SIMPSON DS, 1985, CLIN RES, V33, pA288; SIMPSON DS, 1985, CLIN RES, V33, pA228; SZENTIVANYI A, 1980, J ALLERGY CLIN IMMUN, V65, P5, DOI 10.1016/0091-6749(80)90170-0; TASHKIN DP, 1982, AM REV RESPIR DIS, V125, P185	47	21	21	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1986	77	6					871	879		10.1016/0091-6749(86)90386-6	http://dx.doi.org/10.1016/0091-6749(86)90386-6			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	C8694	3011874				2022-12-18	WOS:A1986C869400013
J	FAIRSHTER, RD; BUSSE, WW				FAIRSHTER, RD; BUSSE, WW			THEOPHYLLINE - HOW MUCH IS ENOUGH	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note									UNIV WISCONSIN,DEPT MED,DIV ALLERGY & CLIN IMMUNOL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison	FAIRSHTER, RD (corresponding author), UNIV CALIF IRVINE,IRVINE MED CTR,DEPT MED,DIV PULM,101 CITY DR S,ORANGE,CA 92668, USA.							ANDERSSON KE, 1980, EUR J RESPIR DIS, V61, P17; BARCLAY J, 1981, BRIT J CLIN PHARMACO, V11, P203, DOI 10.1111/j.1365-2125.1981.tb01125.x; BIERMAN CW, 1977, PEDIATRICS, V60, P845; CHERNIACK R, 1984, NEW PERSPECTIVES LON; CHIPPS BE, 1980, J ALLERGY CLIN IMMUN, V65, P61, DOI 10.1016/0091-6749(80)90178-5; COLEMAN RA, 1976, BRIT J PHARMACOL, V57, P51, DOI 10.1111/j.1476-5381.1976.tb07655.x; CUSHLEY MJ, 1984, AM REV RESPIR DIS, V129, P380; DALY JW, 1981, LIFE SCI, V28, P2083, DOI 10.1016/0024-3205(81)90614-7; DASTA J, 1979, AM J HOSP PHARM, V36, P613, DOI 10.1093/ajhp/36.5.613; DECOTIIS B A, 1980, American Review of Respiratory Disease, V121, P125; EATON ML, 1982, CHEST, V82, P538, DOI 10.1378/chest.82.5.538; FAIRSHTER RD, 1985, AM J MED, V79, P48, DOI 10.1016/0002-9343(85)90088-9; FAIRSHTER RD, 1984, ROY SOC MED INT C S, V78, P247; FAIRSHTER RD, 1983, BR J CLIN PRAC S, V23, P68; HAMBLETON G, 1977, LANCET, V1, P381; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; HENDELES L, 1980, EUR J RESPIR DIS, V61, P103; HENDELES L, 1983, PHARMACOTHERAPY, V3, P2; JACKSON RH, 1964, DIS CHEST, V45, P75, DOI 10.1378/chest.45.1.75; KLEIN JJ, 1983, AM REV RESPIR DIS, V127, P413, DOI 10.1164/arrd.1983.127.4.413; LICHTENSTEIN L, 1978, SCIENCE, V161, P902; MASSELLI R, 1971, J PEDIATR, V76, P777; MATTHYS H, 1980, EUR J RESPIR DIS, V61, P98; MCWILLIAMS BC, 1984, AM REV RESPIR DIS, V130, P193; MITENKO PA, 1973, NEW ENGL J MED, V289, P600, DOI 10.1056/NEJM197309202891202; NIEWOEHNER DE, 1984, CHEST, V86, P161, DOI 10.1378/chest.86.2.161; NISSIM JE, 1980, J ALLERGY CLIN IMMUN, V65, P180; ORANGE RP, 1971, J EXP MED, V134, pS136; PAUWELS R, 1984, SUSTAINED RELEASE TH, P9; PHILLIPS MJ, 1981, BRIT J DIS CHEST, V75, P181, DOI 10.1016/0007-0971(81)90051-6; POLLOCK J, 1977, PEDIATRICS, V60, P840; RACHELEFSKY GS, 1978, ANN ALLERGY, V40, P252; RACINEUX JL, 1981, CLIN RES PROC, V17, P799; SPECTOR SL, 1978, CHEST, V73, P976, DOI 10.1378/chest.73.6.976; SULLIVAN TJ, 1975, J IMMUNOL, V114, P1480; TURNERWARWICK M, 1957, BRIT MED J, V2, P67, DOI 10.1136/bmj.2.5036.67; VOZEH S, 1982, AM REV RESPIR DIS, V125, P181; WEINBERG.MM, 1974, J PEDIATR-US, V84, P421; WEINBERGER M, 1981, MED CLIN N AM, V65, P579, DOI 10.1016/S0025-7125(16)31515-2	39	21	21	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1986	77	4					646	648		10.1016/0091-6749(86)90361-1	http://dx.doi.org/10.1016/0091-6749(86)90361-1			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	A9381	3958394	Bronze			2022-12-18	WOS:A1986A938100020
J	BERNSTEIN, DI; GALLAGHER, JS; ULMER, A; BERNSTEIN, IL				BERNSTEIN, DI; GALLAGHER, JS; ULMER, A; BERNSTEIN, IL			PROSPECTIVE EVALUATION OF CHYMOPAPAIN SENSITIVITY IN PATIENTS UNDERGOING CHEMONUCLEOLYSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											BERNSTEIN, DI (corresponding author), UNIV CINCINNATI,MED CTR,DEPT MED,DIV IMMUNOL,231 BETHESDA AVE,ML 563,CINCINNATI,OH 45267, USA.							BAUR X, 1979, CLIN ALLERGY, V9, P75, DOI 10.1111/j.1365-2222.1979.tb01525.x; BAUR X, 1982, CLIN ALLERGY, V12, P9, DOI 10.1111/j.1365-2222.1982.tb03121.x; BERNSTEIN DI, 1984, J ALLERGY CLIN IMMUN, V74, P258, DOI 10.1016/0091-6749(84)90255-0; BERNSTEIN IL, 1976, J ALLERGY CLIN IMMUN, V57, P141, DOI 10.1016/0091-6749(76)90033-6; BERNSTEIN IL, 1983, JAMA-J AM MED ASSOC, V250, P1167, DOI 10.1001/jama.250.9.1167; FRANZ T, 1971, J ALLERGY, V47, P170, DOI 10.1016/S0091-6749(71)80295-6; GUMBY P, 1983, JAMA, V249, P1115; KAPSALIS AA, 1978, CLIN EXP IMMUNOL, V33, P150; MANSFIELD LE, 1983, J ALLERGY CLIN IMMUN, V71, P371, DOI 10.1016/0091-6749(83)90064-7; NOVEY HS, 1979, J ALLERGY CLIN IMMUN, V63, P98, DOI 10.1016/0091-6749(79)90198-2; SAGONA MA, 1985, J ALLERGY CLIN IMMUN, V75, P659, DOI 10.1016/0091-6749(85)90090-9; WIDE L, 1967, LANCET, V2, P1105; 1983, CHEMONUCLEOLYSIS ANA	13	21	21	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	3					458	465		10.1016/0091-6749(85)90727-4	http://dx.doi.org/10.1016/0091-6749(85)90727-4			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ARC09	3897344				2022-12-18	WOS:A1985ARC0900007
J	BALLOW, M; MENDELSON, L; DONSHIK, P; ROOKLIN, A; RAPACZ, P				BALLOW, M; MENDELSON, L; DONSHIK, P; ROOKLIN, A; RAPACZ, P			POLLEN-SPECIFIC IGG ANTIBODIES IN THE TEARS OF PATIENTS WITH ALLERGIC-LIKE CONJUNCTIVITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CROZER CHESTER MED CTR,CHESTER,PA		BALLOW, M (corresponding author), UNIV CONNECTICUT,CTR HLTH,DEPT PEDIAT,FARMINGTON,CT 06032, USA.				NATIONAL EYE INSTITUTE [R01EY002036] Funding Source: NIH RePORTER; NEI NIH HHS [EY02036] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AALBERSE RC, 1983, J IMMUNOL, V130, P722; BALLOW M, 1980, J ALLERGY CLIN IMMUN, V66, P112, DOI 10.1016/0091-6749(80)90057-3; BALLOW M, 1983, AM J OPHTHALMOL, V95, P161, DOI 10.1016/0002-9394(83)90009-0; BALLOW M, 1982, Journal of Allergy and Clinical Immunology, V69, P114; BLUESTONE R, 1975, BRIT J OPHTHALMOL, V59, P279, DOI 10.1136/bjo.59.5.279; CHANDLER JW, 1974, INVEST OPHTH VISUAL, V13, P151; DONOVAN R, 1970, INT ARCH ALLER A IMM, V37, P154, DOI 10.1159/000230229; EASTY DL, 1980, T OPHTHAL SOC UK, V100, P98; GWYNN CM, 1982, LANCET, V1, P254; GWYNN CM, 1982, CLIN ALLERGY, V12, P459, DOI 10.1111/j.1365-2222.1982.tb01644.x; JOHNSON AR, 1975, IMMUNOLOGY, V28, P1067; LICHTENSTEIN LM, 1968, J IMMUNOL, V101, P317; MATHEWS KP, 1981, J ALLERGY CLIN IMMUN, V68, P46, DOI 10.1016/0091-6749(81)90122-6; NAKAGAWA T, 1981, CLIN ALLERGY, V11, P21, DOI 10.1111/j.1365-2222.1981.tb01561.x; PATTEN JT, 1978, ALLERGY PRINCIPLES P, P1116; PEPYS J, 1979, CLIN ALLERGY, V9, P645, DOI 10.1111/j.1365-2222.1979.tb00491.x; SETTIPANE GA, 1965, J ALLERGY, V3, P37; Sparks K, 1983, Diagn Immunol, V1, P269; STANWORTH D R, 1973, Clinical Allergy, V3, P37, DOI 10.1111/j.1365-2222.1973.tb01307.x; Theodore F.H., 1958, OCULAR ALLERGY; TOORENENBERGEN AW, 1982, INT ARCH ALLER A IMM, V67, P117; VANTOORENENBERGEN AW, 1981, INT ARCH ALLER A IMM, V65, P432, DOI 10.1159/000232784; YAMAMOTO GK, 1979, AM J OPHTHALMOL, V17, P58	23	21	21	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	3					376	380		10.1016/0091-6749(84)90411-1	http://dx.doi.org/10.1016/0091-6749(84)90411-1			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SK155	6699317				2022-12-18	WOS:A1984SK15500012
J	PAWLOWSKI, NA; ABRAHAM, E; HAMILL, A; SCOTT, WA				PAWLOWSKI, NA; ABRAHAM, E; HAMILL, A; SCOTT, WA			THE CYCLOOXYGENASE AND LIPOXYGENASE ACTIVITIES OF PLATELET-DEPLETED HUMAN-MONOCYTES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SQUIBB INST MED RES,PRINCETON,NJ 08540		PAWLOWSKI, NA (corresponding author), ROCKEFELLER UNIV,NEW YORK,NY 10021, USA.				NCI NIH HHS [CA-30198] Funding Source: Medline; NHLBI NIH HHS [HL-27186] Funding Source: Medline; NIAID NIH HHS [AI-07012] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA030198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI007012, R01AI007012] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOCKMAN RS, 1976, PROSTAGLANDINS, V21, P9; BORGEAT P, 1979, P NATL ACAD SCI USA, V76, P2148, DOI 10.1073/pnas.76.5.2148; BOYUM A, 1976, SCAND J IMMUNOL   S5, V5, P9; COHN ZA, 1978, J IMMUNOL, V121, P813; COLVIN RB, 1975, J EXP MED, V142, P1377, DOI 10.1084/jem.142.6.1377; GOLDSTEIN IM, 1978, J EXP MED, V148, P787, DOI 10.1084/jem.148.3.787; GOODWIN JS, 1977, J EXP MED, V146, P1719, DOI 10.1084/jem.146.6.1719; HAMBERG M, 1974, P NATL ACAD SCI USA, V71, P3824, DOI 10.1073/pnas.71.10.3824; HAMBERG M, 1975, P NATL ACAD SCI USA, V72, P2994, DOI 10.1073/pnas.72.8.2994; JORG A, 1982, J EXP MED, V155, P390, DOI 10.1084/jem.155.2.390; KENNEDY MS, 1980, PROSTAGLANDINS, V20, P135; KUEHL FA, 1980, SCIENCE, V210, P978, DOI 10.1126/science.6254151; KURLAND JI, 1978, J EXP MED, V147, P952, DOI 10.1084/jem.147.3.952; LINDGREN JA, 1981, FEBS LETT, V128, P329, DOI 10.1016/0014-5793(81)80110-X; MORLEY J, 1979, Prostaglandins, V17, P730; MUSSON RA, 1979, J IMMUNOL, V122, P2026; PALMER RMJ, 1983, IMMUNOLOGY, V50, P65; PASSWELL JH, 1979, J IMMUNOL, V123, P115; PAWLOWSKI NA, 1983, J EXP MED, V158, P393, DOI 10.1084/jem.158.2.393; PAWLOWSKI NA, 1982, J EXP MED, V155, P1653, DOI 10.1084/jem.155.6.1653; PLOW EF, 1982, P NATL ACAD SCI-BIOL, V79, P3711, DOI 10.1073/pnas.79.12.3711; ROUZER CA, 1982, J BIOL CHEM, V257, P2002; SAMUELSSON B, 1978, ANNU REV BIOCHEM, V47, P997, DOI 10.1146/annurev.bi.47.070178.005025; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SCOTT WA, 1982, J EXP MED, V155, P1148, DOI 10.1084/jem.155.4.1148; SCOTT WA, 1982, J EXP MED, V155, P535, DOI 10.1084/jem.155.2.535; SCOTT WA, 1982, PATHOBIOLOGY ENDOTHE, P349; SCOTT WA, 1982, J EXP MED, V156, P1077	28	21	21	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	3					324	330		10.1016/0091-6749(84)90124-6	http://dx.doi.org/10.1016/0091-6749(84)90124-6			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TQ633	6432875				2022-12-18	WOS:A1984TQ63300004
J	MCLEAN, JA; BACON, JR; MATHEWS, KP; BANAS, J; CAPATI, D; BAYNE, NK				MCLEAN, JA; BACON, JR; MATHEWS, KP; BANAS, J; CAPATI, D; BAYNE, NK			EFFECTS OF ASPIRIN ON NASAL RESPONSES IN ATOPIC SUBJECTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MICHIGAN,SCH MED,MONTGOMERY ALLERGY RES LAB,ANN ARBOR,MI 48104; UNIV MICHIGAN,SCH MED,DEPT INTERNAL MED,ANN ARBOR,MI 48104	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NIAID NIH HHS [AI 10391] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANGGARD E, 1969, ANNALS OTOLOGY RHINO, V78, P657; BOWEN BK, 1977, BMJ-BRIT MED J, V2, P1052, DOI 10.1136/bmj.2.6094.1052; DRAZEN JM, 1980, P NATL ACAD SCI-BIOL, V77, P4354, DOI 10.1073/pnas.77.7.4354; ENGINEER DM, 1978, BRIT J PHARMACOL, V64, P211, DOI 10.1111/j.1476-5381.1978.tb17291.x; ENGINEER DM, 1978, BRIT J PHARMACOL, V62, P61, DOI 10.1111/j.1476-5381.1978.tb07006.x; FISH JE, 1981, AM REV RESPIR DIS, V123, P609; FLOWER RJ, 1976, BRIT J PHARMACOL, V56, P229, DOI 10.1111/j.1476-5381.1976.tb07446.x; FLOWER RJ, 1974, PHARMACOL RES COMMUN, V26, P33; JACKSON RT, 1970, CURR THER RES CLIN E, V12, P711; LEONARDS JR, 1972, ARCH INTERN MED, V129, P457, DOI 10.1001/archinte.129.3.457; MARONE G, 1979, J IMMUNOL, V123, P1669; MATHEWS KP, 1981, INT ARCH ALLER A IMM, V66, P218, DOI 10.1159/000232821; MCLEAN JA, 1976, J ALLERGY CLIN IMMUN, V57, P153, DOI 10.1016/0091-6749(76)90034-8; MCLEAN JA, 1979, ANN OTO RHINOL LARYN, V88, P228, DOI 10.1177/000348947908800214; MCLEAN JA, 1977, J ALLERGY CLIN IMMUN, V59, P165, DOI 10.1016/0091-6749(77)90220-2; MONCADA S, 1976, PROSTAGLANDINS, V12, P715, DOI 10.1016/0090-6980(76)90048-4; OKAZAKI T, 1977, J ALLERGY CLIN IMMUN, V60, P360, DOI 10.1016/0091-6749(77)90067-7; PETERS SP, 1982, J IMMUNOL, V129, P797; RAINSFORD KD, 1975, AGENTS ACTIONS, V5, P326, DOI 10.1007/BF02205240; ROBERTS LJ, 1980, NEW ENGL J MED, V303, P1400, DOI 10.1056/NEJM198012113032405; SHOLKOFF SD, 1967, ARTHRITIS RHEUM, V10, P348, DOI 10.1002/art.1780100405; SIEGEL MI, 1979, P NATL ACAD SCI USA, V76, P3774, DOI 10.1073/pnas.76.8.3774; SILVOSO GR, 1979, ANN INTERN MED, V91, P517, DOI 10.7326/0003-4819-91-4-517; SOBOTKA AK, 1979, J ALLERGY CLIN IMMUN, V63, P191; TOLMAN EL, 1975, PROSTAGLANDINS, V9, P349, DOI 10.1016/0090-6980(75)90139-2; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; WOJNAR RJ, 1980, J ALLERGY CLIN IMMUN, V66, P37, DOI 10.1016/0091-6749(80)90136-0	27	21	21	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	2					187	192		10.1016/0091-6749(83)90528-6	http://dx.doi.org/10.1016/0091-6749(83)90528-6			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RD959	6350409	Bronze			2022-12-18	WOS:A1983RD95900013
J	RICE, MC; LIEBERMAN, P; SIEGLE, RL; MASON, J				RICE, MC; LIEBERMAN, P; SIEGLE, RL; MASON, J			INVITRO HISTAMINE-RELEASE INDUCED BY RADIOCONTRAST MEDIA AND VARIOUS CHEMICAL ANALOGS IN REACTOR AND CONTROL SUBJECTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV TENNESSEE,CTR HLTH SCI,DIV ALLERGY IMMUNOL,MEMPHIS,TN 38163; UNIV TENNESSEE,CTR HLTH SCI,DEPT MED,MEMPHIS,TN 38163; UNIV TENNESSEE,CTR HLTH SCI,DEPT PATHOL,MEMPHIS,TN 38163; UNIV TENNESSEE,CTR HLTH SCI,DEPT RADIOL,MEMPHIS,TN 38163; BAPTIST MEM HOSP,MEMPHIS,TN 38146	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; Baptist Memorial Hospital Memphis								ARROYAVE CM, 1980, INVEST RADIOL, V15, pS21, DOI 10.1097/00004424-198011001-00007; BEAVEN MA, 1972, CLIN CHIM ACTA, V37, P91, DOI 10.1016/0009-8981(72)90419-6; BENTLEY PE, 1968, THESIS U LOUISVILLE; BRASCH RC, 1970, INVEST RADIOL, V5, P510, DOI 10.1097/00004424-197011000-00017; FINDLAY SR, 1981, J CLIN INVEST, V67, P1604, DOI 10.1172/JCI110195; FREYRIA AM, 1982, J ALLERGY CLIN IMMUN, V69, P397, DOI 10.1016/0091-6749(82)90152-X; GROPPE G, 1974, AGENTS ACTIONS, V4, P143; LASSER EC, 1974, RADIOLOGY, V110, P49, DOI 10.1148/110.1.49; MILLER WL, 1975, J ALLERGY CLIN IMMUN, V56, P291, DOI 10.1016/0091-6749(75)90103-7; RICE M, 1981, J ALLERGY CLIN IMM S, V67, P71; RING J, 1978, CLIN EXP IMMUNOL, V34, P302; RING J, 1978, CLIN EXP IMMUNOL, V32, P105; ROCKOFF SD, 1971, INVEST RADIOL, V6, P110, DOI 10.1097/00004424-197103000-00004; ROCKOFF SD, 1970, INVEST RADIOL, V5, P503, DOI 10.1097/00004424-197011000-00016; ROCKOFF SD, 1972, INVEST RADIOL, V7, P177; ROCKOFF SD, 1971, INVEST RADIOL, V6, P186; ROCKOFF SD, 1970, INVEST RADIOL, V6, P503; SHAFF RE, 1979, ANAL BIOCHEM, V94, P425, DOI 10.1016/0003-2697(79)90385-3; SIEGLE RL, 1976, INVEST RADIOL, V11, P98, DOI 10.1097/00004424-197603000-00004; SIEGLE RL, 1980, INVEST RADIOL, V15, pS13, DOI 10.1097/00004424-198011001-00005; TENNANT JR, 1964, TRANSPLANTATION, V2, P685, DOI 10.1097/00007890-196411000-00001	21	21	22	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	2					180	186		10.1016/0091-6749(83)90527-4	http://dx.doi.org/10.1016/0091-6749(83)90527-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RD959	6193159	Bronze			2022-12-18	WOS:A1983RD95900012
J	OHMAN, JL; MARSH, DG; GOLDMAN, M				OHMAN, JL; MARSH, DG; GOLDMAN, M			ANTIBODY-RESPONSES FOLLOWING IMMUNOTHERAPY WITH CAT PELT EXTRACT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									TUFTS UNIV,SCH MED,DEPT MED,BOSTON,MA 02111; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21218	Tufts University; Johns Hopkins University	OHMAN, JL (corresponding author), VET ADM OUTPATIENT CLIN,ALLERGY LAB,17 COURT ST,BOSTON,MA 02108, USA.							ANDERSON MC, 1981, J IMMUNOL, V127, P972; BLACK PL, 1976, IMMUNOGENETICS, V3, P349, DOI 10.1007/BF01576967; HOLDFORDSTREVEN.V, 1973, CLIN ALLERGY, V6, P225; MULLIGAN JJ, 1966, J IMMUNOL, V96, P324; OHMAN JL, 1976, CLIN ALLERGY, V6, P419, DOI 10.1111/j.1365-2222.1976.tb01926.x; OHMAN JL, 1976, J ALLERGY CLIN IMMUN, V57, P560, DOI 10.1016/0091-6749(76)90007-5; OHMAN JL, 1973, J ALLERGY CLIN IMMUN, V52, P231, DOI 10.1016/0091-6749(73)90061-4; OHMAN JL, 1974, J IMMUNOL, V113, P1668; OHMAN JL, 1977, J ALLERGY CLIN IMMUN, V60, P317, DOI 10.1016/0091-6749(77)90112-9; PLATTSMILLS TAE, 1978, J IMMUNOL, V120, P1201; TAYLOR WW, 1978, J ALLERGY CLIN IMMUN, V61, P283, DOI 10.1016/0091-6749(78)90048-9	11	21	21	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	69	3					320	326						7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NF697	7061773				2022-12-18	WOS:A1982NF69700010
J	SALVAGGIO, JE				SALVAGGIO, JE			OVERVIEW OF OCCUPATIONAL IMMUNOLOGICAL LUNG-DISEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											SALVAGGIO, JE (corresponding author), TULANE UNIV,SCH MED,CLIN IMMUNOL SECT,NEW ORLEANS,LA 70112, USA.				NIAID NIH HHS [AI-13401] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGARWAL MK, 1981, J ALLERGY CLIN IMMUN, V68, P194, DOI 10.1016/0091-6749(81)90183-4; BUTCHER BT, 1980, J ALLERGY CLIN IMMUN, V66, P213, DOI 10.1016/0091-6749(80)90041-X; BUTCHER BT, 1977, AM REV RESPIR DIS, V116, P411, DOI 10.1164/arrd.1977.116.3.411; CAMPBELL JM, 1932, BRIT MED J, V2, P1143; CHANYEUNG M, 1980, J ALLERGY CLIN IMMUN, V65, P333, DOI 10.1016/0091-6749(80)90209-2; CHANYEUNG M, 1973, AM REV RESPIR DIS, V108, P1094; DAVIES RJ, 1977, J ALLERGY CLIN IMMUN, V60, P223, DOI 10.1016/0091-6749(77)90134-8; DOLL NJ, 1981, J ALLERGY CLIN IMMUN, V68, P281; FIGLEY KD, 1929, JAMA, V90, P79; FINK JN, 1971, ANN INTERN MED, V74, P293, DOI 10.7326/0003-4819-74-2-293; GAUMER HR, 1981, CLIN EXP IMMUNOL, V44, P108; Introna F, 1966, Minerva Medicoleg, V86, P176; KANG KY, 1977, J ALLERGY CLIN IMMUN, V59, P425, DOI 10.1016/0091-6749(77)90005-7; KARASEK SR, 1911, PRELIMINARY REPORT I, P97; KARR RM, 1978, J ALLERGY CLIN IMMUN, V61, P54, DOI 10.1016/0091-6749(78)90474-8; KARR RM, 1980, CLIN IMMUNOLOGY; LOPEZ M, 1976, ANNU REV MED, V27, P453, DOI 10.1146/annurev.me.27.020176.002321; MACCIA CA, 1976, AM REV RESPIR DIS, V113, P701; MARX JJ, 1973, J IMMUNOL, V111, P590; MOORE VL, 1981, J IMMUNOL, V127, P339; MORGAN WKC, 1975, OCCUPATIONAL LUNG DI; NADEL JA, 1965, J APPL PHYSIOL, V20, P164, DOI 10.1152/jappl.1965.20.1.164; ONEIL CE, AM CHEM SOC S COTTON; PEPYS J, 1969, MONOGR ALLERGY, V4; RAMAZZINI B, 1940, MORBUS ARTIFICUM DIA; SALE SR, 1981, J ALLERGY CLIN IMMUN, V68, P188, DOI 10.1016/0091-6749(81)90182-2; SALVAGGIO J, 1979, US DHEW NIH79387 PUB; SCHUYLER M, 1977, AM REV RESPIR DIS, V116, P147; STANKUS RP, 1981, BASIC CLIN ASPECTS G; TURNERWARWICK M, 1973, P ROY SOC MED, V66, P927, DOI 10.1177/003591577306600949; WILSON MR, 1980, CLIN ALLERGY, V10, P303, DOI 10.1111/j.1365-2222.1980.tb02111.x; WILSON MR, 1977, J ALLERGY CLIN IMMUN, V60, P218, DOI 10.1016/0091-6749(77)90133-6; WILSON MR, 1980, OCCUPATIONAL LUNG DI; Zaidi SH., 1969, EXPT PNEUMOCONIOSIS; ZEISS CR, 1977, J ALLERGY CLIN IMMUN, V60, P96, DOI 10.1016/0091-6749(77)90033-1; ZISKIND M, 1976, AM REV RESPIR DIS, V113, P643	36	21	21	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	70	1					5	10		10.1016/0091-6749(82)90193-2	http://dx.doi.org/10.1016/0091-6749(82)90193-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NY715	7045188				2022-12-18	WOS:A1982NY71500004
J	VOSS, MJ; BUSH, RK; MISCHLER, EH; PETERS, ME				VOSS, MJ; BUSH, RK; MISCHLER, EH; PETERS, ME			ASSOCIATION OF ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS AND CYSTIC-FIBROSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Discussion									UNIV WISCONSIN,CTR CLIN SCI,DEPT MED,ALLERGY SECT,MADISON,WI 53792; UNIV WISCONSIN,DEPT PEDIAT,MADISON,WI 53792; UNIV WISCONSIN,DEPT RADIOL,MADISON,WI 53792	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison								Allan J D, 1975, Clin Allergy, V5, P255, DOI 10.1111/j.1365-2222.1975.tb01860.x; BARDANA EJ, 1975, AM J DIS CHILD, V129, P1164, DOI 10.1001/archpedi.1975.02120470020005; BARRON R, 1977, PREVALENCE ATOPY CYS, P23; BATTEN J. C., 1967, MOD PROBL PAEDIATR, V10, P227; BRUETON MJ, 1980, ARCH DIS CHILD, V55, P348, DOI 10.1136/adc.55.5.348; DISANTAGNESE PA, 1955, PEDIATRICS, V15, P683; GALANT SP, 1976, AM REV RESPIR DIS, V114, P325; GIBSON LE, 1959, PEDIATRICS, V23, P545; HINSON KFW, 1952, THORAX, V7, P317, DOI 10.1136/thx.7.4.317; IMBEAU SA, 1977, AM J DIS CHILD, V131, P1127, DOI 10.1001/archpedi.1977.02120230073013; IMBEAU SA, 1978, J ALLERGY CLIN IMMUN, V62, P243, DOI 10.1016/0091-6749(78)90214-2; LEWISTON NJ, 1973, ALLERGIC BRONCHOPULM, P47; McCarthy D S, 1971, Clin Allergy, V1, P415, DOI 10.1111/j.1365-2222.1971.tb00793.x; McCarthy DS, 1971, CLIN ALLERGY, V1, P261, DOI DOI 10.1111/J.1365-2222.1971.TB; MCCARTHY DS, 1969, 5TH P INT CYST FIBR, P194; MEARNS M, 1965, THORAX, V20, P385, DOI 10.1136/thx.20.5.385; MEARNS M, 1967, LANCET, V1, P538; NELSON LA, 1979, AM REV RESPIR DIS, V120, P863; NICHOLS D, 1979, AM J MED, V67, P631, DOI 10.1016/0002-9343(79)90246-8; ORES CN, 1975, ALLERGIC BRONCHOPULM, P20; PATTERSON R, 1977, AM J MED, V63, P257, DOI 10.1016/0002-9343(77)90240-6; RACHELEFSKY GS, 1974, AM J DIS CHILD, V128, P355, DOI 10.1001/archpedi.1974.02110280085010; SAFIRSTEIN BH, 1973, AM REV RESPIR DIS, V108, P450; SCHWARTZ RH, 1981, J ALLERGY CLIN IMMUN, V68, P290, DOI 10.1016/0091-6749(81)90154-8; SCHWARTZ RH, 1970, AM J DIS CHILD, V120, P432, DOI 10.1001/archpedi.1970.02100100096009; SILVERMAN M, 1978, ARCH DIS CHILD, V53, P873, DOI 10.1136/adc.53.11.873; SLAVIN RG, 1978, ALLERGY PRINCIPLES P, P843; TURNER MW, 1978, ARCH DIS CHILD, V53, P631, DOI 10.1136/adc.53.8.631; WARNER JO, 1976, ARCH DIS CHILD, V51, P507, DOI 10.1136/adc.51.7.507; WARREN CPW, 1975, CLIN ALLERGY, V1, P1; WOOD RE, 1975, AM REV RESPIR DIS, V111, P733; WOOD RE, 1976, AM REV RESPIR DIS, V113, P833	32	21	21	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	69	6					536	546		10.1016/0091-6749(82)90181-6	http://dx.doi.org/10.1016/0091-6749(82)90181-6			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NT025	7076997				2022-12-18	WOS:A1982NT02500012
J	AHMED, T; FERNANDEZ, RJ; WANNER, A				AHMED, T; FERNANDEZ, RJ; WANNER, A			AIRWAY RESPONSES TO ANTIGEN CHALLENGE IN ALLERGIC RHINITIS AND ALLERGIC-ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											AHMED, T (corresponding author), MT SINAI MED CTR,DIV PULM DIS,MIAMI BEACH,FL 33140, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL020989] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-20989] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHMED T, 1979, FED PROC, V38, P1110; BARNETT TB, 1967, J APPL PHYSIOL, V22, P707, DOI 10.1152/jappl.1967.22.4.707; BRUCE CA, 1975, J ALLERGY CLIN IMMUN, V56, P331, DOI 10.1016/0091-6749(75)90126-8; BULOW K, 1978, RESPIRATION, V36, P19; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; COMROE JH, 1951, AM J MED, V10, P408, DOI 10.1016/0002-9343(51)90285-9; DESPAS PJ, 1972, J CLIN INVEST, V51, P3235, DOI 10.1172/JCI107150; DOGGETT W E, 1976, American Review of Respiratory Disease, V113, P158; DOSMAN J, 1975, J CLIN INVEST, V55, P1090, DOI 10.1172/JCI108010; DRAZEN JM, 1976, J APPL PHYSIOL, V41, P396, DOI 10.1152/jappl.1976.41.3.396; DUBOIS AB, 1956, J CLIN INVEST, V35, P327, DOI 10.1172/JCI103282; DUBOIS AB, 1956, J CLIN INVEST, V35, P322, DOI 10.1172/JCI103281; FAIRSHTER RD, 1977, J ALLERGY CLIN IMMUN, V59, P243, DOI 10.1016/0091-6749(77)90157-9; FAIRSHTER RD, 1979, J ALLERGY CLIN IMMUN, V63, P39, DOI 10.1016/0091-6749(79)90160-X; FAIRSHTER RD, 1979, RESPIRATION, V37, P301, DOI 10.1159/000194043; FELARCA AB, 1966, J ALLERGY, V37, P223, DOI 10.1016/0021-8707(66)90117-1; FISH JE, 1980, J ALLERGY CLIN IMMUN, V65, P154, DOI 10.1016/0091-6749(80)90201-8; FISH JE, 1976, AM REV RESPIR DIS, V113, P579; GELB AF, 1975, AM REV RESPIR DIS, V112, P401; GROSSMAN J, 1975, J ALLERGY CLIN IMMUN, V55, P49, DOI 10.1016/S0091-6749(75)80007-8; HILLER C, 1978, AM REV RESPIR DIS, V118, P311; HUTCHEON M, 1974, AM REV RESPIR DIS, V110, P458; INGRAM RH, 1977, J CLIN INVEST, V59, P696, DOI 10.1172/JCI108688; ITKIN IH, 1967, J ALLERGY, V40, P245, DOI 10.1016/0021-8707(67)90087-1; LAVELLE TF, 1978, AM REV RESPIR DIS, V117, P845; MCCARTHY D, 1973, AM REV RESPIR DIS, V107, P559, DOI 10.1164/arrd.1973.107.4.559; MENDENHALL W, 1977, STATISTICS PSYCHOL, P246; MORGAN EJ, 1976, THORAX, V31, P80, DOI 10.1136/thx.31.1.80; PERMUTT S, 1977, ASTHMA PHYSL IMMUNOP, P266; TOWNLEY RG, 1965, J ALLERGY, V36, P121, DOI 10.1016/0021-8707(65)90161-9; WAGNER PD, 1978, AM REV RESPIR DIS, V117, P409	31	21	21	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	67	2					135	145		10.1016/0091-6749(81)90009-9	http://dx.doi.org/10.1016/0091-6749(81)90009-9			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LB947	6108972				2022-12-18	WOS:A1981LB94700009
J	MIYAMOTO, T; AKIYAMA, K; OHTA, K; URATA, C; HORIUCHI, Y				MIYAMOTO, T; AKIYAMA, K; OHTA, K; URATA, C; HORIUCHI, Y			STUDIES IN ATOPIC ASTHMA WITH EMPHASIS ON CORRELATION AMONG VARIOUS TESTS AND VARIOUS ANTIBODIES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											MIYAMOTO, T (corresponding author), UNIV TOKYO,SCH MED,DEPT MED & PHYS THERAPY,BUNKYO KU,TOKYO 113,JAPAN.							AKIYAMA K, IN PRESS; BROWN WG, 1979, J ALLERGY CLIN IMMUN, V63, P328; BRYANT D H, 1975, Clinical Allergy, V5, P145, DOI 10.1111/j.1365-2222.1975.tb01847.x; BUSINCO L, 1979, CLIN ALLERGY, V9, P459, DOI 10.1111/j.1365-2222.1979.tb02509.x; FOUCARD T, 1976, CLIN ALLERGY, V6, P429, DOI 10.1111/j.1365-2222.1976.tb01927.x; KLINMAN NR, 1969, CLIN EXP IMMUNOL, V4, P473; MAUNSELL K, 1968, LANCET, V1, P1267; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; MCALLEN MK, 1970, BRIT MED J, V2, P501, DOI 10.1136/bmj.2.5708.501; MIYAMOTO T, 1968, J ALLERGY, V42, P14, DOI 10.1016/0021-8707(68)90128-7; MIYAMOTO T, 1970, ANN ALLERGY, V28, P405; MIYAMOTO T, 1968, JAP J ALLERGY, V17, P91; MIYAMOTO T, 1960, JAPANESE J ALLERGY, V9, P968; MURANAKA M, 1974, J ALLERGY CLIN IMMUN, V54, P32, DOI 10.1016/S0091-6749(74)80006-0; NATHAN RA, 1979, J ALLERGY CLIN IMMUN, V64, P491, DOI 10.1016/0091-6749(79)90058-7; OSHIMA Y, 1964, AM REV RESPIR DIS, V90, P632; PAULI G, 1977, CLIN ALLERGY, V7, P337, DOI 10.1111/j.1365-2222.1977.tb01461.x; SPECTOR SL, 1974, MED CLIN N AM, V58, P71, DOI 10.1016/S0025-7125(16)32178-2; STENIUS B, 1969, LANCET, V2, P455; TOWNLEY RG, 1975, J ALLERGY CLIN IMMUN, V56, P429; VOORHORS.R, 1967, J ALLERGY, V39, P325, DOI 10.1016/0021-8707(67)90045-7	21	21	21	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	67	4					279	284		10.1016/0091-6749(81)90022-1	http://dx.doi.org/10.1016/0091-6749(81)90022-1			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LL697	6162873				2022-12-18	WOS:A1981LL69700005
J	VANDELLEN, RG				VANDELLEN, RG			SKIN TESTING FOR PENICILLIN ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material											VANDELLEN, RG (corresponding author), MAYO CLIN & MAYO FDN,DIV ALLERG DIS,200 1ST ST SW,ROCHESTER,MN 55901, USA.							ADKINSON NF, 1971, NEW ENGL J MED, V285, P22, DOI 10.1056/NEJM197107012850104; BOGER WP, 1953, J ALLERGY, V24, P383, DOI 10.1016/0021-8707(53)90038-0; COLEMAN W P, 1956, Va Med Mon (1918), V83, P6; DOGLIOTTI M, 1968, DERMATOLOGICA, V136, P489, DOI 10.1159/000254145; GREEN GR, 1977, J ALLERGY CLIN IMMUN, V60, P339, DOI 10.1016/0091-6749(77)90064-1; IDSOE O, 1968, B WORLD HEALTH ORGAN, V38, P159; LEVINE BB, 1969, J ALLERGY, V43, P231, DOI 10.1016/0021-8707(69)90066-5; SOLLEY GO, 1979, J ALLERGY CLIN IMMUN, V63, P184; VANDELLEN RG, 1970, MED CLIN N AM, V54, P997, DOI 10.1016/S0025-7125(16)32617-7	9	21	21	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	68	3					169	170		10.1016/0091-6749(81)90179-2	http://dx.doi.org/10.1016/0091-6749(81)90179-2			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MG544	6267114				2022-12-18	WOS:A1981MG54400001
J	CHIPPS, BE; SOBOTKA, AK; SANDERS, JP; TEETS, KC; NORMAN, PS; LICHTENSTEIN, LM				CHIPPS, BE; SOBOTKA, AK; SANDERS, JP; TEETS, KC; NORMAN, PS; LICHTENSTEIN, LM			EFFECT OF THEOPHYLLINE AND TERBUTALINE ON IMMEDIATE SKIN-TESTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV,GOOD SAMARITAN HOSP,SCH MED,DEPT MED,BALTIMORE,MD 21239; JOHNS HOPKINS UNIV,GOOD SAMARITAN HOSP,SCH MED,DEPT PEDIAT,BALTIMORE,MD 21239	Johns Hopkins University; Johns Hopkins University								CHIPPS BE, 1978, ANN ALLERGY, V41, P211; DECHTIARUK W, 1975, CLIN CHEM, V21, P1038; FINE S R, 1977, Annals of Allergy, V38, P440; GALANT SP, 1973, J ALLERGY CLIN IMMUN, V51, P11, DOI 10.1016/0091-6749(73)90003-1; IMBEAU SA, 1978, J ALLERGY CLIN IMMUN, V62, P193, DOI 10.1016/0091-6749(78)90207-5; MOSKO MM, 1950, J ALLERGY, V21, P242, DOI 10.1016/0021-8707(50)90132-8; NORMAN PS, 1976, MANUAL CLIN IMMUNOLO; PATTERSON RM, 1972, ALLERGIC DISEASES DI, P79; PERPER RJ, 1972, INT ARCH ALLER A IMM, V43, P837, DOI 10.1159/000230901; SLY RM, 1977, PEDIATRIC ALLERGY, P295; SPECTOR SL, 1978, CHEST, V73, P976, DOI 10.1378/chest.73.6.976; SPEER F, 1973, ALLERGY IMMUNOLOGY C, P362; TUFT L, 1936, J ALLERGY, V7, P238; WEINBERG.MM, 1974, J PEDIATR-US, V84, P421	14	21	21	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	65	1					61	64		10.1016/0091-6749(80)90178-5	http://dx.doi.org/10.1016/0091-6749(80)90178-5			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JB459	7350205	Bronze			2022-12-18	WOS:A1980JB45900010
J	HASSELBACHER, P; HAHN, J				HASSELBACHER, P; HAHN, J			INVITRO EFFECTS OF RADIOGRAPHIC CONTRAST-MEDIA ON THE COMPLEMENT-SYSTEM	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											HASSELBACHER, P (corresponding author), DARTMOUTH COLL,SCH MED,CONNECT TISSUE DIS SECT,HANOVER,NH 03755, USA.				NIADDK NIH HHS [AM 14780, 7-K08-AM-00587-02] Funding Source: Medline	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARROYAVE CM, 1977, CLIN EXP IMMUNOL, V29, P89; ARROYAVE CM, 1976, J IMMUNOL, V117, P1866; BJERRUM OJ, 1975, SCAND J IMMUNOL S, V2, P89; COGEN FC, 1978, J ALLERGY CLIN IMMUN, V61, P145, DOI 10.1016/0091-6749(78)90294-4; ENDRICH B, 1979, RADIOLOGY, V132, P331, DOI 10.1148/132.2.331; FRITZLER MJ, 1978, J CAN MED ASS, V119, P901; GANROT PO, 1972, SCAND J CLIN LAB INV, V29, P39, DOI 10.3109/00365517209102749; HASSELBACHER P, 1979, J ALLERGY CLIN IMMUN, V64, P294, DOI 10.1016/0091-6749(79)90147-7; HASSELBACHER P, 1979, ARTHRITIS RHEUM, V22, P243, DOI 10.1002/art.1780220306; HASSELBACHER P, 1979, CLIN RES, V27, pA586; HASSELBACHER P, 1979, ARTHRITIS RHEUM-US, V22, P571, DOI 10.1002/art.1780220603; HASSELBACHER P, 1979, CLIN RES, V27, pA654; KOLB WP, 1978, J IMMUNOL, V121, P1232; Lang J H, 1967, Invest Radiol, V2, P396, DOI 10.1097/00004424-196711000-00017; LANG JH, 1976, INVEST RADIOL, V11, P303, DOI 10.1097/00004424-197607000-00007; LASSER EC, 1979, J ALLERGY CLIN IMMUN, V64, P105, DOI 10.1016/0091-6749(79)90043-5; LASSER EC, 1977, RADIOLOGY, V125, P1; LASSER EC, 1979, AM J ROENTGENOL, V132, P171, DOI 10.2214/ajr.132.2.171; LASSER EC, 1974, INVEST RADIOL, V9, pA6, DOI 10.1097/00004424-197407000-00001; LIEBERMAN P, 1978, J ALLERGY CLIN IMMUN, V61, P145, DOI 10.1016/0091-6749(78)90297-X; LIEBERMAN P, 1978, J ALLERGY CLIN IMMUN, V62, P174, DOI 10.1016/0091-6749(78)90103-3; RING J, 1979, Z IMMUNITATSFORSCH, V155, P200; RING J, 1978, CLIN EXP IMMUNOL, V32, P105; RING J, 1978, J LAB CLIN MED, V92, P584; SIMON RA, 1978, J ALLERGY CLIN IMMUN, V61, P145, DOI 10.1016/0091-6749(78)90295-6; TILL G, 1977, FED PROC, V36, P1264; WITTEN DM, 1975, JAMA-J AM MED ASSOC, V231, P974; ZIR LM, 1974, NEW ENGL J MED, V291, P134, DOI 10.1056/NEJM197407182910306	28	21	21	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	66	3					217	222		10.1016/0091-6749(80)90042-1	http://dx.doi.org/10.1016/0091-6749(80)90042-1			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KH358	6251127				2022-12-18	WOS:A1980KH35800008
J	INOUE, S; TESHIMA, H; AGO, Y; NAGATA, S				INOUE, S; TESHIMA, H; AGO, Y; NAGATA, S			COLD URTICARIA ASSOCIATED WITH IMMUNOGLOBULIN-M SERUM FACTOR	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											INOUE, S (corresponding author), KYUSHU UNIV,SCH MED,DEPT PSYCHOSOMAT MED,HIGASHI KU,FUKUOKA 812,JAPAN.							AVRAMEAS S, 1969, IMMUNOCHEMISTRY, V6, P53, DOI 10.1016/0019-2791(69)90178-5; BENTLEYPHILLIPS CB, 1976, LANCET, V2, P63; BRAY GW, 1931, J ALLERGY, V3, P367; BROWN GE, 1930, J ALLERG, V1, P193; Costanzi J J, 1967, Clin Exp Immunol, V2, P167; COSTANZI JJ, 1969, J LAB CLIN MED, V74, P902; DEFEO CP, 1962, ARCH DERMATOL, V85, P784; FITZPATRICK TB, 1963, ARCH DERMATOL, V87, P495; HAMBRICK GW, 1960, ARCH DERMATOL, V81, P1048; HARBER LC, 1965, ARCH DERMATOL, V92, P334, DOI 10.1001/archderm.92.3.334; HIPPE E, 1970, BLOOD-J HEMATOL, V35, P68, DOI 10.1182/blood.V35.1.68.68; Horton BT, 1936, J AMER MED ASSOC, V107, P1263, DOI 10.1001/jama.1936.02770420001001; HOUSER DD, 1970, AM J MED, V49, P23, DOI 10.1016/S0002-9343(70)80110-3; ISHIZAKA K, 1960, J IMMUNOL, V85, P163; KAPLAN AP, 1975, J ALLERGY CLIN IMMUN, V55, P394, DOI 10.1016/0091-6749(75)90078-0; KELLY FJ, 1953, AM J MED, V5, P431; KIMURA I, 1971, EXPT METHODS IMMUNOL, P266; KOBACKER JL, 1935, JAMA-J AM MED ASSOC, V105, P662; KUROKI K, 1972, AUTONOMIC NERV SYST, V9, P1; MATHOV E, 1950, Ann Allergy, V8, P366; Mayer M.M., 1961, EXPT IMMUNOCHEMISTRY, P133; NELSON CT, 1959, ARCH DERMATOL, V79, P737; RAJKA E, 1951, Ann Allergy, V9, P642; RAWNSLEY HM, 1968, ARCH DERMATOL, V98, P12, DOI 10.1001/archderm.98.1.12; RITZMANN SE, 1961, ARCH INTERN MED, V107, P754, DOI 10.1001/archinte.1961.03620050120014; SHERMAN WB, 1950, J ALLERGY, V21, P414, DOI 10.1016/0021-8707(50)90017-7; SHORE PA, 1959, J PHARMACOL EXP THER, V127, P182; SOTER NA, 1976, NEW ENGL J MED, V294, P687, DOI 10.1056/NEJM197603252941302; TAKEYA T, 1976, OTOLOGICA KUKUOKA, V22, P608; WANDERER AA, 1971, J ALLERGY CLIN IMMUN, V48, P13, DOI 10.1016/0091-6749(71)90050-9; WASSERMAN SI, 1977, J CLIN INVEST, V60, P189, DOI 10.1172/JCI108756	31	21	23	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	66	4					299	304		10.1016/0091-6749(80)90025-1	http://dx.doi.org/10.1016/0091-6749(80)90025-1			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KM254	7419832				2022-12-18	WOS:A1980KM25400007
J	MANO, K; AKBARZADEH, A; KOESNADI, K; SANO, Y; BEWTRA, A; TOWNLEY, R				MANO, K; AKBARZADEH, A; KOESNADI, K; SANO, Y; BEWTRA, A; TOWNLEY, R			EFFECT OF HYDROCORTISONE ON BETA-ADRENERGIC RECEPTORS IN LUNG-TISSUE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	21	21	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	63	3					147	147						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GN274					2022-12-18	WOS:A1979GN27400042
J	NEIJENS, HJ; DEGENHART, HJ; RAATGEEP, HC; KERREBIJN, KF				NEIJENS, HJ; DEGENHART, HJ; RAATGEEP, HC; KERREBIJN, KF			STUDY ON THE SIGNIFICANCE OF BRONCHIAL HYPER-REACTIVITY IN THE BRONCHUS OBSTRUCTION AFTER INHALATION OF CAT DANDER ALLERGEN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											NEIJENS, HJ (corresponding author), ERASMUS UNIV,SOPHIA CHILDRENS HOSP,SCH MED,DEPT PAEDIAT,SUBDEPT RESP DIS,ROTTERDAM,NETHERLANDS.							AALBERSE RC, 1973, IMMUNOCHEMISTRY, V10, P295, DOI 10.1016/0019-2791(73)90025-6; Abramowitz M., 1973, HDB MATH FUNCTIONS; AUSTEN KF, 1976, MOL BIOL ASPECTS ACU, P293; BRYANT D H, 1975, Clinical Allergy, V5, P145, DOI 10.1111/j.1365-2222.1975.tb01847.x; BRYANT DH, 1975, CLIN ALLERGY, V6, P373; Daniel C., 1971, FITTING EQUATIONS DA; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; FERRON GA, 1976, AM REV RESPIR DIS, V114, P899; FINNEY DJ, 1964, STATISTICAL METHOD B; GOKEMEYER JDM, 1976, THESIS GRONINGEN; Kerrebijn K F, 1977, Acta Paediatr Scand Suppl, P3; LICHTENS.LM, 1968, SCIENCE, V161, P902, DOI 10.1126/science.161.3844.902; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; OREHEK J, 1977, AM REV RESPIR DIS, V115, P937; PATTERSON R, 1976, J CLIN INVEST, V57, P586, DOI 10.1172/JCI108314; POPA V, 1973, J ALLERGY CLIN IMMUN, V51, P344, DOI 10.1016/0091-6749(73)90073-0; RADERMECKER M, 1972, Clinical Allergy, V2, P247, DOI 10.1111/j.1365-2222.1972.tb01289.x; Snedecor G.W., 1980, STAT METHODS, V7; STALLMAN PJ, 1977, THESIS U AMSTERDAM; VOORHORST R, 1969, HOUSE DUST ATOPY; VRIES KD, 1964, BRONCHITIS, V2, P167; VRIES KD, 1970, BRONCHITIS, V3, P359; WALKER SH, 1967, BIOMETRIKA, V54, P167, DOI 10.1093/biomet/54.1-2.167; WIDE L, 1967, LANCET, V2, P1105	24	21	21	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	64	6					507	515		10.1016/0091-6749(79)90060-5	http://dx.doi.org/10.1016/0091-6749(79)90060-5			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HX840	92487	Bronze			2022-12-18	WOS:A1979HX84000006
J	CHANDRASEKHAR, AJ; ROBINSON, J; BARR, L				CHANDRASEKHAR, AJ; ROBINSON, J; BARR, L			ANTIBODY DEPOSITION IN PLEURA - FINDING IN DRUG-INDUCED LUPUS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											CHANDRASEKHAR, AJ (corresponding author), LOYOLA UNIV,STRITCH SCH MED,FOSTER G MCGRAW HOSP,DEPT INTERNAL MED,MAYWOOD,IL 60153, USA.							AARDEN LA, 1975, ANN NY ACAD SCI, V254, P505, DOI 10.1111/j.1749-6632.1975.tb29197.x; ALARCONSEGOVIA D, 1978, NATURE, V271, P67, DOI 10.1038/271067a0; BLOMGREN SE, 1972, AM J MED, V52, P338, DOI 10.1016/0002-9343(72)90021-6; FRIES JF, 1975, SYSTEMIC LUPUS ERYTH, P135; HUNDER GG, 1970, ARTHRITIS RHEUM-US, V13, P448, DOI 10.1002/art.1780130415; POTTS DE, 1975, AM J MED, V58, P417, DOI 10.1016/0002-9343(75)90608-7; SHARP GC, 1976, NEW ENGL J MED, V295, P1149, DOI 10.1056/NEJM197611182952101; 1974, ARTHRITIS RHEUMATISM, V17, pS701	8	21	22	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	61	6					399	402		10.1016/0091-6749(78)90120-3	http://dx.doi.org/10.1016/0091-6749(78)90120-3			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FC593	659731				2022-12-18	WOS:A1978FC59300009
J	SUTTON, PL; KOUP, JR; ROSE, JQ; MIDDLETON, E				SUTTON, PL; KOUP, JR; ROSE, JQ; MIDDLETON, E			PHARMACOKINETICS OF THEOPHYLLINE IN PREGNANCY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	21	21	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	61	3					174	174		10.1016/0091-6749(78)90392-5	http://dx.doi.org/10.1016/0091-6749(78)90392-5			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ES173					2022-12-18	WOS:A1978ES17300153
J	BURKE, GP; SMITH, KA; STOCKING, RIG; FERM, M; MCINTYRE, OR				BURKE, GP; SMITH, KA; STOCKING, RIG; FERM, M; MCINTYRE, OR			ANTI-KEYHOLE LIMPET HEMOCYANIN ANTIBODY IN NORMAL UNSENSITIZED INDIVIDUALS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									DARTMOUTH MED SCH,DEPT MED,HEMATOL ONCOL SECT,HANOVER,NH 03755; NORRIS COTTON CANC CTR,HANOVER,NH	Dartmouth College; Norris Cotton Cancer Center								AMKRAUT AA, 1969, J IMMUNOL, V103, P1301; CAMPBELL D, 1964, METHODS IMMUNOBIOLOG, P60; CURTIS JE, 1970, CLIN EXP IMMUNOL, V6, P473; CURTIS JE, 1972, CLIN EXP IMMUNOL, V10, P171; CURTIS JE, 1971, J LAB CLIN MED, V78, P61; de Gast G C, 1973, Acta Med Scand, V194, P303; FOX RA, 1973, CLIN EXP IMMUNOL, V14, P473; FRICK O L, 1970, Federation Proceedings, V29, P573; GREEN AA, 1971, J IMMUNOL, V107, P293; HARRIS J, 1971, CAN MED ASSOC J, V104, P389; HERSCOWITZ HB, 1972, IMMUNOLOGY, V22, P51; HERSCOWITZ HB, 1974, J IMMUNOL METHODS, V6, P331; LEHANE DE, 1974, ONCOLOGY, V30, P458, DOI 10.1159/000224989; LEHANE DE, 1975, CANCER RES, V35, P2724; MOROZ LA, 1973, IMMUNOLOGY, V25, P441; PAUL S, 1974, INT ARCH ALLER A IMM, V47, P155, DOI 10.1159/000231209; SALVAGGIO J, 1969, J ALLERGY, V44, P344, DOI 10.1016/0021-8707(69)90026-4; SCOTT DW, 1970, CLIN EXP IMMUNOL, V6, P313; SWANSON MA, 1967, NEW ENGL J MED, V277, P163, DOI 10.1056/NEJM196707272770401; TUCHINDA M, 1972, INT ARCH ALLER A IMM, V42, P533, DOI 10.1159/000230634	20	21	21	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	59	4					309	313		10.1016/0091-6749(77)90052-5	http://dx.doi.org/10.1016/0091-6749(77)90052-5			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DB886	850020				2022-12-18	WOS:A1977DB88600006
J	PATTERSON, R; IRONS, JS; KELLY, JF; MATTSON, JR; OH, SH				PATTERSON, R; IRONS, JS; KELLY, JF; MATTSON, JR; OH, SH			PULMONARY INFILTRATES WITH EOSINOPHILIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note									NORTHWESTERN UNIV, MED CTR, DEPT MED, SECT ALLERGY IMMUNOL, CHICAGO, IL USA	Northwestern University								BEAVER PC, 1958, AM J TROP MED HYG, V7, P100, DOI 10.4269/ajtmh.1958.7.100; BELL RJM, 1964, LANCET, V1, P1249; BENTLEY HP, 1961, AM J MED, V30, P310, DOI 10.1016/0002-9343(61)90102-4; BENVENISTI DS, 1969, ANN INTERN MED, V71, P731, DOI 10.7326/0003-4819-71-4-731; BERK JE, 1945, JAMA-J AM MED ASSOC, V127, P354, DOI 10.1001/jama.1945.02860060052023; BOOTH BH, 1972, ALLERGIC DISEASES DI; BOUSSER J, 1957, Sang, V28, P553; BRAY DA, 1970, J AMER MED ASSOC, V214, P369, DOI 10.1001/jama.214.2.369; CARRINGT.CB, 1969, NEW ENGL J MED, V280, P787, DOI 10.1056/NEJM196904102801501; CHURG J, 1951, AM J PATHOL, V27, P277; CROFTON JW, 1952, THORAX, V7, P1, DOI 10.1136/thx.7.1.1; DANARAJ TJ, 1966, AM J TROP MED HYG, V15, P183, DOI 10.4269/ajtmh.1966.15.183; ENGFELDT B, 1956, ACTA MED SCAND, V153, P337; EPSTEIN WL, 1956, JAMA-J AM MED ASSOC, V162, P95, DOI 10.1001/jama.1956.02970190011003; FIEGENBERG DS, 1967, ARCH INTERN MED, V120, P85, DOI 10.1001/archinte.120.1.85; FORD RM, 1966, AM REV RESPIR DIS, V93, P797; FROHNERT PP, 1967, AM J MED, V43, P8, DOI 10.1016/0002-9343(67)90144-1; GELPI AP, 1968, AM J MED, V44, P377, DOI 10.1016/0002-9343(68)90109-5; HAILEY FJ, 1969, NEW ENGL J MED, V281, P1087, DOI 10.1056/NEJM196911132812002; HOFF AMANDA, 1942, AMER REV TUBERC, V45, P194; KLINGHOFFER JF, 1954, ANN INTERN MED, V40, P343, DOI 10.7326/0003-4819-40-2-343; Kussmaul A., 1866, DTSCH ARCH KLIN MED, V1, P484; LIEBOW AA, 1969, MEDICINE, V48, P251, DOI 10.1097/00005792-196907000-00001; Loffler W, 1932, BEITR KLIN TUBERK, V79, P368; MELAM H, 1971, AM J DIS CHILD, V121, P424, DOI 10.1001/archpedi.1971.02100160094014; MILLER H, 1945, NEW ENGL J MED, V232, P7, DOI 10.1056/NEJM194501042320102; MOK CH, 1968, CLIN PEDIATR, V7, P565, DOI 10.1177/000992286800700912; PATTERSON R, 1968, University of Michigan Medical Center Journal, V34, P8; PATTERSON R, 1973, AM J MED, V54, P16, DOI 10.1016/0002-9343(73)90078-8; PEPYS J, 1969, MONOGRAPHS ALLERGY H, V4; PERRAULT JL, 1971, ANN INTERN MED, V74, P951, DOI 10.7326/0003-4819-74-6-951; PHILLS JA, 1972, NEW ENGL J MED, V286, P965, DOI 10.1056/NEJM197205042861802; PIERCE LE, 1967, BLOOD-J HEMATOL, V29, P540, DOI 10.1182/blood.V29.4.540.540; REEDER WH, 1952, ANN INTERN MED, V36, P1217, DOI 10.7326/0003-4819-36-5-1217; REICHLIN S, 1953, ANN INTERN MED, V38, P113, DOI 10.7326/0003-4819-38-1-113; RODMAN T, 1958, ANN INTERN MED, V48, P668, DOI 10.7326/0003-4819-48-3-668; ROSE GA, 1957, Q J MED, V26, P43; RUPE CE, 1966, MOD TREAT, V3, P1280; SLAVIN RG, 1972, ALLERGIC DISEASES DI; Slowey JF, 1944, ANN INTERN MED, V21, P130, DOI 10.7326/0003-4819-21-1-130; SMITH WG, 1964, AUSTRALAS ANN MED, V13, P40, DOI 10.1111/imj.1964.13.1.40; STILLMAN RG, 1912, MED REC NY, V81, P594; STRAND H, 1964, LANCET, V1, P1357; SUNDERMAN F, 1961, ARCH INTERN MED, V107, P405, DOI 10.1001/archinte.1961.03620030093014; TOCKER AM, 1949, J ALLERGY, V20, P211, DOI 10.1016/0021-8707(49)90098-2; TSCHUMY WILLIAM, 1958, ANN INTERNAL MED, V49, P665; WEINBERG AN, 1972, NEW ENGL J MED, V286, P1205; WOLD DE, 1956, AM REV TUBERC PULM, V74, P445; WRIGHT DO, 1946, ARCH INTERN MED, V78, P303, DOI 10.1001/archinte.1946.00220030050003; 1960, BRIT MED J, V1, P1399	50	21	21	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1974	53	4					245	255		10.1016/0091-6749(74)90088-8	http://dx.doi.org/10.1016/0091-6749(74)90088-8			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	S6732	4151708				2022-12-18	WOS:A1974S673200009
J	ROSENFEL.GB; PARTRIDG.RE; BARTHOLO.W; MURPHEY, WH; SINGLETO.CM				ROSENFEL.GB; PARTRIDG.RE; BARTHOLO.W; MURPHEY, WH; SINGLETO.CM			HEREDITARY ANGIONEUROTIC EDEMA (HANE) AND SYSTEMIC LUPUS-ERYTHEMATOSUS (SLE) IN ONE OF IDENTICAL TWIN GIRLS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	21	21	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1974	53	2					68	69						2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	S0380					2022-12-18	WOS:A1974S038000009
J	CARR, RH; BUSSE, WW; REED, CE				CARR, RH; BUSSE, WW; REED, CE			FAILURE OF CATECHOLAMINES TO INHIBIT EPIDERMAL MITOSIS IN-VITRO	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WISCONSIN, MED SCH, DEPT MED, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison								ARNOLD A, 1968, EXPERIENTIA, V24, P1010, DOI 10.1007/BF02138713; BAMSHAD J, 1969, J INVEST DERMATOL, V52, P100, DOI 10.1038/jid.1969.14; BULLOUGH WS, 1962, BIOL REV, V37, P307, DOI 10.1111/j.1469-185X.1962.tb01615.x; BULLOUGH WS, 1955, EXP CELL RES, V9, P108, DOI 10.1016/0014-4827(55)90164-6; FISHER LB, 1968, BRIT J DERMATOL, V80, P75, DOI 10.1111/j.1365-2133.1968.tb12263.x; HEMELS HGW, 1970, BRIT J DERMATOL, V83, P312, DOI 10.1111/j.1365-2133.1970.tb15706.x; JOHNSON LA, 1965, ARCH DERMATOL, V92, P621, DOI 10.1001/archderm.92.6.621; JUHLIN L, 1961, J INVEST DERMATOL, V37, P201, DOI 10.1038/jid.1961.107; LANDS A. M., 1967, LIFE SCI, V6, P2241, DOI 10.1016/0024-3205(67)90031-8; LOBITZ WC, 1953, AMA ARCH DERM SYPH, V67, P575, DOI 10.1001/archderm.1953.01540060037006; MAKINO S, 1970, J ALLERGY, V46, P178, DOI 10.1016/0021-8707(70)90096-1; MALAMUD DANIEL, 1967, LIFE SCI, V6, P1765, DOI 10.1016/0024-3205(67)90147-6; MIER PD, 1970, BRIT J DERMATOL, V83, P359, DOI 10.1111/j.1365-2133.1970.tb15716.x; MIER PD, 1970, BRIT J DERMATOL, V83, P364, DOI 10.1111/j.1365-2133.1970.tb15717.x; RYAN WL, 1968, SCIENCE, V162, P1484, DOI 10.1126/science.162.3861.1484; SCHNEYER CA, 1969, P SOC EXP BIOL MED, V131, P71; SOLOMON LM, 1964, J INVEST DERMATOL, V43, P193, DOI 10.1038/jid.1964.142; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; VONEULER U, 1961, ACTA PHYSIOL SCAND, V51, P348, DOI 10.1111/j.1748-1716.1961.tb02145.x; WARNDORF.JA, 1970, BRIT J DERMATOL, V83, P306, DOI 10.1111/j.1365-2133.1970.tb15705.x; Whitfield A, 1938, BRIT J DERMATOL SYPH, V50, P71, DOI 10.1111/j.1365-2133.1938.tb10475.x	21	21	21	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1973	51	5					255	262		10.1016/0091-6749(73)90127-9	http://dx.doi.org/10.1016/0091-6749(73)90127-9			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P5931	4697355				2022-12-18	WOS:A1973P593100001
J	ROBERTS, RC; WENZEL, FJ; EMANUEL, DA				ROBERTS, RC; WENZEL, FJ; EMANUEL, DA			SERUM IMMUNOGLOBULIN LEVELS IN FARMERS LUNG-DISEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MARSHFIELD CLIN,MARSHFIELD,WI; MARSHFIELD CLIN FDN MED RES & EDUC,510 N ST JOSEPH AVE,MARSHFIELD,WI 54449	Marshfield Clinic; Marshfield Clinic								ABLIN RJ, 1972, CLIN MED, V79, P27; ALLANSMITH M, 1968, J PEDIATR-US, V72, P276, DOI 10.1016/S0022-3476(68)80324-5; BIEGEL AA, 1968, AM REV RESPIR DIS, V97, P217; EDWARDS JH, 1972, CLIN EXP IMMUNOL, V11, P341; Goldstein A, 1964, BIOSTATISTICS; MANCINI G, 1963, PROTIDES BIOLOGICAL; MARTINEZTELLO FJ, 1968, J IMMUNOL, V101, P989; PATTERSON R, 1973, AM J MED, V54, P16, DOI 10.1016/0002-9343(73)90078-8; PEPYS J, 1963, LANCET, V2, P607; PEPYS J, 1969, PULMONARY ASPERGILLO; RICHARDSON HB, 1972, DHEW NIH73432 PUBL, P88; SALVAGGIO J, 1969, AM J MED, V46, P538, DOI 10.1016/0002-9343(69)90073-4; WENZEL FJ, 1965, NEW YORK STATE J MED, V65, P3032; 1971, WHO463 TECH REP, P62	14	21	21	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1973	52	5					297	302		10.1016/0091-6749(73)90048-1	http://dx.doi.org/10.1016/0091-6749(73)90048-1			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	R2087	4201036	Bronze			2022-12-18	WOS:A1973R208700006
J	YOCUM, MW; JOHNSTONE, DE; CONDEMI, JJ				YOCUM, MW; JOHNSTONE, DE; CONDEMI, JJ			LEUKOCYTE HISTAMINE-RELEASE IN HYMENOPTERA ALLERGIC PATIENTS - CORRELATION WITH SKIN-TEST REACTIVITY AND CHANGES FOLLOWING HYPOSENSITIZATION THERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV ROCHESTER, STRONG MEM HOSP, SCH MED & DENT, DEPT MED & PEDIAT, ROCHESTER, NY 14642 USA	University of Rochester								BARNARD JH, 1971, ANN ALLERGY, V29, P372; BERNTON HS, 1965, J ALLERGY, V36, P315, DOI 10.1016/0021-8707(65)90038-9; BROWN H, 1968, J ALLERGY, V41, P92; CLOCK RO, 1917, J INFECT DIS, V21, P387; FEINGOLD B F, 1971, Journal of Asthma Research, V9, P55, DOI 10.3109/02770907109105041; HABERMAN.E, 1972, SCIENCE, V177, P314, DOI 10.1126/science.177.4046.314; HJORTH NIELS, 1957, ACTA ALLERGOL, V11, P249, DOI 10.1111/j.1398-9995.1957.tb03036.x; LEVY DA, 1967, J IMMUNOL, V99, P1062; LEVY DA, 1971, J CLIN INVEST, V50, P360, DOI 10.1172/JCI106503; LICHTENS.LM, 1969, AM J MED, V46, P163, DOI 10.1016/0002-9343(69)90001-1; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; LICHTENSTEIN LM, 1966, J IMMUNOL, V96, P169; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; MAY CD, 1972, J ALLERGY CLIN IMMUN, V49, P54, DOI 10.1016/0091-6749(72)90123-6; MELAM H, 1971, J ALLERGY, V47, P262, DOI 10.1016/S0091-6749(71)80004-0; MUELLER HL, 1959, NEW ENGL J MED, V261, P374, DOI 10.1056/NEJM195908202610803; MUELLER HL, 1971, IMMUNOLOGIC DISEASES; PRUZANSKY JJ, 1967, J ALLERGY, V39, P44, DOI 10.1016/0021-8707(67)90126-8; SADAN N, 1969, NEW ENGL J MED, V280, P623, DOI 10.1056/NEJM196903202801201; SCHWARTZ HJ, 1965, J AMER MED ASSOC, V194, P703, DOI 10.1001/jama.194.7.703; SHORE PA, 1959, J PHARMACOL EXP THER, V127, P182; SHULMAN S, 1968, PROG ALLERGY, V12, P246, DOI 10.1159/000287268; SULLIVAN CLEMENT J., 1939, JOUR ALLERGY, V10, P551, DOI 10.1016/S0021-8707(39)90249-2	23	21	21	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1973	52	5					265	277		10.1016/0091-6749(73)90045-6	http://dx.doi.org/10.1016/0091-6749(73)90045-6			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	R2087	4126910				2022-12-18	WOS:A1973R208700003
J	ISHIKAWA, T; ARBESMAN, CE; YU, MC				ISHIKAWA, T; ARBESMAN, CE; YU, MC			ELECTRON-MICROSCOPIC DEMONSTRATION OF PHAGOCYTOSIS OF CANDIDA-ALBICANS BY HUMAN EOSINOPHILIC LEUKOCYTES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note																		ARCHER GT, 1969, IMMUNOLOGY, V17, P177; BLOOM W, 1969, TEXTBOOK HISTOLOGY, P150; ISHIKAWA T, 1972, J ALLERGY CLIN IMMUN, V49, P311, DOI 10.1016/0091-6749(72)90099-1; ISHIKAWA T, 1971, FED P, V30, P2694; LEHRER RI, 1971, INFECT IMMUN, V3, P800, DOI 10.1128/IAI.3.6.800-802.1971; LITT M, 1964, ANN NY ACAD SCI, V116, P964, DOI 10.1111/j.1749-6632.1964.tb52562.x; Milloning G., 1961, J APPL PHYS, V32, P1637; OPIE E, 1964, AM J MED SCI, V127, P477; ROSS R, 1966, J EXP MED, V124, P653, DOI 10.1084/jem.124.4.653; SABESIN SM, 1963, P SOC EXP BIOL MED, V112, P667, DOI 10.3181/00379727-112-28134; ZUCKERFRANKLIN D, 1964, J EXP MED, V120, P569, DOI 10.1084/jem.120.4.569; ZUCKERFRANKLIN D, 1966, J EXP MED, V124, P521, DOI 10.1084/jem.124.3.521	12	21	21	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1972	50	3					183	&		10.1016/0091-6749(72)90049-8	http://dx.doi.org/10.1016/0091-6749(72)90049-8			0	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	N4708	4559108	Bronze			2022-12-18	WOS:A1972N470800008
J	LONG, DL; KRAMER, CL				LONG, DL; KRAMER, CL			AIR SPORA OF 2 CONTRASTING ECOLOGICAL SITES IN KANSAS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		ADAMS KF, 1968, ACTA ALLERGOL, V23, P265, DOI 10.1111/j.1398-9995.1968.tb04059.x; ADAMS KF, 1964, ACTA ALLERGOL, V19, P11, DOI 10.1111/j.1398-9995.1964.tb03220.x; GREGORY PH, 1967, J GEN MICROBIOL, V17, P135; HAMILTON ELIZABETH D., 1959, ACTA ALLERGOL, V13, P143, DOI 10.1111/j.1398-9995.1959.tb02761.x; HIRST JM, 1952, ANN APPL BIOL, V39, P257, DOI 10.1111/j.1744-7348.1952.tb00904.x; KRAMER C. L., 1959, TRANS KANSAS A CAD SCI, V62, P184, DOI 10.2307/3626975; KRAMER C. L., 1964, TRANS KANS ACAD SCI, V67, P442, DOI 10.2307/3626874; KRAMER CL, 1966, PHYTOPATHOLOGY, V56, P517; KRAMER CL, 1969, MYCOLOGIA, V61, P87; LACEY ME, 1962, J GEN MICROBIOL, V29, P485, DOI 10.1099/00221287-29-3-485; LONG DL, 1970, THESIS KANSAS STATE; PADY SM, 1962, T KANS ACAD SCI, V54, P168; PADY SM, PERIODICITY SPORE RE; SREERAMULU T., 1959, TRANS BRIT MYCOL SOC, V42, P177	14	21	21	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1972	49	5					255	&		10.1016/0091-6749(72)90093-0	http://dx.doi.org/10.1016/0091-6749(72)90093-0			0	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M4215	5019944				2022-12-18	WOS:A1972M421500001
J	MAY, CD; LYMAN, MS; ALBERTO, R; ADUNA, N				MAY, CD; LYMAN, MS; ALBERTO, R; ADUNA, N			MEASUREMENT OF BLOCKING ANTIBODY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note																		Cooke RA, 1935, J EXP MED, V62, P733, DOI 10.1084/jem.62.6.733; LICHTENSTEIN LM, 1966, J IMMUNOL, V96, P169; LOVELESS M, 1944, J ALLERGY, V15, P311; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; MAY CD, 1971, J ALLERGY, V47, P111; MAY CD, 1970, J ALLERGY, V46, P73, DOI 10.1016/0021-8707(70)90075-4	6	21	21	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1972	49	1					54	&		10.1016/0091-6749(72)90123-6	http://dx.doi.org/10.1016/0091-6749(72)90123-6			0	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	L3388	4108809				2022-12-18	WOS:A1972L338800007
J	Delemarre, T; Bochner, BS; Simon, HU; Bachert, C				Delemarre, Tim; Bochner, Bruce S.; Simon, Hans-Uwe; Bachert, Claus			Rethinking neutrophils and eosinophils in chronic rhinosinusitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Chronic rhinosinusitis; type 2 inflammation; eosino-phils; neutrophils; activation; extracellular traps; Charcot-Leyden crystals; IL-17; biologicals	NASAL POLYPS; STAPHYLOCOCCUS-AUREUS; GENE-EXPRESSION; SINUS SURGERY; EXTRACELLULAR TRAPS; HEALING QUALITY; GM-CSF; INFLAMMATION; ASTHMA; DNA	Chronic rhinosinusitis (CRS) often is characterized by an eosinophilic inflammatory pattern, nowadays referred to as type 2 inflammation, although the mucosal inflammation is dominated by neutrophils in about a third of the patients. Neutrophils are typically predominant in 50% of patients with CRS without nasal polyps, but also are found to play a role in patients with severe type 2 CRS with nasal polyp disease. This review aims at summarizing the current understanding of the eosinophilic and neutrophilic inflammation in CRS pathophysiology, and provides a discussion of their reciprocal interactions and the clinical impact of the mixed presentation in patients with severe type 2 CRS with nasal polyps. A solid understanding of these interactions is of utmost importance when treating uncontrolled severe CRS with nasal polyps with biologicals that are preferentially directed toward type 2 inflammation. We here focus on recent findings on both eosinophilic and neutrophilic granulocytes, their subgroups and the activation status, and their interactions in CRS. (J Allergy Clin Immunol 2021;148:327-35.)	[Delemarre, Tim; Bachert, Claus] Univ Ghent, Upper Airways Res Lab, Fac Med, Ghent, Belgium; [Bochner, Bruce S.] Northwestern Univ, Div Allergy & Immunol, Dept Med, Feinberg Sch Med, Chicago, IL USA; [Simon, Hans-Uwe] Univ Bern, Inst Pharmacol, Bern, Switzerland; [Simon, Hans-Uwe] Sechenov Univ, Dept Clin Immunol & Allergol, Moscow, Russia; [Simon, Hans-Uwe] Kazan Fed Univ, Inst Fundamental Med & Biol, Lab Mol Immunol, Kazan, Russia; [Bachert, Claus] Karolinska Inst, Div ENT Dis, CLINTEC, Stockholm, Sweden; [Bachert, Claus] Sun Yat Sen Univ, Int Airway Res Ctr, Affiliated Hosp 1, Guangzhou, Peoples R China	Ghent University; Northwestern University; Feinberg School of Medicine; University of Bern; Sechenov First Moscow State Medical University; Kazan Federal University; Karolinska Institutet; Sun Yat Sen University	Bachert, C (corresponding author), Univ Ghent, Upper Airways Res Lab, Dept Head & Skin, UZ Ghent, C Heymanslaan 10, B-9000 Ghent, Belgium.	Claus.Bachert@ugent.be	Bachert, Claus/J-8825-2012		Flams wetenschappelijk Onderzeok (FWO) Flanders [1515516N]; Flams wetenschappelijk Onderzeok (FWO) Flanders (Excellence of Science [EOS]) [GOG2318N]; Inter-university Attraction Poles [P7/30]; Sanofi [A17/TT/1942, A19/TT/0828]; National Institute of Allergy and Infectious Diseases [U19AI136443]; Swiss National Science Foundation [310030_184816]; Russian Government	Flams wetenschappelijk Onderzeok (FWO) Flanders(FWO); Flams wetenschappelijk Onderzeok (FWO) Flanders (Excellence of Science [EOS]); Inter-university Attraction Poles(Belgian Federal Science Policy Office); Sanofi; National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Russian Government	C.B. was supported by grants from Flams wetenschappelijk Onderzeok (FWO) Flanders (grant no. 1515516N, Excellence of Science [EOS] project no. GOG2318N) , the Inter-university Attraction Poles Grant P7/30, and Sanofi (grant nos. A17/TT/1942 and A19/TT/0828) . B.S.B. is supported in part by a grant from the National Institute of Allergy and Infectious Diseases (grant no. U19AI136443) . H.- U.S. is supported by grants from the Swiss National Science Foundation (grant no. 310030_184816) . H.- U.S. also ac-knowledges financial support by the Russian Government Program "Recruitment of the Leading Scientists into the Russian Institutions of Higher	Ahern S, 2019, MEDICINA-LITHUANIA, V55, DOI 10.3390/medicina55040095; Arebro J, 2019, ALLERGY, V74, P2499, DOI 10.1111/all.13919; Arebro J, 2017, SCI REP-UK, V7, DOI 10.1038/srep43568; Bachert C, 2001, J ALLERGY CLIN IMMUN, V107, P607, DOI 10.1067/mai.2001.112374; Bachert C, 2021, J ALLERGY CLIN IMMUN, V147, P29, DOI 10.1016/j.jaci.2020.11.013; Bachert C, 2020, J ALLERGY CLIN IMMUN, V145, P725, DOI 10.1016/j.jaci.2020.01.020; Bachert C, 2019, LANCET, V394, P1638, DOI 10.1016/S0140-6736(19)31881-1; Bachert C, 2018, J ALLERGY CLIN IMMUN, V141, P1543, DOI 10.1016/j.jaci.2018.03.004; Bachert C, 2016, JAMA-J AM MED ASSOC, V315, P469, DOI 10.1001/jama.2015.19330; Bachert C, 2017, J ALLERGY CLIN IMMUN, V140, P1024, DOI 10.1016/j.jaci.2017.05.044; Bagley CJ, 1997, J ALLERGY CLIN IMMUN, V99, P725, DOI 10.1016/S0091-6749(97)80002-4; Barretto KT, 2020, ALLERGY, V75, P2127, DOI 10.1111/all.14297; Bochner BS, 2021, ALLERGY ASTHMA IMMUN, V13, P8, DOI 10.4168/aair.2021.13.1.8; Bochner BS, 2016, GLYCOBIOLOGY, V26, P546, DOI 10.1093/glycob/cww024; Buchheit KM, 2020, J ALLERGY CLIN IMMUN, V145, P1574, DOI 10.1016/j.jaci.2020.02.035; Calus L, 2019, CLIN TRANSL ALLERGY, V9, DOI 10.1186/s13601-019-0269-4; Cao YJ, 2019, CLIN EXP ALLERGY, V49, P990, DOI 10.1111/cea.13408; Chakravarti A, 2009, LAB INVEST, V89, P1084, DOI 10.1038/labinvest.2009.74; Chalmers JD, 2020, NEW ENGL J MED, V383, P2127, DOI 10.1056/NEJMoa2021713; Cherry WB, 2008, J ALLERGY CLIN IMMUN, V121, P1484, DOI 10.1016/j.jaci.2008.04.005; Cho SH, 2016, J ALLER CL IMM-PRACT, V4, P575, DOI 10.1016/j.jaip.2016.04.015; Clancy DM, 2017, FEBS J, V284, P1712, DOI 10.1111/febs.14075; COX G, 1995, J IMMUNOL, V154, P4719; De Greve G, 2017, CLIN TRANSL ALLERGY, V7, DOI 10.1186/s13601-017-0157-8; De Volder J, 2020, BIOCHEM PHARMACOL, V182, DOI 10.1016/j.bcp.2020.114292; DeConde AS, 2017, LARYNGOSCOPE, V127, P550, DOI 10.1002/lary.26391; Delemarre T, 2021, J ALLERGY CLIN IMMUN, V147, P179, DOI 10.1016/j.jaci.2020.08.036; Delemarre T, 2020, CLIN TRANSL ALLERGY, V10, DOI 10.1186/s13601-020-00348-5; Delemarre T, 2020, J ALLERGY CLIN IMMUN, V146, P337, DOI 10.1016/j.jaci.2020.04.040; Delgado-Rizo V, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00081; Derycke L, 2012, J CYST FIBROS, V11, P193, DOI 10.1016/j.jcf.2011.11.007; Derycke L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097581; Dicker AJ, 2018, J ALLERGY CLIN IMMUN, V141, P117, DOI 10.1016/j.jaci.2017.04.022; Dupuch V, 2018, INT FORUM ALLERGY RH, V8, P584, DOI 10.1002/alr.22079; Dworski R, 2011, J ALLERGY CLIN IMMUN, V127, P1260, DOI 10.1016/j.jaci.2010.12.1103; Ekstedt S, 2019, EUR RESPIR J, V54, DOI 10.1183/13993003.congress-2019.PA4092; FRIGAS E, 1991, EUR RESPIR J, V4, pS123; Garley M, 2018, ARCH IMMUNOL THER EX, V66, P21, DOI 10.1007/s00005-017-0476-4; Geering B, 2013, TRENDS IMMUNOL, V34, P398, DOI 10.1016/j.it.2013.04.002; Gevaert E, 2020, J ALLERGY CLIN IMMUN, V145, P427, DOI 10.1016/j.jaci.2019.08.027; Gevaert E, 2017, J ALLERGY CLIN IMMUN, V139, P1849, DOI 10.1016/j.jaci.2017.01.019; Gevaert P, 2020, J ALLERGY CLIN IMMUN, V146, P595, DOI 10.1016/j.jaci.2020.05.032; Gevaert P, 2013, J ALLERGY CLIN IMMUN, V131, P110, DOI 10.1016/j.jaci.2012.07.047; Gevaert P, 2011, J ALLERGY CLIN IMMUN, V128, P989, DOI 10.1016/j.jaci.2011.07.056; Gonzalez-Gil A, 2021, J ALLERGY CLIN IMMUN, V147, P1442, DOI 10.1016/j.jaci.2020.08.001; Gorski SA, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0221113; Grabcanovic-Musija F, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0221-7; Green RH, 2002, THORAX, V57, P875, DOI 10.1136/thorax.57.10.875; Grunwell JR, 2019, J ALLER CL IMM-PRACT, V7, P516, DOI 10.1016/j.jaip.2018.08.024; Gurrola J, 2017, J ALLERGY CLIN IMMUN, V140, P1499, DOI 10.1016/j.jaci.2017.10.006; HASKELL MD, 1995, BLOOD, V86, P4627, DOI 10.1182/blood.V86.12.4627.bloodjournal86124627; Hastie AT, 2010, J ALLERGY CLIN IMMUN, V125, P1028, DOI 10.1016/j.jaci.2010.02.008; Hauser LJ, 2017, INT FORUM ALLERGY RH, V7, P957, DOI 10.1002/alr.21994; Hulse KE, 2015, CLIN EXP ALLERGY, V45, P328, DOI 10.1111/cea.12472; Hunter D, 2014, J ALLERGY CLIN IMMUN, V133, P901, DOI 10.1016/j.jaci.2013.09.035; Huvenne W, 2010, ALLERGY, V65, P1013, DOI 10.1111/j.1398-9995.2009.02313.x; Hwang CS, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-44627-z; Hwang JW, 2019, CLIN EXP ALLERGY, V49, P1306, DOI 10.1111/cea.13448; Ikeda K, 2013, LARYNGOSCOPE, V123, pE1, DOI 10.1002/lary.24154; Irvin C, 2014, J ALLERGY CLIN IMMUN, V134, P1175, DOI 10.1016/j.jaci.2014.05.038; Joanna G, 2017, SWISS MED WKLY, V147, DOI 10.4414/smw.2017.14489; Julius P, 1999, EUR RESPIR J, V13, P1253, DOI 10.1034/j.1399-3003.1999.13f07.x; Kao SST, 2019, INT FORUM ALLERGY RH, V9, P1220, DOI 10.1002/alr.22401; Karin J, LARYNGOSCOPE, DOI [10.1002/lary, DOI 10.1002/LARY]; Kato A, 2015, ALLERGOL INT, V64, P121, DOI 10.1016/j.alit.2014.12.006; Khan A, 2019, RHINOLOGY, V57, P32, DOI 10.4193/Rhin17.255; Kikuchi I, 2006, AM J RESP CELL MOL, V34, P760, DOI 10.1165/rcmb.2005-0303OC; Kim DK, 2021, RHINOLOGY, V59, P173, DOI 10.4193/Rhin20.373; Kim DK, 2020, ALLERGY ASTHMA IMMUN, V12, P42, DOI 10.4168/aair.2020.12.1.42; Kim YS, 2019, ALLERGY ASTHMA IMMUN, V11, P691, DOI 10.4168/aair.2019.11.5.691; Konig K, 2016, ALLERGY ASTHMA CL IM, V12, DOI 10.1186/s13223-016-0123-3; Laidlaw TM, 2019, LARYNGOSCOPE, V129, pE61, DOI 10.1002/lary.27564; Lan F, 2020, ALLERGY ASTHMA IMMUN, V12, P1, DOI 10.4168/aair.2020.12.1.1; Lavin J, 2017, LARYNGOSCOPE, V127, P2210, DOI 10.1002/lary.26555; Liao B, 2018, ALLERGY, V73, P1459, DOI 10.1111/all.13411; LILES WC, 1995, BLOOD, V86, P3181; Liu H, 1999, AM J PHYSIOL-LUNG C, V276, pL28, DOI 10.1152/ajplung.1999.276.1.L28; Liu Z, 2004, J ALLERGY CLIN IMMUN, V114, P783, DOI 10.1016/j.jaci.2004.04.052; Lou HF, 2016, RHINOLOGY, V54, P150, DOI [10.4193/Rhin15.271, 10.4193/Rhino15.271]; Matsumoto K, 1998, AM J RESP CELL MOL, V18, P860, DOI 10.1165/ajrcmb.18.6.3159; Moore WC, 2014, J ALLERGY CLIN IMMUN, V133, P1557, DOI 10.1016/j.jaci.2013.10.011; Morshed M, 2012, ALLERGY, V67, P1127, DOI 10.1111/j.1398-9995.2012.02868.x; MOY JN, 1993, J ALLERGY CLIN IMMUN, V92, P598, DOI 10.1016/0091-6749(93)90084-S; Nakagome K, 2012, INT ARCH ALLERGY IMM, V158, P96, DOI 10.1159/000337801; NAKAMURA H, 1992, J CLIN INVEST, V89, P1478, DOI 10.1172/JCI115738; Nishio T, 2019, ALLERGOL INT, V68, P515, DOI 10.1016/j.alit.2019.05.004; Nonaka M, 1999, INT ARCH ALLERGY IMM, V119, P314, DOI 10.1159/000024209; OHNO I, 1991, AM J RESP CELL MOL, V5, P505, DOI 10.1165/ajrcmb/5.6.505; Pauwels B, 2015, EXPERT REV CLIN IMMU, V11, P349, DOI 10.1586/1744666X.2015.1010517; Perez-Novo CA, 2005, J ALLERGY CLIN IMMUN, V115, P1189, DOI 10.1016/j.jaci.2005.02.029; Perez-Novo CA, 2006, AM J RHINOL, V20, P456, DOI 10.2500/ajr.2006.20.2873; Persson EK, 2019, SCIENCE, V364, P751, DOI 10.1126/science.aaw4295; Pujols L, 2008, ALLERGY, V63, P1377, DOI 10.1111/j.1398-9995.2008.01745.x; Qi SH, 2020, RHINOLOGY, V58, P166, DOI 10.4193/Rhin19.296; Radermecker C, 2019, NAT IMMUNOL, V20, P1444, DOI 10.1038/s41590-019-0496-9; Ray A, 2017, TRENDS IMMUNOL, V38, P942, DOI 10.1016/j.it.2017.07.003; Rodriguez-Alcazar JF, 2019, J IMMUNOL, V202, P550, DOI 10.4049/jimmunol.1800107; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Shimizu S, 2015, AM J RHINOL ALLERGY, V29, P235, DOI 10.2500/ajra.2015.29.4183; Silvestre-Roig C, 2016, BLOOD, V127, P2173, DOI 10.1182/blood-2016-01-688887; Simon HU, 1997, J IMMUNOL, V158, P3902; Smith TL, 2010, OTOLARYNG HEAD NECK, V142, P55, DOI 10.1016/j.otohns.2009.10.009; Soler ZM, 2010, OTOLARYNG HEAD NECK, V142, P64, DOI 10.1016/j.otohns.2009.10.005; Soler ZM, 2009, OTOLARYNG HEAD NECK, V141, P454, DOI 10.1016/j.otohns.2009.06.085; Soragni A, 2015, MOL CELL, V57, P1011, DOI 10.1016/j.molcel.2015.01.026; Sridhar S, 2019, RESP RES, V20, DOI 10.1186/s12931-018-0968-8; Staudacher AG, 2020, ANN ALLERG ASTHMA IM, V125, P490, DOI 10.1016/j.anai.2020.06.043; Stevens WW, 2019, J ALLER CL IMM-PRACT, V7, P2812, DOI 10.1016/j.jaip.2019.05.009; Succar EF, 2020, ALLERGY, V75, P713, DOI 10.1111/all.14071; Suh JD, 2010, OTOLARYNG CLIN N AM, V43, P521, DOI 10.1016/j.otc.2010.02.010; Sun B, 2018, CELL MOL IMMUNOL, V15, P782, DOI 10.1038/cmi.2017.163; Tan BK, 2017, J ALLERGY CLIN IMMUN, V139, P699, DOI 10.1016/j.jaci.2016.06.063; Teufelberger AR, 2018, J ALLERGY CLIN IMMUN, V141, P549, DOI 10.1016/j.jaci.2017.05.004; Thammavongsa V, 2013, SCIENCE, V342, P863, DOI 10.1126/science.1242255; Tomassen P, 2016, J ALLERGY CLIN IMMUN, V137, P1449, DOI 10.1016/j.jaci.2015.12.1324; Toussaint M, 2017, NAT MED, V23, P681, DOI 10.1038/nm.4332; Uddin M, 2010, THORAX, V65, P684, DOI 10.1136/thx.2009.120741; Ueki S, 2018, BLOOD, V132, P2183, DOI 10.1182/blood-2018-04-842260; Ueki S, 2016, J ALLERGY CLIN IMMUN, V137, P258, DOI 10.1016/j.jaci.2015.04.041; Ueki S, 2013, BLOOD, V121, P2074, DOI 10.1182/blood-2012-05-432088; Van Zele T, 2006, ALLERGY, V61, P1280, DOI 10.1111/j.1398-9995.2006.01225.x; Van Zele T, 2004, J ALLERGY CLIN IMMUN, V114, P981, DOI 10.1016/j.jaci.2004.07.013; Van Zele T, 2014, AM J RHINOL ALLERGY, V28, P192, DOI 10.2500/ajra.2014.28.4033; Vlaminck S, 2021, AM J RHINOL ALLERGY, V35, P449, DOI 10.1177/1945892420961964; Vlaminck S, 2014, AM J RHINOL ALLERGY, V28, P260, DOI 10.2500/ajra.2014.28.4024; Voynow JA, 2004, AM J PHYSIOL-LUNG C, V287, pL1293, DOI 10.1152/ajplung.00140.2004; Wang H, 2018, J ALLERGY CLIN IMMUN, V141, P1646, DOI 10.1016/j.jaci.2017.12.972; Wang XD, 2016, J ALLERGY CLIN IMMUN, V138, P1344, DOI 10.1016/j.jaci.2016.05.041; Wang X, 2014, INFLAMMATION, V37, P871, DOI 10.1007/s10753-013-9807-8; Warnatsch A, 2017, IMMUNITY, V46, P421, DOI 10.1016/j.immuni.2017.02.013; Watelet JB, 2006, HISTOPATHOLOGY, V48, P174, DOI 10.1111/j.1365-2559.2005.02310.x; Watelet JB, 2005, LARYNGOSCOPE, V115, P56, DOI 10.1097/01.mlg.0000150674.30237.3f; Watelet JB, 2004, WOUND REPAIR REGEN, V12, P412, DOI 10.1111/j.1067-1927.2004.012411.x; Watelet JB, 2004, ALLERGY, V59, P54, DOI 10.1046/j.1398-9995.2003.00364.x; Wei Y, 2020, J ALLERGY CLIN IMMUN, V145, P1002, DOI 10.1016/j.jaci.2020.01.009; Wen WP, 2012, J ALLERGY CLIN IMMUN, V129, P1522, DOI 10.1016/j.jaci.2012.01.079; Wong CK, 2010, AM J RESP CELL MOL, V43, P305, DOI 10.1165/rcmb.2009-0168OC; Wu W, 2014, J ALLERGY CLIN IMMUN, V133, P1280, DOI 10.1016/j.jaci.2013.11.042; Xue LZ, 2015, J ALLERGY CLIN IMMUN, V135, P1358, DOI 10.1016/j.jaci.2014.09.006; Yoshimura Tsuyoshi, 2008, Allergol Int, V57, P429, DOI 10.2332 allergolint.O-08-545; Yousefi S, 2008, NAT MED, V14, P949, DOI 10.1038/nm.1855; Yousefi S, 2019, EUR J IMMUNOL, V49, P221, DOI 10.1002/eji.201747053; Yousefi S, 2012, CURR OPIN IMMUNOL, V24, P736, DOI 10.1016/j.coi.2012.08.010; Yun Y, 2020, ALLERGOL INT, V69, P232, DOI 10.1016/j.alit.2019.11.002; Zhang N, 2016, ALLERGY, V71, P295, DOI 10.1111/all.12809; Zhang Y, 2017, J ALLERGY CLIN IMMUN, V140, P1230, DOI 10.1016/j.jaci.2017.09.009	146	20	21	1	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2021	148	2					327	335		10.1016/j.jaci.2021.03.024	http://dx.doi.org/10.1016/j.jaci.2021.03.024		AUG 2021	9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TZ7BX	33895002	Green Accepted			2022-12-18	WOS:000684625700007
J	Al Kindi, A; Williams, H; Matsuda, K; Alkahtani, AM; Saville, C; Bennett, H; Alshammari, Y; Tan, SY; O'Neill, C; Tanaka, A; Matsuda, H; Arkwright, PD; Pennock, JL				Al Kindi, Arwa; Williams, Helen; Matsuda, Kenshiro; Alkahtani, Abdullah M.; Saville, Charis; Bennett, Hayley; Alshammari, Yasmine; Tan, Soo Y.; O'Neill, Catherine; Tanaka, Akane; Matsuda, Hiroshi; Arkwright, Peter D.; Pennock, Joanne L.			Staphylococcus aureus second immunoglobulin-binding protein drives atopic dermatitis via IL-33	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Staphylococcus aureus; atopic dermatitis; second immunoglobulin-binding protein; Sbi; virulence factor; skin; kerati-nocytes; IL-33; TSLP; type 2 immune response	THYMIC STROMAL LYMPHOPOIETIN; SKIN; EXPRESSION; KERATINOCYTES; FILAGGRIN; ALPHA	Background: Staphylococcus aureus is the dominant infective trigger of atopic dermatitis (AD). How this bacterium drives type 2 allergic pathology in the absence of infection in patients with AD is unclear. Objective: We sought to identify the S aureus?derived virulence factor(s) that initiates the cutaneous type 2-promoting immune response responsible for AD. Methods: In vitro human keratinocyte cell culture, ex vivo human skin organ explants, and the eczema-prone Nishikinezumi Cinnamon/Tokyo University of Agriculture and Technology strain mouse were used as model systems to assess type 2-promoting immune responses to S aureus. Identification of the bioactive factor was accomplished using fast protein liquid chromatography and mass spectrometry. Bioactivity was confirmed by cloning and expression in an Escherichia coli vector system, and S aureus second immunoglobulin-binding protein (Sbi) mutant strains confirming loss of activity. Results: S aureus was unique among staphylococcal species in its ability to induce the rapid release of constitutive IL-33 from human keratinocytes independent of the Toll-like receptor pathway. Using the eczema-prone Nishiki-nezumi Cinnamon/ Tokyo University of Agriculture and Technology strain mouse model, we showed that IL-33 was essential for inducing the immune response to S aureus in vivo. By fractionation and candidate testing, we identified Sbi as the predominant staphylococcus-derived virulence factor that directly drives IL-33 release from human keratinocytes. Immunohistology of skin demonstrated that corneodesmosin, a component of corneodesmosomes that form key intercellular adhesive structures in the stratum corneum, was disrupted, resulting in reduction of skin barrier function. Conclusions: S aureus-derived Sbi is a unique type 2-promoting virulence factor capable of initiating the type 2-promoting cytokine activity underlying AD. (J Allergy Clin Immunol 2021;147:1354-68.)	[Al Kindi, Arwa; Williams, Helen; Saville, Charis; Alshammari, Yasmine; Arkwright, Peter D.; Pennock, Joanne L.] Univ Manchester, Lydia Becker Inst Immunol & Inflammat, Manchester, Lancs, England; [Matsuda, Kenshiro] Univ Tsukuba, Ctr Innovat Drug Discovery, Tsukuba, Ibaraki, Japan; [Alkahtani, Abdullah M.] King Khalid Univ, Dept Med Microbiol & Parasitol, Abha, Saudi Arabia; [Bennett, Hayley] Univ Manchester, Genome Editing Unit, Manchester, Lancs, England; [Tan, Soo Y.] Natl Univ Hlth Syst, Singapore, Singapore; [O'Neill, Catherine] Univ Manchester, Div Dermatol & Musculoskeletal Sci, Manchester, Lancs, England; [Tanaka, Akane] Tokyo Univ Agr & Technol, Lab Comparat Anim Med, Tokyo, Japan; [Matsuda, Hiroshi] Tokyo Univ Agr & Technol, Lab Vet Mol Pathol & Therapeut, Tokyo, Japan	University of Manchester; University of Tsukuba; King Khalid University; University of Manchester; National University of Singapore; University of Manchester; Tokyo University of Agriculture & Technology; Tokyo University of Agriculture & Technology	Arkwright, PD (corresponding author), Univ Manchester, Lydia Becker Inst Immunol & Inflammat, Core Technol Facil, Room 2-21,46 Grafton St, Manchester M13 9NT, Lancs, England.	peter.arkwright@manchester.ac.uk	Pennock, Jo/AGZ-1209-2022; Tanaka, Akane/G-1158-2013	Pennock, Jo/0000-0002-8304-2905; Tanaka, Akane/0000-0002-7906-5047; Alshammari, Yasmine/0000-0002-5655-741X; Matsuda, Kenshiro/0000-0002-7960-1663	LEO Foundation [LF16080]; Government of the Sultanate of Oman; Japan Society for the Promotion of Science [17H06669, 16H06383, 19H00969, 18KK0191]; Biotechnology & Biological Sciences Research Council (BBSRC); Wellcome; University of Manchester Strategic Fund	LEO Foundation(LEO Pharma); Government of the Sultanate of Oman; Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Biotechnology & Biological Sciences Research Council (BBSRC)(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome; University of Manchester Strategic Fund	This research was supported by the LEO Foundation (project grant no. LF16080). A.A.K. received a scholarship from the Government of the Sultanate of Oman. The Grant-in-Aid for Scientific Research grants Start-up number 17H06669 (to K.M.), S #16H06383 (to H.M.), and A #19H00969 and Fostering Joint International Research B #18KK0191 (to A.T.) were provided by the Japan Society for the Promotion of Science. The University of Manchester flow cytometry core facility-flow cytometers used in this study were purchased with grants from Biotechnology & Biological Sciences Research Council (BBSRC), Wellcome, and the University of Manchester Strategic Fund.	Al Kindi A, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02242; Amagai Y, 2013, BIOL PHARM BULL, V36, P1248, DOI 10.1248/bpb.b13-00333; Askarian F, 2018, FEMS MICROBIOL REV, V42, P656, DOI 10.1093/femsre/fuy025; Aufiero B, 2007, INT J DERMATOL, V46, P687, DOI 10.1111/j.1365-4632.2007.03161.x; Berscheid A, 2012, INT J MED MICROBIOL, V302, P84, DOI 10.1016/j.ijmm.2012.01.002; Brauweiler AM, 2020, J INVEST DERMATOL, V140, P915, DOI 10.1016/j.jid.2019.09.004; Byrd AL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal4651; Casanova JL, 2018, SEMIN IMMUNOL, V36, P1, DOI 10.1016/j.smim.2017.12.008; Chen YL, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aax2945; Gonzalez CD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131879; Diep BA, 2006, LANCET, V367, P731, DOI 10.1016/S0140-6736(06)68231-7; Esposito S, 2016, CURR OPIN INFECT DIS, V29, P109, DOI 10.1097/QCO.0000000000000239; Fischer A, 2018, SEMIN IMMUNOL, V36, P13, DOI 10.1016/j.smim.2017.12.001; Fyhrquist N, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12253-y; Geoghegan JA, 2018, TRENDS MICROBIOL, V26, P484, DOI 10.1016/j.tim.2017.11.008; Honda T, 2020, J ALLERGY CLIN IMMUN, V145, P1136, DOI 10.1016/j.jaci.2020.02.008; Jang H, 2016, J INVEST DERMATOL, V136, P127, DOI 10.1038/JID.2015.363; Jonca N, 2002, J BIOL CHEM, V277, P5024, DOI 10.1074/jbc.M108438200; Jonca N, 2010, OPEN DERMATOL J, V4, P36; Kim J, 2019, ALLERGY ASTHMA IMMUN, V11, P593, DOI 10.4168/aair.2019.11.5.593; Kishibe M, 2019, J DERMATOL SCI, V95, P50, DOI 10.1016/j.jdermsci.2019.06.007; Koch TK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047638; Lacey KA, 2016, PATHOGENS, V5, DOI 10.3390/pathogens5010022; Lan F, 2018, AM J RESP CRIT CARE, V198, P452, DOI 10.1164/rccm.201710-2112OC; Leung DYM, 2020, J ALLERGY CLIN IMMUN, V145, P1485, DOI 10.1016/j.jaci.2020.02.021; Lowe AJ, 2018, ANN ALLERG ASTHMA IM, V120, P145, DOI 10.1016/j.anai.2017.11.023; Lunjani N, 2019, CURR OPIN ALLERGY CL, V19, P328, DOI 10.1097/ACI.0000000000000542; Matsui K, 2020, J PHARM PHARM SCI, V23, P86, DOI 10.18433/jpps30847; Meephansan J, 2013, J DERMATOL SCI, V71, P107, DOI 10.1016/j.jdermsci.2013.04.014; Moussion C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003331; Nakamura Y, 2013, NATURE, V503, P397, DOI 10.1038/nature12655; Noguchi A, 2017, J DERMATOL SCI, V86, P54, DOI 10.1016/j.jdermsci.2016.12.015; Paller AS, 2019, J ALLERGY CLIN IMMUN, V143, P26, DOI 10.1016/j.jaci.2018.11.015; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Poulakou G, 2019, CURR OPIN INFECT DIS, V32, P77, DOI 10.1097/QCO.0000000000000527; Proctor LM, 2019, NATURE, V569, P641, DOI 10.1038/s41586-019-1238-8; Segawa R, 2018, J DERMATOL SCI, V89, P290, DOI 10.1016/j.jdermsci.2017.12.008; Simpson EL, 2016, NEW ENGL J MED, V375, P2335, DOI 10.1056/NEJMoa1610020; Smith EJ, 2011, INFECT IMMUN, V79, P3801, DOI 10.1128/IAI.05075-11; Smith FJD, 2006, NAT GENET, V38, P337, DOI 10.1038/ng1743; Stentzel S, 2017, J ALLERGY CLIN IMMUN, V139, P492, DOI 10.1016/j.jaci.2016.03.045; Teufelberger AR, 2018, J ALLERGY CLIN IMMUN, V141, P549, DOI 10.1016/j.jaci.2017.05.004; Vu AT, 2010, J ALLERGY CLIN IMMUN, V126, P985, DOI 10.1016/j.jaci.2010.09.002; Wang XN, 2019, MEDIAT INFLAMM, V2019, DOI 10.1155/2019/2945083; Weidinger S, 2016, LANCET, V387, P1109, DOI 10.1016/S0140-6736(15)00149-X; Yoshikawa FSY, 2019, TOXINS, V11, DOI 10.3390/toxins11060321; Zhang LH, 1998, MICROBIOL-UK, V144, P985, DOI 10.1099/00221287-144-4-985	47	20	20	3	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2021	147	4					1354	+		10.1016/j.jaci.2020.09.023	http://dx.doi.org/10.1016/j.jaci.2020.09.023		APR 2021	18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RX3VK	33011245	Green Submitted			2022-12-18	WOS:000647154500001
J	Ebo, DG; Bridts, CH; Mertens, CH; Sabato, V				Ebo, Didier G.; Bridts, Chris H.; Mertens, Christel H.; Sabato, Vito			Principles, potential, and limitations of ex vivo basophil activation by flow cytometry in allergology: A narrative review	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Allergy; anaphylaxis; basophil; basophil activation; CD63; CD203c; flow cytometry; histamine; HistaFlow; IgE; mast cell; mast cell activation		The major challenge of allergy diagnosis lies in the development of accessible and reliable diagnostics allowing correct prediction of the clinical outcome following exposure to the offending allergen(s) and cross-reactive structures. Since the late nineties, evidence has accumulated that flow-assisted analysis and quantification of ex vivo?activated basophils (according to the basophil activation test [BAT]) might meet this requirement for different IgE-dependent allergies and particular forms of autoimmune urticaria. Other so-called nondiagnostic applications of the BAT involve therapeutic monitoring, followup of natural histories, and identification of allergenic recognition sites. However, it has also become clear that appropriate use of the BAT necessitates knowledge about degranulation metrics and guidance to guarantee correct execution and interpretation of the results. Here, we have reviewed the most relevant applications and limitations of the BAT. Some personal statements and views about its perspectives are made. (J Allergy Clin Immunol 2021;147:1143-53.)	[Ebo, Didier G.; Bridts, Chris H.; Mertens, Christel H.; Sabato, Vito] Antwerp Univ, Fac Med & Hlth Sci, Dept Immunol, Allergol,Rheumatol, Antwerp, Belgium; [Ebo, Didier G.; Bridts, Chris H.; Mertens, Christel H.; Sabato, Vito] Antwerp Univ, Infla Med Ctr Excellence, Antwerp, Belgium; [Ebo, Didier G.; Bridts, Chris H.; Mertens, Christel H.; Sabato, Vito] Antwerp Univ Hosp, Immunol, Allergol, Rheumatol, Antwerp, Belgium; [Ebo, Didier G.; Sabato, Vito] AZ Jan Palfijn Gent, Dept Immunol & Allergol, Ghent, Belgium	University of Antwerp; University of Antwerp; University of Antwerp	Ebo, DG (corresponding author), Univ Antwerp, Fac Med & Hlth Sci, Immunol Allergol Rheumatol, Campus Drie Eiken T5-95,Univ Pl 1, B-2610 Antwerp, Belgium.	immuno@uantwerpen.be	Mertens, Christel/T-8085-2017; EBO, Didier/H-4894-2016	Mertens, Christel/0000-0003-2359-0771; EBO, Didier/0000-0003-0672-7529	Research Foundation Flanders [1800614N, 1804518N]	Research Foundation Flanders(FWO)	D.E. is a senior clinical researcher of the Research Foundation Flanders (grant 1800614N). Vito Sabato is a senior clinical researcher of the Research Foundation Flanders (grant 1804518N).	Acosta GS, 2020, J ALLERGY CLIN IMMUN, V146, P894, DOI 10.1016/j.jaci.2020.03.015; Alenius H, 1996, CLIN EXP ALLERGY, V26, P341, DOI 10.1046/j.1365-2222.1996.d01-312.x; Aljadi Z, 2019, CLIN IMMUNOL, V209, DOI 10.1016/j.clim.2019.108268; Aranda A, 2011, ALLERGY, V66, P247, DOI 10.1111/j.1398-9995.2010.02460.x; Bahri Rajia, 2020, Methods Mol Biol, V2163, P227, DOI 10.1007/978-1-0716-0696-4_19; Bahri R, 2018, J ALLERGY CLIN IMMUN, V142, P485, DOI 10.1016/j.jaci.2018.01.043; Bidad K, 2014, CYTOM PART B-CLIN CY, V86, P183, DOI 10.1002/cyto.b.21148; Black KM, 1996, INT ARCH ALLERGY IMM, V111, P142, DOI 10.1159/000237359; Bonadonna P, 2012, ALLERGY, V67, P962, DOI 10.1111/j.1398-9995.2012.02849.x; Bridts Chris H, 2020, Methods Mol Biol, V2163, P183, DOI 10.1007/978-1-0716-0696-4_15; Cady CT, 2010, IMMUNOL LETT, V130, P57, DOI 10.1016/j.imlet.2009.12.001; Campos L, 2019, CURR ALLERGY ASTHM R, V19, DOI 10.1007/s11882-019-0852-8; Celesnik N, 2012, ALLERGY, V67, P1594, DOI 10.1111/all.12044; Chapuis A, 2018, J ALLER CL IMM-PRACT, V6, P1772, DOI 10.1016/j.jaip.2018.01.021; Chen Q, 2017, J EUR ACAD DERMATOL, V31, P463, DOI 10.1111/jdv.13912; Chinthrajah RS, 2019, LANCET, V394, P1437, DOI 10.1016/S0140-6736(19)31793-3; Chinthrajah RS, 2018, ANN ALLERG ASTHMA IM, V121, P69, DOI 10.1016/j.anai.2018.04.020; Commins SP, 2020, EXPERT REV CLIN IMMU, V16, P667, DOI 10.1080/1744666X.2020.1782745; Dahlen B, 2011, CLIN EXP ALLERGY, V41, P1091, DOI 10.1111/j.1365-2222.2011.03763.x; Decuyper II, 2018, ALLERGY, V73, P1911, DOI 10.1111/all.13491; Decuyper II, 2020, J ALLER CL IMM-PRACT, V8, P2421, DOI 10.1016/j.jaip.2020.03.031; Decuyper II, 2020, ALLERGY, V75, P616, DOI 10.1111/all.14040; Decuyper II, 2019, J ALLER CL IMM-PRACT, V7, P983, DOI 10.1016/j.jaip.2018.09.017; Deng S, 2019, WORLD ALLERGY ORGAN, V12, DOI 10.1016/j.waojou.2019.100043; Devouassoux G, 1999, J ALLERGY CLIN IMMUN, V104, P811, DOI 10.1016/S0091-6749(99)70292-7; Dreborg S, 2018, J ALLER CL IMM-PRACT, V6, P1089, DOI 10.1016/j.jaip.2017.10.038; Eberlein B, 2012, J ALLERGY CLIN IMMUN, V130, P155, DOI 10.1016/j.jaci.2012.02.008; Eberlein-Konig B, 2006, ALLERGY, V61, P897, DOI 10.1111/j.1398-9995.2006.01099.x; Ebo DG, 2007, J INVEST ALLERG CLIN, V17, P357; Ebo DG, 2007, CLIN EXP ALLERGY, V37, P1668, DOI 10.1111/j.1365-2222.2007.02819.x; Ebo DG, 2007, CYTOM PART B-CLIN CY, V72B, P196, DOI 10.1002/cyto.b.20142; Ebo DG, 2006, ALLERGY, V61, P935, DOI 10.1111/j.1398-9995.2006.01094.x; Ebo DG, 2013, INT ARCH ALLERGY IMM, V161, P220, DOI 10.1159/000346721; Ebo DG, 2004, CLIN EXP ALLERGY, V34, P137, DOI 10.1111/j.1365-2222.2004.01837.x; Ebo DG, 2005, CYTOM PART B-CLIN CY, V64B, P28, DOI 10.1002/cyto.b.20042; Ebo DG, 2002, ALLERGY, V57, P706, DOI 10.1034/j.1398-9995.2002.23553.x; Ebo Didier G, 2020, Methods Mol Biol, V2163, P197, DOI 10.1007/978-1-0716-0696-4_16; Ebo DG, 2020, CYTOM PART B-CLIN CY, V98, P483, DOI 10.1002/cyto.b.21868; Ebo DG, 2020, J ALLER CL IMM-PRACT, V8, P1410, DOI 10.1016/j.jaip.2019.11.018; Ebo DG, 2012, J IMMUNOL METHODS, V375, P30, DOI 10.1016/j.jim.2011.09.003; Ejrnaes AM, 2006, CLIN EXP ALLERGY, V36, P273, DOI 10.1111/j.1365-2222.2006.02442.x; Elst J, 2020, BRIT J ANAESTH, V125, P970, DOI 10.1016/j.bja.2020.06.024; Elst Jessy, 2020, Methods Mol Biol, V2163, P219, DOI 10.1007/978-1-0716-0696-4_18; Erdmann SM, 2005, INT ARCH ALLERGY IMM, V136, P230, DOI 10.1159/000083949; Erdmann SM, 2004, ALLERGY, V59, P1102, DOI 10.1111/j.1398-9995.2004.00624.x; Faber MA, 2015, J ALLERGY CLIN IMMUN, V135, P1645, DOI 10.1016/j.jaci.2014.12.1919; Faber M, 2014, CURR PHARM DESIGN, V20, P954, DOI 10.2174/13816128113199990046; FAHLBUSCH B, 1995, INT ARCH ALLERGY IMM, V108, P119, DOI 10.1159/000237128; Falcone Franco H, 2020, Methods Mol Biol, V2163, P35, DOI 10.1007/978-1-0716-0696-4_2; Falcone Franco H, 2014, Methods Mol Biol, V1192, P35, DOI 10.1007/978-1-4939-1173-8_2; Feng ML, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00030; Fernandez TD, 2009, ALLERGY, V64, P242, DOI 10.1111/j.1398-9995.2008.01713.x; Fernandez TD, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003679; Finkelman FD, 2016, J ALLERGY CLIN IMMUN, V137, P1674, DOI 10.1016/j.jaci.2016.02.015; Ford LS, 2013, J ALLERGY CLIN IMMUN, V131, P180, DOI 10.1016/j.jaci.2012.06.003; Gentinetta T, 2011, J ALLERGY CLIN IMMUN, V128, P1227, DOI 10.1016/j.jaci.2011.07.021; Gernez Y, 2011, INT ARCH ALLERGY IMM, V154, P318, DOI 10.1159/000321824; Giavi S, 2016, ALLERGY, V71, P1575, DOI 10.1111/all.12905; Giavina-Bianchi P, 2017, J ALLER CL IMM-PRACT, V5, P728, DOI 10.1016/j.jaip.2016.11.006; Gibbs BF, 2012, EXP DERMATOL, V21, P884, DOI 10.1111/exd.12018; Glaumann S, 2012, ALLERGY, V67, P242, DOI 10.1111/j.1398-9995.2011.02754.x; Goldberg MR, 2015, J ALLERGY CLIN IMMUN, V136, P1601, DOI 10.1016/j.jaci.2015.05.040; Gomez E, 2013, J ALLERGY CLIN IMMUN, V132, P975, DOI 10.1016/j.jaci.2013.07.016; Harrer A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013707; Hauswirth AW, 2007, INT J IMMUNOPATH PH, V20, P267, DOI 10.1177/039463200702000207; Hayen SM, 2018, CLIN EXP ALLERGY, V48, P890, DOI 10.1111/cea.13134; Heinemann A, 2003, PHARMACOLOGY, V67, P49, DOI 10.1159/000066786; Hennersdorf F, 2005, CELL RES, V15, P325, DOI 10.1038/sj.cr.7290301; Hoffmann HJ, 2015, ALLERGY, V70, P1393, DOI 10.1111/all.12698; Huston DP, 2018, J ALLER CL IMM-PRACT, V6, P1171, DOI 10.1016/j.jaip.2018.06.001; Irinyi B, 2013, BRIT J DERMATOL, V168, P656, DOI 10.1111/j.1365-2133.2012.11179.x; Iweala OI, 2020, J ALLERGY CLIN IMMUN, V146, P450, DOI 10.1016/j.jaci.2020.02.006; Joulia R, 2017, J ALLERGY CLIN IMMUN, V140, P1159, DOI 10.1016/j.jaci.2017.03.030; Keet CA, 2012, J ALLERGY CLIN IMMUN, V129, P448, DOI 10.1016/j.jaci.2011.10.023; Kepley CL, 2000, J IMMUNOL, V165, P5913, DOI 10.4049/jimmunol.165.10.5913; Kim EH, 2019, J ALLERGY CLIN IMMUN, V144, P1320, DOI 10.1016/j.jaci.2019.07.030; Kim SH, 2018, ASIA PAC ALLERGY, V8, DOI 10.5415/apallergy.2018.8.e6; KNOL EF, 1991, J ALLERGY CLIN IMMUN, V88, P328, DOI 10.1016/0091-6749(91)90094-5; Korosec P, 2013, INT ARCH ALLERGY IMM, V161, P363, DOI 10.1159/000348500; Kosnik M, 2005, ALLERGY, V60, P1401, DOI 10.1111/j.1398-9995.2005.00894.x; Krithika N, 2018, EUR ANN ALLERGY CLIN, V50, P243, DOI 10.23822/EurAnnACI.1764-1489.64; Lalek N, 2010, CLIN EXP ALLERGY, V40, P1186, DOI 10.1111/j.1365-2222.2010.03524.x; Larsen JN, 2019, METHODS MOL BIOL, V2020, P63, DOI 10.1007/978-1-4939-9591-2_5; Larsen LF, 2018, ALLERGY, V73, P137, DOI 10.1111/all.13243; Leysen J, 2013, CYTOM PART B-CLIN CY, V84B, P65, DOI 10.1002/cyto.b.21074; MacGlashan D, 2010, CLIN EXP ALLERGY, V40, P1365, DOI 10.1111/j.1365-2222.2010.03572.x; MacGlashan D, 2012, INT ARCH ALLERGY IMM, V159, P243, DOI 10.1159/000332150; MacGlashan DW, 2013, J ALLERGY CLIN IMMUN, V132, P777, DOI 10.1016/j.jaci.2013.06.038; Matsui T, 2020, IMMUN INFLAMM DIS, V8, P188, DOI 10.1002/iid3.294; Maurer M, 2020, INT ARCH ALLERGY IMM, V181, P321, DOI 10.1159/000507218; Mayorga C, 2019, J ALLERGY CLIN IMMUN, V143, P56, DOI 10.1016/j.jaci.2018.09.022; Mayorga C, 2013, INT ARCH ALLERGY IMM, V160, P377, DOI 10.1159/000343023; McNeil BD, 2015, NATURE, V519, P237, DOI 10.1038/nature14022; Mehlich J, 2019, J ALLERGY CLIN IMMUN, V143, P182, DOI 10.1016/j.jaci.2018.06.049; Moneret-Vautrin DA, 1999, ANN ALLERG ASTHMA IM, V82, P33, DOI 10.1016/S1081-1206(10)62657-9; Mueller-Wirth N, 2020, ALLERGY, V75, P3237, DOI 10.1111/all.14497; Mukai K, 2017, J ALLERGY CLIN IMMUN, V140, P1202, DOI 10.1016/j.jaci.2017.03.052; Mukai K, 2017, J ALLERGY CLIN IMMUN, V139, P889, DOI 10.1016/j.jaci.2016.04.060; Nachshon L, 2019, J ALLER CL IMM-PRACT, V7, P2775, DOI 10.1016/j.jaip.2019.05.031; Netchiporouk E, 2016, INT ARCH ALLERGY IMM, V171, P81, DOI 10.1159/000451084; Nopp A, 2006, ALLERGY, V61, P298, DOI 10.1111/j.1398-9995.2006.00987.x; Nullens S, 2013, CYTOM PART B-CLIN CY, V84B, P173, DOI 10.1002/cyto.b.21084; Ocmant A, 2009, CLIN EXP ALLERGY, V39, P1234, DOI 10.1111/j.1365-2222.2009.03292.x; Ott H, 2011, KLIN PADIATR, V223, P27, DOI 10.1055/s-0030-1268430; Patil SU, 2019, J ALLERGY CLIN IMMUN, V144, P1310, DOI 10.1016/j.jaci.2019.07.028; Patil SU, 2018, CYTOM PART B-CLIN CY, V94, P667, DOI 10.1002/cyto.b.21537; Pramod SN, 2007, CLIN EXP IMMUNOL, V148, P391, DOI 10.1111/j.1365-2249.2007.03368.x; Reier-Nilsen T, 2018, CLIN EXP ALLERGY, V48, P415, DOI 10.1111/cea.13078; Rietveld MJA, 2016, INT ARCH ALLERGY IMM, V169, P125, DOI 10.1159/000444996; Rubio A, 2011, ALLERGY, V66, P92, DOI 10.1111/j.1398-9995.2010.02432.x; Ruinemans-Koerts J, 2019, CLIN EXP ALLERGY, V49, P350, DOI 10.1111/cea.13307; Sabato V, 2011, J INVEST ALLERG CLIN, V21, P527; Sabato V, 2017, J ALLERGY CLIN IMMUN, V139, pAB168, DOI 10.1016/j.jaci.2016.12.550; Sabato V, 2012, CYTOM PART B-CLIN CY, V82B, P132, DOI 10.1002/cyto.b.21003; Santos AF, 2020, J ALLERGY CLIN IMMUN, V146, P344, DOI 10.1016/j.jaci.2020.03.035; Santos AF, 2018, J ALLERGY CLIN IMMUN, V142, P689, DOI 10.1016/j.jaci.2018.03.011; Santos AF, 2016, CLIN TRANSL ALLERGY, V6, DOI 10.1186/s13601-016-0098-7; Santos AF, 2015, J ALLERGY CLIN IMMUN, V135, P179, DOI 10.1016/j.jaci.2014.09.001; Santos AF, 2014, J ALLERGY CLIN IMMUN, V134, P645, DOI 10.1016/j.jaci.2014.04.039; Sanz ML, 2001, CLIN EXP ALLERGY, V31, P1007, DOI 10.1046/j.1365-2222.2001.01122.x; Sato S, 2010, INT ARCH ALLERGY IMM, V152, P54, DOI 10.1159/000312126; Schmid JM, 2014, J ALLERGY CLIN IMMUN, V134, P741, DOI 10.1016/j.jaci.2014.04.029; Sharif H, 2019, J ALLERGY CLIN IMMUN, V144, P738, DOI 10.1016/j.jaci.2019.02.023; Shreffler WG, 2009, J ALLERGY CLIN IMMUN, V123, P43, DOI [10.1016/j.jaci.2008.12.1128, 10.1016/j.jaci.2008.09.051]; Song Y, 2015, ANN ALLERG ASTHMA IM, V114, P319, DOI 10.1016/j.anai.2015.01.006; Sturm EM, 2010, CYTOM PART B-CLIN CY, V78B, P308, DOI 10.1002/cyto.b.20526; Sturm GJ, 2009, ALLERGY, V64, P1319, DOI 10.1111/j.1398-9995.2009.02004.x; Sturm GJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020842; Takazawa T, 2019, BRIT J ANAESTH, V123, pE117, DOI 10.1016/j.bja.2019.01.002; Thevenot J, 2019, J INVEST ALLERG CLIN, V29, P141, DOI 10.18176/jiaci.0350; Tomassen MMM, 2007, J EXP BOT, V58, P1151, DOI 10.1093/jxb/erl288; Tsai M, 2020, J ALLERGY CLIN IMMUN, V145, P885, DOI 10.1016/j.jaci.2019.10.038; Uyttebroek AP, 2014, ALLERGY, V69, P1324, DOI 10.1111/all.12468; Van Gasse AL, 2017, ALLERGY, V72, P2039, DOI 10.1111/all.13236; Van Gasse AL, 2019, J ALLER CL IMM-PRACT, V7, P998, DOI 10.1016/j.jaip.2018.09.034; Van Gasse AL, 2015, J ALLER CL IMM-PRACT, V3, P396, DOI 10.1016/j.jaip.2014.12.002; vanderVeen MJ, 1997, J ALLERGY CLIN IMMUN, V100, P327, DOI 10.1016/S0091-6749(97)70245-8; Verweij MM, 2012, CYTOM PART B-CLIN CY, V82B, P101, DOI 10.1002/cyto.b.20629; Watson BM, 2014, INT ARCH ALLERGY IMM, V165, P255, DOI 10.1159/000370068; Wedi B, 2020, ALLERGY, V75, P2229, DOI 10.1111/all.14213; Yoshimura C, 2002, J ALLERGY CLIN IMMUN, V109, P817, DOI 10.1067/mai.2002.123532; Zenarruzabeitia O, 2019, J ALLERGY CLIN IMMUN, V143, P700, DOI 10.1016/j.jaci.2018.05.022; Zitnik SEK, 2012, PEDIAT ALLERG IMM-UK, V23, P167, DOI 10.1111/j.1399-3038.2011.01233.x	143	20	21	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2021	147	4					1143	1153		10.1016/j.jaci.2020.10.027	http://dx.doi.org/10.1016/j.jaci.2020.10.027		APR 2021	11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RJ1NP	33152367				2022-12-18	WOS:000637368900003
J	Keet, C; Plesa, M; Szelag, D; Shreffler, W; Wood, R; Dunlop, J; Peng, R; Dantzer, J; Hamilton, RG; Togias, A; Pistiner, M				Keet, Corinne; Plesa, Mihaela; Szelag, Daria; Shreffler, Wayne; Wood, Robert; Dunlop, Joan; Peng, Roger; Dantzer, Jennifer; Hamilton, Robert G.; Togias, Alkis; Pistiner, Michael			Ara h 2?specific IgE is superior to whole peanut extract?based serology or skin prick test for diagnosis of peanut allergy in infancy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Peanut allergy; screening; diagnostic test; Ara h-2; skin prick test; peanut components	FOOD ALLERGY; COMPONENTS	Background: Screening of high-risk infants for peanut allergy (PA) before introduction is now recommended in the United States, but the optimal approach is not clear. Objective: We sought to compare the diagnostic test characteristics of peanut skin prick test (SPT), peanut-specific IgE (sIgE), and sIgE to peanut components in a screening population of infants before known peanut exposure. Methods: Infants aged 4 to 11 months with (1) no history of peanut ingestion, testing, or reaction and (2) (a) moderate severe eczema, (b) history of food allergy, and/or (c) first-degree relative with a history of PA received peanut SPT, peanut-sIgE and component-IgE testing, and, depending on SPT wheal size, oral food challenge or observed feeding. Receiver-operator characteristic areas under the curve (AUCs) were compared, and diagnostic sensitivity and specificity were calculated. Results: A total of 321 subjects completed the enrollment visit (median age, 7.2 months; 58% males), and 37 (11%) were found to have PA. Overall, Ara h 2-sIgE at a cutoff point of 0.1 kUa/L discriminated between allergic and nonallergic best (AUC, 0.96; sensitivity, 94%; specificity, 98%), compared with peanut-sIgE at 0.1 kUa/L (AUC, 0.89; sensitivity, 100%; specificity, 78%) or 0.35 kUa/L (AUC, 0.91; sensitivity, 97%; specificity, 86%), or SPT at wheal size 3 mm (AUC, 0.90; sensitivity, 92%; specificity, 88%) or 8 mm (AUC, 0.87; sensitivity, 73%; specificity, 99%). Ara h 1-sIgE and Ara h 3-sIgE did not add to prediction of PA when included in a model with Ara h 2-sIgE, and Ara h 8-sIgE discriminated poorly (AUC, 0.51). Conclusions: Measurement of only Ara h 2-sIgE should be considered if screening of high-risk infants is performed before peanut introduction. (J Allergy Clin Immunol 2021;147:977-83.)	[Keet, Corinne; Plesa, Mihaela; Szelag, Daria; Wood, Robert; Dunlop, Joan; Dantzer, Jennifer] Johns Hopkins Sch Med, Div Pediat Allergy Immunol & Rheumatol, Dept Pediat, Baltimore, MD USA; [Keet, Corinne] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA; [Shreffler, Wayne; Pistiner, Michael] Harvard Med Sch, Mass Gen Hosp Children, Dept Pediat, Div Pediat Allergy & Immunol, Boston, MA 02115 USA; [Peng, Roger] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD USA; [Hamilton, Robert G.] Johns Hopkins Sch Med, Dept Med, Div Allergy & Clin Immunol, Baltimore, MD USA; [Togias, Alkis] NIAID, Div Allergy Immunol & Transplantat, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Harvard University; Harvard Medical School; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Keet, C (corresponding author), Johns Hopkins Sch Med, Div Pediat Allergy Immunol & Rheumatol, 600 N Wolfe St,Ste 1102, Baltimore, MD 21218 USA.	Ckeet1@jhmi.edu		Keet, Corinne/0000-0002-6585-239X	National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) [1U01AI125290]; National Center for Advancing Translational Sciences (NCATS), a component of the NIH [UL1 TR003098]; NIH Roadmap for Medical Research; Pearl M. Stetler Fund;  [1UL1TR002541-01]	National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Center for Advancing Translational Sciences (NCATS), a component of the NIH; NIH Roadmap for Medical Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pearl M. Stetler Fund; 	This study was funded by the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) (grant no. 1U01AI125290). This publication was made possible by the Johns Hopkins Institute for Clinical and Translational Research (ICTR), which is funded in part by the National Center for Advancing Translational Sciences (NCATS) (grant no. UL1 TR003098), a component of the NIH, and the NIH Roadmap for Medical Research. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of the Johns Hopkins ICTR, NCATS, or NIH. The project described was supported by grant number 1UL1TR002541-01. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources, the NCATS, or the NIH. J.D. is funded by the Pearl M. Stetler Fund.	[Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; Caubet JC, 2012, IMMUNOL ALLERGY CLIN, V32, P97, DOI 10.1016/j.iac.2011.11.002; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Garcia-Blanca A, 2015, PEDIAT ALLERG IMM-UK, V26, P497, DOI 10.1111/pai.12418; Keet C, 2021, J ALLERGY CLIN IMMUN; Keet CA, 2016, J ALLERGY CLIN IMMUN, V137, P1761, DOI 10.1016/j.jaci.2016.03.008; Klemans RJB, 2015, CLIN EXP ALLERGY, V45, P720, DOI 10.1111/cea.12412; de Oliveira LCL, 2013, J ALLER CL IMM-PRACT, V1, P394, DOI 10.1016/j.jaip.2013.05.010; Martinet J, 2016, INT ARCH ALLERGY IMM, V169, P216, DOI 10.1159/000446181; Nicolaou N, 2011, CURR OPIN ALLERGY CL, V11, P222, DOI 10.1097/ACI.0b013e32834656c2; Nilsson C, 2020, PEDIAT ALLERG IMM-UK, V31, P303, DOI 10.1111/pai.13201; Sicherer SH, 2018, J ALLERGY CLIN IMMUN, V141, P41, DOI 10.1016/j.jaci.2017.11.003; Togias A, 2017, J ALLERGY CLIN IMMUN, V139, P29, DOI 10.1016/j.jaci.2016.10.010; Tsai WY, 2008, STAT MED, V27, P15, DOI 10.1002/sim.2930; Valcour A, 2017, ANN ALLERG ASTHMA IM, V119, P262, DOI 10.1016/j.anai.2017.06.021	15	20	20	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2021	147	3					977	+		10.1016/j.jaci.2020.11.034	http://dx.doi.org/10.1016/j.jaci.2020.11.034		MAR 2021	9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RG4QF	33483152	Green Accepted			2022-12-18	WOS:000635524300002
J	Keet, C; Pistiner, M; Plesa, M; Szelag, D; Shreffler, W; Wood, R; Dunlop, J; Peng, R; Dantzer, J; Togias, A				Keet, Corinne; Pistiner, Michael; Plesa, Mihaela; Szelag, Daria; Shreffler, Wayne; Wood, Robert; Dunlop, Joan; Peng, Roger; Dantzer, Jennifer; Togias, Alkis			Age and eczema severity, but not family history, are major risk factors for peanut allergy in infancy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; peanut allergy; prevention; early introduction	FOOD ALLERGY; FEEDING GUIDELINES; PREVENTION; GENETICS; SOCIETY	Background: Whether to screen high-risk groups before early peanut introduction is controversial. Objective: We sought to determine the risk of peanut allergy (PA) before peanut introduction for infants with (1) moderate severe eczema, (2) another food allergy (FA), and/or (3) a first degree relative with peanut allergy (FH). Methods: Infants aged 4 to 11 months with no history of peanut ingestion, testing, or reaction and at least 1 of the above risk factors received peanut skin prick test and, depending on skin prick test wheal size, oral food challenge or observed feeding. Results: A total of 321 subjects completed the enrollment visit (median age, 7.2 months; 58% males); 78 had eczema only, 11 FA only, 107 FH only, and 125 had multiple risk factors. Overall, 18% of 195 with eczema, 19% of 59 with FA, and 4% of 201 with FH had PA. Only 1% of 115 with FH and no eczema had PA. Among those with eczema, older age (odds ratio [OR], 1.3; 95% CI, 1.04-1.68 per month), higher SCORing Atopic Dermatitis score (OR, 1.19; 95% CI, 1.06-1.34 per 5 points), black (OR, 5.79; 95% CI, 1.92-17.4 compared with white), or Asian race (OR, 6.98; 95% CI, 1.92-25.44) and suspected or diagnosed other FA (OR, 3.98; 95% CI, 1.62-9.80) were associated with PA. Conclusions: PA is common in infants with moderate-severe eczema, whereas FH without eczema is not a major risk factor, suggesting screening only in those with significant eczema. Even within the first year of life, introduction at later ages is associated with a higher risk of PA among those with eczema, supporting introduction of peanut as early as possible. (J Allergy Clin Immunol 2021;147:984-91.)	[Keet, Corinne; Plesa, Mihaela; Szelag, Daria; Wood, Robert; Dunlop, Joan; Dantzer, Jennifer] Johns Hopkins Sch Med, Div Pediat Allergy Immunol & Rheumatol, Dept Pediat, Baltimore, MD USA; [Keet, Corinne] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA; [Pistiner, Michael; Shreffler, Wayne] Harvard Med Sch, MassGen Hosp Children, Div Pediat Allergy & Immunol, Dept Pediat, Boston, MA 02115 USA; [Peng, Roger] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD USA; [Togias, Alkis] NIAID, Div Allergy Immunol & Transplantat, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Harvard University; Harvard Medical School; Massachusetts General Hospital; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Keet, C (corresponding author), Johns Hopkins Sch Med, Pediat Allergy Immunol & Rheumatol, 600 N Wolfe St,Ste 1102, Baltimore, MD 21218 USA.	Ckeet1@jhmi.edu		Keet, Corinne/0000-0002-6585-239X	National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases [1U01AI125290]; National Center for Advancing Translational Sciences (NCATS), a component of the NIH [UL1 TR003098]; NIH Roadmap for Medical Research; Pearl M. Stetler Fund;  [1UL1TR002541-01]	National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Center for Advancing Translational Sciences (NCATS), a component of the NIH; NIH Roadmap for Medical Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pearl M. Stetler Fund; 	This study was funded by the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (grant no. 1U01AI125290). This publication was made possible by the Johns Hopkins Institute for Clinical and Translational Research (ICTR), which is funded in part by the National Center for Advancing Translational Sciences (NCATS) (grant no. UL1 TR003098), a component of the NIH, and the NIH Roadmap for Medical Research. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of the Johns Hopkins ICTR, NCATS, or NIH. The project described was supported by grant number 1UL1TR002541-01. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources, the NCATS, or the NIH. J.D. is funded by the Pearl M. Stetler Fund.	Assa'ad A, 2017, ANN ALLERG ASTHMA IM, V118, P125, DOI 10.1016/j.anai.2016.11.014; Australian Society of Clinical Immunolgy and Allergy, 2016, INF FEED ALL PREV; Baker SS, 2000, PEDIATRICS, V106, P346; British Society for Allergy & Clinical Immunology, 2018, PREV FOOD ALL HIGH R; Brough HA, 2020, ALLERGY, V75, P2185, DOI 10.1111/all.14304; Du Toit G, 2015, NEW ENGL J MED, V372, P803, DOI 10.1056/NEJMoa1414850; Du Toit G, 2013, J ALLERGY CLIN IMMUN, V131, P135, DOI 10.1016/j.jaci.2012.09.015; Dunlop JH, 2019, J ALLERGY CLIN IMMUN, V144, P1727, DOI 10.1016/j.jaci.2019.08.009; E1. Fondation Pour La Dermatite Atopique Recherche et Education, SCORAD POSCORAD APPL; European Food Safety Authority, 2019, AGE START COMPL FEED; Fewtrell M, 2017, J PEDIATR GASTR NUTR, V64, P119, DOI 10.1097/MPG.0000000000001454; Greenhawt M, 2018, ANN ALLERG ASTHMA IM, V120, P620, DOI 10.1016/j.anai.2018.03.001; Greer FR, 2008, PEDIATRICS, V121, P183, DOI 10.1542/peds.2007-3022; Greer FR, 2019, PEDIATRICS, V143, DOI 10.1542/peds.2019-0281; Hong XM, 2009, CURR OPIN PEDIATR, V21, P770, DOI 10.1097/MOP.0b013e32833252dc; Hourihane JO, 1996, BRIT MED J, V313, P518, DOI 10.1136/bmj.313.7056.518; Johnson J, 2019, J ALLERGY CLIN IMMUN, V143, pAB421, DOI 10.1016/j.jaci.2018.12.945; Joshi PA, 2019, MED J AUSTRALIA, V210, P89, DOI 10.5694/mja2.12102; Keet CA, 2014, ANN ALLERG ASTHMA IM, V112, P222, DOI 10.1016/j.anai.2013.12.007; Koplin JJ, 2014, ALLERGY, V69, P1639, DOI 10.1111/all.12487; Koplin JJ, 2013, CLIN EXP ALLERGY, V43, P826, DOI 10.1111/cea.12090; Koplin JJ, 2016, J ALLERGY CLIN IMMUN, V138, P1131, DOI 10.1016/j.jaci.2016.04.011; Koplin JJ, 2013, INT J ENV RES PUB HE, V10, P5364, DOI 10.3390/ijerph10115364; Lavine E, 2015, CLIN EXP ALLERGY, V45, P249, DOI 10.1111/cea.12403; Lawson K, 2017, ALLERGY, V72, P1267, DOI 10.1111/all.13127; Liem Joel J, 2008, Allergy Asthma Clin Immunol, V4, P144, DOI 10.1186/1710-1492-4-4-144; Marenholz I, 2015, CURR OPIN ALLERGY CL, V15, P426, DOI 10.1097/ACI.0000000000000194; Martin PE, 2015, CLIN EXP ALLERGY, V45, P255, DOI 10.1111/cea.12406; McGowan EC, 2015, ANN ALLERG ASTHMA IM, V115, P85, DOI 10.1016/j.anai.2015.04.021; Natsume O, 2017, LANCET, V389, P276, DOI 10.1016/S0140-6736(16)31418-0; Netting MJ, 2017, J ALLER CL IMM-PRACT, V5, P1617, DOI 10.1016/j.jaip.2017.03.013; Perkin MR, 2016, NEW ENGL J MED, V374, P1733, DOI 10.1056/NEJMoa1514210; Rona RJ, 2007, J ALLERGY CLIN IMMUN, V120, P638, DOI 10.1016/j.jaci.2007.05.026; SCORAD, EUR TASK FORC AT DER; SCORAD & PO-SCORAD Applications, SCORAD POSCORAD APPL; Shaker M, 2018, ALLERGY, V73, P1707, DOI 10.1111/all.13446; Shaker MS, 2019, ALLERGY, V74, P2251, DOI 10.1111/all.13846; STALDER JF, 1993, DERMATOLOGY, V186, P23, DOI 10.1159/000247298; Tey D, 2014, J ALLERGY CLIN IMMUN, V133, P476, DOI 10.1016/j.jaci.2013.11.019; Togias A, 2017, J ALLERGY CLIN IMMUN, V139, P29, DOI 10.1016/j.jaci.2016.10.010; Volertas S, 2020, J ALLER CL IMM-PRACT, V8, P1091, DOI 10.1016/j.jaip.2019.12.008; Winters A, 2019, J ALLERGY CLIN IMMUN, V143, P2326, DOI 10.1016/j.jaci.2019.02.016; World Health Organization, COMPLEMENTARY FEEDIN	43	20	20	1	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2021	147	3					984	+		10.1016/j.jaci.2020.11.033	http://dx.doi.org/10.1016/j.jaci.2020.11.033		MAR 2021	13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RG4QF	33483153	Green Accepted			2022-12-18	WOS:000635524300003
J	Ueland, T; Heggelund, L; Lind, A; Holten, AR; Tonby, K; Michelsen, AE; Jenum, S; Jorgensen, MJ; Barratt-Due, A; Skeie, LG; Nordoy, I; Fraz, MSA; Quist-Paulsen, E; Pischke, SE; Johal, SK; Hesstvedt, L; Bogen, M; Fevang, B; Halvorsen, B; Muller, F; Bekken, GK; Mollnes, TE; Dudman, S; Aukrust, P; Dyrhol-Riise, AM; Holter, JC				Ueland, Thor; Heggelund, Lars; Lind, Andreas; Holten, Aleksander R.; Tonby, Kristian; Michelsen, Annika E.; Jenum, Synne; Jorgensen, Marthe J.; Barratt-Due, Andreas; Skeie, Linda G.; Nordoy, Ingvild; Fraz, Mai Sasaki Aanensen; Quist-Paulsen, Else; Pischke, Soren E.; Johal, Simreen K.; Hesstvedt, Liv; Bogen, Mette; Fevang, Borre; Halvorsen, Bente; Mueller, Fredrik; Bekken, Gry Kloumann; Mollnes, Tom E.; Dudman, Susanne; Aukrust, Pal; Dyrhol-Riise, Anne M.; Holter, Jan C.			Elevated plasma sTIM-3 levels in patients with severe COVID-19	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						COVID-19; outcome; T cell; TIM-3; neutrophil	T-CELL; CORONAVIRUS	Background: The pathogenesis of coronavirus disease 2019 (COVID-19) is still incompletely understood, but it seems to involve immune activation and immune dysregulation. Objective: We examined the parameters of activation of different leukocyte subsets in COVID-19-infected patients in relation to disease severity. Methods: We analyzed plasma levels of myeloperoxidase (a marker of neutrophil activation), soluble (s) CD25 (sCD25) and soluble T-cell immunoglobulin mucin domain-3 (sTIM-3) (markers of T-cell activation and exhaustion), and sCD14 and sCD163 (markers of monocyte/macrophage activation) in 39 COVID-19-infected patients at hospital admission and 2 additional times during the first 10 days in relation to their need for intensive care unit (ICU) treatment. Results: Our major findings were as follows: (1) severe clinical outcome (ICU treatment) was associated with high plasma levels of sTIM-3 and myeloperoxidase, suggesting activated and potentially exhausted T cells and activated neutrophils, respectively; (2) in contrast, sCD14 and sCD163 showed no association with need for ICU treatment; and (3) levels of sCD25, sTIM-3, and myeloperoxidase were inversely correlated with degree of respiratory failure, as assessed by the ratio of PaO2 to fraction of inspired oxygen, and were positively correlated with the cardiac marker N-terminal pro-B-type natriuretic peptide. Conclusion: Our findings suggest that neutrophil activation and, in particular, activated T cells may play an important role in the pathogenesis of COVID-19 infection, suggesting that T-cell-targeted treatment options and downregulation of neutrophil activation could be of importance in this disorder.	[Ueland, Thor; Michelsen, Annika E.; Nordoy, Ingvild; Fraz, Mai Sasaki Aanensen; Fevang, Borre; Halvorsen, Bente; Aukrust, Pal] Oslo Univ Hosp, Res Inst Internal Med, Oslo, Norway; [Fevang, Borre; Aukrust, Pal] Oslo Univ Hosp, Sect Clin Immunol & Infect Dis, Oslo, Norway; [Lind, Andreas; Quist-Paulsen, Else; Johal, Simreen K.; Mueller, Fredrik; Dudman, Susanne; Holter, Jan C.] Oslo Univ Hosp, Dept Microbiol, Oslo, Norway; [Holten, Aleksander R.; Barratt-Due, Andreas; Pischke, Soren E.] Oslo Univ Hosp, Div Emergencies & Crit Care, Oslo, Norway; [Tonby, Kristian; Jenum, Synne; Jorgensen, Marthe J.; Skeie, Linda G.; Hesstvedt, Liv; Dyrhol-Riise, Anne M.] Oslo Univ Hosp, Dept Infect Dis, Oslo, Norway; [Ueland, Thor; Michelsen, Annika E.; Jorgensen, Marthe J.; Quist-Paulsen, Else; Halvorsen, Bente; Mueller, Fredrik; Dudman, Susanne; Aukrust, Pal; Dyrhol-Riise, Anne M.; Holter, Jan C.] Univ Oslo, Inst Clin Med, Oslo, Norway; [Pischke, Soren E.; Mollnes, Tom E.] Univ Oslo, Dept Immunol, Oslo, Norway; [Ueland, Thor; Mollnes, Tom E.; Aukrust, Pal] Univ Tromso, KG Jebsen TREC, Fac Hlth Sci, Tromso, Norway; [Nordoy, Ingvild; Mollnes, Tom E.] Nordland Hosp, Res Lab, Bodo, Norway; [Mollnes, Tom E.] Norwegian Univ Sci & Technol, Ctr Mol Inflammat Res, Trondheim, Norway; [Heggelund, Lars] Univ Bergen, Fac Med, Dept Clin Sci, Bergen, Norway; [Heggelund, Lars; Bekken, Gry Kloumann] Drammen Hosp, Dept Internal Med, Drammen, Norway; [Bogen, Mette] Vestre Viken Hosp Trust, Dept Lab Med, Drammen, Norway	University of Oslo; University of Oslo; University of Oslo; University of Oslo; University of Oslo; University of Oslo; University of Oslo; UiT The Arctic University of Tromso; Norwegian University of Science & Technology (NTNU); University of Bergen	Ueland, T (corresponding author), Oslo Univ Hosp, Rikshosp, Res Inst Internal Med, PB 4950 Nydalen, N-0424 Oslo, Norway.	thor.ueland@medisin.uio.no	Dudman, Susanne/A-8411-2013; Heggelund, Lars/GSN-0026-2022; Lind, Andreas/AAN-3730-2021; Dudman, Susanne/ABC-5434-2020; Pischke, Soeren Erik/AAX-9676-2021	Dudman, Susanne/0000-0001-5047-4982; Lind, Andreas/0000-0002-8289-8410; Dudman, Susanne/0000-0001-5047-4982; Pischke, Soeren Erik/0000-0003-2543-3251; Ueland, Thor/0000-0001-5005-0784	Research Council of Norway [312780]	Research Council of Norway(Research Council of Norway)	This project has received a private donation from Vivaldi Invest A/S, which is owned by Jon Stephenson von Tetzchner, and has also received funding from COVID-19 Emergency Call for Proposals: Collaborative and Knowledge-building Projects for the Fight Against Coronavirus Disease (COVID-19) from the Research Council of Norway (grant no. 312780).	Ali SA, 2020, J INFECT PUBLIC HEAL, V13, P644, DOI [10.1016/j.jiph.2020.02.033, 10.1016/j.jiph.2019.02.033]; [Anonymous], LANCET, DOI DOI 10.1016/S0140-6736(20)30211-7; Bernheim A, 2020, RADIOLOGY, V295, P685, DOI 10.1148/radiol.2020200463; Carenzo L, 2020, ANAESTHESIA, V75, P928, DOI 10.1111/anae.15072; Diao B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00827; Fujita Y, 2020, ARTHRITIS RES THER, V22, DOI 10.1186/s13075-020-02263-3; Giamarellos-Bourboulis EJ, 2020, CELL HOST MICROBE, V27, P992, DOI 10.1016/j.chom.2020.04.009; Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017; Hoel H, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofaa033; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Hofmann U, 2016, EUR HEART J, V37, P873, DOI 10.1093/eurheartj/ehv639; Klebanoff SJ, 1999, P ASSOC AM PHYSICIAN, V111, P383, DOI 10.1111/paa.1999.111.5.383; Klenerman P, 2005, NAT IMMUNOL, V6, P873, DOI 10.1038/ni1241; Li YL, 2020, LAB INVEST, V100, P794, DOI 10.1038/s41374-020-0431-6; Madison JA, 2020, JCI INSIGHT, V5; Mohammadizad H, 2019, MICROB PATHOGENESIS, V128, P323, DOI 10.1016/j.micpath.2019.01.026; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Otterdal K, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3593-8; Saeidi A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02569; SEKO Y, 1995, J CLIN INVEST, V96, P1035, DOI 10.1172/JCI118089; Verdecchia P, 2020, EUR J INTERN MED, V76, P14, DOI 10.1016/j.ejim.2020.04.037; Walls AC, 2020, CELL, V181, P281, DOI [10.1016/j.cell.2020.02.058, 10.1016/j.cell.2020.11.032]; Wang XJ, 2011, J INFECTION, V62, P292, DOI 10.1016/j.jinf.2011.02.013; Wei JF, 2020, HEART, V106, P1154, DOI 10.1136/heartjnl-2020-317007; Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017; Zilber E, 2019, AIDS, V33, P1253, DOI 10.1097/QAD.0000000000002165	27	20	21	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2021	147	1					92	98		10.1016/j.jaci.2020.09.007	http://dx.doi.org/10.1016/j.jaci.2020.09.007		JAN 2021	7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QA7UA	32971109	Green Accepted, Green Published, Green Submitted, Bronze			2022-12-18	WOS:000613645900012
J	Zhou, LL; Liu, T; Huang, B; Luo, M; Chen, ZH; Zhao, ZY; Wang, J; Leung, D; Yang, XT; Chan, KW; Liu, YK; Xiong, LY; Chen, PY; Wang, HL; Ye, LP; Liang, HQ; Masters, SL; Lew, AM; Gong, ST; Bai, F; Yang, J; Lee, PPW; Yang, WL; Zhang, Y; Lau, YL; Geng, LL; Zhang, YX; Cui, J				Zhou, Lingli; Liu, Tao; Huang, Bing; Luo, Man; Chen, Zhanghua; Zhao, Zhiyao; Wang, Jun; Leung, Daniel; Yang, Xingtian; Chan, Koon Wing; Liu, Yukun; Xiong, Liya; Chen, Peiyu; Wang, Hongli; Ye, Liping; Liang, Hanquan; Masters, Seth L.; Lew, Andrew M.; Gong, Sitang; Bai, Fan; Yang, Jing; Lee, Pamela Pui-Wah; Yang, Wanling; Zhang, Yan; Lau, Yu-Lung; Geng, Lanlan; Zhang, Yuxia; Cui, Jun			Excessive deubiquitination of NLRP3-R779C variant contributes to very-early-onset inflammatory bowel disease development	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						NLRP3; VEOIBD; deubiquitinase; JOSD2; BRCC3	NALP3 INFLAMMASOME; ARTICULAR SYNDROME; NLRP3; REVEALS	Background: Very-early-onset inflammatory bowel disease (VEOIBD) is a chronic inflammatory disease of the gastrointestinal tract occurring during infancy or early childhood. NOD-like receptor family, pyrin domain containing 3 (NLRP3) inflammasome has emerged as a crucial regulator of intestinal homeostasis; however, whether NLRP3 variants may modify VEOIBD risk is unknown. Objective: We sought to investigate whether and how a rare NLRP3 variant, found in 3 patients with gastrointestinal symptoms, contributes to VEOIBD development. Methods: Whole-exome sequencing and bioinformatic analysis were performed to screen disease-associated NLRP3 variants from a cohort of children with VEOIBD. Inflammasome activation was determined in reconstituted HEK293T human embryonic kidney cells with NLRP3 inflammasome components, doxycycline-inducible NLRP3 macrophages, as well as PBMCs and biopsies from patients with NLRP3 variants. Pathogenesis of the variants was determined using a dextran sulfate sodium-induced acute colitis model. Results: We identified a dominant gain-of-function missense variant of NLRP3, encoded by rs772009059 (R779C), in 3 patients with gastrointestinal symptoms. Functional analysis revealed that R779C increased NLRP3 inflammasome activation and pyroptosis in macrophages. This was mediated by enhanced deubiquitination of NLRP3 via binding with deubiquitinases BRCC3 and JOSD2, which are highly expressed in myeloid cells. In a dextran sulfate sodium-induced acute colitis model, NLRP3-R779C in hematopoietic cells resulted in more severe colitis, which can be ameliorated via knockdown of BRCC3 or JOSD2. Conclusions: BRCC3 and JOSD2 mediate NLRP3-R779C deubiquitination, which promotes NLRP3 inflammasome activation and the risk of developing VEOIBD.	[Zhou, Lingli; Liu, Tao; Huang, Bing; Luo, Man; Zhao, Zhiyao; Wang, Jun; Liu, Yukun; Xiong, Liya; Chen, Peiyu; Wang, Hongli; Ye, Liping; Liang, Hanquan; Gong, Sitang; Zhang, Yan; Geng, Lanlan; Zhang, Yuxia; Cui, Jun] Sun Yat Sen Univ, Sch Life Sci, MOE Key Lab Gene Funct & Regulat, Dept Gastroenterol, Guangzhou, Peoples R China; [Zhou, Lingli; Liu, Tao; Huang, Bing; Luo, Man; Zhao, Zhiyao; Wang, Jun; Liu, Yukun; Xiong, Liya; Chen, Peiyu; Wang, Hongli; Ye, Liping; Liang, Hanquan; Gong, Sitang; Zhang, Yan; Geng, Lanlan; Zhang, Yuxia; Cui, Jun] Sun Yat Sen Univ, Sch Life Sci, Guangzhou Women & Childrens, Guangzhou Inst Pediat, Guangzhou, Peoples R China; [Huang, Bing] Southern Med Univ, Nanfang Hosp, Dept Gastroenterol, Guangdong Prov Key Lab Gastroenterol, Guangzhou, Peoples R China; [Chen, Zhanghua; Bai, Fan] Peking Univ, Sch Life Sci, Biomed Pioneering Innovat Ctr BIOPIC, Beijing, Peoples R China; [Leung, Daniel; Yang, Xingtian; Chan, Koon Wing; Yang, Jing; Lee, Pamela Pui-Wah; Yang, Wanling; Lau, Yu-Lung] Univ Hong Kong, Dept Pediat & Adolescent Med, Hong Kong, Peoples R China; [Masters, Seth L.; Lew, Andrew M.] Univ Melbourne, Walter & Eliza Hall Inst Med Res, Parkville, Vic, Australia; [Masters, Seth L.; Lew, Andrew M.] Univ Melbourne, Dept Med Biol, Parkville, Vic, Australia; [Masters, Seth L.; Lew, Andrew M.] Univ Melbourne, Dept Microbiol & Immunol, Parkville, Vic, Australia	Sun Yat Sen University; Sun Yat Sen University; Southern Medical University - China; Peking University; University of Hong Kong; University of Melbourne; Walter & Eliza Hall Institute; University of Melbourne; University of Melbourne	Cui, J (corresponding author), Sun Yat Sen Univ, Sch Life Sci, 132 Waihuandong Rd, Guangzhou 510006, Peoples R China.; Zhang, YX (corresponding author), Guangzhou Women & Childrens Med Ctr, 9 Jinsui Rd, Guangzhou 510623, Peoples R China.; Geng, LL (corresponding author), Guangzhou Women & Childrens Med Ctr, 318 Renmin Zhong Rd, Guangzhou 510120, Peoples R China.; Lau, YL (corresponding author), Queen Mary Hosp, 102 Pokfulam Rd, Hong Kong, Peoples R China.	lauylung@hku.hk; genglan_2001@hotmail.com; yuxia.zhang@gwcmc.org; cuij5@mail.sysu.edu.cn	Lau, Yu Lung/C-4322-2009; masters, seth/N-2886-2013	Lau, Yu Lung/0000-0002-4780-0289; masters, seth/0000-0003-4763-576X; Zhou, Lingli/0000-0003-3280-9210	National Natural Science Foundation of China [31870862, 31770978, 91742109, 81873869]; Society for the Relief of Disabled Children, Innovation and Technology Fund, Innovation and Technology Commission, the Government of the Hong Kong Special Administrative Region [ITS/417/18]; Fundamental Research Funds for the Central Universities [19lgpy198]; National Health and Medical Research Council of Australia [1143976, 1150425, 1080321]; Sylvia and Charles Viertel Foundation; HHMI-Wellcome International Research Scholarship	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Society for the Relief of Disabled Children, Innovation and Technology Fund, Innovation and Technology Commission, the Government of the Hong Kong Special Administrative Region; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Sylvia and Charles Viertel Foundation; HHMI-Wellcome International Research Scholarship	This work was supported by the National Natural Science Foundation of China (grant nos. 31870862, 31770978, 91742109, and 81873869), The Society for the Relief of Disabled Children, Innovation and Technology Fund, Innovation and TechnologyCommission, the Government of the Hong Kong Special Administrative Region (ITS/417/18), the Fundamental Research Funds for the Central Universities (19lgpy198), and the National Health andMedical Research Council ofAustralia (grant nos. 1143976, 1150425, and 1080321). S.L.M. acknowledges funding from The Sylvia and Charles Viertel Foundation and HHMI-Wellcome International Research Scholarship.	Aizarani N, 2019, NATURE, V572, P199, DOI 10.1038/s41586-019-1373-2; Aksentijevich I, 2011, NAT REV RHEUMATOL, V7, P468, DOI 10.1038/nrrheum.2011.94; Butler A, 2018, NAT BIOTECHNOL, V36, P411, DOI 10.1038/nbt.4096; Caroli F, 2007, RHEUMATOLOGY, V46, P473, DOI 10.1093/rheumatology/kel269; Coulter TI, 2017, J ALLERGY CLIN IMMUN, V139, P597, DOI 10.1016/j.jaci.2016.06.021; Duncan JA, 2007, P NATL ACAD SCI USA, V104, P8041, DOI 10.1073/pnas.0611496104; Frenkel J, 2004, ARTHRITIS RHEUM, V50, P2719, DOI 10.1002/art.20295; Han S, 2015, J BIOL CHEM, V290, P18124, DOI 10.1074/jbc.M115.645549; Hirota SA, 2011, INFLAMM BOWEL DIS, V17, P1359, DOI 10.1002/ibd.21478; Hochane M, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000152; Huang B, 2019, CELL, V179, P1160, DOI 10.1016/j.cell.2019.10.027; Jostins L, 2012, NATURE, V491, P119, DOI 10.1038/nature11582; Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057; Levine A, 2014, J PEDIATR GASTR NUTR, V58, P795, DOI 10.1097/MPG.0000000000000239; Levine A, 2011, INFLAMM BOWEL DIS, V17, P1314, DOI 10.1002/ibd.21493; Li MX, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003143; Liu T, 2016, CELL REP, V16, P1988, DOI 10.1016/j.celrep.2016.07.019; Mangan MSJ, 2018, NAT REV DRUG DISCOV, V17, P588, DOI [10.1038/nrd.2018.97, 10.1038/nrd.2018.149]; Manthiram K, 2017, NAT IMMUNOL, V18, P832, DOI 10.1038/ni.3777; Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532; Nakanishi H, 2017, P NATL ACAD SCI USA, V114, pE7766, DOI 10.1073/pnas.1702946114; Py BF, 2013, MOL CELL, V49, P331, DOI 10.1016/j.molcel.2012.11.009; Reyfman PA, 2019, AM J RESP CRIT CARE, V199, P1517, DOI 10.1164/rccm.201712-2410OC; Saito M, 2006, ARTHRITIS RHEUM, V54, P2704, DOI 10.1002/art.22151; Sharif H, 2019, NATURE, V570, P338, DOI 10.1038/s41586-019-1295-z; Shi JJ, 2015, NATURE, V526, P660, DOI 10.1038/nature15514; Shim JO, 2019, PEDIATR GASTROENTERO, V22, P41, DOI 10.5223/pghn.2019.22.1.41; Shouval DS, 2016, GASTROENTEROLOGY, V151, P1100, DOI 10.1053/j.gastro.2016.08.055; Song H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13727; Swanson KV, 2019, NAT REV IMMUNOL, V19, P477, DOI 10.1038/s41577-019-0165-0; Tanaka N, 2011, ARTHRITIS RHEUM-US, V63, P3625, DOI 10.1002/art.30512; Uhlig HH, 2014, GASTROENTEROLOGY, V147, P990, DOI 10.1053/j.gastro.2014.07.023; Verma D, 2008, ARTHRITIS RHEUM, V58, P888, DOI 10.1002/art.23286; Wang L, 2020, NAT CELL BIOL, V22, P108, DOI 10.1038/s41556-019-0446-7; Wang Y, 2018, J CLIN IMMUNOL, V38, P854, DOI 10.1007/s10875-018-0568-x; Yan YQ, 2015, CELL, V160, P62, DOI 10.1016/j.cell.2014.11.047; Zhang YX, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00879; Zhu L, 2017, GASTROENTEROL RES, V10, P65, DOI 10.14740/gr740w	38	20	20	3	23	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2021	147	1					267	279		10.1016/j.jaci.2020.09.003	http://dx.doi.org/10.1016/j.jaci.2020.09.003		JAN 2021	13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PS2UA	32941940	Bronze			2022-12-18	WOS:000607781700002
J	Acosta, GS; Kinaciyan, T; Kitzmuller, C; Mobs, C; Pfutzner, W; Bohle, B				Acosta, Gabriela Sanchez; Kinaciyan, Tamar; Kitzmueller, Claudia; Moebs, Christian; Pfuetzner, Wolfgang; Bohle, Barbara			IgE-blocking antibodies following SLIT with recombinant Mal d 1 accord with improved apple allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; birch pollen allergy; birch pollen-related food allergy; IgE; allergen-specific immunotherapy; IgE-blocking antibodies; recombinant allergens; Bet v 1; Mal d 1	BET V 1; GRASS-POLLEN IMMUNOTHERAPY; BIRCH POLLEN; FOOD ALLERGY; SUBLINGUAL IMMUNOTHERAPY; IMMUNOGLOBULIN G4; B-CELLS; SPECIFICITY; INHIBITION; SIT	Background: We recently reported that 16 weeks of sublingual immunotherapy (SLIT) with recombinant (r) Mal d 1, but not rBet v 1, significantly improved birch pollen-related apple allergy. Allergen-specific IgE-blocking IgG antibodies have been associated with clinical efficacy. Objective: We compared the quantity, quality, and IgE-blocking bioactivity of SLIT-induced Mal d 1-specific IgG antibodies in both treatment groups. Methods: Pre- and post-SLIT sera were assessed for rMal d 1-specific IgG antibodies in ELISA and for their ability to inhibit apple allergen-induced upregulation of CD63 on basophils from nontreated individuals with birch pollen-related apple allergy. Post-SLIT sera depleted of IgG1 or IgG4 were compared for their IgE-blocking activity. IgG1 binding to rMal d 1 was competed with rMal d 1 and rBet v 1 in ELISA. Results: SLIT with rMal d 1 and rBet v 1 induced comparable levels of rMal d 1-specific IgG1, IgG2, IgG3, and IgG4 antibodies. Only post-rMal d 1 SLIT sera displayed IgE-blocking activity, which was significantly reduced by depletion of IgG1 and less so by IgG4 depletion. In competition ELISA, IgG1 binding to Mal d 1 in post-rMal d 1 SLIT sera was fully inhibited with rMal d 1 but not with rBet v 1. Correspondingly, Bet v 1 was the more potent competitor for IgG1 binding to Mal d 1 in post-rBet v 1 SLIT sera. Conclusion: rMal d 1 SLIT for 16 weeks induced functional, primarily Mal d 1-specific IgE-blocking antibodies, whereas rBet v 1 SLIT induced Bet v 1-specific, Mal d 1-cross-reactive IgG antibodies with limited cross-blocking activity. These results provide a possible explanation for the limited effectiveness of birch pollen immunotherapy in birch pollen-related food allergy and indicate a dominant protective role of functional IgE-blocking IgG1 antibodies in the early phase of allergy treatment.	[Acosta, Gabriela Sanchez; Kitzmueller, Claudia; Bohle, Barbara] Med Univ Vienna, Dept Pathophysiol & Allergy Res, Vienna, Austria; [Kinaciyan, Tamar] Med Univ Vienna, Dept Dermatol, Vienna, Austria; [Moebs, Christian; Pfuetzner, Wolfgang] Philipps Univ Marburg, Dept Dermatol & Allergol, Marburg, Germany	Medical University of Vienna; Medical University of Vienna; Philipps University Marburg	Bohle, B (corresponding author), Med Univ Vienna, Gen Hosp Vienna, Inst Pathophysiol & Allergy Res, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	barbara.bohle@meduniwien.ac.at		Bohle, Barbara/0000-0002-5105-7985; Kitzmuller, Claudia/0000-0002-3829-8020	Austrian Science Fund [W1212, SFB F4610]; Austrian Nationalbank Jubilaumsfonds [16620, 17589]	Austrian Science Fund(Austrian Science Fund (FWF)); Austrian Nationalbank Jubilaumsfonds	Supported by the Austrian Science Fund, projects W1212 and SFB F4610, and the Austrian Nationalbank Jubilaumsfonds, projects 16620 and 17589.	Aalberse RC, 2009, CLIN EXP ALLERGY, V39, P469, DOI 10.1111/j.1365-2222.2009.03207.x; Ahammer L, 2017, J AGR FOOD CHEM, V65, P1606, DOI 10.1021/acs.jafc.6b05752; Allam JP, 2014, J ALLERGY CLIN IMMUN, V133, P1757, DOI 10.1016/j.jaci.2014.03.026; Asero R, 2004, ALLERGY, V59, P1269, DOI 10.1111/j.1398-9995.2004.00561.x; Asero R, 1998, CLIN EXP ALLERGY, V28, P1368, DOI 10.1046/j.1365-2222.1998.00399.x; Asero R, 2003, ALLERGY, V58, P435, DOI 10.1034/j.1398-9995.2003.00139.x; Bohle B, 2007, J ALLERGY CLIN IMMUN, V120, P707, DOI 10.1016/j.jaci.2007.06.013; Bucher X, 2004, ALLERGY, V59, P1272, DOI 10.1111/j.1398-9995.2004.00626.x; Couroux P, 2019, ALLERGY, V74, P361, DOI 10.1111/all.13606; DEVEY ME, 1990, IMMUNOLOGY, V70, P168; Dodev TS, 2015, ALLERGY, V70, P720, DOI 10.1111/all.12607; Ejrnaes AM, 2006, CLIN EXP ALLERGY, V36, P273, DOI 10.1111/j.1365-2222.2006.02442.x; Fritsch R, 1998, J ALLERGY CLIN IMMUN, V102, P679, DOI 10.1016/S0091-6749(98)70287-8; Gadermaier E, 2016, ALLERGY, V71, P36, DOI 10.1111/all.12710; Geroldinger-Simic M, 2011, J ALLERGY CLIN IMMUN, V127, P616, DOI 10.1016/j.jaci.2010.10.027; Hansen KS, 2004, MOL NUTR FOOD RES, V48, P441, DOI 10.1002/mnfr.200400037; James LK, 2012, J ALLERGY CLIN IMMUN, V130, P663, DOI 10.1016/j.jaci.2012.04.006; James LK, 2011, J ALLERGY CLIN IMMUN, V127, P509, DOI 10.1016/j.jaci.2010.12.1080; Kappen JH, 2017, THER ADV RESPIR DIS, V11, P73, DOI 10.1177/1753465816669662; Kinaciyan T, 2007, J ALLERGY CLIN IMMUN, V119, P937, DOI 10.1016/j.jaci.2006.11.010; Kinaciyan T, 2018, J ALLERGY CLIN IMMUN, V141, P1002, DOI 10.1016/j.jaci.2017.07.036; Kitzmuller C, 2018, J ALLERGY CLIN IMMUN, V141, P293, DOI 10.1016/j.jaci.2017.02.044; Kitzmuller C, 2015, J ALLERGY CLIN IMMUN; Kitzmuller C, 2019, ALLERGY, V74, P1579, DOI 10.1111/all.13779; Layhadi JA, 2019, CURR OPIN ALLERGY CL, V19, P12, DOI 10.1097/ACI.0000000000000499; Mauro M, 2011, INT ARCH ALLERGY IMM, V156, P416, DOI 10.1159/000323909; Modrzynski Marek, 2002, Przegl Lek, V59, P1007; Nouri-Aria KT, 2004, J IMMUNOL, V172, P3252, DOI 10.4049/jimmunol.172.5.3252; Rossi RE, 2007, VACCINE, V25, P957, DOI 10.1016/j.vaccine.2006.08.040; Sancho AI, 2006, J AGR FOOD CHEM, V54, P5917, DOI 10.1021/jf060880m; Scadding GW, 2010, CLIN EXP ALLERGY, V40, P598, DOI 10.1111/j.1365-2222.2010.03462.x; Shamji MH, 2012, ALLERGY, V67, P217, DOI 10.1111/j.1398-9995.2011.02745.x; Shamji MH, 2019, J ALLERGY CLIN IMMUN, V143, P1067, DOI 10.1016/j.jaci.2018.09.039; Son DY, 1999, EUR J NUTR, V38, P201, DOI 10.1007/s003940050063; van de Veen W, 2016, J ALLERGY CLIN IMMUN, V138, P1434, DOI 10.1016/j.jaci.2016.07.022; van Hoffen E, 2011, J ALLERGY CLIN IMMUN, V127, P100, DOI 10.1016/j.jaci.2010.08.021; VANEKKREBITZ M, 1995, BIOCHEM BIOPH RES CO, V214, P538, DOI 10.1006/bbrc.1995.2320; Vieths S, 2002, ANN NY ACAD SCI, V964, P47; VIETHS S, 1994, INT ARCH ALLERGY IMM, V104, P399, DOI 10.1159/000236698; Wachholz PA, 2003, J ALLERGY CLIN IMMUN, V112, P915, DOI 10.1016/S0091-6749(03)02022-0; Werfel T, 2015, ALLERGY, V70, P1079, DOI 10.1111/all.12666	41	20	20	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2020	146	4					894	+		10.1016/j.jaci.2020.03.015	http://dx.doi.org/10.1016/j.jaci.2020.03.015			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	OH2JO	32259540	hybrid			2022-12-18	WOS:000582395800020
J	Kim, EH; Perry, TT; Wood, RA; Leung, DYM; Berin, MC; Burks, AW; Cho, CB; Jones, SM; Scurlock, A; Sicherer, SH; Henning, AK; Dawson, P; Lindblad, RW; Plaut, M; Sampson, HA				Kim, Edwin H.; Perry, Tamara T.; Wood, Robert A.; Leung, Donald Y. M.; Berin, M. Cecilia; Burks, A. Wesley; Cho, Christine B.; Jones, Stacie M.; Scurlock, Amy; Sicherer, Scott H.; Henning, Alice K.; Dawson, Peter; Lindblad, Robert W.; Plaut, Marshall; Sampson, Hugh A.		Consortium Food Allergy Res CoFAR	Induction of sustained unresponsiveness after egg oral immunotherapy compared to baked egg therapy in children with egg allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Egg allergy; baked egg; extensively heated egg; desensitization; sustained unresponsiveness; oral immunotherapy	FOOD ALLERGY; NATURAL-HISTORY; PREVALENCE; CHALLENGES; CHILDHOOD; MATRIX; LIFE	Background: While desensitization and sustained unresponsiveness (SU) have been shown with egg oral immunotherapy (OIT), the benefits of baked egg (BE) therapy for egg allergy have not been well studied. Objectives: This study sought to evaluate the safety and efficacy of BE ingestion compared with egg OIT in participants allergic to unbaked egg but tolerant to BE. Methods: Children who are BE-tolerant but unbaked egg reactive ages 3 to 16 years were randomized to 2 years of treatment with either BE or egg OIT. Double-blind, placebocontrolled food challenges were conducted after 1 and 2 years of treatment to assess for desensitization, and after 2 years of treatment followed by 8 to 10 weeks off of treatment to assess for SU. Mechanistic studies were conducted to assess for immune modulation. A cohort of participants who are BE-reactive underwent egg OIT and identical double-blind, placebo-controlled food challenges as a comparator group. Results: Fifty participants (median age 7.3 years) were randomized and initiated treatment. SU was achieved in 3 of 27 participants assigned to BE (11.1%) versus 10 of 23 participants assigned to egg OIT (43.5%) (P =.009). In the BE-reactive comparator group, 7 of 39 participants (17.9%) achieved SU. More participants who are BE-tolerant withdrew from BE versus from egg OIT (29.6% vs 13%). Dosing symptom frequency in participants who are BE-tolerant was similar with BE and egg OIT, but more frequent in participants who are BE-reactive. Egg white-specific IgE, skin testing, and basophil activation decreased similarly after BE and egg OIT. Conclusions: Among children allergic to unbaked egg but tolerant to BE, those treated with egg OIT were significantly more likely to achieve SU than were children ingesting BE.	[Kim, Edwin H.; Burks, A. Wesley] Univ N Carolina, Sch Med, Dept Med & Pediat, Chapel Hill, NC 27515 USA; [Perry, Tamara T.; Jones, Stacie M.; Scurlock, Amy] Univ Arkansas Med Sci, Dept Pediat, Little Rock, AR 72205 USA; [Perry, Tamara T.; Jones, Stacie M.; Scurlock, Amy] Arkansas Childrens Hosp, 800 Marshall St, Little Rock, AR 72202 USA; [Wood, Robert A.] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; [Leung, Donald Y. M.; Cho, Christine B.] Natl Jewish Hlth, Dept Pediat, Denver, CO USA; [Berin, M. Cecilia; Sicherer, Scott H.; Sampson, Hugh A.] Icahn Sch Med Mt Sinai, Dept Pediat, New York, NY 10029 USA; [Henning, Alice K.; Dawson, Peter; Lindblad, Robert W.] Emmes, Rockville, MD USA; [Plaut, Marshall] NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of Arkansas System; University of Arkansas Medical Sciences; Arkansas Children's Hospital; Johns Hopkins University; National Jewish Health; Icahn School of Medicine at Mount Sinai; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Kim, EH (corresponding author), 3004C Mary Ellen Jones Bldg 116 Manning Dr, Chapel Hill, NC 27599 USA.	edwinkim@email.unc.edu		berin, cecilia/0000-0002-9051-9249; Kim, Edwin/0000-0001-6418-1785	National Institutes of Health-National Institute of Allergy and Infectious Diseases [U19AI066738, U01AI066560]; National Center for Research Resources, a component of the National Institutes of Health [UL1 TR-002535, UL1 TR-000067, UL1 TR-003107, UL1 TR-000083, UL1 TR-000424]	National Institutes of Health-National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Center for Research Resources, a component of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	Supported by National Institutes of Health-National Institute of Allergy and Infectious Diseases (U19AI066738 and U01AI066560). The project was also supported by grants from the National Center for Research Resources, a component of the National Institutes of Health: UL1 TR-002535 (National Jewish Health), UL1 TR-000067 (Icahn School of Medicine at Mount Sinai), UL1 TR-003107 (University of Arkansas for Medical Sciences), UL1 TR-000083 (University of North Carolina School of Medicine), and UL1 TR-000424 (Johns Hopkins University School of Medicine). The contents are solely the responsibility of the authors and do not necessarily represent the official view of National Center for Research Resources or National Institutes of Health.	Bird JA, 2019, J ALLER CL IMM-PRACT, V7, P667, DOI 10.1016/j.jaip.2018.07.013; Burks AW, 2012, NEW ENGL J MED, V367, P233, DOI 10.1056/NEJMoa1200435; Cooke SK, 1997, J IMMUNOL, V159, P2026; Jones SM, 2016, J ALLERGY CLIN IMMUN, V137, P1117, DOI 10.1016/j.jaci.2015.12.1316; Lemon-Mule H, 2008, J ALLERGY CLIN IMMUN, V122, P977, DOI 10.1016/j.jaci.2008.09.007; Leonard SA, 2012, J ALLERGY CLIN IMMUN, V130, P473, DOI 10.1016/j.jaci.2012.06.006; Lieberman JA, 2012, J ALLERGY CLIN IMMUN, V129, P1682, DOI 10.1016/j.jaci.2012.04.007; Nowak-Wegrzyn A, 2009, CURR OPIN ALLERGY CL, V9, P234, DOI 10.1097/ACI.0b013e32832b88e7; Nowak-Wegrzyn A, 2009, J ALLERGY CLIN IMMUN, V123, pS365, DOI 10.1016/j.jaci.2009.03.042; Peters RL, 2017, J ALLERGY CLIN IMMUN, V140, P145, DOI 10.1016/j.jaci.2017.02.019; Peters RL, 2014, J ALLERGY CLIN IMMUN, V133, P485, DOI 10.1016/j.jaci.2013.11.032; Rona RJ, 2007, J ALLERGY CLIN IMMUN, V120, P638, DOI 10.1016/j.jaci.2007.05.026; Sampson HA, 2012, J ALLERGY CLIN IMMUN, V130, P1260, DOI 10.1016/j.jaci.2012.10.017; Sicherer SH, 2014, J ALLERGY CLIN IMMUN, V133, P492, DOI 10.1016/j.jaci.2013.12.1041; Sopo SM, 2016, PEDIAT ALLERG IMM-UK, V27, P465, DOI 10.1111/pai.12570; Stensgaard A, 2017, CLIN EXP ALLERGY, V47, P530, DOI 10.1111/cea.12849; Tang MLK, 2017, INTERN MED J, V47, P256, DOI 10.1111/imj.13362	17	20	21	1	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2020	146	4					851	+		10.1016/j.jaci.2020.05.040	http://dx.doi.org/10.1016/j.jaci.2020.05.040			22	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	OH2JO	32535135	Green Accepted			2022-12-18	WOS:000582395800016
J	Bartsch, YC; Eschweiler, S; Leliavski, A; Lunding, HB; Wagt, S; Petry, J; Lilienthal, GM; Rahmoller, J; de Haan, N; Holscher, A; Erapaneedi, R; Giannou, AD; Aly, L; Sato, R; de Neef, LA; Winkler, A; Braumann, D; Hobusch, J; Kuhnigk, K; Kremer, V; Steinhaus, M; Blanchard, V; Gemoll, T; Habermann, JK; Collin, M; Salinas, G; Manz, RA; Fukuyama, H; Korn, T; Waisman, A; Yogev, N; Huber, S; Rabe, B; Rose-John, S; Busch, H; Berberich-Siebelt, F; Holscher, C; Wuhrer, M; Ehlers, M				Bartsch, Yannic C.; Eschweiler, Simon; Leliavski, Alexei; Lunding, Hanna B.; Wagt, Sander; Petry, Janina; Lilienthal, Gina-Maria; Rahmoller, Johann; de Haan, Noortje; Holscher, Alexandra; Erapaneedi, Raghu; Giannou, Anastasios D.; Aly, Lilian; Sato, Ryota; de Neef, Louise A.; Winkler, Andre; Braumann, Dominique; Hobusch, Juliane; Kuhnigk, Kyra; Kremer, Vanessa; Steinhaus, Moritz; Blanchard, Veronique; Gemoll, Timo; Habermann, Jens K.; Collin, Mattias; Salinas, Gabriela; Manz, Rudolf A.; Fukuyama, Hidehiro; Korn, Thomas; Waisman, Ari; Yogev, Nir; Huber, Samuel; Rabe, Bjorn; Rose-John, Stefan; Busch, Hauke; Berberich-Siebelt, Friederike; Holscher, Christoph; Wuhrer, Manfred; Ehlers, Marc			IgG Fc sialylation is regulated during the germinal center reaction following immunization with different adjuvants	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Antibodies; IgG glycosylation; vaccination; adjuvants; germinal center; T follicular cells; IL-6; IL-27R; IL-17; IFN-gamma	IFN-GAMMA RECEPTOR; HELPER T-CELLS; ANTIINFLAMMATORY ACTIVITY; ANTIBODY GLYCOSYLATION; PLASMA-CELL; B-CELLS; INFLAMMATION; RESPONSES; IMMUNE; SIGNATURES	Background: Effector functions of IgG Abs are regulated by their Fc N-glycosylation pattern. IgG Fc glycans that lack galactose and terminal sialic acid residues correlate with the severity of inflammatory (auto)immune disorders and have also been linked to protection against viral infection and discussed in the context of vaccine-induced protection. In contrast, sialylated IgG Abs have shown immunosuppressive effects. Objective: We sought to investigate IgG glycosylation programming during the germinal center (GC) reaction following immunization of mice with a foreign protein antigen and different adjuvants. Methods: Mice were analyzed for GC T-cell, B-cell, and plasma cell responses, as well as for antigen-specific serum IgG subclass titers and Fc glycosylation patterns. Results: Different adjuvants induce distinct IgG(+) GC B-cell responses with specific transcriptomes and expression levels of the alpha 2,6-sialyltransferase responsible for IgG sialylation that correspond to distinct serum IgG Fc glycosylation patterns. Low IgG Fc sialylation programming in GC B cells was overall highly dependent on the Foxp3(-) follicular helper T (TFH) cell-inducing cytokine IL-6, here in particular induced by water-inoil adjuvants and Mycobacterium tuberculosis. Furthermore, low IgG Fc sialylation programming was dependent on adjuvants that induced IL-27 receptor-dependent IFN-gamma(+) TFH1 cells, IL-6/IL-23-dependent IL-17A(+) T-FH17 cells, and high ratios of TFH cells to Foxp31 follicular regulatory T cells. Here, the 2 latter were dependent on M tuberculosis and its cord factor. Conclusion: This study's findings regarding adjuvant-dependent GC responses and IgG glycosylation programming may aid in the development of novel vaccination strategies to induce IgG Abs with both high affinity and defined Fc glycosylation patterns in the GC.	[Bartsch, Yannic C.; Eschweiler, Simon; Leliavski, Alexei; Lunding, Hanna B.; Wagt, Sander; Petry, Janina; Lilienthal, Gina-Maria; Rahmoller, Johann; Winkler, Andre; Braumann, Dominique; Hobusch, Juliane; Kuhnigk, Kyra; Kremer, Vanessa; Steinhaus, Moritz; Ehlers, Marc] Univ Lubeck, Inst Nutr Med, Labs Immunol & Antibody Glycan Anal, Lubeck, Germany; [Bartsch, Yannic C.; Eschweiler, Simon; Leliavski, Alexei; Lunding, Hanna B.; Wagt, Sander; Petry, Janina; Lilienthal, Gina-Maria; Rahmoller, Johann; Winkler, Andre; Braumann, Dominique; Hobusch, Juliane; Kuhnigk, Kyra; Kremer, Vanessa; Steinhaus, Moritz; Ehlers, Marc] Univ Med Ctr Schleswig Holstein, Lubeck, Germany; [de Haan, Noortje; de Neef, Louise A.; Wuhrer, Manfred] Leiden Univ, Med Ctr, Ctr Prote & Metabol, Leiden, Germany; [Rahmoller, Johann] Univ Med Ctr Schleswig Holstein, Dept Anesthesiol & Intens Care, Kiel, Germany; [Holscher, Alexandra; Holscher, Christoph] Res Ctr Borstel, Infect Immunol, Borstel, Germany; [Erapaneedi, Raghu; Berberich-Siebelt, Friederike] Univ Wurzburg, Inst Pathol, Wurzburg, Germany; [Giannou, Anastasios D.; Huber, Samuel] Univ Med Ctr Hamburg Eppendorf, Dept Med 1, Hamburg, Germany; [Aly, Lilian] Tech Univ Munich, Klinikum Rechts Isar, Dept Neurol, Munich, Germany; [Sato, Ryota; Fukuyama, Hidehiro] RIKEN Ctr Integrat Med Sci, Lab Lymphocyte Differentiat, Yokohama, Kanagawa, Japan; [Winkler, Andre] Leibniz Inst, German Rheumatism Res Ctr, Lab Tolerance & Autoimmun, Berlin, Germany; [Braumann, Dominique; Blanchard, Veronique] Charite Univ Med Berlin, Inst Lab Med Clin Chem & Pathobiochem, Berlin, Germany; [Braumann, Dominique; Blanchard, Veronique] Free Univ Berlin, Humboldt Univ Berlin, Berlin, Germany; [Braumann, Dominique; Blanchard, Veronique] Berlin Inst Hlth, Berlin, Germany; [Gemoll, Timo; Habermann, Jens K.] Univ Lubeck, Dept Surg, Sect Translat Surg Oncol & Biobanking, Lubeck, Germany; [Winkler, Andre; Braumann, Dominique; Gemoll, Timo; Habermann, Jens K.] Univ Med Ctr Schleswig Holstein, Kiel, Germany; [Collin, Mattias] Lund Univ, Dept Clin Sci, Div Infect Med, Lund, Sweden; [Salinas, Gabriela] Univ Med Ctr Gottingen, Inst Human Genet, NGS Integrat Genom, Gottingen, Germany; [Manz, Rudolf A.] Univ Lubeck, Inst Syst Inflammat Res, Lubeck, Germany; [Korn, Thomas] SyNergy, Munich Cluster Syst Neurol, Munich, Germany; [Waisman, Ari] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Inst Mol Med, Mainz, Germany; [Yogev, Nir] Univ Hosp Cologne, Clin & Polyclin Dermatol & Venerol, Cologne, Germany; [Rabe, Bjorn; Rose-John, Stefan] Univ Kiel, Inst Biochem, Kiel, Germany; [Busch, Hauke] Univ Lubeck, Lubeck Inst Expt Dermatol, Lubeck, Germany; [Berberich-Siebelt, Friederike] Univ Wurzburg, Comprehens Canc Ctr Mainfranken, Wurzburg, Germany; [Holscher, Christoph] Partner Site Hamburg Lubeck Borstel Riems, German Ctr Infect Res, Hamburg, Germany; [Ehlers, Marc] Univ Lubeck, Airway Res Ctr North, Lubeck, Germany	University of Lubeck; University of Kiel; Schleswig Holstein University Hospital; University of Kiel; Schleswig Holstein University Hospital; Forschungszentrum Borstel; University of Wurzburg; University of Hamburg; University Medical Center Hamburg-Eppendorf; Technical University of Munich; RIKEN; Deutsches Rheuma-Forschungszentrum (DRFZ); Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Berlin Institute of Health; University of Lubeck; University of Kiel; Schleswig Holstein University Hospital; Lund University; University of Gottingen; University of Lubeck; Johannes Gutenberg University of Mainz; University of Cologne; University of Kiel; University of Lubeck; University of Wurzburg; German Center for Infection Research; University of Lubeck	Ehlers, M (corresponding author), Univ Lubeck, Ratzeburger Allee 160, D-23562 Lubeck, Germany.	marc.ehlers@uksh.de	Collin, Mattias/C-6398-2009; Korn, Thomas/AAE-6960-2019; Fukuyama, Hidehiro/N-5276-2018; Wuhrer, Manfred/ABE-9168-2020; Manz, Rudolf A/C-8340-2011; Hölscher, Christoph/O-1732-2018; Ehlers, Marc/C-9441-2011; Fukuyama, Hidehiro/AAY-6256-2021; Busch, Hauke/R-6452-2016	Collin, Mattias/0000-0002-6166-7410; Korn, Thomas/0000-0002-3633-0955; Fukuyama, Hidehiro/0000-0002-6457-0630; Wuhrer, Manfred/0000-0002-0814-4995; Hölscher, Christoph/0000-0002-7520-9146; Ehlers, Marc/0000-0002-5383-8603; Fukuyama, Hidehiro/0000-0002-6457-0630; Braumann, Dominique/0000-0001-9987-0257; Eschweiler, Simon/0000-0002-6379-8588; de Haan, Noortje/0000-0001-7026-6750; Busch, Hauke/0000-0003-4763-4521; Blanchard, Veronique/0000-0002-5980-6450; Huber, Samuel/0000-0001-9325-8227	Else Kroner-Fresenius Foundation [2014_A91]; Deutsche Forschungsgemeinschaft (German Research Foundation) [257739680 (EH 221/8-1), 269234613, EH 221/9-1, 398859914 (EH 221/10-1), 400912066 (EH 221/11-1), 179309734, 1727, 222374435 (iRTG 1911), 49701054, EXC 306, 390884018, EXC 2167, 303]; University of Lubeck; German Center for Infection Research (DZIF) [TTU 02.705]	Else Kroner-Fresenius Foundation; Deutsche Forschungsgemeinschaft (German Research Foundation)(German Research Foundation (DFG)); University of Lubeck; German Center for Infection Research (DZIF)	M.E. was funded by the Else Kroner-Fresenius Foundation (2014_A91) and the Deutsche Forschungsgemeinschaft (German Research Foundation)-257739680 (EH 221/8-1); 269234613 (Clinical Research Unit 303, EH 221/9-1); 398859914 (EH 221/10-1); 400912066 (EH 221/11-1); 179309734 (Research Training Group (RTG) 1727); 222374435 (iRTG 1911); 49701054 (Germany's Excellence Strategies-EXC 306); and 390884018 (EXC 2167, Precision Medicine in Chronic Inflammation [PMI]). A.L. received junior grants from the University of L_ubeck and the EXC 306. Y.C.B. and H.B.L. were members of the RTG 1727. C.H. was supported by the German Center for Infection Research (DZIF; TTU 02.705).	Ackerman ME, 2013, J CLIN INVEST, V123, P2183, DOI 10.1172/JCI65708; Alter G, 2018, SEMIN IMMUNOL, V39, P102, DOI 10.1016/j.smim.2018.05.003; Anthony RM, 2011, NATURE, V475, P110, DOI 10.1038/nature10134; Arkatkar T, 2017, J EXP MED, V214, P3207, DOI 10.1084/jem.20170580; Barr TA, 2012, J EXP MED, V209, P1001, DOI 10.1084/jem.20111675; Bartsch YC, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01183; Batten M, 2010, J EXP MED, V207, P2895, DOI 10.1084/jem.20100064; Collin M, 2013, EXP DERMATOL, V22, P511, DOI 10.1111/exd.12171; de Haan N, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00608; Ding YN, 2013, J IMMUNOL, V191, P1614, DOI 10.4049/jimmunol.1300479; Domeier PP, 2016, J EXP MED, V213, P715, DOI 10.1084/jem.20151722; Epp A, 2018, J ALLERGY CLIN IMMUN, V141, P399, DOI 10.1016/j.jaci.2017.06.021; Garbers C, 2018, NAT REV DRUG DISCOV, V17, P395, DOI 10.1038/nrd.2018.45; Ghilardi N, 2004, J IMMUNOL, V172, P2827, DOI 10.4049/jimmunol.172.5.2827; Hansen KD, 2012, BIOSTATISTICS, V13, P204, DOI 10.1093/biostatistics/kxr054; Heink S, 2017, NAT IMMUNOL, V18, P74, DOI 10.1038/ni.3632; Hess C, 2013, J CLIN INVEST, V123, P3788, DOI 10.1172/JCI65938; Hsu HC, 2008, NAT IMMUNOL, V9, P166, DOI 10.1038/ni1552; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; Inoue T, 2018, IMMUNOL REV, V283, P138, DOI 10.1111/imr.12640; Ise W, 2019, IMMUNOL REV, V288, P64, DOI 10.1111/imr.12751; Ise W, 2018, IMMUNITY, V48, P702, DOI 10.1016/j.immuni.2018.03.027; Jackson SW, 2016, J EXP MED, V213, P733, DOI 10.1084/jem.20151724; Jennewein MF, 2017, TRENDS IMMUNOL; Jones GW, 2010, J IMMUNOL, V184, P2130, DOI 10.4049/jimmunol.0901528; Kaneko Y, 2006, SCIENCE, V313, P670, DOI 10.1126/science.1129594; Kao D, 2017, EUR J IMMUNOL, V47, P2070, DOI 10.1002/eji.201747208; Karsten CM, 2012, NAT MED, V18, P1401, DOI 10.1038/nm.2862; Knudsen NPH, 2016, SCI REP-UK, V6, DOI 10.1038/srep19570; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; Kurata I, 2019, ANN RHEUM DIS, V78, P1488, DOI 10.1136/annrheumdis-2019-215195; Lauc G, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003225; Lee SK, 2012, IMMUNITY, V37, P880, DOI 10.1016/j.immuni.2012.10.010; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Lilienthal GM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00958; Lofano G, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aat7796; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Luthje K, 2012, NAT IMMUNOL, V13, P491, DOI 10.1038/ni.2261; Luo WJ, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-161; Mahan AE, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005456; Manz RA, 1997, NATURE, V388, P133, DOI 10.1038/40540; Nakae S, 2002, IMMUNITY, V17, P375, DOI 10.1016/S1074-7613(02)00391-6; Nimmerjahn F, 2005, SCIENCE, V310, P1510, DOI 10.1126/science.1118948; Oefner CM, 2012, J ALLERGY CLIN IMMUN, V129, P1647, DOI 10.1016/j.jaci.2012.02.037; Ohmi Y, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11205; Pagan JD, 2018, CELL, V172, P564, DOI 10.1016/j.cell.2017.11.041; Pfeifle R, 2017, NAT IMMUNOL, V18, P104, DOI 10.1038/ni.3579; Pincetic A, 2014, NAT IMMUNOL, V15, P707, DOI 10.1038/ni.2939; Price AE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039750; Quintana A, 2013, BRAIN BEHAV IMMUN, V27, P162, DOI 10.1016/j.bbi.2012.10.011; Reinhardt RL, 2009, NAT IMMUNOL, V10, P385, DOI 10.1038/ni.1715; Riteau N, 2016, J IMMUNOL, V197, P3884, DOI 10.4049/jimmunol.1600883; Sage PT, 2016, IMMUNOL REV, V271, P246, DOI 10.1111/imr.12411; Shenderov K, 2013, J IMMUNOL, V190, P5722, DOI 10.4049/jimmunol.1203343; Song WZ, 2019, IMMUNOL REV, V288, P85, DOI 10.1111/imr.12740; Vaccari M, 2016, NAT MED, V22, P762, DOI 10.1038/nm.4105; Vaeth M, 2014, J EXP MED, V211, P545, DOI 10.1084/jem.20130604; Vaeth M, 2012, P NATL ACAD SCI USA, V109, P16258, DOI 10.1073/pnas.1203870109; Velu V, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01272; Vinuesa CG, 2016, ANNU REV IMMUNOL, V34, P335, DOI 10.1146/annurev-immunol-041015-055605; Wang TT, 2015, CELL, V162, P160, DOI 10.1016/j.cell.2015.06.026; Weinstein JS, 2016, NAT IMMUNOL, V17, P1197, DOI 10.1038/ni.3554; Yoshida H, 2001, IMMUNITY, V15, P569, DOI 10.1016/S1074-7613(01)00206-0; Zheng Y, 2007, NATURE, V445, P648, DOI 10.1038/nature05505; Zhou LA, 2007, NAT IMMUNOL, V8, P967, DOI 10.1038/ni1488	66	20	20	1	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2020	146	3					652	+		10.1016/j.jaci.2020.04.059	http://dx.doi.org/10.1016/j.jaci.2020.04.059			26	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NN7PN	32445838	hybrid			2022-12-18	WOS:000568978400002
J	Liew, WC; Sundaram, GM; Quah, S; Lum, GG; Tan, JSL; Ramalingam, R; Common, JEA; Tang, MBY; Lane, EB; Thng, STG; Prabha, S				Liew, Wen Chiy; Sundaram, Gopinath M.; Quah, Shan; Lum, Guo Guang; Tan, Jonathan S. L.; Ramalingam, Rajkumar; Common, John E. A.; Tang, Mark B. Y.; Lane, E. Birgitte; Thng, Steven Tien Guan; Sampath, Prabha			Belinostat resolves skin barrier defects in atopic dermatitis by targeting the dysregulated miR-335:SOX6 axis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						MicroRNA; atopic dermatitis; barrier defect; chronic inflammation	MICRORNA EXPRESSION; SOX6; PROTEIN; DIFFERENTIATION; TRANSCRIPTION; KERATINOCYTES; MORPHOGENESIS; INHIBITION; SUPPRESSES; CARTILAGE	Background: Atopic dermatitis (AD) is a common chronic inflammatory skin disease. Skin barrier defects contribute to disease initiation and development; however, underlying mechanisms remain elusive. Objective: To understand the underlying cause of barrier defect, we investigated aberrant expression of specific microRNAs (miRNAs) in AD. Delineating the molecular mechanism of dysregulated miRNA network, we focused on identification of specific drugs that can modulate miRNA expression and repair the defective barrier in AD. Methods: A screen for differentially expressed miRNAs between healthy skin and AD lesional skin resulted in the identification of miR-335 as the most consistently downregulated miRNA in AD. Using in silico prediction combined with experimental validation, we characterized downstream miR-335 targets and elucidated the molecular pathways by which this microRNA maintains epidermal homeostasis in healthy skin. Results: miR-335 was identified as a potent inducer of keratinocyte differentiation; it exerts this effect by directly repressing SOX6. By recruiting SMARCA complex components, SOX6 suppresses epidermal differentiation and epigenetically silences critical genes involved in keratinocyte differentiation. In AD lesional skin, miR-335 expression is aberrantly lost. SOX6 is abnormally expressed throughout the epidermis, where it impairs skin barrier development. We demonstrate that miR-335 is epigenetically regulated by histone deacetylases; a screen for suitable histone deacetylase inhibitors identified belinostat as a candidate drug that can restore epidermal miR-335 expression and rescue the defective skin barrier in AD. Conclusion: Belinostat is of clinical significance not only as a candidate drug for AD treatment, but also as a potential means of stopping the atopic march and further progression of this systemic allergic disease.	[Liew, Wen Chiy; Sundaram, Gopinath M.; Quah, Shan; Lum, Guo Guang; Tan, Jonathan S. L.; Common, John E. A.; Lane, E. Birgitte; Thng, Steven Tien Guan; Sampath, Prabha] Agcy Sci Technol & Res, Skin Res Inst Singapore, Singapore, Singapore; [Liew, Wen Chiy; Sundaram, Gopinath M.; Ramalingam, Rajkumar] Inst Med Biol, Singapore, Singapore; [Liew, Wen Chiy; Sampath, Prabha] Natl Univ Singapore, Dept Biochem, Yong Loo Lin Sch Med, Singapore, Singapore; [Tang, Mark B. Y.] Mt Alvernia Med Ctr, Skin Specialists & Laser Clin, Singapore, Singapore; [Thng, Steven Tien Guan] Natl Skin Ctr, Singapore, Singapore; [Sampath, Prabha] Duke NUS Med Sch, Program Canc & Stem Cell Biol, Singapore, Singapore	Agency for Science Technology & Research (A*STAR); Skin Research Institute of Singapore (SRIS); Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Medical Biology (IMB); National University of Singapore; National Skin Centre; National University of Singapore	Prabha, S (corresponding author), ASTAR, Skin Res Inst Singapore, 8A Biomed Grove,05-41 Immunos, Singapore 138648, Singapore.	prabha.sampath@sris.a-star.edu.sg	Common, John/Q-6412-2018	Common, John/0000-0002-3280-7365	Biomedical Research Council of Singapore; Agency for Science, Technology, and Research; National Healthcare Group (NHG) Skin Innovation Grant [SIG18006]	Biomedical Research Council of Singapore(Agency for Science Technology & Research (A*STAR)); Agency for Science, Technology, and Research(Agency for Science Technology & Research (A*STAR)); National Healthcare Group (NHG) Skin Innovation Grant	This work was supported by the Biomedical Research Council of Singapore; and an Agency for Science, Technology, and Research and National Healthcare Group (NHG) Skin Innovation Grant (SIG18006).	Agrawal R, 2014, CURR ALLERGY ASTHM R, V14, DOI 10.1007/s11882-014-0433-9; An CI, 2011, BMC DEV BIOL, V11, DOI 10.1186/1471-213X-11-59; Andl T, 2006, CURR BIOL, V16, P1041, DOI 10.1016/j.cub.2006.04.005; Boguniewicz M, 2010, J ALLERGY CLIN IMMUN, V125, P4, DOI 10.1016/j.jaci.2009.11.027; Carrion SL, 2014, EXP DERMATOL, V23, P211, DOI 10.1111/exd.12333; Chikh A, 2011, EMBO J, V30, P4261, DOI 10.1038/emboj.2011.302; Choi J, 2015, P NATL ACAD SCI USA, V112, pE718, DOI 10.1073/pnas.1418592112; Cork MJ, 2009, J INVEST DERMATOL, V129, P1892, DOI 10.1038/jid.2009.133; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; Dugas JC, 2010, NEURON, V65, P597, DOI 10.1016/j.neuron.2010.01.027; Fogg MI, 2003, J ALLERGY CLIN IMMUN, V112, P796, DOI 10.1016/S0091-6749(03)01715-9; Hagiwara N, 2011, DEV DYNAM, V240, P1311, DOI 10.1002/dvdy.22639; Han Y, 2008, MOL CELL BIOL, V28, P4999, DOI 10.1128/MCB.00695-08; Hildebrand J, 2011, J INVEST DERMATOL, V131, P20, DOI 10.1038/jid.2010.268; Hogan Mary Beth, 2012, J Allergy (Cairo), V2012, P901940, DOI 10.1155/2012/901940; Hsieh TH, 2015, MOL THER, V23, P656, DOI 10.1038/mt.2014.247; Iguchi H, 2007, J BIOL CHEM, V282, P19052, DOI 10.1074/jbc.M700460200; Kadoch C, 2015, SCI ADV, V1, DOI 10.1126/sciadv.1500447; Kamachi Y, 2000, TRENDS GENET, V16, P182, DOI 10.1016/S0168-9525(99)01955-1; Kim TH, 2010, INT IMMUNOPHARMACOL, V10, P1310, DOI 10.1016/j.intimp.2010.08.004; Koumangoye RB, 2015, MOL CANCER, V14, DOI 10.1186/s12943-014-0284-y; Lefebvre V, 1998, EMBO J, V17, P5718, DOI 10.1093/emboj/17.19.5718; Liu CJ, 2007, FRONT BIOSCI, V12, P3899, DOI 10.2741/2359; Lopez AT, 2018, AM J CLIN DERMATOL, V19, P805, DOI 10.1007/s40257-018-0380-7; Markova NG, 2007, J INVEST DERMATOL, V127, P1126, DOI 10.1038/sj.jid.5700684; Martens JA, 2003, CURR OPIN GENET DEV, V13, P136, DOI 10.1016/S0959-437X(03)00022-4; Moll I, 1998, J INVEST DERMATOL, V111, P251, DOI 10.1046/j.1523-1747.1998.00265.x; Murakami A, 2001, NUCLEIC ACIDS RES, V29, P3347, DOI 10.1093/nar/29.16.3347; Nachtigall PG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119804; Okuda S, 2017, NUCLEIC ACIDS RES, V45, pD1107, DOI 10.1093/nar/gkw1080; Paller AS, 2019, J ALLERGY CLIN IMMUN, V143, P46, DOI 10.1016/j.jaci.2018.11.006; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Rao M, 2008, CELL CYCLE, V7, P647, DOI 10.4161/cc.7.5.5446; RICE RH, 1994, J CELL SCI, V107, P1985; Rozalski M, 2016, POSTEP DERM ALERGOL, V33, P157, DOI 10.5114/ada.2016.60606; Sarnowska E, 2016, TRENDS PLANT SCI, V21, P594, DOI 10.1016/j.tplants.2016.01.017; Scott GK, 2006, CANCER RES, V66, P1277, DOI 10.1158/0008-5472.CAN-05-3632; Shi YL, 2012, J DERMATOL SCI, V68, P99, DOI 10.1016/j.jdermsci.2012.09.001; Simpson EL, 2016, SEMIN CUTAN MED SURG, V35, pS84, DOI 10.12788/j.sder.2016.041; Sonkoly E, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000610; Sonkoly E, 2010, J ALLERGY CLIN IMMUN, V126, P581, DOI 10.1016/j.jaci.2010.05.045; Specjalski K, 2019, ARCH IMMUNOL THER EX, V67, P213, DOI 10.1007/s00005-019-00547-4; Steelant B, 2019, J ALLERGY CLIN IMMUN, V144, P1242, DOI 10.1016/j.jaci.2019.04.027; STEVEN AC, 1994, J CELL SCI, V107, P693; Sundaram GM, 2017, J EXP MED, V214, P2889, DOI 10.1084/jem.20170354; Sundaram GM, 2013, NATURE, V495, P103, DOI 10.1038/nature11890; Tiscornia G, 2006, NAT PROTOC, V1, P241, DOI 10.1038/nprot.2006.37; Trzeciak M, 2017, ACTA DERM-VENEREOL, V97, P36, DOI 10.2340/00015555-2482; Wang XY, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2124-x; Weidinger S, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/s41572-018-0001-z; Weidinger S, 2016, LANCET, V387, P1109, DOI 10.1016/S0140-6736(15)00149-X; Wu GP, 2015, ALLERGY ASTHMA IMMUN, V7, P449, DOI 10.4168/aair.2015.7.5.449; Yi R, 2006, NAT GENET, V38, P356, DOI 10.1038/ng1744; Yi R, 2009, P NATL ACAD SCI USA, V106, P498, DOI 10.1073/pnas.0810766105; Zeng YP, 2016, MOL CELL BIOCHEM, V416, P63, DOI 10.1007/s11010-016-2696-z	55	20	21	4	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2020	146	3					606	+		10.1016/j.jaci.2020.02.007	http://dx.doi.org/10.1016/j.jaci.2020.02.007			27	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NO0HS	32088305	hybrid			2022-12-18	WOS:000569168900013
J	Jackson, DJ; Bacharier, LB; Calatroni, A; Gill, MA; Hu, J; Liu, AH; Wheatley, LM; Gem, JE; Gruchalla, RS; Hershey, GKK; Kattan, M; Kercsmar, CM; Kim, H; O'Connor, GT; Patel, S; Pongracic, JA; Wood, RA; Busse, WW				Jackson, Daniel J.; Bacharier, Leonard B.; Calatroni, Agustin; Gill, Michelle A.; Hu, Jack; Liu, Andrew H.; Wheatley, Lisa M.; Gem, James E.; Gruchalla, Rebecca S.; Hershey, Gurjit K. Khurana; Kattan, Meyer; Kercsmar, Carolyn M.; Kim, Haejin; O'Connor, George T.; Patel, Shilpa; Pongracic, Jacqueline A.; Wood, Robert A.; Busse, William W.			Serum IL-6: A biomarker in childhood asthma?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							SEVERITY; CHILDREN		[Jackson, Daniel J.; Gem, James E.; Busse, William W.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA; [Bacharier, Leonard B.] Washington Univ, Sch Med, St Louis, MO USA; [Calatroni, Agustin; Hu, Jack] Rho Inc, Chapel Hill, NC USA; [Gill, Michelle A.; Gruchalla, Rebecca S.] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA; [Liu, Andrew H.] Childrens Hosp Colorado, Denver, CO USA; [Liu, Andrew H.] Univ Colorado, Sch Med, Denver, CO USA; [Wheatley, Lisa M.] NIAID, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Hershey, Gurjit K. Khurana; Kercsmar, Carolyn M.] Cincinnati Childrens Hosp, Cincinnati, OH USA; [Kattan, Meyer] Columbia Univ, Coll Phys & Surg, New York, NY USA; [Kim, Haejin] Henry Ford Hlth Syst, Detroit, MI USA; [O'Connor, George T.] Boston Univ, Sch Med, Boston, MA 02118 USA; [Patel, Shilpa] Childrens Natl Hlth Syst, Washington, DC USA; [Pongracic, Jacqueline A.] Ann Robert H Lurie Childrens Hosp Chicago, Chicago, IL USA; [Wood, Robert A.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA	University of Wisconsin System; University of Wisconsin Madison; Washington University (WUSTL); Rho; University of Texas System; University of Texas Southwestern Medical Center Dallas; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Cincinnati Children's Hospital Medical Center; Columbia University; Henry Ford Health System; Henry Ford Hospital; Boston University; Children's National Health System; Ann & Robert H. Lurie Children's Hospital of Chicago; Johns Hopkins University	Jackson, DJ (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA.	djj@medicine.wise.edu	Patel, Shilpa/GPC-8726-2022; Patel, Shilpa/AAL-5416-2021	Patel, Shilpa/0000-0002-9287-1430; Bacharier, Leonard/0000-0003-0432-2704	National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) [1UM1AI114271-01]; National Center for Research Resources (NCRR); National Center for Advancing Translational Sciences (NCATS), NIH; NCRR/NIH [UL1TR000451, UL1RR025780, UL1TR000075 Q1, NCATS/NIH UL1TR000154, UL1TR001082, UL1TR000077-04, UL1TR000040, UL1TR000150, UL1TR001105]	National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Center for Research Resources (NCRR)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Center for Advancing Translational Sciences (NCATS), NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NCRR/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	This project has been funded in whole or in part with federal funds from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) 1UM1AI114271-01. Additional support was provided by the National Center for Research Resources (NCRR), and the National Center for Advancing Translational Sciences (NCATS), NIH (under grant nos. NCRR/NIH UL1TR000451, UL1RR025780, UL1TR000075 Q1 and NCATS/NIH UL1TR000154, UL1TR001082, UL1TR000077-04, UL1TR000040, UL1TR000150, and UL1TR001105).	Jevnikar Z, 2019, J ALLERGY CLIN IMMUN, V143, P577, DOI 10.1016/j.jaci.2018.05.026; O'Byrne PM, 2009, AM J RESP CRIT CARE, V179, P19, DOI 10.1164/rccm.200807-1126OC; ORTEGA DB, 2018, J ALLERGY CLIN IMMUN, V6; Peters MC, 2016, LANCET RESP MED, V4, P574, DOI 10.1016/S2213-2600(16)30048-0; Pongracic JA, 2016, J ALLERGY CLIN IMMUN, V138, P1030, DOI 10.1016/j.jaci.2016.06.059; Wildfire JJ, 2012, J ALLERGY CLIN IMMUN, V129, P694, DOI 10.1016/j.jaci.2011.12.962; Zoratti EM, 2016, J ALLERGY CLIN IMMUN, V138, P1016, DOI 10.1016/j.jaci.2016.06.061	7	20	20	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2020	145	6					1701	+		10.1016/j.jaci.2020.01.021	http://dx.doi.org/10.1016/j.jaci.2020.01.021			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LW4ZZ	32004524	Green Accepted, Bronze			2022-12-18	WOS:000539157800029
J	Ravn, NH; Halling, AS; Berkowitz, AG; Rinnov, MR; Silverberg, JI; Egeberg, A; Thyssen, JP				Ravn, Nina H.; Halling, Anne-Sofie; Berkowitz, Aviva G.; Rinnov, Maria R.; Silverberg, Jonathan I.; Egeberg, Alexander; Thyssen, Jacob P.			How does parental history of atopic disease predict the risk of atopic dermatitis in a child? A systematic review and meta-analysis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Atopic dermatitis; atopic disease; parental history; predisposition; meta-analysis; systematic review	INDOOR ENVIRONMENTAL-FACTORS; DOMESTIC WATER HARDNESS; BREAST-FEEDING DURATION; OF-FUNCTION VARIANTS; CORD BLOOD-IGE; 1ST 2 YEARS; ALLERGIC DISEASES; BIRTH COHORT; SCHOOL-CHILDREN; FOOD ALLERGY	Background: Parental history of atopic disease is a well-established risk factor for the development of atopic dermatitis (AD), but several aspects of this association remain unclear. Objective: We sought to determine the association of parental history of atopic disease with AD in offspring. Methods: We searched PubMed and EMBASE through June 2018 for relevant records and adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Pooled odds ratios (ORs) with 95% CI were calculated using random-effects models. Results: A total of 163 records covering 149 unique studies were included. Of these, 119 studies were included in the meta-analysis. Individuals with parental history of atopic disease had increased odds of AD (OR, 1.81; 95% CI, 1.65-1.99). Parental asthma (OR, 1.56; 95% CI, 1.18-2.05) and allergic rhinitis (OR, 1.68; 95% CI, 1.34-2.11) had a smaller effect than AD (OR, 3.30; 95% CI, 2.46-4.42). The effect of maternal and paternal history was comparable for all atopic diseases. An increase in odds was observed when comparing the effect of having 1 (OR, 1.30; 95% CI, 1.15-1.47) or 2 atopic parents (OR, 2.08; 95% CI, 1.83-2.36), as well as having a parent with 1 (OR, 1.49; 95% CI, 1.28-1.74) or more atopic diseases (OR, 2.32; 95% CI, 1.92-2.81). Conclusions: This study provides evidence-based risk estimates that may guide physicians who counsel parents with a history of atopic disease about their children's risk of AD. This information is of particular importance for future efforts toward establishing prophylactic interventions for AD on a general population level.	[Ravn, Nina H.; Halling, Anne-Sofie; Rinnov, Maria R.; Egeberg, Alexander; Thyssen, Jacob P.] Univ Copenhagen, Herlev & Gentofte Hosp, Dept Dermatol & Allergy, Hellerup, Denmark; [Berkowitz, Aviva G.] Montefiore Med Ctr, 111 E 210th St, Bronx, NY 10467 USA; [Silverberg, Jonathan I.] Northwestern Univ, Dept Dermatol Prevent Med & Med Social Sci, Feinberg Sch Med, Chicago, IL 60611 USA; [Thyssen, Jacob P.] Herlev & Gentofte Hosp, Natl Allergy Res Ctr, Hellerup, Denmark	University of Copenhagen; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Northwestern University; Feinberg School of Medicine	Thyssen, JP (corresponding author), Herlev & Gentofte Hosp, Dept Dermatol & Allergy, Gentofte Hosp Vej 15, DK-2100 Hellerup, Denmark.	Jacob.pontoppidan.thyssen@regionh.dk	Egeberg, Alexander/AFO-3479-2022; silverberg, jonathan/ABH-2765-2021; Thyssen, Jacob/ABD-8517-2020; Halling, Anne-Sofie/AAW-2738-2020	Egeberg, Alexander/0000-0001-8257-1816; silverberg, jonathan/0000-0003-3686-7805; Halling, Anne-Sofie/0000-0003-0166-6560; Rinnov, Maria Rasmussen/0000-0003-4624-6180	Lundbeck Foundation [R139-2012-12679] Funding Source: researchfish; Novo Nordisk Fonden [NNF18OC0033054] Funding Source: researchfish	Lundbeck Foundation(Lundbeckfonden); Novo Nordisk Fonden(Novo Nordisk Foundation)		ABERG N, 1993, CLIN EXP ALLERGY, V23, P829, DOI 10.1111/j.1365-2222.1993.tb00260.x; Agata H, 1999, ANN ALLERG ASTHMA IM, V82, P586, DOI 10.1016/S1081-1206(10)63171-7; Aguilar D, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179125; Alford SH, 2004, J ALLERGY CLIN IMMUN, V114, P1046, DOI 10.1016/j.jaci.2004.08.036; Allam JP, 2005, ALLERGY, V60, P743, DOI 10.1111/j.1398-9995.2005.00815.x; Alm B, 2012, ALLERGY, V67, P217; AlMakoshi A, 2015, PEDIAT ALLERG IMM-UK, V26, P811, DOI 10.1111/pai.12380; Apfelbacher CJ, 2011, ALLERGY, V66, P206, DOI 10.1111/j.1398-9995.2010.02464.x; Arshad SH, 2012, J ALLERGY CLIN IMMUN, V130, P427, DOI 10.1016/j.jaci.2012.03.042; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Awasthi S, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1467-1; Baek JO, 2013, INT ARCH ALLERGY IMM, V162, P79, DOI 10.1159/000351403; Bamai YA, 2018, SCI TOTAL ENVIRON, V618, P1408, DOI 10.1016/j.scitotenv.2017.09.270; Barman M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067920; Barraza-Villarreal A, 2011, AM J RESP CRIT CARE, V183; Garrido JB, 2010, ALLERGOL IMMUNOPATH, V38, P174, DOI 10.1016/j.aller.2009.10.008; Bedolla-Barajas M, 2018, ALLERGOL IMMUNOPATH, V46, P31, DOI 10.1016/j.aller.2017.01.010; Belyhun Y, 2010, CLIN EXP ALLERGY, V40, P619, DOI 10.1111/j.1365-2222.2010.03479.x; Benn CS, 2004, AM J EPIDEMIOL, V160, P217, DOI 10.1093/aje/kwh208; Bergmann RL, 1997, CLIN EXP ALLERGY, V27, P752, DOI 10.1046/j.1365-2222.1997.310899.x; Bergmann RL, 2002, CLIN EXP ALLERGY, V32, P205, DOI 10.1046/j.1365-2222.2002.01274.x; Bertelsen RJ, 2014, J ALLERGY CLIN IMMUN, V133, P165, DOI 10.1016/j.jaci.2013.07.032; BerthJones J, 1997, BRIT J DERMATOL, V136, P498, DOI 10.1046/j.1365-2133.1997.d01-1224.x; Bieber T, 2017, J ALLERGY CLIN IMMUN, V139, pS58, DOI 10.1016/j.jaci.2017.01.008; Bin LH, 2016, ALLERGY ASTHMA CL IM, V12, DOI 10.1186/s13223-016-0158-5; Bohme M, 2003, CLIN EXP ALLERGY, V33, P1226, DOI 10.1046/j.1365-2222.2003.01749.x; Bolat E, 2017, ALLERGOL IMMUNOPATH, V45, P362, DOI 10.1016/j.aller.2017.01.002; Bolte G, 2003, CLIN EXP ALLERGY, V33, P770, DOI 10.1046/j.1365-2222.2003.01665.x; Brown SJ, 2011, J ALLERGY CLIN IMMUN, V127, P661, DOI 10.1016/j.jaci.2011.01.031; Bundhoo A, 2015, CLIN EXP ALLERGY, V45, P1085, DOI 10.1111/cea.12508; Cabridain C, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-024974; Cerny V, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207998; Chalmers JR, 2017, TRIALS, V18, DOI 10.1186/s13063-017-2031-3; Chang W. T., 2005, Acta Paediatrica Taiwanica, V46, P272; Chang YS, 2016, JAMA PEDIATR, V170, P236, DOI 10.1001/jamapediatrics.2015.3943; CHEN TC, 1990, ARCH NEUROL-CHICAGO, V47, P1227, DOI 10.1001/archneur.1990.00530110087022; Cho YM, 2014, J ASTHMA, V51, P373, DOI 10.3109/02770903.2013.876648; Civelek E, 2011, J INVEST ALLERG CLIN, V21, P270; Cogswell JJ, 2000, CLIN EXP ALLERGY, V30, P1; COOKSON WOCM, 1992, LANCET, V340, P381, DOI 10.1016/0140-6736(92)91468-N; Cooper PJ, 2016, J ALLERGY CLIN IMMUN, V137, P899, DOI 10.1016/j.jaci.2015.07.044; Cox HE, 1998, BRIT J DERMATOL, V138, P182; Cuello-Garcia C, 2017, CLIN EXP ALLERGY, V47, P1468, DOI 10.1111/cea.13042; Cuello-Garcia CA, 2015, J ALLERGY CLIN IMMUN, V136, P952, DOI [10.1016/j.jaci.2015.07.021, 10.1016/j.jaci.2015.04.031]; Czarnowicki T, 2019, J ALLERGY CLIN IMMUN, V143, P1, DOI 10.1016/j.jaci.2018.10.032; Czarnowicki T, 2017, J ALLERGY CLIN IMMUN, V139, P1723, DOI 10.1016/j.jaci.2017.04.004; Deckers IAG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039803; Deng QH, 2016, CHEMOSPHERE, V152, P459, DOI 10.1016/j.chemosphere.2016.03.032; Di Pietrantonj C, 2006, STAT MED, V25, P2299, DOI 10.1002/sim.2287; Diepgen TL, 1996, J INVEST DERMATOL, V106, P977, DOI 10.1111/1523-1747.ep12338475; Dogruel D, 2016, ALLERGOL IMMUNOPATH, V44, P214, DOI 10.1016/j.aller.2015.07.002; DOLD S, 1992, ARCH DIS CHILD, V67, P1018, DOI 10.1136/adc.67.8.1018; Dom S, 2009, PEDIAT ALLERG IMM-UK, V20, P438, DOI 10.1111/j.1399-3038.2008.00834.x; DOTTERUD LK, 1995, ACTA DERM-VENEREOL, V75, P50; Doull IJM, 1996, CLIN EXP ALLERGY, V26, P613; Dunlop AL, 2006, PEDIAT ALLERG IMM-UK, V17, P103, DOI 10.1111/j.1399-3038.2005.00372.x; Ece A, 2001, TURKISH J PEDIATR, V43, P286; El-Heis S, 2016, CLIN EXP ALLERGY, V46, P1337, DOI 10.1111/cea.12782; Elbert NJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187999; Eller E, 2010, PEDIAT ALLERG IMM-UK, V21, P307, DOI 10.1111/j.1399-3038.2009.00914.x; Elmose C, 2015, J ALLERGY CAIRO, V2015; Engebretsen KA, 2017, J ALLERGY CLIN IMMUN, V139, P1568, DOI 10.1016/j.jaci.2016.11.021; Enomoto T, 2014, ALLERGOL INT, V63, P575, DOI 10.2332/allergolint.13-OA-0683; Erbas B, 2013, ALLERGY, V68, P58; Esparza-Gordillo J, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005076; Farooqi IS, 1998, THORAX, V53, P927, DOI 10.1136/thx.53.11.927; Fedortsiv O, 2012, ADV MED SCI-POLAND, V57, P282, DOI 10.2478/v10039-012-0034-6; FERGUSSON DM, 1990, PEDIATRICS, V86, P541; FERGUSSON DM, 1982, J EPIDEMIOL COMMUN H, V36, P118, DOI 10.1136/jech.36.2.118; Ferreira MA, 2017, NAT GENET, V49, P1752, DOI 10.1038/ng.3985; Ferreira MAR, 2019, J ALLERGY CLIN IMMUN, V143, P691, DOI 10.1016/j.jaci.2018.03.012; Flohr C, 2004, J ALLERGY CLIN IMMUN, V114, P150, DOI 10.1016/j.jaci.2004.04.027; Flohr C, 2014, ALLERGY, V69, P56, DOI 10.1111/all.12343; Folsgaard NV, 2012, CLIN EXP ALLERGY, V42, P1596, DOI 10.1111/j.1365-2222.2012.04048.x; Font-Ribera L, 2015, ENVIRON RES, V142, P579, DOI 10.1016/j.envres.2015.07.013; Forno Erick, 2008, Clin Mol Allergy, V6, P11, DOI 10.1186/1476-7961-6-11; Fu YJ, 2013, PEDIAT ALLERG IMM-UK, V24, P178, DOI 10.1111/pai.12050; Fuertes E, 2015, ALLERGY, V70, P873, DOI 10.1111/all.12609; Fukao T., 2005, ALLERGOL INT, V54, P521, DOI DOI 10.2332/ALLERGOLINT.54.521; Fukiwake N, 2008, EUR J DERMATOL, V18, P571, DOI 10.1684/ejd.2008.0479; Gillespie J, 2006, J ALLERGY CLIN IMMUN, V118, P1265, DOI 10.1016/j.jaci.2006.07.051; Girolomoni G, 2003, ALLERGY, V58, P420, DOI 10.1034/j.1398-9995.2003.00112.x; Gough H, 2015, PEDIAT ALLERG IMM-UK, V26, P431, DOI 10.1111/pai.12410; Govaere E, 2009, PEDIATR DERMATOL, V26, P129, DOI 10.1111/j.1525-1470.2008.00801.x; Graif Y, 2004, ANN ALLERG ASTHMA IM, V92, P245, DOI 10.1016/S1081-1206(10)61555-4; Gunaratne AW, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010085.pub2; Guner SN, 2011, ALLERGOL IMMUNOPATH, V39, P140, DOI 10.1016/j.aller.2010.05.004; Gupta R, 2004, CLIN EXP ALLERGY, V34, P520, DOI 10.1111/j.1365-2222.2004.1935.x; Gustafsson D, 1996, ALLERGY, V51, P789, DOI 10.1111/j.1398-9995.1996.tb00024.x; Hamann CR, 2015, J ALLERGY CLIN IMMUN, V135, P1070, DOI 10.1016/j.jaci.2014.07.066; Hammad H, 2015, IMMUNITY, V43, P29, DOI 10.1016/j.immuni.2015.07.007; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Harris JM, 2001, BRIT J DERMATOL, V144, P795, DOI 10.1046/j.1365-2133.2001.04135.x; Harrop J, 2007, CLIN EXP ALLERGY, V37, P526, DOI 10.1111/j.1365-2222.2007.02679.x; Herberth G, 2011, ALLERGY, V66, P1065, DOI 10.1111/j.1398-9995.2011.02587.x; Hesselmar B, 2001, PEDIATR ALLERGY IMMU, V12, P208, DOI 10.1034/j.1399-3038.2001.012004208.x; Hicks WB, 2011, PEDIAT ALLERG IMM-UK, V22, P684, DOI 10.1111/j.1399-3038.2011.01160.x; Hinz D, 2012, ALLERGY, V67, P380, DOI 10.1111/j.1398-9995.2011.02767.x; Holmlund U, 2003, CLIN EXP ALLERGY, V33, P455, DOI 10.1046/j.1365-2222.2003.01629.x; Hong S, 2014, ALLERGY ASTHMA PROC, V35, P66, DOI 10.2500/aap.2014.35.3716; Horimukai K, 2014, J ALLERGY CLIN IMMUN, V134, P824, DOI 10.1016/j.jaci.2014.07.060; Hsu NY, 2012, ARCH ENVIRON OCCUP H, V67, P155, DOI 10.1080/19338244.2011.598890; Hua MC, 2019, PEDIAT ALLERG IMM-UK, V30, P204, DOI 10.1111/pai.13011; Illi S, 2014, ANN ALLERG ASTHMA IM, V112, P132, DOI 10.1016/j.anai.2013.11.019; Irvine AD, 2011, NEW ENGL J MED, V365, P1315, DOI 10.1056/NEJMra1011040; Jedrychowski Wieslaw, 2006, International Journal of Occupational Medicine and Environmental Health, V19, P70, DOI 10.2478/v10001-006-0010-0; Jedrychowski W, 2011, SCI TOTAL ENVIRON, V409, P5205, DOI 10.1016/j.scitotenv.2011.08.068; Jin JJ, 2016, MOL CELL PROBE, V30, P168, DOI 10.1016/j.mcp.2016.03.006; Johnke H, 2006, PEDIAT ALLERG IMM-UK, V17, P591, DOI 10.1111/j.1399-3038.2006.00453.x; Jones A P, 2003, Monaldi Arch Chest Dis, V59, P38; Kantor R, 2017, EXPERT REV CLIN IMMU, V13, P15, DOI 10.1080/1744666X.2016.1212660; Karino S, 2008, ANN ALLERG ASTHMA IM, V101, P153, DOI 10.1016/S1081-1206(10)60203-7; Kawano Y, 2005, ASIAN PAC J ALLERGY, V23, P1; Kelbore AG, 2015, BMC DERMATOL, V15, DOI 10.1186/s12895-015-0034-x; Kelleher M, 2015, J ALLERGY CLIN IMMUN, V135, P930, DOI 10.1016/j.jaci.2014.12.013; Kim HB, 2016, ALLERGY ASTHMA PROC, V37, P64, DOI 10.2500/aap.2016.37.3913; Kim HB, 2012, J KOREAN MED SCI, V27, P1320, DOI 10.3346/jkms.2012.27.11.1320; Kim JH, 2013, J KOREAN MED SCI, V28, P516, DOI 10.3346/jkms.2013.28.4.516; KJELLMAN NIM, 1977, ACTA PAEDIATR SCAND, V66, P465, DOI 10.1111/j.1651-2227.1977.tb07928.x; Knudsen TM, 2018, J ALLERGY CLIN IMMUN, V142, P765, DOI [10.1016/j.jaci..2018.07.007, 10.1016/j.jaci.2018.07.007]; Kramer MS, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000133.pub3; Kramer U, 2004, BRIT J DERMATOL, V150, P111, DOI 10.1111/j.1365-2133.2004.05710.x; KUEHR J, 1992, ALLERGY, V47, P650, DOI 10.1111/j.1398-9995.1992.tb02390.x; Kulig M, 2000, J ALLERGY CLIN IMMUN, V105, P274, DOI 10.1016/S0091-6749(00)90076-9; Kurosaka Fumitake, 2011, Allergology International, V60, P317, DOI 10.2332/allergolint.10-OA-0246; Kurt E, 2007, PEDIAT ALLERG IMM-UK, V18, P566, DOI 10.1111/j.1399-3038.2007.00551.x; Kurzius-Spencer M, 2005, PEDIAT ALLERG IMM-UK, V16, P19, DOI 10.1111/j.1399-3038.2005.00233.x; Kwon JH, 2015, PEDIAT ALLERG IMM-UK, V26, P352, DOI 10.1111/pai.12393; Lee JT, 2004, ANN ACAD MED SINGAP, V33, P71; Lee JY, 2012, INT ARCH ALLERGY IMM, V157, P363, DOI 10.1159/000328778; Lee SML, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107567; Lee SL, 2004, PEDIAT ALLERG IMM-UK, V15, P72, DOI 10.1046/j.0905-6157.2003.00109.x; Lee WS, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/3793679; Lee YL, 2007, BRIT J DERMATOL, V157, P1217, DOI 10.1111/j.1365-2133.2007.08215.x; Lee YA, 2000, NAT GENET, V26, P470, DOI 10.1038/82625; Letourneau NL, 2017, ALLERGY ASTHMA CL IM, V13, DOI 10.1186/s13223-017-0199-4; LEUNG R, 1994, CLIN EXP ALLERGY, V24, P353, DOI 10.1111/j.1365-2222.1994.tb00246.x; Lim RH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010134; Linneberg A, 2006, J ALLERGY CLIN IMMUN, V117, P184, DOI 10.1016/j.jaci.2005.09.042; Litonjua AA, 2005, J ALLERGY CLIN IMMUN, V115, P1056, DOI 10.1016/j.jaci.2005.02.006; Liu CA, 2003, J ALLERGY CLIN IMMUN, V112, P899, DOI 10.1016/j.jaci.2003.08.030; Logan CA, 2019, CLIN EXP ALLERGY, V49, P199, DOI 10.1111/cea.13245; Loo EXL, 2015, INT ARCH ALLERGY IMM, V166, P273, DOI 10.1159/000381342; Lowe A, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-024594; Lu C, 2017, J DERMATOL SCI, V85, P85, DOI 10.1016/j.jdermsci.2016.11.004; LUOMA R, 1983, ALLERGY, V38, P339, DOI 10.1111/j.1398-9995.1983.tb04128.x; Marcon A, 2011, RESP MED, V105, P204, DOI 10.1016/j.rmed.2010.09.009; Marenholz I, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9804; Martel MJ, 2009, J PEDIATR-US, V155, P707, DOI 10.1016/j.jpeds.2009.05.004; Martin PE, 2013, CLIN EXP ALLERGY, V43, P642, DOI 10.1111/cea.12092; Martindale S, 2005, AM J RESP CRIT CARE, V171, P121, DOI 10.1164/rccm.200402-220OC; Matsuoka S, 1999, PEDIATR INT, V41, P46, DOI 10.1046/j.1442-200x.1999.01011.x; McKeever TM, 2001, THORAX, V56, P758, DOI 10.1136/thorax.56.10.758; Mgeladze N, 2009, Georgian Med News, P68; Miska EA, 2016, SCIENCE, V354, P59, DOI 10.1126/science.aaf4945; Miyahara H, 2011, CLIN EXP ALLERGY, V41, P186, DOI 10.1111/j.1365-2222.2010.03634.x; Miyake Y, 2004, ACTA PAEDIATR, V93, P380, DOI [10.1111/j.1651-2227.2004.tb02965.x, 10.1080/08035250410022819]; Miyake Y, 2011, INT ARCH ALLERGY IMM, V154, P328, DOI 10.1159/000321825; Miyake Y, 2009, PEDIATR ALLERGY IMMU, V20, P234, DOI 10.1111/j.1399-3038.2008.00778.x; Moberg C, 2006, BRIT J DERMATOL, V155, P557, DOI 10.1111/j.1365-2133.2006.07372.x; Moher David, 2009, Ann Intern Med, V151, P264, DOI [10.1136/bmj.b2535, 10.1016/j.ijsu.2010.02.007]; Moore MM, 2004, PEDIATRICS, V113, P468, DOI 10.1542/peds.113.3.468; Mortz CG, 2015, ACTA DERM-VENEREOL, V95, P968, DOI 10.2340/00015555-2128; Mpairwe H, 2014, PEDIAT ALLERG IMM-UK, V25, P481, DOI 10.1111/pai.12251; Munblit D, 2017, NUTRIENTS, V9; Nakamura T, 2019, BRIT J DERMATOL, V181, P1272, DOI 10.1111/bjd.17853; Nakamura T, 2017, ALLERGY, V72, P555; Nakamura Y, 2000, J Epidemiol, V10, P74; Naleway AL, 2003, ANN INTERN MED, V139, P1, DOI 10.7326/0003-4819-139-1-200307010-00006; Neaville WA, 2003, J ALLERGY CLIN IMMUN, V112, P740, DOI 10.1016/S0091-6749(03)01868-2; Nguyen CM, 2015, J DERMATOL SCI, V80, P89, DOI 10.1016/j.jdermsci.2015.08.004; Novak N, 2003, J ALLERGY CLIN IMMUN, V112, P252, DOI 10.1067/mai.2003.1595; Nwaru BI, 2014, ALLERGY, V69, P87, DOI 10.1111/all.12307; Nwaru BI, 2012, BRIT J NUTR, V108, P720, DOI 10.1017/S0007114511005940; O'Donovan SM, 2016, J ALLERGY CLIN IMMUN, V137, P108, DOI 10.1016/j.jaci.2015.05.035; Obihara CC, 2005, EUR RESPIR J, V25, P970, DOI 10.1183/09031936.05.00116504; Ochiai S, 2014, CHEMOSPHERE, V94, P48, DOI 10.1016/j.chemosphere.2013.09.009; Oh JW, 2004, J KOREAN MED SCI, V19, P716, DOI 10.3346/jkms.2004.19.5.716; Olesen AB, 1997, BRIT MED J, V314, P1003, DOI 10.1136/bmj.314.7086.1003; Osborn DA, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003664.pub6; Overgaard LEK, 2017, ALLERGY, V72, P1768, DOI 10.1111/all.13157; Ozawa N, 2014, ALLERGOL INT, V63, P261, DOI 10.2332/allergolint.13-OA-0613; Paller AS, 2019, J ALLERGY CLIN IMMUN, V143, P46, DOI 10.1016/j.jaci.2018.11.006; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Papathoma E, 2016, PEDIAT ALLERG IMM-UK, V27, P419, DOI 10.1111/pai.12552; Parazzini F, 2014, PEDIAT ALLERG IMM-UK, V25, P43, DOI 10.1111/pai.12165; Park YH, 2010, ALLERGY ASTHMA IMMUN, V2, P28, DOI 10.4168/aair.2010.2.1.28; Park YM, 2016, ASIAN PAC J ALLERGY, V34, P65, DOI 10.12932/AP0621.34.1.2016; Paternoster L, 2015, NAT GENET, V47, P1449, DOI 10.1038/ng.3424; Perkin MR, 2016, J ALLERGY CLIN IMMUN, V138, P509, DOI 10.1016/j.jaci.2016.03.031; Peters AS, 2010, J ALLERGY CLIN IMMUN, V126, P590, DOI 10.1016/j.jaci.2010.06.020; Petherick ES, 2016, RESP MED, V119, P122, DOI 10.1016/j.rmed.2016.08.017; Pols DHJ, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-018091; Poninska J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016933; Portelli MA, 2015, CLIN EXP ALLERGY, V45, P21, DOI 10.1111/cea.12327; Pulendran B, 2012, SCIENCE, V337, P431, DOI 10.1126/science.1221064; Purvis DJ, 2005, BRIT J DERMATOL, V152, P742, DOI 10.1111/j.1365-2133.2005.06540.x; Rajani PS, 2018, FRONT PEDIATR, V6, DOI 10.3389/fped.2018.00218; Ranciere F, 2013, ALLERGY, V68, P1158, DOI 10.1111/all.12208; Rastogi S, 2018, J AM ACAD DERMATOL, V79, P1028, DOI 10.1016/j.jaad.2018.07.017; Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554; Rindsjo E, 2010, ALLERGY, V65, P822, DOI 10.1111/j.1398-9995.2009.02266.x; Rodriguez E, 2009, J ALLERGY CLIN IMMUN, V123, P1361, DOI 10.1016/j.jaci.2009.03.036; Rothenbacher D, 2005, CLIN EXP ALLERGY, V35, P1014, DOI 10.1111/j.1365-2222.2005.02298.x; Roy A, 2018, PEDIAT ALLERG IMM-UK, V29, P144, DOI 10.1111/pai.12834; Sahakyan A, 2006, EUR J EPIDEMIOL, V21, P723, DOI 10.1007/s10654-006-9061-6; Sarafino EP, 2000, PEDIAT ALLERG IMM-UK, V11, P80, DOI 10.1034/j.1399-3038.2000.00065.x; Sasaki M, 2016, ALLERGOL INT, V65, P420, DOI 10.1016/j.alit.2016.03.007; Saunes M, 2011, BMC DERMATOL, V11, DOI 10.1186/1471-5945-11-11; Schafer T, 2000, BRIT J DERMATOL, V143, P992, DOI 10.1046/j.1365-2133.2000.03832.x; Schatz M, 2014, J ALLER CL IMM-PRACT, V2, P645, DOI 10.1016/j.jaip.2014.09.004; Schmitt J, 2011, ALLERGY, V66, P404, DOI 10.1111/j.1398-9995.2010.02487.x; Schoos AM, 2017, ALLERGY, V72, P552; Sebok B, 2006, J EUR ACAD DERMATOL, V20, P418, DOI 10.1111/j.1468-3083.2006.01490.x; Shah PS, 2011, ANN ALLERG ASTHMA IM, V106, P245, DOI 10.1016/j.anai.2010.12.006; Shinohara M, 2017, PEDIAT ALLER IMM PUL, V30, P155, DOI 10.1089/ped.2017.0758; Silverberg JI, 2015, BRIT J DERMATOL, V173, P1400, DOI 10.1111/bjd.14031; Simpson EL, 2014, J ALLERGY CLIN IMMUN, V134, P818, DOI 10.1016/j.jaci.2014.08.005; Simpson EL, 2010, J AM ACAD DERMATOL, V63, P587, DOI 10.1016/j.jaad.2009.11.011; Snijders BFP, 2007, J PEDIATR-US, V151, P347, DOI 10.1016/j.jpeds.2007.03.022; Soto-Quiros ME, 2002, PEDIATR PULM, V33, P237, DOI 10.1002/ppul.10070; Soto-Ramirez N, 2017, CLIN EXP ALLERGY, V47, P1285, DOI 10.1111/cea.12998; Stelmach I, 2015, ALLERGY ASTHMA PROC, V36, pE72, DOI 10.2500/aap.2015.36.3867; Sugiyama M, 2007, PEDIATRICS, V119, pE716, DOI 10.1542/peds.2006-0893; Sugiyama Takako, 2002, Allergology International, V51, P139, DOI 10.1046/j.1440-1592.2002.00250.x; Sybilski AJ, 2015, J DERMATOL, V42, P140, DOI 10.1111/1346-8138.12731; Talay F, 2008, ACTA PAEDIATR, V97, P459, DOI 10.1111/j.1651-2227.2008.00726.x; Tamsmark TH, 2001, ACTA PAEDIATR, V90, P982; Tariq SM, 1998, J ALLERGY CLIN IMMUN, V101, P587, DOI 10.1016/S0091-6749(98)70164-2; TAYLOR B, 1983, J EPIDEMIOL COMMUN H, V37, P95, DOI 10.1136/jech.37.2.95; TAYLOR B, 1984, LANCET, V2, P1255, DOI 10.1016/S0140-6736(84)92805-8; Taylor-Robinson DC, 2016, BRIT J DERMATOL, V174, P569, DOI 10.1111/bjd.14310; Tran MM, 2018, J ALLERGY CLIN IMMUN, V141, P601, DOI 10.1016/j.jaci.2017.08.024; Tromp IIM, 2011, ARCH PEDIAT ADOL MED, V165, P933, DOI 10.1001/archpediatrics.2011.93; Ukawa S, 2013, INT ARCH OCC ENV HEA, V86, P777, DOI 10.1007/s00420-012-0814-0; van den Oord RAHM, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2433; van Elten TM, 2015, ALLERGY, V70, P1468, DOI 10.1111/all.12703; Veerapaneni V, 2017, J ALLERGY CLIN IMMUN, V139, pAB205, DOI 10.1016/j.jaci.2016.12.666; Venkataraman D, 2014, J ALLERGY CLIN IMMUN, V134, P876, DOI 10.1016/j.jaci.2014.07.033; Vos T, 2012, LANCET, V380, P2163, DOI 10.1016/S0140-6736(12)61729-2; Wadonda-Kabondo N, 2004, ARCH DIS CHILD, V89, P917, DOI 10.1136/adc.2003.034033; Wang IJ, 2016, ANN ALLERG ASTHMA IM, V116, P139, DOI 10.1016/j.anai.2015.11.016; Wang IJ, 2010, ANN ALLERG ASTHMA IM, V105, P124, DOI 10.1016/j.anai.2010.04.017; Wang I-Jen, 2006, Acta Paediatr Taiwan, V47, P238; Weidinger S, 2008, J ALLERGY CLIN IMMUN, V121, P1203, DOI 10.1016/j.jaci.2008.02.014; Weidinger S, 2016, LANCET, V387, P1109, DOI 10.1016/S0140-6736(15)00149-X; Wen HJ, 2009, BRIT J DERMATOL, V161, P1166, DOI 10.1111/j.1365-2133.2009.09412.x; Wen HJ, 2011, PEDIAT ALLERG IMM-UK, V22, P695, DOI 10.1111/j.1399-3038.2011.01177.x; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P383, DOI 10.1111/j.1365-2133.1994.tb08530.x; Wolkewitz M, 2007, BRIT J DERMATOL, V156, P693, DOI 10.1111/j.1365-2133.2006.07659.x; Wu CC, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/132142; Yepes-Nunez JJ, 2018, ALLERGY, V73, P37, DOI 10.1111/all.13241; Yew YW, 2019, J AM ACAD DERMATOL, V81, P1018, DOI 10.1016/j.jaad.2019.01.090; Yotsumoto S, 2000, BRIT J DERMATOL, V142, P370, DOI 10.1046/j.1365-2133.2000.03312.x; Yu YM, 2015, BRIT J NUTR, V113, P975, DOI 10.1017/S000711451500001X; Ziyab AH, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/2184193; Zutavern A, 2005, CLIN EXP ALLERGY, V35, P1301, DOI 10.1111/j.1365-2222.2005.02350.x	257	20	20	2	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2020	145	4					1182	1193		10.1016/j.jaci.2019.12.899	http://dx.doi.org/10.1016/j.jaci.2019.12.899			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LA0FR	31887393	Bronze			2022-12-18	WOS:000523633400015
J	Amatuni, GS; Sciortino, S; Currier, RJ; Naides, SJ; Church, JA; Puck, JM				Amatuni, George S.; Sciortino, Stanley; Currier, Robert J.; Naides, Stanley J.; Church, Joseph A.; Puck, Jennifer M.			Reference intervals for lymphocyte subsets in preterm and term neonates without immune defects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Flow cytometry; memory T cell; naive T cell; neonatal immunity; newborn screening; preterm birth; reference range/reference interval; severe combined immunodeficiency; T-cell receptor excision circle; T-cell subsets	SEVERE COMBINED IMMUNODEFICIENCY; CHILDREN; INFANTS; AGE	Background: In 6.5 years of newborn screening for severe combined immunodeficiency in California, 3,252,156 infants had DNA from dried blood spots (DBSs) assayed for T-cell receptor excision circles. Infants with T-cell receptor excision circle values of less than a designated cutoff on a single DBS, 2 DBS samples with insufficient PCR amplification, or known genetic risk of immunodeficiency had peripheral blood complete blood counts and lymphocyte subsets assayed in a single flow cytometry laboratory. Cases in which immune defects were ruled out were available for analysis. Objective: We sought to determine reference intervals for lymphocyte subsets in racially/ethnically diverse preterm and term newborns who proved to be unaffected by any T-lymphopenic immune disorder. Methods: Effective gestational age (GA) was defined as GA at birth plus postnatal age at the time of sample collection. After determining exclusion criteria, we analyzed demographic and clinical information, complete and differential white blood cell counts, and lymphocyte subsets for 301 infants, with serial measurements for 33 infants. Lymphocyte subset measurements included total T cells, helper and cytotoxic T-cell subsets, naive and memory phenotype of each T-cell subset, B cells, and natural killer cells. Results: Reference intervals were generated for absolute numbers and lymphocyte subsets from infants with effective GAs of 22 to 52 weeks. Sex and ethnicity were not significant determinants of lymphocyte subset counts in this population. Lymphocyte counts increased postnatally. Conclusion: This study provides a baseline for interpreting comprehensive lymphocyte data in preterm and term infants, aiding clinicians to determine which newborns require further evaluations for immunodeficiency.	[Amatuni, George S.; Currier, Robert J.; Puck, Jennifer M.] Univ Calif San Francisco, Dept Pediat, Sch Med, San Francisco, CA USA; [Amatuni, George S.] Einstein Coll Med, Dept Cell Biol, Stem Cell Inst, Bronx, NY USA; [Sciortino, Stanley] Calif Dept Publ Hlth, Genet Dis Screening Program, Richmond, CA USA; [Naides, Stanley J.] Quest Diagnost Nichols Inst, Immunol Dept, San Juan Capistrano, CA USA; [Church, Joseph A.] Univ So Calif, Keck Sch Med, Dept Pediat, Los Angeles, CA USA; [Church, Joseph A.] Childrens Hosp Los Angeles, Los Angeles, CA USA; [Puck, Jennifer M.] Univ Calif San Francisco, Inst Human Genet, San Francisco, CA USA; [Puck, Jennifer M.] Univ Calif San Francisco, Smith Cardiovasc Res Inst, San Francisco, CA USA; [Puck, Jennifer M.] Univ Calif San Francisco, Benioff Childrens Hosp, San Francisco, CA USA	University of California System; University of California San Francisco; Yeshiva University; Albert Einstein College of Medicine; California Department of Public Health; Nichols Institute; University of Southern California; Children's Hospital Los Angeles; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Puck, JM (corresponding author), UCSF, Dept Pediat, Div Allergy Immunol & Blood & Marrow Transplant, Box 3118,555 Mission Bay Blvd South,Rm SC-252K, San Francisco, CA 94143 USA.	Jennifer.Puck@ucsf.edu			Primary Immune Deficiency Treatment Consortium, a member of the Rare Diseases Clinical Research Network (RDCRN) - National Institute of Allergy and Infectious Diseases, National Institutes of Health [R01 AI105776, U54 AI082973]; Primary Immune Deficiency Treatment Consortium, a member of the Rare Diseases Clinical Research Network (RDCRN) - Office of Rare Diseases Research, National Center for Advancing Translational Sciences, National Institutes of Health [R01 AI105776, U54 AI082973]; Jeffrey Modell Foundation; Lisa and Douglas Goldman Fund; Michelle Platt-Ross Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U54AI082973] Funding Source: NIH RePORTER	Primary Immune Deficiency Treatment Consortium, a member of the Rare Diseases Clinical Research Network (RDCRN) - National Institute of Allergy and Infectious Diseases, National Institutes of Health; Primary Immune Deficiency Treatment Consortium, a member of the Rare Diseases Clinical Research Network (RDCRN) - Office of Rare Diseases Research, National Center for Advancing Translational Sciences, National Institutes of Health; Jeffrey Modell Foundation; Lisa and Douglas Goldman Fund; Michelle Platt-Ross Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	J.M.P. received support from R01 AI105776; U54 AI082973 from the Primary Immune Deficiency Treatment Consortium, a member of the Rare Diseases Clinical Research Network (RDCRN) funded by the National Institute of Allergy and Infectious Diseases and the Office of Rare Diseases Research, National Center for Advancing Translational Sciences, National Institutes of Health; the Jeffrey Modell Foundation; the Lisa and Douglas Goldman Fund; and the Michelle Platt-Ross Foundation. J.A.C. received support from the Jeffrey Modell Foundation.	Amatuni GS, 2019, PEDIATRICS, V143, DOI 10.1542/peds.2018-2300; [Anonymous], 2018, IDF SCID NEWB SCREEN; [Anonymous], 2013, PRET BIRTH CHILD HLT; Bitton Natalie, 2012, Pediatr Dent, V34, P144; Chan K, 2005, J ALLERGY CLIN IMMUN, V115, P391, DOI 10.1016/j.jaci.2004.10.012; Chrzanowska KH, 1998, CLIN GENET, V53, P308; Hannon WH, 2013, NBS06A CLSI; Huenecke S, 2016, SCAND J IMMUNOL, V84, P291, DOI 10.1111/sji.12474; Huo YL, 2017, J ALLERGY CLIN IMMUN, V140, P605, DOI 10.1016/j.jaci.2017.01.033; Jyonouchi S, 2013, PEDIATRICS, V132, pE484, DOI 10.1542/peds.2012-3815; Kwan A, 2014, JAMA-J AM MED ASSOC, V312, P729, DOI 10.1001/jama.2014.9132; Kwan A, 2013, J ALLERGY CLIN IMMUN, V132, P140, DOI 10.1016/j.jaci.2013.04.024; Mandala WL, 2014, J ALLERGY CLIN IMMUN, V134, P759, DOI 10.1016/j.jaci.2014.06.030; Puck JM, 2012, J ALLERGY CLIN IMMUN, V129, P607, DOI 10.1016/j.jaci.2012.01.032; Rechavi E, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01448; Shearer WT, 2003, J ALLERGY CLIN IMMUN, V112, P973, DOI 10.1016/j.jaci.2003.07.003; Verbsky J, 2012, J ALLERGY CLIN IMMUN, V129, P622, DOI 10.1016/j.jaci.2011.12.004; Vogel BH, 2014, J CLIN IMMUNOL, V34, P289, DOI 10.1007/s10875-014-0006-7	18	20	21	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2019	144	6					1674	1683		10.1016/j.jaci.2019.05.038	http://dx.doi.org/10.1016/j.jaci.2019.05.038			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JT0NR	31220471	Bronze, Green Accepted			2022-12-18	WOS:000500694900024
J	Borbet, TC; Zhang, XZ; Muller, A; Blaser, MJ				Borbet, Timothy C.; Zhang, Xiaozhou; Mueller, Anne; Blaser, Martin J.			The role of the changing human microbiome in the asthma pandemic	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Asthma; allergy; microbiome; Helicobacter pylori	HELICOBACTER-PYLORI INFECTION; ALLERGIC AIRWAY INFLAMMATION; DENDRITIC CELLS; GUT MICROBIOME; COLONIZATION; DISEASE; DIVERSITY; INDUCTION; TOLERANCE; GASTRITIS	Asthma and allergy incidence continue to increase globally. We have made significant strides in treating disease, but it is becoming more apparent that we need to advance our knowledge into the origins of asthmatic disease. Much recent work has indicated that microbiome composition influences immune regulation and that multiple health care factors have driven a loss in microbiome diversity in modern human populations. Evidence is growing of microbiota-driven influences on immune development, asthma susceptibility, and asthma pathogenesis. The focus of this review is to highlight the strides the field has made in characterizing the constituents of the human gastrointestinal microbiota, such as Helicobacter pylori, other members of the neonatal intestinal microbiota, and microbial peptides and metabolites that influence host immunity and immune response to allergens. As we delve further into this field of research, the goal will be to find actionable and clinical interventions to identify at-risk populations earlier to prevent disease onset. Manipulation of the host microbial community during infancy might be an especially promising approach.	[Borbet, Timothy C.] NYU, Sch Med, Dept Pathol, New York, NY 10003 USA; [Zhang, Xiaozhou; Mueller, Anne] Inst Mol Canc Res, Zurich, Switzerland; [Blaser, Martin J.] Rutgers State Univ, Ctr Adv Biotechnol & Med, 679 Hoes Lane West,Room 106A, Piscataway, NJ 08854 USA	New York University; Rutgers State University New Brunswick	Blaser, MJ (corresponding author), Rutgers State Univ, Ctr Adv Biotechnol & Med, 679 Hoes Lane West,Room 106A, Piscataway, NJ 08854 USA.; Muller, A (corresponding author), Univ Zurich, Inst Mol Krebsforsch, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	mueller@imcr.uzh.ch; martin.blaser@cabm.rutgers.edu		Borbet, Timothy/0000-0001-7638-6382; Blaser, Martin/0000-0003-2447-2443	NIH [TL1TR001447, U01AI122285]; Sergei S. Zlinkoff Fund for Medical Research Education; Leducq Foundation; SNF [BSCGIO_157841/1]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI122285] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Sergei S. Zlinkoff Fund for Medical Research Education; Leducq Foundation(Leducq Foundation); SNF; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	T.C.B. is supported by TL1TR001447 from the NIH. T.C.B. and M.J.B. by Sergei S. Zlinkoff Fund for Medical Research & Education, Leducq Foundation Transatlantic Program in Cardiovascular Disease, and U01AI122285 from the NIH. A.M. is supported by SNF grant no. BSCGIO_157841/1.	Altobelli A, 2019, MBIO, V10, DOI 10.1128/mBio.00261-19; Amberbir A, 2011, CLIN EXP ALLERGY, V41, P1422, DOI 10.1111/j.1365-2222.2011.03831.x; Arnold B, 2005, TRENDS IMMUNOL, V26, P406, DOI 10.1016/j.it.2005.06.002; Arnold IC, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007866; Arnold IC, 2018, J EXP MED, V215, P2055, DOI 10.1084/jem.20172049; Arnold IC, 2017, CELL REP, V21, P3860, DOI 10.1016/j.celrep.2017.12.015; Arnold IC, 2011, J CLIN INVEST, V121, P3088, DOI 10.1172/JCI45041; Arnold IC, 2011, GASTROENTEROLOGY, V140, P199, DOI 10.1053/j.gastro.2010.06.047; Arrieta MC, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab2271; Asher I, 2014, INT J TUBERC LUNG D, V18, P1269, DOI 10.5588/ijtld.14.0170; Atarashi K, 2013, NATURE, V500, P232, DOI 10.1038/nature12331; Backert S, 2016, CANCER RES, V76, P4028, DOI 10.1158/0008-5472.CAN-16-1680; Bello MGD, 2018, SCIENCE, V362, P33, DOI 10.1126/science.aau8816; Bik EM, 2006, P NATL ACAD SCI USA, V103, P732, DOI 10.1073/pnas.0506655103; Blaser MJ, 2006, EMBO REP, V7, P956, DOI 10.1038/sj.embor.7400812; Blaser MJ, 2018, CELL, V172, P1173, DOI 10.1016/j.cell.2018.02.040; Blaser MJ, 2017, NAT REV IMMUNOL, V17, P461, DOI 10.1038/nri.2017.77; Blaser MJ, 2009, NAT REV MICROBIOL, V7, P887, DOI 10.1038/nrmicro2245; Bokulich NA, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad7121; Boursi B, 2015, EUR J CANCER, V51, P2655, DOI 10.1016/j.ejca.2015.08.015; Burnet FM, 1949, PRODUCTION ANTIBODIE; Cabridain C, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-024974; Cahenzli J, 2013, CELL HOST MICROBE, V14, P559, DOI 10.1016/j.chom.2013.10.004; Chen Y, 2008, J INFECT DIS, V198, P553, DOI 10.1086/590158; Chen Y, 2007, ARCH INTERN MED, V167, P821, DOI 10.1001/archinte.167.8.821; Chung HC, 2012, CELL, V149, P1578, DOI 10.1016/j.cell.2012.04.037; Clemente JC, 2015, SCI ADV, V1, DOI 10.1126/sciadv.1500183; Cook KW, 2014, GUT, V63, P1550, DOI 10.1136/gutjnl-2013-306253; de Aguero MG, 2016, SCIENCE, V351, P1296, DOI 10.1126/science.aad2571; Edelson BT, 2010, J EXP MED, V207, P823, DOI 10.1084/jem.20091627; Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302; Engler DB, 2015, INFLAMM BOWEL DIS, V21, P854, DOI 10.1097/MIB.0000000000000318; Engler DB, 2014, P NATL ACAD SCI USA, V111, P11810, DOI 10.1073/pnas.1410579111; Fujimura KE, 2015, CELL HOST MICROBE, V17, P592, DOI 10.1016/j.chom.2015.04.007; Gensollen T, 2016, SCIENCE, V352, P539, DOI 10.1126/science.aad9378; Geva-Zatorsky N, 2017, CELL, V168, P928, DOI 10.1016/j.cell.2017.01.022; Harris PR, 2008, GASTROENTEROLOGY, V134, P491, DOI 10.1053/j.gastro.2007.11.006; Harrison OJ, 2019, SCIENCE, V363, P43, DOI 10.1126/science.aat6280; Herbarth O, 2007, J EPIDEMIOL COMMUN H, V61, P638, DOI 10.1136/jech.2006.046706; Herbst T, 2011, AM J RESP CRIT CARE, V184, P198, DOI 10.1164/rccm.201010-1574OC; Honda K, 2016, NATURE, V535, P75, DOI 10.1038/nature18848; Hussain K, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00071; Huttenhower C, 2012, NATURE, V486, P207, DOI 10.1038/nature11234; Ivanov II, 2009, CELL, V139, P485, DOI 10.1016/j.cell.2009.09.033; Kamangar F, 2006, JNCI-J NATL CANCER I, V98, P1445, DOI 10.1093/jnci/djj393; Kienesberger S, 2016, CELL REP, V14, P1395, DOI 10.1016/j.celrep.2016.01.017; Kyburz A, 2019, J ALLERGY CLIN IMMUN, V143, P1496, DOI 10.1016/j.jaci.2018.07.046; Lebwohl B, 2013, AM J EPIDEMIOL, V178, P1721, DOI 10.1093/aje/kwt234; Levan SR, 2019, NAT MICROBIOL, V4, P1851, DOI 10.1038/s41564-019-0498-2; Ley RE, 2008, NAT REV MICROBIOL, V6, P776, DOI 10.1038/nrmicro1978; Li L, 2019, AM J CLIN DERMATOL, V20, P367, DOI 10.1007/s40257-018-0404-3; Maixner F, 2016, SCIENCE, V351, P162, DOI 10.1126/science.aad2545; MARSHALL BJ, 1984, LANCET, V1, P1311; Metsala J, 2015, CLIN EXP ALLERGY, V45, P137, DOI 10.1111/cea.12356; Mitre E, 2018, JAMA PEDIATR, V172, DOI 10.1001/jamapediatrics.2018.0315; Moodley Y, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002693; Naik S, 2015, NATURE, V520, P104, DOI 10.1038/nature14052; NOMURA A, 1994, ANN INTERN MED, V120, P977, DOI 10.7326/0003-4819-120-12-199406150-00001; Ochman H, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000546; Oertli M, 2013, P NATL ACAD SCI USA, V110, P3047, DOI 10.1073/pnas.1211248110; Patrick D, 2018, OPEN FORUM INFECT S, V5, pS27; Reibman J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004060; Robinson K, 2008, GUT, V57, P1375, DOI 10.1136/gut.2007.137539; Rokkas T, 2015, UNITED EUR GASTROENT, V3, P539, DOI 10.1177/2050640615580889; Russell SL, 2013, GUT MICROBES, V4, P158, DOI 10.4161/gmic.23567; Schuijs MJ, 2015, SCIENCE, V349, P1106, DOI 10.1126/science.aac6623; Shiotani A, 2008, J GASTROEN HEPATOL, V23, pE29, DOI 10.1111/j.1440-1746.2007.05107.x; Smits SA, 2017, SCIENCE, V357, P802, DOI 10.1126/science.aan4834; Stokholm J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02573-2; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Tanoue T, 2019, NATURE, V565, P600, DOI 10.1038/s41586-019-0878-z; Teo SM, 2018, CELL HOST MICROBE, V24, P341, DOI 10.1016/j.chom.2018.08.005; Ursell LK, 2012, J ALLERGY CLIN IMMUN, V129, P1204, DOI 10.1016/j.jaci.2012.03.010; Vangay P, 2018, CELL, V175, P962, DOI 10.1016/j.cell.2018.10.029; Wypych TP, 2019, NAT IMMUNOL, V20, P1279, DOI 10.1038/s41590-019-0451-9; Xu M, 2018, NATURE, V554, P373, DOI 10.1038/nature25500; Yatsunenko T, 2012, NATURE, V486, P222, DOI 10.1038/nature11053; Zakeri A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01027; Zhang XS, 2018, ELIFE, V7, DOI 10.7554/eLife.37816	79	20	23	1	22	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2019	144	6					1457	1467		10.1016/j.jaci.2019.10.022	http://dx.doi.org/10.1016/j.jaci.2019.10.022			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JT0NR	31812180	Bronze, Green Accepted			2022-12-18	WOS:000500694900001
J	Sordillo, JE; Rifas-Shiman, SL; Switkowski, K; Coull, B; Gibson, H; Rice, M; Platts-Mills, TAE; Kloog, I; Litonjua, AA; Gold, DR; Oken, E				Sordillo, Joanne E.; Rifas-Shiman, Sheryl L.; Switkowski, Karen; Coull, Brent; Gibson, Heike; Rice, Mary; Platts-Mills, Thomas A. E.; Kloog, Itai; Litonjua, Augusto A.; Gold, Diane R.; Oken, Emily			Prenatal oxidative balance and risk of asthma and allergic disease in adolescence	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; allergic sensitization; nutrients; air pollution; oxidative balance; antioxidants; pro-oxidants; oxidative stress	FISH-OIL SUPPLEMENTATION; CORD BLOOD; VITAMIN-D; SMOKE EXPOSURE; FATTY-ACIDS; CHILDHOOD; ASSOCIATIONS; PARACETAMOL; RECEPTORS; PREGNANCY	Background: Fetal oxidative balance (achieved when protective prenatal factors counteract sources of oxidative stress) might be critical for preventing asthma and allergic disease. Objective: We examined prenatal intakes of hypothesized protective nutrients (including antioxidants) in conjunction with potential sources of oxidative stress in models of adolescent asthma and allergic disease. Methods: We used data from 996 mother-child pairs in Project Viva. Exposures of interest were maternal prepregnancy body mass index and prenatal nutrients (energy-adjusted intakes of vitamins D, C, and E; beta-carotene; folate; choline; and n-3 and n-6 polyunsaturated fatty acids [PUFAs]), air pollutant exposures (residence-specific third-trimester black carbon or particulate matter with a diameter of less than 2.5 mm [PM2.5]), acetaminophen, and smoking. Outcomes were offspring's current asthma, allergic rhinitis, and allergen sensitization at a median age of 12.9 years. We performed logistic regression. Continuous exposures were log-transformed and modeled as z scores. Results: We observed protective associations for vitamin D (odds ratio [OR], 0.69 [95% CI, 0.53-0.89] for allergic rhinitis), the sum of the n-3 PUFAs eicosapentaenoic acid and docosahexaenoic acid (OR, 0.81 [95% CI, 0.66-0.99] for current asthma), and the n-3 PUFA alpha-linolenic acid (OR, 0.78 [95% CI, 0.64-0.95] for allergen sensitization and OR, 0.80 [95% CI 0.65-0.99] for current asthma). Black carbon and PM2.5 were associated with an approximately 30% increased risk for allergen sensitization. No multiplicative interactions were observed for protective nutrient intakes with sources of oxidative stress. Conclusions: We identified potential protective prenatal nutrients (vitamin D and n-3 PUFAs), as well as adverse prenatal pro-oxidant exposures that might alter the risk of asthma and allergic disease into adolescence.	[Sordillo, Joanne E.; Rifas-Shiman, Sheryl L.; Switkowski, Karen; Oken, Emily] Harvard Med Sch, Dept Populat Med, Div Chron Dis Res Lifecourse CoRAL, Boston, MA 02115 USA; [Sordillo, Joanne E.; Rifas-Shiman, Sheryl L.; Switkowski, Karen; Oken, Emily] Harvard Pilgrim Hlth Care Inst, Boston, MA USA; [Coull, Brent; Gibson, Heike] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA USA; [Rice, Mary] Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA; [Platts-Mills, Thomas A. E.] Beth Israel Deaconess Med Ctr, Dept Med, Div Pulm Crit Care & Sleep Med, Boston, MA 02215 USA; [Litonjua, Augusto A.] Univ Virginia Hlth Syst, Asthma & Allerg Dis Ctr, Charlottesville, VA USA; [Kloog, Itai; Gold, Diane R.] Univ Rochester, Med Ctr, Div Pediat Pulm Med, Rochester, NY 14642 USA; [Gold, Diane R.] Harvard Med Sch, Brigham & Womens Hosp, Channing Div Network Med, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard Pilgrim Health Care; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Beth Israel Deaconess Medical Center; University of Virginia; University of Rochester; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Sordillo, JE (corresponding author), 401 Pk Dr,Landmark Ctr East,4th Floor, Boston, MA 02215 USA.	Joanne_Sordillo@harvardpilgrim.org		Platts-Mills, Thomas/0000-0002-1263-329X	National Institutes of Health [R01AI102960]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD034568, R01HD085993] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI102960] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grant R01AI102960.	Addo KA, 2019, ENVIRON EPIGENETICS, V5, DOI 10.1093/eep/dvz010; Adorini L, 2004, J STEROID BIOCHEM, V89-90, P437, DOI 10.1016/j.jsbmb.2004.03.013; [Anonymous], 2014, C DIGEST, V94, P3; Beckhaus AA, 2015, ALLERGY, V70, P1588, DOI 10.1111/all.12729; Bisgaard H, 2016, NEW ENGL J MED, V375, P2530, DOI 10.1056/NEJMoa1503734; Bunyavanich S, 2016, J ALLERGY CLIN IMMUN, V137, P1063, DOI 10.1016/j.jaci.2015.11.031; Burke H, 2012, PEDIATRICS, V129, P735, DOI 10.1542/peds.2011-2196; Ciaccio CE, 2013, CURR ALLERGY ASTHM R, V13, P687, DOI 10.1007/s11882-013-0389-1; Donahue SMA, 2009, PROSTAG LEUKOTR ESS, V80, P289, DOI 10.1016/j.plefa.2009.02.007; Dunstan JA, 2003, CLIN EXP ALLERGY, V33, P442, DOI 10.1046/j.1365-2222.2003.01590.x; Fawzi WW, 2004, ANN EPIDEMIOL, V14, P754, DOI 10.1016/j.annepidem.2004.03.001; Gold DR, 2006, J ALLERGY CLIN IMMUN, V117, P931, DOI 10.1016/j.jaci.2005.12.1322; Hossein-nezhad A, 2013, MAYO CLIN PROC, V88, P720, DOI 10.1016/j.mayocp.2013.05.011; Kloog I, 2011, ATMOS ENVIRON, V45, P6267, DOI 10.1016/j.atmosenv.2011.08.066; Krauss-Etschmann S, 2008, J ALLERGY CLIN IMMUN, V121, P464, DOI 10.1016/j.jaci.2007.09.018; Li XY, 2017, BBA-GEN SUBJECTS, V1861, P577, DOI 10.1016/j.bbagen.2016.12.018; Lockett GA, 2015, PEDIAT ALLERG IMM-UK, V26, P394, DOI 10.1111/pai.12408; Magnus MC, 2016, INT J EPIDEMIOL, V45, P512, DOI 10.1093/ije/dyv366; Martin CL, 2019, EPIGENETICS-US, V14, P325, DOI 10.1080/15592294.2019.1581594; Maslova E, 2019, ANN ALLERG ASTHMA IM, V122, P120, DOI 10.1016/j.anai.2018.09.450; Nuttall SL, 2003, J CLIN PHARM THER, V28, P289, DOI 10.1046/j.1365-2710.2003.00493.x; Oken E, 2015, INT J EPIDEMIOL, V44, P37, DOI 10.1093/ije/dyu008; Peters JL, 2013, CURR OPIN ALLERGY CL, V13, P187, DOI 10.1097/ACI.0b013e32835e82d3; Pham MN, 2018, CURR ALLERGY ASTHM R, V18, DOI 10.1007/s11882-018-0811-9; PROVVEDINI DM, 1983, SCIENCE, V221, P1181, DOI 10.1126/science.6310748; Rice MB, 2018, J ALLERGY CLIN IMMUN, V141, P1932, DOI 10.1016/j.jaci.2017.11.062; Ried JS, 2013, ALLERGY, V68, P629, DOI 10.1111/all.12110; Riedl M, 2005, J ALLERGY CLIN IMMUN, V115, P221, DOI 10.1016/j.jaci.2004.11.047; Rifas-Shiman SL, 2006, PAEDIATR PERINAT EP, V20, P35, DOI 10.1111/j.1365-3016.2006.00691.x; Rothman K., 1998, MODERN EPIDEMIOLOGY; Rotroff DM, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-3310-1; Sbihi H, 2015, ENVIRON HEALTH PERSP, V123, P902, DOI 10.1289/ehp.1408700; Shaheen SO, 2005, CLIN EXP ALLERGY, V35, P18, DOI 10.1111/j.1365-2222.2005.02151.x; Sharma S, 2014, J ALLERGY CLIN IMMUN, V133, P1246, DOI 10.1016/j.jaci.2013.10.039; Shore SA, 2008, J ALLERGY CLIN IMMUN, V121, P1087, DOI 10.1016/j.jaci.2008.03.004; Sordillo JE, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28216-0; Sordillo JE, 2015, J ALLERGY CLIN IMMUN, V135, P441, DOI 10.1016/j.jaci.2014.07.065; Stolwijk AM, 1999, J EPIDEMIOL COMMUN H, V53, P235, DOI 10.1136/jech.53.4.235; Thacher JD, 2016, ALLERGY, V71, P239, DOI 10.1111/all.12792; US Department of Agriculture Agricultural Research Service, USDA NUTR DAT STAND; Wada M, 2007, J BIOL CHEM, V282, P22254, DOI 10.1074/jbc.M703169200; Westberg AP, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.01152-2018; WILLETT WC, 1987, AM J CLIN NUTR, V45, P354, DOI 10.1093/ajcn/45.1.354; Wolsk HM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186657; Zahran HS, 2018, MMWR-MORBID MORTAL W, V67, P149, DOI 10.15585/mmwr.mm6705e1; Zanobetti A, 2014, OCCUP ENVIRON MED, V71, P201, DOI 10.1136/oemed-2013-101526; Zhang HH, 2017, ENVIRON RES, V159, P519, DOI 10.1016/j.envres.2017.08.038	47	20	20	1	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2019	144	6					1534	+		10.1016/j.jaci.2019.07.044	http://dx.doi.org/10.1016/j.jaci.2019.07.044			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JT0NR	31437488	Green Accepted, Bronze			2022-12-18	WOS:000500694900012
J	Mehr, S; Lee, E; Hsu, P; Anderson, D; de Jong, E; Bosco, A; Campbell, DE				Mehr, Sam; Lee, Eric; Hsu, Peter; Anderson, Denise; de Jong, Emma; Bosco, Anthony; Campbell, Dianne E.			Innate immune activation occurs in acute food protein-induced enterocolitis syndrome reactions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									[Mehr, Sam; Lee, Eric; Hsu, Peter; Campbell, Dianne E.] Childrens Hosp Westmead, Dept Allergy & Immunol, Sydney, NSW, Australia; [Lee, Eric; Hsu, Peter; Campbell, Dianne E.] Univ Sydney, Child & Adolescent Hlth, Sydney, NSW, Australia; [Anderson, Denise; de Jong, Emma; Bosco, Anthony] Univ Western Australia, Telethon Kids Inst, Perth, Australia	University of Sydney; University of Sydney; Telethon Kids Institute; University of Western Australia	Campbell, DE (corresponding author), Childrens Hosp Westmead, Dept Allergy & Immunol, Sydney, NSW, Australia.; Campbell, DE (corresponding author), Univ Sydney, Child & Adolescent Hlth, Sydney, NSW, Australia.	dianne.campbell1@health.nsw.gov.au	Bosco, Anthony/AAC-6900-2022; de Jong, Emma/AHC-9300-2022	de Jong, Emma/0000-0002-2501-6119; Campbell, Dianne/0000-0002-0907-6963; Anderson, Denise/0000-0003-0643-4136; Bosco, Anthony/0000-0002-4335-615X	Allergy and Immunology Foundation of Australasia, Australia	Allergy and Immunology Foundation of Australasia, Australia	Supported by the Allergy and Immunology Foundation of Australasia, Australia.	Adams EJ, 2015, CELL IMMUNOL, V296, P31, DOI 10.1016/j.cellimm.2015.04.008; Anders S, 2013, NAT PROTOC, V8, P1765, DOI 10.1038/nprot.2013.099; Berin MC, 2015, J ALLERGY CLIN IMMUN, V135, P1108, DOI 10.1016/j.jaci.2014.12.1948; Goswami R, 2017, J ALLERGY CLIN IMMUN, V139, P1885, DOI 10.1016/j.jaci.2016.12.971; Hurgobin B, 2018, RESPIROLOGY, V23, P1117, DOI 10.1111/resp.13401; Kimura M, 2016, PEDIATR INT, V58, P826, DOI 10.1111/ped.12938; Kramer A, 2014, BIOINFORMATICS, V30, P523, DOI 10.1093/bioinformatics/btt703; Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559; Nowak-Wegrzyn A, 2017, J ALLERGY CLIN IMMUN, V139, P1111, DOI 10.1016/j.jaci.2016.12.966	9	20	21	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2019	144	2					600	+		10.1016/j.jaci.2019.04.021	http://dx.doi.org/10.1016/j.jaci.2019.04.021			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IN6LC	31059725	Bronze			2022-12-18	WOS:000478789300028
J	Levin, AM; Gui, HS; Hernandez-Pacheco, N; Yang, M; Xiao, SJ; Yang, JJ; Hochstadt, S; Barczak, AJ; Eckalbar, WL; Rynkowski, D; Samedy, LA; Kwok, PY; Pino-Yanes, M; Erle, DJ; Lanfear, DE; Burchard, EG; Williams, LK				Levin, Albert M.; Gui, Hongsheng; Hernandez-Pacheco, Natalia; Yang, Mao; Xiao, Shujie; Yang, James J.; Hochstadt, Samantha; Barczak, Andrea J.; Eckalbar, Walter L.; Rynkowski, Dean; Samedy, Lesly-Anne; Kwok, Pui-Yan; Pino-Yanes, Maria; Erle, David J.; Lanfear, David E.; Burchard, Esteban G.; Williams, L. Keoki			Integrative approach identifies corticosteroid response variant in diverse populations with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Pharmacogenetics; EDDM3B; RNASE2; eosinophil-derived neurotoxin; transcriptome; eosinophils	EOSINOPHIL CATIONIC PROTEIN; GENOME-WIDE ASSOCIATION; IMPROVED LUNG-FUNCTION; INHALED CORTICOSTEROIDS; EXACERBATIONS; IMPROVEMENT; ADULTS; COMBINATION; IMPUTATION; ADHERENCE	Background: Although inhaled corticosteroid (ICS) medication is considered the cornerstone treatment for patients with persistent asthma, few ICS pharmacogenomic studies have involved nonwhite populations. Objective: We sought to identify genetic predictors of ICS response in multiple population groups with asthma. Methods: The discovery group comprised African American participants from the Study of Asthma Phenotypes and Pharmacogenomic Interactions by Race-Ethnicity (SAPPHIRE) who underwent 6 weeks of monitored ICS therapy (n = 244). A genome-wide scan was performed to identify single nucleotide polymorphism (SNP) variants jointly associated (ie, the combined effect of the SNP and SNP 3 ICS treatment interaction) with changes in asthma control. Top associations were validated by assessing the joint association with asthma exacerbations in 3 additional groups: African Americans (n=803 and n=563) and Latinos (n = 1461). RNA sequencing data from 408 asthmatic patients and 405 control subjects were used to examine whether genotype was associated with gene expression. Results: One variant, rs3827907, was significantly associated with ICS-mediated changes in asthma control in the discovery set (P = 7.79 x 10(-8)) and was jointly associated with asthma exacerbations in 3 validation cohorts (P = .023, P = .029, and P = .041). RNA sequencing analysis found the rs3827907 C-allele to be associated with lower RNASE2 expression (P = 6.10 x 10(-4)). RNASE2 encodes eosinophil-derived neurotoxin, and the rs3827907 C-allele appeared to particularly influence ICS treatment response in the presence of eosinophilic inflammation (ie, high pretreatment eosinophil-derived neurotoxin levels or blood eosinophil counts). Conclusion: We identified a variant, rs3827907, that appears to influence response to ICS treatment in multiple population groups and likely mediates its effect through eosinophils.	[Levin, Albert M.] Henry Ford Hlth Syst, Dept Publ Hlth Sci, Detroit, MI USA; [Gui, Hongsheng; Yang, Mao; Xiao, Shujie; Hochstadt, Samantha; Rynkowski, Dean; Lanfear, David E.; Williams, L. Keoki] Henry Ford Hlth Syst, Ctr Individualized & Genom Med Res CIGMA, 1 Ford Pl,3A, Detroit, MI 48202 USA; [Pino-Yanes, Maria; Lanfear, David E.; Williams, L. Keoki] Henry Ford Hlth Syst, Dept Internal Med, Detroit, MI USA; [Hernandez-Pacheco, Natalia] Univ La Laguna, Hosp Univ NS de Candelaria, Res Unit, Santa Cruz De Tenerife, Spain; [Yang, James J.] Univ Michigan, Sch Nursing, Ann Arbor, MI 48109 USA; [Barczak, Andrea J.; Eckalbar, Walter L.; Erle, David J.] Univ Calif San Francisco, Lung Biol Ctr, San Francisco, CA 94143 USA; [Barczak, Andrea J.; Eckalbar, Walter L.; Erle, David J.] Univ Calif San Francisco, Funct Genom Core, San Francisco, CA 94143 USA; [Samedy, Lesly-Anne; Burchard, Esteban G.] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA; [Samedy, Lesly-Anne; Burchard, Esteban G.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Kwok, Pui-Yan] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; [Kwok, Pui-Yan] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA; [Pino-Yanes, Maria] Inst Salud Carlos III, CIBER Enfermedades Resp, Madrid, Spain; [Pino-Yanes, Maria] Univ La Laguna, Dept Biochem Microbiol Cell Biol & Genet, Genom & Hlth Grp, Tenerife, Spain	Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital; Universidad de la Laguna; University of Michigan System; University of Michigan; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; CIBER - Centro de Investigacion Biomedica en Red; CIBERES; Instituto de Salud Carlos III; Universidad de la Laguna	Williams, LK (corresponding author), Henry Ford Hlth Syst, Ctr Individualized & Genom Med Res CIGMA, 1 Ford Pl,3A, Detroit, MI 48202 USA.	kwillia5@hfhs.org	Hernandez-Pacheco, Natalia/AAY-2619-2020; Kwok, Pui-Yan/F-7725-2014; Pino-Yanes, Maria/C-8498-2017; Gui, Hongsheng/D-1063-2013	Hernandez-Pacheco, Natalia/0000-0002-6313-1847; Kwok, Pui-Yan/0000-0002-5087-3059; Pino-Yanes, Maria/0000-0003-0332-437X; Samedy, Lesly-Anne/0000-0002-3914-0970; Gui, Hongsheng/0000-0002-0460-7446	Fund for Henry Ford Hospital; Instituto de Salud Carlos III (ISCIII) [FI16/00136]; Ramon y Cajal Program, Spanish Ministry of Economy, Industry, and Competitiveness [RYC-2015-17205]; ISCIII through Strategic Action for Health Research (AES) [AC15/00015]; European Community (EC) within the Active and Assisted Living (AAL) Programme framework; ERACoSysMed 1st Joint Transnational Call from the European Union; American Asthma Foundation; Sandler Family Foundation; RWJF Amos Medical Faculty Development Program; US National Institutes of Health: National Institute of Allergy and Infectious Diseases [U19AI077439, R01AI079139, R01AI061774]; National Heart, Lung, and Blood Institute [K99HL135403, R01HL117004, X01HL134589, R01HL079055, R01HL118267]; National Institute of Diabetes and Digestive and Kidney Diseases [R01DK064695, R01DK113003]; National Institute on Minority Health and Health Disparities [P60MD006902, R01MD010443]; National Institute of Health and Environmental [R01ES015794, R21ES024844]; European Social Funds from the European Union (ESF)-"ESF invests in your future"; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL117004, R01HL141992, R01HL118267, K99HL135403, R01HL079055] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI077439, R01AI079139, R01AI061774] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064695, R01DK113003] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R21ES024844, R01ES015794] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007546] Funding Source: NIH RePORTER	Fund for Henry Ford Hospital; Instituto de Salud Carlos III (ISCIII)(Instituto de Salud Carlos IIIEuropean Commission); Ramon y Cajal Program, Spanish Ministry of Economy, Industry, and Competitiveness; ISCIII through Strategic Action for Health Research (AES); European Community (EC) within the Active and Assisted Living (AAL) Programme framework; ERACoSysMed 1st Joint Transnational Call from the European Union; American Asthma Foundation; Sandler Family Foundation; RWJF Amos Medical Faculty Development Program; US National Institutes of Health: National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD)); National Institute of Health and Environmental; European Social Funds from the European Union (ESF)-"ESF invests in your future"; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Supported by the Fund for Henry Ford Hospital (to A.M.L., D.E.L., and L.K.W.); a fellowship (FI16/00136) from the Instituto de Salud Carlos III (ISCIII) and cofunded by the European Social Funds from the European Union (ESF)-"ESF invests in your future'' (to N.H.-P.); the Ramon y Cajal Program (RYC-2015-17205) by the Spanish Ministry of Economy, Industry, and Competitiveness (to M.P.-Y.); an award (AC15/00015) by the ISCIII through Strategic Action for Health Research (AES) and European Community (EC) within the Active and Assisted Living (AAL) Programme framework (to M.P.-Y.); a SysPharmPedia grant from the ERACoSysMed 1st Joint Transnational Call from the European Union under the Horizon 2020 (to M.P.-Y.); the American Asthma Foundation (to L.K.W. and E.G.B.); the Sandler Family Foundation (to E.G.B.); the RWJF Amos Medical Faculty Development Program (to E.G.B.); Harry Wm. and Diana V. Hind Distinguished Professor in Pharmaceutical Sciences II (to E.G.B.); and the following institutes of the US National Institutes of Health: National Institute of Allergy and Infectious Diseases (U19AI077439 to D.J.E. and R01AI079139 and R01AI061774 to L.K.W.), the National Heart, Lung, and Blood Institute (K99HL135403 to W.L.E., R01HL117004 and X01HL134589 to E.G.B., and R01HL079055, R01HL118267, and X01HL134589 to L.K.W.), the National Institute of Diabetes and Digestive and Kidney Diseases (R01DK064695 and R01DK113003 to L.K.W.), the National Institute of Health and Environmental (R01ES015794 and R21ES024844 to E.G.B.), and the National Institute on Minority Health and Health Disparities (P60MD006902 and R01MD010443 to E.G.B.).	Akinbami Lara J, 2012, NCHS Data Brief, P1; Apter AJ, 2003, J ALLERGY CLIN IMMUN, V111, P1219, DOI 10.1067/mai.2003.1479; Berry M, 2007, THORAX, V62, P1043, DOI 10.1136/thx.2006.073429; Bustamante CD, 2011, NATURE, V475, P163, DOI 10.1038/475163a; Dahlin A, 2015, IMMUN INFLAMM DIS, V3, P350, DOI 10.1002/iid3.73; Das S, 2016, NAT GENET, V48, P1284, DOI 10.1038/ng.3656; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Galanter JM, 2011, J ALLERGY CLIN IMMUN, V128, P37, DOI 10.1016/j.jaci.2011.03.050; Gon Y, 2015, ALLERGY ASTHMA PROC, V36, pE113, DOI 10.2500/aap.2015.36.3884; Gould W, 2010, J ALLERGY CLIN IMMUN, V126, P1131, DOI 10.1016/j.jaci.2010.08.002; Grundberg E, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001279; Hawkins GA, 2009, J ALLERGY CLIN IMMUN, V123, P1376, DOI 10.1016/j.jaci.2009.01.049; Hoffmann TJ, 2011, GENOMICS, V98, P422, DOI 10.1016/j.ygeno.2011.08.007; Kim CK, 2010, J ASTHMA, V47, P568, DOI 10.3109/02770901003792833; Kitch BT, 2004, CHEST, V126, P1875, DOI 10.1378/chest.126.6.1875; Ko FWS, 2012, RESPIROLOGY, V17, P370, DOI 10.1111/j.1440-1843.2011.02105.x; Lappalainen T, 2013, NATURE, V501, P506, DOI 10.1038/nature12531; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Lonsdale J, 2013, NAT GENET, V45, P580, DOI 10.1038/ng.2653; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Meijer RJ, 2002, CLIN EXP ALLERGY, V32, P1096, DOI 10.1046/j.1365-2222.2002.01412.x; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Niimi A, 1998, CLIN EXP ALLERGY, V28, P233; Park HW, 2014, J ALLERGY CLIN IMMUN, V133, P664, DOI 10.1016/j.jaci.2013.12.1042; Pavord ID, 1999, LANCET, V353, P2213, DOI 10.1016/S0140-6736(99)01813-9; Perera MA, 2011, CLIN PHARMACOL THER, V89, P408, DOI 10.1038/clpt.2010.322; Price DB, 2015, LANCET RESP MED, V3, P849, DOI 10.1016/S2213-2600(15)00367-7; Qiu WL, 2014, HUM MOL GENET, V23, P5017, DOI 10.1093/hmg/ddu191; Rhodes L., 2004, Morbidity and Mortality Weekly Report, V53, P145; Sato R, 2009, J ASTHMA, V46, P677, DOI 10.1080/02770900902972160; Schatz M, 2006, J ALLERGY CLIN IMMUN, V117, P549, DOI 10.1016/j.jaci.2006.01.011; Sin DD, 2004, JAMA-J AM MED ASSOC, V292, P367, DOI 10.1001/jama.292.3.367; Sleiman PMA, 2010, NEW ENGL J MED, V362, P36, DOI 10.1056/NEJMoa0901867; Suissa S, 2001, J ALLERGY CLIN IMMUN, V107, P937, DOI 10.1067/mai.2001.115653; Suissa S, 2000, NEW ENGL J MED, V343, P332, DOI 10.1056/NEJM200008033430504; Tantisira KG, 2012, AM J RESP CRIT CARE, V185, P1286, DOI 10.1164/rccm.201111-2061OC; Tantisira KG, 2011, NEW ENGL J MED, V365, P1173, DOI 10.1056/NEJMoa0911353; Tantisira KG, 2004, HUM MOL GENET, V13, P1353, DOI 10.1093/hmg/ddh149; Tantisira KG, 2004, P NATL ACAD SCI USA, V101, P18099, DOI 10.1073/pnas.0408532102; Tomassini M, 1996, J ALLERGY CLIN IMMUN, V97, P1350, DOI 10.1016/S0091-6749(96)70204-X; Torgerson DG, 2011, NAT GENET, V43, P887, DOI 10.1038/ng.888; Vijverberg SJH, 2015, CLIN EXP ALLERGY, V45, P1051, DOI 10.1111/cea.12492; Walsh GM, 2001, CURR OPIN HEMATOL, V8, P28, DOI 10.1097/00062752-200101000-00006; Wang Y, 2015, PHARMACOGENOMICS J, V15, P422, DOI 10.1038/tpj.2014.83; Wells KE, 2016, J ALLERGY CLIN IMMUN, V137, P1364, DOI 10.1016/j.jaci.2015.12.1334; Wells KE, 2012, J ALLERGY CLIN IMMUN, V129, P1274, DOI 10.1016/j.jaci.2011.12.974; Westra HJ, 2013, NAT GENET, V45, P1238, DOI 10.1038/ng.2756; Williams LK, 2007, J ALLERGY CLIN IMMUN, V120, P1153, DOI 10.1016/j.jaci.2007.08.020; Williams LK, 2011, J ALLERGY CLIN IMMUN, V128, P1185, DOI 10.1016/j.jaci.2011.09.011; Williams LK, 2004, J ALLERGY CLIN IMMUN, V114, P1288, DOI 10.1016/j.jaci.2004.09.028	50	20	20	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2019	143	5					1791	1802		10.1016/j.jaci.2018.09.034	http://dx.doi.org/10.1016/j.jaci.2018.09.034			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HW6FP	30367910	Green Accepted, Bronze			2022-12-18	WOS:000466784600015
J	Kyburz, A; Fallegger, A; Zhang, XZ; Altobelli, A; Artola-Boran, M; Borbet, T; Urban, S; Paul, P; Munz, C; Floess, S; Huehn, J; Cover, TL; Blaser, MJ; Taube, C; Muller, A				Kyburz, Andreas; Fallegger, Angela; Zhang, Xiaozhou; Altobelli, Aleksandra; Artola-Boran, Mariela; Borbet, Timothy; Urban, Sabine; Paul, Petra; Munz, Christian; Floess, Stefan; Huehn, Jochen; Cover, Timothy L.; Blaser, Martin J.; Taube, Christian; Mueller, Anne			Transmaternal Helicobacter pylori exposure reduces allergic airway inflammation in offspring through regulatory T cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic airway inflammation; microbial interventions during pregnancy; immune regulation; immune tolerance; metagenomics; epigenetic regulation of allergy and asthma	EARLY-CHILDHOOD; ATOPIC SENSITIZATION; DENDRITIC CELLS; GUT MICROBIOTA; ASTHMA; DISEASE; COLONIZATION; ACQUISITION; ASSOCIATION; ACTIVATION	Background: Transmaternal exposure to tobacco, microbes, nutrients, and other environmental factors shapes the fetal immune system through epigenetic processes. The gastric microbe Helicobacter pylori represents an ancestral constituent of the human microbiota that causes gastric disorders on the one hand and is inversely associated with allergies and chronic inflammatory conditions on the other. Objective: Here we investigate the consequences of transmaternal exposure to H pylori in utero and/or during lactation for susceptibility to viral and bacterial infection, predisposition to allergic airway inflammation, and development of immune cell populations in the lungs and lymphoid organs. Methods: We use experimental models of house dust mite-or ovalbumin-induced airway inflammation and influenza A virus or Citrobacter rodentium infection along with metagenomics analyses, multicolor flow cytometry, and bisulfite pyrosequencing, to study the effects of H pylori on allergy severity and immunologic and microbiome correlates thereof. Results: Perinatal exposure to H pylori extract or its immunomodulator vacuolating cytotoxin confers robust protective effects against allergic airway inflammation not only in first-but also second-generation offspring but does not increase susceptibility to viral or bacterial infection. Immune correlates of allergy protection include skewing of regulatory over effector T cells, expansion of regulatory T-cell subsets expressing CXCR3 or retinoic acid-related orphan receptor gt, and demethylation of the forkhead box P3 (FOXP3) locus. The composition and diversity of the gastrointestinal microbiota is measurably affected by perinatal H pylori exposure. Conclusion: We conclude that exposure to H pylori has consequences not only for the carrier but also for subsequent generations that can be exploited for interventional purposes.	[Kyburz, Andreas; Fallegger, Angela; Zhang, Xiaozhou; Altobelli, Aleksandra; Artola-Boran, Mariela; Urban, Sabine; Mueller, Anne] Univ Zurich, Inst Mol Canc Res, Winterthurerstr 190, CH-8057 Zurich, Switzerland; [Borbet, Timothy; Blaser, Martin J.] Univ Zurich, Inst Expt Immunol, Zurich, Switzerland; [Paul, Petra; Munz, Christian] NYU, Langone Med Ctr, Human Microbiome Program, New York, NY USA; [Floess, Stefan; Huehn, Jochen] Helmholtz Ctr Infect Res, Dept Expt Immunol, Braunschweig, Germany; [Cover, Timothy L.] Vanderbilt Univ, Med Ctr, Nashville, TN USA; [Cover, Timothy L.] Vet Affairs Tennessee Valley Healthcare Syst, Nashville, TN USA; [Taube, Christian] Univ Hosp Essen, Ruhrlandklin, Dept Pulm Med, Essen, Germany	University of Zurich; University of Zurich; New York University; NYU Langone Medical Center; Helmholtz Association; Helmholtz-Center for Infection Research; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; University of Duisburg Essen	Muller, A (corresponding author), Univ Zurich, Inst Mol Canc Res, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	mueller@imcr.uzh.ch	; Cover, Timothy/I-3814-2015	Blaser, Martin/0000-0003-2447-2443; Taube, Christian/0000-0002-3546-1398; Borbet, Timothy/0000-0001-7638-6382; Munz, Christian/0000-0001-6419-1940; Zhang, Xiaozhou/0000-0002-8442-6783; Cover, Timothy/0000-0001-8503-002X	Swiss National Science Foundation Temporary Backup Schemes Consolidator Grant [BSCGIO_157841/1]; Clinical Research Priority Program on Human Hemato-Lymphatic Diseases, University of Zurich; National Institutes of Health [AI039657, CA116087, U01AI22285, TL1TR001447]; Department of Veterans Affairs [BX000627]; Swiss National Science Foundation [310030_162560]; HFSPO [LT000438/2014]; Marie Curie Fellowships [PIEF-GA-2013-623055]; CD fund;  [P30CA016087]; NATIONAL CANCER INSTITUTE [P30CA016087, P01CA116087] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [TL1TR001447] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039657] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000627] Funding Source: NIH RePORTER	Swiss National Science Foundation Temporary Backup Schemes Consolidator Grant; Clinical Research Priority Program on Human Hemato-Lymphatic Diseases, University of Zurich; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Veterans Affairs(US Department of Veterans Affairs); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); HFSPO(Human Frontier Science Program); Marie Curie Fellowships(European Commission); CD fund; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Veterans Affairs(US Department of Veterans Affairs)	Supported by the Swiss National Science Foundation Temporary Backup Schemes Consolidator Grant BSCGIO_157841/1 and the Clinical Research Priority Program on Human Hemato-Lymphatic Diseases, University of Zurich (both to A.M.). Additional funds were supplied by the National Institutes of Health (grants AI039657 and CA116087) and Department of Veterans Affairs BX000627 (all to T.L.C.), as well as the Swiss National Science Foundation (project grant 310030_162560 to C.M.). P.P. is supported by HFSPO (LT000438/2014) and Marie Curie Fellowships (PIEF-GA-2013-623055). We further acknowledge National Institutes of Health support (U01AI22285 to M.J.B.), training grant support (TL1TR001447 to T.B.), the NYUMC Genome Technology Center for sequencing assistance (partially supported by P30CA016087), and support through the C&D fund.	Alcantara-Neves Neuza Maria, 2014, BMC Res Notes, V7, P817, DOI 10.1186/1756-0500-7-817; Amberbir A, 2014, CLIN EXP ALLERGY, V44, P563, DOI 10.1111/cea.12289; Amberbir A, 2011, CLIN EXP ALLERGY, V41, P1422, DOI 10.1111/j.1365-2222.2011.03831.x; Arnold IC, 2011, J CLIN INVEST, V121, P3088, DOI 10.1172/JCI45041; Baru AM, 2010, EUR J IMMUNOL, V40, P2259, DOI 10.1002/eji.200939972; Bogunovic M, 2009, IMMUNITY, V31, P513, DOI 10.1016/j.immuni.2009.08.010; Brand S, 2011, J ALLERGY CLIN IMMUN, V128, P618, DOI 10.1016/j.jaci.2011.04.035; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Burzyn D, 2013, NAT IMMUNOL, V14, P1007, DOI 10.1038/ni.2683; Caporaso JG, 2012, ISME J, V6, P1621, DOI 10.1038/ismej.2012.8; Chen Y, 2008, J INFECT DIS, V198, P553, DOI 10.1086/590158; Chen Y, 2007, ARCH INTERN MED, V167, P821, DOI 10.1001/archinte.167.8.821; Conrad ML, 2009, J EXP MED, V206, P2869, DOI 10.1084/jem.20090845; Coombes JL, 2007, J EXP MED, V204, P1757, DOI 10.1084/jem.20070590; Debarry J, 2007, J ALLERGY CLIN IMMUN, V119, P1514, DOI 10.1016/j.jaci.2007.03.023; Dominguez-Bello MG, 2010, P NATL ACAD SCI USA, V107, P11971, DOI 10.1073/pnas.1002601107; Edelson BT, 2010, J EXP MED, V207, P823, DOI 10.1084/jem.20091627; Ege MJ, 2006, J ALLERGY CLIN IMMUN, V117, P817, DOI 10.1016/j.jaci.2005.12.1307; Engler DB, 2014, P NATL ACAD SCI USA, V111, P11810, DOI 10.1073/pnas.1410579111; Gonzalez-Rivera C, 2016, INFECT IMMUN, V84, P2662, DOI 10.1128/IAI.00254-16; Hagner S, 2013, ALLERGY, V68, P322, DOI 10.1111/all.12094; Joeris T, 2017, MUCOSAL IMMUNOL, V10, P845, DOI 10.1038/mi.2017.22; Kabisch R, 2016, J IMMUNOL, V196, P4246, DOI 10.4049/jimmunol.1501062; Kenney AD, 2017, ANNU REV GENET, V51, P241, DOI 10.1146/annurev-genet-120116-023425; Kim JM, 2007, NAT IMMUNOL, V8, P191, DOI 10.1038/ni1428; Koch KN, 2015, J CLIN INVEST, V125, P3297, DOI 10.1172/JCI79337; Koch MA, 2009, NAT IMMUNOL, V10, P595, DOI 10.1038/ni.1731; Kyburz A, 2017, CLIN EXP ALLERGY, V47, P1331, DOI 10.1111/cea.12996; Kyburz A, 2016, DIGEST DIS, V34, P230, DOI 10.1159/000443357; Levine AG, 2017, NATURE, V546, P421, DOI 10.1038/nature22360; Li YF, 2005, CHEST, V127, P1232, DOI 10.1378/chest.127.4.1232; Oertli M, 2013, P NATL ACAD SCI USA, V110, P3047, DOI 10.1073/pnas.1211248110; Oertli M, 2012, J CLIN INVEST, V122, P1082, DOI 10.1172/JCI61029; Ohnmacht C, 2015, SCIENCE, V349, P989, DOI 10.1126/science.aac4263; Pedros C, 2015, J IMMUNOL, V195, P1608, DOI 10.4049/jimmunol.1402562; Polansky JK, 2008, EUR J IMMUNOL, V38, P1654, DOI 10.1002/eji.200838105; Ponte EV, 2014, J ASTHMA, V51, P1022, DOI 10.3109/02770903.2014.936454; Prescott SL, 2011, J ALLERGY CLIN IMMUN, V128, P886, DOI 10.1016/j.jaci.2011.05.017; Rautava S, 2012, NAT REV GASTRO HEPAT, V9, P565, DOI 10.1038/nrgastro.2012.144; Rehan VK, 2013, AM J PHYSIOL-LUNG C, V305, pL501, DOI 10.1152/ajplung.00078.2013; Renz H, 2017, J ALLERGY CLIN IMMUN, V140, P24, DOI 10.1016/j.jaci.2017.05.015; Schaub Bianca, 2009, J Allergy Clin Immunol, V123, P774, DOI 10.1016/j.jaci.2009.01.056; Sefik E, 2015, SCIENCE, V349, P993, DOI 10.1126/science.aaa9420; Sugai M, 2011, J IMMUNOL, V186, P6515, DOI 10.4049/jimmunol.1001671; Toker A, 2013, J IMMUNOL, V190, P3180, DOI 10.4049/jimmunol.1203473; Varol C, 2009, IMMUNITY, V31, P502, DOI 10.1016/j.immuni.2009.06.025; Veenbergen S, 2016, MUCOSAL IMMUNOL, V9, P894, DOI 10.1038/mi.2015.118; Vogel K, 2008, J ALLERGY CLIN IMMUN, V122, P307, DOI 10.1016/j.jaci.2008.05.016; Wang Q, 2013, HELICOBACTER, V18, P41, DOI 10.1111/hel.12012; West CE, 2015, CLIN EXP ALLERGY, V45, P43, DOI 10.1111/cea.12332; West CE, 2014, CURR OPIN CLIN NUTR, V17, P261, DOI 10.1097/MCO.0000000000000044; Weyermann M, 2009, AM J GASTROENTEROL, V104, P182, DOI 10.1038/ajg.2008.61; Yang BH, 2016, MUCOSAL IMMUNOL, V9, P444, DOI 10.1038/mi.2015.74; Zheng Y, 2009, NATURE, V458, P351, DOI 10.1038/nature07674; Zhou XY, 2013, EUR J GASTROEN HEPAT, V25, P460, DOI 10.1097/MEG.0b013e32835c280a	55	20	21	1	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2019	143	4					1496	+		10.1016/j.jaci.2018.07.046	http://dx.doi.org/10.1016/j.jaci.2018.07.046			28	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HR7QE	30240703	Green Accepted, Green Submitted, Bronze			2022-12-18	WOS:000463348900025
J	Valera, FCP; Ruffin, M; Adam, D; Maille, E; Ibrahim, B; Berube, J; Rousseau, S; Brochiero, E; Desrosiers, MY				Valera, Fabiana C. P.; Ruffin, Manon; Adam, Damien; Maille, Emilie; Ibrahim, Badr; Berube, Julie; Rousseau, Simon; Brochiero, Emmanuelle; Desrosiers, Martin Y.			Staphylococcus aureus impairs sinonasal epithelial repair: Effects in patients with chronic rhinosinusitis with nasal polyps and control subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Staphylococcus aureus; chronic rhinosinusitis; repair; nasal epithelial cells; lamellipodia; Rho-associated coiled-coil kinase inhibitor; Y-27632	CELL-CELL JUNCTIONS; PSEUDOMONAS-AERUGINOSA; DELETERIOUS IMPACT; BARRIER FUNCTION; WOUND CLOSURE; INHIBITION; ASSOCIATION; KINASE; TOXIN; ALPHA	Background: The effect of Staphylococcus aureus on nasal epithelial repair has never been assessed in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Objective: This study aimed to determine whether (1) nasal epithelial cell cultures from patients with CRSwNP and control subjects repair differently; (2) S aureus exoproducts compromise nasal epithelial repair; (3) S aureus alters lamellipodial dynamics; and (4) deleterious effects could be counteracted by the Rho-associated coiled-coil kinase inhibitor Y-27632. Methods: Primary nasal epithelial cells (pNECs) collected during surgeries were cultured and injured under 3 conditions: (1) basal conditions, (2) exposed to S aureus exoproducts, and (3) exposed to S aureus exoproducts and Y-27632. Epithelial repair, lamellipodial dynamics, and cytoskeletal organization were assessed. Results: Under basal conditions, pNEC cultures from patients with CRSwNP presented significantly lower repair rates and reduced lamellipodial protrusion length and velocity than those from control subjects. S aureus exoproducts significantly decreased repair rates and protrusion dynamics in both control subjects and patients with CRSwNP; however, the effect of S aureus on cell protrusions was more sustained over time in patients with CRSwNP. Under basal conditions, immunofluorescence assays showed significantly reduced percentages of cells with lamellipodia at the wound edge in patients with CRSwNP compared with control subjects. S aureus altered cell polarity and decreased the percentage of cells with lamellipodia in both groups. Finally, Y-27632 prevented the deleterious effects of S aureus exoproducts on CRSwNP repair rates, as well as on lamellipodial dynamics and formation. Conclusions: S aureus exoproducts significantly alter epithelial repair and lamellipodial dynamics on pNECs, and this impairment was more pronounced in patients with CRSwNP. Importantly, Y-27632 restored epithelial repair and lamellipodial dynamics in the presence of S aureus exoproducts.	[Valera, Fabiana C. P.; Ruffin, Manon; Adam, Damien; Maille, Emilie; Ibrahim, Badr; Brochiero, Emmanuelle; Desrosiers, Martin Y.] CRCHUM, Montreal, PQ, Canada; [Valera, Fabiana C. P.] Univ Sao Paulo FMRP USP, Ribeirao Preto Med Sch, Div Otorhinolaryngol, Ribeirao Preto, Brazil; [Ruffin, Manon; Adam, Damien; Brochiero, Emmanuelle] Univ Montreal, Dept Med, Montreal, PQ, Canada; [Ibrahim, Badr; Desrosiers, Martin Y.] CHUM, Dept Otolaryngol, 900 Rue St Denis, Montreal, PQ H2X 0A9, Canada; [Berube, Julie; Rousseau, Simon] McGill Univ, Hlth Ctr, Meakins Christie Labs, Res Inst, Montreal, PQ, Canada	Universite de Montreal; Universidade de Sao Paulo; Universite de Montreal; Universite de Montreal; McGill University	Desrosiers, MY (corresponding author), CHUM, Dept Otolaryngol, 900 Rue St Denis, Montreal, PQ H2X 0A9, Canada.	desrosiers_martin@hotmail.com	Valera, Fabiana Cardoso Pereira/D-3787-2012	Valera, Fabiana Cardoso Pereira/0000-0002-6605-5317; Ruffin, Manon/0000-0002-4454-7492; Rousseau, Simon/0000-0002-8773-575X	FAPESP, Sao Paulo Research Foundation. Brazil [2016/00772-1]; Respiratory Health Network of Quebec; Canadian Institutes of Health Research (CIHR) [PJT148593]; les Fonds de Recherche du Quebec en Sante; CRCHUM; Universite de Montreal	FAPESP, Sao Paulo Research Foundation. Brazil(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Respiratory Health Network of Quebec; Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); les Fonds de Recherche du Quebec en Sante; CRCHUM; Universite de Montreal	Supported by FAPESP, Sao Paulo Research Foundation. Brazil (grant no. 2016/00772-1-Scholarship to F.C.V.). The Respiratory Health Network of Quebec supported our Respiratory Tissue and Cell Biobank of CRCHUM. This work was supported by the Canadian Institutes of Health Research (CIHR, grant PJT148593 to E.B.), les Fonds de Recherche du Quebec en Sante (fellowships to M.R. and D.A.), and CRCHUM and Universite de Montreal (scholarship to E.B.).	Arason AJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088683; Bilodeau C, 2016, J CYST FIBROS, V15, P43, DOI 10.1016/j.jcf.2015.04.002; Bosse Y, 2009, HUM GENET, V125, P305, DOI 10.1007/s00439-009-0626-9; Boyer L, 2006, J CELL BIOL, V173, P809, DOI 10.1083/jcb.200509009; Brothers KM, 2015, SCI REP-UK, V5, DOI 10.1038/srep14003; Choi S, 2015, AM J PHYSIOL-LUNG C, V309, pL983, DOI 10.1152/ajplung.00062.2015; Cormier C, 2014, INT FORUM ALLERGY RH, V4, P207, DOI 10.1002/alr.21276; Corriveau MN, 2009, AM J RHINOL ALLERGY, V23, P461, DOI 10.2500/ajra.2009.23.3367; Crosby LM, 2010, AM J PHYSIOL-LUNG C, V298, pL715, DOI 10.1152/ajplung.00361.2009; Dach K, 2009, INFECT IMMUN, V77, P5583, DOI 10.1128/IAI.00121-09; de Bentzmann S, 2000, LAB INVEST, V80, P209, DOI 10.1038/labinvest.3780024; De Greve G, 2017, CLIN TRANSL ALLERGY, V7, DOI 10.1186/s13601-017-0157-8; DeConde AS, 2017, LARYNGOSCOPE, V127, P550, DOI 10.1002/lary.26391; DeConde AS, 2016, AM J RHINOL ALLERGY, V30, P134, DOI 10.2500/ajra.2016.30.4297; Desai LP, 2004, AM J PHYSIOL-LUNG C, V287, pL1134, DOI 10.1152/ajplung.00022.2004; Duan C, 2016, PLOS ONE, V11, P1; Eiffler I, 2016, AM J PHYSIOL-LUNG C, V311, pL676, DOI 10.1152/ajplung.00090.2016; Elamin E, 2014, AM J PHYSIOL-GASTR L, V306, pG677, DOI 10.1152/ajpgi.00236.2013; Erskine S, 2016, RHINOLOGY, V54, P311, DOI [10.4193/Rhin15.361, 10.4193/Rhino15.361]; Georas SN, 2014, J ALLERGY CLIN IMMUN, V134, P509, DOI 10.1016/j.jaci.2014.05.049; Gevaert E, 2017, J ALLERGY CLIN IMMUN, V139, P1849, DOI 10.1016/j.jaci.2017.01.019; Girault A, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0263-x; Girault A, 2014, AM J PHYSIOL-CELL PH, V306, pC307, DOI 10.1152/ajpcell.00226.2013; Hermann I, 2015, AM J RESP CELL MOL, V52, P14, DOI 10.1165/rcmb.2014-0082OC; Hilliard JJ, 2015, ANTIMICROB AGENTS CH, V59, P299, DOI 10.1128/AAC.03918-14; Hopkins C, 2009, LARYNGOSCOPE, V119, P2459, DOI 10.1002/lary.20653; Horani A, 2013, AM J RESP CELL MOL, V49, P341, DOI 10.1165/rcmb.2013-0046TE; Iorio V, 2015, ADV WOUND CARE, V4, P250, DOI 10.1089/wound.2014.0533; Kim CS, 2000, LARYNGOSCOPE, V110, P2085; Kim R, 2013, INT FORUM ALLERGY RH, V3, P349, DOI [10.1002/alr.21117, 10.2500/ajra.2013.27.3974]; Kohanski MA, 2015, JAMA OTOLARYNGOL, V141, P341, DOI 10.1001/jamaoto.2014.3550; Ljubimov AV, 2015, PROG RETIN EYE RES, V49, P17, DOI 10.1016/j.preteyeres.2015.07.002; Loxham M, 2017, J ALLERGY CLIN IMMUN, V139, P1736, DOI 10.1016/j.jaci.2017.04.005; Maille E, 2011, AM J PHYSIOL-LUNG C, V301, pL945, DOI 10.1152/ajplung.00149.2011; Malik Z, 2015, INT FORUM ALLERGY RH, V5, P551, DOI 10.1002/alr.21517; Marano RJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep13296; Meltzer Eli O, 2004, J Allergy Clin Immunol, V114, P155, DOI 10.1016/j.jaci.2004.09.029; Menko AS, 2014, EXP CELL RES, V322, P133, DOI 10.1016/j.yexcr.2013.12.021; Mfuna-Endam L, 2011, CURR ALLERGY ASTHM R, V11, P236, DOI 10.1007/s11882-011-0189-4; Moore M, 2004, AM J RESP CELL MOL, V30, P379, DOI 10.1165/rcmb.2003-0019OC; Narimatsu T, 2013, INVEST OPHTH VIS SCI, V54, P4555, DOI 10.1167/iovs.12-11572; Trinh NTN, 2015, EUR RESPIR J, V45, P1590, DOI 10.1183/09031936.00076214; Nguyen TNT, 2012, EUR RESPIR J, V40, P1390, DOI 10.1183/09031936.00221711; Orlandi RR, 2016, INT FORUM ALLERGY RH, V6, pS22, DOI 10.1002/alr.21695; Popoff Michel R, 2014, Small GTPases, V5, DOI 10.4161/sgtp.28209; Pothoven KL, 2015, J ALLERGY CLIN IMMUN, V136, P737, DOI 10.1016/j.jaci.2015.01.043; Purkey MT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089329; Ruffin M, 2016, FASEB J, V30, P3011, DOI 10.1096/fj.201500166R; Saint-Criq V, 2018, THORAX, V73, P49, DOI 10.1136/thoraxjnl-2017-210298; Schleimer RP, 2017, ANNU REV PATHOL-MECH, V12, P331, DOI 10.1146/annurev-pathol-052016-100401; Soler ZM, 2011, LARYNGOSCOPE, V121, P2672, DOI 10.1002/lary.21847; Soong G, 2011, J BIOL CHEM, V286, P35891, DOI 10.1074/jbc.M111.295386; Soyka MB, 2012, J ALLERGY CLIN IMMUN, V130, P1087, DOI 10.1016/j.jaci.2012.05.052; Steffen A, 2004, EMBO J, V23, P749, DOI 10.1038/sj.emboj.7600084; Stevens WW, 2015, J ALLERGY CLIN IMMUN, V136, P1442, DOI 10.1016/j.jaci.2015.10.009; Sun C.C., 2015, PLOS ONE, V10, P1; Tan NCW, 2014, ALLERGY, V69, P1364, DOI 10.1111/all.12457; Tan NCW, 2013, INT FORUM ALLERGY RH, V3, P261, DOI 10.1002/alr.21154; Teufelberger AR, 2018, J ALLERGY CLIN IMMUN, V141, P549, DOI 10.1016/j.jaci.2017.05.004; Thanasumpun T, 2015, AM J OTOLARYNG, V36, P686, DOI 10.1016/j.amjoto.2015.04.010; Trinh NTN, 2008, AM J PHYSIOL-LUNG C, V295, pL866, DOI 10.1152/ajplung.90224.2008; Wise SK, 2013, INT FORUM ALLERGY RH, V3, P439, DOI 10.1002/alr.21158; Yin J, 2008, AM J PHYSIOL-CELL PH, V295, pC378, DOI 10.1152/ajpcell.90624.2007; Yu XM, 2014, SCI REP-UK, V4, DOI 10.1038/srep04619; Yu XM, 2013, HISTOPATHOLOGY, V63, P686, DOI 10.1111/his.12211; Zhang N, 2016, ALLERGY, V71, P295, DOI 10.1111/all.12809; Zhang Z, 2015, INT FORUM ALLERGY RH, V5, P724, DOI 10.1002/alr.21532; Zuo W, 2015, NATURE, V517, P616, DOI 10.1038/nature13903	68	20	21	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2019	143	2					591	+		10.1016/j.jaci.2018.05.035	http://dx.doi.org/10.1016/j.jaci.2018.05.035			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HK2DJ	29935218	Bronze			2022-12-18	WOS:000457718700019
J	Felton, JM; Lucas, CD; Dorward, DA; Duffin, R; Kipari, T; Vermeren, S; Robb, CT; MacLeod, KG; Serrels, B; Schwarze, J; Haslett, C; Dransfield, I; Rossi, AG				Felton, Jennifer M.; Lucas, Christopher D.; Dorward, David A.; Duffin, Rodger; Kipari, Tiina; Vermeren, Sonja; Robb, Calum T.; MacLeod, Kenneth G.; Serrels, Bryan; Schwarze, Juergen; Haslett, Christopher; Dransfield, Ian; Rossi, Adriano G.			Mer-mediated eosinophil efferocytosis regulates resolution of allergic airway inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eosinophil; apoptosis; phagocytosis; Mer; inflammation resolution; allergic airway inflammation; airway resistance	RECEPTOR TYROSINE KINASE; PRO-RESOLVING MEDIATORS; APOPTOTIC NEUTROPHILS; CELL-DEATH; PHAGOCYTOSIS; LUNG; GLUCOCORTICOIDS; MACROPHAGES; INHIBITORS; INFECTION	Background: Eosinophils play a central role in propagation of allergic diseases, including asthma. Both recruitment and retention of eosinophils regulate pulmonary eosinophilia, but the question of whether alterations in apoptotic cell clearance by phagocytes contributes directly to resolution of allergic airway inflammation remains unexplored. Objectives: In this study we investigated the role of the receptor tyrosine kinase Mer in mediating apoptotic eosinophil clearance and allergic airway inflammation resolution in vivo to establish whether apoptotic cell clearance directly affects the resolution of allergic airway inflammation. Methods: Alveolar and bone marrow macrophages were used to study Mer-mediated phagocytosis of apoptotic eosinophils. Allergic airway inflammation resolution was modeled in mice by using ovalbumin. Fluorescently labeled apoptotic cells were administered intratracheally or eosinophil apoptosis was driven by administration of dexamethasone to determine apoptotic cell clearance in vivo. Results: Inhibition or absence of Mer impaired phagocytosis of apoptotic human and mouse eosinophils by macrophages. Merdeficient mice showed delayed resolution of ovalbumin-induced allergic airway inflammation, together with increased airway responsiveness to aerosolized methacholine, increased bronchoalveolar lavage fluid protein levels, altered cytokine production, and an excess of uncleared dying eosinophils after dexamethasone treatment. Alveolar macrophage phagocytosis was significantly Mer dependent, with the absence of Mer attenuating apoptotic cell clearance in vivo to enhance inflammation in response to apoptotic cells. Conclusions: We demonstrate that Mer-mediated apoptotic cell clearance by phagocytes contributes to resolution of allergic airway inflammation, suggesting that augmenting apoptotic cell clearance is a potential therapeutic strategy for treating allergic airway inflammation.	[Felton, Jennifer M.; Lucas, Christopher D.; Dorward, David A.; Duffin, Rodger; Kipari, Tiina; Vermeren, Sonja; Robb, Calum T.; Schwarze, Juergen; Haslett, Christopher; Dransfield, Ian; Rossi, Adriano G.] Univ Edinburgh, Queens Med Res Inst, MRC Ctr Inflammat Res, Rm W2-01, Edinburgh EH16 4TJ, Midlothian, Scotland; [MacLeod, Kenneth G.; Serrels, Bryan] Univ Edinburgh, MRC Inst Genet & Mol Med, Western Gen Hosp Campus, Edinburgh, Midlothian, Scotland	University of Edinburgh; University of Edinburgh	Lucas, CD (corresponding author), Univ Edinburgh, Queens Med Res Inst, MRC Ctr Inflammat Res, Rm W2-01, Edinburgh EH16 4TJ, Midlothian, Scotland.	christopher.lucas@ed.ac.uk	Schwarze, Jürgen/F-7396-2011; MacLeod, Kenneth/GWU-8940-2022; Vermeren, Sonja/AAK-7442-2020	Vermeren, Sonja/0000-0002-8460-0884; Duffin, Rodger/0000-0002-3425-9745; Felton, Jennifer/0000-0002-5004-0794; Dransfield, Ian/0000-0001-5848-7059; Lucas, Christopher/0000-0002-7523-0295	Wellcome Trust [206566/Z/17/Z, WT096497]; UK Medical Research Council [MR/K013386/1]; Wellcome Trust-University of Edinburgh Institutional Strategic Support Fund [1S2-101/02]; MRC [G0601481, MR/K013386/1, G0901697] Funding Source: UKRI	Wellcome Trust(Wellcome TrustEuropean Commission); UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust-University of Edinburgh Institutional Strategic Support Fund; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by the Wellcome Trust 206566/Z/17/Z (to C.D.L.), WT096497 (to D.A.D), the UK Medical Research Council (MR/K013386/1 to A.G.R., C.H., R.D., C.T.R., T.K., and J.M.F.) and a Wellcome Trust-University of Edinburgh Institutional Strategic Support Fund (1S2-101/02 to C.D.L.).	Basil MC, 2016, NAT REV IMMUNOL, V16, P51, DOI 10.1038/nri.2015.4; Cai BS, 2016, P NATL ACAD SCI USA, V113, P6526, DOI 10.1073/pnas.1524292113; Camenisch TD, 1999, J IMMUNOL, V162, P3498; Chiang N, 2012, NATURE, V484, P524, DOI 10.1038/nature11042; Choi JY, 2013, J PHARMACOL EXP THER, V344, P447, DOI 10.1124/jpet.112.199778; D'Cruz PM, 2000, HUM MOL GENET, V9, P645, DOI 10.1093/hmg/9.4.645; Dorward DA, 2017, THORAX, V72, P928, DOI 10.1136/thoraxjnl-2017-210030; Dorward DA, 2014, METHODS MOL BIOL, V1178, P177, DOI 10.1007/978-1-4939-1016-8_16; Dorward DA, 2014, METHODS MOL BIOL, V1124, P159, DOI 10.1007/978-1-62703-845-4_10; Dransfield I, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.18; Duncan CJA, 2003, EUR RESPIR J, V22, P484, DOI 10.1183/09031936.03.00109803a; Dyer KD, 2008, J IMMUNOL, V181, P4004, DOI 10.4049/jimmunol.181.6.4004; Felton JM, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00302; Fernandez-Boyanapalli R, 2013, J ALLERGY CLIN IMMUN, V131, P1041, DOI 10.1016/j.jaci.2012.09.028; Fullerton JN, 2016, NAT REV DRUG DISCOV, V15, P551, DOI 10.1038/nrd.2016.39; Gibbings SL, 2017, AM J RESP CELL MOL, V57, P66, DOI 10.1165/rcmb.2016-0361OC; Grabiec AM, 2017, J ALLERGY CLIN IMMUN, V140, P1144, DOI 10.1016/j.jaci.2017.03.024; Han CZ, 2016, NATURE, V539, P570, DOI 10.1038/nature20141; Hoodless LJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep36980; Huynh MLN, 2005, AM J RESP CRIT CARE, V172, P972, DOI 10.1164/rccm.200501-035OC; Juncadella IJ, 2013, NATURE, V493, P547, DOI 10.1038/nature11714; Kano G, 2013, J ALLERGY CLIN IMMUN, V132, P437, DOI 10.1016/j.jaci.2013.03.024; Lambrecht BN, 2015, NAT IMMUNOL, V16, P45, DOI 10.1038/ni.3049; Lee YJ, 2012, J LEUKOCYTE BIOL, V91, P921, DOI 10.1189/jlb.0611289; Liu YQ, 1999, J IMMUNOL, V162, P3639; Lu QX, 1999, NATURE, V398, P723, DOI 10.1038/19554; Lu QX, 2001, SCIENCE, V293, P306, DOI 10.1126/science.1061663; Lucas CD, 2014, MUCOSAL IMMUNOL, V7, P857, DOI 10.1038/mi.2013.102; Lucas CD, 2015, AM J RESP CRIT CARE, V191, P626, DOI 10.1164/rccm.201408-1565OC; Lucas CD, 2013, FASEB J, V27, P1084, DOI 10.1096/fj.12-218990; McColl A, 2009, J IMMUNOL, V183, P2167, DOI 10.4049/jimmunol.0803503; Meagher LC, 1996, J IMMUNOL, V156, P4422; Michlewska S, 2009, FASEB J, V23, P844, DOI 10.1096/fj.08-121228; Persson C, 2014, AM J RESP CRIT CARE, V189, P628, DOI 10.1164/rccm.201311-2069OE; Poon IKH, 2014, NAT REV IMMUNOL, V14, P166, DOI 10.1038/nri3607; Quiros M, 2017, J CLIN INVEST, V127, P3516, DOI 10.1172/JCI90229; Radonjic-Hoesli S, 2017, J ALLERGY CLIN IMMUN, V140, P1632, DOI 10.1016/j.jaci.2017.01.044; Rosenberg HF, 2013, NAT REV IMMUNOL, V13, P9, DOI 10.1038/nri3341; Rossi AG, 2006, NAT MED, V12, P1056, DOI 10.1038/nm1468; Rothlin CV, 2007, CELL, V131, P1124, DOI 10.1016/j.cell.2007.10.034; Vanden Berghe T, 2013, METHODS, V61, P117, DOI 10.1016/j.ymeth.2013.02.011; Zagorska A, 2014, NAT IMMUNOL, V15, P920, DOI 10.1038/ni.2986	42	20	20	1	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2018	142	6					1884	+		10.1016/j.jaci.2018.01.029	http://dx.doi.org/10.1016/j.jaci.2018.01.029			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HD2BJ	29428392	Green Published, Green Accepted, hybrid			2022-12-18	WOS:000452315800022
J	Niemeyer-van der Kolk, T; van Maaren, MS; van Doorn, MBA				Niemeyer-van der Kolk, Tessa; van Maaren, Maurits S.; van Doorn, Martijn B. A.			Personalized omalizumab treatment improves clinical benefit in patients with chronic spontaneous urticaria	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							CELLS		[Niemeyer-van der Kolk, Tessa; van Doorn, Martijn B. A.] Ctr Human Drug Res, Leiden, Netherlands; [Niemeyer-van der Kolk, Tessa; van Doorn, Martijn B. A.] Univ Med Ctr Rotterdam, Erasmus MC, Dept Dermatol, Rotterdam, Netherlands; [van Maaren, Maurits S.] Erasmus MC, Dept Internal Med, Allergol, Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC	van Doorn, MBA (corresponding author), Ctr Human Drug Res, Leiden, Netherlands.; van Doorn, MBA (corresponding author), Univ Med Ctr Rotterdam, Erasmus MC, Dept Dermatol, Rotterdam, Netherlands.	m.b.a.vandoorn@erasmusmc.nl		Niemeyer - van der Kolk, Tessa/0000-0002-3221-1609				Church MK, 2018, IMMUNOL REV, V282, P232, DOI 10.1111/imr.12632; Kaplan A, 2013, J ALLERGY CLIN IMMUN, V132, P101, DOI 10.1016/j.jaci.2013.05.013; Maurer M, 2018, J ALLERGY CLIN IMMUN, V141, P1138, DOI 10.1016/j.jaci.2017.10.018; Maurer M, 2013, NEW ENGL J MED, V368, P924, DOI 10.1056/NEJMoa1215372; Metz M, 2017, THERANOSTICS, V7, P1266, DOI 10.7150/thno.18304; Metz M, 2014, J DERMATOL SCI, V73, P57, DOI 10.1016/j.jdermsci.2013.08.011; Saini SS, 2015, J INVEST DERMATOL, V135, P925, DOI [10.1038/jid.2014.512, 10.1038/jid.2014.306]; Turk M, 2018, ALLERGOL INT, V67, P85, DOI 10.1016/j.alit.2017.05.003; Urgert MC, 2015, BRIT J DERMATOL, V173, P404, DOI 10.1111/bjd.13845	9	20	20	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2018	142	6					1992	1994		10.1016/j.jaci.2018.07.032	http://dx.doi.org/10.1016/j.jaci.2018.07.032			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HD2BJ	30144475	Bronze, Green Submitted			2022-12-18	WOS:000452315800038
J	Zissler, UM; Ulrich, M; Jakwerth, CA; Rothkirch, S; Guerth, F; Weckmann, M; Schiemann, M; Haller, B; Schmidt-Weber, CB; Chaker, AM				Zissler, Ulrich M.; Ulrich, Moritz; Jakwerth, Constanze A.; Rothkirch, Sandra; Guerth, Ferdinand; Weckmann, Markus; Schiemann, Matthias; Haller, Bernhard; Schmidt-Weber, Carsten B.; Chaker, Adam M.			Biomatrix for upper and lower airway biomarkers in patients with allergic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							B-CELLS; EXPRESSION		[Zissler, Ulrich M.; Ulrich, Moritz; Jakwerth, Constanze A.; Rothkirch, Sandra; Guerth, Ferdinand; Schmidt-Weber, Carsten B.; Chaker, Adam M.] Tech Univ Munich, Ctr Allergy & Environm ZAUM, Munich, Germany; [Zissler, Ulrich M.; Ulrich, Moritz; Jakwerth, Constanze A.; Rothkirch, Sandra; Guerth, Ferdinand; Schmidt-Weber, Carsten B.; Chaker, Adam M.] Helmholtz Ctr Munich, German Res Ctr Environm Hlth, Munich, Germany; [Zissler, Ulrich M.; Ulrich, Moritz; Jakwerth, Constanze A.; Rothkirch, Sandra; Guerth, Ferdinand; Schmidt-Weber, Carsten B.; Chaker, Adam M.] German Ctr Lung Res DZL, CPC M, Munich, Germany; [Ulrich, Moritz; Rothkirch, Sandra; Chaker, Adam M.] Tech Univ Munich, Sch Med, Dept Otorhinolaryngol & Head & Neck Surg, Munich, Germany; [Weckmann, Markus] Univ Lubeck, Childrens Hosp, Dept Pediat Allergy & Pulmonol, Lubeck, Germany; [Weckmann, Markus] German Ctr Lung Res DZL, ARCN, Lubeck, Germany; [Schiemann, Matthias] Tech Univ Munich, Inst Med Microbiol Immunol & Hyg, Munich, Germany; [Haller, Bernhard] Tech Univ Munich, Sch Med, Inst Med Stat & Epidemiol, Munich, Germany	Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; University of Lubeck; Technical University of Munich; Technical University of Munich	Zissler, UM (corresponding author), Tech Univ Munich, Ctr Allergy & Environm ZAUM, Munich, Germany.; Zissler, UM (corresponding author), Helmholtz Ctr Munich, German Res Ctr Environm Hlth, Munich, Germany.; Zissler, UM (corresponding author), German Ctr Lung Res DZL, CPC M, Munich, Germany.	ulrich.zissler@tum.de	Zissler, Ulrich Matthias/GSD-3514-2022; Haller, Bernhard/I-1943-2019; Weckmann, Markus/GXG-3428-2022; Schmidt-Weber, Carsten B./AAU-1621-2021; Zissler, Ulrich/GRO-1107-2022; Zissler, Ulrich Matthias/AAP-2878-2020	Zissler, Ulrich Matthias/0000-0003-4826-3419; Haller, Bernhard/0000-0002-9723-393X; Weckmann, Markus/0000-0001-5342-979X; Schmidt-Weber, Carsten B./0000-0002-3203-8084; Zissler, Ulrich Matthias/0000-0003-4826-3419; Chaker, Adam/0000-0002-5117-4073	German Center for Lung Research (DZL)	German Center for Lung Research (DZL)	Supported by the German Center for Lung Research (DZL).	Asano T, 2017, ANN AM THORAC SOC, V14, P667, DOI 10.1513/AnnalsATS.201609-720OC; Baines KJ, 2014, J ALLERGY CLIN IMMUN, V133, P997, DOI 10.1016/j.jaci.2013.12.1091; Mantel PY, 2007, PLOS BIOL, V5, P2847, DOI 10.1371/journal.pbio.0050329; Oliveria JP, 2018, J ALLERGY CLIN IMMUN, V141, P1495, DOI 10.1016/j.jaci.2017.11.013; Poole A, 2014, J ALLERGY CLIN IMMUN, V133, P670, DOI 10.1016/j.jaci.2013.11.025; Tangye SG, 2002, J IMMUNOL, V169, P4298, DOI 10.4049/jimmunol.169.8.4298; van de Veen W, 2013, J ALLERGY CLIN IMMUN, V131, P1204, DOI 10.1016/j.jaci.2013.01.014; Zissler UM, 2016, MUCOSAL IMMUNOL, V9, P917, DOI 10.1038/mi.2015.110	8	20	21	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2018	142	6					1980	1983		10.1016/j.jaci.2018.07.027	http://dx.doi.org/10.1016/j.jaci.2018.07.027			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HD2BJ	30121290	Bronze			2022-12-18	WOS:000452315800033
J	Farahi, N; Loutsios, C; Tregay, N; Wright, AKA; Berair, R; Lok, LSC; Gillett, D; Cullum, I; Simmonds, RP; Summers, C; Wong, A; Solanki, CK; Buscombe, J; Pang, PH; Thavakumar, A; Peters, AM; Brightling, CE; Condliffe, AM; Chilvers, ER				Farahi, Neda; Loutsios, Chrystalla; Tregay, Nicola; Wright, Adam K. A.; Berair, Rachid; Lok, Laurence S. C.; Gillett, Daniel; Cullum, Ian; Simmonds, Rosalind P.; Summers, Charlotte; Wong, Anna; Solanki, Chandra K.; Buscombe, John; Pang, Pee Hwee; Thavakumar, Arthikkaa; Peters, A. Michael; Brightling, Christopher E.; Condliffe, Alison M.; Chilvers, Edwin R.			In vivo imaging reveals increased eosinophil uptake in the lungs of obese asthmatic patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							DERMATOPHAGOIDES-PTERONYSSINUS ALLERGEN; P 23; RECOMBINANT		[Farahi, Neda; Loutsios, Chrystalla; Tregay, Nicola; Lok, Laurence S. C.; Simmonds, Rosalind P.; Condliffe, Alison M.; Chilvers, Edwin R.] Univ Cambridge, Sch Clin Med, Dept Med, Div Resp Med, Cambridge, England; [Wright, Adam K. A.; Berair, Rachid; Pang, Pee Hwee; Thavakumar, Arthikkaa; Brightling, Christopher E.] Inst Lung Hlth, NIHR Resp Biomed Res Unit, Leicester, Leics, England; [Gillett, Daniel; Cullum, Ian; Wong, Anna; Solanki, Chandra K.; Buscombe, John] CUHNHSFT, Addenbrookes Hosp, Dept Nucl Med, Cambridge, England; [Summers, Charlotte] Univ Cambridge, Sch Clin Med, Dept Med, Div Anaesthesia, Cambridge, England; [Peters, A. Michael] Brighton & Sussex Med Sch, Div Clin & Lab Invest, Brighton, E Sussex, England	University of Cambridge; University of Leicester; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Cambridge; University of Brighton; University of Sussex	Farahi, N (corresponding author), Univ Cambridge, Sch Clin Med, Dept Med, Div Resp Med, Cambridge, England.	nf231@cam.ac.uk	; Summers, Charlotte/A-6973-2012	Pang, Pee Hwee/0000-0002-0027-5026; Chilvers, Edwin/0000-0002-4230-9677; Summers, Charlotte/0000-0002-7269-2873; brightling, chris/0000-0002-9345-4903; Lok, Laurence/0000-0002-9364-4213; Farahi, Neda/0000-0001-5793-3205; Berair, Rachid/0000-0002-0513-0627	National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre; NIHR Leicester Biomedical Research Centre; Medical Research Council [MR/J00345X/1]; Wellcome Trust [098351/Z/12/Z]; Wellcome Trust Senior Fellowship [WT082265]; AirPROM 7th EU; NIHR Cambridge Clinical Research Facility; Asthma UK [08/11]; MRC [MC_PC_17208, MR/J00345X/1] Funding Source: UKRI	National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre(National Institute for Health Research (NIHR)); NIHR Leicester Biomedical Research Centre; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); Wellcome Trust Senior Fellowship(Wellcome Trust); AirPROM 7th EU; NIHR Cambridge Clinical Research Facility(General Electric); Asthma UK; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This research was cofunded by the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre, NIHR Leicester Biomedical Research Centre, Asthma UK (08/11), the Medical Research Council (grant no. MR/J00345X/1), the Wellcome Trust (grant no. 098351/Z/12/Z), Wellcome Trust Senior Fellowship (grant no. WT082265 to C.E.B.), and AirPROM 7th EU Framework grant, and supported by the NIHR Cambridge Clinical Research Facility. The views expressed are those of the authors and not necessarily those of the National Health Service, the NIHR, or the Department of Health and Social Care.	Banerjee S, 2014, J IMMUNOL, V192, P4867, DOI 10.4049/jimmunol.1400064; CHUA KY, 1990, INT ARCH ALLER A IMM, V91, P124, DOI 10.1159/000235102; Desai D, 2013, AM J RESP CRIT CARE, V188, P657, DOI 10.1164/rccm.201208-1470OC; Erwin EA, 2005, J ALLERGY CLIN IMMUN, V115, P1029, DOI 10.1016/j.jaci.2004.12.1131; Farahi N, 2012, BLOOD, V120, P4068, DOI 10.1182/blood-2012-07-443424; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Lukawska JJ, 2014, J ALLERGY CLIN IMMUN, V133, P233, DOI 10.1016/j.jaci.2013.06.031; Lupinek C, 2014, METHODS, V66, P106, DOI 10.1016/j.ymeth.2013.10.008; Persson C, 2014, AM J RESP CRIT CARE, V189, P628, DOI 10.1164/rccm.201311-2069OE; Ruparelia P, 2011, EUR J NUCL MED MOL I, V38, P911, DOI 10.1007/s00259-010-1715-7; Simon HU, 2010, J ALLERGY CLIN IMMUN, V126, P45, DOI 10.1016/j.jaci.2010.03.042; Swoboda I, 2007, J IMMUNOL, V178, P6290, DOI 10.4049/jimmunol.178.10.6290; Turato G, 2018, AM J RESP CRIT CARE, V197, P1216, DOI 10.1164/rccm.201708-1684LE; Weghofer M, 2008, ALLERGY, V63, P758, DOI 10.1111/j.1398-9995.2008.01647.x; Weghofer M, 2008, INT ARCH ALLERGY IMM, V147, P101, DOI 10.1159/000135696; Weghofer M, 2013, J IMMUNOL, V190, P3059, DOI 10.4049/jimmunol.1202288; Zieglmayer P, 2017, J ALLERGY CLIN IMMUN, V140, P266, DOI 10.1016/j.jaci.2016.12.986	17	20	20	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2018	142	5					1659	+		10.1016/j.jaci.2018.07.011	http://dx.doi.org/10.1016/j.jaci.2018.07.011			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GZ5BL	30071200	Green Accepted, Green Published, hybrid			2022-12-18	WOS:000449429800035
J	Kessel, C; Fuehner, S; Zell, J; Zimmermann, B; Drewianka, S; Brockmeyer, S; Holzinger, D; Hinze, C; Wittkowski, H; Foell, D				Kessel, Christoph; Fuehner, Sabrina; Zell, Jana; Zimmermann, Bastian; Drewianka, Stephan; Brockmeyer, Sonja; Holzinger, Dirk; Hinze, Claas; Wittkowski, Helmut; Foell, Dirk			Calcium and zinc tune autoinflammatory Toll-like receptor 4 signaling by S100A12	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							JUVENILE IDIOPATHIC ARTHRITIS; DISEASE; ASSOCIATION; GENOTYPE; HOMEOSTASIS; METABOLISM; IMPUTATION; ENDOTOXIN; PROTEINS; COMPLEX		[Kessel, Christoph; Fuehner, Sabrina; Zell, Jana; Brockmeyer, Sonja; Holzinger, Dirk; Hinze, Claas; Wittkowski, Helmut; Foell, Dirk] Univ Childrens Hosp, Dept Pediat Rheumatol & Immunol, Munster, Germany; [Zimmermann, Bastian; Drewianka, Stephan] Biaffin GmbH & CoKG, Kassel, Germany; [Holzinger, Dirk] Univ Hosp, Dept Child & Adolescent Med, Essen, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munster; University of Duisburg Essen	Kessel, C (corresponding author), Univ Childrens Hosp, Dept Pediat Rheumatol & Immunol, Munster, Germany.	christoph.kessel@uni-muenster.de; dfoell@uni-muenster.de	Kessel, Christoph/AAG-4079-2020	Kessel, Christoph/0000-0002-0638-2949; Hinze, Claas/0000-0001-9247-4729; Holzinger, Dirk/0000-0002-8062-8820	Muenster University medical faculty [KE121201]; German Research Foundation (DFG) [WI3176/2-1, Fo354/3-1]	Muenster University medical faculty; German Research Foundation (DFG)(German Research Foundation (DFG))	This study was supported by grants from the intramural innovative medical research program of Muenster University medical faculty (grant no. KE121201 to C.K.) and the German Research Foundation (DFG, grant no. WI3176/2-1 to H.W. and grant no. Fo354/3-1 to D.F.).	Besecker BY, 2011, AM J CLIN NUTR, V93, P1356, DOI 10.3945/ajcn.110.008417; BOWERS GN, 1986, CLIN CHEM, V32, P1437; Bruzzone S, 2006, BIOCHEM J, V393, P697, DOI 10.1042/BJ20051302; Cunden LS, 2016, CHEM SCI, V7, P1338, DOI 10.1039/c5sc03655k; Das S, 2016, NAT GENET, V48, P1284, DOI 10.1038/ng.3656; De Leon-Rodriguez L, 2012, INORG CHIM ACTA, V393, P12, DOI 10.1016/j.ica.2012.06.026; Delaneau O, 2013, NAT METHODS, V10, P5, DOI 10.1038/nmeth.2307; Dubben S, 2010, J LEUKOCYTE BIOL, V87, P833, DOI 10.1189/jlb.0409241; Foell D, 2013, AM J RESP CRIT CARE, V187, P1324, DOI 10.1164/rccm.201209-1602OC; Foell D, 2010, JAMA-J AM MED ASSOC, V303, P1266, DOI 10.1001/jama.2010.375; Frosch M, 2009, ARTHRITIS RHEUM-US, V60, P883, DOI 10.1002/art.24349; Gaetke LM, 1997, AM J PHYSIOL-ENDOC M, V272, pE952, DOI 10.1152/ajpendo.1997.272.6.E952; Gohar F, 2016, ARTHRITIS RHEUMATOL, V68, P3010, DOI 10.1002/art.39784; Holzinger D, 2015, J ALLERGY CLIN IMMUN, V136, P1337, DOI 10.1016/j.jaci.2015.04.016; Hubisz MJ, 2009, MOL ECOL RESOUR, V9, P1322, DOI 10.1111/j.1755-0998.2009.02591.x; Johnson EO, 2013, HUM GENET, V132, P509, DOI 10.1007/s00439-013-1266-7; Kastner DL, 2010, CELL, V140, P784, DOI 10.1016/j.cell.2010.03.002; Kessel C, 2017, ARTHRITIS RHEUMATOL, V69, P1480, DOI 10.1002/art.40099; Kessel C, 2013, CLIN IMMUNOL, V147, P229, DOI 10.1016/j.clim.2012.11.008; Liston A, 2017, NAT REV IMMUNOL, V17, P208, DOI 10.1038/nri.2016.151; Marenholz I, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01220-0; McCarthy S, 2016, NAT GENET, V48, P1279, DOI 10.1038/ng.3643; Moroz OV, 2009, BMC BIOCHEM, V10, DOI 10.1186/1471-2091-10-11; Purcell S, 2003, BIOINFORMATICS, V19, P149, DOI 10.1093/bioinformatics/19.1.149; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Sampson HA, 2012, J ALLERGY CLIN IMMUN, V130, P1260, DOI 10.1016/j.jaci.2012.10.017; Schmermund A, 2002, AM HEART J, V144, P212, DOI 10.1067/mhj.2002.123579; Volzke H, 2011, INT J EPIDEMIOL, V40, P294, DOI 10.1093/ije/dyp394; Vogl T, 2007, NAT MED, V13, P1042, DOI 10.1038/nm1638; Vogl T, 2018, J CLIN INVEST, V128, P1852, DOI 10.1172/JCI89867; Wittkowski H, 2011, ANN RHEUM DIS, V70, P2075, DOI 10.1136/ard.2011.152496; Wittkowski H, 2008, ARTHRITIS RHEUM-US, V58, P3924, DOI 10.1002/art.24137; Yang H, 2015, J EXP MED, V212, P5, DOI 10.1084/jem.20141318	33	20	20	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2018	142	4					1370	+		10.1016/j.jaci.2018.06.027	http://dx.doi.org/10.1016/j.jaci.2018.06.027			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GV7RG	30010542	Bronze			2022-12-18	WOS:000446327300044
J	Lee, PY; Huang, YL; Zhou, Q; Schnappauf, O; Hershfield, MS; Li, Y; Ganson, NJ; Moura, NS; Delmonte, OM; Stone, SS; Rivkin, MJ; Pai, SY; Lyons, T; Sundel, RP; Hsu, VW; Notarangelo, LD; Aksentijevich, I; Nigrovic, PA				Lee, Pui Y.; Huang, Yuelong; Zhou, Qing; Schnappauf, Oskar; Hershfield, Michael S.; Li, Ying; Ganson, Nancy J.; Moura, Natalia Sampaio; Delmonte, Ottavia M.; Stone, Scellig S.; Rivkin, Michael J.; Pai, Sung-Yun; Lyons, Todd; Sundel, Robert P.; Hsu, Victor W.; Notarangelo, Luigi D.; Aksentijevich, Ivona; Nigrovic, Peter A.			Disrupted N-linked glycosylation as a disease mechanism in deficiency of ADA2	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							AMINO-ACID; ALLERGEN		[Lee, Pui Y.; Sundel, Robert P.; Nigrovic, Peter A.] Brigham & Womens Hosp, Div Immunol, 75 Francis St, Boston, MA 02115 USA; [Lee, Pui Y.; Huang, Yuelong; Li, Ying; Hsu, Victor W.; Nigrovic, Peter A.] Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, 75 Francis St, Boston, MA 02115 USA; [Zhou, Qing; Schnappauf, Oskar; Moura, Natalia Sampaio; Aksentijevich, Ivona] NHGRI, Inflammatory Dis Sect, Bethesda, MD 20892 USA; [Hershfield, Michael S.; Ganson, Nancy J.] Duke Univ, Sch Med, Dept Med & Biochem, Durham, NC USA; [Delmonte, Ottavia M.; Notarangelo, Luigi D.] NIAID, Lab Clin Immunol & Microbiol, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Stone, Scellig S.] Boston Childrens Hosp, Dept Neurosurg, Boston, MA USA; [Rivkin, Michael J.] Boston Childrens Hosp, Dept Neurol Psychiat & Radiol, Boston, MA USA; [Pai, Sung-Yun] Boston Childrens Hosp, Div Hematol Oncol, Boston, MA USA; [Pai, Sung-Yun] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; [Lyons, Todd] Boston Childrens Hosp, Div Emergency Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Duke University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard University; Boston Children's Hospital	Lee, PY (corresponding author), Brigham & Womens Hosp, Div Immunol, 75 Francis St, Boston, MA 02115 USA.; Lee, PY (corresponding author), Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, 75 Francis St, Boston, MA 02115 USA.	pui.lee@childrens.harvard.edu	Aksentijevich, Ivona/AAF-1335-2019; Pai, Sung-Yun/AAH-7762-2019	Pai, Sung-Yun/0000-0002-0158-8147; Stone, Scellig/0000-0002-4546-6790	National Institute of Arthritis and Musculoskeletal and Skin Diseases [R01AR065538, P30AR070253]; Fundacion Bechara (PAN), National Institutes of Health (NIH) [T32AI007512]; Rheumatology Research Foundation Investigator Award; Boston Children's Hospital Faculty Career Development Fellowship; Division of Intramural Research, National Institute of Allergy and Infectious Diseases, NIH; Division of Intramural Research, National Human Genome Research Institute, NIH; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [ZIAHG200372] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007512, ZIAAI001222] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR065538, P30AR070253] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM058615] Funding Source: NIH RePORTER	National Institute of Arthritis and Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Fundacion Bechara (PAN), National Institutes of Health (NIH); Rheumatology Research Foundation Investigator Award; Boston Children's Hospital Faculty Career Development Fellowship; Division of Intramural Research, National Institute of Allergy and Infectious Diseases, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Division of Intramural Research, National Human Genome Research Institute, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant nos. R01AR065538 and P30AR070253) and the Fundacion Bechara (PAN), National Institutes of Health (NIH; grant no. T32AI007512), the Rheumatology Research Foundation Investigator Award and Boston Children's Hospital Faculty Career Development Fellowship (P.Y.L.), the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, NIH (L.D.N.), the Division of Intramural Research, National Human Genome Research Institute, NIH (I.A.).	Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; Caorsi R, 2017, ANN RHEUM DIS, V76, P1648, DOI 10.1136/annrheumdis-2016-210802; Caorsi R, 2016, PEDIATR RHEUMATOL, V14, DOI 10.1186/s12969-016-0111-7; Chamcheu JC, 2017, ANTIOXID REDOX SIGN, V26, P49, DOI 10.1089/ars.2016.6769; Elkan PN, 2014, NEW ENGL J MED, V370, P921, DOI 10.1056/NEJMoa1307362; Esnault S, 2017, CLIN EXP ALLERGY, V47, P488, DOI 10.1111/cea.12876; Esnault S, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0669-8; Hashem H, 2017, CURR RHEUMATOL REP, V19, DOI 10.1007/s11926-017-0699-8; KASTURI L, 1995, J BIOL CHEM, V270, P14756, DOI 10.1074/jbc.270.24.14756; Kelly EAB, 1997, AM J RESP CRIT CARE, V156, P1421, DOI 10.1164/ajrccm.156.5.9703054; Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057; MURAOKA T, 1990, ANAL BIOCHEM, V187, P268, DOI 10.1016/0003-2697(90)90455-I; Nanthapisal S, 2016, ARTHRITIS RHEUMATOL, V68, P2314, DOI 10.1002/art.39699; Ng PC, 2003, NUCLEIC ACIDS RES, V31, P3812, DOI 10.1093/nar/gkg509; Ohtsubo K, 2006, CELL, V126, P855, DOI 10.1016/j.cell.2006.08.019; Papadopoulos JS, 2007, BIOINFORMATICS, V23, P1073, DOI 10.1093/bioinformatics/btm076; SLAATS EH, 1985, J CLIN CHEM CLIN BIO, V23, P677; Terada M, 2004, AM J RESP CRIT CARE, V169, P373, DOI 10.1164/rccm.200308-1156OC; Vogt G, 2005, NAT GENET, V37, P692, DOI 10.1038/ng1581; Zavialov AV, 2010, J BIOL CHEM, V285, P12367, DOI 10.1074/jbc.M109.083527; Zhou Q, 2014, NEW ENGL J MED, V370, P911, DOI 10.1056/NEJMoa1307361	21	20	20	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2018	142	4					1363	+		10.1016/j.jaci.2018.05.038	http://dx.doi.org/10.1016/j.jaci.2018.05.038			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GV7RG	29936104	Green Accepted, Bronze			2022-12-18	WOS:000446327300041
J	Sorkness, RL; Zoratti, EM; Kattan, M; Gergen, PJ; Evans, MD; Visness, CM; Gill, M; Hershey, GKK; Kercsmar, CM; Liu, AH; O'Connor, GT; Pongracic, JA; Pillai, D; Sorkness, CA; Togias, A; Wood, RA; Busse, WW				Sorkness, Ronald L.; Zoratti, Edward M.; Kattan, Meyer; Gergen, Peter J.; Evans, Michael D.; Visness, Cynthia M.; Gill, Michelle; Hershey, Gurjit K. Khurana; Kercsmar, Carolyn M.; Liu, Andrew H.; O'Connor, George T.; Pongracic, Jacqueline A.; Pillai, Dinesh; Sorkness, Christine A.; Togias, Alkis; Wood, Robert A.; Busse, William W.			Obstruction phenotype as a predictor of asthma severity and instability in children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Small-airways dysfunction; asthma exacerbation; airflow limitation; airway closure	INNER-CITY CHILDREN; SMALL AIRWAYS; BRONCHODILATOR RESPONSE; CHILDHOOD ASTHMA; LUNG-FUNCTION; RISK-FACTORS; OSCILLOMETRY; ADOLESCENTS; CONTRIBUTE	Background: Small-airways instability resulting in premature airway closure has been recognized as a risk for asthma severity and poor control. Although spirometry has limited sensitivity for detecting small-airways dysfunction, a focus on the air-trapping component of obstruction might identify a risk factor for asthma instability. Objective: We sought to use spirometric measurements to identify patterns of airway obstruction in children and define obstruction phenotypes that relate to asthma instability. Methods: Prebronchodilation and postbronchodilation spirometric data were obtained from 560 children in the Asthma Phenotypes in the Inner City study. An air-trapping obstruction phenotype (A Trpg) was defined as a forced vital capacity (FVC) z score of less than 21.64 or an increase in FVC of 10% of predicted value or greater with bronchodilation. The airflow limitation phenotype (A Limit) had an FEV1/FVC z score of less than 21.64 but not A Trpg. The no airflow limitation or air-trapping criteria (None) phenotype had neither ATrpg nor A Limit. The 3 obstruction phenotypes were assessed as predictors of number of exacerbations, asthma severity, and airway lability. Results: Patients with the ATrpg phenotype (14% of the cohort) had more exacerbations during the 12-month study compared with those with the A Limit (P<.03) and None (P<.001) phenotypes. Patients with the A Trpg phenotype also had the highest Composite Asthma Severity Index score, the highest asthma treatment step, the greatest variability in FEV1 over time, and the greatest sensitivity to methacholine challenge. Conclusions: A Trpg and A Limit patterns of obstruction, as defined by using routine spirometric measurements, can identify obstruction phenotypes that are indicators of risk for asthma severity and instability.	[Sorkness, Ronald L.; Sorkness, Christine A.] Univ Wisconsin, Sch Pharm, 777 Highland Ave, Madison, WI 53705 USA; [Sorkness, Ronald L.; Sorkness, Christine A.; Busse, William W.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA; [Sorkness, Ronald L.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pediat, Madison, WI USA; [Evans, Michael D.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Biostat & Med Informat, Madison, WI USA; [Zoratti, Edward M.] Henry Ford Hlth Syst, Detroit, MI USA; [Zoratti, Edward M.] Wayne State Univ, Sch Med, Detroit, MI USA; [Kattan, Meyer] Columbia Univ, Coll Phys & Surg, New York, NY USA; [Gergen, Peter J.; Togias, Alkis] NIAID, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Visness, Cynthia M.] Rho Fed Syst Div, Chapel Hill, NC USA; [Gill, Michelle] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA; [Hershey, Gurjit K. Khurana; Kercsmar, Carolyn M.] Cincinnati Childrens Hosp, Cincinnati, OH USA; [Liu, Andrew H.] Childrens Hosp Colorado, Aurora, CO USA; [Liu, Andrew H.] Univ Colorado, Sch Med, Aurora, CO USA; [O'Connor, George T.] Boston Univ, Sch Med, Boston, MA 02118 USA; [Pongracic, Jacqueline A.] Ann & Robert H Lurie Childrens Hosp, Chicago, IL USA; [Pillai, Dinesh] Childrens Natl Hlth Syst, Washington, DC USA; [Pillai, Dinesh] George Washington Univ, Sch Med & Hlth Sci, Washington, DC 20052 USA; [Wood, Robert A.] Johns Hopkins Sch Med, Baltimore, MD USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Henry Ford Health System; Henry Ford Hospital; Wayne State University; Columbia University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Texas System; University of Texas Southwestern Medical Center Dallas; Cincinnati Children's Hospital Medical Center; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Boston University; Ann & Robert H. Lurie Children's Hospital of Chicago; Children's National Health System; George Washington University; Johns Hopkins University; Johns Hopkins Medicine	Sorkness, RL (corresponding author), Univ Wisconsin, Sch Pharm, 777 Highland Ave, Madison, WI 53705 USA.	ronald.sorkness@wisc.edu		Evans, Michael/0000-0001-7449-3993	National Institute of Allergy and Infectious Diseases (NIAID)/National Institutes of Health (NIH); Department of Health and Human Services [HHSN272200900052C, HHSN272201000052I]; National Center for Research Resources (NCRR); National Center for Advancing Translational Sciences (NCATS)/NIH [NCRR/NIH UL1TR000451, UL1RR025780, UL1TR000075, NCATS/NIH UL1TR000154, UL1TR001082, UL1TR000077-04, UL1TR000040, UL1TR000150, UL1TR001105, UM1AI114271]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001082, UL1TR001105, UL1TR000150, UL1TR001422, UL1TR000040, UL1TR000451, UL1TR000077, UL1TR000154, UL1TR000075] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025780] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [UM1AI114271, UM2AI117870] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases (NIAID)/National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Department of Health and Human Services; National Center for Research Resources (NCRR)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Center for Advancing Translational Sciences (NCATS)/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This project has been funded in whole or in part with federal funds from the National Institute of Allergy and Infectious Diseases (NIAID)/National Institutes of Health (NIH) and the Department of Health and Human Services (under contract nos. HHSN272200900052C and HHSN272201000052I). Additional support was provided by the National Center for Research Resources (NCRR) and the National Center for Advancing Translational Sciences (NCATS)/NIH (under grant nos. NCRR/NIH UL1TR000451, UL1RR025780, UL1TR000075 and NCATS/NIH UL1TR000154, UL1TR001082, UL1TR000077-04, UL1TR000040, UL1TR000150, UL1TR001105 and UM1AI114271). GlaxoSmithKline provided Ventolin, Flovent, Advair, and Flonase under a clinical trial agreement with the NIH/NIAID but did not have a role in the development or approval of the protocol, conduct of the trial, data analysis, manuscript preparation, or the decision to submit the manuscript for publication.	Anafi RC, 2003, J APPL PHYSIOL, V94, P1003, DOI 10.1152/japplphysiol.00569.2002; Burgel PR, 2011, EUR RESPIR REV, V20, P23, DOI 10.1183/09059180.00010410; Busacker A, 2009, CHEST, V135, P48, DOI 10.1378/chest.08-0049; Dweik RA, 2011, AM J RESP CRIT CARE, V184, P602, DOI 10.1164/rccm.9120-11ST; Gibbons WJ, 1996, AM J RESP CRIT CARE, V153, P582, DOI 10.1164/ajrccm.153.2.8564102; In't Veen CCM, 2000, AM J RESP CRIT CARE, V161, P1902; Kelly VJ, 2013, J APPL PHYSIOL, V115, P1360, DOI 10.1152/japplphysiol.00093.2013; Liu AH, 2016, J ALLERGY CLIN IMMUN, V138, P1042, DOI 10.1016/j.jaci.2016.06.060; Macklem PT, 1998, AM J RESP CRIT CARE, V157, pS181, DOI 10.1164/ajrccm.157.5.rsaa-2; Mahut B, 2010, RESP MED, V104, P1230, DOI 10.1016/j.rmed.2010.05.005; MEAD J, 1967, J APPL PHYSIOL, V22, P95, DOI 10.1152/jappl.1967.22.1.95; MERKUS PJFM, 1993, AM REV RESPIR DIS, V148, P1484, DOI 10.1164/ajrccm/148.6_Pt_1.1484; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Pongracic JA, 2016, J ALLERGY CLIN IMMUN, V138, P1030, DOI 10.1016/j.jaci.2016.06.059; Pyrgos G, 2011, J APPL PHYSIOL, V110, P472, DOI 10.1152/japplphysiol.00603.2010; Quanjer PH, 2014, EUR RESPIR J, V43, P1051, DOI 10.1183/09031936.00128113; Quanjer PH, 2012, EUR RESPIR J, V40, P1324, DOI 10.1183/09031936.00080312; Sharma S, 2008, J ALLERGY CLIN IMMUN, V122, P921, DOI 10.1016/j.jaci.2008.09.004; Shi YX, 2013, J ALLERGY CLIN IMMUN, V131, P718, DOI 10.1016/j.jaci.2012.09.022; Shi YX, 2012, J ALLERGY CLIN IMMUN, V129, P671, DOI 10.1016/j.jaci.2011.11.002; Sorkness RL, 2008, J APPL PHYSIOL, V104, P394, DOI 10.1152/japplphysiol.00329.2007; Sorkness RL, 2011, J ALLERGY CLIN IMMUN, V127, P1073, DOI 10.1016/j.jaci.2010.12.1079; Tse SM, 2013, J ALLERGY CLIN IMMUN, V132, P554, DOI 10.1016/j.jaci.2013.03.031; Wildfire JJ, 2012, J ALLERGY CLIN IMMUN, V129, P694, DOI 10.1016/j.jaci.2011.12.962; Zeidler MR, 2006, EUR RESPIR J, V27, P307, DOI 10.1183/09031936.06.00005605; Zoratti EM, 2016, J ALLERGY CLIN IMMUN, V138, P1016, DOI 10.1016/j.jaci.2016.06.061	26	20	21	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2018	142	4					1090	+		10.1016/j.jaci.2017.09.047	http://dx.doi.org/10.1016/j.jaci.2017.09.047			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GV7RG	29146272	Green Accepted, Bronze			2022-12-18	WOS:000446327300010
J	Pyrillou, K; Chairakaki, AD; Tamvakopoulos, C; Andreakos, E				Pyrillou, Katerina; Chairakaki, Aikaterini-Dimitra; Tamvakopoulos, Constantin; Andreakos, Evangelos			Dexamethasone induces omega 3-derived immunoresolvents driving resolution of allergic airway inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							RESOLVING LIPID MEDIATORS; ASTHMA		[Pyrillou, Katerina; Chairakaki, Aikaterini-Dimitra; Andreakos, Evangelos] Acad Athens, Biomed Res Fdn, Immunobiol Lab, Athens, Greece; [Pyrillou, Katerina; Tamvakopoulos, Constantin] Acad Athens, Biomed Res Fdn, Ctr Clin Expt Surg & Translat Res, Div Pharmacol Pharmacotechnol, Athens, Greece	Academy of Athens; Academy of Athens	Andreakos, E (corresponding author), Acad Athens, Biomed Res Fdn, Immunobiol Lab, Athens, Greece.	vandreakos@bioacademy.gr		Tamvakopoulos, Constantin/0000-0001-9627-4812; Pyrillou, Katerina/0000-0003-0375-7810	Hellenic Ministry of Education, Research and Religious Affairs and the Hellenic Ministry of Health; PREDICTA from the European Commission [260895]; MIDAS from the Hellenic Ministry of Education, Research and Religious Affairs [MIS 377047]; RESOLVE-ASTHMA from the Hellenic Ministry of Education, Research and Religious Affairs [2601]	Hellenic Ministry of Education, Research and Religious Affairs and the Hellenic Ministry of Health; PREDICTA from the European Commission; MIDAS from the Hellenic Ministry of Education, Research and Religious Affairs; RESOLVE-ASTHMA from the Hellenic Ministry of Education, Research and Religious Affairs	This work was supported by core funding from the Hellenic Ministry of Education, Research and Religious Affairs and the Hellenic Ministry of Health, and by the research grants PREDICTA (contract no. 260895) from the European Commission, MIDAS (contract no. MIS 377047), and RESOLVE-ASTHMA (contract no. 2601) from the Hellenic Ministry of Education, Research and Religious Affairs.	Kazani S, 2013, J ALLERGY CLIN IMMUN, V132, P547, DOI 10.1016/j.jaci.2013.01.058; Koltsida O, 2013, EMBO MOL MED, V5, P762, DOI 10.1002/emmm.201201891; Levy BD, 2005, AM J RESP CRIT CARE, V172, P824, DOI 10.1164/rccm.200410-1413OC; Levy BD, 2001, NAT IMMUNOL, V2, P612, DOI 10.1038/89759; Levy BD, 2007, J IMMUNOL, V178, P496, DOI 10.4049/jimmunol.178.1.496; Miyata J, 2013, J ALLERGY CLIN IMMUN, V131, P353, DOI 10.1016/j.jaci.2012.07.048; Serhan CN, 2014, NATURE, V510, P92, DOI 10.1038/nature13479; Spite M, 2010, CIRC RES, V107, P1170, DOI 10.1161/CIRCRESAHA.110.223883; Vachier I, 2005, J ALLERGY CLIN IMMUN, V115, P55, DOI 10.1016/j.jaci.2004.09.038	9	20	20	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2018	142	2					691	695		10.1016/j.jaci.2018.04.004	http://dx.doi.org/10.1016/j.jaci.2018.04.004			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GP2LN	29698628	Green Submitted, Bronze			2022-12-18	WOS:000440664400041
J	Bachmann, MF; Zeltins, A; Kalnins, G; Balke, I; Fischer, N; Rostaher, A; Tars, K; Favrot, C				Bachmann, Martin F.; Zeltins, Andris; Kalnins, Gints; Balke, Ina; Fischer, Nina; Rostaher, Ana; Tars, Kaspars; Favrot, Claude			Vaccination against IL-31 for the treatment of atopic dermatitis in dogs	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									[Bachmann, Martin F.] Univ Bern, Inselspital, RIA Immunol, Bern, Switzerland; [Bachmann, Martin F.] Univ Oxford, Nuffield Dept Med, Jenner Inst, Oxford, England; [Zeltins, Andris; Kalnins, Gints; Balke, Ina; Tars, Kaspars] Latvian Biomed Res & Study Ctr, Riga, Latvia; [Zeltins, Andris] Saiba GmbH, Alte Tosstalstr, Ramismuhle, Switzerland; [Fischer, Nina; Rostaher, Ana; Favrot, Claude] Univ Zurich, Vetsuisse Fac, Dermatol Unit, Wonterthurerstr, Zurich, Switzerland	University of Bern; University Hospital of Bern; University of Oxford; Jenner Institute; Latvian Biomedical Research & Study Centre; University of Zurich	Bachmann, MF (corresponding author), Univ Bern, Inselspital, RIA Immunol, Bern, Switzerland.; Bachmann, MF (corresponding author), Univ Oxford, Nuffield Dept Med, Jenner Inst, Oxford, England.	martin.bachmann@me.com	Balke, Ina/AAG-6618-2020; Zeltins, Andris/AAI-1017-2021	Rostaher, Ana/0000-0002-1940-0341; Fischer, Nina/0000-0002-0142-226X; Balke, Ina/0000-0002-5171-7744	Swiss National Science Foundation (SNF) [CRSII3_154490]; Benchmark Ltd.	Swiss National Science Foundation (SNF)(Swiss National Science Foundation (SNSF)); Benchmark Ltd.	This project was supported by funding of the Swiss National Science Foundation (SNF; grant no. CRSII3_154490) and Benchmark Ltd.	Bachmann MF, 2010, NAT REV IMMUNOL, V10, P787, DOI 10.1038/nri2868; Cavelti-Weder C, 2016, MOL THER, V24, P1003, DOI 10.1038/mt.2015.227; Cosgrove SB, 2013, VET DERMATOL, V24, P587, DOI 10.1111/vde.12088; Furue M, 2018, ALLERGY, V73, P29, DOI 10.1111/all.13239; Hillier A, 2001, VET IMMUNOL IMMUNOP, V81, P147, DOI 10.1016/S0165-2427(01)00296-3; Zeltins A, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0030-8	6	20	24	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2018	142	1					279	281		10.1016/j.jaci.2017.12.994	http://dx.doi.org/10.1016/j.jaci.2017.12.994			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GM1OC	29627081	Bronze			2022-12-18	WOS:000437837500030
J	Liu, XY; Yang, KY; Wang, MQ; Kwok, JSL; Zeng, X; Yang, ZY; Xiao, XJ; Lau, CPY; Li, Y; Huang, ZM; Ba, JG; Yim, AKY; Ouyang, CY; Ngai, SM; Chan, TF; Leung, ELH; Liu, L; Liu, ZG; Tsui, SKW				Liu, Xiao-Yu; Yang, Kevin Yi; Wang, Ming-Qiang; Kwok, Jamie Sui-Lam; Zeng, Xi; Yang, Zhiyuan; Xiao, Xiao-Jun; Lau, Carol Po-Ying; Li, Ying; Huang, Zhi-ming; Ba, Jin-ge; Yim, Aldrin Kay-Yuen; Ouyang, Chun-Yan; Ngai, Sai-Ming; Chan, Ting-Fung; Leung, Elaine Lai-Han; Liu, Liang; Liu, Zhi-Gang; Tsui, Stephen Kwok-Wing			High-quality assembly of Dermatophagoides pteronyssinus genome and transcriptome reveals a wide range of novel allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							HOUSE-DUST MITE; DER-P-II		[Liu, Xiao-Yu; Xiao, Xiao-Jun; Huang, Zhi-ming; Ba, Jin-ge; Ouyang, Chun-Yan; Liu, Zhi-Gang] Shenzhen Univ, Sch Med, State Key Lab Resp Dis Allergy, Shenzhen, Peoples R China; [Yang, Kevin Yi; Wang, Ming-Qiang; Kwok, Jamie Sui-Lam; Zeng, Xi; Yang, Zhiyuan; Lau, Carol Po-Ying; Tsui, Stephen Kwok-Wing] Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Hong Kong, Peoples R China; [Yang, Kevin Yi; Wang, Ming-Qiang; Kwok, Jamie Sui-Lam; Zeng, Xi; Yang, Zhiyuan; Tsui, Stephen Kwok-Wing] Chinese Univ Hong Kong, Hong Kong Bioinformat Ctr, Hong Kong, Hong Kong, Peoples R China; [Li, Ying; Leung, Elaine Lai-Han; Liu, Liang] Macau Univ Sci & Technol, Macau Inst Appl Res Med & Hlth, State Key Lab Qual Res Chinese Med, Macau, Peoples R China; [Yim, Aldrin Kay-Yuen; Ngai, Sai-Ming; Chan, Ting-Fung] Chinese Univ Hong Kong, Sch Life Sci, Hong Kong, Hong Kong, Peoples R China; [Tsui, Stephen Kwok-Wing] Chinese Univ Hong Kong, Fac Med, Ctr Microbial Genom & Prote, Hong Kong, Hong Kong, Peoples R China	Shenzhen University; State Key Laboratory of Respiratory Disease; Chinese University of Hong Kong; Chinese University of Hong Kong; Macau University of Science & Technology; Chinese University of Hong Kong; Chinese University of Hong Kong	Liu, ZG (corresponding author), Shenzhen Univ, Sch Med, State Key Lab Resp Dis Allergy, Shenzhen, Peoples R China.	lzg@szu.edu.cn; kwtsui@cuhk.edu.hk	Chan, TingFung/A-6161-2013; Lau, Carol PY/G-2577-2017; Li, Ying/L-7292-2019; Yang, Kevin/AAA-2623-2021; Tsui, Stephen Kwok-Wing/E-4385-2015	Chan, TingFung/0000-0002-0489-3884; Lau, Carol PY/0000-0002-9240-092X; Yang, Kevin/0000-0002-4200-745X; Tsui, Stephen Kwok-Wing/0000-0003-0686-4259				Bordas-Le Floch V, 2017, PLOS ONE, V12; Chan TF, 2015, J ALLERGY CLIN IMMUN, V135, P539, DOI 10.1016/j.jaci.2014.09.031; Davis MD, 2005, J BIOL CHEM, V280, P9833, DOI 10.1074/jbc.M412356200; Fujimura T, 2017, ALLERGY, V72, P1728, DOI 10.1111/all.13192; HEYMANN PW, 1989, J ALLERGY CLIN IMMUN, V83, P1055, DOI 10.1016/0091-6749(89)90447-8; Huss K, 2001, J ALLERGY CLIN IMMUN, V107, P48, DOI 10.1067/mai.2001.111146; Kelley DR, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-3-r28; Koren S, 2017, GENOME RES, V27, P722, DOI 10.1101/gr.215087.116; Mayol K, 2011, BLOOD, V118, P4863, DOI 10.1182/blood-2011-06-362574; MEYER CH, 1994, CLIN EXP ALLERGY, V24, P1041, DOI 10.1111/j.1365-2222.1994.tb02741.x; Pereira JP, 2009, NAT IMMUNOL, V10, P403, DOI 10.1038/ni.1710; Simao FA, 2015, BIOINFORMATICS, V31, P3210, DOI 10.1093/bioinformatics/btv351	12	20	21	1	23	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2018	141	6					2268	2271		10.1016/j.jaci.2017.11.038	http://dx.doi.org/10.1016/j.jaci.2017.11.038			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GI7SD	29305317	hybrid			2022-12-18	WOS:000434701600031
J	Souwer, Y; Kormelink, TG; Taanman-Kueter, EW; Muller, FJ; van Capel, TMM; Varga, DV; Bar-Ephraim, YE; Teunissen, MBM; van Ham, SM; Kuijpers, TW; Wouters, D; Meyaard, L; de Jong, EC				Souwer, Yuri; Kormelink, Tom Groot; Taanman-Kueter, Esther W.; Muller, Femke J.; van Capel, Toni M. M.; Varga, Domonkos V.; Bar-Ephraim, Yotam E.; Teunissen, Marcel B. M.; van Ham, S. Marieke; Kuijpers, Taco W.; Wouters, Diana; Meyaard, Linde; de Jong, Esther C.			Human T(H)17 cell development requires processing of dendritic cell-derived CXCL8 by neutrophil elastase	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									[Souwer, Yuri; Muller, Femke J.; Varga, Domonkos V.; Bar-Ephraim, Yotam E.] Univ Amsterdam, Dept Cell Biol & Histol, Acad Med Ctr, Amsterdam, Netherlands; [Kormelink, Tom Groot; Taanman-Kueter, Esther W.; van Capel, Toni M. M.; de Jong, Esther C.] Univ Amsterdam, Dept Expt Immunol, Acad Med Ctr, Amsterdam, Netherlands; [Teunissen, Marcel B. M.] Univ Amsterdam, Dept Dermatol, Acad Med Ctr, Amsterdam, Netherlands; [van Ham, S. Marieke; Wouters, Diana] Univ Amsterdam, Acad Med Ctr, Dept Immunopathol, Sanquin Blood Supply & Landsteiner Lab, Amsterdam, Netherlands; [Kuijpers, Taco W.] Univ Amsterdam, Acad Med Ctr, Emma Childrens Hosp, Amsterdam, Netherlands; [Kuijpers, Taco W.] Univ Amsterdam, Acad Med Ctr, Dept Blood Cell Res, Sanquin Blood Supply & Landsteiner Lab, Amsterdam, Netherlands; [Meyaard, Linde] Univ Med Ctr Utrecht, Dept Immunol, Lab Translat Immunol, Utrecht, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Utrecht University; Utrecht University Medical Center	de Jong, EC (corresponding author), Univ Amsterdam, Dept Expt Immunol, Acad Med Ctr, Amsterdam, Netherlands.	e.c.dejong@amc.nl	Teunissen, Marcel BM/D-6512-2012	Meyaard, Linde/0000-0003-0707-4793	Landsteiner Foundation for Blood Research (LSBR) [0816]; Dutch Technology Foundation STW [10725]; Netherlands Organization for Scientific Research (NWO) Vici [91815608]	Landsteiner Foundation for Blood Research (LSBR); Dutch Technology Foundation STW(Technologiestichting STW); Netherlands Organization for Scientific Research (NWO) Vici(Netherlands Organization for Scientific Research (NWO))	This work was supported by grants from the Landsteiner Foundation for Blood Research (LSBR, grant no. 0816), the Dutch Technology Foundation STW (grant no. 10725), and Netherlands Organization for Scientific Research (NWO) Vici (grant no. 91815608).	Bardoel BW, 2014, CELL HOST MICROBE, V15, P526, DOI 10.1016/j.chom.2014.04.011; Breedveld A, 2017, J LEUKOCYTE BIOL, V102, P1003, DOI 10.1189/jlb.4MR0217-048RR; Croteau-Chonka DC, 2017, AM J RESP CRIT CARE, V195, P179, DOI 10.1164/rccm.201601-0107OC; Kamenyeva O, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004827; Li Y, 2010, GENET EPIDEMIOL, V34, P816, DOI 10.1002/gepi.20533; Millstein J, 2016, BIOINFORMATICS, V32, P2364, DOI 10.1093/bioinformatics/btw135; Morohoshi Y, 2006, J GASTROENTEROL, V41, P318, DOI 10.1007/s00535-005-1768-8; PADRINES M, 1994, FEBS LETT, V352, P231, DOI 10.1016/0014-5793(94)00952-X; Puel A, 2011, SCIENCE, V332, P65, DOI 10.1126/science.1200439; Torgerson DG, 2011, NAT GENET, V43, P887, DOI 10.1038/ng.888; Van Avondt K, 2016, J IMMUNOL, V196, P3686, DOI 10.4049/jimmunol.1501650; van Beelen AJ, 2007, IMMUNITY, V27, P660, DOI 10.1016/j.immuni.2007.08.013; Weaver CT, 2013, ANNU REV PATHOL-MECH, V8, P477, DOI 10.1146/annurev-pathol-011110-130318	13	20	20	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2018	141	6					2286	2289		10.1016/j.jaci.2018.01.003	http://dx.doi.org/10.1016/j.jaci.2018.01.003			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GI7SD	29391256	Bronze			2022-12-18	WOS:000434701600037
J	De Vita, V; McGonagle, D				De Vita, Valerio; McGonagle, Dennis			Hidradenitis suppurativa as an autoinflammatory keratinization disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ACNE		[De Vita, Valerio] Univ Naples Federico II, Dermatol Unit, Naples, Italy; [McGonagle, Dennis] Univ Leeds, Leeds Inst Mol Med, Sect Musculoskeletal Dis, Leeds, W Yorkshire, England; [McGonagle, Dennis] Leeds Teaching Hosp, NIHR Leeds Musculoskeletal Biomed Res Unit, Leeds, W Yorkshire, England	University of Naples Federico II; University of Leeds; Leeds Biomedical Research Centre; University of Leeds	De Vita, V (corresponding author), Univ Naples Federico II, Dermatol Unit, Naples, Italy.	valeriodevita@yahoo.it						Akiyama M, 2017, J ALLERGY CLIN IMMUN, V140, P1545, DOI 10.1016/j.jaci.2017.05.019; Johnston A, 2017, J ALLERGY CLIN IMMUN, V140, P109, DOI 10.1016/j.jaci.2016.08.056; Kelly G, 2015, BRIT J DERMATOL, V173, P1431, DOI 10.1111/bjd.14075; Thomi R, 2017, J EUR ACAD DERMATOL, V31, P2091, DOI 10.1111/jdv.14389; Vinkel C, 2017, INT J DERMATOL, V56, P811, DOI 10.1111/ijd.13603; von Laffert M, 2011, BRIT J DERMATOL, V164, P367, DOI 10.1111/j.1365-2133.2010.10034.x; von Laffert M, 2010, EXP DERMATOL, V19, P533, DOI 10.1111/j.1600-0625.2009.00915.x	7	20	20	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2018	141	5					1953	1953		10.1016/j.jaci.2018.01.010	http://dx.doi.org/10.1016/j.jaci.2018.01.010			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GF7KX	29501350	Bronze			2022-12-18	WOS:000432148200057
J	Shen, XF; Pasha, MA; Hidde, K; Khan, A; Liang, MW; Guan, WX; Ding, YT; Haczku, A; Yang, Q				Shen, Xiaofei; Pasha, Muhammad Asghar; Hidde, Kelsi; Khan, Adil; Liang, Mingwei; Guan, Wenxian; Ding, Yitao; Haczku, Angela; Yang, Qi			Group 2 innate lymphoid cells promote airway hyperresponsiveness through production of VEGFA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							INFLAMMATION		[Shen, Xiaofei; Guan, Wenxian; Ding, Yitao] Nanjing Univ, Sch Med, Dept Gen Surg, Nanjing Drum Tower Hosp,Affiliated Hosp, Nanjing, Jiangsu, Peoples R China; [Shen, Xiaofei; Hidde, Kelsi; Khan, Adil; Liang, Mingwei; Yang, Qi] Albany Med Coll, Dept Immunol & Microbial Dis, Albany, NY 12208 USA; [Pasha, Muhammad Asghar] Albany Med Coll, Div Allergy Immunol, Dept Med, Albany, NY 12208 USA; [Haczku, Angela] Univ Calif Davis, Pulm Crit Care & Sleep Div, Davis, CA 95616 USA	Nanjing University; Albany Medical College; Albany Medical College; University of California System; University of California Davis	Haczku, A (corresponding author), Univ Calif Davis, Pulm Crit Care & Sleep Div, Davis, CA 95616 USA.	haczku@ucdavis.edu; yangq@mail.amc.edu	Shen, Xiaofei/HDL-7300-2022; Haczku, Angela/A-8486-2013	Shen, Xiaofei/0000-0002-5816-1814; Haczku, Angela/0000-0002-1301-4941	US National Institutes of Health [R01AG057782, K22AI116728, R21AI116121]; Albany Medical College; University of California-Davis Pulmonary, Critical Care, and Sleep Division; National Key Clinical Specialist Construction Program of China [2012-649]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI105046, R21AI116121, K22AI116728] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG057782] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Albany Medical College; University of California-Davis Pulmonary, Critical Care, and Sleep Division; National Key Clinical Specialist Construction Program of China; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This study was supported by the US National Institutes of Health (grant nos. R01AG057782, K22AI116728, R21AI116121), the Albany Medical College (start-up funds to Q.Y.), and the University of California-Davis Pulmonary, Critical Care, and Sleep Division (start-up funds to A.H.), and the National Key Clinical Specialist Construction Program of China (grant no. 2012-649).	Artis D, 2015, NATURE, V517, P293, DOI 10.1038/nature14189; Detoraki A, 2009, J ALLERGY CLIN IMMUN, V123, P1142, DOI 10.1016/j.jaci.2009.01.044; Doherty TA, 2012, AM J PHYSIOL-LUNG C, V303, pL577, DOI 10.1152/ajplung.00174.2012; Kouzaki H, 2011, J IMMUNOL, V186, P4375, DOI 10.4049/jimmunol.1003020; Lee CG, 2004, NAT MED, V10, P1095, DOI 10.1038/nm1105; Nakano T, 2013, J ALLERGY CLIN IMMUN, V132, P1224, DOI 10.1016/j.jaci.2013.06.041; National Asthma Education and Prevention Program, 2007, HYPERLIPIDAEMIA; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Snelgrove RJ, 2014, J ALLERGY CLIN IMMUN, V134, P583, DOI 10.1016/j.jaci.2014.02.002; Yang Q, 2016, J ALLERGY CLIN IMMUN, V137, P571, DOI 10.1016/j.jaci.2015.06.037; Yang Q, 2015, NAT IMMUNOL, V16, P1044, DOI 10.1038/ni.3248; Yang Q, 2013, IMMUNITY, V38, P694, DOI 10.1016/j.immuni.2012.12.003; Yang Q, 2011, J IMMUNOL, V187, P5505, DOI 10.4049/jimmunol.1102039; Zhang KN, 2017, J IMMUNOL, V198, P1798, DOI 10.4049/jimmunol.1601421	14	20	21	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2018	141	5					1929	+		10.1016/j.jaci.2018.01.005	http://dx.doi.org/10.1016/j.jaci.2018.01.005			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GF7KX	29382598	Green Accepted, Bronze, Green Submitted			2022-12-18	WOS:000432148200049
J	Venkateshaiah, SU; Zhu, X; Rajavelu, P; Niranjan, R; Manohar, M; Verma, AK; Lasky, JA; Mishra, A				Venkateshaiah, Sathisha Upparahalli; Zhu, Xiang; Rajavelu, Priya; Niranjan, Rituraj; Manohar, Murli; Verma, Alok K.; Lasky, Joseph A.; Mishra, Anil			Regulatory effects of IL-15 on allergen-induced airway obstruction	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergen; asthma; airway hyperresponsiveness; methacholine; IL-10; IL-15	EOSINOPHILIC ESOPHAGITIS; ASTHMATIC REACTION; T-CELLS; INFLAMMATION; LUNG; HYPERRESPONSIVENESS; EXPRESSION; CYTOKINE; HYPERREACTIVITY; INTERLEUKIN-13	Background: Airway obstruction is a physiologic feature of asthma, and IL-15 might have an important role in asthma pathogenesis. Objective: We tested the hypothesis that regulation of IL-15 is critical for preservation of allergen-induced airway hyperresponsiveness (AHR), airway resistance, and compliance in response to methacholine. Methods: Airway inflammation, AHR, resistance, and compliance were assessed in Il15 gene-deficient mice and IL-15-overexpressing mice in an allergen-induced murine model of asthma. We assessed eosinophil numbers by using anti-major basic protein immunostaining, goblet cell hyperplasia by using periodic acid-Schiff staining, and cytokine and chemokine levels by performing quantitative PCR and ELISA. Results: We made a novel observation that IL-15 deficiency promotes baseline airway resistance in naive mice. Moreover, rIL-15 delivery to the lung downregulates expression of proinflammatory cytokines and improves allergen-induced AHR, airway resistance, and compliance. These observations were further validated in doxycycline-inducible CC10-IL-15 bitransgenic mice. Doxycycline-exposed, Aspergillus species extract-challenged CC10-IL-15 bitransgenic mice exhibited significantly reduced levels of proinflammatory cytokines (IL-4, IL-5, and IL-13) and decreased goblet cell hyperplasia. Airway obstruction, including AHR and airway resistance, was diminished in allergen-challenged doxycycline-exposed compared with non-doxycycline-exposed CC10-IL-15 bitransgenic mice. Mechanistically, we observed that IL-15-mediated protection of airway obstruction is associated with induced IFN-gamma- and IL-10-producing regulatory CD4(+) CD25(+) forkhead box p3 (Foxp3)(+) T cells. Additionally, we found that a human IL-15 agonist (ALT-803) improved airway resistance and compliance in an experimental asthma model. Conclusion: We report our novel finding that IL-15 has a potent inhibitory effect on the airway obstruction that occurs in response to environmental allergens.	[Venkateshaiah, Sathisha Upparahalli; Manohar, Murli; Verma, Alok K.; Lasky, Joseph A.; Mishra, Anil] Tulane Univ, Sch Med, Dept Med, TEDC,Sect Pulm Dis, New Orleans, LA 70112 USA; [Zhu, Xiang; Rajavelu, Priya; Niranjan, Rituraj] Cincinnati Childrens Hosp Med Ctr, Sect Allergy & Immunol, Cincinnati, OH 45229 USA	Tulane University; Cincinnati Children's Hospital Medical Center	Mishra, A (corresponding author), Tulane Univ, Sch Med, TEDC, 1430 Tulane Ave,SL-9, New Orleans, LA 70112 USA.; Mishra, A (corresponding author), Tulane Univ, Sch Med, Sect Pulm Dis, 1430 Tulane Ave,SL-9, New Orleans, LA 70112 USA.	amishra@tulane.edu	Manohar, Murli/R-8619-2018; Verma, Alok K/AAD-6514-2019	VERMA, ALOK/0000-0001-9301-9162	National Institutes of Health [R01 AI080581]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI080581] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK067255] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported in part by National Institutes of Health grant R01 AI080581 (to A.M.).	Agrawal DK, 2010, CURR ALLERGY ASTHM R, V10, P39, DOI 10.1007/s11882-009-0081-7; Ahmad T, 2011, INT IMMUNOPHARMACOL, V11, P74, DOI 10.1016/j.intimp.2010.10.008; Akuthota P, 2011, J INNATE IMMUN, V3, P113, DOI 10.1159/000323433; Al Heialy S, 2011, RESPIROLOGY, V16, P589, DOI 10.1111/j.1440-1843.2011.01974.x; Al-Muhsen S, 2011, J ALLERGY CLIN IMMUN, V128, P451, DOI 10.1016/j.jaci.2011.04.047; Araujo LM, 2004, EUR J IMMUNOL, V34, P327, DOI 10.1002/eji.200324151; Barnes PJ, 2008, NAT REV IMMUNOL, V8, P183, DOI 10.1038/nri2254; Barnes PJ, 2003, ANN INTERN MED, V139, P359, DOI 10.7326/0003-4819-139-5_Part_1-200309020-00012; Bierbaum S, 2006, ALLERGY, V61, P576, DOI 10.1111/j.1398-9995.2006.01059.x; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; Brusasco V, 1985, J APPL PHYSIOL, V1990, P2209; Cohn L, 1998, J IMMUNOL, V161, P3813; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; Dubois S, 2006, P NATL ACAD SCI USA, V103, P12075, DOI 10.1073/pnas.0605212103; DURHAM SR, 1988, J ALLERGY CLIN IMMUN, V82, P764, DOI 10.1016/0091-6749(88)90077-2; Fulkerson PC, 2006, P NATL ACAD SCI USA, V103, P16418, DOI 10.1073/pnas.0607863103; Fulkerson PC, 2006, AM J RESP CELL MOL, V35, P337, DOI 10.1165/rcmb.2005-0474OC; Glaab T, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-63; Hadeiba H, 2003, J IMMUNOL, V170, P5502, DOI 10.4049/jimmunol.170.11.5502; Hogan SP, 1998, IMMUNOL CELL BIOL, V76, P454, DOI 10.1046/j.1440-1711.1998.00766.x; Hogan SP, 2001, NAT IMMUNOL, V2, P353, DOI 10.1038/86365; HOGG JC, 1968, NEW ENGL J MED, V278, P1355, DOI 10.1056/NEJM196806202782501; Hogg JC, 2004, NEW ENGL J MED, V350, P2645, DOI 10.1056/NEJMoa032158; HOLGATE S, 1993, THORAX, V48, P103, DOI 10.1136/thx.48.2.103; Hoymann HG, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00156; HUANG SK, 1995, J IMMUNOL, V155, P2688; Humbert M, 1997, J ALLERGY CLIN IMMUN, V99, P657, DOI 10.1016/S0091-6749(97)70028-9; Karagiannis SN, 2003, EUR J IMMUNOL, V33, P1030, DOI 10.1002/eji.200323185; Kearley J, 2005, J EXP MED, V202, P1539, DOI 10.1084/jem.20051166; Kennedy MK, 1996, J CLIN IMMUNOL, V16, P134, DOI 10.1007/BF01540911; Komai-Koma M, 2001, CLIN EXP ALLERGY, V31, P1441, DOI 10.1046/j.1365-2222.2001.01174.x; LAM S, 1987, J ALLERGY CLIN IMMUN, V80, P44, DOI 10.1016/S0091-6749(87)80189-6; Laza-Stanca V, 2011, PLOS PATHOG, V8, P1; Lodolce JP, 1998, IMMUNITY, V9, P669, DOI 10.1016/S1074-7613(00)80664-0; Mattes J, 2001, J IMMUNOL, V167, P1683, DOI 10.4049/jimmunol.167.3.1683; Mishra A, 2001, J CLIN INVEST, V107, P83, DOI 10.1172/JCI10224; Mishra A, 2007, AM J PHYSIOL-LUNG C, V293, pL305, DOI 10.1152/ajplung.00147.2007; Morosco G, 2007, J ALLERGY CLIN IMMUN, V120, pS93, DOI 10.1016/j.jaci.2007.09.043; Morris JC, 2006, P NATL ACAD SCI USA, V103, P401, DOI 10.1073/pnas.0509575103; Murray CJL, 2012, LANCET, V380, P2197, DOI 10.1016/S0140-6736(12)61689-4; Niranjan R, 2013, IMMUNOL CELL BIOL, V91, P408, DOI 10.1038/icb.2013.21; O'Byrne PM, 2003, CHEST, V123, p411S, DOI 10.1378/chest.123.3_suppl.411S; Pope SM, 2005, J BIOL CHEM, V280, P13952, DOI 10.1074/jbc.M406037200; Postma DS, 1998, AM J RESP CRIT CARE, V158, pS187, DOI 10.1164/ajrccm.158.supplement_2.13tac170; Rayapudi M, 2010, J LEUKOCYTE BIOL, V88, P337, DOI 10.1189/jlb.0110025; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROSSI GA, 1991, AM REV RESPIR DIS, V144, P379, DOI 10.1164/ajrccm/144.2.379; Rothenberg ME, 2011, J IMMUNOL, V187, P4873, DOI 10.4049/jimmunol.1004159; Shim JJ, 2001, AM J PHYSIOL-LUNG C, V280, pL134, DOI 10.1152/ajplung.2001.280.1.L134; SKLOOT G, 1995, J CLIN INVEST, V96, P2393, DOI 10.1172/JCI118296; Tepper RS, 2012, J ALLERGY CLIN IMMUN, V129, pS65, DOI 10.1016/j.jaci.2011.12.986; To T, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-204; Tournoy KG, 2000, CLIN EXP ALLERGY, V30, P775; Umetsu DT, 2006, CURR OPIN IMMUNOL, V18, P727, DOI 10.1016/j.coi.2006.09.007; van Scott MR, 2000, AM J PHYSIOL-LUNG C, V278, pL667, DOI 10.1152/ajplung.2000.278.4.L667; Waldmann TA, 1999, ANNU REV IMMUNOL, V17, P19, DOI 10.1146/annurev.immunol.17.1.19; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Xia JX, 2010, CLIN IMMUNOL, V134, P130, DOI 10.1016/j.clim.2009.09.011; Xu WX, 2013, CANCER RES, V73, P3075, DOI 10.1158/0008-5472.CAN-12-2357; YANAI M, 1992, J APPL PHYSIOL, V72, P1016, DOI 10.1152/jappl.1992.72.3.1016; Yang M, 2003, J ALLERGY CLIN IMMUN, V112, P935, DOI 10.1016/j.jaci.2003.08.010; Zhu X, 2010, GASTROENTEROLOGY, V139, P182, DOI 10.1053/j.gastro.2010.03.057; Zuo L, 2010, J IMMUNOL, V185, P660, DOI 10.4049/jimmunol.1000471	64	20	20	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2018	141	3					906	+		10.1016/j.jaci.2017.05.025	http://dx.doi.org/10.1016/j.jaci.2017.05.025			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FY6PR	28606589	Green Accepted, Bronze			2022-12-18	WOS:000426974800011
J	Rastogi, D; Nico, J; Johnston, AD; Tobias, TAM; Jorge, Y; Macian, F; Greally, JM				Rastogi, Deepa; Nico, John; Johnston, Andrew D.; Tobias, Toni Adrianne M.; Jorge, Yurydia; Macian, Fernando; Greally, John M.			CDC42-related genes are upregulated in helper T cells from obese asthmatic children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; obesity; helper T cell transcriptome; children	PULMONARY-FUNCTION; ACTIVATION; CDC42; INFLAMMATION; ADOLESCENTS; NEUTROPHILS; PREVALENCE; RECEPTORS; PHENOTYPE; SEVERITY	Background: Pediatric obesity-related asthma is more severe and less responsive to medications than asthma in normal-weight children. Obese asthmatic children have nonatopic T-H(1)-polarized systemic inflammation that correlates with pulmonary function deficits, but the pathways underlying T-H(1)-polarized inflammation are not well understood. Objective: We compared the CD4(+) T-cell transcriptome in obese children with asthma with that in normal-weight children with asthma to identify key differentially expressed genes associated with T-H(1)-polarized inflammation. Methods: CD4(+) T-cell transcriptome-wide differential gene expression was compared between 21 obese and 21 normal-weight children by using directional RNA sequencing. High-confidence differentially expressed genes were verified in the first cohort and validated in a second cohort of 20 children (10 obese and 10 normal-weight children) by using quantitative RT-PCR. Results: Transcriptome-wide differential gene expression among obese asthmatic children was enriched for genes, including VAV2, DOCK5, PAK3, PLD1, CDC42EP4, and CDC42PBB, which are associated with CDC42, a small guanosine triphosphate protein linked to T-cell activation. Upregulation of MLK3 and PLD1, genes downstream of CDC42 in the mitogen-activated protein kinase and mammalian target of rapamycin pathways and the inverse correlation of CDC42EP4 and DOCK5 transcript counts with FEV1/FVC ratio together support a role of CDC42 in the T-H(1) polarization and pulmonary function deficits found in patients with obesity-related asthma. Conclusions: Our study identifies the CDC42 pathway as a novel target that is upregulated in T-H cells of obese asthmatic children, suggesting its role in nonatopic T-H(1)-polarized systemic inflammation and pulmonary function deficits found in patients with pediatric obesity-related asthma.	[Rastogi, Deepa; Nico, John; Tobias, Toni Adrianne M.; Jorge, Yurydia] Albert Einstein Coll Med, Dept Pediat, Bronx, NY 10467 USA; [Johnston, Andrew D.; Greally, John M.] Albert Einstein Coll Med, Dept Genet, Bronx, NY 10467 USA; [Macian, Fernando] Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10467 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Rastogi, D (corresponding author), Childrens Hosp Montefiore, Albert Einstein Coll Med, 3415 Bainbridge Ave, Bronx, NY 10467 USA.	drastogi@montefiore.org	Greally, John/AAF-9540-2019	Greally, John/0000-0001-6069-7960; Macian, Fernando/0000-0003-2666-035X; Rastogi, Deepa/0000-0001-5714-9250; Johnston, Andrew/0000-0002-5769-3106	Feldstein Medical Foundation; National Institutes of Health/National Center for Research Resources CTSA grant from the National Center for Advancing Translational Sciences (NCATS), a component of the NIH [1 UL1 TR001073-01, 1 TL1 TR001072-01, 1 KL2 TR001071-01];  [K23 HL118733]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR001071, UL1TR001073, TL1TR001072] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL118733] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK020541] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER	Feldstein Medical Foundation; National Institutes of Health/National Center for Research Resources CTSA grant from the National Center for Advancing Translational Sciences (NCATS), a component of the NIH; ; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Supported in part by K23 HL118733 (to D.R.), the Feldstein Medical Foundation, National Institutes of Health/National Center for Research Resources CTSA grant 1 UL1 TR001073-01, 1 TL1 TR001072-01, and 1 KL2 TR001071-01 (Albert Einstein Institute of Clinical and Translational Research) from the National Center for Advancing Translational Sciences (NCATS), a component of the NIH. The views expressed in this article do not communicate an official position of the NIH/NCRR.	Abe K, 2000, J BIOL CHEM, V275, P10141, DOI 10.1074/jbc.275.14.10141; Akinbami LJ, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-2354; Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106; Arshi M, 2010, RESPIROLOGY, V15, P779, DOI 10.1111/j.1440-1843.2010.01767.x; Busse WW, 2011, NEW ENGL J MED, V364, P1005, DOI 10.1056/NEJMoa1009705; Chen YC, 2013, OBES REV, V14, P222, DOI 10.1111/j.1467-789X.2012.01055.x; Chen Y, 2009, PEDIATR PULM, V44, P216, DOI 10.1002/ppul.20854; Cottrell L, 2011, AM J RESP CRIT CARE, V183, P441, DOI 10.1164/rccm.201004-0603OC; Delgoffe GM, 2011, NAT IMMUNOL, V12, P295, DOI 10.1038/ni.2005; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Fang YM, 2003, CURR BIOL, V13, P2037, DOI 10.1016/j.cub.2003.11.021; Flicek P, 2014, NUCLEIC ACIDS RES, V42, pD749, DOI 10.1093/nar/gkt1196; Georas SN, 2005, EUR RESPIR J, V26, P1119, DOI 10.1183/09031936.05.00006005; Guilbert TW, 2014, J ALLER CL IMM-PRACT, V2, P664, DOI 10.1016/j.jaip.2014.09.010; Henage LG, 2006, J BIOL CHEM, V281, P3408, DOI 10.1074/jbc.M508800200; Holt PG, 2011, CHEST, V139, P1165, DOI 10.1378/chest.10-2397; Kaga S, 1998, J IMMUNOL, V160, P4182; Kyriakis JM, 2012, PHYSIOL REV, V92, P689, DOI 10.1152/physrev.00028.2011; Lang JE, 2012, J ASTHMA, V49, P456, DOI 10.3109/02770903.2012.677895; Lee SML, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107567; Liu BP, 2000, MOL CELL BIOL, V20, P7160, DOI 10.1128/MCB.20.19.7160-7169.2000; Macintyre AN, 2014, CELL METAB, V20, P61, DOI 10.1016/j.cmet.2014.05.004; McGarry ME, 2015, CHEST, V147, P1591, DOI 10.1378/chest.14-2689; Namekata K, 2014, PROG RETIN EYE RES, V43, P1, DOI 10.1016/j.preteyeres.2014.06.005; Ogawa K, 2014, J EXP MED, V211, P1401, DOI 10.1084/jem.20131926; Ogden CL, 2012, JAMA-J AM MED ASSOC, V307, P483, DOI 10.1001/jama.2012.40; Pernis AB, 2009, AUTOIMMUN REV, V8, P199, DOI 10.1016/j.autrev.2008.07.044; Peters MC, 2016, LANCET RESP MED, V4, P574, DOI 10.1016/S2213-2600(16)30048-0; Podnar J., 2014, CURR PROTOC MOL BIOL, V106, P1; Quinn EM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140049; Ramos-Barbon D, 2010, AM J RESP CRIT CARE, V182, P317, DOI 10.1164/rccm.200905-0745OC; Rastogi D, 2015, AM J RESP CRIT CARE, V191, P149, DOI 10.1164/rccm.201409-1587OC; Rastogi D, 2012, CHEST, V141, P895, DOI 10.1378/chest.11-0930; Salazar-Fontana LI, 2003, J IMMUNOL, V171, P2225, DOI 10.4049/jimmunol.171.5.2225; Salo PM, 2014, J ALLERGY CLIN IMMUN, V134, P350, DOI 10.1016/j.jaci.2013.12.1071; Scott HA, 2016, ALLERGY, V71, P1037, DOI 10.1111/all.12891; Stentz FB, 2005, BIOCHEM BIOPH RES CO, V335, P491, DOI 10.1016/j.bbrc.2005.07.109; Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003; Tskvitaria-Fuller I, 2006, J IMMUNOL, V177, P1708, DOI 10.4049/jimmunol.177.3.1708; Usui I, 2003, J BIOL CHEM, V278, P13765, DOI 10.1074/jbc.M208904200; Vicente-Manzanares M, 2004, NAT REV IMMUNOL, V4, P110, DOI 10.1038/nri1268; Wang RN, 2011, IMMUNITY, V35, P871, DOI 10.1016/j.immuni.2011.09.021; Watanabe M, 2014, J IMMUNOL, V193, P5660, DOI 10.4049/jimmunol.1400885; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Zhong B, 2003, BLOOD, V101, P3240, DOI 10.1182/blood-2001-12-0180	45	20	20	4	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2018	141	2					539	+		10.1016/j.jaci.2017.04.016	http://dx.doi.org/10.1016/j.jaci.2017.04.016			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FV2PQ	28479334	Green Accepted, Bronze			2022-12-18	WOS:000424410800011
J	Mahlaoui, N; Jais, JP; Brosselin, P; Mignot, C; Beaurain, B; Brito, C; Costes, L; Courteille, V; De Vergnes, N; Alcais, A; Fischer, A				Mahlaoui, Nizar; Jais, Jean-Philippe; Brosselin, Pauline; Mignot, Cecile; Beaurain, Beatrice; Brito, Carolina; Costes, Laurence; Courteille, Virginie; De Vergnes, Nathalie; Alcais, Alexandre; Fischer, Alain		CEREDIH Prevalence Study	Prevalence of primary immunodeficiencies in France is underestimated	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							DISEASES		[Mahlaoui, Nizar; Jais, Jean-Philippe; Brosselin, Pauline; Mignot, Cecile; Beaurain, Beatrice; Brito, Carolina; Costes, Laurence; Courteille, Virginie; De Vergnes, Nathalie; Alcais, Alexandre; Fischer, Alain] Necker Enfants Malad Univ Hosp, AP HP, French Natl Reference Ctr Primary Immune Deficien, Paris, France; [Mahlaoui, Nizar; Fischer, Alain] Necker Enfants Malad Univ Hosp, AP HP, Pediat Immunohaematol & Rheumatol Unit, Paris, France; [Mahlaoui, Nizar; Jais, Jean-Philippe; Alcais, Alexandre; Fischer, Alain] Paris Descartes Univ, Sorbonne Paris Cite, Imagine Inst, Paris, France; [Mahlaoui, Nizar; Alcais, Alexandre] INSERM, UMR 1163, Lab Human Genet Infect Dis, Necker Branch, Paris, France; [Jais, Jean-Philippe] Paris Descartes Univ, INSERM, UMRS 1138, Team 22, Paris, France; [Jais, Jean-Philippe] Necker Enfants Malad Univ Hosp, Biostat Unit, Paris, France; [Fischer, Alain] INSERM, UMR 1163, Paris, France; [Fischer, Alain] Coll France, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; College de France	Fischer, A (corresponding author), Necker Enfants Malad Univ Hosp, AP HP, French Natl Reference Ctr Primary Immune Deficien, Paris, France.; Fischer, A (corresponding author), Necker Enfants Malad Univ Hosp, AP HP, Pediat Immunohaematol & Rheumatol Unit, Paris, France.; Fischer, A (corresponding author), Paris Descartes Univ, Sorbonne Paris Cite, Imagine Inst, Paris, France.; Fischer, A (corresponding author), INSERM, UMR 1163, Paris, France.; Fischer, A (corresponding author), Coll France, Paris, France.	alain.fischer@inserm.fr	MAHLAOUI, Nizar/AAH-6103-2020; Alcais, Alexandre/J-5882-2017; HACHULLA, ERIC/R-8488-2018	MAHLAOUI, Nizar/0000-0002-0030-8094; Alcais, Alexandre/0000-0002-1012-2226; HACHULLA, ERIC/0000-0001-7432-847X	French Association of Patients with Primary Immunodeficiencies (Immunodeficience primitive-Recherche-Information-Soutien; IRIS); French Ministry of Health; LFB; GSK; CSL Behring; Shire; Octapharma; Binding Site; Jeffrey Modell Foundation; patient association AT-Europe; patient association Trophee Guillaume	French Association of Patients with Primary Immunodeficiencies (Immunodeficience primitive-Recherche-Information-Soutien; IRIS); French Ministry of Health; LFB; GSK(GlaxoSmithKline); CSL Behring; Shire; Octapharma; Binding Site; Jeffrey Modell Foundation; patient association AT-Europe; patient association Trophee Guillaume	The CEREDIH received support from the French Association of Patients with Primary Immunodeficiencies (Immunodeficience primitive-Recherche-Information-Soutien; IRIS) and is funded by the French Ministry of Health. It additionally received unrestricted educational grants from LFB, GSK, CSL Behring, Shire, Octapharma, Binding Site, the Jeffrey Modell Foundation, and the patient associations AT-Europe and Trophee Guillaume.	Beaute J, 2010, CLIN IMMUNOL, V135, P264, DOI 10.1016/j.clim.2010.02.021; Kindle G, 2014, CURR OPIN ALLERGY CL, V14, P501, DOI 10.1097/ACI.0000000000000113; Picard C, 2015, J CLIN IMMUNOL, V35, P696, DOI 10.1007/s10875-015-0201-1; Rocchetti I, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-160	4	20	24	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2017	140	6					1731	+		10.1016/j.jaci.2017.06.020	http://dx.doi.org/10.1016/j.jaci.2017.06.020			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FO9KI	28732644				2022-12-18	WOS:000417206000037
J	Schoos, AMM; Chawes, BL; Melen, E; Bergstrom, A; Kull, I; Wickman, M; Bonnelykke, K; Bisgaard, H; Rasmussen, MA				Schoos, Ann-Marie M.; Chawes, Bo L.; Melen, Erik; Bergstrom, Anna; Kull, Inger; Wickman, Magnus; Bonnelykke, Klaus; Bisgaard, Hans; Rasmussen, Morten A.			Sensitization trajectories in childhood revealed by using a cluster analysis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Sensitization; patterns; asthma; rhinitis; eczema; specific IgE; children	1ST 6 YEARS; NONALLERGIC RHINITIS; ALLERGIC SENSITIZATION; ATOPIC-DERMATITIS; CROSS-REACTIVITY; YOUNG-CHILDREN; FOOD ALLERGENS; BIRTH COHORT; RISK-FACTORS; ASTHMA	Background: Assessment of sensitization at a single time point during childhood provides limited clinical information. We hypothesized that sensitization develops as specific patterns with respect to age at debut, development over time, and involved allergens and that such patterns might be more biologically and clinically relevant. Objective: We sought to explore latent patterns of sensitization during the first 6 years of life and investigate whether such patterns associate with the development of asthma, rhinitis, and eczema. Methods: We investigated 398 children from the at-risk Copenhagen Prospective Studies on Asthma in Childhood 2000 (COPSAC(2000)) birth cohort with specific IgE against 13 common food and inhalant allergens at the ages of 1/2, 1 1/2, 4, and 6 years. An unsupervised cluster analysis for 3-dimensional data (nonnegative sparse parallel factor analysis) was used to extract latent patterns explicitly characterizing temporal development of sensitization while clustering allergens and children. Subsequently, these patterns were investigated in relation to asthma, rhinitis, and eczema. Verification was sought in an independent unselected birth cohort (BAMSE) constituting 3051 children with specific IgE against the same allergens at 4 and 8 years of age. Results: The nonnegative sparse parallel factor analysis indicated a complex latent structure involving 7 age-and allergen-specific patterns in the COPSAC(2000) birth cohort data: (1) dog/cat/horse, (2) timothy grass/birch, (3) molds, (4) house dust mites, (5) peanut/wheat flour/mugwort, (6) peanut/soybean, and (7) egg/milk/wheat flour. Asthma was solely associated with pattern 1 (odds ratio [OR], 3.3; 95% CI, 1.5-7.2), rhinitis with patterns 1 to 4 and 6 (OR, 2.2-4.3), and eczema with patterns 1 to 3 and 5 to 7 (OR, 1.6-2.5). All 7 patterns were verified in the independent BAMSE cohort (R-2 > 0.89). Conclusion: This study suggests the presence of specific sensitization patterns in early childhood differentially associated with development of clinical outcomes. Using such patterns in future research might provide more robust and clinically relevant results.	[Schoos, Ann-Marie M.; Chawes, Bo L.; Bonnelykke, Klaus; Bisgaard, Hans; Rasmussen, Morten A.] Univ Copenhagen, COPSAC, Copenhagen Prospect Studies Asthma Childhood Herl, Copenhagen, Denmark; [Melen, Erik; Bergstrom, Anna; Wickman, Magnus] Karolinska Inst, Sodersjukhuset, Inst Environm Med, Stockholm, Sweden; [Kull, Inger] Karolinska Inst, Sodersjukhuset, Dept Clin Sci & Educ, Stockholm, Sweden; [Melen, Erik; Kull, Inger; Wickman, Magnus] Soder Sjukhuset, Sachs Childrens Hosp, Stockholm, Sweden; [Rasmussen, Morten A.] Univ Copenhagen, Dept Food Sci, Fac Sci, Copenhagen, Denmark	University of Copenhagen; Karolinska Institutet; Sodersjukhuset Hospital; Karolinska Institutet; Sodersjukhuset Hospital; Sodersjukhuset Hospital; University of Copenhagen	Bisgaard, H (corresponding author), Univ Copenhagen, Copenhagen Prospect Studies Asthma Childhood, Danish Pediat Asthma Ctr, Gentofte Hosp, Ledreborg Alle 34, DK-2820 Gentofte, Denmark.	bisgaard@copsac.com	Bisgaard, Hans/N-4761-2016; Schoos, Ann-Marie Malby/AAO-7677-2020; Rasmussen, Morten/AAE-9517-2020	Bisgaard, Hans/0000-0003-4131-7592; Schoos, Ann-Marie Malby/0000-0002-5827-0885; Rasmussen, Morten/0000-0001-7431-5206; Bonnelykke, Klaus/0000-0003-2003-1018; Chawes, Bo/0000-0001-6846-6243	Swedish Research Council; Swedish Heart-Lung Foundation; Stockholm County Council (ALF); Swedish Research Council Formas	Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Heart-Lung Foundation(Swedish Heart-Lung Foundation); Stockholm County Council (ALF)(Stockholm County Council); Swedish Research Council Formas(Swedish Research CouncilSwedish Research Council Formas)	Copenhagen Prospective Studies on Asthma in Childhood (COPSAC) is funded by private and public research funds all listed on www.copsac.com. The Lundbeck Foundation, Danish State Budget, Danish Council for Strategic Research, Danish Council for Independent Research, and Capital Region Research Foundation have provided core support for COPSAC. BAMSE is funded by the Swedish Research Council, Swedish Heart-Lung Foundation, Stockholm County Council (ALF), and Swedish Research Council Formas. The funding agencies did not have any role in design and conduct of the study; collection, management, and interpretation of the data; or preparation, review, or approval of the manuscript.	Allen G., 2012, INT C ARTIFICIAL INT; Ballardini N, 2006, ALLERGY, V61, P337, DOI 10.1111/j.1398-9995.2005.00936.x; Ballmer-Weber BK, 2008, CURR OPIN ALLERGY CL, V8, P270, DOI 10.1097/ACI.0b013e3282ffb157; Bisgaard H, 2004, ANN ALLERG ASTHMA IM, V93, P381, DOI 10.1016/S1081-1206(10)61398-1; Bisgaard H, 2006, NEW ENGL J MED, V354, P1998, DOI 10.1056/NEJMoa054692; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; BraunFahrlander C, 1997, PEDIATR ALLERGY IMMU, V8, P75, DOI 10.1111/j.1399-3038.1997.tb00147.x; Bro R, 1997, CHEMOMETR INTELL LAB, V38, P149, DOI 10.1016/S0169-7439(97)00032-4; Brockow I, 2009, J INVEST ALLERG CLIN, V19, P180; Carlsten C, 2013, ANN ALLERG ASTHMA IM, V110, P24, DOI 10.1016/j.anai.2012.10.005; Casquete-Roman E, 2012, ANN ALLERG ASTHMA IM, V109, P215, DOI 10.1016/j.anai.2012.07.003; Chawes BLK, 2009, ALLERGY, V64, P1547, DOI 10.1111/j.1398-9995.2009.02085.x; Chawes BLK, 2011, DAN MED BULL, V58; Chawes BLK, 2010, J ALLERGY CLIN IMMUN, V126, P567, DOI 10.1016/j.jaci.2010.06.026; Eggleston PA, 1998, J ALLERGY CLIN IMMUN, V102, P563, DOI 10.1016/S0091-6749(98)70272-6; Flohr C, 2014, J INVEST DERMATOL, V134, P345, DOI 10.1038/jid.2013.298; Henderson J, 2008, THORAX, V63, P974, DOI 10.1136/thx.2007.093187; Jimenez-Lopez JC, 2012, MOL BIOL REP, V39, P123, DOI 10.1007/s11033-011-0717-2; Kull I, 2010, J ALLERGY CLIN IMMUN, V125, P1013, DOI 10.1016/j.jaci.2010.01.051; Lazic N, 2013, ALLERGY, V68, P764, DOI 10.1111/all.12134; Lowe AJ, 2007, CLIN EXP ALLERGY, V37, P536, DOI 10.1111/j.1365-2222.2007.02691.x; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Mittag D, 2004, J ALLERGY CLIN IMMUN, V114, P1410, DOI 10.1016/j.jaci.2004.09.014; Papalexakis EE, 2013, IEEE T SIGNAL PROCES, V61, P493, DOI 10.1109/TSP.2012.2225052; Schmitz R, 2013, INT ARCH ALLERGY IMM, V162, P263, DOI 10.1159/000353344; Schoos A-M Malby, 2016, J ALLERGY CLIN IMMUN, V137, pe4; Schoos AMM, 2016, J ALLERGY CLIN IMMUN, V137, P844, DOI 10.1016/j.jaci.2015.10.004; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; Simpson A, 2010, AM J RESP CRIT CARE, V181, P1200, DOI 10.1164/rccm.200907-1101OC; Stoltz DJ, 2013, CLIN EXP ALLERGY, V43, P233, DOI 10.1111/cea.12050; Tillander H, 2014, J ALLERGY CLIN IMMUN, V133, P580, DOI 10.1016/j.jaci.2013.09.009; Verdino P, 2008, J IMMUNOL, V180, P2313, DOI 10.4049/jimmunol.180.4.2313	32	20	21	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2017	140	6					1693	1699		10.1016/j.jaci.2017.01.041	http://dx.doi.org/10.1016/j.jaci.2017.01.041			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FO9KI	28347735	Bronze			2022-12-18	WOS:000417206000024
J	Asarnoj, A; Hamsten, C; Lupinek, C; Melen, E; Andersson, N; Anto, JM; Bousquet, J; Valenta, R; van Hage, M; Wickman, M				Asarnoj, Anna; Hamsten, Carl; Lupinek, Christian; Melen, Erik; Andersson, Niklas; Anto, Josep M.; Bousquet, Jean; Valenta, Rudolf; van Hage, Marianne; Wickman, Magnus		MeDALL Consortium	Prediction of peanut allergy in adolescence by early childhood storage protein-specific IgE signatures: The BAMSE population-based birth cohort	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							SENSITIZATION		[Asarnoj, Anna; Hamsten, Carl; van Hage, Marianne] Karolinska Inst, Dept Med, Immunol & Allergy Unit, Stockholm, Sweden; [Asarnoj, Anna] Karolinska Univ Hosp, Stockholm, Sweden; [Asarnoj, Anna] Karolinska Univ Hosp, Astrid Lindgren Childrens Hosp, Stockholm, Sweden; [Lupinek, Christian; Valenta, Rudolf] Med Univ Vienna, Ctr Pathophysiol Infectiol & Immunol, Dept Pathophysiol & Allergy Res, Div Immunopathol, Vienna, Austria; [Melen, Erik; Andersson, Niklas; Wickman, Magnus] Karolinska Inst, Inst Environm Med, Stockholm, Sweden; [Melen, Erik; Wickman, Magnus] Sachs Childrens Hosp, Dept Pediat, Stockholm, Sweden; [Anto, Josep M.] Ctr Res Environm Epidemiol CREAL, ISGlobal, Barcelona, Sweden; [Anto, Josep M.] Hosp del Mar, Res Inst, IMIM, Barcelona, Spain; [Anto, Josep M.] UPF, Barcelona, Spain; [Anto, Josep M.] CIBERESP, Barcelona, Spain; [Bousquet, Jean] Univ Hosp, Montpellier, France; [Bousquet, Jean] INSERM, VIMA Ageing & Chron Dis, Paris, France; [Bousquet, Jean] Epidemiol & Publ Hlth Approaches, Paris, France; [Bousquet, Jean] Univ Versailles St Quentin En Yvelines, UMR S 1168, UVSQ, Versailles, France; [Wickman, Magnus] Karolinska Inst, Ctr Allergy Res, Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Medical University of Vienna; Karolinska Institutet; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Pompeu Fabra University; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; Universite de Montpellier; CHU de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Karolinska Institutet	Asarnoj, A (corresponding author), Karolinska Inst, Dept Med, Immunol & Allergy Unit, Stockholm, Sweden.; Asarnoj, A (corresponding author), Karolinska Univ Hosp, Stockholm, Sweden.; Asarnoj, A (corresponding author), Karolinska Univ Hosp, Astrid Lindgren Childrens Hosp, Stockholm, Sweden.	anna.asarnoj@ki.se	Bousquet, Jean/O-4221-2019; Andersson, Niklas/AAN-1633-2020; Asarnoj, Anna/ABC-4112-2020; Lupinek, Christian/I-3311-2019; van Hage, Marianne/A-9678-2017; Anto, J M/H-2676-2014	Andersson, Niklas/0000-0001-9785-7462; Lupinek, Christian/0000-0002-8612-8245; van Hage, Marianne/0000-0003-3091-1596; Anto, J M/0000-0002-4736-8529; Asarnoj, Anna/0000-0002-0797-2369; Bousquet, Jean/0000-0002-4061-4766; Valenta, Rudolf/0000-0001-5944-3365; Hamsten, Carl/0000-0002-1830-9431	Swedish Asthma and Allergy Research Foundation; Stockholm County Council; Swedish Research Council of Health, Working Life and Welfare; Swedish Research Council; Swedish Society of Medicine; Swedish Heart-Lung Foundation; Swedish Cancer and Allergy Foundation; Konsul Th Berg's Foundation; Magnus Bergvall Foundation; Swedish Association for Allergology; European Commission's Seventh Framework 29 Program MeDALL (Mechanisms for the Development of Allergy) [261357]; Austrian Science Fund (FWF) [F4605]	Swedish Asthma and Allergy Research Foundation; Stockholm County Council(Stockholm County Council); Swedish Research Council of Health, Working Life and Welfare; Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Society of Medicine; Swedish Heart-Lung Foundation(Swedish Heart-Lung Foundation); Swedish Cancer and Allergy Foundation; Konsul Th Berg's Foundation; Magnus Bergvall Foundation; Swedish Association for Allergology; European Commission's Seventh Framework 29 Program MeDALL (Mechanisms for the Development of Allergy); Austrian Science Fund (FWF)(Austrian Science Fund (FWF))	This study was supported by the Swedish Asthma and Allergy Research Foundation; Stockholm County Council; the Swedish Research Council of Health, Working Life and Welfare; the Swedish Research Council; the Swedish Society of Medicine; the Swedish Heart-Lung Foundation; the Swedish Cancer and Allergy Foundation; the Konsul Th Berg's Foundation, the Magnus Bergvall Foundation, the Swedish Association for Allergology, the European Commission's Seventh Framework 29 Program MeDALL (Mechanisms for the Development of Allergy) under grant agreement no. 261357, and in part by grant no. F4605 of the Austrian Science Fund (FWF).	Arshad SH, 2014, J ALLERGY CLIN IMMUN, V134, P1462, DOI 10.1016/j.jaci.2014.09.026; Asarnoj A, 2012, J ALLERGY CLIN IMMUN, V130, P468, DOI 10.1016/j.jaci.2012.05.019; Eller E, 2013, ALLERGY, V68, P190, DOI 10.1111/all.12075; Lupinek C, 2014, METHODS, V66, P106, DOI 10.1016/j.ymeth.2013.10.008; Nicolaou N, 2011, J ALLERGY CLIN IMMUN, V127, P684, DOI 10.1016/j.jaci.2010.12.012; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Valenta R, 2015, GASTROENTEROLOGY, V148, P1120, DOI 10.1053/j.gastro.2015.02.006; Vereda A, 2011, J ALLERGY CLIN IMMUN, V127, P603, DOI 10.1016/j.jaci.2010.09.010; Wickman M, 2002, PEDIATR ALLERGY IMMU, V13, P11, DOI 10.1034/j.1399-3038.13.s.15.10.x	9	20	20	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2017	140	2					587	+		10.1016/j.jaci.2016.12.973	http://dx.doi.org/10.1016/j.jaci.2016.12.973			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FC5BK	28192142	Green Accepted, Bronze			2022-12-18	WOS:000406855500033
J	Cevikbas, F; Braz, JM; Wang, XD; Solorzano, C; Sulk, M; Buhl, T; Steinhoff, M; Basbaum, AI				Cevikbas, Ferda; Braz, Joao M.; Wang, Xidao; Solorzano, Carlos; Sulk, Mathias; Buhl, Timo; Steinhoff, Martin; Basbaum, Allan I.			Synergistic antipruritic effects of gamma aminobutyric acid A and B agonists in a mouse model of atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; baclofen; chronic itch; GABA; GABAergic progenitor cell transplants; muscimol; pruritogens	SPINAL-CORD; DORSAL-HORN; NEUROPATHIC PAIN; ITCH SENSATION; NERVE INJURY; BACLOFEN; PRURITUS; MICE; MANAGEMENT; GABA	Background: Despite recent insights into the pathophysiology of acute and chronic itch, chronic itch remains an often intractable condition. Among major contributors to chronic itch is dysfunction of spinal cord gamma aminobutyric acidergic (GABAergic) inhibitory controls. Objectives: We sought to test the hypothesis that selective GABA agonists as well as cell transplant-derived GABA are antipruritic against acute itch and in a transgenic mouse model of atopic dermatitis produced by overexpression of the T(H)2 cell-associated cytokine, IL-31 (IL-31Tg mice). Methods: We injected wild-type and IL-31Tg mice with combinations of GABA-A (muscimol) or GABA-B (baclofen) receptor agonists 15 to 20 minutes prior to injection of various pruritogens (histamine, chloroquine, or endothelin-1) and recorded spontaneous scratching before and after drug administration. We also tested the antipruritic properties of intraspinal transplantation of precursors of GABAergic interneurons in the IL-31Tg mice. Results: Systemic muscimol or baclofen are antipruritic against both histamine-dependent and -independent pruritogens, but the therapeutic window using either ligand alone was very small. In contrast, combined subthreshold doses of baclofen and muscimol produced a significant synergistic antipruritic effect, with no sedation. Finally, transplant-mediated long-term enhancement of GABAergic signaling not only reduced spontaneous scratching in the IL-31Tg mice but also dramatically resolved the associated skin lesions. Conclusions: Although additional research is clearly needed, existing approved GABA agonists should be considered in the management of chronic itch, notably atopic dermatitis.	[Cevikbas, Ferda; Braz, Joao M.; Wang, Xidao; Solorzano, Carlos; Basbaum, Allan I.] Univ Calif San Francisco, Dept Anat, Rock Hall Bldg,1550 4th St, San Francisco, CA 94158 USA; [Cevikbas, Ferda; Sulk, Mathias; Buhl, Timo; Steinhoff, Martin] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA; [Sulk, Mathias] Univ Hosp Munster, Dept Dermatol, Munster, Germany; [Buhl, Timo] Univ Med Ctr Gottingen, Dept Dermatol, Gottingen, Germany; [Steinhoff, Martin] Univ Coll Dublin, Dept Dermatol, Dublin, Ireland; [Steinhoff, Martin] Univ Coll Dublin, Charles Inst Translat Dermatol, Dublin, Ireland; [Steinhoff, Martin] Hamad Med Corp, Dept Dermatol & Venerol, Doha, Qatar; [Steinhoff, Martin] Qatar Univ, Sch Med, Doha, Qatar	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Munster; University of Gottingen; University College Dublin; University College Dublin; Hamad Medical Corporation; Qatar University	Braz, JM (corresponding author), Univ Calif San Francisco, Dept Anat, Rock Hall Bldg,1550 4th St, San Francisco, CA 94158 USA.	joao.braz2@ucsf.edu	Buhl, Timo/AFP-7298-2022		National Institutes of Health (NIH) [AR059402, NS78326, NS14627]; UK Wellcome Trust; Science Foundation Ireland; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR059402] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R35NS097306, R01NS014627, R01NS078326] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); UK Wellcome Trust(Wellcome Trust); Science Foundation Ireland(Science Foundation IrelandEuropean Commission); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	Supported by grants from the National Institutes of Health (NIH): AR059402 (M.S.), NS78326 (J.M.B.), and NS14627 (A.I.B.); a grant from the UK Wellcome Trust (A.I.B.); and the IvP award from Science Foundation Ireland (M.S.).	Akiyama T, 2013, NEUROSCIENCE, V250, P697, DOI 10.1016/j.neuroscience.2013.07.035; Akiyama T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022665; Alabed S, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000203.pub3; [Anonymous], 2016, CLIN NEUROL NEUROSUR; [Anonymous], 2016, J PAIN; Basbaum AI, 2016, PAIN, V157, pS42, DOI 10.1097/j.pain.0000000000000441; Ben Smail D, 2005, ARCH PHYS MED REHAB, V86, P494, DOI 10.1016/j.apmr.2004.09.001; Boguniewicz M, 2011, IMMUNOL REV, V242, P233, DOI 10.1111/j.1600-065X.2011.01027.x; Braz JM, 2014, J CLIN INVEST, V124, P3612, DOI 10.1172/JCI75214; Braz JM, 2012, NEURON, V74, P663, DOI 10.1016/j.neuron.2012.02.033; Cevikbas F, 2014, J ALLERGY CLIN IMMUN, V133, P448, DOI 10.1016/j.jaci.2013.10.048; Dillon SR, 2004, NAT IMMUNOL, V5, P752, DOI 10.1038/ni1084; Foster E, 2015, NEURON; Gracies JM, 1997, MUSCLE NERVE, pS92; Han L, 2013, NAT NEUROSCI, V16, P174, DOI 10.1038/nn.3289; Hara K, 1999, ANESTH ANALG, V89, P422, DOI 10.1097/00000539-199908000-00032; Hong J, 2011, SEMIN CUTAN MED SURG, V30, P71, DOI 10.1016/j.sder.2011.05.002; Ibuki T, 1997, NEUROSCIENCE, V76, P845, DOI 10.1016/S0306-4522(96)00341-7; Imamachi N, 2009, P NATL ACAD SCI USA, V106, P11330, DOI 10.1073/pnas.0905605106; Kardon AP, 2014, NEURON, V82, P573, DOI 10.1016/j.neuron.2014.02.046; Klein PA, 1999, ARCH DERMATOL, V135, P1522, DOI 10.1001/archderm.135.12.1522; Leslie TA, 2015, HANDB EXP PHARMACOL, V226, P337, DOI 10.1007/978-3-662-44605-8_18; Lever I, 2003, EUR J NEUROSCI, V18, P1169, DOI 10.1046/j.1460-9568.2003.02848.x; LEVY RA, 1979, EUR J PHARMACOL, V57, P43, DOI 10.1016/0014-2999(79)90102-X; LEVY RA, 1977, J PHARMACOL EXP THER, V202, P437; Mishra SK, 2013, SCIENCE, V340, P968, DOI 10.1126/science.1233765; Petitjean H, 2015, CELL REP, V13, P1246, DOI 10.1016/j.celrep.2015.09.080; Rolland B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098062; Ross SE, 2010, NEURON, V65, P886, DOI 10.1016/j.neuron.2010.02.025; Seeliger S, 2003, FASEB J, V17, P1871, DOI 10.1096/fj.02-1112com; Singer EM, 2013, J INVEST DERMATOL, V133, P2783, DOI 10.1038/jid.2013.227; SINGH PN, 1981, BRIT J ANAESTH, V53, P831, DOI 10.1093/bja/53.8.831; Solorzano C, 2015, J NEUROSCI, V35, P648, DOI 10.1523/JNEUROSCI.2955-14.2015; Steinhoff M, 2012, J ALLERGY CLIN IMMUN, V130, P1015, DOI 10.1016/j.jaci.2012.08.006; Steinhoff M, 2011, SEMIN CUTAN MED SURG, V30, P127, DOI 10.1016/j.sder.2011.05.001; Sun YG, 2007, NATURE, V448, P700, DOI 10.1038/nature06029; Sun YG, 2009, SCIENCE, V325, P1531, DOI 10.1126/science.1174868; Walker P, 1998, J PAIN SYMPTOM MANAG, V16, P125, DOI 10.1016/S0885-3924(98)00039-6; Wang XD, 2013, NEURON, V78, P312, DOI 10.1016/j.neuron.2013.03.001; WILCOX GL, 1988, ANN NY ACAD SCI, V525, P228, DOI 10.1111/j.1749-6632.1988.tb38608.x; WILSON PR, 1978, EUR J PHARMACOL, V51, P323, DOI 10.1016/0014-2999(78)90423-5; Zeilhofer HU, 2012, ANNU REV PHARMACOL, V52, P111, DOI 10.1146/annurev-pharmtox-010611-134636	42	20	20	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2017	140	2					454	+		10.1016/j.jaci.2017.02.001	http://dx.doi.org/10.1016/j.jaci.2017.02.001			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FC5BK	28232084	Green Accepted, Bronze			2022-12-18	WOS:000406855500018
J	Kostjukovits, S; Klemetti, P; Valta, H; Martelius, T; Notarangelo, LD; Seppanen, M; Taskinen, M; Makitie, O				Kostjukovits, Svetlana; Klemetti, Paula; Valta, Helena; Martelius, Timi; Notarangelo, Luigi D.; Seppanen, Mikko; Taskinen, Mervi; Makitie, Outi			Analysis of clinical and immunologic phenotype in a large cohort of children and adults with cartilage-hair hypoplasia	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							COMMON VARIABLE IMMUNODEFICIENCY; TRANSPLANTATION; DEFICIENCY; ANTIBODIES		[Kostjukovits, Svetlana; Klemetti, Paula; Valta, Helena; Martelius, Timi; Seppanen, Mikko; Taskinen, Mervi; Makitie, Outi] Univ Helsinki, Childrens Hosp, Helsinki, Finland; [Kostjukovits, Svetlana; Klemetti, Paula; Valta, Helena; Martelius, Timi; Seppanen, Mikko; Taskinen, Mervi; Makitie, Outi] Helsinki Univ Hosp, Helsinki, Finland; [Kostjukovits, Svetlana; Makitie, Outi] Folkhalsan Res Ctr, Helsinki, Finland; [Kostjukovits, Svetlana] Malmi Dist Hosp, Dept Pediat, Pietarsaari, Finland; [Martelius, Timi] Univ Helsinki, Adult Immunodeficiency Unit, Inflammat Ctr, Helsinki, Finland; [Notarangelo, Luigi D.] NIAID, Lab Host Def, Div Intramural Res, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Makitie, Outi] Karolinska Univ Hosp, Karolinska Inst & Clin Genet, Ctr Mol Med, Stockholm, Sweden	University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Folkhalsan Research Center; University of Helsinki; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Karolinska Institutet; Karolinska University Hospital	Makitie, O (corresponding author), Univ Helsinki, Childrens Hosp, Helsinki, Finland.; Makitie, O (corresponding author), Helsinki Univ Hosp, Helsinki, Finland.; Makitie, O (corresponding author), Folkhalsan Res Ctr, Helsinki, Finland.; Makitie, O (corresponding author), Karolinska Univ Hosp, Karolinska Inst & Clin Genet, Ctr Mol Med, Stockholm, Sweden.	outi.makitie@helsinki.fi	; Vakkilainen, Svetlana/O-1768-2014	Seppanen, Mikko/0000-0001-9733-3650; Vakkilainen, Svetlana/0000-0002-4573-3297; Martelius, Timi/0000-0002-3678-958X	Sigrid Juselius Foundation; Academy of Finland; Folkhalsan Research Foundation; Helsinki University Hospital Research Funds; Swedish Childhood Cancer Foundation; Foundation for Pediatric Research; Finnish Medical Foundation; Doctoral School in Health Sciences at the University of Helsinki; Intramural Research program of the National Institutes of Health, National Institute of Allergy and Infectious Diseases; Novo Nordisk Fonden [NNF16OC0021322] Funding Source: researchfish; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001222] Funding Source: NIH RePORTER	Sigrid Juselius Foundation(Sigrid Juselius Foundation); Academy of Finland(Academy of Finland); Folkhalsan Research Foundation; Helsinki University Hospital Research Funds; Swedish Childhood Cancer Foundation(European Commission); Foundation for Pediatric Research; Finnish Medical Foundation; Doctoral School in Health Sciences at the University of Helsinki; Intramural Research program of the National Institutes of Health, National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Novo Nordisk Fonden(Novo Nordisk Foundation); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The study was funded by the Sigrid Juselius Foundation (O.M.), the Academy of Finland (O.M.), the Folkhalsan Research Foundation (O.M.), the Helsinki University Hospital Research Funds (O.M. and M.T.), the Swedish Childhood Cancer Foundation (O.M.), the Foundation for Pediatric Research (O.M. and M.T.), the Finnish Medical Foundation (S.K.), and the Doctoral School in Health Sciences at the University of Helsinki (S.K.). The research was supported in part by the Intramural Research program of the National Institutes of Health, National Institute of Allergy and Infectious Diseases.	Aalto SM, 1998, J MED VIROL, V56, P186, DOI 10.1002/(SICI)1096-9071(199811)56:3&lt;186::AID-JMV2&gt;3.0.CO;2-3; [Anonymous], 2015, J CLIN IMMUNOL; Boldt A, 2014, CYTOM PART B-CLIN CY, V86, P191, DOI 10.1002/cyto.b.21162; Bordon V, 2010, BLOOD, V116, P27, DOI 10.1182/blood-2010-01-259168; de la Fuente MA, 2011, J ALLERGY CLIN IMMUN, V128, P139, DOI 10.1016/j.jaci.2011.03.042; Driessen GJ, 2011, BLOOD, V118, P6814, DOI 10.1182/blood-2011-06-361881; Guggenheim R, 2006, BONE MARROW TRANSPL, V38, P751, DOI 10.1038/sj.bmt.1705520; Jaaskelainen AJ, 2014, J MICROBIOL METH, V100, P27, DOI 10.1016/j.mimet.2014.02.011; Kristiansen M, 1997, APMIS, V105, P843, DOI 10.1111/j.1699-0463.1997.tb05093.x; Makitie O, 2000, J PEDIATR-US, V137, P487, DOI 10.1067/mpd.2000.108102; Makitie O, 2001, ARCH DIS CHILD, V84, P65, DOI 10.1136/adc.84.1.65; Rider NL, 2009, CLIN IMMUNOL, V131, P119, DOI 10.1016/j.clim.2008.11.001; Sajanti E. M, 2014, J IMMUNOL; Schatorje EJH, 2012, SCAND J IMMUNOL, V75, P436, DOI 10.1111/j.1365-3083.2012.02671.x; Shearer WT, 2003, J ALLERGY CLIN IMMUN, V112, P973, DOI 10.1016/j.jaci.2003.07.003; Sorensen RU, 2014, STIEHMS IMMUNE DEFIC, P413; SUGITA K, 1993, INT J HEMATOL, V57, P27; Thiel CT, 2007, AM J HUM GENET, V81, P519, DOI 10.1086/521034; Timby N, 2015, J PEDIATR GASTR NUTR, V60, P384, DOI 10.1097/MPG.0000000000000624; VLUG A, 1994, ANN BIOL CLIN-PARIS, V52, P561; Wehr C, 2008, BLOOD, V111, P77, DOI 10.1182/blood-2007-06-091744	21	20	20	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2017	140	2					612	+		10.1016/j.jaci.2017.02.016	http://dx.doi.org/10.1016/j.jaci.2017.02.016			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FC5BK	28284971	Bronze, Green Accepted			2022-12-18	WOS:000406855500043
J	McGeachie, MJ; Davis, JS; Kho, AT; Dahlin, A; Sordillo, JE; Sun, MY; Lu, Q; Weiss, ST; Tantisira, KG				McGeachie, Michael J.; Davis, Joshua S.; Kho, Alvin T.; Dahlin, Amber; Sordillo, Joanne E.; Sun, Maoyun; Lu, Quan; Weiss, Scott T.; Tantisira, Kelan G.			Asthma remission: Predicting future airways responsiveness using an miRNA network	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[McGeachie, Michael J.; Davis, Joshua S.; Dahlin, Amber; Sordillo, Joanne E.; Weiss, Scott T.; Tantisira, Kelan G.] Brigham & Womens Hosp, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA; [McGeachie, Michael J.; Davis, Joshua S.; Kho, Alvin T.; Dahlin, Amber; Sordillo, Joanne E.; Weiss, Scott T.; Tantisira, Kelan G.] Harvard Med Sch, Boston, MA 02115 USA; [Kho, Alvin T.] Boston Childrens Hosp, Computat Hlth Informat Program, Boston, MA USA; [Sun, Maoyun; Lu, Quan] Harvard TH Chan Sch Publ Hlth, Program Mol & Integrat Physiol Sci, Dept Environm Hlth, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University; Harvard T.H. Chan School of Public Health	McGeachie, MJ (corresponding author), Brigham & Womens Hosp, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA.; McGeachie, MJ (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.	michael.mcgeachie@channing.harvard.edu			National Institutes of Health (NIH) [R01 HL127332, R01 HL129935, U01 HL65899]; Parker B. Francis Foundation; NIH [T32 HL007427, K25 HL091124];  [K01 HL130629];  [P01 HL132825];  [R37 HL066289];  [R00 HL109162];  [R01 HL114769]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL114769, R01HL127332, T32HL007427, U01HL065899, R01HL129935, R00HL109162, P01HL132825, T32HL007118, K01HL130629] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Parker B. Francis Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; ; ; ; ; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work is supported by the National Institutes of Health (NIH) (grant nos. R01 HL127332, R01 HL129935, and U01 HL65899). M.J.M. is supported by a grant from the Parker B. Francis Foundation. J.S.D. is supported by the NIH (grant no. T32 HL007427). A.T.K. is supported by the NIH (grant no. K25 HL091124). A.D. is supported by grant no. K01 HL130629. J.E.S. is supported by grant no. R00 HL109162. M.S. and Q.L. are supported by grant no. R01 HL114769. S.T.W. is supported by grant nos. P01 HL132825 and R37 HL066289.	Cherniack R, 1999, CONTROL CLIN TRIALS, V20, P91; Clemmer GL, 2015, J ALLERGY CLIN IMMUN; Garcia-Garcia F, 2016, BIOINFORMATICS, V32, P2809, DOI 10.1093/bioinformatics/btw334; Hu RX, 2014, FASEB J, V28, P2347, DOI 10.1096/fj.13-247247; KASS RE, 1995, J AM STAT ASSOC, V90, P773, DOI 10.1080/01621459.1995.10476572; Kho AT, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157998; Kozomara A, 2014, NUCLEIC ACIDS RES, V42, pD68, DOI 10.1093/nar/gkt1181; McGeachie MJ, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003676; Provost F, 2001, MACH LEARN, V42, P203, DOI 10.1023/A:1007601015854; Sawicki GS, 2010, ANN ALLERG ASTHMA IM, V104, P30, DOI 10.1016/j.anai.2009.11.004; Silander T, 2002, UNCERTAINTY ARTIFICI, P360; Weiss ST, 2016, NEW ENGL J MED, V375	12	20	20	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2017	140	2					598	+		10.1016/j.jaci.2017.01.023	http://dx.doi.org/10.1016/j.jaci.2017.01.023			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FC5BK	28238746	Green Accepted, Bronze			2022-12-18	WOS:000406855500037
J	Morita, H; Nakae, S; Saito, H; Matsumoto, K				Morita, Hideaki; Nakae, Susumu; Saito, Hirohisa; Matsumoto, Kenji			IL-33 in clinical practice: Size matters?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						IL-33; alarmin; innate lymphoid cell; biological activity	INNATE LYMPHOID-CELLS; INFLAMMATION; INTERLEUKIN-33; ALARMIN		[Morita, Hideaki; Saito, Hirohisa; Matsumoto, Kenji] Natl Res Inst Child Hlth & Dev, Dept Allergy & Clin Immunol, Tokyo, Japan; [Morita, Hideaki] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland; [Nakae, Susumu] Univ Tokyo, Inst Med Sci, Ctr Expt Med & Syst Biol, Lab Syst Biol, Tokyo, Japan	National Center for Child Health & Development - Japan; Swiss Institute of Allergy & Asthma Research; University of Zurich; University of Tokyo	Matsumoto, K (corresponding author), Natl Res Inst Child Hlth & Dev, Dept Allergy & Clin Immunol, Setagaya Ku, 2-10-1 Okura, Tokyo, Japan.	matsumoto-k@ncchd.go.jp	Morita, Hideaki/ADL-2008-2022; Morita, Hideaki/S-2214-2016	Morita, Hideaki/0000-0003-0928-8322; Saito, Hirohisa/0000-0002-6630-8337	MSD(Merck Sharp and Dohme); Kyorin Pharmaceutical; AstraZeneca; Maruho; Teijin Pharma; Chugai Pharmaceutical	MSD(Merck Sharp and Dohme)(Merck & Company); Kyorin Pharmaceutical; AstraZeneca(AstraZeneca); Maruho; Teijin Pharma; Chugai Pharmaceutical	H. Saito is employed by the National Center for Child Health & Development, Japan; has personally received payment for lectures from MSD(Merck Sharp and Dohme), Shiseido, GlaxoSmithKline, and Kyowa Hakko Kirin; and has personally received travel expenses from the World Allergy Organization, and his institution has received a grant from Ministry of Health, Labour & Welfare, Japan, for other works. K. Matsumoto is employed by National Research Institute for Child Health and Development; received payment for lectures from MSD (Merck Sharp and Dohme), Kyorin Pharmaceutical, AstraZeneca, Maruho, Teijin Pharma, and Chugai Pharmaceutical. The rest of the authors declare that they have no relevant conflicts of interest.	Akdis M, 2016, J ALLERGY CLIN IMMUN, V138, P984, DOI 10.1016/j.jaci.2016.06.033; Cohen ES, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9327; Kouzaki H, 2011, J IMMUNOL, V186, P4375, DOI 10.4049/jimmunol.1003020; Lefrancais E, 2014, P NATL ACAD SCI USA, V111, P15502, DOI 10.1073/pnas.1410700111; Lefrancais E, 2012, P NATL ACAD SCI USA, V109, P1673, DOI 10.1073/pnas.1115884109; Luthi AU, 2009, IMMUNITY, V31, P84, DOI 10.1016/j.immuni.2009.05.007; Martin NT, 2016, NAT IMMUNOL, V17, P122, DOI 10.1038/ni.3370; Morita H, 2016, J ALLERGY CLIN IMMUN, V138, P1253, DOI 10.1016/j.jaci.2016.09.011; Nile CJ, 2010, IMMUNOLOGY, V130, P172, DOI 10.1111/j.1365-2567.2009.03221.x; Takeda T, 2016, J ALLERGY CLIN IMMUN, V138, P1395, DOI 10.1016/j.jaci.2016.01.032	10	20	21	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2017	140	2					381	383		10.1016/j.jaci.2017.03.042	http://dx.doi.org/10.1016/j.jaci.2017.03.042			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FC5BK	28478050	Bronze			2022-12-18	WOS:000406855500006
J	Alberici, F; Smith, RM; Fonseca, M; Willcocks, LC; Jones, RB; Holle, JU; Wieczorek, S; Neumann, T; Martorana, D; Gregorini, G; Sinico, RA; Bruchfeld, A; Gunnarsson, I; Ohlsson, S; Baslund, B; Tesar, V; Hruskova, Z; Cid, MC; Vaglio, A; Lyons, PA; Smith, KGC; Jayne, DRW				Alberici, Federico; Smith, Rona M.; Fonseca, Mariana; Willcocks, Lisa C.; Jones, Rachel B.; Holle, Julia U.; Wieczorek, Stefan; Neumann, Thomas; Martorana, Davide; Gregorini, Gina; Sinico, Renato A.; Bruchfeld, Annette; Gunnarsson, Iva; Ohlsson, Sophie; Baslund, Bo; Tesar, Vladimir; Hruskova, Zdenka; Cid, Maria C.; Vaglio, Augusto; Lyons, Paul A.; Smith, Kenneth G. C.; Jayne, David R. W.			Association of a TNFSF13B (BAFF) regulatory region single nucleotide polymorphism with response to rituximab in antineutrophil cytoplasmic antibody-associated vasculitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ACTIVATING FACTOR GENE; OUTCOMES; THERAPY		[Alberici, Federico; Smith, Rona M.; Fonseca, Mariana; Willcocks, Lisa C.; Jones, Rachel B.; Lyons, Paul A.; Smith, Kenneth G. C.; Jayne, David R. W.] Univ Cambridge, Sch Clin Med, Dept Med, Cambridge, England; [Alberici, Federico; Sinico, Renato A.] San Carlo Borromeo Hosp, ASST Santi Paolo & Carlo, Nephrol & Immunol Unit, Milan, Italy; [Alberici, Federico] Univ Parma, Dept Clin & Expt Med, Parma, Italy; [Holle, Julia U.] Klinikum Bad Bramstedt, Dept Rheumatol Immunol & Vasculitis Clin, Bad Bramstedt, Germany; [Wieczorek, Stefan] Ruhr Univ Bochum, Dept Human Genet, Bochum, Germany; [Neumann, Thomas] Jena Univ Hosp, Dept Internal Med 3, Jena, Germany; [Martorana, Davide] Univ Hosp Parma, Med Genet Unit, Parma, Italy; [Gregorini, Gina] AO Spedali Civili, Dept Nephrol, Brescia, Italy; [Sinico, Renato A.] Univ Milano Bicocca, Sch Med & Surg, Dept Med & Surg, Monza, Italy; [Bruchfeld, Annette] Karolinska Univ Hosp, Dept Renal Med, Solna, Sweden; [Bruchfeld, Annette] Karolinska Inst, Solna, Sweden; [Gunnarsson, Iva] Karoliska Inst, Karolinska Univ Hosp, Rheumatol Unit, Dept Med, Solna, Sweden; [Ohlsson, Sophie] Skane Univ Hosp, Dept Nephrol & Transplantat, Gothenburg, Sweden; [Baslund, Bo] Copenhagen Univ Hosp, Rigshosp, Dept Infect Dis & Rheumatol, Copenhagen, Denmark; [Tesar, Vladimir] Charles Univ Prague, Fac Med 1, Dept Nephrol, Prague, Czech Republic; [Tesar, Vladimir] Gen Univ Hosp Prague, Prague, Czech Republic; [Cid, Maria C.] Univ Barcelona, Hosp Clin, Dept Syst Autoimmune Dis, Vasculitis Res Unit, Barcelona, Spain; [Vaglio, Augusto] Univ Hosp Parma, Nephrol Unit, Parma, Italy	University of Cambridge; San Carlo Borromeo Hospital; University of Parma; University Hospital of Parma; Ruhr University Bochum; Friedrich Schiller University of Jena; University of Parma; University Hospital of Parma; Hospital Spedali Civili Brescia; University of Milano-Bicocca; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Lund University; Skane University Hospital; Rigshospitalet; University of Copenhagen; Charles University Prague; General University Hospital Prague; University of Barcelona; Hospital Clinic de Barcelona; University of Parma; University Hospital of Parma	Alberici, F (corresponding author), Univ Cambridge, Sch Clin Med, Dept Med, Cambridge, England.; Alberici, F (corresponding author), San Carlo Borromeo Hosp, ASST Santi Paolo & Carlo, Nephrol & Immunol Unit, Milan, Italy.	federico.alberici@gmail.com	Ohlsson, Sophie/W-9495-2019; Hrušková, Zdenka/O-2079-2017; Vaglio, Augusto/AHE-8117-2022; Martorana, Davide/K-6374-2016; Alberici, Federico/AAC-5289-2022	Ohlsson, Sophie/0000-0002-5253-1650; Hrušková, Zdenka/0000-0002-2658-365X; Vaglio, Augusto/0000-0002-3814-9172; Martorana, Davide/0000-0002-7572-7031; Alberici, Federico/0000-0002-1686-5709; Smith, Kenneth/0000-0003-3829-4326; Jones, Rachel/0000-0003-4790-283X; Jayne, David/0000-0002-1712-0637; Tesar, Vladimir/0000-0001-6982-0689	National Institute of Health Research Cambridge Biomedical Research Centre; European Renal Association-European Dialysis and Transplant Association long-term fellowship; Regione Emilia-Romagna within the Programma di Ricerca Regione-Universita; MRC [MR/L019027/1] Funding Source: UKRI; Medical Research Council [MR/L019027/1] Funding Source: researchfish; National Institute for Health Research [NF-SI-0515-10015, NF-SI-0514-10109] Funding Source: researchfish	National Institute of Health Research Cambridge Biomedical Research Centre(National Institute for Health Research (NIHR)); European Renal Association-European Dialysis and Transplant Association long-term fellowship; Regione Emilia-Romagna within the Programma di Ricerca Regione-Universita(Regione Emilia Romagna); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	This study was supported by the National Institute of Health Research Cambridge Biomedical Research Centre (http://www.cambridge-brc.org.uk). F.A. has been supported by a European Renal Association-European Dialysis and Transplant Association long-term fellowship between September 2012 and September 2013. A.V. and D.M. were supported by the grant "A tailored approach to the immune monitoring and clinical management of viral and autoimmune diseases," given by the Regione Emilia-Romagna within the Programma di Ricerca Regione-Universita 2010-12.	Bader L, 2010, CLIN RHEUMATOL, V29, P1031, DOI 10.1007/s10067-010-1526-z; Burkett K, 2004, HUM HERED, V57, P200, DOI 10.1159/000081447; de Groot K, 2001, CLIN NEPHROL, V55, P31; E12, 2014, SNPS BAS WHOL GEN AS; Fabris M, 2013, ARTHRITIS RHEUM-US, V65, P88, DOI 10.1002/art.37707; Guillevin L, 2014, NEW ENGL J MED, V371, P1771, DOI 10.1056/NEJMoa1404231; Hothorn T, 2006, AM STAT, V60, P257, DOI 10.1198/000313006X118430; Jones RB, 2010, NEW ENGL J MED, V363, P211, DOI 10.1056/NEJMoa0909169; Kim SH, 2015, JAMA NEUROL, V72, P989, DOI 10.1001/jamaneurol.2015.1276; Leandro MJ, 2006, ARTHRITIS RHEUM-US, V54, P613, DOI 10.1002/art.21617; Marquez A, 2013, MOL BIOL REP, V40, P4851, DOI 10.1007/s11033-013-2583-6; Nasrallah M, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0778-z; Nossent JC, 2008, RHEUMATOLOGY, V47, P1311, DOI 10.1093/rheumatology/ken246; Racila E, 2008, CLIN CANCER RES, V14, P6697, DOI 10.1158/1078-0432.CCR-08-0745; Roberts DM, 2015, J AUTOIMMUN, V57, P60, DOI 10.1016/j.jaut.2014.11.009; Robledo G, 2012, DNA CELL BIOL, V31, P1486, DOI 10.1089/dna.2012.1684; Ruyssen-Witrand A, 2013, RHEUMATOLOGY, V52, P636, DOI 10.1093/rheumatology/kes344; Therneau TM, 2000, STAT BIOL HEALTH; Treon SP, 2005, J CLIN ONCOL, V23, P474, DOI 10.1200/JCO.2005.06.059; Watts R, 2007, ANN RHEUM DIS, V66, P222, DOI 10.1136/ard.2006.054593; Willcocks LC, 2010, P NATL ACAD SCI USA, V107, P7881, DOI 10.1073/pnas.0915133107	21	20	20	2	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2017	139	5					1684	+		10.1016/j.jaci.2016.08.051	http://dx.doi.org/10.1016/j.jaci.2016.08.051			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ET7HI	27780742	Bronze, Green Submitted			2022-12-18	WOS:000400465300032
J	Krouse, RZ; Sorkness, CA; Wildfire, JJ; Calatroni, A; Gruchalla, R; Hershey, GKK; Kattan, M; Liu, AH; Makhija, M; Teach, SJ; West, JB; Wood, RA; Zoratti, EM; Gergen, PJ				Krouse, Rebecca Z.; Sorkness, Christine A.; Wildfire, Jeremy J.; Calatroni, Agustin; Gruchalla, Rebecca; Hershey, Gurjit K. Khurana; Kattan, Meyer; Liu, Andrew H.; Makhija, Melanie; Teach, Stephen J.; West, Joseph B.; Wood, Robert A.; Zoratti, Edward M.; Gergen, Peter J.			Minimally important differences and risk levels for the Composite Asthma Severity Index	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							MATRIX MICROFIBRILLAR PROTEIN; MYASTHENIA-GRAVIS; MOLECULAR-CLONING; AUTOANTIBODIES; IDENTIFICATION; AUTOANTIGENS; ANTIBODIES; CHILDREN; BIOGPS; CELLS		[Krouse, Rebecca Z.; Wildfire, Jeremy J.; Calatroni, Agustin] Rho Fed Syst Div Inc, Chapel Hill, NC 27517 USA; [Sorkness, Christine A.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA; [Gruchalla, Rebecca] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA; [Hershey, Gurjit K. Khurana] Cincinnati Childrens Hosp, Cincinnati, OH USA; [Kattan, Meyer] Columbia Univ, Coll Phys & Surg, New York, NY USA; [Liu, Andrew H.] Natl Jewish Hlth, Denver, CO USA; [Liu, Andrew H.] Childrens Hosp Colorado, Aurora, CO USA; [Liu, Andrew H.] Univ Colorado, Sch Med, Aurora, CO USA; [Makhija, Melanie] Ann & Robert H Lurie Childrens Hosp Chicago, Chicago, IL 60611 USA; [Teach, Stephen J.] Childrens Natl Hlth Syst, Washington, DC USA; [West, Joseph B.] Boston Univ, Sch Med, Boston, MA 02118 USA; [Wood, Robert A.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Zoratti, Edward M.] Henry Ford Hlth Syst, Detroit, MI USA; [Gergen, Peter J.] NIAID, 9000 Rockville Pike, Bethesda, MD 20892 USA	University of Wisconsin System; University of Wisconsin Madison; University of Texas System; University of Texas Southwestern Medical Center Dallas; Cincinnati Children's Hospital Medical Center; Columbia University; National Jewish Health; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Ann & Robert H. Lurie Children's Hospital of Chicago; Children's National Health System; Boston University; Johns Hopkins University; Henry Ford Health System; Henry Ford Hospital; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Krouse, RZ (corresponding author), Rho Fed Syst Div Inc, Chapel Hill, NC 27517 USA.	Rebecca_Krouse@rhoworld.com			National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services [HHSN272200900052C, HHSN272201000052I, 1UM1AI114271-01]; National Center for Advancing Translational Sciences, NIH [NCRR/NIH UL1TR000451, UL1RR025780, UL1TR000075, UL1TR000154, UL1TR001082, UL1TR000077-04, UL1TR000040, UL1TR000150, UL1TR001105]; National Center for Research Resources; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000040, UL1TR000154, UL1TR000451, UL1TR000150, UL1TR001425, UL1TR000077, UL1TR001105, UL1TR000075, UL1TR001082] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025780] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [UM2AI117870] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services; National Center for Advancing Translational Sciences, NIH; National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This project has been funded in whole or in part with federal funds from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services (contract nos. HHSN272200900052C, HHSN272201000052I, and 1UM1AI114271-01). Additional support was provided by the National Center for Research Resources, and National Center for Advancing Translational Sciences, NIH (grant nos. NCRR/NIH UL1TR000451, UL1RR025780, UL1TR000075, UL1TR000154, UL1TR001082, UL1TR000077-04, UL1TR000040, UL1TR000150, and UL1TR001105). Glaxo SmithKline (GSK) provided Ventolin, Flovent, Advair, and Flonase under a clinical trial agreement with NIH-NIAID; GSK did not have a role in the development or approval of the protocol, conduct of the trial, data analysis, manuscript preparation, or the decision to submit the manuscript for publication.	Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106; Arnett FC, 1999, ARTHRITIS RHEUM-US, V42, P2656, DOI 10.1002/1529-0131(199912)42:12<2656::AID-ANR22>3.0.CO;2-N; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Busse WW, 2011, NEW ENGL J MED, V364, P1005, DOI 10.1056/NEJMoa1009705; Eisenberg E, 2013, TRENDS GENET, V29, P569, DOI 10.1016/j.tig.2013.05.010; GORDON T, 1992, J CLIN INVEST, V90, P992, DOI 10.1172/JCI115976; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Liu AH, 2016, J ALLERGY CLIN IMMUN, V138, P1042, DOI 10.1016/j.jaci.2016.06.060; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; MAPPOURAS DG, 1995, CLIN EXP IMMUNOL, V100, P336; Marinkovich MP, 1996, J INVEST DERMATOL, V106, P734, DOI 10.1111/1523-1747.ep12345782; McGlothlin AE, 2014, JAMA-J AM MED ASSOC, V312, P1342, DOI 10.1001/jama.2014.13128; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; PHILLIPS TM, 1981, ANN NY ACAD SCI, V377, P360, DOI 10.1111/j.1749-6632.1981.tb33744.x; PIETROPAOLO M, 1993, J CLIN INVEST, V92, P359, DOI 10.1172/JCI116574; Pinto S, 2013, P NATL ACAD SCI USA, V110, pE3497, DOI 10.1073/pnas.1308311110; Pongracic JA, 2016, J ALLERGY CLIN IMMUN, V138, P1030, DOI 10.1016/j.jaci.2016.06.059; Provenzano C, 2010, J NEUROIMMUNOL, V218, P102, DOI 10.1016/j.jneuroim.2009.11.004; Real A, 2015, CALCIFIED TISSUE INT, V97, P125, DOI 10.1007/s00223-015-0023-4; Riches PL, 2009, NEW ENGL J MED, V361, P1459, DOI 10.1056/NEJMoa0810925; Sasaki H, 2001, SURG TODAY, V31, P1036; Schatz M, 2009, J ALLERGY CLIN IMMUN, V124, P719, DOI 10.1016/j.jaci.2009.06.053; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Smith CJA, 2012, EUR J ENDOCRINOL, V166, P391, DOI 10.1530/EJE-11-1015; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; Tan FK, 1999, J IMMUNOL, V163, P1066; Tang JA, 1997, CHINESE MED J-PEKING, V110, P698; Tung JW, 2007, CLIN LAB MED, V27, P453, DOI 10.1016/j.cll.2007.05.001; Wildfire JJ, 2012, J ALLERGY CLIN IMMUN, V129, P694, DOI 10.1016/j.jaci.2011.12.962; Wu CL, 2013, NUCLEIC ACIDS RES, V41, pD561, DOI 10.1093/nar/gks1114; Wu C, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-11-r130; Yamano T, 2015, IMMUNITY, V42, P1048, DOI 10.1016/j.immuni.2015.05.013; Zingaretti C, 2012, MOL CELL PROTEOMICS, V11, P1885, DOI 10.1074/mcp.M112.018713; Zoratti EM, 2016, J ALLERGY CLIN IMMUN, V138, P1016, DOI 10.1016/j.jaci.2016.06.061	35	20	20	2	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2017	139	3					1052	1055		10.1016/j.jaci.2016.08.041	http://dx.doi.org/10.1016/j.jaci.2016.08.041			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EP3QC	27744028	Green Accepted, Bronze			2022-12-18	WOS:000397295800044
J	Navarini, AA; Hruz, P; Berger, CT; Hou, TZ; Schwab, C; Gabrysch, A; Higgins, R; Frede, N; Sgier, BCP; Kampe, O; Burgener, AV; Marquardsen, F; Baldin, F; Bigler, M; Kistner, A; Jauch, A; Bignucolo, O; Meyer, B; Meienberg, F; Mehling, M; Jeker, LT; Heijnen, I; Daikeler, TD; Gebbers, JO; Grimbacher, B; Sansom, DM; Jeker, R; Hess, C; Recher, M				Navarini, Alexander A.; Hruz, Petr; Berger, Christoph T.; Hou, Tie Zheng; Schwab, Charlotte; Gabrysch, Annemarie; Higgins, Rebecca; Frede, Natalie; Sgier, Barbara-Christina Padberg; Kampe, Olle; Burgener, Anne-Valerie; Marquardsen, Florian; Baldin, Fabian; Bigler, Marc; Kistner, Anne; Jauch, Annaise; Bignucolo, Olivier; Meyer, Benedikt; Meienberg, Fabian; Mehling, Matthias; Jeker, Lukas T.; Heijnen, Ingmar; Daikeler, Thomas D.; Gebbers, Jan-Olaf; Grimbacher, Bodo; Sansom, David M.; Jeker, Raphael; Hess, Christoph; Recher, Mike			Vedolizumab as a successful treatment of CTLA-4-associated autoimmune enterocolitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							IMMUNE DYSREGULATION; ADVERSE EVENTS; THERAPY		[Navarini, Alexander A.; Higgins, Rebecca] Univ Hosp, Dept Dermatol, Zurich, Switzerland; [Hruz, Petr] Univ Hosp, Gastroenterol, Basel, Switzerland; [Berger, Christoph T.; Bigler, Marc; Kistner, Anne] Univ Hosp, Dept Biomed, Translat Immunol, Basel, Switzerland; [Hou, Tie Zheng; Sansom, David M.] UCL, Inst Immun & Transplantat, Royal Free Campus, London, England; [Schwab, Charlotte; Gabrysch, Annemarie; Grimbacher, Bodo] Univ Freiburg, Med Ctr, Ctr Chron Immunodeficiency, Fac Med, Freiburg, Germany; [Sgier, Barbara-Christina Padberg; Gebbers, Jan-Olaf] Cantonal Hosp Graubunden, Inst Pathol, Chur, Switzerland; [Kampe, Olle] Karolinska Inst, Dept Med Solna, Stockholm, Sweden; [Kampe, Olle] Uppsala Univ, Sci Life Lab, Dept Med Sci, Uppsala, Sweden; [Hess, Christoph] Univ Hosp, Dept Biomed, Immunobiol Lab, Basel, Switzerland; [Marquardsen, Florian; Baldin, Fabian; Jauch, Annaise; Meyer, Benedikt; Recher, Mike] Univ Hosp, Dept Biomed, Immunodeficiency Lab, Basel, Switzerland; [Bignucolo, Olivier] Univ Basel, SIB Swiss Inst Bioinformat & Biozentrum, Basel, Switzerland; [Burgener, Anne-Valerie; Meienberg, Fabian] Univ Hosp, Endocrinol, Basel, Switzerland; [Mehling, Matthias] Univ Hosp, Dept Biomed, Translat Neuroimmunol, Basel, Switzerland; [Heijnen, Ingmar] Univ Basel Hosp, Div Med Immunol, Lab Med, Basel, Switzerland; [Daikeler, Thomas D.] Univ Hosp, Rheumatol, Basel, Switzerland; [Jeker, Raphael] Kantonsspital Graubunden, Dept Internal Med, Chur, Switzerland	University of Zurich; University Zurich Hospital; University of London; University College London; University of Freiburg; Kantonsspital Graubunden; Karolinska Institutet; Uppsala University; Swiss Institute of Bioinformatics; University of Basel; University of Basel; Kantonsspital Graubunden	Recher, M (corresponding author), Univ Hosp, Dept Biomed, Immunodeficiency Lab, Basel, Switzerland.	mike.recher@usb.ch	HOU, TIEZHENG/B-4848-2015; Berger, Christoph T/I-6126-2019; Bignucolo, Olivier/AAP-2975-2021; Navarini, Alexander/C-5504-2014	Berger, Christoph T/0000-0002-1730-8824; Bignucolo, Olivier/0000-0003-4735-049X; Mehling, Matthias/0000-0001-8599-1226; Sansom, David/0000-0001-6506-3115; Navarini, Alexander/0000-0001-7059-632X; Hruz, Petr/0000-0003-2767-0445; Recher, Mike/0000-0002-9121-6936; Bigler, Marc/0000-0002-8232-6228	Swiss National Science Foundation [PP00P3_144863, PZ00P3_148000]; Gebert Ruf foundation [GRS-058/14]; BMBF [01E01303, 01ZX1306F]; Novo Nordisk Fonden [NNF16OC0021532, NNF14OC0011003, NNF13OC0005975] Funding Source: researchfish	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Gebert Ruf foundation; BMBF(Federal Ministry of Education & Research (BMBF)); Novo Nordisk Fonden(Novo Nordisk Foundation)	This work was supported by Swiss National Science Foundation grants to M.R. (grant no. PP00P3_144863) and C.T.B. (grant no. PZ00P3_148000). M.R. and C.H. were supported by the Gebert Ruf foundation (grant no. GRS-058/14). This work was supported in part by the BMBF grants 01E01303 and 01ZX1306F to B.G.	Bertrand A, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0455-8; De Rycke L, 2003, ARTHRITIS RHEUM, V48, P1015, DOI 10.1002/art.10876; Feagan BG, 2013, NEW ENGL J MED, V369, P699, DOI 10.1056/NEJMoa1215734; Hagan M, 2015, EXPERT OPIN DRUG SAF, V14, P1473, DOI 10.1517/14740338.2015.1063612; Kuehn HS, 2014, SCIENCE, V345, P1623, DOI 10.1126/science.1255904; Marthey L, 2016, J CROHNS COLITIS, V10, P395, DOI 10.1093/ecco-jcc/jjv227; Picard C, 2015, J CLIN IMMUNOL, V35, P696, DOI 10.1007/s10875-015-0201-1; Quirk SK, 2015, TRANSL RES, V166, P412, DOI 10.1016/j.trsl.2015.06.005; Rakhmanov M, 2009, P NATL ACAD SCI USA, V106, P13451, DOI 10.1073/pnas.0901984106; Sawada K, 2008, BRIT J HAEMATOL, V142, P505, DOI 10.1111/j.1365-2141.2008.07216.x; Schubert D, 2014, NAT MED, V20, P1410, DOI 10.1038/nm.3746	11	20	22	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2017	139	3					1043	1046		10.1016/j.jaci.2016.08.042	http://dx.doi.org/10.1016/j.jaci.2016.08.042			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EP3QC	27908448	Green Submitted, Bronze			2022-12-18	WOS:000397295800041
J	Shubin, NJ; Glukhova, VA; Clauson, M; Truong, P; Abrink, M; Pejler, G; White, NJ; Deutsch, GH; Reeves, SR; Vaisar, T; James, RG; Piliponsky, AM				Shubin, Nicholas J.; Glukhova, Veronika A.; Clauson, Morgan; Truong, Phuong; Abrink, Magnus; Pejler, Gunnar; White, Nathan J.; Deutsch, Gail H.; Reeves, Stephen R.; Vaisar, Tomas; James, Richard G.; Piliponsky, Adrian M.			Proteome analysis of mast cell releasates reveals a role for chymase in the regulation of coagulation factor XIIIA levels via proteolytic degradation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mast cells; proteases; chymase; proteomics	CHRONIC RHINOSINUSITIS; SERINE-PROTEASE; NASAL POLYPS; A-SUBUNIT; MOUSE; EXPRESSION; INFLAMMATION; SEPSIS; PLASMA; MICE	Background: Mast cells are significantly involved in IgE-mediated allergic reactions; however, their roles in health and disease are incompletely understood. Objective: We aimed to define the proteome contained in mast cell releasates on activation to better understand the factors secreted by mast cells that are relevant to the contribution of mast cells in diseases. Methods: Bone marrow-derived cultured mast cells (BMCMCs) and peritoneal cell-derived mast cells were used as "surrogates'' for mucosal and connective tissue mast cells, respectively, and their releasate proteomes were analyzed by mass spectrometry. Results: Our studies showed that BMCMCs and peritoneal cell-derived mast cells produced substantially different releasates following IgE-mediated activation. Moreover, we observed that the transglutaminase coagulation factor XIIIA (FXIIIA) was one of the most abundant proteins contained in the BMCMC releasates. Mast cell-deficient mice exhibited increased FXIIIA plasma and activity levels as well as reduced bleeding times, indicating that mast cells are more efficient in their ability to downregulate FXIIIA than in contributing to its amounts and functions in homeostatic conditions. We found that human chymase and mouse mast cell protease-4 (the mouse homologue of human chymase) had the ability to reduce FXIIIA levels and function via proteolytic degradation. Moreover, we found that chymase deficiency led to increased FXIIIA amounts and activity, as well as reduced bleeding times in homeostatic conditions and during sepsis. Conclusions: Our study indicates that the mast cell protease content can shape its releasate proteome. Moreover, we found that chymase plays an important role in the regulation of FXIIIA via proteolytic degradation.	[Shubin, Nicholas J.; Glukhova, Veronika A.; Clauson, Morgan; Truong, Phuong; Reeves, Stephen R.; James, Richard G.; Piliponsky, Adrian M.] Seattle Childrens Res Inst, Ctr Immun & Immunotherapies, 1900 9th Ave,Rm 721, Seattle, WA 98101 USA; [Abrink, Magnus] Swedish Univ Agr Sci, Dept Biomed Sci & Vet Publ Hlth, Uppsala, Sweden; [Pejler, Gunnar] Uppsala Univ, Dept Med Biochem & Microbiol, Uppsala, Sweden; [Pejler, Gunnar] Swedish Univ Agr Sci, Dept Anat Physiol & Biochem, Uppsala, Sweden; [White, Nathan J.] Univ Washington, Dept Med, Div Emergency Med, Seattle, WA USA; [Deutsch, Gail H.] Seattle Childrens Res Inst, Dept Labs, Seattle, WA USA; [Reeves, Stephen R.; Piliponsky, Adrian M.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA; [Vaisar, Tomas] Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA USA	Seattle Children's Hospital; Swedish University of Agricultural Sciences; Uppsala University; Swedish University of Agricultural Sciences; University of Washington; University of Washington Seattle; Seattle Children's Hospital; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Piliponsky, AM (corresponding author), Seattle Childrens Res Inst, Ctr Immun & Immunotherapies, 1900 9th Ave,Rm 721, Seattle, WA 98101 USA.	adrian.piliponsky@seattlechildrens.org	Åbrink, Magnus/AAK-8346-2020	Reeves, Stephen/0000-0002-8552-6022; Vaisar, Tomas/0000-0002-7406-6606; White, Nathan/0000-0002-3752-310X; Abrink, Magnus/0000-0002-1335-3927; Deutsch, Gail/0000-0002-0571-0285	National Institutes of Health (NIH) [HL113351-01]; American Heart Association [12GRNT9680021]; NIH [5R00HL103768-04]; American Association of Immunologists (AAI Careers in Immunology Fellowship); National Center for Advancing Translational Sciences, a component of the NIH [KL2 TR000421]; Parker B. Francis Fellowship; Swedish Research Council; University of Washington's Proteomics Resource [UWPR95794]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR000421, KL2TR002317] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K99HL103768, R00HL103768, R01HL113351] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Association of Immunologists (AAI Careers in Immunology Fellowship); National Center for Advancing Translational Sciences, a component of the NIH; Parker B. Francis Fellowship; Swedish Research Council(Swedish Research CouncilEuropean Commission); University of Washington's Proteomics Resource; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Research for this work was supported by grants for A.M.P. from the National Institutes of Health (NIH) (grant no. HL113351-01) and the American Heart Association (grant no. 12GRNT9680021), for R.G.J. from the NIH (grant no. 5R00HL103768-04), and for N.J.S. by a fellowship from the American Association of Immunologists (2015 AAI Careers in Immunology Fellowship). N.J.W. is supported, in part, by the National Center for Advancing Translational Sciences (grant no. KL2 TR000421), a component of the NIH. S.R.R. was supported by the Parker B. Francis Fellowship. M.A. was supported by the Swedish Research Council. This work is supported in part by the University of Washington's Proteomics Resource (grant no. UWPR95794).	Andersson MK, 2008, MOL IMMUNOL, V45, P766, DOI 10.1016/j.molimm.2007.06.360; Andersson MK, 2009, INT IMMUNOL, V21, P95, DOI 10.1093/intimm/dxn128; Bagoly Z, 2008, THROMB HAEMOSTASIS, V99, P668, DOI 10.1160/TH07-09-0577; Bagoly Z, 2012, THROMB RES, V129, pS77, DOI 10.1016/j.thromres.2012.02.040; Bounab Y, 2013, MOL CELL PROTEOMICS, V12, P2874, DOI 10.1074/mcp.M112.025908; Clair JMS, 2004, J CLIN INVEST, V113, P628, DOI 10.1172/JCI200419062; Cordell PA, 2010, BLOOD, V115, P2674, DOI 10.1182/blood-2009-08-231316; Dardik R, 2007, CELL PHYSIOL BIOCHEM, V19, P113, DOI 10.1159/000099199; de Castro RO, 2012, J BIOL CHEM, V287, P8194, DOI 10.1074/jbc.M111.326850; Douaiher J, 2014, ADV IMMUNOL, V122, P211, DOI 10.1016/B978-0-12-800267-4.00006-7; DUCKERT F, 1972, ANN NY ACAD SCI, V202, P190, DOI 10.1111/j.1749-6632.1972.tb16331.x; DVORAK AM, 1992, J LEUKOCYTE BIOL, V51, P557, DOI 10.1002/jlb.51.6.557; Eckert RL, 2014, PHYSIOL REV, V94, P383, DOI 10.1152/physrev.00019.2013; Galli SJ, 2015, ADV IMMUNOL, V126, P45, DOI 10.1016/bs.ai.2014.11.002; Ge Y, 2001, AM J PATHOL, V158, P281, DOI 10.1016/S0002-9440(10)63967-3; Griffin K, 2015, LANCET, V385, P39; Jayo A, 2009, EUR J CELL BIOL, V88, P423, DOI 10.1016/j.ejcb.2009.04.002; Kato A, 2009, J IMMUNOL, V182, P7233, DOI 10.4049/jimmunol.0801375; Katona E, 2001, J IMMUNOL METHODS, V258, P127, DOI 10.1016/S0022-1759(01)00479-3; Lauer P, 2002, THROMB HAEMOSTASIS, V88, P967, DOI 10.1055/s-0037-1613342; Lee YM, 1998, AM J PATHOL, V153, P931, DOI 10.1016/S0002-9440(10)65634-9; Levi M, 1999, THROMB HAEMOSTASIS, V82, P695; Lilla JN, 2011, BLOOD, V118, P6930, DOI 10.1182/blood-2011-03-343962; Loof TG, 2011, BLOOD, V118, P2589, DOI 10.1182/blood-2011-02-337568; Malbec O, 2007, J IMMUNOL, V178, P6465, DOI 10.4049/jimmunol.178.10.6465; Muszbek L, 2011, PHYSIOL REV, V91, P931, DOI 10.1152/physrev.00016.2010; Nahrendorf M, 2006, CIRCULATION, V113, P1196, DOI 10.1161/CIRCULATIONAHA.105.602094; Patel KN, 2010, J THROMB HAEMOST, V8, P1403, DOI 10.1111/j.1538-7836.2010.03853.x; Pejler G, 2010, BLOOD, V115, P4981, DOI 10.1182/blood-2010-01-257287; Piliponsky AM, 2012, AM J PATHOL, V181, P875, DOI 10.1016/j.ajpath.2012.05.013; Prieto-Garcia A, 2012, J BIOL CHEM, V287, P7834, DOI 10.1074/jbc.M111.325712; RAZIN E, 1984, J IMMUNOL, V132, P1479; Roy A, 2014, J BIOL CHEM, V289, P237, DOI 10.1074/jbc.M112.435156; Sarvary A, 2004, CELL IMMUNOL, V228, P81, DOI 10.1016/j.cellimm.2004.04.007; Schouten M, 2008, J LEUKOCYTE BIOL, V83, P536, DOI 10.1189/jlb.0607373; SCUDAMORE CL, 1995, GUT, V37, P235, DOI 10.1136/gut.37.2.235; Stankovic Katia, 2005, Eur J Intern Med, V16, P387, DOI 10.1016/j.ejim.2005.02.013; STEVENS RL, 1994, P NATL ACAD SCI USA, V91, P128, DOI 10.1073/pnas.91.1.128; Takabayashi T, 2013, J ALLERGY CLIN IMMUN, V132, P584, DOI 10.1016/j.jaci.2013.02.003; Takabayashi T, 2012, J ALLERGY CLIN IMMUN, V130, P410, DOI 10.1016/j.jaci.2012.02.046; Tchougounova E, 2003, J EXP MED, V198, P423, DOI 10.1084/jem.20030671; Wada T, 2010, J CLIN INVEST, V120, P2867, DOI 10.1172/JCI42680; Wastling JM, 1997, IMMUNOLOGY, V90, P308, DOI 10.1046/j.1365-2567.1997.00155.x; Yamaoka K, 2009, INT ARCH ALLERGY IMM, V149, P73, DOI 10.1159/000211376; Zeerleder S, 2007, THROMB RES, V119, P311, DOI 10.1016/j.thromres.2006.02.003; Zhao W, 2005, J IMMUNOL, V175, P2635, DOI 10.4049/jimmunol.175.4.2635	46	20	20	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2017	139	1					323	334		10.1016/j.jaci.2016.03.051	http://dx.doi.org/10.1016/j.jaci.2016.03.051			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EK5WM	27302551	Bronze, Green Accepted			2022-12-18	WOS:000393996800033
J	Pagovich, OE; Wang, B; Chiuchiolo, MJ; Kaminsky, SM; Sondhi, D; Jose, CL; Price, CC; Brooks, SF; Mezey, JG; Crystal, RG				Pagovich, Odelya E.; Wang, Bo; Chiuchiolo, Maria J.; Kaminsky, Stephen M.; Sondhi, Dolan; Jose, Clarisse L.; Price, Christina C.; Brooks, Sarah F.; Mezey, Jason G.; Crystal, Ronald G.			Anti-hIgE gene therapy of peanut-induced anaphylaxis in a humanized murine model of peanut allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Peanut allergy; food allergy; omalizumab; IgE; gene therapy; mouse model	SELECTIVE IGE DEFICIENCY; FOOD ALLERGY; OMALIZUMAB; RISK; HYPERSENSITIVITY; ASTHMA; INFECTIONS; EXPRESSION; MALIGNANCY; SAFETY	Background: Peanuts are the most common food to provoke fatal or near-fatal anaphylactic reactions. Treatment with an anti-hIgE mAb is efficacious but requires frequent parenteral administration. Objective: Based on the knowledge that peanut allergy is mediated by peanut-specific IgE, we hypothesized that a single administration of an adeno-associated virus (AAV) gene transfer vector encoding for anti-hIgE would protect against repeated peanut exposure in the host with peanut allergy. Methods: We developed a novel humanized murine model of peanut allergy that recapitulates the human anaphylactic response to peanuts in NOD-scid IL2Rgamma null mice transferred with blood mononuclear cells from donors with peanut allergy and then sensitized with peanut extract. As therapy, we constructed an adeno-associated rh. 10 serotype vector coding for a full-length, high-affinity, anti-hIgE antibody derived from the Fab fragment of the anti-hIgE mAb omalizumab (AAVrh.10anti-hIgE). In the reconstituted mice peanut-specific IgE was induced by peanut sensitization and hypersensitivity, and reactions were provoked by feeding peanuts to mice with symptoms similar to those of human subjects with peanut allergy. Results: A single administration of AAVrh.10anti-hIgE vector expressed persistent levels of anti-hIgE. The anti-hIgE vector, administered either before sensitization or after peanut sensitization and manifestation of the peanut-induced phenotype, blocked IgE-mediated alterations in peanut-induced histamine release, anaphylaxis scores, locomotor activity, and free IgE levels and protected animals from death caused by anaphylaxis. Conclusion: If this degree of persistent efficacy translates to human subjects, AAVrh. 10anti-hIgE could be an effective 1-time preventative therapy for peanut allergy and possibly other severe, IgE-mediated allergies.	[Pagovich, Odelya E.; Wang, Bo; Chiuchiolo, Maria J.; Kaminsky, Stephen M.; Sondhi, Dolan; Jose, Clarisse L.; Brooks, Sarah F.; Mezey, Jason G.; Crystal, Ronald G.] Weill Cornell Med Coll, Dept Med Genet, 1300 York Ave,Box 164, New York, NY 10065 USA; [Wang, Bo] Sichuan Univ, West China Hosp, Dept Resp Med, Chengdu, Peoples R China; [Price, Christina C.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA; [Price, Christina C.] Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06510 USA; [Mezey, Jason G.] Cornell Univ, Dept Biol Stat & Computat Biol, Ithaca, NY USA	Cornell University; Sichuan University; Yale University; Yale University; Cornell University	Crystal, RG (corresponding author), Weill Cornell Med Coll, Dept Med Genet, 1300 York Ave,Box 164, New York, NY 10065 USA.	geneticmedicine@med.cornell.edu	Kaminsky, Stephen/J-5141-2016	Kaminsky, Stephen/0000-0003-1869-834X	Parker B. Francis Fellowship Program; Department of Genetic Medicine, Weill Cornell Medical College; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000457] Funding Source: NIH RePORTER	Parker B. Francis Fellowship Program; Department of Genetic Medicine, Weill Cornell Medical College; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	Supported by the Parker B. Francis Fellowship Program and the Department of Genetic Medicine, Weill Cornell Medical College.	Ali AK, 2012, J ASTHMA ALLERGY, V5, P1, DOI 10.2147/JAA.S29811; [Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; Babu KS, 2013, EXPERT OPIN BIOL TH, V13, P765, DOI 10.1517/14712598.2013.782391; Brehm MA, 2013, J INFECT DIS, V208, pS125, DOI 10.1093/infdis/jit319; Burton OT, 2011, IMMUNOL REV, V242, P128, DOI 10.1111/j.1600-065X.2011.01024.x; Busse W, 2012, J ALLERGY CLIN IMMUN, V129, P983, DOI 10.1016/j.jaci.2012.01.033; Cooper PJ, 2008, ALLERGY, V63, P409, DOI 10.1111/j.1398-9995.2007.01601.x; Cummings AJ, 2010, ALLERGY, V65, P933, DOI 10.1111/j.1398-9995.2010.02342.x; Du Toit G, 2015, NEW ENGL J MED, V372, P803, DOI 10.1056/NEJMoa1414850; Fanta CH, 2009, NEW ENGL J MED, V360, P1002, DOI 10.1056/NEJMra0804579; Greenblatt MB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044664; Hastie E, 2015, HUM GENE THER, V26, P257, DOI 10.1089/hum.2015.025; Hicks MJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003611; Hox V, 2015, J ALLERGY CLIN IMMUN, V135, P729, DOI 10.1016/j.jaci.2014.11.003; Kim Harold L, 2010, Allergy Asthma Clin Immunol, V6, P32, DOI 10.1186/1710-1492-6-32; Koppelman SJ, 2010, MOL NUTR FOOD RES, V54, P1711, DOI 10.1002/mnfr.201000011; Lai TW, 2015, SCI REP-UK, V5, DOI 10.1038/srep08191; Leung DYM, 2003, NEW ENGL J MED, V348, P986, DOI 10.1056/NEJMoa022613; Li XM, 2000, J ALLERGY CLIN IMMUN, V106, P150, DOI 10.1067/mai.2000.107395; Li XM, 2001, J ALLERGY CLIN IMMUN, V108, P639, DOI 10.1067/mai.2001.118787; Lieberman JA, 2013, CURR ALLERGY ASTHM R, V13, P78, DOI 10.1007/s11882-012-0316-x; Liu Andrew H, 2010, J Allergy Clin Immunol, V126, P798, DOI 10.1016/j.jaci.2010.07.026; Long A, 2014, J ALLERGY CLIN IMMUN, V134, P560, DOI 10.1016/j.jaci.2014.02.007; Magen E, 2015, ALLERGY ASTHMA PROC, V36, P225, DOI 10.2500/aap.2015.36.3825; Magen E, 2014, ALLERGY ASTHMA PROC, V35, pE27, DOI 10.2500/aap.2014.35.3734; Mingozzi F, 2011, NAT REV GENET, V12, P341, DOI 10.1038/nrg2988; Nowak-Wegrzyn A, 2011, J ALLERGY CLIN IMMUN, V127, P558, DOI 10.1016/j.jaci.2010.12.1098; Pate Mariah B, 2010, Clin Mol Allergy, V8, P3, DOI 10.1186/1476-7961-8-3; Roy K, 1999, NAT MED, V5, P387, DOI 10.1038/7385; Sampson HA, 2013, J ALLER CL IMM-PRACT, V1, P15, DOI 10.1016/j.jaip.2012.10.009; Sands MS, 2011, METHODS MOL BIOL, V807, P141, DOI 10.1007/978-1-61779-370-7_6; Schneider LC, 2013, J ALLERGY CLIN IMMUN, V132, P1368, DOI 10.1016/j.jaci.2013.09.046; Sheikh SZ, 2013, EXPERT REV CLIN IMMU, V9, P551, DOI [10.1586/ECI.13.33, 10.1586/eci.13.33]; Sicherer SH, 2013, J ALLER CL IMM-PRACT, V1, P1, DOI 10.1016/j.jaip.2012.10.004; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1322, DOI 10.1016/j.jaci.2010.03.029; Simons FER, 2011, WORLD ALLERGY ORGAN, V4, P13, DOI 10.1097/WOX.0b013e318211496c; Sondhi D, 2012, HUM GENE THER METHOD, V23, P324, DOI 10.1089/hgtb.2012.120; Taylor SL, 2010, FOOD CHEM TOXICOL, V48, P814, DOI 10.1016/j.fct.2009.12.013; Therneau TM., SURVIVAL SURVIVAL AN; van der Heijden J, 2013, J ALLERGY CLIN IMMUN, V131, P1408, DOI 10.1016/j.jaci.2013.02.009; van der Laan LJW, 2011, EXPERT OPIN BIOL TH, V11, P315, DOI 10.1517/14712598.2011.548799; Van Gramberg Jenna L, 2013, J Allergy (Cairo), V2013, P635695, DOI 10.1155/2013/635695; Weigmann B, 2012, J ALLERGY CLIN IMMUN, V129, P1126, DOI 10.1016/j.jaci.2011.11.036; Winter WE, 2000, ARCH PATHOL LAB MED, V124, P1382; Wu LC, 2014, NAT REV IMMUNOL, V14, P247, DOI 10.1038/nri3632	45	20	21	3	29	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2016	138	6					1652	+		10.1016/j.jaci.2016.03.053	http://dx.doi.org/10.1016/j.jaci.2016.03.053			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EF0MK	27372563				2022-12-18	WOS:000390019300021
J	Aygoren-Pursun, E; Magerl, M; Graff, J; Martinez-Saguer, I; Kreuz, W; Longhurst, H; Nasr, I; Bas, M; Strassen, U; Fang, L; Cornpropst, M; Dobo, S; Collis, P; Sheridan, WP; Maurer, M				Aygoeren-Puersuen, Emel; Magerl, Markus; Graff, Jochen; Martinez-Saguer, Inmaculada; Kreuz, Wolfhart; Longhurst, Hilary; Nasr, Iman; Bas, Murat; Strassen, Ulrich; Fang, Lei; Cornpropst, Melanie; Dobo, Sylvia; Collis, Phil; Sheridan, William P.; Maurer, Marcus			Prophylaxis of hereditary angioe-dema attacks: A randomized trial of oral plasma kallikrein inhibition with avoralstat	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							EDEMA; DEFICIENCY; BRADYKININ; VALIDATION		[Aygoeren-Puersuen, Emel] Johann Wolfgang Goethe Univ Hosp, Ctr Pediat 3, Dept Hematol Oncol & Hemostasis, Comprehens Care Ctr Thrombosis & Hemostasis, Frankfurt, Germany; [Magerl, Markus; Maurer, Marcus] Charite, Dept Dermatol & Allergy, Allergie Ctr Charite, Berlin, Germany; [Graff, Jochen] Goethe Univ Frankfurt, Inst Clin Pharmacol, Frankfurt, Germany; [Martinez-Saguer, Inmaculada; Kreuz, Wolfhart] Haemophilia Ctr Rhine Main, Frankfurt, Germany; [Longhurst, Hilary; Nasr, Iman] Barts Hlth NHS Trust, Dept Immunol, London, England; [Bas, Murat; Strassen, Ulrich] Tech Univ Munich, Klinikum Rechts Isar, HNO Klin, Munich, Germany; [Fang, Lei] Pharstat Inc, Durham, NC USA; [Cornpropst, Melanie; Dobo, Sylvia; Collis, Phil; Sheridan, William P.] BioCryst Pharmaceut Inc, Durham, NC USA	Goethe University Frankfurt; Goethe University Frankfurt Hospital; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Goethe University Frankfurt; Barts Health NHS Trust; Technical University of Munich	Maurer, M (corresponding author), Charite, Dept Dermatol & Allergy, Allergie Ctr Charite, Berlin, Germany.	Marcus.Maurer@charite.de	Magerl, Markus/ABI-5335-2020; Maurer, Marcus/ABG-2174-2020	Magerl, Markus/0000-0001-9218-5468; Maurer, Marcus/0000-0002-4121-481X				Babu YS, 2014, J ALLERGY CLIN IMMUN, V133, pAB40, DOI 10.1016/j.jaci.2013.12.167; Bork K, 2012, J ALLERGY CLIN IMMUN, V130, P692, DOI 10.1016/j.jaci.2012.05.055; Bygum A, 2009, BRIT J DERMATOL, V161, P1153, DOI 10.1111/j.1365-2133.2009.09366.x; DONALDSON VH, 1963, AM J MED, V35, P37, DOI 10.1016/0002-9343(63)90162-1; FIELDS T, 1983, J ALLERGY CLIN IMMUN, V72, P54, DOI 10.1016/0091-6749(83)90052-0; Nussberger J, 1998, LANCET, V351, P1693, DOI 10.1016/S0140-6736(97)09137-X; Riedl M, 2011, ANN ALLERG ASTHMA IM, V106, P316, DOI 10.1016/j.anai.2010.12.012; Weller K, 2013, ALLERGY, V68, P1185, DOI 10.1111/all.12209; Weller K, 2012, ALLERGY, V67, P1289, DOI 10.1111/all.12007; Zuraw BL, 2013, J ALLER CL IMM-PRACT, V1, P458, DOI 10.1016/j.jaip.2013.07.002; Zuraw BL, 2010, NEW ENGL J MED, V363, P513, DOI 10.1056/NEJMoa0805538	11	20	20	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2016	138	3					934	+		10.1016/j.jaci.2016.03.043	http://dx.doi.org/10.1016/j.jaci.2016.03.043			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DY9ZM	27302552				2022-12-18	WOS:000385496000042
J	Loke, P; Koplin, J; Beck, C; Field, M; Dharmage, SC; Tang, MLK; Allen, KJ				Loke, Paxton; Koplin, Jennifer; Beck, Cara; Field, Michael; Dharmage, Shyamali C.; Tang, Mimi L. K.; Allen, Katrina J.			Statewide prevalence of school children at risk of anaphylaxis and rate of adrenaline autoinjector activation in Victorian government schools, Australia	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Prevalence; anaphylaxis; adrenaline autoinjector; school students	CHILDHOOD FOOD ALLERGY; METAANALYSIS; EPINEPHRINE; TRENDS; LIFE	Background: The prevalence of school students at risk of anaphylaxis in Victoria is unknown and has not been previously studied. Similarly, rates of adrenaline autoinjector usage in the school environment have yet to be determined given increasing prescription rates. Objectives: We sought to determine time trends in prevalence of school children at risk of anaphylaxis across all year levels and the annual usage rate of adrenaline autoinjectors in the school setting relative to the number of students at risk of anaphylaxis. Methods: Statewide surveys from more than 1,500 government schools including more than 550,000 students were used and prevalence rates (%) with 95% CIs were calculated. Results: The overall prevalence of students at risk of anaphylaxis has increased 41% from 0.98% (95% CI, 0.95-1.01) in 2009 to 1.38% (95% CI, 1.35-1.41) in 2014. There was a significant drop in reporting of anaphylaxis risk with transition from the final year of primary school to the first year of secondary school, suggesting a change in parental reporting of anaphylaxis risk among secondary school students. The number of adrenaline autoinjectors activated per 1000 students at risk of anaphylaxis ranged from 6 to 8 per year, with consistently higher activation use in secondary school students than in primary school students. Conclusions: Statewide prevalence of anaphylaxis risk has increased in children attending Victorian government schools. However, adrenaline autoinjector activation has remained fairly stable despite known increase in the rates of prescription.	[Loke, Paxton; Tang, Mimi L. K.; Allen, Katrina J.] Royal Childrens Hosp, Dept Allergy & Immunol, Parkville, Vic, Australia; [Koplin, Jennifer; Beck, Cara; Field, Michael; Dharmage, Shyamali C.; Tang, Mimi L. K.; Allen, Katrina J.] Murdoch Childrens Res Inst, Parkville, Vic, Australia; [Koplin, Jennifer; Dharmage, Shyamali C.] Univ Melbourne, Ctr Biostat & Epidemiol, Parkville, Vic, Australia; [Beck, Cara; Tang, Mimi L. K.; Allen, Katrina J.] Univ Melbourne, Dept Paediat, Parkville, Vic, Australia; [Allen, Katrina J.] Univ Manchester, Inst Inflammat & Repair, Manchester, Lancs, England	Royal Children's Hospital Melbourne; Murdoch Children's Research Institute; University of Melbourne; University of Melbourne; University of Manchester	Allen, KJ (corresponding author), Royal Childrens Hosp, Murdoch Childrens Res Inst, Flemington Rd, Parkville, Vic 3052, Australia.	katie.allen@rch.org.au	Tang, Mimi/ABD-8350-2020; Allen, Katrina/I-4361-2018	Tang, Mimi/0000-0002-3839-5293; Allen, Katrina/0000-0002-1921-4493; Beck, Cara/0000-0001-9423-6687; Koplin, Jennifer/0000-0002-7576-5142	National Health and Medical Research Council of Australia	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia)	J.K., S.C.D., and K.J.A. hold National Health and Medical Research Council of Australia fellowship awards.	Allen CW, 2007, MED J AUSTRALIA, V187, P542, DOI 10.5694/j.1326-5377.2007.tb01402.x; Colver A, 2006, BMJ-BRIT MED J, V333, P494, DOI 10.1136/bmj.333.7566.494; Kemp AS, 2003, J PAEDIATR CHILD H, V39, P372, DOI 10.1046/j.1440-1754.2003.00157.x; Koplin JJ, 2015, INT J EPIDEMIOL, V44, P1161, DOI 10.1093/ije/dyu261; Lieberman JA, 2010, ANN ALLERG ASTHMA IM, V105, P282, DOI 10.1016/j.anai.2010.07.011; Liew WK, 2009, J ALLERGY CLIN IMMUN, V123, P434, DOI 10.1016/j.jaci.2008.10.049; Mabbott V, 2011, AUSTR STAT MED 2011; McIntyre CL, 2005, PEDIATRICS, V116, P1134, DOI 10.1542/peds.2004-1475; Mullins RJ, 2010, CLIN EXP ALLERGY, V40, P1523, DOI 10.1111/j.1365-2222.2010.03573.x; Mullins RJ, 2015, J ALLERGY CLIN IMMUN, V136, P367, DOI 10.1016/j.jaci.2015.05.009; Noimark L, 2012, CLIN EXP ALLERGY, V42, P284, DOI 10.1111/j.1365-2222.2011.03912.x; Nwaru BI, 2014, ALLERGY, V69, P992, DOI 10.1111/all.12423; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, P668, DOI 10.1016/j.jaci.2011.01.039; Peters RL, 2015, J ALLERGY CLIN IMMUN, V135; Pinczower GD, 2013, J ALLERGY CLIN IMMUN, V131, P238, DOI 10.1016/j.jaci.2012.09.038; Poulos LM, 2007, J ALLERGY CLIN IMMUN, V120, P878, DOI 10.1016/j.jaci.2007.07.040; Rona RJ, 2007, J ALLERGY CLIN IMMUN, V120, P638, DOI 10.1016/j.jaci.2007.05.026; Sampson MA, 2006, J ALLERGY CLIN IMMUN, V117, P1440, DOI 10.1016/j.jaci.2006.03.009; Shemesh E, 2013, PEDIATRICS, V131, pE10, DOI 10.1542/peds.2012-1180; Simons FER, 2015, WORLD ALLERGY ORGAN, V8, DOI 10.1186/s40413-015-0080-1; Umasunthar T, 2013, CLIN EXP ALLERGY, V43, P1333, DOI 10.1111/cea.12211; White MV, 2015, ALLERGY ASTHMA PROC, V36, P306, DOI 10.2500/aap.2015.36.3859	22	20	25	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2016	138	2					529	535		10.1016/j.jaci.2016.02.014	http://dx.doi.org/10.1016/j.jaci.2016.02.014			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DS5PY	27084405	Bronze			2022-12-18	WOS:000380835800024
J	Li, JG; Leyva-Castillo, JM; Hener, P; Eisenmann, A; Zaafouri, S; Jonca, N; Serre, G; Birling, MC; Li, M				Li, Jiagui; Leyva-Castillo, Juan Manuel; Hener, Pierre; Eisenmann, Aurelie; Zaafouri, Sarra; Jonca, Nathalie; Serre, Guy; Birling, Marie-Christine; Li, Mei			Counterregulation between thymic stromal lymphopoietin- and IL-23-driven immune axes shapes skin inflammation in mice with epidermal barrier defects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Epidermal barrier; corneodesmosin; atopic dermatitis; peeling skin syndrome type B; thymic stromal lymphopoietin; IL-23; T(H)2; T(H)17; IL-1 beta; skin inflammation; mouse model	ATOPIC-DERMATITIS; MOUSE KERATINOCYTES; TSLP; EXPRESSION; IL-23; CELLS; ACTIVATION; CYTOKINES; DISEASE; DYSFUNCTION	Background: Epidermal barrier dysfunction has been recognized as a critical factor in the initiation and exacerbation of skin inflammation, particularly in patients with atopic dermatitis (AD) and AD-like congenital disorders, including peeling skin syndrome type B. However, inflammatory responses developed in barrier-defective skin, as well as the underlying mechanisms, remained incompletely understood. Objective: We aimed to decipher inflammatory axes and the cytokine network in mouse skin on breakdown of epidermal stratum corneum barrier. Methods: We generated Cdsn(iep-/-) mice with corneodesmosin ablation in keratinocytes selectively in an inducible manner. We characterized inflammatory responses and cytokine expression by using histology, immunohistochemistry, ELISA, and quantitative PCR. We combined mouse genetic tools, antibody-mediated neutralization, signal-blocking reagents, and topical antibiotic treatment to explore the inflammatory axes. Results: We show that on breakdown of the epidermal stratum corneum barrier, type 2 and type 17 inflammatory responses are developed simultaneously, driven by thymic stromal lymphopoietin (TSLP) and IL-23, respectively. Importantly, we reveal a counterregulation between these 2 inflammatory axes. Furthermore, we show that protease-activated receptor 2 signaling is involved in mediating the TSLP/type 2 axis, whereas skin bacteria are engaged in induction of the IL-23/type 17 axis. Moreover, we find that IL-1 beta is induced in skin of Cdsn(iep-/-) mice and that blockade of IL-1 signaling suppresses both TSLP and IL-23 expression and ameliorates skin inflammation. Conclusion: The inflammatory phenotype in barrier-defective skin is shaped by counterregulation between the TSLP/type 2 and IL-23/type 17 axes. Targeting IL-1 signaling could be a promising therapeutic option for controlling skin inflammation in patients with peeling skin syndrome type B and other diseases related to epidermal barrier dysfunction, including AD.	[Li, Jiagui; Leyva-Castillo, Juan Manuel; Hener, Pierre; Eisenmann, Aurelie; Li, Mei] Univ Strasbourg, CNRS UMR7104, INSERM U964, Inst Genet & Biol Mol & Cellulaire, Illkirch Graffenstaden, France; [Zaafouri, Sarra; Jonca, Nathalie; Serre, Guy] Univ Toulouse 3, CNRS UMR 165, INSERM U1056, Differenciat Epiderm & Autoimmun Rhumatoide, Toulouse, France; [Birling, Marie-Christine] Inst Clin Souris, Illkirch Graffenstaden, France; [Li, Mei] Univ Strasbourg, Inst Adv Study, Strasbourg, France; [Li, Mei] Freiburg Inst Adv Studies, Freiburg, Germany; [Leyva-Castillo, Juan Manuel] Harvard Med Sch, Childrens Hosp, Div Immunol, Boston, MA USA; [Leyva-Castillo, Juan Manuel] Harvard Med Sch, Dept Pediat, Boston, MA USA	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School	Li, M (corresponding author), Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France.	mei@igbmc.fr	Jonca, Nathalie/AAX-3870-2020	Jonca, Nathalie/0000-0003-3602-0102; Leyva Castillo, Juan Manuel/0000-0001-7394-4457; Birling, Marie-Christine/0000-0002-3372-8108; Li, Mei/0000-0003-4225-6699	l'Agence Nationale de la Recherche [ANR-13-BSV1-0024, ANR-15-CE14-0009]; Fondation Simone et Cino Del Duca (Institut de France); Joint Programme of the Freiburg Institute for Advanced Studies (FRIAS) and the University of Strasbourg Institute for Advanced Study (USIAS); Societe Francaise d'Allergologie (SFA); Association pour la Recherche a l'IGBMC; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (INSERM); Universite de Strasbourg (Unistra)	l'Agence Nationale de la Recherche(French National Research Agency (ANR)); Fondation Simone et Cino Del Duca (Institut de France); Joint Programme of the Freiburg Institute for Advanced Studies (FRIAS) and the University of Strasbourg Institute for Advanced Study (USIAS); Societe Francaise d'Allergologie (SFA); Association pour la Recherche a l'IGBMC; Centre National de la Recherche Scientifique (CNRS)(Centre National de la Recherche Scientifique (CNRS)); Institut National de la Sante et de la Recherche Medicale (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Universite de Strasbourg (Unistra)	Supported by l'Agence Nationale de la Recherche (grant nos. ANR-13-BSV1-0024 and ANR-15-CE14-0009), Fondation Simone et Cino Del Duca (Institut de France), the Joint Programme of the Freiburg Institute for Advanced Studies (FRIAS) and the University of Strasbourg Institute for Advanced Study (USIAS), Societe Francaise d'Allergologie (SFA), the Association pour la Recherche a l'IGBMC, the Centre National de la Recherche Scientifique (CNRS), the Institut National de la Sante et de la Recherche Medicale (INSERM), and the Universite de Strasbourg (Unistra).	Bjerkan L, 2015, MUCOSAL IMMUNOL, V8, P49, DOI 10.1038/mi.2014.41; Bogiatzi SI, 2012, J ALLERGY CLIN IMMUN, V130, P233, DOI 10.1016/j.jaci.2012.04.038; Boguniewicz M, 2013, J ALLERGY CLIN IMMUN, V132, P511, DOI 10.1016/j.jaci.2013.06.030; Boguniewicz M, 2011, IMMUNOL REV, V242, P233, DOI 10.1111/j.1600-065X.2011.01027.x; Briot A, 2010, J INVEST DERMATOL, V130, P2736, DOI 10.1038/jid.2010.233; Briot A, 2009, J EXP MED, V206, P1135, DOI 10.1084/jem.20082242; Cai YH, 2011, IMMUNITY, V35, P596, DOI 10.1016/j.immuni.2011.08.001; Cho JS, 2010, J CLIN INVEST, V120, P1762, DOI 10.1172/JCI40891; Choy DF, 2012, J ALLERGY CLIN IMMUN, V130, P1335, DOI 10.1016/j.jaci.2012.06.044; Cork MJ, 2009, J INVEST DERMATOL, V129, P1892, DOI 10.1038/jid.2009.133; Croxford AL, 2012, EUR J IMMUNOL, V42, P2263, DOI 10.1002/eji.201242598; Dhingra N, 2013, J ALLERGY CLIN IMMUN, V132, P498, DOI 10.1016/j.jaci.2013.04.043; Dinarello CA, 2013, SEMIN IMMUNOL, V25, P469, DOI 10.1016/j.smim.2013.10.008; Eyerich K, 2013, ALLERGY, V68, P974, DOI 10.1111/all.12184; Frateschi S, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1162; Furio L, 2014, J EXP MED, V211, P499, DOI 10.1084/jem.20131797; Gauvreau GM, 2014, NEW ENGL J MED, V370, P2102, DOI 10.1056/NEJMoa1402895; Gittler JK, 2012, J ALLERGY CLIN IMMUN, V130, P1344, DOI 10.1016/j.jaci.2012.07.012; Guenova E, 2015, P NATL ACAD SCI USA, V112, P2163, DOI 10.1073/pnas.1416922112; Hener P, 2011, J INVEST DERMATOL, V131, P2324, DOI 10.1038/jid.2011.208; Hovnanian A, 2013, CELL TISSUE RES, V351, P289, DOI 10.1007/s00441-013-1558-1; Kezic S, 2012, J ALLERGY CLIN IMMUN, V129, P1031, DOI 10.1016/j.jaci.2011.12.989; Kobayashi T, 2015, IMMUNITY, V42, P756, DOI 10.1016/j.immuni.2015.03.014; Koga C, 2008, J INVEST DERMATOL, V128, P2625, DOI 10.1038/jid.2008.111; Kubo A, 2012, J CLIN INVEST, V122, P440, DOI 10.1172/JCI57416; Kypriotou M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067869; Lambrecht BN, 2012, NAT MED, V18, P684, DOI 10.1038/nm.2737; Leclerc EA, 2009, J CELL SCI, V122, P2699, DOI 10.1242/jcs.050302; Leyva-Castillo JM, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3847; Li CJ, 2010, P NATL ACAD SCI USA, V107, P4687, DOI 10.1073/pnas.0912807107; Li M, 2005, P NATL ACAD SCI USA, V102, P14795, DOI 10.1073/pnas.0507385102; Li M, 2006, P NATL ACAD SCI USA, V103, P11736, DOI 10.1073/pnas.0604575103; Li M, 2009, J INVEST DERMATOL, V129, P498, DOI 10.1038/jid.2008.232; Matsumoto M, 2008, P NATL ACAD SCI USA, V105, P6720, DOI 10.1073/pnas.0709345105; Moniaga CS, 2013, AM J PATHOL, V182, P841, DOI 10.1016/j.ajpath.2012.11.039; Montes-Torres A, 2015, J CLIN MED, V4, P593, DOI 10.3390/jcm4040593; Murthy A, 2012, IMMUNITY, V36, P105, DOI 10.1016/j.immuni.2012.01.005; Naik S, 2012, SCIENCE, V337, P1115, DOI 10.1126/science.1225152; Nakamura Y, 2013, NATURE, V503, P397, DOI 10.1038/nature12655; Neurath MF, 2007, NAT MED, V13, P26, DOI 10.1038/nm0107-26; Oji V, 2010, AM J HUM GENET, V87, P274, DOI 10.1016/j.ajhg.2010.07.005; Oyoshi MK, 2009, J ALLERGY CLIN IMMUN, V124, P485, DOI 10.1016/j.jaci.2009.05.042; Peterson LW, 2014, NAT REV IMMUNOL, V14, P141, DOI 10.1038/nri3608; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Samuelov L, 2014, J ALLERGY CLIN IMMUN, V134, P808, DOI 10.1016/j.jaci.2014.07.061; Sonesson A, 2011, EXP DERMATOL, V20, P1004, DOI 10.1111/j.1600-0625.2011.01391.x; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Suarez-Farinas M, 2013, J ALLERGY CLIN IMMUN, V132, P361, DOI 10.1016/j.jaci.2013.04.046; Taylor BC, 2009, J EXP MED, V206, P655, DOI 10.1084/jem.20081499; Teng MWL, 2015, NAT MED, V21, P719, DOI 10.1038/nm.3895; Volpe E, 2014, J ALLERGY CLIN IMMUN, V134, P373, DOI 10.1016/j.jaci.2014.04.022; Vu AT, 2010, J ALLERGY CLIN IMMUN, V126, P985, DOI 10.1016/j.jaci.2010.09.002; Werfel T, 2015, CURR OPIN ALLERGY CL, V15, P446, DOI 10.1097/ACI.0000000000000199; Wilson SR, 2013, CELL, V155, P285, DOI 10.1016/j.cell.2013.08.057; Yockey LJ, 2013, J INVEST DERMATOL, V133, P2714, DOI 10.1038/jid.2013.228; Yoo J, 2005, J EXP MED, V202, P541, DOI 10.1084/jem.20041503; Zhang Z, 2009, P NATL ACAD SCI USA, V106, P1536, DOI 10.1073/pnas.0812668106; Ziegler SF, 2012, J ALLERGY CLIN IMMUN, V130, P845, DOI 10.1016/j.jaci.2012.07.010	58	20	21	2	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2016	138	1					150	+		10.1016/j.jaci.2016.01.013	http://dx.doi.org/10.1016/j.jaci.2016.01.013			25	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DR1IL	26993035	Bronze			2022-12-18	WOS:000379659100017
J	Happel, CS; Stone, KD; Freeman, AF; Shah, NN; Wang, A; Lyons, JJ; Guerrerio, PA; Hickstein, DD; Su, HC				Happel, Corinne S.; Stone, Kelly D.; Freeman, Alexandra F.; Shah, Nirali N.; Wang, Angela; Lyons, Jonathan J.; Guerrerio, Pamela A.; Hickstein, Dennis D.; Su, Helen C.			Food allergies can persist after myeloablative hematopoietic stem cell transplantation in dedicator of cytokinesis 8-deficient patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							BONE-MARROW-TRANSPLANTATION; FARM MILK CONSUMPTION; DOCK8 DEFICIENCY; CHILDHOOD ASTHMA; LONG; ASSOCIATION; EXPRESSION; MICRORNAS		[Happel, Corinne S.; Su, Helen C.] NIAID, Lab Host Defenses, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Stone, Kelly D.; Lyons, Jonathan J.; Guerrerio, Pamela A.] NIAID, Lab Allerg Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Freeman, Alexandra F.] NIAID, Lab Clin Infect Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Shah, Nirali N.] NCI, Pediat Oncol Branch, NIH, Bethesda, MD 20892 USA; [Hickstein, Dennis D.] NCI, Expt Transplantat & Immunol Branch, NIH, Bethesda, MD 20892 USA; [Wang, Angela] Frederick Natl Lab Canc Res, Clin Res Directorate, Clin Monitoring Res Program, Leidos Biomed Res, Frederick, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Su, HC (corresponding author), NIAID, Lab Host Defenses, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	hsu@niaid.nih.gov	Guerrerio, Pamela/S-9360-2019; Su, Helen C/H-9541-2015	Su, Helen C/0000-0002-5582-9110; Lyons, Jonathan/0000-0002-2346-8189	NATIONAL CANCER INSTITUTE [ZIABC011374] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001193, ZIAAI001202] Funding Source: NIH RePORTER; CCR NIH HHS [HHSN261200800001C] Funding Source: Medline; Intramural NIH HHS [ZIA AI001193-02] Funding Source: Medline; NCI NIH HHS [HHSN261200800001E] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); CCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aydin SE, 2015, J CLIN IMMUNOL, V35, P189, DOI 10.1007/s10875-014-0126-0; Barlogis V, 2011, J ALLERGY CLIN IMMUN, V128, P420, DOI 10.1016/j.jaci.2011.03.025; Bittner TC, 2010, KLIN PADIATR, V222, P351, DOI 10.1055/s-0030-1265135; Bosco A, 2010, MUCOSAL IMMUNOL, V3, P399, DOI 10.1038/mi.2010.13; Boztug H, 2012, PEDIATR HEMAT ONCOL, V29, P585, DOI 10.3109/08880018.2012.714844; Brick T, 2016, J ALLERGY CLIN IMMUN, V137, P1699, DOI 10.1016/j.jaci.2015.10.042; Burge SW, 2013, NUCLEIC ACIDS RES, V41, pD226, DOI 10.1093/nar/gks1005; Chawes BL, 2015, J ALLERGY CLIN IMMUN, V135, P1450; Chen X, 2010, CELL RES, V20, P1128, DOI 10.1038/cr.2010.80; Cobb BS, 2006, J EXP MED, V203, P2519, DOI 10.1084/jem.20061692; Cuellar-Rodriguez J, 2015, BIOL BLOOD MARROW TR, V21, P1037, DOI 10.1016/j.bbmt.2015.01.022; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Frischmeyer-Guerrerio PA, 2008, J ALLERGY CLIN IMMUN, V122, P1031, DOI 10.1016/j.jaci.2008.08.032; Hata T, 2010, BIOCHEM BIOPH RES CO, V396, P528, DOI 10.1016/j.bbrc.2010.04.135; He S, 2013, BLOOD, V121, P4663, DOI 10.1182/blood-2012-07-441360; Hourihane JO, 2005, ALLERGY, V60, P536, DOI 10.1111/j.1398-9995.2005.00752.x; Hsu SD, 2014, NUCLEIC ACIDS RES, V42, pD78, DOI 10.1093/nar/gkt1266; Illi S, 2012, J ALLERGY CLIN IMMUN, V129, P1470, DOI 10.1016/j.jaci.2012.03.013; Khan F, 2009, BLOOD, V113, P279, DOI 10.1182/blood-2008-01-128686; Kong Y, 2011, GENOMICS, V98, P152, DOI 10.1016/j.ygeno.2011.05.009; Kosaka Nobuyoshi, 2010, Silence, V1, P7, DOI 10.1186/1758-907X-1-7; Kozomara A, 2014, NUCLEIC ACIDS RES, V42, pD68, DOI 10.1093/nar/gkt1181; Kumar M, 2011, J ALLERGY CLIN IMMUN, V128, P1077, DOI 10.1016/j.jaci.2011.04.034; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Litonjua AA, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-52; Loss G, 2015, J ALLERGY CLIN IMMUN, V135, P56, DOI 10.1016/j.jaci.2014.08.044; Loss G, 2011, J ALLERGY CLIN IMMUN, V128, P766, DOI 10.1016/j.jaci.2011.07.048; Lotz MT, 2012, CURR ALLERGY ASTHM R, V12, P380, DOI 10.1007/s11882-012-0278-z; Message SD, 2008, P NATL ACAD SCI USA, V105, P13562, DOI 10.1073/pnas.0804181105; Metin A, 2012, PEDIATR TRANSPLANT, V16, P398, DOI 10.1111/j.1399-3046.2011.01641.x; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Ober C, 2006, GENES IMMUN, V7, P95, DOI 10.1038/sj.gene.6364284; Okoye IS, 2014, P NATL ACAD SCI USA, V111, pE3081, DOI 10.1073/pnas.1406322111; Okoye IS, 2014, IMMUNITY, V41, P89, DOI [10.1016/j.immuni.2014.05.019, 10.1016/j.immuni.2014.08.008]; Stacklies W, 2007, BIOINFORMATICS, V23, P1164, DOI 10.1093/bioinformatics/btm069; Tarazona S, 2011, GENOME RES, V21, P2213, DOI 10.1101/gr.124321.111; Vercelli D, 2008, NAT REV IMMUNOL, V8, P169, DOI 10.1038/nri2257; Voleti B, 2005, J IMMUNOL, V175, P3386, DOI 10.4049/jimmunol.175.5.3386; Waser M, 2007, CLIN EXP ALLERGY, V37, P661, DOI 10.1111/j.1365-2222.2006.02640.x; Xue LZ, 2012, J IMMUNOL, V188, P694, DOI 10.4049/jimmunol.1102474; Zhang Q, 2009, NEW ENGL J MED, V361, P2046, DOI 10.1056/NEJMoa0905506	42	20	20	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2016	137	6					1895	+		10.1016/j.jaci.2015.11.017	http://dx.doi.org/10.1016/j.jaci.2015.11.017			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DO1GT	26827248	Bronze, Green Accepted			2022-12-18	WOS:000377527200036
J	Migliavacca, M; Assanelli, A; Ferrua, F; Cicalese, MP; Biffi, A; Frittoli, M; Silvani, P; Chidini, G; Calderini, E; Mandelli, A; Camporesi, A; Milani, R; Farinelli, G; Nicoletti, R; Ciceri, F; Aiuti, A; Bernardo, ME				Migliavacca, Maddalena; Assanelli, Andrea; Ferrua, Francesca; Cicalese, Maria Pia; Biffi, Alessandra; Frittoli, Marta; Silvani, Paolo; Chidini, Giovanna; Calderini, Edoardo; Mandelli, Anna; Camporesi, Anna; Milani, Raffaella; Farinelli, Giada; Nicoletti, Roberto; Ciceri, Fabio; Aiuti, Alessandro; Bernardo, Maria Ester			Pioglitazone as a novel therapeutic approach in chronic granulomatous disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							STEM-CELL TRANSPLANTATION; REAL-TIME PCR; MUTATIONS; DIAGNOSIS; CHILDREN; UNIFRAC		[Migliavacca, Maddalena; Ferrua, Francesca; Cicalese, Maria Pia; Biffi, Alessandra; Frittoli, Marta; Aiuti, Alessandro; Bernardo, Maria Ester] Ist Sci San Raffaele, San Raffaele Telethon Inst Gene Therapy TIGET, Pediat Immunohematol & Bone Marrow Transplantat U, I-20132 Milan, Italy; [Assanelli, Andrea; Ciceri, Fabio] Ist Sci San Raffaele, Hematol & Bone Marrow Transplantat Unit, I-20132 Milan, Italy; [Silvani, Paolo] Hosp San Raffaele, Dept Anesthesia & Crit Care, I-20132 Milan, Italy; [Chidini, Giovanna; Calderini, Edoardo] Osped Maggiore Policlin, Fdn IRCCS Ca Granda, Dept Anesthesia & Crit Care, Pediat Intens Care Unit, Milan, Italy; [Camporesi, Anna; Milani, Raffaella] Children Hosp V Buzzi, Pediat Anesthesia & Intens Care, Milan, Italy; [Milani, Raffaella] Ist Sci San Raffaele, Cytometry Lab, I-20132 Milan, Italy; [Farinelli, Giada] Ist Sci San Raffaele, San Raffaele Telethon Inst Gene Therapy TIGET, I-20132 Milan, Italy; [Nicoletti, Roberto] Ist Sci San Raffaele, Dept Radiol, I-20132 Milan, Italy	Fondazione Telethon; San Raffaele Telethon Institute For Gene Therapy (Sr-Tiget); Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; IRCCS Ca Granda Ospedale Maggiore Policlinico; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Fondazione Telethon; San Raffaele Telethon Institute For Gene Therapy (Sr-Tiget); Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Aiuti, A (corresponding author), Ist Sci San Raffaele, San Raffaele Telethon Inst Gene Therapy TIGET, Pediat Immunohematol & Bone Marrow Transplantat U, I-20132 Milan, Italy.	a.aiuti@hsr.it	AIUTI, ALESSANDRO/K-3918-2016; Ferrua, Francesca/K-4340-2016; Calderini, Edoardo/AAE-2595-2022; Biffi, Alessandra/AAA-8890-2019; Calderini, Edoardo/P-4826-2015	AIUTI, ALESSANDRO/0000-0002-5398-1717; Ferrua, Francesca/0000-0002-5695-4490; Calderini, Edoardo/0000-0002-7466-9407; Camporesi, Anna/0000-0002-1160-1456	Telethon [TGTGSK06] Funding Source: Medline	Telethon(Fondazione Telethon)		Beckham JD, 2005, J INFECTION, V50, P322, DOI 10.1016/j.jinf.2004.07.011; Bernardo ME, 2012, BLOOD, V120, P473, DOI 10.1182/blood-2012-04-423822; Caporaso JG, 2012, ISME J, V6, P1621, DOI 10.1038/ismej.2012.8; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Cole T, 2013, J ALLERGY CLIN IMMUN, V132, P1150, DOI 10.1016/j.jaci.2013.05.031; Di Matteo G, 2009, MOL IMMUNOL, V46, P1935, DOI 10.1016/j.molimm.2009.03.016; Edgar RC, 2013, NAT METHODS, V10, P996, DOI [10.1038/NMETH.2604, 10.1038/nmeth.2604]; Edgar RC, 2010, BIOINFORMATICS, V26, P2460, DOI 10.1093/bioinformatics/btq461; Fernandez-Boyanapalli RF, 2015, J ALLERGY CLIN IMMUN, V135, P517, DOI 10.1016/j.jaci.2014.10.034; Gennery AR, 2010, J ALLERGY CLIN IMMUN, V126, P602, DOI 10.1016/j.jaci.2010.06.015; Gennery AR, 2010, J ALLERGY CLIN IMMUN, V126, pe1; Gungor T, 2014, LANCET, V383, P436, DOI [10.1016/s0140-6736(13)62069-3, 10.1016/S0140-6736(13)62069-3]; Holland SM, 2010, CLIN REV ALLERG IMMU, V38, P3, DOI 10.1007/s12016-009-8136-z; Huttenhower C, 2012, NATURE, V486, P207, DOI 10.1038/nature11234; Knorr L, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-62; Lieberthal AS, 2006, PEDIATRICS, V118, P1774, DOI 10.1542/peds.2006-2223; Lozupone C, 2005, APPL ENVIRON MICROB, V71, P8228, DOI 10.1128/AEM.71.12.8228-8235.2005; Lozupone C, 2011, ISME J, V5, P169, DOI 10.1038/ismej.2010.133; Mansbach JM, 2012, ARCH PEDIAT ADOL MED, V166, P700, DOI 10.1001/archpediatrics.2011.1669; McMurdie PJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061217; Methe BA, 2012, NATURE, V486, P215, DOI 10.1038/nature11209; Ott MG, 2006, NAT MED, V12, P401, DOI 10.1038/nm1393; Quast C, 2013, NUCLEIC ACIDS RES, V41, pD590, DOI 10.1093/nar/gks1219; Roos D, 2010, BLOOD CELL MOL DIS, V44, P291, DOI 10.1016/j.bcmd.2010.01.009; Team R Core, 2014, R LANG ENV STAT COMP; Winchell JM, 2008, J CLIN MICROBIOL, V46, P3116, DOI 10.1128/JCM.00440-08	26	20	21	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2016	137	6					1913	+		10.1016/j.jaci.2016.01.033	http://dx.doi.org/10.1016/j.jaci.2016.01.033			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DO1GT	27056268	hybrid, Green Published			2022-12-18	WOS:000377527200042
J	Hosoki, K; Boldogh, I; Aguilera-Aguirre, L; Sun, Q; Itazawa, T; Hazra, T; Brasier, AR; Kurosky, A; Sur, S				Hosoki, Koa; Boldogh, Istvan; Aguilera-Aguirre, Leopoldo; Sun, Qian; Itazawa, Toshiko; Hazra, Tapas; Brasier, Allan R.; Kurosky, Alexander; Sur, Sanjiv			Myeloid differentiation protein 2 facilitates pollen- and cat dander-induced innate and allergic airway inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic inflammation; antigen; cat dander; pollen; MD2; neutrophil; nuclear factor kappa B; ragweed; Toll-like receptor 4	RECEPTOR 4; BACTERIAL LIPOPOLYSACCHARIDE; ASTHMA; MD-2; ACTIVATION; TLR4; SENSITIZATION; NEUTROPHILS; BINDING; RESPONSIVENESS	Background: The National Health and Nutrition Examination Survey identified several pollens and cat dander as among the most common allergens that induce allergic sensitization and allergic diseases. We recently reported that ragweed pollen extract (RWPE) requires Toll-like receptor 4 (TLR4) to stimulate CXCL-mediated innate neutrophilic inflammation, which in turn facilitates allergic sensitization and airway inflammation. Myeloid differentiation protein 2 (MD2) is a TLR4 coreceptor, but its role in pollen-and cat dander-induced innate and allergic inflammation has not been critically evaluated. Objective: We sought to elucidate the role of MD2 in inducing pollen-and cat dander-induced innate and allergic airway inflammation. Methods: TCMNull (TLR4(Null), CD14(Null), MD2(Null)), TLR4(Hi), and TCMHi cells and human bronchial epithelial cells with small interferingRNA-induced downregulation of MD2 were stimulated with RWPE, other pollen allergic extracts, or cat dander extract (CDE), and activation of nuclear factor kappa B(NF-kappa B), secretion of the NF-kappa B-dependent CXCL8, or both were quantified. Wild-type mice or mice with small interfering RNA knockdown of lung MD2 were challenged intranasally with RWPE or CDE, and innate and allergic inflammation was quantified. Results: RWPE stimulated MD2-dependent NF-kappa B activation and CXCL secretion. Likewise, Bermuda, rye, timothy, pigweed, Russian thistle, cottonwood, walnut, and CDE stimulated MD2-dependent CXCL secretion. RWPE and CDE challenge induced MD2-dependent and CD14-independent innate neutrophil recruitment. RWPE induced MD2-dependent allergic sensitization and airway inflammation. Conclusions: MD2 plays an important role in induction of allergic sensitization to cat dander and common pollens relevant to human allergic diseases.	[Hosoki, Koa; Sun, Qian; Itazawa, Toshiko; Brasier, Allan R.; Sur, Sanjiv] Univ Texas Med Branch, Dept Internal Med, Div Allergy & Immunol, Galveston, TX 77555 USA; [Boldogh, Istvan; Aguilera-Aguirre, Leopoldo] Univ Texas Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA; [Boldogh, Istvan; Hazra, Tapas; Brasier, Allan R.; Kurosky, Alexander; Sur, Sanjiv] Univ Texas Med Branch, Sealy Ctr Mol Med, Galveston, TX 77555 USA; [Hazra, Tapas] Univ Texas Med Branch, Dept Internal Med, Div Pulm Crit Care & Sleep Med, Galveston, TX 77555 USA; [Kurosky, Alexander] Univ Texas Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Sur, S (corresponding author), Univ Texas Med Branch, 301 Univ Blvd, Galveston, TX 77555 USA.	sasur@UTMB.edu	; Aguilera-Aguirre, Leopoldo/B-9864-2012	Hosoki, Koa/0000-0003-4228-2176; Aguilera-Aguirre, Leopoldo/0000-0001-7964-7402; Brasier, Allan/0000-0002-5012-4090	National Institutes of Allergy and Infectious Diseases [P01 AI062885-06]; National Institute of Environmental Health Sciences (NIEHS) [RO1 ES18948]; National Heart, Lung, and Blood Institute Proteomic Center [N01HV00245]; NIEHS [T32 ES007254]; Leon Bromberg Professorship at the University of Texas Medical Branch; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001439] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI062885] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES018948, T32ES007254] Funding Source: NIH RePORTER	National Institutes of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institute of Environmental Health Sciences (NIEHS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); National Heart, Lung, and Blood Institute Proteomic Center; NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Leon Bromberg Professorship at the University of Texas Medical Branch; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by National Institutes of Allergy and Infectious Diseases grant P01 AI062885-06, National Institute of Environmental Health Sciences (NIEHS) grant RO1 ES18948, and National Heart, Lung, and Blood Institute Proteomic Center grant N01HV00245, NIEHS grant T32 ES007254, and a Leon Bromberg Professorship at the University of Texas Medical Branch.	Alvira CM, 2007, AM J RESP CRIT CARE, V175, P805, DOI 10.1164/rccm.200608-1162OC; Ben Haij N, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-123; Boldogh I, 2005, J CLIN INVEST, V115, P2169, DOI 10.1172/JCI24422; Correia JD, 2001, J BIOL CHEM, V276, P21129, DOI 10.1074/jbc.M009164200; Erridge C, 2008, J BIOL CHEM, V283, P24748, DOI 10.1074/jbc.M800352200; Haeberle HA, 2004, J VIROL, V78, P2232, DOI 10.1128/JVI.78.5.2232-2241.2004; Hajjar AM, 2002, NAT IMMUNOL, V3, P354, DOI 10.1038/ni777; Hammad H, 2009, NAT MED, V15, P410, DOI 10.1038/nm.1946; Herre J, 2013, J IMMUNOL, V191, P1529, DOI 10.4049/jimmunol.1300284; Hoskins A, 2013, AM J RESP CRIT CARE, V187, P34, DOI 10.1164/rccm.201204-0786OC; Hosoki K., 2015, AM J RESP CELL MOL B; Hosoki K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126035; HUNT LW, 1994, AM J RESP CRIT CARE, V149, P1471, DOI 10.1164/ajrccm.149.6.8004300; Jatakanon A, 1999, AM J RESP CRIT CARE, V160, P1532, DOI 10.1164/ajrccm.160.5.9806170; Junker Y, 2012, J EXP MED, V209, P2395, DOI 10.1084/jem.20102660; Lammermann T, 2013, NATURE, V498, P371, DOI 10.1038/nature12175; Li DQ, 2011, J ALLERGY CLIN IMMUN, V128, P1318, DOI 10.1016/j.jaci.2011.06.041; Lien E, 2000, J CLIN INVEST, V105, P497, DOI 10.1172/JCI8541; Lommatzsch M, 2006, J ALLERGY CLIN IMMUN, V118, P91, DOI 10.1016/j.jaci.2006.02.034; Mantovani A, 2011, NAT REV IMMUNOL, V11, P519, DOI 10.1038/nri3024; McCaskill J, 2013, MOL THER-NUCL ACIDS, V2, DOI 10.1038/mtna.2013.22; METZGER WJ, 1986, CHEST, V89, P477, DOI 10.1378/chest.89.4.477; Mocsai A, 2013, J EXP MED, V210, P1283, DOI 10.1084/jem.20122220; Nagai Y, 2002, NAT IMMUNOL, V3, P667, DOI 10.1038/ni809; Oyoshi MK, 2012, IMMUNITY, V37, P747, DOI 10.1016/j.immuni.2012.06.018; Peluso MR, 2010, PLANTA MED, V76, P1536, DOI 10.1055/s-0029-1241013; Rada B, 2014, AM J RESP CELL MOL, V50, P125, DOI 10.1165/rcmb.2013-0254OC; Raghavan B, 2012, EMBO REP, V13, P1109, DOI 10.1038/embor.2012.155; Salo PM, 2014, J ALLERGY CLIN IMMUN, V134, P350, DOI 10.1016/j.jaci.2013.12.1071; Salo PM, 2011, J ALLERGY CLIN IMMUN, V127, P1226, DOI 10.1016/j.jaci.2010.12.1106; Shalaby KH, 2013, J IMMUNOL, V191, P922, DOI 10.4049/jimmunol.1103644; Sharma S, 2012, PEDIAT ALLERG IMM-UK, V23, P315, DOI 10.1111/j.1399-3038.2011.01243.x; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Shirey KA, 2013, NATURE, V497, P498, DOI 10.1038/nature12118; Sporik R, 1999, THORAX, V54, P675, DOI 10.1136/thx.54.8.675; SUR S, 1993, AM REV RESPIR DIS, V148, P713, DOI 10.1164/ajrccm/148.3.713; Trompette A, 2009, NATURE, V457, P585, DOI 10.1038/nature07548; Viriyakosol S, 2001, J BIOL CHEM, V276, P38044; Wang XH, 2013, FASEB J, V27, P2713, DOI 10.1096/fj.12-222992; Wang Z, 2015, MOL BIOSYST, V11, P1933, DOI 10.1039/c5mb00085h; Wild JS, 2000, J IMMUNOL, V164, P2701, DOI 10.4049/jimmunol.164.5.2701	41	20	21	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2016	137	5					1506	+		10.1016/j.jaci.2015.09.036	http://dx.doi.org/10.1016/j.jaci.2015.09.036			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DM2MF	26586036	Green Accepted, Bronze			2022-12-18	WOS:000376180200027
J	Huang, CC; Kim, YS; Olson, WP; Li, FX; Guo, CX; Luo, WQ; Huang, AJW; Liu, Q				Huang, Cheng-Chiu; Kim, Yu Shin; Olson, William P.; Li, Fengxian; Guo, Changxiong; Luo, Wenqin; Huang, Andrew J. W.; Liu, Qin			A histamine-independent itch pathway is required for allergic ocular itch	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							PLATELET-ACTIVATING-FACTOR; PATHOPHYSIOLOGY		[Huang, Cheng-Chiu; Li, Fengxian; Guo, Changxiong; Liu, Qin] Washington Univ, Sch Med, Dept Anesthesiol, St Louis, MO 63110 USA; [Huang, Cheng-Chiu; Li, Fengxian; Guo, Changxiong; Liu, Qin] Washington Univ, Sch Med, Ctr Study Itch, St Louis, MO 63110 USA; [Kim, Yu Shin] Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; [Olson, William P.; Luo, Wenqin] Univ Penn, Sch Med, Dept Neurosci, Philadelphia, PA 19104 USA; [Li, Fengxian] Southern Med Univ, Dept Anesthesiol, Zhujiang Hosp, Guangzhou, Guangdong, Peoples R China; [Huang, Andrew J. W.; Liu, Qin] Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Johns Hopkins University; University of Pennsylvania; Southern Medical University - China; Washington University (WUSTL)	Liu, Q (corresponding author), Washington Univ, Sch Med, Dept Anesthesiol, St Louis, MO 63110 USA.; Liu, Q (corresponding author), Washington Univ, Sch Med, Ctr Study Itch, St Louis, MO 63110 USA.; Liu, Q (corresponding author), Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA.	liuqi@anest.wustl.edu		LI, FENGXIAN/0000-0002-3307-1468; Huang, Andrew JW/0000-0003-1939-9149	NATIONAL EYE INSTITUTE [R01EY024704] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F31NS092297] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY024704, R01EY024704] Funding Source: Medline; NINDS NIH HHS [R01 NS083702, F31 NS092297] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Galli SJ, 2008, NATURE, V454, P445, DOI 10.1038/nature07204; Gill P, 2015, J ALLERGY CLIN IMMUN, V135, P1424, DOI 10.1016/j.jaci.2015.04.019; Hu Y, 2007, ALLERGY, V62, P917, DOI 10.1111/j.1398-9995.2007.01414.x; Metcalfe DD, 1997, PHYSIOL REV, V77, P1033, DOI 10.1152/physrev.1997.77.4.1033; Ono SJ, 2005, J ALLERGY CLIN IMMUN, V115, P118, DOI 10.1016/j.jaci.2004.10.042; Raap U, 2011, CURR OPIN ALLERGY CL, V11, P420, DOI 10.1097/ACI.0b013e32834a41c2; Shim WS, 2007, J NEUROSCI, V27, P2331, DOI 10.1523/JNEUROSCI.4643-06.2007; Wilson SR, 2011, NAT NEUROSCI, V14, P595, DOI 10.1038/nn.2789; WOODWARD DF, 1995, J PHARMACOL EXP THER, V272, P758	9	20	22	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2016	137	4					1267	+		10.1016/j.jaci.2015.08.047	http://dx.doi.org/10.1016/j.jaci.2015.08.047			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DI2TG	26521042	Green Accepted, Bronze			2022-12-18	WOS:000373351200042
J	Oliver, ET; Sterba, PM; Devine, K; Vonakis, BM; Saini, SS				Oliver, Eric Tyrell; Sterba, Patricia Meghan; Devine, Kelly; Vonakis, Becky M.; Saini, Sarbjit Singh			Altered expression of chemoattractant receptor-homologous molecule expressed on T(H)2 cells on blood basophils and eosinophils in patients with chronic spontaneous urticaria	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CRTH2		[Oliver, Eric Tyrell; Sterba, Patricia Meghan; Devine, Kelly; Vonakis, Becky M.; Saini, Sarbjit Singh] Johns Hopkins Univ, Sch Med, Dept Med, Div Clin Immunol & Allergy, Baltimore, MD 21205 USA	Johns Hopkins University	Oliver, ET (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Div Clin Immunol & Allergy, Baltimore, MD 21205 USA.	eolive15@jhmi.edu	Vonakis, Becky/GSN-7958-2022	Vonakis, Becky/0000-0003-4174-6514				Diamant Z, 2014, CLIN EXP ALLERGY, V44, P1044, DOI 10.1111/cea.12357; Hamada Kazuyuki, 2004, Allergology International, V53, P179, DOI 10.1111/j.1440-1592.2004.00323.x; Ito Y, 2011, ALLERGY, V66, P1107, DOI 10.1111/j.1398-9995.2011.02570.x; Palikhe NS, 2009, PHARMACOGENOMICS, V10, P375, DOI 10.2217/14622416.10.3.375; Puxeddu I, 2013, INT ARCH ALLERGY IMM, V162, P330, DOI 10.1159/000354922; RORSMAN H, 1961, ACTA ALLERGOL, V16, P185, DOI 10.1111/j.1398-9995.1961.tb02894.x; Saini SS, 2014, IMMUNOL ALLERGY CLIN, V34, P33, DOI 10.1016/j.iac.2013.09.012; Tedeschi A, 2013, EUR ANN ALLERGY CLIN, V45, P188; Yahara H, 2010, J EUR ACAD DERMATOL, V24, P75, DOI 10.1111/j.1468-3083.2009.03267.x	9	20	21	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2016	137	1					304	306		10.1016/j.jaci.2015.06.004	http://dx.doi.org/10.1016/j.jaci.2015.06.004			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DA3UK	26194547	Bronze			2022-12-18	WOS:000367724300024
J	Kenney, P; Hilberg, O; Laursen, AC; Peel, RG; Sigsgaard, T				Kenney, Peter; Hilberg, Ole; Laursen, Anne Cathrine; Peel, Robert George; Sigsgaard, Torben			Preventive effect of nasal filters on allergic rhinitis: A randomized, double-blind, placebo-controlled crossover park study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Seasonal allergic rhinitis; nasal filter; placebo controlled; randomized controlled trial; total nasal symptom score; total ocular symptom score; pollen; efficacy; allergen avoidance; prevention	QUALITY-OF-LIFE; CLINICAL-TRIAL; SPRAY; SYMPTOMS; EFFICACY; OUTDOOR; SAFETY; ASTHMA; IMPACT; ONSET	Background: A recently reported small, out-of-season environmental exposure unit study found nasal filters to be efficacious in preventing seasonal allergic rhinitis (AR). However, nasal filters still need to show efficacy in a natural setting in a regular pollen season. Objective: We sought to evaluate the efficacy of nasal filters (Rhinix; Rhinix ApS, Aarhus, Denmark) for the prevention of symptoms related to seasonal AR. Methods: The trial was a single-center, randomized (1: 1), double-blind, placebo-controlled crossover clinical trial (NCT02108574) conducted over 2 days in the main grass pollen season in June 2014 in Aarhus, Denmark, on 65 adults with proven grass allergy. A total nasal symptom score (TNSS) consisting of blocked nose, runny nose, nasal itching, and sneezing was used to evaluate symptoms. The difference in daily(Sigma) TNSS (the sum of 13 ratings) was the primary outcome measure. The difference in maximum TNSS (highest score, 13 ratings) was also evaluated. Results: The nasal filters significantly reduced daily(Sigma) TNSSs (P = .03) and maximum TNSSs (P = .03) compared with placebo. Median relative reductions were 40% for daily(Sigma) TNSSs (P = .02), 43% for maximum TNSSs (P = .004), 83% for daily(Sigma) sneezing (P = .001), 75% for daily(Sigma) watery eyes (P = .02), and 53% for daily(Sigma) runny nose (P = .005) when compared with placebo. The nasal filters were well tolerated, and no serious adverse events were recorded. Conclusion: Statistically significant and clinically relevant reductions were achieved for the primary outcome measure of daily(Sigma) TNSS, for maximum TNSS and for a subset of individual symptoms. The results support the preventive role of nasal filters for managing seasonal AR.	[Kenney, Peter; Sigsgaard, Torben] Aarhus Univ, Dept Publ Hlth, Sect Environm Occupat & Hlth, DK-8000 Aarhus C, Denmark; [Kenney, Peter] Rhinix ApS, Aarhus, Denmark; [Hilberg, Ole] Aarhus Univ Hosp, Dept Resp Dis & Allergol, DK-8000 Aarhus, Denmark; [Laursen, Anne Cathrine] Aarhus Univ, Aarhus, Denmark; [Peel, Robert George] Aarhus Univ, Dept Environm Sci, Roskilde, Denmark	Aarhus University; Aarhus University; Aarhus University; Aarhus University	Sigsgaard, T (corresponding author), Aarhus Univ, Dept Publ Hlth, Sect Environm Occupat & Hlth, Bartholins Alle 2,Bldg 1260, DK-8000 Aarhus C, Denmark.	ts@ph.au.dk	Sigsgaard, Torben/AAC-1292-2020; Peel, Robert/B-9683-2013	Sigsgaard, Torben/0000-0002-2043-7571; Peel, Robert/0000-0001-9948-9528	Rhinix ApS, Aarhus, Denmark	Rhinix ApS, Aarhus, Denmark	Supported by Rhinix ApS, Aarhus, Denmark, and designed to be consistent with recommendations provided in the US Food and Drug Administration document for clinical development of drug products for allergic rhinitis (Guidance for Industry, US Department of Health and Human Services, US Food and Drug Administration Center for Drug Evaluation and Research, April 2000).	Akerlund Anders, 2005, J Allergy Clin Immunol, V115, pS460, DOI 10.1016/j.jaci.2004.12.016; Berkowitz RB, 1999, ALLERGY ASTHMA PROC, V20, P167, DOI 10.2500/108854199778553037; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Clayton D, 1987, STAT CONSULTANT ACTI, P42; CONNELL JT, 1969, J ALLERGY, V43, P33, DOI 10.1016/0021-8707(69)90018-5; D'Amato G, 2013, EUR ANN ALLERGY CLIN, V45, P167; D'Amato G, 2012, EUR ANN ALLERGY CLIN, V44, P83; Day J. H., 2006, Clinical and Experimental Allergy Reviews, V6, P31, DOI 10.1111/j.1365-2222.2005.00099.x; FDA-Food and Drug Administration, 2000, GUID IND FUM LEV HUM, P1; Georgitis JW, 2000, ANN ALLERG ASTHMA IM, V84, P451, DOI 10.1016/S1081-1206(10)62280-6; Greiner AN, 2011, LANCET, V378, P2112, DOI 10.1016/S0140-6736(11)60130-X; Kaiser HB, 2007, J ALLERGY CLIN IMMUN, V119, P1430, DOI 10.1016/j.jaci.2007.02.022; Kenney P, 2014, J ALLERGY CLIN IMMUN, V133, pe1; Kenney P, 2014, J ALLERGY CLIN IMMUN, V133, P1477, DOI 10.1016/j.jaci.2014.01.004; Leynaert B, 2000, AM J RESP CRIT CARE, V162, P1391, DOI 10.1164/ajrccm.162.4.9912033; Meltzer Eli O, 2012, J Fam Pract, V61, pS5; Meltzer EO, 1999, ANN ALLERG ASTHMA IM, V83, P311, DOI 10.1016/S1081-1206(10)62671-3; Meltzer EO, 1996, J ALLERGY CLIN IMMUN, V97, P617, DOI 10.1016/S0091-6749(96)70307-X; Meltzer EO, 2005, J ALLERGY CLIN IMMUN, V115, P791, DOI 10.1016/j.jaci.2005.01.040; Meltzer EO, 2003, ANN ALLERG ASTHMA IM, V90, P79, DOI 10.1016/S1081-1206(10)63618-6; Meltzer EO, 2001, ANN ALLERG ASTHMA IM, V86, P286, DOI 10.1016/S1081-1206(10)63300-5; O'Meara TJ, 2005, ALLERGY, V60, P529, DOI 10.1111/j.1398-9995.2005.00741.x; Plaut M, 2005, NEW ENGL J MED, V353, P1934, DOI 10.1056/NEJMcp044141; Schoenwetter WF, 2004, CURR MED RES OPIN, V20, P305, DOI 10.1185/030079903125003053; Stuck BA, 2004, J ALLERGY CLIN IMMUN, V113, P663, DOI 10.1016/j.jaci.2003.12.589; Thompson AK, 2000, ANN ALLERG ASTHMA IM, V85, P338, DOI 10.1016/S1081-1206(10)62543-4; WEILER JM, 1994, J ALLERGY CLIN IMMUN, V94, P972, DOI 10.1016/0091-6749(94)90115-5	28	20	21	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2015	136	6					1566	U213		10.1016/j.jaci.2015.05.015	http://dx.doi.org/10.1016/j.jaci.2015.05.015			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CX9RZ	26141263	Bronze			2022-12-18	WOS:000366044300018
J	Magnusson, J; Kull, I; Westman, M; Hakansson, N; Wolk, A; Melen, E; Wickman, M; Bergstrom, A				Magnusson, Jessica; Kull, Inger; Westman, Marit; Hakansson, Niclas; Wolk, Alicja; Melen, Erik; Wickman, Magnus; Bergstrom, Anna			Fish and polyunsaturated fat intake and development of allergic and nonallergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Adolescent; allergic rhinitis; BAMSE; children; diet; fatty acid; fish; nonallergic rhinitis; prospective studies; vitamin D	HEALTH SURVEY; ACID INTAKE; VITAMIN-D; ASTHMA; DISEASES; AGE; CONSUMPTION; PREVALENCE; ECZEMA; RISK	Background: Rhinitis is one of the most common diseases in childhood. Fish, polyunsaturated fatty acid (PUFA), and vitamin D intakes have been hypothesized to affect the risk of allergic disease; however, it is unclear whether these are linked to the development of rhinitis. Objective: We sought to assess potential associations between consumption of fish, dietary n-3 and n-6 PUFAs, and vitamin D at age 8 years and development of allergic rhinitis (AR) and nonallergic rhinitis (NAR) between the ages of 8 and 16 years. Methods: We included 1970 participants from a birth cohort. Data on dietary intake was obtained from a food frequency questionnaire at age 8 years. The rhinitis definition was based on questionnaires and IgE measures. Results: The prevalence of rhinitis symptoms at age 8 years was 19% (n = 380). Among the 1590 children without rhinitis symptoms at age 8 years, 21% (n = 337) had AR between ages 8 and 16 years, and 15% (n = 236) had NAR. Regular intake of oily fish and higher long-chain n-3 PUFA intake were associated with a reduced risk of cumulative incidence of NAR (adjusted odds ratio, 0.52 [95% CI, 0.32-0.87] for oily fish; odds ratio, 0.45 [95% CI, 0.30-0.67] for highest vs lowest tertile of long-chain n-3 PUFAs; P trend <.001). The results for rhinitis, irrespective of AR and NAR, were in line with the findings for NAR. Conclusion: Regular consumption of oily fish and dietary long-chain n-3 PUFAs in childhood might decrease the risk of rhinitis, especially NAR, between the ages of 8 and 16 years.	[Magnusson, Jessica; Kull, Inger; Hakansson, Niclas; Wolk, Alicja; Melen, Erik; Wickman, Magnus; Bergstrom, Anna] Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden; [Kull, Inger] Karolinska Inst, Dept Educ & Clin Sci, S-10401 Stockholm, Sweden; [Westman, Marit] Karolinska Inst, Dept Clin Sci Intervent & Technol, S-10401 Stockholm, Sweden; [Kull, Inger; Melen, Erik; Wickman, Magnus] South Gen Hosp, Sachs Childrens Hosp, Dept Pediat, Stockholm, Sweden; [Westman, Marit] Karolinska Univ Hosp, Dept ENT Dis, Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital	Magnusson, J (corresponding author), Box 210, SE-17177 Stockholm, Sweden.	Jessica.Magnusson@ki.se	; Hakansson, Niclas/L-7913-2013	Kull, Inger/0000-0001-6096-3771; Hakansson, Niclas/0000-0001-7673-5554	Stockholm County Council; Swedish Research Council; Swedish Research Council Formas; Swedish Heart-Lung Foundation; Swedish Asthma and Allergy Association; Swedish Research Council for Health, Working Life and Welfare; European Commission [261357]	Stockholm County Council(Stockholm County Council); Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Research Council Formas(Swedish Research CouncilSwedish Research Council Formas); Swedish Heart-Lung Foundation(Swedish Heart-Lung Foundation); Swedish Asthma and Allergy Association; Swedish Research Council for Health, Working Life and Welfare(Swedish Research CouncilSwedish Research Council for Health Working Life & Welfare (Forte)); European Commission(European CommissionEuropean Commission Joint Research Centre)	Supported by the Stockholm County Council; the Swedish Research Council; the Swedish Research Council Formas; the Swedish Heart-Lung Foundation; the Swedish Asthma and Allergy Association; the Swedish Research Council for Health, Working Life and Welfare; and the European Commission's Seventh Framework 29 Program MeDALL (grant agreement no. 261357). Thermo Fisher Scientific kindly provided the reagents. The funding sources had no active role in the conducted research.	Alm B, 2011, PEDIAT ALLERG IMM-UK, V22, P398, DOI 10.1111/j.1399-3038.2011.01153.x; Andreasyan K, 2005, ALLERGY, V60, P671, DOI 10.1111/j.1398-9995.2005.00757.x; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Ballardini N, 2012, ALLERGY, V67, P537, DOI 10.1111/j.1398-9995.2012.02786.x; Barbieri H. E., 2006, RIKSMATEN CHILDREN 2; Beard S, 2014, PRIMARY CARE, V41, P33, DOI 10.1016/j.pop.2013.10.005; Bergstrom L., 1991, Var Foda, V43, P439; Black PN, 1997, EUR RESPIR J, V10, P6, DOI 10.1183/09031936.97.10010006; Bousquet J, 2008, ALLERGY, V63, P842, DOI 10.1111/j.1398-9995.2008.01715.x; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Chatzi L, 2007, THORAX, V62, P677, DOI 10.1136/thx.2006.069419; Dunder T, 2001, ALLERGY, V56, P425, DOI 10.1034/j.1398-9995.2001.056005425.x; Ekstrom S, 2015, CLIN EXP ALLERGY, V45, P283, DOI 10.1111/cea.12340; Farchi S, 2003, EUR RESPIR J, V22, P772, DOI 10.1183/09031936.03.00006703; Hoff S, 2005, EUR J CLIN NUTR, V59, P1071, DOI 10.1038/sj.ejcn.1602213; Hollams EM, 2011, EUR RESPIR J, V38, P1320, DOI 10.1183/09031936.00029011; Huang SL, 2001, CLIN EXP ALLERGY, V31, P259, DOI 10.1046/j.1365-2222.2001.00938.x; Huang SL, 2001, CLIN EXP ALLERGY, V31, P1875, DOI 10.1046/j.1365-2222.2001.01222.x; Jacobs TS, 2014, J ALLERGY CLIN IMMUN, V134, P737, DOI 10.1016/j.jaci.2014.03.028; Keil T, 2010, PEDIAT ALLERG IMM-UK, V21, P962, DOI 10.1111/j.1399-3038.2010.01046.x; Kremmyda LS, 2011, CLIN REV ALLERG IMMU, V41, P36, DOI 10.1007/s12016-009-8186-2; Kull I, 2004, J ALLERGY CLIN IMMUN, V114, P755, DOI 10.1016/j.jaci.2004.07.036; Kull I, 2006, ALLERGY, V61, P1009, DOI 10.1111/j.1398-9995.2006.01115.x; Kurukulaaratchy RJ, 2015, J ALLERGY CLIN IMMUN, V135, P143, DOI 10.1016/j.jaci.2014.06.017; Lieberman P, 2014, CURR ALLERGY ASTHM R, V14, DOI 10.1007/s11882-014-0439-3; Magnusson J, 2013, AM J CLIN NUTR, V97, P1324, DOI 10.3945/ajcn.112.045377; Miles EA, 2014, CURR PHARM DESIGN, V20, P946, DOI 10.2174/138161282006140220125732; Miyake Y, 2007, J AM COLL NUTR, V26, P279, DOI 10.1080/07315724.2007.10719612; Miyake Y, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-358; Muehleisen B, 2013, J ALLERGY CLIN IMMUN, V131, P324, DOI 10.1016/j.jaci.2012.12.1562; Nafstad P, 2003, J ASTHMA, V40, P343, DOI 10.1081/JAS-120018633; Nordic Council of Ministers, 2014, NORD NUTR REC 2012 I; Rondon C, 2014, J ALLERGY CLIN IMMUN, V133, P1026, DOI 10.1016/j.jaci.2013.10.034; Sole D, 2015, J PEDIAT-BRAZIL, V91, P30, DOI 10.1016/j.jped.2014.05.002; Trak-Fellermeier MA, 2004, EUR RESPIR J, V23, P575, DOI 10.1183/09031936.04.00074404; Virtanen SM, 2010, BRIT J NUTR, V103, P266, DOI 10.1017/S0007114509991541; Wendell SG, 2014, J ALLERGY CLIN IMMUN, V133, P1255, DOI 10.1016/j.jaci.2013.12.1087; West CE, 2010, CURR OPIN PEDIATR, V22, P635, DOI 10.1097/MOP.0b013e32833d96ef; Westman M, 2013, ALLERGY, V68, P1571, DOI 10.1111/all.12267; Westman M, 2012, J ALLERGY CLIN IMMUN, V129, P403, DOI 10.1016/j.jaci.2011.09.036; Willett WC, 1997, AM J CLIN NUTR, V65, P1220, DOI 10.1093/ajcn/65.4.1220S	41	20	20	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2015	136	5					1247	+		10.1016/j.jaci.2015.05.030	http://dx.doi.org/10.1016/j.jaci.2015.05.030			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CW1YE	26152316	hybrid			2022-12-18	WOS:000364787200013
J	Romberg, N; Virdee, M; Chamberlain, N; Oe, T; Schickel, JN; Perkins, T; Cantaert, T; Rachid, R; Rosengren, S; Palazzo, R; Geha, R; Cunningham-Rundles, C; Meffre, E				Romberg, Neil; Virdee, Manmeet; Chamberlain, Nicolas; Oe, Tyler; Schickel, Jean-Nicolas; Perkins, Tiffany; Cantaert, Tineke; Rachid, Rima; Rosengren, Sally; Palazzo, Regina; Geha, Raif; Cunningham-Rundles, Charlotte; Meffre, Eric			TNF receptor superfamily member 13b (TNFRSF13B) hemizygosity reveals transmembrane activator and CAML interactor haploinsufficiency at later stages of B-cell development	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						TNFRSF13B; transmembrane activator and CAML interactor; B-cell tolerance; common variable immune deficiency; Smith-Magenis syndrome	COMMON VARIABLE IMMUNODEFICIENCY; T-FOLLICULAR HELPER; TACI MUTATIONS; DEFICIENCY; TOLERANCE; LIGAND; EXPRESSION; APRIL; BAFF	Background: Heterozygous C104R or A181E TNF receptor superfamily member 13b (TNFRSF13B) mutations impair removal of autoreactive B cells, weaken B-cell activation, and convey to patients with common variable immune deficiency (CVID) an increased risk for autoimmunity. How mutant transmembrane activator and CAML interactor (TACI) influences wild-type TACI function is unclear; different models suggest either a dominant negative effect or haploinsufficiency. Objective: We investigated potential TACI haploinsufficiency by analyzingpatientswith antibody-deficient Smith-Magenis syndrome (SMS) who possess only 1 TNFRSF13B allele and antibody-deficient patients carrying one c.204insA TNFRSF13B null mutation. Methods: We tested the reactivity of antibodies isolated from single B cells from patients with SMS and patients with a c.204insA TNFRSF13B mutation and compared them with counterparts from patients with CVID with heterozygous C104R or A181E TNFRSF13B missense mutations. We also assessed whether loss of a TNFRSF13B allele induced haploinsufficiency in naive and memory B cells and recapitulated abnormal immunologic features typical of patients with CVID with heterozygous TNFRSF13B missense mutations. Results: We found that loss of a TNFRSF13B allele does not affect TACI expression, activation responses, or establishment of central B-cell tolerance in naive B cells. Additionally, patients with SMS and those with a c.204insA TNFRSF13B mutation display normal regulatory T-cell function and peripheral B-cell tolerance. The lack of a TNFRSF13B allele did result in decreased TACI expression on memory B cells, resulting in impaired activation and antibody secretion. Conclusion: TNFRSF13B hemizygosity does not recapitulate autoimmune features of CVID-associated C104R and A181E TNFRSF13B mutations, which likely encode dominant negative products, but instead reveals selective TACI haploinsufficiency at later stages of B-cell development.	[Romberg, Neil; Virdee, Manmeet; Perkins, Tiffany; Palazzo, Regina] Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06511 USA; [Chamberlain, Nicolas; Oe, Tyler; Schickel, Jean-Nicolas; Cantaert, Tineke; Meffre, Eric] Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06511 USA; [Meffre, Eric] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06511 USA; [Rachid, Rima; Geha, Raif] Harvard Univ, Childrens Hosp, Sch Med, Dept Pediat,Div Immunol, Boston, MA 02115 USA; [Rosengren, Sally] Univ Connecticut, Sch Med, Dept Pediat, Hartford, CT 06112 USA; [Cunningham-Rundles, Charlotte] Mt Sinai Med Ctr, Dept Med, New York, NY 10029 USA	Yale University; Yale University; Yale University; Harvard University; Boston Children's Hospital; Harvard Medical School; University of Connecticut; Icahn School of Medicine at Mount Sinai	Meffre, E (corresponding author), Yale Univ, Sch Med, 300 George St, New Haven, CT 06511 USA.	neil.romberg@yale.edu; eric.meffre@yale.edu	cantaert, tineke/HGB-2648-2022	cantaert, tineke/0000-0002-8911-1502; Romberg, Neil/0000-0002-1881-5318; Oe, Tyler/0000-0001-7178-7822	National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) [AI071087, AI082713, AI095848]; NIH/NIAID [AI061093, K23AI115001]; NIH/National Institute of Child Health and Human Development [K12HD0141401-10]; NIH/National Center for Advancing Translational Sciences [UL1 TR000142]; Rubicon, Netherlands Organization for Scientific Research; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI115001, U24AI086037, R21AI095848, R18AI048693, U19AI082713, R01AI071087, P01AI061093] Funding Source: NIH RePORTER	National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH/NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH/National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIH/National Center for Advancing Translational Sciences; Rubicon, Netherlands Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by grant nos. AI071087, AI082713, and AI095848 from the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID; to E.M.), AI061093 from the NIH/NIAID (to E.M and C.C.-R.), K23AI115001 from the NIH/NIAID, K12HD0141401-10 from the NIH/National Institute of Child Health and Human Development, and UL1 TR000142 from the NIH/National Center for Advancing Translational Sciences (to N.R.). T.C. received support from Rubicon, Netherlands Organization for Scientific Research.	Al-Herz W, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00162; Arumugakani G, 2010, J CLIN IMMUNOL, V30, P292, DOI 10.1007/s10875-009-9351-3; Castigli E, 2005, NAT GENET, V37, P829, DOI 10.1038/ng1601; Castigli E, 2005, J EXP MED, V201, P35, DOI 10.1084/jem.20032000; Castigli E, 2007, J ALLERGY CLIN IMMUN, V120, P885, DOI 10.1016/j.jaci.2007.06.012; Chinen J, 2011, J ALLERGY CLIN IMMUN, V127, P1579, DOI 10.1016/j.jaci.2011.02.046; Conley ME, 1999, CLIN IMMUNOL, V93, P190, DOI 10.1006/clim.1999.4799; Cunningham-Rundles C, 2010, BLOOD, V116, P7, DOI 10.1182/blood-2010-01-254417; Elsea SH, 2008, EUR J HUM GENET, V16, P412, DOI 10.1038/sj.ejhg.5202009; Garibyan L, 2007, J CLIN INVEST, V117, P1550, DOI 10.1172/JCI31023; He B, 2010, NAT IMMUNOL, V11, P836, DOI 10.1038/ni.1914; Herve M, 2007, J EXP MED, V204, P1583, DOI 10.1084/jem.20062287; Isnardi I, 2008, IMMUNITY, V29, P746, DOI 10.1016/j.immuni.2008.09.015; Janssen E, 2014, J ALLERGY CLIN IMMUN, V134, P1365, DOI 10.1016/j.jaci.2014.07.042; Katsenelson N, 2007, EUR J IMMUNOL, V37, P1785, DOI 10.1002/eji.200636800; Kinnunen T, 2013, BLOOD, V121, P1595, DOI 10.1182/blood-2012-09-457465; Knight AK, 2007, CLIN IMMUNOL, V124, P182, DOI 10.1016/j.clim.2007.04.012; Lee JJ, 2010, J ALLERGY CLIN IMMUN, V126, P1234, DOI 10.1016/j.jaci.2010.08.017; Lee JJ, 2009, BLOOD, V114, P2254, DOI 10.1182/blood-2008-11-189720; Litinskiy MB, 2002, NAT IMMUNOL, V3, P822, DOI 10.1038/ni829; Martinez-Gallo M, 2013, J ALLERGY CLIN IMMUN, V131, P468, DOI 10.1016/j.jaci.2012.10.029; Meffre E, 2011, ANN NY ACAD SCI, V1246, P1, DOI 10.1111/j.1749-6632.2011.06347.x; Meyers G, 2011, P NATL ACAD SCI USA, V108, P11554, DOI 10.1073/pnas.1102600108; Morita R, 2011, IMMUNITY, V34, P108, DOI 10.1016/j.immuni.2010.12.012; Ng YS, 2004, J EXP MED, V200, P927, DOI 10.1084/jem.20040920; Nurieva RI, 2009, SCIENCE, V325, P1001, DOI 10.1126/science.1176676; Ou XJ, 2012, P NATL ACAD SCI USA, V109, P15401, DOI 10.1073/pnas.1200386109; Romberg N, 2013, J CLIN INVEST, V123, P4283, DOI 10.1172/JCI69854; Salzer U, 2005, NAT GENET, V37, P820, DOI 10.1038/ng1600; Salzer U, 2009, BLOOD, V113, P1967, DOI 10.1182/blood-2008-02-141937; Sauer AV, 2012, J CLIN INVEST, V122, P2141, DOI 10.1172/JCI61788; Tsuji S, 2011, BLOOD, V118, P5832, DOI 10.1182/blood-2011-05-353961; Wardemann H, 2003, SCIENCE, V301, P1374, DOI 10.1126/science.1086907; Wehr C, 2008, BLOOD, V111, P77, DOI 10.1182/blood-2007-06-091744; Wu YM, 2000, J BIOL CHEM, V275, P35478, DOI 10.1074/jbc.M005224200; Yu GP, 2009, CLIN IMMUNOL, V131, P240, DOI 10.1016/j.clim.2008.12.006; Zhang L, 2007, J ALLERGY CLIN IMMUN, V120, P1178, DOI 10.1016/j.jaci.2007.10.001	37	20	20	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2015	136	5					1315	1325		10.1016/j.jaci.2015.05.012	http://dx.doi.org/10.1016/j.jaci.2015.05.012			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CW1YE	26100089	Green Accepted			2022-12-18	WOS:000364787200022
J	Collison, AM; Sokulsky, LA; Sherrill, JD; Nightingale, S; Hatchwell, L; Talley, NJ; Walker, MM; Rothenberg, ME; Mattes, J				Collison, Adam M.; Sokulsky, Leon A.; Sherrill, Joseph D.; Nightingale, Scott; Hatchwell, Luke; Talley, Nicholas J.; Walker, Marjorie M.; Rothenberg, Marc E.; Mattes, Joerg			TNF-related apoptosis-inducing ligand (TRAIL) regulates midline-1, thymic stromal lymphopoietin, inflammation, and remodeling in experimental eosinophilic esophagitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eosinophilic esophagitis; allergy; tissue remodeling; fibrosis; cytokine; TNF-related apoptosis-inducing ligand; midline-1; protein phosphatase 2Ac; nuclear factor kappa B; thymic stromal lymphopoietin; IL-25; CCL20; CCL24; CCL11	PROTEIN PHOSPHATASE 2A; ALLERGIC AIRWAYS DISEASE; ELIMINATION DIET; SERINE/THREONINE PHOSPHATASE; EPITHELIAL-CELLS; GENE-EXPRESSION; CHILDREN; ADULTS; IDENTIFICATION; FLUTICASONE	Background: Eosinophilic esophagitis (EoE) is an inflammatory disorder of the esophagus defined by eosinophil infiltration and tissue remodeling with resulting symptoms of esophageal dysfunction. TNF-related apoptosis-inducing ligand (TRAIL) promotes inflammation through upregulation of the E3 ubiquitin-ligase midline-1 (MID1), which binds to and deactivates the catalytic subunit of protein phosphatase 2Ac, resulting in increased nuclear factor kappa B activation. Objective: We sought to elucidate the role of TRAIL in EoE. Methods: We used Aspergillus fumigatus to induce EoE in TRAIL-sufficient (wild-type) and TRAIL-deficient (TRAIL 2/2) mice and targeted MID1 in the esophagus with small interfering RNA. We also treated mice with recombinant thymic stromal lymphopoietin (TSLP) and TRAIL. Results: TRAIL deficiency and MID1 silencing with small interfering RNA reduced esophageal eosinophil and mast cell numbers and protected against esophageal circumference enlargement, muscularis externa thickening, and collagen deposition. MID1 expression and nuclear factor kappa B activation were reduced in TRAIL 2/2 mice, whereas protein phosphatase 2Ac levels were increased compared with those seen in wild-type control mice. This was associated with reduced expression of CCL24, CCL11, CCL20, IL-5, IL-13, IL-25, TGFB, and TSLP. Treatment with TSLP reconstituted hallmark features of EoE in TRAIL 2/2 mice and recombinant TRAIL induced esophageal TSLP expression in vivo in the absence of allergen. Post hoc analysis of gene array data demonstrated significant upregulation of TRAIL and MID1 in a cohort of children with EoE compared with that seen in controls. Conclusion: TRAIL regulates MID1 and TSLP, inflammation, fibrosis, smooth muscle hypertrophy, and expression of inflammatory effector chemokines and cytokines in experimental EoE.	[Collison, Adam M.; Sokulsky, Leon A.; Hatchwell, Luke; Mattes, Joerg] Univ Newcastle, Expt & Translat Resp Med, Newcastle, NSW 2300, Australia; [Collison, Adam M.; Sokulsky, Leon A.; Hatchwell, Luke; Mattes, Joerg] Univ Newcastle, Prior Res Ctr Asthma & Resp Dis, Newcastle, NSW 2300, Australia; Hunter Med Res Inst, Newcastle, NSW, Australia; [Nightingale, Scott] Newcastle Childrens Hosp, Dept Gastroenterol, Newcastle, NSW, Australia; [Nightingale, Scott; Talley, Nicholas J.; Walker, Marjorie M.; Mattes, Joerg] Univ Newcastle, Fac Hlth & Med, Newcastle, NSW 2300, Australia; [Sherrill, Joseph D.; Rothenberg, Marc E.] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Allergy & Immunol, Cincinnati, OH 45221 USA; [Mattes, Joerg] Newcastle Childrens Hosp, Paediat Resp & Sleep Med Dept, Newcastle, NSW, Australia	University of Newcastle; University of Newcastle; Hunter Medical Research Institute; University of Newcastle; University of Newcastle; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Collison, AM (corresponding author), Hunter Med Res Inst, Expt & Translat Resp Med Grp, Lookout Rd, New Lambton, NSW 2305, Australia.	Adam.Collison@newcastle.edu.au	MATTES, JOERG/M-5179-2019; Collison, Adam/G-7718-2013	Collison, Adam/0000-0002-3074-3046; Nightingale, Scott/0000-0003-0986-7105	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI083450, R37AI045898] Funding Source: NIH RePORTER; NIAID NIH HHS [R37 AI045898, R01 AI083450, R01AI083450, R37AI045898] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aceves SS, 2010, J ALLERGY CLIN IMMUN, V126, P1198, DOI 10.1016/j.jaci.2010.08.050; Aceves SS, 2009, IMMUNOL ALLERGY CLIN, V29, P197, DOI 10.1016/j.iac.2008.10.003; Aceves SS, 2007, J ALLERGY CLIN IMMUN, V119, P206, DOI 10.1016/j.jaci.2006.10.016; Cherian S, 2006, ARCH DIS CHILD, V91, P1000, DOI 10.1136/adc.2006.100974; Collison A, 2014, AM J RESP CELL MOL, V51, P86, DOI 10.1165/rcmb.2013-0490OC; Collison A, 2013, NAT MED, V19, P232, DOI 10.1038/nm.3049; Cultrone A, 2013, EUR J IMMUNOL, V43, P1053, DOI 10.1002/eji.201142340; de Souza Alves CC, 2013, PLOS ONE, V8; DeBrosse CW, 2010, J ALLERGY CLIN IMMUN, V126, P112, DOI 10.1016/j.jaci.2010.05.027; Dellon ES, 2013, AM J GASTROENTEROL, V108, P679, DOI 10.1038/ajg.2013.71; Dzeletovic I, 2011, DIGEST DIS SCI, V56, P435, DOI 10.1007/s10620-010-1503-z; Faubion WA, 1998, J PEDIATR GASTR NUTR, V27, P90, DOI 10.1097/00005176-199807000-00016; Fu DX, 2003, J BIOL CHEM, V278, P1487, DOI 10.1074/jbc.M210631200; Gonsalves N, 2012, GASTROENTEROLOGY, V142, P1451, DOI 10.1053/j.gastro.2012.03.001; Gonzalez-Cervera J, 2012, J CLIN GASTROENTEROL, V46, P855, DOI 10.1097/MCG.0b013e3182432259; Hatchwell L, 2014, J ALLERGY CLIN IMMUN, V133, P1720, DOI 10.1016/j.jaci.2013.11.014; Kagalwalla AF, 2006, CLIN GASTROENTEROL H, V4, P1097, DOI 10.1016/j.cgh.2006.05.026; Kottyan LC, 2014, NAT GENET, V46, P895, DOI 10.1038/ng.3033; Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040; Lipka S, 2014, GASTROINTEST ENDOSC, V80, P592, DOI 10.1016/j.gie.2014.02.012; Lucendo AJ, 2011, J ALLERGY CLIN IMMUN, V128, P1037, DOI 10.1016/j.jaci.2011.08.007; McConnell JL, 2010, BIOCHEMISTRY-US, V49, P1713, DOI 10.1021/bi901837h; Mishra A, 2003, GASTROENTEROLOGY, V125, P1419, DOI 10.1016/j.gastro.2003.07.007; Mishra A, 2001, J CLIN INVEST, V107, P83, DOI 10.1172/JCI10224; Mishra A, 2002, J IMMUNOL, V168, P2464, DOI 10.4049/jimmunol.168.5.2464; Muller M, 2012, WORLD J GASTROENTERO, V18, P6960, DOI 10.3748/wjg.v18.i47.6960; Noel RJ, 2004, CLIN GASTROENTEROL H, V2, P568, DOI 10.1016/S1542-3565(04)00240-X; Noel RJ, 2004, NEW ENGL J MED, V351, P940, DOI 10.1056/NEJM200408263510924; Noti M, 2013, NAT MED, V19, P1005, DOI 10.1038/nm.3281; Pasha SF, 2007, DIS ESOPHAGUS, V20, P311, DOI 10.1111/j.1442-2050.2007.00721.x; Persad R, 2012, J PEDIATR GASTR NUTR, V55, P251, DOI 10.1097/MPG.0b013e31824b6391; Robertson NM, 2002, J IMMUNOL, V169, P5986, DOI 10.4049/jimmunol.169.10.5986; Rothenberg ME, 2010, NAT GENET, V42, P289, DOI 10.1038/ng.547; Shanley TP, 2001, J IMMUNOL, V166, P966, DOI 10.4049/jimmunol.166.2.966; Sherrill JD, 2014, GENES IMMUN, V15, P361, DOI 10.1038/gene.2014.27; Soon IS, 2013, J PEDIATR GASTR NUTR, V57, P72, DOI 10.1097/MPG.0b013e318291fee2; Spergel JM, 2012, J ALLERGY CLIN IMMUN, V130, P461, DOI 10.1016/j.jaci.2012.05.021; Watkins GR, 2012, J BIOL CHEM, V287, P24207, DOI 10.1074/jbc.M112.368613; Weckmann M, 2007, NAT MED, V13, P1308, DOI 10.1038/nm1660; Weckmann M, 2011, PEDIAT ALLERG IMM-UK, V22, P25, DOI 10.1111/j.1399-3038.2010.01027.x; Wen FQ, 2002, AM J RESP CELL MOL, V26, P484, DOI 10.1165/ajrcmb.26.4.4784; Wu JX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077795; Zhu HB, 2004, MOL THER, V9, P666, DOI 10.1016/j.ymthe.2004.02.007; Zuo L, 2010, J IMMUNOL, V185, P660, DOI 10.4049/jimmunol.1000471	44	20	20	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2015	136	4					971	982		10.1016/j.jaci.2015.03.031	http://dx.doi.org/10.1016/j.jaci.2015.03.031			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CT7EJ	25981737	Green Accepted			2022-12-18	WOS:000362976300016
J	Khatry, DB; Gossage, DL; Geba, GP; Parker, JM; Jarjour, NN; Busse, WW; Molfino, NA				Khatry, Deepak B.; Gossage, David L.; Geba, Gregory P.; Parker, Joseph M.; Jarjour, Nizar N.; Busse, William W.; Molfino, Nestor A.			Discriminating sputum-eosinophilic asthma: Accuracy of cutoffs in blood eosinophil measurements versus a composite index, ELEN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							COUNT		[Khatry, Deepak B.; Parker, Joseph M.] Medimmune Inc, Gaithersburg, MD 20878 USA; [Gossage, David L.] Gilead Sci, Seattle, WA USA; [Geba, Gregory P.] Regeneron, Tarrytown, NY USA; [Jarjour, Nizar N.; Busse, William W.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Allergy Pulm & Crit Care Div, Madison, WI USA; [Molfino, Nestor A.] KaloBios Pharmaceut, San Francisco, CA USA	AstraZeneca; Medimmune; Gilead Sciences; Regeneron; University of Wisconsin System; University of Wisconsin Madison	Khatry, DB (corresponding author), Medimmune Inc, Gaithersburg, MD 20878 USA.	khatryd@medimmune.com	Khatry, Deepak/Q-5070-2019	Khatry, Deepak/0000-0002-2388-9434				Arron JR, 2014, EUR RESPIR J, V43, P627, DOI 10.1183/09031936.00117013; Castro M, 2014, LANCET RESP MED, V2, P879, DOI 10.1016/S2213-2600(14)70201-2; Hastie AT, 2013, J ALLERGY CLIN IMMUN, V132, P72, DOI 10.1016/j.jaci.2013.03.044; Lim HF, 2015, EXPERT REV RESP MED, V9, P135, DOI 10.1586/17476348.2015.1000867; Ortega HG, 2014, NEW ENGL J MED, V371, P1198, DOI 10.1056/NEJMoa1403290; Petsky HL, 2012, THORAX, V67, P199, DOI 10.1136/thx.2010.135574; Spector SL, 2012, J ASTHMA, V49, P807, DOI 10.3109/02770903.2012.713428; Szefler SJ, 2012, J ALLERGY CLIN IMMUN, V129, pS9, DOI 10.1016/j.jaci.2011.12.979; Wenzel S, 2013, NEW ENGL J MED, V368, P2455, DOI 10.1056/NEJMoa1304048; Yap E, 2013, INTERN MED J, V43, P46, DOI 10.1111/j.1445-5994.2011.02565.x; Zhang XY, 2014, CLIN EXP ALLERGY, V44, P1137, DOI 10.1111/cea.12345	11	20	20	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2015	136	3					812	+		10.1016/j.jaci.2015.03.006	http://dx.doi.org/10.1016/j.jaci.2015.03.006			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CQ9EA	25913197	Bronze			2022-12-18	WOS:000360913300039
J	Wegrzyn, AS; Jakiela, B; Ruckert, B; Jutel, M; Akdis, M; Sanak, M; Akdis, CA				Wegrzyn, Agnieszka S.; Jakiela, Bogdan; Rueckert, Beate; Jutel, Marek; Akdis, Muebeccel; Sanak, Marek; Akdis, Cezmi A.			T-cell regulation during viral and nonviral asthma exacerbations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ROLES; FOXP3		[Wegrzyn, Agnieszka S.; Rueckert, Beate; Akdis, Muebeccel; Akdis, Cezmi A.] Univ Zurich, Swiss Inst Allergy & Asthma Res, Zurich, Switzerland; [Wegrzyn, Agnieszka S.; Rueckert, Beate; Akdis, Muebeccel; Akdis, Cezmi A.] Christine Kuhne Ctr Allergy Res & Educ, Davos, Switzerland; [Jakiela, Bogdan; Sanak, Marek] Jagiellonian Univ, Dept Internal Med, Krakow, Poland; [Jutel, Marek] Wroclaw Med Univ, Dept Clin Immunol, Wroclaw, Poland	Swiss Institute of Allergy & Asthma Research; University of Zurich; Jagiellonian University; Wroclaw Medical University	Wegrzyn, AS (corresponding author), Univ Zurich, Swiss Inst Allergy & Asthma Res, Zurich, Switzerland.	wegrzyn.as@gmail.com; akdisac@siaf.uzh.ch	Jakiela, Bogdan/CAA-1861-2022; Sanak, Marek/AAV-1628-2021; Akdis, Cezmi/AAV-4844-2020	Jakiela, Bogdan/0000-0003-0444-981X; Sanak, Marek/0000-0001-7635-8103; Akdis, Cezmi/0000-0001-8020-019X; Wegrzyn, Agnieszka Slawomira/0000-0001-9502-9911; JUTEL, MAREK/0000-0003-1555-9379				Akdis M, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Akdis M, 2014, J ALLERGY CLIN IMMUN, V133, P621, DOI 10.1016/j.jaci.2013.12.1088; Akdis M, 2012, J ALLERGY CLIN IMMUN, V129, P1438, DOI 10.1016/j.jaci.2012.05.003; Akdis M, 2011, J ALLERGY CLIN IMMUN, V127, P701, DOI 10.1016/j.jaci.2010.11.050; Grzanka J, 2013, INT IMMUNOPHARMACOL, V16, P343, DOI 10.1016/j.intimp.2013.02.004; Jackson DJ, 2011, J ALLERGY CLIN IMMUN, V128, P1165, DOI 10.1016/j.jaci.2011.10.024; Karagiannidis C, 2004, J ALLERGY CLIN IMMUN, V114, P1425, DOI 10.1016/j.jaci.2004.07.014; Lloyd CM, 2013, J ALLERGY CLIN IMMUN, V131, P1267, DOI 10.1016/j.jaci.2013.02.016; Purwar R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016245; Takahashi K, 2011, J ALLERGY CLIN IMMUN, V128, P1067, DOI 10.1016/j.jaci.2011.06.018	10	20	20	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2015	136	1					194	197		10.1016/j.jaci.2014.12.1866	http://dx.doi.org/10.1016/j.jaci.2014.12.1866			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CM2WE	25605274	Green Submitted			2022-12-18	WOS:000357542200024
J	Jin, P; Andiappan, AK; Quek, JM; Lee, B; Au, BJ; Sio, YY; Irwanto, A; Schurmann, C; Grabe, HJ; Suri, BK; Matta, SA; Westra, HJ; Franke, L; Esko, T; Sun, LD; Zhang, XJ; Liu, H; Zhang, FR; Larbi, A; Xu, X; Poidinger, M; Liu, JJ; Chew, FT; Rotzschke, O; Shi, L; Wang, DY				Jin, Peng; Andiappan, Anand Kumar; Quek, Jia Min; Lee, Bernett; Au, Bijin; Sio, Yang Yie; Irwanto, Astrid; Schurmann, Claudia; Grabe, Hans Joergen; Suri, Bani Kaur; Matta, Sri Anusha; Westra, Harm-Jan; Franke, Lude; Esko, Tonu; Sun, Liangdan; Zhang, Xuejun; Liu, Hong; Zhang, Furen; Larbi, Anis; Xu, Xin; Poidinger, Michael; Liu, Jianjun; Chew, Fook Tim; Rotzschke, Olaf; Shi, Li; Wang, De Yun			A functional brain-derived neurotrophic factor (BDNF) gene variant increases the risk of moderate-to-severe allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Brain-derived neurotrophic factor; moderate-to-severe allergic rhinitis; Singapore Chinese; neurotrophins; genetic association	ACTIVITY-DEPENDENT SECRETION; ATOPIC-DERMATITIS; PRODUCE NEUROTROPHINS; ASSOCIATION ANALYSIS; ASTHMA; DISEASES; BURDEN; PATHOPHYSIOLOGY; IDENTIFICATION; POLYMORPHISMS	Background: Brain-derived neurotrophic factor (BDNF) is a secretory protein that has been implicated in the pathogenesis of allergic rhinitis (AR), atopic asthma, and eczema, but it is currently unknown whether BDNF polymorphisms influence susceptibility to moderate-to-severe AR. Objective: We sought to identify disease associations and the functional effect of BDNF genetic variants in patients with moderate-to-severe AR. Methods: Tagging single nucleotide polymorphisms (SNPs) spanning the BDNF gene were selected from the human HapMap Han Chinese from Beijing (CHB) data set, and associations with moderate-to-severe AR were assessed in 2 independent cohorts of Chinese patients (2216 from Shandong province and 1239 living in Singapore). The functional effects of the BDNF genetic variants were determined by using both in vitro and ex vivo assays. Results: The tagging SNP rs10767664 was significantly associated with the risk of moderate-to-severe AR in both Singapore Chinese (P = .0017; odds ratio, 1.324) and Shandong Chinese populations (P = .039; odds ratio, 1.180). The coding nonsynonymous SNP rs6265 was in perfect linkage with rs10767664 and conferred increased BDNF protein secretion by a human cell line in vitro. Subjects bearing the AA genotype of rs10767664 exhibited increased risk of moderate-to-severe AR and displayed increased BDNF protein and total IgE levels in plasma. Using a large-scale expression quantitative trait locus study, we demonstrated that BDNF SNPs are significantly associated with altered BDNF concentrations in peripheral blood. Conclusion: A common genetic variant of the BDNF gene is associated with increased risk of moderate-to-severe AR, and the AA genotype is associated with increased BDNF mRNA levels in peripheral blood. Together, these data indicate that functional BDNF gene variants increase the risk of moderate-to-severe AR.	[Jin, Peng; Shi, Li] Shandong Univ, Qilu Hosp, Dept Otolaryngol, Minist Hlth,Key Lab Otolaryngol, Jinan 250012, Shandong, Peoples R China; [Andiappan, Anand Kumar; Lee, Bernett; Au, Bijin; Larbi, Anis; Poidinger, Michael; Rotzschke, Olaf] Singapore Immunol Network SIgN, Singapore, Singapore; [Irwanto, Astrid; Liu, Jianjun] ASTAR, GIS, Singapore, Singapore; [Andiappan, Anand Kumar; Quek, Jia Min; Sio, Yang Yie; Suri, Bani Kaur; Matta, Sri Anusha; Chew, Fook Tim] Natl Univ Singapore, Dept Biol Sci, Singapore 117548, Singapore; [Schurmann, Claudia] Univ Med Greifswald, Interfac Inst Genet & Funct Genom, Dept Funct Genom, Greifswald, Germany; [Grabe, Hans Joergen] Univ Med Greifswald, Dept Psychiat & Psychotherapy, HELIOS Hosp Stralsund, Greifswald, Germany; [Westra, Harm-Jan; Franke, Lude] Univ Groningen, Univ Med Ctr Groningen, Dept Genet, NL-9700 AB Groningen, Netherlands; [Esko, Tonu] Univ Tartu, Estonian Genome Ctr, Tartu, Estonia; [Sun, Liangdan; Zhang, Xuejun] Anhui Med Univ, Hosp 1, Inst Dermatol, Hefei, Peoples R China; [Sun, Liangdan; Zhang, Xuejun] Anhui Med Univ, Hosp 1, Dept Dermatol, Hefei, Peoples R China; [Sun, Liangdan; Zhang, Xuejun] Anhui Med Univ, Minist Natl Sci & Technol, State Key Lab Incubat Base Dermatol, Hefei, Peoples R China; [Sun, Liangdan; Zhang, Xuejun] Anhui Med Univ, Key Lab Dermatol, Minist Educ, Hefei, Peoples R China; [Sun, Liangdan; Zhang, Xuejun] Anhui Med Univ, Collaborat Innovat Ctr Complex & Severe Skin Dis, Hefei, Peoples R China; [Liu, Hong; Zhang, Furen] Shandong Univ, Shandong Prov Hosp Skin Dis, Jinan 250100, Peoples R China; [Liu, Hong; Zhang, Furen] Shandong Acad Med Sci, Shandong Prov Inst Dermatol & Venereol, Jinan, Peoples R China; [Liu, Hong; Zhang, Furen] Shandong Prov Key Lab Dermatovenereol, Jinan, Peoples R China; [Liu, Hong; Zhang, Furen] Shandong Prov Med Ctr Dermatovenereol, Jinan, Peoples R China; [Xu, Xin] Head & Neck Surg Hosp, Qingdao Caretaker Otolaryngol, Qingdao, Peoples R China; [Jin, Peng; Wang, De Yun] Natl Univ Singapore, Natl Univ Hlth Syst, Yong Loo Lin Sch Med, Dept Otolaryngol, Singapore 117548, Singapore	Shandong University; Agency for Science Technology & Research (A*STAR); A*STAR - Singapore Immunology Network (SIgN); Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); National University of Singapore; Greifswald Medical School; Greifswald Medical School; University of Groningen; University of Tartu; Anhui Medical University; Anhui Medical University; Anhui Medical University; Anhui Medical University; Anhui Medical University; Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong University; Shandong First Medical University & Shandong Academy of Medical Sciences; University of Jinan; Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong First Medical University & Shandong Academy of Medical Sciences; National University of Singapore	Wang, DY (corresponding author), Natl Univ Singapore, Natl Univ Hlth Syst, Dept Otolaryngol, 1E Kent Ridge Rd, Singapore 119228, Singapore.	shili126@sina.com; entwdy@nus.edu.org	Roetzschke, Olaf/GXH-0012-2022; Franke, Lude/P-7036-2016; Jin, Peng/GPF-7083-2022; Chew, Fook Tim/E-7259-2010; Schurmann, Claudia/L-1204-2016; Liu, Jianjun/AAK-4989-2020; Andiappan, Anand Kumar/AAT-2336-2021; Larbi, Anis/ABE-5868-2020	Franke, Lude/0000-0002-5159-8802; Chew, Fook Tim/0000-0003-1337-5146; Schurmann, Claudia/0000-0003-4158-9192; Liu, Jianjun/0000-0002-3255-3019; Andiappan, Anand Kumar/0000-0002-8442-1544; Poidinger, Michael/0000-0002-1047-2277; Esko, Tonu/0000-0003-1982-6569	Singapore Immunology Network [SIgN-06-006, SIgN-08-020, SIgN-10-029]; National Medical Research Council of Singapore [NMRC/1150/2008]; Biomedical Research Council, Singapore; Agency for Science, Technology and Research (A*STAR); Science Development Funding Agency of Shandong Province, China [2010G0020258]; National University of Singapore's Graduate Research Scholarship program	Singapore Immunology Network(Agency for Science Technology & Research (A*STAR)); National Medical Research Council of Singapore(National Medical Research Council, Singapore); Biomedical Research Council, Singapore(Agency for Science Technology & Research (A*STAR)); Agency for Science, Technology and Research (A*STAR)(Agency for Science Technology & Research (A*STAR)); Science Development Funding Agency of Shandong Province, China; National University of Singapore's Graduate Research Scholarship program(National University of Singapore)	Supported by grants from the Singapore Immunology Network (SIgN-06-006, SIgN-08-020 and SIgN-10-029); the National Medical Research Council of Singapore (NMRC/1150/2008); the Biomedical Research Council, Singapore; the Agency for Science, Technology and Research (A*STAR); the Science Development Funding Agency of Shandong Province, China (2010G0020258); and the National University of Singapore's Graduate Research Scholarship program, which supported students involved in the study.	Andiappan AK, 2011, CYTOKINE, V56, P218, DOI 10.1016/j.cyto.2011.05.008; Andiappan AK, 2010, BMC GENET, V11, DOI 10.1186/1471-2156-11-36; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Braun A, 2004, BRIT J PHARMACOL, V141, P431, DOI 10.1038/sj.bjp.0705638; Canonica GW, 2007, ALLERGY, V62, P17, DOI 10.1111/j.1398-9995.2007.01549.x; Chen ZY, 2004, J NEUROSCI, V24, P4401, DOI 10.1523/JNEUROSCI.0348-04.2004; Demoly Pascal, 2013, Clin Transl Allergy, V3, P7, DOI 10.1186/2045-7022-3-7; Egan MF, 2003, CELL, V112, P257, DOI 10.1016/S0092-8674(03)00035-7; Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; Hahn C, 2006, J ALLERGY CLIN IMMUN, V117, P787, DOI 10.1016/j.jaci.2005.12.1339; Hoffjan S, 2009, MOL CELL PROBE, V23, P35, DOI 10.1016/j.mcp.2008.10.005; Hon KLE, 2007, BRIT J DERMATOL, V157, P922, DOI 10.1111/j.1365-2133.2007.08149.x; Jornot L, 2007, RHINOLOGY, V45, P129; Kabesch M, 2010, CURR OPIN ALLERGY CL, V10, P407, DOI 10.1097/ACI.0b013e32833dc779; Kobayashi H, 2002, BLOOD, V99, P2214, DOI 10.1182/blood.V99.6.2214; Liu H, 2012, AM J HUM GENET, V91, P935, DOI 10.1016/j.ajhg.2012.09.010; Martinowich K, 2007, NAT NEUROSCI, V10, P1089, DOI 10.1038/nn1971; Miller FD, 2002, SCIENCE, V295, P1471, DOI 10.1126/science.1069897; Muller GC, 2010, CLIN EXP ALLERGY, V40, P1755, DOI 10.1111/j.1365-2222.2010.03618.x; Nockher WA, 2006, J ALLERGY CLIN IMMUN, V117, P583, DOI 10.1016/j.jaci.2005.11.049; Nockher WA, 2002, CLIN EXP ALLERGY, V32, P1266, DOI 10.1046/j.1365-2745.2002.01489.x; Nockher WA, 2003, CYTOKINE GROWTH F R, V14, P559, DOI 10.1016/S1359-6101(03)00071-6; Noga O, 2002, CLIN EXP ALLERGY, V32, P1348, DOI 10.1046/j.1365-2745.2002.01442.x; Pawankar Ruby, 2012, World Allergy Organ J, V5, pS212, DOI 10.1097/WOX.0b013e318201d831; Postma DS, 2000, AM J RESP CRIT CARE, V162, pS118, DOI 10.1164/ajrccm.162.supplement_2.ras-13; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Raap U, 2008, ALLERGY, V63, P468, DOI 10.1111/j.1398-9995.2008.01626.x; Raap U, 2005, J ALLERGY CLIN IMMUN, V115, P1268, DOI 10.1016/j.jaci.2005.02.007; Raap U, 2010, CURR OPIN ALLERGY CL, V10, P8, DOI 10.1097/ACI.0b013e328334f5de; Reed SD, 2004, PHARMACOECONOMICS, V22, P345, DOI 10.2165/00019053-200422060-00002; Schatz M, 2007, ALLERGY, V62, P9, DOI 10.1111/j.1398-9995.2007.01548.x; Szczepankiewicz A, 2007, PEDIAT ALLERG IMM-UK, V18, P293, DOI 10.1111/j.1399-3038.2007.00525.x; Szczepankiewicz Aleksandra, 2010, World Allergy Organ J, V3, P235, DOI 10.1097/WOX.0b013e3181eedb68; Szczepankiewicz A, 2009, INT ARCH ALLERGY IMM, V149, P343, DOI 10.1159/000205580; Tetsuya W, 2013, AM THOR SOC INT C, pA2400; Vercelli D, 2008, NAT REV IMMUNOL, V8, P169, DOI 10.1038/nri2257; Wang DY, 2011, ASIA PAC ALLERGY, V1, P152, DOI 10.5415/apallergy.2011.1.3.152; Westra HJ, 2013, NAT GENET, V45, P1238, DOI 10.1038/ng.2756; Zeilinger S, 2009, ALLERGY, V64, P1790, DOI 10.1111/j.1398-9995.2009.02131.x	40	20	21	1	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2015	135	6					1486	U151		10.1016/j.jaci.2014.12.1870	http://dx.doi.org/10.1016/j.jaci.2014.12.1870			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CK0ZC	25649076	Bronze			2022-12-18	WOS:000355933400011
J	Arshad, SH; Venter, C; Roberts, G; Dean, T; Kurukulaaratchy, R				Arshad, S. Hasan; Venter, Carina; Roberts, Graham; Dean, Taraneh; Kurukulaaratchy, Ramesh			The natural history of peanut sensitization and allergy in a birth cohort	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							FOOD ALLERGY; PREVALENCE; LIFE		[Arshad, S. Hasan; Venter, Carina; Roberts, Graham; Dean, Taraneh; Kurukulaaratchy, Ramesh] David Hide Asthma & Allergy Res Ctr, Isle Of Wight, England; [Arshad, S. Hasan; Roberts, Graham; Kurukulaaratchy, Ramesh] Univ Southampton, Fac Med, Clin & Expt Sci, Southampton SO9 5NH, Hants, England; [Venter, Carina; Dean, Taraneh] Univ Portsmouth, Sch Hlth Sci & Social Work, Portsmouth, Hants, England	University of Southampton; University of Portsmouth	Arshad, SH (corresponding author), David Hide Asthma & Allergy Res Ctr, Isle Of Wight, England.	sha@soton.ac.uk		Roberts, Graham/0000-0003-2252-1248; Dean, Taraneh/0000-0002-0123-7646	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL082925] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL082925] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arbes SJ, 2005, J ALLERGY CLIN IMMUN, V116, P377, DOI 10.1016/j.jaci.2005.05.017; BOYCE JA, 2010, J ALLERGY CLIN IMMUN, V126, P1105, DOI DOI 10.1016/j.jaci.2010.10.008; Dean T, 2007, J ALLERGY CLIN IMMUN, V120, P1166, DOI 10.1016/j.jaci.2007.06.042; DunnGalvin A, 2011, J ALLERGY CLIN IMMUN, V127, P633, DOI 10.1016/j.jaci.2010.12.004; Nicolaou N, 2010, J ALLERGY CLIN IMMUN, V125, P191, DOI 10.1016/j.jaci.2009.10.008; Roberts G, 2012, CLIN EXP ALLERGY, V42, P1501, DOI 10.1111/j.1365-2222.2012.04074.x; Rona RJ, 2007, J ALLERGY CLIN IMMUN, V120, P638, DOI 10.1016/j.jaci.2007.05.026; Savage JH, 2007, J ALLERGY CLIN IMMUN, V120, P717, DOI 10.1016/j.jaci.2007.07.027; Skolnick HS, 2001, J ALLERGY CLIN IMMUN, V107, P367, DOI 10.1067/mai.2001.112129	9	20	20	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2014	134	6					1462	1463		10.1016/j.jaci.2014.09.026	http://dx.doi.org/10.1016/j.jaci.2014.09.026			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AW1UG	25441300	Green Accepted, Green Submitted, Bronze			2022-12-18	WOS:000346075400035
J	Kamili, QUA; Seeborg, FO; Saxena, K; Nicholas, SK; Banerjee, PP; Angelo, LS; Mace, EM; Forbes, LR; Martinez, C; Wright, TS; Orange, JS; Hanson, IC				Kamili, Qurat Ul Ain; Seeborg, Filiz O.; Saxena, Kapil; Nicholas, Sarah K.; Banerjee, Pinaki P.; Angelo, Laura S.; Mace, Emily M.; Forbes, Lisa R.; Martinez, Caridad; Wright, Teresa S.; Orange, Jordan S.; Hanson, Imelda Celine			Severe cutaneous human papillomavirus infection associated with natural killer cell deficiency following stem cell transplantation for severe combined immunodeficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							DISEASE		[Kamili, Qurat Ul Ain] Baylor Coll Med, Div Internal Med, Sect Immunol Allergy & Rheumatol, Houston, TX 77030 USA; [Seeborg, Filiz O.; Saxena, Kapil; Nicholas, Sarah K.; Forbes, Lisa R.; Orange, Jordan S.; Hanson, Imelda Celine] Texas Childrens Hosp, Baylor Coll Med, Dept Pediat, Sect Immunol Allergy & Rheumatol, Houston, TX 77030 USA; [Banerjee, Pinaki P.; Angelo, Laura S.; Mace, Emily M.; Forbes, Lisa R.; Orange, Jordan S.] Texas Childrens Hosp, Baylor Coll Med, Ctr Human Immunobiol, Dept Pediat, Houston, TX 77030 USA; [Martinez, Caridad] Baylor Coll Med, Ctr Cell & Gene Therapy, Texas Childrens Canc Ctr, Dept Pediat, Houston, TX 77030 USA; [Wright, Teresa S.] Texas Childrens Hosp, Baylor Coll Med, Dept Dermatol & Pediat, Sect Pediat Dermatol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Texas Children's Cancer Center; Baylor College of Medicine	Kamili, QUA (corresponding author), Baylor Coll Med, Div Internal Med, Sect Immunol Allergy & Rheumatol, Houston, TX 77030 USA.	kamili@bcm.edu		Hanson, Imelda/0000-0001-9457-0757; Mace, Emily/0000-0003-0226-7393; orange, jordan/0000-0001-7117-7725	NIAID NIH HHS [AI067946, R56 AI067946, R01 AI067946] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI067946, R01AI067946] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Buckley RH, 2011, IMMUNOL RES, V49, P25, DOI 10.1007/s12026-010-8191-9; Gaspar HB, 2004, BRIT J HAEMATOL, V127, P232, DOI 10.1111/j.1365-2141.2004.05176.x; Gennery AR, 2010, J ALLERGY CLIN IMMUN, V126, P602, DOI 10.1016/j.jaci.2010.06.015; Laffort C, 2004, LANCET, V363, P2051, DOI 10.1016/S0140-6736(04)16457-X; Leiding JW, 2012, J ALLERGY CLIN IMMUN, V130, P1030, DOI 10.1016/j.jaci.2012.07.049; Orange JS, 2013, J ALLERGY CLIN IMMUN, V132, P515, DOI 10.1016/j.jaci.2013.07.020; Orange JS, 2011, J CLIN INVEST, V121, P1535, DOI 10.1172/JCI44862; Orange JS, 2002, J CLIN INVEST, V109, P1501, DOI 10.1172/JCI200214858	8	20	20	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2014	134	6					1451	1453		10.1016/j.jaci.2014.07.009	http://dx.doi.org/10.1016/j.jaci.2014.07.009			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AW1UG	25159470	Green Accepted			2022-12-18	WOS:000346075400031
J	van der Veer, E; Arends, S; van der Hoek, S; Versluijs, JB; de Monchy, JGR; Elberink, JNGO; van Doormaal, JJ				van der Veer, Eveline; Arends, Suzanne; van der Hoek, Sjoukje; Versluijs, Joris B.; de Monchy, Jan G. R.; Elberink, Joanna N. G. Oude; van Doormaal, Jasper J.			Predictors of new fragility fractures after diagnosis of indolent systemic mastocytosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Systemic mastocytosis; fragility fractures; fracture risk scoring tool; bone turnover markers; bone mineral density; alcohol; sex; urticaria pigmentosa; serum type I collagen C-telopeptide	BONE TURNOVER MARKERS; OSTEOPOROTIC FRACTURE; MAST-CELLS; EPIDEMIOLOGY; HISTAMINE; INVOLVEMENT; URINE; WOMEN; RISK	Background: Fragility fractures (FFxs) and osteoporosis occur frequently in patients with indolent systemic mastocytosis (ISM), even before 50 years of age. Objective: We sought to develop a prediction model to identify individual patients with ISM at risk of new FFxs. Methods: Data on lifetime fractures and trauma circumstances were collected from vertebral morphometry, patients' records, and questionnaires. Clinical, lifestyle, and bone characteristics were measured. Patients receiving treatment for osteoporosis before ISM diagnosis or with missing bone data were excluded from FFx risk assessment. Results: In total, 389 lifetime fractures occurred in 127 of the 221 patients with ISM (age, 19-77 years), including 90 patients with 264 FFxs. Median follow-up after diagnosis was 5.4 years (range, 0.4-15.3 years), with 5- and 10-year FFx risks of 23% +/- 3% and 31% +/- 4%, respectively. Male sex, high levels of bone resorption (serum type I collagen C-telopeptide), low hip bone mineral density, absence of urticaria pigmentosa, and alcohol intake at the time of ISM diagnosis were independent predictors of future FFxs. The MastFx score, a prediction model using these 5 characteristics, showed good accuracy (area under the curve, 0.80) to determine the risk of new FFxs. QFracture, a validated risk scoring tool for persons aged 30 to 99 years, was not useful in patients with ISM. Conclusion: The MastFx score distinguishes patients with ISM at high, intermediate, and low risk of new FFxs. The included characteristics sex, serum type I collagen C-telopeptide, hip bone mineral density, urticaria pigmentosa, and alcohol intake are easy to collect in clinical practice. The high occurrence of FFxs in patients with ISM underlines the importance of optimizing bone quality and early start of therapeutic prevention in patients at risk.	[van der Veer, Eveline; Versluijs, Joris B.] Univ Groningen, Univ Med Ctr Groningen, Lab Med, NL-9700 AB Groningen, Netherlands; [Arends, Suzanne; van der Hoek, Sjoukje; de Monchy, Jan G. R.; Elberink, Joanna N. G. Oude; van Doormaal, Jasper J.] Univ Groningen, Univ Med Ctr Groningen, NL-9700 AB Groningen, Netherlands; [Elberink, Joanna N. G. Oude] Univ Groningen, Univ Med Ctr Groningen, GRIAC Res Inst, NL-9700 AB Groningen, Netherlands	University of Groningen; University of Groningen; University of Groningen	van der Veer, E (corresponding author), Univ Med Ctr Groningen, Dept Lab Med, HPC EA40,POB 30-001, NL-9700 RB Groningen, Netherlands.	e.van.der.veer@umcg.nl	Arends, Suzanne/M-5436-2015	Arends, Suzanne/0000-0002-4422-7640; van der Veer, Eveline/0000-0002-4825-9981				Alvarez-Twose I, 2010, J ALLERGY CLIN IMMUN, V125, P1269, DOI 10.1016/j.jaci.2010.02.019; Arends S, 2011, OSTEOPOROSIS INT, V22, P1431, DOI 10.1007/s00198-010-1338-7; Barete S, 2010, ANN RHEUM DIS, V69, P1838, DOI 10.1136/ard.2009.124511; Brockow K, 2005, CLIN IMMUNOL, V115, P216, DOI 10.1016/j.clim.2005.01.011; Chiappetta N, 2006, SEMIN ARTHRITIS RHEU, V36, P32, DOI 10.1016/j.semarthrit.2006.03.004; Cooper C, 2004, J BONE MINER RES, V19, P1976, DOI 10.1359/JBMR.040902; Escribano L, 2009, J ALLERGY CLIN IMMUN, V124, P514, DOI 10.1016/j.jaci.2009.05.003; Granerus G, 1998, BRIT J DERMATOL, V139, P858; Guillaume N, 2013, AM J MED, V126, DOI 10.1016/j.amjmed.2012.07.018; Hedstrom EM, 2010, ACTA ORTHOP, V81, P148, DOI 10.3109/17453671003628780; Horny HP AC, 2008, WHO CLASSIFICATION T, P54; Ismail AA, 2002, OSTEOPOROSIS INT, V13, P565, DOI 10.1007/s001980200074; Ivaska KK, 2010, J BONE MINER RES, V25, P393, DOI 10.1359/jbmr.091006; Kanis JA, 2002, LANCET, V359, P1929, DOI 10.1016/S0140-6736(02)08761-5; Kanis JA, 2000, OSTEOPOROSIS INT, V11, P669, DOI 10.1007/s001980070064; Kanis JA, 2001, OSTEOPOROSIS INT, V12, P417, DOI 10.1007/s001980170112; KEYZER JJ, 1981, CLIN CHIM ACTA, V113, P165, DOI 10.1016/0009-8981(81)90150-9; KEYZER JJ, 1982, CLIN CHIM ACTA, V121, P379, DOI 10.1016/0009-8981(82)90247-9; LONGLEY J, 1995, J AM ACAD DERMATOL, V32, P545, DOI 10.1016/0190-9622(95)90336-4; Murphy M, 2001, PEDIATR DERMATOL, V18, P539, DOI 10.1046/j.1525-1470.2001.1862011a.x; National Clinical Guideline Centre, 2012, OST FRAG FRACT RISK; OOSTING E, 1988, AGENTS ACTIONS, V23, P307, DOI 10.1007/BF02142572; Rajgopal R, 2008, THROMB RES, V122, P293, DOI 10.1016/j.thromres.2006.10.025; Rossini M, 2011, BONE, V49, P880, DOI 10.1016/j.bone.2011.07.004; Rubin KH, 2013, J BONE MINER RES, V28, P1701, DOI 10.1002/jbmr.1956; Seitz S, 2013, OSTEOPOROSIS INT, V24, P2325, DOI 10.1007/s00198-013-2305-x; STICHERLING M, 1995, BRIT J DERMATOL, V132, P464, DOI 10.1111/j.1365-2133.1995.tb08685.x; Theoharides TC, 2002, INT ARCH ALLERGY IMM, V128, P344, DOI 10.1159/000063858; Theoharides TC, 2012, BBA-MOL BASIS DIS, V1822, P21, DOI 10.1016/j.bbadis.2010.12.014; Valent P, 2007, EUR J CLIN INVEST, V37, P435, DOI 10.1111/j.1365-2362.2007.01807.x; Valent P, 2012, INT ARCH ALLERGY IMM, V157, P215, DOI 10.1159/000328760; van der Veer E, 2012, ALLERGY, V67, P431, DOI 10.1111/j.1398-9995.2011.02780.x; Vasikaran S, 2011, OSTEOPOROSIS INT, V22, P391, DOI 10.1007/s00198-010-1501-1	34	20	20	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2014	134	6					1413	1421		10.1016/j.jaci.2014.05.003	http://dx.doi.org/10.1016/j.jaci.2014.05.003			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AW1UG	24985401	Bronze			2022-12-18	WOS:000346075400025
J	Theoharides, TC; Petra, AI; Stewart, JM; Tsilioni, I; Panagiotidou, S; Akin, C				Theoharides, Theoharis C.; Petra, Anastasia I.; Stewart, Julia M.; Tsilioni, Irene; Panagiotidou, Smaro; Akin, Cem			High serum corticotropin-releasing hormone (CRH) and bone marrow mast cell CRH receptor expression in a mastocytosis patient	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ENDOTHELIAL GROWTH-FACTOR; INNER-CITY CHILDREN; CONSENSUS PROPOSAL; CLASSIFICATION; CRITERIA		[Theoharides, Theoharis C.; Petra, Anastasia I.; Stewart, Julia M.; Tsilioni, Irene; Panagiotidou, Smaro] Tufts Univ, Tufts Med Ctr, Sch Med, Dept Integrat Physiol & Pathobiol,Mol Immunopharm, Boston, MA 02111 USA; [Theoharides, Theoharis C.] Tufts Univ, Tufts Med Ctr, Sch Med, Dept Internal Med, Boston, MA 02111 USA; [Akin, Cem] Harvard Univ, Brigham & Womens Hosp, Mastocytosis Ctr, Sch Med, Chestnut Hill, MA USA	Tufts Medical Center; Tufts University; Tufts Medical Center; Tufts University; Harvard University; Brigham & Women's Hospital	Theoharides, TC (corresponding author), Tufts Univ, Tufts Med Ctr, Sch Med, Dept Integrat Physiol & Pathobiol,Mol Immunopharm, Boston, MA 02111 USA.	theoharis.theoharides@tufts.edu		Akin, Cem/0000-0001-6301-4520	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047652] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR47652] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alysandratos KD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048934; Asadi S, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-85; Cao J, 2005, J IMMUNOL, V174, P7665, DOI 10.4049/jimmunol.174.12.7665; DOHRENWEND BS, 1978, J HEALTH SOC BEHAV, V19, P205, DOI 10.2307/2136536; Donelan J, 2006, P NATL ACAD SCI USA, V103, P7759, DOI 10.1073/pnas.0602210103; Donohue KM, 2013, J ALLERGY CLIN IMMUN, V131, P736, DOI 10.1016/j.jaci.2012.12.1573; Kempuraj D, 2004, ENDOCRINOLOGY, V145, P43, DOI 10.1210/en.2003-0805; Reyes M, 2011, ANN ALLERG ASTHMA IM, V107, P42, DOI 10.1016/j.anai.2011.03.004; Slominski AT, 2013, ENDOCR REV, V34, P827, DOI 10.1210/er.2012-1092; Theoharides TC, 2009, CLIN EXP DERMATOL, V34, pE163, DOI 10.1111/j.1365-2230.2008.03043.x; Valent P, 2001, LEUKEMIA RES, V25, P603, DOI 10.1016/S0145-2126(01)00038-8; Valent P, 2012, INT ARCH ALLERGY IMM, V157, P215, DOI 10.1159/000328760; Vasiadi M, 2012, J ALLERGY CLIN IMMUN, V129, P1410, DOI 10.1016/j.jaci.2012.01.041; Whyatt R.M., 2014, ENV HLTH PERSPECT	14	20	20	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2014	134	5					1197	1199		10.1016/j.jaci.2014.05.023	http://dx.doi.org/10.1016/j.jaci.2014.05.023			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AT4UN	24985398				2022-12-18	WOS:000344938900029
J	Jacobs, TS; Forno, E; Brehm, JM; Acosta-Perez, E; Han, YY; Blatter, J; Colon-Semidey, A; Alvarez, M; Canino, G; Celedon, JC				Jacobs, Tammy S.; Forno, Erick; Brehm, John M.; Acosta-Perez, Edna; Han, Yueh-Ying; Blatter, Joshua; Colon-Semidey, Angel; Alvarez, Maria; Canino, Glorisa; Celedon, Juan C.			Underdiagnosis of allergic rhinitis in underserved children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							SOCIOECONOMIC-STATUS; ASTHMA; ETHNICITY		[Jacobs, Tammy S.; Forno, Erick; Brehm, John M.; Han, Yueh-Ying; Blatter, Joshua; Celedon, Juan C.] Univ Pittsburgh, Childrens Hosp Pittsburgh, UPMC, Div Pediat Pulm Med Allergy & Immunol, Pittsburgh, PA 15213 USA; [Acosta-Perez, Edna; Colon-Semidey, Angel; Alvarez, Maria; Canino, Glorisa] Univ Puerto Rico, Behav Sci Res Inst, San Juan, PR 00936 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Puerto Rico; University of Puerto Rico Medical Sciences Campus	Jacobs, TS (corresponding author), Univ Pittsburgh, Childrens Hosp Pittsburgh, UPMC, Div Pediat Pulm Med Allergy & Immunol, Pittsburgh, PA 15213 USA.	juan.celedon@chp.edu	Forno, Erick/I-1476-2019; Alvarez, Maria/GZH-1345-2022; Pérez, Edna Acosta/AAW-6672-2021	Forno, Erick/0000-0001-6497-9885; acosta, edna/0000-0001-7101-3157; Blatter, Joshua/0000-0002-4948-1023	NHLBI NIH HHS [R01 HL117191, R01 HL079966, HL079966, HL117191] Funding Source: Medline; NICHD NIH HHS [K12 HD052892] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079966, R01HL117191] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bunyavanich S, 2010, ALLERGY, V65, P256, DOI 10.1111/j.1398-9995.2009.02159.x; Celedon JC, 2004, CHEST, V125, P85, DOI 10.1378/chest.125.1.85; delaMaza A, 1997, BIOPHYS J, V72, P1668, DOI 10.1016/S0006-3495(97)78812-X; Ebo DG, 2007, CLIN EXP ALLERGY, V37, P1668, DOI 10.1111/j.1365-2222.2007.02819.x; Forno E, 2009, CURR OPIN ALLERGY CL, V9, P154, DOI 10.1097/ACI.0b013e3283292207; Leynaert N, 2004, J ALLERGY CLIN IMMUN, V113, P86, DOI 10.1016/j.jaci.2003.10.010; Litonjua AA, 2005, J ALLERGY CLIN IMMUN, V115, P751, DOI 10.1016/j.jaci.2004.12.1138; Magnan A, 2008, ALLERGY, V63, P292, DOI 10.1111/j.1398-9995.2007.01584.x; Nazario Sylvette, 2011, Bol Asoc Med P R, V103, P18; Pawankar Ruby, 2012, World Allergy Organ J, V5, pS212, DOI 10.1097/WOX.0b013e318201d831; Small Mark, 2013, Clin Transl Allergy, V3, P33, DOI 10.1186/2045-7022-3-33	11	20	20	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2014	134	3					737	+		10.1016/j.jaci.2014.03.028	http://dx.doi.org/10.1016/j.jaci.2014.03.028			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AO5GR	24797420	Green Accepted			2022-12-18	WOS:000341372400032
J	Lagresle-Peyrou, C; Millili, M; Luce, S; Boned, A; Sadek, H; Rouiller, J; Frange, P; Cros, G; Cavazzana, M; Andre-Schmutz, I; Schiff, C				Lagresle-Peyrou, Chantal; Millili, Michele; Luce, Sonia; Boned, Annie; Sadek, Hanem; Rouiller, Julien; Frange, Pierre; Cros, Guilhem; Cavazzana, Marina; Andre-Schmutz, Isabelle; Schiff, Claudine			The BLNK adaptor protein has a nonredundant role in human B-cell differentiation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Agammaglobulinemia; B-lymphocyte; lymphopoiesis; BLNK protein; gene rearrangement; pre-B-cell receptor; SCID-hu mouse; gene therapy	SEVERE COMBINED IMMUNODEFICIENCY; ACUTE LYMPHOBLASTIC-LEUKEMIA; BONE-MARROW; TUMOR-SUPPRESSOR; SCID PATIENTS; PRE-BCR; GENE; RECEPTOR; EXPRESSION; SLP-65	Background: Expression of the pre-B-cell receptor (pre-BCR) by pre-BII cells constitutes a crucial checkpoint in B-cell differentiation. Mutations that affect the pre-B-cell receptor result in early B-cell differentiation blockades that lead to primary B-cell immunodeficiencies. BLNK adaptor protein has a key role in the pre-B-cell receptor signaling cascade, as illustrated by the abnormal B-cell development in the 4 patients with BLNK gene defects reported to date. However, the BLNK protein's precise function in human B-cell differentiation has not been completely specified. Methods: B-cell development, including IgVH and Vk chain repertoires analysis, was studied in the bone marrow of a new case of BLNK deficiency in vitro and in vivo. Results: Here, we report on a patient with agammaglobulinemia, with a total absence of circulating B cells. We detected a homozygous mutation in BLNK, which leads to the complete abrogation of BLNK protein expression. In the bone marrow, we identified a severe differentiation blockade at the pre-BI-to pre-BII-cell transition. IgVH gene rearrangements and selection of the IgH repertoire were normal, whereas the patient's pre-BI cells showed very restricted usage of the IgVk repertoire. Complementation of bone marrow progenitors from the patient with the BLNK gene and transplantation into NOD/SCID/gcko mice allowed the complete restoration of B-cell differentiation and a normal usage of the IgVk genes.	[Lagresle-Peyrou, Chantal; Sadek, Hanem; Rouiller, Julien; Cavazzana, Marina] INSERM, CIC BT 502, F-75015 Paris, France; [Lagresle-Peyrou, Chantal; Luce, Sonia; Sadek, Hanem; Rouiller, Julien; Cavazzana, Marina; Andre-Schmutz, Isabelle] Univ Paris 05, Sorbonne Paris Cite, Inst Imagine, INSERM,U1163, Paris, France; [Millili, Michele; Boned, Annie; Schiff, Claudine] Aix Marseille Univ, UM2, Fac Sci Luminy, Ctr Immunol Marseille Luminy, Marseille, France; [Millili, Michele; Boned, Annie; Schiff, Claudine] INSERM, U1104, F-75015 Paris, France; [Millili, Michele; Boned, Annie; Schiff, Claudine] CNRS, UMR7280, F-75700 Paris, France; [Frange, Pierre; Cros, Guilhem] Hop Necker Enfants Malad, Unite Immunol Hematol & Rhumatol Pediat, Paris, France; [Frange, Pierre] Univ Paris 05, Sorbonne Paris Cite, EA 3620, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Andre-Schmutz, I (corresponding author), INSERM, Inst Imagine, U1163, 24 Blvd Montparnasse, F-75015 Paris, France.	isabelle.andre-schmutz@inserm.fr; schiff@ciml.univ-mrs.fr	Peyrou, Chantal Lagresle/AAK-9689-2020; Sadek, Hanem/H-7888-2017; Peyrou, Chantal Lagresle/H-2911-2017; Frange, Pierre/O-6311-2017; Andre-Schmutz, Isabelle/M-1279-2016; Andre, Isabelle/F-6263-2013	Peyrou, Chantal Lagresle/0000-0002-2216-6453; Sadek, Hanem/0000-0003-0756-0193; Peyrou, Chantal Lagresle/0000-0002-2216-6453; Andre, Isabelle/0000-0002-3905-9910; Cavazzana, Marina/0000-0002-0264-0891	INSERM; Centre National de la Recherche Scientifique	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Centre National de la Recherche Scientifique(Centre National de la Recherche Scientifique (CNRS))	This work was supported by institutional grants from INSERM and Centre National de la Recherche Scientifique.	Conley ME, 2012, J EXP MED, V209, P463, DOI 10.1084/jem.20112533; Conley ME, 2009, ANNU REV IMMUNOL, V27, P199, DOI 10.1146/annurev.immunol.021908.132649; Corbett SJ, 1997, J MOL BIOL, V270, P587, DOI 10.1006/jmbi.1997.1141; Espeli M, 2006, SEMIN IMMUNOL, V18, P56, DOI 10.1016/j.smim.2005.11.002; Flemming A, 2003, NAT IMMUNOL, V4, P38, DOI 10.1038/ni862; Hayashi K, 2003, IMMUNITY, V18, P825, DOI 10.1016/S1074-7613(03)00142-0; Hayashi K, 2000, P NATL ACAD SCI USA, V97, P2755, DOI 10.1073/pnas.040575697; Hystad ME, 2007, J IMMUNOL, V179, P3662, DOI 10.4049/jimmunol.179.6.3662; Imai C, 2004, LEUKEMIA, V18, P922, DOI 10.1038/sj.leu.2403349; Johnson K, 2008, IMMUNITY, V28, P335, DOI 10.1016/j.immuni.2007.12.019; Jumaa H, 2003, NATURE, V423, P452, DOI 10.1038/nature01608; Jumaa H, 1999, IMMUNITY, V11, P547, DOI 10.1016/S1074-7613(00)80130-2; Keenan RA, 2008, SCIENCE, V321, P696, DOI 10.1126/science.1157533; Kersseboom R, 2003, J EXP MED, V198, P91, DOI 10.1084/jem.20030615; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; Lagresle-Peyrou C, 2008, MOL THER, V16, P396, DOI 10.1038/sj.mt.6300353; MACCHI P, 1995, NATURE, V377, P65, DOI 10.1038/377065a0; Meffre E, 2001, J CLIN INVEST, V108, P879, DOI 10.1172/JCI13051; Minegishi Y, 1999, SCIENCE, V286, P1954, DOI 10.1126/science.286.5446.1954; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; Noordzij JG, 2003, BLOOD, V101, P1446, DOI 10.1182/blood-2002-01-0187; Noordzij JG, 2002, BLOOD, V100, P2145; Pappu R, 1999, SCIENCE, V286, P1949, DOI 10.1126/science.286.5446.1949; Puel A, 1998, NAT GENET, V20, P394, DOI 10.1038/3877; Rickert RC, 2013, NAT REV IMMUNOL, V13, P578, DOI 10.1038/nri3487; Schebesta M, 2002, IMMUNITY, V17, P473, DOI 10.1016/S1074-7613(02)00418-1; Sprangers M, 2006, ONCOGENE, V25, P5180, DOI 10.1038/sj.onc.1209520; tenBoekel E, 1997, IMMUNITY, V7, P357; van Lochem EG, 2004, CYTOM PART B-CLIN CY, V60B, P1, DOI 10.1002/cyto.b.20008; van Zelm MC, 2008, AM J HUM GENET, V82, P320, DOI 10.1016/j.ajhg.2007.10.011	30	20	20	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2014	134	1					145	+		10.1016/j.jaci.2013.12.1083	http://dx.doi.org/10.1016/j.jaci.2013.12.1083			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AL2BH	24582315				2022-12-18	WOS:000338930300019
J	Pillai, P; Fang, CL; Chan, YC; Shamji, MH; Harper, C; Wu, SY; Ohm-Laursen, L; Durham, SR; Menzies-Gow, A; Rajakulasingam, RK; Ying, S; Corrigan, CJ; Gould, HJ				Pillai, Prathap; Fang, Cailong; Chan, Yih-Chih; Shamji, Mohamed H.; Harper, Clare; Wu, Shih-Ying; Ohm-Laursen, Line; Durham, Stephen R.; Menzies-Gow, Andrew; Rajakulasingam, Raj K.; Ying, Sun; Corrigan, Chris J.; Gould, Hannah J.			Allergen-specific IgE is not detectable in the bronchial mucosa of nonatopic asthmatic patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							IMMUNOGLOBULIN-E; BIOPSIES; RNA		[Pillai, Prathap; Fang, Cailong; Chan, Yih-Chih; Harper, Clare; Wu, Shih-Ying; Ohm-Laursen, Line; Ying, Sun; Corrigan, Chris J.; Gould, Hannah J.] Kings Coll London, Dept Asthma Allergy & Resp Sci, London WC2R 2LS, England; [Pillai, Prathap; Fang, Cailong; Chan, Yih-Chih; Harper, Clare; Wu, Shih-Ying; Ohm-Laursen, Line; Ying, Sun; Corrigan, Chris J.; Gould, Hannah J.] Kings Coll London, Randall Div Cell & Mol Biophys, London WC2R 2LS, England; [Shamji, Mohamed H.; Durham, Stephen R.; Menzies-Gow, Andrew] Univ London Imperial Coll Sci Technol & Med, Sect Allergy & Clin Immunol NHLI, London, England; [Rajakulasingam, Raj K.] Homerton Univ Hosp NHS Fdn Trust, Dept Resp Med & Allergy, London, England	University of London; King's College London; University of London; King's College London; Imperial College London	Pillai, P (corresponding author), Kings Coll London, Dept Asthma Allergy & Resp Sci, London WC2R 2LS, England.	prathap.pillai@kcl.ac.uk	Pillai, Prathap/ABF-7476-2021; Shamji, Mohamed/AAU-8811-2020; Shamji, Mohamed/AAD-1788-2019	Shamji, Mohamed/0000-0003-3425-3463; Wu, Shih-Ying/0000-0002-9772-0877; Ohm-Laursen, Line/0000-0003-3105-3888; Gould, Hannah/0000-0003-0411-688X	MRC [G1100090, G0200485] Funding Source: UKRI; Medical Research Council [G1000758B] Funding Source: researchfish; Asthma UK [MRC-AsthmaUKCentre] Funding Source: researchfish; Medical Research Council [G1100090, G1000758, G0200485] Funding Source: Medline; Wellcome Trust [091449/Z/10/Z] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Asthma UK; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Bachert C, 2012, J INTERN MED, V272, P133, DOI 10.1111/j.1365-2796.2012.02559.x; Beeh KM, 2000, EUR RESPIR J, V16, P609, DOI 10.1034/j.1399-3003.2000.16d07.x; Dakhama A, 2004, AM J RESP CRIT CARE, V170, P952, DOI 10.1164/rccm.200311-1610oc; Humbert M, 1996, AM J RESP CRIT CARE, V153, P1931, DOI 10.1164/ajrccm.153.6.8665058; Humbert M, 1996, AM J RESP CRIT CARE, V154, P1497, DOI 10.1164/ajrccm.154.5.8912771; Rondon C, 2007, J ALLERGY CLIN IMMUN, V119, P899, DOI 10.1016/j.jaci.2007.01.006; Takhar P, 2007, J ALLERGY CLIN IMMUN, V119, P213, DOI 10.1016/j.jaci.2006.09.045; Valenta R, 2000, J ALLERGY CLIN IMMUN, V105, P432, DOI 10.1067/mai.2000.104783; Ying S, 2001, J ALLERGY CLIN IMMUN, V107, P686, DOI 10.1067/mai.2001.114339	9	20	20	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2014	133	6					1770	1772		10.1016/j.jaci.2014.03.027	http://dx.doi.org/10.1016/j.jaci.2014.03.027			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AI2FI	24794682				2022-12-18	WOS:000336672500037
J	Jacobs, RL; Harper, N; He, WJ; Andrews, CP; Rather, CG; Ramirez, DA; Ahuja, SK				Jacobs, Robert L.; Harper, Nathan; He, Weijing; Andrews, Charles P.; Rather, Cynthia G.; Ramirez, Daniel A.; Ahuja, Sunil K.			Effect of confounding cofactors on responses to pollens during natural season versus pollen challenge chamber exposure	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; pollen; challenge; confounding; season	ALLERGIC RHINOCONJUNCTIVITIS; VALIDATION; EFFICACY; UNIT	Background: The severity of allergic rhinoconjunctivitis (AR) symptomatology elicited after exposure to pollen in the absence versus the presence of confounding cofactors, such as in a pollen challenge chamber (PCC) and the natural pollinating season, respectively, might differ. Objective: We sought to determine the correlation of AR severity in the natural season versus out-of-season PCC exposures. Methods: Twenty-four Virginia live oak (VLO)-positive, 14 VLO-negative, 16 mountain cedar (MC) 2 positive, 8 MCnegative, and 26 ragweed-positive participants recorded AR symptoms (total symptom score [TSS]) during the VLO, MC, and ragweed pollinating seasons and during 2 consecutive PCC exposures of 3 hours each to these pollens separately. Results: The TSSs recorded before the natural season were higher than the pre-PCC values. This prepriming was greater among VLO 1 than MC 1 participants, and it blunted further increases in TSSs during the VLO natural season. Nonatopic participants were nonreactive in the PCC. There was wide variation in the level of AR symptomatology after exposure to VLO, MC, or ragweed pollen in the PCC. Prepriming formed the basis for higher AR responses observed in the natural season than in the PCC, resulting in the identification of distinct PCC/natural season endophenotypes and a partial correlation between the TSSs recorded in the natural season versus those recorded in the PCC (r = 5 0.34, 0.54, and 0.65 for VLO+, MC+, and ragweed-positive participants, respectively). Conclusions: Prepriming in the natural pollinating season might obscure the true correlation between AR severity in the natural season versus the PCC. By mitigating confounding cofactors, PCC exposures have utility for evaluation of novel AR therapeutics.	[Jacobs, Robert L.; Andrews, Charles P.; Rather, Cynthia G.; Ramirez, Daniel A.] Biogen Res Chamber LLC, San Antonio, TX 78229 USA; [Harper, Nathan; He, Weijing; Ahuja, Sunil K.] South Texas Vet Hlth Care Syst, Vet Adm Ctr Personalized Med, San Antonio, TX USA; [Harper, Nathan; He, Weijing; Ahuja, Sunil K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA; [Ahuja, Sunil K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol & Immunol, San Antonio, TX 78229 USA; [Ahuja, Sunil K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Jacobs, RL (corresponding author), Biogen Res Chamber LLC, 8299 Fredericksburg Rd, San Antonio, TX 78229 USA.	robert.jacobs7025@sbcglobal.net		Andrews, Charles/0000-0002-8944-8404; Jacobs, Robert/0000-0002-2831-9086	Doris Duke Distinguished Clinical Scientist Award; Burroughs Wellcome Clinical Scientist in Translational Research Award; Max and Minnie Tomerlin Voelcker Scholar Award; Center for Personalized Medicine at the South Texas Veterans Health Care System	Doris Duke Distinguished Clinical Scientist Award(Doris Duke Charitable Foundation (DDCF)); Burroughs Wellcome Clinical Scientist in Translational Research Award; Max and Minnie Tomerlin Voelcker Scholar Award; Center for Personalized Medicine at the South Texas Veterans Health Care System	the Doris Duke Distinguished Clinical Scientist Award, the Burroughs Wellcome Clinical Scientist in Translational Research Award, the Max and Minnie Tomerlin Voelcker Scholar Award, and the Center for Personalized Medicine at the South Texas Veterans Health Care System.	Adkinson NF, 2009, MIDDLETONS ALLERGY 7, P973; Akerlund Anders, 2005, J Allergy Clin Immunol, V115, pS460, DOI 10.1016/j.jaci.2004.12.016; Badorrek P, 2011, ANN ALLERG ASTHMA IM, V106, P336, DOI 10.1016/j.anai.2010.12.018; Berkowitz RB, 2002, ANN ALLERG ASTHMA IM, V89, P38, DOI 10.1016/S1081-1206(10)61909-6; Bernstein JA, 2012, J ALLERGY CLIN IMMUN, V130, P128, DOI 10.1016/j.jaci.2012.05.032; Bhattacharyya N, 2011, LARYNGOSCOPE, V121, P1830, DOI 10.1002/lary.22034; Blaiss MS, 2007, ALLERGY ASTHMA PROC, V28, P393, DOI 10.2500/aap.2007.28.3013; Blaiss MS, 1999, ANN ALLERG ASTHMA IM, V83, P449, DOI 10.1016/S1081-1206(10)62850-5; Carr TF, 2012, ALLERGY ASTHMA P S1, V33, pS6; Cox LS, 2012, J ALLERGY CLIN IMMUN, V130, P1327, DOI 10.1016/j.jaci.2012.08.032; Day JH, 1999, ANN ALLERG ASTHMA IM, V83, P83, DOI 10.1016/S1081-1206(10)62616-6; Ellis AK, 2010, ANN ALLERG ASTHMA IM, V104, P293, DOI 10.1016/j.anai.2010.01.012; Everitt J.H., 2007, WEEDS S TEXAS NO MEX; Hashiguchi K, 2009, INT ARCH ALLERGY IMM, V149, P141, DOI 10.1159/000189197; Hohlfeld JM, 2010, CLIN EXP ALLERGY, V40, P998, DOI 10.1111/j.1365-2222.2010.03498.x; Jacobs RL, 2012, J ALLERGY CLIN IMMUN, V130, P122, DOI 10.1016/j.jaci.2012.03.031; Jacobs RL, 2011, ANN ALLERG ASTHMA IM, V107, P133, DOI 10.1016/j.anai.2011.04.009; Lin SY, 2013, JAMA-J AM MED ASSOC, V309, P1278, DOI 10.1001/jama.2013.2049; Ronborg SM, 1996, ALLERGY, V51, P82, DOI 10.1111/j.1398-9995.1996.tb00039.x	20	20	20	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2014	133	5					1340	U558		10.1016/j.jaci.2013.09.051	http://dx.doi.org/10.1016/j.jaci.2013.09.051			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AG5HS	24331377				2022-12-18	WOS:000335450700015
J	Padjas, A; Kehar, R; Aleem, S; Mejza, F; Bousquet, J; Schunemann, HJ; Brozek, JL				Padjas, Agnieszka; Kehar, Rohan; Aleem, Sohaib; Mejza, Filip; Bousquet, Jean; Schuenemann, Holger J.; Brozek, Jan L.			Methodological rigor and reporting of clinical practice guidelines in patients with allergic rhinitis: QuGAR study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic rhinitis; guidelines; Appraisal of Guidelines for Research and Evaluation instrument; methodology	EAACI POSITION PAPER; BSACI GUIDELINES; MANAGEMENT; RHINOSINUSITIS; ASTHMA; QUALITY; IMPACT; COLLABORATION; DIAGNOSIS	Background: There are several clinical practice guidelines about the management of allergic rhinitis (AR) being used by clinicians. Objective: We sought to assess the methodological rigor and transparency of reporting of clinical practice guidelines for the management of AR. Methods: We systematically searched MEDLINE, the TRIP database, and professional society Web sites for all guidelines about the management of AR published in English after the year 2000. Four reviewers independently assessed the rigor of development and reporting of included guidelines using the Appraisal of Guidelines for Research and Evaluation II instrument. Results: Our search revealed 432 records, of which 34 full-text articles were assessed for eligibility and 10 fulfilled inclusion criteria. Overall methodological rigor and reporting of guidelines varied from fulfilling most of the Appraisal of Guidelines for Research and Evaluation II criteria to almost none. Across all guidelines, the best reported domain was clarity of presentation, and the least rigorously addressed domain was applicability of guidelines. Agreement beyond chance among the 4 appraisers was fair. Conclusions: Guideline users should be aware of the difference in the rigor of development and quality of reporting of guidelines about the management of AR. They should choose higher-quality guidelines to use in their practice and teaching. For most reviewed guidelines, there is room for improvement, particularly in the domains of applicability and implementation.	[Padjas, Agnieszka; Mejza, Filip] Jagiellonian Univ, Coll Med, Dept Med, Krakow, Poland; [Kehar, Rohan] McMaster Univ, Undergrad Med Educ Program, Hamilton, ON L8S 4K1, Canada; [Schuenemann, Holger J.; Brozek, Jan L.] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8S 4K1, Canada; [Schuenemann, Holger J.; Brozek, Jan L.] McMaster Univ, Dept Med, Hamilton, ON L8S 4K1, Canada; [Aleem, Sohaib] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA; [Bousquet, Jean] Hop Arnaud de Villeneuve, Serv Malad Resp, Montpellier, France; [Bousquet, Jean] INSERM, U1018, CESP, Montpellier, France	Jagiellonian University; Collegium Medicum Jagiellonian University; McMaster University; McMaster University; McMaster University; Dartmouth College; Universite de Montpellier; CHU de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Brozek, JL (corresponding author), McMaster Univ, Dept Clin Epidemiol & Biostat, Hlth Sci Ctr 2C19, 1280 Main St West, Hamilton, ON L8S 4K1, Canada.	brozekj@mcmaster.ca	Bousquet, Jean/O-4221-2019	Schunemann, Holger/0000-0003-3211-8479	Almirall; AstraZeneca; Chiesi; GlaxoSmithKline; Meda; Merck; MSD; Novartis; OM Pharma; Sanofi-Aventis; Schering-Plough; Takeda; Teva; Uriach	Almirall(Almirall); AstraZeneca(AstraZeneca); Chiesi(Chiesi Pharmaceuticals Inc); GlaxoSmithKline(GlaxoSmithKline); Meda; Merck(Merck & Company); MSD; Novartis(Novartis); OM Pharma; Sanofi-Aventis(Sanofi-Aventis); Schering-Plough(Merck & CompanySchering Plough Corporation); Takeda(Takeda Pharmaceutical Company Ltd); Teva(Teva Pharmaceutical Industries); Uriach	J. Bousquet has received honoraria for scientific and advisory boards from Actelion, Almirall, Meda, Merck, MSD, Novartis, Sanofi-Aventis, Takeda, Teva, and Uriach and the Board of Directors of Stallergenes; receives payment for lectures during meetings from Almirall, AstraZeneca, Chiesi, GlaxoSmithKline, Meda, Merck, MSD, Novartis, OM Pharma, Sanofi-Aventis, Schering-Plough, Takeda, Teva, and Uriach; and receives travel/accommodation/meeting expenses unrelated to activities listed from Actelion, Almirall, Meda, Merck, MSD, Novartis, Sanofi-Aventis, Takeda, Teva, and Uriach. S. Aleem is employed by the Dartmouth Hitchcock Medical Center. The rest of the authors declare that they have no relevant conflicts of interest.	Alonso-Coello P, 2010, QUAL SAF HEALTH CARE, V19, DOI 10.1136/qshc.2010.042077; Angier E, 2010, PRIM CARE RESP J, V19, P217, DOI 10.4104/pcrj.2010.00044; [Anonymous], 2011, PRIM CARE RESP J, V20, P11; Asher I, 2004, INT ARCH ALLERGY IMM, V135, P83, DOI 10.1159/000080524; Bachert C, 2007, B-ENT, V3, P175; Blaiss MS, 2004, CURR MED RES OPIN, V20, P1937, DOI 10.1185/030079904X13266; Blaiss MS, 2003, ANN ALLERG ASTHMA IM, V90, P16, DOI 10.1016/S1081-1206(10)61655-9; Bonini S, 2006, ALLERGY, V61, P681, DOI 10.1111/j.1398-9995.2006.01080.x; Bousquet J, 2008, ALLERGY, V63, P990, DOI 10.1111/j.1398-9995.2008.01642.x; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Braido F, 2010, ALLERGY, V65, P959, DOI 10.1111/j.1398-9995.2010.02383.x; Brozek JL, 2010, J ALLERGY CLIN IMMUN, V126, P466, DOI 10.1016/j.jaci.2010.06.047; Chipps B, 2011, J ALLERGY CLIN IMMUN, V127, P1640, DOI 10.1016/j.jaci.2011.01.070; Cluzeau F, 2003, QUAL SAF HEALTH CARE, V12, P18; Costa David J, 2009, Prim Care Respir J, V18, P250, DOI 10.4104/pcrj.2009.00028; DeGuzman DA, 2011, ALLERGIC RHINITIS; Desrosiers M, CANADIAN CLIN PRACTI; Fokkens W, 2005, ALLERGY, V60, P583, DOI 10.1111/j.1398-9995.2005.00830.x; Fokkens W, 2007, RHINOLOGY, V45, P97; Incaudo GA, 2006, IMMUNOL ALLERGY CLIN, V26, P137, DOI 10.1016/j.iac.2005.10.005; Keat SJ, MANAGEMEN RHINOSINUS; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Map of Medicine, 2010, SEAS ALL RHIN MAP ME; Mielke PW, 2007, SPRINGER SER STAT, P1, DOI 10.1007/978-0-387-69813-7; Moscato G, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-16; Nassef M, 2006, CURR MED RES OPIN, V22, P2541, DOI 10.1185/030079906X158057; National Institute for Health and Clinical Excellence, 2008, ALL RHIN NHS CLIN KN; Okubo Kimihiro, 2011, Allergology International, V60, P171, DOI [10.2332/allergolint.11-RAI-0334, 10.2332/allergolint. 11-RAI-0334]; Oxman Andrew D, 2006, Health Res Policy Syst, V4, P28, DOI 10.1186/1478-4505-4-28; Potter PC, 2006, SAMJ S AFR MED J, V96, P1269; Price David, 2006, Prim Care Respir J, V15, P58, DOI 10.1016/j.pcrj.2005.11.002; Ressel GW, 2002, AM FAM PHYSICIAN, V66, P2164; Savage J, 2005, J R SOC PROMO HEALTH, V125, P172, DOI 10.1177/146642400512500410; Scadding GK, 2008, CLIN EXP ALLERGY, V38, P19, DOI 10.1111/j.1365-2222.2007.02888.x; Scadding GK, 2008, CLIN EXP ALLERGY, V38, P260, DOI 10.1111/j.1365-2222.2007.02889.x; Shea BJ, 2007, BMC MED RES METHODOL, V7, DOI 10.1186/1471-2288-7-10; Siow JK, 2010, SINGAP MED J, V51, P190; Skye EP, 2007, ACUTE RHINOSINUSITIS; Spector S, 2011, J ALLERGY CLIN IMMUN, V127, P1643; Spector S, 2011, J ALLERGY CLIN IMMUN, V127, P1641, DOI 10.1016/j.jaci.2011.01.071; Thomas Mike, 2008, Prim Care Respir J, V17, P79, DOI 10.3132/pcrj.2008.00029; van Cauwenberge P, 2000, ALLERGY, V55, P116, DOI 10.1034/j.1398-9995.2000.00526.x; Vlayen J, 2005, INT J QUAL HEALTH C, V17, P235, DOI 10.1093/intqhc/mzi027; Wallace DV, 2008, J ALLERGY CLIN IMMUN, V122, pS1, DOI 10.1016/j.jaci.2008.06.003	45	20	24	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2014	133	3					777	+		10.1016/j.jaci.2013.08.029	http://dx.doi.org/10.1016/j.jaci.2013.08.029			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EK	24139606	Bronze			2022-12-18	WOS:000332397600020
J	Szefler, SJ				Szefler, Stanley J.			Advances in pediatric asthma in 2013: Coordinating asthma care	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Airway remodeling; asthma; asthma control; asthma exacerbations; early intervention in asthma; biomarkers; environment; genetics; inhaled corticosteroids; leukotriene receptor antagonists; long-acting beta-adrenergic agonists; personalized medicine; severe asthma; therapeutics	RESPIRATORY SYNCYTIAL VIRUS; EXHALED NITRIC-OXIDE; CHILDHOOD ASTHMA; NATIONAL HEART; AIRWAY INFLAMMATION; PRESCHOOL-CHILDREN; WHEEZE PHENOTYPES; MATERNAL OBESITY; YOUNG-CHILDREN; ADULT ASTHMA	Last year's "Advances in pediatric asthma: moving toward asthma prevention" concluded that "We are well on our way to creating a pathway around wellness in asthma care and also to utilize new tools to predict the risk for asthma and take steps to not only prevent asthma exacerbations but also to prevent the early manifestations of the disease and thus prevent its evolution to severe asthma." This year's summary will focus on recent advances in pediatric asthma on prenatal and postnatal factors altering the natural history of asthma, assessment of asthma control, and new insights regarding potential therapeutic targets for altering the course of asthma in children, as indicated in Journal of Allergy and Clinical Immunology publications in 2013 and early 2014. Recent reports continue to shed light on methods to understand factors that influence the course of asthma, methods to assess and communicate levels of control, and new targets for intervention, as well as new immunomodulators. It will now be important to carefully assess risk factors for the development of asthma, as well as the risk for asthma exacerbations, and to improve the way we communicate this information in the health care system. This will allow parents, primary care physicians, specialists, and provider systems to more effectively intervene in altering the course of asthma and to further reduce asthma morbidity and mortality.	[Szefler, Stanley J.] Childrens Hosp Colorado, Asthma Res Program, Sect Pediat Pulm Med, Breathing Inst,Dept Pediat, Aurora, CO 80045 USA	Children's Hospital Colorado	Szefler, SJ (corresponding author), Childrens Hosp Colorado, Sect Pulm Med, Pediat Asthma Res Program, Breathing Inst, 13123 E 16th Ave,Box 395, Aurora, CO 80045 USA.	Stanley.Szefler@childrenscolorado.org		Szefler, Stanley/0000-0002-6911-3199	Public Health Services Research Grants [AI-90052, ES-18181, HL-98075]; Denver Post Charities, a McCormick Foundation; Colorado Cancer, Cardiovascular and Pulmonary Disease Program; National Center for Research Resources/National Institutes of Health (NIH) [UL1 RR025780]; NIH/National Center for Advancing Translational Sciences [UL1 TR000154]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001082] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000051] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL098075] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES018181] Funding Source: NIH RePORTER	Public Health Services Research Grants; Denver Post Charities, a McCormick Foundation; Colorado Cancer, Cardiovascular and Pulmonary Disease Program; National Center for Research Resources/National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIH/National Center for Advancing Translational Sciences; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported in part by Public Health Services Research Grants AI-90052, ES-18181, and HL-98075; the Denver Post Charities, a McCormick Foundation; and the Colorado Cancer, Cardiovascular and Pulmonary Disease Program. Supported in part by Colorado CTSA Grant UL1 RR025780 from the National Center for Research Resources/National Institutes of Health (NIH) and UL1 TR000154 from the NIH/National Center for Advancing Translational Sciences.	Ahluwalia SK, 2013, J ALLERGY CLIN IMMUN, V132, P830, DOI 10.1016/j.jaci.2013.05.005; Apter AJ, 2013, J ALLERGY CLIN IMMUN, V131, P47, DOI 10.1016/j.jaci.2012.11.020; Assa'ad AH, 2013, J ALLERGY CLIN IMMUN, V132, P1097, DOI 10.1016/j.jaci.2013.08.036; Bardach NS, 2013, PEDIATRICS, V132, P429, DOI 10.1542/peds.2012-3527; Barnes PJ, 2013, J ALLERGY CLIN IMMUN, V131, P636, DOI 10.1016/j.jaci.2012.12.1564; Beigelman A, 2013, J ALLERGY CLIN IMMUN, V131, P1518, DOI 10.1016/j.jaci.2013.01.034; Belgrave DCM, 2013, J ALLERGY CLIN IMMUN, V132, P575, DOI 10.1016/j.jaci.2013.05.041; Blanken MO, 2013, NEW ENGL J MED, V368, P1791, DOI 10.1056/NEJMoa1211917; Bringolf-Isler B, 2013, J ALLERGY CLIN IMMUN, V132, P743, DOI 10.1016/j.jaci.2013.03.042; Brunst KJ, 2013, J ALLERGY CLIN IMMUN, V131, P592, DOI 10.1016/j.jaci.2012.10.042; Busse WW, 2013, J ALLERGY CLIN IMMUN, V131, P339, DOI 10.1016/j.jaci.2012.10.013; Cabana MD, 2014, J ALLERGY CLIN IMMUN, V133, P27, DOI 10.1016/j.jaci.2013.10.026; Cadman RV, 2013, J ALLERGY CLIN IMMUN, V131, P369, DOI 10.1016/j.jaci.2012.10.032; Caliskan M, 2013, NEW ENGL J MED, V368, P1398, DOI 10.1056/NEJMoa1211592; Carolan BJ, 2013, J ALLERGY CLIN IMMUN, V131, P627, DOI 10.1016/j.jaci.2013.01.010; Castro M, 2013, J ALLERGY CLIN IMMUN, V131, P377, DOI 10.1016/j.jaci.2012.12.669; Castro-Rodriguez JA, 2013, J ALLERGY CLIN IMMUN, V132, P1311, DOI 10.1016/j.jaci.2013.09.006; Collins SA, 2013, PEDIATR PULM, V48, P683, DOI 10.1002/ppul.22766; Coogan PF, 2013, J ALLERGY CLIN IMMUN, V131, P1058, DOI 10.1016/j.jaci.2012.10.023; Donohue KM, 2013, J ALLERGY CLIN IMMUN, V131, P736, DOI 10.1016/j.jaci.2012.12.1573; Donohue KM, 2013, J ALLERGY CLIN IMMUN, V131, P361, DOI 10.1016/j.jaci.2012.11.036; Dreyfus DH, 2013, J ALLERGY CLIN IMMUN, V132, P1278, DOI 10.1016/j.jaci.2013.02.039; Elazab N, 2013, PEDIATRICS, V132, pE666, DOI 10.1542/peds.2013-0246; Figueiredo CA, 2013, J ALLERGY CLIN IMMUN, V131, P1064, DOI 10.1016/j.jaci.2013.01.016; Gergen PJ, 2013, J ALLERGY CLIN IMMUN, V131, P1526, DOI 10.1016/j.jaci.2013.03.011; Gold DR, 2013, J ALLERGY CLIN IMMUN, V131, P1537, DOI 10.1016/j.jaci.2013.03.012; Granell R, 2013, J ALLERGY CLIN IMMUN, V131, P685, DOI 10.1016/j.jaci.2012.09.021; Guan WJ, 2013, J ALLERGY CLIN IMMUN, V131, P332, DOI 10.1016/j.jaci.2012.08.020; Hafkamp-de Groen E, 2013, J ALLERGY CLIN IMMUN, V132, P1303, DOI 10.1016/j.jaci.2013.07.007; Halonen M, 2013, AM J RESP CRIT CARE, V188, P35, DOI 10.1164/rccm.201207-1265OC; Harpsoe MC, 2013, J ALLERGY CLIN IMMUN, V131, P1033, DOI 10.1016/j.jaci.2012.09.008; Huang YJ, 2013, AM J RESP CRIT CARE, V187, P1382, DOI 10.1164/rccm.201303-0488WS; James KM, 2013, J ALLERGY CLIN IMMUN, V132, P227, DOI 10.1016/j.jaci.2013.01.009; Jang J, 2013, ANN ALLERG ASTHMA IM, V111, P516, DOI 10.1016/j.anai.2013.09.007; Jia CE, 2013, J ALLERGY CLIN IMMUN, V131, P695, DOI 10.1016/j.jaci.2012.08.023; Just J, 2013, ANN ALLERG ASTHMA IM, V111, P256, DOI 10.1016/j.anai.2013.07.002; Kalliola S, 2013, J ALLERGY CLIN IMMUN, V131, P730, DOI 10.1016/j.jaci.2013.01.005; Kang SH, 2013, ANN ALLERG ASTHMA IM, V110, P364, DOI 10.1016/j.anai.2013.03.008; Kazani S, 2013, J ALLERGY CLIN IMMUN, V132, P547, DOI 10.1016/j.jaci.2013.01.058; Khoshgoo N, 2013, PEDIATR PULM, V48, P317, DOI 10.1002/ppul.22739; Kim JM, 2013, PEDIATRICS, V131, P1155, DOI 10.1542/peds.2013-0343; Kiss M, 2013, J ALLERGY CLIN IMMUN, V132, P264, DOI 10.1016/j.jaci.2013.05.044; Konradsen JR, 2013, J ALLERGY CLIN IMMUN, V132, P328, DOI 10.1016/j.jaci.2013.03.003; Konstantinou GN, 2013, J ALLERGY CLIN IMMUN, V131, P87, DOI 10.1016/j.jaci.2012.10.033; Kozyrskyj AL, 2013, AM J RESP CRIT CARE, V187, P1160, DOI 10.1164/rccm.201304-0649ED; Laviolette M, 2013, J ALLERGY CLIN IMMUN, V132, P1086, DOI 10.1016/j.jaci.2013.05.020; Lemanske RF, 2013, NEW ENGL J MED, V368, P1839, DOI 10.1056/NEJMe1302063; Linder JE, 2013, J ALLERGY CLIN IMMUN, V131, P69, DOI 10.1016/j.jaci.2012.09.033; Lloyd CM, 2013, J ALLERGY CLIN IMMUN, V131, P1267, DOI 10.1016/j.jaci.2013.02.016; Lu KD, 2013, J ALLERGY CLIN IMMUN, V131, P1017, DOI 10.1016/j.jaci.2012.12.1570; Lu TX, 2013, J ALLERGY CLIN IMMUN, V132, P3, DOI 10.1016/j.jaci.2013.04.039; Malinovschi A, 2013, J ALLERGY CLIN IMMUN, V132, P821, DOI 10.1016/j.jaci.2013.06.007; Marri PR, 2013, J ALLERGY CLIN IMMUN, V131, P346, DOI 10.1016/j.jaci.2012.11.013; McGrady ME, 2013, PEDIATRICS, V132, P730, DOI 10.1542/peds.2013-1451; Miyata J, 2013, J ALLERGY CLIN IMMUN, V131, P353, DOI 10.1016/j.jaci.2012.07.048; Moore WC, 2013, AM J RESP CRIT CARE, V188, P521, DOI 10.1164/rccm.201307-1203ED; Muehleisen B, 2013, J ALLERGY CLIN IMMUN, V131, P324, DOI 10.1016/j.jaci.2012.12.1562; Murphy SK, 2013, AM J RESP CRIT CARE, V187, P563, DOI 10.1164/rccm.201301-0178ED; Nair P, 2013, J ALLERGY CLIN IMMUN, V132, P81, DOI 10.1016/j.jaci.2013.05.007; Nicodemus-Johnson J, 2013, J ALLERGY CLIN IMMUN, V131, P1496, DOI 10.1016/j.jaci.2013.01.037; Noonan M, 2013, J ALLERGY CLIN IMMUN, V132, P567, DOI 10.1016/j.jaci.2013.03.051; Nwaru BI, 2013, J ALLERGY CLIN IMMUN, V131, P78, DOI 10.1016/j.jaci.2012.10.028; O'Byrne PM, 2013, J ALLERGY CLIN IMMUN, V132, P70, DOI 10.1016/j.jaci.2013.03.052; O'Reilly R, 2013, J ALLERGY CLIN IMMUN, V131, P1024, DOI 10.1016/j.jaci.2012.08.044; Oh MA, 2013, PEDIATR PULM, V48, P563, DOI 10.1002/ppul.22705; Okelo SO, 2013, PEDIATRICS, V132, P517, DOI 10.1542/peds.2013-0779; Okelo SO, 2013, J ALLERGY CLIN IMMUN, V132, P55, DOI 10.1016/j.jaci.2013.01.007; Ortega VE, 2014, J ALLERGY CLIN IMMUN, V133, P16, DOI 10.1016/j.jaci.2013.10.040; Ownby DR, 2013, J ALLERGY CLIN IMMUN, V132, P836, DOI 10.1016/j.jaci.2013.06.046; Pandey RC, 2013, J ALLERGY CLIN IMMUN, V131, P1245, DOI 10.1016/j.jaci.2012.12.675; Pandey RC, 2013, J ALLERGY CLIN IMMUN, V131, P602, DOI 10.1016/j.jaci.2012.10.061; Papi A, 2013, J ALLERGY CLIN IMMUN, V132, P1075, DOI 10.1016/j.jaci.2013.05.028; Pavord ID, 2013, J ALLERGY CLIN IMMUN, V132, P828, DOI 10.1016/j.jaci.2013.07.045; Portnoy J, 2013, J ALLERGY CLIN IMMUN, V132, P802, DOI 10.1016/j.jaci.2013.04.061; Rank MA, 2013, ANN ALLERG ASTHMA IM, V110, P354, DOI 10.1016/j.anai.2013.02.012; Rank MA, 2013, J ALLERGY CLIN IMMUN, V131, P724, DOI 10.1016/j.jaci.2012.11.038; Rebane A, 2013, J ALLERGY CLIN IMMUN, V132, P15, DOI 10.1016/j.jaci.2013.04.011; Renz H, 2013, J ALLERGY CLIN IMMUN, V132, P1287, DOI 10.1016/j.jaci.2013.08.043; Rzehak P, 2013, J ALLERGY CLIN IMMUN, V131, P1528, DOI 10.1016/j.jaci.2013.01.001; Sadatsafavi M, 2013, J ALLERGY CLIN IMMUN, V132, P63, DOI 10.1016/j.jaci.2013.02.007; Saglani S, 2013, J ALLERGY CLIN IMMUN, V132, P676, DOI 10.1016/j.jaci.2013.04.012; Salazar F, 2013, J ALLERGY CLIN IMMUN, V132, P27, DOI 10.1016/j.jaci.2013.02.001; Shi YX, 2013, J ALLERGY CLIN IMMUN, V131, P718, DOI 10.1016/j.jaci.2012.09.022; Sutherland ER, 2014, J ALLERGY CLIN IMMUN, V133, P34, DOI 10.1016/j.jaci.2013.10.025; Szefler SJ, 2014, J ALLERGY CLIN IMMUN, V133, P3, DOI 10.1016/j.jaci.2013.10.018; Szefler SJ, 2013, J ALLERGY CLIN IMMUN, V131, P36, DOI 10.1016/j.jaci.2012.11.009; Tegethoff M, 2013, PEDIATRICS, V132, P483, DOI 10.1542/peds.2012-3686; Thompson EE, 2013, J ALLERGY CLIN IMMUN, V132, P39, DOI 10.1016/j.jaci.2012.12.1575; Tse SM, 2013, J ALLERGY CLIN IMMUN, V132, P554, DOI 10.1016/j.jaci.2013.03.031; van der Wiel E, 2013, J ALLERGY CLIN IMMUN, V131, P646, DOI 10.1016/j.jaci.2012.12.1567; van Leeuwen JC, 2013, J ALLERGY CLIN IMMUN, V131, P1427, DOI 10.1016/j.jaci.2012.10.014; Wechsler ME, 2013, J ALLERGY CLIN IMMUN, V132, P1295, DOI 10.1016/j.jaci.2013.08.009; Wechsler ME, 2013, NEW ENGL J MED, V368, P2511, DOI 10.1056/NEJMe1305426; Wenzel S, 2013, NEW ENGL J MED, V368, P2455, DOI 10.1056/NEJMoa1304048; Wright RJ, 2013, AM J RESP CRIT CARE, V187, P1186, DOI 10.1164/rccm.201208-1530OC; Yoo JK, 2013, J ALLERGY CLIN IMMUN, V132, P1263, DOI 10.1016/j.jaci.2013.06.006; Zetstra-van der Woude PA, 2013, J ALLERGY CLIN IMMUN, V131, P711, DOI 10.1016/j.jaci.2012.08.027	97	20	21	0	26	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2014	133	3					654	661		10.1016/j.jaci.2014.01.012	http://dx.doi.org/10.1016/j.jaci.2014.01.012			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EK	24581430	Green Accepted			2022-12-18	WOS:000332397600005
J	Tam, JS; Jackson, WT; Hunter, D; Proud, D; Grayson, MH				Tam, Jonathan S.; Jackson, William T.; Hunter, Desire; Proud, David; Grayson, Mitchell H.			Rhinovirus specific IgE can be detected in human sera	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							VIRAL-INFECTIONS; CHILDREN; ASTHMA; SECRETIONS; ILLNESSES		[Tam, Jonathan S.; Hunter, Desire; Grayson, Mitchell H.] Med Coll Wisconsin, Dept Pediat, Sect Allergy & Immunol, Milwaukee, WI 53226 USA; [Jackson, William T.; Grayson, Mitchell H.] Med Coll Wisconsin, Dept Microbiol & Mol Genet, Milwaukee, WI 53226 USA; [Proud, David] Univ Calgary, Dept Physiol & Pharmacol, Calgary, AB, Canada	Medical College of Wisconsin; Medical College of Wisconsin; University of Calgary	Tam, JS (corresponding author), Med Coll Wisconsin, Dept Pediat, Sect Allergy & Immunol, Milwaukee, WI 53226 USA.	wheeze@allergist.com	Grayson, Mitchell/AAX-3674-2020	Grayson, Mitchell/0000-0002-4673-2122	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL087778] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL087778, R01 HL087778] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Busse WW, 2011, NEW ENGL J MED, V364, P1005, DOI 10.1056/NEJMoa1009705; Grayson MH, 2007, J EXP MED, V204, P2759, DOI 10.1084/jem.20070360; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Jartti T, 2008, EUR RESPIR J, V32, P314, DOI 10.1183/09031936.00161907; Pellegrino MG, 2002, AIDS RES HUM RETROV, V18, P363, DOI 10.1089/088922202753519142; PROUD D, 1994, J INFECT DIS, V169, P1007, DOI 10.1093/infdis/169.5.1007; Richards AL, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1003046; Sly PD, 2010, J ALLERGY CLIN IMMUN, V125, P1202, DOI 10.1016/j.jaci.2010.01.024; Smith-Norowitz TA, 2012, J INFLAMM RES, V5, P111, DOI 10.2147/JIR.S34152; WELLIVER RC, 1981, NEW ENGL J MED, V305, P841, DOI 10.1056/NEJM198110083051501	10	20	20	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2013	132	5					1241	1243		10.1016/j.jaci.2013.07.011	http://dx.doi.org/10.1016/j.jaci.2013.07.011			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	242JH	23992751	Green Accepted			2022-12-18	WOS:000326235600036
J	Wang, MQ; Ramirez, J; Han, JY; Jia, Y; Domenico, J; Seibold, MA; Hagman, JR; Gelfand, EW				Wang, Meiqin; Ramirez, Julita; Han, Junyan; Jia, Yi; Domenico, Joanne; Seibold, Max A.; Hagman, James R.; Gelfand, Erwin W.			The steroidogenic enzyme Cyp11a1 is essential for development of peanut-induced intestinal anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Cyp11a1; peanut allergy; T(H)2; T(H)17; CD4 T cells	SIDE-CHAIN CLEAVAGE; CONGENITAL ADRENAL-HYPERPLASIA; CD4(+) T-CELLS; AIRWAY HYPERRESPONSIVENESS; TRANSCRIPTIONAL REGULATION; MURINE MODEL; GENE; AMINOGLUTETHIMIDE; EXPRESSION; GLUCOCORTICOIDS	Background: Cytochrome P450, family 11, subfamily A, polypeptide 1 (Cyp11a1), a cytochrome P450 enzyme, is the first and rate-limiting enzyme in the steroidogenic pathway, converting cholesterol to pregnenolone. Cyp11a1 expression is increased in activated T cells. Objectives: We sought to determine the role of Cyp11a1 activation in the development of peanut allergy and T-H cell functional differentiation. Methods: A Cyp11a1 inhibitor, aminoglutethimide (AMG), was administered to peanut-sensitized and challenged mice. Clinical symptoms, intestinal inflammation, and Cyp11a1 levels were assessed. The effects of Cyp11a1 inhibition on T(H)1, T(H)2, and T(H)17 differentiation were determined. Cyp11a1 gene silencing was performed with Cyp11a1-targeted short hairpin RNA. Results: Peanut sensitization and challenge resulted in diarrhea, inflammation, and increased levels of Cyp11a1, IL13, and IL17A mRNA in the small intestine. Inhibition of Cyp11a1 with AMG prevented allergic diarrhea and inflammation. Levels of pregnenolone in serum were reduced in parallel. AMG treatment decreased IL13 and IL17A mRNA expression in the small intestine without affecting Cyp11a1 mRNA or protein levels. In vitro the inhibitor decreased IL13 and IL17A mRNA and protein levels in differentiated T(H)2 and T(H)17 CD4 T cells, respectively, without affecting GATA3, retinoic acid-related orphan receptor gamma t (ROR gamma t), or T(H)1 cells and IFNG and T-bet expression. Short hairpin RNA-mediated silencing of Cyp11a1 in polarized T(H)2 CD4 T cells significantly decreased pregnenolone and IL13 mRNA and protein levels. Conclusion: Cyp11a1 plays an important role in the development of peanut allergy, regulating peanut-induced allergic responses through effects on steroidogenesis, an essential pathway in T(H)2 differentiation. Cyp11a1 thus serves as a novel target in the regulation and treatment of peanut allergy.	[Wang, Meiqin; Han, Junyan; Jia, Yi; Domenico, Joanne; Gelfand, Erwin W.] Natl Jewish Hlth, Dept Pediat, Div Cell Biol, Denver, CO 80206 USA; [Ramirez, Julita; Hagman, James R.; Gelfand, Erwin W.] Natl Jewish Hlth, Integrated Dept Immunol, Denver, CO 80206 USA; [Seibold, Max A.] Natl Jewish Hlth, Ctr Genes Environm & Hlth, Denver, CO 80206 USA	National Jewish Health; National Jewish Health; National Jewish Health	Gelfand, EW (corresponding author), Natl Jewish Hlth, 1400 Jackson St, Denver, CO 80206 USA.	gelfande@njhealth.org	Hagman, James/R-7013-2019	Hagman, James/0000-0002-5436-8455	National Institutes of Health [T32 AI-07405, AI-81878, AI-98417, HL-36577, AI-77609]; Eugene F. and Easton M. Crawford Charitable Lead Unitrust; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036577] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI081878, R01AI098417, R01AI077609, T32AI007405, R56AI077609] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [K01OD010554] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Eugene F. and Easton M. Crawford Charitable Lead Unitrust; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Supported by National Institutes of Health grants T32 AI-07405 (to J.R.), AI-81878 and AI-98417 (to J.R.H.), and HL-36577 and AI-77609 (to E.W.G.). M. W. was supported by a fellowship from the Eugene F. and Easton M. Crawford Charitable Lead Unitrust. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, and Blood Institute or the National Institutes of Health.	al Kandari Hessa, 2006, J Clin Endocrinol Metab, V91, P2821, DOI 10.1210/jc.2005-2230; Ashino S, 2010, INT IMMUNOL, V22, P503, DOI 10.1093/intimm/dxq034; Barnes PJ, 2011, BRIT J PHARMACOL, V163, P29, DOI 10.1111/j.1476-5381.2010.01199.x; Beyer K, 2002, J ALLERGY CLIN IMMUN, V109, P707, DOI 10.1067/mai.2002.122503; Brandt EB, 2003, J CLIN INVEST, V112, P1666, DOI 10.1172/JCI19785; CHROUSOS GP, 1995, NEW ENGL J MED, V332, P1351, DOI 10.1056/NEJM199505183322008; Cima I, 2004, J EXP MED, V200, P1635, DOI 10.1084/jem.20031958; Cima I, 2006, IMMUNOL LETT, V106, P99, DOI 10.1016/j.imlet.2006.04.005; COCCONI G, 1994, BREAST CANCER RES TR, V30, P57, DOI 10.1007/BF00682741; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; De Bosscher K, 2003, ENDOCR REV, V24, P488, DOI 10.1210/er.2002-0006; De Bosscher K, 2009, MOL ENDOCRINOL, V23, P281, DOI 10.1210/me.2008-0283; DeLong JH, 2011, J ALLERGY CLIN IMMUN, V127, P1211, DOI 10.1016/j.jaci.2011.02.028; DEXTER RN, 1967, J CLIN ENDOCR METAB, V27, P473, DOI 10.1210/jcem-27-4-473; Pham D, 2012, J IMMUNOL, V189, P832, DOI 10.4049/jimmunol.1200854; Faubion WA, 2001, GASTROENTEROLOGY, V121, P255, DOI 10.1053/gast.2001.26279; Gross Bradley A, 2007, Neurosurg Focus, V23, pE10; HARRIS AL, 1982, CANCER RES, V42, P3405; Islam SA, 2012, NAT MED, V18, P705, DOI 10.1038/nm.2760; Kim CJ, 2008, J CLIN ENDOCR METAB, V93, P696, DOI 10.1210/jc.2007-2330; Knight AK, 2007, AM J PHYSIOL-GASTR L, V293, pG1234, DOI 10.1152/ajpgi.00323.2007; Kolls JK, 2004, IMMUNITY, V21, P467, DOI 10.1016/j.immuni.2004.08.018; Komine O, 2003, J EXP MED, V198, P51, DOI 10.1084/jem.20021200; Kruit WHJ, 2004, ANTI-CANCER DRUG, V15, P843, DOI 10.1097/00001813-200410000-00004; Lajoie S, 2010, NAT IMMUNOL, V11, P928, DOI 10.1038/ni.1926; LaVoie HA, 2009, EXP BIOL MED, V234, P880, DOI 10.3181/0903-MR-97; Li XM, 2000, J ALLERGY CLIN IMMUN, V106, P150, DOI 10.1067/mai.2000.107395; Maier H, 2003, NUCLEIC ACIDS RES, V31, P5483, DOI 10.1093/nar/gkg785; Mueller M, 2006, J EXP MED, V203, P2057, DOI 10.1084/jem.20060357; Musselman CA, 2012, P NATL ACAD SCI USA, V109, P787, DOI 10.1073/pnas.1113655109; Ohnishi H, 2008, J ALLERGY CLIN IMMUN, V121, P864, DOI 10.1016/j.jaci.2008.01.035; Oka H, 2000, CELL IMMUNOL, V206, P7, DOI 10.1006/cimm.2000.1715; PANG S, 1992, ENDOCRINOLOGY, V131, P181, DOI 10.1210/en.131.1.181; PAYNE AH, 1990, BIOL REPROD, V42, P399, DOI 10.1095/biolreprod42.3.399; Pazirandeh A, 1999, FASEB J, V13, P893, DOI 10.1096/fasebj.13.8.893; Pons L, 2004, J ALLERGY CLIN IMMUN, V114, P915, DOI 10.1016/j.jaci.2004.06.049; Prussin C, 2009, J ALLERGY CLIN IMMUN, V124, P1326, DOI 10.1016/j.jaci.2009.09.048; Rhen T, 2005, NEW ENGL J MED, V353, P1711, DOI 10.1056/NEJMra050541; Sher N, 2007, MOL ENDOCRINOL, V21, P948, DOI 10.1210/me.2006-0226; Shih MCM, 2011, MOL CELL ENDOCRINOL, V336, P80, DOI 10.1016/j.mce.2010.12.017; STUARTHARRIS R, 1985, CLIN ENDOCRINOL, V22, P219, DOI 10.1111/j.1365-2265.1985.tb01083.x; Tajima T, 2001, J CLIN ENDOCR METAB, V86, P3820, DOI 10.1210/jc.86.8.3820; Tomkinson A, 2001, AM J RESP CRIT CARE, V163, P721, DOI 10.1164/ajrccm.163.3.2005010; Wang MQ, 2012, J ALLERGY CLIN IMMUN, V130, P932, DOI 10.1016/j.jaci.2012.07.032; Wang MQ, 2010, J ALLERGY CLIN IMMUN, V126, P306, DOI 10.1016/j.jaci.2010.05.017; Wei G, 2011, IMMUNITY, V35, P299, DOI 10.1016/j.immuni.2011.08.007; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; YANG XM, 1993, ENDOCRINOLOGY, V132, P1977, DOI 10.1210/en.132.5.1977; Zhu JF, 2010, ANNU REV IMMUNOL, V28, P445, DOI 10.1146/annurev-immunol-030409-101212	49	20	21	1	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2013	132	5					1174	+		10.1016/j.jaci.2013.05.027	http://dx.doi.org/10.1016/j.jaci.2013.05.027			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	242JH	23870673	Green Accepted			2022-12-18	WOS:000326235600020
J	Kumar, R; Nguyen, EA; Roth, LA; Oh, SS; Gignoux, CR; Huntsman, S; Eng, C; Moreno-Estrada, A; Sandoval, K; Penaloza-Espinosa, RI; Lopez-Lopez, M; Avila, PC; Farber, HJ; Tcheurekdjian, H; Rodriguez-Cintron, W; Rodriguez-Santana, JR; Serebrisky, D; Thyne, SM; Williams, LK; Winkler, C; Bustamante, CD; Perez-Stable, EJ; Borrell, LN; Burchard, EG				Kumar, Rajesh; Nguyen, Elizabeth A.; Roth, Lindsey A.; Oh, Sam S.; Gignoux, Christopher R.; Huntsman, Scott; Eng, Celeste; Moreno-Estrada, Andres; Sandoval, Karla; Penaloza-Espinosa, Rosenda I.; Lopez-Lopez, Marisol; Avila, Pedro C.; Farber, Harold J.; Tcheurekdjian, Haig; Rodriguez-Cintron, William; Rodriguez-Santana, Jose R.; Serebrisky, Denise; Thyne, Shannon M.; Williams, L. Keoki; Winkler, Cheryl; Bustamante, Carlos D.; Perez-Stable, Eliseo J.; Borrell, Luisa N.; Burchard, Esteban G.			Factors associated with degree of atopy in Latino children in a nationwide pediatric sample: The Genes-environments and Admixture in Latino Asthmatics (GALA II) study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Latino; atopy; region of origin; genetic ancestry; immigration; kin test; aeroallergen	DAY-CARE ATTENDANCE; DUST-MITE ALLERGEN; BLOOD IGE LEVELS; BIRTH COHORT; SOCIOECONOMIC-STATUS; CHILDHOOD ASTHMA; PUERTO-RICAN; 1ST YEAR; COCKROACH ALLERGEN; MEXICAN-AMERICANS	Background: Atopy varies by ethnicity, even within Latino groups. This variation might be due to environmental, sociocultural, or genetic factors. Objective: We sought to examine risk factors for atopy within a nationwide study of US Latino children with and without asthma. Methods: Aeroallergen skin test responses were analyzed in 1830 US Latino subjects. Key determinants of atopy included country/region of origin, generation in the United States, acculturation, genetic ancestry, and site to which subjects migrated. Serial multivariate zero-inflated negative binomial regressions stratified by asthma status examined the association of each key determinant variable with the number of positive skin test responses. In addition, the independent effect of each key variable was determined by including all key variables in the final models. Results: In baseline analyses African ancestry was associated with 3 times (95% CI, 1.62-5.57) as many positive skin test responses in asthmatic participants and 3.26 times (95% CI, 1.02-10.39) as many positive skin test responses in control participants. Generation and recruitment site were also associated with atopy in crude models. In final models adjusted for key variables, asthmatic patients of Puerto Rican (exp[beta] [95% CI], 1.31 [1.021.69]) and mixed (exp[beta] [95% CI], 1.27 [1.03-1.56]) ethnicity had a greater probability of positive skin test responses compared with Mexican asthmatic patients. Ancestry associations were abrogated by recruitment site but not region of origin. Conclusions: Puerto Rican ethnicity and mixed origin were associated with degree of atopy within US Latino children with asthma. African ancestry was not associated with degree of atopy after adjusting for recruitment site. Local environment variation, represented by site, was associated with degree of sensitization.	[Kumar, Rajesh] Northwestern Univ, Childrens Mem Hosp, Div Allergy & Immunol, Chicago, IL 60614 USA; [Kumar, Rajesh] Northwestern Univ, Dept Pediat, Feinberg Sch Med, Chicago, IL 60611 USA; [Nguyen, Elizabeth A.; Roth, Lindsey A.; Oh, Sam S.; Gignoux, Christopher R.; Huntsman, Scott; Eng, Celeste; Perez-Stable, Eliseo J.; Burchard, Esteban G.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA; [Moreno-Estrada, Andres; Sandoval, Karla; Bustamante, Carlos D.] Stanford Univ, Dept Genet, Sch Med, Stanford, CA 94305 USA; [Penaloza-Espinosa, Rosenda I.; Lopez-Lopez, Marisol] Univ Autonoma Metropolitana Xochimilco, Div Biol & Hlth Sci, Dept Syst Biol, Mexico City, DF, Mexico; [Avila, Pedro C.] Northwestern Univ, Div Allergy Immunol, Feinberg Sch Med, Chicago, IL 60611 USA; [Farber, Harold J.] Texas Childrens Hosp, Baylor Coll Med, Dept Pediat, Sect Pulmonol, Houston, TX 77030 USA; [Tcheurekdjian, Haig] Case Western Reserve Univ, Allergy Immunol Associates, Cleveland, OH 44106 USA; [Tcheurekdjian, Haig] Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA; [Tcheurekdjian, Haig] Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; [Rodriguez-Cintron, William] Vet Caribbean Hlth Care Syst, San Juan, PR USA; [Rodriguez-Santana, Jose R.] CSP, Ctr Neumol Pediatr, San Juan, PR USA; [Serebrisky, Denise] Jacobi Med Ctr, Pediat Pulm Div, Bronx, NY USA; [Thyne, Shannon M.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA USA; [Williams, L. Keoki] Henry Ford Hlth Syst, Dept Internal Med, Detroit, MI USA; [Winkler, Cheryl] NCI, Ctr Canc Res, Basic Res Lab, SAIC Frederick, Frederick, MD 21701 USA; [Borrell, Luisa N.] CUNY, Dept Hlth Sci, Grad Program Publ Hlth, Lehman Coll, Bronx, NY USA; [Burchard, Esteban G.] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Northwestern University; Feinberg School of Medicine; University of California System; University of California San Francisco; Stanford University; Universidad Autonoma Metropolitana - Mexico; Northwestern University; Feinberg School of Medicine; Baylor College of Medicine; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Jacobi Medical Center; University of California System; University of California San Francisco; Henry Ford Health System; Henry Ford Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; City University of New York (CUNY) System; Lehman College (CUNY); University of California System; University of California San Francisco	Kumar, R (corresponding author), Childrens Mem Hosp, Div Allergy & Clin Immunol, 2300 Childrens Plaza,Box 60, Chicago, IL 60614 USA.	rkumar@childrensmemorial.org	Moreno-Estrada, Andres/AAP-4657-2021; Borrell, Luisa N./G-8753-2018; Moreno-Estrada, Andres/R-3950-2017	Moreno-Estrada, Andres/0000-0001-8329-8292; Borrell, Luisa N./0000-0002-0560-4853; Moreno-Estrada, Andres/0000-0001-8329-8292; Nguyen, Elizabeth/0000-0002-8070-6382; Bustamante, Carlos D./0000-0002-4187-7920; Kumar, Rajesh/0000-0002-1962-7108; Sandoval, Karla/0000-0002-6175-2463	National Institutes of Health [ES015794, AI077439, HL088133, HL078885, CA113710, AI079139, HL004464, HL104608, AI061774, HL079055, DK064695, M01-RR00188, HHSN26120080001E, MD006902]; Flight Attendant Medical Research Institute (FAMRI); RWJF Amos Medical Faculty; Sandler Foundation; American Asthma Foundation; Ernest S. Bazley Grant; National Heart, Lung, and Blood Institute K23 [K23HL093023]; National Institute on Minority Health and Health Disparities of the National Institutes of Health [P60MD006902]; National Institutes of Health, National Cancer Institute, Center for Cancer Research; National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health (NIH); NHLBI/National Institute of Allergy and Infectious Diseases (NIAID); EMD China; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIAID; Merck; NATIONAL CANCER INSTITUTE [R25CA113710, ZIABC010022] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000188] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL004464, R01HL078885, K23HL093023, R01HL079055, R01HL088133, R01HL104608, T32HL007185] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI079139, U19AI077439, R01AI061774] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064695] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES015794] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U19GM061390] Funding Source: NIH RePORTER; National Institute on Minority Health and Health Disparities [P60MD006902] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Flight Attendant Medical Research Institute (FAMRI); RWJF Amos Medical Faculty; Sandler Foundation; American Asthma Foundation; Ernest S. Bazley Grant; National Heart, Lung, and Blood Institute K23(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute on Minority Health and Health Disparities of the National Institutes of Health; National Institutes of Health, National Cancer Institute, Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHLBI/National Institute of Allergy and Infectious Diseases (NIAID); EMD China; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Merck(Merck & Company); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))	Supported in part by the National Institutes of Health grants (ES015794, AI077439, HL088133, HL078885, CA113710, AI079139, HL004464, HL104608, AI061774, HL079055, DK064695, and M01-RR00188; HHSN26120080001E; and MD006902); the Flight Attendant Medical Research Institute (FAMRI); an RWJF Amos Medical Faculty Development Award (to E. G. B.); the Sandler Foundation; the American Asthma Foundation (to E. G. B); an Ernest S. Bazley Grant (to P.C.A.); National Heart, Lung, and Blood Institute K23 (K23HL093023, to R.K.). In addition, the research reported in this publication was also supported by the National Institute on Minority Health and Health Disparities of the National Institutes of Health under award no. P60MD006902. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Furthermore, the content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government. This research was supported in part by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research.; Disclosure of potential conflict of interest: R. Kumar, E. A. Nguyen, S. S. Oh, S. Huntsman, C. Eng, A. Moreno-Estrada, K. Sandoval, R. I. Penaloza- Espinosa, M. Lopez-Lopez, P. C. Avila, W. Rodriguez-Cintron, J. R. Rodriguez-Santana, D. Serebrisky, S. M. Thyne, C. Winkler, C. D. Bustamante, E. J. Perez-Stable, L. N. Borrell, and E. G. Burchard received research support from the National Heart, Lung, and Blood Institute (NHLBI) and the National Institutes of Health (NIH). C. R. Gignoux has received research support from the NHLBI and NIH and owns stock in 23 and Me. L. A. Roth, S. Huntsman, C. Eng, D. Serebrisky, and C. D. Bustamante have received research support from the NHLBI. P. C. Avila has received research support from the NHLBI/National Institute of Allergy and Infectious Diseases (NIAID). H. J. Farber has received grants from the NIH and NHLBI and has received honoraria for talks on asthma from EMD China. L. K. Williams has received research support from the NHLBI, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and NIAID and has received research support from Merck. The rest of the authors declare that they have no relevant conflicts of interest.	Alexander DH, 2009, GENOME RES, V19, P1655, DOI 10.1101/gr.094052.109; Basehore MJ, 2004, J ALLERGY CLIN IMMUN, V114, P80, DOI 10.1016/j.jaci.2004.05.035; Bisgaard H, 2011, J ALLERGY CLIN IMMUN, V128, P646, DOI 10.1016/j.jaci.2011.04.060; Bolte G, 2003, CLIN EXP ALLERGY, V33, P770, DOI 10.1046/j.1365-2222.2003.01665.x; Borrell LN, 2006, SOC SCI MED, V63, P1415, DOI 10.1016/j.socscimed.2006.04.008; Braaback L, 2011, CLIN EXP ALLERGY, V41, P1108, DOI 10.1111/j.1365-2222.2011.03744.x; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Brugge D, 2008, J ASTHMA, V45, P785, DOI 10.1080/02770900802179957; Brugge D, 2007, ENVIRON HEALTH-GLOB, V6, DOI 10.1186/1476-069X-6-13; Bryc K, 2010, P NATL ACAD SCI USA, V107, P8954, DOI 10.1073/pnas.0914618107; Campo P, 2006, J ALLERGY CLIN IMMUN, V118, P1271, DOI 10.1016/j.jaci.2006.08.008; Celedon JC, 1999, PEDIATRICS, V104, P495, DOI 10.1542/peds.104.3.495; Celedon JC, 2004, CHEST, V125, P85, DOI 10.1378/chest.125.1.85; Celedon JC, 2007, J ALLERGY CLIN IMMUN, V120, P144, DOI 10.1016/j.jaci.2007.03.037; Chew GL, 2009, INDOOR AIR, V19, P193, DOI 10.1111/j.1600-0668.2008.00578.x; Choudhry Shweta, 2007, Proc Am Thorac Soc, V4, P226, DOI 10.1513/pats.200701-029AW; Cole SR, 2010, INT J EPIDEMIOL, V39, P417, DOI 10.1093/ije/dyp334; Devereux G, 2002, CLIN EXP ALLERGY, V32, P43, DOI 10.1046/j.0022-0477.2001.01267.x; DEYO RA, 1985, AM J PUBLIC HEALTH, V75, P51, DOI 10.2105/AJPH.75.1.51; Eggleston PA, 1998, J ALLERGY CLIN IMMUN, V102, P563, DOI 10.1016/S0091-6749(98)70272-6; Eldeirawi KM, 2007, ANN ALLERG ASTHMA IM, V99, P236, DOI 10.1016/S1081-1206(10)60659-X; Flores C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0026807; Foster BA, 2009, PEDIATRICS, V124, P1152, DOI 10.1542/peds.2008-2746; Galanter JM, 2011, J ALLERGY CLIN IMMUN, V128, P37, DOI 10.1016/j.jaci.2011.03.050; Gehring U, 2002, AM J RESP CRIT CARE, V166, P939, DOI 10.1164/rccm.200203-256OC; Gern JE, 2004, J ALLERGY CLIN IMMUN, V113, P307, DOI 10.1016/j.jaci.2003.11.017; Gustafsson D, 2000, ALLERGY, V55, P240, DOI 10.1034/j.1398-9995.2000.00391.x; Hagendorens MM, 2005, CLIN EXP ALLERGY, V35, P733, DOI 10.1111/j.1365-2222.2005.02254.x; Hijazi N, 2000, THORAX, V55, P775, DOI 10.1136/thorax.55.9.775; Hjern A, 1999, PEDIATR ALLERGY IMMU, V10, P101, DOI 10.1034/j.1399-3038.1999.00023.x; Hoffmann TJ, 2011, GENOMICS, V98, P422, DOI 10.1016/j.ygeno.2011.08.007; Homa DM, 2000, AM J RESP CRIT CARE, V161, P504, DOI 10.1164/ajrccm.161.2.9906025; Hunninghake GM, 2008, AM J RESP CRIT CARE, V177, P830, DOI 10.1164/rccm.200711-1697OC; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; Johnson CC, 1998, AM J EPIDEMIOL, V147, P1145; Kerkhof M, 2005, PEDIAT ALLERG IMM-UK, V16, P10, DOI 10.1111/j.1399-3038.2005.00217.x; Khan LK, 1997, INT J OBESITY, V21, P91, DOI 10.1038/sj.ijo.0800367; Kumar R, 2008, CURR OPIN PEDIATR, V20, P682, DOI 10.1097/MOP.0b013e3283154f26; Lara M, 2006, PEDIATRICS, V117, P43, DOI 10.1542/peds.2004-1714; Leaderer BP, 2002, ENVIRON HEALTH PERSP, V110, P419, DOI 10.1289/ehp.02110419; Lester LA, 2001, J ALLERGY CLIN IMMUN, V108, P357, DOI 10.1067/mai.2001.117796; LEUNG R, 1994, THORAX, V49, P1205, DOI 10.1136/thx.49.12.1205; LEUNG RC, 1994, MED J AUSTRALIA, V161, P418, DOI 10.5694/j.1326-5377.1994.tb127522.x; Litonjua AA, 2001, J ALLERGY CLIN IMMUN, V107, P41, DOI 10.1067/mai.2001.111143; Litonjua AA, 2005, J ALLERGY CLIN IMMUN, V115, P751, DOI 10.1016/j.jaci.2004.12.1138; Ly NP, 2008, CHEST, V133, P107, DOI 10.1378/chest.07-2130; Lyons TW, 2011, ANN ALLERG ASTHMA IM, V106, P301, DOI 10.1016/j.anai.2010.12.009; Martin MA, 2007, AM J PUBLIC HEALTH, V97, P1290, DOI 10.2105/AJPH.2006.092239; Matricardi PM, 2001, ANN ALLERG ASTHMA IM, V87, P24, DOI 10.1016/S1081-1206(10)62336-8; Matsui EC, 2003, J ALLERGY CLIN IMMUN, V112, P87, DOI 10.1067/mai.2003.1588; McKeever TM, 2001, THORAX, V56, P758, DOI 10.1136/thorax.56.10.758; Nicolaou NC, 2008, J ALLERGY CLIN IMMUN, V122, P500, DOI 10.1016/j.jaci.2008.06.033; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Patel S, 2009, ALLERGY, V64, P1766, DOI 10.1111/j.1398-9995.2009.02099.x; Platts-Mills TAE, 2007, J ALLERGY CLIN IMMUN, V120, P1058, DOI 10.1016/j.jaci.2007.06.032; Salari K, 2005, GENET EPIDEMIOL, V29, P76, DOI 10.1002/gepi.20079; Salari K, 2007, PAEDIATR PERINAT EP, V21, P15, DOI 10.1111/j.1365-3016.2007.00880.x; Scirica CV, 2007, J ALLERGY CLIN IMMUN, V119, P81, DOI 10.1016/j.jaci.2006.09.002; Sears MR, 2002, LANCET, V360, P901, DOI 10.1016/S0140-6736(02)11025-7; Sternthal MJ, 2011, J ALLERGY CLIN IMMUN, V128, P337, DOI 10.1016/j.jaci.2011.05.008; Thornton CA, 2010, CURR ALLERGY ASTHM R, V10, P444, DOI 10.1007/s11882-010-0148-5; Vergara C, 2009, HUM GENET, V125, P565, DOI 10.1007/s00439-009-0649-2; VONMUTIUS E, 1994, AM J RESP CRIT CARE, V149, P358, DOI 10.1164/ajrccm.149.2.8306030; Wright RJ, 2004, J ALLERGY CLIN IMMUN, V113, P1051, DOI 10.1016/j.jaci.2004.03.032; Wright RJ, 2007, PAEDIATR PERINAT EP, V21, P8, DOI 10.1111/j.1365-3016.2007.00879.x; Yang JJ, 2008, J ALLERGY CLIN IMMUN, V122, P820, DOI 10.1016/j.jaci.2008.07.044	66	20	21	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2013	132	4					896	+		10.1016/j.jaci.2013.02.046	http://dx.doi.org/10.1016/j.jaci.2013.02.046			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	227FR	23684070	Green Accepted			2022-12-18	WOS:000325096500017
J	Schnyder, B; Adam, J; Rauch, A; Thurnheer, MC; Pichler, WJ				Schnyder, Benno; Adam, Jacqueline; Rauch, Andri; Thurnheer, Maria C.; Pichler, Werner J.			HLA-B*57:01(+) abacavir-naive individuals have specific T cells but no patch test reactivity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							DRUG HYPERSENSITIVITY; PEPTIDE REPERTOIRE		[Schnyder, Benno; Adam, Jacqueline; Pichler, Werner J.] Univ Bern, Inselspital, Clin Rheumatol & Clin Immunol Allergy, CH-3010 Bern, Switzerland; [Rauch, Andri; Thurnheer, Maria C.] Univ Bern, Inselspital, Dept Infect Dis, CH-3010 Bern, Switzerland	University of Bern; University Hospital of Bern; University of Bern; University Hospital of Bern	Schnyder, B (corresponding author), Univ Bern, Inselspital, Clin Rheumatol & Clin Immunol Allergy, CH-3010 Bern, Switzerland.	werner.pichler@insel.ch	Rauch, Andri/E-9948-2017; Thurnheer, Christine/CAH-0185-2022	Rauch, Andri/0000-0001-5297-6062; Thurnheer, Christine/0000-0003-1357-0347; Pichler, Werner J./0000-0002-8117-359X				Adam J, 2012, EUR J IMMUNOL, V42, P1706, DOI 10.1002/eji.201142159; Adam J, 2011, BRIT J CLIN PHARMACO, V71, P701, DOI 10.1111/j.1365-2125.2010.03764.x; Chessman D, 2008, IMMUNITY, V28, P822, DOI 10.1016/j.immuni.2008.04.020; Illing PT, 2012, NATURE, V486, P554, DOI 10.1038/nature11147; Jiang XD, 2012, NATURE, V483, P227, DOI 10.1038/nature10851; Mallal S, 2008, NEW ENGL J MED, V358, P568, DOI 10.1056/NEJMoa0706135; Norcross MA, 2012, AIDS, V26, pF21, DOI 10.1097/QAD.0b013e328355fe8f; Ostrov DA, 2012, P NATL ACAD SCI USA, V109, P9959, DOI 10.1073/pnas.1207934109	8	20	20	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2013	132	3					756	758		10.1016/j.jaci.2013.04.013	http://dx.doi.org/10.1016/j.jaci.2013.04.013			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207OS	23706613				2022-12-18	WOS:000323612000035
J	Dutre, T; Al Dousary, S; Zhang, N; Bachert, C				Dutre, Tineke; Al Dousary, Surayie; Zhang, Nan; Bachert, Claus			Allergic fungal rhinosinusitis-more than a fungal disease?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							STAPHYLOCOCCUS-AUREUS; ENTEROTOXINS; ASTHMA; IGE		[Dutre, Tineke; Zhang, Nan; Bachert, Claus] Ghent Univ Hosp, Dept Otorhinolaryngol, Upper Airways Res Lab, Ghent, Belgium; [Al Dousary, Surayie] King Saud Univ, Coll Med, Dept Otorhinolaryngol, Riyadh 11461, Saudi Arabia	Ghent University; Ghent University Hospital; King Saud University	Dutre, T (corresponding author), Ghent Univ Hosp, Dept Otorhinolaryngol, Upper Airways Res Lab, Ghent, Belgium.	Claus.Bachert@ugent.be	Bachert, Claus/J-8825-2012; Zhang, Nan/AAQ-3944-2020					Bachert C, 2012, J ALLERGY CLIN IMMUN, V130, P376, DOI 10.1016/j.jaci.2012.05.012; Bachert C, 2010, J ALLERGY CLIN IMMUN, V126, P962, DOI 10.1016/j.jaci.2010.07.007; Chakrabarti A, 2009, LARYNGOSCOPE, V119, P1809, DOI 10.1002/lary.20520; Clark DW, 2013, INT FORUM ALLERGY RH, V3, P89, DOI 10.1002/alr.21090; Corriveau MN, 2009, AM J RHINOL ALLERGY, V23, P461, DOI 10.2500/ajra.2009.23.3367; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Gevaert P, 2013, J ALLERGY CLIN IMMUN, V131, P110, DOI 10.1016/j.jaci.2012.07.047; Krysko O, 2011, ALLERGY, V66, P396, DOI 10.1111/j.1398-9995.2010.02498.x; Schubert MS, 2009, MED MYCOL, V47, pS324, DOI 10.1080/13693780802314809	9	20	20	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2013	132	2					487	489		10.1016/j.jaci.2013.02.040	http://dx.doi.org/10.1016/j.jaci.2013.02.040			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	194KL	23608727				2022-12-18	WOS:000322631700032
J	Kim, HY; Chang, YJ; Chuang, YT; Lee, HH; Kasahara, DI; Martin, T; Hsu, JT; Savage, PB; Shore, SA; Freeman, GJ; DeKruyff, RH; Umetsu, DT				Kim, Hye Young; Chang, Ya-Jen; Chuang, Ya-Ting; Lee, Hyun-Hee; Kasahara, David I.; Martin, Thomas; Hsu, Joyce T.; Savage, Paul B.; Shore, Stephanie A.; Freeman, Gordon J.; DeKruyff, Rosemarie H.; Umetsu, Dale T.			T-cell immunoglobulin and mucin domain 1 deficiency eliminates airway hyperreactivity triggered by the recognition of airway cell death	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						TIM-1; natural killer T; apoptosis; asthma	RESPIRATORY SYNCYTIAL VIRUS; HEPATITIS-A VIRUS; ADAPTIVE IMMUNITY; CHILDHOOD ASTHMA; GENETIC-VARIANTS; APOPTOTIC CELLS; ALLERGIC-ASTHMA; MOUSE MODEL; NKT CELLS; IN-VIVO	Background: Studies of asthma have been limited by a poor understanding of how nonallergic environmental exposures, such as air pollution and infection, are translated in the lung into inflammation and wheezing. Objective: Our goal was to understand the mechanism of nonallergic asthma that leads to airway hyperreactivity (AHR), a cardinal feature of asthma independent of adaptive immunity. Method: We examined mouse models of experimental asthma in which AHR was induced by respiratory syncytial virus infection or ozone exposure using mice deficient in T-cell immunoglobulin and mucin domain 1 (TIM1/HAVCR1), an important asthma susceptibility gene. Results: TIM1(-/-) mice did not have airways disease when infected with RSVor when repeatedly exposed to ozone, a major component of air pollution. On the other hand, the TIM1(-/-) mice had allergen-induced experimental asthma, as previously shown. The RSV-and ozone-induced pathways were blocked by treatment with caspase inhibitors, indicating an absolute requirement for programmed cell death and apoptosis. TIM-1-expressing, but not TIM-1-deficient, natural killer T cells responded to apoptotic airway epithelial cells by secreting cytokines, which mediated the development of AHR. Conclusion: We defined a novel pathway in which TIM-1, a receptor for phosphatidylserine expressed by apoptotic cells, drives the development of asthma by sensing and responding to injured and apoptotic airway epithelial cells.	[Kim, Hye Young; Chang, Ya-Jen; Chuang, Ya-Ting; Lee, Hyun-Hee; Hsu, Joyce T.; DeKruyff, Rosemarie H.; Umetsu, Dale T.] Harvard Univ, Sch Med, Childrens Hosp, Div Immunol & Allergy, Boston, MA 02115 USA; [Kasahara, David I.; Shore, Stephanie A.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Mol & Integrat Physiol Sci Program, Boston, MA 02115 USA; [Martin, Thomas] Harvard Univ, Sch Med, Childrens Hosp, Div Resp Dis, Boston, MA 02115 USA; [Savage, Paul B.] Brigham Young Univ, Provo, UT 84602 USA; [Freeman, Gordon J.] Harvard Univ, Sch Med, Dept Med, Dana Farber Canc Inst,Dept Med Oncol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Boston Children's Hospital; Harvard Medical School; Brigham Young University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Umetsu, DT (corresponding author), Harvard Univ, Sch Med, Div Immunol, Childrens Hosp,Karp Labs, Rm 10127,1 Blackfan Circle, Boston, MA 02115 USA.	dale.umetsu@childrens.harvard.edu	Freeman, Gordon/AAC-5380-2019; Chang, Ya-Jen/O-1584-2018; Savage, Paul B/E-1448-2011; Kim, Hye Young/AAF-7609-2020; Savage, Paul B/HGB-3414-2022	Freeman, Gordon/0000-0002-7210-5616; Chang, Ya-Jen/0000-0003-1377-6142; Savage, Paul B/0000-0002-4642-6109; Kim, Hye Young/0000-0001-5978-512X; Savage, Paul B/0000-0002-4642-6109; Hsu, Joyce/0000-0002-1825-4733	Boston Children's Hospital; National Institutes ofHealth (NIH); McGill University; NIH; NIH/National Institute of Allergy and Infectious Diseases; CoStim; Genentech; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI089955, P01AI054456] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES013307] Funding Source: NIH RePORTER	Boston Children's Hospital; National Institutes ofHealth (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); McGill University; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); CoStim; Genentech(Roche HoldingGenentech); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	J. T. Hsu has received research support from Boston Children's Hospital and has received travel support from the Pediatric Academic Societies. S. A. Shore is employed by Harvard University; has received research support fromthe National Institutes ofHealth (NIH); and has received lecture fees fromtheChristie Lecture, McGill University. G. J. Freeman has received research support fromthe NIH and has patents on TIM molecules. R. H. DeKruyff has received research support from the NIH/National Institute of Allergy and Infectious Diseases, has patents on TIM molecule function, and receives royalties from Patent licensing. D. T. Umetsu has received research support from CoStim and Genentech, has patents on TIM molecules and other molecules, and receives royalties from patents on natural killer T cells. The rest of the authors declare that they have no relevant conflicts of interest.	Akbari O, 2003, NAT MED, V9, P582, DOI 10.1038/nm851; Anderson GP, 2008, LANCET, V372, P1107, DOI 10.1016/S0140-6736(08)61452-X; ARIS RM, 1993, AM REV RESPIR DIS, V148, P1363, DOI 10.1164/ajrccm/148.5.1363; Auerbach A, 2012, CURR OPIN ALLERGY CL, V12, P133, DOI 10.1097/ACI.0b013e32835113d6; Barlow JL, 2011, CLIN EXP ALLERGY, V41, P1012, DOI 10.1111/j.1365-2222.2011.03728.x; Cohen L, 2007, AM J RESP CRIT CARE, V176, P138, DOI 10.1164/rccm.200607-1062OC; Culley FJ, 2002, J EXP MED, V196, P1381, DOI 10.1084/jem.20020943; Deszcz L, 2005, J GEN VIROL, V86, P1379, DOI 10.1099/vir.0.80754-0; DEVLIN RB, 1991, AM J RESP CELL MOL, V4, P72, DOI 10.1165/ajrcmb/4.1.72; Ding Q, 2011, J CLIN INVEST, V121, P3645, DOI 10.1172/JCI46274; Encinas JA, 2005, J ALLERGY CLIN IMMUN, V116, P1343, DOI 10.1016/j.jaci.2005.08.031; Falsey AR, 2005, NEW ENGL J MED, V352, P1749, DOI 10.1056/NEJMoa043951; Fitzpatrick AM, 2009, J ALLERGY CLIN IMMUN, V123, P146, DOI 10.1016/j.jaci.2008.10.047; Freeman GJ, 2010, IMMUNOL REV, V235, P172, DOI 10.1111/j.0105-2896.2010.00903.x; Gao PS, 2005, J ALLERGY CLIN IMMUN, V115, P982, DOI 10.1016/j.jaci.2005.01.035; Gent JF, 2003, JAMA-J AM MED ASSOC, V290, P1859, DOI 10.1001/jama.290.14.1859; Graves PE, 2005, J ALLERGY CLIN IMMUN, V116, P650, DOI 10.1016/j.jaci.2005.05.004; Griffith TS, 2011, IMMUNITY, V35, P456, DOI 10.1016/j.immuni.2011.08.011; Hall CB, 2009, NEW ENGL J MED, V360, P588, DOI 10.1056/NEJMoa0804877; Havasi A, 2011, KIDNEY INT, V80, P29, DOI 10.1038/ki.2011.120; Henson PM, 2008, AM J PHYSIOL-LUNG C, V294, pL601, DOI 10.1152/ajplung.00320.2007; Jemielity S, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003232; Kepp O, 2009, APOPTOSIS, V14, P364, DOI 10.1007/s10495-008-0303-9; Kim HY, 2011, J CLIN INVEST, V121, P1111, DOI 10.1172/JCI44182; Kim HY, 2010, NAT IMMUNOL, V11, P577, DOI 10.1038/ni.1892; Kobayashi N, 2007, IMMUNITY, V27, P927, DOI 10.1016/j.immuni.2007.11.011; Kotelkin A, 2003, J VIROL, V77, P9156, DOI 10.1128/JVI.77.17.9156-9172.2003; Krishnamoorthy N, 2012, NAT MED, V18, P1525, DOI 10.1038/nm.2896; Lee HH, 2010, J IMMUNOL, V185, P5225, DOI 10.4049/jimmunol.1001116; Li ZW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027137; Matangkasombut P, 2009, J ALLERGY CLIN IMMUN, V123, P1181, DOI 10.1016/j.jaci.2009.02.013; Matricardi PM, 2002, J ALLERGY CLIN IMMUN, V110, P381, DOI 10.1067/mai.2002.126658; Matricardi PM, 1997, BRIT MED J, V314, P999, DOI 10.1136/bmj.314.7086.999; McIntire JJ, 2003, NATURE, V425, P576, DOI 10.1038/425576a; McIntire JJ, 2001, NAT IMMUNOL, V2, P1109, DOI 10.1038/ni739; Miyanishi M, 2007, NATURE, V450, P435, DOI 10.1038/nature06307; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Moussion C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003331; Nuchnoi P, 2008, ANN HUM GENET, V72, P327, DOI 10.1111/j.1469-1809.2007.00424.x; Pichavant M, 2008, J EXP MED, V205, P385, DOI 10.1084/jem.20071507; Santiago C, 2007, IMMUNITY, V27, P941, DOI 10.1016/j.immuni.2007.11.008; Shore SA, 2002, J APPL PHYSIOL, V92, P1019, DOI 10.1152/japplphysiol.00381.2001; Sonar SS, 2010, J CLIN INVEST, V120, P2767, DOI 10.1172/JCI39543; Tolbert PE, 2000, AM J EPIDEMIOL, V151, P798, DOI 10.1093/oxfordjournals.aje.a010280; Triantaphyllopoulos K, 2011, AM J PHYSIOL-LUNG C, V300, pL691, DOI 10.1152/ajplung.00252.2010; Uchida Y, 2010, HEPATOLOGY, V51, P1363, DOI 10.1002/hep.23442; Umetsu SE, 2005, NAT IMMUNOL, V6, P447, DOI 10.1038/ni1186; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; Vandivier RW, 2006, CHEST, V129, P1673, DOI 10.1378/chest.129.6.1673; Villenave R, 2012, P NATL ACAD SCI USA, V109, P5040, DOI 10.1073/pnas.1110203109; Welliver TP, 2007, J INFECT DIS, V195, P1126, DOI 10.1086/512615; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Westerly BD, 2010, IMMUNOL ALLERGY CLIN, V30, P523, DOI 10.1016/j.iac.2010.08.006; Wichukchinda N, 2010, AIDS, V24, P1625, DOI 10.1097/QAD.0b013e32833a8e6d; Wong CHY, 2011, SCIENCE, V334, P101, DOI 10.1126/science.1210301; Wu Q, 2009, J INVEST ALLERG CLIN, V19, P146; Xiao S, 2012, P NATL ACAD SCI USA, V109, P12105, DOI 10.1073/pnas.1120914109	57	20	23	1	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2013	132	2					414	+		10.1016/j.jaci.2013.03.025	http://dx.doi.org/10.1016/j.jaci.2013.03.025			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	194KL	23672783	Green Accepted			2022-12-18	WOS:000322631700020
J	Hofmann, C; Scheurer, S; Rost, K; Graulich, E; Jamin, A; Foetisch, K; Saloga, J; Vieths, S; Steinbrink, K; Adler, HS				Hofmann, Claudia; Scheurer, Stephan; Rost, Kathrin; Graulich, Edith; Jamin, Annette; Foetisch, Kay; Saloga, Joachim; Vieths, Stefan; Steinbrink, Kerstin; Adler, Henric S.			Cor a 1-reactive T cells and IgE are predominantly cross-reactive to Bet v 1 in patients with birch pollen-associated food allergy to hazelnut	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T-cell cross-reactivity; birch pollen allergy; hazelnut; carrot; food allergy; Bet v 1; Cor a 1; Dau c 1; oral allergy syndrome; type I allergy; IgE; pathogenesis-related proteins	DAU C 1; DENDRITIC CELLS; ORAL ALLERGY; OVERLAPPING PEPTIDES; MAJOR ALLERGEN; HELPER-CELLS; TREE POLLEN; IMMUNOTHERAPY; IDENTIFICATION; BET-V-1	Background: IgE- and T-cell cross-reactivity contribute to the birch pollen-food syndrome. Objectives: We performed a comprehensive analysis of T-cell cross-reactivity in primary cell cultures, facilitating the identification of allergen-specific T-cell subpopulations from individual patients. Methods: Patients with birch pollen allergy and associated food allergy to hazelnuts, carrots, or both were analyzed for IgE cross-reactivity, T-cell responses, and T-cell cross-reactivity to recombinant Bet v 1.0101 (Bet v 1; birch), Cor a 1.0401 (Cor a 1; hazelnut), and Dau c 1.0104 (Dau c 1; carrot). A novel flow cytometry-based method using a 2-step staining process with fluorescent dyes was established to identify subpopulations of cross-reactive T cells. Results: IgE-binding inhibition tests of individual sera revealed that the vast majority of Cor a 1-reactive IgE was cross-reactive to Bet v 1, whereas Bet v 1-reactive IgE was only partially inhibited by preincubation with Cor a 1. Primary stimulation of T cells with Bet v 1 or Cor a 1 resulted in a significant increase in specific responses to Cor a 1 or Bet v 1 after secondary stimulation, respectively, indicating T-cell cross-reactivity between birch and hazelnut allergens in all patients of the study cohort. Preactivation with Dau c 1 induced less pronounced effects. A novel flow cytometry-based proliferation assay identified a predominant Cor a 1/Bet v 1-cross-reactive T-cell subpopulation within highly Bet v 1/Cor a 1-responsive T cells. Conclusion: Analysis of primary allergen-specific T cells combined with flow cytometry-based proliferation assays facilitates investigation of allergen-specific T-cell subpopulations in subjects and might be helpful to evaluate the effect of birchspecific immunotherapy on pollen-associated food allergies.	[Hofmann, Claudia; Rost, Kathrin; Graulich, Edith; Saloga, Joachim; Steinbrink, Kerstin; Adler, Henric S.] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Dermatol, D-55131 Mainz, Germany; [Scheurer, Stephan; Jamin, Annette; Foetisch, Kay; Vieths, Stefan] Paul Ehrlich Inst, Langen, Germany	Johannes Gutenberg University of Mainz; Paul Ehrlich Institute	Steinbrink, K (corresponding author), Johannes Gutenberg Univ Mainz, Univ Med Ctr Mainz, Langenbeckstr 1, D-55131 Mainz, Germany.	kerstin.steinbrink@unimedizin-mainz.de; HenricAdler@gmx.de	Scheurer, Stephan/A-6509-2019	Scheurer, Stephan/0000-0002-2859-562X	German Research Foundation [52/TPA7, DFG STE791/4-5, STE791/5-1]; ALK-Abello; Foundation for Innovation (Mainz); University of Mainz; German Federal Ministry of Health; German Research Foundation (Deutsche Forschungsgemeinschaft [DVG VI 165/6-1, GVG VI 165/71]; Research Fund of the German Food Industry (Forschungskreis der Ernahrungsindustrie, FEI), Monsanto; Pioneer Hi-Bred International; Food Allergy Research& Resource Program; European Directorate for the Quality of Medicines and Health Care (EDQM); German Federal Ministry for Education and Research	German Research Foundation(German Research Foundation (DFG)); ALK-Abello; Foundation for Innovation (Mainz); University of Mainz; German Federal Ministry of Health; German Research Foundation (Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Research Fund of the German Food Industry (Forschungskreis der Ernahrungsindustrie, FEI), Monsanto; Pioneer Hi-Bred International; Food Allergy Research& Resource Program; European Directorate for the Quality of Medicines and Health Care (EDQM); German Federal Ministry for Education and Research(Federal Ministry of Education & Research (BMBF))	Supported by the German Research Foundation (Transregio 52/TPA7, DFG STE791/4-5, STE791/5-1) to K.S. and the Foundation Rhineland-Palatinate to (K.S. and H.S.A.) and intramural grants (to K.S.).; Disclosure of potential conflict of interest: J. Saloga has been supported by one or more grants from ALK-Abello, the Foundation for Innovation (Mainz), and the University of Mainz. S. Vieths has received honoraria from the Food Allergy Resource and Research Program; has received support from the German Federal Ministry of Health, the German Research Foundation (Deutsche Forschungsgemeinschaft, DVG VI 165/6-1 and GVG VI 165/71), the Research Fund of the German Food Industry (Forschungskreis der Ernahrungsindustrie, FEI), Monsanto, Pioneer Hi-Bred International, the Food Allergy Research& Resource Program, the European Directorate for the Quality of Medicines and Health Care (EDQM), and the German Federal Ministry for Education and Research; is a member of the Executive Committee of the European Academy of Allergy and Clinical Immunology (EAACI); serves on subcommittees of the International Union of Immunological Societies (IUIS); is a registered expert for the European Agency for the Evaluation of Medicinal Products (EMEA) and the European Pharmacopoeia Commission; is chairman of Technical Committee 275 Working Group 12 "Food Allergens'' for CEN (the European Committee for Standardization); and is a member of the Food Allergy Working Group of the Deutsche Gesellschaft fur Allergie und Klinische Immunologie (DGAKI). The rest of the authors declare that they have no relevant conflicts of interest.	Adler HS, 2010, J IMMUNOL, V184, P6025, DOI 10.4049/jimmunol.0901327; Akdis CA, 2011, J ALLERGY CLIN IMMUN, V127, P18, DOI 10.1016/j.jaci.2010.11.030; Bellinghausen I, 2000, J ALLERGY CLIN IMMUN, V105, P988, DOI 10.1067/mai.2000.105526; Bohle B, 2007, ALLERGY, V62, P3, DOI 10.1111/j.1398-9995.2006.01258.x; Bohle B, 2005, CLIN EXP ALLERGY, V35, P1392, DOI 10.1111/j.1365-2222.2005.02332.x; Bohle B, 2003, EUR J IMMUNOL, V33, P3303, DOI 10.1002/eji.200324321; Bolhaar STHP, 2004, CLIN EXP ALLERGY, V34, P761, DOI 10.1111/j.1365-2222.2004.1939.x; Breiteneder H, 2000, J ALLERGY CLIN IMMUN, V106, P27, DOI 10.1067/mai.2000.106929; Bucher X, 2004, ALLERGY, V59, P1272, DOI 10.1111/j.1398-9995.2004.00626.x; DeWitt AM, 2002, CLIN EXP ALLERGY, V32, P1329, DOI 10.1046/j.1365-2222.2002.01467.x; EBNER C, 1993, J IMMUNOL, V150, P1047; EBNER C, 1995, J ALLERGY CLIN IMMUN, V95, P962, DOI 10.1016/S0091-6749(95)70096-X; EBNER C, 1993, MOL IMMUNOL, V30, P1323, DOI 10.1016/0161-5890(93)90093-Q; EBNER C, 1993, EUR J IMMUNOL, V23, P1523, DOI 10.1002/eji.1830230719; Egger M, 2006, ALLERGY, V61, P461, DOI 10.1111/j.1398-9995.2006.00994.x; ERIKSSON NE, 1982, ALLERGY, V37, P437, DOI 10.1111/j.1398-9995.1982.tb02323.x; Fritsch R, 1998, J ALLERGY CLIN IMMUN, V102, P679, DOI 10.1016/S0091-6749(98)70287-8; Gottschalk PG, 2005, J BIOPHARM STAT, V15, P437, DOI 10.1081/BIP-200056532; Hammad H, 2001, BLOOD, V98, P1135, DOI 10.1182/blood.V98.4.1135; Hansen KS, 2004, MOL NUTR FOOD RES, V48, P441, DOI 10.1002/mnfr.200400037; HIRSCHWEHR R, 1992, J ALLERGY CLIN IMMUN, V90, P927, DOI 10.1016/0091-6749(92)90465-E; Hoffmann-Sommergruber K, 1999, CLIN EXP ALLERGY, V29, P840, DOI 10.1046/j.1365-2222.1999.00529.x; Jahn-Schmid B, 2005, J ALLERGY CLIN IMMUN, V116, P213, DOI 10.1016/j.jaci.2005.04.019; Katelaris CH, 2010, CURR OPIN ALLERGY CL, V10, P246, DOI 10.1097/ACI.0b013e32833973fb; Kazemi-Shirazi L, 2000, J ALLERGY CLIN IMMUN, V105, P116, DOI 10.1016/S0091-6749(00)90186-6; Kinaciyan T, 2007, J ALLERGY CLIN IMMUN, V119, P937, DOI 10.1016/j.jaci.2006.11.010; Klinglmayr E, 2009, ALLERGY, V64, P647, DOI 10.1111/j.1398-9995.2008.01844.x; Lauer I, 2008, MOL NUTR FOOD RES, V52, pS262, DOI 10.1002/mnfr.200700426; Luttkopf D, 2002, MOL IMMUNOL, V38, P515, DOI 10.1016/S0161-5890(01)00087-6; Ma SH, 2003, J ALLERGY CLIN IMMUN, V112, P784, DOI 10.1016/S0091-6749(03)02008-6; Mari A, 2005, CURR OPIN ALLERGY CL, V5, P267, DOI 10.1097/01.all.0000168793.27948.b0; Markovic-Housley Z, 2009, ACTA CRYSTALLOGR D, V65, P1206, DOI 10.1107/S0907444909034854; Mittag D, 2006, MOL IMMUNOL, V43, P268, DOI 10.1016/j.molimm.2005.02.008; Smole U, 2010, ALLERGY, V65, P1388, DOI 10.1111/j.1398-9995.2010.02407.x; Smole U, 2010, IMMUNOBIOLOGY, V215, P903, DOI 10.1016/j.imbio.2009.11.003; Takishita T, 2005, ALLERGY, V60, P211, DOI 10.1111/j.1398-9995.2005.00660.x; van Ree R, 2004, CURR OPIN ALLERGY CL, V4, P235, DOI [10.1097/00130832-200406000-00017, 10.1097/01.all.0000129457.27092.8f]; Vieths S, 2002, ANN NY ACAD SCI, V964, P47; Weigt H, 2004, J IMMUNOL, V172, P6080, DOI 10.4049/jimmunol.172.10.6080; Wensing M, 2002, J ALLERGY CLIN IMMUN, V110, P435, DOI 10.1067/mai.2002.126380; WUTHRICH B, 1995, INT ARCH ALLERGY IMM, V106, P149, DOI 10.1159/000236836	41	20	21	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2013	131	5					1384	U209		10.1016/j.jaci.2012.10.037	http://dx.doi.org/10.1016/j.jaci.2012.10.037			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	144AU	23246018				2022-12-18	WOS:000318912200016
J	Eissa, NT				Eissa, N. Tony			The exosome in lung diseases: Message in a bottle	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						MicroRNA; asthma; exosome; pulmonary; microparticles	BRONCHOALVEOLAR LAVAGE FLUID; CELLS; MACROPHAGES; MICRORNAS		[Eissa, N. Tony] Baylor Coll Med, Dept Med, Houston, TX 77030 USA	Baylor College of Medicine	Eissa, NT (corresponding author), Baylor Coll Med, 1 Baylor Plaza,BCM 285 Suite 535E, Houston, TX 77030 USA.	teissa@bcm.edu						Bang C, 2012, INT J BIOCHEM CELL B, V44, P2060, DOI 10.1016/j.biocel.2012.08.007; Clayton A, 2007, CANCER RES, V67, P7458, DOI 10.1158/0008-5472.CAN-06-3456; Denzer K, 2000, J IMMUNOL, V165, P1259, DOI 10.4049/jimmunol.165.3.1259; Esser J, 2010, J ALLERGY CLIN IMMUN, V126, P1032, DOI 10.1016/j.jaci.2010.06.039; Greene CM, 2013, CURR OPIN PULM MED, V19, P66, DOI 10.1097/MCP.0b013e32835a5bc8; Kesimer M, 2009, FASEB J, V23, P1858, DOI 10.1096/fj.08-119131; Lasser C, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-9; Lee C, 2012, CIRCULATION, V126, P2601, DOI 10.1161/CIRCULATIONAHA.112.114173; Levanen B, 2013, J ALLERGY CLIN IMMUN, V131, P894, DOI 10.1016/j.jaci.2012.11.039; Paredes PT, 2012, ALLERGY, V67, P911, DOI 10.1111/j.1398-9995.2012.02835.x; Qazi KR, 2010, THORAX, V65, P1016, DOI 10.1136/thx.2009.132027; Simpson RJ, 2008, PROTEOMICS, V8, P4083, DOI 10.1002/pmic.200800109; Singh PP, 2012, J IMMUNOL, V189, P777, DOI 10.4049/jimmunol.1103638; Thery Clotilde, 2011, F1000 Biol Rep, V3, P15, DOI 10.3410/B3-15; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596	15	20	21	1	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2013	131	3					904	905		10.1016/j.jaci.2013.01.021	http://dx.doi.org/10.1016/j.jaci.2013.01.021			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	098ZM	23360758				2022-12-18	WOS:000315587800035
J	Ierodiakonou, D; Postma, DS; Koppelman, GH; Gerritsen, J; ten Hacken, NHT; Timens, W; Boezen, HM; Vonk, JM				Ierodiakonou, Despo; Postma, Dirkje S.; Koppelman, Gerard H.; Gerritsen, Jorrit; ten Hacken, Nick H. T.; Timens, Wim; Boezen, H. Marike; Vonk, Judith M.			TGF-beta 1 polymorphisms and asthma severity, airway inflammation, and remodeling	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							DISEASE; EXPRESSION; RATS		[Ierodiakonou, Despo; Boezen, H. Marike; Vonk, Judith M.] Beatrix Childrens Hosp, Dept Epidemiol, Groningen, Netherlands; [Postma, Dirkje S.; ten Hacken, Nick H. T.] Beatrix Childrens Hosp, Dept Pulmonol, Groningen, Netherlands; [Koppelman, Gerard H.; Gerritsen, Jorrit] Beatrix Childrens Hosp, Dept Pediat Pulmonol & Pediat Allergol, Groningen, Netherlands; [Timens, Wim] Univ Groningen, Univ Med Ctr Groningen, Dept Pathol & Med Biol, Groningen, Netherlands; [Ierodiakonou, Despo; Postma, Dirkje S.; Koppelman, Gerard H.; Gerritsen, Jorrit; ten Hacken, Nick H. T.; Timens, Wim; Boezen, H. Marike; Vonk, Judith M.] Univ Groningen, Univ Med Ctr Groningen, Groningen Res Inst Asthma & COPD, Groningen, Netherlands	University of Groningen; University of Groningen; University of Groningen; University of Groningen; University of Groningen	Ierodiakonou, D (corresponding author), Beatrix Childrens Hosp, Dept Epidemiol, Groningen, Netherlands.	j.m.vonk@umcg.nl	Koppelman, Gerard/AAG-9187-2020; Vonk, Judith M/ABA-3009-2020; Vonk, Judith/K-8477-2019; Timens, Wim/K-5570-2013	Vonk, Judith M/0000-0001-7531-4547; Vonk, Judith/0000-0001-7531-4547; Timens, Wim/0000-0002-4146-6363; Koppelman, Gerard/0000-0001-8567-3252; Ierodiakonou, Despo/0000-0002-7862-2016				Bosse Y, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-66; Botelho FM, 2011, AM J RESP CELL MOL, V45, P753, DOI 10.1165/rcmb.2010-0404OC; Guo Zhi-hong, 2008, Zhonghua Jiehe He Huxi Zazhi, V31, P42; Huang TJ, 1999, IMMUNOLOGY, V96, P416; Jeffery PK, 2001, AM J RESP CRIT CARE, V164, pS28, DOI 10.1164/ajrccm.164.supplement_2.2106061; Salib RJ, 2009, CLIN EXP ALLERGY, V39, P1128, DOI 10.1111/j.1365-2222.2009.03239.x; ten Brinke A, 2008, CURR OPIN ALLERGY CL, V8, P63, DOI 10.1097/ACI.0b013e3282f3b5b5; Ueda T, 2008, J ALLERGY CLIN IMMUN, V121, P659, DOI 10.1016/j.jaci.2007.10.005; Wu L, 2004, THORAX, V59, P126, DOI 10.1136/thorax.2003.005769	9	20	25	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2013	131	2					582	585		10.1016/j.jaci.2012.08.013	http://dx.doi.org/10.1016/j.jaci.2012.08.013			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	086CT	23111237				2022-12-18	WOS:000314661500040
J	Zanotti, R; Simioni, L; Garcia-Montero, AC; Perbellini, O; Bonadonna, P; Caruso, B; Jara-Acevedo, M; Bonifacio, M; De Matteis, G				Zanotti, Roberta; Simioni, Livio; Garcia-Montero, Andres C.; Perbellini, Omar; Bonadonna, Patrizia; Caruso, Beatrice; Jara-Acevedo, Maria; Bonifacio, Massimiliano; De Matteis, Giovanna			Somatic D816V KIT mutation in a case of adult-onset familial mastocytosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							MAST-CELL DISORDERS; SYSTEMIC MASTOCYTOSIS		[Zanotti, Roberta; Perbellini, Omar; Bonifacio, Massimiliano] Azienda Osped Univ Integrata Verona, Dept Med, Sect Hematol, Verona, Italy; [Zanotti, Roberta; Bonadonna, Patrizia; Bonifacio, Massimiliano] Azienda Osped Univ Integrata Verona, Multidisciplinary Mastocytosis Outpatient Clin, Verona, Italy; [Simioni, Livio] ULSS 2 Feltre, Allergy Serv, Dept Med, Belluno, Italy; [Garcia-Montero, Andres C.; Jara-Acevedo, Maria] Univ Salamanca, CSIC, IBMCC, E-37008 Salamanca, Spain; [Garcia-Montero, Andres C.; Jara-Acevedo, Maria] Inst Biomed Res Salamanca IBSAL, Salamanca, Spain; [Bonadonna, Patrizia] Azienda Osped Univ Integrata Verona, Allergy Unit, Verona, Italy; [Caruso, Beatrice; De Matteis, Giovanna] Azienda Osped Univ Integrata Verona, Verona, Italy	University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; ULSS 1 Dolomiti; Ospedale di Feltre; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; University of Salamanca; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona	Zanotti, R (corresponding author), Azienda Osped Univ Integrata Verona, Dept Med, Sect Hematol, Verona, Italy.	roberta.zanotti@univr.it	Caruso, Beatrice/C-7528-2017; Garcia-Montero, Andres C/B-6558-2017; Bonifacio, Massimiliano/AAL-4520-2020; Montero, Andres/HGA-9093-2022	Caruso, Beatrice/0000-0003-2291-4025; Garcia-Montero, Andres C/0000-0003-4360-1386; Bonifacio, Massimiliano/0000-0003-0716-1686; Jara-Acevedo, Maria/0000-0001-7965-7512; PERBELLINI, Omar/0000-0002-8278-8916				Bodemer C, 2010, J INVEST DERMATOL, V130, P804, DOI 10.1038/jid.2009.281; Bonadonna P, 2009, J ALLERGY CLIN IMMUN, V123, P680, DOI 10.1016/j.jaci.2008.11.018; Broesby-Olsen S, 2012, J ALLERGY CLIN IMMUN, V130, P806, DOI 10.1016/j.jaci.2012.04.013; Daley T, 2001, BLOOD, V98, P880, DOI 10.1182/blood.V98.3.880; Garcia-Montero AC, 2006, BLOOD, V108, P2366, DOI 10.1182/blood-2006-04-015545; Horny HP, 2008, WHO CLASSIFICATION T, P54; Kristensen T, 2011, J MOL DIAGN, V13, P180, DOI 10.1016/j.jmoldx.2010.10.004; Lawley W, 2005, MUTAT RES-FUND MOL M, V572, P1, DOI 10.1016/j.mrfmmm.2004.08.015; Metcalfe DD, 2008, BLOOD, V112, P946, DOI 10.1182/blood-2007-11-078097; Nedoszytko B, 2009, ALLERGY, V64, P287, DOI 10.1111/j.1398-9995.2008.01827.x; Orfao A, 2007, BRIT J HAEMATOL, V138, P12, DOI 10.1111/j.1365-2141.2007.06619.x; Valent P, 2001, LEUKEMIA RES, V25, P603, DOI 10.1016/S0145-2126(01)00038-8	12	20	20	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2013	131	2					605	607		10.1016/j.jaci.2012.11.040	http://dx.doi.org/10.1016/j.jaci.2012.11.040			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	086CT	23374274	Green Submitted			2022-12-18	WOS:000314661500049
J	Bellinghausen, I; Reuter, S; Martin, H; Maxeiner, J; Luxemburger, U; Tureci, O; Grabbe, S; Taube, C; Saloga, J				Bellinghausen, Iris; Reuter, Sebastian; Martin, Helen; Maxeiner, Joachim; Luxemburger, Uli; Tuereci, Oezlem; Grabbe, Stephan; Taube, Christian; Saloga, Joachim			Enhanced production of CCL18 by tolerogenic dendritic cells is associated with inhibition of allergic airway reactivity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chemokines; dendritic cells; T(H)1/T(H)2 cells; allergy; regulation; humanized mice	REGULATORY T-CELLS; C-C CHEMOKINE; IMMUNE REGULATION; EXPRESSION; RESPONSES; HEALTHY; HYPERSENSITIVITY; CC-CHEMOKINE-1; INFLAMMATION; INVOLVEMENT	Background: IL-10-treated dendritic cells (DCs) have been shown to inhibit T-cell responses through induction of anergy and regulatory T cells in various model systems, including allergic inflammation, but the factors being involved in this inhibition are still unclear. Objective: This study set out to analyze such factors produced or induced by IL-10-treated DCs by using gene expression profiling and to explore their function. Methods: CD4(+) T cells from allergic donors were stimulated with autologous monocyte-derived allergen-pulsed mature DCs or IL-10-treated DCs. After 24 hours, the transcriptional profile was analyzed by using Affymetrix technology. Results were validated by using quantitative real-time PCR, protein expression, and functional in vitro and in vivo studies. Results: In CD4(+) T-cell/IL-10-treated DC cocultures the expression of several known genes, such as IL13, IL5 and OX40, was suppressed. Interestingly, there was only one factor that was strongly upregulated: the DC-derived chemokine CCL18. In vitro addition of CCL18 to cocultures of CD4(+) T cells and allergen-pulsed DCs resulted in a similar inhibition of T(H)2 cytokine production as induced by allergen-pulsed IL-10-treated DCs without exogenous CCL18, whereas T(H)1 cytokine production, IL-10 production, and proliferation were not affected. Furthermore, in a humanized mouse model of allergy using PBMC-engrafted NOD-scid-gamma c(-/-) mice, CCL18, but not another T(H)2-associated chemokine, CCL17, inhibited airway reactivity and lung inflammation. Chemotaxis assays revealed that CCL18 preferentially attracted regulatory T cells and, less efficiently, T(H)2 cells. Conclusion: These data demonstrate that CCL18 might represent a molecule of significant importance in immunoregulation and might be a therapeutic target in patients with allergic airway diseases. (J Allergy Clin Immunol 2012;130:1384-93.)	[Bellinghausen, Iris; Grabbe, Stephan; Saloga, Joachim] Johannes Gutenberg Univ Mainz, Dept Dermatol, Univ Med Ctr, D-55131 Mainz, Germany; [Reuter, Sebastian; Martin, Helen; Maxeiner, Joachim; Luxemburger, Uli; Tuereci, Oezlem; Taube, Christian] Johannes Gutenberg Univ Mainz, Med Clin 3, Univ Med Ctr, D-55131 Mainz, Germany; [Luxemburger, Uli; Tuereci, Oezlem] Johannes Gutenberg Univ Mainz, High Dens Microarray Core Facil, Univ Med Ctr, Immunol Res Ctr, D-55131 Mainz, Germany; [Taube, Christian] Leiden Univ, Med Ctr, Dept Pulmonol, Leiden, Netherlands	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Bellinghausen, I (corresponding author), Johannes Gutenberg Univ Mainz, Dept Dermatol, Univ Med Ctr, Langenbeckstr 1, D-55131 Mainz, Germany.	iris.bellinghausen@unimedizin-mainz.de	Reuter, Sebastian/L-1804-2013; Grabe, Stephan/AAJ-4578-2021	Grabe, Stephan/0000-0002-6863-8719; Reuter, Sebastian/0000-0002-1784-0124	Deutsche Forschungsgemeinschaft (DFG) [SFB 548 TP A4, BE 4504/2-1]; German Research Foundation	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); German Research Foundation(German Research Foundation (DFG))	Supported by Deutsche Forschungsgemeinschaft (DFG) SFB 548 TP A4 and BE 4504/2-1 grant.; I. Bellinghausen has received one or more grants from and has received support for travel from the DFG (grant BE 4504/2-1). J. Saloga has received one or more grants from the German Research Foundation, has received one or more grants from or has one or more grants pending with the pharmaceutical industry, and has received one or more payments for lecturing from or is on the speakers' bureau for the pharmaceutical industry. The rest of the authors declare that they have no relevant conflicts of interest.	Adema GJ, 1997, NATURE, V387, P713, DOI 10.1038/42716; Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Auer J, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2294; Azzaoui I, 2011, BLOOD, V118, P3549, DOI 10.1182/blood-2011-02-338780; Bellinghausen I, 2006, CLIN EXP ALLERGY, V36, P1546, DOI 10.1111/j.1365-2222.2006.02601.x; Bellinghausen I, 2001, J ALLERGY CLIN IMMUN, V108, P242, DOI 10.1067/mai.2001.117177; Bruna-Romero O, 2003, J IMMUNOL, V170, P3195, DOI 10.4049/jimmunol.170.6.3195; Chang Y, 2010, FASEB J, V24, P5063, DOI 10.1096/fj.10-162560; De Nadai P, 2006, J IMMUNOL, V176, P6286, DOI 10.4049/jimmunol.176.10.6286; Goebeler M, 2001, AM J PATHOL, V158, P431, DOI 10.1016/S0002-9440(10)63986-7; Gunther C, 2005, J IMMUNOL, V174, P1723, DOI 10.4049/jimmunol.174.3.1723; Kodelja V, 1998, J IMMUNOL, V160, P1411; Levings MK, 2005, BLOOD, V105, P1162, DOI 10.1182/blood-2004-03-1211; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Martin H, 2012, J ALLERGY CLIN IMMUN, V129, P521, DOI 10.1016/j.jaci.2011.09.038; Nibbs RJB, 2000, J IMMUNOL, V164, P1488, DOI 10.4049/jimmunol.164.3.1488; Ozdemir C, 2009, CLIN EXP ALLERGY, V39, P626, DOI 10.1111/j.1365-2222.2009.03242.x; Palomares O, 2010, EUR J IMMUNOL, V40, P1232, DOI 10.1002/eji.200940045; Pardo A, 2001, J LEUKOCYTE BIOL, V70, P610; Peterson S, 2012, J ALLERGY CLIN IMMUN, V129, P119, DOI 10.1016/j.jaci.2011.08.021; Pochetuhen K, 2007, AM J PATHOL, V171, P428, DOI 10.2353/ajpath.2007.061167; Rudensky AY, 2011, IMMUNOL REV, V241, P260, DOI 10.1111/j.1600-065X.2011.01018.x; Schutyser E, 2005, J LEUKOCYTE BIOL, V78, P14, DOI 10.1189/jlb.1204712; Tasaki Y, 1999, GENOMICS, V55, P353, DOI 10.1006/geno.1998.5670; Terashima A, 2008, J EXP MED, V205, P2727, DOI 10.1084/jem.20080698; Vulcano M, 2003, J IMMUNOL, V170, P3843, DOI 10.4049/jimmunol.170.7.3843; Wang R, 2009, P NATL ACAD SCI USA, V106, P13439, DOI 10.1073/pnas.0901965106; Weigmann B, 2012, J ALLERGY CLIN IMMUN, V129, P1126, DOI 10.1016/j.jaci.2011.11.036; Wu K, 2007, CELL MOL IMMUNOL, V4, P269; Ziegler SF, 2006, ANNU REV IMMUNOL, V24, P209, DOI 10.1146/annurev.immunol.24.021605.090547	30	20	22	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2012	130	6					1384	1393		10.1016/j.jaci.2012.08.039	http://dx.doi.org/10.1016/j.jaci.2012.08.039			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	044RP	23102918	Bronze			2022-12-18	WOS:000311641100020
J	Liu, WL; Xia, WT; Fan, YP; Wang, HT; Zuo, KJ; Lai, YY; Li, HB; Liu, Z; Shi, JB; Xu, G				Liu, Wenlong; Xia, Wentong; Fan, Yunping; Wang, Hongtian; Zuo, Kejun; Lai, Yinyan; Li, Huabin; Liu, Zheng; Shi, Jianbo; Xu, Geng			Elevated serum osteopontin level is associated with blood eosinophilia and asthma comorbidity in patients with allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							DISEASE		[Liu, Wenlong; Zuo, Kejun; Lai, Yinyan; Li, Huabin; Shi, Jianbo; Xu, Geng] Sun Yat Sen Univ, Allergy & Canc Ctr, Otorhinolaryngol Hosp, Affiliated Hosp 1, Guangzhou 510275, Guangdong, Peoples R China; [Liu, Wenlong; Zuo, Kejun; Lai, Yinyan; Li, Huabin; Shi, Jianbo; Xu, Geng] Sun Yat Sen Univ, Otorhinolaryngol Inst, Guangzhou 510275, Guangdong, Peoples R China; [Xia, Wentong; Fan, Yunping] Sun Yat Sen Univ, Affiliated Hosp 5, Dept Otolaryngol, Zhuhai, Peoples R China; [Wang, Hongtian] Peoples Liberat Army Gen Hosp, Dept Otolaryngol, Beijing, Peoples R China; [Liu, Zheng] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Otolaryngol, Wuhan 430074, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Chinese People's Liberation Army General Hospital; Huazhong University of Science & Technology	Liu, WL (corresponding author), Sun Yat Sen Univ, Allergy & Canc Ctr, Otorhinolaryngol Hosp, Affiliated Hosp 1, Guangzhou 510275, Guangdong, Peoples R China.	allergyli@163.com						Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Fan YP, 2011, J ALLERGY CLIN IMMUN, V127, P1312, DOI 10.1016/j.jaci.2011.01.059; Klein Jan A, 2010, CLIN EXP ALLERGY, V40, P494; Konno S, 2011, CLIN EXP ALLERGY, V41, P1360, DOI 10.1111/j.1365-2222.2011.03775.x; Puxeddu I, 2010, ALLERGY, V65, P168, DOI 10.1111/j.1398-9995.2009.02148.x; Samitas K, 2011, EUR RESPIR J, V37, P331, DOI 10.1183/09031936.00017810; Simoes DCM, 2009, AM J RESP CRIT CARE, V179, P894, DOI 10.1164/rccm.200807-1081OC; Xanthou G, 2007, NAT MED, V13, P570, DOI 10.1038/nm1580; Xu G, 2010, ALLERGY, V65, P8	9	20	22	0	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2012	130	6					1416	1418		10.1016/j.jaci.2012.06.010	http://dx.doi.org/10.1016/j.jaci.2012.06.010			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	044RP	22846382				2022-12-18	WOS:000311641100025
J	Steinhoff, M; Cevikbas, F; Yeh, I; Chong, K; Buddenkotte, J; Ikoma, A				Steinhoff, Martin; Cevikbas, Ferda; Yeh, Iwei; Chong, Kim; Buddenkotte, Joerg; Ikoma, Akihiko			Evaluation and management of a patient with chronic pruritus	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							ATOPIC-DERMATITIS; ITCH; THERAPIES		[Steinhoff, Martin; Cevikbas, Ferda; Yeh, Iwei; Chong, Kim; Ikoma, Akihiko] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Buddenkotte, Joerg] Univ Hosp Munster, Dept Dermatol, Munster, Germany	University of California System; University of California San Francisco; University of Munster	Steinhoff, M (corresponding author), Univ Calif San Francisco, Med Sci Bldg,Rm S-1268,513 Parnassus Ave, San Francisco, CA 94143 USA.	steinhoffm@derm.ucsf.edu; ikomaa@derm.ucsf.edu	Steinhoff, Martin/F-6312-2013	Steinhoff, Martin/0000-0002-7090-2187; Yeh, Iwei/0000-0002-3941-3561	National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases [AR059402]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR059402] Funding Source: NIH RePORTER	National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Supported by a grant from the National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases (AR059402; to M.S.).	Buddenkotte J, 2010, ADV EXP MED BIOL, V709, P73; Cevikbas F, 2011, CNS NEUROSCI THER, V17, P742, DOI 10.1111/j.1755-5949.2010.00201.x; Elmariah SB, 2011, SEMIN CUTAN MED SURG, V30, P118, DOI 10.1016/j.sder.2011.04.008; Hong J, 2011, SEMIN CUTAN MED SURG, V30, P71, DOI 10.1016/j.sder.2011.05.002; Ikoma A, 2006, NAT REV NEUROSCI, V7, P535, DOI 10.1038/nrn1950; Oaklander AL, 2011, SEMIN CUTAN MED SURG, V30, P87, DOI 10.1016/j.sder.2011.04.006; Pfab F, 2012, CHEM IMMUNOL ALLERGY, V98, P253, DOI 10.1159/000336529; Steinhoff M, 2011, SEMIN CUTAN MED SURG, V30, P127, DOI 10.1016/j.sder.2011.05.001; Tey HL, 2011, BRIT J DERMATOL, V165, P5, DOI 10.1111/j.1365-2133.2011.10217.x; Weisshaar E, 2012, ACTA DERM VENEREOL	10	20	22	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2012	130	4					1015	+		10.1016/j.jaci.2012.08.006	http://dx.doi.org/10.1016/j.jaci.2012.08.006			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017MT	23021147				2022-12-18	WOS:000309594800038
J	Broesby-Olsen, S; Kristensen, TK; Moller, MB; Bindslev-Jensen, C; Vestergaard, H				Broesby-Olsen, Sigurd; Kristensen, Thomas Kielsgaard; Moller, Michael Boe; Bindslev-Jensen, Carsten; Vestergaard, Hanne		Mastocytosis Ctr; Odense Univ Hosp MastOUH	Adult-onset systemic mastocytosis in monozygotic twins with KIT D816V and JAK2 V617F mutations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CUTANEOUS MASTOCYTOSIS		[Broesby-Olsen, Sigurd; Bindslev-Jensen, Carsten] Odense Univ Hosp, Dept Dermatol, DK-5000 Odense, Denmark; [Broesby-Olsen, Sigurd; Bindslev-Jensen, Carsten] Odense Univ Hosp, Allergy Ctr, DK-5000 Odense, Denmark; [Kristensen, Thomas Kielsgaard; Moller, Michael Boe] Odense Univ Hosp, Dept Pathol, DK-5000 Odense, Denmark; [Vestergaard, Hanne] Odense Univ Hosp, Dept Hematol, DK-5000 Odense, Denmark	University of Southern Denmark; Odense University Hospital; University of Southern Denmark; Odense University Hospital; University of Southern Denmark; Odense University Hospital; University of Southern Denmark; Odense University Hospital	Broesby-Olsen, S (corresponding author), Odense Univ Hosp, Dept Dermatol, DK-5000 Odense, Denmark.	sigurd.broesby-olsen@ouh.regionsyddanmark.dk	Møller, Michael B/G-8340-2016; Bindslev-Jensen, Carsten/H-1877-2011; Møller, Michael Boe/AAD-2113-2019	Møller, Michael B/0000-0003-2041-3630; Bindslev-Jensen, Carsten/0000-0002-8940-038X; Møller, Michael Boe/0000-0003-2041-3630				Bodemer C, 2010, J INVEST DERMATOL, V130, P804, DOI 10.1038/jid.2009.281; de la Sotta P, 2011, PEDIATR DERMATOL, V28, P585, DOI 10.1111/j.1525-1470.2011.01351.x; Kristensen T, 2011, J MOL DIAGN, V13, P180, DOI 10.1016/j.jmoldx.2010.10.004; Metcalfe DD, 2008, BLOOD, V112, P946, DOI 10.1182/blood-2007-11-078097; Quaglino P, 2011, J AM ACAD DERMATOL, V65, P680, DOI 10.1016/j.jaad.2010.07.018; Skoda RC, 2010, HAEMATOL-HEMATOL J, V95, P6, DOI 10.3324/haematol.2009.015941; Sotlar K, 2008, J MOL DIAGN, V10, P58, DOI 10.2353/jmoldx.2008.070061; Thachil Jecko, 2011, Br J Haematol, V152, P675, DOI 10.1111/j.1365-2141.2010.08536.x; Wasag B, 2011, EXP HEMATOL, V39, P859, DOI 10.1016/j.exphem.2011.05.009	9	20	20	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2012	130	3					806	808		10.1016/j.jaci.2012.04.013	http://dx.doi.org/10.1016/j.jaci.2012.04.013			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	001LZ	22608575	Bronze			2022-12-18	WOS:000308463500033
J	Marques, OC; Arslanian, C; Ramos, RN; Morato, M; Schimke, L; Soeiro, PV; Jancar, S; Ferreira, JF; Weber, CW; Kuntze, G; Rosario, NA; Carvalho, BTC; Bergami-Santos, PC; Hackett, MJ; Ochs, HD; Torgerson, TR; Barbuto, JAM; Condino-Neto, A				Marques, Otavio Cabral; Arslanian, Christina; Ramos, Rodrigo Nalio; Morato, Mariana; Schimke, LenaFriederike; Soeiro, Paulo Vitor; Jancar, Sonia; Ferreira, Janira Fernandes; Weber, Cristina Worm; Kuntze, Gisele; Rosario-Filho, Nelson Augusto; Costa Carvalho, Beatriz Tavares; Bergami-Santos, Patricia Cruz; Hackett, Mary J.; Ochs, Hans D.; Torgerson, Troy R.; Marzagao Barbuto, Jose Alexandre; Condino-Neto, Antonio			Dendritic cells from X-linked hyper-IgM patients present impaired responses to Candida albicans and Paracoccidioides brasiliensis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CD40 ligand deficiency; fungal infections; dendritic cells; X-linked hyper-IgM syndrome; primary immunodeficiency	TOLL-LIKE RECEPTORS; CD40 LIGAND; DEFECTIVE EXPRESSION; HUMAN MONOCYTES; T-CELLS; IMMUNODEFICIENCY; STIMULATION; ACTIVATION; MUTATIONS; IMMUNITY	Background: Patients with X-linked hyper-IgM syndrome (X-HIGM) due to CD40 ligand (CD40L) mutations are susceptible to fungal pathogens; however, the underlying susceptibility mechanisms remain poorly understood. Objective: To determine whether monocyte-derived dendritic cells (DCs) from patients with X-HIGM exhibit normal responses to fungal pathogens. Methods: DCs from patients and controls were evaluated for the expression of costimulatory (CD80 and CD86) and MHC class II molecules and for their ability to produce IL-12 and IL-10 in response to Candida albicans and Paracoccidioides brasiliensis. We also evaluated the ability of C albicans- and P brasiliensis-pulsed mature DCs to induce autologous T-cell proliferation, generation of T helper (T-H) 17 cells, and production of IFN-gamma, TGF-beta, IL-4, IL-5, and IL-17. Results: Immature DCs from patients with X-HIGM showed reduced expression of CD80, CD86, and HLA-DR, which could be reversed by exogenous trimeric soluble CD40L. Most important, mature DCs from patients with X-HIGM differentiated by coculturing DCs with fungi secreted minimal amounts of IL-12 but substantial amounts of IL-10 compared with mature DCs from normal individuals. Coculture of mature DCs from X-HIGM patients with autologous T cells led to low IFN-g production, whereas IL-4 and IL-5 production was increased. T-cell proliferation and IL-17 secretion were normal. Finally, in vitro incubation with soluble CD40L reversed the decreased IL-12 production and the skewed T-H(2) pattern response. Conclusion: Absence of CD40L during monocyte/DC differentiation leads to functional DC abnormalities, which may contribute to the susceptibility to fungal infections in patients with X-HIGM. (J Allergy Clin Immunol 2012; 129: 778-86.)	[Marques, Otavio Cabral; Arslanian, Christina; Ramos, Rodrigo Nalio; Morato, Mariana; Schimke, LenaFriederike; Soeiro, Paulo Vitor; Jancar, Sonia; Bergami-Santos, Patricia Cruz; Marzagao Barbuto, Jose Alexandre; Condino-Neto, Antonio] Univ Sao Paulo, Dept Immunol, Inst Biomed Sci, BR-05508000 Sao Paulo, Brazil; [Weber, Cristina Worm] Pediat Allergy & Immunol Clin, Caxias Do Sul, Brazil; [Ferreira, Janira Fernandes] Albert Sabin Hosp, Fortaleza, Ceara, Brazil; [Kuntze, Gisele] Pequeno Principe Hosp, Curitiba, Parana, Brazil; [Rosario-Filho, Nelson Augusto] Univ Fed Parana, Dept Pediat, Sch Med, BR-80060000 Curitiba, Parana, Brazil; [Costa Carvalho, Beatriz Tavares] Univ Fed Sao Paulo, Dept Pediat, Div Allergy Immunol & Rheumatol, Sao Paulo, Brazil; [Marques, Otavio Cabral; Schimke, LenaFriederike; Hackett, Mary J.; Ochs, Hans D.; Torgerson, Troy R.] Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA; [Marques, Otavio Cabral; Schimke, LenaFriederike; Hackett, Mary J.; Ochs, Hans D.; Torgerson, Troy R.] Seattle Childrens Hosp, Seattle, WA USA	Universidade de Sao Paulo; Hospital Pequeno Principe; Universidade Federal do Parana; Universidade Federal de Sao Paulo (UNIFESP); University of Washington; University of Washington Seattle; Seattle Children's Hospital	Condino-Neto, A (corresponding author), Univ Sao Paulo, Dept Immunol, Inst Biomed Sci, 1730 Lineu Prestes Ave, BR-05508000 Sao Paulo, Brazil.	condino@icb.usp.br	Barbuto, Jose A. M./H-5299-2011; Bergami-Santos, Patrícia C/E-3802-2012; Condino-Neto, Antonio/D-4762-2012; Carvalho, Beatriz/GXA-0720-2022; Jancar, Sonia/C-5153-2012; Marques, Otavio Cabral/C-8090-2012; Ramos, Rodrigo N/K-3553-2012; SOEIRO PEREIRA, PAULO VITOR/C-8393-2012	Barbuto, Jose A. M./0000-0001-9526-6781; Bergami-Santos, Patrícia C/0000-0002-9316-0729; Condino-Neto, Antonio/0000-0002-1069-3117; Jancar, Sonia/0000-0001-7983-3459; Ramos, Rodrigo N/0000-0003-1249-4733; SOEIRO PEREIRA, PAULO VITOR/0000-0002-7021-3138; Cabral Marques, Otavio/0000-0002-3183-6236	FAPESP [2008/06635-0, 2008/55700-9, 2009/54599-5]; CNPq; Jeffrey Modell Foundation	FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Jeffrey Modell Foundation	We thank FAPESP, CNPq, and the Jeffrey Modell Foundation for financial support and the patients and their families for their participation in this study. We are also grateful to Prof Vera L. G. Calich, PhD, and Claudia Feriotti, MSc, for the donation of P brasiliensis.; This work was supported by Fundacao de Amparo a Pesquisa do Estado de Sao Paulo grant 2008/06635-0 to O. C. M., grant 2008/55700-9 to A. C. N., and grant 2009/54599-5 to J. A. M. B.-and by the Jeffrey Modell Foundation.	ALLEN RC, 1993, SCIENCE, V259, P990, DOI 10.1126/science.7679801; Antachopoulos C, 2007, EUR J PEDIATR, V166, P1099, DOI 10.1007/s00431-007-0527-7; ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Barbuto JAM, 2004, CANCER IMMUNOL IMMUN, V53, P1111, DOI 10.1007/s00262-004-0551-7; Dieu MC, 1998, J EXP MED, V188, P373, DOI 10.1084/jem.188.2.373; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; Doni A, 2006, J LEUKOCYTE BIOL, V79, P797, DOI 10.1189/jlb.0905493; Fontana S, 2003, BLOOD, V102, P4099, DOI 10.1182/blood-2003-04-1244; FULEIHAN R, 1993, P NATL ACAD SCI USA, V90, P2170, DOI 10.1073/pnas.90.6.2170; Garlanda C, 2002, NATURE, V420, P182, DOI 10.1038/nature01195; HOLLENBAUGH D, 1992, EMBO J, V11, P4313, DOI 10.1002/j.1460-2075.1992.tb05530.x; Iezzi G, 2009, P NATL ACAD SCI USA, V106, P876, DOI 10.1073/pnas.0810769106; Jain A, 1999, J CLIN INVEST, V103, P1151, DOI 10.1172/JCI5891; Katzman SD, 2011, J IMMUNOL, V186, P4668, DOI 10.4049/jimmunol.1003786; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; Loures FV, 2009, J IMMUNOL, V183, P1279, DOI 10.4049/jimmunol.0801599; Mamoni RL, 2006, CYTOKINE, V35, P207, DOI 10.1016/j.cyto.2006.08.005; Netea MG, 2002, J INFECT DIS, V185, P1483, DOI 10.1086/340511; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P6550, DOI 10.1073/pnas.89.14.6550; Notarangelo LD, 2009, J ALLERGY CLIN IMMUN, V124, P1161, DOI 10.1016/j.jaci.2009.10.013; Puel A, 2011, SCIENCE, V332, P65, DOI 10.1126/science.1200439; Renner ED, 2008, J ALLERGY CLIN IMMUN, V122, P181, DOI 10.1016/j.jaci.2008.04.037; Romani L, 1997, CURR OPIN IMMUNOL, V9, P484, DOI 10.1016/S0952-7915(97)80099-4; Romani L, 2004, NAT REV IMMUNOL, V4, P11, DOI 10.1038/nri1255; Romani L, 1997, CLIN MICROBIOL REV, V10, P611, DOI 10.1128/CMR.10.4.611; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Sperling AI, 1996, IMMUNOL REV, V153, P155, DOI 10.1111/j.1600-065X.1996.tb00924.x; Subauste CS, 1999, J IMMUNOL, V162, P6690; Takenaka H, 1997, J LEUKOCYTE BIOL, V61, P80, DOI 10.1002/jlb.61.1.80; Upham JW, 2002, INFECT IMMUN, V70, P6583, DOI 10.1128/IAI.70.12.6583-6588.2002; Vautier S, CYTOKINE GROWTH FACT, V21, P405; Villamon E, 2004, MICROBES INFECT, V6, P542, DOI 10.1016/j.micinf.2004.02.015; Visintin A, 2001, J IMMUNOL, V166, P249, DOI 10.4049/jimmunol.166.1.249; Wang JE, 2001, INFECT IMMUN, V69, P2402, DOI 10.1128/IAI.69.4.2402-2406.2001	35	20	20	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2012	129	3					778	786		10.1016/j.jaci.2011.10.026	http://dx.doi.org/10.1016/j.jaci.2011.10.026			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	904IW	22154528				2022-12-18	WOS:000301189300025
J	Pedroza, LA; Kumar, V; Sanborn, KB; Mace, EM; Niinikoski, H; Nadeau, K; Vasconcelos, DD; Perez, E; Jyonouchi, S; Jyonouchi, H; Banerjee, PP; Ruuskanen, O; Condino-Neto, A; Orange, JS				Pedroza, Luis A.; Kumar, Vipul; Sanborn, Keri B.; Mace, Emily M.; Niinikoski, Harri; Nadeau, Kari; Vasconcelos, Dewton de Moraes; Perez, Elena; Jyonouchi, Soma; Jyonouchi, Harumi; Banerjee, Pinaki P.; Ruuskanen, Olli; Condino-Neto, Antonio; Orange, Jordan S.			Autoimmune regulator (AIRE) contributes to Dectin-1-induced TNF-alpha production and complexes with caspase recruitment domain-containing protein 9 (CARD9), spleen tyrosine kinase (Syk), and Dectin-1	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Primary immunodeficiency; innate immunity; chronic mucocutaneous candidiasis; monocytes	CHRONIC MUCOCUTANEOUS CANDIDIASIS; IMMUNOLOGICAL SYNAPSE; ECTODERMAL DYSTROPHY; CYTOKINE PRODUCTION; FUNGAL-INFECTIONS; ACTIVATION; GENE; RECOGNITION; INDUCTION; IMMUNITY	Background: Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) syndrome is a complex immunologic disease caused by mutation of the autoimmune regulator (AIRE) gene. Autoimmunity in patients with APECED syndrome has been shown to result from deficiency of AIRE function in transcriptional regulation of thymic peripheral tissue antigens, which leads to defective T-cell negative selection. Candidal susceptibility in patients with APECED syndrome is thought to result from aberrant adaptive immunity. Objective: To determine whether AIRE could function in anticandidal innate immune signaling, we investigated an extrathymic role for AIRE in the immune recognition of beta-glucan through the Dectin-1 pathway, which is required for defense against Candida species. Methods: Innate immune signaling through the Dectin-1 pathway was assessed in both PBMCs from patients with APECED syndrome and a monocytic cell line. Subcellular localization of AIRE was assessed by using confocal microscopy. Results: PBMCs from patients with APECED syndrome had reduced TNF-alpha responses after Dectin-1 ligation but in part used a Raf-1-mediated pathway to preserve function. In the THP-1 human monocytic cell line, reducing AIRE expression resulted in significantly decreased TNF-a release after Dectin-1 ligation. AIRE formed a transient complex with the known Dectin-1 pathway components phosphorylated spleen tyrosine kinase and caspase recruitment domain-containing protein 9 after receptor ligation and localized with Dectin-1 at the cell membrane. Conclusion: AIRE can participate in the Dectin-1 signaling pathway, indicating a novel extrathymic role for AIRE and a defect that likely contributes to fungal susceptibility in patients with APECED syndrome. (J Allergy Clin Immunol 2012;129:464-72.)	[Pedroza, Luis A.; Kumar, Vipul; Sanborn, Keri B.; Mace, Emily M.; Jyonouchi, Soma; Banerjee, Pinaki P.; Orange, Jordan S.] Childrens Hosp Philadelphia, Dept Pediat, Div Immunol, Philadelphia, PA 19104 USA; [Pedroza, Luis A.] Univ Estadual Campinas, Sch Med, Ctr Investigat Pediat, Sao Paulo, Brazil; [Pedroza, Luis A.; Condino-Neto, Antonio] Univ Sao Paulo, Inst Biomed Sci, Dept Immunol, BR-05508 Sao Paulo, Brazil; [Sanborn, Keri B.; Orange, Jordan S.] Univ Penn, Immunol Grad Grp, Sch Med, Philadelphia, PA 19104 USA; [Niinikoski, Harri; Ruuskanen, Olli] Turku Univ Hosp, Div Immunol & Allergy, FIN-20520 Turku, Finland; [Nadeau, Kari] Stanford Univ, Sch Med, Div Immunol & Allergy, Stanford, CA 94305 USA; [Vasconcelos, Dewton de Moraes] Univ Sao Paulo, Sch Med, Lab Dermatol & Immunodeficiency LIM56, BR-05508 Sao Paulo, Brazil; [Perez, Elena] Univ S Florida, Sch Med, Dept Pediat, Div Allergy & Immunol, Tampa, FL 33620 USA; [Jyonouchi, Harumi] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Pediat, Div Allergy Immunol & Infect Dis, Newark, NJ 07103 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Universidade Estadual de Campinas; Universidade de Sao Paulo; University of Pennsylvania; University of Turku; Stanford University; Universidade de Sao Paulo; State University System of Florida; University of South Florida; Rutgers State University New Brunswick; Rutgers State University Medical Center	Orange, JS (corresponding author), Childrens Hosp Philadelphia, Dept Pediat, Div Immunol, 3615 Civ Ctr Blvd,ARC 907A, Philadelphia, PA 19104 USA.	orange@mail.med.upenn.edu	Condino-Neto, Antonio/D-4762-2012; Vasconcelos, Dewton/AAB-6483-2022; Moraes-Vasconcelos, Dewton/G-2209-2012	Condino-Neto, Antonio/0000-0002-1069-3117; Moraes-Vasconcelos, Dewton/0000-0002-3930-3354; orange, jordan/0000-0001-7117-7725; Mace, Emily/0000-0003-0226-7393; Niinikoski, Harri/0000-0002-7071-918X; Sheehan, Keri/0000-0002-5071-4349	Children's Hospital of Philadelphia; Jeffrey Modell Diagnostic Center; University of Pennsylvania; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (Brazil); Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [09/51747-3, 99/07399-7]; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico [501332/2010-3]	Children's Hospital of Philadelphia; Jeffrey Modell Diagnostic Center; University of Pennsylvania; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (Brazil)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	Supported by Children's Hospital of Philadelphia and the Jeffrey Modell Diagnostic Center (J.S.O.), the Vagelos Scholars program in the Molecular Life Sciences of the University of Pennsylvania (V.K.), Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (Brazil; L.A.P.), Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) grant 09/51747-3 for (L.A.P. and A.C.-N.), FAPESP grant 99/07399-7 (D.d.M.V.), and Conselho Nacional de Desenvolvimento Cientifico e Tecnologico grant 501332/2010-3 (A.C.-N.).	Aaltonen J, 1997, NAT GENET, V17, P399, DOI 10.1038/ng1297-399; Abramson J, 2010, CELL, V140, P123, DOI 10.1016/j.cell.2009.12.030; Agrawal S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013418; Banerjee PP, 2007, J EXP MED, V204, P2305, DOI 10.1084/jem.20061893; Bhui RD, 2008, ANN ALLERG ASTHMA IM, V100, P169, DOI 10.1016/S1081-1206(10)60427-9; Brannstrom J, 2006, CLIN IMMUNOL, V121, P265, DOI 10.1016/j.clim.2006.08.005; Carsetti L, 2009, CELL SIGNAL, V21, P1187, DOI 10.1016/j.cellsig.2009.03.007; Condino-Neto A, 2000, BLOOD, V95, P3548, DOI 10.1182/blood.V95.11.3548.011k36_3548_3554; Deering RP, 2006, CLIN VACCINE IMMUNOL, V13, P68, DOI 10.1128/CVI.13.1.68-76.2006; den Dunnen J, 2009, CANCER IMMUNOL IMMUN, V58, P1149, DOI 10.1007/s00262-008-0615-1; Dennehy KM, 2008, EUR J IMMUNOL, V38, P500, DOI 10.1002/eji.200737741; Ferguson BJ, 2008, J BIOL CHEM, V283, P1723, DOI 10.1074/jbc.M707211200; Ferwerda B, 2009, NEW ENGL J MED, V361, P1760, DOI 10.1056/NEJMoa0901053; Ferwerda G, 2008, CELL MICROBIOL, V10, P2058, DOI 10.1111/j.1462-5822.2008.01188.x; Glocker EO, 2009, NEW ENGL J MED, V361, P1727, DOI 10.1056/NEJMoa0810719; Goodridge HS, 2011, NATURE, V472, P471, DOI 10.1038/nature10071; Gringhuis SI, 2009, NAT IMMUNOL, V10, P203, DOI 10.1038/ni.1692; Gross O, 2006, NATURE, V442, P651, DOI 10.1038/nature04926; Hovius JWR, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.0040031; Kisand K, 2010, J EXP MED, V207, P299, DOI 10.1084/jem.20091669; Kogawa K, 2002, CLIN IMMUNOL, V103, P277, DOI 10.1006/clim.2002.5208; Kogawa K, 2002, IMMUNOL LETT, V80, P195, DOI 10.1016/S0165-2478(01)00314-5; Kumar V, 2011, AM J PATHOL, V178, P983, DOI 10.1016/j.ajpath.2010.12.007; LeibundGut-Landmann S, 2007, NAT IMMUNOL, V8, P630, DOI 10.1038/ni1460; Mathis D, 2009, ANNU REV IMMUNOL, V27, P287, DOI 10.1146/annurev.immunol.25.022106.141532; Netea MG, 2008, NAT REV MICROBIOL, V6, P67, DOI 10.1038/nrmicro1815; Ni L, 2010, J IMMUNOL, V185, P3504, DOI 10.4049/jimmunol.1000999; Pitkanen J, 2001, J BIOL CHEM, V276, P19597, DOI 10.1074/jbc.M008322200; Pitkanen J, 2000, J BIOL CHEM, V275, P16802, DOI 10.1074/jbc.M908944199; Pontynen N, 2008, J MOL MED, V86, P1139, DOI 10.1007/s00109-008-0374-7; Porter KA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011304; Puel A, 2010, J EXP MED, V207, P291, DOI 10.1084/jem.20091983; REIMANN T, 1994, J IMMUNOL, V153, P5740; Robinson MJ, 2009, J EXP MED, V206, P2037, DOI 10.1084/jem.20082818; Saijo S, 2010, IMMUNITY, V32, P681, DOI 10.1016/j.immuni.2010.05.001; Sanborn KB, 2009, J IMMUNOL, V182, P6969, DOI 10.4049/jimmunol.0804337; Ting JPY, 2005, ANNU REV IMMUNOL, V23, P387, DOI 10.1146/annurev.immunol.23.021704.115616	37	20	21	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2012	129	2					464	U287		10.1016/j.jaci.2011.08.027	http://dx.doi.org/10.1016/j.jaci.2011.08.027			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	887TC	21962774	Bronze			2022-12-18	WOS:000299951700026
J	Stenius, F; Borres, M; Bottai, M; Lilja, G; Lindblad, F; Pershagen, G; Scheynius, A; Swartz, J; Theorell, T; Alm, J				Stenius, Fredrik; Borres, Magnus; Bottai, Matteo; Lilja, Gunnar; Lindblad, Frank; Pershagen, Goran; Scheynius, Annika; Swartz, Jackie; Theorell, Tores; Alm, Johan			Salivary cortisol levels and allergy in children: The ALADDIN birth cohort	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; sensitization; salivary cortisol; children; stress	PRENATAL MATERNAL STRESS; RESPONSES; ASTHMA; SENSITIZATION; MOTHERS	Background: Pre- and postnatal stress have been related to allergy in children, but evidence from prospective studies is limited. Several environmental factors can influence the salivary cortisol level, which is used as a measure of activity of the hypothalamic-pituitary-adrenal axis. Objective: The aim of this study was to assess the association between salivary cortisol levels at 6 months of age and allergic manifestations during the first 2 years of life. Methods: Salivary samples for the analysis of cortisol level were collected at 6 months of age on 3 occasions during 1 day from 203 children. Blood samples were collected at 6, 12, and 24 months of age for analyses of specific IgE. Information on allergy-related symptoms was obtained by repeated examinations of the children. Generalized estimating equation statistics were used to calculate the overall risk for outcome measures. Results: The adjusted odds ratio for the relationship between morning cortisol level and IgE sensitization was 1.60 (95% CI, 1.22-2.10, P = .001) and for eczema it was 1.28 (95% CI, 1.03-1.59, P = .026). The odds ratio for afternoon cortisol level in relation to sensitization and eczema was 1.56 (95% CI, 1.26-1.94, P < .001) and 1.33 (95% CI, 1.12-1.58, P = .001), respectively, and for evening cortisol level it was 1.49 (95% CI, 1.22-1.83, P < .001) and 1.37 (95% CI, 1.18-1.59, P < .001). Salivary cortisol level in the evening was associated with food allergy. Conclusion: The association between salivary cortisol levels in infancy and allergic sensitization and allergic symptoms suggests a role of an altered hypothalamic-pituitary-adrenal axis in the etiological process of allergies. (J Allergy Clin Immunol 2011;128:1335-9.)	[Stenius, Fredrik] Sodersjukhuset AB, Sachsska Barnsjukhuset, Sodersjukhuset, Dept Clin Sci & Educ,Karolinska Inst, S-11883 Stockholm, Sweden; [Borres, Magnus] Gothenburg Univ, Sahlgrenska Acad, Dept Pediat, Gothenburg, Sweden; [Borres, Magnus] Phadia AB, Uppsala, Sweden; [Bottai, Matteo; Pershagen, Goran] Karolinska Inst, Inst Environm Med, Solna, Sweden; [Bottai, Matteo] Univ S Carolina, Arnold Sch Publ Hlth, Columbia, SC 29208 USA; [Lindblad, Frank] Uppsala Univ, Dept Neurosci, Uppsala, Sweden; [Lindblad, Frank; Theorell, Tores] Stockholm Univ, Stress Res Inst, S-10691 Stockholm, Sweden; [Scheynius, Annika] Karolinska Inst, Dept Med, Clin Allergy Res Unit, Solna, Sweden; [Swartz, Jackie] Vidar Clin, Jarna, Sweden	Karolinska Institutet; Sodersjukhuset Hospital; University of Gothenburg; Thermo Fisher Scientific; Phadia; Karolinska Institutet; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; Uppsala University; Stockholm University; Karolinska Institutet	Stenius, F (corresponding author), Sodersjukhuset AB, Sachsska Barnsjukhuset, Sodersjukhuset, Dept Clin Sci & Educ,Karolinska Inst, S-11883 Stockholm, Sweden.	fredrik.stenius@sodersjukhuset.se		Pershagen, Goran/0000-0002-9701-1130; Alm, Johan/0000-0002-9062-4479	Swedish Research Council; Swedish Research Council for Working Life and Social Research; Centre for Allergy Research; "Mjolkdroppen'' Society; Karolinska Institutet; Phadia AB; Stockholm County Council; Swedish Asthma and Allergy Research Association; Swedish Pediatric Allergy Society; Swedish Society of Medicine; Cancer and Allergy Fund; Consul ThC Bergh, Ekhaga , "Frimurare Barnhuset'' in Stockholm; Gyllen berg foundation; Hesselman foundation; Samariten foundation; Vardal foundation	Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Research Council for Working Life and Social Research(Swedish Research CouncilSwedish Research Council for Health Working Life & Welfare (Forte)); Centre for Allergy Research; "Mjolkdroppen'' Society; Karolinska Institutet(Karolinska Institutet); Phadia AB(Phadia); Stockholm County Council(Stockholm County Council); Swedish Asthma and Allergy Research Association; Swedish Pediatric Allergy Society; Swedish Society of Medicine; Cancer and Allergy Fund; Consul ThC Bergh, Ekhaga , "Frimurare Barnhuset'' in Stockholm; Gyllen berg foundation; Hesselman foundation; Samariten foundation; Vardal foundation	This work was funded by the Swedish Research Council, the Swedish Research Council for Working Life and Social Research; the Centre for Allergy Research and the "Mjolkdroppen'' Society, Karolinska Institutet; Phadia AB; the Stockholm County Council; the Swedish Asthma and Allergy Research Association; the Swedish Pediatric Allergy Society; the Swedish Society of Medicine; the Cancer and Allergy Fund; Consul ThC Bergh, Ekhaga , "Frimurare Barnhuset'' in Stockholm; and the Gyllen berg, Hesselman, Samariten, and Vardal foundations.; F. Lindblad has received research support from the Swedish Council for Working Life and Social Research. The rest of the authors have declared that they have no conflict of interest.	Alfven T, 2006, ALLERGY, V61, P414, DOI 10.1111/j.1398-9995.2005.00939.x; Alm JS, 1999, LANCET, V353, P1485, DOI 10.1016/S0140-6736(98)09344-1; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Bakkeheim E, 2010, ACTA PAEDIATR, V99, P1705, DOI 10.1111/j.1651-2227.2009.01598.x; Ball TM, 2006, J ALLERGY CLIN IMMUN, V117, P306, DOI 10.1016/j.jaci.2005.11.009; Buske-Kirschbaum A, 2004, PSYCHONEUROENDOCRINO, V29, P705, DOI 10.1016/S0306-4530(03)00100-8; Buske-Kirschbaum A, 2003, PSYCHOSOM MED, V65, P806, DOI 10.1097/01.PSY.0000095916.25975.4F; Buske-Kirschbaum A, 2009, NEUROIMMUNOMODULAT, V16, P325, DOI 10.1159/000216190; Chida Y, 2008, PSYCHOSOM MED, V70, P102, DOI 10.1097/PSY.0b013e31815c1b71; Cookson H, 2009, J ALLERGY CLIN IMMUN, V123, P847, DOI 10.1016/j.jaci.2009.01.042; Dreger LC, 2010, J ALLERGY CLIN IMMUN, V125, P116, DOI 10.1016/j.jaci.2009.09.051; Floistrup H, 2006, J ALLERGY CLIN IMMUN, V117, P59, DOI 10.1016/j.jaci.2005.09.039; Garn H, 2007, IMMUNOBIOLOGY, V212, P441, DOI 10.1016/j.imbio.2007.03.006; Hansen AM, 2003, SCAND J CLIN LAB INV, V63, P303, DOI 10.1080/00365510310001942; KIRSCHBAUM C, 1994, PSYCHONEUROENDOCRINO, V19, P313, DOI 10.1016/0306-4530(94)90013-2; Knackstedt MK, 2005, AM J REPROD IMMUNOL, V54, P63, DOI 10.1111/j.1600-0897.2005.00288.x; Milam J, 2008, J ASTHMA, V45, P319, DOI 10.1080/02770900801930277; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Schleimer RP, 2000, J ALLERGY CLIN IMMUN, V106, P270; Stenius F, 2011, ALLERGY, V66, P1330, DOI 10.1111/j.1398-9995.2011.02662.x; Stenius F, 2010, PSYCHONEUROENDOCRINO, V368, P221; Thomason MJ, 2000, THORAX, V55, P785, DOI 10.1136/thorax.55.9.785; Thornton CA, 2010, CURR ALLERGY ASTHM R, V10, P444, DOI 10.1007/s11882-010-0148-5; Tollenaar MS, 2010, EARLY HUM DEV, V86, P13, DOI 10.1016/j.earlhumdev.2009.12.003; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P383, DOI 10.1111/j.1365-2133.1994.tb08530.x; Wright RJ, 2007, PAEDIATR PERINAT EP, V21, P8, DOI 10.1111/j.1365-3016.2007.00879.x; Wright RJ, 2010, AM J RESP CRIT CARE, V182, P25, DOI 10.1164/rccm.200904-0637OC	27	20	20	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2011	128	6					1335	1339		10.1016/j.jaci.2011.07.038	http://dx.doi.org/10.1016/j.jaci.2011.07.038			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	865WX	21872917	Bronze			2022-12-18	WOS:000298342700025
J	Kilic, A; Sonar, SS; Yildirim, AO; Fehrenbach, H; Nockher, WA; Renz, H				Kilic, Ayse; Sonar, Sanchaita Sriwal; Yildirim, Ali Oender; Fehrenbach, Heinz; Nockher, Wolfgang Andreas; Renz, Harald			Nerve growth factor induces type III collagen production in chronic allergic airway inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic asthma; airway remodeling; type III collagen; nerve growth factor	SIGNALING PATHWAYS; TISSUE FIBROSIS; EXPERIMENTAL ASTHMA; CELL-PROLIFERATION; LUNG FIBROBLASTS; TRANSGENIC MICE; FACTOR-BETA; MAST-CELLS; EXPRESSION; NEUROTROPHINS	Background: Excessive extracellular matrix deposition occurs as a result of repetitive injury-repair cycles and plays a central role in the pathogenesis of chronic inflammatory diseases, such as allergic asthma. The molecular mechanism leading to aberrant collagen deposition is not fully understood. Objective: We sought to test the hypothesis that increased nerve growth factor (NGF) production contributes to collagen deposition in the airways during chronic allergic airway inflammation. Methods: Antibody-blocking experiments were performed in an in vivo model for chronic allergic airway inflammation (allergic asthma), which is accompanied by matrix deposition in the subepithelial compartment of the airways, to study the profibrotic effect of NGF. The signaling pathways were delineated with in vivo and in vitro studies in primary lung fibroblasts. Results: Functional blocking of NGF in chronically affected mice markedly prevented subepithelial fibrosis. Transgenic overexpression of NGF in murine airways resulted in altered airway wall morphology with increased peribronchial collagen deposition and impaired lung physiology in the absence of inflammation. NGF exerted a direct effect on collagen expression in murine lung fibroblasts, which was mainly mediated through the activation of the receptor tropomyosin-related kinase A. NGF-induced collagen expression was dependent on downstream activation of p38 mitogen-activated protein kinase independent of the TGF-beta 1/mothers against decapentaplegic homolog (SMAD) pathway. Conclusion: The results of this study demonstrate that NGF exerts profibrotic activities in the airways by inducing type III collagen production in fibroblasts independently of TGF-beta 1. (J Allergy Clin Immunol 2011;128:1058-66.)	[Kilic, Ayse; Sonar, Sanchaita Sriwal; Nockher, Wolfgang Andreas; Renz, Harald] Univ Marburg, Fac Med, Inst Lab Med & Pathobiochem, D-35043 Marburg, Germany; [Yildirim, Ali Oender] German Res Ctr Environm Hlth GmbH, Inst Lung Biol & Dis iLBD, Munich, Germany; [Fehrenbach, Heinz] Leibniz Zentrum Med & Biowissensch FZB, Forschungszentrum Borstel, Borstel, Germany	Philipps University Marburg; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Forschungszentrum Borstel	Renz, H (corresponding author), Univ Marburg, Fac Med, Inst Lab Med & Pathobiochem, Baldingerstr, D-35043 Marburg, Germany.	renzh@med.uni-marburg.de	Fehrenbach, Heinz/A-9161-2008	Fehrenbach, Heinz/0000-0003-1935-9411; Yildirim, Ali Onder/0000-0003-1969-480X	German National Science Foundation; Deutsche Forschungsgemeinschaft [SFB/TR 22]; Scientific Foundation of the Universitats klinikum Giessen und Marburg GmbH (UGKM); LOEWE-Excellence Centre UGMLC (Universities Giessen and Marburg Lung Centre)	German National Science Foundation(German Research Foundation (DFG)); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Scientific Foundation of the Universitats klinikum Giessen und Marburg GmbH (UGKM); LOEWE-Excellence Centre UGMLC (Universities Giessen and Marburg Lung Centre)	Supported in part by grants from the German National Science Foundation, Deutsche Forschungsgemeinschaft (SFB/TR 22), the Scientific Foundation of the Universitats klinikum Giessen und Marburg GmbH (UGKM), and the LOEWE-Excellence Centre UGMLC (Universities Giessen and Marburg Lung Centre).	Alcorn JF, 2009, AM J RESP CELL MOL, V40, P422, DOI 10.1165/rcmb.2008-0174OC; Bates JHT, 2008, AM J RESP CRIT CARE, V177, P261, DOI 10.1164/rccm.200706-832OC; Bonini S, 1996, P NATL ACAD SCI USA, V93, P10955, DOI 10.1073/pnas.93.20.10955; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; Boulet LP, 1997, CHEST, V112, P45, DOI 10.1378/chest.112.1.45; Chao MV, 2003, NAT REV NEUROSCI, V4, P299, DOI 10.1038/nrn1078; Elias JA, 1999, J CLIN INVEST, V104, P1001, DOI 10.1172/JCI8124; Fattouh R, 2008, AM J RESP CRIT CARE, V177, P593, DOI 10.1164/rccm.200706-958OC; Freund V, 2002, EUR RESPIR J, V20, P458, DOI 10.1183/09031936.02.00269202; Freund-Michel V, 2006, CELL SIGNAL, V18, P621, DOI 10.1016/j.cellsig.2005.06.007; Gross TJ, 2001, NEW ENGL J MED, V345, P517, DOI 10.1056/NEJMra003200; Hahn C, 2006, J ALLERGY CLIN IMMUN, V117, P787, DOI 10.1016/j.jaci.2005.12.1339; Hasan W, 2000, CELL TISSUE RES, V300, P97, DOI 10.1007/s004410050051; Hayashida T, 2003, FASEB J, V17, P1576, DOI 10.1096/fj.03-0037fje; Herz U, 1998, CLIN EXP ALLERGY, V28, P625; Hoyle GW, 1998, AM J RESP CELL MOL, V18, P149, DOI 10.1165/ajrcmb.18.2.2803m; Hsia CCW, 2010, AM J RESP CRIT CARE, V181, P394, DOI 10.1164/rccm.200809-1522ST; Kassel O, 2001, CLIN EXP ALLERGY, V31, P1432, DOI 10.1046/j.1365-2222.2001.01177.x; Kaviratne M, 2004, J IMMUNOL, V173, P4020, DOI 10.4049/jimmunol.173.6.4020; Kawamoto K, 2004, PROG BRAIN RES, V146, P369; Kerzel S, 2003, AM J RESP CELL MOL, V28, P170, DOI 10.1165/rcmb.4811; Kobayashi H, 2002, BLOOD, V99, P2214, DOI 10.1182/blood.V99.6.2214; Lambiase A, 1997, J ALLERGY CLIN IMMUN, V100, P408, DOI 10.1016/S0091-6749(97)70256-2; Lee CG, 2001, J EXP MED, V194, P809, DOI 10.1084/jem.194.6.809; LEVIMONTALCINI R, 1995, J NEUROL SCI, V130, P119, DOI 10.1016/0022-510X(95)00007-O; Lutz M, 2004, EUR J BIOCHEM, V271, P920, DOI 10.1111/j.1432-1033.2004.03994.x; Micera A, 2001, P NATL ACAD SCI USA, V98, P6162, DOI 10.1073/pnas.101130898; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; Nassenstein C, 2003, J EXP MED, V198, P455, DOI 10.1084/jem.20010897; Nilsson G, 1997, EUR J IMMUNOL, V27, P2295, DOI 10.1002/eji.1830270925; Nithya M, 2003, BBA-GEN SUBJECTS, V1620, P25, DOI 10.1016/S0304-4165(02)00501-9; OHNO I, 1992, J CLIN INVEST, V89, P1662, DOI 10.1172/JCI115764; Olgart C, 2001, EUR RESPIR J, V18, P115, DOI 10.1183/09031936.01.00069901; Path G, 2002, AM J RESP CRIT CARE, V166, P818, DOI 10.1164/rccm.200202-134OC; Rodriguez-Barbero A, 2002, FEBS LETT, V513, P282, DOI 10.1016/S0014-5793(02)02337-2; Sonar SS, 2010, EUR RESPIR J, V36, P105, DOI 10.1183/09031936.00165508; Tang WL, 1996, J CLIN INVEST, V98, P2845, DOI 10.1172/JCI119113; Virchow JC, 1998, AM J RESP CRIT CARE, V158, P2002, DOI 10.1164/ajrccm.158.6.9803023; von Schack D, 2001, NAT NEUROSCI, V4, P977, DOI 10.1038/nn730; Wegmann M, 2005, CLIN EXP ALLERGY, V35, P1263, DOI 10.1111/j.1365-2222.2005.02306.x; Werner S, 2003, PHYSIOL REV, V83, P835, DOI 10.1152/physrev.2003.83.3.835; WERT SE, 1993, DEV BIOL, V156, P426, DOI 10.1006/dbio.1993.1090; Wynn TA, 2007, J CLIN INVEST, V117, P524, DOI 10.1172/JCI31487; Yildirim AO, 2008, EUR RESPIR J, V32, P694, DOI 10.1183/09031936.00155107; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909	45	20	22	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2011	128	5					1058	U510		10.1016/j.jaci.2011.06.017	http://dx.doi.org/10.1016/j.jaci.2011.06.017			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	842FJ	21816457	Bronze			2022-12-18	WOS:000296578200020
J	Park, JH; Godbold, JH; Chung, DN; Sampson, HA; Wang, JL				Park, Joon H.; Godbold, James H.; Chung, Danna; Sampson, Hugh A.; Wang, Julie			Comparison of cetirizine and diphenhydramine in the treatment of acute food-induced allergic reactions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							INTRANASAL MIDAZOLAM; SEDATION; ANTIHISTAMINES; PERFORMANCE; CHILDREN; SAFETY		[Park, Joon H.; Sampson, Hugh A.; Wang, Julie] Mt Sinai Sch Med, Dept Pediat, Div Allergy & Immunol, New York, NY USA; [Godbold, James H.; Chung, Danna] Mt Sinai Sch Med, Dept Prevent Med, New York, NY USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Park, JH (corresponding author), Mt Sinai Sch Med, Dept Pediat, Div Allergy & Immunol, New York, NY USA.	Julie.wang@mssm.edu			NCRR NIH HHS [UL1 RR029887, RR026134, UL1RR029887] Funding Source: Medline; NIAID NIH HHS [U19 AI066738, AI066738, P01 AI044236, K23 AI083883, K23 AI083883-03, AI44236, U19 AI044236] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR029887] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI044236, K23AI083883, U19AI044236, U19AI066738] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Acworth JP, 2001, EMERG MED J, V18, P39, DOI 10.1136/emj.18.1.39; ALBERT KS, 1975, J PHARMACOKINET BIOP, V3, P159, DOI 10.1007/BF01067905; Banerji A, 2007, ALLERGY ASTHMA PROC, V28, P418, DOI 10.2500/aap.2007.28.3015; Bender BG, 2003, J ALLERGY CLIN IMMUN, V111, P770, DOI 10.1067/mai.2003.1408; Nowak-Wegrzyn A, 2009, J ALLERGY CLIN IMMUN, V123, pS365, DOI 10.1016/j.jaci.2009.03.042; SCHWEITZER PK, 1994, J ALLERGY CLIN IMMUN, V94, P716, DOI 10.1016/0091-6749(94)90179-1; Simons FER, 2004, NEW ENGL J MED, V351, P2203, DOI 10.1056/NEJMra033121; Simons FER, 2003, J ALLERGY CLIN IMMUN, V111, P1244, DOI 10.1067/mai.2003.1496; Simons FER, 1999, J ALLERGY CLIN IMMUN, V104, P433, DOI 10.1016/S0091-6749(99)70389-1; WILTON NCT, 1988, ANESTHESIOLOGY, V69, P972, DOI 10.1097/00000542-198812000-00032	10	20	21	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2011	128	5					1127	1128		10.1016/j.jaci.2011.08.026	http://dx.doi.org/10.1016/j.jaci.2011.08.026			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	842FJ	21945608	Green Accepted			2022-12-18	WOS:000296578200036
J	Motika, CA; Papachristou, C; Abney, M; Lester, LA; Ober, C				Motika, Caroline A.; Papachristou, Charalampos; Abney, Mark; Lester, Lucille A.; Ober, Carole			Rising prevalence of asthma is sex-specific in a US farming population	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; atopy; farming exposures; prevalence	GENETIC ARCHITECTURE; TETANUS VACCINATION; REDUCED RISK; BIRTH COHORT; EARLY-LIFE; HAY-FEVER; CHILDREN; EXPOSURE; ALLERGY; ATOPY	Background: Asthma prevalence is increasing worldwide in most populations, likely due to a combination of heritable factors and environmental changes. Curiously, however, some European farming populations are protected from asthma, which has been attributed to their traditional lifestyles and farming practices. Objective: We conducted population-based studies of asthma and atopy in the Hutterites of South Dakota, a communal farming population, to assess temporal trends in asthma and atopy prevalence and describe the risk factors for asthma. Methods: We studied 1325 Hutterites (ages 6-91 years) at 2 time points from 1996 to 1997 and from 2006 to 2009 by using asthma questionnaires, pulmonary function and methacholine bronchoprovocation tests, and measures of atopy. Results: The overall prevalence of asthma increased over the 10- to 13-year study period (7.5%-11.1%, P = .049), whereas the overall prevalence of atopy did not change (45.0%-44.8%, P = .95). Surprisingly, the rise in asthma was only among females (5.8%-11.2%, P = .02); the prevalence among males remained largely unchanged (9.4%-10.9%, P = .57). Atopy, which was not associated with asthma risk in 1996 to 1997, was the strongest risk factor for asthma among Hutterites studied in 2006 to 2009 (P = .003). Conclusions: Asthma has increased over a 10- to 13-year period among Hutterite females and atopy has become a significant risk factor for asthma, suggesting a change in environmental exposures that are either sex limited or that elicit a sex-specific response. (J Allergy Clin Immunol 2011;128:774-9.)	[Motika, Caroline A.] Univ Chicago, Dept Med, Sect Pulm & Crit Care, Chicago, IL 60637 USA; [Abney, Mark; Ober, Carole] Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA; [Lester, Lucille A.] Univ Chicago, Dept Pediat, Chicago, IL 60637 USA; [Ober, Carole] Univ Chicago, Dept Obstet & Gynecol, Chicago, IL 60637 USA; [Papachristou, Charalampos] Univ Sci Philadelphia, Dept Math Phys & Stat, Philadelphia, PA USA	University of Chicago; University of Chicago; University of Chicago; University of Chicago	Motika, CA (corresponding author), Univ Chicago Hosp, Dept Med MC 6076, Sect Pulm & Crit Care, 5841 S Maryland Ave, Chicago, IL USA.	caroline.motika@uchospitals.edu		Ober, Carole/0000-0003-4626-9809; Papachristou, Charalampos/0000-0001-7189-074X	NIH [U01 HL49596, P50 HL56399, R01 HL085197];  [K12 HL090003]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K12HL090003, R01HL085197, P50HL056399, U01HL049596] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG002899] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	This study was funded by NIH grants U01 HL49596, P50 HL56399, and R01 HL085197 to C.O.; C. A. M. is supported by K12 HL090003.	[Anonymous], 2008, SUMM HLTH STAT US AD; [Anonymous], 2008, SUMM HLTH STAT US CH; Anto JM, 2010, ALLERGY, V65, P1021, DOI 10.1111/j.1398-9995.2009.02301.x; Arbes SJ, 2005, J ALLERGY CLIN IMMUN, V116, P377, DOI 10.1016/j.jaci.2005.05.017; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Braun-Fahrlander C, 2003, CURR OPIN ALLERGY CL, V3, P325, DOI 10.1097/01.all.0000092600.10871.e0; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Brogger J, 2003, EUR RESPIR J, V21, P468, DOI 10.1183/09031936.03.00056103; Centers for Disease Control and Prevention, 1999, ASTHM CHRON OBSTR PU; Chrischilles E, 2004, J ALLERGY CLIN IMMUN, V113, P66, DOI 10.1016/j.jaci.2003.09.037; Douwes J, 2008, EUR RESPIR J, V32, P603, DOI 10.1183/09031936.00033707; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Elliott L, 2004, EUR RESPIR J, V24, P938, DOI 10.1183/09031936.04.00006404; Ernst P, 2000, AM J RESP CRIT CARE, V161, P1563, DOI 10.1164/ajrccm.161.5.9908119; Gehring U, 2010, AM J RESP CRIT CARE, V181, P596, DOI 10.1164/rccm.200906-0858OC; Ghosh S, 2008, CAN RESPIR J, V15, P146, DOI 10.1155/2008/793913; Goldberg S, 2007, CHEST, V131, P1747, DOI 10.1378/chest.06-2818; Haby MM, 2001, THORAX, V56, P589, DOI 10.1136/thorax.56.8.589; Hostetler J, 1974, HUTTERITE SOC; Hurwitz EL, 2000, J MANIP PHYSIOL THER, V23, P81, DOI 10.1016/S0161-4754(00)90072-1; Karmaus W, 2002, J EPIDEMIOL COMMUN H, V56, P209, DOI 10.1136/jech.56.3.209; Kim JH, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-49; Klintberg B, 2001, EUR RESPIR J, V17, P1151, DOI 10.1183/09031936.01.00027301; Kogevinas M, 1999, LANCET, V353, P1750, DOI 10.1016/S0140-6736(98)07397-8; Lester LA, 2001, J ALLERGY CLIN IMMUN, V108, P357, DOI 10.1067/mai.2001.117796; Mannino David M, 2002, MMWR Surveill Summ, V51, P1; Mapp CE, 2005, AM J RESP CRIT CARE, V172, P280, DOI 10.1164/rccm.200311-1575SO; Marra F, 2006, CHEST, V129, P610, DOI 10.1378/chest.129.3.610; Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x; Matheson MC, 2010, PEDIAT ALLERG IMM-UK, V21, P301, DOI 10.1111/j.1399-3038.2009.00950.x; McConnell R, 2002, LANCET, V359, P386, DOI 10.1016/S0140-6736(02)07597-9; McDonald KL, 2008, J ALLERGY CLIN IMMUN, V121, P626, DOI 10.1016/j.jaci.2007.11.034; Merchant JA, 2005, ENVIRON HEALTH PERSP, V113, P350, DOI 10.1289/ehp.7240; Miyake Y, 2008, CLIN EXP ALLERGY, V38, P1644, DOI 10.1111/j.1365-2222.2008.03074.x; Moorman Jeanne E., 2007, Morbidity and Mortality Weekly Report, V56, P1; Nagel G, 2009, EUR RESPIR J, V33, P993, DOI 10.1183/09031936.00075708; Ober C, 2000, AM J HUM GENET, V67, P1154, DOI 10.1016/S0002-9297(07)62946-2; Ober C, 1999, AM J HUM GENET, V64, P225, DOI 10.1086/302198; Ober C, 2001, AM J HUM GENET, V69, P1068, DOI 10.1086/324025; Ober C, 2008, NEW ENGL J MED, V358, P1682, DOI 10.1056/NEJMoa0708801; Ober C, 2006, CURR ALLERGY ASTHM R, V6, P241, DOI 10.1007/s11882-006-0041-4; Oddy WH, 2009, ADV EXP MED BIOL, V639, P237, DOI 10.1007/978-1-4020-8749-3_17; Papachristou C, 2011, GENET EPIDEMIOL, V35, P291, DOI 10.1002/gepi.20577; Platts-Mills TAE, 2005, PLOS MED, V2, P122, DOI 10.1371/journal.pmed.0020034; Platts-Mills TAE, 2000, ENVIRON HEALTH PERSP, V108, P725, DOI 10.2307/3454409; Preller L, 1996, EUR RESPIR J, V9, P1407, DOI 10.1183/09031936.96.09071407; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Sears MR, 2002, LANCET, V360, P901, DOI 10.1016/S0140-6736(02)11025-7; SHEPS MC, 1965, POP STUD-J DEMOG, V19, P65, DOI 10.2307/2173165; STEINBERG ARTHUR G., 1967, P267; Thomason MJ, 2000, THORAX, V55, P785, DOI 10.1136/thorax.55.9.785; Thomsen SF, 2011, RESP MED, V105, P1147, DOI 10.1016/j.rmed.2011.03.007; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187, DOI 10.1046/j.1365-2222.2000.00801.x; von Hertzen L, 2006, J ALLERGY CLIN IMMUN, V117, P334, DOI 10.1016/j.jaci.2005.11.013; von Mutius E, 2008, IMMUNOL ALLERGY CLIN, V28, P631, DOI 10.1016/j.iac.2008.03.010; Waser M, 2007, CLIN EXP ALLERGY, V37, P661, DOI 10.1111/j.1365-2222.2006.02640.x; Weiss LA, 2006, NAT GENET, V38, P218, DOI 10.1038/ng1726; Wickens K, 2008, CLIN EXP ALLERGY, V38, P1318, DOI 10.1111/j.1365-2222.2008.03024.x; Wilson DH, 2006, MED J AUSTRALIA, V184, P226, DOI 10.5694/j.1326-5377.2006.tb00207.x	59	20	20	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2011	128	4					774	779		10.1016/j.jaci.2011.06.046	http://dx.doi.org/10.1016/j.jaci.2011.06.046			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	841UA	21840584	Green Accepted			2022-12-18	WOS:000296538100011
J	Koppelman, GH; Sayers, I				Koppelman, Gerard H.; Sayers, Ian			Evidence of a genetic contribution to lung function decline in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; airway remodeling; genetic susceptibility; lung function decline	ENDOTHELIAL GROWTH-FACTOR; PLASMINOGEN-ACTIVATOR; PLAUR POLYMORPHISMS; PULMONARY-FUNCTION; CELL-MIGRATION; ADAM33 GENE; AIRWAY; ASSOCIATION; RECEPTOR; ANGIOGENESIS	There has been great progress in identifying new asthma susceptibility genes. In asthmatic subjects there is variable airway remodeling that includes features such as smooth muscle hypertrophy/hyperplasia, basement membrane thickening, and increased extracellular matrix deposition. Does airway remodeling have a genetic contribution in asthma? Data from different murine strains suggest there is a genetic contribution to the development and progression of airway remodeling. In human subjects it is important to consider what surrogate markers of remodeling have been used in genetic studies. Baseline FEV1 and airway hyperresponsiveness are determined by a complex interplay of factors, including nonremodeling mechanisms; however, we consider a decline in FEV1 as a robust marker of remodeling. To date, single nucleotide polymorphisms spanning ADAM33, ESR1, PLAUR, and VEGF have been associated with an excess decline in lung function in asthmatic subjects carrying the rare alleles (FEV1, -13.0 to 55.2 mL/y excess). Interestingly these genes have overlapping functions in proteolytic pathways in the airways. There is accumulating evidence that genetic factors are important in the development of airway remodeling in asthmatic subjects, and further longitudinal studies with additional remodeling phenotypes and genome-wide association studies will identify novel susceptibility genes, leading to new approaches to target remodeling in asthmatic subjects. (J Allergy Clin Immunol 2011;128:479-84.)	[Sayers, Ian] Univ Nottingham, Div Therapeut & Mol Med, Nottingham Resp Biomed Res Unit, Nottingham NG7 2RD, England; [Koppelman, Gerard H.] Univ Groningen, Univ Med Ctr Groningen, Beatrix Childrens Hosp, Dept Pediat Pulmonol & Pediat Allergol, NL-9700 AB Groningen, Netherlands	University of Nottingham; University of Groningen	Sayers, I (corresponding author), Univ Nottingham Hosp, Div Therapeut & Mol Med, Nottingham NG7 2UH, England.	ian.sayers@nottingham.ac.uk	Koppelman, Gerard/AAG-9187-2020	Koppelman, Gerard/0000-0001-8567-3252; Sayers, Ian/0000-0001-5601-5410	Netherlands Asthma Foundation; Medical Research Council UK; Asthma UK	Netherlands Asthma Foundation; Medical Research Council UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Asthma UK	Disclosure of potential conflict of interest: G. H. Koppelman has received research support from the Netherlands Asthma Foundation. I. Sayers has received research support from the Medical Research Council UK and Asthma UK.	Antunes MA, 2009, RESP PHYSIOL NEUROBI, V165, P202, DOI 10.1016/j.resp.2008.12.003; Bakken AM, 2009, J VASC SURG, V49, P1296, DOI 10.1016/j.jvs.2008.12.026; Barton SJ, 2009, J ALLERGY CLIN IMMUN, V123, P1391, DOI 10.1016/j.jaci.2009.03.014; Begin P, 2007, AM J RESP CRIT CARE, V175, P1109, DOI 10.1164/rccm.200607-1012OC; Blasi F, 2002, NAT REV MOL CELL BIO, V3, P932, DOI 10.1038/nrm977; BOULET LP, 1995, AM J RESP CRIT CARE, V152, P865, DOI 10.1164/ajrccm.152.3.7663797; Chetta A, 1997, CHEST, V111, P852, DOI 10.1378/chest.111.4.852; Cho SH, 2001, J ALLERGY CLIN IMMUN, V108, P212, DOI 10.1067/mai.2001.117260; Corrigan CJ, 2011, P NATL ACAD SCI USA, V108, P1579, DOI 10.1073/pnas.1014241108; Dijkstra A, 2006, J ALLERGY CLIN IMMUN, V117, P604, DOI 10.1016/j.jaci.2005.11.023; Dijkstra A, 2006, THORAX, V61, P105, DOI 10.1136/thx.2004.039271; Englert JM, 2008, AM J PATHOL, V172, P583, DOI 10.2353/ajpath.2008.070569; Flores-Delgado G, 2001, BIOCHEM BIOPH RES CO, V283, P661, DOI 10.1006/bbrc.2001.4827; Hancock DB, 2010, NAT GENET, V42, P45, DOI 10.1038/ng.500; Holgate ST, 2006, PULM PHARMACOL THER, V19, P3, DOI 10.1016/j.pupt.2005.02.008; Holgate ST, 2007, J ALLERGY CLIN IMMUN, V120, P1233, DOI 10.1016/j.jaci.2007.10.025; Holloway JW, 2010, J ALLERGY CLIN IMMUN, V125, pS81, DOI 10.1016/j.jaci.2009.10.071; HOPP RJ, 1984, J ALLERGY CLIN IMMUN, V73, P265, DOI 10.1016/S0091-6749(84)80018-4; Hoshino M, 2001, J ALLERGY CLIN IMMUN, V107, P1034, DOI 10.1067/mai.2001.115626; HUBERT HB, 1982, AM REV RESPIR DIS, V125, P409; James AL, 2005, AM J RESP CRIT CARE, V171, P109, DOI 10.1164/rccm.200402-230OC; Jongepier H, 2004, CLIN EXP ALLERGY, V34, P757, DOI 10.1111/j.1365-2222.2004.1938.x; Kicic A, 2010, AM J RESP CRIT CARE, V181, P889, DOI 10.1164/rccm.200907-1071OC; Kim KE, 2009, J IMMUNOL, V182, P3548, DOI 10.4049/jimmunol.0801695; Koppelman GH, 2006, CURR ALLERGY ASTHM R, V6, P103, DOI 10.1007/s11882-006-0047-y; Kuramoto E, 2009, AM J PHYSIOL-LUNG C, V296, pL337, DOI 10.1152/ajplung.90434.2008; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; Lee CG, 2004, NAT MED, V10, P1095, DOI 10.1038/nm1105; Li XN, 2011, J ALLERGY CLIN IMMUN, V127, P1457, DOI 10.1016/j.jaci.2011.01.056; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Pampuch A, 2006, ALLERGY, V61, P234, DOI 10.1111/j.1398-9995.2005.00948.x; Payne DNR, 2003, AM J RESP CRIT CARE, V167, P78, DOI 10.1164/rccm.200205-414OC; Pepe C, 2005, J ALLERGY CLIN IMMUN, V116, P544, DOI 10.1016/j.jaci.2005.06.011; Postma DS, 2011, AM J RESP CRIT CARE, V183, P1588, DOI 10.1164/rccm.201011-1796PP; Prager GW, 2004, CIRC RES, V94, P1562, DOI 10.1161/01.RES.0000131498.36194.6b; Puxeddu I, 2008, J ALLERGY CLIN IMMUN, V121, pe1; Puxeddu I, 2008, J ALLERGY CLIN IMMUN, V121, P1400, DOI 10.1016/j.jaci.2008.03.003; Repapi E, 2010, NAT GENET, V42, P36, DOI 10.1038/ng.501; Rossouw J, 2011, ARTERIOSCL THROM VAS, V31, P464, DOI 10.1161/ATVBAHA.110.215087; Sharma S, 2009, EUR RESPIR J, V33, P1287, DOI 10.1183/09031936.00113008; Shinagawa K, 2003, AM J RESP CRIT CARE, V168, P959, DOI 10.1164/rccm.200210-1188OC; Stewart CE, 2009, BMC MED GENET, V10, DOI 10.1186/1471-2350-10-112; Stewart CE, 2009, BMC MOL BIOL, V10, DOI 10.1186/1471-2199-10-75; Tang MLK, 2006, PHARMACOL THERAPEUT, V112, P474, DOI 10.1016/j.pharmthera.2006.05.001; Tsurikisawa N, 2010, RESP MED, V104, P1271, DOI 10.1016/j.rmed.2010.03.026; van Diemen CC, 2005, AM J RESP CRIT CARE, V172, P329, DOI 10.1164/rccm.200411-1486OC; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; Vonk JM, 2003, THORAX, V58, P322, DOI 10.1136/thorax.58.4.322; Vonk JM, 2010, PHARMACOGENET GENOM, V20, P179, DOI 10.1097/FPC.0b013e328336c7fd; Wenzel SE, 2007, AM J RESP CRIT CARE, V175, P570, DOI 10.1164/rccm.200607-909OC; Wilk JB, 2007, BMC MED GENET, V8, DOI 10.1186/1471-2350-8-S1-S8; Wilk JB, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000429	52	20	22	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2011	128	3					479	484		10.1016/j.jaci.2011.05.036	http://dx.doi.org/10.1016/j.jaci.2011.05.036			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	812HS	21752436				2022-12-18	WOS:000294283400005
J	Chinen, J; Martinez-Gallo, M; Gu, WL; Cols, M; Cerutti, A; Radigan, L; Zhang, L; Potocki, L; Withers, M; Lupski, JR; Cunningham-Rundles, C				Chinen, Javier; Martinez-Gallo, Monica; Gu, Wenli; Cols, Montserrat; Cerutti, Andrea; Radigan, Lin; Zhang, Li; Potocki, Lorraine; Withers, Marjorie; Lupski, James R.; Cunningham-Rundles, Charlotte			Transmembrane activator and CAML interactor (TACI) haploinsufficiency results in B-cell dysfunction in patients with Smith-Magenis syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						B cell; humoral immunity; transmembrane activator and CAML interactor; common variable immunodeficiency; Smith-Magenis syndrome; gene haploinsufficiency	COMMON VARIABLE IMMUNODEFICIENCY; CALCIUM-MODULATOR; TNFRSF13B VARIANTS; IGA DEFICIENCY; BAFF-R; APRIL; MUTATIONS; RECEPTOR; DIFFERENTIATION; EXPRESSION	Background: Heterozygous deleterious mutations in the gene encoding the tumor necrosis factor receptor superfamily member 13b (TNFRSF13B), or transmembrane activator and CAML interactor (TACI), have been associated with the development of common variable immunodeficiency. Smith-Magenis syndrome (SMS) is a genetic disorder characterized by developmental delay, behavioral disturbances, craniofacial anomalies, and recurrent respiratory tract infections. Eighty percent of subjects have a chromosome 17p11.2 microdeletion, which includes TACI. The remaining subjects have mutations sparing this gene. Objective: We examined TACI protein expression and function in patients with SMS to define the role of TACI haploinsufficiency in B-cell function. Methods: We studied TACI expression and function in a cohort of 29 patients with SMS. Results: In patients with SMS with only 1 TACI allele, we found decreased B-cell extracellular and intracellular expression of TACI, reduced binding of a proliferation-inducing ligand, and decreased TACI-induced expression of activation-induced cytidine deaminase mRNA, but these were normal for cells from patients with SMS and 2 TACI alleles. Impaired upregulation of B-cell surface TACI expression by a Toll-like receptor 9 agonist was also observed in cells from patients with 1 TACI allele. Gene sequence analysis of the remaining TACI allele revealed common polymorphisms, with the exception of 1 patient with an amino acid change of uncertain significance. Patients with SMS with the lowest TACI expression had significantly reduced antibody responses to pneumococcal vaccine serotypes. Discussion: Our findings suggest that haploinsufficiency of the TACI gene results in humoral immune dysfunction, highlighting the role of genomic copy number variants in complex traits. (J Allergy Clin Immunol 2011;127:1579-86.)	[Cunningham-Rundles, Charlotte] Mt Sinai Med Ctr, Mt Sinai Sch Med, Dept Med, Inst Immunol, New York, NY 10029 USA; [Chinen, Javier; Lupski, James R.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; [Chinen, Javier; Lupski, James R.] Texas Childrens Hosp, Houston, TX 77030 USA; [Gu, Wenli; Potocki, Lorraine; Withers, Marjorie; Lupski, James R.] Baylor Coll Med, Dept Human & Mol Genet, Houston, TX 77030 USA	Icahn School of Medicine at Mount Sinai; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Cunningham-Rundles, C (corresponding author), Mt Sinai Med Ctr, Mt Sinai Sch Med, Dept Med, Inst Immunol, New York, NY 10029 USA.	Charlotte.Cunningham-Rundles@mssm.edu	Cols, Montserrat/J-3387-2013; Martinez-Gallo, Monica/S-1368-2019	Cols, Montserrat/0000-0001-6578-8378; Martinez-Gallo, Monica/0000-0002-7340-2161; Cerutti, Andrea/0000-0003-3026-4704	National Institutes of Health [AI-101093, AI-467320, AI-48693]; National Institute of Allergy and Infectious Diseases [03-22]; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000188] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI061093, U01AI095613, R18AI048693, R21AI101093, U19AI096187, R01AI074378, R01AI057653] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS058529] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	Supported by National Institutes of Health grants AI-101093, AI-467320, and AI-48693 and National Institute of Allergy and Infectious Diseases Contract 03-22 (C.C.-R.).	[Anonymous], DAT SINGL NUCL POL D; Bi W, 2008, INBORN ERRORS DEV, P1078; Bi WM, 2004, HUM GENET, V115, P515, DOI 10.1007/s00439-004-1187-6; Bossen C, 2008, BLOOD, V111, P1004, DOI 10.1182/blood-2007-09-110874; Castigli E, 2005, NAT GENET, V37, P829, DOI 10.1038/ng1601; Castigli E, 2005, J EXP MED, V201, P35, DOI 10.1084/jem.20032000; Castigli E, 2004, P NATL ACAD SCI USA, V101, P3903, DOI 10.1073/pnas.0307348101; Castigli E, 2007, J ALLERGY CLIN IMMUN, V120, P885, DOI 10.1016/j.jaci.2007.06.012; Darce JR, 2007, J IMMUNOL, V179, P7276, DOI 10.4049/jimmunol.179.11.7276; Edelman EA, 2007, CLIN GENET, V71, P540, DOI 10.1111/j.1399-0004.2007.00815.x; Garibyan L, 2007, J CLIN INVEST, V117, P1550, DOI 10.1172/JCI31023; Greenberg F, 1996, AM J MED GENET, V62, P247, DOI 10.1002/(SICI)1096-8628(19960329)62:3<247::AID-AJMG9>3.3.CO;2-9; He B, 2010, NAT IMMUNOL, V11, P836, DOI 10.1038/ni.1914; Hymowitz SG, 2005, J BIOL CHEM, V280, P7218, DOI 10.1074/jbc.M411714200; Kanswal S, 2008, J IMMUNOL, V181, P976, DOI 10.4049/jimmunol.181.2.976; Katsenelson N, 2007, EUR J IMMUNOL, V37, P1785, DOI 10.1002/eji.200636800; Kaur K, 2007, BLOOD, V110, P2948, DOI 10.1182/blood-2007-01-069245; Kurotaki N, 2005, GENET MED, V7, P479, DOI 10.1097/01.GIM.0000177419.43309.37; Lee JJ, 2010, J ALLERGY CLIN IMMUN, V126, P1234, DOI 10.1016/j.jaci.2010.08.017; Lee JJ, 2008, CURR OPIN ALLERGY CL, V8, P520, DOI 10.1097/ACI.0b013e3283141200; Mackay F, 2008, CYTOKINE GROWTH F R, V19, P263, DOI 10.1016/j.cytogfr.2008.04.006; Martinez-Pomar N, 2009, BLOOD, V114, P2846, DOI 10.1182/blood-2009-05-213025; Mohammadi J, 2009, J CLIN IMMUNOL, V29, P777, DOI 10.1007/s10875-009-9317-5; Ozcan E, 2009, J ALLERGY CLIN IMMUN, V123, P1277, DOI 10.1016/j.jaci.2009.03.019; Pan-Hammarstrom Q, 2007, NAT GENET, V39, P429, DOI 10.1038/ng0407-429; Potocki L, 2003, GENET MED, V5, P430, DOI 10.1097/01.GIM.0000095625.14160.AB; Salzer U, 2005, NAT GENET, V37, P820, DOI 10.1038/ng1600; Salzer U, 2009, BLOOD, V113, P1967, DOI 10.1182/blood-2008-02-141937; Schneider P, 2005, CURR OPIN IMMUNOL, V17, P282, DOI 10.1016/j.coi.2005.04.005; von Bulow GU, 2000, MAMM GENOME, V11, P628, DOI 10.1007/s003350010125; von Bulow GU, 2001, IMMUNITY, V14, P573, DOI 10.1016/S1074-7613(01)00130-3; Wu YM, 2000, J BIOL CHEM, V275, P35478, DOI 10.1074/jbc.M005224200; Xia XZ, 2000, J EXP MED, V192, P137, DOI 10.1084/jem.192.1.137; Zhang L, 2007, J ALLERGY CLIN IMMUN, V120, P1178, DOI 10.1016/j.jaci.2007.10.001	34	20	20	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2011	127	6					1579	1586		10.1016/j.jaci.2011.02.046	http://dx.doi.org/10.1016/j.jaci.2011.02.046			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	769WH	21514638	Green Accepted, Bronze			2022-12-18	WOS:000291048500040
J	Kay, AB				Kay, A. Barry			Calcitonin gene-related peptide- and vascular endothelial growth factor-positive inflammatory cells in late-phase allergic skin reactions in atopic subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; calcitonin gene-related peptide; skin; vasoactive; vascular endothelial growth factor	EXPRESSION; EOSINOPHILS; ANGIOGENESIS; PERMEABILITY; SECRETION; INFILTRATION; LYMPHOCYTES; VASODILATOR; ACTIVATION; MEDIATORS	Background: Allergen-induced late-phase skin reactions are characterized by erythema and edema, but the vasoactive mediators involved remain unclear. Limited evidence from human studies suggests that calcitonin gene-related peptide (CGRP) and vascular endothelial growth factor (VEGF), potent vasodilator and permeability factors, respectively, are expressed by infiltrating inflammatory cells in certain allergic tissue reactions. Objective: We sought to determine whether tissue swelling in allergen-challenged skin sites in atopic subjects is associated with the infiltration of CGRP(+) and VEGF(+) inflammatory cells. Methods: Skin biopsy specimens were obtained from atopic subjects at various times after cutaneous allergen challenge and studied by means of single and double immunohistochemistry and in situ hybridization. Results: CGRP-immunoreactive and CGRP mRNA-positive cell numbers were increased in biopsy specimens from sites of late-phase skin reactions compared with those at the control site (P = .03 and P = .03, respectively). Their numbers paralleled the development and resolution of the edematous late-phase skin reaction, both peaking at 6 hours after allergen challenge. The majority of CGRP-immunoreactive cells were neutrophils and CD3(+) cells, whereas eosinophils were CGRP negative. VEGF-immunopositive cell numbers were also increased in 6-hour biopsy specimens from late-phase skin reactions compared with those seen at control sites (P = .001) with a lesser but significant response (P = .008) at 24 hours. VEGF(+) cells were largely eosinophils, neutrophils, and CD68(+) macrophages. Conclusions: Late-phase skin reactions in atopic subjects were associated with the infiltration of inflammatory cells expressing CGRP and VEGF, suggesting that these vasoactive factors might play a role in the erythema and edema characteristic of allergic inflammation. They could also be considered targets in attempts to control allergic inflammation. (J Allergy Clin Immunol 2011;127:232-7.)	Univ London Imperial Coll Sci Technol & Med, Leukocyte Biol Sect, Natl Heart & Lung Inst, London SW7 2AZ, England	Imperial College London	Kay, AB (corresponding author), Univ London Imperial Coll Sci Technol & Med, Leukocyte Biol Sect, Natl Heart & Lung Inst, Room 360,Sir Alexander Fleming Bldg,S Kensington, London SW7 2AZ, England.	a.b.kay@imperial.ac.uk			Asthma UK; Imperial College London	Asthma UK; Imperial College London(General Electric)	Supported by Asthma UK and Imperial College London.	Brain SD, 2004, PHYSIOL REV, V84, P903, DOI 10.1152/physrev.00037.2003; BRAIN SD, 1985, BRIT J PHARMACOL, V86, P855, DOI 10.1111/j.1476-5381.1985.tb11107.x; BRAIN SD, 1985, NATURE, V313, P54, DOI 10.1038/313054a0; BUCKLEY TL, 1991, BRIT J PHARMACOL, V103, P1515, DOI 10.1111/j.1476-5381.1991.tb09819.x; Byrne AM, 2005, J CELL MOL MED, V9, P777, DOI 10.1111/j.1582-4934.2005.tb00379.x; CLAUSS M, 1990, J EXP MED, V172, P1535, DOI 10.1084/jem.172.6.1535; FREW AJ, 1988, J IMMUNOL, V141, P4158; FREW AJ, 1988, J ALLERGY CLIN IMMUN, V81, P1117, DOI 10.1016/0091-6749(88)90878-0; GAGA M, 1991, J IMMUNOL, V147, P816; Harada Masaru, 2005, Kurume Medical Journal, V52, P89, DOI 10.2739/kurumemedj.52.89; Hoshino M, 2001, J ALLERGY CLIN IMMUN, V107, P1034, DOI 10.1067/mai.2001.115626; Kay AB, 2007, ALLERGY, V62, P495, DOI 10.1111/j.1398-9995.2007.01342.x; Li WJ, 2004, FASEB J, V18, P1603, DOI 10.1096/fj.04-1737fje; Motoyama S, 2004, SHOCK, V22, P234, DOI 10.1097/01.shk.0000132459.68561.f4; Nishigaki Y, 2003, EUR RESPIR J, V21, P774, DOI 10.1183/09031936.03.00085903; Petrov T, 2002, NEUROSCIENCE, V115, P275, DOI 10.1016/S0306-4522(02)00345-7; Phipps S, 2004, J INVEST DERMATOL, V122, P1406, DOI 10.1111/j.0022-202X.2004.22619.x; Puxeddu I, 2005, J ALLERGY CLIN IMMUN, V116, P531, DOI 10.1016/j.jaci.2005.06.007; Springer J, 2003, PULM PHARMACOL THER, V16, P121, DOI 10.1016/S1094-5539(03)00049-X; Tapper H, 2002, BLOOD, V99, P1785, DOI 10.1182/blood.V99.5.1785; Tedeschi A, 2009, ALLERGY, V64, P1616, DOI 10.1111/j.1398-9995.2009.02069.x; Toda M, 2008, BIOMED PHARMACOTHER, V62, P352, DOI 10.1016/j.biopha.2008.02.003; WAGNER L, 2009, URTICARIA ANGIOEDEMA; Wang HC, 2002, J NEUROIMMUNOL, V130, P155, DOI 10.1016/S0165-5728(02)00221-7; WEDMORE CV, 1981, NATURE, V289, P646, DOI 10.1038/289646a0; Ying S, 1999, J IMMUNOL, V163, P3976; Ying S, 2002, J ALLERGY CLIN IMMUN, V109, pS88, DOI 10.1016/S0091-6749(02)81367-7; Yu XJ, 2006, REGUL PEPTIDES, V137, P134, DOI 10.1016/j.regpep.2006.07.001	28	20	21	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2011	127	1					232	237		10.1016/j.jaci.2010.10.028	http://dx.doi.org/10.1016/j.jaci.2010.10.028			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	702SY	21211657				2022-12-18	WOS:000285917300033
J	Jahn-Schmid, B; Wopfner, N; Hubinger, G; Asero, R; Ebner, C; Ferreira, F; Bohle, B				Jahn-Schmid, Beatrice; Wopfner, Nicole; Hubinger, Gudrun; Asero, Riccardo; Ebner, Christof; Ferreira, Fatima; Bohle, Barbara			The T-cell response to Amb a 1 is characterized by 3 dominant epitopes and multiple MHC restriction elements	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							RAGWEED-POLLEN; ALLERGEN; SENSITIZATION; REACTIVITY; IGE		[Jahn-Schmid, Beatrice; Bohle, Barbara] Med Univ Vienna, Ctr Pathophysiol Infectiol & Immunol, Dept Pathophysiol, Vienna, Austria; [Wopfner, Nicole; Hubinger, Gudrun; Ferreira, Fatima] Salzburg Univ, Christian Doppler Lab Allergy Diag & Therapy, A-5020 Salzburg, Austria; [Asero, Riccardo] Clin San Carlo, Paderno Dugnano, Italy; [Bohle, Barbara] Christian Doppler Lab Immunomodulat, Vienna, Austria; [Ebner, Christof] Allergieambulatorium Reumannpl, Vienna, Austria	Medical University of Vienna; Salzburg University	Jahn-Schmid, B (corresponding author), Med Univ Vienna, Ctr Pathophysiol Infectiol & Immunol, Dept Pathophysiol, Vienna, Austria.	beatrice.jahn-schmid@meduniwien.ac.at	Ferreira, Fatima/E-4889-2011; Ferreira, Fatima/AAB-4321-2019	Ferreira, Fatima/0000-0003-0989-2335; Ferreira, Fatima/0000-0003-0989-2335; Bohle, Barbara/0000-0002-5105-7985	Austrian Science Fund (FWF) [T 411] Funding Source: researchfish; Austrian Science Fund FWF [P 20011, T 411] Funding Source: Medline	Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); Austrian Science Fund FWF(Austrian Science Fund (FWF))		Asero R, 2006, CLIN EXP ALLERGY, V36, P658, DOI 10.1111/j.1365-2222.2006.02477.x; BOND JF, 1991, J IMMUNOL, V146, P3380; Burbach GJ, 2009, ALLERGY, V64, P664, DOI 10.1111/j.1398-9995.2009.01975.x; Creticos PS, 2006, NEW ENGL J MED, V355, P1445, DOI 10.1056/NEJMoa052916; HUANG SK, 1991, EUR J IMMUNOL, V21, P1469, DOI 10.1002/eji.1830210621; KING TP, 1967, BIOCHEMISTRY-US, V6, P1992, DOI 10.1021/bi00859a017; RAFNAR T, 1991, J BIOL CHEM, V266, P1229; Wopfner N, 2009, MOL IMMUNOL, V46, P2090, DOI 10.1016/j.molimm.2009.02.005; 1996, Patent No. 9613589	9	20	23	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2010	126	5					1068	1071		10.1016/j.jaci.2010.05.038	http://dx.doi.org/10.1016/j.jaci.2010.05.038			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	674HB	20638115	Bronze			2022-12-18	WOS:000283727100025
J	Pacheco, KA; Rose, CS; Silveira, LJ; Van Dyke, MV; Goelz, K; MacPhail, K; Maier, LA				Pacheco, Karin A.; Rose, Cecile S.; Silveira, Lori J.; Van Dyke, Michael V.; Goelz, Kelly; MacPhail, Kristyn; Maier, Lisa A.			Gene-environment interactions influence airways function in laboratory animal workers	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CD14/-1619; occupational asthma; endotoxin; murine allergen; CD14/-159; laboratory animal allergy	SOLUBLE CD14 LEVELS; SERUM IGE LEVELS; AIRBORNE ENDOTOXIN; EXPOSURE; ASTHMA; ATOPY; POLYMORPHISMS; MOUSE; ASSOCIATION; EXTRACTION	Background: Most diseases, including asthma, result from the interaction between environmental exposures and genetic variants. Functional variants of CD14 negatively affect lung function in farm workers and children exposed to animal allergens and endotoxin. Objective: We hypothesized that CD14 polymorphisms interact with inhaled endotoxin, mouse allergen, or both to decrease airways function in laboratory animal workers. Methods: Three hundred sixty-nine Caucasian workers completed a symptom and work exposure questionnaire, skin prick testing, and spirometry. Individual exposure estimates for endotoxin and murine allergen were calculated by weighting task-based breathing zone concentrations by time reported for each task and length of time in the current job. Real-time PCR was used to assess CD14/-1619, -550, and -159 alleles. Multiple linear regression predicting airways function included an interaction term between genotype and exposure. Results: Workers at the highest quartile of the natural log-transformed cumulative endotoxin exposure and with the endotoxin-responsive CD14/-1619 G allele had significantly lower FEV(1) and forced expiratory flow, midexpiratory phase (FEF(25-75)) percent predicted compared with workers with an AA genotype, with no significant differences noted at lower endotoxin levels for either genotype. The gene-environment effect was marked for atopic workers. Laboratory animal allergy, murine allergen exposure, CD14/-159 or -550 genotype, and a gene-exposure interaction term for these genotypes and exposures did not predict changes in lung function. Conclusions: A significant gene-environment interaction affects airways function in laboratory animal workers. More highly endotoxin-exposed workers with CD14/-1619G alleles have significantly lower FEV(1) and FEF(25-75) percent predicted than those with CD14/-1619AA alleles. Atopic workers are particularly affected by cumulative endotoxin exposures. (J Allergy Clin Immunol 2010;126:232-40.)	[Pacheco, Karin A.; Rose, Cecile S.; Silveira, Lori J.; Van Dyke, Michael V.; Goelz, Kelly; MacPhail, Kristyn; Maier, Lisa A.] Natl Jewish Hlth, Dept Med, Div Environm & Occupat Hlth Sci, Denver, CO 80206 USA; [Rose, Cecile S.; Maier, Lisa A.] Univ Colorado, Sch Med, Dept Med, Div Pulm & Crit Care Sci ences, Denver, CO USA; [Pacheco, Karin A.; Rose, Cecile S.; Maier, Lisa A.] Univ Colorado, Sch Publ Hlth, Dept Environm & Occupat Hlth, Denver, CO 80202 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Colorado School of Public Health; University of Colorado System; University of Colorado Denver	Pacheco, KA (corresponding author), Natl Jewish Hlth, Dept Med, Div Environm & Occupat Hlth Sci, 1400 Jackson St, Denver, CO 80206 USA.	pachecok@njhealth.org	Maier, Lisa/AAA-4378-2020		National Institutes of Allergy and Infectious Diseases (NIAID) [1 K23 AI053572, 1 R01 AI 59618]; National Center for Research Resources/National Institutes of Health [1 UL1 RR025780]; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000051, UL1RR025780] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI053572, R01AI059618] Funding Source: NIH RePORTER	National Institutes of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Center for Research Resources/National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by 1 K23 AI053572 from the National Institutes of Allergy and Infectious Diseases (NIAID), 1 R01 AI 59618 from the NIAID, and 1 UL1 RR025780 from the National Center for Research Resources/National Institutes of Health.	de la Hoz RE, 2009, J OCCUP ENVIRON MED, V51, P992, DOI 10.1097/JOM.0b013e3181b32093; Eder W, 2005, J ALLERGY CLIN IMMUN, V116, P601, DOI 10.1016/j.jaci.2005.05.003; Guerra S, 2004, AM J REPROD IMMUNOL, V52, P204, DOI 10.1111/j.1600-0897.2004.00207.x; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; Korpi A, 2004, J ALLERGY CLIN IMMUN, V113, P677, DOI 10.1016/j.jaci.2003.11.039; LeVan TD, 2005, AM J RESP CRIT CARE, V171, P773, DOI 10.1164/rccm.200404-530OC; Levan TD, 2008, J ALLERGY CLIN IMMUN, V121, P434, DOI 10.1016/j.jaci.2007.08.050; Leynaert B, 2006, J ALLERGY CLIN IMMUN, V118, P658, DOI 10.1016/j.jaci.2006.06.015; Lieutier-Colas F, 2001, CLIN EXP ALLERGY, V31, P1449, DOI 10.1046/j.1365-2222.2001.01180.x; Martinez Fernando D, 2007, Proc Am Thorac Soc, V4, P221, DOI 10.1513/pats.200702-035AW; O'Donnell AR, 2004, AM J RESP CRIT CARE, V169, P615, DOI 10.1164/rccm.200302-278OC; Pacheco KA, 2003, AM J RESP CRIT CARE, V167, P983, DOI 10.1164/rccm.2112062; Pacheco KA, 2006, ANN OCCUP HYG, V50, P563, DOI 10.1093/annhyg/me1019; Simpson A, 2006, AM J RESP CRIT CARE, V174, P386, DOI 10.1164/rccm.200509-1380OC; Smit LAM, 2009, AM J RESP CRIT CARE, V179, P363, DOI 10.1164/rccm.200810-1533OC; Spaan S, 2008, APPL ENVIRON MICROB, V74, P3804, DOI 10.1128/AEM.02537-07; Spaan S, 2007, APPL ENVIRON MICROB, V73, P6134, DOI 10.1128/AEM.00851-07; VENABLES KM, 1993, THORAX, V48, P214, DOI 10.1136/thx.48.3.214; Vercelli D, 2004, J ALLERGY CLIN IMMUN, V113, P381, DOI 10.1016/j.jaci.2004.01.752; Vercelli D, 2009, J ALLERGY CLIN IMMUN, V123, P26, DOI 10.1016/j.jaci.2008.11.031; von Mutius E, 2009, J ALLERGY CLIN IMMUN, V123, P3, DOI 10.1016/j.jaci.2008.10.046; Wang XR, 2005, EUR RESPIR J, V26, P881, DOI 10.1183/09031936.05.00125604; Williams LK, 2006, J ALLERGY CLIN IMMUN, V118, P851, DOI 10.1016/j.jaci.2006.07.007; Zambelli-Weiner A, 2005, J ALLERGY CLIN IMMUN, V115, P1203, DOI 10.1016/j.jaci.2005.03.001	24	20	20	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2010	126	2					232	240		10.1016/j.jaci.2010.04.019	http://dx.doi.org/10.1016/j.jaci.2010.04.019			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	642IL	20579716	Green Accepted, Bronze			2022-12-18	WOS:000281203800006
J	Cruse, G; Yang, WD; Duffy, SM; Chachi, L; Leyland, M; Amrani, Y; Bradding, P				Cruse, Glenn; Yang, Weidong; Duffy, S. Mark; Chachi, Latifah; Leyland, Mark; Amrani, Yassine; Bradding, Peter			Counterregulation of beta(2)-adrenoceptor function in human mast cells by stem cell factor	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						beta(2)-Adrenoceptor; albuterol; asthma; mast cell; desensitization	AIRWAY SMOOTH-MUSCLE; REGULAR INHALED SALBUTAMOL; BETA-ADRENERGIC-RECEPTOR; (S)-ALBUTEROL INCREASES; MONOMERIC IGE; ACTIVATION; ASTHMA; INSULIN; EXPRESSION; HISTAMINE	Background: Mast cells contribute to the pathophysiology of asthma with the sustained release of both preformed and newly generated mediators in response to allergens and other diverse stimuli. Stem cell factor (SCF) is the key human mast cell growth factor, but also primes mast cells for mediator release. SCF expression is markedly increased in asthmatic airways. Short-acting beta(2)-adrenoceptor drugs such as albuterol inhibit human lung mast cell (HLMC) degranulation in vitro in the absence of SCF, but their effect in the presence of SCF is not known. Objective: The aim of this study was to elucidate the effects of albuterol on HLMC function in the presence of SCF. Methods: Mediator release and K(Ca)3.1 ion channel activity were analyzed in purified HLMC. Intracellular signalling and beta(2)-adrenoceptor phosphorylation and internalization were analyzed in the HMC-1 human mast cell line. Results: beta(2)-Adrenoceptor agonist-dependent inhibition of K(Ca)3.1 ion channels and HLMC mediator release was markedly attenuated in the presence of SCF. Remarkably, albuterol actually potentiated IgE-induced histamine release in a dose-dependent manner when both SCF and IgE were present. These effects were related to the SCF-dependent phosphorylation of Tyr350 on the beta(2)-adrenoceptor with immediate uncoupling of the receptor followed by receptor internalization. Conclusion: The potentially beneficial effects of beta(2)-adrenoceptor agonists in asthmatic airways may be blunted as a result of the high concentrations of SCF present. (J Allergy Clin Immunol 2010;125:257-63.)	[Cruse, Glenn; Yang, Weidong; Duffy, S. Mark; Chachi, Latifah; Amrani, Yassine; Bradding, Peter] Univ Leicester, Dept Infect Immun & Inflammat, Leicester, Leics, England; [Leyland, Mark] Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England	University of Leicester; University of Leicester	Cruse, G (corresponding author), Glenfield Gen Hosp, Dept Resp Med, Inst Lung Hlth, Clin Sci Bldg,Groby Rd, Leicester LE3 9QP, Leics, England.	glenncruse@hotmail.com	Cruse, Glenn/B-4597-2012; Cruse, Glenn/AAZ-1093-2021; Amrani, Yassine/Q-6323-2019; Amrani, Yassine/A-1826-2013	Amrani, Yassine/0000-0002-7042-6926; Cruse, Glenn/0000-0002-7511-0082; Bradding, Peter/0000-0001-8403-0319	Asthma UK [04/026]	Asthma UK	Supported by Asthma UK grant no. 04/026.	Ahrens R, 2001, J ALLERGY CLIN IMMUN, V108, P681; Al-Muhsen SZ, 2004, CLIN EXP ALLERGY, V34, P911, DOI 10.1111/j.1365-2222.2004.01975.x; Amrani Y, 2001, MOL PHARMACOL, V60, P646; Berlin AA, 2004, CLIN EXP IMMUNOL, V136, P15, DOI 10.1111/j.1365-2249.2004.02404.x; Berlin AA, 2006, LAB INVEST, V86, P557, DOI 10.1038/labinvest.3700419; BOUVIER M, 1988, MOL PHARMACOL, V33, P133; Bradding P, 2006, J ALLERGY CLIN IMMUN, V117, P1277, DOI 10.1016/j.jaci.2006.02.039; Cho SH, 2001, INT ARCH ALLERGY IMM, V124, P478, DOI 10.1159/000053783; Chong LK, 2003, BRIT J PHARMACOL, V138, P512, DOI 10.1038/sj.bjp.0705050; CHURCH MK, 1987, BRIT J PHARMACOL, V90, P421, DOI 10.1111/j.1476-5381.1987.tb08972.x; COCKCROFT DW, 1993, LANCET, V342, P833, DOI 10.1016/0140-6736(93)92695-P; Cruse G, 2005, EUR RESPIR J, V25, P858, DOI 10.1183/09031936.05.00091704; Da Silva CA, 2006, CLIN EXP ALLERGY, V36, P317; Duffy SM, 2007, EUR J IMMUNOL, V37, P1653, DOI 10.1002/eji.200637024; Duffy SM, 2005, FASEB J, V19, P1006, DOI 10.1096/fj.04-3439fje; Duffy SM, 2001, J IMMUNOL, V167, P4261, DOI 10.4049/jimmunol.167.8.4261; Gavi S, 2006, TRENDS ENDOCRIN MET, V17, P46, DOI 10.1016/j.tem.2006.01.006; Gavi S, 2005, ENDOCRINOLOGY, V146, P450, DOI 10.1210/en.2004-0595; Henderson WR, 2005, J ALLERGY CLIN IMMUN, V116, P332, DOI 10.1016/j.jaci.2005.04.013; Hollins F, 2008, J IMMUNOL, V181, P2772, DOI 10.4049/jimmunol.181.4.2772; Horvath G, 2007, AM J RESP CELL MOL, V36, P53, DOI 10.1165/rcmb.2006-0230OC; Howe AK, 2004, BBA-MOL CELL RES, V1692, P159, DOI 10.1016/j.bbamcr.2004.03.005; Humbert M, 1996, AM J RESP CRIT CARE, V153, P1931, DOI 10.1164/ajrccm.153.6.8665058; Ishizuka T, 1999, J IMMUNOL, V162, P2087; KAROOR V, 1995, J BIOL CHEM, V270, P25305, DOI 10.1074/jbc.270.43.25305; Karoor V, 1996, J BIOL CHEM, V271, P29347, DOI 10.1074/jbc.271.46.29347; Karoor V, 1998, J BIOL CHEM, V273, P33035, DOI 10.1074/jbc.273.49.33035; Liu Y, 2005, J BIOL CHEM, V280, P38976, DOI 10.1074/jbc.M506351200; Lukacs NW, 1996, BLOOD, V87, P2262, DOI 10.1182/blood.V87.6.2262.bloodjournal8762262; Malbon CC, 1998, CELL SIGNAL, V10, P523, DOI 10.1016/S0898-6568(97)00194-0; MAZZONI L, 1994, PULM PHARMACOL, V7, P367, DOI 10.1006/pulp.1994.1043; Mitra S, 1998, MOL PHARMACOL, V53, P347, DOI 10.1124/mol.53.3.347; Nelson HS, 2006, CHEST, V129, P15, DOI 10.1378/chest.129.1.15; Okayama Y, 2006, IMMUNOL RES, V34, P97, DOI 10.1385/IR:34:2:97; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Penn RB, 1996, CLIN REV ALLERG IMMU, V14, P37, DOI 10.1007/BF02772201; Sanmugalingam D, 2000, J LEUKOCYTE BIOL, V68, P38; Schneider E, 2005, J EXP MED, V202, P387, DOI 10.1084/jem.20050195; Swystun VA, 2000, J ALLERGY CLIN IMMUN, V106, P57; TAKAISHI T, 1994, ALLERGY, V49, P837, DOI 10.1111/j.1398-9995.1994.tb00784.x; Tanaka S, 2005, EUR J IMMUNOL, V35, P460, DOI 10.1002/eji.200425622; Taylor DR, 1998, THORAX, V53, P744, DOI 10.1136/thx.53.9.744; TAYLOR DR, 1993, THORAX, V48, P134, DOI 10.1136/thx.48.2.134; Wang HY, 2000, J BIOL CHEM, V275, P36086, DOI 10.1074/jbc.M004404200	44	20	20	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2010	125	1					257	263		10.1016/j.jaci.2009.08.020	http://dx.doi.org/10.1016/j.jaci.2009.08.020			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	544MG	19864009				2022-12-18	WOS:000273660500032
J	Haahtela, T; Tamminen, K; Kava, T; Malmberg, LP; Rytila, P; Nikander, K; Persson, T; Selroos, O				Haahtela, Tari; Tamminen, Klaus; Kava, Tuomo; Malmberg, L. Pekka; Rytila, Paula; Nikander, Kurt; Persson, Tore; Selroos, Olof			Thirteen-year follow-up of early intervention with an inhaled corticosteroid in patients with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; asthma control; budesonide; early intervention; inhaled corticosteroids; prebronchodilator FEV(1); terbutaline	MILD PERSISTENT ASTHMA; NEWLY-DIAGNOSED ASTHMA; NEWLY DETECTED ASTHMA; LONG-TERM TREATMENT; LUNG-FUNCTION; DOUBLE-BLIND; BUDESONIDE; CHILDREN; BETA-2-AGONIST; INFLAMMATION	Background: In a 3-year study, adult patients who recently developed asthma (symptoms for less than I year) were treated for 2 years with the inhaled corticosteroid (ICS) budesonide (early therapy) or terbutaline. During the third year of the study, terbutaline-treated patients received budesonide (delayed therapy). Differences in lung function and bronchial responsiveness to histamine were observed between the 2 groups. Objective: We compared the effects of early versus delayed budesonide therapy after a 10-year follow-up period (13 years after the study began) and current real-life data. Methods: Of the original 103 patients, 90 were re-examined 13 years after study initiation. After the third year of the study, all patients had their medications, including the dose of ICS, individually adjusted. Results: After the follow-up period, lung function was within the normal range for the entire group (all patients); bronchial responsiveness significantly improved compared with baseline data. No statistically significant differences in clinical or functional variables were found between patients given early or delayed budesonide therapy. However, the delayed therapy group had a higher neutrophil count and higher concentrations of eosinophilic cationic protein and myeloperoxidase in induced sputum. This group had also used more asthma medication and hospital days. Conclusions: Patients with relatively mild asthma who received ICS within 12 months of their first asthma symptoms or after a 2-year delay achieved equally good functional control of asthma after 10 years of individualized therapy. However, the delayed therapy group exhibited slightly less optimal disease control and more signs of airway inflammation. (J Allergy Clin Immunol 2009;124:1180-5.)	[Haahtela, Tari; Tamminen, Klaus; Malmberg, L. Pekka; Rytila, Paula] Univ Helsinki, Cent Hosp, Skin & Allergy Hosp, Helsinki, Finland; [Kava, Tuomo] No Karelia Cent Hosp, Joensuu, Finland; [Nikander, Kurt] Respironics, Parsippany, NJ USA; [Nikander, Kurt; Persson, Tore] AstraZeneca R&D, Lund, Sweden; [Selroos, Olof] Semeco, Angelholm, Sweden	University of Helsinki; Helsinki University Central Hospital; AstraZeneca	Haahtela, T (corresponding author), Univ Helsinki, Cent Hosp, Skin & Allergy Hosp, POB 160, Helsinki 00029, Finland.	tari.haahtela@hus.fi			Helsinki University Central Hospital [2303]; AstraZeneca, Finland; AstraZeneca RD, Lund, Sweden; Orion Diagnostics and Stallergenes; Bochringer Ingelheim; GlaxoSmithKline	Helsinki University Central Hospital; AstraZeneca, Finland(AstraZeneca); AstraZeneca RD, Lund, Sweden(AstraZeneca); Orion Diagnostics and Stallergenes; Bochringer Ingelheim; GlaxoSmithKline(GlaxoSmithKline)	Disclosure of potential conflict of interest: T. Haahtela receives honoraria from ALK-Abello. AstraZeneca. Meda Oy. MSD, and Orion Pharma is on the advisory board for MSD and Orion Pharma; and receives grant support from Orion Diagnostics and Stallergenes. K. Tamminen was employed by AstraZeneca Finland until June 2009. T. Kava receives lecture fees from AstraZeneca, Bochringer Ingelheim, GlaxoSmithKline, and MSD and receives financial support for attending meetings from Boehringer Ingelheim. P. Rytila is employed by Orion Pharma. K. Nikander is employed by Philips Respironics. T. Persson is employed by and is a shareholder in AstraZeneca R&D. The rest of the authors have declared that they have no conflict of interest.	Adams RJ, 2001, PEDIATRICS, V107, P706, DOI 10.1542/peds.107.4.706; AGERTOFT L, 1994, RESP MED, V88, P373, DOI 10.1016/0954-6111(94)90044-2; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; Bousquet J, 2007, GLOBAL SURVEILLANCE; Busse WW, 2008, J ALLERGY CLIN IMMUN, V121, P1167, DOI 10.1016/j.jaci.2008.02.029; *GLOB IN ASTHM, 2008, GLOB STRAT ASTHM MAN; Haahtela T, 2008, ALLERGY, V63, P634, DOI 10.1111/j.1398-9995.2008.01712.x; Haahtela T, 2006, THORAX, V61, P663, DOI 10.1136/thx.2005.055699; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; LAITINEN LA, 1992, J ALLERGY CLIN IMMUN, V90, P32, DOI 10.1016/S0091-6749(06)80008-4; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; Metso T, 2001, RESP MED, V95, P48, DOI 10.1053/rmed.2000.0970; O'Byrne PM, 2006, CHEST, V129, P1478, DOI 10.1378/chest.129.6.1478; O'Byrne PM, 2009, AM J RESP CRIT CARE, V179, P19, DOI 10.1164/rccm.200807-1126OC; O'Byrne PM, 2001, AM J RESP CRIT CARE, V164, P1392, DOI 10.1164/ajrccm.164.8.2104102; Panhuysen CIM, 1997, AM J RESP CRIT CARE, V155, P1267, DOI 10.1164/ajrccm.155.4.9105065; Pauwels RA, 2003, LANCET, V361, P1071, DOI 10.1016/S0140-6736(03)12891-7; PEAT JK, 1987, EUR J RESPIR DIS, V70, P171; Selroos O, 2004, RESP MED, V98, P254, DOI 10.1016/j.rmed.2003.10.007; SELROOS O, 1995, CHEST, V108, P1228, DOI 10.1378/chest.108.5.1228; Slutsky AS, 1999, AM J RESP CRIT CARE, V160, P2104; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043, DOI 10.1164/ajrccm.159.4.9806052; Suissa S, 2000, NEW ENGL J MED, V343, P332, DOI 10.1056/NEJM200008033430504; Taylor DR, 2008, EUR RESPIR J, V32, P545, DOI 10.1183/09031936.00155307; Tukiainen H, 2000, RESP MED, V94, P678, DOI 10.1053/rmed.2000.0796	26	20	20	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2009	124	6					1180	1185		10.1016/j.jaci.2009.09.036	http://dx.doi.org/10.1016/j.jaci.2009.09.036			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	536VH	20004779	Bronze			2022-12-18	WOS:000273071500005
J	Melia, E; Freeman, AF; Shea, YR; Hsu, AP; Holland, SM; Olivier, KN				Melia, Elizabeth; Freeman, Alexandra F.; Shea, Yvonne R.; Hsu, Amy P.; Holland, Steven M.; Olivier, Kenneth N.			Pulmonary nontuberculous mycobacterial infections in hyper-IgE syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							DISEASE		[Melia, Elizabeth; Freeman, Alexandra F.; Hsu, Amy P.; Holland, Steven M.; Olivier, Kenneth N.] NIAID, Immunopathogenesis Sect, Lab Clin Infect Dis, Bethesda, MD 20892 USA; [Shea, Yvonne R.] NIH, Microbiol Serv, Dept Lab Med,US Dept Hlth & Human Serv, Warren Grant Magnuson Clin Ctr, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA	Melia, E (corresponding author), NIAID, Immunopathogenesis Sect, Lab Clin Infect Dis, 9000 Rockville Pike, Bethesda, MD 20892 USA.	olivierk@niaid.nih.gov			Intramural NIH HHS [Z99 AI999999] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000647, ZIAAI000646] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Erlewyn-Lajeunesse MDS, 2000, PEDIATR ALLERGY IMMU, V11, P133, DOI 10.1034/j.1399-3038.2000.00091.x; Freeman AF, 2007, J ALLERGY CLIN IMMUN, V119, P1234, DOI 10.1016/j.jaci.2006.12.666; Griffith DE, 2007, AM J RESP CRIT CARE, V175, P367, DOI 10.1164/rccm.200604-571ST; Grimbacher B, 1999, NEW ENGL J MED, V340, P692, DOI 10.1056/NEJM199903043400904; Holland SM, 2007, NEW ENGL J MED, V357, P1608, DOI 10.1056/NEJMoa073687; Kim RD, 2008, AM J RESP CRIT CARE, V178, P1066, DOI 10.1164/rccm.200805-686OC; Kunst H, 2006, EUR RESPIR J, V28, P352, DOI 10.1183/09031936.06.00139005; Noone PG, 2004, AM J RESP CRIT CARE, V169, P459, DOI 10.1164/rccm.200303-365OC; Olivier KN, 2003, AM J RESP CRIT CARE, V167, P828, DOI 10.1164/rccm.200207-678OC	9	20	20	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2009	124	3					617	618		10.1016/j.jaci.2009.07.007	http://dx.doi.org/10.1016/j.jaci.2009.07.007			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	552TG	19733303	Green Accepted			2022-12-18	WOS:000274315900038
J	Rueff, F; Bilo, MB; Jutel, M; Mosbech, H; Muller, U; Przybilla, B				Rueff, Franziska; Bilo, M. Beatrice; Jutel, Marek; Mosbech, Holger; Mueller, Ulrich; Przybilla, Bernhard			Sublingual immunotherapy with venom is not recommended for patients with Hymenoptera venom allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Rueff, Franziska; Przybilla, Bernhard] Univ Munich, AllergieZentrum, Klin & Poliklin Dermatol & Allergol, Munich, Germany; [Bilo, M. Beatrice] Azienda Osped Univ, Allergy Unit, Dept Internal Med Allergy Immunol & Resp Dis, Osped Riuniti Ancona, Ancona, Italy; [Jutel, Marek] Silesian Piasts Univ Med Wroclaw, Dept Clin Immunol, Wroclaw, Poland; [Mosbech, Holger] Rigshosp, Natl Univ Hosp, Allergy Unit, DK-2100 Copenhagen, Denmark; [Mueller, Ulrich] Allergiestn Med Klin, Bern, Switzerland	University of Munich; Wroclaw Medical University; Rigshospitalet; University of Copenhagen	Rueff, F (corresponding author), Univ Munich, AllergieZentrum, Klin & Poliklin Dermatol & Allergol, Munich, Germany.	Franziska.Rueff@med.uni-muenchen.de						GOLDEN DB, 1992, J ALLERGY CLIN IMMUN, V90, P396; GOLDEN DBK, 1980, ANN INTERN MED, V92, P620, DOI 10.7326/0003-4819-92-5-620; GRAFT DF, 1987, J ALLERGY CLIN IMMUN, V80, P162, DOI 10.1016/0091-6749(87)90125-4; MULLER U, 1989, ALLERGY, V44, P412, DOI 10.1111/j.1398-9995.1989.tb04172.x; Rueff F, 2004, ALLERGY, V59, P589, DOI 10.1111/j.1398-9995.2004.00505.x; Severino MG, 2008, J ALLERGY CLIN IMMUN, V122, P44, DOI 10.1016/j.jaci.2008.03.031	6	20	20	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2009	123	1					272	273		10.1016/j.jaci.2008.10.028	http://dx.doi.org/10.1016/j.jaci.2008.10.028			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	399IP	19130944				2022-12-18	WOS:000262793900055
J	Ehlayel, M; de Beaucoudrey, L; Fike, F; Nahas, SA; Feinberg, J; Casanova, JL; Gatti, RA				Ehlayel, Mohammad; de Beaucoudrey, Ludovic; Fike, Francesca; Nahas, Shareef A.; Feinberg, Jacqueline; Casanova, Jean-Laurent; Gatti, Richard A.			Simultaneous presentation of 2 rare hereditary immunodeficiencies: IL-12 receptor beta 1 deficiency and ataxia-telangiectasia	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Ehlayel, Mohammad] Hamad Med Corp, Dept Pediat, Sect Allergy Immunol, Doha, Qatar; [de Beaucoudrey, Ludovic; Feinberg, Jacqueline; Casanova, Jean-Laurent] INSERM, U550, Lab Human Genet Infect Dis, Paris, France; [de Beaucoudrey, Ludovic; Feinberg, Jacqueline; Casanova, Jean-Laurent] Paris Descartes Univ, Necker Med Sch, Paris, France; [Fike, Francesca; Nahas, Shareef A.; Gatti, Richard A.] Univ Calif Los Angeles, Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; [Fike, Francesca; Nahas, Shareef A.; Gatti, Richard A.] Univ Calif Los Angeles, Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA; [Casanova, Jean-Laurent] Hop Necker Enfants Malad, Assistance Publ Hop Paris, Pediat Hematol Immunol Unit, Paris, France	Hamad Medical Corporation; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite	Ehlayel, M (corresponding author), Hamad Med Corp, Dept Pediat, Sect Allergy Immunol, Doha, Qatar.	jean-laurent.casanova@inserm.fr	Casanova, Jean-Laurent/I-3418-2017	Casanova, Jean-Laurent/0000-0002-7782-4169	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI067769] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS052528] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NIAID NIH HHS [AI067769] Funding Source: Medline; NINDS NIH HHS [NS052528] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bener A, 2007, MED PRIN PRACT, V16, P262, DOI 10.1159/000102147; Casanova JL, 2007, SCIENCE, V317, P617, DOI 10.1126/science.1142963; Chun HH, 2003, MOL GENET METAB, V80, P437, DOI 10.1016/j.ymgme.2003.09.008; Elzaouk L, 2006, EXP DERMATOL, V15, P865, DOI 10.1111/j.1600-0625.2006.00479.x; Fieschi C, 2003, J EXP MED, V197, P527, DOI 10.1084/jem.20021769; Filipe-Santos O, 2006, SEMIN IMMUNOL, V18, P347, DOI 10.1016/j.smim.2006.07.010; Lavin MF, 2007, BRIT MED BULL, V81-82, P129, DOI 10.1093/bmb/ldm012; NAHAS SA, 2008, IN PRESS CLIN CHEM; Nowak-Wegrzyn A, 2004, J PEDIATR-US, V144, P505, DOI 10.1016/j.jpeds.2003.12.046; Sun X, 2002, J PEDIATR-US, V140, P724, DOI 10.1067/mpd.2002.123879	10	20	20	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2008	122	6					1217	1219		10.1016/j.jaci.2008.07.005	http://dx.doi.org/10.1016/j.jaci.2008.07.005			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	383ZA	18718650				2022-12-18	WOS:000261711800035
J	Ballow, M				Ballow, Mark			Immunoglobulin therapy: Methods of delivery	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Immunoglobulin intravenous; subcutaneous immunoglobulin; antibody replacement therapy; immune deficiency disorders; primary immunodeficiency	INTRAVENOUS IMMUNOGLOBULIN; SUBCUTANEOUS IMMUNOGLOBULIN; REPLACEMENT; DISEASE		SUNY Buffalo, Women & Childrens Hosp Buffalo, Div Clin Immunol & Allergy, Dept Pediat,Sch Med & Biomed Sci, Buffalo, NY 14222 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Women & Children's Hospital of Buffalo	Ballow, M (corresponding author), SUNY Buffalo, Women & Childrens Hosp Buffalo, Div Clin Immunol & Allergy, Dept Pediat,Sch Med & Biomed Sci, Buffalo, NY 14222 USA.	ballow@buffalo.edu			Talecris Biotherapeutics; Nabi Biopharmaceuticals; Bio Products Laboratory	Talecris Biotherapeutics; Nabi Biopharmaceuticals; Bio Products Laboratory	Biotherapeutics; has consulting arrangements with Grifols: has speaking arrangements with Merck and AstraZeneca has received research support from Talecris Biotherapeutics, Nabi Biopharmaceuticals, and Bio Products Laboratory: and has served as an expert witness in primary immune deficiency and drug reaction litigation.	Berger M, 2004, CLIN IMMUNOL, V112, P1, DOI 10.1016/j.clim.2004.02.002; Ochs HD, 2006, J CLIN IMMUNOL, V26, P265, DOI 10.1007/s10875-006-9021-7; Orange JS, 2006, J ALLERGY CLIN IMMUN, V117, pS525, DOI 10.1016/j.jaci.2006.01.015; Quartier P, 1999, J PEDIATR-US, V134, P589, DOI 10.1016/S0022-3476(99)70246-5; ROIFMAN CM, 1987, LANCET, V1, P1075	5	20	20	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2008	122	5					1038	1039		10.1016/j.jaci.2008.08.012	http://dx.doi.org/10.1016/j.jaci.2008.08.012			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	372ZF	18804269				2022-12-18	WOS:000260940100031
J	Leggat, JA; Gibbons, DL; Haque, SFY; Smith, AL; Wells, JW; Choy, K; Lloyd, CM; Hayday, AC; Noble, A				Leggat, Jamie A.; Gibbons, Deena L.; Haque, Syeda F. Y.; Smith, Adrian L.; Wells, James W.; Choy, Katherine; Lloyd, Clare M.; Hayday, Adrian C.; Noble, Alistair			Innate responsiveness of CD8 memory T-cell populations nonspecifically inhibits allergic sensitization	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CD8 T cell; immunologic memory; innate immunity; allergy; T(H)1/T(H)2; dendritic cell; IL-12	INTERFERON-GAMMA PRODUCTION; AIRWAY INFLAMMATION; IFN-GAMMA; IN-VIVO; ASTHMA; RESPONSES; IL-12; MICE; SUPPRESSION; ENVIRONMENT	Background: Infection or stimulation of the innate immune system by nonspecific microbial antigens is thought to educate the immune system to respond appropriately to allergens, preventing allergy. Objective: To determine the immunologic pathways that might explain how infection/microbial exposure inhibits allergic sensitization. Methods: Immunologic studies of non-antigen-specific functions of CD8 memory cells, their maturation in vivo, and their effects in a mouse asthma model, to test the hypothesis that CD8 memory is shaped by innate immunity in a way that can inhibit allergic disease. Results: We found that CD8 memory T-cell (CD8 Tm) populations bridge innate and adaptive immunity by responding to either antigen or cytokines alone. CD8 Tm populations partially subvert the clonal selection process by activating their neighbors through induction of dendritic cell IL-12. Stimulation of innate or acquired immunity in the lung or gut causes expansion/maturation of CD8 Tm populations, which provide an early source of cytokines, enhance Till immunity, and inhibit allergic sensitization and airway inflammation/hyperresponsiveness in a non-antigen-specific fashion. Conclusion: CD8 T-cell-mediated immune memory is long-lived and can retain its capacity for rapid cytokine release in a nonantigen-specific fashion. This novel type of memory enhances T(H)1 over T(H)2 immunity and prevents allergic sensitization after exposure to environmental antigens or infection. (J Allergy Clin Immunol 2008;122:1014-21.)	[Noble, Alistair] Kings Coll London, Dept Asthma Allergy & Resp Sci, MRC, London SE1 9RT, England; [Gibbons, Deena L.; Haque, Syeda F. Y.; Hayday, Adrian C.] Kings Coll London, Peter Gorer Dept Immunobiol, London SE1 9RT, England; [Smith, Adrian L.] Inst Anim Hlth, Enter Immunol Grp, Compton, England; [Choy, Katherine; Lloyd, Clare M.] Univ London Imperial Coll Sci Technol & Med, MRC, London, England; [Choy, Katherine; Lloyd, Clare M.] Univ London Imperial Coll Sci Technol & Med, Asthma UK Ctr Allerg Mech Asthma, London, England; [Leggat, Jamie A.; Wells, James W.; Noble, Alistair] Kings Coll London, Asthma UK Ctr Allerg Mech Asthma, London SE1 9RT, England	University of London; King's College London; University of London; King's College London; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute; Imperial College London; Imperial College London; University of London; King's College London; University of London; King's College London	Noble, A (corresponding author), Kings Coll London, Dept Asthma Allergy & Resp Sci, MRC, Guys Hosp Campus, London SE1 9RT, England.	alistair.noble@kcl.ac.uk	Noble, Alistair/E-9473-2010; Wells, James W./C-7480-2011	Wells, James W./0000-0002-9618-6940; Gibbons, Deena/0000-0002-7953-3576; HAYDAY, ADRIAN/0000-0002-9495-5793; Lloyd, Clare/0000-0001-8977-6726; Smith, Adrian/0000-0002-7657-6191	Medical Research Council; Asthma UK; Wellcome Trust [057704]; National Institute of Allergy and Infectious Diseases; Biotechnology & Biological Sciences Research Council; Department for Environment, Food and Rural Affairs; Biotechnology and Biological Sciences Research Council [BBS/E/I/00001015, BBS/E/I/00001048] Funding Source: researchfish; Medical Research Council [G0600698B, G0400503B, G0601387] Funding Source: researchfish; MRC [G0601387] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Asthma UK; Wellcome Trust(Wellcome Trust); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Biotechnology & Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Department for Environment, Food and Rural Affairs(Department for Environment, Food & Rural Affairs (DEFRA)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by the Medical Research Council and Asthma UK. C.M.L. is supported by Wellcome Trust Senior Fellowship 057704.; Disclosure of potential conflict of interest: A. Noble has received research support from Asthma UK Charity. 1). L. Gibbons has received research support from the National Institute of Allergy and Infectious Diseases. A. L. Smith has received research support from the Biotechnology & Biological Sciences Research Council and the Department for Environment, Food and Rural Affairs. The rest of the authors have declared that they have no conflict of interest.	Afkarian M, 2002, NAT IMMUNOL, V3, P549, DOI 10.1038/ni794; Constant SL, 2000, EUR J IMMUNOL, V30, P840, DOI 10.1002/1521-4141(200003)30:3<840::AID-IMMU840>3.0.CO;2-L; DIAZSANCHEZ D, 1993, IMMUNOLOGY, V78, P226; Gelman AE, 2004, J IMMUNOL, V172, P6065, DOI 10.4049/jimmunol.172.10.6065; Habu Y, 2007, CLIN EXP MED, V7, P30, DOI 10.1007/s10238-007-0122-2; Hogan RJ, 2002, J IMMUNOL, V169, P4976, DOI 10.4049/jimmunol.169.9.4976; Homann D, 2001, NAT MED, V7, P913, DOI 10.1038/90950; Ishimitsu R, 2001, J IMMUNOL, V166, P1991, DOI 10.4049/jimmunol.166.3.1991; Kambayashi T, 2003, J IMMUNOL, V170, P2399, DOI 10.4049/jimmunol.170.5.2399; Karwot R, 2008, J ALLERGY CLIN IMMUN, V121, P992, DOI 10.1016/j.jaci.2007.12.1172; Kearley J, 2005, J EXP MED, V202, P1539, DOI 10.1084/jem.20051166; Kieper WC, 2001, J IMMUNOL, V166, P5515, DOI 10.4049/jimmunol.166.9.5515; Kraan TCTMV, 1997, J IMMUNOL, V158, P5560; Lertmemongkolchai G, 2001, J IMMUNOL, V166, P1097, DOI 10.4049/jimmunol.166.2.1097; Mailliard RB, 2002, J EXP MED, V195, P473, DOI 10.1084/jem.20011662; Marsland BJ, 2004, P NATL ACAD SCI USA, V101, P6116, DOI 10.1073/pnas.0401582101; Murali-Krishna K, 1999, SCIENCE, V286, P1377, DOI 10.1126/science.286.5443.1377; Noble A, 2003, IMMUNOLOGY, V109, P476, DOI 10.1046/j.1365-2567.2003.01687.x; Smit JJ, 2007, AM J PATHOL, V171, P1944, DOI 10.2353/ajpath.2007.070578; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Suntharalingam G, 2006, NEW ENGL J MED, V355, P1018, DOI 10.1056/NEJMoa063842; THORPE SC, 1988, J ALLERGY CLIN IMMUN, V82, P62, DOI 10.1016/0091-6749(88)90052-8; Tough DF, 2001, J IMMUNOL, V166, P6007, DOI 10.4049/jimmunol.166.10.6007; Upham JW, 2005, CURR OPIN ALLERGY CL, V5, P167, DOI 10.1097/01.all.0000162310.79555.ed; van Rijt LS, 2004, J IMMUNOL METHODS, V288, P111, DOI 10.1016/j.jim.2004.03.004; Wells JW, 2007, J ALLERGY CLIN IMMUN, V119, P226, DOI 10.1016/j.jaci.2006.09.004; Wilson MS, 2005, J EXP MED, V202, P1199, DOI 10.1084/jem.20042572; Yang JF, 1999, EUR J IMMUNOL, V29, P548, DOI 10.1002/(SICI)1521-4141(199902)29:02<548::AID-IMMU548>3.0.CO;2-Z	28	20	21	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2008	122	5					1014	1021		10.1016/j.jaci.2008.08.011	http://dx.doi.org/10.1016/j.jaci.2008.08.011			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	372ZF	18804851	Green Accepted			2022-12-18	WOS:000260940100024
J	Holt, PG				Holt, Patrick G.			Prenatal versus postnatal priming of allergen specific immunologic memory: The debate continues	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						allergen	T-CELL RESPONSES; ENVIRONMENTAL ALLERGENS; CHILDHOOD		[Holt, Patrick G.] Univ Western Australia, Fac Med & Dent, Telethon Inst Child Hlth Res, Div Cell Biol, Perth, WA 6872, Australia; [Holt, Patrick G.] Univ Western Australia, Fac Med & Dent, Ctr Child Hlth Res, Perth, WA 6872, Australia	Telethon Kids Institute; University of Western Australia; University of Western Australia	Holt, PG (corresponding author), Univ Western Australia, Fac Med & Dent, Telethon Inst Child Hlth Res, Div Cell Biol, POB 855, Perth, WA 6872, Australia.	khaas@ichr.uwa.edu.au	Holt, Patrick G/H-1548-2011	Holt, Patrick G/0000-0003-1193-0935				CARINI C, 1987, CLIN ALLERGY, V17, P485, DOI 10.1111/j.1365-2222.1987.tb02044.x; CASALI P, 1989, IMMUNOL TODAY, V10, P364, DOI 10.1016/0167-5699(89)90268-5; Hassan J, 2001, J IMMUNOL, V167, P1970, DOI 10.4049/jimmunol.167.4.1970; HATTEVIG G, 1987, CLIN ALLERGY, V17, P571, DOI 10.1111/j.1365-2222.1987.tb02053.x; Holt PG, 2000, THORAX, V55, P700, DOI 10.1136/thorax.55.8.700; Malhotra I, 2006, J INFECT DIS, V193, P1005, DOI 10.1086/500472; MAURER D, 1995, J IMMUNOL, V154, P6285; Ownby DR, 1996, PEDIATR ALLERGY IMMU, V7, P125, DOI 10.1111/j.1399-3038.1996.tb00119.x; Pfefferle PI, 2008, J ALLERGY CLIN IMMUN, V122, P711, DOI 10.1016/j.jaci.2008.06.035; Prescott SL, 1998, J IMMUNOL, V160, P4730; ROSENAU MJ, 1906, HYG LAB B, V29, P73; Rowe J, 2007, J ALLERGY CLIN IMMUN, V119, P1164, DOI 10.1016/j.jaci.2007.02.016; Szepfalusi Z, 2000, PEDIATR RES, V48, P404, DOI 10.1203/00006450-200009000-00024; Thornton CA, 2004, J IMMUNOL, V173, P3084, DOI 10.4049/jimmunol.173.5.3084	14	20	22	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2008	122	4					717	718		10.1016/j.jaci.2008.08.019	http://dx.doi.org/10.1016/j.jaci.2008.08.019			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	359LU	19014763				2022-12-18	WOS:000259989000013
J	Chinen, J; Shearer, WT				Chinen, Javier; Shearer, William T.			Secondary immunodeficiencies, including HIV infection	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						secondary immunodeficiency; AIDS; immunosuppression; lymphopenia	CELL; PROTEINS	The immune system can be adversely affected by a variety of extrinsic factors, including immunosuppressive drugs, exposure to harsh environmental conditions, hereditary disorders other than primary immunodeficiencies, and acquired metabolic disorders such as diabetic mellitus, with all of these resulting in conditions known as secondary immunodeficiencies. Perhaps the most well known secondary immunodeficiency is caused by HIV infection; however, the most prevalent cause of immunodeficiency worldwide is severe malnutrition, which affects as much as 50% of the population in some impoverished communities. The abnormalities of the immune system induced by secondary immunodeficiencies affect both the innate and the adaptive immunity, may be subtle, and are usually heterogeneous in their clinical manifestations. Treatment of the primary condition often results in the improvement of the compromised immune components of the disease complex. This article updates the concepts of some of the major categories of conditions that can potentially suppress the immune response, including HIV disease, to provide a conceptual frame to assess patients with suspected secondary deficiencies of the immune system.	[Chinen, Javier; Shearer, William T.] Texas Childrens Hosp, Baylor Coll Med, Dept Pediat, Allergy & Immunol Sect, Houston, TX 77030 USA	Baylor College of Medicine	Chinen, J (corresponding author), Texas Childrens Hosp, Baylor Coll Med, Dept Pediat, Allergy & Immunol Sect, 1102 Bates St Houston, Houston, TX 77030 USA.	jxchinen@texaschildrenshospital.org		Shearer, William/0000-0002-2483-2130	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U01HD041983] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072705] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027551, U01AI069441, P30AI036211] Funding Source: NIH RePORTER; NCRR NIH HHS [RR0188] Funding Source: Medline; NHLBI NIH HHS [HL72705] Funding Source: Medline; NIAID NIH HHS [AI27551, AI36211, AI69441] Funding Source: Medline; NICHD NIH HHS [HD79533, HD78522, HD41983] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bonilla FA, 2006, J ALLERGY CLIN IMMUN, V117, pS435, DOI 10.1016/j.jaci.2005.09.051; Brenchley JM, 2004, J EXP MED, V200, P749, DOI 10.1084/jem.20040874; *CDCP, 2005, HIV AIDS SURV REP, V18; Cohen J, 2007, SCIENCE, V315, P1357, DOI 10.1126/science.315.5817.1357; Cunningham-Rundles S, 2005, J ALLERGY CLIN IMMUN, V115, P1119, DOI 10.1016/j.jaci.2005.04.036; *DEP HHS, 2006, GUID US ANT AG HIV I; Douglas SD, 2005, J PEDIATR-US, V147, P723, DOI 10.1016/j.jpeds.2005.09.002; Espert L, 2006, J CLIN INVEST, V116, P2161, DOI 10.1172/JCI26185; Goodenow MM, 2006, J LEUKOCYTE BIOL, V80, P965, DOI 10.1189/jlb.0306148; Harris RS, 2004, NAT REV IMMUNOL, V4, P868, DOI 10.1038/nri1489; Lederman MM, 2006, NAT REV IMMUNOL, V6, P371, DOI 10.1038/nri1848; McMichael AJ, 2006, ANNU REV IMMUNOL, V24, P227, DOI 10.1146/annurev.immunol.24.021605.090605; Newell ML, 2007, LANCET, V369, P617, DOI 10.1016/S0140-6736(07)60288-8; Norris PJ, 2006, AIDS RES HUM RETROV, V22, P757, DOI 10.1089/aid.2006.22.757; Paul ME, 2005, J ALLERGY CLIN IMMUN, V115, P848, DOI 10.1016/j.jaci.2004.11.054; Pawelec G, 2006, ANN NY ACAD SCI, V1067, P56, DOI 10.1196/annals.1354.009; Rich R, 2001, CLIN IMMUNOL, DOI DOI 10.1016/C2015-0-00344-6; Rodriguez B, 2006, JAMA-J AM MED ASSOC, V296, P1498, DOI 10.1001/jama.296.12.1498; Shearer WT, 2005, J ALLERGY CLIN IMMUN, V115, P1297, DOI 10.1016/j.jaci.2005.03.003; Sleasman J. W., 2003, J ALLERGY CLIN IMMUN, V111, P582; STIEHM E, 2004, IMMUNOLOGIC DISORDER; Stoll M, 2004, AUTOIMMUN REV, V3, P243, DOI 10.1016/j.autrev.2003.09.005; Tan HP, 2006, DRUGS, V66, P1535, DOI 10.2165/00003495-200666120-00001; *UNAIDS, 2006, AIDS PAND UPD SPEC R; *WORK GROUP ANT TH, 2007, GUID US ANT AG PED H	25	20	22	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2008	121	2		2			S388	S392		10.1016/j.jaci.2007.06.003	http://dx.doi.org/10.1016/j.jaci.2007.06.003			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	266IB	18241688	Green Accepted			2022-12-18	WOS:000253426600007
J	Jakob, T; Kollisch, GV; Howaldt, M; Bewersdorff, M; Rathkolb, B; Muller, ML; Sandholzer, N; Nitschke, L; Schiennann, M; Mernpel, M; Ollert, M; Neubauer, A; Soewarto, DA; Kremmer, E; Ring, J; Behrendt, H; Flaswinkel, H				Jakob, Thilo; Koellisch, Gabrielle V.; Howaldt, Maike; Bewersdorff, Mayte; Rathkolb, Birgit; Mueller, Marcel L.; Sandholzer, Nadja; Nitschke, Lars; Schiennann, Matthias; Mernpel, Martin; Ollert, Markus; Neubauer, Antonie; Soewarto, Dian A.; Kremmer, Elisabeth; Ring, Johannes; Behrendt, Heidrun; Flaswinkel, Heinrich			Novel mouse mutants with primary cellular immunodeficiencies generated by genome-wide mutagenesis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						N-ethyl-N-nitrosourea mutagenesis; immunodeficiency; Zap70; IgE; rodents	TYROSINE KINASE; ZAP-70; DISEASES; MICE; SELECTION; MUTATION; UPDATE	Background: Primary cellular immunodeficiencies are a group of genetic disorders in which 1 or more components of the cellular immune system are lacking or dysfunctional. Objective: We sought to identify novel mouse mutants that display primary cellular immunodeficiencies. Methods: Genome-wide N-ethyl-N-nitrosourea mutagenesis was performed in mice, followed by a phenotype screen of immunologic blood parameters. Results: We identified novel mouse mutants with isolated B-cell deficiency, combined block in early B- and T-cell development, combined T-cell and natural killer cell reduction, and 3 different forms of T-cell deficiencies. One of the mutants, designated Delta T3, displayed a combined phenotype of increased IgE, absence of peripheral T cells, and block in late thymocyte differentiation. In addition, Delta T3 mice were unable to mount specific Immoral immune responses. Chromosomal mapping and sequencing of candidate genes revealed a novel point mutation in the kinase domain of the T-cell receptor zeta chain-associated protein kinase (Zap70). In contrast to Zap70-deficient mice, Delta T3 mutants displayed normal Zap70 mRNA and residual Zap70 protein levels. Complementation studies with Zap70-deficient mice confirmed that the point mutation found in Zap70 was causative for the Delta T3 phenotype, including increased IgE plasma levels, a phenotype that has not been associated with altered Zap70 function in the past. Conclusion: Random genome-wide mutagenesis combined with a phenotype screen can be used to generate novel mouse mutants with primary cellular immunodeficiencies.	[Jakob, Thilo; Mueller, Marcel L.] Univ Med Ctr Freiburg, Dept Dermatol, Allergy Res Grp, D-79104 Freiburg, Germany; [Howaldt, Maike; Rathkolb, Birgit; Sandholzer, Nadja; Flaswinkel, Heinrich] Ludwig Maximilians Univ Munchen, Gene Ctr, Inst Mol Anim Breeding, D-81377 Munich, Germany; [Koellisch, Gabrielle V.; Bewersdorff, Mayte; Mernpel, Martin; Behrendt, Heidrun] Tech Univ Munich, ZAUM Ctr Allergy & Environm, GSF TUM, Div Environm Dermatol & Allergy, Munich, Germany; [Nitschke, Lars] Univ Erlangen Nurnberg, Dept Genet, D-8520 Erlangen, Germany; [Schiennann, Matthias] Tech Univ Munich, Inst Med Microbiol Immunol & Hygiene, Munich, Germany; [Schiennann, Matthias] Tech Univ Munich, Munich, Germany; [Schiennann, Matthias] GSF Natl Res Ctr Environm & Hlth, Clin Cooperat Grp Antigen Specif Immunotherapy, Neuherberg, Germany; [Ollert, Markus; Ring, Johannes] Tech Univ Munich, Dept Dermatol & Allergy Biederstein, Clin Res div Mol & Clin Allergolotoxicol, Munich, Germany; [Neubauer, Antonie] Univ Munich, Inst Med Microbiol Infect & Epidem Dis, Munich, Germany; [Soewarto, Dian A.] GSF Natl Res Ctr Envrionm & Hlth, Inst Experimental Genet, Neuherberg, Germany; [Kremmer, Elisabeth] GSF Natl Res Ctr Environm & Hlth, Inst Mol Immunol, Munich, Germany	University of Freiburg; University of Munich; Technical University of Munich; University of Erlangen Nuremberg; Technical University of Munich; Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich	Jakob, T (corresponding author), Univ Med Ctr Freiburg, Dept Dermatol, Allergy Res Grp, Hauptstr 7, D-79104 Freiburg, Germany.	thilo.jakob@uniklinik-freiburg.de	Ring, Johannes/GLN-4341-2022; Jakob, Thilo/J-1621-2012; Rathkolb, Birgit/F-7041-2013	Ring, Johannes/0000-0001-8236-3152; Ollert, Markus W./0000-0002-8055-0103				Alessandrini F, 2006, J ALLERGY CLIN IMMUN, V117, P824, DOI 10.1016/j.jaci.2005.11.046; Alessandrini F, 2001, INT ARCH ALLERGY IMM, V124, P25, DOI 10.1159/000053659; ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; Bonilla FA, 2006, J ALLERGY CLIN IMMUN, V117, pS435, DOI 10.1016/j.jaci.2005.09.051; Buckley RH, 2002, J ALLERGY CLIN IMMUN, V109, P747, DOI 10.1067/mai.2002.123617; Buckley RH, 2004, J CLIN INVEST, V114, P1409, DOI 10.1172/JCI200423571; Casanova JL, 2005, J ALLERGY CLIN IMMUN, V116, P426, DOI 10.1016/j.jaci.2005.03.053; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; de Angelis MH, 2000, NAT GENET, V25, P444, DOI 10.1038/78146; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; Eppig JT, 2005, NUCLEIC ACIDS RES, V33, pD471, DOI 10.1093/nar/gki113; Flaswinkel H, 2000, MAMM GENOME, V11, P526, DOI 10.1007/s003350010100; HITOTSUMACHI S, 1985, P NATL ACAD SCI USA, V82, P6619, DOI 10.1073/pnas.82.19.6619; HIVROZ C, 1994, CURR BIOL, V4, P731, DOI 10.1016/S0960-9822(00)00162-7; Hivroz C, 2005, M S-MED SCI, V21, P150, DOI 10.1051/medsci/2005212150; Kadlecek TA, 1998, J IMMUNOL, V161, P4688; NEGISHI I, 1995, NATURE, V376, P435, DOI 10.1038/376435a0; Nicklas W, 2002, LAB ANIM-UK, V36, P20, DOI 10.1258/0023677021911740; Notarangelo L, 2006, J ALLERGY CLIN IMMUN, V117, P883, DOI 10.1016/j.jaci.2005.12.1347; Rosenzweig SD, 2004, J ALLERGY CLIN IMMUN, V113, P620, DOI 10.1016/j.jaci.2004.02.001; RUSSELL WL, 1979, P NATL ACAD SCI USA, V76, P5818, DOI 10.1073/pnas.76.11.5818; Sakaguchi N, 2003, NATURE, V426, P454, DOI 10.1038/nature02119; Schweighoffer E, 2003, IMMUNITY, V18, P523, DOI 10.1016/S1074-7613(03)00082-7; Wiest DL, 1997, IMMUNITY, V6, P663, DOI 10.1016/S1074-7613(00)80442-2	25	20	21	1	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2008	121	1					179	184		10.1016/j.jaci.2007.07.018	http://dx.doi.org/10.1016/j.jaci.2007.07.018			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	251KM	17767948				2022-12-18	WOS:000252372000027
J	Wagner, AH; Wittjen, I; Stojanovic, T; Middel, P; Meingassner, JG; Hecker, M				Wagner, Andreas H.; Wittjen, Inka; Stojanovic, Tomislav; Middel, Peter; Meingassner, Josef G.; Hecker, Markus			Signal transducer and activator of transcription 1 decoy oligodeoxynucleotide suppression of contact hypersensitivity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						contact hypersensitivity; allergic contact dermatitis; signal transducer and activator of transcription 1; decoy oligodeoxynucleotide; gene expression	TOPICAL CALCINEURIN INHIBITORS; ATOPIC-DERMATITIS; GENE-EXPRESSION; SKIN DISEASES; T-CELLS; DECOY; KERATINOCYTES; ELICITATION; PSORIASIS; RESPONSES	Background: Cytokines play a pivotal role in allergy development through activating signaling mechanisms, such as the Janus kinase/signal transducer and activator of transcription (STAT) pathway, which controls the expression of numerous proinflammatory genes. Objective: In comparison with 2 different corticosteroids and a calcineurin inhibitor, the efficacy of a STAT1 decoy oligodeoxynucleotide (dODN)-containing ointment on hapten-induced contact hypersensitivity was examined in 3 different animal models. Methods: After sensitization, the test compounds were administered before hapten challenge, after hapten challenge, or both to different sites of the animal skin. Subsequent erythema and edema formation was scored macroscopically, microscopically, or by a shift in ear weight. Biopsy specimens were taken and processed for histopathology, immunohistochemistry, and real-time PCR analyses. Results: Treatment with the STAT1 dODN but not the corresponding control ODN markedly improved the clinical signs of inflammation in all 3 animal models in a dose-related manner. In guinea pig skin this was accompanied by a distinct decrease in leukocyte infiltration into the dermis after 24 hours. In addition, expression of CD40, IFN-gamma, IL-1 beta, IL-8, IL-12, and TNF-alpha was strongly attenuated. The dODN was equally effective in the domestic pig model when administered therapeutically, and its preventive effect in the mouse model lasted for more than 48 hours. Conclusions: Altogether, treatment with the dODN proved to be at least as effective as treatment with the reference compounds.	[Wagner, Andreas H.; Wittjen, Inka; Hecker, Markus] Univ Heidelberg Hosp, Inst Physiol & Pathophysiol, Div Cardiovasc Physiol, D-69120 Heidelberg, Germany; [Stojanovic, Tomislav] Univ Gottingen, Thoracic & Cardiovasc Surg, Vienna, Austria; [Middel, Peter] Univ Gottingen, Pathol, Vienna, Austria; [Meingassner, Josef G.] Novartis Inst Biomed Res, Vienna, Austria	Ruprecht Karls University Heidelberg; Novartis	Hecker, M (corresponding author), Univ Heidelberg Hosp, Inst Physiol & Pathophysiol, Div Cardiovasc Physiol, Im Neuenheimer Feld 326, D-69120 Heidelberg, Germany.	hecker@physiologie.uni-hd.de						Alomar A, 2004, BRIT J DERMATOL, V151, P3, DOI 10.1111/j.1365-2133.2004.06269.x; Beissert S, 2006, CLIN EXP RHEUMATOL, V24, pS1; Breuer K, 2006, CHEM IMMUNOL ALLERGY, V91, P76; Crameri R, 2006, CURR OPIN IMMUNOL, V18, P761, DOI 10.1016/j.coi.2006.09.001; Dajee M, 2006, J INVEST DERMATOL, V126, P1792, DOI 10.1038/sj.jid.5700307; Dearman RJ, 2000, IMMUNOLOGY, V101, P442, DOI 10.1046/j.1365-2567.2000.00126.x; Denfeld RW, 1996, EUR J IMMUNOL, V26, P2329, DOI 10.1002/eji.1830261009; Dilulio NA, 1999, EUR J IMMUNOL, V29, P3485, DOI 10.1002/(SICI)1521-4141(199911)29:11<3485::AID-IMMU3485>3.0.CO;2-B; Dzau VJ, 2002, CIRC RES, V90, P1234, DOI 10.1161/01.RES.0000025209.24283.73; Esche C, 2004, CURR ALLERGY ASTHM R, V4, P276, DOI 10.1007/s11882-004-0071-8; Fiset PO, 2006, J ALLERGY CLIN IMMUN, V118, P287, DOI 10.1016/j.jaci.2006.03.046; FROSCH PJ, 1979, J AM ACAD DERMATOL, V1, P35, DOI 10.1016/S0190-9622(79)70001-6; Gaspari AA, 1996, EUR J IMMUNOL, V26, P1371, DOI 10.1002/eji.1830260629; Hartmann B, 2006, INFLAMM RES, V55, P322, DOI 10.1007/s00011-006-5141-z; Holschermann H, 2006, CARDIOVASC RES, V71, P527, DOI 10.1016/j.cardiores.2006.05.021; Howie SEM, 1996, J INVEST DERMATOL, V106, P1218, DOI 10.1111/1523-1747.ep12348507; Huckel M, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1869; Ishizaki K, 2007, J IMMUNOL, V178, P605, DOI 10.4049/jimmunol.178.1.605; Isomura I, 2006, J INVEST DERMATOL, V126, P97, DOI 10.1038/sj.jid.5700027; Lauth M, 2000, J MOL MED-JMM, V78, P441, DOI 10.1007/s001090000129; Levin C, 2000, CONTACT DERMATITIS, V43, P317, DOI 10.1034/j.1600-0536.2000.043006317.x; Lowes MA, 2007, NATURE, V445, P866, DOI 10.1038/nature05663; Meingassner JG, 1997, BRIT J DERMATOL, V137, P568, DOI 10.1111/j.1365-2133.1997.tb03788.x; Nakamura H, 2002, GENE THER, V9, P1221, DOI 10.1038/sj.gt.3301724; Nasr IS, 2000, CLIN EXP DERMATOL, V25, P250, DOI 10.1046/j.1365-2230.2000.00628.x; Natsuaki M, 2000, CONTACT DERMATITIS, V43, P267, DOI 10.1034/j.1600-0536.2000.043005267.x; Ohtani M, 2004, CYTOKINE, V25, P246, DOI 10.1016/j.cyto.2003.11.008; Petersen TK, 2006, BASIC CLIN PHARMACOL, V99, P104, DOI 10.1111/j.1742-7843.2006.pto_298.x; Quarcoo D, 2004, J ALLERGY CLIN IMMUN, V114, P288, DOI 10.1016/j.jaci.2004.03.055; Roumestan C, 2003, CLIN EXP ALLERGY, V33, P895, DOI 10.1046/j.1365-2222.2003.01709.x; Saint-Mezard P, 2004, EUR J DERMATOL, V14, P131; Sano S, 2005, NAT MED, V11, P43, DOI 10.1038/nm1162; Stuetz A, 2006, INT ARCH ALLERGY IMM, V141, P199, DOI 10.1159/000095289; Sumi K, 2004, GENE THER, V11, P1763, DOI 10.1038/sj.gt.3302345; Takeshita K, 2004, INT IMMUNOL, V16, P685, DOI 10.1093/intimm/dxh073; Tsuji RF, 2000, J IMMUNOL, V165, P1588, DOI 10.4049/jimmunol.165.3.1588; Vana G, 2000, VET PATHOL, V37, P565, DOI 10.1354/vp.37-6-565; Wagner AH, 2002, BLOOD, V99, P520, DOI 10.1182/blood.V99.2.520	38	20	23	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2008	121	1					158	165		10.1016/j.jaci.2007.09.015	http://dx.doi.org/10.1016/j.jaci.2007.09.015			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	251KM	17981315				2022-12-18	WOS:000252372000023
J	Aspalter, RM; Eibl, MM; Wolf, HM				Aspalter, Rosa M.; Eibl, Martha M.; Wolf, Hermann M.			Defective T-cell activation caused by impairment of the TNF receptor 2 costimulatory pathway in common variable immunodeficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CVID; primary immunodeficiency; T-cell receptor; TNF-alpha; TNF-RII; TRAFI; calcium flux; store operated calcium channels; PKC-theta	KINASE-C-THETA; NF-KAPPA-B; NECROSIS-FACTOR RECEPTOR; IMMUNE-DEFICIENCY; CD69 EXPRESSION; TNF-RII; LYMPHOCYTES; PROTEIN; TCR; RESPONSES	Background: Patients with common variable immunodeficiency have defective T-cell activation after stimulation via T-cell receptor (TCR)/CD28 or by recall antigens. Objective: In the current study, we investigated whether TNF-receptor 2 (RII) costimulation, which is important for sufficient TCR/CD28 stimulation, was significantly impaired in common variable immunodeficiency (CVID). Methods: We studied T-cell activation events such as CD69 induction, calcium flux through store operated calcium channels, protein kinase GO translocation, and costimulation via TNF-RII compared with costimulation via CD28. Results: By measuring TNF receptor-associated factor I expression, which is induced by TCR alone and can be upregulated by either CD28 or TNF-RII costimulation, we show that costimulation via CD28 is intact, whereas costimulation via TNF-RH in these patients is impaired. The ras-activation pathway as tested by CD69 induction, calcium flux through store operated calcium channels, and protein kinase GO translocation were comparable in CVID and control T cells. Conclusion: Taken together, these data indicate that the primary TCR signal as well as the signal derived from CD28 are normal but that TNF-RII-supported TCR costimulation is defective, most likely leading to impairment of an important amplification loop, such as TNF-RII augmented nuclear factor-kappa B activation. Clinical implications: The finding of defective TNF-RII cosignaling in patients with CVID may help to define the activation pathway affected, thus potentially leading to a characterization of the molecular defect and molecular diagnosis in at least some of these patients.	Immunol Outpatient Clini, A-1090 Vienna, Austria		Wolf, HM (corresponding author), Immunol Outpatient Clini, Schwarzspanierstr 15-9-1, A-1090 Vienna, Austria.	hermann.wolf@itk.at		Aspalter, Rosa/0000-0002-0871-1929				Arron JR, 2002, J EXP MED, V196, P923, DOI 10.1084/jem.20020774; Aspalter RM, 2000, CLIN EXP IMMUNOL, V121, P506, DOI 10.1046/j.1365-2249.2000.01317.x; Aspalter RM, 2005, CELL IMMUNOL, V237, P55, DOI 10.1016/j.cellimm.2005.10.001; Aspalter RM, 2003, J LEUKOCYTE BIOL, V74, P572, DOI 10.1189/jlb.0303112; BaierBitterlich G, 1996, MOL CELL BIOL, V16, P1842; Banerjee D, 2005, IMMUNITY, V23, P445, DOI 10.1016/j.immuni.2005.09.012; Bayry J, 2004, BLOOD, V104, P2441, DOI 10.1182/blood-2004-04-1325; BEYAERT R, 1998, CYTOKINES; Boncristiano M, 2000, EUR J IMMUNOL, V30, P2632, DOI 10.1002/1521-4141(200009)30:9<2632::AID-IMMU2632>3.0.CO;2-C; Borovsky Z, 2002, J BIOL CHEM, V277, P21529, DOI 10.1074/jbc.M201613200; Castigli E, 2005, NAT GENET, V37, P829, DOI 10.1038/ng1601; Church LD, 2005, FEBS LETT, V579, P1539, DOI 10.1016/j.febslet.2005.01.051; Cope AP, 1997, J EXP MED, V185, P1573, DOI 10.1084/jem.185.9.1573; Coudronniere N, 2000, P NATL ACAD SCI USA, V97, P3394, DOI 10.1073/pnas.060028097; Cunningham-Rundles C, 2006, J IMMUNOL, V176, P1978, DOI 10.4049/jimmunol.176.3.1978; Cunningham-Rundles C, 2005, CLIN IMMUNOL, V115, P147, DOI 10.1016/j.clim.2004.12.007; DAMBROSIO D, 1994, EUR J IMMUNOL, V24, P616, DOI 10.1002/eji.1830240319; Grafton G, 2001, IMMUNOLOGY, V104, P119, DOI 10.1046/j.0019-2805.2001.01321.x; Grimbacher B, 2003, NAT IMMUNOL, V4, P261, DOI 10.1038/ni902; Hostager BS, 2002, J IMMUNOL, V168, P3318, DOI 10.4049/jimmunol.168.7.3318; IZQUIERDO M, 1993, J EXP MED, V178, P1199, DOI 10.1084/jem.178.4.1199; Kristufek D, 2007, MOL IMMUNOL, V44, P1639, DOI 10.1016/j.molimm.2006.08.003; Lin X, 2000, MOL CELL BIOL, V20, P2933, DOI 10.1128/MCB.20.8.2933-2940.2000; Meller N, 1996, MOL CELL BIOL, V16, P5782; Notarangelo L, 2006, J ALLERGY CLIN IMMUN, V117, P883, DOI 10.1016/j.jaci.2005.12.1347; Ohm-Laursen L, 2005, SCAND J IMMUNOL, V61, P566, DOI 10.1111/j.1365-3083.2005.001603.x; Paccani SR, 2005, BLOOD, V106, P626, DOI 10.1182/blood-2004-05-2051; Paccani SR, 2005, BLOOD, V105, P2042, DOI 10.1182/blood-2004-04-1299; PIMENTELMUINOS FX, 1995, EUR J IMMUNOL, V25, P179, DOI 10.1002/eji.1830250130; RIJKERS GT, 1990, CYTOMETRY, V11, P923, DOI 10.1002/cyto.990110813; RISSO A, 1991, J IMMUNOL, V146, P4105; SALOGA J, 1993, CLIN IMMUNOL IMMUNOP, V67, P232, DOI 10.1006/clin.1993.1070; Salzer U, 2005, NAT GENET, V37, P820, DOI 10.1038/ng1600; Salzer U, 2004, CLIN IMMUNOL, V113, P234, DOI 10.1016/j.clim.2004.07.002; Schwenzer R, 1999, J BIOL CHEM, V274, P19368, DOI 10.1074/jbc.274.27.19368; Scott-Taylor TH, 2004, CLIN EXP IMMUNOL, V138, P484, DOI 10.1111/j.1365-2249.2004.02640.x; Serrano D, 2000, CLIN IMMUNOL, V97, P248, DOI 10.1006/clim.2000.4941; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1993, J IMMUNOL, V151, P4637; TaylorFishwick DA, 1995, EUR J IMMUNOL, V25, P3215, DOI 10.1002/eji.1830251203; Thon V, 1997, CLIN EXP IMMUNOL, V110, P174; Villalba M, 2000, EUR J IMMUNOL, V30, P1587, DOI 10.1002/1521-4141(200006)30:6<1587::AID-IMMU1587>3.0.CO;2-T	42	20	21	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2007	120	5					1193	1200		10.1016/j.jaci.2007.07.004	http://dx.doi.org/10.1016/j.jaci.2007.07.004			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	231TZ	17825894				2022-12-18	WOS:000250973400032
J	Kausar, MA; Vijayan, VK; Bansal, SK; Menon, BK; Vermani, M; Agarwal, MK				Kausar, Mohd A.; Vijayan, Vannan K.; Bansal, Surendra K.; Menon, Bala K.; Vermani, Maansi; Agarwal, Mahendra K.			Mosquitoes as sources of inhalant allergens: Clinicoimmunologic and biochemical studies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							PROTEINS		Univ Delhi, Vallabhbhai Patel Chest Inst, Dept Resp Allergy & Appl Immunol, Delhi 110007, India; Univ Delhi, Vallabhbhai Patel Chest Inst, Dept Resp Med, Delhi 110007, India; Univ Delhi, Vallabhbhai Patel Chest Inst, Dept Biochem, Delhi 110007, India	University of Delhi; University of Delhi; University of Delhi	Kausar, MA (corresponding author), Univ Delhi, Vallabhbhai Patel Chest Inst, Dept Resp Allergy & Appl Immunol, Delhi 110007, India.	agarwalmahendra@rediffmail.com	Vermani, Maansi/ABI-3250-2020; Kausar, Mohd Adnan/AAE-9758-2020; Vermani, Maansi/ABI-2902-2020	Vermani, Maansi/0000-0003-1635-4463; Kausar, Mohd Adnan/0000-0002-8931-9290; 				AGARWAL MK, 1991, ANN ALLERGY, V67, P598; AGARWAL MK, 1981, J ALLERGY CLIN IMMUN, V68, P194, DOI 10.1016/0091-6749(81)90183-4; AGARWAL MK, 2003, TRENDS CLIN BIOCH LA, P314; GLEICH GJ, 1975, J ALLERGY, V2, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larsen JN, 1996, J ALLERGY CLIN IMMUN, V97, P577; Peng ZK, 1997, J ALLERGY CLIN IMMUN, V100, P192, DOI 10.1016/S0091-6749(97)70224-0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	8	20	20	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2007	120	5					1219	1221		10.1016/j.jaci.2007.07.017	http://dx.doi.org/10.1016/j.jaci.2007.07.017			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	231TZ	17716717				2022-12-18	WOS:000250973400037
J	Huss-Marp, J; Kramer, U; Eberlein, B; Pfab, F; Ring, J; Behrendt, H; Gulyas, AF				Huss-Marp, Johannes; Kraemer, Ursula; Eberlein, Bernadette; Pfab, Florian; Ring, Johannes; Behrendt, Heidrun; Gulyas, Akos F.			Reduced exhaled nitric oxide values in children with asthma after inpatient rehabilitation at high altitude	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ALLERGEN AVOIDANCE; MODERATE		ZAUM Ctr Allergy & Environm, GSF TUM, Div Environm Dermatol & Allergy, Munich, Germany; Univ Dusseldorf, IUF, D-4000 Dusseldorf, Germany; Tech Univ Munich, Dept Dermatol & Allergy Biedrstein, D-8000 Munich, Germany; Childrens Hosp Santa Maria, Oberjoch, Germany	Heinrich Heine University Dusseldorf; Leibniz Institut fur Umweltmedizinische Forschung (IUF); Technical University of Munich	Huss-Marp, J (corresponding author), ZAUM Ctr Allergy & Environm, GSF TUM, Div Environm Dermatol & Allergy, Munich, Germany.	huss-marp@lrz.tum.de	Ring, Johannes/GLN-4341-2022	Ring, Johannes/0000-0001-8236-3152				Brown DE, 2006, AM J HUM BIOL, V18, P196, DOI 10.1002/ajhb.20489; *GINA, 2006, GLOB IN ASTHM GUID; Grootendorst DC, 2001, CLIN EXP ALLERGY, V31, P400, DOI 10.1046/j.1365-2222.2001.01022.x; Hahn AG, 2001, COMP BIOCHEM PHYS A, V128, P777, DOI 10.1016/S1095-6433(01)00283-5; Karagiannidis C, 2006, SCAND J IMMUNOL, V63, P304, DOI 10.1111/j.1365-3083.2006.01739.x; Kharitonov SA, 1996, AM J RESP CRIT CARE, V153, P454, DOI 10.1164/ajrccm.153.1.8542158; Le Cras TD, 2001, AM J PHYSIOL-LUNG C, V280, pL575, DOI 10.1152/ajplung.2001.280.4.L575; Petermann Franz, 2004, Pediatric Asthma Allergy & Immunology, V17, P15, DOI 10.1089/088318704322994903; Piacentini GL, 1999, J ALLERGY CLIN IMMUN, V104, P1323, DOI 10.1016/S0091-6749(99)70031-X; Schultze-Werninghaus G, 2006, CHEM IMMUNOL ALLERGY, V91, P16	10	20	20	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2007	120	2					471	472		10.1016/j.jaci.2007.03.039	http://dx.doi.org/10.1016/j.jaci.2007.03.039			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	198VF	17498787				2022-12-18	WOS:000248654900038
J	Palmer, BE; Mack, DG; Martin, AK; Maier, LA; Fontenot, AP				Palmer, Brent E.; Mack, Douglas G.; Martin, Allison K.; Maier, Lisa A.; Fontenot, Andrew P.			CD57 expression correlates with alveolitis severity in subjects with beryllium-induced disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						human; lung; CD4-positive T lymphocytes; beryllium; cytokines; granuloma	CD4(+) T-CELLS; TARGET ORGAN; LYMPHOCYTES; BLOOD; REEXAMINATION; EXPANSION; SUBSETS; VIREMIA; GAMMA	Background: Despite numerous studies in human beings linking surface phenotype of blood T cells with their functional characteristics, little is known about this relationship on antigen-specific CD4(+) T cells residing in a target organ. Objective: The aims of this study were to determine the relationship between CD57 expression, a marker of T-cell senescence, and severity of chronic beryllium disease (CBD) and to determine the phenotypic and functional characteristics that differentiate beryllium-specific CD4(+) T cells in lung and blood. Methods: CD57 expression on beryllium-responsive IFN-gamma-expressing and IL-2-expressing CD4(+) T cells in blood and lung of 17 beryllium-sensitized and 20 CBD subjects was determined. Results: CD57 expression was significantly higher on bronchoalveolar lavage (BAL) than blood CD4(+) T cells in both beryllium-sensitized and CBD subjects. Expression of CD57 on BAL CD4(+) T cells was directly correlated with the lymphocytic alveolitis. In blood and BAL, higher CD57 expression was seen on more differentiated CD4(+) memory T-cell subsets. Although CD57 expression on blood and BAL cells was associated with a reduced proliferative potential, examination of beryllium-specific CD4(+) T cells in blood and lung revealed no difference in CD57 expression on cells that produced IFN-gamma only versus IFN-gamma and IL-2. Conclusion: These data suggest that CD57 expression on CD4(+) T cells is an important phenotypic marker to assess lung inflammation and the functional competence of the CD4(+) T-cell compartment in CBD. Clinical implications: These findings suggest that CD57 is a marker of lung inflammation and potentially, disease severity.	Univ Colorado, Div Clin Immunol B164, Dept Med, Denver, CO 80262 USA; Univ Colorado, Dept Immunol, Denver, CO 80262 USA; Hlth Sci Ctr, Denver, CO USA; Natl Jewish Med & Res Ctr, Dept Med, Denver, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Denver; National Jewish Health	Fontenot, AP (corresponding author), Univ Colorado, Div Clin Immunol B164, Dept Med, 4200 E 9th Ave, Denver, CO 80262 USA.		Maier, Lisa/AAA-4378-2020		NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000051] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062410] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES011810] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR00051] Funding Source: Medline; NHLBI NIH HHS [R01 HL062410, HL62410] Funding Source: Medline; NIEHS NIH HHS [ES011810] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Brenchley JM, 2003, BLOOD, V101, P2711, DOI 10.1182/blood-2002-07-2103; Fontenot AP, 2005, TRENDS IMMUNOL, V26, P543, DOI 10.1016/j.it.2005.08.004; Fontenot AP, 2005, J CLIN INVEST, V115, P2886, DOI 10.1172/JCI24908; Fontenot AP, 2003, J CLIN INVEST, V112, P776, DOI 10.1172/JCI200318317; Fontenot AP, 2002, J CLIN INVEST, V110, P1473, DOI 10.1172/JCI200215846; Imberti L, 1997, BLOOD, V89, P2822, DOI 10.1182/blood.V89.8.2822; Jimenez-Martinez MC, 2004, IMMUNOLOGY, V111, P100, DOI 10.1111/j.1365-2567.2004.01785.x; Kern F, 1999, EUR J IMMUNOL, V29, P2908, DOI 10.1002/(SICI)1521-4141(199909)29:09<2908::AID-IMMU2908>3.0.CO;2-8; LEGAC E, 1992, BLOOD, V79, P1746; Lieberman J, 1999, AIDS, V13, P891, DOI 10.1097/00002030-199905280-00004; Maeda T, 2002, ARTHRITIS RHEUM, V46, P379, DOI 10.1002/art.10133; McNeil AC, 2001, P NATL ACAD SCI USA, V98, P13878, DOI 10.1073/pnas.251539598; MROZ MM, 1991, J ALLERGY CLIN IMMUN, V88, P54, DOI 10.1016/0091-6749(91)90300-D; Newman LS, 1996, ENVIRON HEALTH PERSP, V104, P953, DOI 10.2307/3433017; NEWMAN LS, 1989, AM REV RESPIR DIS, V139, P1479, DOI 10.1164/ajrccm/139.6.1479; Palmer BE, 2005, J IMMUNOL, V175, P8415, DOI 10.4049/jimmunol.175.12.8415; Palmer BE, 2004, J IMMUNOL, V172, P3337, DOI 10.4049/jimmunol.172.5.3337; Papagno L, 2004, PLOS BIOL, V2, P173, DOI 10.1371/journal.pbio.0020020; ROSSMAN MD, 1988, ANN INTERN MED, V108, P687, DOI 10.7326/0003-4819-108-5-687; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Sawyer RT, 2005, J OCCUP ENVIRON MED, V47, P1218, DOI 10.1097/01.jom.0000184884.85325.36; Tinkle SS, 1997, J IMMUNOL, V158, P518; Wahlstrom J, 1999, THORAX, V54, P339, DOI 10.1136/thx.54.4.339; Watanabe H, 2003, PARASITOL INT, V52, P61, DOI 10.1016/S1383-5769(02)00085-5; WILLIAMS WJ, 1986, J CLIN PATHOL, V39, P900, DOI 10.1136/jcp.39.8.900	25	20	21	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2007	120	1					184	191		10.1016/j.jaci.2007.03.009	http://dx.doi.org/10.1016/j.jaci.2007.03.009			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	190NS	17416406				2022-12-18	WOS:000248066400027
J	Sicherer, SH; Leung, DYM				Sicherer, Scott H.; Leung, Donald Y. M.			Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						dermatology; skin disease; urticaria; atopic dermatitis; anaphylaxis; allergy; hypersensitivity disorders; food; drug; insect venom	TOLL-LIKE RECEPTOR-2; ATOPIC-DERMATITIS; T-CELLS; CROSS-REACTIVITY; BIRCH POLLEN; IN-VITRO; CHILDREN; SENSITIZATION; EXPRESSION; EPINEPHRINE	This review highlights some of the research advances in anaphylaxis and hypersensitivity reactions to foods, drugs, and insects and in allergic skin disease that were reported primarily in the Journal in 2006. Advances in diagnosis include identification of food proteins to which IgE binding is associated with severe reactions; elucidation of diagnostic relationships of skin prick test wheal size with outcomes of egg, tree nut, and sesame allergy; evaluation of the diagnostic utility of atopy patch testing for food; and the observation that yellow jacket sting outcomes are influenced by species. Mechanistic observations include the following: heating of birch pollen-related foods disrupts IgE binding but not T-cell epitopes; a simple imbalance of T(H)1/T(H)2 response does not explain variations in clinical expression of peanut allergy; and elucidation of the role of dendritic cells in drug hypersensitivity. With regard to treatment, a rapidly disintegrating epinephrine tablet showed promise for sublingual treatment of anaphylaxis, RNA interference techniques showed promise in creating lower-allergenic foods, and anti-IL-5 showed promise for treatment of eosinophilic esophagitis. Progress in our understanding of the immunology and the etiology of skin barrier dysfunction in atopic dermatitis has also been made. These observations will likely contribute toward optimizing management of these common allergic disorders.	Mt Sinai Sch Med, Elliot & Roslyn Jaffe Food Allergy Inst, Dept Pediat, Div Allergy & Immunol, New York, NY USA; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Natl Jewish Med & Res Ctr,Div Pediat Allergy Immu, Denver, CO 80262 USA	Icahn School of Medicine at Mount Sinai; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Sicherer, SH (corresponding author), Mt Sinai Hosp, Div Allergy Immunol, Box 1198,One Gustave L Levy Pl, New York, NY 10029 USA.	scott.sicherer@mssm.edu						Ahmad-Nejad P, 2004, J ALLERGY CLIN IMMUN, V113, P565, DOI 10.1016/j.jaci.2003.12.583; Akdis CA, 2006, J ALLERGY CLIN IMMUN, V118, P152, DOI 10.1016/j.jaci.2006.03.045; Antunez C, 2006, J ALLERGY CLIN IMMUN, V117, P404, DOI 10.1016/j.jaci.2005.10.032; Asero R, 2006, J ALLERGY CLIN IMMUN, V117, P1113, DOI 10.1016/j.jaci.2005.12.1343; Astier C, 2006, J ALLERGY CLIN IMMUN, V118, P250, DOI 10.1016/j.jaci.2006.04.053; Benson M, 2006, J ALLERGY CLIN IMMUN, V118, P220, DOI 10.1016/j.jaci.2006.03.006; Bilsborough J, 2006, J ALLERGY CLIN IMMUN, V117, P418, DOI 10.1016/j.jaci.2005.10.046; Blanchard C, 2006, J ALLERGY CLIN IMMUN, V118, P1054, DOI 10.1016/j.jaci.2006.07.038; Boguniewicz M, 2006, J ALLERGY CLIN IMMUN, V118, P40, DOI 10.1016/j.jaci.2006.04.044; Bohle B, 2006, J ALLERGY CLIN IMMUN, V118, P242, DOI 10.1016/j.jaci.2006.03.011; Boyce JA, 2006, J ALLERGY CLIN IMMUN, V117, P1415, DOI 10.1016/j.jaci.2006.04.003; Bussmann C, 2006, J ALLERGY CLIN IMMUN, V118, P1292, DOI 10.1016/j.jaci.2006.07.054; Caughey GH, 2006, J ALLERGY CLIN IMMUN, V117, P1411, DOI 10.1016/j.jaci.2006.02.026; Cork MJ, 2006, J ALLERGY CLIN IMMUN, V118, P3, DOI 10.1016/j.jaci.2006.04.042; Elberink JNGO, 2006, J ALLERGY CLIN IMMUN, V118, P699, DOI 10.1016/j.jaci.2006.03.049; Elkhal A, 2006, J ALLERGY CLIN IMMUN, V118, P1363, DOI 10.1016/j.jaci.2006.08.010; Estelle F, 2006, J ALLERGY CLIN IMMUN, V117, P367, DOI 10.1016/j.jaci.2005.12.002; Fernandez-Rivas M, 2006, J ALLERGY CLIN IMMUN, V118, P481, DOI 10.1016/j.jaci.2006.05.012; Fiset PO, 2006, J ALLERGY CLIN IMMUN, V118, P287, DOI 10.1016/j.jaci.2006.03.046; Flinterman AE, 2006, J ALLERGY CLIN IMMUN, V117, P448, DOI 10.1016/j.jaci.2005.11.035; Flinterman AE, 2006, J ALLERGY CLIN IMMUN, V118, P1186, DOI 10.1016/j.jaci.2006.08.017; Flohr C, 2006, J ALLERGY CLIN IMMUN, V118, P1305, DOI 10.1016/j.jaci.2006.08.035; Floistrup H, 2006, J ALLERGY CLIN IMMUN, V117, P59, DOI 10.1016/j.jaci.2005.09.039; Golden DBK, 2006, J ALLERGY CLIN IMMUN, V117, P670, DOI 10.1016/j.jaci.2005.12.1313; Graif Y, 2006, J ALLERGY CLIN IMMUN, V117, P1435, DOI 10.1016/j.jaci.2006.03.004; Grunwald T, 2006, J ALLERGY CLIN IMMUN, V117, P848, DOI 10.1016/j.jaci.2005.12.1331; Ho MHK, 2006, J ALLERGY CLIN IMMUN, V117, P1506, DOI 10.1016/j.jaci.2006.03.029; Homey B, 2006, J ALLERGY CLIN IMMUN, V118, P178, DOI 10.1016/j.jaci.2006.03.047; Howell MD, 2007, J ALLERGY CLIN IMMUN, V119, pS283, DOI 10.1016/j.jaci.2006.12.479; Howell MD, 2006, J ALLERGY CLIN IMMUN, V117, P836, DOI 10.1016/j.jaci.2005.12.1345; Howell MD, 2007, J ALLERGY CLIN IMMUN, V119, P1022, DOI 10.1016/j.jaci.2007.01.044; Kelsay K, 2006, J ALLERGY CLIN IMMUN, V118, P198, DOI 10.1016/j.jaci.2006.04.038; Kelso JM, 2006, J ALLERGY CLIN IMMUN, V117, P464, DOI 10.1016/j.jaci.2005.11.015; Kleine-Tebbe J, 2006, J ALLERGY CLIN IMMUN, V117, P190, DOI 10.1016/j.jaci.2005.08.056; Knight AK, 2006, J ALLERGY CLIN IMMUN, V117, P842, DOI 10.1016/j.jaci.2005.12.1304; Koch S, 2006, J ALLERGY CLIN IMMUN, V117, P163, DOI 10.1016/j.jaci.2005.10.003; Kondo Y, 2006, J ALLERGY CLIN IMMUN, V118, P1382, DOI 10.1016/j.jaci.2006.07.047; Kuehni CE, 2006, J ALLERGY CLIN IMMUN, V118, P528, DOI 10.1016/j.jaci.2006.04.019; Kull I, 2006, J ALLERGY CLIN IMMUN, V118, P1299, DOI 10.1016/j.jaci.2006.08.022; Le LQ, 2006, J ALLERGY CLIN IMMUN, V118, P1176, DOI 10.1016/j.jaci.2006.06.031; Leung DYM, 2006, J ALLERGY CLIN IMMUN, V118, P37, DOI 10.1016/j.jaci.2006.04.045; Lorenz Y, 2006, J ALLERGY CLIN IMMUN, V118, P711, DOI 10.1016/j.jaci.2006.05.014; Lowe AJ, 2006, J ALLERGY CLIN IMMUN, V117, P682, DOI 10.1016/j.jaci.2005.10.027; Maloney JM, 2006, J ALLERGY CLIN IMMUN, V118, P719, DOI 10.1016/j.jaci.2006.05.017; Marenholz I, 2006, J ALLERGY CLIN IMMUN, V118, P866, DOI 10.1016/j.jaci.2006.07.026; McGirt LY, 2006, J ALLERGY CLIN IMMUN, V118, P202, DOI 10.1016/j.jaci.2006.04.033; Mehl A, 2006, J ALLERGY CLIN IMMUN, V118, P923, DOI 10.1016/j.jaci.2006.07.003; Minh HBC, 2006, J ALLERGY CLIN IMMUN, V117, P466, DOI 10.1016/j.jaci.2005.10.020; Morar N, 2006, J ALLERGY CLIN IMMUN, V118, P24, DOI 10.1016/j.jaci.2006.03.037; Neis MM, 2006, J ALLERGY CLIN IMMUN, V118, P930, DOI 10.1016/j.jaci.2006.07.015; Palacin A, 2006, J ALLERGY CLIN IMMUN, V117, P1423, DOI 10.1016/j.jaci.2006.01.026; Rawas-Qalaji MM, 2006, J ALLERGY CLIN IMMUN, V117, P398, DOI 10.1016/j.jaci.2005.12.1310; Rodriguez-Pena R, 2006, J ALLERGY CLIN IMMUN, V118, P949, DOI 10.1016/j.jaci.2006.07.013; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Sampson MA, 2006, J ALLERGY CLIN IMMUN, V117, P1440, DOI 10.1016/j.jaci.2006.03.009; Sanchez-Monge R, 2006, J ALLERGY CLIN IMMUN, V118, P705, DOI 10.1016/j.jaci.2006.04.058; Scarupa MD, 2006, J ALLERGY CLIN IMMUN, V117, P1508, DOI 10.1016/j.jaci.2006.03.034; Scibilia J, 2006, J ALLERGY CLIN IMMUN, V117, P433, DOI [10.1016/j.jaci.2005.10.014, 10.1016/J.JACI.2005.10.014]; Shanmugam G, 2006, J ALLERGY CLIN IMMUN, V117, P950, DOI 10.1016/j.jaci.2005.12.1356; Sicherer SH, 2006, J ALLERGY CLIN IMMUN, V118, P170, DOI 10.1016/j.jaci.2006.04.018; Sicherer SH, 2006, J ALLERGY CLIN IMMUN, V117, P1419, DOI 10.1016/j.jaci.2006.01.051; Sicherer SH, 2006, J ALLERGY CLIN IMMUN, V117, pS470, DOI 10.1016/j.jaci.2005.05.048; Skorpinski EW, 2006, J ALLERGY CLIN IMMUN, V117, P463, DOI 10.1016/j.jaci.2005.10.005; Sonkoly E, 2006, J ALLERGY CLIN IMMUN, V117, P411, DOI 10.1016/j.jaci.2005.10.033; Stein ML, 2006, J ALLERGY CLIN IMMUN, V118, P1312, DOI 10.1016/j.jaci.2006.09.007; Steinhoff M, 2006, J ALLERGY CLIN IMMUN, V118, P190, DOI 10.1016/j.jaci.2006.04.025; Stevenson DD, 2006, J ALLERGY CLIN IMMUN, V118, P801, DOI 10.1016/j.jaci.2006.06.019; Suzukawa M, 2006, J ALLERGY CLIN IMMUN, V117, P1500, DOI 10.1016/j.jaci.2006.02.015; Taieb Alain, 2006, J Allergy Clin Immunol, V117, P378, DOI 10.1016/j.jaci.2005.11.038; Tawde P, 2006, J ALLERGY CLIN IMMUN, V118, P915, DOI 10.1016/j.jaci.2006.05.028; Tenda Y, 2006, J ALLERGY CLIN IMMUN, V118, P725, DOI 10.1016/j.jaci.2006.05.024; Thottingal TB, 2006, J ALLERGY CLIN IMMUN, V118, P905, DOI 10.1016/j.jaci.2006.06.016; Tosi MF, 2005, J ALLERGY CLIN IMMUN, V116, P241, DOI 10.1016/j.jaci.2005.05.036; Vassilopoulou E, 2006, J ALLERGY CLIN IMMUN, V118, P473, DOI 10.1016/j.jaci.2006.04.057; Venter C, 2006, J ALLERGY CLIN IMMUN, V117, P1118, DOI 10.1016/j.jaci.2005.12.1352; Vu AT, 2006, J ALLERGY CLIN IMMUN, V118, P534, DOI 10.1016/j.jaci.2006.04.035; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V117, P213, DOI 10.1016/j.jaci.2005.09.040; Weidinger S, 2005, J ALLERGY CLIN IMMUN, V116, P177, DOI 10.1016/j.jaci.2005.02.034; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P214, DOI 10.1016/j.jaci.2006.05.004; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P277, DOI 10.1016/j.jaci.2006.04.034; Williams H, 2006, J ALLERGY CLIN IMMUN, V118, P209, DOI 10.1016/j.jaci.2006.04.043; Wu Y, 2006, J ALLERGY CLIN IMMUN, V118, P233, DOI 10.1016/j.jaci.2006.03.005; Yasnowsky KM, 2006, J ALLERGY CLIN IMMUN, V117, P1430, DOI 10.1016/j.jaci.2006.02.016; Ying S, 2006, J ALLERGY CLIN IMMUN, V118, P1386, DOI 10.1016/j.jaci.2006.08.030; Yu JW, 2006, J ALLERGY CLIN IMMUN, V118, P466, DOI 10.1016/j.jaci.2006.04.024; Zuberbier T, 2006, J ALLERGY CLIN IMMUN, V118, P226, DOI 10.1016/j.jaci.2006.02.031	86	20	21	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2007	119	6					1462	1469		10.1016/j.jaci.2007.02.013	http://dx.doi.org/10.1016/j.jaci.2007.02.013			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	178PO	17412401				2022-12-18	WOS:000247232800023
J	Ungvavi, I; Tolgyesi, G; Semsei, AF; Nagy, A; Radosits, K; Keszei, M; Kozma, GT; Falus, A; Szalai, C				Ungvavi, Ildiko; Tolgyesi, Gergely; Semsei, Agnes F.; Nagy, Adrienne; Radosits, Karoly; Keszei, Marton; Kozma, Gergely T.; Falus, Andras; Szalai, Csaba			CCR5 Delta 32 mutation, Mycoplasma pneumoniae infection, and asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							RANTES		Semmelweis Univ, Dept Genet Cell & Immunobiol, Budapest, Hungary; Budai Childrens Hosp, Budapest, Hungary; Pediat Pulmonol Ambulance, Siofok, Hungary; Hungarian Acad Sci, Res Grp Paediat & Nephrol, Budapest, Hungary; Hungarian Acad Sci, Sect Immunogenom, Budapest, Hungary; Heim Pal Pediat Hosp, Budapest, Hungary	Semmelweis University; Hungarian Academy of Sciences; Hungarian Academy of Sciences	Ungvavi, I (corresponding author), Semmelweis Univ, Dept Genet Cell & Immunobiol, Budapest, Hungary.	szalai@heimpalkorhaz.hu	Keszei, Marton/F-3295-2014; Szalai, Csaba/A-2041-2008	Keszei, Marton/0000-0002-1158-2179; Falus, Andras/0000-0002-6843-6789; Semsei, Agnes F./0000-0002-8709-2459				Al-Abdulhadi SA, 2005, GENES IMMUN, V6, P24, DOI 10.1038/sj.gene.6364151; Dakhama A, 2003, AM J RESP CELL MOL, V29, P344, DOI 10.1165/rcmb.2002-0291OC; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Johnston SL, 2005, AM J RESP CRIT CARE, V172, P1078, DOI 10.1164/rccm.200412-1743PP; Koya T, 2006, AM J RESP CELL MOL, V35, P147, DOI 10.1165/rcmb.2005-0394OC; Martin RJ, 2006, CLIN CHEST MED, V27, P87, DOI 10.1016/j.ccm.2005.10.004; Szalai C, 2000, LANCET, V355, P66, DOI 10.1016/S0140-6736(05)72005-5; Waites KB, 2004, CLIN MICROBIOL REV, V17, P697, DOI 10.1128/CMR.17.4.697-728.2004; Zhou YH, 1998, J IMMUNOL, V160, P4018	9	20	20	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2007	119	6					1545	1547		10.1016/j.jaci.2007.02.038	http://dx.doi.org/10.1016/j.jaci.2007.02.038			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	178PO	17445875				2022-12-18	WOS:000247232800037
J	Abraham, CM; Ownby, DR; Peterson, EL; Wegienka, G; Zoratti, EM; Williams, LK; Joseph, CLM; Johnson, CC				Abraham, Christina M.; Ownby, Dennis R.; Peterson, Edward L.; Wegienka, Ganesa; Zoratti, Edward M.; Williams, L. Keoki; Joseph, Christine L. M.; Johnson, Christine Cole			The relationship between seroatopy and symptoms of either allergic rhinitis or asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic rhinitis; asthma; self-reported history; seroatopy; allergen-specific IgE	SKIN-TEST REACTIVITY; COMMUNITY RESPIRATORY HEALTH; SERUM IGE LEVELS; POPULATION-SAMPLE; CHILDREN; ATOPY; ASSOCIATION; OWNERSHIP; ADULTS; RISK	Background: Epidemiologic data on allergic rhinitis and asthma are frequently based on self-reported symptoms. Objective: This cross-sectional study examined the relationship between self-reported symptoms and histories of allergic rhinitis or asthma and a marker of allergic sensitization, allergen-specific IgE. Methods: We surveyed 702 pregnant women in Michigan. Blood samples were analyzed for specific IgE to 9 allergens: dust mites (Dermatophagoides farinae and Dermatophagoides pteronyssinus), cat, dog, cockroach, ragweed, timothy grass, egg, and Alternaria alternata. Seratopy was defined as a specific IgE greater than or equal to 0.35 kU/L to any allergen. Results: Seroatopy was found in 66.7% of those with hay fever symptoms, 68.3% with a physician's diagnosis of asthma, and 72.1% of those with both conditions. These results differed significantly from asymptomatic subjects, where 49.8% of patients without hay fever and 50.4% without asthma were seroatopic. Race and education did not modify the relationships. Symptoms related to specific exposures were modest predictors of positive specific IgE to related allergens (positive predictive values from 26.5% to 50.3%). Conclusion: Self-reported symptoms of allergic rhinitis or asthma were significantly associated with allergic sensitization, but the odds ratios were of relatively low magnitude for this historical information to be considered evidence of current allergic sensitization. A 66% to 68% probability existed that those with symptoms of allergic rhinitis or asthma would have a positive specific IgE test. Clinical implications: Self-reported histories of hay fever or asthma alone are only modest predictors of allergic sensitization. When knowledge of allergic sensitization is important, information beyond self-reported symptoms is necessary.	Med Coll Georgia, Div Allergy Immunol, Sect Allergy & Immunol, Augusta, GA 30912 USA; Henry Ford Hlth Syst, Dept Biostat & Res Epidemiol, Detroit, MI USA; Henry Ford Hlth Syst, Dept Internal Med, Detroit, MI USA	University System of Georgia; Augusta University; Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital	Ownby, DR (corresponding author), Med Coll Georgia, Div Allergy Immunol, Sect Allergy & Immunol, BG 244, Augusta, GA 30912 USA.	downby@mail.mcg.edu		Johnson, Christine Cole/0000-0002-6864-6604	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI050681, R01AI059415, R01AI051598, R21AI059415, R01AI050681, R01AI061774] Funding Source: NIH RePORTER; NIAID NIH HHS [AI59415, AI61774, AI50594, AI50681, AI51598] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Almqvist C, 2003, J ALLERGY CLIN IMMUN, V111, P800, DOI 10.1067/mai.2003.1334; Arbes SJ, 2005, J ALLERGY CLIN IMMUN, V116, P377, DOI 10.1016/j.jaci.2005.05.017; BARBEE RA, 1991, CHEST, V99, P20, DOI 10.1378/chest.99.1.20; Bodtger U, 2004, CURR OPIN ALLERGY CL, V4, P5, DOI 10.1097/01.all.0000113671.13639.1f; Bousquet J, 2006, ALLERGY, V61, P671, DOI 10.1111/j.1398-9995.2006.01048.x; BROWN WG, 1979, J ALLERGY CLIN IMMUN, V63, P328, DOI 10.1016/0091-6749(79)90127-1; Burney P, 1997, J ALLERGY CLIN IMMUN, V99, P314, DOI 10.1016/S0091-6749(97)70048-4; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; Celedon JC, 2004, CHEST, V125, P85, DOI 10.1378/chest.125.1.85; Crestani E, 2004, J ALLERGY CLIN IMMUN, V113, P284, DOI 10.1016/j.jaci.2003.11.009; Droste JHJ, 1996, J ALLERGY CLIN IMMUN, V97, P922, DOI 10.1016/S0091-6749(96)80066-2; Gargano D, 2002, ALLERGY, V57, P1044, DOI 10.1034/j.1398-9995.2002.23745.x; Gern JE, 2004, J ALLERGY CLIN IMMUN, V113, P307, DOI 10.1016/j.jaci.2003.11.017; Joseph CLM, 2004, CHEST, V126, P1004, DOI 10.1378/chest.126.3.1004; Kilpelainen M, 2001, ALLERGY, V56, P377, DOI 10.1034/j.1398-9995.2001.056005377.x; Linneberg A, 2000, ALLERGY, V55, P767, DOI 10.1034/j.1398-9995.2000.00672.x; Litonjua AA, 2002, J ALLERGY CLIN IMMUN, V110, P736, DOI 10.1067/mai.2002.128948; Litonjua AA, 1998, AM J RESP CRIT CARE, V158, P176, DOI 10.1164/ajrccm.158.1.9710014; Soderstrom L, 2003, ALLERGY, V58, P921, DOI 10.1034/j.1398-9995.2003.00227.x; Sunyer J, 2004, J ALLERGY CLIN IMMUN, V114, P1033, DOI 10.1016/j.jaci.2004.05.072; Taussig LM, 2003, J ALLERGY CLIN IMMUN, V111, P661, DOI 10.1067/mai.2003.162; TOLLERUD DJ, 1991, AM REV RESPIR DIS, V144, P776, DOI 10.1164/ajrccm/144.4.776; VERVLOET D, 1991, CLIN EXP ALLERGY, V21, P733, DOI 10.1111/j.1365-2222.1991.tb03203.x	23	20	22	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2007	119	5					1099	1104		10.1016/j.jaci.2007.01.024	http://dx.doi.org/10.1016/j.jaci.2007.01.024			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	167CB	17416408				2022-12-18	WOS:000246427200008
J	Campbell, CP; Jackson, AS; Johnson, AR; Thomas, PS; Yates, DH				Campbell, Charlotte P.; Jackson, Abigail S.; Johnson, Anthony R.; Thomas, Paul S.; Yates, Deborah H.			Occupational sensitization to lupin in the workplace: Occupational asthma, rhinitis, and work-aggravated asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						bronchial provocation challenge; hypersensitivity; occupational disease	AIRWAY RESPONSIVENESS; CROSS-ALLERGENICITY; NITRIC-OXIDE; ALLERGY; FLOUR; CHILDREN; ANAPHYLAXIS; PEANUT; ADULTS	Background: Lupin is a legume. Its seed can be ground into flour and incorporated into food as a protein source. Cases of rhinitis, urticaria, and anaphylaxis from ingestion of lupin have been reported as well as asthma. Objective: To present a cross-sectional study of workers in a food processing company who were exposed to lupin and developed occupational allergy secondary to inhaling lupin products. Methods: Subjects were interviewed using a standardized questionnaire, including demographics and current and past symptoms. They underwent skin prick tests (SPTs) to common aeroallergens and lupin products, spirometry, and off-line exhaled nitric oxide measurement. Symptomatic subjects, sensitized to lupin on SPT, underwent methacholine bronchial provocation challenge. Those with bronchial hyperresponsiveness had specific bronchial provocation challenge to lupin. Results: A total of 53154 subjects completed testing (98%). Overall, 21% (11153) had positive SPT results to lupin. The lupin-sensitive group had a trend toward atopy (P = .06). Seven of 11 (64%) subjects in this group were symptomatic; all had rhinitis, and 2 had wheeze. Two subjects had positive methacholine challenges, and 1 had a positive specific bronchial provocation challenge to lupin with both an early-phase and a late-phase response. Conclusion: Allergy to inhaled lupin occurs in the workplace. A high sensitization rate on SPT was found, which correlated with symptoms. The clinical significance of cross-reactivity between legumes on SPT is unclear. Clinical implications: Sensitization to the legume, lupin, can occur from exposure at work and carries a high prevalence of clinical symptoms, which in some cases leads to occupational rhinitis and asthma.	St Vincents Hosp, Dept Thorac Med, Darlinghurst, NSW 2010, Australia; Dust Dis Board Res & Educ Unit, Sydney, NSW, Australia; Univ New S Wales, Sydney, NSW, Australia; Prince Wales Hosp, Sydney, NSW, Australia	St Vincents Hospital Sydney; University of New South Wales Sydney	Yates, DH (corresponding author), St Vincents Hosp, Dept Thorac Med, Darlinghurst, NSW 2010, Australia.	Deborahy88@hotmail.com						American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; *AUSTR GOV NHMRC C, 2004, CLIN PRACT GUID PREV, P7; Balmes J, 2003, AM J RESP CRIT CARE, V167, P787, DOI 10.1164/rccm.167.5.787; BERNHISELBROADBENT J, 1989, J ALLERGY CLIN IMMUN, V83, P435, DOI 10.1016/0091-6749(89)90130-9; Bernstein IL, 1995, ANN ALLERG ASTHMA IM, V75, P543; COCKCROFT DW, 1987, AM REV RESPIR DIS, V135, P264; Crespo JF, 2001, J ALLERGY CLIN IMMUN, V108, P295, DOI 10.1067/mai.2001.116860; Faeste CK, 2004, INT ARCH ALLERGY IMM, V135, P36, DOI 10.1159/000080041; GRIEVE M, MODERN HERBAL LUPINS; Gutierrez D, 1997, CONTACT DERMATITIS, V36, P311, DOI 10.1111/j.1600-0536.1997.tb00012.x; HEFLE SL, 1994, J ALLERGY CLIN IMMUN, V94, P167, DOI 10.1016/0091-6749(94)90036-1; Kharitonov SA, 2000, EUR RESPIR J, V16, P781, DOI 10.1183/09031936.00.16478100; LAMB CF, 2003, AUSTR GOVT DEP FISHE; Matheu V, 1999, ANN ALLERG ASTHMA IM, V83, P406, DOI 10.1016/S1081-1206(10)62838-4; Moneret-Vautrin DA, 1999, J ALLERGY CLIN IMMUN, V104, P883, DOI 10.1016/S0091-6749(99)70303-9; MURPHY S, MANY USES LUPINS; Novembre E, 1999, J ALLERGY CLIN IMMUN, V103, P1214, DOI 10.1016/S0091-6749(99)70203-4; Parisot L, 2001, ALLERGY, V56, P918, DOI 10.1034/j.1398-9995.2001.00254.x; PEAT JK, 1994, EUR RESPIR J, V7, P1805, DOI 10.1183/09031936.94.07101805; Radcliffe M, 2005, LANCET, V365, P1360, DOI 10.1016/S0140-6736(05)61036-7; *REP PROP EUR PARL, 01392002 A5 PUBL HLT; Slutsky AS, 1999, AM J RESP CRIT CARE, V160, P2104; Smith WB, 2004, MED J AUSTRALIA, V181, P219, DOI 10.5694/j.1326-5377.2004.tb06242.x; VENABLES KM, 1989, RESP MED, V83, P437, DOI 10.1016/S0954-6111(89)80078-2; Yates DH, 1998, THORAX, V53, P110, DOI 10.1136/thx.53.2.110; [No title captured]	26	20	21	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2007	119	5					1133	1139		10.1016/j.jaci.2007.01.032	http://dx.doi.org/10.1016/j.jaci.2007.01.032			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	167CB	17379286				2022-12-18	WOS:000246427200013
J	Tsai, YJ; Choudhry, S; Kho, J; Beckman, K; Tsai, HJ; Navarro, D; Matallana, H; Castro, RA; Lilly, CM; Nazario, S; Rodriguez-Santana, JR; Casal, J; Torres, A; Salas, J; Chapela, R; Watson, HG; Meade, K; Avila, PC; Rodriguez-Cintron, W; LeNoir, M; Burchard, EG				Tsai, Yuhjung J.; Choudhry, Shweta; Kho, Jennifer; Beckman, Kenneth; Tsai, Hui-Ju; Navarro, Daniel; Matallana, Henry; Castro, Richard A.; Lilly, Craig M.; Nazario, Sylvette; Rodriguez-Santana, Jose R.; Casal, Jesus; Torres, Alfonso; Salas, Jorge; Chapela, Rocio; Watson, H. George; Meade, Kelley; Avila, Pedro C.; Rodriguez-Cintron, William; LeNoir, Michael; Gonzalez Burchard, Esteban		Genetics Asthma Latino Amer Study; Study African Amer Asthma Genes En	The PTGDR gene is not associated with asthma in 3 ethnically diverse populations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma genetics; PTGDR gene; Latinos; African Americans	PUERTO-RICAN; MEXICAN; HISPANICS; SAMPLE	Background: The prostanoid DP receptor (PTGDR) gene on chromosome 14q22.1 has been identified as an asthma susceptibility gene. A haplotype with decreased transcription factor binding and transcription efficiency was associated with decreased asthma susceptibility in African American and white subjects. The significance of PTGDR gene variants in asthma has yet to be determined in Latinos, the largest US minority population, nor has the association been replicated in other populations. Objective: To determine the role of PTGDR gene variants in asthma susceptibility and asthma-related traits among the Mexican, Puerto Rican, and African American populations. Methods: We determined whether single nucleotide polymorphisms (SNPs) and haplotypes in PTGDR were associated with asthma and asthma-related traits by family-based and cross-sectional cohort analyses in 336 Puerto Rican and 273 Mexican asthmatic trios and by case-control analysis among African American subjects with asthma and healthy controls (n = 352). Results: We identified 13 SNPs in the PTGDR gene, and 6 were further analyzed. There was no significant association between PTGDR variants and asthma by family-based or case-control analyses. SNPs -441C and -197C and haplotype TTT showed marginal association with asthma-related traits in Mexican subjects. SNP -441 genotype TT (P = .05) and haplotype TTT (P = .02) were associated with increased IgE levels in African Americans. Conclusion: We conclude that the PTGDR gene is not a significant risk factor for asthma among Puerto Ricans, Mexicans, or African Americans. Clinical implications: Asthma candidate genes provide insights to pathophysiology and potentially new therapeutic targets, although the PTGDR gene was not found to be a significant risk factor for asthma in 3 populations.	Univ Calif San Francisco, San Francisco, CA 94143 USA; Childrens Hosp & Res Inst, Oakland, CA USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Univ Puerto Rico, Sch Med, San Juan Vet Affairs Med Ctr, San Juan, PR 00936 USA; Pediat Pulm Program San Juan, San Juan, PR USA; Inst Nacl Enfermedades Resp, Mexico City, DF, Mexico; James A Watson Wellness Ctr, Oakland, CA USA; Northwestern Mem Hosp, Chicago, IL USA; Bay Area Pediat, Oakland, CA USA	University of California System; University of California San Francisco; Harvard University; Brigham & Women's Hospital; University of Puerto Rico; University of Puerto Rico Medical Sciences Campus; Northwestern Memorial Hospital	Burchard, EG (corresponding author), Univ Calif San Francisco, Box 2911,Rock Hall 1550,4th St,SF 584C, San Francisco, CA 94143 USA.	Esteban@sfgh.ucsf.edu	Tsai, Hui-Ju/E-3937-2010		NCRR NIH HHS [M01 RR01271, 3M01RR000083-38S3048, M01RR00083-41] Funding Source: Medline; NHLBI NIH HHS [HL56443, K23 HL04464, HL07185, U01-HL 65899, HL51831, HL51823, HL074204] Funding Source: Medline; NIGMS NIH HHS [GM61390] Funding Source: Medline; NIMHD NIH HHS [P60 MD00222] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001271, M01RR000083] Funding Source: NIH RePORTER; NATIONAL CENTER ON MINORITY HEALTH AND HEALTH DISPARITIES [P60MD000222] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL056443, U10HL051823, U10HL074204, K23HL004464, U10HL051831, U01HL065899] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U01GM061390, U19GM061390] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER ON MINORITY HEALTH AND HEALTH DISPARITIES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; *ASTHM PREV HLTH C, 2002, NATL CTR HLTH STAT; Beckett WS, 1996, AM J RESP CRIT CARE, V154, P894, DOI 10.1164/ajrccm.154.4.8887582; BOIE Y, 1995, J BIOL CHEM, V270, P18910, DOI 10.1074/jbc.270.32.18910; Burchard EG, 2004, AM J RESP CRIT CARE, V169, P386, DOI 10.1164/rccm.200309-1293OC; Burchard EG, 2003, NEW ENGL J MED, V348, P1170, DOI 10.1056/NEJMsb025007; CARTERPOKRAS OD, 1993, AM J PUBLIC HEALTH, V83, P580, DOI 10.2105/AJPH.83.4.580; Centers for Disease Control and Prevention (CDC), 1996, MMWR Morb Mortal Wkly Rep, V45, P350; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; Gauderman WJ, 2002, STAT MED, V21, P35, DOI 10.1002/sim.973; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; Homa DM, 2000, AM J RESP CRIT CARE, V161, P504, DOI 10.1164/ajrccm.161.2.9906025; Horvath S, 2001, EUR J HUM GENET, V9, P301, DOI 10.1038/sj.ejhg.5200625; Laird NM, 2000, GENET EPIDEMIOL, V19, pS36, DOI 10.1002/1098-2272(2000)19:1+<::AID-GEPI6>3.3.CO;2-D; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; Martinez FD, 2005, IMMUNOL ALLERGY CLIN, V25, P709, DOI 10.1016/j.iac.2005.09.001; Matsuoka T, 2000, SCIENCE, V287, P2013, DOI 10.1126/science.287.5460.2013; *NCBI DBSNP BUILD, 2006, ENTR SNP SINGL NUCL; O'Connell JR, 1998, AM J HUM GENET, V63, P259, DOI 10.1086/301904; Oguma T, 2004, NEW ENGL J MED, V351, P1752, DOI 10.1056/NEJMoa031785; Ott J, 1999, ANAL HUMAN GENETIC L; SPIELMAN RS, 1993, AM J HUM GENET, V52, P506; *US CENS 2000 BUR, 2000, US CENS 2000; Zambelli-Weiner A, 2005, J ALLERGY CLIN IMMUN, V115, P1203, DOI 10.1016/j.jaci.2005.03.001; Ziv E, 2003, PHARMACOGENOMICS, V4, P431, DOI 10.1517/phgs.4.4.431.22758	25	20	20	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2006	118	6					1242	1248		10.1016/j.jaci.2006.07.045	http://dx.doi.org/10.1016/j.jaci.2006.07.045			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	117NP	17157653	Bronze			2022-12-18	WOS:000242880300006
J	Cortes, L; Carvalho, AL; Todo-Bom, A; Faro, C; Pires, E; Verissimo, P				Cortes, Luisa; Carvalho, Ana Luisa; Todo-Bom, Ana; Faro, Carlos; Pires, Euclides; Verissimo, Paula			Purification of a novel aminopeptidase from the pollen of Parietaria judaica that alters epithelial integrity and degrades neuropeptides	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Parietaria judaica; aminopeptidase; VIP; substance P; angiotensin I; occludin; E-cadherin	MITE ALLERGEN DER-P-1; AMBROSIA-ARTEMISIIFOLIA POLLEN; TIGHT JUNCTIONS; PROTEOLYTIC ACTIVITY; PEPTIDASE; PROTEINS; OCCLUDIN; ENZYMES; ASTHMA; CELLS	Background: Parietaria judaica pollen is a common cause of pollinosis in the Mediterranean area. Objective: This study sought to purify and characterize the peptidase responsible for the majority of proteolytic activity present in the pollen extract of P judaica, and to investigate its contribution to the allergic response. Methods: A serial of chromatographic steps was applied to isolate the peptidase from P judaica's pollen, and its biochemical properties were determined. Bioactive peptides present in the airways were incubated with the peptidase, and their degradation was visualized by direct protein sequencing. In addition, we measured the cellular detachment, by methylene blue binding assay, of an airway-derived epithelial cell line (A549) in the presence of the peptidase, and visualized, by Western blot, the degradation of proteins from intercellular junctions. Results: We purified a 98-kDa peptidase from the pollen of P judaica that was classified as an aminopeptidase on the basis of its biochemical properties and internal amino acid sequence. The aminopeptidase was able to degrade bioactive peptides. Moreover, the aminopeptidase caused cellular detachment of A549 cell line and degradation of occludin and E-cadherin. Conclusion: Our results suggest that the P judaica aminopeptidase can alter the integrity of the epithelium barrier by degrading occludin as well as E-cadherin. In addition, P judaica aminopeptidase can degrade bioactive peptides, which can exacerbate the overall bronchoconstrictive effect detected in asthmatic lungs. Clinical implications: The novel aminopeptidase described here could constitute a relevant therapeutic target in the treatment of allergic disorders induced by the pollen of P judaica.	Univ Coimbra, Ctr Neurosci & Cell Biol Coimbra, P-3000354 Coimbra, Portugal; Univ Coimbra, Dept Biochem, P-3000354 Coimbra, Portugal; Univ Coimbra, Dept Zool, P-3000354 Coimbra, Portugal; Coimbra Univ Hosp, Immunoallergol Serv, Coimbra, Portugal	Universidade de Coimbra; Universidade de Coimbra; Universidade de Coimbra; Universidade de Coimbra; Centro Hospitalar e Universitario de Coimbra (CHUC)	Verissimo, P (corresponding author), Univ Coimbra, Ctr Neurosci & Cell Biol Coimbra, P-3000354 Coimbra, Portugal.	paulav@imagem.ibili.uc.pt	Verissimo, Paula/AAB-2281-2021; Todo Bom, Ana/AHD-3630-2022; Cortes, Luisa/F-7349-2014; Carvalho, Ana Luisa/K-6367-2013	Verissimo, Paula/0000-0003-0532-4242; Cortes, Luisa/0000-0001-5292-4369; Carvalho, Ana Luisa/0000-0001-8368-6666; Faro, Carlos/0000-0002-0480-8379; Pires, Euclides/0000-0002-5853-0165; Todo-Bom, Ana/0000-0002-1850-6689				Bagarozzi DA, 1996, J BIOL CHEM, V271, P26227, DOI 10.1074/jbc.271.42.26227; Bagarozzi DA, 1998, AM J RESP CELL MOL, V18, P363, DOI 10.1165/ajrcmb.18.3.2825; Behrendt H, 2001, CURR OPIN IMMUNOL, V13, P709, DOI 10.1016/S0952-7915(01)00283-7; Chandu D, 2003, J BIOL CHEM, V278, P5548, DOI 10.1074/jbc.M207926200; Colombo P, 2003, INT ARCH ALLERGY IMM, V130, P173, DOI 10.1159/000069520; DAMATO G, 1992, ALLERGY, V47, P443, DOI 10.1111/j.1398-9995.1992.tb00661.x; Gough L, 2003, CLIN EXP ALLERGY, V33, P1159, DOI 10.1046/j.1365-2222.2003.01716.x; Gough L, 2001, CLIN EXP ALLERGY, V31, P1594, DOI 10.1046/j.1365-2222.2001.01207.x; Groneberg DA, 2001, PULM PHARMACOL THER, V14, P391, DOI 10.1006/pupt.2001.0306; Hassim Z, 1998, THORAX, V53, P368, DOI 10.1136/thx.53.5.368; Hoffmann-Sommergruber K, 2000, INT ARCH ALLERGY IMM, V122, P155, DOI 10.1159/000024392; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATHESON N, 1995, AM J RESP CELL MOL, V12, P441, DOI 10.1165/ajrcmb.12.4.7695924; Matheson NR, 1998, J BIOL CHEM, V273, P16771, DOI 10.1074/jbc.273.27.16771; Matsuishi M, 2003, INT J BIOCHEM CELL B, V35, P474, DOI 10.1016/S1357-2725(02)00279-0; Matter K, 2003, NAT REV MOL CELL BIO, V4, P225, DOI 10.1038/nrm1055; MCKAY MJ, 1983, BIOCHEM J, V213, P467, DOI 10.1042/bj2130467; O'Connor TM, 2004, J CELL PHYSIOL, V201, P167, DOI 10.1002/jcp.20061; Robinson C, 2001, CLIN EXP ALLERGY, V31, P186, DOI 10.1046/j.1365-2222.2001.01025.x; Salcedo G, 2004, CLIN EXP ALLERGY, V34, P1336, DOI 10.1111/j.1365-2222.2004.02018.x; Sehgal N, 2005, CURR ALLERGY ASTHM R, V5, P221, DOI 10.1007/s11882-005-0041-9; Thompson PJ, 1998, CLIN EXP ALLERGY, V28, P110; Wan H, 2000, CLIN EXP ALLERGY, V30, P685, DOI 10.1046/j.1365-2222.2000.00820.x; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; Wan H, 2001, CLIN EXP ALLERGY, V31, P279, DOI 10.1046/j.1365-2222.2001.00970.x; Widmer F, 2000, CLIN EXP ALLERGY, V30, P571, DOI 10.1046/j.1365-2222.2000.00784.x	26	20	21	0	6	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2006	118	4					878	884		10.1016/j.jaci.2006.05.029	http://dx.doi.org/10.1016/j.jaci.2006.05.029			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	097GD	17030241				2022-12-18	WOS:000241434200015
J	Shirai, T; Inui, N; Suda, T; Chida, K				Shirai, Toshihiro; Inui, Naoki; Suda, Takafumi; Chida, Kingo			Correlation between peripheral blood T-cell profiles and airway inflammation in atopic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						airway inflammation; atopic asthma; correlation; exhaled nitric oxide; flow cytometry; induced sputum; IFN-gamma; IL-4; peripheral blood; T cell	NITRIC-OXIDE; CYTOKINE PRODUCTION; IFN-GAMMA; CD8(+); CD4(+); LYMPHOCYTES; IMMUNOLOGY; EXPRESSION; TH1	Background: Recent studies suggest that T(H)1/T(H)2 and T(C)1/T(C)2 cell imbalances are implicated in asthma pathogenesis. However, the relationship of T-cell profiles to airway inflammation has not been understood. Objective: The purpose of this study was to clarify the correlation between peripheral blood T-cell profiles and airway inflammatory parameters. Methods: Subjects included 21 patients with atopic asthma and 20 healthy control subjects. After stimulation with phorbol 12-myristate 13-acetate and ionomycin, flow cytometry was used to analyze intracellular cytokine staining for IFN-gamma and IL-4 in peripheral blood CD4(+) and CD8(+) T cells. Airway inflammation was assessed by using exhaled nitric oxide analysis and induced sputum eosinophil counts. Results: There were a significantly increased proportion of IL-4-producing CD4(+) T cells (median, 2.7% [interquartile range, 2.4% to 3.3%] vs 1.8% [interquartile range, 1.3% to 2.7%]) and a lower ratio of IFN-gamma-producing/IL-4-producing CD4(+) T cells (7.3% [interquartile range, 5.8% to 9.5%] vs 10.0% [interquartile range, 8.8% to 13.2%]) in asthmatic patients compared with in healthy subjects (P < .01) but no increase or decrease in the proportion of IFN-gamma-producing CD4(+) T cells. No significant difference was found in the proportion of IFN-gamma- or IL-4-producing CD8(+) T cells between the 2 groups. The proportion of IL-4-producing CD4(+) T cells was significantly correlated with exhaled nitric oxide (r = 0.48, P < .05) and induced sputum eosinophil counts (r = 0.50, P < .05). Conclusion: These findings indicate a correlation between peripheral blood T(H)2 cytokine production and markers of airway inflammation. Clinical implications: There is an association between immune function and clinical indicators in asthma.	Shizuoka Prefectural Gen Hosp, Dept Resp Med, Shizuoka 4200881, Japan; Hamamatsu Univ Sch Med, Dept Internal Med, Div 2, Hamamatsu, Shizuoka 43131, Japan	Shizuoka General Hospital; Hamamatsu University School of Medicine	Shirai, T (corresponding author), Shizuoka Prefectural Gen Hosp, Dept Resp Med, 4-27-1 Kita Ando, Shizuoka 4200881, Japan.	tmjkshi@general-hosp.pref.shizuoka.jp						American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; BARNES PJ, 1995, IMMUNOL TODAY, V16, P128, DOI 10.1016/0167-5699(95)80128-6; Brightling CE, 2002, J ALLERGY CLIN IMMUN, V110, P899, DOI 10.1067/mai.2002.129698; Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507; Cho SH, 2005, AM J RESP CRIT CARE, V171, P224, DOI 10.1164/rccm.200310-1416OC; Cho SH, 2002, CLIN EXP ALLERGY, V32, P427, DOI 10.1046/j.1365-2222.2002.01281.x; Grob M, 2003, ALLERGY, V58, P239, DOI 10.1034/j.1398-9995.2003.00035.x; Inui N, 2001, J ALLERGY CLIN IMMUN, V107, P337, DOI 10.1067/mai.2001.112273; JUNG T, 1993, J IMMUNOL METHODS, V159, P197, DOI 10.1016/0022-1759(93)90158-4; Kay AB, 2001, NEW ENGL J MED, V344, P30, DOI 10.1056/NEJM200101043440106; Kolb H, 1998, IMMUNOL TODAY, V19, P556, DOI 10.1016/S0167-5699(98)01366-8; Krug N, 2001, AM J RESP CELL MOL, V25, P125, DOI 10.1165/ajrcmb.25.1.4194; Kuo ML, 2001, ANN ALLERG ASTHMA IM, V86, P272, DOI 10.1016/S1081-1206(10)63297-8; Larche M, 2003, J ALLERGY CLIN IMMUN, V111, P450, DOI 10.1067/mai.2003.169; Magnan AO, 2000, AM J RESP CRIT CARE, V161, P1790, DOI 10.1164/ajrccm.161.6.9906130; Nagano Y, 2002, J ASTHMA, V39, P247, DOI 10.1081/JAS-120002474; *NHLBI WHO, 2002, PUBL NIH NAT HEART L; OHASHI Y, 1992, AM REV RESPIR DIS, V145, P1469, DOI 10.1164/ajrccm/145.6.1469; PIN I, 1992, THORAX, V47, P25, DOI 10.1136/thx.47.1.25; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Shirai T, 2003, CLIN EXP ALLERGY, V33, P84, DOI 10.1046/j.1365-2222.2003.01578.x; TaylorRobinson AW, 1997, IMMUNOL CELL BIOL, V75, P167, DOI 10.1038/icb.1997.23; Wong CK, 2001, CLIN EXP IMMUNOL, V125, P177, DOI 10.1046/j.1365-2249.2001.01602.x	24	20	22	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2006	118	3					622	626		10.1016/j.jaci.2006.05.005	http://dx.doi.org/10.1016/j.jaci.2006.05.005			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	086BV	16950280	Bronze			2022-12-18	WOS:000240649000014
J	Brandt, EB; Scribner, TA; Akei, HS; Rothenberg, ME				Brandt, Eric B.; Scribner, Troy A.; Akei, Hiroko Saito; Rothenberg, Marc E.			Experimental gastrointestinal allergy enhances pulmonary responses to specific and unrelated allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; lung; intestine; eosinophil; eotaxin; IL-13; house dust mite; ovalbumin; mice	AIRWAY INFLAMMATION; FOOD ALLERGY; PROTEOLYTIC ACTIVITY; PROTEIN ANTIGEN; EGG ALLERGY; ASTHMA; EXPOSURE; MICE; HYPERRESPONSIVENESS; SENSITIZATION	Background: Gastrointestinal allergy often precedes or coexists with respiratory allergy. Objective: We hypothesized that established experimental gastrointestinal allergy would prime for the development of allergic respiratory responses. Methods: BALB/c mice were sensitized with ovalbumin (OVA) in the presence of aluminum potassium sulfate and then subjected to intragastric saline or OVA challenges. After the development of allergen-induced gastrointestinal allergy, mice were intranasally exposed to either saline, OVA, or a neoaeroallergen house dust mite (HDM) extract. Airway inflammation (eg, bronchoalveolar lavage fluid cellularity, cytokine levels, and OVA-specific antibody levels) and airway responsiveness to methacholine exposure were assessed after intranasal allergen exposure. Results: A single intranasal exposure to OVA induced significantly more airway inflammation in intragastric OVA-challenged mice compared with that seen in intragastric saline-treated mice. Kinetic analysis revealed that the observed amplification of lung inflammation was sustained for up to 12 days after the last intragastric OVA challenge after resolution of blood eosinophilia. When mice with gastrointestinal allergy were repeatedly challenged with HDM in the respiratory tract, they experienced enhanced airway inflammation, including bronchoalveolar lavage fluid eosinophilia and increased IL-13 levels. Conclusion: Taken together, our results demonstrate that OVA-induced gastrointestinal allergy enhances not only allergic airway responses to OVA but also to HDM, an unrelated aeroallergen. Clinical implications: Experimental gastrointestinal allergy primes for responses to allergens in the respiratory tract, enhancing antigen-specific antibody and T(H)2 cytokine production, airway inflammation, and airway hyperresponsiveness.	Cincinnati Childrens Hosp, Ctr Med,Coll Med, Dept Pediat, Div Allergy & Immunol, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Rothenberg, ME (corresponding author), Cincinnati Childrens Hosp, Ctr Med,Coll Med, Dept Pediat, Div Allergy & Immunol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	Rothenberg@cchmc.org		Brandt, Eric/0000-0003-0617-4100	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL076383] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042242, R01AI057803] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 076383] Funding Source: Medline; NIAID NIH HHS [AI 057803, R01 AI 42242] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akei HS, 2006, J ALLERGY CLIN IMMUN, V118, P62, DOI 10.1016/j.jaci.2006.04.046; Blanchard C, 2005, CLIN EXP ALLERGY, V35, P1096, DOI 10.1111/j.1365-2222.2005.02299.x; Brandt EB, 2003, J CLIN INVEST, V112, P1666, DOI 10.1172/JCI19785; Brandt EB, 2001, J ALLERGY CLIN IMMUN, V108, P142, DOI 10.1067/mai.2001.116121; Cates EC, 2004, J IMMUNOL, V173, P6384, DOI 10.4049/jimmunol.173.10.6384; Fasce L, 2004, IMMUNOL LETT, V93, P45, DOI 10.1016/j.imlet.2004.01.016; Fattouh R, 2005, AM J RESP CRIT CARE, V172, P314, DOI 10.1164/rccm.200502-198OC; Finkelman FD, 2005, J ALLERGY CLIN IMMUN, V115, P449, DOI 10.1016/j.jaci.2004.12.1125; Forbes E, 2004, GASTROENTEROLOGY, V127, P105, DOI 10.1053/j.gastro.2004.03.057; Ghaemmaghami AM, 2001, EUR J IMMUNOL, V31, P1211, DOI 10.1002/1521-4141(200104)31:4&lt;1211::AID-IMMU1211&gt;3.0.CO;2-R; Gough L, 2003, CLIN EXP ALLERGY, V33, P1159, DOI 10.1046/j.1365-2222.2003.01716.x; Herrick CA, 2003, J IMMUNOL, V170, P2488, DOI 10.4049/jimmunol.170.5.2488; Hsieh KY, 2003, CLIN EXP ALLERGY, V33, P1067, DOI 10.1046/j.1365-2222.2003.01724.x; James J M, 2001, Curr Allergy Rep, V1, P54, DOI 10.1007/s11882-001-0097-0; James JM, 1996, AM J RESP CRIT CARE, V153, P597, DOI 10.1164/ajrccm.153.2.8564104; James JM, 2003, PEDIATRICS, V111, P1625; Johnson JR, 2004, AM J RESP CRIT CARE, V169, P378, DOI 10.1164/rccm.200308-1094OC; Justice JP, 2003, AM J PHYSIOL-LUNG C, V284, pL169, DOI 10.1152/ajplung.00260.2002; Kondo H, 1998, EUR J IMMUNOL, V28, P769, DOI 10.1002/(SICI)1521-4141(199803)28:03<769::AID-IMMU769>3.0.CO;2-H; Lee JJ, 2004, SCIENCE, V305, P1773, DOI 10.1126/science.1099472; Leser C, 2001, J INVEST ALLERG CLIN, V11, P89; Leung TF, 2002, J ASTHMA, V39, P523, DOI 10.1081/JAS-120004922; Ma W, 2002, J CLIN INVEST, V109, P621, DOI 10.1172/JCI200214097; Pope SM, 2005, J IMMUNOL, V175, P5341, DOI 10.4049/jimmunol.175.8.5341; Pope SM, 2005, J BIOL CHEM, V280, P13952, DOI 10.1074/jbc.M406037200; Rhodes HL, 2001, J ALLERGY CLIN IMMUN, V108, P720, DOI 10.1067/mai.2001.119151; Romagnani S, 2004, IMMUNOLOGY, V112, P352, DOI 10.1111/j.1365-2567.2004.01925.x; Rothenberg ME, 1999, J CLIN IMMUNOL, V19, P250, DOI 10.1023/A:1020531322556; Sampson HA, 2004, J ALLERGY CLIN IMMUN, V113, P805, DOI 10.1016/j.jaci.2004.03.014; Shen HHH, 2003, J IMMUNOL, V170, P3296, DOI 10.4049/jimmunol.170.6.3296; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V104, P186, DOI 10.1016/S0091-6749(99)70133-8; Tariq SM, 2000, PEDIATR ALLERGY IMMU, V11, P162, DOI 10.1034/j.1399-3038.2000.00077.x; Taube C, 2004, AM J RESP CELL MOL, V30, P837, DOI 10.1165/rcmb.2003-0395OC; von Hertzen LC, 2004, ALLERGY, V59, P124, DOI 10.1046/j.1398-9995.2003.00433.x; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258	36	20	21	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2006	118	2					420	427		10.1016/j.jaci.2006.06.009	http://dx.doi.org/10.1016/j.jaci.2006.06.009			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	075IH	16890767				2022-12-18	WOS:000239877700018
J	Vercelli, D; Martinez, FD				Vercelli, Donata; Martinez, Fernando D.			The Faustian bargain of genetic association studies: Bigger might not be better, or at least it might not be good enough	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						genetics	ALLERGIC SENSITIZATION; HOUSE-DUST; ASTHMA; CHILDHOOD; POLYMORPHISM; ENDOTOXIN; ARGINASE; CHILDREN; IL-13; ATOPY		Univ Arizona, Coll Med, Resp Ctr, Tucson, AZ 85721 USA	University of Arizona	Vercelli, D (corresponding author), Univ Arizona, Hlth Sci Ctr, Resp Sci Ctr, 1501 N Campbell Ave,Suite 2349, Tucson, AZ 85724 USA.	donata@arc.arizona.edu						[Anonymous], 2005, NAT GENET, V37, P1153, DOI 10.1038/ng1105-1153; Bottema RW, 2005, IMMUNOL ALLERGY CLIN, V25, P621, DOI 10.1016/j.iac.2005.07.002; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Cardwell CR, 2003, DIABETES CARE, V26, P2568, DOI 10.2337/diacare.26.9.2568; Chatila TA, 2005, J ALLERGY CLIN IMMUN, V116, P949, DOI 10.1016/j.jaci.2005.08.047; Eder W, 2005, J ALLERGY CLIN IMMUN, V116, P601, DOI 10.1016/j.jaci.2005.05.003; Hall IP, 2005, THORAX, V60, P357, DOI 10.1136/thx.2005.040790; Kraan TCTMV, 1999, GENES IMMUN, V1, P61, DOI 10.1038/sj.gene.6363630; LeVan TD, 2001, J IMMUNOL, V167, P5838, DOI 10.4049/jimmunol.167.10.5838; Li HL, 2006, J ALLERGY CLIN IMMUN, V117, P119, DOI 10.1016/j.jaci.2005.09.026; Maier LM, 2006, J ALLERGY CLIN IMMUN, V117, P1306, DOI 10.1016/j.jaci.2005.12.1354; Martinez FD, 2005, IMMUNOL ALLERGY CLIN, V25, P709, DOI 10.1016/j.iac.2005.09.001; Meyers DA, 2005, J ALLERGY CLIN IMMUN, V115, P1169, DOI 10.1016/j.jaci.2005.01.070; Ober C, 2006, GENES IMMUN, V7, P95, DOI 10.1038/sj.gene.6364284; Ober C, 2005, CURR OPIN IMMUNOL, V17, P670, DOI 10.1016/j.coi.2005.09.009; Schram D, 2005, ALLERGY, V60, P611, DOI 10.1111/j.1398-9995.2005.00748.x; Seroogy CM, 2005, J ALLERGY CLIN IMMUN, V116, P996, DOI 10.1016/j.jaci.2005.07.015; Strachan DP, 1998, THORAX, V53, P117, DOI 10.1136/thx.53.2.117; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Strachan DP, 1996, BRIT MED J, V312, P1195; Strachan DP, 1997, PEDIAT ALLERG IMM-UK, V8, P161, DOI 10.1111/j.1399-3038.1997.tb00156.x; Strachan DR, 2001, J ALLERGY CLIN IMMUN, V108, P901, DOI 10.1067/mai.2001.119408; Vercelli D, 2004, J ALLERGY CLIN IMMUN, V113, P381, DOI 10.1016/j.jaci.2004.01.752; Vercelli D, 2003, J CLIN INVEST, V111, P1815, DOI 10.1172/JCI200318908; Vercelli D, 2003, CLIN EXP ALLERGY, V33, P153, DOI 10.1046/j.1365-2222.2003.01606.x; Vercelli D, 2003, CURR OPIN ALLERGY CL, V3, P343, DOI 10.1097/01.all.0000092603.76804.e4; Vladich FD, 2005, J CLIN INVEST, V115, P747, DOI 10.1172/JCI200522818; von Mutius E, 2006, ALLERGY, V61, P407, DOI 10.1111/j.1398-9995.2006.01009.x; Weiland SK, 2004, EUR RESPIR J, V24, P406, DOI 10.1183/09031936.04.00090303; Weiss LA, 2006, NAT GENET, V38, P218, DOI 10.1038/ng1726; Williams HC, 1998, BRIT J DERMATOL, V139, P834; Wills-Karp M, 2001, NAT REV IMMUNOL, V1, P69, DOI 10.1038/35095579; Zambelli-Weiner A, 2005, J ALLERGY CLIN IMMUN, V115, P1203, DOI 10.1016/j.jaci.2005.03.001; Zimmermann N, 2003, J CLIN INVEST, V111, P1863, DOI 10.1172/JCI200317912	34	20	20	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2006	117	6					1303	1305		10.1016/j.jaci.2006.03.030	http://dx.doi.org/10.1016/j.jaci.2006.03.030			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	053UX	16750990				2022-12-18	WOS:000238332300015
J	Zhou, X; Buckley, MG; Lau, LC; Sumrners, C; Pumphrey, RSH; Walls, AF				Zhou, X; Buckley, MG; Lau, LC; Sumrners, C; Pumphrey, RSH; Walls, AF			Mast cell carboxypeptidase as a new clinical marker for anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract	62nd Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology	MAR 03-07, 2006	Miami Beach, FL	Amer Acad Allergy, Asthma & Immunol					Univ Southampton, Immunopharmacol Grp, Southampton, Hants, England; St Marys Hosp, Dept Immunol, Manchester, Lancs, England	University of Southampton; University of Manchester									0	20	22	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2006	117	2		S		333	S85	S85		10.1016/j.jaci.2005.12.342	http://dx.doi.org/10.1016/j.jaci.2005.12.342			1	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	019VR		Bronze			2022-12-18	WOS:000235865300333
J	Amin, K; Janson, C; Harvima, I; Venge, P; Nilsson, G				Amin, K; Janson, C; Harvima, I; Venge, P; Nilsson, G			CC chemokine receptors CCR1 and CCR4 are expressed on airway mast cells in allergic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									Uppsala Univ, Dept Med Sci, Uppsala, Sweden; Univ Kuopio, Dept Dermatol, FIN-70211 Kuopio, Finland; Karolinska Inst, Dept Med, Allergy & Clin Immunol Unit, SE-17176 Stockholm, Sweden	Uppsala University; University of Eastern Finland; Karolinska Institutet	Amin, K (corresponding author), Uppsala Univ, Dept Med Sci, Uppsala, Sweden.			Nilsson, Gunnar/0000-0001-6795-5512				Amin K, 2000, AM J RESP CRIT CARE, V162, P2295, DOI 10.1164/ajrccm.162.6.9912001; Blease K, 2000, J IMMUNOL, V165, P1564, DOI 10.4049/jimmunol.165.3.1564; Bradding P, 2003, CURR OPIN ALLERGY CL, V3, P45, DOI 10.1097/01.all.0000053267.39029.fd; Brightling CE, 2005, J LEUKOCYTE BIOL, V77, P759, DOI 10.1189/jlb.0904511; Garcia G, 2005, CURR ALLERGY ASTHM R, V5, P155, DOI 10.1007/s11882-005-0090-0; Holgate ST, 1997, AM J RESP CRIT CARE, V156, P1377, DOI 10.1164/ajrccm.156.5.9610064; Juremalm M, 2005, CHEM IMMUNOL ALLERGY, V87, P130, DOI 10.1159/000087640; Juremalm M, 2002, BIOCHEM BIOPH RES CO, V297, P480, DOI 10.1016/S0006-291X(02)02244-1; Panina-Bordignon P, 2001, J CLIN INVEST, V107, P1357, DOI 10.1172/JCI12655; Romagnani P, 1999, AM J PATHOL, V155, P1195, DOI 10.1016/S0002-9440(10)65222-4	10	20	23	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2005	116	6					1383	1386		10.1016/j.jaci.2005.08.053	http://dx.doi.org/10.1016/j.jaci.2005.08.053			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IJ	16337476				2022-12-18	WOS:000235687000035
J	Corren, J; Fish, H; Gumarange, J				Corren, J; Fish, H; Gumarange, J			Nasal response to natural cat allergen exposure is significantly greater in patients with rhinitis and asthma than in patients with rhinitis alone	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									Univ Calif Los Angeles, Allergy Res Fdn, Dept Med, Los Angeles, CA 90025 USA	University of California System; University of California Los Angeles	Corren, J (corresponding author), Univ Calif Los Angeles, Allergy Res Fdn, Dept Med, 11620 Wilshire Blvd,200, Los Angeles, CA 90025 USA.							Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Braunstahl GJ, 2000, AM J RESP CRIT CARE, V161, P2051, DOI 10.1164/ajrccm.161.6.9906121; STEPHENS L, 1996, J ALLERGY CLIN IMMUN, V97, pS315; Togias A, 2003, J ALLERGY CLIN IMMUN, V111, P1171, DOI 10.1067/mai.2003.1592	4	20	20	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2005	115	1					202	203		10.1016/j.jaci.2004.09.035	http://dx.doi.org/10.1016/j.jaci.2004.09.035			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	886XS	15637570				2022-12-18	WOS:000226267000030
J	Isidoro-Garcia, M; Davila, I; Moreno, E; Lorente, F; Gonzalez-Sarmiento, R				Isidoro-Garcia, M; Davila, I; Moreno, E; Lorente, F; Gonzalez-Sarmiento, R			Analysis of the leukotriene C-4 synthase A(-444)C promoter polymorphism in a Spanish population	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ASTHMA		Univ Salamanca, Dept Med, Mol Med Unit, Salamanca 37007, Spain; Univ Hosp Salamanca, Dept Allergy, Salamanca, Spain	University of Salamanca; University of Salamanca	Isidoro-Garcia, M (corresponding author), Univ Salamanca, Dept Med, Mol Med Unit, Campus Miguel Unamuno, Salamanca 37007, Spain.		Gonzalez-Sarmiento, Rogelio/V-5526-2019; Dávila, Ignacio/K-4453-2012	Gonzalez-Sarmiento, Rogelio/0000-0002-2726-6795; Dávila, Ignacio/0000-0001-8485-5513; MORENO, ESTHER/0000-0003-0953-3025; ISIDORO-GARCIA, MARIA/0000-0002-9013-9422				Kedda MA, 2004, J ALLERGY CLIN IMMUN, V113, P889, DOI 10.1016/j.jaci.2004.02.008; Sampson AP, 2000, THORAX, V55, pS28, DOI 10.1136/thorax.55.suppl_2.S28; Sanak M, 1997, LANCET, V350, P1599, DOI 10.1016/S0140-6736(05)64015-9	3	20	21	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2005	115	1					206	207		10.1016/j.jaci.2004.08.033	http://dx.doi.org/10.1016/j.jaci.2004.08.033			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	886XS	15637574				2022-12-18	WOS:000226267000034
J	Walzer, T; Brawand, P; Swart, D; Tocker, J; De Smedt, T				Walzer, T; Brawand, P; Swart, D; Tocker, J; De Smedt, T			No defect in T-cell priming, secondary response, or tolerance induction in response to inhaled antigens in Fms-like tyrosine kinase 3 ligand-deficient mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						dendritic cells; lung; inflammation; tolerance; knock-out	MATURE DENDRITIC CELLS; FLT3 LIGAND; MOUSE MODEL; AIRWAY HYPERRESPONSIVENESS; INFLAMMATION; PRECURSORS; PROGENITOR; IMMATURE; INCREASE; ASTHMA	Background: Respiratory tract dendritic cells (DCs) are crucial for the regulation of immune responses to inhaled antigens. However, the precise function of the multiple DC subsets present in the lungs and the lung-draining lymph nodes is unknown. Fms-like tyrosine kinase 3 ligand (FLT3L) is a hematopoietic growth factor that drives the development of multiple subsets of DCs in the lymphoid organs. Objective: We sought to study the contribution of DC subsets in the regulation of the balance between tolerance and immunity against respiratory antigens by using FLT3L knockout mice. Methods: Phenotypic analysis of DC subsets in the airways and lungs of FLT3L knockout mice was performed. By using various experimental models, the role of FLT3L-dependent DCs in the priming of naive T cells, the presentation of inhaled antigen to previously primed T(H)2 cells, and intranasal tolerance induction was addressed. Results: FLT3L knockout mice display a 90% reduction in lung parenchyma DCs but a normal number of airway DCs and blood monocytes. FLT3L knockout mice had a normal induction of eosinophilic inflammation in response to intranasal administration of allergen. FLT3L-dependent DCs were not required for the presentation of inhaled antigen to previously primed T(H)2 cells, and normal induction of T-cell tolerance in response to inhaled antigen was observed in FLT3L knockout mice. Conclusion: Airway DC development is independent of FLT3L. FLT3L-dependent DCs are not required for the development and maintenance of airway inflammation or for the induction of intranasal tolerance. Our results point to airway DCs as the major regulators of the balance between tolerance and immunity to inhaled antigens.	Amgen Inc, Seattle, WA 98119 USA	Amgen	Tocker, J (corresponding author), Amgen Inc, 1201 Amgen Court W, Seattle, WA 98119 USA.	tockerj@amgen.com	Walzer, Thierry/L-9418-2014	Walzer, Thierry/0000-0002-0857-8179				Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Akbari O, 2002, NAT MED, V8, P1024, DOI 10.1038/nm745; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Barnden MJ, 1998, IMMUNOL CELL BIOL, V76, P34, DOI 10.1046/j.1440-1711.1998.00709.x; Bjorck P, 2001, BLOOD, V98, P3520, DOI 10.1182/blood.V98.13.3520; Brasel K, 2000, BLOOD, V96, P3029, DOI 10.1182/blood.V96.9.3029.h8003029_3029_3039; Brawand P, 2002, J IMMUNOL, V169, P6711, DOI 10.4049/jimmunol.169.12.6711; Edwan JH, 2004, J IMMUNOL, V172, P5016, DOI 10.4049/jimmunol.172.8.5016; Gilliet M, 2002, HUM IMMUNOL, V63, P1149, DOI 10.1016/S0198-8859(02)00753-X; Hammad H, 2002, J IMMUNOL, V169, P1524, DOI 10.4049/jimmunol.169.3.1524; Herrick CA, 2003, NAT REV IMMUNOL, V3, P405, DOI 10.1038/nri1084; Huh JC, 2003, J EXP MED, V198, P19, DOI 10.1084/jem.20021328; Itano AA, 2003, IMMUNITY, V19, P47, DOI 10.1016/S1074-7613(03)00175-4; Lambrecht BN, 2000, J CLIN INVEST, V106, P551, DOI 10.1172/JCI8107; Lambrecht BN, 2003, NAT REV IMMUNOL, V3, P994, DOI 10.1038/nri1249; Lambrecht BN, 1998, J IMMUNOL, V160, P4090; Lambrecht BN, 1999, AM J RESP CELL MOL, V20, P1165, DOI 10.1165/ajrcmb.20.6.3484; Leon B, 2004, BLOOD, V103, P2668, DOI 10.1182/blood-2003-01-0286; Lutz MB, 2002, TRENDS IMMUNOL, V23, P445, DOI 10.1016/S1471-4906(02)02281-0; Maraskovsky E, 1996, J EXP MED, V184, P1953, DOI 10.1084/jem.184.5.1953; McKenna HJ, 2000, BLOOD, V95, P3489, DOI 10.1182/blood.V95.11.3489; Pulendran B, 1998, J EXP MED, V188, P2075, DOI 10.1084/jem.188.11.2075; SCHONHEGRAD MA, 1991, J EXP MED, V173, P1345, DOI 10.1084/jem.173.6.1345; Shortman K, 2002, NAT REV IMMUNOL, V2, P151, DOI 10.1038/nri746; STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415; Steinman RM, 2002, P NATL ACAD SCI USA, V99, P351, DOI 10.1073/pnas.231606698; van Rijt LS, 2002, BLOOD, V100, P3663, DOI 10.1182/blood-2002-03-0673; Vermaelen K, 2003, AM J RESP CELL MOL, V29, P405, DOI 10.1165/rcmb.2003-0008OC; Vermaelen KY, 2001, J EXP MED, V193, P51, DOI 10.1084/jem.193.1.51; Viney JL, 1998, J IMMUNOL, V160, P5815; Williamson E, 1999, J IMMUNOL, V163, P3668; Wolvers DAW, 1999, J IMMUNOL, V162, P1994; Yamashita N, 2002, CELL IMMUNOL, V219, P92, DOI 10.1016/S0008-8749(02)00565-8	33	20	20	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2005	115	1					192	199		10.1016/j.jaci.2004.08.046	http://dx.doi.org/10.1016/j.jaci.2004.08.046			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	886XS	15637568				2022-12-18	WOS:000226267000028
J	Isogai, S; Taha, R; Tamaoka, M; Yoshizawa, Y; Hamid, Q; Martin, JG				Isogai, S; Taha, R; Tamaoka, M; Yoshizawa, Y; Hamid, Q; Martin, JG			CD8(+) alpha beta T cells can mediate late airway responses and airway eosinophilia in rats	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						lung; allergy; inflammation; T lymphocytes; cytokines	BROWN-NORWAY RATS; SYNCYTIAL VIRUS-INFECTION; MESSENGER-RNA; IMMUNE-RESPONSE; INHALED ANTIGEN; IGE RESPONSES; HYPERRESPONSIVENESS; LYMPHOCYTES; EXPRESSION; ASTHMA	Background: The function of CD8(+) T-cell subsets in mediating late allergic responses is incompletely understood. Objective: We sought to test the hypothesis that CD8(+) up T cells are proinflammatory in the airways in vivo by using a well-characterized animal model and the technique of adoptive transfer Methods: Brown Norway rats were administered CD8(+) up T cells (106) intraperitoneally purified from lymph node cells of either naive or ovalbumin (OVA)-sensitized rats and were challenged with aerosolized OVA 2 days later. Control rats were sensitized to 100 mug of OVA in Al(OH)(3) subcutaneously or sham sensitized to saline and were OVA challenged 2 weeks later. Results: The OVA-sensitized and OVA-challenged group and the recipients of OVA-primed CD8(+) up T cells had significant late airway responses calculated from lung resistance measured for an 8-hour period after challenge compared with the naive CD8(+) up T cell-transferred group and the sham-sensitized control group. The number of eosinophils in bronchoalveolar lavage fluid increased in the OVA-sensitized group and the OVA-primed CD8(+) up T-cell recipients compared with numbers in the naive CD8(+) up T-cell recipients and the shamsensitized control group. IL-4 and IL-5 cytokine mRNA expression in bronchoalveolar lavage fluid increased in the OVA-sensitized group and the OVA-primed CD8(+) up T-cell recipients compared with that in the sham-sensitized group. Conclusion: We conclude that antigen-primed CD8(+) up T cells might have a proinflammatory role in allergen-driven airway responses in the rat.	McGill Univ, Meakins Christie Labs, Dept Med, Montreal, PQ H2X 2P2, Canada; Tokyo Med & Dent Univ, Dept Geriatr & Pulm Med, Tokyo, Japan	McGill University; Tokyo Medical & Dental University (TMDU)	Martin, JG (corresponding author), McGill Univ, Meakins Christie Labs, Dept Med, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.	james.martin@mcgill.ca		Martin, James/0000-0001-7574-5363				Allakhverdi Z, 2000, AM J RESP CRIT CARE, V162, P1123, DOI 10.1164/ajrccm.162.3.9910001; CARBONE A, 1991, IMMUNOL REV, V120, P35; Cautain B, 2002, J IMMUNOL, V168, P162, DOI 10.4049/jimmunol.168.1.162; Chien YH, 1996, ANNU REV IMMUNOL, V14, P511, DOI 10.1146/annurev.immunol.14.1.511; COCKCROFT DW, 1988, CHEST, V94, P178, DOI 10.1378/chest.94.1.178; COYLE AJ, 1995, J EXP MED, V181, P1229, DOI 10.1084/jem.181.3.1229; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; FREW AJ, 1988, J IMMUNOL, V141, P4158; Gil-Torregrosa BC, 2004, EUR J IMMUNOL, V34, P398, DOI 10.1002/eji.200324508; Haczku A, 1997, IMMUNOLOGY, V91, P176, DOI 10.1046/j.1365-2567.1997.d01-2221.x; Hamelmann E, 1996, J EXP MED, V183, P1719, DOI 10.1084/jem.183.4.1719; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; Holmes BJ, 1997, EUR J IMMUNOL, V27, P2657, DOI 10.1002/eji.1830271027; Hussell T, 1997, EUR J IMMUNOL, V27, P3341, DOI 10.1002/eji.1830271233; Ide K, 1999, J IMMUNOL, V163, P396; Isogai S, 2003, J ALLERGY CLIN IMMUN, V112, P547, DOI 10.1067/mai.2003.1682; Isogai S, 2000, EUR RESPIR J, V16, P22, DOI 10.1034/j.1399-3003.2000.16a05.x; Kalish RS, 1999, J ALLERGY CLIN IMMUN, V103, P192, DOI 10.1016/S0091-6749(99)70489-6; Kang J, 1997, Semin Immunol, V9, P171, DOI 10.1006/smim.1997.0069; KOZBOR D, 1989, J EXP MED, V169, P1847, DOI 10.1084/jem.169.5.1847; Lahn M, 2002, P NATL ACAD SCI USA, V99, P8850, DOI 10.1073/pnas.132519299; Lambrecht BN, 2001, CURR OPIN ALLERGY CL, V1, P51, DOI 10.1097/00130832-200102000-00010; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Magnan AO, 2000, AM J RESP CRIT CARE, V161, P1790, DOI 10.1164/ajrccm.161.6.9906130; MCMENAMIN C, 1994, SCIENCE, V265, P1869, DOI 10.1126/science.7916481; MCMENAMIN C, 1993, J EXP MED, V178, P889, DOI 10.1084/jem.178.3.889; Molet S, 1999, J ALLERGY CLIN IMMUN, V104, P205, DOI 10.1016/S0091-6749(99)70137-5; O'Sullivan S, 2001, AM J RESP CRIT CARE, V164, P560, DOI 10.1164/ajrccm.164.4.2102018; OLIVENSTEIN R, 1993, J CLIN INVEST, V92, P1477, DOI 10.1172/JCI116725; ROCK KL, 1990, SCIENCE, V249, P918, DOI 10.1126/science.2392683; SCHILD H, 1994, CELL, V76, P29, DOI 10.1016/0092-8674(94)90170-8; Schwarze J, 1999, J IMMUNOL, V162, P4207; Srikiatkhachorn A, 1997, J EXP MED, V186, P421, DOI 10.1084/jem.186.3.421; Suzuki M, 1999, J IMMUNOL, V163, P5574; Tsuji RF, 2002, J EXP MED, V196, P1277, DOI 10.1084/jem.20020649; Watanabe A, 1997, AM J RESP CELL MOL, V16, P69, DOI 10.1165/ajrcmb.16.1.8998081; WATANABE A, 1995, J CLIN INVEST, V96, P1303, DOI 10.1172/JCI118165; Watanabe J, 2003, J BIOL CHEM, V278, P42361, DOI 10.1074/jbc.M307752200; Zamoyska R, 1998, CURR OPIN IMMUNOL, V10, P82, DOI 10.1016/S0952-7915(98)80036-8	39	20	23	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2004	114	6					1345	1352		10.1016/j.jaci.2004.09.021	http://dx.doi.org/10.1016/j.jaci.2004.09.021			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	877NN	15577833				2022-12-18	WOS:000225577400014
J	Nugent, JS; More, DR; Hagan, LL; Demain, JG; Whisman, BA; Freeman, TM				Nugent, JS; More, DR; Hagan, LL; Demain, JG; Whisman, BA; Freeman, TM			Cross-reactivity between allergens in the venom of the common striped scorpion and the imported fire ant	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						centruroides vittatus; scorpion; venom; cross-reactivity imported fire ant	HYMENOPTERA VENOM	Background: The common striped scorpion, Centruroides vittatus, and the imported fire ant (IFA) are endemic to the south-central United States. There is evidence of venom-specific IgE in patients experiencing hypersensitivity reactions to scorpion stings. The infrequency of repeated scorpion stings and the presence of immediate reactions to an initial sting suggest prior sensitization. Objective: In the present study we evaluated the cross-reactivity of C vittatus venom with IFA whole-body extract (WBE). Methods: Sera were obtained from patients with symptoms of immediate hypersensitivity to C vittatus stings and from scorpion sting-naive patients allergic to IFA venom. Inhibition IgE immunoblots were performed by using scorpion venom and IFA WBE. Skin testing with scorpion venom was performed on scorpion sting-naive patients allergic to IFA venom. Results: Sera from patients with scorpion venom allergy demonstrated IgE binding to multiple allergens of similar sizes against both scorpion venom and IFA WBE. This binding was completely inhibited by preincubation of the sera with scorpion venom and IFA WBE. Pooled sera from patients with IFA venom allergy demonstrated similar bands on IgE immunoblotting against both IFA WBE and scorpion venom, with the latter being completely inhibited by preincubation of the sera with IFA WBE. Skin testing with scorpion venom was positive in 6 of 9 patients with IFA venom allergy. Conclusion: Significant cross-reactivity exists between the venom of C vittatus and IFA WBE. The high sensitization rate to IFA venom in endemic areas may therefore be a risk factor for subsequent immediate reactions to an initial scorpion sting. Patients with immediate hypersensitivity reactions to scorpion stings may potentially benefit from immunotherapy with IFA WBE.	Wilford Hall USAF Med Ctr, Dept Allergy Immunol, San Antonio, TX 78236 USA; Allergy Asthma & Immunol Ctr Alaska, Anchorage, AK USA	United States Department of Defense; United States Air Force	Nugent, JS (corresponding author), SGPFA, AMDS 96,307 Boatner Rd,Suite 114, Eglin AFB, FL 32542 USA.							DEMAIN JG, 1995, J ALLERGY CLIN IMMUN, V95, P135, DOI 10.1016/S0091-6749(95)70163-X; DESHAZO RD, 1990, NEW ENGL J MED, V323, P462, DOI 10.1056/NEJM199008163230707; HOFFMAN DR, 1988, J ALLERGY CLIN IMMUN, V82, P828, DOI 10.1016/0091-6749(88)90085-1; HOFFMAN DR, 1985, J ALLERGY CLIN IMMUN, V75, P611, DOI 10.1016/0091-6749(85)90038-7; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MICKS D W, 1960, Tex Rep Biol Med, V18, P624; STOCKWELL S, 2003, SCORPION EMPORIUM	7	20	23	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2004	114	2					383	386		10.1016/j.jaci.2004.04.016	http://dx.doi.org/10.1016/j.jaci.2004.04.016			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	847OU	15316520	Bronze			2022-12-18	WOS:000223405600027
J	Youssef, LA; Wilson, BS; Oliver, JM				Youssef, LA; Wilson, BS; Oliver, JM			Proteasome-dependent regulation of Syk tyrosine kinase levels in human basophils	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						basophil; Lyn; Syk; Fc epsilon RI; proteasome; ubiquitin	NONRELEASER BASOPHILS; MAST-CELLS; C-CBL; EXPRESSION; RECEPTOR; ZAP-70; PHOSPHORYLATION; UBIQUITINATION; PURIFICATION; PROTEOLYSIS	Background: In human basophils, FcepsilonRI signal initiation, leading to histamine release, relies on activation of Syk protein tyrosine kinase. Basophils from approximately 10%, of unselected donors do not degranulate in response to FcepsilonRI crosslinking. Their unresponsiveness has been linked to the absence of Syk protein despite apparently normal levels of Syk mRNA. Objective: The aim of this study was to explore pathways of Syk protein degradation as a possible posttranslational mechanism for downregulating Syk protein levels in human basophils and other leukocytes. Methods: Highly purified basophils, lymphocytes, and monocytes were incubated in the presence or absence of a panel of cell-permeable inhibitors of proteolytic degradation pathway(s). Subsequently, the protein level of Syk tyrosine kinase was determined by means of Western blotting. In vitro assays were conducted through use of immunoprecipitated basophil Syk and a rabbit reticulocyte lysate system. Results: Three inhibitors of proteasome-mediated degradation-PSI, lactacystin, and ALLN-substantially increased Syk levels in releaser basophils and restored Syk expression in nonreleaser basophils. Caspase inhibitors were less effective, and inhibitors of calpain-mediated proteolysis had no effect. Among other leukocytes tested, only naive CD4(+) T cells had more Syk after proteasome inhibitor treatment. In vitro ubiquitination assays demonstrated that Syk is readily ubiquitinated in vitro and also that Syk ubiquitination is associated with a substantial decrease in total levels of Syk protein. Conclusion: These data provide evidence for a ubiquitin/proteasome-dependent mechanism that contributes to Syk regulation in human basophils and might also be relevant to naive T cells. Understanding this regulatory pathway might lead to strategies for suppressing allergic inflammation while preserving essential Syk-mediated functions in other hematopoietic cells.	Univ New Mexico, Sch Med, Dept Pathol, CRF 203, Albuquerque, NM 87131 USA	University of New Mexico	Youssef, LA (corresponding author), Univ New Mexico, Sch Med, Dept Pathol, CRF 203, 2325 Camino Salud, Albuquerque, NM 87131 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056384] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049814] Funding Source: NIH RePORTER; NHLBI NIH HHS [P50 HL56384] Funding Source: Medline; NIGMS NIH HHS [R01 GM49814] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BJERKE T, 1993, J IMMUNOL METHODS, V157, P49, DOI 10.1016/0022-1759(93)90069-J; CHAN AC, 1994, J IMMUNOL, V152, P4758; Chu DH, 1999, J IMMUNOL, V163, P2610; COSTELLO P, 1997, ONCOGENE, V13, P2595; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; EISEMAN E, 1992, NATURE, V355, P78; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Glickman M.H., 2000, PHYSIOL REV, V82, P373; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; KEPLEY C, 1994, J IMMUNOL METHODS, V175, P1, DOI 10.1016/0022-1759(94)90326-3; Kepley CL, 2000, J IMMUNOL, V165, P5913, DOI 10.4049/jimmunol.165.10.5913; Kepley CL, 1998, J ALLERGY CLIN IMMUN, V102, P304, DOI 10.1016/S0091-6749(98)70100-9; Kepley CL, 1999, J ALLERGY CLIN IMMUN, V104, P279, DOI 10.1016/S0091-6749(99)70367-2; Lavens-Phillips SE, 2000, AM J RESP CELL MOL, V23, P566, DOI 10.1165/ajrcmb.23.4.4123; Lupher ML, 1998, INT J BIOCHEM CELL B, V30, P439, DOI 10.1016/S1357-2725(97)00075-7; Moriya K, 1997, P NATL ACAD SCI USA, V94, P12539, DOI 10.1073/pnas.94.23.12539; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; Ota S, 2000, J BIOL CHEM, V275, P414, DOI 10.1074/jbc.275.1.414; PAOLINI R, 1993, EMBO J, V12, P779, DOI 10.1002/j.1460-2075.1993.tb05712.x; Paolini R, 2001, P NATL ACAD SCI USA, V98, P9611, DOI 10.1073/pnas.161298098; Rao N, 2001, EMBO J, V20, P7085, DOI 10.1093/emboj/20.24.7085; Rao N, 2000, J IMMUNOL, V164, P4616, DOI 10.4049/jimmunol.164.9.4616; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; Turner M, 2000, IMMUNOL TODAY, V21, P148, DOI 10.1016/S0167-5699(99)01574-1; WILSON BS, INFLAMMATORY MECH AL, P197; Yanagi S, 2001, BIOCHEM BIOPH RES CO, V288, P495, DOI 10.1006/bbrc.2001.5788; ZIONCHECK TF, 1988, J BIOL CHEM, V263, P19195	30	20	21	1	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2002	110	3					366	373		10.1067/mai.2002.127562	http://dx.doi.org/10.1067/mai.2002.127562			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	592KM	12209081				2022-12-18	WOS:000177936900004
J	Zhuang, QL; Bisotto, S; Fixman, ED; Mazer, B				Zhuang, QL; Bisotto, S; Fixman, ED; Mazer, B			Suppression of IL-4-and CD40-induced B-lymphocyte activation by intravenous immunoglobulin is not mediated through the inhibitory IgG receptor Fc gamma RIIb	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						antibodies; B lymphocytes; Fc receptors; protein kinases-phosphatases; cellular proliferation; intravenous immunoglobulin; IgE	NEGATIVE REGULATION; GLOBULIN THERAPY; SHIP; RECRUITMENT; PATHWAYS	Background: Intravenous immunoglobulin (IVIG) has been used extensively in the treatment of autoimmune and allergic diseases, but the precise mechanism behind its efficacy remains unclear. Ligation of the low-affinity IgG Fe receptor FcgammaRIIb ran inhibit B-lymphocyte activation. Our laboratory has shown that IVIG suppresses proliferation and IgE production by human B cells stimulated with IL-4 and anti-CD40 antibodies. Objective: We sought to determine whether the regulatory action of IVIG is mediated through binding FcgammaRIIb, phosphorylation of the receptor, and induction of phosphatases, including SH2-containing inositol-5'-phosphatase. Methods: All experiments, were performed on human tonsillar B cells. Phenotyping was performed by means of flow cytometry. Cells were cultured with IL-4 and anti-CD40 antibodies with or without IVIG (10 mg/mL), and FCgammaRIIb receptor activation and phosphorylation were measured by means of Western blot analysis. Results: FcgammaRIIb was the predominant isoform of Fcgamma receptor expressed on tonsillar B cells, and preincubation with IVIG failed to block binding of FcgammaRIIb antibody. Anti-FcgammaRIIb antibodies did not reverse inhibition of B-cell proliferation or IgE production by IVIG. Treatment of stimulated B lymphocytes with IVIG for 1 to 60 minutes did not change the global protein tyrosine phosphorylation pattern, except for tyrosine phosphorylation of an unidentified 30-kd protein. We directly examined tyrosine phosphorylation of FcgammaRIIb and its downstream-associated phosphatase, SH2-containing inositol-5'-phosphatase. Both remained unchanged after IVIG treatment, as did other related phosphatases. Conclusion: These data argue against the involvement of FcgammaRIIb in the inhibition of CD40/IL-4-induced B-cell activation by IVIG.	McGill Univ, Meakins Christie Labs, Montreal, PQ H2X 2P2, Canada; Montreal Childrens Hosp, Div Allergy & Immunol, Montreal, PQ H3H 1P3, Canada	McGill University; McGill University	Mazer, B (corresponding author), McGill Univ, Meakins Christie Labs, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.							Bolland S, 1999, ADV IMMUNOL, V72, P149, DOI 10.1016/S0065-2776(08)60019-X; Bruhns P, 2000, J BIOL CHEM, V275, P37357, DOI 10.1074/jbc.M003518200; Chacko GW, 1996, J IMMUNOL, V157, P2234; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; Gergely J, 1996, SCAND J IMMUNOL, V44, P1; MICKLEM KJ, 1990, J IMMUNOL, V144, P2295; Nakamura K, 1998, J IMMUNOL, V161, P684; Nozawa Y, 1999, Fukushima J Med Sci, V45, P1; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Ono M, 1997, CELL, V90, P293, DOI 10.1016/S0092-8674(00)80337-2; Ott VL, 2001, J ALLERGY CLIN IMMUN, V108, pS95, DOI 10.1067/mai.2001.117822; Ravetch JV, 2001, ANNU REV IMMUNOL, V19, P275, DOI 10.1146/annurev.immunol.19.1.275; Ravetch JV, 2000, SCIENCE, V290, P84, DOI 10.1126/science.290.5489.84; Samuelsson A, 2001, SCIENCE, V291, P484, DOI 10.1126/science.291.5503.484; Sigman K, 1998, J ALLERGY CLIN IMMUN, V102, P421, DOI 10.1016/S0091-6749(98)70130-7; Spellberg B, 1999, NEW ENGL J MED, V341, P57; Zhuang QL, 2001, J ALLERGY CLIN IMMUN, V108, P229, DOI 10.1067/mai.2001.116291	18	20	23	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2002	110	3					480	483		10.1067/mai.2002.127284	http://dx.doi.org/10.1067/mai.2002.127284			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	592KM	12209098	Bronze			2022-12-18	WOS:000177936900021
J	Fish, JE				Fish, JE			Occupational asthma and rhinoconjunctivitis induced by natural rubber latex exposure	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Meeting on Natural Rubber Latex Sensitivity	FEB 09-10, 2001	SAN FRANCISCO, CA	Malaysian Rubber Res Inst		natural rubber latex; occupational asthma; rhinoconjunctivitis	LABORATORY-ANIMAL ALLERGY; IGE ANTIBODIES; METHACHOLINE CHALLENGE; AIRWAY RESPONSIVENESS; MOUSE ALLERGENS; PREVALENCE; SENSITIZATION; GLOVES; APPRENTICES; AEROALLERGENS	A number of reports indicate that occupational exposure to natural rubber latex (NRL) in health care workers can elicit symptoms of rhinoconjunctivitis with or without asthma in selected individuals who are sensitized. The prevalence or risk of NRL-induced asthma in relation to rhinoconjunctivitis is small in comparison with other forms of occupational allergic respiratory disease. The lower risk of NRL-induced asthma appears to be related to poor penetration of the allergen into the lower respiratory tract because of the relatively large particle size of allergen-bearing cornstarch particles. Because of a lack of large prospective studies, little is know about the incidence and natural history of latex-induced respiratory disease. Because of heightened awareness of NRL allergy and changing patterns in glove manufacturing and glove use, it is likely that the occurrence of NRL-induced occupational respiratory disease will decline and its natural history will change. Nevertheless, because large number of individuals are exposed to NRL in various occupations, the incidence, prevalence, and natural history of NRL allergy merit further monitoring.	Thomas Jefferson Univ, Div Pulm & Crit Care Med, Philadelphia, PA 19107 USA	Jefferson University	Fish, JE (corresponding author), Div Pulm, 805 Coll Bldg,Room 805,1025 Walnut St, Philadelphia, PA 19107 USA.							AHMED T, 1981, J ALLERGY CLIN IMMUN, V67, P135, DOI 10.1016/0091-6749(81)90009-9; Allmers H, 1998, J ALLERGY CLIN IMMUN, V102, P841, DOI 10.1016/S0091-6749(98)70026-0; AOYAMA K, 1992, BRIT J IND MED, V49, P41; Archambault S, 2001, J ALLERGY CLIN IMMUN, V107, P921; ARELLANO R, 1992, ANESTHESIOLOGY, V77, P905, DOI 10.1097/00000542-199211000-00011; BAUR X, 1990, LANCET, V335, P912, DOI 10.1016/0140-6736(90)90508-3; Baur X, 1998, AM J IND MED, V33, P114; Baur X, 1998, CLIN EXP ALLERGY, V28, P537; BEEZHOLD D, 1992, ARCH SURG-CHICAGO, V127, P1354; BERNSTEIN DI, 1994, ASTHMA WORKPLACE, P103; BLANC P, 1987, CHEST, V92, P613, DOI 10.1378/chest.92.4.613; BRUGNAMI G, 1995, J ALLERGY CLIN IMMUN, V96, P457, DOI 10.1016/S0091-6749(95)70287-3; CARRILLO T, 1995, J ALLERGY CLIN IMMUN, V96, P699, DOI 10.1016/S0091-6749(95)70273-3; CHANYEUNG M, 1982, AM J MED, V72, P411, DOI 10.1016/0002-9343(82)90497-1; COCKCROFT A, 1981, LANCET, V1, P827; COCKCROFT DW, 1987, AM REV RESPIR DIS, V135, P264; CORMIO L, 1993, CLIN EXP ALLERGY, V23, P618, DOI 10.1111/j.1365-2222.1993.tb00903.x; CORN M, 1988, ANN OCCUP HYG     S1, V32, P435; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; DAVIES GE, 1983, BRIT J IND MED, V40, P442; DAVIES GE, 1981, INT ARCH ALLER A IMM, V64, P302, DOI 10.1159/000232707; DEZOTTI R, 1992, BRIT J IND MED, V49, P596; DEZOTTI R, 1996, EUR J ALLERGY CLIN I, V31, P47; Douglas R, 1997, AUST NZ J MED, V27, P165, DOI 10.1111/j.1445-5994.1997.tb00933.x; FISH JE, 1980, J ALLERGY CLIN IMMUN, V65, P154, DOI 10.1016/0091-6749(80)90201-8; FISH JE, 1998, ALLERGY PRINCIPLES P, P454; Gautrin D, 2000, AM J RESP CRIT CARE, V162, P1222, DOI 10.1164/ajrccm.162.4.2001023; Gautrin D, 2001, AM J RESP CRIT CARE, V163, P899, DOI 10.1164/ajrccm.163.4.2008011; GROSS NJ, 1980, J ALLERGY CLIN IMMUN, V66, P158, DOI 10.1016/0091-6749(80)90064-0; Grzybowski M, 1996, J ALLERGY CLIN IMMUN, V98, P535, DOI 10.1016/S0091-6749(96)70087-8; Hamann CP, 1998, J AM DENT ASSOC, V129, P43, DOI 10.14219/jada.archive.1998.0021; Heilman DK, 1996, J ALLERGY CLIN IMMUN, V98, P325, DOI 10.1016/S0091-6749(96)70157-4; Ho A, 1996, THORAX, V51, P1280, DOI 10.1136/thx.51.12.1280; Hollander A, 1998, EUR RESPIR J, V11, P929, DOI 10.1183/09031936.98.11040929; HUNT LW, 1995, J OCCUP ENVIRON MED, V37, P1204, DOI 10.1097/00043764-199510000-00011; Kaczmarek RG, 1996, ANN ALLERG ASTHMA IM, V76, P51, DOI 10.1016/S1081-1206(10)63406-0; Kibby T, 1997, ANN ALLERG ASTHMA IM, V78, P41, DOI 10.1016/S1081-1206(10)63370-4; KUJALA V, 1995, J LARYNGOL OTOL, V109, P1094, DOI 10.1017/S0022215100132116; Kujala VM, 1996, AM J RHINOL, V10, P67, DOI 10.2500/105065896781795094; KUJALA VM, 1995, AM J IND MED, V28, P89, DOI 10.1002/ajim.4700280108; LAGIER F, 1990, LANCET, V336, P516, DOI 10.1016/0140-6736(90)92076-T; Laoprasert N, 1998, J ALLERGY CLIN IMMUN, V101, pS165; Leung R, 1997, CLIN EXP ALLERGY, V27, P167; Liss GM, 1997, OCCUP ENVIRON MED, V54, P335, DOI 10.1136/oem.54.5.335; LUTSKY II, 1975, ANN ALLERGY, V35, P201; Mace SR, 1998, ANN ALLERG ASTHMA IM, V80, P252, DOI 10.1016/S1081-1206(10)62966-3; Malo JL, 1997, EUR RESPIR J, V10, P1513, DOI 10.1183/09031936.97.10071513; MARCOS C, 1991, ANN ALLERGY, V67, P319; Moneret-Vautrin D. A., 1994, Rhinology (Utrecht), V32, P198; MORALES C, 1989, CLIN EXP ALLERGY, V19, P425, DOI 10.1111/j.1365-2222.1989.tb02409.x; MOSCATO G, 1995, J ALLERGY CLIN IMMUN, V96, P295; MUIR DCF, 1991, LUNG SCI FDN, P1939; *NAT HEART LUNG BL, 1997, 2 NAT HEART LUNG BLO, P1; Nathan RA, 1997, J ALLERGY CLIN IMMUN, V99, pS808, DOI 10.1016/S0091-6749(97)80040-1; NEWILL CA, 1992, AM REV RESPIR DIS, V146, P1494, DOI 10.1164/ajrccm/146.6.1494; NEWMANTAYLOR A, 1977, LANCET, V2, P847; NUTTER AF, 1979, BRIT J DERMATOL, V101, P597, DOI 10.1111/j.1365-2133.1979.tb15107.x; OBRIEN IM, 1979, CLIN ALLERGY, V9, P7, DOI 10.1111/j.1365-2222.1979.tb01517.x; OHMAN JL, 1994, J ALLERGY CLIN IMMUN, V94, P810, DOI 10.1016/0091-6749(94)90147-3; OHMAN JL, 1975, J ALLERGY CLIN IMMUN, V55, P16, DOI 10.1016/S0091-6749(75)80004-2; ORFAN NA, 1994, J ALLERGY CLIN IMMUN, V94, P826, DOI 10.1016/0091-6749(94)90149-X; PAGE E, 1998, 98OO962737 ST JOS HO; PAGGIARO P, 1990, CHEST, V98, P536, DOI 10.1378/chest.98.3.536; PISATI G, 1994, EUR RESPIR J, V7, P332, DOI 10.1183/09031936.94.07020332; Pisati G, 1998, J ALLERGY CLIN IMMUN, V101, P327, DOI 10.1016/S0091-6749(98)70243-X; PLATTSMILLS TAE, 1986, J ALLERGY CLIN IMMUN, V77, P850, DOI 10.1016/0091-6749(86)90383-0; PRICE JA, 1990, CLIN EXP ALLERGY, V20, P71, DOI 10.1111/j.1365-2222.1990.tb02778.x; SEATON A, 1988, BRIT MED J, V296, P531, DOI 10.1136/bmj.296.6621.531-a; SLATER JE, 1994, J ALLERGY CLIN IMMUN, V94, P139, DOI 10.1016/0091-6749(94)90031-0; SLOVAK AJM, 1987, BRIT J IND MED, V44, P129; Sussman GL, 1998, J ALLERGY CLIN IMMUN, V101, P171, DOI 10.1016/S0091-6749(98)70381-1; SWANSON MC, 1994, J ALLERGY CLIN IMMUN, V94, P445, DOI 10.1016/0091-6749(94)90199-6; Tarlo SM, 1997, J ALLERGY CLIN IMMUN, V99, P396, DOI 10.1016/S0091-6749(97)70058-7; TARLO SM, 1994, J ALLERGY CLIN IMMUN, V93, P985, DOI 10.1016/S0091-6749(94)70045-1; TARLO SM, 1990, J ALLERGY CLIN IMMUN, V85, P626, DOI 10.1016/0091-6749(90)90103-B; TOMAZIC VJ, 1994, J ALLERGY CLIN IMMUN, V93, P751, DOI 10.1016/0091-6749(94)90255-0; TURJANMAA K, 1987, CONTACT DERMATITIS, V17, P270, DOI 10.1111/j.1600-0536.1987.tb01476.x; TWIGGS JT, 1982, J ALLERGY CLIN IMMUN, V69, P522, DOI 10.1016/0091-6749(82)90177-4; *US CDC, 1998, MMWR-MORBID MORTAL W, V47, P1022; VANDENPLAS O, 1995, AM J RESP CRIT CARE, V151, P54, DOI 10.1164/ajrccm.151.1.7812572; VANDENPLAS O, 1995, EUR RESPIR J, V8, P1957, DOI 10.1183/09031936.95.08111957; Vandenplas O, 1996, THORAX, V51, P452, DOI 10.1136/thx.51.4.452; VANDENPLAS O, 1995, AM J RESP CRIT CARE, V151, P887; VENABLES KM, 1988, BRIT J IND MED, V45, P660; YASSIN MS, 1994, ANN ALLERGY, V72, P245	85	20	21	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2002	110	2		S			S75	S81		10.1067/mai.2002.125331	http://dx.doi.org/10.1067/mai.2002.125331			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	586ET	12170247				2022-12-18	WOS:000177572200012
J	Szefler, SJ				Szefler, SJ			The natural history of asthma and early intervention	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; natural history; inflammation; early intervention	CONTROLLED TRIAL; LIFE	The understanding of the natural history of asthma has changed significantly during the last 4 decades, with the view that asthma is a disease of chronic inflammation and varying degrees of severity replacing that of it being a disease of reversible airway obstruction. Treatment has progressed in accordance with the growing knowledge about the pathophysiologic mechanisms of asthma. Nevertheless, much remains unknown, especially about how to treat asthma effectively. Pharmacogenetics, an emerging field in which the knowledge of the genetic basis of a disease is applied to its treatment, may ultimately lead investigators to define many unanswered questions about asthma therapy. Asthma occurs early in childhood, but the ideal time for intervention and the most effective treatment strategy are yet unknown for young patients. The lack of response to a therapy may indicate the course of the disease as much as a lack of treatment efficacy. It may be that including such variables as airway hyperresponsiveness in treatment goals will not only become routine but will result in improved long-term asthma treatment as well. The progress in defining asthma and targeting treatment toward specific pathophysiologic mechanisms should lead to better-defined optimal strategies for treating asthma in children.	Natl Jewish Med & Res Ctr, Div Clin Pharmacol, Dept Pediat, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Pediat & Pharmacol, Denver, CO USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Szefler, SJ (corresponding author), Natl Jewish Med & Res Ctr, Div Clin Pharmacol, Dept Pediat, 1400 Jackson St,Room J209, Denver, CO 80206 USA.				NCRR NIH HHS [5M01-RR00051] Funding Source: Medline; NHLBI NIH HHS [HL-36577] Funding Source: Medline; NICHD NIH HHS [HD-37237] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U01HD037237] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000051] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036577] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barnes PJ, 1998, EUR RESPIR J, V12, P1209, DOI 10.1183/09031936.98.12051209; *GINA, 1998, NIH PUBL; Holgate ST, 1997, LANCET, V350, P5; Lazarus SC, 2001, JAMA-J AM MED ASSOC, V285, P2583, DOI 10.1001/jama.285.20.2583; Malmstrom K, 1999, ANN INTERN MED, V130, P487, DOI 10.7326/0003-4819-130-6-199903160-00005; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; *NAEPP, 1997, NIH PUBL; Oswald H, 1997, PEDIATR PULM, V23, P14, DOI 10.1002/(SICI)1099-0496(199701)23:1<14::AID-PPUL2>3.0.CO;2-P; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043, DOI 10.1164/ajrccm.159.4.9806052; Szefler S, 2000, NEW ENGL J MED, V343, P1054; WEISS ST, 1995, EUR RESPIR REV, V5, P303; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888, DOI 10.1164/ajrccm/146.4.888	12	20	20	1	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2002	109	6		S			S549	S553		10.1067/mai.2002.124569	http://dx.doi.org/10.1067/mai.2002.124569			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	568JU	12063511				2022-12-18	WOS:000176539300006
J	Schroeder, JT; Miura, K; Kim, HH; Sin, A; Cianferoni, A; Casolaro, V				Schroeder, JT; Miura, K; Kim, HH; Sin, A; Cianferoni, A; Casolaro, V			Selective expression of nuclear factor of activated T cells 2/c1 in human basophils: Evidence for involvement in IgE-mediated IL-4 generation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						human; basophil; transcription factor; IgE; cytokine; Fc epsilon RI; leukocyte	TRANSCRIPTION FACTOR NFAT1; MIXED LEUKOCYTE-CULTURES; HISTAMINE-RELEASE; PERIPHERAL-BLOOD; NF-AT; CYTOKINE PRODUCTION; MAST-CELLS; SECRETION; PROTEIN; FAMILY	Background: The nuclear factor of activated T cells (NFAT) family of transcription factors plays a key role in rapidly inducing IL4 gene expression in effector T cells. Objective: Because human basophils secrete high levels of IL-4, we have examined whether specific NFAT species are expressed in these cells and whether FcepsilonRI-mediated activation affects their subcellular localization and transcriptional function. Methods: Intracellular NFAT protein was identified by using 2-color flow cytometry; gene expression was done with RTPCR. Subcellular localization of NFAT was assessed by means of Western blotting. Electrophoretic mobility shift assays assessed NFAT involvement in IL-4 transcription. Results: Basophils constitutively expressed high levels of NFAT2. In contrast, NFAT1 (NFATp), which is found in most leukocytes, was not seen in basophils. Low-level staining for NFAT4 was detected but was variably expressed among donor cells. Likewise, NFAT2 mRNA was constitutively expressed in basophils, and message for NFAT4 was seen in 3 of 5 preparations, whereas that for NFAT1 was found in only 1 of 5 preparations. NFAT2 protein accumulated in the nuclei of basophils activated for 1 hour with anti-IgE, and this was inhibited with the addition of FK506. A protein-DNA complex was formed with nuclear lysates from basophils and an IL-4 promoter NFAT consensus probe, with greater binding intensities detected in lysates of activated cells. An antibody to NFAT2 reduced the formation of the complex, whereas no effects were seen with antibodies to NFAT1, NFAT4, or unrelated transcription factors. Conclusions: The selective and specific expression of NFAT2 in basophils is unique among leukocytes. This transcription factor also appears to play a critical role in the FcepsilonRI-mediated production of IL-4 in these cells.	Johns Hopkins Asthma & Allergy Ctr, Div Clin Immunol, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine	Schroeder, JT (corresponding author), Johns Hopkins Asthma & Allergy Ctr, Div Clin Immunol, Unit Off 2,5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.		Casolaro, Vincenzo/E-9144-2010	Casolaro, Vincenzo/0000-0001-9810-0488	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042221, R29AI041463, R01AI041463, R29AI042221, R21AI042221] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-07290, AI-41463, AI-42221] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARAMBURU J, 1995, J EXP MED, V182, P801, DOI 10.1084/jem.182.3.801; BRUNNER T, 1993, J EXP MED, V177, P605, DOI 10.1084/jem.177.3.605; CASOLARO V, 1995, P NATL ACAD SCI USA, V92, P11623, DOI 10.1073/pnas.92.25.11623; CHOI MSK, 1994, IMMUNITY, V1, P179, DOI 10.1016/1074-7613(94)90096-5; Devouassoux G, 1999, J ALLERGY CLIN IMMUN, V104, P811, DOI 10.1016/S0091-6749(99)70292-7; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Gibbs BF, 1996, EUR J IMMUNOL, V26, P2493, DOI 10.1002/eji.1830261033; GILBERT HS, 1975, BLOOD, V46, P279; HUTCHINSON LE, 1995, J BIOL CHEM, V270, P16333, DOI 10.1074/jbc.270.27.16333; Kepley CL, 2000, J IMMUNOL, V165, P5913, DOI 10.4049/jimmunol.165.10.5913; Li HM, 1996, J IMMUNOL, V156, P4833; Lopez-Rodriguez C, 1999, P NATL ACAD SCI USA, V96, P7214, DOI 10.1073/pnas.96.13.7214; Lyakh L, 1997, MOL CELL BIOL, V17, P2475, DOI 10.1128/MCB.17.5.2475; MACGLASHAN D, 1994, J IMMUNOL, V152, P3006; Macian F, 2001, ONCOGENE, V20, P2476, DOI 10.1038/sj.onc.1204386; Miura K, 1999, J IMMUNOL, V162, P4198; PRIESCHL EE, 1995, J IMMUNOL, V154, P6112; Prussin C, 1995, J IMMUNOL METHODS, V188, P117, DOI 10.1016/0022-1759(95)00209-X; Ranger AM, 1998, IMMUNITY, V9, P627, DOI 10.1016/S1074-7613(00)80660-3; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Redrup AC, 1998, J IMMUNOL, V160, P1957; Schroeder JT, 1997, J ALLERGY CLIN IMMUN, V99, P429, DOI 10.1016/S0091-6749(97)70065-4; SCHROEDER JT, 1994, J IMMUNOL, V153, P1808; Schroeder JT, 1998, J LEUKOCYTE BIOL, V63, P692, DOI 10.1002/jlb.63.6.692; Seminario MC, 2001, J ALLERGY CLIN IMMUN, V107, P143, DOI 10.1067/mai.2001.111931; Sherman MA, 1999, J IMMUNOL, V162, P2820; Tan JQ, 1999, J IMMUNOL, V163, P21; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; Weiss DL, 1996, MOL CELL BIOL, V16, P228; Wierenga EA, 1999, INT IMMUNOL, V11, P297, DOI 10.1093/intimm/11.2.297; Xanthoudakis S, 1996, SCIENCE, V272, P892, DOI 10.1126/science.272.5263.892; Yoshida H, 1998, IMMUNITY, V8, P115, DOI 10.1016/S1074-7613(00)80464-1	32	20	20	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2002	109	3					507	513		10.1067/mai.2002.122460	http://dx.doi.org/10.1067/mai.2002.122460			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	534KW	11897999				2022-12-18	WOS:000174586400019
J	Matsumoto, K; Gauvreau, GM; Rerecich, T; Watson, RM; Wood, LJ; O'Byrne, PM				Matsumoto, K; Gauvreau, GM; Rerecich, T; Watson, RM; Wood, LJ; O'Byrne, PM			IL-10 productions in circulating T cells differs between allergen-induced isolated early and dual asthmatic responders	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-10; IL-5; allergens; asthma; early responders; dual responders	PERIPHERAL-BLOOD EOSINOPHILS; CYTOKINE PRODUCTION; ALVEOLAR MACROPHAGES; AIRWAY INFLAMMATION; FLOW-CYTOMETRY; INTERLEUKIN-10; LYMPHOCYTES; RESPONSES; LIPOPOLYSACCHARIDE; EXPRESSION	Background: IL-10 is an anti-inflammatory cytokine released from various cells, including T cells. The role of IL-10 in asthma pathogenesis remains uncertain. Allergen inhalation, by atopic asthmatic subjects results in 2 bronchoconstrictor phenotypes: isolated early response and dual response. Persistence of allergen-induced airway inflammation is a feature of dual responders. Objectives: The kinetics of IL-10 production in circulating T cells were investigated to examine a potential role of IL-10 in allergen-induced responses and airway inflammation. Methods: Fourteen subjects with mild asthma (7 isolated early and 7 dual responders) were challenged with allergen. PBMCs taken before and 24 hours after allergen challenge were processed for intracellular IL-10 staining with fluorescent-conjugated anti-IL-10 antibody. The frequency of IL-10-producing cells was assessed for CD4(+) and CD8(+) T-cell subsets by using flow cytometry. Results: Before allergen administration, the frequency of IL-10-producing CD4+ cells was significantly higher in dual than in isolated early responders. IL-10-producing CD4+ cells significantly increased after allergen in early responders, whereas IL-10-producing CD4+ cells significantly decreased in dual responders. Simultaneous assessments of IL-5-producing T cells did not show any differences between each group before or after allergen administration. Conclusions: These results suggest that the contrasting profiles of IL-10 production may be associated with the different time course of allergen-induced airway inflammation between allergen-induced early and dual responders.	St Josephs Healthcare, Firestone Inst Res Hlth, Asthma Res Grp, Hamilton, ON L8N 4A6, Canada; McMaster Univ, Hamilton, ON, Canada	McMaster University	O'Byrne, PM (corresponding author), St Josephs Healthcare, Firestone Inst Res Hlth, Asthma Res Grp, 50 Charlton Ave E, Hamilton, ON L8N 4A6, Canada.			O'Byrne, Paul/0000-0003-0979-281X				*AM THOR SOC, 1995, AM J RESP CRIT CARE, V152, pS42; Borish L, 1996, J ALLERGY CLIN IMMUN, V97, P1288, DOI 10.1016/S0091-6749(96)70197-5; Borish L, 1998, J ALLERGY CLIN IMMUN, V101, P293, DOI 10.1016/S0091-6749(98)70238-6; CASSATELLA MA, 1993, J EXP MED, V178, P2207, DOI 10.1084/jem.178.6.2207; COCKCROFT DW, 1987, AM REV RESPIR DIS, V135, P264; Cockcroft DW, 1985, AIRWAY RESPONSIVENES, P22; DEL PG, 1993, J IMMUNOL, V150, P353; DEROSE V, 1994, J CLIN INVEST, V94, P1840, DOI 10.1172/JCI117533; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; FIORENTINO DF, 1991, J IMMUNOL, V146, P3444; FREW AJ, 1992, J ALLERGY CLIN IMMUN, V89, P783, DOI 10.1016/0091-6749(92)90431-Z; Gauvreau GM, 1999, AM J RESP CRIT CARE, V160, P640, DOI 10.1164/ajrccm.160.2.9809130; Gauvreau GM, 1996, AM J RESP CRIT CARE, V154, P1267, DOI 10.1164/ajrccm.154.5.8912734; Gosset P, 1999, J ALLERGY CLIN IMMUN, V103, P289, DOI 10.1016/S0091-6749(99)70504-X; Hallden G, 1999, CLIN EXP ALLERGY, V29, P595; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; Haselden BM, 1999, J EXP MED, V189, P1885, DOI 10.1084/jem.189.12.1885; John M, 1998, AM J RESP CRIT CARE, V157, P256, DOI 10.1164/ajrccm.157.1.9703079; JUNG T, 1993, J IMMUNOL METHODS, V159, P197, DOI 10.1016/0022-1759(93)90158-4; Krug N, 1998, CLIN EXP ALLERGY, V28, P10; Krug N, 1996, AM J RESP CELL MOL, V14, P319, DOI 10.1165/ajrcmb.14.4.8600935; MALEFYT RD, 1993, J IMMUNOL, V150, P4754; MATSUMOTO K, 2000, AM J RESP CRIT CARE, V161, pA596; OBYRNE PM, 1987, AM REV RESPIR DIS, V136, P740, DOI 10.1164/ajrccm/136.3.740; Ohkawara Y, 1997, AM J RESP CELL MOL, V16, P510, DOI 10.1165/ajrcmb.16.5.9160833; Prussin C, 1997, J CLIN IMMUNOL, V17, P195, DOI 10.1023/A:1027350226435; ROBINSON D, 1993, AM REV RESPIR DIS, V148, P401, DOI 10.1164/ajrccm/148.2.401; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Robinson DS, 1996, AM J RESP CELL MOL, V14, P113, DOI 10.1165/ajrcmb.14.2.8630259; ROSSI GA, 1991, AM REV RESPIR DIS, V144, P379, DOI 10.1164/ajrccm/144.2.379; Shi HZ, 1998, AM J RESP CRIT CARE, V157, P204, DOI 10.1164/ajrccm.157.1.9703027; TAKANASKI S, 1994, J EXP MED, V180, P711, DOI 10.1084/jem.180.2.711; Wood JJ, 1998, AM J RESP CRIT CARE, V157, P99, DOI 10.1164/ajrccm.157.1.9704125	33	20	21	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2002	109	2					281	286		10.1067/mai.2002.121144	http://dx.doi.org/10.1067/mai.2002.121144			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	528EZ	11842298				2022-12-18	WOS:000174232600013
J	Upham, JW; Sehmi, R; Hayes, LM; Howie, K; Lundahl, J; Denburg, JA				Upham, JW; Sehmi, R; Hayes, LM; Howie, K; Lundahl, J; Denburg, JA			Retinoic acid modulates IL-5 receptor expression and selectivelyinhibits eosinophil-basophil differentiation of hemopoietic progenitor cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						retinoic acid; hemopoiesis; eosinophils; basophils; IL-5 receptor	COLONY-STIMULATING FACTOR; ALPHA SUBUNIT GENE; PROMYELOCYTIC LEUKEMIA; MESSENGER-RNA; LINE HL-60; INTERLEUKIN-5 IL-5; TRANSGENIC MICE; ALL-TRANS; ASTHMA; PROMOTER	Background: IL-5 plays a central role in eosinophil and basophil differentiation, exerting its effects through the IL-5 receptor (IL-5Ralpha). Currently, little is known concerning regulation of IL-5Ralpha expression in the context of commitment of hemopoietic progenitor cells to the eosinophil and basophil lineages. Objective: Because all-trans retinoic acid (ATRA) is known to modulate some aspects of hemopoietic differentiation, we examined the effects of ATRA on eosinophil-basophil differentiation and IL-5Ralpha expression. Methods: Progenitor cells were obtained from bone marrow aspirates and cord blood samples. Enriched populations of CD34(+) cells were isolated by means of positive immunomagnetic selection with MACS beads. Results: In semisolid methylcellulose cultures of normal human bone marrow, ATRA (10(-6) mol/L) selectively suppressed eosinophil-basophil colony-forming units but had no effect on granulocyte-macrophage colony-forming units. Similarly, ATRA (10(-6) mol/L) inhibited eosinophil-basophil differentiation of cord blood CD34(+) cells in liquid culture, whereas neutrophil differentiation proceeded without impediment. Most importantly, these effects of ATRA (10(-8) to 10(-6) mol/L) on CD34(+) cells were associated with a dose-dependent inhibition of IL-5Ralpha but no change in GM-CSF receptor expression, as detected with flow cytometry. Conclusions: These findings indicate that retinoids can differentially regulate expression of IL-5Ralpha, but not GM-CSF receptor, and that these effects have functional consequences in vitro on eosinophil and basophil differentiation.	McMaster Univ, Dept Med, Hamilton, ON L8N 3Z5, Canada; Univ Western Australia, Dept Med, Perth, WA 6009, Australia	McMaster University; University of Western Australia	Denburg, JA (corresponding author), McMaster Univ, Dept Med, HSC 3V46,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.		Upham, John/F-4420-2010	Upham, John/0000-0002-0017-3433				BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; CHIHARA J, 1990, J EXP MED, V172, P1347, DOI 10.1084/jem.172.5.1347; CLUTTERBUCK EJ, 1989, BLOOD, V73, P1504; DENBURG JA, 1985, BLOOD, V66, P312; DENBURG JA, 1994, J ALLERGY CLIN IMMUN, V94, P1135, DOI 10.1016/0091-6749(94)90321-2; DENT LA, 1990, J EXP MED, V172, P1425, DOI 10.1084/jem.172.5.1425; EMA H, 1990, BLOOD, V76, P1956; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; GULBENKIAN AR, 1992, AM REV RESPIR DIS, V146, P263, DOI 10.1164/ajrccm/146.1.263; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; HUTTTAYLOR SR, 1988, BLOOD, V71, P209; INGLEY E, 1991, BLOOD, V78, P339; ISHIZAKA T, 1985, J IMMUNOL, V134, P532; Iwama A, 1999, MOL CELL BIOL, V19, P3940; Kinoshita T, 2000, BLOOD, V95, P2821, DOI 10.1182/blood.V95.9.2821.009k11_2821_2828; LABBAYE C, 1994, BLOOD, V83, P651; Leber BF, 1997, ALLERGY, V52, P1201, DOI 10.1111/j.1398-9995.1997.tb02524.x; MAUSER PJ, 1995, AM J RESP CRIT CARE, V152, P467, DOI 10.1164/ajrccm.152.2.7633694; MIYAJIMA A, 1993, BLOOD, V82, P1960; Monahan J, 1997, J IMMUNOL, V159, P4024; NAKAJIMA H, 1994, BLOOD, V84, P4107, DOI 10.1182/blood.V84.12.4107.bloodjournal84124107; PLAETINCK G, 1990, J EXP MED, V172, P683, DOI 10.1084/jem.172.3.683; ROBINSON DS, 1993, J ALLERGY CLIN IMMUN, V92, P397, DOI 10.1016/0091-6749(93)90118-Y; SAITO H, 1988, P NATL ACAD SCI USA, V85, P2288, DOI 10.1073/pnas.85.7.2288; Sehmi R, 1996, AM J RESP CELL MOL, V15, P645, DOI 10.1165/ajrcmb.15.5.8918371; Sehmi R, 1997, J CLIN INVEST, V100, P2466, DOI 10.1172/JCI119789; Shi HZ, 1997, AM J RESP CELL MOL, V16, P220, DOI 10.1165/ajrcmb.16.3.9070605; SUN ZJ, 1995, J BIOL CHEM, V270, P1462, DOI 10.1074/jbc.270.3.1462; TAKAGI M, 1995, J EXP MED, V181, P889, DOI 10.1084/jem.181.3.889; TAKATSU K, 1994, ADV IMMUNOL, V57, P145, DOI 10.1016/S0065-2776(08)60673-2; Tavernier J, 2000, BLOOD, V95, P1600, DOI 10.1182/blood.V95.5.1600.005k22_1600_1607; TAVERNIER J, 1992, P NATL ACAD SCI USA, V89, P7041, DOI 10.1073/pnas.89.15.7041; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; Tocci A, 1996, BLOOD, V88, P2878, DOI 10.1182/blood.V88.8.2878.bloodjournal8882878; TSAI S, 1992, GENE DEV, V6, P2258, DOI 10.1101/gad.6.12a.2258; VALTIERI M, 1991, BLOOD, V77, P1804; Wang P, 1998, J IMMUNOL, V160, P4427; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; Yasruel Z, 1997, AM J RESP CRIT CARE, V155, P1413, DOI 10.1164/ajrccm.155.4.9105087; ZANDERS ED, 1994, EUR CYTOKINE NETW, V5, P35; Zhang J, 1997, J IMMUNOL, V159, P5412	41	20	20	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2002	109	2					307	313		10.1067/mai.2002.121527	http://dx.doi.org/10.1067/mai.2002.121527			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	528EZ	11842302				2022-12-18	WOS:000174232600017
J	Powell, N; Till, S; Bungre, J; Corrigan, C				Powell, N; Till, S; Bungre, J; Corrigan, C			The immunomodulatory drugs cyclosporin A, mycophenolate mofetil, and sirolimus (rapamycin) inhibit allergen-induced proliferation and IL-5 production by PBMCs from atopic asthmatic patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						asthma; allergen; T cell; interleukin-5; dexamethasone; cyclosporin A; sirolimus; mycophenolate mofetil; therapy	T-CELLS; MESSENGER-RNA; EXPRESSION; GLUCOCORTICOIDS; INTERLEUKIN-5; EOSINOPHILS; DISEASE; CD4(+)	We have used an optimized, physiologically relevant in vitro assay system to show that in a concentration-dependent fashion the immunomodulatory drugs cyclosporin A, mycophenolate mofetil, and sirolimus (rapamycin), as well as the glucocorticoid dexamethasone, inhibit allergen-driven T-cell proliferation and IL-5 production in PBMCs from allergen-sensitized atopic asthmatic individuals at physiologic concentrations. This effect of cyclosporin A might at least partially account for its established clinical efficacy in sparing systemic glucocorticoid therapy while improving lung function in chronic, severe, glucocorticoid-dependent asthma. The data are also compatible with the hypothesis that the newer immunomodulatory drugs mycophenolate mofetil and sirolimus exert similar effects, perhaps with a more favorable benefit/risk ratio.	Imperial Coll Sch Med, Dept Allergy & Clin Immunol, London, England	Imperial College London	Corrigan, C (corresponding author), Guys Hosp, Dept Resp Med & Allergy, 5th Floor Thomas Guy House, London SE1 9RT, England.		Powell, Nicholas/F-3498-2014	Corrigan, Chris/0000-0002-0706-6534; Powell, Nick/0000-0003-3231-6950				Corrigan CJ, 1996, EUR RESPIR J, V9, P2077, DOI 10.1183/09031936.96.09102077; HACZKU A, 1994, J ALLERGY CLIN IMMUN, V93, P510, DOI 10.1016/0091-6749(94)90361-1; Humbert M, 1997, AM J RESP CRIT CARE, V156, P704, DOI 10.1164/ajrccm.156.3.9610033; Khan LN, 2000, AM J RESP CRIT CARE, V162, P1377, DOI 10.1164/ajrccm.162.4.9911117; Lock SH, 1996, AM J RESP CRIT CARE, V153, P509, DOI 10.1164/ajrccm.153.2.8564089; MORI A, 1995, INT IMMUNOL, V7, P449, DOI 10.1093/intimm/7.3.449; Powell N, 2001, CLIN EXP ALLERGY, V31, P69, DOI 10.1046/j.1365-2222.2001.01002.x; Till S, 1997, J ALLERGY CLIN IMMUN, V99, P563, DOI 10.1016/S0091-6749(97)70085-X; Till SJ, 1998, AM J RESP CRIT CARE, V158, P404, DOI 10.1164/ajrccm.158.2.9705007; Ying S, 1997, J IMMUNOL, V158, P3539	10	20	26	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2001	108	6					915	917		10.1067/mai.2001.119742	http://dx.doi.org/10.1067/mai.2001.119742			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	505WK	11742267				2022-12-18	WOS:000172938400005
J	Woodcock, A; Addo-Yobo, EOD; Taggart, SCO; Craven, M; Custovic, A				Woodcock, A; Addo-Yobo, EOD; Taggart, SCO; Craven, M; Custovic, A			Pet allergen levels in homes in Ghana and the United Kingdom	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; risk factors; allergens; Africa	CAT; SENSITIZATION; EXPOSURE	The frequency of cat and/or dog ownership in Ghana is comparable to that in the United Kingdom (similar to 50%). However, in Ghanaian communities pets are predominantly kept outdoors. Levels of pet allergens (Fel d 1 and Can f 1) in 100 Ghanaian homes (49 without pets) were compared with levels in 410 homes in the United Kingdom (258 without pets). Homes with pets in the United Kingdom contained much higher allergen levels than homes with pets hi Ghana (for Fel d 1: mean difference, 275-fold; 95% CI, 129-fold to 594-fold; P < .0001; for Can f 1: mean difference, 75-fold; 95% CI, 33-fold to 169-fold; P < .0001). Homes without cuts in the United Kingdom contained significantly higher levels of Fel d 1 than homes with cats in Ghana (mean difference, 3.7-fold; 95% CI, 2.0-fold to 7.2-fold; P < .0001). In the United Kingdom, homes with dogs contained 75-fold (95% CI, 47-fold to 139-fold) more Can f 1 than homes without dogs, whereas in Ghana, homes with dogs contained 3.1-fold (95% CI, 1.5-fold to 6.1-fold; P = .003) more Can f I than homes without dogs. In the United Kingdom homes with cats contained 77-fold more Fel d 1 (95% CI, 46-fold to 129-fold; P < .0001) than homes without cats; there was no difference in cat allergen levels between homes with cats and homes without cats in Ghana. In conclusion, levels of pet allergens in Ghanaian homes with pets were (1) between 75-fold (dog) and 275-fold (cat) lower than levels in homes with pets in the United Kingdom and (2) lower than or comparable to levels in homes without pets in the United Kingdom.	Wythenshawe Hosp, NW Lung Ctr, Manchester M23 9LT, Lancs, England; Komfo Anokye Teaching Hosp, Dept Child Hlth, Kumasi, Ghana	Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; Kwame Nkrumah University Science & Technology	Custovic, A (corresponding author), Wythenshawe Hosp, NW Lung Ctr, Southmoor Rd, Manchester M23 9LT, Lancs, England.		Custovic, Adnan/A-2435-2012	Custovic, Adnan/0000-0001-5218-7071; Woodcock, Ashley/0000-0002-5428-8578				Custovic A, 1998, THORAX, V53, P33, DOI 10.1136/thx.53.1.33; Custovic A, 1997, AM J RESP CRIT CARE, V155, P94, DOI 10.1164/ajrccm.155.1.9001295; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; INGRAM JM, 1995, J ALLERGY CLIN IMMUN, V96, P449, DOI 10.1016/S0091-6749(95)70286-5; Leung R, 1997, J ALLERGY CLIN IMMUN, V99, P594, DOI 10.1016/S0091-6749(97)70018-6; MILLS TAE, 2001, LANCET, V357, P752; Roost HP, 1999, J ALLERGY CLIN IMMUN, V104, P941, DOI 10.1016/S0091-6749(99)70072-2; Simpson BM, 2001, CLIN EXP ALLERGY, V31, P391, DOI 10.1046/j.1365-2222.2001.01050.x; YOBO EOD, 2000, THESIS U MANCHESTER; Yobo EODA, 1997, THORAX, V52, P161, DOI 10.1136/thx.52.2.161	10	20	21	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2001	108	3					463	465		10.1067/mai.2001.116859	http://dx.doi.org/10.1067/mai.2001.116859			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	476FK	11544469				2022-12-18	WOS:000171215400021
J	Srivastava, K; Li, XM; Bannon, GA; Burks, AW; Eiden, J; Vannest, G; Tuck, R; Rodriguez, R; Sampson, HA				Srivastava, K; Li, XM; Bannon, GA; Burks, AW; Eiden, J; Vannest, G; Tuck, R; Rodriguez, R; Sampson, HA			Investigation of the use of ISS-linked Ara h2 for the treatment of peanut-induced allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract									Mt Sinai Sch Med, New York, NY USA; Univ Arkansas, Sch Med, Little Rock, AR 72204 USA; Dynavax Technol Inc, Berkeley, CA USA	Icahn School of Medicine at Mount Sinai; University of Arkansas System; University of Arkansas Fayetteville; University of Arkansas Little Rock									0	20	20	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2001	107	2		S		765	S233	S233						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	405RE					2022-12-18	WOS:000167172300761
J	Sarinho, E; Schor, D; Veloso, M; Lima, M				Sarinho, E; Schor, D; Veloso, M; Lima, M			BCG scar diameter and asthma: A case-control study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material									Univ Fed Pernambuco, Sect Allergy Asthma & Immunol, Dept Pediat, Recife, PE, Brazil	Universidade Federal de Pernambuco	Sarinho, E (corresponding author), Av Parnamirim 373-202, BR-52060000 Recife, PE, Brazil.							ARANTES GR, 1992, REV SAUDE PUBL, V26, P264, DOI 10.1590/S0034-89101992000400008; Herz U, 1998, J ALLERGY CLIN IMMUN, V102, P867, DOI 10.1016/S0091-6749(98)70030-2; Le Gros G, 1998, CLIN EXP ALLERGY, V28, P92; Sarinho E S, 1994, J Pediatr (Rio J), V70, P91; Sarinho ESC, 1993, ARQ BRAS MED S4, V67, P253; Shimojo N, 1996, CLIN EXP IMMUNOL, V106, P62, DOI 10.1046/j.1365-2249.1996.d01-816.x; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77	7	20	24	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2000	106	6					1199	1200						2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	384ER	11112907				2022-12-18	WOS:000165930300026
J	Kelso, JM				Kelso, JM			Raw egg allergy - A potential issue in vaccine allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							WHITE		USN, Med Ctr, Allergy Clin, San Diego, CA 92134 USA	United States Department of Defense; United States Navy	Kelso, JM (corresponding author), USN, Med Ctr, Allergy Clin, 34800 Bob Wilson Dr,Suite 5, San Diego, CA 92134 USA.							ANET J, 1985, INT ARCH ALLER A IMM, V77, P364, DOI 10.1159/000233846; *CONN LAB, 1986, PACK INS YF VAX YELL; James JM, 1998, J PEDIATR-US, V133, P624, DOI 10.1016/S0022-3476(98)70101-5; Kelso JM, 1999, J ALLERGY CLIN IMMUN, V103, P698, DOI 10.1016/S0091-6749(99)70245-9; OBRIEN TC, 1971, APPL MICROBIOL, V21, P780, DOI 10.1128/AEM.21.4.780-782.1971; Urisu A, 1997, J ALLERGY CLIN IMMUN, V100, P171, DOI 10.1016/S0091-6749(97)70220-3	6	20	20	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2000	106	5					990	990		10.1067/mai.2000.110800	http://dx.doi.org/10.1067/mai.2000.110800			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	417ZK	11080728				2022-12-18	WOS:000167865200030
J	Langeveld-Wildschut, EG; Riedl, H; Thepen, T; Bihari, IC; Bruijnzeel, PLB; Bruijnzeel-Koomen, CAFM				Langeveld-Wildschut, EG; Riedl, H; Thepen, T; Bihari, IC; Bruijnzeel, PLB; Bruijnzeel-Koomen, CAFM			Modulation of the atopy patch test reaction by topical corticosteroids and tar	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							PROLONGED TREATMENT; DERMATITIS; ALLERGEN; INFILTRATION; INHIBITION; ECZEMA	Background: Pharmacologic studies in atopic eczema (AE) are difficult to standardize. Patients with AE differ in the stage of their skin disease (acute, subacute, chronic). Objective: This study was designed to assess macroscopic and microscopic effects of pretreatment with topical glucocorticosteroids (GCSs) and tar on the atopy patch test (APT) reaction in patients with atopic eczema. Methods: Nonlesional skin of the back of patients with AE (n = 6) was treated for 3 weeks at 3 different sites with triamcin-olonacetonide 0.1% in cetamacrogol ointment (GCSs), pix liquida 10% in cetamacrogol ointment (tar), and cetamacrogol ointment (vehicle), respectively. APTs were performed, and biopsy specimens were taken from all these sites (time = 0 and 24 hours) for immunohistochemical analysis. Results: Treatment with both GCSs and tar was able to reduce the macroscopic outcome of the APT reaction. Furthermore, both treatment modalities had an almost equally inhibiting effect on the influx of T cells, eosinophils, and CD1(+), RFD1(+), IFN-gamma (+), and IL-4(+) cells, as well as on the percentage of vessels expressing the adhesion molecules vascular cell adhesion molecule 1 and E-selectin in response to epicutaneous aeroallergen challenge. Conclusion: Although both treatments significantly reduced the various cellular constituents of allergic inflammation, all cell types remained present. In addition, this study shows that the APT fan be used to evaluate the effect of topical antiinflammatory treatments on allergic inflammation in patients with AE.	Univ Utrecht, Med Ctr, Dept Dermatol Allergol, NL-3508 GA Utrecht, Netherlands; TNO, Dept Pharmacol, NL-2280 AA Rijswijk, Netherlands	Utrecht University; Netherlands Organization Applied Science Research	Bruijnzeel-Koomen, CAFM (corresponding author), Univ Utrecht, Med Ctr, Dept Dermatol Allergol, POB 85500, NL-3508 GA Utrecht, Netherlands.							ANDERSSON M, 1987, J ALLERGY CLIN IMMUN, V79, P345, DOI 10.1016/0091-6749(87)90153-9; BRUIJNZEELKOOME.C, 1988, BRIT J DERMATOL, V118, P229; CHARLESWORTH EN, 1989, J CLIN INVEST, V83, P1519, DOI 10.1172/JCI114047; COSTA C, 1989, ACTA DERM-VENEREOL, V69, P41; Green C, 1996, CONTACT DERMATITIS, V35, P331, DOI 10.1111/j.1600-0536.1996.tb02412.x; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; HAXTHAUSEN H, 1956, Acta Derm Venereol, V36, P381; LangeveldWildschut EG, 1996, J ALLERGY CLIN IMMUN, V98, P1019, DOI 10.1016/S0091-6749(96)80186-2; LANGEVELDWILDSCHUT EG, 1995, J ALLERGY CLIN IMMUN, V96, P66, DOI 10.1016/S0091-6749(95)70034-X; MUNKVAD M, 1989, BRIT J DERMATOL, V121, P763, DOI 10.1111/j.1365-2133.1989.tb08219.x; PIPKORN U, 1989, CLIN EXP ALLERGY, V19, P19, DOI 10.1111/j.1365-2222.1989.tb02338.x; PRZYBILLA B, 1994, LANCET, V343, P1342, DOI 10.1016/S0140-6736(94)92474-0; SCHLEIMER RP, 1990, AM REV RESPIR DIS S, V141, P59; SURBER C, 1995, J AM ACAD DERMATOL, V32, P1025, DOI 10.1016/0190-9622(95)91343-2; TabordaBarata L, 1996, CLIN EXP ALLERGY, V26, P68, DOI 10.1111/j.1365-2222.1996.tb00058.x; Thepen T, 1996, J ALLERGY CLIN IMMUN, V97, P828, DOI 10.1016/S0091-6749(96)80161-8; vanderValk PGM, 1996, DERMATOLOGY, V193, P41, DOI 10.1159/000246198	17	20	20	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2000	106	4					737	743		10.1067/mai.2000.109831	http://dx.doi.org/10.1067/mai.2000.109831			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	365ZP	11031345	Bronze			2022-12-18	WOS:000089980600018
J	Borgstrom, L				Borgstrom, L			The pharmacokinetics of inhaled hydroflouroalkane formulations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						inhalation; inhalers; lung deposition; in vitro; in vivo; effects; pharmacokinetics	METERED-DOSE INHALER; LUNG DEPOSITION; DRY POWDER; SALBUTAMOL; CHLOROFLUOROCARBON; BIOAVAILABILITY; INHALATION	To obtain the full picture of a formulation, the in vitro and the in vivo information can be looked upon as components of a "prediction bridge" where the in vitro information can be used to predict lung deposition, which in turn can be used to predict clinical outcome. This bridging concept can be used as a template to evaluate new information on emerging inhaled formulations, The concept was used to evaluate literature data on new hydroflouroalkane formulations of salbutamol and beclomethasone dipropionate (BDP). The new salbutamol hydroflouroalkane formulations seem to have properties similar to those of the old chlorofluorocarbon formulations even if the presented information on effect comparisons is limited. The first BDP hydroflouroalkane Formulation is a solution formulation with in vitro properties that are quite different from those of the old chlorofluorocarbon suspension Formulation. The BDP hydroflouroalkane formulation has a much greater fine particle mass, which eventually results in greater lung deposition and better clinical effect.	AstraZeneca R&D, Expt Med, S-22187 Lund, Sweden; Univ Uppsala, S-75105 Uppsala, Sweden	AstraZeneca; Uppsala University	Borgstrom, L (corresponding author), AstraZeneca R&D, Expt Med, S-22187 Lund, Sweden.							Barry PW, 1997, EUR RESPIR J, V10, P1345, DOI 10.1183/09031936.97.10061345; BIDDISCOMBE MF, 1993, INT J PHARMACEUT, V91, P111, DOI 10.1016/0378-5173(93)90330-I; Bleecker ER, 1998, CHEST, V113, P283, DOI 10.1378/chest.113.2.283; Borgstrom L, 1996, AM J RESP CRIT CARE, V153, P1636, DOI 10.1164/ajrccm.153.5.8630614; Borgstrom L, 1998, J AEROSOL MED, V11, P55, DOI 10.1089/jam.1998.11.55; BUSSE W, 1998, AM J RESP CRIT CARE, V157, pA405; Clark DJ, 1996, BRIT J CLIN PHARMACO, V41, P247, DOI 10.1111/j.1365-2125.1996.tb00191.x; DOCKHORN R, 1995, J ALLERGY CLIN IMMUN, V96, P50, DOI 10.1016/S0091-6749(95)70032-3; Ekholm B. P., 1996, European Respiratory Journal Supplement, V9, p256S; FOSTER L, 1998, AM J RESP CRIT CARE, V157, pA638; HARRISON L, 1997, EUR RESPIR J S25, V10, P349; Harrison LI, 1997, BIOPHARM DRUG DISPOS, V18, P635, DOI 10.1002/(SICI)1099-081X(199710)18:7<635::AID-BDD53>3.0.CO;2-Y; LEACH C, 1996, RESP DRUG DELIVERY, V5, P133; Leach CL, 1998, RESP MED, V92, P3, DOI 10.1016/S0954-6111(98)90211-6; Olsson B, 1996, RESP DRUG DELIVERY, VV, P273; PUREWAL TS, 1996, THORAX S3, V51, pA75; Salat D., 1996, European Respiratory Journal Supplement, V9, p256S; Schultz David, 1996, European Respiratory Journal Supplement, V9, p255S; SCHULTZE M, 1997, J AEROSOL MED, V10, P270; Shaw R. J., 1998, European Respiratory Journal, V12, p436S; Snell NJC, 1999, RESP MED, V93, P123, DOI 10.1016/S0954-6111(99)90302-5; VENTRESCA G, 1994, AM J RESP CRIT CAR S, V149, pA206	22	20	20	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1999	104	6					S246	S249		10.1016/S0091-6749(99)70040-0	http://dx.doi.org/10.1016/S0091-6749(99)70040-0			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	266FD	10588984				2022-12-18	WOS:000084289200040
J	Aron, Y; Bienvenu, T; Hubert, D; Dusser, D; Dall'Ava, J; Polla, BS				Aron, Y; Bienvenu, T; Hubert, D; Dusser, D; Dall'Ava, J; Polla, BS			HLA-DR polymorphism in allergic bronchopulmonary aspergillosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							ASSOCIATION; ALLELES		Univ Paris 05, Grp Hosp & Univ Cochin Port Royal, Physiol Resp Lab, Paris, France; Univ Paris 05, Grp Hosp & Univ Cochin Port Royal, Lab Biochem & Genet Mol, Paris, France; Univ Paris 05, Grp Hosp & Univ Cochin Port Royal, Serv Pneumol, APHP, Paris, France; Univ Paris 05, Grp Hosp & Univ Cochin Port Royal, Serv Physiol, APHP, Paris, France	UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; UDICE-French Research Universities; Universite Paris Cite	Aron, Y (corresponding author), Univ Paris 05, UFR, Physiol Resp Lab, 24 Rue Faubourg St Jacques, F-75679 Paris 14, France.							Aron Y, 1996, CLIN EXP ALLERGY, V26, P821, DOI 10.1111/j.1365-2222.1996.tb00614.x; Aron Y, 1999, AM J RESP CRIT CARE, V159, P1464, DOI 10.1164/ajrccm.159.5.9807046; Chauhan B, 1997, J IMMUNOL, V159, P4072; Chauhan B, 1996, J CLIN INVEST, V97, P2324, DOI 10.1172/JCI118675; Miller PW, 1996, AM J HUM GENET, V59, P45	5	20	20	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1999	104	4	1				891	892		10.1016/S0091-6749(99)70306-4	http://dx.doi.org/10.1016/S0091-6749(99)70306-4			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	248NG	10518840				2022-12-18	WOS:000083281200027
J	Bratton, DL; May, KR; Kailey, JM; Doherty, DE; Leung, DYM				Bratton, DL; May, KR; Kailey, JM; Doherty, DE; Leung, DYM			Staphylococcal toxic shock syndrome toxin-1 inhibits monocyte apoptosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						monocyte; apoptosis; staphylococcal exotoxins; atopic dermatitis; granulocyte-macrophage colony-stimulating factor	COLONY-STIMULATING FACTOR; CELL-DEATH APOPTOSIS; ATOPIC-DERMATITIS; CYTOKINE PRODUCTION; CHEMOTACTIC FACTORS; T-CELLS; SKIN; IGE; PROLIFERATION; KERATINOCYTES	Background: Chronic atopic dermatitis (AD) lesions are associated with colonization by exotoxin-producing Staphylococcus aureus. Evidence suggests that cytokine production in AD, particularly of GM-CSF, prolongs survival of both peripheral blood monocytes and dermal monocyte-macrophages, the predominate inflammatory cell in lesions caused by chronic AD. Objective: We sought to determine whether the staphylococcal exotoxin, toxic shock syndrome toxin-l (TSST-1), could stimulate prosurvival cytokine production in monocytes and thereby inhibit apoptosis. Methods: Cultures of peripheral blood monocytes from normal donors and subjects with AD were incubated with various concentrations of TSST-1, and the incidence of apoptosis was assessed by examining cytospin preparations and the appearance of hypodiploid DNA in the flow cytometer, Culture supernatants mere analyzed for GM-CSF, IL-1 beta, and TNF-alpha by ELISA, Results: TSST-1, in a concentration-dependent manner starting at 0.1 pg/mL, significantly inhibited monocyte apoptosis and resulted in the production of the prosurvival cytokines GM-CSF, IL-1 beta, and TNF-alpha. In coculture conditions with conditioned media from TSST-1-stimulatcd monocytes, with or without neutralizing antibody to the various cytokines, the data show GM-CSF production was responsible for the inhibition of apoptosis, Conclusions: The data strongly suggest that staphylococcal exotoxins known to colonize skin lesions on patients with chronic AD may induce the production of GM-CSF, resulting in inhibition of monocyte-macrophage apoptosis, and thereby contribute to the chronicity of this inflammatory disease.	Natl Jewish Med & Res Ctr, Dept Pediat, Div Allergy Immunol, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Dept Med, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA; Univ Kentucky, Med Ctr, Dept Med, Div Pulm & Crit Care Med, Lexington, KY 40536 USA	National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Kentucky	Bratton, DL (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Div Allergy Immunol, 1400 Jackson St,Room D506, Denver, CO 80206 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034303] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041256] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048211] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL34303] Funding Source: Medline; NIAMS NIH HHS [AR41256] Funding Source: Medline; NIGMS NIH HHS [GM48211] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BORISH L, 1991, J IMMUNOL, V146, P63; BRATTON DL, 1995, J CLIN INVEST, V95, P211, DOI 10.1172/JCI117642; Chan S, 1996, J ALLERGY CLIN IMMUN, V97, P85, DOI 10.1016/S0091-6749(96)70286-5; CHAN SC, 1993, J INVEST DERMATOL, V100, P681, DOI 10.1111/1523-1747.ep12472344; COOPER KD, 1994, J INVEST DERMATOL, V102, P128, DOI 10.1111/1523-1747.ep12371746; DOHERTY DE, 1987, J IMMUNOL, V138, P1762; HAMID Q, 1994, J CLIN INVEST, V94, P870, DOI 10.1172/JCI117408; Herz U, 1998, INT ARCH ALLERGY IMM, V115, P179, DOI 10.1159/000023899; LEUNG DYM, 1995, J ALLERGY CLIN IMMUN, V96, P302, DOI 10.1016/S0091-6749(95)70049-8; LEUNG DYM, 1983, J ALLERGY CLIN IMMUN, V71, P47, DOI 10.1016/0091-6749(83)90546-8; LEUNG DYM, 1993, J CLIN INVEST, V92, P1374, DOI 10.1172/JCI116711; LEYDEN JJ, 1974, BRIT J DERMATOL, V90, P525, DOI 10.1111/j.1365-2133.1974.tb06447.x; MANGAN DF, 1991, J IMMUNOL, V147, P3408; MANGAN DF, 1991, J IMMUNOL, V146, P1541; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MATZ J, 1994, J ALLERGY CLIN IMMUN, V93, P650, DOI 10.1016/S0091-6749(94)70077-X; MIHM MC, 1976, J INVEST DERMATOL, V67, P305, DOI 10.1111/1523-1747.ep12514346; OHMAN JD, 1995, J IMMUNOL, V154, P1956; Pastore S, 1997, J CLIN INVEST, V99, P3009, DOI 10.1172/JCI119496; SCHOLS D, 1995, J IMMUNOL, V154, P3204; Simon HU, 1997, J IMMUNOL, V158, P3902; TOKURA Y, 1994, J INVEST DERMATOL, V102, P31, DOI 10.1111/1523-1747.ep12371727; TREDE NS, 1991, J IMMUNOL, V146, P310; Wedi B, 1997, J ALLERGY CLIN IMMUN, V100, P536, DOI 10.1016/S0091-6749(97)70147-7; Ying S, 1997, P ASSOC AM PHYSICIAN, V109, P42	25	20	23	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1999	103	5	1				895	900		10.1016/S0091-6749(99)70435-5	http://dx.doi.org/10.1016/S0091-6749(99)70435-5			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	199FP	10329825				2022-12-18	WOS:000080470200026
J	Empson, M; Bishop, GA; Nightingale, B; Garsia, R				Empson, M; Bishop, GA; Nightingale, B; Garsia, R			Atopy, anergic status, and cytokine expression in HIV-infected subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; anergy; AIDS; cytokines; HIV	HUMAN-IMMUNODEFICIENCY-VIRUS; MESSENGER-RNA EXPRESSION; RETROVIRUS-INDUCED IMMUNODEFICIENCY; COLONY-STIMULATING FACTOR; BLOOD MONONUCLEAR-CELLS; IFN-GAMMA PRODUCTION; CHRONIC HEPATITIS-C; CD4+ T-CELLS; PERIPHERAL-BLOOD; INTERFERON-GAMMA	Background: In HIV infection T-cell dysfunction resulting in anergy and hypersensitivity reactions precedes T-cell depletion. A shift in the cytokine profile from a type 1 to a type 2 response has been postulated. Objective: We sought to examine the cytokine expression patterns in HIV infection and the relationship to allergy, stage of MV disease, and other laboratory parameters. Methods: A cross-sectional analysis of IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p35, IL-13, and IFN-gamma mRNA expression in PBMCs by noncompetitive dot-blot PCR was performed on blood obtained from 18 HIV-infected subjects. Delayed-type hypersensitivity multitests to detect anergy, skin prick testing and in vitro assay for specific IgE antibodies, assay for total IgE, and enumeration of eosinophils, CD4(+), and CD8(+) T cells were also performed on all subjects, Results: We found evidence of a decline in type 1 cytokines (IL-2, IL-13p35, and IFN-gamma) associated with AIDS, CD4(+) T cells less than 200/mu L, anergy, and atopy, although this only reached statistical significance in anergy, There was no associated significant alteration in type 2 cytokines, Conclusions: This is the first report of an association between low constitutive in vivo expression of IL-12 mRNA and anergy, which supports earlier data from in vitro stimulation studies. The presence of atopy was associated with a more global reduction in cytokine expression. Because the decline in type 1 cytokines was not accompanied by a similar decline in type 2 cytokines, this does suggest a shift in the type 1/type 2 balance.	Royal Prince Alfred Hosp, Dept Clin Immunol, Camperdown, NSW 2050, Australia; Centenary Inst Canc Med & Cell Biol, Camperdown, NSW, Australia; Royal Prince Alfred Hosp, Dept Biochem, Camperdown, NSW 2050, Australia; Westmead Hosp, ICPMR, Westmead, NSW 2145, Australia	University of Sydney; University of Sydney; Centenary Institute; University of Sydney; University of Sydney	Empson, M (corresponding author), Westmead Hosp, ICPMR, Darcy Rd, Westmead, NSW 2145, Australia.							Agarwal SK, 1998, HUM IMMUNOL, V59, P99, DOI 10.1016/S0198-8859(97)00261-9; BARCELLINI W, 1994, AIDS, V8, P757, DOI 10.1097/00002030-199406000-00006; Bishop G A, 1993, Transpl Immunol, V1, P253, DOI 10.1016/0966-3274(93)90033-5; Bishop GA, 1997, IMMUNOL CELL BIOL, V75, P142, DOI 10.1038/icb.1997.19; BLATT SP, 1993, ANN INTERN MED, V119, P177, DOI 10.7326/0003-4819-119-3-199308010-00001; BRADLEY WG, 1994, J ACQ IMMUN DEF SYND, V7, P1; Canaris AD, 1998, SCAND J IMMUNOL, V47, P146, DOI 10.1046/j.1365-3083.1998.00270.x; CARR A, 1991, J CLIN IMMUNOL, V11, P55, DOI 10.1007/BF00917741; CATERINODEARAUJO A, 1994, IMMUNOL TODAY, V15, P498, DOI 10.1016/0167-5699(94)90199-6; CHEHIMI J, 1994, J EXP MED, V179, P1361, DOI 10.1084/jem.179.4.1361; CLERICI M, 1993, SCIENCE, V262, P1721, DOI 10.1126/science.7903123; CLERICI M, 1994, IMMUNOL TODAY, V15, P575, DOI 10.1016/0167-5699(94)90220-8; CLERICI M, 1989, J CLIN INVEST, V84, P1892, DOI 10.1172/JCI114376; CLERICI M, 1994, J CLIN INVEST, V93, P768, DOI 10.1172/JCI117031; CLERICI M, 1993, IMMUNOL TODAY, V14, P107, DOI 10.1016/0167-5699(93)90208-3; CLERICI M, 1993, J CLIN INVEST, V91, P759, DOI 10.1172/JCI116294; COHEN J, 1993, SCIENCE, V262, P175, DOI 10.1126/science.8211135; DIAZMITOMA F, 1995, CLIN EXP IMMUNOL, V102, P31; DIERICH MP, 1993, IMMUNOL TODAY, V14, P435, DOI 10.1016/0167-5699(93)90246-H; DRABICK JJ, 1994, SOUTHERN MED J, V87, P525, DOI 10.1097/00007611-199404000-00021; DURHAM SR, 1992, J IMMUNOL, V148, P2390; EHLERS S, 1991, J EXP MED, V173, P25, DOI 10.1084/jem.173.1.25; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; Fakoya A, 1997, AIDS, V11, P1445, DOI 10.1097/00002030-199712000-00008; FAN J, 1993, J IMMUNOL, V151, P5031; Fauci AS, 1996, ANN INTERN MED, V124, P654, DOI 10.7326/0003-4819-124-7-199604010-00006; FLING JA, 1988, J ALLERGY CLIN IMMUN, V82, P965, DOI 10.1016/0091-6749(88)90132-7; GAZZINELLI RT, 1994, J EXP MED, V180, P2199, DOI 10.1084/jem.180.6.2199; GAZZINELLI RT, 1992, J IMMUNOL, V148, P182; GORDIN FM, 1994, J INFECT DIS, V169, P893, DOI 10.1093/infdis/169.4.893; GRAZIOSI C, 1994, SCIENCE, V265, P248, DOI 10.1126/science.8023143; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HYJEK E, 1995, J IMMUNOL, V155, P4060; ISRAELBIET D, 1992, J ALLERGY CLIN IMMUN, V89, P68, DOI 10.1016/S0091-6749(05)80042-9; KANAGAWA O, 1993, SCIENCE, V262, P240, DOI 10.1126/science.8211142; Karp CL, 1996, SCIENCE, V273, P228, DOI 10.1126/science.273.5272.228; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; Klein SA, 1997, AIDS, V11, P1111, DOI 10.1097/00002030-199709000-00005; KOVACS JA, 1995, NEW ENGL J MED, V332, P567, DOI 10.1056/NEJM199503023320904; Lai CKW, 1996, J ALLERGY CLIN IMMUN, V97, P1320, DOI 10.1016/S0091-6749(96)70201-4; Lowes MA, 1997, J INVEST DERMATOL, V108, P914, DOI 10.1111/1523-1747.ep12292705; MAGGI E, 1987, EUR J IMMUNOL, V17, P1685, DOI 10.1002/eji.1830171202; MAGGI E, 1994, J EXP MED, V180, P489, DOI 10.1084/jem.180.2.489; MAGGI E, 1994, SCIENCE, V265, P244, DOI 10.1126/science.8023142; MANETTI R, 1994, J EXP MED, V180, P2407, DOI 10.1084/jem.180.6.2407; McGuinness PH, 1996, HEPATOLOGY, V23, P676, DOI 10.1002/hep.510230404; MEYAARD L, 1994, BLOOD, V84, P4262, DOI 10.1182/blood.V84.12.4262.bloodjournal84124262; Meyaard L, 1996, J IMMUNOL, V157, P2712; MEYAARD L, 1993, IMMUNOL TODAY, V14, P161, DOI 10.1016/0167-5699(93)90279-T; MOSMANN TR, 1994, SCIENCE, V265, P193, DOI 10.1126/science.8023139; Napoli J, 1996, HEPATOLOGY, V24, P759; NAVIKAS V, 1994, CLIN EXP IMMUNOL, V96, P59; Ohashi Y, 1996, SCAND J IMMUNOL, V43, P680, DOI 10.1046/j.1365-3083.1996.d01-269.x; PAGANELLI R, 1995, J EXP MED, V181, P423, DOI 10.1084/jem.181.1.423; PAGANELLI R, 1991, J ALLERGY CLIN IMMUN, V88, P416, DOI 10.1016/0091-6749(91)90107-Y; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PANTALEO G, 1995, ANNU REV IMMUNOL, V13, P487, DOI 10.1146/annurev.immunol.13.1.487; Park CS, 1996, J ALLERGY CLIN IMMUN, V97, P1121, DOI 10.1016/S0091-6749(96)70267-1; RE MC, 1992, VIRAL IMMUNOL, V5, P185, DOI 10.1089/vim.1992.5.185; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROMAGNANI S, 1995, J CLIN IMMUNOL, V15, P121, DOI 10.1007/BF01543103; ROMAGNANI S, 1994, AIDS RES HUM RETROV, V10, P3; ROSENTHAL D, 1991, ARCH DERMATOL, V127, P206, DOI 10.1001/archderm.127.2.206; SEDER RA, 1995, J EXP MED, V182, P1067, DOI 10.1084/jem.182.4.1067; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; SHER A, 1992, IMMUNOL REV, V127, P183, DOI 10.1111/j.1600-065X.1992.tb01414.x; SMALL CB, 1993, J INFECT DIS, V167, P283, DOI 10.1093/infdis/167.2.283; Snijders A, 1996, J IMMUNOL, V156, P1207; THAN S, 1997, J INFECT DIS, V175, P46; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.iy.13.040195.001343; Uherova P, 1996, J INFECT DIS, V174, P483, DOI 10.1093/infdis/174.3.483; VIGANO A, 1995, J ALLERGY CLIN IMMUN, V95, P627, DOI 10.1016/S0091-6749(95)70326-8; VIGANO A, 1995, J PEDIATR-US, V126, P368, DOI 10.1016/S0022-3476(95)70450-7; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Westby M, 1998, CLIN EXP IMMUNOL, V111, P257; WRIGHT DN, 1990, J ALLERGY CLIN IMMUN, V85, P445, DOI 10.1016/0091-6749(90)90154-V; YAMAMURA M, 1991, SCIENCE, V254, P277, DOI 10.1126/science.1925582	78	20	21	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1999	103	5	1				833	842		10.1016/S0091-6749(99)70427-6	http://dx.doi.org/10.1016/S0091-6749(99)70427-6			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	199FP	10329817				2022-12-18	WOS:000080470200018
J	Miyazawa, K; Mori, A; Okudaira, H				Miyazawa, K; Mori, A; Okudaira, H			IL-6 synthesis by rheumatoid synoviocytes is autonomously upregulated at the transcriptional level	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Conference on New Trends in Immunopharmacology 1997	JUL   12, 1997	TOKYO, JAPAN	Novartis Pharma K K Tokyo		rheumatoid arthritis; IL-6; synoviocytes; NF-kappa B; RBP-J kappa	NF-KAPPA-B; STIMULATORY FACTOR-II; REGULATORY ELEMENTS; HUMAN-FIBROBLASTS; T-CELL; ARTHRITIS; INTERLEUKIN-6; GENE; CYTOKINES; RECEPTOR	Background: Involvement of IL-6 in the pathogenesis of rheumatoid arthritis has recently been demonstrated, but the mechanism of its production by rheumatoid synoviocytes is still poorly defined. Objective: The purpose of this study was to clarify the cellular and molecular mechanisms involved in the spontaneous production of IL-6 by fibroblast-like synoviocytes obtained from patients with rheumatoid arthritis. Methods: Cloned synoviocytes were established by the limiting dilution method. IL-6 synthesis was evaluated by ELISA and Northern blot analysis. IL-6 gene transcription and transcription factors were analyzed by the transient transfection of luciferase reporter plasmids and the electrophoretic mobility shift assay, respectively. Results: IL-6 synthesis by cloned rheumatoid synoviocytes was spontaneously upregulated at the transcriptional level. Enhanced IL-6 production by high-producing clones was independent of cytokines from other cell populations or autocrine production of tumor necrosis factor-a and IL-I, Deletion analysis showed that the IL-6 promoter was regulated by 2 positive elements (-159 to -142 base pair and -77 to -59 base pair). The transcriptional activity of the latter element was upregulated in clones showing high IL-6 production. The binding activity of NF-KB p50/p65 heterodimer and RBP-Ja was enhanced in these clones. Conclusion: IL-6 production by rheumatoid synoviocytes is autonomously upregulated at the transcriptional level and spontaneous activation of NF-kappa B and RBP-J kappa seems to be involved.	Univ Tokyo, Dept Med & Phys Therapy, Fac Med, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo	Okudaira, H (corresponding author), Univ Tokyo, Dept Med & Phys Therapy, Fac Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.							AKIRA S, 1993, ADV IMMUNOL, V56, P1; ALTMAN R, 1986, ARTHRITIS RHEUM, V29, P1039, DOI 10.1002/art.1780290816; AMETT FC, 1988, ARTHRITIS RHEUM, V31, P315; AREND WP, 1995, ARTHRITIS RHEUM, V38, P151, DOI 10.1002/art.1780380202; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCALA R, 1991, J EXP MED, V173, P569, DOI 10.1084/jem.173.3.569; BUCHAN G, 1988, CLIN EXP IMMUNOL, V71, P295; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CONTENT J, 1985, EUR J BIOCHEM, V152, P253, DOI 10.1111/j.1432-1033.1985.tb09191.x; DENDORFER U, 1994, MOL CELL BIOL, V14, P4443, DOI 10.1128/MCB.14.7.4443; FIRESTEIN GS, 1990, J IMMUNOL, V144, P3347; GOTO M, 1987, J CLIN INVEST, V80, P786, DOI 10.1172/JCI113135; GUERNE PA, 1989, J CLIN INVEST, V83, P585, DOI 10.1172/JCI113921; Handel ML, 1995, ARTHRITIS RHEUM, V38, P1762, DOI 10.1002/art.1780381209; HARRIS ED, 1990, NEW ENGL J MED, V322, P1277, DOI 10.1056/nejm199005033221805; HIRANO T, 1990, IMMUNOL TODAY, V11, P443, DOI 10.1016/0167-5699(90)90173-7; HIRANO T, 1988, EUR J IMMUNOL, V18, P1797, DOI 10.1002/eji.1830181122; ISSHIKI H, 1990, MOL CELL BIOL, V10, P2757, DOI 10.1128/MCB.10.6.2757; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; LEEUWEN MA, 1995, ANN RHEUM DIS, V54, P33; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Marok R, 1996, ARTHRITIS RHEUM, V39, P583, DOI 10.1002/art.1780390407; Medvedev AE, 1996, J BIOL CHEM, V271, P9778, DOI 10.1074/jbc.271.16.9778; MIHARA M, 1995, BRIT J RHEUMATOL, V34, P321; PANAYI GS, 1992, ARTHRITIS RHEUM-US, V35, P729, DOI 10.1002/art.1780350702; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; SCHMITZ R, 1991, EMBO J, V10, P3805; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SENGUPTA TK, 1995, J EXP MED, V181, P1015, DOI 10.1084/jem.181.3.1015; SUTHERLAND GR, 1988, HUM GENET, V79, P335; TAO JY, 1985, NUCLEIC ACIDS RES, V13, P2485; TUN T, 1994, NUCLEIC ACIDS RES, V22, P965, DOI 10.1093/nar/22.6.965; VANDAMME J, 1987, EUR J IMMUNOL, V17, P1, DOI 10.1002/eji.1830170102; WALTHER Z, 1988, J IMMUNOL, V140, P974; WENDLING D, 1993, J RHEUMATOL, V20, P259; YASUKAWA K, 1987, EMBO J, V6, P2939, DOI 10.1002/j.1460-2075.1987.tb02598.x; YOSHIZAKI K, 1996, P C JAP SOC IMM PAC, P115	39	20	20	1	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1999	103	5	2	S			S437	S444		10.1016/S0091-6749(99)70159-4	http://dx.doi.org/10.1016/S0091-6749(99)70159-4			8	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	199TV	10329846				2022-12-18	WOS:000080500200005
J	Krug, N; Tschernig, T; Balke, K; Erpenbeck, VJ; Meyer, L; Bode, U; Hohlfeld, JM; Pabst, R; Fabel, H				Krug, N; Tschernig, T; Balke, K; Erpenbeck, VJ; Meyer, L; Bode, U; Hohlfeld, JM; Pabst, R; Fabel, H			Enhanced expression of Fas ligand (CD95L) on T cells after segmental allergen provocation in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						apoptosis; Fas; Fas ligand; T cell; asthma	PERIPHERAL-BLOOD; BRONCHOALVEOLAR LAVAGE; DEATH APOPTOSIS; ATOPIC ASTHMA; IN-VITRO; LYMPHOCYTES; LUNG; ACTIVATION; ANTIGEN; TISSUE	Background: Little is known about the termination of the T-cell driven inflammation found in patients with allergic asthma. Objective: Because signals delivered through Fas/Fas ligand can lead to T-cell apoptosis, we investigated the expression of Fas and Fas ligand on peripheral blood- and bronchoalveolar lavage fluid (BALF)-derived T cells and the percentage of apoptotic BALF cells in asthma. Methods: Nine atopic subjects with mild asthma and 9 control subjects underwent segmental sham and allergen challenge. Flow cytometry was used to determine the T-cell expression of Fas and Fas ligand, and the terminal dUTP nick end labeled technique was applied to detect apoptotic BALF cells. Results: In asthmatic and control subjects almost all T cells in the BALF expressed Fas antigen without changes after saline or allergen challenge. A small percentage of T cells in BALF expressed the Fas ligand, In asthmatic subjects, but not in control subjects, there was a significant increase in Fas ligand after allergen challenge (CD3: 0.8% +/- 0.6% [baseline] vs 3.2% +/- 1.2% [allergen challenge]; CD4: 1.8% +/- 0.0% vs 4.3% +/- 1.8%; CD8: 2.8% +/- 2.4% vs 9.1% +/- 4.8%) but not after saline challenge, with a significant correlation to the percentage of BALF eosinophils. Apoptotic BALF cells were localized exclusively in macrophages at a very tow frequency (0.03% to 0.15%) and without changes after saline or allergen challenge in both groups. Conclusion: In asthma there is an upregulation of Fas ligand on T cells in BALF after allergen challenge. Because there is no evidence for increased apoptosis, this phenomenon may reflect antigen-induced T-cell activation rather than apoptosis.	Hannover Med Sch, Dept Resp Med, D-30625 Hannover, Germany; Hannover Med Sch, Dept Funct & Appl Anat, D-30625 Hannover, Germany	Hannover Medical School; Hannover Medical School	Krug, N (corresponding author), Hannover Med Sch, Dept Resp Med, Carl Neuberg Str 1, D-30625 Hannover, Germany.			Hohlfeld, Jens/0000-0003-2646-6186				Akbar AN, 1997, IMMUNOL TODAY, V18, P72, DOI 10.1016/S0167-5699(97)01003-7; ALDERSON MR, 1995, J EXP MED, V181, P71, DOI 10.1084/jem.181.1.71; ALDERSON MR, 1993, J EXP MED, V178, P2231, DOI 10.1084/jem.178.6.2231; Bode U, 1997, EUR J IMMUNOL, V27, P2087, DOI 10.1002/eji.1830270837; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; GOCHUICO BR, 1998, AM J PHYSIOL, V274, P6444; Herry I, 1996, AM J RESP CELL MOL, V15, P339, DOI 10.1165/ajrcmb.15.3.8810637; KABELITZ D, 1993, IMMUNOL TODAY, V14, P338, DOI 10.1016/0167-5699(93)90231-9; Krug N, 1996, AM J RESP CRIT CARE, V153, P1391, DOI 10.1164/ajrccm.153.4.8616571; Krug N, 1998, CLIN EXP ALLERGY, V28, P10; Krug N, 1996, AM J RESP CELL MOL, V14, P319, DOI 10.1165/ajrcmb.14.4.8600935; Milik AM, 1997, J CLIN INVEST, V99, P1082, DOI 10.1172/JCI119236; MIYAWAKI T, 1992, J IMMUNOL, V149, P3753; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; PRETOLANI M, 1997, AM J RESP CRIT CARE, V155, pA817; ROBINSON DS, 1993, THORAX, V48, P26, DOI 10.1136/thx.48.1.26; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; SALTINI C, 1990, J EXP MED, V171, P1123, DOI 10.1084/jem.171.4.1123; SHEFFER AL, 1992, EUR RESPIR J, V5, P601; Spinozzi F, 1998, ANN INTERN MED, V128, P363, DOI 10.7326/0003-4819-128-5-199803010-00004; SUDA T, 1995, J IMMUNOL, V154, P3806; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; WALKER C, 1992, AM REV RESPIR DIS, V146, P109, DOI 10.1164/ajrccm/146.1.109; WALTER S, 1995, EUR J IMMUNOL, V25, P1199, DOI 10.1002/eji.1830250510; WESSELBORG S, 1993, J IMMUNOL, V150, P4338	27	20	24	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1999	103	4					649	655		10.1016/S0091-6749(99)70238-1	http://dx.doi.org/10.1016/S0091-6749(99)70238-1			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	186HY	10200015				2022-12-18	WOS:000079723900019
J	Rais, M; Unzeitig, J; Grant, JA				Rais, M; Unzeitig, J; Grant, JA			Refractory exacerbations of hereditary angioedema with associated Helicobacter pylori infection	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							CHRONIC URTICARIA; GASTRITIS		Univ Texas, Med Branch, Dept Internal Med, Allergy & Immunol Div, Galveston, TX 77555 USA; Mercy Reg Med Ctr, Laredo, TX USA	University of Texas System; University of Texas Medical Branch Galveston	Grant, JA (corresponding author), Univ Texas, Med Branch, Dept Internal Med, Allergy & Immunol Div, 301 Univ Blvd, Galveston, TX 77555 USA.							ADKINSON D, 1993, J ALLERGY CLIN IMMUN, V91, P364; Bohmeyer J, 1996, HAUTARZT, V47, P106, DOI 10.1007/s001050050385; DONALDSON VH, 1963, AM J MED, V35, P37, DOI 10.1016/0002-9343(63)90162-1; SIM TC, 1990, AM J MED, V88, P656, DOI 10.1016/0002-9343(90)90535-L; Wedi B, 1998, INT ARCH ALLERGY IMM, V116, P288, DOI 10.1159/000023958	5	20	20	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1999	103	4					713	714		10.1016/S0091-6749(99)70249-6	http://dx.doi.org/10.1016/S0091-6749(99)70249-6			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	186HY	10200026				2022-12-18	WOS:000079723900030
J	Essayan, DM; Krishnaswamy, G; Oriente, A; Lichtenstein, LM; Huang, SK				Essayan, DM; Krishnaswamy, G; Oriente, A; Lichtenstein, LM; Huang, SK			Differential regulation of antigen-induced IL-4 and IL-13 generation from T lymphocytes by IFN-alpha	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						human; T lymphocyte; cytokine; IL-4; IL-13; IFN-alpha	NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS; BLOOD MONONUCLEAR-CELLS; INTERFERON-ALPHA; SJOGRENS-SYNDROME; SYSTEMIC-SCLEROSIS; GENE-EXPRESSION; SALIVARY-GLANDS; B-CELLS; INTERLEUKIN-13; RESPONSES	Background: IL-4 and IL-13 are related cytokines with similar functional properties. Differential regulation of IL-4 and IL-13 has not been described. Objective: We have examined the effects of IFN-alpha on antigen-driven proliferation, IL-4 generation, and IL-13 generation from human PBMCs and T-cell clones. Methods: Proliferation was assessed by H-3-thymidine incorporation. Cytokine generation was assessed by reverse transcription PCR and ELISA, Messenger RNA stability was assessed in the presence of actinomycin D. Results: IFN-alpha induced a concentration-dependent inhibition of antigen-driven proliferation of T-H1 and T-H2 clones (median effective concentration, 150 to 200 U/mL); the sensitivity of T-H1 and T-H2 clones to IFN-alpha was not significantly different (P = .6). IFN-alpha induced an analogous concentration-dependent inhibition of antigen-driven IL-13 generation from T-H1 and T-H2 clones (median effective concentration, 100 U/mL); this effect was evident by 12 hours of culture and persisted beyond 48 hours. However, IL-4 generation from T-H2 clones was insensitive to IFN-alpha at all concentrations and times tested (1 to 10,000 U/mL). A similar inhibitory effect of IFN-alpha on mitogen-driven proliferation and IL-13 generation from PBMCs was demonstrated; once again, IL-4 generation from PBMCs was insensitive to IFN-alpha. IL-13 mRNA stability was unaffected by IFN-alpha, suggesting transcriptional regulation. Conclusion: IFN-alpha differentially regulates antigen-stimulated IL-4 and IL-13 generation.	Johns Hopkins Univ, Sch Med, Dept Med, Div Clin Immunol, Baltimore, MD 21205 USA; E Tennessee State Univ, Dept Med, Johnson City, TN 37614 USA	Johns Hopkins University; East Tennessee State University	Huang, SK (corresponding author), Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle,Rm 1A12, Baltimore, MD 21224 USA.		KRISHNASWAMY, GUHA/AAR-8844-2021; Huang, Shau-Ku/F-5509-2010; Krishnaswamy, Guha/R-9076-2019	KRISHNASWAMY, GUHA/0000-0002-9848-6197; 	NIAID NIH HHS [AI40274, AI34002] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI034002, R01AI040274] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aman MJ, 1996, J BIOL CHEM, V271, P29265, DOI 10.1074/jbc.271.46.29265; BAMBOROUGH P, 1994, PROTEIN ENG, V7, P1077, DOI 10.1093/protein/7.9.1077; Berkman N, 1996, IMMUNOLOGY, V87, P599, DOI 10.1046/j.1365-2567.1996.477579.x; Braun CM, 1997, J ALLERGY CLIN IMMUN, V100, P400, DOI 10.1016/S0091-6749(97)70255-0; BRINKMANN V, 1995, J IMMUNOL, V154, P3078; deVries JE, 1996, CHEM IMMUNOL, V63, P204; ESSAYAN DM, 1994, J IMMUNOL, V153, P3408; Essayan DM, 1996, J ALLERGY CLIN IMMUN, V98, P1035, DOI 10.1016/S0091-6749(96)80188-6; Essayan DM, 1997, BIOCHEM PHARMACOL, V53, P1055, DOI 10.1016/S0006-2952(97)00102-0; Essayan DM, 1997, J PHARMACOL EXP THER, V282, P505; ESSAYAN DM, 1995, AM J RESP CELL MOL, V13, P692, DOI 10.1165/ajrcmb.13.6.7576707; FINKELMAN FD, 1991, J EXP MED, V174, P1179, DOI 10.1084/jem.174.5.1179; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; Hasegawa M, 1997, J RHEUMATOL, V24, P328; Horie S, 1997, INTERNAL MED, V36, P179, DOI 10.2169/internalmedicine.36.179; HUANG SK, 1995, J IMMUNOL, V155, P2688; HUANG SK, 1994, J IMMUNOL METHODS, V168, P167, DOI 10.1016/0022-1759(94)90052-3; IADEMARCO MF, 1995, J CLIN INVEST, V95, P264, DOI 10.1172/JCI117650; KAHARI VM, 1988, BIOCHIM BIOPHYS ACTA, V968, P45, DOI 10.1016/0167-4889(88)90042-0; KEEGAN AD, 1995, P NATL ACAD SCI USA, V92, P7681, DOI 10.1073/pnas.92.17.7681; Kraan TCTMV, 1996, J IMMUNOL, V156, P1818; Krishnaswamy G, 1996, J INTERF CYTOK RES, V16, P819, DOI 10.1089/jir.1996.16.819; MALEFYT RD, 1995, INT IMMUNOL, V7, P1405, DOI 10.1093/intimm/7.9.1405; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; McKenzie A N, 1995, Cancer Treat Res, V80, P367; Ohyama Y, 1996, ARTHRITIS RHEUM, V39, P1376, DOI 10.1002/art.1780390816; Parronchi P, 1996, EUR J IMMUNOL, V26, P697, DOI 10.1002/eji.1830260328; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; SHIOZAWA S, 1993, BRIT J RHEUMATOL, V32, P52; STEVENS W, 1992, BRIT J RHEUMATOL, V31, P683; Villarreal GM, 1996, IMMUNOL LETT, V49, P105, DOI 10.1016/0165-2478(95)02490-5; Wenner CA, 1996, J IMMUNOL, V156, P1442	32	20	20	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1999	103	3	1				451	457		10.1016/S0091-6749(99)70470-7	http://dx.doi.org/10.1016/S0091-6749(99)70470-7			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	176WU	10069879				2022-12-18	WOS:000079175700014
J	Phipatanakul, W; Kesavanathan, J; Eggleston, PA; Johnson, EF; Wood, RA				Phipatanakul, W; Kesavanathan, J; Eggleston, PA; Johnson, EF; Wood, RA			The value of acoustic rhinometry in assessing nasal responses to cat exposure	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						acoustic rhinometry; cat challenge; cat allergen	INHALATION CHALLENGE; RHINOMANOMETRY; RHINITIS; ANTIGEN	Background: Acoustic rhinometry (AR) uses sonar principles to map the anatomy of the nasal cavity and has been used in other studies to assess acute airway responses to allergen exposure. Objective: The purpose of this study was to evaluate the utility of AR in assessing acute airway responses to cat allergen exposure by using a well-characterized cat exposure model. Methods: Thirty subjects with a history of cat-induced rhinitis and a positive skin prick test response to cat allergen underwent an environmental cat challenge, Of these 30 subjects, 10 also had repeat challenges at lower levels of antigen to determine whether there was a dose response. Five subjects with negative skin test responses to cat were recruited as control subjects, During the 1-hour cat exposure, upper and lower respiratory symptoms were scored every 5 minutes, and spirometry and AR were obtained every 15 minutes. Results: Although 29 of 30 subjects had changes in AR measurements, no correlations were detected between upper respiratory symptom scores and any of the changes observed in AR. In comparing the baseline challenges with lower antigen level challenges, upper respiratory symptom scores differed significantly (P = .002), whereas AR responses were nearly identical. Subjects without cat allergy did exhibit less response by AR (P = .05 to .13), but the greatest differences remained in the upper respiratory symptoms scores (P < .0001). Conclusion: We conclude that although AR does provide an objective measure of nasal response to allergen exposure, it has significant limitations. These are evidenced by the lack of correlation with symptoms, the inability to measure a dose response, and the changes noted even among the control subjects.	Johns Hopkins Univ, Sch Med, Dept Pediat, Div Allergy & Immunol, Baltimore, MD 21205 USA; USA, ERDEC, Aberdeen Proving Ground, MD USA	Johns Hopkins University	Wood, RA (corresponding author), Johns Hopkins Hosp, CMSC 1102,600 N Wolfe St, Baltimore, MD 21287 USA.				NIAID NIH HHS [AI07007] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAJIA J, 1997, ACTA OTORRINOLARINGO, V48, P31; Bollinger ME, 1996, J ALLERGY CLIN IMMUN, V97, P907, DOI 10.1016/S0091-6749(96)80064-9; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; GRYMER L F, 1991, Rhinology (Utrecht), V29, P35; HILBERG O, 1989, J APPL PHYSIOL, V66, P295, DOI 10.1152/jappl.1989.66.1.295; HILBERG O, 1995, ANN ALLERG ASTHMA IM, V74, P516; Kesavanathan J, 1996, J TOXICOL ENV HEALTH, V48, P295, DOI 10.1080/009841096161348; Lane AP, 1996, ANN OTO RHINOL LARYN, V105, P811; MAYHEW TM, 1993, CLIN OTOLARYNGOL, V18, P220; Nielsen LP, 1996, CLIN EXP ALLERGY, V26, P1268, DOI 10.1111/j.1365-2222.1996.tb00524.x; RASP G, 1993, LARYNGO RHINO OTOL, V72, P125, DOI 10.1055/s-2007-997869; ROITHMANN R, 1994, J OTOLARYNGOL, V23, P454; WOOD RA, 1993, CLIN EXP ALLERGY, V23, P542; Zweiman B, 1997, J ALLERGY CLIN IMMUN, V100, P624, DOI 10.1016/S0091-6749(97)70166-0	15	20	20	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1998	102	6	1				896	901		10.1016/S0091-6749(98)70325-2	http://dx.doi.org/10.1016/S0091-6749(98)70325-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	150XE	9847428				2022-12-18	WOS:000077690700004
J	Hargreave, FE				Hargreave, FE			Induced sputum and response to glucocorticoids	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Festschrift Meeting in Honor of Jerry Dolovich	MAY   24, 1997	HAMILTON, CANADA	McMaster Univ, Fac Hlth Sci, Astra Canada			AIRWAY INFLAMMATION; EOSINOPHILIC BRONCHITIS; ASTHMATIC RESPONSES; CATIONIC PROTEIN; CHRONIC COUGH; INDEXES; EXACERBATIONS; OBSTRUCTION; COUNTS; CELLS	Jerry Dolovich has generated substantial new work that has had an international impact on the understanding and treatment of asthma and other airway diseases. For this, he is recognized as a Distinguished Clinician of the American Academy of Asthma, Allergy and Immunology. I have focused on some of this recent work with us using induced sputum to measure indices of airway inflammation noninvasively. The results illustrate that sputum eosinophilia (1) does not necessarily correlate with the severity of symptoms of severity of abnormalities of airway function, (2) does not always occur in exacerbations of asthma, and (3) may be a predictor clinical benefit to steroid treatment, which will be useful in practice. The observations imply that airway inflammation needs to be measured to understand the pathogenesis, pathophysiology, and treatment of asthma and other airway diseases.	McMaster Univ, Dept Med, Hamilton, ON, Canada	McMaster University	Hargreave, FE (corresponding author), McMaster Univ, Firestone Reg Chest & Allergy Unit, 50 Charlton Ave E, Hamilton, ON L8N 4A6, Canada.							Berlyne G. S., 1997, European Respiratory Journal Supplement, V10, p184S; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DOLOVICH J, 1981, THORAX, V36, P641, DOI 10.1136/thx.36.9.614; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; EFTHIMIADIS A, 1995, J ALLERGY CLIN IMMUN, V95, P281; EFTHIMIADIS A, 1997, EUR RESPIR J, V10, P1335; FAHY JV, 1995, J ALLERGY CLIN IMMUN, V95, P843, DOI 10.1016/S0091-6749(95)70128-1; GELDER CM, 1995, THORAX, V50, P1033, DOI 10.1136/thx.50.10.1033; GIBSON PG, 1989, THORAX, V44, P693, DOI 10.1136/thx.44.9.693; GIBSON PG, 1989, LANCET, V1, P1346; GIBSON PG, 1995, CLIN EXP ALLERGY, V25, P127, DOI 10.1111/j.1365-2222.1995.tb01017.x; GIRGISGABARDO A, 1994, J ALLERGY CLIN IMMUN, V93, P945, DOI 10.1016/0091-6749(94)90390-5; Gollash H., 1889, FORTSCHR MED, V7, P361; Haley KJ, 1998, AM J RESP CRIT CARE, V157, P1; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; HARGREAVE FE, 1990, J ALLERGY CLIN IMMUN, V85, P1098, DOI 10.1016/0091-6749(90)90056-A; Kidney JC, 1996, AM J RESP CRIT CARE, V153, P540, DOI 10.1164/ajrccm.153.2.8564094; MAESTRELLI P, 1995, AM J RESP CRIT CARE, V152, P1926, DOI 10.1164/ajrccm.152.6.8520757; OBYRNE PM, 1987, AM REV RESPIR DIS, V136, P740, DOI 10.1164/ajrccm/136.3.740; Osler WB, 1892, PRINCIPLES PRACTICE; Parameswaran K, 1998, EUR RESPIR J, V11, P1405, DOI 10.1183/09031936.98.11061405; Parameswaran K, 1998, J ALLERGY CLIN IMMUN, V101, pS116; PIN I, 1992, AM REV RESPIR DIS, V145, P1265, DOI 10.1164/ajrccm/145.6.1265; PIN I, 1992, THORAX, V47, P25, DOI 10.1136/thx.47.1.25; Pizzichini E, 1998, EUR RESPIR J, V11, P828, DOI 10.1183/09031936.98.11040828; Pizzichini E, 1997, J ALLERGY CLIN IMMUN, V99, P539, DOI 10.1016/S0091-6749(97)70082-4; Pizzichini E, 1996, AM J RESP CRIT CARE, V154, P308, DOI 10.1164/ajrccm.154.2.8756799; Pizzichini E, 1998, AM J RESP CRIT CARE, V157, pA836; PIZZICHINI MM, 1998, IN PRESS EUR RESP J; Pizzichini MMM, 1996, AM J RESP CRIT CARE, V154, P866, DOI 10.1164/ajrccm.154.4.8887576; Pizzichini MMM, 1997, AM J RESP CRIT CARE, V155, P1501, DOI 10.1164/ajrccm.155.5.9154849; PIZZICHINI MMM, 1998, IN PRESS AM J RESP C; SOLLEY GO, 1977, J CLIN INVEST, V7, P503; Stanescu D, 1996, THORAX, V51, P267, DOI 10.1136/thx.51.3.267; TURNER MO, 1995, THORAX, V50, P1057, DOI 10.1136/thx.50.10.1057	36	20	20	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1998	102	5					S102	S105		10.1016/S0091-6749(98)70040-5	http://dx.doi.org/10.1016/S0091-6749(98)70040-5			4	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	139MR	9819318	Bronze			2022-12-18	WOS:000077033400036
J	Miura, K; Hubbard, WC; MacGlashan, DW				Miura, K; Hubbard, WC; MacGlashan, DW			Phosphorylation of cytosolic phospholipase A2 by IL-3 is associated with increased free arachidonic acid generation and leukotriene C4 release in human basophils	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						human basophils; IL-3; arachidonic acid; leukotriene C4; cytosolic phospholipase A2	COLONY-STIMULATING FACTOR; MACROPHAGE CELL-LINE; MAP KINASE; HYDROLYZING PHOSPHOLIPASE-A2; MEDIATOR RELEASE; HUMAN-LUNG; ACTIVATION; INTERLEUKIN-3; A(2); PROTEIN	Background: Human basophils secrete leukotriene C4 (LTC4) in response to various stimuli, and a short treatment with IL-3 enhances LTC4 release, although IL-3 alone does not induce LTC4 release. However, the mechanism of this priming effect of IL-3 for LTC4 generation remains unknown in human basophils, Objective: This study was designed to explore the mechanisms by which short treatments with IL-3 enhance stimulated secretion of LTC4, with a focus on the activation of cytosolic phospholipase A2 (cPLA2), Methods: The phosphorylation state of cPLA2 in human basophils was examined by its shift in electrophoretic mobility as detected by Western blotting. Free arachidonic acid (AA) and LTC4 were measured by gas chromatography-negative ion chemical ionization mass spectrometry and LTC4-specific RIA, respectively. Result: Human basophils expressed cPLA2, IL-3, as well as the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate, caused a shift in the electrophoretic mobility of cPLA2, which indicated phosphorylation of cPLA2 and therefore its activation. Ionomycin at a concentration of 0.1 mu g/mL was used to induce a modest elevation of cytosolic calcium response ([Ca2+](I)), no apparent cPLA2 phosphorylation, and little free AA and LTC4 generation. Pretreatment with IL-3 (1 to 10 ng/mL) markedly enhanced ionomycin (0.1 mu g/mL) mediated AA and LTC4 generation. The concentration dependence of cPLA2 phosphorylation by IL-3 and its effects on free AA and LTC4 generation were similar. The selective PKC inhibitors, bis-indolylmaleimide II and Ro-31-8220 inhibited the phorbol 12-myristate 13-acetate-mediated cPLA2 electrophoretic mobility shift, but not the IL-3-mediated shift, suggesting that the IL-3 effect is PKC independent. Both the anaphylatoxin split product of the C component C5 (C5a) and f-Met-Leu-Phe induced PKC-independent cPLA2 phosphorylation with a similar time course most notable for the absence of observable changes in cPLA2 phosphorylation before vated in response to C5a, there was no phosphorylation of cPLA2, and by the time cPLA2 became phosphorylated, [Ca2+](I) had returned to resting levels. Treatment with IL-3 preconditioned the cPLA2 by causing its phosphorylation so that the transient [Ca2+], response, which followed stimulation by C5a, could induce the generation of free AA and LTC4. Conclusion: Taken together, these results suggest that the effect of IL-3 for free AA generation and LTC4 release might be due to induction of cPLA2 phosphorylation, The studies demonstrated a need for synchronous cPLA2 phosphorylation and elevations in [Ca2+](I).	Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine	MacGlashan, DW (corresponding author), Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.							Balboa MA, 1996, J BIOL CHEM, V271, P32381, DOI 10.1074/jbc.271.50.32381; BARBOUR SE, 1993, J BIOL CHEM, V268, P21875; BITTORF T, 1994, CELL SIGNAL, V6, P305, DOI 10.1016/0898-6568(94)90035-3; BOKOCH GM, 1995, BLOOD, V86, P1649, DOI 10.1182/blood.V86.5.1649.bloodjournal8651649; BRUNNER T, 1993, J EXP MED, V177, P605, DOI 10.1084/jem.177.3.605; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; DIEZ E, 1992, J BIOL CHEM, V267, P18342; GILBERT HS, 1975, BLOOD, V46, P279; HAYES EC, 1983, J IMMUNOL, V131, P429; HUBBARD WC, 1986, PROSTAGLANDINS, V32, P889, DOI 10.1016/0090-6980(86)90097-3; Hundley TR, 1998, J PHARMACOL EXP THER, V284, P847; KRAMER RM, 1995, J BIOL CHEM, V270, P14816, DOI 10.1074/jbc.270.24.14816; KURIMOTO Y, 1991, EUR J IMMUNOL, V21, P361, DOI 10.1002/eji.1830210217; KURIMOTO Y, 1989, J EXP MED, V170, P467, DOI 10.1084/jem.170.2.467; LESLIE CC, 1988, BIOCHIM BIOPHYS ACTA, V963, P476, DOI 10.1016/0005-2760(88)90316-5; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MACGLASHAN D, 1991, J LEUKOCYTE BIOL, V49, P29, DOI 10.1002/jlb.49.1.29; MACGLASHAN D, 1989, J CELL BIOL, V109, P123, DOI 10.1083/jcb.109.1.123; MACGLASHAN D, 1994, J IMMUNOL, V152, P3006; MACGLASHAN DW, 1993, J IMMUNOL, V151, P6358; MACGLASHAN DW, 1986, J IMMUNOL, V136, P2231; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; OKUDA K, 1992, BLOOD, V79, P2880; QIU ZH, 1993, J BIOL CHEM, V268, P24506; SCHLEIMER RP, 1989, J IMMUNOL, V143, P1310; Serhan CN, 1996, FASEB J, V10, P1147, DOI 10.1096/fasebj.10.10.8751717; SHARP JD, 1991, J BIOL CHEM, V266, P14850; Steinhilber D, 1994, Pharm Acta Helv, V69, P3, DOI 10.1016/0031-6865(94)90024-8; WARNER JA, 1989, J LEUKOCYTE BIOL, V45, P558, DOI 10.1002/jlb.45.6.558; WIJKANDER J, 1992, BIOCHEM BIOPH RES CO, V184, P118, DOI 10.1016/0006-291X(92)91166-N; XING MZ, 1992, J BIOL CHEM, V267, P25966; XU XX, 1994, J BIOL CHEM, V269, P31693; Yamaguchi M, 1996, J ALLERGY CLIN IMMUN, V97, P1279, DOI 10.1016/S0091-6749(96)70196-3	37	20	20	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1998	102	3					512	520		10.1016/S0091-6749(98)70142-3	http://dx.doi.org/10.1016/S0091-6749(98)70142-3			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	124ZN	9768595				2022-12-18	WOS:000076212800029
J	King, TP; Lu, G; Agosto, H				King, TP; Lu, G; Agosto, H			Antibody responses to bee melittin (Api m 4) and hornet antigen 5 (Dol m 5) in mice treated with the dominant T-cell epitope peptides	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen; Dol m 5; bee; hornet; Api m 4; peptide immunotherapy	IMMUNOTHERAPY; ALLERGEN; TOLERANCE; NAIVE	Background: Mice treated with the dominant T-cell epitope peptides of allergens were reported to have reduced peptide- or allergen-specific T-cell responses on subsequent immunization, but the extent of reduction of allergen-specific antibodies is not clear. Objective: This study was done to compare the extent of reduction of T-cell and antibody responses in peptide-treated mice. Two allergens were tested. Bee melittin (Api m 4), an allergen of 26 amino acid residues, has a single dominant Tor B-cell epitope. Hornet antigen 5 (Dol m 5), an allergen of 204 amino acid residues, has multiple dominant T- or B-cell epitopes. Methods: Mice were treated with T-cell peptides of Api m 4 or Dol m 5 and then immunized biweekly with their respective allergen with alum adjuvant. T-cell peptides tested were residues 7-19 of Api m 4 and residues 41-60, 141-160, and 176-195 of Dol m 5. T-cell responses at week 9 or 11 were assayed by proliferation of spleen cell cultures. Antibody responses of different isotypes were measured biweekly by ELISA. Results: Partial reduction of 30% to 50% of T-cell responses to peptide or allergen was observed in bee and hornet peptide-treated mice. About 65% reduction of Api m 4-specific antibody response was observed early in the immune response but gradually subsided to about 40% late in the response. Partial reduction of about 40% of Dol m 5-specific antibody response was only observed early in the immune response. Conclusion: Peptide treatment is partially effective in the reduction of T-cell responses of univalent or multivalent allergens. It is also partially effective in the reduction of antibody response of a univalent allergen, but it is poorly effective for a multivalent allergen.	Rockefeller Univ, New York, NY 10021 USA	Rockefeller University	King, TP (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.				NIAID NIH HHS [AI-17021] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017021] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akdis CA, 1996, J CLIN INVEST, V98, P1676, DOI 10.1172/JCI118963; Bauer L, 1997, CLIN EXP IMMUNOL, V107, P536, DOI 10.1046/j.1365-2249.1997.d01-953.x; Bellinghausen I, 1997, EUR J IMMUNOL, V27, P1131, DOI 10.1002/eji.1830270513; BRINER TJ, 1993, P NATL ACAD SCI USA, V90, P7608, DOI 10.1073/pnas.90.16.7608; CRETICOS PS, 1997, J ALLERGY CLIN IMMUN, V99, P401; DURHAM SR, 1995, INT ARCH ALLERGY IMM, V107, P282, DOI 10.1159/000237003; FEHLNER PF, 1991, J IMMUNOL, V146, P799; HOYNE GF, 1993, J EXP MED, V178, P1783, DOI 10.1084/jem.178.5.1783; KING TP, 1995, J IMMUNOL, V154, P577; King TP, 1997, J ALLERGY CLIN IMMUN, V99, P630, DOI 10.1016/S0091-6749(97)70025-3; KING TP, 1984, J IMMUNOL, V133, P2668; Lack G, 1997, J ALLERGY CLIN IMMUN, V99, P530, DOI 10.1016/S0091-6749(97)70081-2; MARCOTTE GV, 1997, J ALLERGY CLIN IMMUN, V99, P405; Motulsky H., 1995, INTUITIVE BIOSTATIST; MULLER U, 1996, NEW TRENDS ALLERGY, P345; NORMAN PS, 1993, CURR OPIN IMMUNOL, V5, P968, DOI 10.1016/0952-7915(93)90114-8; NORMAN PS, 1997, J ALLERGY CLIN IMMUN, V99, P127; OBrien RM, 1997, CLIN EXP ALLERGY, V27, P46, DOI 10.1046/j.1365-2222.1997.d01-424.x; RIA F, 1990, NATURE, V343, P381, DOI 10.1038/343381a0; Simons FER, 1996, INT IMMUNOL, V8, P1937, DOI 10.1093/intimm/8.12.1937; vanNeerven RJJ, 1996, IMMUNOL TODAY, V17, P526, DOI 10.1016/0167-5699(96)10058-X; WALLNER BP, 1994, ALLERGY, V49, P302, DOI 10.1111/j.1398-9995.1994.tb02272.x	22	20	32	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1998	101	3					397	403		10.1016/S0091-6749(98)70254-4	http://dx.doi.org/10.1016/S0091-6749(98)70254-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZC570	9525458				2022-12-18	WOS:000072593900019
J	Moneret-Vautrin, DA; Kanny, G; Thevenin, F				Moneret-Vautrin, DA; Kanny, G; Thevenin, F			A population study of food allergy in France: A survey concerning 33,110 individuals.	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract									Univ Hosp, Nancy, France	CHU de Nancy			Kanny, Gisèle/AHA-8910-2022						0	20	20	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1998	101	1	2			366	S87	S87						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YW339					2022-12-18	WOS:000071924800366
J	Togias, A; Corren, J; Shapiro, G; Reimann, JD; von Schlegell, A; Wighton, TG; Adelman, DC				Togias, A; Corren, J; Shapiro, G; Reimann, JD; von Schlegell, A; Wighton, TG; Adelman, DC			Anti-IgE treatment reduces skin test (ST) reactivity.	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	20	20	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1998	101	1	2			706	S171	S171						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YW339					2022-12-18	WOS:000071924800706
J	Liccardi, G; Szepfalusi, Z; Noschese, P; Nentwich, I; DAmato, M; DAmato, G				Liccardi, G; Szepfalusi, Z; Noschese, P; Nentwich, I; DAmato, M; DAmato, G			Allergy to chicken meat without sensitization to egg proteins: A case report	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							POLLEN		UNIV VIENNA,DEPT PEDIAT,VIENNA,AUSTRIA	University of Vienna	Liccardi, G (corresponding author), HOSP A CARDARELLI,DIV PNEUMOL & ALLERGOL,DEPT CHEST DIS,PIAZZA ARENELLA 7-H,I-80128 NAPLES,ITALY.		D'Amato, Maria/H-3074-2012	D'Amato, Maria/0000-0002-5906-5701; Szepfalusi, Zsolt/0000-0003-4852-3102				AAS K, 1972, ACTA ALLERGOL, V27, P439; ANIBARRO B, 1993, J ALLERGY CLIN IMMUN, V92, P628, DOI 10.1016/0091-6749(93)90089-X; DAmato G, 1996, ANN ALLERG ASTHMA IM, V77, P147, DOI 10.1016/S1081-1206(10)63501-6; DREBORG S, 1983, ALLERGY, V38, P167, DOI 10.1111/j.1398-9995.1983.tb01602.x; IPSEN H, 1983, J ALLERGY CLIN IMMUN, V72, P150, DOI 10.1016/0091-6749(83)90523-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; OFFMAN DR, 1988, J ALLERGY CLIN IMMUN, V81, P484; SZEPFALUSI Z, 1994, J ALLERGY CLIN IMMUN, V93, P932, DOI 10.1016/0091-6749(94)90388-3	8	20	20	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1997	100	4					577	579		10.1016/S0091-6749(97)70154-4	http://dx.doi.org/10.1016/S0091-6749(97)70154-4			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YA529	9338556	Bronze			2022-12-18	WOS:A1997YA52900025
J	Sarlo, K; Ritz, HL; Fletcher, ER; Schrotel, KR; Clark, ED				Sarlo, K; Ritz, HL; Fletcher, ER; Schrotel, KR; Clark, ED			Proteolytic detergent enzymes enhance the allergic antibody responses of guinea pigs to nonproteolytic detergent enzymes in a mixture: Implications for occupational exposure	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						enzymes; enzyme mixtures; guinea pig models; allergic responses	IGE ANTIBODY; DERMATOPHAGOIDES-FARINAE; COMMON AEROALLERGENS; BACILLUS-SUBTILIS; WORKERS; SMOKING; DUST; HYPERSENSITIVITY; PREVALENCE; PROTEASES	A guinea pig intratracheal test was developed to assess the respiratory allergenicity of enzymes used in the detergent industry. Information gained from this test was used in a process for setting operational exposure guidelines to protect worker health. Mixtures of enzyme proteins were given to guinea pigs once per week for 10 weeks to determine whether there were interactions among enzymes that affected the induction of antibody responses to each enzyme in the mixture, Passive cutaneous anaphylaxis antibody titers against each enzyme were measured in sera. Mixtures of two or three enzymes always consisted of a protease (Alcalase, Savinase; Novo Industri A/S) with an alpha-amylase (Termamyl; Novo Industri A/S), a lipase (Lipolase; Novo Industri A/S), or both. Control animals were exposed to single enzymes. The antibody titers to Termamyl and Lipolase were significantly greater in animals dosed with the protease-containing mixtures as compared with control animals dosed with a single enzyme. Antibody titers to the protease were unchanged in the presence of additional enzymes in the mixture. Complete inactivation of protease activity abrogated the enhanced antibody response to Lipolase. Inhalation exposure of guinea pigs to a mixture of Alcalase and Lipolase also resulted in higher antibody titers to Lipolase as compared with animals exposed by inhalation to Lipolase alone, showing that the enhanced response was not due to intratracheal delivery of antigen to the respiratory tract. These results show that proteolytic enzymes in a mixture enhance antibody responses to other enzymes. This should be considered when defining exposure guidelines for protease-containing enzyme mixtures.			Sarlo, K (corresponding author), PROCTER & GAMBLE CO,MIAMI VALLEY LABS,POB 538707,CINCINNATI,OH 45253, USA.							*ACGIH, 1990, AM C GOV IND HYG THR, P38; ANDO T, 1993, CLIN EXP ALLERGY, V23, P777, DOI 10.1111/j.1365-2222.1993.tb00366.x; ARLIAN LG, 1990, INT ARCH ALLER A IMM, V91, P278, DOI 10.1159/000235128; FLINDT MLH, 1969, LANCET, V1, P1177; FLOOD DFS, 1985, BRIT J IND MED, V42, P43; FRANZ T, 1971, J ALLERGY, V47, P170, DOI 10.1016/S0091-6749(71)80295-6; GERGEN PJ, 1987, J ALLERGY CLIN IMMUN, V80, P669, DOI 10.1016/0091-6749(87)90286-7; GREENBERG M, 1970, BMJ-BRIT MED J, V2, P629, DOI 10.1136/bmj.2.5710.629; HARTLEY BS, 1959, BIOCHIM BIOPHYS ACTA, V34, P243, DOI 10.1016/0006-3002(59)90254-9; HOW MJ, 1978, CLIN ALLERGY, V8, P347, DOI 10.1111/j.1365-2222.1978.tb00470.x; ISHIZAKI T, 1987, ANN ALLERGY, V58, P265; JUNIPER CP, 1977, J SOC OCCUP MED, V27, P3; KAROL MH, 1985, FUND APPL TOXICOL, V5, P459, DOI 10.1016/0272-0590(85)90093-4; LIU FJ, 1994, CLIN EXP ALLERGY, V24, P949; MAMULA MJ, 1993, IMMUNOL TODAY, V14, P151, DOI 10.1016/0167-5699(93)90274-O; MATSUMURA Y, 1970, AM REV RESPIR DIS, V102, P430; MCMURRAIN KD, 1970, JOM-J OCCUP MED, V12, P416; MCSHARRY C, 1986, IMMUNOL TODAY, V7, P98; NEWHOUSE ML, 1970, LANCET, V1, P689; OVARY Z, 1963, J EXP MED, V117, P951, DOI 10.1084/jem.117.6.951; PEPYS J, 1969, LANCET, V1, P1181; PERSSON CGA, 1995, CLIN EXP ALLERGY, V23, P807; RITZ HL, 1993, FUND APPL TOXICOL, V21, P31, DOI 10.1006/faat.1993.1068; ROTHGEB TM, 1988, J AM OIL CHEM SOC, V65, P806, DOI 10.1007/BF02542537; SARLO K, 1990, J ALLERGY CLIN IMMUN, V86, P393, DOI 10.1016/S0091-6749(05)80103-4; Sarlo K., 1991, J ALLERGY CLIN IMMUN, V87, P816; SARLO K, IN PRESS FUNDAM APPL; SHAPIRO RS, 1971, J ALLERGY, V47, P76, DOI 10.1016/S0091-6749(71)80373-1; SNEDECOR GW, 1980, STATISTICAL METHODS, P93; STEWART GA, 1989, LANCET, V2, P154, DOI 10.1016/S0140-6736(89)90203-1; Stewart GA, 1996, CLIN EXP ALLERGY, V26, P1020, DOI 10.1111/j.1365-2222.1996.tb00641.x; STEWART GA, 1989, LANCET, V2, P462; STEWART GA, 1994, ALLERGY, V49, P553, DOI 10.1111/j.1398-9995.1994.tb01128.x; SULTZ HA, 1970, AM J PUBLIC HEALTH N, V60, P891, DOI 10.2105/AJPH.60.5.891; VENABLES KM, 1985, BRIT MED J, V290, P201, DOI 10.1136/bmj.290.6463.201; WEILL H, 1971, J AMER MED ASSOC, V217, P425, DOI 10.1001/jama.217.4.425; ZETTERSTROM O, 1985, J ALLERGY CLIN IMMUN, V75, P594, DOI 10.1016/0091-6749(85)90035-1	37	20	21	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1997	100	4					480	487		10.1016/S0091-6749(97)70139-8	http://dx.doi.org/10.1016/S0091-6749(97)70139-8			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YA529	9338541				2022-12-18	WOS:A1997YA52900009
J	Teran, LM; Park, HS; Djukanovic, R; Roberts, K; Holgate, S				Teran, LM; Park, HS; Djukanovic, R; Roberts, K; Holgate, S			Cultured nasal polyps from nonatopic and atopic patients release RANTES spontaneously and after stimulation with phytohemagglutinin	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						nasal polyps; RANTES; eosinophils; lymphocytes; endothelial cells	CHEMOKINE RANTES; GM-CSF; HUMAN EOSINOPHILS; CYTOKINE RANTES; SMOOTH-MUSCLE; MESSENGER-RNA; T-CELL; CHEMOATTRACTANT; RECRUITMENT; EXPRESSION	Background: Eosinophil infiltration of tissue is a hallmark of nasal polyposis in both nonatopic and atopic patients. These cells are thought to play a key role in the nasal polyp inflammatory process. Objective: The objective of this study was to investigate whether cultured nasal polyps derived from nonatopic and atopic patients release RANTES both spontaneously and after phytohemagglutinin (PHA) stimulation. Methods: Nasal polyps were obtained from 12 subjects (6 nonatopic and 6 atopic), cut into 2 to 3 mm large specimens, and cultured for 48 hours with or without PHA. RANTES was measured in the culture supernatant by ELISA (R&D Systems, U.K.). Results: Immunoreactive RANTES was found to be present in the culture supernatant of nasal polyps derived from both nonatopic and atopic patients with no difference between the two groups (median: 3.8 vs 2.9 pg/mg/ml). On incubation with PHA, nasal polyps from both nonatopic and atopic patients released sevenfold and Ii-fold greater amounts of RANTES than unstimulated samples. As determined by immunohistochemistry, RANTES was localized to the vascular endothelium in nasal polyps from both groups of patients. Conclusions: This study demonstrates that cultured nasal polyps derived from both nonatopic and atopic patients release RANTES spontaneously and after PHA stimulation. This observation and the finding that RANTES is present in nasal polyp endothelial cells suggest that this chemokine may be an important mediator of eosinophil and lymphocyte recruitment in both nonatopic and atopic nasal polyposis.	UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND	University of Southampton			Park, Hae-Sim/S-7974-2019; Teran, Luis/AAI-9815-2021	Park, Hae-Sim/0000-0003-2614-0303; Teran, Luis Manuel/0000-0003-1806-1779; Djukanovic, Ratko/0000-0001-6039-5612				Beck LA, 1996, J ALLERGY CLIN IMMUN, V98, P766, DOI 10.1016/S0091-6749(96)70126-4; BRITTEN KM, 1993, BIOTECH HISTOCHEM, V68, P271, DOI 10.3109/10520299309105629; Davidsson A., 1996, Journal of Allergy and Clinical Immunology, V97, P192, DOI 10.1016/S0091-6749(96)80257-0; EBISAWA M, 1994, J IMMUNOL, V153, P2153; FLAVAHAN NA, 1988, AM REV RESPIR DIS, V138, P685, DOI 10.1164/ajrccm/138.3.685; GILAT D, 1994, J IMMUNOL, V153, P4899; HAMILOS DL, 1995, J ALLERGY CLIN IMMUN, V96, P537, DOI 10.1016/S0091-6749(95)70298-9; HASTIE AT, 1987, AM REV RESPIR DIS, V135, P685; KAMEYOSHI Y, 1992, J EXP MED, V176, P587, DOI 10.1084/jem.176.2.587; KAPP A, 1994, J INVEST DERMATOL, V102, P906, DOI 10.1111/1523-1747.ep12383399; Krug N, 1996, AM J RESP CELL MOL, V14, P319, DOI 10.1165/ajrcmb.14.4.8600935; MARFAINGKOKA A, 1995, J IMMUNOL, V154, P1870; MEURER R, 1993, J EXP MED, V178, P1913, DOI 10.1084/jem.178.6.1913; OHNO I, 1991, AM J RESP CELL MOL, V5, P505, DOI 10.1165/ajrcmb/5.6.505; OHNO I, 1992, J CLIN INVEST, V89, P1662, DOI 10.1172/JCI115764; Ponath PD, 1996, J CLIN INVEST, V97, P604, DOI 10.1172/JCI118456; Rajakulasingam K., 1996, Journal of Allergy and Clinical Immunology, V97, P193, DOI 10.1016/S0091-6749(96)80261-2; ROT A, 1995, BIOL CHEMOKINE RANTE, P35; RUBBIABRANDT L, 1991, VIRCHOWS ARCH B, V60, P73, DOI 10.1007/BF02899530; SCHALL TJ, 1994, CURR OPIN IMMUNOL, V6, P865, DOI 10.1016/0952-7915(94)90006-X; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SCHALL TJ, 1988, J IMMUNOL, V141, P1018; SIM TC, 1995, AM J RESP CRIT CARE, V152, P927, DOI 10.1164/ajrccm.152.3.7545059; SLAVIN RG, 1992, ARCH OTOLARYNGOL, V72, P19; Teran LM, 1996, CLIN EXP ALLERGY, V26, P1005, DOI 10.1111/j.1365-2222.1996.tb00640.x; Teran LM, 1996, J IMMUNOL, V157, P1806; TERAN LM, 1995, EUR RESPIR J, V8, P168; VALENTINE MA, 1985, EUR J IMMUNOL, V15, P851, DOI 10.1002/eji.1830150821; Wagenmann M, 1996, J ALLERGY CLIN IMMUN, V97, P470; WONG DTW, 1990, J EXP MED, V172, P673, DOI 10.1084/jem.172.3.673; YING S, 1995, J EXP MED, V181, P2153, DOI 10.1084/jem.181.6.2153	31	20	22	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1997	100	4					499	504		10.1016/S0091-6749(97)70142-8	http://dx.doi.org/10.1016/S0091-6749(97)70142-8			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YA529	9338544				2022-12-18	WOS:A1997YA52900012
J	Staudenmayer, H				Staudenmayer, H			Multiple chemical sensitivities or idiopathic environmental intolerances: Psychophysiologic foundation of knowledge for a psychogenic explanation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							CHILDHOOD ABUSE; PROVOCATION; ILLNESS				Staudenmayer, H (corresponding author), BEHAV MED & BIOFEEDBACK CLIN DENVER,5800 E EVANS AVE,DENVER,CO 80222, USA.							American Psychiatric Association, 1994, DIAGNOSTIC STAT MANU, V4th ed.; BLACK DW, 1990, JAMA-J AM MED ASSOC, V264, P3166, DOI 10.1001/jama.264.24.3166; CULLEN MR, 1987, OCCUP MED, V2, P655; Custer WV, 1996, REGUL TOXICOL PHARM, V24, pS182, DOI 10.1006/rtph.1996.0094; DAGER SR, 1995, AM J PSYCHIAT, V152, P666; Hummel T, 1996, REGUL TOXICOL PHARM, V24, pS79, DOI 10.1006/rtph.1996.0082; *INT PROGR CHEM SA, 1996, REGUL TOXICOL PHARM, V24, pS188; JEWETT DL, 1990, NEW ENGL J MED, V323, P429, DOI 10.1056/NEJM199008163230701; KEHRL H, 1995, ASP ENV MED C SEPT 7; Millon T., 1996, DISORDERS PERSONALIT; PAVLOV IP, 1951, TYPES HIGHER NERVOUS, V3, P344; Putnam F, 1994, CHILD ADOLESCENT PSY, V3, P663; Salvaggio JE, 1996, REGUL TOXICOL PHARM, V24, pS16, DOI 10.1006/rtph.1996.0072; SCHWARZ ED, 1994, PSYCHIAT CLIN N AM, V17, P311; Southwick Steven M., 1995, P335; STAUDENMAYER H, 1993, REGUL TOXICOL PHARM, V18, P44, DOI 10.1006/rtph.1993.1043; STAUDENMAYER H, 1993, ANN ALLERGY, V71, P538; STAUDENMAYER H, 1995, J OCCUP ENVIRON MED, V37, P704, DOI 10.1097/00043764-199506000-00012; STRAIGHT JM, 1997, INDOOR AIR POLLUTION, P305; TEICHER MH, 1993, J NEUROPSYCH CLIN N, V5, P301; Terr AL, 1993, ALLERGY PRINCIPLES P, V2, P1767; vanderKolk BA, 1996, AM J PSYCHIAT, V153, P83	22	20	20	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1997	99	4					434	437						4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WU274	9111484				2022-12-18	WOS:A1997WU27400002
J	Macarthur, C; Calpin, C; Parkin, PC; Feldman, W				Macarthur, C; Calpin, C; Parkin, PC; Feldman, W			Factors associated with pediatric asthma readmissions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							CHILDREN		UNIV TORONTO,DEPT PEDIAT,TORONTO,ON M5S 1A1,CANADA	University of Toronto	Macarthur, C (corresponding author), HOSP SICK CHILDREN,DIV GEN PEDIAT,OUTCOMES RES TEAM,555 UNIV AVE,TORONTO,ON M5G 1X8,CANADA.							BARNES PJ, 1995, NEW ENGL J MED, V332, P868, DOI 10.1056/NEJM199503303321307; KIRSHNER B, 1990, J CLIN EPIDEMIOL, V43, P765, DOI 10.1016/0895-4356(90)90236-I; MITCHELL EA, 1994, THORAX, V49, P33, DOI 10.1136/thx.49.1.33; STORR J, 1988, ARCH DIS CHILD, V63, P774, DOI 10.1136/adc.63.7.774; STRACHAN DP, 1992, BRIT MED J, V304, P819, DOI 10.1136/bmj.304.6830.819	5	20	21	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1996	98	5	1				992	993		10.1016/S0091-6749(96)80017-0	http://dx.doi.org/10.1016/S0091-6749(96)80017-0			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VU764	8939164	Bronze			2022-12-18	WOS:A1996VU76400017
J	Felix, K; Ferrandiz, R; Einarsson, P; Dreborg, S				Felix, K; Ferrandiz, R; Einarsson, P; Dreborg, S			Allergens of horse dander: Comparison among breeds and individual animals by immunoblotting	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						horse dander allergens; horse breeds; allergen extracts; sodium dodecylsulfate-polyacrylamide gel electrophoresis; immunoblotting; IgE	PURIFICATION	Some patients who are allergic to horses have reported that they can tolerate certain breeds, and the presence of breed-specific allergens has been suggested. Breeders and patients with asthma have claimed that Bashkir horses are nonallergenic. We used sodium dodecylsulfate-polyacrylamide gel electrophoresis and immunoblotting to determine IgE-binding profiles of extracts of dander obtained from horses of several breeds. We found considerable inter-breed and within-breed variation but no breed-specific allergens. Danders from all breeds investigated contained the most important allergens, and the allergenic content of dander from Bashkir horses was similar to that of other breeds. Differences in scale production could account for differences in sensitivity to breeds and individual horses.	LINKOPING UNIV,FAC HLTH SCI,DEPT PAEDIAT,LINKOPING,SWEDEN	Linkoping University								DANDEU JP, 1993, J CHROMATOGR-BIOMED, V621, P23, DOI 10.1016/0378-4347(93)80072-C; FERRANDIZ R, 1995, CLIN EXP ALLERGY, V25, P922, DOI 10.1111/j.1365-2222.1995.tb00393.x; FIELDSGAARD BE, 1993, ALLERGY, V48, P535; FRANKE D, 1990, INT ARCH ALLER A IMM, V92, P309, DOI 10.1159/000235195; KING TP, 1994, B WORLD HEALTH ORGAN, V72, P797; LINDGREN S, 1988, J ALLERGY CLIN IMMUN, V82, P196, DOI 10.1016/0091-6749(88)90999-2; LOWENSTEIN H, 1976, INT ARCH ALLER A IMM, V51, P48, DOI 10.1159/000231578	7	20	21	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1996	98	1					169	171		10.1016/S0091-6749(96)70239-7	http://dx.doi.org/10.1016/S0091-6749(96)70239-7			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VA692	8765831				2022-12-18	WOS:A1996VA69200020
J	Hiratsuka, S; Yoshida, A; Ishioka, C; Kimata, H				Hiratsuka, S; Yoshida, A; Ishioka, C; Kimata, H			Enhancement of in vitro spontaneous IgE production by topical steroids in patients with atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgE production; topical steroid; eczema; atopic dermatitis; Il-4; sodium cromoglycate	HUMAN B-CELLS; VASOACTIVE-INTESTINAL-PEPTIDE; SELECTIVELY INHIBITS IGE; NATURAL-KILLER CELLS; IGG4 PRODUCTION; CROMOGLYCATE SOLUTION; HUMAN-LYMPHOCYTES; IMMUNOGLOBULIN-E; SUBSTANCE-P; INVITRO	Background: Atopic dermatitis (AD) is an inflammatory skin disease. Although topical steroids are widely used for AD, management of severe AD is not satisfactory because of relapse or occasional aggravation of symptoms. Moreover, glucocorticoids induce in vitro IgE production. On the other hand, topical sodium cromoglycate (SCG) solution is a safe and effective treatment for AD. Methods: We treated 43 patients with AD with SCG solution (n = 21) or with topical steroids, beclomethasone dipropionate (BD) ointment (n = 22). After 2 weeks, clinical evaluation and spontaneous immunoglobin production by peripheral blood B cells or surface IgE(+) B cells from patients in the SCG and BD groups were assessed. Results: Both SCG and BD treatment remarkably eczema. However, although SCG treatment decreased spontaneous IgE production by B cells without affecting production of IgG, IgM, or IgA, BD treatment selectively increased spontaneous IgE production. SCG treatment also decreased IgE production by surface IgE(+) B cells, whereas BD treatment increased it. Conclusion: Topical steroid treatment increases in vitro spontaneous IgE production by B cells. This indicates that topical steroids may decrease inflammation; however, a large-scale study on the effect of topical steroids on IgE production in vitro and in vivo may be necessary.	KYOTO UNIV HOSP,DEPT PEDIAT,SAKYO KU,KYOTO 60601,JAPAN; SHINKORI HOSP,DEPT PEDIAT,KYOTO,JAPAN	Kyoto University								BANCHEREAU J, 1992, ADV IMMUNOL, V52, P125, DOI 10.1016/S0065-2776(08)60876-7; BOGUNIEWICZ M, 1990, AM J MED, V88, P365, DOI 10.1016/0002-9343(90)90490-5; DIAZ P, 1984, J ALLERGY CLIN IMMUN, V74, P41, DOI 10.1016/0091-6749(84)90085-X; FISHER A, 1991, IMMUNOLOGY, V74, P228; JABARA HH, 1991, J IMMUNOL, V147, P1557; KAY AB, 1987, J ALLERGY CLIN IMMUN, V80, P1, DOI 10.1016/S0091-6749(87)80183-5; KIMATA H, 1991, EUR J IMMUNOL, V21, P137, DOI 10.1002/eji.1830210121; KIMATA H, 1988, J CLIN INVEST, V82, P160, DOI 10.1172/JCI113565; KIMATA H, 1994, J EXP MED, V180, P727, DOI 10.1084/jem.180.2.727; KIMATA H, 1994, ARCH DIS CHILD, V70, P119, DOI 10.1136/adc.70.2.119; KIMATA H, 1992, J EXP MED, V176, P1227, DOI 10.1084/jem.176.4.1227; KIMATA H, 1992, CELL IMMUNOL, V141, P422, DOI 10.1016/0008-8749(92)90160-Q; KIMATA H, 1995, EUR J IMMUNOL, V25, P302, DOI 10.1002/eji.1830250151; KIMATA H, 1990, CLIN EXP ALLERGY, V20, P281, DOI 10.1111/j.1365-2222.1990.tb02684.x; KIMATA H, 1994, EUR J PEDIATR, V153, P66, DOI 10.1007/s004310050087; KIMATA H, 1995, J ALLERGY CLIN IMMUN, V95, P771, DOI 10.1016/S0091-6749(95)70185-0; KIMATA H, 1987, CELL IMMUNOL, V107, P74, DOI 10.1016/0008-8749(87)90267-X; KIMATA H, 1993, J IMMUNOL, V151, P6723; KIMATA H, 1992, CELL IMMUNOL, V144, P429, DOI 10.1016/0008-8749(92)90257-P; KIMATA H, 1991, CLIN EXP IMMUNOL, V84, P395; KIMATA H, 1993, J IMMUNOL, V150, P4630; KIMATA H, 1995, J IMMUNOL, V154, P3557; MARK P, 1993, CHEST, V104, P389; RAJIKA G, 1989, ACTA DERM-VENEREOL, V144, P13; RENZ H, 1994, J ALLERGY CLIN IMMUN, V93, P658, DOI 10.1016/S0091-6749(94)70078-8; ROUSSET F, 1991, J ALLERGY CLIN IMMUN, V87, P58, DOI 10.1016/0091-6749(91)90213-8; SNYERS L, 1990, P NATL ACAD SCI USA, V87, P2838, DOI 10.1073/pnas.87.7.2838; SUMIMOTO S, 1992, ARCH DIS CHILD, V67, P277, DOI 10.1136/adc.67.3.277; VANDERPOUWKRAAN T, 1991, EUR J IMMUNOL, V21, P385, DOI 10.1002/eji.1830210220; WU CY, 1991, J CLIN INVEST, V87, P870, DOI 10.1172/JCI115092	30	20	21	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1996	98	1					107	113		10.1016/S0091-6749(96)70232-4	http://dx.doi.org/10.1016/S0091-6749(96)70232-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VA692	8765824	Bronze			2022-12-18	WOS:A1996VA69200013
J	Akasawa, A; Hsieh, LS; Lin, Y				Akasawa, A; Hsieh, LS; Lin, Y			Comparison of latex-specific IgE binding among nonammoniated latex, ammoniated latex, and latex glove allergenic extracts by ELISA and immunoblot inhibition	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						latex allergens; latex proteins; latex glove		Background: Nonammoniated latex, ammoniated latex, and latex glove extracts have been used as source materials for the preparation of allergenic extracts for the diagnosis of latex allergy. These materials showed different patterns of protein bands and immunoreactive bands. However, their IgE-reactive repertoires were not compared. Objective: The goals of this study were to compare the IgE reactivity and to define the common IgE-reactive epitopes among three latex allergenic extracts. Methods: Two serum pools were obtained from adults and children with latex allergy to evaluate the IgE reactivity among three latex extracts. IgE reactivity and IgE-reactive proteins were compared by inhibition ELISA and inhibition immunoblot methods, respectively. Results: In this study inhibition curves were similar for nonammoniated latex and ammoniated latex but were different when the latex glove extracts were used. Several protein bands of ammoniated latex and latex glove extracts could not be inhibited by the nonammoniated latex. The ammoniated latex and latex glove extracts were able to remove all the latex-specific IgE from the serum. Conclusion: The IgE-reactive proteins differ among different latex extracts. Ammoniated latex and latex glove extracts contain more complete immunoreactive repertoires for detecting IgE antibodies. Our study provide useful information for selecting the latex extract.	CBER,FD,DIV ALLERGEN PROD & PARASITOL,LAB IMMUNOCHEM,ROCKVILLE,MD 20852	US Food & Drug Administration (FDA)								AKASAWA A, 1995, J ALLERGY CLIN IMMUN, V95, P1196, DOI 10.1016/S0091-6749(95)70076-5; ALENIUS H, 1994, ANN ALLERGY, V73, P315; HAMILTON RG, 1994, J LAB CLIN MED, V123, P594; SLATER JE, 1992, J ALLERGY CLIN IMMUN, V89, P673, DOI 10.1016/0091-6749(92)90373-A	4	20	20	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1996	97	5					1116	1120		10.1016/S0091-6749(96)70266-X	http://dx.doi.org/10.1016/S0091-6749(96)70266-X			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	UL261	8626990				2022-12-18	WOS:A1996UL26100013
J	Kincaid, RL				Kincaid, RL			The role of calcineurin in immune system responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	New Trends in Immunopharmacology 1994 Conference	JUL   23, 1994	TOKYO, JAPAN	Sandoz Pharm Ltd			DEPENDENT PROTEIN PHOSPHATASE; CYCLOSPORINE-A; CELLULAR-REGULATION; ANTIGEN RECEPTOR; BINDING PROTEIN; ACTIVATION; CALMODULIN; DOMAIN; IDENTIFICATION; CYCLOPHILIN				Kincaid, RL (corresponding author), VERITAS INC,11700 BUNNELL CT,POTOMAC,MD 20854, USA.							CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; FERREIRA A, 1993, MOL BIOL CELL, V4, P1225, DOI 10.1091/mbc.4.12.1225; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FRANTZ B, 1994, EMBO J, V13, P861, DOI 10.1002/j.1460-2075.1994.tb06329.x; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; GOLDFELD AE, 1994, J EXP MED, V180, P763, DOI 10.1084/jem.180.2.763; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; HUBBARD MJ, 1989, BIOCHEMISTRY-US, V28, P1868, DOI 10.1021/bi00430a066; HULTSCH T, 1990, J IMMUNOL, V144, P2659; HUSI H, 1994, J BIOL CHEM, V269, P14199; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P297, DOI 10.1111/j.1432-1033.1983.tb07362.x; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P255, DOI 10.1111/j.1432-1033.1983.tb07357.x; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; KINCAID RL, 1987, NATURE, V330, P176, DOI 10.1038/330176a0; KINCAID RL, 1988, P NATL ACAD SCI USA, V85, P8983, DOI 10.1073/pnas.85.23.8983; KINCAID RL, 1993, ADV PROT PHOSPHATASE, V7, P543; KLEE CB, 1979, P NATL ACAD SCI USA, V76, P6270, DOI 10.1073/pnas.76.12.6270; KLEE CB, 1978, BIOCHEMISTRY-US, V17, P120, DOI 10.1021/bi00594a017; KUBO M, 1994, J BIOL CHEM, V269, P19441; KUBO M, 1994, INT IMMUNOL, V6, P179, DOI 10.1093/intimm/6.2.179; LI W, 1993, J BIOL CHEM, V268, P14040; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MCCAFFREY PG, 1993, J BIOL CHEM, V268, P3747; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; MERAT DL, 1985, J BIOL CHEM, V260, P1053; MOMAYEZI M, 1987, J CELL BIOL, V105, P181, DOI 10.1083/jcb.105.1.181; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; STEWART AA, 1982, FEBS LETT, V137, P80, DOI 10.1016/0014-5793(82)80319-0; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; TAMURA J, 1990, FASEB J, V4, pA2236; THALER CD, 1990, J CELL BIOL, V111, P1939, DOI 10.1083/jcb.111.5.1939; TSIEN RY, 1982, NATURE, V295, P68, DOI 10.1038/295068a0; UEKI K, 1993, FASEB J, V7, pA1158; ULLMAN KS, 1990, ANNU REV IMMUNOL, V8, P421, DOI 10.1146/annurev.immunol.8.1.421; WALLACE RW, 1978, J BIOL CHEM, V254, P377	40	20	20	2	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1995	96	6	2	S			1170	1177		10.1016/S0091-6749(95)70202-4	http://dx.doi.org/10.1016/S0091-6749(95)70202-4			8	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TQ509	8543774				2022-12-18	WOS:A1995TQ50900013
J	Kurata, H; Arai, T; Yokota, T; Arai, K				Kurata, H; Arai, T; Yokota, T; Arai, K			Differential expression of granulocyte-macrophage colony-stimulating factor and IL-3 receptor subunits on human CD34(+) cells and leukemic cell lines	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	New Trends in Immunopharmacology 1994 Conference	JUL   23, 1994	TOKYO, JAPAN	Sandoz Pharm Ltd		GM-CSF receptor; IL-3 receptor; c-kit; CD34; anti-receptor antibody; hematopoietic stem cell	GM-CSF RECEPTOR; RECOMBINANT HUMAN INTERLEUKIN-3; HEMATOPOIETIC PROGENITOR CELLS; GROWTH-FACTOR RECEPTORS; COMMON BETA-SUBUNIT; HUMAN MYELOID CELLS; NECROSIS-FACTOR-ALPHA; HUMAN-BONE-MARROW; SIGNAL-TRANSDUCTION; C-KIT	Cytokines transduce their signals through specific receptors. Receptors for granulocyte-macrophage colony-stimulating factor (GM-CSF), IL-3, and IL-5 share the common signal transducing subunit (beta c), whereas the a subunits function as specific ligand binding components. In this study we prepared specific mouse monoclonal antibodies against human GM-CSF receptor-alpha subunit (hGMR alpha) by immunizing mice with Ba/F3 cells transfected with hGMR alpha complementary DNA. Using these anti-hGMR alpha antibodies in combination with antibodies against IL-3 receptor-alpha (IL-3R alpha), beta c subunits, and c-kit, we examined expression patterns and modulation of these receptor subunits on sever-al human hematopoietic cells, including CD34(+) cells and leukemic cell lines. GMR alpha and IL-3R alpha were expressed on GM-CSF- and IL-3-responsive cell lines, such as TF-1 and UT-7, whereas the expression levels were much lower on UT-7E, a GM-CSF- and IL-3-unresponsive subline of UT-7. The GMR alpha subunit was expressed only on mature granulocytes and monocytes, and IL-3R alpha was expressed on monocytes but not on mature granulocytes, and none of these subunits were expressed on lymphocytes. For CD34(+) cells, GMR alpha was expressed more abundantly on CD34(+)CD33(high) cells than on CD34(+)CD33(low) cells, whereas IL-3R alpha was expressed more abundantly on CD34(+)CD33(low) cells than on CD34(+)CD33(high) and CD34(+)CD33(neg) cells. Slight but significant expression of the beta c subunit was detected on CD34(+) cells. Expression of not only GMR alpha and IL-3R alpha subunits but also c-kit was specifically downregulated by 48-hour incubation with their respective ligands. Receptor transmodulation between GM-CSF, IL-3, and stem cell factor (or kit ligand) was not detected on CD34(+) cells in 48-hour cultures. We also detected upregulation of these or subunits by IL-1 alpha and interferon-gamma on leukemic cell lines. Our. study showed expression levels for each receptor subunit-including GMR, IL-3R, and c-kit on human bone marrow and peripheral blood cells and leukemic cell lines-and revealed differential regulation of the expression of the receptor subunits.	UNIV TOKYO,INST MED SCI,DEPT MOLEC & DEV BIOL,MINATO KU,TOKYO 108,JAPAN; SAITAMA MED SCH,GEN MED CTR,DEPT LAB MED,MOROYAMA,SAITAMA,JAPAN; SCI UNIV TOKYO,TOKYO 162,JAPAN	University of Tokyo; Saitama Medical University; Tokyo University of Science			Yokota, Takashi/F-6021-2011; Yokota, Takashi/J-8483-2015					ANDREWS RG, 1989, J EXP MED, V169, P1721, DOI 10.1084/jem.169.5.1721; ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; ASHMAN LK, 1991, BLOOD, V78, P30; BENDER JG, 1991, BLOOD, V77, P2591; BERNSTEIN ID, 1991, BLOOD, V77, P2316; BRIDDELL RA, 1992, BLOOD, V79, P3159; BRIZZI MF, 1990, BRIT J HAEMATOL, V76, P203, DOI 10.1111/j.1365-2141.1990.tb07872.x; BRIZZI MF, 1991, J CELL PHYSIOL, V148, P24, DOI 10.1002/jcp.1041480104; BRUGGER W, 1993, BLOOD, V81, P2579; BUDEL LM, 1990, BLOOD, V75, P1439; BUDEL LM, 1989, BLOOD, V74, P565; BYRNE PV, 1981, J CELL BIOL, V91, P848, DOI 10.1083/jcb.91.3.848; CANNISTRA SA, 1990, P NATL ACAD SCI USA, V87, P93, DOI 10.1073/pnas.87.1.93; CANNISTRA SA, 1990, J BIOL CHEM, V265, P12656; CARACCIOLO D, 1987, J EXP MED, V166, P1851, DOI 10.1084/jem.166.6.1851; CAUX C, 1990, BLOOD, V75, P2292; CHIBA S, 1990, LEUKEMIA, V4, P29; DIPERSIO J, 1988, J BIOL CHEM, V263, P1834; DUBREUIL P, 1991, P NATL ACAD SCI USA, V88, P2341, DOI 10.1073/pnas.88.6.2341; EGELAND T, 1991, BLOOD, V78, P3192; ELBAZ O, 1991, BLOOD, V77, P989; ELLIOTT MJ, 1989, BLOOD, V74, P2349; EMA H, 1990, BLOOD, V75, P1941; EMA H, 1990, BLOOD, V76, P1956; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GESNER T, 1989, BLOOD, V74, P2652; HALLEK M, 1992, BLOOD, V80, P1736; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HESTDAL K, 1992, BLOOD, V80, P2486; Heyworth C M, 1991, Growth Factors, V5, P87, DOI 10.3109/08977199109000274; HUANG S, 1994, BLOOD, V83, P1515, DOI 10.1182/blood.V83.6.1515.bloodjournal8361515; IKEBUCHI K, 1988, P NATL ACAD SCI USA, V85, P3445, DOI 10.1073/pnas.85.10.3445; IKEBUCHI K, 1987, P NATL ACAD SCI USA, V84, P9035, DOI 10.1073/pnas.84.24.9035; IKEBUCHI K, 1988, BLOOD, V72, P2007; ISHIZAKAIKEDA E, 1993, P NATL ACAD SCI USA, V90, P123, DOI 10.1073/pnas.90.1.123; JACOBSEN SEW, 1991, BLOOD, V77, P1706; JACOBSEN SEW, 1992, BLOOD, V80, P678; KATAYAMA N, 1993, BLOOD, V82, P2353; KATO JY, 1990, BLOOD, V75, P1780; KHWAJA A, 1993, BRIT J HAEMATOL, V85, P42, DOI 10.1111/j.1365-2141.1993.tb08643.x; KITAMURA T, 1991, INT IMMUNOL, V3, P571, DOI 10.1093/intimm/3.6.571; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KITAMURA T, 1991, P NATL ACAD SCI USA, V88, P5082, DOI 10.1073/pnas.88.12.5082; KITAMURA T, 1992, BLOOD, V80, P84; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KOMATSU N, 1993, BLOOD, V82, P456; KOMATSU N, 1991, CANCER RES, V51, P341; KURATA H, 1994, ADV CELL MOL BIOL M, P111; KUWAKI T, 1989, BIOCHEM BIOPH RES CO, V161, P16, DOI 10.1016/0006-291X(89)91553-2; LIBOI E, 1992, BLOOD, V80, P1183; LOPEZ AF, 1990, J CELL PHYSIOL, V145, P69, DOI 10.1002/jcp.1041450111; LOPEZ AF, 1989, P NATL ACAD SCI USA, V86, P7022, DOI 10.1073/pnas.86.18.7022; LOPEZ AF, 1992, IMMUNOL TODAY, V13, P495, DOI 10.1016/0167-5699(92)90025-3; LOPEZ AF, 1988, BLOOD, V72, P1797; LOTEM J, 1989, BLOOD, V74, P579; LU L, 1987, Journal of Immunology, V139, P1823; MCARTHUR GA, 1994, BLOOD, V83, P972; MCCLANAHAN T, 1993, BLOOD, V81, P2903; METCALF D, 1992, BLOOD, V79, P2861; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MIGLIACCIO G, 1992, BLOOD, V79, P2620; MIGLIACCIO G, 1988, BLOOD, V72, P248; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MIYAJIMA A, 1993, BLOOD, V82, P1960; MIYAJIMA A, 1987, GENE, V58, P273, DOI 10.1016/0378-1119(87)90382-9; NEIL S, 1993, CELL, V74, P587; NICOLA NA, 1987, IMMUNOL TODAY, V8, P134, DOI 10.1016/0167-5699(87)90140-X; NICOLA NA, 1985, J CELL PHYSIOL, V124, P313, DOI 10.1002/jcp.1041240222; NICOLA NA, 1989, ANNU REV BIOCHEM, V58, P45; NICOLA NA, 1993, BLOOD, V82, P1724, DOI 10.1182/blood.V82.6.1724.bloodjournal8261724; Nicola NA, 1988, GROWTH FACTORS, V1, P41, DOI 10.3109/08977198809000245; OGAWA M, 1991, J EXP MED, V174, P63, DOI 10.1084/jem.174.1.63; OGAWA M, 1993, BLOOD, V81, P2844; OGOROCHI T, 1992, BLOOD, V79, P895; OKUDA K, 1991, BLOOD, V78, P1928; ONETTOPOTHIER N, 1990, BLOOD, V75, P59; ONETTOPOTHIER N, 1990, LEUKEMIA, V4, P329; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PAPAYANNOPOULOU T, 1991, BLOOD, V78, P1403; PARK LS, 1989, BLOOD, V74, P56; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; REISNER Y, 1982, BLOOD, V59, P360; RHYNER K, 1986, BRIT J HAEMATOL, V64, P601, DOI 10.1111/j.1365-2141.1986.tb02216.x; ROBERTS PJ, 1994, BLOOD, V84, P1064; ROLINK AG, 1989, J EXP MED, V169, P1693, DOI 10.1084/jem.169.5.1693; SAELAND S, 1988, BLOOD, V72, P1580; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SANTOLI D, 1987, J IMMUNOL, V139, P3348; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SATO N, 1993, BLOOD, V82, P752; SEALAND S, 1989, BLOOD, V73, P1195; SHIOHARA M, 1993, BLOOD, V81, P1435; SIENA S, 1991, BLOOD, V77, P400; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; SUTHERLAND HJ, 1989, BLOOD, V74, P1563; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; TESTA U, 1993, BLOOD, V81, P1442; WALKER F, 1985, CELL, V43, P269, DOI 10.1016/0092-8674(85)90032-7; WATANABE Y, 1992, BLOOD, V80, P2215; WOGNUM AW, 1994, BLOOD, V84, P764	101	20	24	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1995	96	6	2	S			1083	1099		10.1016/S0091-6749(95)70194-X	http://dx.doi.org/10.1016/S0091-6749(95)70194-X			17	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TQ509	8543766				2022-12-18	WOS:A1995TQ50900005
J	CASTRO, FFM; ANTILA, MA; CROCE, J				CASTRO, FFM; ANTILA, MA; CROCE, J			OCCUPATIONAL ALLERGY CAUSED BY URTICATING HAIR OF BRAZILIAN SPIDER	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note									UNIV HOSP SAO PAULO,FAC MED,SERV ALLERGY & IMMUNOL,SAO PAULO,BRAZIL; PONTIFICIAL CATHOLIC UNIV,FAC MED,SOROCABA,BRAZIL	Universidade de Sao Paulo; Pontificia Universidade Catolica de Sao Paulo			Castro, Fabio/AAP-5433-2020; Castro, Fabio FM/C-1082-2017	Castro, Fabio FM/0000-0002-6211-5773				Cooke J.A.L., 1972, American Museum Novitates, VNo. 2498, P1; COOKE JAL, 1973, AM J TROP MED HYG, V22, P130, DOI 10.4269/ajtmh.1973.22.130; LOWRY OH, 1951, J BIOL CHEM, V193, P265; RATCLIFFE BC, 1977, J MED ENTOMOL, V13, P745, DOI 10.1093/jmedent/13.6.745; STULTING RD, 1983, AM J OPHTHALMOL, V96, P118, DOI 10.1016/0002-9394(83)90475-0	5	20	22	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1995	95	6					1282	1285		10.1016/S0091-6749(95)70087-0	http://dx.doi.org/10.1016/S0091-6749(95)70087-0			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RD309	7797797				2022-12-18	WOS:A1995RD30900018
J	CHANG, ZN; LIU, CC; TAM, MF; PENG, HJ; TSAI, JJ; HAN, SH				CHANG, ZN; LIU, CC; TAM, MF; PENG, HJ; TSAI, JJ; HAN, SH			CHARACTERIZATION OF THE ISOFORMS OF THE GROUP-I ALLERGEN OF CYNODON-DACTYLON	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CYNODON DACTYLON; GRASS POLLEN; GROUP I ALLERGEN; ISOFORM	BERMUDA GRASS-POLLEN; CYN-D-I; KENTUCKY BLUEGRASS POLLEN; AMINO-ACID-SEQUENCE; MAJOR ALLERGEN; MONOCLONAL-ANTIBODIES; P-I; IDENTIFICATION; PROTEIN; ISOALLERGENS	Background: The group I allergen of Cynodon dactylon, Cyn d I, was found to consist of four to 10 isoforms. Methods: We studied the isoforms with the use of two-dimensional gel electrophoresis. The antigenic difference of the isoforms was evaluated by radioimmunoprecipitation with monoclonal antibodies (MAbs). The acidic isoforms and the basic and neutral isoforms were further isolated by MAb-affinity chromatograghy for RAST and competitive RAST In addition, the N-terminal sequence was evaluated by microsequencing. Results: A total of 11 isoforms were found in Cyn d I in extracts prepared from different sources of Bermuda grass pollen (BGP). They were either acidic (Cyn d I-A, I-B, I-C, I-D, I-E, I-F, I-G, I-H, and I-I), neutral (Cyn d I-X), or basic (Cyn d I-J). Cyn d I-G, with an isoelectric point of approximately 6.4, was constantly present in all the pollen preparations, whereas the content of the basic Cyn d I-J varied from less than 5% to greater than 20%. The molecular weight of the basic and neutral isoforms were slightly lower than those of the acidic isoforms. All isoforms shared a common antigenic determinant(s) recognizable by MAb 4-37, and the basic and neutral isoforms possessed a unique antigenic determinant(s) recognizable by MAb 1-61. RAST showed that both the acidic Cyn d I and the basic and neutral Cyn d I were recognized by human IgE in the pooled sera of persons allergic to BGP. Competitive RAST showed a high crossreactivity between the acidic and the basic and neutral isoforms. A 95% sequence identify also existed between the N-terminal 20 amino acid residues of basic Cyn d I-J and the dominant acidic isoform Cyn d I-G. Conclusions: We present study disclosed that basic Cyn d I-J is an important allergen and that the content of this isoform varies in different lots of BGP.	NATL YANG MING MED COLL, SCH MED TECHNOL, TAIPEI 112, TAIWAN; ACAD SINICA, INST MOL BIOL, TAIPEI, TAIWAN; VET GEN HOSP, DEPT MED RES, TAIPEI 11217, TAIWAN; CATHAY HOSP, ALLERGY & IMMUNOL SECT, TAIPEI, TAIWAN; NATL YANG MING MED COLL, INST MICROBIOL & IMMUNOL, TAIPEI 11221, TAIWAN	National Yang Ming Chiao Tung University; Academia Sinica - Taiwan; Cathay General Hospital; National Yang Ming Chiao Tung University								AYUSO R, 1993, MOL IMMUNOL, V30, P1347, DOI 10.1016/0161-5890(93)90095-S; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chang HN, 1984, CLIN MED J, V34, P376; CHANG LH, 1990, ELECTROPHORESIS, V11, P589, DOI 10.1002/elps.1150110710; CHANG Z-N, 1988, Proceedings of the National Science Council Republic of China Part B Life Sciences, V12, P140; CHANG ZN, 1991, ALLERGY, V46, P520, DOI 10.1111/j.1398-9995.1991.tb00615.x; EKRAMODDOULLAH AKM, 1990, INT ARCH ALLER A IMM, V93, P371, DOI 10.1159/000235268; FORD SA, 1987, J ALLERGY CLIN IMMUN, V79, P711, DOI 10.1016/0091-6749(87)90201-6; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HAN SH, 1993, J ALLERGY CLIN IMMUN, V91, P1035, DOI 10.1016/0091-6749(93)90217-4; HAN SH, 1993, J ALLERGY CLIN IMMUN, V92, P549, DOI 10.1016/0091-6749(93)90079-U; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HJELMELAND LM, 1979, ANAL BIOCHEM, V95, P201, DOI 10.1016/0003-2697(79)90206-9; MATTHIESEN F, 1989, J ALLERGY CLIN IMMUN, V83, P1124, DOI 10.1016/0091-6749(89)90456-9; MATTHIESEN F, 1991, J ALLERGY CLIN IMMUN, V88, P763, DOI 10.1016/0091-6749(91)90184-P; MEYERS RL, 1971, J ALLERGY, V47, P100; OLSEN E, 1991, J IMMUNOL, V147, P205; ONG EK, 1993, GENE, V134, P235, DOI 10.1016/0378-1119(93)90099-O; ORREN A, 1977, S AFR MED J, V51, P586; PEREZ M, 1990, J BIOL CHEM, V265, P16210; ROBERTS AM, 1992, INT ARCH ALLERGY IMM, V98, P178, DOI 10.1159/000236182; SCHUMACHER MJ, 1985, ANN ALLERGY, V55, P584; SHEN HD, 1988, CLIN ALLERGY, V18, P401, DOI 10.1111/j.1365-2222.1988.tb02888.x; Shen Horng-Der, 1992, Proceedings of the National Science Council Republic of China Part B Life Sciences, V16, P177; SILVANOVICH A, 1991, J BIOL CHEM, V266, P1204; SINGH MB, 1991, P NATL ACAD SCI USA, V88, P1384, DOI 10.1073/pnas.88.4.1384; SMITH PM, 1994, INT ARCH ALLERGY IMM, V104, P57, DOI 10.1159/000236709; SUPHIOGLU C, 1992, LANCET, V339, P569, DOI 10.1016/0140-6736(92)90864-Y; TRINCA JC, 1962, MED J AUSTRALIA, V1, P969, DOI 10.5694/j.1326-5377.1962.tb27045.x	29	20	21	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1995	95	6					1206	1214		10.1016/S0091-6749(95)70077-3	http://dx.doi.org/10.1016/S0091-6749(95)70077-3			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RD309	7797789				2022-12-18	WOS:A1995RD30900008
J	BAGNASCO, M; PESCE, GP; CARETTO, A; PAOLIERI, F; PRONZATO, C; VILLAGGIO, B; GIORDANO, C; BETTERLE, C; CANONICA, GW				BAGNASCO, M; PESCE, GP; CARETTO, A; PAOLIERI, F; PRONZATO, C; VILLAGGIO, B; GIORDANO, C; BETTERLE, C; CANONICA, GW			FOLLICULAR THYROID-CELLS OF AUTOIMMUNE-THYROIDITIS MAY COEXPRESS ICAM-1 (CD54) AND ITS NATURAL LIGAND LFA-1 (CD11A/CD18)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ICAM-1; LFA-1; THYROID AUTOIMMUNITY; EPITHELIAL CELLS; CELL ADHESION	INTERCELLULAR-ADHESION MOLECULE-1; FUNCTION-ASSOCIATED ANTIGEN-3; HUMAN T-CELLS; EPITHELIAL-CELLS; GRAVES-DISEASE; EXPRESSION; RECEPTORS; LYMPHOCYTES; RELEVANCE; INDUCTION	The leukocyte functional associated antigen-1 (LFA-1)-intercellular adhesion molecule-1 (CD11a-CD18/CD54) intercellular adhesion system plays a crucial role in several immunologic phenomena, including adhesion between lymphocytes and epithelial cells. In previous studies evidence for CD54 expression on thyroid follicular cells in Hashimoto's thyroiditis was provided. In this study we evaluated the possible expression of CD11a and CD18 antigens on thyrocytes of patients with Hashimoto's thyroiditis and on thyrocytes of patients with Graves' disease and simple goiter as controls; we used both alkaline phosphatase immunostaining and indirect immunofluorescence on cryostatic tissue sections. The results showed that LFA-1 (both CD11a and CD18) positivity on thyroid follicles may occur in glands of patients with Hashimoto's disease, with a pattern very similar to that of CD54: this was observed in five of seven specimens. Conversely, no positivity was observed in tissues from patients with Graves' disease or goiter: notably, isolated follicular cells from Graves' goiter tissues are induced in culture to express CD54, but not LFA-1. Using double-staining techniques, we were able to show that in specimens from patients with Hashimoto's disease, the same follicular structures coexpressed LFA-1 and CD54. Such a coexpression of the two ligands further emphasizes the possible role of this adhesion system in the pathogenesis of epithelial damage, through bidirectional interactions between thyroid epithelial cells and infiltrating LFA-1 or CD54-positive mononuclear cells.	UNIV PADOA,IST SEMEIOT MED,PADUA,ITALY; UNIV GENOA,DIPARTIMENTO MED INTERNA,CATTEDRA NEFROL,GENOA,ITALY; UNIV PALERMO,MED CLIN,CATTEDRA ENDOCRINOL,PALERMO,ITALY	University of Genoa; University of Palermo	BAGNASCO, M (corresponding author), UNIV GENOA,DIPARTIMENTO MED INTERNA,SERV ALLERGOL & IMMUNOL CLIN,VIALE BENEDETTO XV,6,I-16132 GENOA,ITALY.		GIORDANO, Carla/R-4296-2017; canonica, giorgio walter/ABF-2037-2020	GIORDANO, Carla/0000-0003-1731-9395; canonica, giorgio walter/0000-0001-8467-2557; Pesce, Giampaola/0000-0002-6294-9110				BAGNASCO M, 1991, CLIN EXP IMMUNOL, V83, P309; BAGNASCO M, 1992, SEMIN CLIN IMMUNOL, V4, P19; CANONICA GW, 1991, SCHWEIZ MED WOCHENSC, V40, P38; CERDAN C, 1989, CELL IMMUNOL, V123, P44; CIAMPOLILLO A, 1990, J ENDOCRINOL INVEST, V1, P177; CIPRANDI G, 1993, J ALLERGY CLIN IMMUN, V91, P783, DOI 10.1016/0091-6749(93)90198-O; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; CUTOLO M, 1992, ARTHRITIS RHEUM-US, V35, P1007, DOI 10.1002/art.1780350905; DEFOUGEROLLES AR, 1992, J EXP MED, V175, P185, DOI 10.1084/jem.175.1.185; DUSTIN ML, 1991, ANNU REV IMMUNOL, V9, P27, DOI 10.1146/annurev.iy.09.040191.000331; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; GEARING AJH, 1993, IMMUNOL TODAY, V14, P506, DOI 10.1016/0167-5699(93)90267-O; HANAFUSA T, 1983, LANCET, V2, P1111; KRENSKY AM, 1984, J IMMUNOL, V132, P2180; LONDEI M, 1985, SCIENCE, V228, P85, DOI 10.1126/science.3871967; LONDEI M, 1984, NATURE, V312, P639, DOI 10.1038/312639a0; MAKGOBA MW, 1988, NATURE, V331, P86, DOI 10.1038/331086a0; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MARTIN A, 1990, ENDOCRINOLOGY, V127, P651, DOI 10.1210/endo-127-2-651; MIYAZAKI A, 1992, CLIN EXP IMMUNOL, V89, P52; OLIVE D, 1989, HUAMN T CELL CLONES, P173; PAOLIERI F, 1992, J ENDOCRINOL INVEST, V15, P63, DOI 10.1007/BF03348664; PIRCHER H, 1986, EUR J IMMUNOL, V16, P172, DOI 10.1002/eji.1830160212; SHAW S, 1986, NATURE, V323, P262, DOI 10.1038/323262a0; SHAW S, 1990, LEUKOCYTE ADHESION MOLECULES, P236; SOBEL RA, 1990, AM J PATHOL, V136, P1309; SPRINGER TA, 1987, ANNU REV IMMUNOL, V5, P223, DOI 10.1146/annurev.immunol.5.1.223; STAUNTON DE, 1989, NATURE, V339, P61, DOI 10.1038/339061a0; TOLOSA E, 1992, J AUTOIMMUN, V5, P119, DOI 10.1016/S0896-8411(05)80056-3; TOLOSA E, 1992, J AUTOIMMUN, V5, P107, DOI 10.1016/S0896-8411(05)80055-1; VOLPES R, 1990, HEPATOLOGY, V12, P59, DOI 10.1002/hep.1840120110; WACHOLTZ MC, 1989, J EXP MED, V170, P431, DOI 10.1084/jem.170.2.431; WEETMAN AP, 1989, J ENDOCRINOL, V122, P185, DOI 10.1677/joe.0.1220185; WEGNER CD, 1990, SCIENCE, V247, P456, DOI 10.1126/science.1967851; ZEROMSKI J, 1992, CLIN EXP IMMUNOL, V89, P474; ZHENG RQH, 1990, J AUTOIMMUN, V3, P727, DOI 10.1016/S0896-8411(05)80039-3; 1990, LANCET, V336, P1351	37	20	20	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1995	95	5	1				1036	1043		10.1016/S0091-6749(95)70105-2	http://dx.doi.org/10.1016/S0091-6749(95)70105-2			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QY917	7751500				2022-12-18	WOS:A1995QY91700016
J	BENDER, B; MILGROM, H				BENDER, B; MILGROM, H			NEUROPSYCHIATRIC EFFECTS OF MEDICATIONS FOR ALLERGIC DISEASES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							CHILDREN RECEIVING DECONGESTANTS; VISUAL HALLUCINATIONS; ASTHMATIC-CHILDREN; THEOPHYLLINE; PERFORMANCE; PHENYLPROPANOLAMINE; DIPHENHYDRAMINE; TERFENADINE; RHINITIS; CORTICOSTEROIDS		NATL JEWISH CTR IMMUNOL & RESP MED,DEPT PEDIAT,DENVER,CO 80206; NATL JEWISH CTR IMMUNOL & RESP MED,DEPT PSYCHIAT,DENVER,CO 80206; NATL JEWISH CTR IMMUNOL & RESP MED,DEPT MED,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,DENVER,CO	National Jewish Health; National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver								BAIN DJG, 1983, BRIT MED J, V287, P654, DOI 10.1136/bmj.287.6393.654; BENDER B, 1992, JAMA-J AM MED ASSOC, V267, P2621; BENDER BG, 1991, ANN ALLERGY, V66, P414; BENDER BG, 1991, PEDIATR PULM, V11, P233, DOI 10.1002/ppul.1950110309; BRIZER DA, 1982, AM J PSYCHIAT, V139, P1343; Cantu TG, 1991, ANN INTERN MED, V114, P1027, DOI 10.7326/0003-4819-114-12-1027; CHAN CYJ, 1991, DICP ANN PHARMAC, V25, P130, DOI 10.1177/106002809102500204; CLARKE CH, 1978, BRIT J CLIN PHARMACO, V6, P31, DOI 10.1111/j.1365-2125.1978.tb01678.x; DALTON R, 1990, SOUTHERN MED J, V83, P64, DOI 10.1097/00007611-199001000-00020; DRUCE HM, 1990, J ALLERGY CLIN IMMUN, V86, P344, DOI 10.1016/S0091-6749(05)80097-1; FITZPATRICK MF, 1992, AM REV RESPIR DIS, V145, P1355, DOI 10.1164/ajrccm/145.6.1355; GOWDY JM, 1972, J AMER MED ASSOC, V221, P585, DOI 10.1001/jama.221.6.585; GUILL MF, 1986, J ALLERGY CLIN IMMUN, V78, P4, DOI 10.1016/0091-6749(86)90107-7; HERRIDGE CF, 1968, BRIT MED J, V2, P160, DOI 10.1136/bmj.2.5598.160; HIGGINS ST, 1989, PHARMACOL BIOCHEM BE, V34, P303, DOI 10.1016/0091-3057(89)90316-X; JOAD JP, 1986, J ALLERGY CLIN IMMUN, V78, P1147, DOI 10.1016/0091-6749(86)90264-2; JOFFE RT, 1988, GEN HOSP PSYCHIAT, V10, P56, DOI 10.1016/0163-8343(88)90085-0; KANE FJ, 1966, AM J PSYCHIAT, V123, P484, DOI 10.1176/ajp.123.4.484; KHURANA AK, 1988, AM J OPHTHALMOL, V105, P91, DOI 10.1016/0002-9394(88)90128-6; KOFF M, 1966, J AMER MED ASSOC, V198, P1034; KOPPEL C, 1987, J TOXICOL-CLIN TOXIC, V25, P53; LAKE CR, 1991, BIOL PSYCHIAT, V30, P401, DOI 10.1016/0006-3223(91)90296-X; LAKE CR, 1990, AM J MED, V89, P195, DOI 10.1016/0002-9343(90)90299-S; LAKE CR, 1988, PHARMACOPSYCHIATRY, V21, P171, DOI 10.1055/s-2007-1014671; LINDGREN S, 1992, NEW ENGL J MED, V327, P926, DOI 10.1056/NEJM199209243271305; MAZER B, 1990, J ALLERGY CLIN IMMUN, V86, P243, DOI 10.1016/S0091-6749(05)80071-5; MILGROM H, 1993, AM REV RESPIR DIS, V147, pS33, DOI 10.1164/ajrccm/147.6_Pt_2.S33; MILGROM H, 1993, AM REV RESPIR DIS, V147, P471, DOI 10.1164/ajrccm/147.2.471; MOSER L, 1978, EUR J CLIN PHARMACOL, V14, P417, DOI 10.1007/BF00716383; NORMAN PS, 1985, J ALLERGY CLIN IMMUN, V76, P366, DOI 10.1016/0091-6749(85)90655-4; NORVENIUS G, 1979, LANCET, V2, P1367; PUAR HS, 1984, SOUTHERN MED J, V77, P1604, DOI 10.1097/00007611-198412000-00037; SANKEY RJ, 1984, BRIT MED J, V288, P1369, DOI 10.1136/bmj.288.6427.1369; SCHLIEPER A, 1991, J PEDIATR-US, V118, P449, DOI 10.1016/S0022-3476(05)82167-5; SEIDEL WF, 1987, ANN ALLERGY, V59, P58; SEPPALA T, 1983, ACTA PHARMACOL TOX, V52, P68; SILLS JA, 1984, BRIT MED J, V288, P1912, DOI 10.1136/bmj.288.6434.1912-c; SIMONS FER, 1988, J ALLERGY CLIN IMMUN, V81, P975, DOI 10.1016/0091-6749(88)90164-9; STEIN MA, 1993, ANN ALLERGY, V70, P135; VUURMAN EFPM, 1993, ANN ALLERGY, V71, P121; WERTHEIMER AI, 1985, PHENYLPROPANOLAMINE, P37; 1971, SEMIN PSYCHIAT, V3, P406; 1985, FED REG         1108, V50, P46582; 1989, AM ASTHMA REPORT	44	20	20	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1995	95	2					523	528		10.1016/S0091-6749(95)70314-4	http://dx.doi.org/10.1016/S0091-6749(95)70314-4			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QH697	7852668				2022-12-18	WOS:A1995QH69700004
J	SLATER, JE; TRYBUL, DE				SLATER, JE; TRYBUL, DE			IMMUNODETECTION OF LATEX ANTIGENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							CONTACT URTICARIA; ALLERGEN CONTENTS; RUBBER; GLOVES; IGE	Background: Protein antigens in latex products can cause type I reactions. In the past antigens have been measured by protein assays, high-performance liquid chromatography, RAST inhibition, and skin tests. We examined the use of a mouse monoclonal antibody (CRI-C) to later in the detection of latex antigens. Methods: CRI-C was raised by standard techniques after immunization of a BALB/c mouse with ammoniated latex. Medical gloves were extracted and assayed with: (1) standard protein assays, (2) RAST inhibition assays with sera from health care workers allergic to latex and patients with spina bifida, (3) an ELISA with a biotinylated form of CRI-C (BIC). Reference proteins included bovine serum albumin for the protein assays and nonammoniated latex and affinity-purified C antigen for the immunoassays. Results: Among the protein assays, the best correlation was between the Bradford and bicinchoninic acid assays. In absolute numbers the Bradford assay produced the lowest results, and OD280 the highest. The OD280 BCA, and Bradford methods ''detected'' protein in vinyl gloves. The results of RAST inhibition and BiC ELISA correlated with the protein assays. These immunoassays appeared to be more specific than the protein assays. Conclusions: The BiC ELISA is an easy and reproducible in vitro assay of relevant latex antigen. Clinical correlation will be required for validation.	CHILDRENS RES INST,CTR CANC & TRANSPLANTAT BIOL,WASHINGTON,DC; GEORGE WASHINGTON UNIV,SCH MED & HLTH SCI,DEPT PEDIAT,WASHINGTON,DC 20052	George Washington University	SLATER, JE (corresponding author), CHILDRENS NATL MED CTR,DEPT ALLERGY & IMMUNOL,111 MICHIGAN AVE NW,WASHINGTON,DC 20010, USA.							ALENIUS H, 1993, J ALLERGY CLIN IMMUN, V91, P240; ANDERSON FA, 1992, 1992 INT LAT C SENS, P69; BOYLE KT, 1992, J ALLERGY CLIN IMMUN, V89, P224; Centers for Disease Control (CDC), 1991, MMWR Morb Mortal Wkly Rep, V40, P443; HARLOW E, 1988, ANTIBODIES LABORATOR; JONES RT, 1992, J ALLERGY CLIN IMMUN, V89, P225; LEYNADIER F, 1991, ALLERGY, V46, P619, DOI 10.1111/j.1398-9995.1991.tb00633.x; LIGHT DR, 1989, J BIOL CHEM, V264, P18589; OWNBY DR, 1991, AM J ROENTGENOL, V156, P903, DOI 10.2214/ajr.156.5.2017949; SLATER JE, 1992, J ALLERGY CLIN IMMUN, V89, P673, DOI 10.1016/0091-6749(92)90373-A; SLATER JE, 1990, ANN ALLERGY, V65, P411; SLATER JE, 1992, ANN ALLERGY, V68, P203; SLATER JE, 1994, J ALLERGY CLIN IMMUN, V93, P644, DOI 10.1016/S0091-6749(94)70076-1; TOMAZIC VJ, 1992, CLIN IMMUNOL IMMUNOP, V64, P89, DOI 10.1016/0090-1229(92)90185-Q; TOMAZIC VJ, 1992, 1992 INT LAT C SENS, P37; TURJANMAA K, 1988, CONTACT DERMATITIS, V19, P362, DOI 10.1111/j.1600-0536.1988.tb02953.x; TURJANMAA K, 1989, CONTACT DERMATITIS, V20, P360, DOI 10.1111/j.1600-0536.1989.tb03173.x; YUNGINGER JW, 1993, J ALLERGY CLIN IMMUN, V91, P241; Yunginger JW, 1992, MANUAL CLIN LAB IMMU, V4th, P678	19	20	21	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1994	93	5					825	830		10.1016/0091-6749(94)90372-7	http://dx.doi.org/10.1016/0091-6749(94)90372-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NL919	8182222				2022-12-18	WOS:A1994NL91900003
J	BURKS, AW; COCKRELL, G; CONNAUGHTON, C; HELM, RM				BURKS, AW; COCKRELL, G; CONNAUGHTON, C; HELM, RM			EPITOPE SPECIFICITY AND IMMUNOAFFINITY PURIFICATION OF THE MAJOR PEANUT ALLERGEN, ARA-H-I	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							MONOCLONAL-ANTIBODIES; ANAPHYLACTIC REACTIONS; ATOPIC-DERMATITIS; P-I; FOOD; PROTEINS; DERMATOPHAGOIDES; IDENTIFICATION; ANTIGENS	The antigenic and allergenic structure of Ara h I, a major allergen of peanuts, was investigated with the use of seven monoclonal antibodies obtained from BALB/c mice immunized with purified Ara h I. Previous work with monoclonal antibodies produced to allergens has primarily been done with inhalant allergens. Only recently have the major allergens of various foods been determined so that investigations with monoclonal antibodies into the allergenic epitopes could begin. When used as a solid phase in an ELISA, these monoclonal antibodies captured peanut antigen, which bound human IgE from patients with positive results to challenges to peanuts. The Ara h I monoclonal antibodies were found to be specific for peanut antigens when binding for other legumes was examined In ELISA inhibition studies with the monoclonal antibodies, we identified four different antigenic sites on Ara h I. In related studies with pooled human IgE serum from patients with positive results to challenges to peanuts, we identified three similar IgE-binding epitopes. As a means of purifying the Ara h I allergen, we prepared an immunoaffinity column with monoclonal antibody 8D9. We eluted from this column the allergen Ara h L which had a mean molecular weight of 63.5 kd and which bound human IgE from individual and pooled serum of patients with peanut sensitivity.	UNIV ARKANSAS MED SCI HOSP,LITTLE ROCK,AR	University of Arkansas System; University of Arkansas Medical Sciences	BURKS, AW (corresponding author), ARKANSAS CHILDRENS HOSP,800 MARSHALL ST,LITTLE ROCK,AR 72202, USA.				NIAID NIH HHS [R29AI26629-03] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI026629] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON JA, 1984, NIH842442 PUBL; BURKS AW, 1986, NEW ENGL J MED, V314, P560, DOI 10.1056/NEJM198602273140907; BURKS AW, 1992, J ALLERGY CLIN IMMUN, V90, P962, DOI 10.1016/0091-6749(92)90469-I; BURKS AW, 1991, J ALLERGY CLIN IMMUN, V88, P172, DOI 10.1016/0091-6749(91)90325-I; CHAPMAN MD, 1987, J IMMUNOL, V139, P1479; CHAPMAN MD, 1989, CURR OPIN IMMUNOL, V1, P647, DOI 10.1016/0952-7915(89)90035-6; DESTGROTH SF, 1980, J IMMUNOL METHODS, V35, P1, DOI 10.1016/0022-1759(80)90146-5; ESCH RE, 1989, J IMMUNOL, V142, P179; HOFFMAN DR, 1974, J ALLERGY CLIN IMMUN, V54, P165, DOI 10.1016/0091-6749(74)90053-0; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMANSKE RF, 1987, CLIN REV ALLERG, V5, P23; MARSH DG, 1975, ANTIGENS, V3, P271; METCALFE DD, 1985, CLIN REV ALLERG, V3, P331, DOI 10.1007/BF02992999; MOURAD W, 1988, J IMMUNOL, V141, P3486; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OHEHIR RE, 1987, IMMUNOLOGY, V62, P635; SAMPSON HA, 1985, J PEDIATR-US, V107, P669, DOI 10.1016/S0022-3476(85)80390-5; SAMPSON HA, 1990, J ALLERGY CLIN IMMUN, V86, P1, DOI 10.1016/S0091-6749(05)80115-0; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; SUTTON R, 1982, J IMMUNOL METHODS, V52, P183, DOI 10.1016/0022-1759(82)90044-8; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4352; YUNGINGER JW, 1988, JAMA-J AM MED ASSOC, V260, P1450, DOI 10.1001/jama.260.10.1450; YUNGINGER JW, 1987, 4TH P INT P EHRL SEM, P251	24	20	21	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1994	93	4					743	750		10.1016/0091-6749(94)90254-2	http://dx.doi.org/10.1016/0091-6749(94)90254-2			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NH497	7513004				2022-12-18	WOS:A1994NH49700007
J	ROSSI, GL; CORSICO, A; MOSCATO, G				ROSSI, GL; CORSICO, A; MOSCATO, G			OCCUPATIONAL ASTHMA CAUSED BY MILK-PROTEINS - REPORT ON A CASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note									IRCCS, FDN CLIN LAVORO, MED CTR PAVIA, RESP ALLERGY UNIT, I-27100 PAVIA, ITALY; UNIV PAVIA, SPECIALIZAT SCH ALLERGOL & CLIN IMMUNOL, I-27100 PAVIA, ITALY	University of Pavia; University of Pavia			Corsico, Angelo Guido/AAC-8138-2019	Corsico, Angelo Guido/0000-0002-8716-4694				BATES DV, 1992, CHEST, V102, pS257, DOI 10.1378/chest.102.3.257S; BERNHISELBROADBENT J, 1989, J ALLERGY CLIN IMMUN, V84, P701, DOI 10.1016/0091-6749(89)90298-4; Kettlehut B., 1988, ALLERGY PRINCIPLES P, V3, P1481; MAESTRELLI P, 1992, CLIN EXP ALLERGY, V22, P103; MOIRA CY, 1986, AM REV RESPIR DIS, V133, P686	5	20	20	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1994	93	4					799	801		10.1016/0091-6749(94)90261-5	http://dx.doi.org/10.1016/0091-6749(94)90261-5			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NH497	8163790				2022-12-18	WOS:A1994NH49700014
J	OOSTERHOFF, Y; JANSEN, MAM; POSTMA, DS; KOETER, GH				OOSTERHOFF, Y; JANSEN, MAM; POSTMA, DS; KOETER, GH			AIRWAY RESPONSIVENESS TO ADENOSINE 5'-MONOPHOSPHATE IN SMOKERS AND NONSMOKERS WITH ATOPIC ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note							BRONCHOCONSTRICTION; METHACHOLINE; CHALLENGE		UNIV GRONINGEN HOSP,DEPT PULM MED,POB 30001,9700 RB GRONINGEN,NETHERLANDS	University of Groningen								AALBERS R, 1991, AM REV RESPIR DIS, V144, P352, DOI 10.1164/ajrccm/144.2.352; BUCZKO GB, 1984, AM REV RESPIR DIS, V129, P15; JOYCE H, 1991, THORAX, V646, pP474; NG WH, 1990, BRIT J CLIN PHARMACO, V30, pS89, DOI 10.1111/j.1365-2125.1990.tb05474.x; OCONNOR BJ, 1992, AM REV RESPIR DIS, V146, P560, DOI 10.1164/ajrccm/146.3.560; OOSTERHOFF Y, 1993, AM REV RESPIR DIS, V147, P553, DOI 10.1164/ajrccm/147.3.553; PAUWELS R, 1988, CLIN ALLERGY, V18, P317, DOI 10.1111/j.1365-2222.1988.tb02878.x; PHILLIPS GD, 1988, CLIN SCI, V75, P429, DOI 10.1042/cs0750429; STANKUS RP, 1988, J ALLERGY CLIN IMMUN, V82, P331, DOI 10.1016/0091-6749(88)90003-6	9	20	20	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1993	92	5					773	776		10.1016/0091-6749(93)90023-9	http://dx.doi.org/10.1016/0091-6749(93)90023-9			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MG982	8227870				2022-12-18	WOS:A1993MG98200021
J	WILLIESJACOBO, LJ; DENSONLINO, JM; ROSAS, A; OCONNOR, RD; WILSON, NW				WILLIESJACOBO, LJ; DENSONLINO, JM; ROSAS, A; OCONNOR, RD; WILSON, NW			SOCIOECONOMIC-STATUS AND ALLERGY IN CHILDREN WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note							HOSPITALIZATION		UNIV CALIF SAN DIEGO,SCH MED,DEPT PEDIAT,SAN DIEGO,CA 92103; SHARP REES STEALY MED GRP,SAN DIEGO,CA	University of California System; University of California San Diego	WILLIESJACOBO, LJ (corresponding author), W VIRGINIA UNIV,MED CTR,SCH MED,HLTH SCI CTR,DEPT PEDIAT,ALLERGY & IMMUNOL SECT,G190,MORGANTOWN,WV 26506, USA.							CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; DENSONLINO JM, IN PRESS EFFECT EC S; EVANS R, 1987, CHEST, V91, pS65, DOI 10.1378/chest.91.6_Supplement.65S; MURRAY AB, 1983, PEDIATRICS, V71, P418; WISSOW LS, 1988, AM J PUBLIC HEALTH, V78, P777, DOI 10.2105/AJPH.78.7.777	5	20	20	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1993	92	4					630	632		10.1016/0091-6749(93)90090-3	http://dx.doi.org/10.1016/0091-6749(93)90090-3			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	MC590	8409124				2022-12-18	WOS:A1993MC59000018
J	ARAKAWA, H; LOTVALL, J; KAWIKOVA, I; TEE, R; HAYES, J; LOFDAHL, CG; TAYLOR, AJN; SKOOGH, BE				ARAKAWA, H; LOTVALL, J; KAWIKOVA, I; TEE, R; HAYES, J; LOFDAHL, CG; TAYLOR, AJN; SKOOGH, BE			AIRWAY ALLERGY TO TRIMELLITIC ANHYDRIDE IN GUINEA-PIGS - DIFFERENT TIME COURSES OF IGG(1) TITER AND AIRWAY RESPONSES TO ALLERGEN CHALLENGE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						OCCUPATIONAL ASTHMA; VASCULAR PERMEABILITY; SENSITIZATION; PLASMA EXUDATION; MATURATION	MOLECULAR WEIGHT CHEMICALS; INTRADERMAL SENSITIZATION; MICROVASCULAR LEAKAGE; PULMONARY HEMORRHAGE; ACID ANHYDRIDES; INHALATION; HISTAMINE; RESPONSIVENESS; ASTHMA; AGENTS	Background: Trimellitic anhydride (TMA) is a low molecular weight chemical that may cause occupational asthma in human beings. The objectives of this study were to determine the time course of immune and airway responses to TMA in guinea pigs and to relate the immunologic response to the immediate responses in lung resistance (R(L)) and plasma exudation induced by allergen challenge. Methods: We studied the effects of time course after sensitization on airway response to TMA in guinea pigs actively sensitized to free TMA, given by intradermal injection (0.1 ml of 0.3% TMA in com oil). During weeks 1, 2, 3, 5, and 8 after sensitization, anesthetized animals were challenged with TMA conjugated to guinea pig serum albumin (TMA-GPSA), instilled via the airway route. Nonsensitized animals were challenged with the same amount of conjugate 4 weeks after intradermal injection of com oil only. In the same animal, we measured both R(L) to monitor airflow obstruction and extravasation of Evans blue dye (20 mg/kg) to quantify airway plasma exudation. Results: Instillation of TMA-GPSA (0.5%; 50 mul) into the tracheal lumen caused a significant increase in R(L), reaching a maximum at 2.5 minutes after the instillation in the 1-week group (9.0 +/- 5.9 cm H2O/ml/sec) and between 5 and 6 minutes in the 2-, 3-, 5-, and 8-week groups (9.4 +/- 4.8, 12.7 +/- 5.5, 3.7 +/- 1.1, and 1.7 +/- 0.2 cm H2O/ml/sec, respectively). The maximal increase in R(L) after the challenge in nonsensitized animals was 0.39 +/- 0.05 cm H2O/ml/sec. TMA-GPSA also produced significant extravasation of Evans blue dye at all airway levels in the senzitized groups, and the amount of dye in the peripheral airways was significantly greater than that in the trachea. Furthermore, the level of Evans blue dye in airway tissue increased with the time after sensitization, up to the latest time point tested (8 weeks). Specific IgG1 antibodies to TMA-GPSA demonstrated by ELISA were detected in all animals in the 3-, 5-, and 8-week groups, with maximal levels 5 weeks after sensitization. Specific IgG1 titers to TMA-GPSA significantly correlated with the level of Evans blue dye induced by challenge with TMA-GPSA but not with the increase in R(L). Conclusions: Intradermal sensitization to free TMA induces specific airway allergy for a long period after sensitization. Specific IgG1 antibodies to allergen may influence allergen-induced plasma exudation rather than the airflow obstruction in this animal model of TMA-induced asthma.	GOTHENBURG UNIV,DEPT PHARMACOL,DIV CLIN PHARMACOL,LUNG PHARMACOL GRP,S-41124 GOTHENBURG,SWEDEN; GOTHENBURG UNIV,DEPT INTERNAL MED,DIV PULM MED,S-41124 GOTHENBURG,SWEDEN; ROYAL BROMPTON NATL HEART & LUNG INST,DEPT OCCUPAT & ENVIRONM MED,LONDON,ENGLAND; ST VINCENTS HOSP,DEPT PULM MED,DUBLIN 4,IRELAND; ST VINCENTS HOSP,CTR EDUC & RES,DUBLIN 4,IRELAND	University of Gothenburg; University of Gothenburg; Imperial College London; University College Dublin; University College Dublin			kawikova, ivana/GXG-1819-2022	Lotvall, Jan/0000-0001-9195-9249				AHMAD D, 1979, LANCET, V2, P328; ANDERSSON P, 1980, ALLERGY, V35, P65, DOI 10.1111/j.1398-9995.1980.tb01718.x; ARAKAWA H, 1992, EUR J PHARMACOL, V215, P51, DOI 10.1016/0014-2999(92)90607-6; ARAKAWA H, 1993, AM REV RESPIR DIS, V147, P1116, DOI 10.1164/ajrccm/147.5.1116; BERNSTEIN DI, 1982, J ALLERGY CLIN IMMUN, V69, P311, DOI 10.1016/S0091-6749(82)80009-2; BOTHAM PA, 1988, TOXICOL LETT, V41, P159, DOI 10.1016/0378-4274(88)90089-6; BOTHAM PA, 1989, TOXICOL LETT, V47, P25, DOI 10.1016/0378-4274(89)90083-0; COCKCROFT DW, 1979, AM REV RESPIR DIS, V120, P1053; DURHAM SR, 1987, J ALLERGY CLIN IMMUN, V79, P398, DOI 10.1016/0091-6749(87)90161-8; FAWCETT IW, 1977, CLIN ALLERGY, V7, P1, DOI 10.1111/j.1365-2222.1977.tb01418.x; HAYES JP, 1992, AM REV RESPIR DIS, V146, P1311, DOI 10.1164/ajrccm/146.5_Pt_1.1311; HAYES JP, 1992, CLIN EXP ALLERGY, V22, P694, DOI 10.1111/j.1365-2222.1992.tb00193.x; HAYES JP, 1992, AM REV RESPIR DIS, V146, P1306, DOI 10.1164/ajrccm/146.5_Pt_1.1306; HERBERT FA, 1979, CHEST, V76, P546, DOI 10.1378/chest.76.5.546; LYDYARD P, 1989, IMMUNOLOGY; ROGERS DF, 1989, J PHARMACOL METHOD, V21, P309, DOI 10.1016/0160-5402(89)90068-5; TOPPING MD, 1986, J ALLERGY CLIN IMMUN, V77, P834, DOI 10.1016/0091-6749(86)90381-7; VENABLES KM, 1989, BRIT J IND MED, V46, P222; VONNEERGAARD K, 1927, Z KLIN MED, V105, P51; ZEISS CR, 1977, J ALLERGY CLIN IMMUN, V60, P96, DOI 10.1016/0091-6749(77)90033-1	20	20	20	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1993	92	3					425	434		10.1016/0091-6749(93)90121-U	http://dx.doi.org/10.1016/0091-6749(93)90121-U			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LX309	8360393				2022-12-18	WOS:A1993LX30900008
J	BARLAN, IB; GEHA, RS; SCHNEIDER, LC				BARLAN, IB; GEHA, RS; SCHNEIDER, LC			THERAPY FOR PATIENTS WITH RECURRENT INFECTIONS AND LOW SERUM IGG3 LEVELS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note							ALLOTYPE		CHILDRENS HOSP MED CTR,DIV IMMUNOL,300 LONGWOOD AVE,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School					NIAID NIH HHS [1UO1AI31541-01, 1PO1AI28046] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI028046, U01AI031541] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		GOLDBLATT D, 1990, J INFECT DIS, V162, P1128, DOI 10.1093/infdis/162.5.1128; GRUBB R, 1986, ACTA PATH MICRO IM C, V94, P187; HASSAN MS, 1992, J IMMUNOL, V148, P2555; SHAPIRO GG, 1991, PEDIATRICS, V87, P311; SKVARIL F, 1986, MONOGR ALLERGY, V19, P134	5	20	20	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1993	92	2					353	355		10.1016/0091-6749(93)90179-J	http://dx.doi.org/10.1016/0091-6749(93)90179-J			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LT469	8349944				2022-12-18	WOS:A1993LT46900016
J	BARNES, PJ				BARNES, PJ			EFFECT OF NEDOCROMIL SODIUM ON AIRWAY SENSORY NERVES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							GUINEA-PIG AIRWAYS; BRADYKININ-INDUCED BRONCHOCONSTRICTION; DIOXIDE-INDUCED BRONCHOCONSTRICTION; SULFUR-DIOXIDE; CHOLINERGIC NEUROTRANSMISSION; ATOPIC SUBJECTS; INHIBITION; CROMOGLYCATE; ASTHMA; RESPONSES	There is increasing evidence that the sensory nerves of the airway play a role in the asthmatic response. Nerve endings are exposed by the epithelial shedding that occurs with asthma. They may become sensitized and activated by inflammatory mediators and may release neuropeptides that then spread and amplify the inflammatory process in the airways. Nedocromil sodium may prevent the sensory nerves from becoming sensitized and inhibit their activation. This possibility is suggested because nedocromil is highly effective against several indirect challenges that involve sensory nerve stimulation. Nedocromil sodium was able to inhibit the bronchoconstriction induced in patients with asthma by exposure to bradykinin, sulfur dioxide, metabisulfite, and ultrasonically nebulized water. Cough, which is a prominent symptom of asthma, is believed to be a result of sensory nerve activation. In several long-term clinical studies, nedocromil sodium reduces the severity of cough among patients with asthma. Studies are needed to define how nedocromil sodium acts on the sensory nerves.			BARNES, PJ (corresponding author), NATL HEART & LUNG INST,DEPT THORAC MED,LONDON,ENGLAND.			Barnes, Peter/0000-0002-5122-4018				ALTOUNYAN REC, 1986, EUR J RESPIR DIS, V69, P274; BARNES PJ, 1988, PHARMACOL REV, V40, P49; BARNES PJ, 1986, AM REV RESPIR DIS, V134, P1289; BARNES PJ, 1986, LANCET, V1, P242; BELVISI MG, 1988, BRIT J PHARMACOL, V95, P413, DOI 10.1111/j.1476-5381.1988.tb11661.x; BELVISI MG, 1989, J APPL PHYSIOL, V66, P268, DOI 10.1152/jappl.1989.66.1.268; BELVISI MG, 1989, BRIT J PHARMACOL, V97, P1125; CHERNIACK R M, 1990, Chest, V97, P1299; COLERIDGE JCG, 1984, REV PHYSIOL BIOCH P, V99, P1, DOI 10.1007/BFb0027715; DIXON CMS, 1987, THORAX, V42, P462, DOI 10.1136/thx.42.6.462; DIXON CMS, 1989, BRIT J CLIN PHARMACO, V27, P831, DOI 10.1111/j.1365-2125.1989.tb03446.x; DIXON CMS, 1988, AM REV RESPIR DIS, V137, pA238; DIXON M, 1979, BRIT J PHARMACOL, V67, P569, DOI 10.1111/j.1476-5381.1979.tb08703.x; FERREIRA SH, 1988, NATURE, V334, P698, DOI 10.1038/334698a0; FROSSARD N, 1987, EUR J PHARMACOL, V141, P519, DOI 10.1016/0014-2999(87)90578-4; FROSSARD N, 1989, J PHARMACOL EXP THER, V248, P292; FULLER RW, 1987, AM REV RESPIR DIS, V135, P176; GRIEF J, 1989, CHEST, V96, P583; GRUNDSTROM N, 1985, N-S ARCH PHARMACOL, V328, P236, DOI 10.1007/BF00515547; ICHINOSE M, 1990, J PHARMACOL EXP THER, V252, P1207; ICHINOSE M, 1989, EUR J PHARMACOL, V174, P489; Jackson D M, 1989, Pulm Pharmacol, V2, P179, DOI 10.1016/0952-0600(89)90018-5; JACKSON DM, 1988, BRIT J PHARMACOL, V93, P609, DOI 10.1111/j.1476-5381.1988.tb10317.x; KAUFMAN MP, 1980, J APPL PHYSIOL, V48, P511, DOI 10.1152/jappl.1980.48.3.511; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; NICHOL GM, 1989, THORAX, V44, P1009, DOI 10.1136/thx.44.12.1009; OLLERENSHAW SL, 1991, EUR RESPIR J, V4, P673; ROBERTS AM, 1983, PHYSIOLOGIST, V25, P226; ROBUSCHI M, 1987, CLIN ALLERGY, V17, P69, DOI 10.1111/j.1365-2222.1987.tb02321.x; ROGERS DF, 1989, LANCET, V1, P930; SANTAMBROGIO G, 1982, PHYSIOL REV, V62, P531, DOI 10.1152/physrev.1982.62.2.531; SARIA A, 1988, AM REV RESPIR DIS, V137, P1330, DOI 10.1164/ajrccm/137.6.1330; SEKIZAWA K, 1987, J PHARMACOL EXP THER, V243, P1211; TAN WC, 1982, THORAX, V37, P671, DOI 10.1136/thx.37.9.671; UEDA N, 1984, J PHARMACOL EXP THER, V230, P469; VERLEDEN GM, 1991, AM REV RESPIR DIS, V143, P114, DOI 10.1164/ajrccm/143.1.114	36	20	20	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1993	92	1	2				182	186		10.1016/0091-6749(93)90103-M	http://dx.doi.org/10.1016/0091-6749(93)90103-M			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LQ354	8393025				2022-12-18	WOS:A1993LQ35400009
J	CHURCH, MK; HOLGATE, ST				CHURCH, MK; HOLGATE, ST			ADENOSINE-INDUCED BRONCHOCONSTRICTION AND ITS INHIBITION BY NEDOCROMIL SODIUM	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							BRADYKININ-INDUCED BRONCHOCONSTRICTION; LUNG MAST-CELLS; NON-ATOPIC ASTHMA; INHALED ADENOSINE; MEDIATOR RELEASE; IMMEDIATE BRONCHOCONSTRICTION; BRONCHIAL PROVOCATION; ORAL TERFENADINE; CROMOGLYCATE; 5'-MONOPHOSPHATE	The inhalation of adenosine or adenosine-5'-monophosphate (AMP) causes a reproducible and transient bronchoconstriction in both atopic and nonatopic asthmatic subjects that is not followed by a late-phase response. The response may be prevented by prophylactic treatment with histamine H-1-receptor antagonists, local anesthetics, and atropine, which suggests that both mast cell mediator release and neuronal reflexes are involved. Adenosine- and AMP-induced bronchoconstriction are both blocked by cromolyn sodium and nedocromil sodium, with the PD20FEV1 for the latter approximately four times lower than that of cromolyn sodium in atopic asthmatic patients and approximately 23 times lower than that of cromolyn sodium in nonatopic asthmatic patients. We suggest that AMP-induced bronchoconstriction, in combination with other indirect-acting provicants, may be used to determine the effectiveness and mechanism of action of antiasthmatic drugs.			CHURCH, MK (corresponding author), SOUTHAMPTON GEN HOSP,IMMUNOPHARMACOL GRP,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND.							ALTOUNYAN REC, 1986, EUR J RESPIR DIS, V69, P274; ALTOUNYAN REC, 1987, EUR J RESPIR DI S147, V69, P277; AUTY RM, 1986, EUR J RESPIR DIS, V69, P120; CHAN W, 1986, CLIN SCI, V70, pP65; CHURCH MK, 1986, J ALLERGY CLIN IMMUN, V78, P670, DOI 10.1016/0091-6749(86)90044-8; CHURCH MK, 1986, BRIT J PHARMACOL, V87, P233, DOI 10.1111/j.1476-5381.1986.tb10176.x; CRIMI N, 1986, EUR J RESPIR DIS, V69, P258; CURZEN N, 1987, THORAX, V42, P946, DOI 10.1136/thx.42.12.946; CUSHLEY MJ, 1983, BRIT J CLIN PHARMACO, V15, P161, DOI 10.1111/j.1365-2125.1983.tb01481.x; DAHL R, 1986, EUR J RESPIR DIS, V69, P263; DAXUN Z, 1989, J ALLERGY CLIN IMMUN, V83, P152, DOI 10.1016/0091-6749(89)90490-9; DIXON CMS, 1988, THORAX, V43, pP225; DIXON M, 1980, BRIT J PHARMACOL, V70, P11, DOI 10.1111/j.1476-5381.1980.tb10898.x; EADY RP, 1989, INT ARCH ALLER A IMM, V88, P240, DOI 10.1159/000234797; FAIN JN, 1979, MOL CELL BIOCHEM, V25, P143; FULLER RW, 1987, AM REV RESPIR DIS, V135, P176; GODARD P, 1987, American Review of Respiratory Disease, V135, pA318; HOLGATE ST, 1984, J ALLERGY CLIN IMMUN, V74, P302, DOI 10.1016/0091-6749(84)90262-8; HUGHES PJ, 1984, BIOCHEM PHARMACOL, V33, P3847, DOI 10.1016/0006-2952(84)90050-9; JACKSON DM, 1977, BRIT J PHARMACOL, V61, P257, DOI 10.1111/j.1476-5381.1977.tb08413.x; JUNIPER EF, 1987, CLIN ALLERGY, V17, P523, DOI 10.1111/j.1365-2222.1987.tb02048.x; KONIG P, 1987, J ALLERGY CLIN IMMUN, V79, P64, DOI 10.1016/S0091-6749(87)80018-0; LEUNG KBP, 1986, EUR J RESPIR DIS, V69, P223; MANN JS, 1986, J APPL PHYSIOL, V61, P1667, DOI 10.1152/jappl.1986.61.5.1667; MARQUARDT DL, 1978, J IMMUNOL, V120, P871; OKAYAMA M, 1986, AM REV RESPIR DIS, V133, pA93; PEACHELL PT, 1988, AM REV RESPIR DIS, V138, P1143, DOI 10.1164/ajrccm/138.5.1143; PHILLIPS GD, 1987, THORAX, V42, P939, DOI 10.1136/thx.42.12.939; PHILLIPS GD, 1989, AM REV RESPIR DIS, V139, P463, DOI 10.1164/ajrccm/139.2.463; PHILLIPS GD, 1990, AM REV RESPIR DIS, V141, P9, DOI 10.1164/ajrccm/141.1.9; PHILLIPS GD, 1988, CLIN SCI, V75, P429, DOI 10.1042/cs0750429; PHILLIPS GD, 1989, AM REV RESPIR DIS, V140, P321, DOI 10.1164/ajrccm/140.2.321; PHILLIPS GD, 1989, EUR RESPIR J, V2, P210; POLOSA R, 1988, THORAX, V43, pP864; RAFFERTY P, 1987, AM REV RESPIR DIS, V136, P369, DOI 10.1164/ajrccm/136.2.369; RICHARDS R, 1989, CLIN EXP ALLERGY, V19, P285, DOI 10.1111/j.1365-2222.1989.tb02385.x; ROBUSCHI M, 1987, CLIN ALLERGY, V17, P69, DOI 10.1111/j.1365-2222.1987.tb02321.x; SPRY CJF, 1986, EUR J RESPIR DIS, V69, P241; THOREL T, 1988, INT ARCH ALLER A IMM, V85, P232, DOI 10.1159/000234508; VERLEDEN GM, 1991, AM REV RESPIR DIS, V143, P114, DOI 10.1164/ajrccm/143.1.114	40	20	20	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1993	92	1	2				190	194		10.1016/0091-6749(93)90105-O	http://dx.doi.org/10.1016/0091-6749(93)90105-O			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LQ354	8393027				2022-12-18	WOS:A1993LQ35400011
J	OHMAN, JL; SPARROW, D; MACDONALD, MR				OHMAN, JL; SPARROW, D; MACDONALD, MR			NEW ONSET WHEEZING IN AN OLDER MALE-POPULATION - EVIDENCE OF ALLERGEN SENSITIZATION IN A LONGITUDINAL-STUDY - RESULTS OF THE NORMATIVE AGING STUDY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						WHEEZING; AGING; IGE ANTIBODY; MITE ALLERGEN; CAT ALLERGEN; SMOKING; LONGITUDINAL	SKIN-TEST REACTIVITY; SERUM IGE; ASTHMA; SAMPLE; EPIDEMIOLOGY; ASSOCIATION; ANTIBODIES; POLLEN	Background: Thirty-nine male subjects, with new-onset wheezing, were selected from participants in the Department of Veterans Affairs Normative Aging Study and compared with 74 age-matched controls. Wheezing was defined by responses to a standardized and regularly administered questionnaire. The subjects with wheezing had a reduced FEV1 compared with controls (p = 0.005), but most had values above 80% predicted. Current smoking was more common in subjects with wheezing (36.8% vs 8.11% in controls, p < 0.001). The mean age of both subjects and controls was 64 years. Methods: Allergen-specific IgE antibodies were measured, starting with sera at the time of the most recent questionnaire, and on the average 3.1, 7.6, and 12.3 years before that, with use of stored serum samples. Results: Total IgE did not differ significantly between the groups. IgE binding to dust mite antigen was detected in 13% to 15% of the subjects with wheezing compared with fewer than 7% of the controls over four time intervals (p = 0.014). IgE binding to cat and ragweed antigens did wt differ significantly between groups. If current nonsmokers were analyzed separately, IgE binding to cat allergen was also slightly greater in subjects with wheezing compared with controls (p = 0.054). Sequential analysis of IgE antibody levels to mite antigen, over time, indicated that IgE antibody antedated the onset of wheezing. Conclusions: New-onset wheezing in an older adult male population is significantly associated with allergic sensitization to dust mite. There was a borderline association with sensitization to cat in noncurrent smokers only. This supports the hypothesis that a subgroup may have allergic triggers to their symptoms.	DEPT VET AFFAIRS OUTPATIENT CLIN,BOSTON,MA		OHMAN, JL (corresponding author), TUFTS UNIV,NEW ENGLAND MED CTR,SCH MED,750 WASHINGTON ST,BOSTON,MA 02111, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045089] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI024848, R01AI028586] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45089] Funding Source: Medline; NIAID NIH HHS [IMS 5RO1 AI28586, AITC 7P50AI24848] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARBEE RA, 1976, ANN INTERN MED, V84, P129, DOI 10.7326/0003-4819-84-2-129; BARBEE RA, 1991, CHEST, V99, P20, DOI 10.1378/chest.99.1.20; BARBEE RA, 1981, J ALLERGY CLIN IMMUN, V68, P106, DOI 10.1016/0091-6749(81)90167-6; BARBEE RA, 1987, J ALLERGY CLIN IMMUN, V79, P16, DOI 10.1016/S0091-6749(87)80010-6; BELL B, 1972, AGING HUM DEVELOP, V3, P5, DOI 10.2190/GGVP-XLB5-PC3N-EF0G; BURROWS B, 1976, ANN INTERN MED, V84, P134, DOI 10.7326/0003-4819-84-2-134; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; DELESPESSE G, 1977, CLIN ALLERGY, V7, P155, DOI 10.1111/j.1365-2222.1977.tb01436.x; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; HAGY GW, 1969, J ALLERGY, V44, P323, DOI 10.1016/0021-8707(69)90024-0; HANNEUSE Y, 1978, CLIN ALLERGY, V8, P165, DOI 10.1111/j.1365-2222.1978.tb00461.x; KING TP, 1962, BIOCHEMISTRY-US, V1, P709, DOI 10.1021/bi00910a027; OHMAN JL, 1974, J IMMUNOL, V113, P1668; POLLART SM, 1988, J ALLERGY CLIN IMMUN, V82, P224, DOI 10.1016/0091-6749(88)91003-2; POLLART SM, 1989, J ALLERGY CLIN IMMUN, V83, P875, DOI 10.1016/0091-6749(89)90100-0; RAWLE FC, 1983, CLIN ALLERGY, V13, P409, DOI 10.1111/j.1365-2222.1983.tb02616.x	16	20	20	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1993	91	3					752	757		10.1016/0091-6749(93)90195-L	http://dx.doi.org/10.1016/0091-6749(93)90195-L			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KU203	8454798				2022-12-18	WOS:A1993KU20300008
J	DIXIT, AB; LEWIS, WH; WEDNER, HJ				DIXIT, AB; LEWIS, WH; WEDNER, HJ			THE ALLERGENS OF EPICOCCUM-NIGRUM LINK .1. IDENTIFICATION OF THE ALLERGENS BY IMMUNOBLOTTING	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						EPICOCCUM-NIGRUM; ATMOSPHERIC ISOLATES; MOLD GROWTH; SPORE; MYCELIUM; SKIN TESTING; SDS PAGE; IMMUNOBLOTTING; IGE BINDING; ALLERGY	HYMENOPTERA VENOM; ALTERNARIA; PROTEINS; POLLEN; ELISA	Two atmospheric isolates of Epicoccum nigrum (EN) were grown under sporulation conditions. Dialyzed extracts of spores, (> 95% pure) and pure mycelia were used for skin testing, sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and immunoblotting. By skin testing, 49 of the 126 atopic patients were found to be sensitive to EN in St. Louis, Mo., and Corpus Christi, Texas, combined. On immunoblotting, which was performed on 17 sera, 44 bands (12.3 to 119.0 kd) were detected; six were unique to spore, four were unique to mycelium, and 34 were common to both. No single band bound IgE from all sera. The most frequent band corresponding to 42 kd occurred in 11 sera. Five other bands were recognized by more than one half, whereas the remainder bound fewer sera. All skin test-positive patients had positive immunoblots; the number of bands recognized varied from three to 25. Spore or mycelium-specific, as well as common bands were recognized by 13 of 17 sera. Two sera recognized only spore and mycelium-specific bands. Only spore-specific bands were bound by two sera. No strain differences were detected. The binding patterns were comparable in the sera from both St. Louis, Mo., and Corpus Christi, Texas. These data suggest that EN is a significant allergen in urban communities. Allergenic proteins occur in both spore and mycelium, suggesting that both must be included in the reagents for skin testing and immunotherapy.	WASHINGTON UNIV,SCH MED,DEPT MED,DIV ALLERGY & IMMUNOL,660 S EUCLID AVE,BOX 8122,ST LOUIS,MO 63110; WASHINGTON UNIV,DEPT BIOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R43AI108042, F32AI008042] Funding Source: NIH RePORTER; NIAID NIH HHS [AI08042] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGRAWAL MK, 1982, J ALLERGY CLIN IMMUN, V70, P437; Baldo B. A., 1989, Protein blotting: methodology, research and diagnostic applications., P111; BOUSQUET J, 1988, ALLERGY PRINCIPLES P, P419; BUDD TW, 1983, J ALLERGY CLIN IMMUN, V71, P277, DOI 10.1016/0091-6749(83)90081-7; BUSH RK, 1987, CLIN REV ALLERG, V5, P3; CHAPMAN J, 1986, J ALLERGY CLIN IMMUN, V77, P200; CHAPMAN JA, 1984, ANN ALLERGY, V52, P411; DIXIT A, 1991, Journal of Allergy and Clinical Immunology, V87, P180, DOI 10.1016/0091-6749(91)91450-8; GRAVESEN S, 1983, 30TH C EUR AC ALL CL; Grillot R., 1990, Aerobiologia, V6, P58, DOI 10.1007/BF02539046; GUEVARA J, 1982, ELECTROPHORESIS, V3, P197, DOI 10.1002/elps.1150030404; HOFFMAN DR, 1979, J ALLERGY CLIN IMMUN, V63, P213; HOFFMAN DR, 1987, J ALLERGY CLIN IMMUN, V80, P307, DOI 10.1016/0091-6749(87)90036-4; HOFFMAN DR, 1987, J ALLERGY CLIN IMMUN, V80, P300, DOI 10.1016/0091-6749(87)90035-2; HOFFMAN DR, 1984, MOULD ALLERGY, P104; JONG SC, 1989, AM TYPE CULTURE COLL, P39; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS W, 1991, Journal of Allergy and Clinical Immunology, V87, P182, DOI 10.1016/0091-6749(91)91458-6; LORIA RC, 1989, J ALLERGY CLIN IMMUN, V84, P9, DOI 10.1016/0091-6749(89)90172-3; MALLOCH D, 1981, MOLDS THEIR ISOLATIO, P25; MEYER GH, 1983, ANN ALLERGY, V51, P26; PARIS S, 1990, J ALLERGY CLIN IMMUN, V85, P941, DOI 10.1016/0091-6749(90)90081-E; PORTNOY J, 1987, ANN ALLERGY, V59, P39; Prince H. E., 1947, ANN ALLERGY, V5, P434; PRINCE HE, 1944, ANN ALLERGY, V2, P500; SALVAGGIO J, 1981, J ALLERGY CLIN IMMUN, V68, P327, DOI 10.1016/0091-6749(81)90131-7; SCHOL-SCHWARZ M. BEATRICE, 1959, TRANS BRIT MYCOL SOC, V42, P149; SORENSON WG, 1974, ANN ALLERGY, V33, P131; WEDNER H J, 1990, Journal of Allergy and Clinical Immunology, V85, P275; WEDNER HJ, 1989, J ALLERGY CLIN IMMUN, V84, P263, DOI 10.1016/0091-6749(89)90334-5; WILSON P, 1990, Journal of Allergy and Clinical Immunology, V85, P171; YODER OC, 1982, ADV PLANT PATHOL, P94	32	20	22	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1992	90	1					11	20		10.1016/S0091-6749(06)80006-0	http://dx.doi.org/10.1016/S0091-6749(06)80006-0			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JE255	1629496				2022-12-18	WOS:A1992JE25500002
J	SHALIT, M; TEDESCHI, A; MIADONNA, A; LEVISCHAFFER, F				SHALIT, M; TEDESCHI, A; MIADONNA, A; LEVISCHAFFER, F			DESFERAL (DESFERRIOXAMINE) - A NOVEL ACTIVATOR OF CONNECTIVE TISSUE-TYPE MAST-CELLS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						DESFERAL; SKIN; MAST CELL; HISTAMINE RELEASE	RAPID DESENSITIZATION; ANAPHYLACTIC REACTION; DIFFERENTIAL RELEASE; HISTAMINE-RELEASE; HETEROGENEITY; PEPTIDES; SULFATE; STIMULI; SKIN	The effect of Desferal (desferrioxamine), an iron-chelating agent with allergic side effects, was examined on human basophils and rodent mast cells (MCs) in vitro and in the human skin. Even at a high concentration (100 mg/ml), the drug neither induced histamine release (HR) from human basophils nor primed these cells to release higher amounts of histamine when they were activated with f-met-peptide or anti-IgE antibodies. In contrast, in all seven subjects studied, intradermal injection of Desferal (0.1 mg/ml to 100 mg/ml) elicited classic wheal-and-flare responses. Ingestion of 10 mg of cetirizine, an H-1 antagonist, 3 hours before the intracutaneous administration of Desferal, significantly reduced the diameters of both wheal-and-flare reactions, indicating that the drug caused local HR. Desferal also induced HR from rat peritoneal MCs in vitro but had no effect on mouse bone marrow-derived MCs. These results suggest that Desferal has a direct, IgE-independent, stimulatory effect on connective tissue-type MCs. Thus, it may be used as a positive control in skin testing.	HADASSAH MED CTR, DIV MED, ALLERGY & CLIN IMMUNOL UNIT, JERUSALEM, ISRAEL; HEBREW UNIV JERUSALEM, HADASSAH MED SCH, DEPT PHARMACOL, IL-91010 JERUSALEM, ISRAEL; UNIV MILAN, DEPT INTERNAL MED 1, I-20122 MILAN, ITALY	Hebrew University of Jerusalem; Hadassah University Medical Center; Hebrew University of Jerusalem; University of Milan								ATHANASIOU A, 1977, LANCET, V2, P616; BENYON RC, 1989, BRIT J PHARMACOL, V97, P898, DOI 10.1111/j.1476-5381.1989.tb12030.x; BLOOMFIELD SE, 1978, J PEDIAT OPHTH STRAB, V15, P154; BOUSQUET J, 1983, LANCET, V2, P859; CASALE TB, 1984, J ALLERGY CLIN IMMUN, V73, P775, DOI 10.1016/0091-6749(84)90447-0; DAVIES SC, 1983, LANCET, V2, P181; DOLOVICH J, 1983, ANN ALLERGY, V50, P241; GROSMAN N, 1981, AGENTS ACTIONS, V11, P196, DOI 10.1007/BF01967614; IRANI AMA, 1989, CLIN EXP ALLERGY, V19, P143, DOI 10.1111/j.1365-2222.1989.tb02357.x; ISHIZAKA T, 1979, MAST CELLS, P21; LAGUNOFF D, 1983, ANNU REV PHARMACOL, V23, P331, DOI 10.1146/annurev.pa.23.040183.001555; LEVISCHAFFER F, 1989, INT ARCH ALLER A IMM, V90, P352, DOI 10.1159/000235052; LEVISCHAFFER F, 1985, J IMMUNOL, V135, P3454; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; LOWMAN MA, 1988, J ALLERGY CLIN IMMUN, V81, P574, DOI 10.1016/0091-6749(88)90199-6; LOWMAN MA, 1988, BRIT J PHARMACOL, V95, P121, DOI 10.1111/j.1476-5381.1988.tb16555.x; MILLER KB, 1981, LANCET, V1, P1059; PEARCE FL, 1989, INT ARCH ALLER A IMM, V88, P129, DOI 10.1159/000234764; RAZIN E, 1984, J IMMUNOL, V132, P1479; SHAFF RE, 1979, ANAL BIOCHEM, V94, P425, DOI 10.1016/0003-2697(79)90385-3; SHALIT M, 1986, LIFE SCI, V39, P903, DOI 10.1016/0024-3205(86)90372-3; SULLIVAN TJ, 1988, ALLERGY PRINCIPLES P, P1523; UMEMOTO L, 1976, J ALLERGY CLIN IMMUN, V58, P60, DOI 10.1016/0091-6749(76)90107-X; WEISS ME, 1988, CLIN ALLERGY, V18, P515, DOI 10.1111/j.1365-2222.1988.tb02904.x	24	20	21	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1991	88	6					854	860		10.1016/0091-6749(91)90241-F	http://dx.doi.org/10.1016/0091-6749(91)90241-F			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GW262	1720796				2022-12-18	WOS:A1991GW26200005
J	VANWYE, JE; HSU, YP; LANE, RS; TERR, AI; MOSS, RB				VANWYE, JE; HSU, YP; LANE, RS; TERR, AI; MOSS, RB			IGE ANTIBODIES IN TICK BITE-INDUCED ANAPHYLAXIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note							AUSTRALIAN PARALYSIS TICK; IXODES-HOLOCYCLUS; PACIFICUS		STANFORD UNIV,MED CTR,SCH MED,DEPT PEDIAT,STANFORD,CA 94305; STANFORD UNIV,MED CTR,SCH MED,DEPT MED,STANFORD,CA 94305; UNIV CALIF BERKELEY,DEPT ENTOMOL SCI,BERKELEY,CA 94720	Stanford University; Stanford University; University of California System; University of California Berkeley			Moss, Richard B./S-9218-2019	Moss, Richard B./0000-0003-3611-4221				BURGDORFER W, 1985, AM J TROP MED HYG, V34, P925, DOI 10.4269/ajtmh.1985.34.925; Davis GE, 1937, PUBLIC HEALTH REP, V52, P281, DOI 10.2307/4582108; Furman D.P., 1984, Bulletin of the California Insect Survey, V25, P1; GAUCI M, 1990, J IMMUNOL METHODS, V126, P51, DOI 10.1016/0022-1759(90)90010-S; GAUCI M, 1989, CLIN EXP ALLERGY, V19, P279, DOI 10.1111/j.1365-2222.1989.tb02384.x; GREGSON J. D., 1942, Proceedings of the Entomological Society of British Columbia, V38, P5; HSU YP, 1991, J ALLERGY CLIN IMMUN, P87; HUGHES LE, 1976, AM J TROP MED HYG, V25, P513, DOI 10.4269/ajtmh.1976.25.513; MCBRIDE PT, 1989, ACI NEWS, V1, P50; MOSS RB, 1987, J ALLERGY CLIN IMMUN, V79, P387, DOI 10.1016/0091-6749(87)90160-6; VANWYE JE, 1991, NEW ENGL J MED, V324, P777	11	20	21	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1991	88	6					968	970		10.1016/0091-6749(91)90257-O	http://dx.doi.org/10.1016/0091-6749(91)90257-O			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GW262	1744369				2022-12-18	WOS:A1991GW26200021
J	ZURAW, BL; ALTMAN, LC				ZURAW, BL; ALTMAN, LC			ACUTE CONSUMPTION OF C1-INHIBITOR IN A PATIENT WITH ACQUIRED C1-INHIBITOR DEFICIENCY SYNDROME	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						C1-INHIBITOR; ACQUIRED; DEFICIENCY; ANGIOEDEMA; ANAPHYLAXIS; COMPLEMENT; KALLIKREIN; KININOGEN; AUTOANTIBODY	C1 ESTERASE INHIBITOR; ANTIBODY IMMUNOSORBENT-ASSAY; HEREDITARY ANGIOEDEMA; 1ST COMPONENT; HUMAN-PLASMA; COMPLEMENT; ACTIVATION; KALLIKREIN; AUTOANTIBODY; COMPLEXES	Acquired C1-inhibitor (C1 INH) deficiency is usually found in association with an underlying disease that is believed to be responsible for increased C1 INH catabolism, ultimately leading to the development of C1 INH deficiency. We report a remarkable patient with acquired C1 INH deficiency in whom a unique progression of complement- and contact-system abnormalities has been observed. S. G. suffers from recurrent episodes of angioedema and hypotension. Results of repeated complement studies were initially normal, and the patient was diagnosed as having idiopathic anaphylaxis. Two years later, the patient was found to develop acute consumption of C1 INH with activation of the complement and contact systems during episodes of angioedema. The patient continued to have normal C1 INH levels and to have no evidence for complement- or contact-system activation between attacks of angioedema. One year later, her course evolved into a more typical course for acquired C1 INH deficiency consisting of continuously low functional C1 INH levels with evidence of activation of the complement and contact systems. S. G. provides a unique insight into the development of acquired C1 INH deficiency.	UNIV WASHINGTON, DEPT MED, DIV ALLERGY & INFECT DIS, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle	ZURAW, BL (corresponding author), SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.			Zuraw, Bruce/0000-0003-0640-6768	NCRR NIH HHS [RR00833] Funding Source: Medline; NIAID NIH HHS [AI10386] Funding Source: Medline; NIDCR NIH HHS [DEO 8229-04] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI010386] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE008229] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALSENZ J, 1987, NEW ENGL J MED, V316, P1360, DOI 10.1056/NEJM198705283162202; Caldwell JR, 1972, CLIN IMMUNOL IMMUNOP, V1, P39; CURD JG, 1980, J EXP MED, V152, P742, DOI 10.1084/jem.152.3.742; DAY NK, 1976, CLIN EXP IMMUNOL, V26, P189; FRANK MM, 1972, NEW ENGL J MED, V286, P808, DOI 10.1056/NEJM197204132861503; GEHA RS, 1985, NEW ENGL J MED, V312, P534, DOI 10.1056/NEJM198502283120902; GELFAND JA, 1979, MEDICINE, V58, P321, DOI 10.1097/00005792-197907000-00004; HACK CE, 1981, J IMMUNOL, V127, P1450; HENTGES F, 1986, J ALLERGY CLIN IMMUN, V78, P860, DOI 10.1016/0091-6749(86)90231-9; JACKSON J, 1986, NATURE, V323, P722, DOI 10.1038/323722a0; JACKSON J, 1989, J CLIN INVEST, V83, P698, DOI 10.1172/JCI113934; KAPLAN AP, 1985, BLOOD, V66, P636; LANDERMAN NS, 1962, J ALLERGY, V33, P330, DOI 10.1016/0021-8707(62)90032-1; LEWIN MF, 1983, J BIOL CHEM, V258, P6415; MALBRAN A, 1988, J ALLERGY CLIN IMMUN, V81, P1199, DOI 10.1016/0091-6749(88)90891-3; SCHREIBER AD, 1976, BLOOD, V48, P567; SHEFFER AL, 1985, J ALLERGY CLIN IMMUN, V75, P640, DOI 10.1016/0091-6749(85)90087-9; SPRENGER JD, 1987, J ALLERGY CLIN IMMUN, V79, P236; STRANG CJ, 1988, J EXP MED, V168, P1685, DOI 10.1084/jem.168.5.1685; VANDERGRAAF F, 1983, J CLIN INVEST, V71, P149, DOI 10.1172/JCI110743; ZICCARDI RJ, 1980, CLIN IMMUNOL IMMUNOP, V15, P465, DOI 10.1016/0090-1229(80)90058-6; ZURAW B, 1987, J ALLERGY CLIN IMMUN, V79, P177; ZURAW B L, 1990, Journal of Allergy and Clinical Immunology, V85, P208; ZURAW BL, 1986, J ALLERGY CLIN IMMUN, V78, P1115, DOI 10.1016/0091-6749(86)90259-9; ZURAW BL, 1986, J CLIN INVEST, V78, P567, DOI 10.1172/JCI112610	25	20	20	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1991	88	6					908	918		10.1016/0091-6749(91)90248-M	http://dx.doi.org/10.1016/0091-6749(91)90248-M			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GW262	1744362				2022-12-18	WOS:A1991GW26200012
J	CHRISTIE, PE; SPUR, BW; LEE, TH				CHRISTIE, PE; SPUR, BW; LEE, TH			THE EFFECT OF INHALATION OF THE LEUKOTRIENE RECEPTOR ANTAGONIST, SK-AND-F 104353, ON LEUKOTRIENE C4-INDUCED AND LEUKOTRIENE E4-INDUCED BRONCHOCONSTRICTION IN SUBJECTS WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						LEUKOTRIENE; ASTHMA; RECEPTOR; LEUKOTRIENE ANTAGONIST	SLOW-REACTING SUBSTANCE; GUINEA-PIG LUNG; AIRWAY RESPONSIVENESS; HISTAMINE; PHARMACOLOGY; ANAPHYLAXIS; POTENT; HYPERRESPONSIVENESS; METHACHOLINE; ICI-204,219	The effect of prior inhalation of the sulfidopeptide leukotriene receptor antagonist, SK&F 104353 (963 +/- 43.7-mu-g; mean +/- SEM), on (LTC4)- and leukotriene E4 (LTE4)-induced bronchoconstriction has been studied in six subjects with asthma (six male subjects, aged 24 to 36 years). Inhalation challenges with either synthetic LTC4 or LTE4 were performed after prior inhalation of aerosolized SK&F 104353 or placebo in a double-blind, randomized fashion. Airway responsiveness to each agonist was determined by the cumulative dose of agonist required to induce a 35% fall in specific airway conductance (PD35) as determined by linear interpolation of the log dose-response curve. There was no change in baseline specific airway conductance after inhalation of either placebo or SK&F 104353. LTC4- and LTE4-induced bronchoconstrictions were significantly inhibited by aerosolized inhalation of SK&F 104353 30 minutes before challenge. The geometric mean (GM) PD35 of LTC4 on the open-therapy and placebo-therapy days was 0.043 nmol (range, 0.01 to 0.1 nmol) and 0.036 nmol (range, 0.01 to 0.1 nmol), respectively. On the treatment day with SK&F 104353, it was not possible to obtain a GM PD35 LTC4 up to a maximum concentration of 0.52 nmol LTC4 (p < 0.01). The GM PD35 of LTE4 on the open-therapy and placebo-therapy days was 0.30 nmol (range, 0.13 to 0.76 nmol) and 0.39 nmol (range, 0.14 to 0.9 nmol), respectively. On the treatment day with SK&F 104353, it was not possible to obtain a GM PD35 LTE4 up to a maximum concentration of 5 nmol LTE4 (p < 0.005). Thus, LTC4- and LTE4-induced bronchoconstrictions are both inhibited by SK&F 104353.	UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,DEPT ALLERGY & ALLIED RESP DISORDERS,LONDON SE1 9RT,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London				Lee, Tak/0000-0002-7554-4059; Spur, Bernd/0000-0002-7581-4741				AHARONY D, 1989, J PHARMACOL EXP THER, V248, P581; ARM JP, 1990, AM REV RESPIR DIS, V142, P1112, DOI 10.1164/ajrccm/142.5.1112; ARM JP, 1989, AM REV RESPIR DIS, V140, P148, DOI 10.1164/ajrccm/140.1.148; ARM JP, 1988, J ALLERGY CLIN IMMUN, V82, P654, DOI 10.1016/0091-6749(88)90979-7; AUGSTEIN J, 1973, NATURE-NEW BIOL, V245, P215, DOI 10.1038/newbio245215a0; BABER RJ, 1978, GLIM SYSTEM RELEASE; BARNES NC, 1984, THORAX, V39, P500, DOI 10.1136/thx.39.7.500; BUCKNER CK, 1986, J PHARMACOL EXP THER, V237, P558; CHOWIENCZYK PJ, 1981, J APPL PHYSIOL, V50, P672, DOI 10.1152/jappl.1981.50.3.672; CRETICOS PS, 1989, J ALLERGY CLIN IMMUN, V83, P187; DAVIDSON AB, 1987, AM REV RESPIR DIS, V135, P333; DRAZEN JM, 1980, P NATL ACAD SCI-BIOL, V77, P4354, DOI 10.1073/pnas.77.7.4354; DRAZEN JM, 1981, P NATL ACAD SCI-BIOL, V78, P3195, DOI 10.1073/pnas.78.5.3195; DRAZEN JM, 1984, CLIN RES, V32, P528; DRAZEN JM, 1983, LEUKOTRIENES PROSTAC, P125; EISER N, 1989, AM REV RESPIR DIS, V143, P462; EVANS JM, 1988, BR J CLIN PHARM, V26, P677; FLEISCH JH, 1985, J PHARMACOL EXP THER, V233, P148; FORDHUTCHINSON AW, 1990, ADV PROSTAGLANDIN TH, V21, P9; HAY DWP, 1987, J PHARMACOL EXP THER, V243, P474; HOGABOOM GK, 1983, BIOCHEM BIOPH RES CO, V116, P113; JONES TR, 1989, CAN J PHYSIOL PHARM, V67, P17, DOI 10.1139/y89-004; JOOS GF, 1991, PULM PHARMACOL THER, V4, P37, DOI 10.1016/0952-0600(91)90037-4; KRELL RD, 1990, AM REV RESPIR DIS, V141, P978, DOI 10.1164/ajrccm/141.4_Pt_1.978; KRELL RD, 1983, PROSTAGLANDINS, V25, P171, DOI 10.1016/0090-6980(83)90102-8; KRILIS S, 1983, J CLIN INVEST, V71, P909, DOI 10.1172/JCI110845; LAM S, 1988, J ALLERGY CLIN IMMUN, V81, P711, DOI 10.1016/0091-6749(88)91043-3; LEE TH, 1984, P NATL ACAD SCI-BIOL, V81, P4922, DOI 10.1073/pnas.81.15.4922; LEE TH, 1981, LANCET, V2, P304; LEWIS RA, 1980, BIOCHEM BIOPH RES CO, V96, P271, DOI 10.1016/0006-291X(80)91210-3; NICOSIA S, 1989, FASEB J, V3, P1941, DOI 10.1096/fasebj.3.8.2542112; OHICKEY SP, 1988, EUR RESPIR J, V1, P913; ORNING L, 1985, BIOCHEM BIOPH RES CO, V130, P214, DOI 10.1016/0006-291X(85)90404-8; PHILLIPS GD, 1988, J PHARMACOL EXP THER, V246, P732; PONG SS, 1983, P NATL ACAD SCI-BIOL, V80, P7415, DOI 10.1073/pnas.80.24.7415; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SMITH LJ, 1990, AM REV RESPIR DIS, V141, P988, DOI 10.1164/ajrccm/141.4_Pt_1.988; SMITH LJ, 1985, AM REV RESPIR DIS, V131, P368; SNYDER DW, 1987, J PHARMACOL EXP THER, V243, P548; TAYLOR GW, 1989, LANCET, V1, P584; TORPHY TJ, IN PRESS ANN NY ACAD; WASSERMAN MA, 1986, ADV PROSTAGLANDIN TH, V17, P532; XUAN ATD, 1990, J ALLERGY CLIN IMMUN, V85, P865, DOI 10.1016/0091-6749(90)90070-K	43	20	20	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1991	88	2					193	198		10.1016/0091-6749(91)90328-L	http://dx.doi.org/10.1016/0091-6749(91)90328-L			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GB225	1652604				2022-12-18	WOS:A1991GB22500007
J	ADVENIER, C; CANDENAS, ML; NALINE, E; DEVOS, C				ADVENIER, C; CANDENAS, ML; NALINE, E; DEVOS, C			THE EFFECT OF CETIRIZINE ON THE HUMAN ISOLATED BRONCHUS - INTERACTION WITH SALBUTAMOL	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						HISTAMINE ANTAGONISTS; ADRENERGIC BETA-RECEPTOR AGONISTS; CETIRIZINE; SALBUTAMOL; MEPYRAMINE; ACETYLCHOLINE; HUMAN ISOLATED BRONCHI; HUMAN AIRWAYS	PIG ISOLATED TRACHEA; EPITHELIUM REMOVAL; SMOOTH-MUSCLE; ASTHMA; METHACHOLINE; ANTAGONISTS; RESPONSIVENESS; PHARMACOLOGY; TERFENADINE; HISTAMINE	The effects of cetirizine (C), a new generation, nonsedative, H-1-antihistamine drug, were studied on human isolated bronchi. C is a potent antagonist of the bronchial muscle contraction induced by histamine, irrespective of whether C is administered by cumulative addition or prophylactically. In the former case, this effect of C was significant at a concentration of 3 x 10(-8) mol/L and was maximal at a concentration of 10(-5) mol/L. The -log of concentration of C causing 50% of the maximal effect induced was 7.30 +/- 0.05 (n = 6), and the effect produced was not significantly modified by bronchial epithelium removal. When C was administered prophylactically, the concentration-response curves to histamine were displaced to the right, but the reduction of maximum histamine response suggests a noncompetitive type of antagonism. C is devoid of notable anticholinergic effects. At concentrations of 10(-8) to 10(-7) mol/L, C proved capable of enhancing the relaxant effect produced by salbutamol (10(-7) to 3 x 10(-7) mol/L) on human isolated bronchi that had been contracted by either histamine or acetylcholine (ACh). The synergy appeared to be additive or potentiating, depending on salbutamol (SAL) concentrations. Under similar conditions, mepyramine does not potentiate the effects of SAL against histamine. Finally, at concentrations of 10(-8) to 10(-6) mol/L, C reduced the functional antagonism observed between SAL and ACh, as can be observed by the increase, in the presence of C, of the maximal relaxant effect of SAL on contractions produced by 10(-3) mol/L of ACh. We may, therefore, conclude that C appears to be a specific antihistamine on human isolated bronchi and that it appears to potentiate the bronchodilator effect of SAL on this preparation.	LAB PHARMACOL PARIS,PARIS,FRANCE; UCB,PHARMACEUT SECTOR,BRAINE LALLEUD,BELGIUM	UCB Pharma SA	ADVENIER, C (corresponding author), UNIV PARIS 05,PHARMACOL LAB,15 RUE ECOLE MED,F-75270 PARIS 06,FRANCE.		Candenas, L./P-3247-2014	Candenas, L./0000-0001-7886-1095				ADVENIER C, 1988, J ALLERGY CLIN IMMUN, V82, P40, DOI 10.1016/0091-6749(88)90049-8; ADVENIER C, 1986, BRIT J PHARMACOL, V88, P33, DOI 10.1111/j.1476-5381.1986.tb09468.x; ADVENIER C, 1984, BRIT J PHARMACOL, V82, P727, DOI 10.1111/j.1476-5381.1984.tb10812.x; ARUNLAKSHANA O, 1959, BRIT J PHARM CHEMOTH, V14, P48, DOI 10.1111/j.1476-5381.1959.tb00928.x; BARNES PJ, 1989, J ALLERGY CLIN IMMUN, V83, P1013, DOI 10.1016/0091-6749(89)90441-7; BOWMAN WC, 1980, TXB PHARM, V12, P2; BRIK A, 1987, J ALLERGY CLIN IMMUN, V80, P51, DOI 10.1016/S0091-6749(87)80190-2; BRINK G, 1980, BRIT J PHARMACOL, V69, P383; CANDENAS ML, 1990, J PHARM PHARMACOL, V42, P102, DOI 10.1111/j.2042-7158.1990.tb05362.x; CHARLESWORTH EN, 1989, J ALLERGY CLIN IMMUN, V83, P905, DOI 10.1016/0091-6749(89)90104-8; DEVILLIER P, 1988, BRIT J PHARMACOL, V94, P675, DOI 10.1111/j.1476-5381.1988.tb11575.x; DEVOS C, 1987, ALLERGOL IMMUNOL CLI, V2, P81; DEVOS C, 1987, ALLERGOLOGIA IMMUNOL, V2, P82; FADEL R, 1987, CLIN ALLERGY, V17, P373, DOI 10.1111/j.1365-2222.1987.tb02027.x; FARMER SG, 1986, BRIT J PHARMACOL, V89, P407, DOI 10.1111/j.1476-5381.1986.tb10274.x; FINNERTY JP, 1990, BRIT J CLIN PHARMACO, V29, P79, DOI 10.1111/j.1365-2125.1990.tb03605.x; GHOSH S K, 1990, Clinical and Experimental Allergy, V20, P39; GOLDIE RG, 1986, BRIT J PHARMACOL, V87, P5, DOI 10.1111/j.1476-5381.1986.tb10150.x; HOLGATE ST, 1985, J ALLERGY CLIN IMMUN, V76, P375, DOI 10.1016/0091-6749(85)90657-8; HOLGATE ST, 1989, J ALLERGY CLIN IMMUN, V83, P537, DOI 10.1016/0091-6749(89)90035-3; LUNDBLAD KAL, 1988, BRIT J PHARMACOL, V93, P909, DOI 10.1111/j.1476-5381.1988.tb11479.x; MICHEL L, 1988, J ALLERGY CLIN IMMUN, V82, P101, DOI 10.1016/0091-6749(88)90058-9; NALINE E, 1989, AM REV RESPIR DIS, V140, P679, DOI 10.1164/ajrccm/140.3.679; NIMEGEERS CJE, 1982, DRUG DEVELOP RES, V2, P559; PECHADRE JC, 1988, EUR J CLIN PHARMACOL, V35, P255, DOI 10.1007/BF00558262; REINHARDT D, 1982, KLIN WOCHENSCHR, V60, P983, DOI 10.1007/BF01716959; SIMONS FER, 1989, J ALLERGY CLIN IMMUN, V84, P845, DOI 10.1016/0091-6749(89)90377-1; SNYDER SH, 1987, ANN ALLERGY, V59, P4; TAYTARD A, 1987, BRIT J CLIN PHARMACO, V24, P743, DOI 10.1111/j.1365-2125.1987.tb03240.x; TORPHY TJ, 1985, J PHARMACOL EXP THER, V233, P409; TORPHY TJ, 1983, J PHARMACOL EXP THER, V227, P694; TRZECIAKOWSKI JP, 1983, ALLERGY PRINCIPLES P, V1, P575; VANDENBRINK FG, 1973, EUR J PHARMACOL, V22, P279, DOI 10.1016/0014-2999(73)90027-7; WOOD SG, 1987, ANN ALLERGY, V59, P31	34	20	22	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1991	88	1					104	113		10.1016/0091-6749(91)90307-A	http://dx.doi.org/10.1016/0091-6749(91)90307-A			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FY204	1677016				2022-12-18	WOS:A1991FY20400013
J	MAROM, ZM; GOSWAMI, SK				MAROM, ZM; GOSWAMI, SK			RESPIRATORY MUCUS HYPERSECRETION (BRONCHORRHEA) - A CASE DISCUSSION - POSSIBLE MECHANISM(S) AND TREATMENT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							HUMAN AIRWAYS INVITRO; GLYCOCONJUGATE SECRETION; EPITHELIAL-CELLS; ERYTHROMYCIN; CULTURE; ASTHMA	The mechanism(s) underlying mucus hypersecretion (bronchorrhea) and the treatment of this condition are poorly understood. We have previously demonstrated that erythromycin inhibited mucus secretion from human airways and from secretory epithelial cells in vitro. We encountered a patient with airway obstruction marked by severe bronchorrhea, who previously had responded only to inhaled bronchodilators and high-dose prednisone. Many attempts to wean him from prednisone had failed. During the course of his disease, he had developed an IgG antibody to vasoactive intestinal peptide, had increased amounts of mucus secreted by his respiratory epithelial cells, and demonstrated hyperreactive airways as measured by methacholine challenge provocation test. Erythromycin was added to his therapy. The effect of erythromycin treatment was quite dramatic and included clinical and laboratory improvement. After a short trial of erythromycin, the patient tolerated low, every-other-day doses of prednisone. There was a significant reduction in the volume of his bronchorrhea, a major decrease in the epithelial mucins in his total expectorated mucus, complete inhibition of his airway hyperresponsiveness to inhaled methacholine, and significant reduction in the level of IgG antibody to vasoactive intestinal peptide. This response was specific for erythromycin since other antibiotics did not have any clinical, biochemical, or physiologic effects. We conclude that erythromycin may play a role in the treatment of patients with bronchorrhea and may have a steroid-sparing effect. Additional studies with larger numbers of patients are indicated.			MAROM, ZM (corresponding author), MT SINAI MED CTR,DIV PULM & CRIT CARE MED,1 GUSTAVE L LEVY PL,BOX 1232,NEW YORK,NY 10029, USA.				PHS HHS [37254] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADLER KB, 1990, AM J RESP CELL MOL, V2, P145, DOI 10.1165/ajrcmb/2.2.145; AMIN DN, 1991, AM J RESP CELL MOL, V4, P135, DOI 10.1165/ajrcmb/4.2.135; CARSTAIRS JR, 1986, J PHARMACOL EXP THER, V239, P249; GOSWAMI SK, 1990, AM REV RESPIR DIS, V141, P72, DOI 10.1164/ajrccm/141.1.72; HAWKES R, 1982, ANAL BIOCHEM, V119, P142, DOI 10.1016/0003-2697(82)90677-7; HELEN L, 1989, AM J RESPIR CELL MOL, V1, P41; HJELM H, 1972, FEBS LETT, V28, P73, DOI 10.1016/0014-5793(72)80680-X; KALINER M, 1984, J ALLERGY CLIN IMMUN, V73, P318, DOI 10.1016/0091-6749(84)90403-2; KALINER M, 1986, AM REV RESPIR DIS, V134, P612; KEAL EE, 1975, NEW DIRECTIONS ASTHM, P223; KIM KC, 1989, EXP LUNG RES, V15, P299, DOI 10.3109/01902148909087860; LUNDGREN JD, 1990, J ALLERGY CLIN IMMUN, V85, P399, DOI 10.1016/0091-6749(90)90147-V; LUNDGREN JD, 1988, AM REV RESPIR DIS, V137, P353, DOI 10.1164/ajrccm/137.2.353; MAROM Z, 1984, J EXP MED, V159, P844, DOI 10.1084/jem.159.3.844; MAROM Z, 1984, AM REV RESPIR DIS, V129, P62; MAROM Z, 1986, AM REV RESPIR DIS, V133, P211; MAROM Z M, 1988, American Review of Respiratory Disease, V137, P6; OLLERENSHAW S, 1989, NEW ENGL J MED, V320, P1244, DOI 10.1056/NEJM198905113201904; SHELHAMER JH, 1980, J CLIN INVEST, V66, P1400, DOI 10.1172/JCI109993; SPERBER K, 1990, J ALLERGY CLIN IMMUN, V87, P490; STAROS JV, 1986, ANAL BIOCHEM, V156, P220, DOI 10.1016/0003-2697(86)90176-4; SUEZ D, 1986, J ALLERGY CLIN IMMUN, V77, P330, DOI 10.1016/S0091-6749(86)80113-0	22	20	20	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1991	87	6					1050	1055		10.1016/0091-6749(91)92149-U	http://dx.doi.org/10.1016/0091-6749(91)92149-U			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FR066	2045610				2022-12-18	WOS:A1991FR06600003
J	VANMEGEN, YJB; KLAASSEN, ABM; DEMIRANDA, JFR; VANGINNEKEN, CAM; WENTGES, BTR				VANMEGEN, YJB; KLAASSEN, ABM; DEMIRANDA, JFR; VANGINNEKEN, CAM; WENTGES, BTR			ALTERATIONS OF MUSCARINIC ACETYLCHOLINE-RECEPTORS IN THE NASAL-MUCOSA OF ALLERGIC PATIENTS IN COMPARISON WITH NONALLERGIC INDIVIDUALS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							CHOLINERGIC RECEPTORS; RAT; HYPERREACTIVITY; METHACHOLINE; RHINITIS; DISEASE; AIRWAYS; SYSTEM; GLANDS	Cholinergic nasal hyperresponsiveness in nasal allergy may be due to changes of the characteristics in muscarinic cholinergic receptors. Radioligand receptor binding and in vitro autoradiographic studies of nasal mucosa in nonallergic (NA) and allergic patients were performed to investigate this hypothesis. The heterogeneous NA group was subdivided into control individuals and patients with chronic sinusitis and vasomotor rhinitis. The H-3-(-)-Quinuclidinylbenzilate binding to muscarinic receptors in human nasal mucosa membranes was saturable and of high affinity in all groups. No significant differences could be demonstrated between the subgroups of the NA patients. In allergic patients the dissociation constants and receptor densities were significantly decreased in comparison with those of NA and with those of control individuals. No differences in agonist binding or coupling of the muscarinic receptor to the effector system via the G protein could be observed in allergic patients. In vitro autoradiographic experiments demonstrated specific H-3-(-)-Quinuclidinylbenzilate labeling of the glandular acini in NA and allergic patients. No specific labeling could be observed in the epithelium, blood vessels, or connective tissue. In conclusion, the increased sensitivity and decreased muscarinic receptor number may reflect the cholinergic-induced hypersecretion in nasal allergy but are probably too small to explain the complex allergic reaction.	CATHOLIC UNIV NIJMEGEN,DEPT OTORHINOLARYNGOL,NIJMEGEN,NETHERLANDS; CATHOLIC UNIV NIJMEGEN,DEPT PHARMACOL,NIJMEGEN,NETHERLANDS	Radboud University Nijmegen; Radboud University Nijmegen								Andersen, 1982, NOSE UPPER AIRWAY PH, P45; BARNES PJ, 1986, AM REV RESPIR DIS, V134, P1289; BIRDSALL NJM, 1984, TRENDS PHARM SCI S, V1, P4; BORUM P, 1983, EUR J RESPIR DIS, V64, P65; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLAMP JR, 1978, BRIT MED BULL, V34, P25, DOI 10.1093/oxfordjournals.bmb.a071455; CORRADO OJ, 1986, THORAX, V41, P863, DOI 10.1136/thx.41.11.863; DEMIRANDA JFR, 1985, EUR J PHARMACOL, V113, P441, DOI 10.1016/0014-2999(85)90094-9; DEVILLIER P, 1988, EUR RESPIR J, V1, P356; DRUCE HM, 1985, J ALLERGY CLIN IMMUN, V76, P445, DOI 10.1016/0091-6749(85)90725-0; FLEMING WW, 1972, J PHARMACOL-PARIS, V181, P339; FLETCHER R, 1963, COMPUT J, V6, P163, DOI 10.1093/comjnl/6.2.163; FRYER AD, 1984, BRIT J PHARMACOL, V83, P973, DOI 10.1111/j.1476-5381.1984.tb16539.x; HAHN HL, 1986, B EUR PHYSIOPATH RES, V22, P112; HANCOCK AA, 1988, TRENDS PHARMACOL SCI, V9, P29, DOI 10.1016/0165-6147(88)90239-8; ISHIBE T, 1983, ARCH OTO-RHINO-LARYN, V238, P167, DOI 10.1007/BF00454309; ISHII T, 1972, ARCH KLIN EXP OHR, V201, P1, DOI 10.1007/BF00302192; JOAD JP, 1987, LIFE SCI, V41, P157; KILBINGER H, 1984, TRENDS PHARMACOL SCI, V5, P103, DOI 10.1016/0165-6147(84)90383-3; KLAASSEN ABM, 1986, ARCH OTOLARYNGOL, V112, P428; KLAASSEN ABM, 1987, ACTA OTO-LARYNGOL, V104, P545, DOI 10.3109/00016488709128287; KONNO A, 1987, ORL J OTO-RHINO-LARY, V49, P103, DOI 10.1159/000275915; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCKINNEY M, 1984, ANNU REV PHARMACOL, V24, P121; MYGIND N, 1974, Rhinology (Utrecht), V12, P131; MYGIND N, 1982, J ALLERGY CLIN IMMUN, V70, P149, DOI 10.1016/0091-6749(82)90036-7; Mygind N, 1978, NASAL ALLERGY; NADEL JA, 1984, ANNU REV MED, V35, P451, DOI 10.1146/annurev.med.35.1.451; NATHANSON NM, 1987, ANNU REV NEUROSCI, V10, P195, DOI 10.1146/annurev.ne.10.030187.001211; PASSALI D, 1983, Rhinology (Utrecht), V21, P321; PATOW CA, 1984, AM J OTOLARYNG, V5, P334, DOI 10.1016/S0196-0709(84)80003-4; RAAIJMAKERS JAM, 1984, CLIN SCI, V66, P585, DOI 10.1042/cs0660585; ROGERS AW, 1973, TECHNIQUES AUTORADIO; THAETE LG, 1981, AM J ANAT, V162, P243, DOI 10.1002/aja.1001620306; TOS M, 1977, ACTA OTO-LARYNGOL, V83, P498, DOI 10.3109/00016487709128878; van Koppen C J, 1989, Pulm Pharmacol, V2, P131, DOI 10.1016/0952-0600(89)90037-9; VANKOPPEN CJ, 1985, NAUNYNSCHMIEDEBERGS, V333, P247; VANMEGEN YJB, 1988, EUR J PHARMACOL, V145, P7, DOI 10.1016/0014-2999(88)90342-1; VECERINA S, 1983, Rhinology (Utrecht), V21, P73	39	20	20	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1991	87	2					521	529		10.1016/0091-6749(91)90011-C	http://dx.doi.org/10.1016/0091-6749(91)90011-C			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EX987	1993812				2022-12-18	WOS:A1991EX98700010
J	NACLERIO, RM				NACLERIO, RM			THE ROLE OF HISTAMINE IN ALLERGIC RHINITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											NACLERIO, RM (corresponding author), JOHNS HOPKINS UNIV, SCH MED, CTR ASTHMA & ALLERGY, UNIT OFF 7, 301 BAYVIEW BLVD, BALTIMORE, MD 21205 USA.				NIDCD NIH HHS [DC00320] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC000320] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		BASCOM R, 1988, J ALLERGY CLIN IMMUN, V81, P570, DOI 10.1016/0091-6749(88)90198-4; CASTELLS M, 1988, J ALLERGY CLIN IMMUN, V82, P348, DOI 10.1016/0091-6749(88)90005-X; GAFFEY MJ, 1988, PEDIATR INFECT DIS J, V7, P223, DOI 10.1097/00006454-198803000-00032; GOMEZ E, 1986, J ALLERGY CLIN IMMUN, V78, P637, DOI 10.1016/0091-6749(86)90082-5; IIOPOULOS O, 1989, J ALLERGY CLIN IMMUN, V83, P236; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NACLERIO RM, 1988, J INFECT DIS, V157, P133, DOI 10.1093/infdis/157.1.133; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; NACLERIO RM, 1986, J ALLERGY CLIN IMMUN, V78, P874, DOI 10.1016/0091-6749(86)90233-2; NACLERIO RM, 1990, AM REV RESPIR DIS, V142, P167, DOI 10.1164/ajrccm/142.1.167; NACLERIO RM, 1989, LARYNGOSCOPE, V99, P596; PIPKORN U, 1987, J CLIN INVEST, V80, P957, DOI 10.1172/JCI113188; PIPKORN U, 1987, NEW ENGL J MED, V316, P1506, DOI 10.1056/NEJM198706113162403; PROUD D, 1990, J INFECT DIS, V161, P120, DOI 10.1093/infdis/161.1.120; WALDEN SM, 1988, J ALLERGY CLIN IMMUN, V81, P282, DOI 10.1016/0091-6749(88)90690-2	15	20	20	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1990	86	4	2	S			628	632		10.1016/S0091-6749(05)80227-1	http://dx.doi.org/10.1016/S0091-6749(05)80227-1			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EH093	1977783				2022-12-18	WOS:A1990EH09300008
J	ALAM, R; FORSYTHE, PA; RANKIN, JA; BOYARS, MC; LETTBROWN, MA; GRANT, JA				ALAM, R; FORSYTHE, PA; RANKIN, JA; BOYARS, MC; LETTBROWN, MA; GRANT, JA			SENSITIVITY OF BASOPHILS TO HISTAMINE RELEASING FACTOR(S) OF VARIOUS ORIGIN - DEPENDENCY ON ALLERGIC PHENOTYPE OF THE DONOR AND SURFACE-BOUND IGE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV TEXAS,MED BRANCH,DEPT MED,DIV ALLERGY IMMUNOL,GALVESTON,TX 77550; UNIV TEXAS,MED BRANCH,DEPT MED,DIV PULM,GALVESTON,TX 77550; YALE UNIV,SCH MED,NEW HAVEN,CT 06510; W HAVEN VET HOSP,RES SERV,DIV PULM MED,NEW HAVEN,CT	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Yale University					NIAID NIH HHS [AI-22940] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022940] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALAM R, 1989, J ALLERGY CLIN IMMUN, V83, P236; ALAM R, 1985, IMMUNOL LETT, V11, P111, DOI 10.1016/0165-2478(85)90152-X; ALAM R, 1989, J IMMUNOL, V142, P3431; ALAM R, 1987, J ALLERGY CLIN IMMUN, V79, P103, DOI 10.1016/S0091-6749(87)80023-4; ALAM R, 1989, J IMMUNOL, V142, P3951; BAEZA ML, 1988, J IMMUNOL, V141, P2688; BRZEZINSKABLASZCZYK E, 1987, AGENTS ACTIONS, V21, P26, DOI 10.1007/BF01974916; BUSSE WW, 1986, J ALLERGY CLIN IMMUN, V78, P90, DOI 10.1016/0091-6749(86)90119-3; FINDLAY SR, 1980, AM REV RESPIR DIS, V122, P53; GITTLEN SD, 1988, FASEB J, V2, pA1232; HAAKFRENDSCHO M, 1988, J CLIN INVEST, V82, P17, DOI 10.1172/JCI113567; LETTBROWN MA, 1984, CELL IMMUNOL, V87, P445, DOI 10.1016/0008-8749(84)90013-3; LICHTENSTEIN LM, 1988, J ALLERGY CLIN IMMUN, V81, P814, DOI 10.1016/0091-6749(88)90936-0; MACDONALD SM, 1989, J IMMUNOL, V142, P3527; MACDONALD SM, 1987, J IMMUNOL, V139, P506; MCCLEAN SP, 1989, J ALLERGY CLIN IMMUN, V83, P236; NEIJENS HJ, 1984, AM REV RESPIR DIS, V130, P744; ORCHARD MA, 1986, J IMMUNOL, V136, P2240; PRUZANSKY JJ, 1983, J IMMUNOL, V131, P1949; RANKIN JA, 1989, J CLIN INVEST, V83, P1691, DOI 10.1172/JCI114069; SCHULMAN ES, 1988, J IMMUNOL, V140, P2369; SUBRAMANIAN N, 1987, J IMMUNOL, V138, P271; THUESON DO, 1979, J IMMUNOL, V123, P633; THUESON DO, 1979, J IMMUNOL, V123, P626; WARNER JA, 1986, J IMMUNOL, V136, P2583; WHITE MV, 1989, J ALLERGY CLIN IMMUN, V83, P237; WHITE MV, 1987, J IMMUNOL, V139, P1624; WHITE MV, 1988, J IMMUNOL, V141, P3575	28	20	20	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1990	86	1					73	81		10.1016/S0091-6749(05)80125-3	http://dx.doi.org/10.1016/S0091-6749(05)80125-3			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DQ688	1695233				2022-12-18	WOS:A1990DQ68800011
J	DEGROOT, H; VANSWIETEN, P; AALBERSE, RC				DEGROOT, H; VANSWIETEN, P; AALBERSE, RC			EVIDENCE FOR A FEL-D-I-LIKE MOLECULE IN THE BIG CATS (FELIDAE SPECIES)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,PUBLICAT SECRETARIAT,POB 9406,1006 AK AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,EXPTL & CLIN IMMUNOL LAB,AMSTERDAM,NETHERLANDS	University of Amsterdam								AALBERSE RC, 1981, J ALLERGY CLIN IMMUN, V68, P356, DOI 10.1016/0091-6749(81)90133-0; AALBERSE RC, 1980, ALLERGY, V35, P236, DOI 10.1111/j.1398-9995.1980.tb01759.x; AALBERSE RC, 1983, CLIN REV ALLERG, V1, P289; Blamoutier, 1963, REV FRANC ALLERGY, V3, P115; BRUYNZEEL PLB, 1979, INT ARCH ALLER A IMM, V58, P344, DOI 10.1159/000232211; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; COLLIER GE, 1985, EVOLUTION, V39, P473, DOI 10.1111/j.1558-5646.1985.tb00389.x; DEGROOT H, 1988, J ALLERGY CLIN IMMUN, V82, P778, DOI 10.1016/0091-6749(88)90079-6; HEINER DC, 1980, J ALLERGY CLIN IMMUN, V65, P201; HUSSAIN R, 1986, J IMMUNOL, V136, P1859; LEITERMANN K, 1984, J ALLERGY CLIN IMMUN, V74, P147, DOI 10.1016/0091-6749(84)90278-1; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; MUNROASHMAN D, 1963, ACTA ALLERGOL, V18, P168, DOI 10.1111/j.1398-9995.1963.tb03159.x; OHMAN JL, 1976, CLIN ALLERGY, V6, P419, DOI 10.1111/j.1365-2222.1976.tb01926.x; OHMAN JL, 1974, J IMMUNOL, V113, P1668; PERELMUTTER L, 1983, CLIN REV ALLERG, V1, P267; ROWNTREE S, 1987, J ALLERGY CLIN IMMUN, V80, P622, DOI 10.1016/0091-6749(87)90017-0; SIRAGANIAN RP, 1975, J IMMUNOL METHODS, V7, P283, DOI 10.1016/0022-1759(75)90025-3; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; SPICER AJ, 1969, BRIT MED J, V1, P116, DOI 10.1136/bmj.1.5636.116; STAPEL SO, UNPUB AALBERSE RC IG; VANDERZEE JS, 1988, J ALLERGY CLIN IMMUN, V82, P270, DOI 10.1016/0091-6749(88)91011-1; VANDERZEE JS, 1988, J ALLERGY CLIN IMMUN, V81, P884, DOI 10.1016/0091-6749(88)90946-3	23	20	20	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1990	86	1					107	116		10.1016/S0091-6749(05)80130-7	http://dx.doi.org/10.1016/S0091-6749(05)80130-7			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DQ688	1695231	Bronze			2022-12-18	WOS:A1990DQ68800016
J	GERRITSEN, J; KOETER, GH; DEMONCHY, JGR; CAMPAGNE, JGV; KNOL, K				GERRITSEN, J; KOETER, GH; DEMONCHY, JGR; CAMPAGNE, JGV; KNOL, K			CHANGE IN AIRWAY RESPONSIVENESS TO INHALED HOUSE DUST FROM CHILDHOOD TO ADULTHOOD	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SOPHIA HOSP,ZWOLLE,NETHERLANDS; STATE UNIV GRONINGEN HOSP,DEPT INTERNAL MED,DIV PULMONOL,9713 EZ GRONINGEN,NETHERLANDS; STATE UNIV GRONINGEN HOSP,DEPT INTERNAL MED,DIV ALLERGY,9713 EZ GRONINGEN,NETHERLANDS	University of Groningen; University of Groningen	GERRITSEN, J (corresponding author), STATE UNIV GRONINGEN HOSP,DEPT PEDIAT,DIV PEDIAT PULMONOL,59 OOSTERSINGEL,9713 EZ GRONINGEN,NETHERLANDS.							ATKINS PC, 1978, J ALLERGY CLIN IMMUN, V62, P149, DOI 10.1016/0091-6749(78)90099-4; BARBEE RA, 1987, J ALLERGY CLIN IMMUN, V79, P16, DOI 10.1016/S0091-6749(87)80010-6; BOOIJ-NOORD H, 1972, Clinical Allergy, V2, P43, DOI 10.1111/j.1365-2222.1972.tb01267.x; BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P399, DOI 10.1016/0091-6749(83)90069-6; BRONSKY EA, 1969, PEDIATR CLIN N AM, V16, P85; CAMPAGNE JGV, 1972, THESIS ASSEN; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; COCKCROFT DW, 1983, LANCET, V2, P253; de Vries K, 1968, Bronches, V18, P439; DEMONCHY JGR, 1985, AGENTS ACTIONS, V16, P252; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DEMONCHY JGR, 1986, THESIS GRONINGEN, P145; DEVRIES K, 1962, INT ARCH ALLER A IMM, V20, P93, DOI 10.1159/000229248; DURHAM SR, 1984, J ALLERGY CLIN IMMUN, V74, P49, DOI 10.1016/0091-6749(84)90086-1; EISER NM, 1983, B EUR PHYSIOPATH RES, V19, P495; GERRITSEN J, 1990, J ALLERGY CLIN IMMUN, V85, P116, DOI 10.1016/0091-6749(90)90232-S; GERRITSEN J, 1989, BRONCHITIS, V4, P337; GOKEMEIJER JDM, 1976, THESIS GRONINGEN; HERXHEIMER H, 1952, INT ARCH ALLER A IMM, V3, P323, DOI 10.1159/000227979; KALINER MM, 1984, J ALLERGY CLIN IMMUN, V73, P311, DOI 10.1016/0091-6749(84)90401-9; KEYZER JJ, 1984, J ALLERGY CLIN IMMUN, V74, P240, DOI 10.1016/0091-6749(84)90252-5; KNOL K, 1965, THESIS GRONINGEN; LAM S, 1983, J ALLERGY CLIN IMMUN, V72, P134, DOI 10.1016/0091-6749(83)90520-1; MARTIN AJ, 1980, BRIT MED J, V280, P1397, DOI 10.1136/bmj.280.6229.1397; METZGER WJ, 1985, CLIN REV ALLERG, V3, P145, DOI 10.1007/BF02992980; NAGY L, 1982, NEW ENGL J MED, V306, P497, DOI 10.1056/NEJM198203043060901; QUANJER PH, 1983, B EUR PHYSIOPATHOL S, V19, P5; ROBERTSON DG, 1974, J ALLERGY CLIN IMMUN, V54, P244, DOI 10.1016/0091-6749(74)90067-0; SPECTOR S, 1979, J ALLERGY CLIN IMMUN, V64, P580, DOI 10.1016/0091-6749(79)90016-2; VANDERLENDE R, 1972, SCAND J RESPIR DIS, V53, P218; VANLOOKERENCAMP.JG, 1969, SCAND J RESPIR DIS, V50, P76; WARNER JO, 1978, LANCET, V2, P912; WILLIAMS H, 1969, BRIT MED J, V4, P321, DOI 10.1136/bmj.4.5679.321; Zapletal A, 1987, PROGR RESPIRATION RE, P114; [No title captured]	36	20	20	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1990	85	6					1083	1089		10.1016/0091-6749(90)90054-8	http://dx.doi.org/10.1016/0091-6749(90)90054-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DK509	1693930				2022-12-18	WOS:A1990DK50900015
J	VENABLES, KM; TAYLOR, AJN				VENABLES, KM; TAYLOR, AJN			EXPOSURE-RESPONSE RELATIONSHIPS IN ASTHMA CAUSED BY TETRACHLOROPHTHALIC ANHYDRIDE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											VENABLES, KM (corresponding author), BROMPTON HOSP,NATL HEART & LUNG INST,DEPT OCCUPAT MED,FULHAM RD,LONDON SW3 6HP,ENGLAND.							CHANYEUNG M, 1973, AM REV RESPIR DIS, V108, P1094; CHESTER EH, 1977, CLIN ALLERGY, V7, P15, DOI 10.1111/j.1365-2222.1977.tb01419.x; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COTES JE, 1979, LUNG FUNCTION ASSESS; EUROPE SAM, 1977, MATERIAL SAFETY DATA; FAWCETT IW, 1977, CLIN ALLERGY, V7, P1, DOI 10.1111/j.1365-2222.1977.tb01418.x; HENDRICK DJ, 1988, THORAX, V43, P501, DOI 10.1136/thx.43.6.501; HOWE W, 1983, J ALLERGY CLIN IMMUN, V71, P5, DOI 10.1016/0091-6749(83)90539-0; KERN RICHARD A., 1939, JOUR ALLERGY, V10, P164, DOI 10.1016/S0021-8707(39)90050-X; LAM S, 1983, J ALLERGY CLIN IMMUN, V72, P134, DOI 10.1016/0091-6749(83)90520-1; OHTA T, 1978, JPN J IND HEALTH, V20, P228; PURNELL CJ, 1982, 2 P INT C AN TECHN E, P203; SCHLUETER DP, 1978, J OCCUP ENVIRON MED, V20, P183, DOI 10.1097/00043764-197803000-00006; VENABLES KM, 1987, J ALLERGY CLIN IMMUN, V80, P212, DOI 10.1016/0091-6749(87)90131-X; VENABLES KM, 1989, BRIT J IND MED, V46, P222; WARD MJ, 1983, CLIN ALLERGY, V13, P154; YEUNG M, 1985, THORAX, V40, P241, DOI 10.1136/thx.40.4.241	18	20	20	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1990	85	1	1				55	58		10.1016/0091-6749(90)90221-O	http://dx.doi.org/10.1016/0091-6749(90)90221-O			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CM378	2299106				2022-12-18	WOS:A1990CM37800009
J	ZORA, JA; SWANSON, MC; YUNGINGER, JW				ZORA, JA; SWANSON, MC; YUNGINGER, JW			A STUDY OF THE PREVALENCE AND CLINICAL-SIGNIFICANCE OF VENOM-SPECIFIC IGE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO CLIN & MAYO FDN,ALLERG DIS RES LAB,406 GUGGENHEIM BLDG,ROCHESTER,MN 55905; MAYO GRAD SCH MED,MAYO MED SCH,DEPT PEDIAT,ROCHESTER,MN 55901; MAYO GRAD SCH MED,MAYO MED SCH,DEPT INTERNAL MED ALLERGY,ROCHESTER,MN 55901	Mayo Clinic; Mayo Clinic; Mayo Clinic					NCRR NIH HHS [RR-585] Funding Source: Medline; NIAID NIH HHS [AI-21398] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021398] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adolphson C. R., 1986, MANUAL CLIN LABORATO, P652; GEORGITIS JW, 1985, J ALLERGY CLIN IMMUN, V76, P803, DOI 10.1016/0091-6749(85)90752-3; GOLDEN D B K, 1982, Journal of Allergy and Clinical Immunology, V69, P124; HERBERT FA, 1982, ANN ALLERGY, V48, P12; HOFFMAN DR, 1979, ANN ALLERGY, V43, P211; HOFFMAN DR, 1983, J ALLERGY CLIN IMMUN, V71, P193, DOI 10.1016/0091-6749(83)90099-4; HOFFMAN DR, 1979, ANN ALLERGY, V42, P224; HUNT KJ, 1976, ANN INTERN MED, V85, P56, DOI 10.7326/0003-4819-85-1-56; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; JARISCH R, 1982, ARCH DERMATOL RES, V273, P173; LICHTENSTEIN LM, 1979, J ALLERGY CLIN IMMUN, V64, P5, DOI 10.1016/0091-6749(79)90075-7; NORMAN PS, 1983, ALLERGY PRINCIPLES P, P295; PARKER JL, 1982, J ALLERGY CLIN IMMUN, V69, P200, DOI 10.1016/0091-6749(82)90100-2; PATRIZZI R, 1979, ALLERGY, V34, P249, DOI 10.1111/j.1398-9995.1979.tb01705.x; SANTRACH PJ, 1980, ANN ALLERGY, V45, P130; SETTIPANE GA, 1970, ACTA ALLERGOL, V25, P286, DOI 10.1111/j.1398-9995.1970.tb01264.x; SETTIPANE GA, 1972, J ALLERGY CLIN IMMUN, V50, P146, DOI 10.1016/0091-6749(72)90045-0; SOBOTKA AK, 1978, J IMMUNOL, V121, P2477; STUCKEY M, 1982, LANCET, V2, P41; SWANSON MC, 1985, J ALLERGY CLIN IMMUN, V76, P724, DOI 10.1016/0091-6749(85)90678-5	20	20	22	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1988	81	1					77	82		10.1016/0091-6749(88)90223-0	http://dx.doi.org/10.1016/0091-6749(88)90223-0			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M0274	3339194				2022-12-18	WOS:A1988M027400012
J	CHANYEUNG, M; CHAN, H; SALARI, H; WALL, R; TSE, KS				CHANYEUNG, M; CHAN, H; SALARI, H; WALL, R; TSE, KS			GRAIN-DUST EXTRACT INDUCED DIRECT RELEASE OF MEDIATORS FROM HUMAN-LUNG TISSUE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV BRITISH COLUMBIA,VANCOUVER GEN HOSP,DEPT MED,DIV RESP,VANCOUVER V5Z 1M9,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT PHARMACOL,VANCOUVER V6T 1W5,BC,CANADA	University of British Columbia; University of British Columbia								BORGEAT P, 1985, ADV LIPID RES, V21, P47; CHANYEUNG M, 1980, AM REV RESPIR DIS, V121, P329; CHANYEUNG M, 1979, CHEST, V75, P461, DOI 10.1378/chest.75.4.461; CHANYEUNG M, 1985, P INT S HLTH SAFETY; COREY P, 1982, BRIT J IND MED, V39, P330; DASILVA WD, 1967, J EXP MED, V126, P1027, DOI 10.1084/jem.126.6.1027; DAVIES RJ, 1976, AM REV RESPIR DIS, V114, P1011; DOPICO GA, 1983, AM REV RESPIR DIS, V128, P399, DOI 10.1164/arrd.1983.128.3.399; DOPICO GA, 1982, CHEST, V81, P55, DOI 10.1378/chest.81.1.55; EGGLESTON PA, 1984, AM REV RESPIR DIS, V130, P86; ENARSON D, UNPUB RELATIONSHIP E; KRUGER PG, 1982, ACTA PHYSIOL SCAND, V114, P467, DOI 10.1111/j.1748-1716.1982.tb07011.x; MAIER RV, 1981, PROGR CLIN BIOL RES, V62, P123; MELL LD, 1979, J LIQ CHROMATOGR, V2, P1393, DOI 10.1080/01483917908060145; MUNDIE TG, 1986, AM REV RESPIR DIS, V133, P1181; OLENCHOCK SA, 1980, ANN ALLERGY, V44, P23; OLENCHOCK SA, 1978, J ALLERGY CLIN IMMUN, V62, P295, DOI 10.1016/0091-6749(78)90161-6; Ramazzini B, 1940, DEMORBIS ARTIFICIUM; SALARI H, 1986, J CHROMATOGR, V378, P35, DOI 10.1016/S0378-4347(00)80697-0; SALARI H, 1987, CLIN EXP IMMUNOL, V67, P211; SALARI H, 1985, J EXP MED, V162, P1904, DOI 10.1084/jem.162.6.1904; SALARI H, 1986, IMMUNOLOGY, V58, P222; SHANAHAN F, 1984, J ALLERGY CLIN IMMUN, V74, P499, DOI 10.1016/0091-6749(84)90385-3; TABONA M, 1984, CHEST, V85, P782, DOI 10.1378/chest.85.6.782; WALL RA, UNPUB HISTAMINE ASSA; WARREN CPW, 1984, P C AGR DUST NEW ORL; WARREN P, 1974, J ALLERGY CLIN IMMUN, V53, P139, DOI 10.1016/0091-6749(74)90002-5	27	20	20	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1987	80	3	1				279	284		10.1016/0091-6749(87)90032-7	http://dx.doi.org/10.1016/0091-6749(87)90032-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K1036	2442234	Bronze			2022-12-18	WOS:A1987K103600008
J	HINDIALEXANDER, MC				HINDIALEXANDER, MC			ASTHMA EDUCATION-PROGRAMS - THEIR ROLE IN ASTHMA MORBIDITY AND MORTALITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SUNY BUFFALO,DEPT MED,DIV ALLERGY,BUFFALO,NY 14260	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo								BELLIA V, 1984, RESPIRATION, V46, P328, DOI 10.1159/000194707; BURDON JGW, 1982, AM REV RESPIR DIS, V126, P825; BURKI NK, 1984, AM REV RESPIR DIS, V129, P225; CHAI H, 1968, J ALLERGY, V41, P23, DOI 10.1016/0021-8707(68)90005-1; HALFON N, 1986, AM J PUBLIC HEALTH, V76, P1308, DOI 10.2105/AJPH.76.11.1308; HINDIALEXANDER M, 1987, 33RD ANN M AM AC ALL; HINDIALEXANDER MC, 1984, J ALLERGY CLIN IMMUN, V74, P505, DOI 10.1016/0091-6749(84)90386-5; HINDIALEXANDER MC, 1986, NEW ENGL REG ALLERGY, V7, P462; HINDIALEXANDER MC, 1985, CHEST, V87, pS100; HOLROYD KA, 1986, SELF MANAGEMENT CHRO; LI JTC, 1985, AM J MED, V79, P10, DOI 10.1016/0002-9343(85)90081-6; NEWACHECK PW, 1986, AM J PUBLIC HEALTH, V76, P178, DOI 10.2105/AJPH.76.2.178; OLSON LG, 1984, AUST NZ J MED, V14, P231, DOI 10.1111/j.1445-5994.1984.tb03756.x; RUBINFELD AR, 1976, LANCET, V1, P882; RUBINFELD AR, 1977, CHEST, V72, P154, DOI 10.1378/chest.72.2.154; SHIM CS, 1980, AM J MED, V68, P11, DOI 10.1016/0002-9343(80)90155-2; SHIM CS, 1983, ARCH INTERN MED, V143, P890; SLY PD, 1985, AM J DIS CHILD, V139, P479, DOI 10.1001/archpedi.1985.02140070053032; TAPLIN PS, 1978, J ASTHMA RES, V16, P15, DOI 10.3109/02770907809106608; WILLIAMS MH, 1982, HOSP PRACT       OCT, P95; 1983, THORAX, V38, P801; 1983, J ALLERGY CLIN IMMUN, V72, P555; 1985, MED SCI UPDATE, V4, P7; 1984, PHS1982 US DEP HLTH, P33	24	20	20	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1987	80	3	2	S			492	494		10.1016/0091-6749(87)90083-2	http://dx.doi.org/10.1016/0091-6749(87)90083-2			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	K1037	3624704	Bronze			2022-12-18	WOS:A1987K103700030
J	OHMAN, JL; LORUSSO, JR; LEWIS, S				OHMAN, JL; LORUSSO, JR; LEWIS, S			CAT ALLERGEN CONTENT OF COMMERCIAL HOUSE DUST EXTRACTS - COMPARISON WITH DUST EXTRACTS FROM CAT-CONTAINING ENVIRONMENT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									VET ADM OUTPATIENT CLIN,ALLERGY LAB,BOSTON,MA 02108; TUFTS UNIV,SCH MED,BOSTON,MA 02111	Tufts University					NIAID NIH HHS [P50 AI-18023-02] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI018023] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARDANA EJ, 1972, J ALLERGY CLIN IMMUN, V50, P208, DOI 10.1016/0091-6749(72)90015-2; BERNSTEI.IL, 1973, J ALLERGY CLIN IMMUN, V51, P22, DOI 10.1016/0091-6749(73)90004-3; KAWAI T, 1972, J ALLERGY CLIN IMMUN, V50, P117, DOI 10.1016/0091-6749(72)90007-3; LEITERMANN K, 1984, J ALLERGY CLIN IMMUN, V74, P147, DOI 10.1016/0091-6749(84)90278-1; LORUSSO JR, 1986, J ALLERGY CLIN IMMUN, V77, P130; MCCULLOUGH JA, 1986, J ALLERGY CLIN IMMUN, V77, P130; OHMAN JL, 1976, CLIN ALLERGY, V6, P419, DOI 10.1111/j.1365-2222.1976.tb01926.x; OHMAN JL, 1983, J ALLERGY CLIN IMMUN, V72, P288, DOI 10.1016/0091-6749(83)90033-7; PAULI B, 1979, J ALLERGY CLIN IMMUN, V64, P245; PEPYS J, 1968, LANCET, V1, P1270; SCHWARTZ B, 1986, J ALLERGY CLIN IMMUN, V77, P203; SIRAGANIAN RP, 1979, J ALLERGY CLIN IMMUN, V64, P526, DOI 10.1016/0091-6749(79)90063-0	12	20	20	1	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1987	79	6					955	959		10.1016/0091-6749(87)90246-6	http://dx.doi.org/10.1016/0091-6749(87)90246-6			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	H9044	3584750				2022-12-18	WOS:A1987H904400018
J	LOWENSTEIN, H; GRAVESEN, S; LARSEN, L; LIND, P; SCHWARTZ, B				LOWENSTEIN, H; GRAVESEN, S; LARSEN, L; LIND, P; SCHWARTZ, B			INDOOR ALLERGENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											LOWENSTEIN, H (corresponding author), PROT LAB,SIGURDSGADE 34,DK-2200 COPENHAGEN N,DENMARK.							Al-Doory Y, 1984, MOULD ALLERGY; AUKRUST L, 1985, Allergy (Copenhagen), V40, P43, DOI 10.1111/j.1398-9995.1985.tb02641.x; BARTHOLOME K, 1984, Journal of Allergy and Clinical Immunology, V73, P160; CARLSEN SD, 1979, ALLERGY, V34, P155, DOI 10.1111/j.1398-9995.1979.tb01563.x; CHAPMAN MD, 1980, J IMMUNOL, V125, P587; FORD AW, 1985, INT ARCH ALLER A IMM, V76, P58, DOI 10.1159/000233662; GRAVESEN S, 1972, ACTA ALLERGOL, V27, P337, DOI 10.1111/j.1398-9995.1972.tb01433.x; GRAVESEN S, 1978, ALLERGY, V33, P268, DOI 10.1111/j.1398-9995.1978.tb01547.x; Gravesen S, 1983, Ecol Dis, V2, P411; GRAVESEN S, 1979, ALLERGY, V34, P135, DOI 10.1111/j.1398-9995.1979.tb01562.x; GRAVESEN S, 1986, ALLERGY, V41, P27; GRAVESEN S, 1979, 10 P INT C ALL JER; GRAVESEN S, 1982, ALLERGY, V37, P1; Halmai Z, 1971, Allerg Immunol (Leipz), V17, P69; HOFFMAN DR, 1981, ANN ALLERGY, V46, P310; KAUFFMAN JF, 1984, J ALLERGY CLIN IMMUN, V73, P567; KJELLMAN B, 1983, ALLERGY, V38, P65, DOI 10.1111/j.1398-9995.1983.tb00858.x; KOIVIKKO A, 1985, ALLERGY S3, V40, P1; KORSGAARD J, 1983, ALLERGY, V38, P85, DOI 10.1111/j.1398-9995.1983.tb01591.x; LARSEN LS, 1981, ALLERGY, V36, P15, DOI 10.1111/j.1398-9995.1981.tb01819.x; LIND P, 1985, J ALLERGY CLIN IMMUN, V76, P753, DOI 10.1016/0091-6749(85)90682-7; LIND P, 1979, ALLERGY, V34, P319; LIND P, 1984, ALLERGY, V39, P259, DOI 10.1111/j.1398-9995.1984.tb00863.x; LIND P, 1984, ALLERGY S, V2, P39; LONGBOTTOM JL, 1983, 11 P INT C ALL CLIN, P525; LOWENSTEIN H, 1985, ALLERGY, V40, P430, DOI 10.1111/j.1398-9995.1985.tb02682.x; Lowenstein H, 1983, 11 P INT C ALL CLIN, P545; LOWENSTEIN H, 1979, 1ST P INT WHO IND CL; MARSH DG, 1975, ANTIGENS, V3, P271; MAUNSELL K, 1968, LANCET, V1, P1267; MITCHELL WF, 1969, ANN ALLERGY, V27, P93; MIYAMOTO T, 1968, J ALLERGY, V42, P14, DOI 10.1016/0021-8707(68)90128-7; NYHOLM L, 1983, J ALLERGY CLIN IMMUN, V71, P461, DOI 10.1016/0091-6749(83)90462-1; PRAHL P, 1981, ALLERGY, V36, P561, DOI 10.1111/j.1398-9995.1981.tb01874.x; RAO V R M, 1975, Clinical Allergy, V5, P209, DOI 10.1111/j.1365-2222.1975.tb01854.x; RUDOLPH R, 1983, 11 P INT C ALL CLIN, P437; SCHWARTZ B, 1984, Journal of Allergy and Clinical Immunology, V73, P156; STEWART GA, 1982, INT ARCH ALLER A IMM, V69, P224, DOI 10.1159/000233175; TOVEY ER, 1981, AM REV RESPIR DIS, V124, P630; TOVEY ER, 1981, NATURE, V289, P592, DOI 10.1038/289592a0; VANTO T, 1983, ACTA PAEDIATR SCAND, V72, P571, DOI 10.1111/j.1651-2227.1983.tb09773.x; VIANDER M, 1983, INT ARCH ALLER A IMM, V71, P252, DOI 10.1159/000233399; VOORHORST R, 1967, HOUSE DUST ATOPY HOU; WILKENJENSEN K, 1984, ATLAS MOULDS EUROPE	44	20	20	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1986	78	5	2	S			1035	1039		10.1016/0091-6749(86)90300-3	http://dx.doi.org/10.1016/0091-6749(86)90300-3			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	E9719	3782664				2022-12-18	WOS:A1986E971900021
J	PLAUT, M; KAZIMIERCZAK, W; LICHTENSTEIN, LM				PLAUT, M; KAZIMIERCZAK, W; LICHTENSTEIN, LM			ABNORMALITIES OF BASOPHIL RELEASABILITY IN ATOPIC AND ASTHMATIC INDIVIDUALS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											PLAUT, M (corresponding author), JOHNS HOPKINS UNIV,GOOD SAMARITAN HOSP,SCH MED,DEPT MED,DIV CLIN IMMUNOL,5601 LOCH RAVEN BLVD,BALTIMORE,MD 21239, USA.				NIAID NIH HHS [AI 12810, AI 08270, AI 02790] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI008270, R37AI008270] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BANKS J, 1984, Journal of Allergy and Clinical Immunology, V73, P184; BEER DJ, 1984, J ALLERGY CLIN IMMUN, V73, P439, DOI 10.1016/0091-6749(84)90353-1; BIAS WB, 1978, GENETIC DETERMINANTS, P127; BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P399, DOI 10.1016/0091-6749(83)90069-6; BOUSHEY HA, 1980, AM REV RESPIR DIS, V121, P389; CANONICA GW, 1979, J IMMUNOL, V123, P2669; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; COCKCROFT DW, 1979, AM REV RESPIR DIS, V120, P1053; CONOLLY ME, 1976, J CLIN INVEST, V58, P1307, DOI 10.1172/JCI108586; CONROY MC, 1977, J IMMUNOL, V118, P1317; CZARNETZKI BM, 1976, J INVEST DERMATOL, V67, P276, DOI 10.1111/1523-1747.ep12514261; DAHLEN SE, 1983, P NATL ACAD SCI-BIOL, V80, P1712, DOI 10.1073/pnas.80.6.1712; FINDLAY SR, 1980, AM REV RESPIR DIS, V122, P53; FOREMAN JC, 1979, J PHARMACOL EXP THER, V210, P75; GALANT SP, 1978, NEW ENGL J MED, V299, P933, DOI 10.1056/NEJM197810262991707; GERBLICH AA, 1984, NEW ENGL J MED, V310, P1349, DOI 10.1056/NEJM198405243102103; GILLESPIE E, 1972, J CLIN INVEST, V51, P2941, DOI 10.1172/JCI107118; GOLDSTEIN B, 1979, J IMMUNOL, V123, P1873; GRANT JA, 1977, J ALLERGY CLIN IMMUN, V60, P306, DOI 10.1016/0091-6749(77)90110-5; GREAVES MW, 1974, CLIN ALLERGY, V4, P265, DOI 10.1111/j.1365-2222.1974.tb01384.x; HSIEH KH, 1980, ANN ALLERGY, V44, P177; ISHIZAKA K, 1983, LYMPHOKINES, V8, P41; ISHIZAKA K, 1983, ALLERGY PRINCIPLES P, P43; KALINER M, 1982, ANN INTERN MED, V96, P349, DOI 10.7326/0003-4819-96-3-349; KAPLAN AP, 1978, J ALLERGY CLIN IMMUN, V61, P350, DOI 10.1016/0091-6749(78)90113-6; KATZ DH, 1980, IMMUNOLOGY, V41, P1; KAZIMIERCZAK W, 1984, AM REV RESPIR DIS, V129, P592; KAZIMIERCZAK W, 1984, J IMMUNOL, V132, P399; KAZIMIERCZAK W, 1983, J ALLERGY CLIN IMMUN, V71, P93, DOI 10.1016/0091-6749(83)90141-0; KERN F, 1976, J CLIN INVEST, V57, P1369, DOI 10.1172/JCI108405; KNAUER KA, 1984, INT ARCH ALLER A IMM, V74, P29, DOI 10.1159/000233511; LAM S, 1979, J ALLERGY CLIN IMMUN, V63, P28, DOI 10.1016/0091-6749(79)90158-1; LEE TH, 1984, AM REV RESPIR DIS, V129, P409; LEE TH, 1982, J CLIN INVEST, V69, P889, DOI 10.1172/JCI110528; LICHTENS.LM, 1968, AM J MED, V44, P514, DOI 10.1016/0002-9343(68)90052-1; LICHTENSTEIN LM, 1984, AM REV RESPIR DIS, V129, P657, DOI 10.1164/arrd.1984.129.5.657; MALVEAUX FJ, 1978, J CLIN INVEST, V62, P176, DOI 10.1172/JCI109103; MARSH DG, 1981, NEW ENGL J MED, V305, P1551, DOI 10.1056/NEJM198112243052603; MAY CD, 1982, CLIN ALLERGY, V12, P229, DOI 10.1111/j.1365-2222.1982.tb02523.x; MCFADDEN ER, 1984, J ALLERGY CLIN IMMUN, V73, P413, DOI 10.1016/0091-6749(84)90347-6; MEURS H, 1982, J ALLERGY CLIN IMMUN, V70, P272, DOI 10.1016/0091-6749(82)90063-X; MURRAY AB, 1983, PEDIATRICS, V71, P418; NAGY L, 1982, NEW ENGL J MED, V306, P497, DOI 10.1056/NEJM198203043060901; ODONNELL MC, 1983, J EXP MED, V157, P1981, DOI 10.1084/jem.157.6.1981; PETERS SP, 1985, INT ARCH ALLER A IMM, V76, P344, DOI 10.1159/000233719; PLATTSMILLS TAE, 1982, LANCET, V2, P675; SAMPSON HA, 1983, J ALLERGY CLIN IMMUN, V71, P473, DOI 10.1016/0091-6749(83)90464-5; SANO Y, 1983, J ALLERGY CLIN IMMUN, V72, P495, DOI 10.1016/0091-6749(83)90587-0; SCHLEIMER RP, 1982, J IMMUNOL, V129, P1632; SCHULMAN ES, 1985, AM REV RESPIR DIS, V131, P230; SIRAGANIAN RP, 1977, J IMMUNOL, V119, P2078; STILES GL, 1984, PHYSIOL REV, V64, P661, DOI 10.1152/physrev.1984.64.2.661; TUNG R, 1982, J IMMUNOL, V128, P2067; VENTER JC, 1980, SCIENCE, V207, P1361, DOI 10.1126/science.6153472; VLAGOPOULOS P, 1980, J ALLERGY CLIN IMMUN, V65, P212	55	20	20	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1986	78	5	2	S			968	973		10.1016/0091-6749(86)90287-3	http://dx.doi.org/10.1016/0091-6749(86)90287-3			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	E9719	2431023				2022-12-18	WOS:A1986E971900008
J	REYNOLDS, HY				REYNOLDS, HY			LUNG IMMUNOLOGY AND ITS CONTRIBUTION TO THE IMMUNOPATHOGENESIS OF CERTAIN RESPIRATORY-DISEASES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											REYNOLDS, HY (corresponding author), YALE UNIV,SCH MED,PULM SECT,NEW HAVEN,CT 06510, USA.				PHS HHS [22302] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AALBERSE RC, 1983, J IMMUNOL, V130, P722; BECK CS, 1981, AM REV RESPIR DIS, V124, P94; CALVANICO NJ, 1980, J LAB CLIN MED, V96, P129; COHEN AB, 1971, J CLIN INVEST, V50, P1390, DOI 10.1172/JCI106622; DANIELE RP, 1975, J CLIN INVEST, V56, P986, DOI 10.1172/JCI108179; DAVIS GS, 1982, AM REV RESPIR DIS, V126, P611; DELACROIX DL, 1982, IMMUNOLOGY, V47, P383; DOHN MN, 1985, AM REV RESPIR DIS, V132, P390; FALK GA, 1972, AM REV RESPIR DIS, V105, P14; FICK RB, 1986, AM REV RESPIR DIS, V133, P418; HALPERN GM, 1984, IMMUNOL ALLERGY PRAC, V6, P246; HANCE AJ, 1985, J IMMUNOL, V134, P284; HEINER DC, 1984, AM J MED, V76, P1, DOI 10.1016/0002-9343(84)90313-9; HOLIAN A, 1983, J RETICULOENDOTH SOC, V33, P157; HORWITZ MA, 1981, J EXP MED, V153, P398, DOI 10.1084/jem.153.2.398; HORWITZ MA, 1981, J EXP MED, V153, P386, DOI 10.1084/jem.153.2.386; HORWITZ MA, 1983, J CLIN INVEST, V71, P1686, DOI 10.1172/JCI110923; HORWITZ MA, 1980, J CLIN INVEST, V66, P441, DOI 10.1172/JCI109874; HUNNINGHAKE GW, 1979, AM J PATHOL, V97, P149; HUNNINGHAKE GW, 1981, NEW ENGL J MED, V305, P429, DOI 10.1056/NEJM198108203050804; KALTREIDER HB, 1976, J IMMUNOL, V116, P428; KEIMOWITZ RI, 1964, J LAB CLIN MED, V63, P54; KILIAN M, 1980, J IMMUNOL, V124, P2596; KILIAN M, 1983, B EUR PHYSIOPATH RES, V19, P99; LAWRENCE EC, 1978, J CLIN INVEST, V62, P832, DOI 10.1172/JCI109195; MANDEL MA, 1976, NEW ENGL J MED, V295, P694, DOI 10.1056/NEJM197609232951303; MERRILL W, 1986, AM REV RESPIR DIS, V133, pA392; MERRILL WW, 1980, J LAB CLIN MED, V96, P494; MERRILL WW, 1983, CLIN CHEST MED, V4, P71; MERRILL WW, 1984, AM REV RESPIR DIS, V130, P905; MERRILL WW, 1985, AM REV RESPIR DIS, V131, P584, DOI 10.1164/arrd.1985.131.4.584; MERRILL WW, 1982, AM REV RESPIR DIS, V125, pA268; MERRILL WW, 1982, AM REV RESPIR DIS, V122, P617; MORDELETDAMBRINE M, 1984, AM REV RESPIR DIS, V130, P305; MULKS MH, 1980, J INFECT DIS, V141, P450, DOI 10.1093/infdis/141.4.450; NAEGEL GP, 1984, AM REV RESPIR DIS, V129, P413; NASH TW, 1984, J CLIN INVEST, V74, P771, DOI 10.1172/JCI111493; NATHAN CF, 1980, NEW ENGL J MED, V303, P622, DOI 10.1056/NEJM198009113031106; NIEDERMAN MS, 1986, AM REV RESPIR DIS, V133, P255; OXELIUS VA, 1981, NEW ENGL J MED, V304, P1476, DOI 10.1056/NEJM198106113042408; OXELIUS VA, 1984, AM J MED, V76, P7, DOI 10.1016/0002-9343(84)90314-0; OXELIUS VA, 1982, NEW ENGL J MED, V306, P515, DOI 10.1056/NEJM198203043060905; PATTERSON R, 1980, AM REV RESPIR DIS, V96, P129; PINGLETON SK, 1983, AM REV RESPIR DIS, V128, P1035; RANKIN JA, 1986, AM REV RESPIR DIS, V133, P186; RANKIN JA, 1983, AM REV RESPIR DIS, V127, P442, DOI 10.1164/arrd.1983.127.4.442; REYNIER Y, 1984, NEUROCHIRURGIE, V30, P1; REYNOLDS HY, 1982, CHEST, V81, P626, DOI 10.1378/chest.81.5.626; REYNOLDS HY, 1975, J IMMUNOL, V114, P1813; REYNOLDS HY, 1975, J CLIN INVEST, V56, P376, DOI 10.1172/JCI108102; REYNOLDS HY, 1978, LUNG, V155, P225, DOI 10.1007/BF02730695; REYNOLDS HY, 1974, J LAB CLIN MED, V84, P559; REYNOLDS HY, 1981, CURRENT PULMONOLOGY, V3, P381; REYNOLDS HY, 1978, SECRETORY IMMUNITY I, P553; ROBINSON BWS, 1984, J CLIN INVEST, V74, P942, DOI 10.1172/JCI111513; SALTINI C, 1984, AM REV RESPIR DIS, V130, P650; SANDRON D, 1986, EUR J RESPIR DIS, V68, P177; SHELLITO J, 1985, AM REV RESPIR DIS, V131, P678; SIBER GR, 1980, NEW ENGL J MED, V303, P178, DOI 10.1056/NEJM198007243030402; STROBER W, 1976, NEW ENGL J MED, V294, P351, DOI 10.1056/NEJM197602122940701; Tomasi TB, 1985, ADV HOST DEFENSE MEC, V4, P31; UMETSU DT, 1985, NEW ENGL J MED, V313, P1247, DOI 10.1056/NEJM198511143132002; VAERMAN JP, 1966, SCIENCE, V153, P647, DOI 10.1126/science.153.3736.647; WIGGINS J, 1983, THORAX, V38, P102, DOI 10.1136/thx.38.2.102; YOUNG KR, 1985, ANN INTERN MED, V103, P522, DOI 10.7326/0003-4819-103-4-522; ZWILLING BS, 1982, AM REV RESPIR DIS, V125, P448	66	20	20	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1986	78	5	1				833	847		10.1016/0091-6749(86)90227-7	http://dx.doi.org/10.1016/0091-6749(86)90227-7			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	E9713	3537080				2022-12-18	WOS:A1986E971300002
J	ATKINS, FM				ATKINS, FM			A CRITICAL-EVALUATION OF CLINICAL-TRIALS IN ADVERSE REACTIONS TO FOODS IN ADULTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV COLORADO,SCH MED,DENVER,CO 80202	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	ATKINS, FM (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,DEP PEDIAT,1400 JACKSON,DENVER,CO 80206, USA.							ATKINS FM, 1985, J ALLERGY CLIN IMMUN, V75, P348, DOI 10.1016/0091-6749(85)90071-5; ATKINS FM, 1985, J ALLERGY CLIN IMMUN, V75, P356, DOI 10.1016/0091-6749(85)90072-7; BERNSTEIN M, 1982, J ALLERGY CLIN IMMUN, V70, P205, DOI 10.1016/0091-6749(82)90043-4; BOCK SA, 1978, J ALLERGY CLIN IMMUN, V62, P327, DOI 10.1016/0091-6749(78)90132-X; BOCK SA, 1977, CLIN ALLERGY, V7, P375, DOI 10.1111/j.1365-2222.1977.tb01466.x; Bock SA, J ALLERGY CLIN IMMUN; BUCHBINDER EM, 1983, JAMA-J AM MED ASSOC, V250, P2973, DOI 10.1001/jama.250.21.2973; COHEN SH, 1979, J ALLERGY CLIN IMMUN, V64, P270, DOI 10.1016/0091-6749(79)90143-X; FARAH DA, 1985, GUT, V26, P164, DOI 10.1136/gut.26.2.164; GOLBERT TM, 1969, J ALLERGY, V44, P96, DOI 10.1016/0021-8707(69)90005-7; GRAHAM DT, 1950, J ALLERGY, V21, P478, DOI 10.1016/0021-8707(50)90095-5; INGELFINGER FJ, 1949, NEW ENGL J MED, V241, P303, DOI 10.1056/NEJM194908252410805; KIDD JM, 1983, J ALLERGY CLIN IMMUN, V71, P407, DOI 10.1016/0091-6749(83)90070-2; LOVELESS MH, 1950, J ALLERGY, V21, P489, DOI 10.1016/0021-8707(50)90097-9; MALANSKY L, 1971, CONN MED, V35, P5; MALISH D, 1981, J ALLERGY CLIN IMMUN, V67, P35, DOI 10.1016/0091-6749(81)90042-7; MANSFIELD LE, 1983, J ALLERGY CLIN IMMUN, V71, P371, DOI 10.1016/0091-6749(83)90064-7; MAULITZ RM, 1979, J ALLERGY CLIN IMMUN, V63, P433, DOI 10.1016/0091-6749(79)90218-5; MAY CD, 1982, J ALLERGY CLIN IMMUN, V69, P255, DOI 10.1016/S0091-6749(82)80001-8; MAY CD, 1985, J ALLERGY CLIN IMMUN, V75, P329, DOI 10.1016/0091-6749(85)90067-3; NOYES JH, 1979, J ALLERGY CLIN IMMUN, V63, P242, DOI 10.1016/0091-6749(79)90107-6; PARKER JL, 1981, J ALLERGY CLIN IMMUN, V67, P78, DOI 10.1016/0091-6749(81)90050-6; PEARSON DJ, 1983, LANCET, V1, P1259; RIX KJB, 1984, BRIT J PSYCHIAT, V145, P121, DOI 10.1192/bjp.145.2.121; SAMPSON HA, 1984, J ALLERGY CLIN IMMUN, V74, P26, DOI 10.1016/0091-6749(84)90083-6; SAMPSON HA, 1983, J ALLERGY CLIN IMMUN, V71, P473, DOI 10.1016/0091-6749(83)90464-5	26	20	20	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1986	78	1	2	S			174	182		10.1016/0091-6749(86)90010-2	http://dx.doi.org/10.1016/0091-6749(86)90010-2			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	D2997	3722645	Bronze			2022-12-18	WOS:A1986D299700010
J	BURTIN, C; NOIROT, C; GIROUX, C; SCHEINMANN, P				BURTIN, C; NOIROT, C; GIROUX, C; SCHEINMANN, P			DECREASED SKIN-RESPONSE TO INTRADERMAL HISTAMINE IN CANCER-PATIENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CTR MED RECH & TRAITEMENTS DIETETIQUES FORCILLES,FEROLLES ATTILLY,FRANCE; HOP AVICENNE,SERV EXPLORAT FONCTIONNELLES PHYSIOL,F-93000 BOBIGNY,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13	BURTIN, C (corresponding author), FAC MED NECKER ENFANTS MALADES,U200,156 RUE VAUGIRARD,F-75730 PARIS 15,FRANCE.							AGUAYO AJ, 1971, ARCH NEUROL-CHICAGO, V24, P106, DOI 10.1001/archneur.1971.00480320034003; ALDERSON M, 1974, LANCET, V2, P1475; ALLEGRA J, 1976, CANCER RES, V36, P3225; AXELROD FB, 1983, DISORDERS RESPIRATOR, P872; BARBEE RA, 1981, J ALLERGY CLIN IMMUN, V68, P15, DOI 10.1016/0091-6749(81)90117-2; BURTIN C, 1983, BRIT J CANCER, V47, P367, DOI 10.1038/bjc.1983.55; BURTIN C, 1983, NEW ENGL J MED, V308, P591; BURTIN C, 1982, BRIT J CANCER, V45, P54, DOI 10.1038/bjc.1982.7; BURTIN C, 1981, CANCER LETT, V12, P195, DOI 10.1016/0304-3835(81)90068-9; BURTIN C, 1985, J NATL CANCER I, V74, P671; FISHERMAN EW, 1960, J ALLERGY, V31, P74, DOI 10.1016/0021-8707(60)90026-5; FOREMAN J, 1983, AGENTS ACTIONS, V13, P105, DOI 10.1007/BF01967311; HUGUES WF, 1979, ANN ALLERGY, V43, P163; LOGAN J, 1953, N Z Med J, V52, P210; LYNCH NR, 1978, CANCER IMMUNOL IMMUN, V4, P223; LYNCH NR, 1977, IMMUNOLOGY, V32, P645; MACKAY WD, 1966, BRIT J CANCER, V20, P434, DOI 10.1038/bjc.1966.52; MCKEE WD, 1967, J ALLERGY, V39, P294, DOI 10.1016/0021-8707(67)90093-7; MCLEOD JG, 1984, PERIPHERAL NEUROPATH, V2, P2180; MEERS PD, 1973, LANCET, V1, P884; ROSENBAUM JT, 1977, CANCER-AM CANCER SOC, V39, P11, DOI 10.1002/1097-0142(197701)39:1<11::AID-CNCR2820390104>3.0.CO;2-M; SEBILLE A, 1978, J NEUROL SCI, V38, P89, DOI 10.1016/0022-510X(78)90249-6; SILVA MRE, 1966, HDB EXPT PHARM, P238; SIMONS FER, 1984, J ALLERGY CLIN IMMUN, V73, P69, DOI 10.1016/0091-6749(84)90486-X; STUCKEY MS, 1985, J ALLERGY CLIN IMMUN, V75, P373, DOI 10.1016/0091-6749(85)90074-0; TANOOKA H, 1982, J NATL CANCER I, V69, P1305; URE DM, 1969, SCOTT MED J, V74, P51	27	20	20	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1986	78	1	1				83	89		10.1016/0091-6749(86)90118-1	http://dx.doi.org/10.1016/0091-6749(86)90118-1			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	D2996	3722637				2022-12-18	WOS:A1986D299600013
J	DAVIS, KC; MEKORI, YA; KOHLER, PF; SCHOCKET, AL				DAVIS, KC; MEKORI, YA; KOHLER, PF; SCHOCKET, AL			POSSIBLE ROLE OF DIET IN DELAYED PRESSURE URTICARIA - PRELIMINARY-REPORT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV COLORADO,SCH MED,DEPT MED,DIV CLIN IMMUNOL,BOULDER,CO 80309; PRESBYTERIAN ST LUKES MED CTR,DENVER,CO	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder								BUSH RK, 1977, CLIN ALLERGY, V7, P369, DOI 10.1111/j.1365-2222.1977.tb01465.x; DAVIS KC, 1984, J ALLERGY CLIN IMMUN, V73, P810, DOI 10.1016/0091-6749(84)90451-2; DESHAZO RD, 1979, J IMMUNOL, V122, P692; DOLOVICH J, 1972, J ALLERGY CLIN IMMUN, V49, P43, DOI 10.1016/0091-6749(72)90122-4; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; GALANT SP, 1973, CLIN ALLERGY, V3, P362; GENTON C, 1985, J ALLERGY CLIN IMMUN, V76, P40, DOI 10.1016/0091-6749(85)90802-4; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P160, DOI 10.1016/0091-6749(82)90037-9; JAMES J, 1971, BRIT J DERMATOL, V84, P227, DOI 10.1111/j.1365-2133.1971.tb14212.x; JUHLIN L, 1980, INT J DERMATOL, V19, P548, DOI 10.1111/j.1365-4362.1980.tb00802.x; SHATIN H, 1962, ARCH DERMATOL, V85, P784; SMITH JA, 1983, ANN ALLERGY, V51, P30; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; SOLOMON LM, 1966, ARCH DERMATOL, V94, P156; SUSSMAN GL, 1982, J ALLERGY CLIN IMMUN, V70, P337, DOI 10.1016/0091-6749(82)90022-7; Wadsworth A, 1938, J IMMUNOL, V35, P217	16	20	20	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1986	77	4					566	569		10.1016/0091-6749(86)90346-5	http://dx.doi.org/10.1016/0091-6749(86)90346-5			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	A9381	3958383				2022-12-18	WOS:A1986A938100006
J	SIMONS, KJ; SINGH, M; GILLESPIE, CA; SIMONS, FER				SIMONS, KJ; SINGH, M; GILLESPIE, CA; SIMONS, FER			AN INVESTIGATION OF THE H1-RECEPTOR ANTAGONIST TRIPROLIDINE - PHARMACOKINETICS AND ANTIHISTAMINIC EFFECTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MANITOBA,FAC MED,DEPT PEDIAT & CHILD HLTH,ALLERGY & CLIN IMMUNOL SECT,WINNIPEG R3T 2N2,MANITOBA,CANADA	University of Manitoba	SIMONS, KJ (corresponding author), UNIV MANITOBA,FAC PHARM,WINNIPEG R3T 2N2,MANITOBA,CANADA.							BRITTON MG, 1979, ANN ALLERGY, V42, P330; BYE C, 1974, BRIT J CLIN PHARMACO, V1, P71, DOI 10.1111/j.1365-2125.1974.tb00209.x; BYE CE, 1977, EUR J CLIN PHARMACOL, V12, P181, DOI 10.1007/BF00609857; CONNELL JT, 1982, J INT MED RES, V10, P341, DOI 10.1177/030006058201000505; DEANGELIS RL, 1977, J PHARM SCI, V66, P841, DOI 10.1002/jps.2600660627; DIAMOND L, 1981, ANN ALLERGY, V47, P87; EMPEY DW, 1975, ANN ALLERGY, V34, P41; FINDLAY JWA, 1984, J PHARM SCI, V73, P1339, DOI 10.1002/jps.2600731003; FOWLE ASE, 1971, EUR J CLIN PHARMACOL, V3, P215, DOI 10.1007/BF00565009; Gibaldi M, 1982, PHARMACOKINETICS; GOTH A, 1981, CLIN PHARM PRINCIPLE, P251; HUANG SM, 1982, EUR J CLIN PHARMACOL, V22, P359, DOI 10.1007/BF00548406; NICHOLSON AN, 1979, BRIT J CLIN PHARMACO, V8, P321, DOI 10.1111/j.1365-2125.1979.tb04712.x; PECK AW, 1975, EUR J CLIN PHARMACOL, V8, P455, DOI 10.1007/BF00562321; SIMONS FER, 1982, J ALLERGY CLIN IMMUN, V69, P376, DOI 10.1016/0091-6749(82)90149-X; SIMONS FER, 1982, J ALLERGY CLIN IMMUN, V70, P458, DOI 10.1016/0091-6749(82)90009-4; SIMONS FER, 1984, CLIN REV ALLERG, V2, P237; Steel R.G.D., 1980, PRINCIPLES STAT; THOMPSON JA, 1981, J PHARM SCI-US, V70, P1284, DOI 10.1002/jps.2600701127; YACOBI A, 1980, J PHARM SCI, V69, P1077, DOI 10.1002/jps.2600690924	20	20	21	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1986	77	2					326	330		10.1016/S0091-6749(86)80112-9	http://dx.doi.org/10.1016/S0091-6749(86)80112-9			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	A0899	3944383				2022-12-18	WOS:A1986A089900010
J	MORRIS, EC; SMITH, TF; KELLY, LB				MORRIS, EC; SMITH, TF; KELLY, LB			COCKROACH IS A SIGNIFICANT ALLERGEN FOR INNER-CITY CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	20	20	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1986	77	1	2	S			206	206						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	AZD38					2022-12-18	WOS:A1986AZD3800338
J	ATKINS, P; MERTON, H; KARPINK, P; WELIKY, I; ZWEIMAN, B				ATKINS, P; MERTON, H; KARPINK, P; WELIKY, I; ZWEIMAN, B			AZELASTINE INHIBITION OF SKIN-TEST REACTIVITY IN HUMANS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	20	20	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	1					167	167		10.1016/0091-6749(85)90385-9	http://dx.doi.org/10.1016/0091-6749(85)90385-9			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ACF22		Bronze			2022-12-18	WOS:A1985ACF2200250
J	GOLDSTEIN, RA; HURD, SS				GOLDSTEIN, RA; HURD, SS			SUMMARY AND RECOMMENDATIONS OF A WORKSHOP ON THE INVESTIGATIVE USE OF FIBEROPTIC BRONCHOSCOPY AND BRONCHOALVEOLAR LAVAGE IN INDIVIDUALS WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material											GOLDSTEIN, RA (corresponding author), NIAID,IMMUNOPATHOL BRANCH,WESTWOOD BLDG,ROOM 755,BETHESDA,MD 20205, USA.							ARNOUX B, 1980, EUR J CLIN INVEST, V10, P437, DOI 10.1111/j.1365-2362.1980.tb02082.x; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CHRISTIANSEN SC, 1985, J ALLERGY CLIN IMMUN, V75, P177, DOI 10.1016/0091-6749(85)90424-5; CRIMI E, 1983, ALLERGY, V38, P553, DOI 10.1111/j.1398-9995.1983.tb04139.x; FELS AOS, 1982, P NATL ACAD SCI-BIOL, V79, P7866, DOI 10.1073/pnas.79.24.7866; GODARD P, 1981, NOV PRESSE MED, V10, P3131; GODARD P, 1982, BRONCHES ASTHMATIQUE, P49; JOSEPH M, 1983, J CLIN INVEST, V71, P221, DOI 10.1172/JCI110762; MARTIN TR, 1984, AM REV RESPIR DIS, V129, P106; METZGER WJ, 1985, CHEST, V87, P16; RANKIN JA, 1984, CHEST, V85, P723, DOI 10.1378/chest.85.6.723; TOMIOKA M, 1984, AM REV RESPIR DIS, V129, P1000; TONNEL AB, 1983, LANCET, V1, P1406	13	20	21	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	2					145	147						3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	APE88					2022-12-18	WOS:A1985APE8800004
J	LOWHAGEN, O; RAK, S				LOWHAGEN, O; RAK, S			BRONCHIAL HYPERREACTIVITY AFTER TREATMENT WITH SODIUM CROMOGLYCATE IN ATOPIC ASTHMATIC-PATIENTS NOT EXPOSED TO RELEVANT ALLERGENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											LOWHAGEN, O (corresponding author), GOTHENBURG UNIV, SAHLGRENS HOSP, DEPT MED 1, ASTHMA & ALLERGY RES CTR, S-41345 GOTHENBURG, SWEDEN.							ALLEN DH, 1979, CHEST, V75, P235; ALTOUNYAN REC, 1980, CLIN ALLERGY, V10, P481, DOI 10.1111/j.1365-2222.1980.tb02162.x; ALTOUNYAN REC, 1970, DISODIUM CROMOGLYCAT, P47; ATKINS PC, 1978, J ALLERGY CLIN IMMUN, V62, P149, DOI 10.1016/0091-6749(78)90099-4; ATKINS PC, 1977, ANN INTERN MED, V86, P415, DOI 10.7326/0003-4819-86-4-415; AUSTEN KF, 1975, AM REV RESPIR DIS, V112, P423; BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P399, DOI 10.1016/0091-6749(83)90069-6; BOUSHEY HA, 1980, AM REV RESPIR DIS, V121, P389; BROGDEN RN, 1974, DRUGS, V7, P164, DOI 10.2165/00003495-197407030-00002; BRUCE C, 1976, THORAX, V31, P724, DOI 10.1136/thx.31.6.724; CADE JF, 1971, LANCET, V2, P186; CHARLES TJ, 1979, CLIN SCI, V57, P39, DOI 10.1042/cs0570039; CHURCH MK, 1978, MED ACT DRUGS TODAY, V14, P281; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COCKCROFT DW, 1977, THORAX, V32, P429, DOI 10.1136/thx.32.4.429; DAVIES RJ, 1982, PHARMACOL THERAPEUT, V17, P279, DOI 10.1016/0163-7258(82)90018-3; DICKSON W, 1979, MAST CELL ITS ROLE H, P343; DICKSON W, 1970, DISODIUM CROMOGLYCAT, P105; FABBRI LM, 1983, ANN ALLERGY, V50, P195; GRIFFIN MP, 1983, J ALLERGY CLIN IMMUN, V71, P331, DOI 10.1016/0091-6749(83)90088-X; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; HARGREAVE FE, 1982, EUR J RESPIR DIS, V63, P79; HEGARDT B, 1980, ALLERGY, V35, P113, DOI 10.1111/j.1398-9995.1980.tb01725.x; JUNIPER EF, 1981, THORAX, V36, P575, DOI 10.1136/thx.36.8.575; JUNIPER EF, 1982, THORAX, V37, P288, DOI 10.1136/thx.37.4.288; KANG B, 1976, BMJ-BRIT MED J, V1, P867, DOI 10.1136/bmj.1.6014.867; KAUFFMAN HF, 1983, CLIN ALLERGY, V13, P219, DOI 10.1111/j.1365-2222.1983.tb02591.x; KERR JW, 1970, BMJ-BRIT MED J, V2, P139, DOI 10.1136/bmj.2.5702.139; LEE TH, 1983, LANCET, V1, P520; LOWHAGEN O, 1983, EUR J RESPIR DIS, V64, P466; LOWHAGEN O, 1979, ALLERGY, V34, P395, DOI 10.1111/j.1398-9995.1979.tb02009.x; LOWHAGEN O, 1980, ALLERGY, V35, P521, DOI 10.1111/j.1398-9995.1980.tb01799.x; MURRAY AB, 1981, J ALLERGY CLIN IMMUN, V68, P119, DOI 10.1016/0091-6749(81)90169-X; NARASBHAT K, 1976, J ALLERGY CLIN IMMUN, V58, P647, DOI 10.1016/0091-6749(76)90176-7; PEGELOW KO, 1974, ACTA ALLERGOL, V29, P365, DOI 10.1111/j.1398-9995.1974.tb01472.x; ROSENTHAL R R, 1980, American Review of Respiratory Disease, V121, P90; RYAN G, 1982, THORAX, V37, P423, DOI 10.1136/thx.37.6.423; RYO UY, 1971, J ALLERGY, V47, P96; SCHOEFFEL RE, 1979, MAST CELL ITS ROLE H, P271; SIMON RA, 1977, J ALLERGY CLIN IMMUN, V60, P312, DOI 10.1016/0091-6749(77)90111-7; WOENNE R, 1979, AM REV RESPIR DIS, V119, P927; [No title captured]	42	20	20	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	3					343	347		10.1016/0091-6749(85)90070-3	http://dx.doi.org/10.1016/0091-6749(85)90070-3			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AEB46	3919076				2022-12-18	WOS:A1985AEB4600004
J	CRAMER, EB; MIGLIORISI, G; POLOGE, L; ABRAHAMS, E; PAWLOWSKI, NA; COHN, Z; SCOTT, WA				CRAMER, EB; MIGLIORISI, G; POLOGE, L; ABRAHAMS, E; PAWLOWSKI, NA; COHN, Z; SCOTT, WA			EFFECT OF LEUKOTRIENES ON ENDOTHELIUM AND THE TRANSENDOTHELIAL MIGRATION OF NEUTROPHILS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ROCKEFELLER UNIV,NEW YORK,NY 10021	Rockefeller University	CRAMER, EB (corresponding author), SUNY DOWNSTATE MED CTR,DEPT ANAT & CELL BIOL,BROOKLYN,NY 11203, USA.							ALAM I, 1979, ANAL BIOCHEM, V93, P339; BAENZIGER NL, 1980, BIOCHEM BIOPH RES CO, V92, P1435, DOI 10.1016/0006-291X(80)90447-7; BJORK J, 1982, INFLAMMATION, V6, P189, DOI 10.1007/BF00916243; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BRAY MA, 1981, PROSTAGLANDINS, V22, P213, DOI 10.1016/0090-6980(81)90036-8; CRAMER EB, 1983, P NATL ACAD SCI-BIOL, V80, P4109, DOI 10.1073/pnas.80.13.4109; CRAMER EB, 1980, P NATL ACAD SCI-BIOL, V77, P4069, DOI 10.1073/pnas.77.7.4069; DAHLEN SE, 1981, P NATL ACAD SCI-BIOL, V78, P3887, DOI 10.1073/pnas.78.6.3887; Foltz C M, 1982, Prog Clin Biol Res, V89, P353; FURIE MB, 1984, J CELL BIOL, V98, P103; GOETZL EJ, 1981, J EXP MED, V153, P482, DOI 10.1084/jem.153.2.482; HARVATH L, 1980, J IMMUNOL METHODS, V37, P39, DOI 10.1016/0022-1759(80)90179-9; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JAFFE EA, 1973, J CLIN INVEST, V52, P2757, DOI 10.1172/JCI107471; LEWIS RA, 1981, J EXP MED, V154, P1243, DOI 10.1084/jem.154.4.1243; LINDBOM L, 1982, ACTA PHYSIOL SCAND, V116, P105, DOI 10.1111/j.1748-1716.1982.tb10607.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; PALMBLAD J, 1981, BLOOD, V58, P658; SMEDEGARD G, 1982, NATURE, V295, P327, DOI 10.1038/295327a0; UNGER WG, 1971, NATURE, V233, P336, DOI 10.1038/233336b0; WAGNER DD, 1982, J CELL BIOL, V95, P355, DOI 10.1083/jcb.95.1.355; WEKSLER BB, 1978, J CLIN INVEST, V62, P923, DOI 10.1172/JCI109220	22	20	20	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	3					386	390		10.1016/0091-6749(84)90136-2	http://dx.doi.org/10.1016/0091-6749(84)90136-2			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TQ633	6088615				2022-12-18	WOS:A1984TQ63300016
J	DELEHUNT, JC; YERGER, L; AHMED, T; ABRAHAM, WM				DELEHUNT, JC; YERGER, L; AHMED, T; ABRAHAM, WM			INHIBITION OF ANTIGEN-INDUCED BRONCHOCONSTRICTION BY METHYLPREDNISOLONE SUCCINATE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											DELEHUNT, JC (corresponding author), MT SINAI MED CTR,DIV PULM DIS,MIAMI BEACH,FL 33140, USA.				NHLBI NIH HHS [HL-27748, HL-02668] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K11HL002668] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAM WM, 1981, AM REV RESPIR DIS, V124, P554; ABRAHAM WM, 1983, AM REV RESPIR DIS, V128, P39; AHMED T, 1983, J ALLERGY CLIN IMMUN, V17, P224; BLACKWELL GJ, 1980, NATURE, V287, P147, DOI 10.1038/287147a0; BONE JF, 1962, AM J VET RES, V23, P1113; BOOIJNOORD H, 1971, J ALLERGY CLIN IMMUN, V48, P344, DOI 10.1016/0091-6749(71)90080-7; COOK CD, 1957, J CLIN INVEST, V36, P440, DOI 10.1172/JCI103441; DELEHUNT JC, 1983, FED PROC, V42, P905; DOHERTY GB, 1981, ANN ALLERGY, V46, P241; Flower R, 1978, Adv Prostaglandin Thromboxane Res, V3, P105; FORSBERG K, 1981, AGENTS ACTIONS, V11, P391, DOI 10.1007/BF01982476; GOADBY P, 1964, J PHARM PHARMACOL, V16, P108, DOI 10.1111/j.2042-7158.1964.tb07428.x; HICKS R, 1970, J PHARM PHARMACOL, V22, P170, DOI 10.1111/j.2042-7158.1970.tb08493.x; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; PETERS SP, 1981, NATURE, V292, P455, DOI 10.1038/292455a0; PETERS SP, 1982, LEUKOTRIENES OTHER L, P315; SCHLEIMER RP, 1981, NATURE, V292, P454, DOI 10.1038/292454a0; SCHMULTZLER W, 1974, INT ARCH ALLERGY APP, V49, P209; SULLIVAN TJ, 1979, J IMMUNOL, V122, P431; WANNER A, 1979, J APPL PHYSIOL, V47, P917, DOI 10.1152/jappl.1979.47.5.917; WEBB R, 1981, MED CLIN N AM, V65, P1073	21	20	20	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	4					479	483		10.1016/0091-6749(84)90358-0	http://dx.doi.org/10.1016/0091-6749(84)90358-0			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SM089	6368648	Bronze			2022-12-18	WOS:A1984SM08900009
J	KATZ, RM				KATZ, RM			RHINITIS IN THE ATHLETE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ALLERGY RES FDN INC,LOS ANGELES,CA		KATZ, RM (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT PEDIAT,LOS ANGELES,CA 90024, USA.							DECOTIS BA, 1980, AM REV RESPIR DIS, V117, P64; GALLAGHER TM, 1975, DIFFERENTIAL DIAGNOS; KABAN LB, 1977, PLAST RECONSTR SURG, V59, P15, DOI 10.1097/00006534-197701000-00002; Kolski G B, 1982, Clin Sports Med, V1, P397; MELTZER EO, 1983, PEDIATR CLIN N AM, V30, P847; MICHELS MI, 1967, J ANN ALLERGY, V25, P559; MYGIND N, 1982, J ALLERGY CLIN IMMUN, V70, P149, DOI 10.1016/0091-6749(82)90036-7; RICHERSON HB, 1968, J ALLERGY, V41, P269, DOI 10.1016/0021-8707(68)90032-4	8	20	20	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	5					708	711		10.1016/0091-6749(84)90311-7	http://dx.doi.org/10.1016/0091-6749(84)90311-7			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SS046	6143772				2022-12-18	WOS:A1984SS04600018
